<SEC-DOCUMENT>0001453687-25-000060.txt : 20250313
<SEC-HEADER>0001453687-25-000060.hdr.sgml : 20250313
<ACCEPTANCE-DATETIME>20250313070647
ACCESSION NUMBER:		0001453687-25-000060
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		150
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250313
DATE AS OF CHANGE:		20250313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cartesian Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37798
		FILM NUMBER:		25733813

	BUSINESS ADDRESS:	
		STREET 1:		7495 NEW HORIZON WAY
		CITY:			FREDERICK
		STATE:			MD
		ZIP:			21703
		BUSINESS PHONE:		301-348-8698

	MAIL ADDRESS:	
		STREET 1:		7495 NEW HORIZON WAY
		CITY:			FREDERICK
		STATE:			MD
		ZIP:			21703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SELECTA BIOSCIENCES INC
		DATE OF NAME CHANGE:	20090109
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rnac-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f87b4d67-655c-40f8-bf99-5c1eb72d37a4,g:ec248d9b-f7a4-4998-8c2a-3c79ab383104,d:da4b385316634ae2a3d2c21207c427f6-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:rnac="http://www.cartesiantherapeutics.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rnac-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-32">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0001453687</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-61">373</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-52" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-337">0.0333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-63" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-438">0.05</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-64" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-439">0.0333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-52" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-440">0.0333</ix:nonFraction><ix:nonNumeric contextRef="c-68" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="f-467">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="c-68" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="f-469">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" id="f-651">http://fasb.org/us-gaap/2024#GainLossOnDerivativeInstrumentsNetPretax</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-743">http://fasb.org/us-gaap/2024#AssetImpairmentCharges</ix:nonNumeric><ix:nonNumeric contextRef="c-258" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1259">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-261" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1260">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-259" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1261">http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-262" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1262">http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rnac-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>rnac:segment</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="extension_option"><xbrli:measure>rnac:extension_option</xbrli:measure></xbrli:unit><xbrli:unit id="operating_lease"><xbrli:measure>rnac:operating_lease</xbrli:measure></xbrli:unit><xbrli:unit id="business_day"><xbrli:measure>rnac:business_day</xbrli:measure></xbrli:unit><xbrli:unit id="day"><xbrli:measure>rnac:day</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>rnac:vote</xbrli:measure></xbrli:unit><xbrli:unit id="obligation"><xbrli:measure>rnac:obligation</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rnac:ChristopherJewellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rnac:ChristopherJewellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rnac:ChristopherJewellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-04</xbrli:startDate><xbrli:endDate>2024-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-27</xbrli:startDate><xbrli:endDate>2024-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-27</xbrli:startDate><xbrli:endDate>2024-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:Descartes08ForMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:Descartes08ForSLEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rnac:ForwardContractToIssueSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rnac:ForwardContractToIssueSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rnac:SeriesAPreferredStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rnac:SeriesAPreferredStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rnac:ContingentValueRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-06</xbrli:startDate><xbrli:endDate>2023-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SOBIPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">rnac:ProbabilityOfSuccessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">rnac:ProbabilityOfSuccessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">rnac:MeasurementInputRevenueVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">rnac:ProbabilityOfSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rnac:ContingentValueRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rnac:ContingentValueRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rnac:ContingentValueRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-05</xbrli:startDate><xbrli:endDate>2023-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-13</xbrli:startDate><xbrli:endDate>2023-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-12</xbrli:startDate><xbrli:endDate>2024-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rnac:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rnac:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-28</xbrli:startDate><xbrli:endDate>2024-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-07</xbrli:startDate><xbrli:endDate>2024-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-30</xbrli:startDate><xbrli:endDate>2024-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-31</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A704QuinceOrchardRoadLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A704QuinceOrchardRoadLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:MoscowRussiaLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:MoscowRussiaLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rnac:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-11</xbrli:startDate><xbrli:endDate>2023-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rnac:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rnac:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rnac:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rnac:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.TimothyA.SpringerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:TASPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.ChafenLuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.ChafenLuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-25</xbrli:startDate><xbrli:endDate>2024-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-25</xbrli:startDate><xbrli:endDate>2024-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-13</xbrli:startDate><xbrli:endDate>2023-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-12</xbrli:startDate><xbrli:endDate>2024-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-11</xbrli:startDate><xbrli:endDate>2024-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-15</xbrli:startDate><xbrli:endDate>2023-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-08</xbrli:startDate><xbrli:endDate>2024-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-08</xbrli:startDate><xbrli:endDate>2024-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-08</xbrli:startDate><xbrli:endDate>2024-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-11</xbrli:startDate><xbrli:endDate>2024-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-11</xbrli:startDate><xbrli:endDate>2024-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rnac:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-05</xbrli:startDate><xbrli:endDate>2023-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:A2022OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-06</xbrli:startDate><xbrli:endDate>2022-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:A2022OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-28</xbrli:startDate><xbrli:endDate>2020-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-18</xbrli:startDate><xbrli:endDate>2019-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rnac:CommonWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rnac:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-18</xbrli:startDate><xbrli:endDate>2019-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rnac:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-20</xbrli:startDate><xbrli:endDate>2022-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rnac:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartestianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartestianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoBioworksHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartestianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartestianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:AstellasGeneTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:AstellasGeneTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:AstellasGeneTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:AstellasGeneTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:AstellasGeneTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-28</xbrli:startDate><xbrli:endDate>2024-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-10</xbrli:startDate><xbrli:endDate>2022-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">rnac:NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">rnac:NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">rnac:NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.TimothyA.SpringerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:TASPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.ChafenLuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.TimothyA.SpringerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.TimothyA.SpringerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:TASPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SevenOneEightThreeFourIrrevocableTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:BiogenM.A.Inc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:NationalCancerInstituteAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-16</xbrli:startDate><xbrli:endDate>2019-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-25</xbrli:startDate><xbrli:endDate>2021-10-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-13</xbrli:startDate><xbrli:endDate>2022-06-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-19</xbrli:startDate><xbrli:endDate>2023-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GenovisABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:CyrusBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-07</xbrli:startDate><xbrli:endDate>2021-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SeriesBPreferredStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:CyrusBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:CyrusBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:CyrusBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:AskBioLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:AskBioLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:LegacySelectaProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:LegacySelectaProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:Descartes08ForMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:Descartes08ForMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:EarlyStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:EarlyStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ida4b385316634ae2a3d2c21207c427f6_1"></div><div style="min-height:18pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">    </span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.885%"><tr><td style="width:1.0%"/><td style="width:18.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.188%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.743%"><tr><td style="width:0.1%"/><td style="width:2.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#254;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.743%"><tr><td style="width:0.1%"/><td style="width:2.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ____ to ____</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-37798</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Cartesian Therapeutics, Inc.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.183%"><tr><td style="width:1.0%"/><td style="width:4.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">26-1622110</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</span></div><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">7495 New Horizon Way</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Frederick</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">MD</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">21703</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">301</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">348-8698</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number,&#160;including area code</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.457%"><tr><td style="width:1.0%"/><td style="width:40.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.651%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">RNAC</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(g) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Value Rights</span></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.          Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.      Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.   <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.885%"><tr><td style="width:1.0%"/><td style="width:14.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#254;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#254;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attested to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:112%">o</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#254;</ix:nonNumeric></span></div><div style="height:14.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">    </span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate market value of common stock held by non-affiliates of the registrant based on the closing price of the registrant&#8217;s common stock as reported on the Nasdaq Stock Market on June&#160;28, 2024, the last business day of the registrant&#8217;s most recently completed second quarter, was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-29">193,901,954</ix:nonFraction>.</span></div><div style="margin-bottom:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;28, 2025, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">25,907,101</ix:nonFraction> shares of common stock, par value $0.0001 per share, outstanding.</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">   </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive Proxy Statement relating to its 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div></ix:nonNumeric><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.885%"><tr><td style="width:1.0%"/><td style="width:18.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.188%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:14.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">    </span></div></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.143%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_16">Part I</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_28">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_28">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_28">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_58">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_58">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_58">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_61">Item 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_61">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_61">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_64">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_64">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_64">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_67">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_67">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_67">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_70">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_70">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_70">54</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_88">Part II</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_91">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_91">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_91">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_94">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_94">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_94">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_97">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_97">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_97">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_124">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_124">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_124">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_127">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_127">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_127">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_130">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_130">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_130">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_133">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_133">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_133">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_139">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_139">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_142">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_142">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_142">70</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_145">Part III</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_148">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_148">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_148">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_151">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_151">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_151">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_154">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_154">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_154">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_157">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_157">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_157">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_160">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_160">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_160">71</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_163">Part IV</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_169">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_169">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_169">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_172">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_172">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_172">75</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_175">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_175">76</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">    </span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, or the Annual Report, contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, the plans and objectives of management for future operations and future results of anticipated products, and the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221;, or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under the sections in this Annual Report titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any future payouts under the contingent value right, or CVR, issued to our holders of record as of the close of business on December 4, 2023;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve the expected benefits or opportunities and related timing with respect to the Merger (as defined below) or to monetize any of our legacy assets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our future results of operations and financial position, business strategy, and the length of time that we believe our existing cash resources will fund our operations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our market size and our potential growth opportunities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our preclinical and clinical development activities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on third-parties, including contract research organizations, or CROs, in the conduct of our pre-clinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety profile of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential therapeutic benefits and economic value of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and results of preclinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impairment of our goodwill and indefinite lived intangible assets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, current or potential bank failures;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global events, including the ongoing conflicts between Russia and Ukraine and between Hamas and Israel and geopolitical tensions in China on our operations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of political uncertainty on our product development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to prevent or minimize the effects of litigation and other contingencies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our status as a preclinical and development-stage company and our expectation to incur losses in the future, and the possibility that we never achieve or maintain profitability;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties with respect to our ability to access future capital;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maximize the value of our pipeline of product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our unproven approach to therapeutic intervention;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary regulatory approvals;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">    </span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to grow our manufacturing capabilities and resources;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture our product candidates, which in some cases are manufactured on a patient-by-patient basis;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to access manufacturing facilities and to receive or manufacture sufficient quantities of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our existing or future collaborations or licenses and to seek new collaborations, licenses or partnerships;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of pandemics or similar events on our operations, the continuity of our business, including our preclinical studies and clinical trials, and general economic conditions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce our intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal, state, and foreign regulatory requirements, including U.S. Food and Drug Administration, or FDA, regulation of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and retain key executives and retain qualified personnel; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry, including the impact of government regulation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we operate in an evolving environment. New risks and uncertainties may emerge from time to time, and it is not possible for management to predict all risk and uncertainties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report and the documents that we reference in this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_19"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.  Business</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate History and Background</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (formerly known as Selecta Biosciences, Inc., or Selecta) was incorporated in Delaware on December 10, 2007, and is headquartered in Frederick, Maryland. On November 13, 2023, the Company and the Delaware corporation which, immediately prior to the Merger (as defined below), was known as Cartesian Therapeutics, Inc., or Old Cartesian, entered into an Agreement and Plan of Merger, or the Merger Agreement, by and among the Company, Sakura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, or First Merger Sub, Sakura Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company, or Second Merger Sub, and Old Cartesian. Pursuant to the Merger Agreement, and simultaneously with execution thereof, (i) First Merger Sub merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corporation, or the First Step Surviving Corporation, and became a wholly owned subsidiary of the Company, or the First Merger, and (ii) immediately following the First Merger, Old Cartesian (as the First Step Surviving Corporation) merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving company, or the Surviving Company, and continued under the name &#8220;Cartesian Bio, LLC&#8221;, or the Second Merger and, together with the First Merger, the Merger. In connection with the Merger and pursuant to the Merger Agreement, the Company (which was known as Selecta Biosciences, Inc. until immediately prior to the Merger) changed its corporate name to Cartesian Therapeutics, Inc. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biotechnology company </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">pioneering mRNA cell therapy for the treatment of autoimmune diseases. We leverage our proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell&#8217;s genetic material. Therefore, our mRNA cell therapies are distinguished by their capacity to be dosed repeatedly like conventional drugs, administered in an outpatient setting, and given without pre-treatment chemotherapy required with many conventional cell therapies. In a placebo-controlled Phase 2b clinical trial in patients with myasthenia gravis, or MG, a chronic autoimmune disease that causes disabling muscle weakness and fatigue, we observed that our lead product candidate, Descartes-08, generated a deep and durable clinical benefit where we observed an average MG-ADL (Activities of Daily Living) reduction of 5.5 points at Month 4 with a third of patients achieving minimal symptom expression at Month 6 and 80% of participants reaching Month 12 maintained a clinically meaningful response. Durability of response in MG is commonly measured over a period of 26 to 52 weeks, and maintenance of response over that period is considered durable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune diseases, where the immune system mistakenly attacks the body, are a family of more than 80 disorders. Autoimmune diseases are typically treated with immunosuppressant medications, such as steroids. These treatments must be administered continually and carry risks, including infection, osteoporosis, and metabolic disease. Newer agents that block the complement pathway or inhibit the neonatal Fc receptor, or FcRn, must also typically be administered continually. We believe there is a significant unmet need for outpatient treatments, completed over a short period of time, that provide deep, durable clinical benefit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell therapies have the potential to provide this benefit, but conventional cell therapies that use DNA are associated with toxicities, including cytokine release syndrome, or CRS, neurotoxicity, transformation to cancer, and death. Further, conventional cell therapies typically require pre-treatment with chemotherapy, which suppresses the immune system and increases the risk of infection, anemia, and neurotoxicity. As a result, conventional DNA cell therapies typically require close monitoring in an inpatient setting, increasing the total cost of care and generally limiting their reach to only the sickest patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our mRNA cell therapies have the potential to deliver deep, durable clinical benefit to a broad group of patients with autoimmune diseases because they can be administered over a short period of time, in an outpatient setting, and without pre-treatment chemotherapy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our proprietary technology and manufacturing platform to develop mRNA cell therapies for autoimmune diseases. Our mRNA CAR-T modality is a personalized approach that collects a patient&#8217;s T-cells and uses mRNA to introduce a chimeric antigen receptor, or CAR, into the cell. The CAR redirects the T-cells to target and destroy pathogenic self-reactive cells. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes key information about our development pipeline.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:18pt"><img src="rnac-20241231_g1.jpg" alt="10-K Pipeline Slide.jpg" style="height:280px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen, or BCMA, that we are developing for the treatment of autoimmune diseases. Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy, or RMAT, Designation by the FDA for the treatment of MG as well as a Rare Pediatric Disease Designation for the treatment of juvenile dermatomyositis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Descartes-08 for the Treatment of MG</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, we reported topline results from a Phase 2b randomized, double-blind, placebo-controlled trial in patients with MG. The trial achieved its primary endpoint with statistical significance in the pre-specified modified intent-to-treat, or mITT, efficacy population, with 71% (10/14) of patients treated with Descartes-08 observed to have 5-point or greater improvements in MG Composite, or MGC, score at Month 3 compared to 25% (3/12) of patients treated with placebo (p=0.018). In addition, the trial also achieved its primary endpoint with statistical significance in the per-protocol population, with 69% (11/16) of patients treated with Descartes-08 observed to have 5-point or greater improvements in MGC score at Month 3 compared to 33% (5/15) of patients treated with placebo (p=0.048).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with previously reported results from the Phase 2a open-label portion of the trial, Descartes-08 responders experienced deep improvements across the MG severity scales at Month 3 (average MG-ADL (Activities of Daily Living) = -5.6; MGC= -8.3; QMG (Quantitative MG) = -5.0; QoL-15r (Quality of Life Revised Scale) = -7.9). A 2-point improvement in MG-ADL and 3-point improvement in MGC and QMG scales are considered &#8220;clinically meaningful&#8221; by expert consensus published in peer-reviewed journals. The improvements seen at Month 3 persisted or further improved in patients evaluated at their Month 4 (n=5) and Month 6 (n=3) follow-up visits, as of the June 19, 2024 data cutoff date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, we reported updated results from this trial. Deepening of responses was observed over time with participants included in the primary efficacy dataset who continued follow-up (n=12) experiencing an average MG-ADL reduction of 5.5 (&#177;1.1) at Month 4. At Month 4, particularly deep responses were observed in participants without prior exposure to biologic therapies (n=7), including complement or neonatal fragment crystallizable receptor inhibitors, with an average MG-ADL reduction of 6.6 (&#177;1.5). Responses were observed to further deepen at Month 6, with 33% (4/12) of participants in the primary efficacy dataset and 57% (4/7) of participants with no prior exposure to biologic therapy observed to have minimum symptom expression, defined as an MG-ADL score of 0 or 1. Responses were observed to be durable through Month 12, with 80% (4/5) of evaluable participants from the primary efficacy dataset maintaining a clinically meaningful response, defined as a reduction in MG-ADL score of at least 2 points. Of the two participants with no prior exposure to biologic therapy that reached Month 12, both maintained at least a clinically meaningful response, with one continuing to demonstrate minimum symptom expression. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with previously reported results from the Phase 2a open-label portion of the trial, Descartes-08 continued to be observed as well-tolerated, supporting outpatient administration without the need for lymphodepleting chemotherapy. Consistent with previously reported data, Descartes-08 was observed to be well-tolerated across the safety dataset (n=36), and adverse events were transient and mostly mild. Notably, there were no cases of CRS, and no cases of immune effector cell-associated neurotoxicity syndrome, or ICANS. In addition, treatment with Descartes-08 was not observed to lead to a decrease in vaccine titers for common viruses and was not associated with increased rates of infection or hypogammaglobulinemia.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within this data readout, we also announced updated trial results from a Phase 2a open-label trial of Descartes-08 in patients with MG from certain retreated patients. Two participants were previously retreated, and experienced rapid improvement in clinical scores and maintained minimum symptom expression for up to one year after receiving a second </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment cycle. A third participant received a second treatment cycle and at the participant&#8217;s Month 2 visit, two weeks after the last Descartes-08 infusion, achieved a 4-point reduction in MG-ADL and 6-point reduction in MGC scores from baseline, without reports of CRS or ICANS. The time course and magnitude of treatment response upon retreatment were similar to the time course and magnitude of treatment response observed when the participants were first treated. Four of the seven remaining participants from the Phase 2a portion of the trial maintained clinically meaningful responses for at least one year following initial dosing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to commence our Phase 3 AURORA trial of Descartes-08 in patients with MG in the first half of 2025. The randomized, double-blind, placebo-controlled Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive, or AChR Ab+, MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG-ADL score of three points or more at Month 4 compared to placebo. Secondary endpoints will assess safety and tolerability and the proportion of participants with a reduction of four points or more in MGC score, as well as improvements in other validated MG severity scales, including Quantitative MG, QMG, and MG Quality of Life Revised Scale, or MG-QoL-15R. In January 2025, we received written agreement from the FDA under the Special Protocol Assessment, or SPA, process on the overall design of our planned AURORA trial. The SPA agreement indicates that the FDA has determined that the proposed trial design is acceptable to support a future Biologics License Application, or BLA, for Descartes-08 in MG, subject to the ultimate outcome of the trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:18pt"><img src="rnac-20241231_g2.jpg" alt="10-K Aurora formatted.jpg" style="height:304px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Descartes-08 for the Treatment of Other Autoimmune Diseases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing Descartes-08 for the treatment of other autoimmune diseases. In July 2024, the first patient was dosed in our Phase 2 trial of Descartes-08 for the treatment of systemic lupus erythematosus, or SLE, a chronic autoimmune disease that causes systemic inflammation affecting multiple organ systems. A data readout of this trial is expected in the second half of 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, we filed an amendment to the investigational new drug application, or IND, for a pediatric basket trial for juvenile dermatomyositis, or JDM, juvenile SLE, juvenile MG, anti-neutrophil cytoplasmic antibody-associated vasculitis, as well as other conditions. Our Phase 2 basket trial in pediatric patients is expected to initiate in the second half of 2025. The FDA has also granted Descartes-08 Rare Pediatric Disease Designation for the treatment of JDM. The FDA grants Rare Pediatric Disease Designation for serious and life-threatening diseases that primarily affect children ages 18 years or younger and fewer than 200,000 people in the United States. Under the FDA&#8217;s Rare Pediatric Disease Designation and priority review voucher programs, if Decartes-08 is approved for marketing in JDM, Cartesian may qualify for a priority review voucher that can be redeemed to receive priority review of a subsequent marketing application for a different product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Descartes-15</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descartes-15 is our next-generation autologous anti-BCMA mRNA CAR-T. In preclinical studies, we have observed Descartes-15 to be 10-fold more potent than Descartes-08. We are testing the safety of Descartes-15 in an open label, single-arm Phase 1 trial in patients with relapsed/refractory multiple myeloma. This trial remains ongoing with three patients dosed to date. We expect that the Phase 1 trial data will inform our clinical development plan for Descartes-15 in autoimmune diseases.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations of Current DNA-Based Cell Therapy Treatments in Autoimmune Disease</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conventional DNA cell therapies have been associated with CRS, neurological toxicities and Parkinsonism, infection, risk of secondary malignancy, and death. The acute toxicities are from exponential amplification of the modified cell, and the pre-treatment chemotherapy administered to enable cell amplification.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conventional DNA-engineered CAR-T cells are in clinical development for several autoimmune diseases. DNA CAR-T cells are typically administered to patients in a subtherapeutic dose, which means that the cells must proliferate to reach therapeutic numbers in the body. However, this proliferation is not controlled in magnitude or duration, varies from patient to patient, and can be unpredictable. This proliferation occurs because the CAR gene is irreversibly integrated into the T-cell&#8217;s genome, causing a cascade in which every daughter cell carries the same CAR as the parent cells. The resulting unconstrained proliferation frequently exceeds the toxicity threshold, leading to serious adverse events. In November 2023, the FDA announced that it is investigating the risk of T-cell malignancies in approved DNA CAR-T cell immunotherapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proliferation of DNA CAR-T cells has typically required pre-treatment chemotherapy, usually fludarabine and cyclophosphamide administered for several days before CAR-T cell treatment. This chemotherapy is toxic, suppressing the immune system and increasing the risk of infection, anemia, and neurotoxicity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks and requirements, conventional DNA cell therapies are administered under close monitoring in an inpatient setting, increasing their cost and limiting their reach to only the sickest patients.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations of Current Biologic Treatments in Autoimmune Disease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently approved biologic therapies for MG, such as complement inhibitors and FcRn inhibitors have significantly improved treatment options, but they come with limitations such as incomplete response, immunosuppression risks, high treatment burden, lack of disease modification and potential for emerging resistance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not all patients with AChR+ MG respond adequately to currently approved biologics. The variability in treatment response may be due to differences in disease mechanisms, with some patients having disease drivers beyond complement activation (for complement inhibitors) or immunoglobulin G, or IgG, reduction (for FcRn inhibitors). Additionally, some individuals experience an initial improvement but later lose response, requiring adjustments in their treatment strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologic therapies used for MG can increase the risk of infections. Complement inhibitors in particular, heighten susceptibility to Neisseria infections, necessitating vaccination and, in some cases, prophylactic antibiotic use. Patients receiving FcRn inhibitors may also experience an increased risk of infections due to immunoglobulin depletion. The long-term safety of these treatments remains an area of active study.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently approved biologic therapies require frequent infusions, which can be burdensome for patients. Efgartigimod requires weekly infusions in repeated cycles, while eculizumab is administered every two weeks and ravulizumab every eight weeks. While ravulizumab reduces the frequency of infusions compared to eculizumab, both of these treatments require ongoing maintenance, which may impact patient quality of life. Access to infusion centers or home infusion services further adds to the logistical challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All existing biologic therapies for MG manage symptoms rather than addressing the root cause of the disease. These treatments do not eliminate the underlying autoimmune process or autoreactive B and T cells, meaning patients typically require lifelong therapy. While symptom control is critical, the need for continuous treatment highlights the unmet need for therapies that could induce long-term remission.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, the effectiveness of complement inhibitors may vary among patients due to differences in complement system activity or genetic factors. Some individuals may have upregulated alternative complement pathways or specific gene polymorphisms that reduce the efficacy of eculizumab and ravulizumab. This variability underscores the importance of identifying biomarkers that could help predict response and guide personalized treatment strategies.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Autoimmune Disease Solution</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that mRNA cell therapy has the potential to be a potent yet safer alternative to DNA cell therapy for treating autoimmune diseases. As the data in our clinical trials indicates, the mRNA cell therapies we are developing have the potential to deliver deep and durable clinical benefits to many patients with autoimmune diseases because they can be administered over a short period of time, in an outpatient setting, and without pre-treatment chemotherapy. These attributes may extend the reach and potential of mRNA cell therapy to a broader group of patients with autoimmunity. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA CAR-T cells locate their target, become activated, and proliferate like DNA CAR-T cells. However, because mRNA does not replicate and degrades naturally over time, the maximum number of mRNA molecules can be determined by the dose. The actual number of mRNA molecules declines to zero over time. The number of mRNA molecules determines the degree of CAR protein expression, and the persistence of the mRNA molecules determines the duration of mRNA CAR-T cell activity. Thus, unlike DNA CAR-T cells, our mRNA CAR-T cells provide pharmacokinetic control. In other words, a patient&#8217;s exposure to our cells is determined by the dose. The time, course and duration of that exposure are substantially determined by </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the nature of the mRNA we use. Therefore, while DNA CAR-T therapies are administered at subtherapeutic levels, we can administer a therapeutic number of mRNA CAR-T cells and re-dose these cells over time, much like a conventional drug. Because the mRNA cannot be replicated, we believe, and have thus far observed, that mRNA CAR-T cells do not cause the types of severe toxicity associated with DNA CAR-T cells. Also, because mRNA CAR-T is dosed at a therapeutic dose and does not rely on cell proliferation to reach the therapeutic window, there is no need to administer pre-treatment chemotherapy. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we have administered Descartes-08 to over 100 patients suffering from one of MG, multiple myeloma, and other diseases in open-label trials on an outpatient basis, many at community clinics. We have not observed product-related CRS, neurotoxicity or infection of any grade. The most common product-related adverse events observed, headache, nausea, and fever, were self-limited and resolved within 72 hours of onset. One participant with MG with a history of allergic reaction to biologics developed hives after the third infusion and was hospitalized for monitoring. The patient&#8217;s hives resolved completely after a brief course of steroids.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Descartes-08</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descartes-08, our lead mRNA cell therapy candidate, is an autologous mRNA CAR-T product targeting BCMA in clinical development for generalized MG and SLE. In contrast to conventional DNA-based CAR T-cell therapies, mRNA CAR-T administration is designed to not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has been granted Orphan Drug Designation and RMAT Designation by the FDA for the treatment of MG, and Rare Pediatric Disease Designation for the treatment of JDM.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Descartes-08 for the Treatment of MG</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descartes-08 has been granted Orphan Drug Designation by the FDA for the treatment of MG. We chose MG as our lead indication because the pathogenesis for MG is common to many autoimmune diseases.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Background Information About MG</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MG is a rare autoimmune disease that causes debilitating muscle weakness and fatigue. It is estimated to affect over 120,000 patients in the U.S. and Europe. MG patients develop antibodies that lead to an immunological attack on critical signaling proteins at the junction between nerve and muscle cells, thereby inhibiting the ability of nerves to communicate properly with muscles. This results in muscle weakness in tissues throughout the body, potentially manifesting in partial paralysis of eye movements, problems in chewing and swallowing, respiratory problems, speech difficulties and weakness in skeletal muscles. As the disease progresses, symptom-free periods become less frequent and disease exacerbations can last for months. Disease symptoms reach their maximum levels within two to three years in approximately 80% of patients. Up to 20% of MG patients experience a respiratory crisis at least once in their lives. During the crisis phase, decline in respiratory function can become life-threatening. Patients in crisis often require intubation and mechanical ventilation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no known cures for MG and the current standard of care consists of chronic use of steroids and other immunosuppressants. These treatments must be administered continually and carry risks such as infection, osteoporosis, and metabolic diseases. Newer agents, such as those that block the complement pathway or inhibit FcRn, are typically administered continually.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have completed the Phase 1/2 trial of Descartes-08 in MG, which consisted of a Phase 1b portion, a Phase 2a portion, and a Phase 2b portion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of the Phase 1b portion of the trial was to determine the maximum tolerated dose of Descartes-08 for patients with MG. We observed Descartes-08 to be well-tolerated by the three patients who participated in this portion of the trial with no CRS or other serious product-related adverse events.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of the Phase 2a portion of the trial was to determine the optimal dosing schedule for patients with MG using the highest dose level tested in Phase 1b (52.5 x106 cells/kg). This portion of the trial was designed to assess the safety and preliminary efficacy of Descartes-08 when administered across three different treatment schedules (six doses given twice-weekly, once-weekly, or once-monthly). This portion of the trial evaluated 11 patients with particularly advanced disease as assessed by both patient and clinician-reported outcomes. 79% of the 14 patients included in the Phase 1b and Phase 2a portions of the trial were classified at screening to have Class III or IV disease, as defined by the Myasthenia Gravis Foundation of America, indicating they had moderate-to-severe weakness affecting their muscles.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the Phase 2a portion of the trial, published in the Lancet Neurology in July 2023, indicated that after six weekly infusions of Descartes-08, the average improvement in all disease severity scores was three-to-five-fold greater than what is considered clinically meaningful by expert consensus. As shown in the figure below, clinical improvements persisted in all patients at Month 9, and in five of the seven remaining patients at a final, 12-month follow-up. Descartes-08 was observed to be well-tolerated with no reports of dose-limiting toxicities, CRS or neurotoxicity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="rnac-20241231_g3.jpg" alt="10-K ph2a data.jpg" style="height:168px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A&#8211;C: Mean change from Baseline (line) and standard error (bands) in Myasthenia Gravis Activities of Daily Living Score (MG-ADL, A), Quantitative Myasthenia Gravis Score (QMG, B), Myasthenia Gravis Composite Score (MGC, C) during 12 months of follow-up for MG-001 participants who received six once-weekly doses (n=7). MG-ADL is self-reported; MGC and QMG are neurologist-assessed. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All three participants with detectable anti-acetylcholine receptor antibody levels before treatment had an average 42% reduction in antibody levels by Month 6. These reductions deepened to 68% by Month 9 and persisted at Month 12. In summary, we observed continued clinical improvement and autoantibody reductions after BCMA directed mRNA CAR-T treatment for MG that persisted through the one-year follow-up period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Follow-on results of the Phase 2b portion of the trial were presented in December 2024. The trial reached its primary endpoint to assess the proportion of patients achieving a five-point or greater reduction in their MGC score at day 85. Patients received six weekly infusions at the dose established in Phase 1b (52.5 x106 cells/kg). The trial also involved a crossover component, in which any patient originally assigned to placebo was given the opportunity to receive Descartes-08 after completing trial treatment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Phase 2b trial, we observed a deepening of responses after Month 3 in the primary efficacy data set. Two MG composite responders at Month 3 withdrew from the study before Month 4 for personal reasons (total number of participants at Month 4 and Month 6 was 12). Of the 12 participants as of the readout date, eight had reached Month 9 follow-up and five had reached Month 12 follow-up, thus completing the trial. Results of the study showed an average MG-ADL reduction of 5.5 points at Month 4 (chart below on the left) and an average MGC reduction of 7.1 for Descartes-08 treated patients (chart below on the right), both of which exceed the thresholds clinicians generally consider clinically meaningful, defined as a reduction in MG-ADL score of at least two points and a reduction in MGC score of at least three points. Additionally, at Month 6, one third of all participants were observed to achieve minimal symptom expression. This is consistent with what we observed in the Phase 2a trial, where deepest responses were observed to occur at Month 6 and Month 9.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:18pt"><img src="rnac-20241231_g4.jpg" alt="10-K Primary Endpoint.jpg" style="height:277px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, 80% of all participants who reached Month 12, including both responders and non-responders at Month 3, were observed to maintain clinically meaningful responses as measured by both MG-ADL and MGC. We also observed that 57% of the participants with no prior exposure to biologic therapy, achieved minimal symptom expression at Month 6. Of the two participants with no prior exposure to biologic therapy that reached Month 12, both were observed to maintain at least a clinically meaningful response with one continuing to maintain minimal symptom expression. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:18pt"><img src="rnac-20241231_g5.jpg" alt="10-K No prior biologics.jpg" style="height:294px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety profile observed in the follow-up portion of the Phase 2b trial was in line with what we reported at the time of our top line data readout as well as the Phase 2a portion of the trial. Of note, there was a Grade 2 upper respiratory infection reported in both the Descartes-08 and placebo groups. There were no other new adverse events, or AEs, reported, including no hypogammaglobulinemia and other infections and no difference in vaccine titers between Descartes-08 and placebo.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="text-align:center"><img src="rnac-20241231_g6.jpg" alt="10-K Safety Data.jpg" style="height:321px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously reported that there were three participants in the Phase 2a portion of the trial who were observed to have a response to Descartes-08, but then reverted to baseline, two patients one year after treatment and the other 1.5 years after treatment. As previously reported, there were two participants who were retreated and experienced rapid improvements in clinical scores and maintained minimum symptom expression for up to one year after receiving a second treatment cycle. The time course and magnitude of treatment response upon retreatment were similar to those seen when the participants were first treated. Notably, in the one participant who completed their 12-month retreatment follow-up visit, the duration of response was observed to be longer than that patient&#8217;s initial response, and this patient had maintained minimum symptom expression at Month 12. The third retreated participant, at their Month 2 visit, which was 2 weeks after their last Descartes-08 infusion, achieved a 4-point reduction in MG-ADL and 6-point reduction in MGC scores from baseline, without reports of CRS or ICANS. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="rnac-20241231_g7.jpg" alt="10-K retreated patients.jpg" style="height:310px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Descartes-08 for the Treatment of Systemic Lupus Erythematosus</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing Descartes-08 for the treatment of SLE, a chronic autoimmune disease that causes systemic inflammation which affects multiple organ systems.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Background Information About Systemic Lupus Erythematosus</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SLE is a chronic, immune-mediated connective tissue disease that can impact nearly all major organ systems. The most common manifestations of SLE are cutaneous and musculoskeletal symptoms, although neurological, gastrointestinal, hematological, and renal symptoms are regularly observed as well. Patients with SLE are at a substantially increased risk of infection and cardiovascular disease, contributing to estimated 10- and 15-year mortality rates of 9% and 15%, respectively. SLE is the most common form of lupus, representing approximately 70% of lupus patients, and approximately three million adults worldwide are estimated to have SLE.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Next Steps</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently initiated a multi-center open-label single-arm Phase 2 trial, for which we have received FDA IND allowance. The primary objective of this trial is to evaluate the safety, tolerability, and manufacturing feasibility of Descartes-08 mRNA CAR-T cells administered as six once-weekly outpatient infusions of 52.5x106 cells/kg without pre-treatment chemotherapy in approximately 30 patients with SLE. We also filed an amendment to the IND application with our Descartes-08 product candidate in pediatric autoimmune disease in December 2024. This Phase 2 SLE trial of Descartes-08 remains ongoing and a preliminary data readout is expected in the second half of 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Descartes-15</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using our proprietary technology and manufacturing platform, we designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. We believe this is a particularly important feature to increase the durability of CAR expression on the surface of these cells. We observed that Descartes-15 was 10-fold more potent than Descartes-08 in preclinical studies, as illustrated in the below charts. In November 2023, we received IND allowance from the FDA to initiate the Phase 1 trial to test the safety of Descartes-15 in patients with multiple myeloma and dosing is underway in this trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:18pt"><img src="rnac-20241231_g8.jpg" alt="dc-15 update.jpg" style="height:397px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Next Steps</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1 dose escalation trial is designed to assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma. Following the Phase 1 dose escalation trial, we expect to subsequently assess Descartes-15 in autoimmune indications. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established wholly-owned internal manufacturing and research and development capabilities, which allow us to optimize processes rapidly and in an iterative manner. Our main manufacturing facility is located in Frederick, Maryland, and operates under current good manufacturing practice, or cGMP. This facility has sufficient capacity to support current clinical needs and can potentially transition to support commercial manufacturing of our maturing pipeline of innovative mRNA cell therapies for the treatment of autoimmune diseases. We believe the Frederick facility will allow us to scale our wholly-owned, in-house cGMP manufacturing capabilities for late-stage clinical and commercial supply of our mRNA cell therapy product candidates, while continuing to maintain control over product quality and production. We also maintain  additional manufacturing space located in Gaithersburg, Maryland.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture Descartes-08 in-house and are typically able to process and release lots for infusion within approximately three weeks. Our autologous cell therapy product candidates, including Descartes-08, are manufactured on a patient-by-patient basis. We have optimized our manufacturing processes through over 200 cGMP runs. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain, maintain, protect, defend and enforce proprietary protection for our drug candidates and other discoveries, inventions, trade secrets and know-how that are critical to our business operations. Our success also depends in part on our ability to operate without infringing, misappropriating or otherwise violating the proprietary rights of others, and in part on our ability to prevent others from infringing, misappropriating or violating our proprietary rights. A discussion of risks relating to intellectual property is provided under the section titled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue developing intellectual property, and we intend to aggressively protect our position in key technologies. Our patents are focused on several key technologies, including the use of our mRNA CAR-T technology and other developments in our mRNA cell therapy pipeline. As of December 31, 2024, we had seven issued patents worldwide, including three patents issued in the United States (U.S. Patent Nos. 10,934,337, 11,220,535, and 11,999,773) and four patents issued outside the United States (Japanese Patent No. 7,379,654, Canadian Patent No. 3,158,025, Israeli Patent No. 285909, and Korean Patent No. 102588292. Our issued patents and any patents issuing from our pending applications are set to expire on various dates in 2040 through 2044. Additionally, as of December 31, 2024, we had 13 patent applications pending worldwide, including three U.S. applications, eight applications in ex-U.S. jurisdictions, and 2 International (PCT) applications. A patent granted on U.S. Patent Application No. 18/654,279 will expire on March 13, 2040, a patent granted on U.S. Patent Application No. 17/919,092 will expire on April 15, 2041, and a patent granted on U.S. Patent Application No. 18/292,670 will expire on July 28, 2042, barring any potential patent term adjustment or terminal disclaimers. These U.S. patent applications are directed to compositions of matter, and U.S. Patent Application No. 18/292,670 is also directed to methods of use. In addition, PCT/US2024/020251 was filed on March 15, 2024, a composition-of-matter and method-of-use PCT application, and any national stage application based on it will expire on March 15, 2044. Also, PCT/US2024/020815 was filed on March 20, 2024, a composition-of-matter and method-of-use PCT application, and any national stage applications based on it will expire on March 20, 2044. In addition, a patent granted on any of European patent application 20773688.5, AU 2020241428, CA 3199205, CN 202080020956.1, IN 202117036675, KR 2023-7034215, or MX/a/2021/011196 will expire March 2040 and a patent granted on European patent application 21789568.9 will expire April 2041. All of these patent applications are composition-of-matter applications.  In addition, we had two registered marks protecting our brand and prospective products both domestically and internationally. With respect to the legacy Selecta assets, as of December 31, 2024, we had (i) 102 issued patents worldwide, including 11 patents issued in the United States and 91 issued outside the United States, set to expire on various dates in 2032 through 2043, (ii) 65 patent applications pending worldwide, including 12 U.S. applications and 53 applications outside the United States and (iii) two registered marks. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on trade secrets, know-how, trademarks, confidential information, other proprietary information and continuing technological innovation to develop, strengthen and maintain our competitive position. We seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees, consultants, contractors and collaborators, third-parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality and invention assignment agreements upon the commencement of employment or consulting relationships with us. However, such confidentiality agreements can be breached, and we may not have adequate remedies for any such breach. For more information regarding the risks related to our intellectual property, see the section titled  &#8220;Risk factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Agreements</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biogen License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 8, 2023, we entered into a non-exclusive, sublicensable, worldwide, perpetual license agreement, or the Biogen Agreement, with Biogen MA, Inc., or Biogen, to research, develop, make, use, offer, sell and import products or processes containing or using an engineering T-cell modified with an mRNA comprising, or encoding a protein comprising, certain sequences licensed under the Biogen Agreement for the prevention, treatment, palliation and management of autoimmune diseases and disorders, excluding cancers, neoplastic disorders, and paraneoplastic disorders. We are not obligated to pay Biogen any expenses, fees, or royalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the Biogen Agreement for any reason or no reason, and Biogen may terminate the agreement after a notice-and-cure period of 30 days if we fail to pay a fee owed to Biogen or for any other material breach of the agreement. The Biogen Agreement will otherwise expire when all claims of all issued patents within the patents and patent applications licensed to us under the Biogen Agreement have expired or been finally rendered revoked, invalid or unenforceable by a decision of a court or government agency.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biogen Agreement encompasses patents and patent applications in the PCT/US2010/026825 patent family, which was filed March 10, 2010. In general, all patents that issue in this family have an expected expiration date of March 10, 2030, subject to potential patent term adjustments and/or extensions. For the U.S. patents and applications in this family, U.S. Patent 9,034,324 was awarded 677 days of patent term adjustment, which would extend the expiration date of this patent to January 16, 2032, absent any challenges to the patent term. The other issued patent in this family was not awarded any patent term adjustment, so its expected expiration date is March 10, 2030.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NCI License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 16, 2019, we entered into a non-exclusive, worldwide license agreement, or the NCI Agreement, with the U.S. Department of Health and Human Services, represented by the National Cancer Institute of the National Institutes of Health, or NCI.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NCI Agreement, we were granted a license under certain NCI patents and patent applications designated in the agreement, to make, use, sell, offer and import products and processes within the scope of the patents and applications licensed under the NCI Agreement when developing and manufacturing anti-BCMA CAR-T cell products for the treatment of MG, pemphigus vulgaris, and immune thrombocytopenic purpura according to methods designated in the NCI Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our entry into the NCI Agreement, we paid to NCI a one-time $100,000 license royalty payment. Under the NCI Agreement, we are further required to pay NCI a low five-digit annual royalty. We must also pay earned royalties on net sales in a low single-digit percentage and pay up to $0.8 million in benchmark royalties upon our achievement of designated benchmarks that are based on the commercial development plan agreed between the parties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NCI Agreement, we must use reasonable commercial efforts to bring licensed products and licensed processes to the point of Practical Application (as defined in the NCI Agreement). Upon our first commercial sale, we must use reasonable commercial efforts to make licensed products and licensed processes reasonably accessible to the United States public. After our first commercial sale, we must make reasonable quantities of licensed products or materials produced via licensed processes available to patient assistance programs and develop educational materials detailing the licensed products. Unless we obtain a waiver from NCI, we must have licensed products and licensed processes manufactured substantially in the United States. Prior to the first commercial sale, upon NCI&#8217;s request, we are obligated to provide NCI with commercially reasonable quantities of licensed products made through licensed processes to be used for in vitro research.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we must use reasonable commercial efforts to initiate a Phase 3 clinical trial of a licensed product by the fourth quarter of 2024, submit a BLA with respect to a licensed product by the fourth quarter of 2026, and make a first commercial sale of a licensed product by the fourth quarter of 2028.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NCI Agreement terminates upon the expiration of the last to expire of the patent rights licensed thereunder, if not sooner terminated. The NCI License Agreement encompasses patents and patent applications in the PCT/US2013/032029 patent family, which was filed March 15, 2013. In general, all patents that issue in this family have an expected expiration of March 15, 2033, subject to potential patent term adjustments and/or extensions. For the U.S. patents and applications in this family, only two patents were awarded patent term adjustments. U.S. Patent 9,765,342 was awarded 297 days of patent term adjustment, which would extend the expiration date of this patent to January 6, 2034, absent any challenges to the patent term. The other patent, U.S. Patent 10,876,123, was awarded three days of patent term adjustment, but this patent is subject to terminal disclaimers filed against other family members, so this patent will not extend beyond the March 15, 2033 date. The other issued patents in this family were not awarded any patent term adjustment, so the expected expiration date for these patents also remains March 15, 2033. There is also a pending patent application which, if issued, will expire on March 15, 2033, but could also be subject to patent term adjustment and to any potential future terminal disclaimers.  NCI has the right to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminate this agreement, after giving written notice and providing a cure period in accordance with its terms, if we are in default of a material obligation. We have the unilateral right to terminate the agreement in any country or territory by giving NCI 60 days&#8217; written notice. We agreed to indemnify NCI against any liability arising out of our, sublicensees&#8217; or third-parties&#8217; use of the licensed patent rights and licensed products or licensed processes developed in connection with the licensed patent rights.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sobi License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, we entered into a License and Development Agreement with Swedish Orphan Biovitrum AB (publ.), or Sobi, which was amended on October 31, 2023, or, as so amended, the Sobi License. Pursuant to the Sobi License, we granted Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize a drug candidate known as SEL-212, which is currently in development for the treatment of chronic refractory gout. Pursuant to the Sobi License, Sobi agreed to make milestone payments totaling up to $630.0 million to us upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier. Any proceeds received from milestone payments or royalties relating to the Sobi License would be required to be distributed to holders of CVRs, net of certain deductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transactions contemplated by the Sobi License were consummated on July 28, 2020. Sobi may terminate the Sobi License for any reason upon 180 days&#8217; written notice, whereby all rights granted under the Sobi License would revert back to us. In addition, if Sobi were to terminate the Sobi License, we have the option to obtain a license to all patents and know-how necessary to exploit SEL-212 in existence as of the termination date from Sobi in return for making an equitable royalty payment to Sobi.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future. Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of any other cell therapy product candidates that we develop, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic or biosimilar products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descartes-08 may compete with products of other companies in the MG market, including Argenx SE, UCB S.A., Johnson &amp; Johnson, Alexion Pharmaceuticals, Inc. and Cabaletta Bio, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies developing CAR-T therapies include large, fully integrated pharmaceutical companies such as Novartis AG, Gilead Sciences, Inc., through its Kite Pharma, Inc. subsidiary, Bristol-Myers Squibb Company, AstraZeneca PLC and Janssen Pharmaceuticals, Inc. and biopharmaceutical companies such as Kyverna Therapeutics, Inc. and Cabaletta Bio, Inc.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our cell therapy product candidates are subject to regulation in the United States as &#8220;biologics&#8221; or &#8220;biological products.&#8221; We expect to seek approval of Descartes-08 through a single BLA reviewed by FDA&#8217;s Center for Biologics Evaluation and Research, or CBER.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or the FD&amp;C Act, and the Public Health Service Act, or the PHS Act, and other federal, state, local and foreign statutes and regulations. Descartes-08 and any other product candidates that we develop must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regard our mRNA-modified products as cell therapy products and not as genetic engineering or gene therapy products, because mRNA modifications are not embodied in DNA or incorporated into a genome. However, it is possible that in some jurisdictions, regulations on genetic engineering or genetic therapy may intentionally or unintentionally apply to our technology. This could create additional regulatory burden.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Biological Products Development Process</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a biologic, including a cell therapy, may be marketed in the United States is summarized below.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biological product candidates are preclinically tested before any testing is done in humans. These tests, or non-clinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal requirements including good laboratory practices, or GLPs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical study sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND which must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical study on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns, non-compliance with regulatory requirements, or other issues. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. In addition to these requirements, biological product candidates may also require evaluation and assessment by an institutional biosafety committee, or IBC, that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at an institution participating in a clinical trial..</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are conducted under protocols detailing the objectives of the clinical study, dosing procedures, patient selection and exclusion criteria, and the parameters to be used to monitor patient safety. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations, including with respect to good clinical practice, or GCP, requirements, including the requirement that all research subjects provide informed consent. Further, each clinical study must be reviewed and approved by an institutional review board, or IRB, at or servicing each institution at which the clinical study will be conducted. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1. The biological product candidate is evaluated in a limited population of patients or healthy volunteers to identify the maximum tolerated dose, recommended Phase 2 dose, possible adverse effects and safety risks. For the types of products and therapeutic areas we focus on, Phase 1 studies will generally be done in patients and not healthy volunteers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2. The biological product candidate is evaluated in a broader population to evaluate safety further and preliminarily evaluate the efficacy of the product for specific targeted diseases, and to determine the optimal dosing schedule.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell and gene therapy products may differ from the traditional clinical trial phases. For example, clinical trials for cell and gene therapy products are often structured as a hybrid Phase 1/2 trial where a small group of participants with the disease are enrolled and both safety and efficacy tests are performed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the SPA process, a sponsor may seek agreement from the FDA on critical features of a proposed protocol for their adequacy to support marketing approval. In response to a request for an SPA agreement, the FDA issues a letter to the sponsor indicating its agreement or non-agreement with elements of the proposed protocol. An SPA agreement documents the FDA&#8217;s concurrence with the adequacy and acceptability of specific critical elements of the protocol design, and the FDA may not change an SPA agreement once the trial is underway unless the sponsor or applicant agrees in writing or the FDA identifies a </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial scientific issue essential to determining the safety or effectiveness of the drug after the testing has begun. Even if the sponsor conducts the trial in accordance with an SPA agreement and the trial meets its endpoints with statistical significance, there is no guarantee that the FDA will accept or approve a marketing application. For example, the FDA could determine that the overall balance of risks and benefits for the product candidate is not adequate to support approval, or only justifies approval for a narrow set of clinical uses or approval with restricted distribution or other post-approval requirements or limitations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or the sponsor or a separate data safety monitoring board may suspend or terminate a clinical study at any time on various grounds. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product candidate has been associated with unexpected serious harm to patients or otherwise in the interest of patient welfare.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors of clinical trials of FDA-regulated products, including biologics, are also required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the completion of clinical trials of a biological product candidate, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal trials, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain a pediatric assessment unless the applicant has obtained a waiver or deferral. Pediatric assessment contains data gathered from pediatric studies using appropriate formulations for each age group for which the assessment is required and other data adequate to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors with an application for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration must submit an initial Pediatric Study Plan, or PSP, (or a deferral or waiver, as appropriate) within 60 days of an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug Fee User Act, as amended, or PDUFA, each BLA must be accompanied by a substantial user fee. Fee waiver or reductions are available under certain circumstances, including for the first application filed by a small business. In addition, no user fees are assessed on BLAs on products designated as orphan drugs unless the product also includes a non-orphan indication.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 60 days following submission of the application, the FDA conducts a preliminary review of a BLA to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information before deciding whether to accept a BLA for filing. The FDA may refuse to file any BLA that it deems incomplete or otherwise not reviewable and may request additional information. If the submission is accepted for filing, the FDA substantively reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, and manufactured in accordance with appropriate procedures and controls to ensure product quality. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a non-binding recommendation on approval. The FDA may waive the review by an advisory committee and is not bound by the recommendation of an advisory committee, but it often follows such recommendations. During the biological product approval process, the FDA also will review proposed product labeling and will determine whether a Risk Evaluation and Mitigate Strategy, or REMS, is necessary to assure the safe use of the biological product candidate. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will inspect the facilities in which the product is manufactured to determine whether the manufacturing processes and facilities are in compliance with cGMPs. The FDA may also audit the clinical investigation sites to determine that they have complied with GCPs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the submission of relevant data and information, the FDA may ultimately deny approval or seek additional information from the applicant. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than the applicant interprets the same data. The FDA may also raise questions about product manufacturing and quality control. If the FDA denies approval of a BLA in its then-current form, the FDA will issue a complete response letter detailing deficiencies in the application. If a response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the performance goals agreed to by the FDA under PDUFA is to review 90% of standard BLAs in 10 months from the filing date and 90% of priority BLAs in six months from the filing date, whereupon a review decision is to be made. Two </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional months are added to these timelines for new molecular entities. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Designation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the submission of a BLA, the FDA may grant orphan designation to drugs or biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and marketing the product for this type of disease or condition will be recovered from sales in the United States. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan exclusivity, which means the FDA may not approve any other application to market the &#8220;same drug&#8221; for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer with orphan exclusivity is unable to assure sufficient quantities of the approved orphan product. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same biological product as defined by the FDA or if our product candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descartes-08 has been granted Orphan Drug Designation for the treatment of MG..</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA offers various programs, including the Fast Track program, Breakthrough Therapy designation, and the RMAT designation that are intended to expedite or facilitate the process for reviewing new biological products that meet certain criteria. Specifically, new biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biologic may request that the FDA designate the biologic as a Fast Track product at any time during the clinical development of the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of treatment, diagnosis, or prevention compared to available therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, a product may be eligible for accelerated approval. The FDA may approve a product for a serious or life-threatening disease or condition based on a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a biological product subject to accelerated approval perform adequate and well-controlled post-marketing clinical studies to confirm such benefit. The Food and Drug Omnibus Reform Act of 2022, or FDORA, added the failure to conduct post-approval studies with due diligence or to submit timely progress reports on such studies to the list of prohibited acts under the FD&amp;C Act, which means that any such failures, whether they result from a sponsor&#8217;s actions or the actions of third-parties, could provide the basis for enforcement actions. In addition, the FDA currently requires as a condition for accelerated approval that promotional materials be submitted prior to use, which could adversely impact the timing of the commercial launch of the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the provisions of The Food and Drug Safety and Innovation Act, or FDASIA, the FDA established a Breakthrough Therapy Designation which is intended to expedite the development and review of products that treat serious or life-threatening diseases or conditions. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the features of Fast Track designation, as well as more intensive FDA interaction and guidance. Fast Track, priority review, accelerated approval, and breakthrough therapy designations do not change the standards for approval and may not necessarily expedite the development or approval process.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the 21st Century Cures Act established what the FDA describes as RMAT designation. The RMAT designation program is intended to facilitate an efficient development program for, and expedite review of, any product that meets the following criteria: (i) the product qualifies as an RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (ii) the product is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii) preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides all the benefits of Breakthrough Therapy Designation, including early interactions to discuss any potential surrogate or intermediate endpoints to be used to support accelerated approval, eligibility for rolling review and potential eligibility for priority review. Product candidates granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of clinical trial sites, including through expansion of trials to additional sites, as appropriate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descartes-08 has been granted RMAT designation for the treatment of MG.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-approval Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to cGMP requirements. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biological products include record-keeping requirements, reporting of adverse effects and reporting updated safety and efficacy information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, known as &#8220;off-label use,&#8221; and the requirement to balance information provided about a product&#8217;s benefits with important safety information. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions, expensive and onerous government investigations, and adverse publicity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conventional DNA-modified CAR-T cell products have been subject to extensive post-approval surveillance requirements. Because the mRNA of our products is temporary, we do not believe that our mRNA-modified products will be subject to requirements of this nature, although other post-approval requirements will apply.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars and Exclusivity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, or ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical study or studies. The FDA has approved a number of products under these provisions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To our knowledge, the definition of &#8220;biosimilar&#8221; with regard to an mRNA-modified cell therapy has not been expressly stated in statute, regulation, or guidance, and has not been reviewed by a court. The regulatory pathway for a biosimilar to one of our products thus remains somewhat uncertain.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. A biological product may also obtain pediatric exclusivity in the United States. For a biological product, pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods. This six-month exclusivity, which runs from the end of other exclusivity protection, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study or studies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA is complex and continues to be interpreted and implemented by the FDA. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Regulation Outside of the United States</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in countries outside the United States prior to the commencement of clinical studies or marketing of the product in those countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements and process governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Economic Area, or EEA, which is composed of the 27 member states of the European Union, or EU, plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. To obtain an MA in the EEA, we must submit a marketing authorization application, which is similar to the U.S. BLA. There are two types of MAs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU MA, which is issued by the European Commission through the Centralized Procedure, is based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced therapy medicinal products (comprising gene therapy, somatic cell therapy and tissue engineered products), among others. The Centralized Procedure is optional for other products containing a new active substance not yet authorized in the EEA, or for other products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. Under the Centralized Procedure the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases. Under the accelerated procedure the standard 210 days review period is reduced to 150 days.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EU law also provides opportunities for market exclusivity. Upon receiving MA, &#8220;new active substances&#8221; generally receive eight years of data exclusivity, which prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic or biosimilar application, and an additional two years of market exclusivity, during which no generic or biosimilar product can be marketed. The ten years of exclusivity will be extended to a maximum of eleven years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new active substance which would be eligible for the relevant periods of data and market exclusivity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (i) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for certain financial and exclusivity incentives. In particular, orphan medicinal products in the EU can receive ten years of market exclusivity, during which time no MA application shall be accepted, and no MA shall be granted for a similar medicinal product for the same indication. The 10-year market exclusivity for orphan medicinal products may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation. Additionally, MA may be granted to a similar product during the 10-year period of market exclusivity for the same therapeutic indication at any time in certain circumstances, including if the second applicant can establish in its application that its product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, for any new medicinal product that is protected by or eligible for a supplementary protection certificate, pediatric clinical trials must be conducted in accordance with a pediatric investigation plan, or PIP, that has been approved by the EMA. Normally, the pediatric clinical trials must be completed before the initial MA application for the relevant indication.  However, the EMA may grant a deferral of the studies in order not to delay the approval of the product in adults and the EMA may waive the requirement to conduct studies in certain circumstances, such as if the relevant condition does not occur in </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">children.  If pediatric clinical trials are completed in accordance with an agreed PIP, the product will be entitled to a six-month extension of its supplementary protection certificate.  However, if the product is authorized as an orphan medicinal product, it is entitled to a two-year extension of its 10 years of orphan exclusivity and not to an extension of the supplementary protection certificate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When conducting clinical trials in the EU, we must adhere to the provisions of the EU Clinical Trials Regulation (EU) No 536/2014. If the sponsor of the clinical trial is not established within the EU, it must appoint an entity within the EU to act as its legal representative, who shall be responsible for ensuring compliance with the sponsor&#8217;s obligations under the Regulation and be the addressee for all communications. The sponsor must take out a clinical trial insurance policy, and in most EU countries the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to commencing a clinical trial in the EU, we must obtain a clinical trial authorization, or CTA, in each Member State in which the trial will be conducted.  There is a centralized application procedure where one national authority leads the scientific review of the application, while each concerned member state complete an ethical review of any CTA. The application for a CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Any substantial changes to the trial protocol or other information submitted with the CTAs must be notified to or approved by the relevant competent authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to data privacy and security laws in the jurisdictions outside of the U.S. in which we are established, run clinical trials or in which we sell or market our products once approved. For example, in Europe we are subject to Regulation (EU) 2016/679 (General Data Protection Regular, or GDPR) in relation to our collection, control, processing and other use of personal data (i.e., data relating to an identifiable living individual). We process personal data in relation to participants in our clinical trials in the EEA, including the health and medical information of these participants. The GDPR is directly applicable in each EU Member State, however, it provides that EU Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data (including health and medical information), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. The GDPR imposes accountability and transparency obligations regarding personal data. We are also subject to EU rules with respect to cross-border transfers of personal data out of the EU and EEA. We are subject to the supervision of local data protection authorities in those EU jurisdictions where we are established or otherwise subject to the GDPR. A breach of the GDPR could result in significant fines, regulatory investigations, reputational damage, orders to cease/ change our use of data, enforcement notices, as well potential civil claims including class action type litigation where individuals suffer harm. Moreover, the United Kingdom leaving the EU could also lead to further legislative and regulatory changes. It remains unclear how the United Kingdom data protection laws or regulations will develop in the medium to longer term and how data transfer to the United Kingdom from the EU will be regulated. However, the United Kingdom has transposed the GDPR into domestic law with the Data Protection Act 2018, which remains in force following the United Kingdom&#8217;s departure from the EU.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly (regardless of knowledge of this specific statute) and willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, formulary managers, and other third-parties on the other. The majority of states also similar have anti-kickback laws, which in some cases apply to items and services reimbursed by private insurance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal false claims and civil monetary penalties laws, including the civil False Claims Act, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Manufacturers can be held liable under false claims laws, even if they do not submit claims to the government, where they are found to have caused submission of false claims by, among other things, providing incorrect coding or billing advice about their products to customers that file claims, or by engaging or off-label promotion to customers that file claims. Violation of the federal Anti-Kickback Statute may also constitute a false or fraudulent claim for purposes of the federal civil False Claims Act. Actions under the civil False Claims Act may be brought by the Department of Justice or as a qui tam action </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by a private individual in the name of the government. Many states also have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Physician Payments Sunshine Act requires applicable manufacturers to annually report certain payments and &#8220;transfers of value&#8221; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care providers, as well as ownership and investment interests held by physicians and their immediate family members.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanctions under these federal and state fraud and abuse laws may include civil monetary penalties and criminal fines, exclusion from government healthcare programs, and imprisonment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health act of 2009, or HITECH, and their respective implementing regulations, impose specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates. Among other things, HITECH made HIPAA&#8217;s security standards directly applicable to, as well as imposed certain other privacy obligations on, &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Even when HIPAA does not apply, according to the Federal Trade Commission, or FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a).</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological products for which we obtain regulatory approval. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities, managed care plans, private health insurers and other organizations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for determining whether a third-party payor will provide coverage for a pharmaceutical or biological product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decision by a third-party payor not to cover our product candidates could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#8217;s decision to provide coverage for a pharmaceutical or biological product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. The EU recently adopted Regulation (EU) 2021/2282 on health technology assessment, which provides a framework for Member States to cooperate on health technology assessments at the EU level. The regulation is directly applicable in all EU Member States which is in a phased period of applicability since January 12, 2025, although pricing will still be determined nationally. Moreover, at the national level, EU Member States may restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Member States may approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products in the marketplace. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel trade (arbitrage between low-priced and high-priced member states) can further reduce prices. Special pricing and reimbursement rules may apply to orphan drugs. Inclusion of orphan drugs in reimbursement systems tend to focus on the medical usefulness, need, quality and economic benefits to patients and the healthcare system as for any product. Acceptance of any medicinal product for reimbursement may come with cost, use and often volume restrictions, which again can vary by country. In addition, results-based rules of reimbursement may apply. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and local governments in the U.S. have established and continue to consider policies to limit the growth of healthcare costs, including the cost of prescription drugs. Recently there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for prescription drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the federal level, for example, the Inflation Reduction Act of 2022, or IRA, was signed into law. Key provisions of the IRA include the following, among others:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The IRA requires manufacturers to pay rebates for Medicare Part B and Part D drugs whose price increases exceed inflation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The IRA eliminates the so-called &#8220;donut hole&#8221; under Medicare Part D beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees&#8217; prescription costs for brand drugs below the out-of-pocket maximum and 20% once the out-of-pocket maximum has been reached.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The IRA delays the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The IRA directs the Centers for Medicare and Medicaid Services, or CMS, to engage in price-capped negotiation for certain Medicare Part B and Part D products. Specifically, the IRA&#8217;s Price Negotiation Program applies to high-expenditure single-source drugs and biologics that have been approved for at least seven or 11 years, respectively, among other negotiation selection criteria, beginning with 10 high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The negotiated prices will be capped at a statutorily determined ceiling price. There are certain statutory exemptions from the IRA&#8217;s Price Negotiation Program, such as for a drug that has only a single orphan drug designation and is approved only for an indication or indications within the scope of such designation. The IRA&#8217;s Price Negotiation Program is currently the subject of legal challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties or a potential excise tax. The IRA permits the Secretary of Health and Human Services, or the HHS Secretary, to implement many of the IRA&#8217;s provisions through guidance, as opposed to regulation, for the initial years. The effect of the IRA is anticipated to have significant effects on the pharmaceutical industry and may reduce the prices pharmaceutical manufacturers can charge and reimbursement pharmaceutical manufacturers can receive for approved products, among other effects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States. This included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013, and, due to subsequent legislative amendments, will stay in effect through 2027 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals and imaging centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump Administration has discussed several changes to the reach and oversight of the FDA, which could affect its relationship with the biotechnology and pharmaceutical industries, transparency in decision making and ultimately the cost and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">availability of prescription drugs. Drug pricing is an active area for regulatory reform at both the federal and state levels, and additional significant changes to current drug pricing and reimbursement structures in the U.S. could be forthcoming. It remains unclear how any new legislation or regulation might affect the prices we may obtain for any of our product candidates for which regulatory approval is obtained.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employees and Human Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Cartesian Therapeutics, we consider human capital to be an essential driver of our business and successful strategy creation and execution. Our people, driven by our collaborative, pioneering, and patient-focused culture, propel our business forward, strengthening us for long-term success.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had 66 full-time employees, 54 of whom are primarily engaged in research and development activities and 12 of whom are primarily engaged in corporate functions. 58% of our employees have at least one of a Masters, PhD, or MD degree. All employees reside and work in the United States and our employees are not represented by a labor union. We consider our employee relations to be strong and in good standing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to continually engage our talented and diverse workforce to drive value creation both for our business and ultimately our patient populations. We believe in a proactive approach to talent management focusing on retention of key talent, critical role successor identification, and impactful employment development. Additional priority areas intended to drive engagement include successful recruitment of diverse talent, continual promotion of professional development at all levels, introduction, and evolution of business-friendly human resources solutions, coupled with an intentional culture dialog aimed to drive a high engagement, high performance, patient centric culture.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive attraction and retention of our high-quality, experienced, and diverse workforce, we invest in the physical, emotional, and financial well-being of our employees. These investments include a competitive mix of compensation and generous insurance benefits. To assist employees with the rising cost of healthcare, we pay 100% of an employee&#8217;s deductible and co-insurance payments. All employees are eligible to participate in our equity compensation programs. All employees are awarded new hire equity and annual equity. Employees are also eligible to receive an annual cash bonus and to participate in a 401(k) retirement plan with an industry competitive company match.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and other information. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at http://www.sec.gov. We make available on our website at www.cartesiantherapeutics.com, free of charge, copies of these reports as soon as reasonably practicable after filing or furnishing these reports with the SEC. Additionally, our Code of Business Conduct and Ethics is available on our website. The hyperlink to our website is included as an inactive textual reference only, and the information on our website is not incorporated by reference in this Annual Report on Form 10-K or in any other filings we make with the SEC.</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_25"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves various risks. You should carefully read and consider the matters discussed in this Annual Report under the heading &#8220;Risk Factors,&#8221; which include the following risks: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">We are a development-stage company, and we expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding in order to complete development of our product candidates and commercialize our products, if approved. If we are unable to raise capital when needed and on terms favorable to us, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We develop our mRNA-based product candidates by leveraging our proprietary technology and our manufacturing platform, which is an unproven approach to the treatment of autoimmune disease. We are early in most of our clinical development efforts and may not be successful in our efforts to build a pipeline of product candidates and develop marketable drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical drug development is inherently risky and involves a lengthy and expensive process, which is subject to a number of factors, many of which are outside of our control. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to continue to grow our manufacturing capabilities and resources and we must incur significant costs to develop this expertise and/or rely on third-parties to manufacture our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely, and expect to continue to rely, on third-parties, including CROs, to conduct our clinical trials, and those third-parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or our licensors are unable to adequately protect our proprietary technology, or obtain and maintain issued patents that are sufficient to protect our product candidates, others could compete against us more directly, which would negatively impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have been in the past and may in the future be subject to stockholder litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_28"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.  Risk Factors </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should consider carefully the risks described below, together with the other information included or incorporated by reference in this Annual Report. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_34"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development of our Product Candidates</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We develop our mRNA-based product candidates by leveraging our proprietary technology and our manufacturing platform, which is an unproven approach to the treatment of autoimmune disease. We are early in most of our clinical development efforts and may not be successful in our efforts to build a pipeline of product candidates and develop marketable drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mRNA approach to develop product candidates for the treatment of autoimmune diseases is an unproven approach. Our most advanced product candidate, Descartes-08, is in the initial phase of Phase 3 clinical development. We have not demonstrated the ability to successfully complete any Phase 3 or other pivotal clinical trials, obtain regulatory approvals, manufacture a commercial product, or arrange for a third-party to do so on our behalf, or conduct other sales and marketing activities necessary for successful product commercialization. We may have problems identifying new product candidates and applying our technologies to other areas. Even if we are successful in identifying new product candidates, they may not be suitable for clinical development, including as a result of manufacturing difficulties, harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. The success of our product candidates will depend on several factors, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design, initiation and completion of preclinical studies and clinical trials with positive results;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on third-parties, including but not limited to collaborators, licensees, clinical research organizations and contract manufacturing organizations;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates and not infringing or violating patents or other intellectual property of third-parties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturability, manufacturing, logistics, and stability of our cell therapies, including autologous cell therapies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">growing our internal cGMP manufacturing capabilities to support commercial manufacturing or making arrangements with third-party manufacturers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our products, if and when approved, by patients and the medical community;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our products, if approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining an acceptable safety profile of our products following approval; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining and growing an organization of scientists and businesspeople who can develop and commercialize our product candidates and technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully execute on of any of the foregoing for any reason would effectively prevent or delay approval of our lead and other product candidates.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development is inherently risky and involves a lengthy and expensive process which is subject to a number of factors, many of which are outside of our control. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development is expensive, time consuming and involves significant risk. It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval, and the risk of failure through the development process is high. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete manufacturing and preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Manufacturing cell therapies, particularly those modified with mRNA, is a new field.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical development is costly and inherently uncertain. Early preclinical results may not be predictive of future results, however, if our technology proves to be ineffective or unsafe as a result of, among other things, adverse side effects, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the clinical development and commercialization of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidate for its intended indications. Clinical testing is expensive, difficult to design and implement, can take many years to complete and its outcome is inherently uncertain. A failed clinical trial can occur at any stage of testing. Moreover, the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, we may not be able to complete, or may be required to deviate from the current clinical trial protocol for a variety of reasons.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positive results in preclinical development or early-stage clinical trials, and we cannot be certain that we will not face similar setbacks. Serious adverse events</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SAEs, caused by, or other unexpected properties of, any product candidates that we may choose to develop could cause us, an institutional review board or regulatory authority to interrupt, delay or halt clinical trials of one or more of such product candidates and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable non-U.S. regulatory authorities. If any product candidate that we may choose to develop is associated with SAEs or other unexpected properties, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which those undesirable characteristics would be expected to be less prevalent, less severe or more tolerable from a risk-benefit perspective. Moreover, preclinical and clinical data is often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory authority approval. If we fail to produce positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be negatively impacted.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot be certain as to what type and how many clinical trials the FDA will require us to conduct before we may gain regulatory approval to market any of our product candidates in the United States or other countries, if any. Prior to approving a new therapeutic product, the FDA generally requires that safety and efficacy be demonstrated in two adequate and well-controlled clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval for, or commercialize, our product candidates, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce unfavorable, incomplete or inconclusive results;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to manufacture our product candidates, which in some cases such as mRNA CAR-T, are manufactured on a patient-by-patient basis;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or may place a clinical hold on existing clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with CROs or clinical trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to recruit suitable patients to participate in a clinical trial, the number of patients required for clinical trials of our product candidates may be larger than we expect, enrollment in these clinical trials may be slower than we expect or participants may drop out of these clinical trials at a higher rate than we expect, or enrollment could be affected by unforeseen geopolitical conflict;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of clinical trial sites required for clinical trials of our product candidates may be larger than we expect;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investigators, regulators, data safety monitoring boards or institutional review boards may require that we or our investigators suspend or terminate clinical research, or we may decide to do so ourselves;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investigators may deviate from the trial protocol, fail to conduct the trial in accordance with regulatory requirements or misreport study data;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we expect or we may have insufficient resources to pursue or complete certain aspects of our clinical trial programs or to do so within the timeframe we planned;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of raw materials or manufactured product candidates (whether provided by us or third-parties) or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or in a timely manner, or we may experience interruptions in supply;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratories that we rely upon to perform certain quality control tests may become unavailable, or their services could be delayed;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we expect;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our clinical trial design or our interpretation of data from preclinical studies and clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design of our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regarding trials managed by our existing or any future collaborators, our collaborators may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but potentially suboptimal for us; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">geopolitical events may affect international and overseas trial sites in ways beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, or if we are forced to delay or abandon certain clinical trials or other testing in order to conserve capital resources, we may:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for our product candidates, if at all;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain marketing approval in some countries and not in others;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have a product removed from the market after obtaining marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated. Authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in clinical testing or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In addition, from time to time our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which could cause the value of our common stock to decline and limit our ability to obtain additional financing.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may conduct clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations or the complexity of regulatory burdens may otherwise adversely impact us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening and conducting clinical trials at trial sites outside the United States may involve additional regulatory, administrative and financial burdens, including compliance with foreign and local requirements relating to regulatory submission and clinical trial practices. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with GCPs and the FDA must be able to validate the data from the trial through an onsite inspection, if necessary. Generally, the patient population for any clinical trials conducted outside the United States must be representative of the population for which we intend to seek approval in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. Nonetheless, there can be no assurance that the FDA will accept data from trials conducted outside the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay or permanently halt our development of any applicable product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional risks inherent in conducting international clinical trials include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign regulatory requirements that could burden or limit our ability to conduct our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased costs and heightened supply constraints associated with the acquisition of standard of care drugs and/or combination or comparator agents for which we may bear responsibility in certain jurisdictions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">administrative burdens of conducting clinical trials under multiple foreign regulatory schema;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign exchange fluctuations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">more burdensome manufacturing, customs, shipment and storage requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cultural differences in medical practice and clinical research;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of consistency in standard of care from country to country;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminished protection of intellectual property in some countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in country or regional regulatory requirements; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">geopolitical instability or wars in regions outside of the United States where we conduct clinical trials may impact ongoing clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to qualify for or obtain various designations from regulators that would have the potential to expedite the review process of one or more of our product candidates and even if we do receive one or more such designations there is no guarantee that they will ultimately expedite the process, or aid in our obtaining marketing approval or provide market exclusivity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There exist several designations that we can apply for from the FDA and other regulators that would provide us with various combinations of the potential for expedited regulatory review, certain financial incentives as well as the potential for post-approval exclusivity for a period of time. These designations include but are not limited to orphan drug designation, breakthrough therapy designation, accelerated approval, fast track status and priority review for our product candidates. For example, Descartes-08 has been granted Orphan Drug Designation and RMAT Designation by the FDA for the treatment of MG. Descartes-08 also received Rare Pediatric Disease Designation by the FDA for the treatment of JDM. We expect to seek one or more of these designations for our other current and future product candidates. There can be no assurance that any of our other product candidates will qualify for any of these designations. There can also be no assurance that any of our product candidates that do qualify for these designations will be granted such designations or that the FDA will not revoke a designation it grants at a later date, or that Congress will not change the law about a designation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there can be no assurance that any of our product candidates that are granted such designations, including Descartes-08, will ever benefit from such designations or that the FDA would not withdraw such designations once granted. Were we to receive a designation that promised a period of market exclusivity, such as orphan drug exclusivity, such exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. In particular, the scope of exclusivity afforded for mRNA-modified cell therapy products may not be well defined. Further with respect to orphan drug status, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim, top-line or preliminary data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a full analyses of all data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim, top-line or preliminary data may not be representative of final data. If final data is not as positive as earlier interim, top-line or preliminary we have released, our business prospects would be significantly harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. As a result, preliminary and top-line data should not be relied upon in making an investment decision in our securities.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials, could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities and could result in decreased market acceptance of any of our product candidates, if approved. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, our </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FDA issued a statement that it is investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous CAR-T cell immunotherapies. While the FDA noted that it currently believes that the overall benefits of these products continue to outweigh their potential risks for their approved uses, the FDA stated that it is investigating the identified risk of T-cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action. Further, in January 2024, the FDA announced it would require a so-called &#8220;boxed warning&#8221; be added to the prescribing information for all six then-currently approved CAR-T therapies. A boxed warning is the strongest safety labeling the FDA may require. However, because all currently approved CAR T-cell immunotherapies are in oncology indications, there can be no assurance that FDA will reach the same risk-benefit analysis in other indications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe our mRNA-based CAR-T product candidates may have a differentiated toxicity profile than currently approved DNA-based CAR-T therapies, there can be no assurance that the FDA would not treat Descartes-08 or any of our other product candidates similar to approved DNA-based CAR-T therapies. The FDA&#8217;s investigation may impact the FDA&#8217;s review of product candidates that we are developing, or that we may seek to develop in the future, which may, among other things, result in additional regulatory scrutiny of our product candidates, delay the timing for receiving any regulatory approvals or impose additional post-approval requirements on any of our product candidates that receive regulatory approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any drug-related side effects observed in our clinical trials could also affect patient enrollment in our clinical trials or the ability of any enrolled patients to complete such trials or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such product;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a boxed warning or a contraindication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may impose additional restrictions on the marketing of, or the manufacturing processes for, the particular product;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients, or become subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be required to develop a risk evaluation and mitigation strategies, or REMS, plan to prevent, monitor and/or manage a specific serious risk by informing, educating and/or reinforcing actions to reduce the frequency and/or severity of the event.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA and other government agencies and/or potentially shifting priorities under the new presidential administration could hinder the FDA&#8217;s and/or those other government agencies&#8217; ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products, provide feedback on clinical trials and development programs, meet with sponsors and otherwise review regulatory submissions can be affected by a variety of factors, including government budget and funding levels; ability to hire and retain key personnel and accept the payment of user fees; and statutory, regulatory, and policy changes, among other factors. Average review times at the FDA may fluctuate as a result. In addition, government funding of other government agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also increase the time necessary for new drugs to be reviewed and/or approved by necessary government agencies or to otherwise respond to regulatory submissions, which would adversely affect our business. For example, the Trump Administration has discussed several changes to the reach and oversight of the FDA, which could affect its relationship with the pharmaceutical industry, transparency in decision making and ultimately the cost and availability of prescription drugs.  Additionally, over the last several years, the U.S. government has shut down multiple times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and stop critical activities. If funding for the FDA is reduced, FDA priorities change or a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have in the past received grant funding from the National Institutes of Health, or NIH, and under the terms of previously awarded grants we expect to continue to receive grant funding from the NIH. Although we do not consider any of these grants material to our business, a prolonged impact on the availability of grant funding from government agencies could adversely impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing and our Dependence on Third-Parties </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to grow our manufacturing capabilities and resources and we must incur significant costs to develop this expertise and/or rely on third-parties to manufacture our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have growing manufacturing capabilities, and in order to continue to develop our current product candidates, apply for regulatory approvals and, if approved, commercialize future products, we will need to continue to develop, contract for, or otherwise arrange for any necessary external manufacturing capabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture our product candidates internally. There are risks inherent in biological manufacturing and we may not meet our delivery time requirements or provide adequate amounts of material to meet our needs, and we may make errors in manufacturing, any of which could delay our clinical trials and result in additional expense to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our autologous cell therapy product candidates, including Descartes-08, are made on a patient-by-patient basis, rendering their manufacture less predictable and requiring more demanding logistics.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on one or more third-party laboratories to perform certain quality control tests. These laboratories could become unavailable, or provision of their services could be delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as we scale up our manufacturing, we may encounter further challenges. Furthermore, competition for supply from our manufacturers from other companies, a breach or violation by such manufacturers of their contractual or regulatory obligations or a dispute with such manufacturers would cause delays in our discovery and development efforts, as well as additional expense to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In developing manufacturing capabilities by building our own manufacturing facilities, we have incurred substantial expenditures, and expect to incur significant additional expenditures in the future. Also, we have had to, and will likely need to continue to recruit, hire, and train qualified employees to staff our facilities. If we are unable to manufacture sufficient quantities of material or if we encounter problems with our facilities in the future, we may also need to secure alternative suppliers, and such alternative suppliers may not be available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner. In addition, to the extent we or our partners rely on contract manufacturing organizations, or CMOs, to supply our product candidates, any delays or disruptions in supply could have a material adverse impact on the research and development activities and potential commercialization of our or our partners&#8217; product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for any products that we may develop is subject to the FDA and foreign regulatory authority approval process and we will need to meet, or will need to contract with CMOs who can meet, all applicable FDA and foreign regulatory authority requirements on an ongoing basis. Our failure or the failure of any CMO to meet required regulatory authority requirements could result in the delayed submission of regulatory applications, or delays in receiving regulatory approval for any of our or our current or future collaborators&#8217; product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we have existing, or enter into future, manufacturing arrangements with third-parties, we depend, and will depend in the future, on these third-parties to perform their obligations in a timely manner and consistent with contractual and regulatory requirements, including those related to quality control and quality assurance. The failure of any CMO to perform its obligations as expected, or, to the extent we manufacture all or a portion of our product candidates ourselves, our failure to execute on our manufacturing requirements, could adversely affect our business in a number of ways, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our current or future collaborators may not be able to initiate or continue clinical trials of product candidates that are under development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our current or future collaborators may be delayed in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may lose the cooperation of our collaborators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our facilities and those of our CMOs, and our products could be the subject of inspections by regulatory authorities that could have a negative outcome and result in delays in supply;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to cease distribution or recall some or all batches of our products or take action to recover clinical trial material from clinical trial sites; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ultimately, we may not be able to meet the clinical and commercial demands for our products.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third-parties to conduct our clinical trials, and those third-parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, and expect to continue to rely, on third-parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct and manage our clinical trials, including our planned Phase 3 clinical trials of Descartes-08. We also expect to rely on other third-parties to store and distribute drug supplies for our clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we rely on these third-parties for research and development activities, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCP regulations, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, safety and welfare of trial participants are protected. Other countries&#8217; regulatory agencies also have requirements for clinical trials. If we or any of our CROs or third-party contractors fail to comply with applicable GCPs, the data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, www.ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, these third-parties may also have relationships with other entities, some of which may be our competitors. If these third-parties do not successfully carry out their contractual duties, do not comply with confidentiality obligations, do not meet expected deadlines, experience work stoppages, terminate their agreements with us or need to be replaced, or do not conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may need to enter into new arrangements with alternative third-parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated, or may need to be repeated. If any of the foregoing occur, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates or in commercializing our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of our Product Candidates and Legal Compliance Matters</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy, safety and potential advantages compared to alternative treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture and distribute cell therapies in a timely and secure manner;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products for sale at competitive prices;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product labeling or product insert requirements of the FDA or foreign regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling, including any black box warning or REMS;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new treatments and of physicians to prescribe these treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire and retain a sales force;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement for our product candidates, once approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no sales organization. If we are unable to establish effective sales, marketing and distribution capabilities, or enter into agreements with third-parties with such capabilities, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any product candidate for which we obtain marketing approval, we will need to establish a sales and marketing organization or make arrangements with third-parties to perform sales and marketing functions and we may not be successful in doing so. We expect to build a focused sales and marketing infrastructure to market or co-promote our product candidates in the United States and potentially elsewhere, if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, including from biosimilars, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug and biologic products and technologies is highly competitive and is characterized by rapid and substantial technological development and product innovations. We are aware that pharmaceutical and biotechnology companies, offer or are pursuing the development of pharmaceutical products or technologies that may address one or more indications that our product candidates target, as well as smaller, early-stage companies, that offer or are pursuing the development of pharmaceutical products or technologies that may address one or more indications that our product candidates target. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources, established presence in the market and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and reimbursement for product candidates and in marketing approved products than we do.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These third-parties compete with us in recruiting and retaining qualified scientific, sales and marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market, especially for any competitor developing a cell therapy product that will likely share our same regulatory approval requirements. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic or biosimilar products.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA was enacted as part of the ACA to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is still being interpreted and implemented by the FDA, and as a result, its ultimate impact, implementation, and meaning are subject to uncertainty. However, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any product candidate approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any of our product candidates, the products may become subject to unfavorable pricing regulations or third-party coverage or reimbursement policies, any of which would have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval, especially novel products like our cell therapy product candidates, and may be particularly difficult because of the higher prices associated with such product candidates. Our ability to commercialize any product candidates successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining adequate reimbursement for our products may be difficult. We cannot be certain if we will obtain an adequate level of reimbursement for our products by third-party payors. Even if we do obtain adequate levels of reimbursement, third-party payors, such as government or private healthcare insurers, carefully review and question the coverage of, and challenge the prices charged for, products. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Third-party payors often require that pharmaceutical companies provide them with predetermined discounts from list prices and are challenging the prices charged for products. We may also be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. Some third-party payors may require pre-approval of coverage for new and innovative therapies, such as our product candidates, before they will provide reimbursement. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control, including possible price reductions, even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. There can be no assurance that our product candidates, if they are approved for sale in the United States or in other countries, will be considered medically necessary for a specific indication or cost-effective, or that coverage or an adequate level of reimbursement will be available.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there is heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. There can be no assurance that our product candidates, will not be subject to heightened governmental scrutiny, unfavorable regulatory inquiry or action, or Congressional inquiry.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory investigations, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any product candidates or products that we may develop;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of clinical trial participants or increased difficulty in enrolling future participants;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation or to reach a settlement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial payments to trial participants or patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced resources of our management to pursue our business strategy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any products that we may develop;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management&#8217;s attention from our primary business; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain general liability, product liability and umbrella liability insurance. Our existing insurance coverage may not fully cover potential liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. A product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the commercialization of any product candidates we develop.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements with physicians, others who may be in a position to generate business for us, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal False Claims Act, which impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government claims for payment that are false or fraudulent. Private individuals (e.g., whistleblowers) can bring these actions on behalf of the government; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which imposes criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by HITECH, and their respective implementing regulations, which also impose obligations, including mandatory contractual terms, on certain types of people and entities with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, or the Sunshine Act, which requires applicable manufacturers of certain products for which payment is available under a federal healthcare program to report annually to the government information related to certain payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care professionals beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by the physicians and their immediate family members;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by third-party payors, including private insurers; and requirements to comply with federal and pharmaceutical industry compliance guidelines;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state data privacy and price transparency laws, many of which differ from each other in significant ways and often are broader than and not preempted by HIPAA or the Sunshine Act, thus complicating compliance efforts; by way of example, the California Consumer Privacy Act, or CCPA, which went into effect January 1, 2020, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for &#8220;protected health information&#8221; maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of certain protected information, such as the GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the EU (including health data); in addition, the United Kingdom leaving the EU could also lead to further legislative and regulatory changes. It remains unclear how the United Kingdom data protection laws or regulations will develop in the medium to longer term and how data transfer to the United Kingdom from the EU will be regulated. However, the United Kingdom has transposed the GDPR into domestic law with the Data Protection Act 2018, which remains in force following the United Kingdom&#8217;s departure from the EU.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third-parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom may recommend, purchase and/or prescribe our product candidates, if approved, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, or if global health concerns were to again prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations administered by the U.S. Commerce Department&#8217;s Bureau of Industry and Security, U.S. customs regulations, various economic and trade sanctions regulations including those administered or enforced by relevant government authorities, such as by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control or the U.S. Department of State, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism, or PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. U.S. sanctions laws and regulations may govern or restrict our business and activities in certain countries and with certain persons. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other partners from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third-parties for clinical trials outside of the United States, to sell our product candidates abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Our violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or third-parties we rely upon fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our contract manufacturers and other third-parties with whom we do business are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including biological materials and chemicals. Our operations also produce hazardous waste products. We generally contract with third-parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. The failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_43"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a development-stage company, and we expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the year ended December 31, 2022, we have incurred significant operating losses since our inception. We incurred a net loss of $77.4 million and $219.7 million for the years ended December 31, 2024, and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $692.1 million. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through public offerings and private placements of our securities, funding received from collaboration and license arrangements and a credit facility. We currently have no source of product revenue, and we do not expect to generate product revenue for the foreseeable future. We expect to devote substantially all of our financial resources and efforts to developing our mRNA-based therapies for the treatment of autoimmune diseases, identifying potential product candidates and conducting preclinical studies and our clinical trials. We are in the early stages of clinical development of most of our product candidates. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We expect that our expenses will increase substantially as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the research and development of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase and develop our manufacturing and distribution capacities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discover and develop additional product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to maintain and enter into collaboration, licensing and other agreements, including, but not limited to research and development, and/or commercialization agreements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially establish a sales, marketing and distribution infrastructure and scale up internal manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio, including through licensing arrangements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter any issues with any of the above, including, but not limited to, failed studies, complex results, safety issues or other regulatory, manufacturing or scale-up challenges; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">are exposed to broad macroeconomic conditions including inflation and supply chain tightness which could result in us paying more, or being unable, to access goods and services.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval and securing reimbursement for these product candidates, manufacturing, marketing and selling any products for which we may obtain regulatory approval, and establishing and managing our collaborations at various stages of a product candidate&#8217;s development. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical and biological product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA or other regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our product candidates, our expenses could increase and product revenue could be further delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to remain profitable would depress our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or continue our operations.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding in order to complete development of our product candidates and commercialize our products, if approved. If we are unable to raise capital when needed and on terms favorable to us, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue research and development for other product candidates. Additionally, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Accordingly, we will need to obtain substantial additional funding to continue operations. If we are unable to raise capital when </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed or on attractive terms, we could be forced to delay, reduce or eliminate our clinical trials, our other research and development programs or any future commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents and restricted cash as of December 31, 2024, will enable us to fund our operating expenses and capital expenditure requirements into mid-2027. We may pursue additional cash resources through public or private equity or debt financings, by establishing collaborations with other companies or through the monetization of potential royalty and/or milestone payments pursuant to our existing collaboration and license arrangements. Management&#8217;s expectations with respect to our ability to fund current and long-term planned operations are based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, we may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. However, there is no guarantee that any of these strategic or financing opportunities will be executed on favorable terms, and some could be dilutive to existing stockholders. If we are unable to obtain additional funding on a timely basis, we may be forced to significantly curtail, delay, or discontinue one or more of our planned research or development programs or be unable to expand our operations, meet long-term obligations or otherwise capitalize on our commercialization of our product candidates. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our clinical trials, preclinical development, manufacturing, laboratory testing and logistics;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of product candidates that we pursue and the speed with which we pursue development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our headcount growth and associated costs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, from commercial sales of our product candidates for which we receive marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Market volatility resulting from the ongoing conflicts in Ukraine and the Middle East and current global macroeconomic conditions or other factors could also adversely impact our ability to access capital as and when needed. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders, and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs, including our clinical trial programs, or the commercialization of any product candidates, or be unable to sustain or expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have net operating loss carryforwards, or NOLs, for federal and state income tax purposes that may be available to offset our future taxable income, if any. In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to use its pre-change NOLs to offset future taxable income. If the IRS, challenges our analysis that existing NOLs will not expire before </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilization due to previous ownership changes, or if we undergo an ownership change, our ability to use our NOLs could be limited by Section 382 of the Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our ability to use NOLs of companies that we may acquire in the future may be subject to limitations. As a result, we may not be able to use a material portion of the NOLs reflected on our balance sheet, even if we attain profitability. Under current law, NOLs that arose before January 1, 2018 may be carried forward up to 20 years. NOLs that arose after 2017 may be used to offset at most 80% of our taxable income to the extent not offset by pre-2018 NOLs and such NOLs can be carried forward indefinitely. As a result, we may become required to pay federal income taxes in future years despite having generated losses for federal income tax purposes in prior years.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have recorded a material amount of goodwill and indefinite-lived intangible assets in connection with the Merger. We may record impairment charges, which would adversely impact our financial position and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded a material amount of goodwill and indefinite-lived intangible assets on our balance sheet in connection with the Merger. We review our goodwill and intangible assets for impairment at least annually, or whenever events or changes in circumstances indicate that the carrying amounts of these assets may not be recoverable, in accordance with Accounting Standards Codification Topic 350, Intangibles - Goodwill and Other.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One potential indicator of goodwill impairment is whether the fair value of our equity, as measured by our market capitalization, is below the net book value of our equity. Whether our market capitalization triggers an impairment charge in any future period will depend on the underlying reasons for the decline in stock price, the significance of the decline and the length of time the stock price has been trading at such prices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the determination as to whether our indefinite-lived intangible assets related to Descartes-08 are impaired is heavily dependent on the results of our ongoing clinical trials, as well as other factors, such as the potential market for Descartes-08, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we determine in a future period that impairment exists for any reason, we would record an impairment charge, which could be material and which would reduce the underlying asset&#8217;s value in the period such determination is made, which would adversely impact our financial position and results of operations. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred substantial expenses related to the integration of Old Cartesian.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial expenses in connection with the Merger and the subsequent integration of Old Cartesian with Selecta. There are a large number of processes, policies, procedures, operations, technologies and systems that must be integrated, including purchasing, accounting and finance, sales, billing, payroll, research and development, marketing and benefits. Both we and Old Cartesian have incurred significant transaction expenses in connection with the drafting and negotiation of the Merger Agreement and significant severance expenses as a result of the Merger. While we and Old Cartesian have assumed that a certain level of expenses will be incurred, there are many factors beyond our control that could affect the total amount or the timing of the integration expenses. Moreover, many of the expenses that have been and will be incurred are, by their nature, difficult to estimate accurately. These integration expenses have resulted in our taking significant charges against earnings following the completion of the Merger, and the amount and timing of such charges are uncertain at present.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our licensors are unable to adequately protect our proprietary technology, or obtain and maintain issued patents that are sufficient to protect our product candidates, others could compete against us more directly, which would negatively impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner or in all jurisdictions. As we reach the statutory deadlines for deciding whether and where to initiate prosecution in specific foreign jurisdictions by filing national stage applications based on our Patent Cooperation Treaty, or PCT, applications, we will have to decide whether and where to pursue patent protection for the various inventions claimed in our patent portfolio, and we will only have the opportunity to obtain patents in those jurisdictions where we pursue protection. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. It is possible that defects of form in the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preparation or filing of our patents or patent applications may exist, or may arise in the future, such as, with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability to prevent competition from third-parties, which may have an adverse impact on our business. We also cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete and thorough, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents covering technology that we license from third-parties. We may also require the cooperation of our licensors to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, we have obligations under our licenses, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license could have a material adverse impact on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patent licenses are non-exclusive. In those cases, a competitor could obtain a license to the same or similar technology from the licensor. We have at least one exclusive patent license that is restricted to a particular field of use. A competitor could obtain a license to a similar technology outside of that field of use.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot provide any assurances that the issued patents we currently own, or any future patents, include claims with a scope sufficient to protect our product candidates or otherwise provide any competitive advantage.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is possible that a patent claim may provide coverage for some but not all parts of a product candidate or third-party product. These and other factors may provide opportunities for our competitors to design around our patents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, other parties may have developed technologies that may be related or competitive to our approach, and may have filed or may file patent applications, and may have received or may receive patents that may overlap or conflict with our patent applications, either by claiming similar methods or by claiming subject matter that could dominate our patent position. In addition, it may be some time before we understand how the patent office reacts to our patent claims and whether they identify prior art of relevance that we have not already considered.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in any owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions, nor can we know whether those from whom we may license patents were the first to make the inventions claimed or were the first to file. For these and other reasons, the issuance, scope, validity, enforceability and commercial value of our patent rights are subject to a level of uncertainty. Our pending and future patent applications may not result in patents being issued that protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or other patent office, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third-parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Furthermore, an adverse decision in an interference proceeding can result in a third-party receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize our product candidates. The issuance, scope, validity, enforceability and commercial value of our patents are subject to a level of uncertainty.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. Due to legal standards relating to patentability, validity, enforceability and claim scope of patents covering biotechnological and pharmaceutical inventions, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Even if issued, a patent&#8217;s validity, inventorship, ownership or enforceability is not conclusive. Accordingly, rights under any existing patent or any patents we might obtain or license may not cover our product candidates, or may not provide us with sufficient protection for our product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic pharmaceutical companies.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how, information, or technology that is not covered by our patents. Although our agreements require all of our employees to assign their inventions to us, and we require all of our employees, consultants, advisors and any other third-parties who have access to our trade secrets, proprietary know-how and other confidential information and technology to enter into appropriate confidentiality agreements, we cannot be certain that our trade secrets, proprietary know-how, and other confidential information and technology will not be subject to unauthorized disclosure or that our competitors will not otherwise gain access to or independently develop substantially equivalent trade secrets, proprietary know-how, and other information and technology. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property globally. If we are unable to prevent unauthorized disclosure of our intellectual property related to our product candidates and technology to third-parties, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business and operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any litigation to enforce or defend our patent rights, even if we were to prevail, could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. Even if we are successful, domestic or foreign litigation, or USPTO or foreign patent office proceedings, may result in substantial costs and distraction to our management. We may not be able, alone or with our licensors or potential collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets and know-how, our business and competitive position would be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third-parties. We also seek to enter into confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Our trade secrets may also be obtained by third-parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor, our competitive position would be harmed.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, recent patent reform legislation could further increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act America Invents Act, or the Leahy-Smith Act, included provisions that affect the way patent applications are prosecuted and may also affect patent litigation, including first-to-file provisions. A third-party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third-party. This requires us to be cognizant of the time from invention to filing of a patent application. Thus, for our U.S. patent applications containing a priority claim after March 16, 2013, the date such provisions became effective, there is a greater level of uncertainty in the patent law. Moreover, some of the patent applications in our portfolio will be subject to examination under the pre-Leahy-Smith Act law and regulations, while other patents applications in our portfolio will be subject to examination under the law and regulations, as amended by the Leahy-Smith Act. This introduces additional complexities into the prosecution and management of our portfolio.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Leahy-Smith Act limits where a patentee may file a patent infringement suit and provides opportunities for third-parties to challenge any issued patent in the USPTO. These provisions apply to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal court necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a federal court action.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, a third-party may attempt to use the USPTO procedures to invalidate our patent claims because it may be easier for them to do so relative to challenging the patent in a federal court action. It is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. From time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress or the USPTO may change the standards of patentability, and any such changes could have a negative impact on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on these and other decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change or be interpreted in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that may issue to us in the future. In addition, these events may adversely affect our ability to defend any patents that may issue in procedures in the USPTO or in courts.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third-parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. While no such litigation has been brought against us and we have not been held by any court to have infringed a third-party&#8217;s intellectual property rights, we cannot guarantee that our technology, product candidates or use of our product candidates do not infringe third-party patents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of numerous patents and pending applications owned by third-parties, and we monitor patents and patent applications in the fields in which we are developing product candidates, both in the United States and elsewhere. However, we may have failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Other parties may allege that our product candidates or the use of our technologies infringes patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including interference or derivation proceedings before the USPTO and similar bodies in other countries. Third-parties may assert infringement claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. If we are found, or believe there is a risk we may be found, to infringe a third-party&#8217;s intellectual property rights, we could be required or may choose to obtain a license from such third-party to continue developing and marketing our product candidates and technology. However, we may not be able to obtain any such license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims that we have misappropriated the confidential information or trade secrets of third-parties could have a similar negative impact on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in such proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. There could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these risks coming to fruition could have a material adverse impact on our business.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, and our issued patents covering our product candidates could be found invalid or unenforceable or could be interpreted narrowly if challenged in court.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. If we initiated legal proceedings against a third-party to enforce a patent, if and when issued, covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement, or failure to claim patent-eligible subject matter. Grounds for unenforceability assertions include allegations that someone connected with the prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third-parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our product candidates or competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Moreover, even if not found invalid or unenforceable, the claims of our patents could be construed narrowly or in a manner that does not cover the allegedly infringing technology in question. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The lives of our patents may not be sufficient to effectively protect our products and business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent life has expired, we may be open to competition. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. If we do not have sufficient patent life to protect our product candidates, proprietary technologies and their uses, our business and results of operations will be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and, in some jurisdictions, during the pendency of a patent application. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have an adverse effect on our business.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to certain intellectual property, through licenses from third-parties and under patents and patent applications that we own, to develop our product candidates. Because we may find that our programs require the use of proprietary rights held by third-parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third-parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third-parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may also engage advisors and consultants who are concurrently employed at universities or other organizations or who perform services for other entities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we try to ensure that our employees, advisors and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, advisors or consultants have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such party&#8217;s former or current employer or in violation of an agreement with another party. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees, consultants, advisors and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third-parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Similarly, we may be subject to claims that an employee, advisor or consultant performed work for us that conflicts with that person&#8217;s obligations to a third-party, such as an employer, and thus, that the third-party has an ownership interest in the intellectual property arising out of work performed for us. Litigation may be necessary to defend against these claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than in the United States, assuming that rights are obtained in the United States and assuming that rights are pursued outside the United States. In this regard, in addition to the United States, we also seek to protect our intellectual property rights in other countries. The statutory deadlines for pursuing patent protection in individual foreign jurisdictions are based on the priority date of each of our patent applications. For all of the patent families in our portfolio, including the families that may provide coverage for our lead product candidate, the relevant statutory deadlines have not yet expired. Therefore, for each of the patent families that we believe provide coverage for our lead product candidate, we will need to decide whether and where to pursue additional protection outside the United States. In addition, the laws of some foreign countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, for our existing patent rights outside the United States and any foreign patent rights we may decide to pursue in the future, we may not be able to obtain relevant claims and/or we may not be able to prevent third-parties from practicing our inventions in all countries </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as in the United States. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third-parties from so competing.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain additional protection under the Hatch-Waxman Act and similar foreign legislation extending the terms of our patents for our product candidates, our business may be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA regulatory approval for our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. Patent term restorations, however, are limited to a maximum of five years and cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval by the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application for patent term extension is subject to approval by the USPTO, in conjunction with the FDA. It takes at least six months to obtain approval of the application for patent term extension. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened, our competitors may obtain earlier approval of competing products and our ability to generate revenues could be materially adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_49"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Operations</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on Carsten Brunn, Ph.D., our President and Chief Executive Officer, as well as the other principal members of our management, scientific, clinical, and manufacturing teams. Although we have entered into employment agreements or offer letters with Dr. Brunn and other executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, technology and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we have incurred and expect to continue to incur significant legal, accounting and other expenses. If we are unable to maintain effective internal control over financial reporting, we may not have adequate, accurate or timely financial information, and we may be unable to meet our reporting obligations as a public company or comply with the requirements of the SEC or Section 404 of the Sarbanes-Oxley Act of 2002. This could result in a restatement of our financial statements, the imposition of sanctions, including the inability of registered broker dealers to make a market in our common stock, or investigation by regulatory authorities. Any such action or other negative results caused by our inability to meet our reporting requirements or comply with legal and regulatory requirements or by disclosure of an accounting, reporting or control </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issue could adversely affect the trading price of our securities and our business. Material weaknesses in our internal control over financial reporting could also reduce our ability to obtain financing or could increase the cost of any financing we obtain. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in connection with the audit of our financial statements for the year ended December 31, 2023, we identified a material weakness in our internal control over financial reporting. As of December 31, 2024, this material weakness has been remediated, but we may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal control over financial reporting, which may result in material misstatements of our consolidated financial statements or cause us to fail to meet our periodic reporting obligations.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with maintaining our subsidiary in Russia or expanding operations internationally could adversely affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our U.S. operations, we maintain a wholly owned subsidiary in Russia, Selecta (RUS). However, we are in the process of winding down all remaining operations of this subsidiary. We may face risks associated with winding down the operations of our subsidiary in Russia, or with any international operations, including possible unfavorable regulatory, pricing and reimbursement, legal, political, tax and labor conditions, and risks associated with our compliance with evolving international sanctions, which could harm our business. We may also rely on collaborators to commercialize any approved product candidates outside of the United States. Doing business internationally involves a number of risks, including but not limited to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us to obtain and maintain regulatory approvals for the use of our product candidates in various countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional potentially relevant third-party patent rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities and difficulties in obtaining protection of and enforcing our intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in staffing and managing foreign operations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing multiple-payor reimbursement regimes, government payors or patient self-pay systems;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limits on our ability to penetrate international markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our product candidates and exposure to foreign currency exchange rate fluctuations, which could result in increased operating expenses and reduced revenues;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, political and economic instability, including wars, events of terrorism and political unrest, outbreak of disease, including pandemics, boycotts, curtailment of trade and other business restrictions, economic sanctions, and economic weakness, including inflation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in diplomatic and trade relationships;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restriction on cross-border investment, including enhanced oversight by the Committee on Foreign Investment in the United States and substantial restrictions on investment from China;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain expenses including, among others, expenses for travel, translation and insurance;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legal risks, including use of the legal system by the government to benefit itself or affiliated entities at our expense, including expropriation of property;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the FCPA its books and records provisions, or its anti-bribery provisions; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks that we may suffer reputational harm as a result of our operations in Russia.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations, including our development programs, could be materially disrupted in the event of system failures, security breaches, violations of data protection laws or data loss or damage by us or third-parties on which we rely, including our CROs or other contractors or consultants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of third-parties on which we rely, including our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could have a material adverse effect on our business operations, including a material disruption of our development programs. Unauthorized disclosure of sensitive or confidential patient or employee data, including personally identifiable information, whether through breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by our employees or third-parties, could result in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws and regulations around the world. To the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. For example, the loss of or damage to clinical trial data, such as from completed or ongoing clinical trials, for any of our product candidates would likely result in delays in our marketing approval efforts and significantly increased costs in an effort to recover or reproduce the data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have previously been, and expect to remain, the target of cyber-attacks. As we become more dependent on information technologies to conduct our operations, cyber incidents, including deliberate attacks, such as ransomware attacks, and attempts to gain unauthorized access to computer systems and networks, may increase in frequency and sophistication. These incidents pose a risk to the security of our systems and networks, the confidentiality and the availability and integrity of our data and these risks apply both to us, and to third-parties on whose systems we rely for the conduct of our business. While we do not believe the effect of these incidents has historically been material to our results of operations, financial condition or prospects, cyber threats are persistent and constantly evolving. Such threats have increased in frequency, scope and potential impact in recent years, which increases the difficulty of detecting and successfully defending against them. As cyber threats continue to evolve, we may be required to incur additional expenses in order to enhance our protective measures or to remediate any information security vulnerability. There can be no assurance that we or our third-party providers will be successful in preventing cyber-attacks or mitigating their effects. Similarly, there can be no assurance that our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants will be successful in protecting our clinical and other data that is stored on their systems. Any cyber-attack or destruction or loss of data could have a material adverse effect on our business and prospects. In addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyber-attacks or destruction or loss of data and may incur significant additional expense to implement further data protection measures. It is also possible that unauthorized access to data may be obtained through inadequate use of security controls by our suppliers or other vendors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have general liability insurance coverage, our insurance may not cover all claims, continue to be available on reasonable terms or be sufficient in amount to cover one or more large claims. Additionally, the insurer may disclaim coverage as to any claim. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, prospects, operating results and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions or joint ventures could disrupt our business, cause dilution to our stockholders and otherwise harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire other businesses, product candidates or technologies as well as pursue strategic alliances, joint ventures, technology licenses or investments in complementary businesses. We have not made any acquisitions to date, and our ability to do so successfully is unproven. Any of these transactions could be material to our financial condition and operating results and expose us to many risks, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption in our relationships with future customers or with current or future distributors or suppliers as a result of such a transaction;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected liabilities related to acquired companies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management time and focus from operating our business to acquisition integration challenges;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible write-offs or impairment charges relating to acquired businesses; and</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to develop a sales force for any additional product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign acquisitions involve unique risks in addition to those mentioned above, including those related to integration of operations across different cultures and languages, currency risks and the particular economic, political and regulatory risks associated with specific countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the expected benefit of any acquisition may not materialize. Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_52"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Common Stock</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is likely to be volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the price at which you purchased. The market price for our common stock may be influenced by many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results or progress, or changes in approach or timelines, of clinical trials of our product candidates or those of our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure or discontinuation of any of our development programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement of, termination of, or any development related to any collaboration or licensing arrangement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">development of new product candidates that may address our markets and make our product candidates less attractive;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in physician, hospital or healthcare provider practices that may make our product candidates less useful;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or market expectation of additional financing efforts;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial estimates, projections or development timelines of the investment community or that we provide to the public;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or expected changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sale of common stock by us or our stockholders in the future as well as the overall trading volume of our common stock;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the composition of our stockholder base;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">activity in the options market for shares of our common stock;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our executive officers, directors, and principal stockholders, if they choose to act together, will continue to have the ability to control or significantly influence all matters submitted to stockholders for approval.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our executive officers, directors and stockholders who own more than 5% of our outstanding common stock and their respective affiliates, in the aggregate, hold shares representing approximately 64.5% of our outstanding voting stock as of December 31, 2024</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, assuming the conversion of all shares of all outstanding shares of Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share, or Series A Preferred Stock, and Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share, or Series B Preferred Stock, into common stock, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68.4%, assuming no conversion of outstanding shares of Series A Preferred Stock and Series B Preferred Stock into common stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> As a result, if some or all of these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation or sale of all or substantially all of our assets.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our restated certificate of incorporation, as amended, or the Charter, and amended and restated by-laws may delay or prevent an acquisition or a change in management. These provisions include a prohibition on actions by written consent of our stockholders and the ability of our board of directors, or the Board of Directors, to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our Board of Directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the Board of Directors, which is responsible for appointing the members of management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our Charter specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders. This provision of our Charter applies to actions arising under the Securities Act and the Exchange Act. We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents and may result in increased litigation costs for our stockholders. We note that there is uncertainty as to whether a court would enforce these provisions and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section 22 of the Securities Act generally creates concurrent jurisdiction for state and federal courts over suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been in the past and may in the future be subject to stockholder litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. Involvement in such litigation, could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2024, Paul Wymer, a purported stockholder of our Company, filed an action against us and members of our Board of Directors in the U.S. District Court for the Southern District of New York, titled Wymer v. Cartesian Therapeutics, Inc., et al., No. 24-cv-01288.  The complaint alleged that the defendants violated Sections 14(a) and 20(a) of the Exchange Act by failing to disclose purportedly material information to our stockholders in our Preliminary and Definitive Proxy Statements filed on January 31, 2024, and February 14, 2024, respectively, in connection with the solicitation of stockholder approval of a proposal to convert our Series A Preferred Stock into our common stock, subject to certain beneficial ownership limitations, or the Series A Conversion Proposal.  The complaint sought injunctive relief enjoining or rescinding the Merger, issuance of an amended proxy statement, and attorneys&#8217; fees and costs.  Additional similar lawsuits may be filed.  This action was subsequently dismissed on March 11, 2024.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 7, 2024, Justin Sloan, a purported stockholder of our Company, filed a putative class action on behalf of himself and similarly situated stockholders of the Company against our Company and members of our Board of Directors in the Court of Chancery of the State of Delaware, titled Sloan v. Barabe, et al., No. 2024-0105. The complaint alleged that the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">individual defendants breached their fiduciary duties by failing to disclose purportedly material information to our Company&#8217;s stockholders in our Preliminary Proxy Statement filed on January 31, 2024 in connection with the solicitation of stockholder approval of the Series A Conversion Proposal. The complaint seeks a temporary injunction against the stockholder vote on the Series A Conversion Proposal, compensatory damages, pre-and post-judgment interest, and attorneys&#8217; fees and costs. At a telephonic hearing on February 28, 2024, the Court denied the Plaintiff&#8217;s motion to expedite the proceedings, rejecting Plaintiff&#8217;s argument that the lawsuit raised colorable disclosure claims warranting expedited treatment. Additional similar lawsuits may be filed. This action was subsequently dismissed on March 13, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2020, a stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Company&#8217;s Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al. The complaint alleged that the individual defendants breached their fiduciary duties and committed corporate waste when they authorized a private placement transaction, announced on December 19, 2019, at a price allegedly below fair value. The complaint further alleges that the four defendant directors who participated in the private placement were unjustly enriched in connection with the transaction. On September 25, 2020, the defendants filed a motion to dismiss the lawsuit. On November 6, 2020, the plaintiff filed an amended complaint, and the defendants filed a second motion to dismiss on January 8, 2021. On December 31, 2020, we received a litigation demand letter from two other putative stockholders relating to the same private placement transaction. On April 12, 2021, the Court of Chancery in the State of Delaware granted a motion to stay the litigation pending a review by a Special Committee appointed by the Company&#8217;s Board of Directors. While the litigation was stayed, the parties reached an agreement in principle to settle the matter, and on March 18, 2022, they submitted a Stipulation and Agreement of Settlement and other documentation to the Court for its approval of the settlement. On July 21, 2022, the Court held a settlement hearing, at which the settlement was approved. On August 1, 2022, the Court entered an Order and Final Judgment which dismissed the action, and all claims contained therein, with prejudice. We could receive other demands or be subject to other litigation. We intend to vigorously defend against any demands which we believe to be without merit.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance as to the outcome of any stockholder litigation. Unfavorable outcomes in class action litigation could require us to pay extensive damages, which could delay or prevent our ability to develop our product candidates and harm our operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_58"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.  Unresolved Staff Comments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_61"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C.  Cybersecurity</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-36" continuedAt="f-36-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-37" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-38">One of the key responsibilities of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-39" escape="true">Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Board of Directors administers its cybersecurity risk oversight function directly and through the Audit Committee, which conducts regular risk assessments related to all matters affecting the enterprise, including cybersecurity, and receives periodic reports on the Company&#8217;s cybersecurity risks and activities.</ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-41" continuedAt="f-41-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-40" continuedAt="f-40-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-42" escape="true">Our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-43">Chief Financial Officer and our Senior Director, Head of IT</ix:nonNumeric> are the Company employees responsible for developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We partner with external cybersecurity vendors to enact a layered defense approach with controls deployed that seek to meet the requirements of the NIST Cybersecurity Framework.</ix:nonNumeric> </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-40-1" continuedAt="f-40-2"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-44" escape="true"><ix:continuation id="f-41-1"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Financial Officer has served as a biotechnology executive for 20 years, whose responsibilities have included direct oversight of his companies&#8217; cybersecurity risks. Our Senior Director, Head of IT has served as an Information Technology professional for over ten years and has held senior IT positions across several companies including a large pharmaceutical company.</span></div></ix:continuation></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-45" continuedAt="f-45-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. Our Senior Director, Head of IT oversees the cybersecurity program through risk management, employee security training, and oversight and escalation of threat monitoring and incident response. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. In the event of a major security incident, we have established an escalation path for stakeholder notification and remediation efforts, and major incidents are immediately escalated to the Head of IT, Chief Financial Officer, and Chief Operations Officer. In 2024, we proactively conducted a thorough and robust cybersecurity assessment, performed by an external cybersecurity partner, to evaluate our risks and identify key areas to improve our cybersecurity posture. We have implemented processes when evaluating third-party service providers, for example by reviewing available audit reports including the System and </span></div></ix:nonNumeric></ix:continuation></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-36-1"><ix:continuation id="f-45-1" continuedAt="f-45-2"><ix:continuation id="f-40-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organization Controls (SOC 2) reports and requesting disclosure of any previous cybersecurity events. We also perform quality audits of certain regulated vendors, which includes an assessment of the vendor&#8217;s information technology system and associated controls.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we conduct periodic risk assessments to identify and monitor against potential cybersecurity threats and incidents, as well as assess for any changes in our business practices that may affect our cybersecurity position. This risk oversight includes identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks and address any identified gaps in existing safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity program is delegated to our Senior Director, Head of IT, who reports on IT operations, risk mitigation and assessment efforts, and other general cybersecurity matters to our Chief Financial Officer, to manage the risk assessment and mitigation process. </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-45-2">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-46"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-47">We continue to work with third-party cybersecurity vendors to assist us in best practices for implementing strengthened cybersecurity procedures</ix:nonNumeric>. All Company employees and third-party vendors are instructed to promptly report any suspected breach of its security measures that may affect our Company to the Senior Director, Head of IT.</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-48" escape="true">Our Chief Financial Officer and Senior Director, Head of IT provide periodic briefings to the Audit Committee regarding our Company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third-parties, and related matters. The Audit Committee provides regular updates to the full <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-49">Board of Directors</ix:nonNumeric> on such reports.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-50">We have not encountered cybersecurity challenges that have materially impaired our operations or financial standing.</ix:nonNumeric> For additional information regarding risks from cybersecurity threats, please refer to Item 1A, &#8220;Risk Factors,&#8221; in this Annual Report on Form 10-K.</span></div></ix:continuation><div><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_64"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.  Properties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are currently located at 7495 New Horizon Way, Frederick, Maryland and consists of 29,050 total square feet of integrated manufacturing and office space under a lease that expires in June 2031.  Additionally, we lease approximately 7,909 total square feet of office, laboratory, and manufacturing space in Gaithersburg, Maryland under a lease that expires in January 2027 and 32,294 total square feet of office and laboratory space in Watertown, Massachusetts under a lease that expires in May 2028.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_67"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.  Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_70"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_88"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_91"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.  Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is publicly traded on The Nasdaq Stock Market under the symbol &#8220;RNAC.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;28, 2025, there were approximately 25,907,101 shares of our common stock outstanding held by approximately 107 holders of record. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not expect to pay any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our Board of Directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the Board of Directors deems relevant, and subject to the restrictions contained in any future financing instruments.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph set forth below compares the cumulative total stockholder return on our common stock between December&#160;31, 2019 and December 31, 2024, with the cumulative total return of (a) the Nasdaq Composite Index and (b) the Nasdaq Biotechnology Index, over the same period. This graph assumes the investment of $100 at the market close on December&#160;31, 2019 in our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes the reinvestment of dividends, if any. The stock price performance of the following graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison Of Cumulative Total Return Cartesian Therapeutics, Inc.,</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nasdaq Composite Index and Nasdaq Biotechnology Index</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><img src="rnac-20241231_g9.jpg" alt="Total Return.jpg" style="height:309px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of Section</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities or the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our equity compensation plans in Item 12 of Part III of this Annual Report is incorporated herein by reference. Any future determination to pay dividends will be made at the discretion of our Board of Directors and will depend </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our Board of Directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer or Affiliated Purchasers</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not repurchase any of our equity securities during the quarter ended December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities and Use of Proceeds from Registered Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_94"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.  [Reserved]</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_97"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes thereto and other financial information included elsewhere in this Annual Report on Form 10-K. In addition to historical information, some of the information contained in the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. You should review the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></div><div id="ida4b385316634ae2a3d2c21207c427f6_103"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company pioneering mRNA cell therapy for the treatment of autoimmune diseases. We leverage our proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell&#8217;s genetic material. Therefore, our mRNA cell therapies are distinguished by their capacity to be dosed repeatedly like conventional drugs, administered in an outpatient setting, and given without pre-treatment chemotherapy required with many conventional cell therapies. In a placebo-controlled Phase 2b clinical trial in patients with myasthenia gravis, or MG, a chronic autoimmune disease that causes disabling muscle weakness and fatigue, we observed that our lead product candidate, Descartes-08, generated a deep and durable clinical benefit where we observed an average MG-ADL reduction of 5.5 points at Month 4 with a third of patients achieving minimal symptom expression at Month 6 and 80% of participants reaching Month 12 maintained a clinically meaningful response. Durability of response in MG is commonly measured over a period of 26 to 52 weeks, and maintenance of response over that period is considered durable.</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_106"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merger</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023, the Company (formerly known as Selecta) merged with the private Delaware corporation which, immediately prior to the Merger, was known as Cartesian Therapeutics, Inc., in accordance with the terms of the Merger Agreement, by and among Selecta, First Merger Sub, Second Merger Sub, and Old Cartesian. Pursuant to the Merger Agreement, First Merger Sub merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corporation and became a wholly owned subsidiary of Selecta. Immediately following the First Merger, Old Cartesian merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity. In connection with the Second Merger, Old Cartesian changed its name to Cartesian Bio, LLC. In connection with the Merger and pursuant to the Merger Agreement, the Company changed its corporate name to Cartesian Therapeutics, Inc. See Note 4 of the accompanying notes to the consolidated financial statements appearing elsewhere in this Annual Report.</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_109"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through public offerings and private placements of our securities, funding received from research grants, collaboration and license arrangements and a credit facility. We do not have any products approved for sale and have not generated any product sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the year ended December 31, 2022, we have incurred significant operating losses since our inception. We incurred a net loss of $77.4 million and $219.7 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $692.1 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance Descartes-08 for MG into Phase 3 development;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to develop our preclinical and clinical-stage product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio, including through licensing arrangements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional staff, including clinical, scientific and management personnel; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional costs associated with continuing to operate as a public company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our research and development expenses for the years ended December 31, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.652%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legacy Selecta programs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for MG</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Early stage programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development facilities and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, and license and collaboration agreements. We may be unable to raise capital when needed or on reasonable terms, if at all, which would force us to delay, limit, reduce or terminate our product development or future commercialization efforts. We will need to generate significant revenues to achieve profitability, and we may never do so.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the closing of the Merger, we entered into a securities purchase agreement, or the 2023 Securities Purchase Agreement, pursuant to which we agreed to issue 149,330.115 shares of Series A Preferred Stock, in exchange for aggregate gross proceeds of $60.25 million, or the 2023 Private Placement. We granted customary registration rights to investors in connection with the 2023 Private Placement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2024, we entered into a securities purchase agreement, or the 2024 Securities Purchase Agreement, for a private investment in public equity financing, or the 2024 Private Placement, which provided for the issuance of 3,563,247 shares of common stock and 2,937,903 shares of Series B Preferred Stock, each at a purchase price of $20.00 per share. The 2024 Private Placement resulted in gross proceeds of approximately $130.0&#160;million before deducting placement agent fees and other offering expenses. We granted customary registration rights to investors in connection with the 2024 Private Placement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents, and restricted cash as of December 31, 2024 will enable us to fund our operating expenses and capital expenditure requirements into mid-2027. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial information presented below includes the accounts of Cartesian Therapeutics, Inc. and our wholly owned subsidiaries, Selecta (RUS) LLC, a Russian limited liability company, or Selecta (RUS), Selecta Biosciences Security Corporation, a Massachusetts securities corporation which was dissolved in December 2024, and Cartesian Bio, LLC, a Delaware limited liability company, which is a variable interest entity for which we are the primary beneficiary. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and license revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales. Our revenue consists primarily of collaboration and license revenue, which includes amounts recognized related to upfront and milestone payments for research and development funding under collaboration and license agreements. We expect that any revenue we generate will fluctuate from quarter to quarter because of the timing and amounts of fees, research and development reimbursements and other payments from collaborators. We do not expect to generate revenue from product sales for at least the next several years. If we or our collaborators fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval as needed, our ability to generate future revenue will be harmed, and will affect the results of our operations and financial position. For further descriptions of the agreements underlying our collaboration and license revenue, see Notes 3 and 14 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant revenue</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, we generate grant revenue which consists of funding received to perform specific research and development services under grant arrangements. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist of internal and external research and development costs, which primarily include fees paid to contract research organizations, internal manufacturing- and quality-related expenses, process development costs, internal research and development expenses, as well as fees paid to contract manufacturing organizations. These costs are primarily associated with compensation expenses for our research and development employees, capital equipment and supplies for our process development and manufacturing process, and other related expenses. Our internal research and development employees as well as our indirect costs are shared across multiple development programs and are not solely dedicated to individual programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Conducting a significant amount of research and development is central to our business model. Product candidates in clinical development generally have higher development costs than those in earlier stages of development, primarily due to the size, duration and cost of clinical trials. The successful development of our clinical and preclinical product candidates is highly uncertain. Clinical development timelines, the probability of success and development costs can differ materially from our expectations. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those which we currently expect will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time to complete any clinical development.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, business development and support functions. Other general and administrative expenses include facility-related costs not otherwise allocated to research and development expenses, travel expenses for our general and administrative personnel and professional fees for auditing, tax and corporate legal services, including intellectual property-related legal services.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of long-lived assets consists of impairment charges on our long-lived assets.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of income earned on our cash, cash equivalents and marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of interest expense on amounts borrowed under our credit facilities and loss on extinguishment of debt.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists of non-operating income and non-operating expenses. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in fair value of warrant liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common warrants classified as liabilities are remeasured quarterly at fair value with the change in fair value recognized as a component of earnings.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in fair value of contingent value right liability</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The contingent value right liability is remeasured quarterly at fair value with the change in fair value recognized as a component of earnings.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in fair value of forward contract liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward contract liabilities associated with the delayed issuance of the Series A Preferred Stock related to the Merger and 2023 Private Placement are remeasured quarterly and upon settlement at fair value with the change in fair value recognized as a component of earnings.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2024 and 2023</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.656%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and license revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,004&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43,897)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86,416)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency transaction, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent value right liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of forward contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,137)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(238,710)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,424)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219,710)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaboration and license revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, we recognized $38.3&#160;million of collaboration and license revenue, compared to $26.0 million for the year ended December&#160;31, 2023, an increase of $12.3 million. The increase was primarily due to an increase in revenue recognized under the Sobi License resulting from the $30.0 million unconstrained development milestone recognized during the year ended December 31, 2024 and recognition of the remaining deferred revenue under the License and Development Agreement, or the Astellas Agreement, with Audentes Therapeutics, Inc., or Astellas, upon notice of termination during the year ended December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grant revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, we recognized $0.6 million of grant revenue. We received funding approval from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, or NINDS, during the year ended December 31, 2024, and there was no grant revenue during the year ended December&#160;31, 2023.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and development expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a comparison of research and development expenses for the years ended December 31, 2024 and 2023 (in thousands, except percentages):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legacy Selecta programs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,676)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for MG</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Early stage programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development facilities and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26,155)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the year ended December 31, 2024, our research and development expenses were $45.1 million, compared to $71.3 million for the year ended December 31, 2023, a decrease of $26.2 million. The expenses associated with legacy Selecta programs decreased $25.7 million due to the wind down of the legacy Selecta programs as part of our strategic reprioritization. The increase in expenses for Descartes-08 for MG was primarily related to the expenses for the ongoing Phase 2b trial and the preparations for the Phase 3 AURORA trial that were incurred following the Merger. Our research and development employee expenses decreased $6.4 million due to a one-time cash charge to salaries and benefits as a result of our restructuring in 2023. The decrease in our research and development stock-based compensation expense was primarily the result of the settlement of equity compensation awards in connection with the Merger. The increase in our research and development facilities and other expenses was primarily the result of our lease of integrated manufacturing and office space in Frederick, Maryland that commenced May 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and administrative expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, our general and administrative expenses were $30.1 million, compared to $40.5 million for the year ended December 31, 2023, a decrease of $10.4 million. The decrease in costs was primarily the result of reductions in expenses incurred for stock compensation and professional fees in connection with the Merger.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Impairment of long-lived assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, our impairment of long-lived assets was $7.6 million, compared to $0.7 million for the year ended December 31, 2023, an increase of $6.9 million. During the year ended December 31, 2024, we recorded a full impairment charge of $7.6 million after evaluating the right-of-use assets and related furniture and fixtures upon our decision to cease use of our office and laboratory space at 65 Grove Street, Watertown, Massachusetts. During the year ended December 31, 2023, we recorded an impairment charge of $0.7 million related to the partial impairment of a right-of-use asset at 65 Grove Street, Watertown, Massachusetts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest income</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the year ended December 31, 2024 was $7.4&#160;million, compared to $5.0 million for the year ended  December 31, 2023, an increase of $2.4 million. The increase in interest income was due to increased investment balances.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2024, we recognized no interest expense. Interest expense for the year ended December 31, 2023 comprised interest expense and amortization of the carrying costs of our credit facilities and loss on extinguishment of debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in fair value of warrant liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the year ended December 31, 2024, we recognized $2.6 million of income from the decrease in the fair value of warrant liabilities, compared to $12.7 million for the year ended December 31, 2023, a decrease of $10.1 million. Fair value of warrant liabilities was determined utilizing the Black-Scholes valuation methodology. The decrease in warrant value was primarily driven by a decrease in the per-share price of our common stock and the expiration of the warrants we issued in 2019, or the 2019 Warrants, during the year ended December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in fair value of contingent value right liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, we recognized $36.9 million of expense associated with the increase in the fair value of contingent value right liability, compared to $18.3 million of expense for the year ended December 31, 2023, an increase of $18.6 million. The fair value of the contingent value right liability as of December 31, 2024 was determined </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilizing a Monte Carlo simulation model and as of December 31, 2023 was determined utilizing a discounted cash flow valuation methodology. The increase in the fair value of CVR liability was primarily due to changes in the amount and timing of anticipated payments and the passage of time.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in fair value of forward contract liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, we recognized $6.9 million of expense associated with the increase in the fair value of Series A Preferred Stock forward contract liabilities, compared to $149.6 million of expense for the year ended December 31, 2023, a decrease of $142.7 million. The increase in the fair value of the Series A Preferred Stock forward contract liabilities during the year ended December 31, 2023 was primarily driven by an increase in the per-share price of our common stock since the date of the Merger and 2023 Private Placement. A portion of the forward contract liability was settled during the year ended December 31, 2023 and there was no such forward contract liability prior to the Merger. The increase in the fair value of the Series A Preferred Stock forward contract liabilities during the year ended December 31, 2024 was primarily driven by an increase in the per-share price of our common stock since December 31, 2023 through settlement. The remaining Series A Preferred Stock forward contract liability was settled during the year ended December 31, 2024. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other income, net</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2024, we recognized other income, net of $0.6&#160;million, compared to $0.7 million for the year ended December 31, 2023, a decrease of $0.1 million.  The decrease was primarily driven by a decrease in sublease income. The terms of our subleases expired during the year ended December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, we recognized a deferred tax expense of $0.3 million relating to a change in state tax rate applied to the indefinite deferred tax liability.  During the year ended December 31, 2023, we recognized a current tax benefit of $19.0 million relating to the benefit of legacy Selecta tax attributes that reduced deferred tax liabilities during the year.</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_118"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for net income for the year ended December 31, 2022, we have incurred recurring net losses since our inception. We expect that we will continue to incur losses and that such losses will increase for the foreseeable future. We expect that our research and development and general and administrative expenses will continue to increase and, as a result, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, third-party funding, potential royalty and/or milestone monetization transactions and other collaborations and strategic alliances.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our cash, cash equivalents, and restricted cash were $214.3 million as of December 31, 2024, of which $1.7 million was restricted cash related to lease commitments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing cash equivalents, we from time to time have received and may receive in the future research and development funding pursuant to our collaboration and license agreements. Currently, funding from payments under our collaboration agreements represent our only source of committed external funds. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The liability associated with the contingent value rights agreement, or CVR Agreement, entered into on December 6, 2023, will be settled solely through cash flow received under the Sobi License and any other Gross Proceeds (as such term is defined in the CVR Agreement) net of certain agreed deductions. Under the CVR Agreement, 100% of all milestone payments, royalties, and other amounts paid to us or our controlled entities under the Sobi License, and any other Gross Proceeds, in each case net of certain agreed deductions, will be distributed to holders of the CVRs. There is no contractual obligation for us to fund any amount related to the CVR liability.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-licenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we entered into the Biogen Agreement with Biogen to research, develop, make, use, offer, sell and import products or processes containing or using an engineering T-cell modified with an mRNA comprising, or encoding a protein comprising, certain sequences licensed under the Biogen Agreement for the prevention, treatment, palliation and management of autoimmune diseases and disorders, excluding cancers, neoplastic disorders, and paraneoplastic disorders. We are not obligated to pay Biogen any expenses, fees, or royalties. For further description of the Biogen Agreement, see Note 16 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective September 2019, we entered into the NCI Agreement with NCI. Under the NCI Agreement, we were granted a license under certain NCI patents and patent applications designated in the agreement, to make, use, sell, offer and import products and processes within the scope of the patents and applications licensed under the NCI Agreement when developing and manufacturing anti-BCMA CAR-T cell products for the treatment of MG, pemphigus vulgaris, and immune thrombocytopenic purpura according to methods designated in the NCI Agreement. In connection with our entry into the NCI </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreement, we paid to NCI a one-time $0.1 million license royalty payment. Under the NCI Agreement, we are further required to pay NCI a low five-digit annual royalty. We must also pay earned royalties on net sales in a low single-digit percentage and pay up to $0.8 million in benchmark royalties upon our achievement of designated benchmarks that are based on the commercial development plan agreed between the parties. For further description of the NCI Agreement, see Note 16 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we and Ginkgo Bioworks Holdings, Inc., or Ginkgo, entered into a Collaboration and License Agreement, or the First Ginkgo Agreement, and paid Ginkgo a $0.5 million one-time upfront payment. In June 2022, we paid $0.5 million and issued 29,761 shares of our common stock then-valued at $1.0 million to Ginkgo for the achievement of certain preclinical milestones under the First Ginkgo Agreement. In January 2022, we entered into a Collaboration and License Agreement, or the Second Ginkgo Agreement, and paid Ginkgo a $1.5 million one-time upfront payment. In July 2023, we paid $1.0 million and issued 44,642 shares of our common stock then-valued at $1.5 million to Ginkgo for the achievement of certain preclinical milestones under the Second Ginkgo Agreement. For further description of the First Ginkgo Agreement and the Second Ginkgo Agreement, see Note 16 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in October 2021, we entered into an Exclusive License Agreement with Genovis AB (publ.), or Genovis, or the Genovis Agreement, and paid Genovis a $4.0 million one-time upfront payment. In February 2023, as a result of the sublicense of Xork, a bacterial IgG protease, to Astellas, we made a $4.0&#160;million payment to Genovis. The Genovis Agreement was terminated effective September 13, 2024. For further description of the Genovis Agreement, see Note 16 to our consolidated financial statements included elsewhere in this Annual Report. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2021, we entered into a Collaboration and License Agreement, or the Cyrus Agreement, with Cyrus Biotechnology, Inc., or Cyrus, and purchased 2,326,934 shares of Cyrus&#8217; Series B Preferred Stock, par value $0.0001 per share, at a purchase price of $0.8595 per share for an aggregate purchase price of $2.0 million. In October 2023, we notified Cyrus of our termination of the Cyrus Agreement, effective December 29, 2023. For further description of the Cyrus Agreement, see Note 16 to our consolidated financial statements included elsewhere in this Annual Report. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-licenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we entered into the Astellas Agreement with Astellas. Under this agreement, Astellas obtained the sole and exclusive right to commercialize Xork for use in Pompe disease in combination with an Astellas gene therapy investigational or authorized product, with a current focus on AT845. In connection with entry into this agreement, we received a $10.0 million upfront payment and are eligible to receive $340.0 million for certain additional development and commercial milestones plus royalties on any potential commercial sales where Xork is used as a pre-treatment for AT845. As a result of the sublicense of Xork to Astellas, we made a $4.0 million payment to Genovis in February 2023. The Astellas Agreement was terminated effective June 6, 2024. For further description of the Astellas Agreement, see Note 14 to our consolidated financial statements included elsewhere in this Annual Report. Amounts paid and remaining obligations with regard to the Xork product candidate not reimbursed by Astellas through the Astellas Agreement were subject to potential reimbursement through deductions to CVR distributions as described in Note 6 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, we entered into a License Agreement, or the Takeda Agreement, with Takeda Pharmaceuticals USA, Inc, or Takeda. We received a $3.0 million upfront payment and were entitled to receive up to $1.124 billion in future additional payments over the course of the partnership that were contingent on the achievement of development or commercial milestones or Takeda&#8217;s election to continue its activities at specified development stages. The Takeda Agreement was terminated effective July 25, 2023. For further description of the Takeda Agreement, see Note 14 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into the Sobi License. Sobi paid us a one-time, upfront payment of $75.0 million, and upon the closing of a private placement of our common stock to Sobi at a price of $138.468 per share, we received an additional $25.0 million from Sobi. We are eligible to receive $630.0 million in milestone payments upon the achievement of various development and regulatory milestones and sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier. Sobi has agreed to fund the Phase 3 clinical program of SEL-212, which commenced in September 2020. In July 2022, we received $10.0 million for the completion of the enrollment of the DISSOLVE II trial. In July 2024, we received $30.0&#160;million for the milestone associated with the initiation of a rolling biologics license application to the FDA for SEL-212 for the potential treatment of chronic refractory gout by Sobi. Proceeds from milestone payments and royalties on sales of SEL-212, if any, are required to be distributed, net of certain agreed deductions, to holders of the CVRs. For further description of the Sobi License, see Note 14 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in June 2020, we and Sarepta Therapeutics, Inc., or Sarepta, entered into a Research License and Option Agreement, or the Sarepta Agreement. Sarepta paid us a $2.0 million upfront payment upon closing and $3.0 million for the achievement of certain preclinical milestones in June 2021. In August 2022, we received a payment of $2.0 million in exchange for a nine-month extension to Sarepta&#8217;s options to both Duchenne muscular dystrophy and certain limb-girdle muscular </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dystrophies and a payment of $4.0 million for the achievement of certain non-clinical milestones. In March 2023, we were notified by Sarepta that Sarepta would not be exercising its exclusive option under the Sarepta Agreement. The Sarepta Agreement terminated upon the expiration of the option in March 2023. For further description of the Sarepta Agreement, see Note 14 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 25, 2021, we entered into a Sales Agreement, or the 2021 Sales Agreement, with Leerink Partners LLC, or Leerink Partners (and then known as SVB Leerink LLC), to sell shares of our common stock, from time to time, through an &#8220;at the market&#8221; equity offering program under which Leerink Partners will act as sales agent. The shares of common stock sold pursuant to the 2021 Sales Agreement, if any, would be issued and sold pursuant to a registration statement filed with the Securities and Exchange Commission, or SEC, for aggregate gross sales proceeds of up to $75.0 million. During the years ended December 31, 2024 and 2023, we sold no shares of our common stock pursuant to the 2021 Sales Agreement. On December 13, 2024, we and Leerink Partners entered into a Sales Agreement, or the 2024 Sales Agreement. The 2024 Sales Agreement supersedes the 2021 Sales Agreement, which is no longer in effect. Under the 2024 Sales Agreement, we may issue and sell shares of our common stock, from time to time, through Leerink Partners for aggregate gross sales proceeds of up to $100.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023, we entered into the 2023 Securities Purchase Agreement with (i) Dr. Timothy A. Springer, a member of our Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Seven One Eight Three Four Irrevocable Trust, a trust associated with Dr. Murat Kalayoglu, a co-founder and the former chief executive officer of Old Cartesian, who joined our Board of Directors effective immediately after the effective time of the Merger, providing for the 2023 Private Placement. In the 2023 Private Placement, we issued and sold an aggregate of 149,330.115 shares of Series A Preferred Stock for an aggregate purchase price of $60.25 million, of which 50,189.789 shares of Series A Preferred Stock were issued and sold in the year ended December 31, 2023 for gross proceeds of $20.25 million, and 99,140.326 shares of Series A Preferred Stock were issued and sold during the year ended December 31, 2024 for gross proceeds of $40.0 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2024, we entered into the 2024 Securities Purchase Agreement for the 2024 Private Placement with certain institutional and accredited investors, or the Purchasers. In the 2024 Private Placement, we issued and sold an aggregate of 3,563,247 shares of common stock and 2,937,903 shares of Series B Preferred Stock for which we generated gross proceeds of approximately $130.0&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously maintained a term loan of up to $35.0 million, of which $25.0 million was funded in August 2020. In September 2023, we entered into a payoff letter with Oxford Finance LLC and Silicon Valley Bank, a division of First-Citizens Bank &amp; Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for SVBB (as successor to Silicon Valley Bank)), the lenders under the term loan, pursuant to which we paid all outstanding amounts under such term loan, together with accrued interest and a prepayment penalty, resulting in the full extinguishment of such term loan. The total payoff amount was $22.3 million, consisting of the remaining principal amount due of $19.8 million, the final payment fee of $2.3 million, the prepayment penalty of $0.2 million, and less than $0.1 million of accrued interest.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If in the future we seek debt financing, the terms of such debt could restrict our operating and financial flexibility by imposing liens on our assets and covenants on the operation of our business.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future funding requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, we have not generated any revenue from product sales. We do not know when, or if, we will generate revenue from product sales. We will not generate significant revenue from product sales unless and until we obtain regulatory approval and commercialize one of our current or future product candidates. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses, milestone and royalty payments for in-licenses, and general overhead costs. We expect that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are subject to risks in the development of our products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We expect that we will need substantial additional funding to support our continuing operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had an accumulated deficit of $692.1 million. We anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of our product candidates, conducting preclinical studies and clinical trials, and our administrative organization. We will require substantial additional financing to fund our operations and to continue to execute our strategy, and we will pursue a range of options to secure additional capital.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly evaluate various potential sources of additional funding such as strategic collaborations, license agreements, debt issuance, potential royalty and/or milestone monetization transactions and the issuance of equity instruments to fund our operations. If we raise additional funds through strategic collaborations and alliances, which may include existing collaboration partners, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms that are not favorable to us. To the extent that we raise additional capital through the sale of equity instruments, the ownership interest of our existing stockholders will be diluted, and other preferences may be necessary that adversely affect the rights of existing stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents, and restricted cash as of December 31, 2024 will enable us to fund our operating expenses and capital expenditure requirements into mid-2027. We may pursue additional cash resources through public or private equity or debt financings, by establishing collaborations with other companies or through the monetization of potential royalty and/or milestone payments pursuant to our existing collaboration and license arrangements. Management&#8217;s expectations with respect to our ability to fund current and long-term planned operations are based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, we may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. However, there is no guarantee that any of these strategic or financing opportunities will be executed on favorable terms, and some could be dilutive to existing stockholders. If we are unable to obtain additional funding on a timely basis, we may be forced to significantly curtail, delay, or discontinue one or more of our planned research or development programs or be unable to expand our operations, meet long-term obligations or otherwise capitalize on our commercialization of our product candidates. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our clinical trials, preclinical development, manufacturing, laboratory testing and logistics;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of product candidates that we pursue and the speed with which we pursue development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our headcount growth and associated costs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, from commercial sales of our product candidates for which we receive marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Requirements due to Contractual Obligations and Other Commitments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are under agreement to lease approximately 32,294 square feet of laboratory and office space in Watertown, Massachusetts through May 2028. Remaining lease payments from December 31, 2024 through the end of the lease term total approximately $9.7 million. Payments made and remaining obligations on this lease liability are subject to potential reimbursement through deductions to CVR distributions as described in Note 6 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, in connection with the Merger, we acquired two leases for office and laboratory space in Gaithersburg, Maryland, which expire in January 2027. Annualized rent is approximately $0.3 million and remaining lease payments from December 31, 2024 through the end of the lease term total approximately $0.7 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we entered into an agreement to lease approximately 19,199 square feet of integrated manufacturing and office space in Fredericksburg, Maryland. In May 2024, we entered into an amendment to lease an additional approximately 7,842 square feet at the same site. In August 2024, we entered into a second amendment to lease an additional approximately 2,009 square feet at the same site. The lease, as amended, expires in June 2031. Annualized base rent under the leases is approximately $1.2 million and is subject to annual increases in accordance with the terms of the lease agreement. The leases provide for a tenant improvement allowance of $0.8 million. Remaining lease payments from December 31, 2024 through the end of the lease term total approximately $8.1 million.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are also party to certain license and collaboration agreements with Biogen, NCI, and Shenyang Sunshine Pharmaceutical Co., Ltd., or 3SBio. We may be obligated to make certain future payments which are contingent upon future events such as our achievement of specified regulatory and commercial milestones, or royalties on net product sales under these agreements. As of December 31, 2024, we were unable to estimate the timing or likelihood of achieving these milestones or </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">generating future product sales. Payments made and remaining obligations on the license agreement with 3SBio are subject to potential reimbursement through deductions to CVR distributions as described in Note 6 to our consolidated financial statements included elsewhere in this Annual Report. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Cash Flows</span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash provided by and (used in):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,750)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December 31, 2024 was $23.7 million compared to $51.2 million in the same period in 2023. The decrease in net cash used in operating activities of $27.5 million was primarily due to $17.9 million of net loss, adjusted for non-cash items, and $5.8 million of cash used in changes in operating assets and liabilities, in each case during the year ended December 31, 2024 compared to $56.1 million of net loss, adjusted for non-cash items, and $4.9 million of cash provided by changes in operating assets and liabilities during the year ended December 31, 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December 31, 2024 was $8.7 million compared to net cash provided by investing activities of $34.6 million in the same period in 2023, a decrease of $43.3 million. The net cash used in investing activities for the year ended December 31, 2024 consisted primarily of purchases of property and equipment. The net cash provided by investing activities for the year ended December 31, 2023 was primarily proceeds from the maturities of marketable securities and cash assumed in the Merger offset by purchases of property and equipment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2024 was $168.4 million compared to net cash used in financing activities of $13.1 million in the same period in 2023, an increase of $181.5 million. The net cash provided by financing activities for the year ended December 31, 2024 was primarily the result of proceeds of the 2024 Private Placement and the 2023 Private Placement. The net cash used in financing activities for the year ended December 31, 2023 was primarily the result of repayments of principal on outstanding debt and settlement of equity awards in the Merger partially offset by proceeds from the 2023 Private Placement.  </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently adopted or issued accounting pronouncements refer to Note 3 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we did not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_121"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgements that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in our consolidated financial statements. Actual results may differ from these estimates under different assumptions or conditions and could have a material impact on our reported results. While our significant accounting policies are more fully described in the notes to our consolidated financial statements included elsewhere in this Annual Report, we believe the following accounting policies to be the most critical in understanding the judgments and estimates we use in preparing our consolidated financial statements:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Right Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CVRs distributed pursuant to the terms of the CVR Agreement represent financial instruments that are accounted for under the fair value option election in ASC Topic 825, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments (ASC 825)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the fair value option election, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the CVRs are initially measured at the aggregate estimated fair value of the CVRs and will be subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the CVR liability was determined using a discounted cash flow methodology as of December 31, 2023 and a Monte Carlo simulation model as of December 31, 2024 to estimate future cash flows associated with the legacy assets, including the expected milestone and royalty payments under the Sobi License, net of deductions. Changes in fair value of the CVR liability are presented in the consolidated statements of operations and comprehensive loss. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, expected volatility of future revenues (Monte Carlo simulation model) and risk-adjustment discount rates (discounted cash flow methodology), which represent a Level 3 measurement within the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and License Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. Pursuant to ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers (ASC 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. If a promised good or service is not distinct, it is combined with other promised goods or services into a performance obligation. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Revenue: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently generate revenue through collaboration and license agreements with strategic collaborators for the development and commercialization of product candidates. Collaboration and license agreements with customers are generally accounted for in accordance with ASC 606. We analyze collaboration arrangements by first assessing whether they are within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (ASC 808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and evaluate whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. Collaboration agreements with customers that are not within the scope of ASC 808 are accounted for in accordance with ASC 606. To the extent the collaboration agreement is within the scope of ASC 808, we also assess whether any aspects of the agreement are within the scope of other accounting literature (specifically ASC 606). If we conclude that some or all aspects of the agreement are distinct and represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606. We recognize the shared costs incurred that are not within the scope of other accounting literature as a component of the related expense in the period incurred by analogy to ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development (ASC 730)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and record reimbursements from counterparties as an offset to the related research and development costs. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under the agreements in accordance with ASC 606, we perform the five steps above. As part of the accounting for the arrangement, we must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;We use key assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success. The assumptions used to determine the stand-alone selling price and our satisfaction of performance obligations have a material effect on our collaboration and license revenue and may prove to be wrong. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of our arrangements typically include one or more of the following: (i) upfront fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; (iii) royalties on net sales of licensed products; (iv) reimbursements or cost-sharing of research and development expenses; and (v) profit/loss sharing arising from co-promotion arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other promised goods and services identified in the arrangement, we recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. If not distinct, the license is combined with other promised goods and services in the contract. For licenses that are combined with other promised goods and services, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Optional licenses are evaluated to determine if </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they are issued at a discount, and therefore, represent material rights and should be accounted for as separate performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes developmental and regulatory milestone payments, we evaluate whether the achievement of each milestone specifically relates to our efforts to satisfy a performance obligation or transfer a distinct good or service within a performance obligation. If the achievement of a milestone is considered a direct result of our efforts to satisfy a performance obligation or transfer a distinct good or service and the receipt of the payment is based upon the achievement of the milestone, the associated milestone value is allocated to that distinct good or service. If the milestone payment is not specifically related to our efforts to satisfy a performance obligation or transfer a distinct good or service, the amount is allocated to all performance obligations using the relative standalone selling price method. We also evaluate the milestone to determine whether they are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price to be allocated, otherwise, such amounts are constrained and excluded from the transaction price.&#160;At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the transaction price.&#160;Any such adjustments to the transaction price are allocated to the performance obligations on the same basis as at contract inception. Amounts allocated to a satisfied performance obligation shall be recognized as revenue, or as a reduction of revenue, in the period in which the transaction price changes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Supply Services: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are evaluated to determine if they are distinct and optional. For optional services that are distinct, we assess if they are priced at a discount, and therefore, provide a material right to the licensee to be accounted for as separate performance obligations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied) in accordance with the royalty recognition constraint.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expenses, and we outsource a significant portion of these costs to third-parties. Third-party clinical trial expenses include patient costs, clinical research organization costs and costs for data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued clinical trial cost. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Non-refundable&#160;advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. We also record accruals for estimated ongoing clinical research and development costs. When evaluating the adequacy of the accrued liabilities, we analyze progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by us materially affecting our results of operations. The historical clinical accrual estimates made by us have not been materially different from the actual costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we issued the 2019 Warrants in connection with a securities purchase agreement between us and a group of institutional investors and certain members of our Board of Directors. Pursuant to the terms of the 2019 Warrants, we could have been required to settle the common warrants in cash in the event of certain acquisitions of us and, as a result, the 2019 Warrants were required to be measured at fair value and reported as a liability on the balance sheet.&#160; The outstanding 2019 Warrants expired on December 23, 2024 in accordance with their terms. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we issued warrants in connection with an underwritten offering of shares of common stock and warrants to purchase shares of common stock, or the 2022 Warrants. Pursuant to the terms of the 2022 Warrants, we could be required to settle the 2022 Warrants in cash in the event we are acquired under certain circumstances and, as a result, the 2022 Warrants are required to be measured at fair value and reported as a liability on the balance sheet. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded the fair value of the 2019 Warrants and 2022 Warrants upon issuance using the Black-Scholes valuation model, and are required to revalue the common warrants at each reporting date and upon exercise or expiration with any changes in fair value recorded on our statement of operations. In December 2022, we amended the terms of the outstanding 2019 Warrants held by certain members of our Board of Directors to remove the cash settlement provision (as so amended, the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended 2019 Warrants).  As a result, the Amended 2019 Warrants were remeasured at fair value on December 20, 2022 and reclassified from a liability to equity on the balance sheet. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs used to determine estimated fair value of the common warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The estimates used to determine the fair value of these common warrants represent our best estimates, but may prove to be wrong. Therefore, the change in fair value of warrant liabilities could be materially different in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for all stock-based compensation granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of estimated forfeitures. To the extent that actual forfeitures differ from our estimates, the differences are recorded as a cumulative adjustment in the period the estimates were adjusted. Stock-based compensation expense recognized in the consolidated financial statements is based on awards that ultimately vest. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in determining the fair value of stock-based awards represent our best estimates, but the estimates involve inherent uncertainties and the application of our judgment. As a result, if factors change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different in the future.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We qualify as a &#8220;smaller reporting company&#8221; under the rules of the Securities Act and the Exchange Act. As a result, we may choose to take advantage of certain scaled disclosure requirements available specifically to smaller reporting companies. We will remain a smaller reporting company until the last day of the fiscal year in which the aggregate market value of our common stock held by non-affiliated persons and entities, or our public float, is more than $700 million as of the last business day of our most recently completed second fiscal quarter, or until the fiscal year following the year in which we have at least $100 million in revenue and at least $250 million in public float as of the last business day of our most recently completed second fiscal quarter.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_124"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company under the rules of the Securities Act and the Exchange Act and are not required to provide this information required under this item.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_127"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.  Financial Statements and Supplementary Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements together with the report of our independent registered public company accounting firm, required to be filed pursuant to this Item 8 are appended to this Annual Report. An index of those consolidated financial statements is found in Item 15.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_130"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.  Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_133"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.  Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), that are designed to ensure information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principle financial officer, to allow timely decisions regarding required disclosure. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore, the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies and procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of controls, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our system of controls to enhance, where necessary, our control policies and procedures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Remediation of Previously Identified Material Weakness</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We previously reported a material weakness, identified in 2023, in our internal controls specifically related to the documentation of the assumptions supporting the valuation of the in-process research and development intangible assets acquired in connection with the Old Cartesian material business combination and the initial and on-going contingent value right obligation issued at that time to legacy Selecta stockholders. This material weakness included a lack of sufficient documentation to provide evidence of the associated management review controls. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we have not entered into any business combination transactions since November 2023, the annual impairment testing required for our in-process research and development intangible assets necessitates similar valuation processes and controls. For example, both could require the development of sophisticated long-range cash flow forecasts, by indication and market, appropriately adjusted for probability of success, which include but are not limited to: (i) revenues from product sales and/or royalties; (ii) expenses, including costs of goods sold, research and development, general and administrative and sales and marketing; (iii) expectations of long-term effective tax rates; (iv) consideration of capital expenditures which may be required in order to achieve revenue; and (v) working capital requirements. The resulting forecasts are then subjected to a discounted cash flow analysis in order to arrive at an estimate of fair value. A similar cash flow forecasting process and discounted cash flow analysis is utilized at each reporting period to determine the estimated fair value of the contingent value right obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the Company&#8217;s required annual impairment testing (performed as of October 1, 2024) of its in-process research and development intangible assets, management documented and reviewed the significant inputs and assumptions used in the purchase accounting for the Old Cartesian material business combination. As proscribed in &#8220;ASC 350 &#8211; Intangibles &#8211; Goodwill and Other,&#8221; management began with a qualitative assessment to determine whether it was necessary to perform the quantitative testing. Management&#8217;s qualitative assessment resulted in a determination that it was not more likely than not that the Company&#8217;s in-process research and development assets were impaired. Therefore, quantitative testing was not required to be performed. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At each reporting period during fiscal 2024, management documented and reviewed the significant inputs and assumptions used by the Company&#8217;s third-party valuation firm to determine the estimated fair value of the contingent value right obligation. Cash flow forecasts were prepared by management, along with the necessary documentation and memoranda evidencing that the required controls were in place and operating effectively. These cash flow forecasts were then subjected to discounted cash flow analysis to determine the estimated fair value of the contingent value right obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based upon management&#8217;s assessment, we have concluded that our disclosure controls and procedures were designed and operating effectively as of December 31, 2024 and, therefore, the previously identified material weakness was remediated.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f) and 15d-15(f), to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Internal control over financial reporting includes our policies and procedures, such as our Code of Business Conduct and Ethics, which (i) require our employees, officers and directors to adhere to certain ethical standards; (ii) require the maintenance of records, in reasonable detail, to help to ensure that our transactions, assets and liabilities are accurately and fairly recorded; (iii) provide reasonable assurance that transactions are authorized by our management and directors and are recorded as necessary to allow for the accurate preparation of financial statements in accordance with U.S. GAAP; and (iv) provide reasonable assurance regarding the safeguarding of our assets and the prevention or timely detection of the unauthorized acquisition, use or disposition of our assets, which could have a material effect on the financial statements. Internal control over financial reporting includes the controls themselves, management&#8217;s monitoring of those controls, actions taken to correct any deficiencies identified and oversight of our internal control environment by the Audit Committee of our Board of Directors. Any system of internal control has inherent limitations and therefore may not prevent or detect misstatements. Projections of any evaluation of the effectiveness of internal control over financial reporting to future periods are subject to the risk that controls may become inadequate over time because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management assessed the effectiveness of our internal control over financial reporting as of the end of our fiscal year 2024 and has reviewed the results of this assessment with the Audit Committee of our Board of Directors. Management based its assessment on criteria established in &#8220;Internal Control - Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Except as described above under &#8220;&#8212;Remediation of Previously Identified Material Weakness,&#8221; there have been no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to an exemption established for &#8220;smaller reporting companies.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_139"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.  Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-4" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-51" escape="true">On <ix:nonNumeric contextRef="c-5" name="ecd:TrdArrAdoptionDate" id="f-52">December 23, 2024</ix:nonNumeric>, <ix:nonNumeric contextRef="c-5" name="ecd:TrdArrIndName" id="f-53">Christopher Jewell</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-5" name="ecd:TrdArrIndTitle" id="f-54">Chief Scientific Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-55">adopted</ix:nonNumeric> a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Dr. Jewell&#8217;s plan provides for the exercise of vested stock options and the potential associated sale of up to <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-56">15,000</ix:nonFraction> shares of our common stock until and including December 31, 2025. The foregoing exercises or sales, if any, will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and <ix:nonNumeric contextRef="c-5" name="ecd:TrdArrExpirationDate" id="f-57">December 31, 2025</ix:nonNumeric>.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fiscal quarter ended December 31, 2024, no other officer or director, as defined in Rule 16a-1(f) of the Exchange Act, informed us of the <ix:nonNumeric contextRef="c-7" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-58">adoption</ix:nonNumeric>, modification or <ix:nonNumeric contextRef="c-7" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-59"><ix:nonNumeric contextRef="c-7" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-60">termination</ix:nonNumeric></ix:nonNumeric> of any &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as those terms are defined in Item 408 of Regulation S-K . </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_142"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_145"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_148"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.  Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference from the information in our Proxy Statement for our 2025 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_151"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.  Executive Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference from the information in our Proxy Statement for our 2025 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_154"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference from the information in our Proxy Statement for our 2025 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_157"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.  Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference from the information in our Proxy Statement for our 2025 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_160"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.  Principal Accountant Fees and Services</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference from the information in our Proxy Statement for our 2025 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_163"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_169"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.  Exhibits, Financial Statement Schedules</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(1) Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the &#8220;Index to Consolidated Financial Statements&#8221; on page F-1 below for the list of financial statements filed as part of this report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(2) Financial Statement Schedules</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial schedules have been omitted because the required information is either presented in the consolidated financial statements filed as part of this Annual Report on Form 10-K or the notes thereto or is not required.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(3) Exhibits</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex21.htm">2.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex21.htm">Agreement and Plan of Merger, dated November 13, 2023, by and among Selecta Biosciences, Inc., Sakura Merger Sub I, Inc., Sakura Merger Sub II, LLC, and Cartesian Therapeutics, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/13/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000110465916129891/a16-14002_1ex3d1.htm">3.1(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000110465916129891/a16-14002_1ex3d1.htm">Restated Certificate of Incorporation of Selecta Biosciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/29/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368722000109/exhibit31_charteramendment.htm">3.1(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368722000109/exhibit31_charteramendment.htm">Certificate of Amendment to the Restated Certificate of Incorporation of Selecta Biosciences, Inc., dated June 21, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/21/2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex33.htm">3.1(c)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex33.htm">Certificate of Amendment to the Restated Certificate of Incorporation of Selecta Biosciences, Inc., dated November 13, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/13/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368724000048/exhibit32certificateofamen.htm">3.1(d)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368724000048/exhibit32certificateofamen.htm">Certificate of Amendment to the Restated Certificate of Incorporation, as amended, of Cartesian Therapeutics, Inc., dated March 28, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/28/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523276086/d549858dex32.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523276086/d549858dex32.htm">Amended and Restated By-laws of Cartesian Therapeutics, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/13/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit41rnacspecimensto.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit41rnacspecimensto.htm">Specimen Stock Certificate evidencing the shares of common stock</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000104746916013398/a2228672zex-4_6.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000104746916013398/a2228672zex-4_6.htm">Form of Warrant to Purchase Shares of Series E Preferred Stock, dated December 31, 2015, issued by the Registrant to Oxford Finance LLC and Square One Bank, together with a schedule of warrant holders</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-211555</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/24/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000096/exhibit41sobiregistrat.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000096/exhibit41sobiregistrat.htm">Registration Rights Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000129/exhibit42sobirraandame.htm">4.4</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000129/exhibit42sobirraandame.htm">Registration Rights Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ), as amended on November 4, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/5/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000104/exhibit41formofwarrant.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000104/exhibit41formofwarrant.htm">Form of Warrant to Purchase Stock, dated August 31, 2020, issued by Selecta Biosciences, Inc. to Oxford Finance LLC and Silicon Valley Bank, together with a schedule of warrants.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312522098074/d535347dex41.htm">4.6</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312522098074/d535347dex41.htm">Form of Common Stock Purchase Warrant, dated April 11, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/6/2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex21.htm">4.7</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex21.htm">Form of Contingent Value Rights Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/13/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex102.htm">4.8</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex102.htm">Registration Rights Agreement, by and among Selecta Biosciences, Inc. and certain purchasers party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/13/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex34.htm">4.9(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex34.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/13/2023</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368724000048/exhibit31certificateofamen.htm">4.9(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368724000048/exhibit31certificateofamen.htm">Certificate of Amendment to the Certificate of Designation of Series A Non-Voting Convertible Preferred Stock, dated March 26, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/28/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/ef20031962_ex3-1.htm">4.10</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/ef20031962_ex3-1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/2/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000114036124032080/ef20031962_ex10-2.htm">4.11</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000114036124032080/ef20031962_ex10-2.htm">Form of Registration Rights Agreement, dated as of July 2, 2024, by and among the Registrant and the Investors named therein.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/2/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit412descriptionofsec.htm">4.12</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit412descriptionofsec.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000114036124035433/ny20033174x1_ex10-1.htm">10.1#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000114036124035433/ny20033174x1_ex10-1.htm">Amended and Restated 2016 Incentive Award Plan and form of award agreements thereunder</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-281204</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000104746916013718/a2228810zex-10_3.htm">10.2#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000104746916013718/a2228810zex-10_3.htm">2016 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-211555</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103_employmentinduc.htm">10.3#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103_employmentinduc.htm">Amended and Restated Cartesian Therapeutics, Inc. 2018 Employment Inducement Incentive Award Plan, and forms of award agreements thereunder</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000114036124002120/ny20014884x3_ex99-1.htm">10.4#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000114036124002120/ny20014884x3_ex99-1.htm">Cartesian Therapeutics, Inc. 2016 Stock Incentive Plan, and forms of award agreements thereunder</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-276486</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/12/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit105non-employeedire.htm">10.5#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit105non-employeedire.htm">Non-Employee Director Compensation Program</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000104746916013398/a2228672zex-10_5.htm">10.6#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000104746916013398/a2228672zex-10_5.htm">Form of Indemnification Agreement for Directors and Officers</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-211555</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/24/2016</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368717000053/exhibit106_63017.htm">10.7&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368717000053/exhibit106_63017.htm">Amended and Restated License Agreement, dated as of May 31, 2017, by and between the Registrant and Shenyang Sunshine Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/11/2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000104746916013398/a2228672zex-10_10.htm">10.8&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000104746916013398/a2228672zex-10_10.htm">Manufacturing Services Agreement, dated as of August 1, 2014, by and between the Registrant and Shenyang Sunshine Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-211555</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/24/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368719000157/exhibit103leaseagreeme.htm">10.9(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368719000157/exhibit103leaseagreeme.htm">Lease Agreement by and between BRE-BMR Grove LLC and Selecta Biosciences, Inc. dated July 23, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/8/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368722000137/exhibit101_firstamendmentt.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368722000137/exhibit101_firstamendmentt.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368722000137/exhibit101_firstamendmentt.htm">(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368722000137/exhibit101_firstamendmentt.htm">First Amendment to Lease by and between BRE-BMR Grove LLC and Selecta Biosciences, Inc. dated September 1, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/3/2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1011aleaseagreement.htm">10.10(a)&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1011aleaseagreement.htm">Lease Agreement by and between 704 Quince Orchard Owner, LLC and Cartesian Therapeutics, Inc. dated May 11, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1011bfirstamendment.htm">10.10(b)&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1011bfirstamendment.htm">First Amendment to Lease Agreement by and between 704 Quince Orchard Owner, LLC and Cartesian Therapeutics, Inc. dated March 22, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1011csecondamendmen.htm">10.10(c)&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1011csecondamendmen.htm">Second Amendment to Lease Agreement by and between 704 Quince Orchard Owner, LLC and Cartesian Therapeutics, Inc. dated May 3, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11(c)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1012leasebetween749.htm">10.11(a)&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1012leasebetween749.htm">Lease Agreement by and between 7495 RP, LLC and Cartesian Therapeutics, Inc. dated February 28, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000082/firstamendmenttoleaseagree.htm">10.11(b)&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000082/firstamendmenttoleaseagree.htm">First Amendment to Lease Agreement by and between 7495 RP, LLC and the Registrant dated May 7, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/8/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000124/ex101secondamendmenttoleas.htm">10.11(c)&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000124/ex101secondamendmenttoleas.htm">Second Amendment to Lease Agreement by and between 7495 RP, LLC and the Registrant dated August 30, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/7/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368718000061/exhibit102_brunnemployment.htm">10.12#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368718000061/exhibit102_brunnemployment.htm">Employment Agreement, dated as of September 25, 2018, by and between the Registrant and Carsten Brunn, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/27/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368723000040/exhibit1015_employmentagre.htm">10.13#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368723000040/exhibit1015_employmentagre.htm">Employment Agreement, dated as of November 9, 2022, by and between the Registrant and Blaine Davis</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000052/exhibit101employmentagreem.htm">10.14#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000052/exhibit101employmentagreem.htm">Employment Agreement, dates as of March 26, 2024, by and between the Registrant and Christopher Jewell, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/1/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000052/exhibit102employmentagreem.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000052/exhibit102employmentagreem.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000052/exhibit102employmentagreem.htm">#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000052/exhibit102employmentagreem.htm">Employment Agreement, dates as of March 28, 2024, by and between the Registrant and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000052/exhibit102employmentagreem.htm">Metin K</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000052/exhibit102employmentagreem.htm">urtoglu, M.D., Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/1/2024</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000096/exhibit102sobilicensea.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000096/exhibit102sobilicensea.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000096/exhibit102sobilicensea.htm">(a)&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000096/exhibit102sobilicensea.htm">License and Development Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1015bamendmentno1to.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1015bamendmentno1to.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1015bamendmentno1to.htm">(b)&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1015bamendmentno1to.htm">Amendment No. 1 to License and Development Agreement, dated as of October 31, 2023, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1016patentlicenseno.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1016patentlicenseno.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1016patentlicenseno.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1016patentlicenseno.htm">Patent License Agreement, between Cartesian Therapeutics, Inc. and the U.S. Department of Health and Human Services, as represented by the National Cancer Institute of the National Institutes of Health, dated September 16, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1017patentlicenseag.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1017patentlicenseag.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1017patentlicenseag.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit1017patentlicenseag.htm">Patent License Agreement by and between Biogen MA, Inc. and Cartesian Therapeutics, Inc., dated September 8, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex103.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex103.htm">19</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex103.htm">#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex103.htm">Form of Retention Bonus Letter</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/13/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex101.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex101.htm">0</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex101.htm">Securities Purchase Agreement, dated as of November 13, 2023, by and among Selecta Biosciences, Inc. and each purchaser identified on Annex A thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/13/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000114036124049412/ny20039376x2_ex1-2.htm">10.21</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1453687/000114036124049412/ny20039376x2_ex1-2.htm">Sales Agreement, dated as of December 13, 2024, by and between the Registrant and Leerink Partners LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-283803</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit191insidertradingpo.htm">19.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit191insidertradingpo.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-62">Cartesian Therapeutics, Inc. Insider Trading Policy</ix:nonNumeric></a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211subsidiariesofca.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211subsidiariesofca.htm">Subsidiaries of Cartesian Therapeutics, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231_12312024.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231_12312024.htm">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311_12312024.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311_12312024.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312_12312024.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312_12312024.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321_12312024.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321_12312024.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit97compensationclawb.htm">97</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000036/exhibit97compensationclawb.htm">Cartesian Therapeutics, Inc. Compensation Clawback Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"># Indicates management contract or compensatory plan.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Certain annexes, schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224; Certain confidential information contained in this exhibit, marked by brackets and asterisks, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because the information (i) is not material and (ii) is the type of information that the Company both customarily and actually treats as private and confidential.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_172"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.  Form 10-K Summary</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_175"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.966%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CARTESIAN THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;13, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Carsten Brunn, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Carsten Brunn, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer, and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Blaine Davis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blaine Davis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Carrie S. Cox</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrie S. Cox</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy C. Barabe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy C. Barabe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Nishan de Silva, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nishan de Silva, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Murat Kalayoglu, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Murat Kalayoglu, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kemal Malik MBBS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kemal Malik, MBBS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Singer, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Singer, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy Springer, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Springer, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Patrick Zenner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patrick Zenner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:11pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:11pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_178"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cartesian Therapeutics, Inc. and Subsidiaries</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Index to Consolidated Financial Statements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pages</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_181">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-63">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_181">F-2</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_184">Consolidated Balance Sheets at December 31, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_184">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_184">4</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_187">Consolidated Statements of Operations and Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_187">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_187"> for the years ended December 31, 2024</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_187"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_187"> 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_187">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_187">5</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_190">Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_190">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_190"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_190"> 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_190">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_190">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_190">6</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_196">Consolidated Statements of Cash Flows for the years ended December 31, 2024</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_196"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_196"> 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_196">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_196">7</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_199">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_199">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_199">8</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_181"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Cartesian Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Cartesian Therapeutics, Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the Audit Committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.673%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Valuation of contingent value right</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Description of the Matter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3, the Company estimates the fair value of the Contingent Value Right (&#8220;CVR&#8221;) using a Monte Carlo simulation to estimate future cash flows associated with the legacy assets, including the expected milestone and royalty payments under the Sobi License, net of deductions. Changes in the fair value of the liability are presented in the consolidated statements of operations and comprehensive loss.  The liability value is calculated based on significant inputs that are not observable in the market such as estimated cash flows, estimated probabilities of success, and expected volatilities of revenues, which represent a Level 3 measurement within the fair value hierarchy.  For the year ended December 31, 2024, the Company recorded the change in the fair value of the contingent value right liability of $(36.9 million). As of December 31, 2024, the Company recorded the contingent value right liability and the contingent value right liability, net of current portion of $7.8 million and $387.7 million, respectively.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the fair value of the CVR liability was complex due to the significant judgment required in estimating the fair value. In particular, the fair value estimate required the use of valuation methodologies that were sensitive to significant assumptions including expected milestone and royalty payments and discount rate which are based on estimates of future market or economic conditions.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the fair value of the CVR liability, our audit procedures included, among others, assessing the appropriateness of the valuation methodology and testing the significant assumptions and the completeness and accuracy of the underlying data used by the Company. We compared the assumptions for expected milestone and royalty payments to projected industry revenue growth rates and other factors considered by management in developing the model. We involved our valuation specialist to assist in evaluating the valuation methodologies and discount rate used to value the CVR liability. We also performed sensitivity analyses to evaluate the changes in the fair value of the CVR liability that would result from changes in the significant assumptions.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-64">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2009.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-65">Boston, Massachusetts</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;13, 2025</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_184"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cartesian Therapeutics, Inc. and Subsidiaries</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data and par value)</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-66">212,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-67">76,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-68">872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">5,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="3" id="f-70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">2,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">216,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">90,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-76">9,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-77">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-78">5,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-79">10,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-80">150,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-81">150,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-82">48,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-83">48,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-86">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-87">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-88">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-90">435,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-91">305,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities, convertible preferred stock, and stockholders&#8217; deficit</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-92">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-93">3,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-94">12,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-95">15,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-96">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-97">2,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-99">2,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:WarrantsAndRightsOutstandingCurrent" format="ixt:fixed-zero" scale="3" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:WarrantsAndRightsOutstandingCurrent" scale="3" id="f-101">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent value right liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:ContingentValueRightLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-102">7,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:ContingentValueRightLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-103">15,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-105">28,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-106">22,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-107">68,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-108">11,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-109">8,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-111">3,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:WarrantsAndRightsOutstandingNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-112">3,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:WarrantsAndRightsOutstandingNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-113">5,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent value right liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:ContingentValueRightLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-114">387,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:ContingentValueRightLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-115">342,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-116">16,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-117">15,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-118">441,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-119">444,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 19)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-8" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-120"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-9" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-121"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-122"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-123">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-124">no</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-125">548,375</ix:nonFraction> shares authorized as of December 31, 2024 and December 31, 2023, respectively; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:fixed-zero" scale="0" id="f-126"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-127">no</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-128"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-129">435,120.513</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-131">296,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options for Series A Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-133">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-134"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-135">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-136">134,904.563</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-137">no</ix:nonFraction> shares authorized as of December 31, 2024 and December 31, 2023, respectively; <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-138"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-139">120,790.402</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-140"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-141">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series B Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-144"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-145">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-146">437,927</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-147">no</ix:nonFraction> shares authorized as of December 31, 2024 and December 31, 2023, respectively; <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-148"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-149">437,927</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-150"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-151">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-154"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-155">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-156">9,427,168.437</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-157">9,451,625</ix:nonFraction> shares authorized as of December 31, 2024 and December 31, 2023, respectively;  <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-158"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-159"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-160"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-161">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2024 and December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-164"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-165">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-166"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-167">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December 31, 2024 and December 31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-168"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-169">25,767,369</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-170"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-171">5,397,597</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-172">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-173">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-174">689,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-175">179,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-176">692,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-177">614,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-178">4,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-179">4,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">6,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">440,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities, convertible preferred stock, and stockholders&#8217; deficit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">435,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-183">305,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_187"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cartesian Therapeutics,&#160;Inc. and Subsidiaries</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and license revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-184">38,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-185">26,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="f-186">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-188">38,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-189">26,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-190">45,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-191">71,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-192">30,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-193">40,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-194">7,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="f-195">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-196">82,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-197">112,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-198">43,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-199">86,416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-200">7,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-201">4,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency transaction, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-203">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:fixed-zero" scale="3" id="f-204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-205">2,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-206">2,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-207">12,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent value right liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:FairValueAdjustmentOfContingentValueRightLiability" format="ixt:num-dot-decimal" scale="3" id="f-208">36,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:FairValueAdjustmentOfContingentValueRightLiability" format="ixt:num-dot-decimal" scale="3" id="f-209">18,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of forward contract liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="f-210">6,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="f-211">149,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-212">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-213">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-214">77,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-215">238,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-216">287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-217">19,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-218">77,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-219">219,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-220">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-221">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-223">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-224">77,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-225">219,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share allocable to common stockholders:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-226">4.48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-227">49.76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-228">4.49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-229">49.76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-230">17,276,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-231">5,170,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-232">17,357,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-233">5,170,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_190"></div><hr style="page-break-after:always"/><div style="min-height:14.4pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cartesian Therapeutics,&#160;Inc. and Subsidiaries</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.336%"><tr><td style="width:1.0%"/><td style="width:24.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.045%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.045%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.228%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.045%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.228%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.045%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.228%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.228%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:4.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.228%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.228%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options for </span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A</span></td><td colspan="6" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="6" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">paid-in</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">comprehensive</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">equity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(deficit)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-241">5,101,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-242">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">493,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-244">394,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">4,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-246">93,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Series A Preferred Stock in private placement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="rnac:TemporaryEquityStockIssuedDuringPeriodShares" scale="0" id="f-247">619.627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="f-248">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Series A Preferred Stock in connection with the Merger and settlement of related forward contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="rnac:TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares" format="ixt:num-dot-decimal" scale="0" id="f-249">384,930.724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue" format="ixt:num-dot-decimal" scale="3" id="f-250">261,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Series A Preferred Stock in connection with private placement and settlement of related forward contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="rnac:TemporaryEquityStockIssuedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-251">49,570.162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-252">34,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-253">6,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-254">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-255">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-256">21,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock forward in connection with the Merger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger" format="ixt:num-dot-decimal" scale="3" id="f-257">2,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger" format="ixt:num-dot-decimal" scale="3" id="f-258">2,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Merger and settlement of related forward contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-259">224,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of replacement options in Merger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger" format="ixt:num-dot-decimal" scale="3" id="f-260">3,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger" format="ixt:num-dot-decimal" scale="3" id="f-261">6,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger" format="ixt:num-dot-decimal" scale="3" id="f-262">6,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock, license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="rnac:StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-263">44,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="rnac:StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-264">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-265">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Settlement of outstanding equity awards at Merger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="rnac:AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="3" id="f-266">6,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="3" id="f-267">6,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distribution of contingent value rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="rnac:AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="f-268">340,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="f-269">340,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition" scale="3" id="f-270">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-271">20,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-272">20,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-273">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-274">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-275">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-276">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-277">219,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-278">219,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-279">435,120.513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-280">296,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-281">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-286">5,397,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-287">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-288">179,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-289">614,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-290">4,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-291">440,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Series A Preferred Stock in connection with private placement and settlement of related forward contract</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="rnac:TemporaryEquityStockIssuedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-292">99,140.326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-293">75,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="rnac:TemporaryEquityTransferOfPreferredStockToPermanentEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-294">534,260.839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:TemporaryEquityTransferOfPreferredStockToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="f-295">372,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="f-296">3,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="rnac:TransferOfTemporaryEquityToPermanentEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-297">534,260.839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="rnac:TransferOfTemporaryEquityToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="f-298">375,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:TransferOfTemporaryEquityToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="f-299">375,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of Series A Preferred Stock to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-300">413,470.437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-301">13,782,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-302">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-303">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="f-304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Series B Preferred Stock and common stock in connection with private placement, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-305">5,585</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-306">2,937,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-307">3,563,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-308">124,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-309">124,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of Series B Preferred Stock to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-310">2,499,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-311">2,499,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-312">458,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-313">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-314">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="rnac:StockIssuedDuringPeriodSharesCommonWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-315">65,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="rnac:StockIssuedDuringPeriodValueCommonWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="f-316">2,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:StockIssuedDuringPeriodValueCommonWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="f-317">2,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-318">6,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-319">6,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-320">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-321">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-322">77,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-323">77,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-327">120,790.402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-329">437,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-331">25,767,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-332">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-333">689,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-334">692,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-335">4,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-336">6,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On April 4, 2024, the Company effected a 1-for-30 reverse split of its issued and outstanding shares of common stock, or the Reverse Stock Split. As a result of the Reverse Stock Split, all figures in this Annual Report on Form 10-K relating to shares of the Company&#8217;s common stock (such as share amounts, per share amounts, and conversion rates and prices), including but not limited to, the consolidated financial statements and footnotes included herein, have been adjusted to reflect the Reverse Stock Split for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:14.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_196"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cartesian Therapeutics,&#160;Inc. and Subsidiaries&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:74.273%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.841%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Amounts in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-338">77,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-339">219,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-340">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="f-341">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-343">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-344">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-345">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-346">7,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="f-347">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:11.25pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-348">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-349">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-350">6,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-351">22,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-353">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant liabilities revaluation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-354">2,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-355">12,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent value right liability revaluation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:FairValueAdjustmentOfContingentValueRightLiability" format="ixt:num-dot-decimal" scale="3" id="f-356">36,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:FairValueAdjustmentOfContingentValueRightLiability" format="ixt:num-dot-decimal" scale="3" id="f-357">18,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract liabilities revaluation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="f-358">6,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="f-359">149,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="f-361">740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision (benefit) for deferred taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-362">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-363">19,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-364">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-365">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled receivable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="rnac:IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-366">2,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="rnac:IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent" scale="3" id="f-367">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, deposits and other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-368">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-369">1,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-370">2,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-371">2,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-372">5,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-373">5,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-374">6,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-375">2,761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in operating activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-376">23,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-377">51,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash assumed in acquisition of Old Cartesian</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="f-379">6,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-381">28,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-382">9,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-383">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the sale of property and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-384">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash (used in) provided by investing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-386">8,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-387">34,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of Series A Preferred Stock, gross in private placement</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:num-dot-decimal" scale="3" id="f-388">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:num-dot-decimal" scale="3" id="f-389">20,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of principal, final payment fee, and prepayment penalty on debt</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-391">27,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock and Series B Preferred Stock in private placement</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="3" id="f-392">124,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity offering costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-394">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of common warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="f-396">2,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of outstanding equity awards at Merger</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:PaymentForSettlementOfEquityAwardsInBusinessCombination" format="ixt:fixed-zero" scale="3" id="f-398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:PaymentForSettlementOfEquityAwardsInBusinessCombination" format="ixt:num-dot-decimal" scale="3" id="f-399">6,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-400">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:fixed-zero" scale="3" id="f-402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-403">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash provided by (used in) financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-404">168,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-405">13,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-406">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-407">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-408">135,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-409">29,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-410">78,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-411">108,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-412">214,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-413">78,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplement cash flow information</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-415">1,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, license agreement in stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-417">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property and equipment not yet paid</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-418">847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-419">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity offering costs in accrued liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:EquityOfferingCostsInAccruedLiabilities" scale="3" id="f-420">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="rnac:EquityOfferingCostsInAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="f-421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="height:25.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_199"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cartesian Therapeutics, Inc. and Subsidiaries</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="ida4b385316634ae2a3d2c21207c427f6_202"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-422" continuedAt="f-422-1" escape="true">Description of the Business</ix:nonNumeric></span></div><ix:continuation id="f-422-1" continuedAt="f-422-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cartesian Therapeutics, Inc., or the Company, (formerly known as Selecta Biosciences, Inc., or Selecta) </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> incorporated in Delaware on December 10, 2007, and is headquartered in Frederick, Maryland. The Company is a clinical-stage biotechnology company </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pioneering mRNA cell therapy for the treatment of autoimmune diseases leveraging its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company believes its mRNA cell therapies have the potential to deliver deep, durable clinical benefit to a broad group of patients with autoimmune diseases because they can be administered over a short period of time, in an outpatient setting, and without pre-treatment chemotherapy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023, the Company acquired, in accordance with the terms of the Agreement and Plan of Merger, or the Merger Agreement, the assets of the Delaware corporation which, immediately prior to the Merger (as defined below), was known as Cartesian Therapeutics, Inc., or Old Cartesian, as disclosed in Note 4. The transaction was structured as a stock-for-stock transaction pursuant to which all of Old Cartesian&#8217;s outstanding shares of capital stock were exchanged based on a fixed exchange ratio for consideration of <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-423">224,099</ix:nonFraction> shares of the common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-424">0.0001</ix:nonFraction> per share, of the Company, or the common stock, and <ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-425">384,930.724</ix:nonFraction> shares of the newly designated Series A Non-Voting Convertible Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-426">0.0001</ix:nonFraction> per share, or the Series A Preferred Stock. The Series A Preferred Stock is intended to have economic rights similar to the common stock, but with only limited voting rights. Additionally, the Company assumed all outstanding stock options of Old Cartesian. The common stock and Series A Preferred Stock related to the Merger were issued on December 5, 2023. For additional information, see Note 4.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company entered into a definitive agreement, or the 2023 Securities Purchase Agreement, for a private investment in public equity transaction, or the 2023 Private Placement, with the Investors (as defined below). The 2023 Securities Purchase Agreement provides for the issuance to the Investors of an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-427">149,330.115</ix:nonFraction> shares of Series A Preferred Stock for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-4" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-428">60.25</ix:nonFraction>&#160;million. For additional information, see Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, a contractual contingent value right, or CVR, was distributed to the holders of record of the Company&#8217;s common stock and 2022 Warrants (as defined below) as of the close of business on December 4, 2023, but was not distributed to holders of shares of common stock or Series A Preferred Stock issued to stockholders of Old Cartesian or the Investors in the transactions. Holders of the CVRs will be entitled to receive certain payments from proceeds received by the Company, if any, related to the disposition or monetization of the Company&#8217;s legacy assets following the issuance of the CVRs. For additional information, see Note 6.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2024, the Company&#8217;s stockholders approved the Conversion Proposal (as defined below). For additional information, see Note 11.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on March 27, 2024, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s restated certificate of incorporation, as amended, or the Charter, to effect a reverse stock split of the Company&#8217;s issued and outstanding common stock, at a ratio in the range of 1-for-20 and 1-for-30, with such ratio to be determined at the discretion of the Company&#8217;s board of directors, or the Board of Directors. The Board of Directors subsequently approved a final reverse stock split ratio of 1-for-30, and the Company effected the Reverse Stock Split on April 4, 2024. As a result of the Reverse Stock Split, all figures in this Annual Report on Form 10-K relating to shares of the Company&#8217;s common stock (such as share amounts, per share amounts, and conversion rates and prices), have been adjusted to reflect the Reverse Stock Split for all periods presented, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Shares of common stock underlying outstanding stock options, restricted stock units and warrants were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with their terms. Additionally, the conversion ratio of the Company&#8217;s Series A Preferred Stock was proportionally adjusted. Stockholders entitled to fractional shares as a result of the Reverse Stock Split received a cash payment in lieu of receiving fractional shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2024, the Company entered into a securities purchase agreement, or the 2024 Securities Purchase Agreement, for a private investment in public equity financing, or the 2024 Private Placement, which provided for the issuance of <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-429">3,563,247</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-430">2,937,903</ix:nonFraction> shares of Series B Non-Voting Convertible Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-59" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-431">0.0001</ix:nonFraction> per share, or the Series B Preferred Stock, each at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-432">20.00</ix:nonFraction> per share. The 2024 Private Placement resulted in gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="rnac:SaleOfStockGrossConsiderationReceivedOnTransaction" scale="6" id="f-433">130.0</ix:nonFraction> million before deducting placement agent fees and other offering expenses. On September 20, 2024, the Company&#8217;s stockholders approved the Series B Conversion Proposal (as defined below). For additional information, see Note 11.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-422-2" continuedAt="f-422-3"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates are in preclinical and clinical development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-434">692.1</ix:nonFraction> million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research and development of its product candidates and its administrative organization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company&#8217;s cash, cash equivalents, and restricted cash were $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="rnac:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" scale="6" id="f-435">214.3</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="f-436">1.7</ix:nonFraction> million was restricted cash related to lease commitments. The Company believes the cash, cash equivalents and restricted cash as of December 31, 2024 will enable it to fund its current planned operations for at least the next 12 months from the date of issuance of these financial statements, though it may pursue additional cash resources through public or private equity or debt financings or by establishing collaborations with other companies. However, there is no guarantee that any of these strategic or financing opportunities will be executed on favorable terms, and some could be dilutive to existing stockholders. Further, the liability associated with the CVR Agreement (as defined below) will be settled solely through cash flow received under the Company&#8217;s License and Development Agreement, or as so amended, the Sobi License, with Swedish Orphan Biovitrum AB (publ.), or Sobi, and any other Gross Proceeds (as defined in the CVR Agreement) net of certain agreed deductions. Under the CVR Agreement, <ix:nonFraction unitRef="number" contextRef="c-62" decimals="INF" name="rnac:ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" scale="-2" id="f-437">100</ix:nonFraction>% of all milestone payments, royalties and other amounts paid to the Company or controlled entities under the Sobi License, and any other Gross Proceeds will be distributed, net of specified deductions, to holders of the CVRs. There is no obligation to the Company to fund any amount related to the CVR liability. See Note 6.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-422-3"> If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations or otherwise capitalize on its commercialization of its product candidates.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_2257"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-441" continuedAt="f-441-1" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-441-1" continuedAt="f-441-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-442" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Selecta (RUS), LLC, or Selecta (RUS), a Russian limited liability corporation, Selecta Biosciences Security Corporation, a Massachusetts securities corporation which the Company dissolved in December 2024, and Cartesian Bio, LLC, a Delaware limited liability company, which is a variable interest entity for which the Company is the primary beneficiary. All significant intercompany accounts and transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-443" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company&#8217;s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: estimated fair value of the intangible assets acquired in connection with the Merger, estimated fair value of the CVRs, deferred income taxes, revenue recognition, estimated accrued research and development expenses, stock-based compensation expense, estimated fair value of the liability-classified warrants, and impairment of long-lived assets. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-444" continuedAt="f-444-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-444-1"><ix:continuation id="f-441-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision maker, or the CODM, for the purposes of assessing performance and allocating resources. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-445">one</ix:nonFraction> operating segment, which prior to the Merger related to the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases and subsequent to the Merger relates to the research and development of cell therapy product candidates. The Company&#8217;s CODM function is fulfilled by its Chief Executive Officer. The CODM function assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations and comprehensive loss. The CODM function uses net loss to monitor budget versus actual results to assess performance of the segment. Segment assets are the same as total assets on the Company&#8217;s consolidated balance sheets. All long-lived assets are located in the United States. Long-lived assets consist of property and equipment, net, and operating lease right-of-use assets.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_205"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-446" continuedAt="f-446-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-446-1" continuedAt="f-446-2"><ix:nonNumeric contextRef="c-1" name="rnac:CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" id="f-447" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents, Marketable Securities and Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Marketable securities consist of securities with remaining maturities greater than 90 days when purchased. The Company classifies these marketable securities as available-for-sale and records them at fair value in the accompanying consolidated balance sheets. Marketable securities with less than one year until maturity are classified as short term, while marketable securities with maturities greater than one year are classified as long term. Unrealized gains or losses are included in accumulated other comprehensive loss. Premiums or discounts from par value are amortized to interest income over the life of the underlying investment. Although available to be sold to meet operating needs or otherwise, securities are generally held through maturity. The cost of securities sold is determined based on the specific identification method for purposes of recording realized gains and losses. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also in the past invested in equity securities of a company whose securities are not publicly traded and where fair value is not readily available. This investment is recorded using cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. The Company monitors this investment to evaluate whether any increase or decline in its value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. This investment is included in investments in the consolidated balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-448" continuedAt="f-448-1" escape="true"><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-448-1">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term deposits, investments, accounts receivable, and unbilled receivables. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company&#8217;s deposits are financially creditworthy and, accordingly, minimal risk exists with respect to those balances.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-449" continuedAt="f-449-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s financial instruments consist mainly of cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and other current liabilities, investments, warrants to purchase common stock, forward contract liabilities, and contingent value rights. The carrying amounts of cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities approximate their estimated fair value due to their short-term maturities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy is used to prioritize the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements), and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Level 2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-446-2" continuedAt="f-446-3"><ix:continuation id="f-449-1"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of warrant liabilities and contingent value rights are determined using Level 3 inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the consolidated balance sheet for investments approximate fair value and are assessed for impairment quarterly.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-450" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, generally <ix:nonNumeric contextRef="c-65" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-451">seven years</ix:nonNumeric> for furniture and fixtures, <ix:nonNumeric contextRef="c-66" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-452">five years</ix:nonNumeric> for laboratory equipment, software and office equipment and <ix:nonNumeric contextRef="c-67" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-453">three years</ix:nonNumeric> for computer equipment. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Major additions and betterments are capitalized. Maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to operations as incurred. Costs incurred for construction in progress are recorded as assets and are not amortized until the construction is substantially complete and the assets are ready for their intended use.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-454" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are tested at the lowest level for which identifiable independent cash flows are available. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. The Company recognized an impairment charge on its right of use assets and related furniture and fixtures during the year ended December 31, 2024 and on a right-of-use asset during the year ended December 31, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-455" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs and fees paid to lenders are recorded as a direct deduction from the face amount of the related debt. Debt issuance costs are amortized over the term of the related debt using the effective interest method and recorded as interest expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-456" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in the equity of a business entity during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss consists of: (i)&#160;all components of net loss and (ii)&#160;all components of comprehensive loss other than net loss, referred to as other comprehensive loss. Other comprehensive loss is comprised of unrealized gains and losses on debt securities and foreign currency translation adjustments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-457" continuedAt="f-457-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and License Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. Pursuant to ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers (ASC 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. If a promised good or service is not distinct, it is combined with other promised goods or services into a performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-457-1"><ix:continuation id="f-446-3" continuedAt="f-446-4"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Revenue: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently generates its revenue through collaboration and license agreements with strategic collaborators for the development and commercialization of product candidates. Collaboration and license agreements with customers are generally accounted for in accordance with ASC 606. The Company analyzes collaboration arrangements by first assessing whether they are within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (ASC 808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and evaluates whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. Collaboration agreements with customers that are not within the scope of ASC 808 are accounted for in accordance with ASC 606. To the extent the collaboration agreement is within the scope of ASC 808, the Company also assesses whether any aspects of the agreement are within the scope of other accounting literature (specifically ASC 606). If the Company concludes that some or all aspects of the agreement are distinct and represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606. The Company recognizes the shared costs incurred that are not within the scope of other accounting literature as a component of the related expense in the period incurred by analogy to ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development (ASC 730)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and records reimbursements from counterparties as an offset to the related research and development costs. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under the agreements in accordance with ASC 606, the Company performs the five steps above. As part of the accounting for the arrangement, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;The Company uses key assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Company&#8217;s arrangements typically include one or more of the following: (i) upfront fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; (iii) royalties on net sales of licensed products; (iv) reimbursements or cost-sharing of research and development expenses; and (v) profit/loss sharing arising from co-promotion arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promised goods and services identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. If not distinct, the license is combined with other promised goods and services in the contract. For licenses that are combined with other promised goods and services, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Optional licenses are evaluated to determine if they are issued at a discount, and therefore, represent material rights and accounted for as separate performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes developmental and regulatory milestone payments, the Company evaluates whether the achievement of each milestone specifically relates to the Company&#8217;s efforts to satisfy a performance obligation or transfer a distinct good or service within a performance obligation. If the achievement of a milestone is considered a direct result of the Company&#8217;s efforts to satisfy a performance obligation or transfer a distinct good or service and the receipt of the payment is based upon the achievement of the milestone, the associated milestone value is allocated to that distinct good or service. If the milestone payment is not specifically related to the Company&#8217;s effort to satisfy a performance obligation or transfer a distinct good or service, the amount is allocated to all performance obligations using the relative standalone selling price method. The Company also evaluates the milestone to determine whether they are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price to be allocated, otherwise, such amounts are constrained and excluded from the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the transaction price.&#160;Any such adjustments to the transaction price are allocated to the performance obligations on the same basis as at contract inception. Amounts allocated to a satisfied performance obligation shall be recognized as revenue, or as a reduction of revenue, in the period in which the transaction price changes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Supply Services: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are evaluated to determine if they are distinct and optional. For optional services that are distinct, the Company assesses if they are priced at a discount, and therefore, provide a material right to the licensee to be accounted for as separate performance obligations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied) in accordance with the royalty recognition constraint.</span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-446-4" continuedAt="f-446-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="f-458" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with government-sponsored organizations for research and development related activities that provide for payments for reimbursable costs. The Company recognizes grant revenue from these contracts as it performs services under these arrangements when the funding is committed. Expenses associated with these contracts are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations and comprehensive loss as the Company has determined it is the primary obligor under the arrangements relative to the research and development services it performs as lead technical expert. Amounts incurred that are subject to reimbursement from the sponsor are recorded as accounts receivable on the consolidated balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-459" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred in the research and development of the Company&#8217;s products are expensed as incurred. Research and development expenses include costs incurred in performing research and development activities, including salaries and benefits, stock-based compensation expenses, facilities cost, overhead costs, contract services, supplies and other outside costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="rnac:ClinicalTrialCostsPolicyTextBlock" id="f-460" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third-parties. Third-party clinical trial expenses include patient costs, clinical research organization costs and costs for data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued clinical trial cost. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Non-refundable&#160;advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. The Company also records accruals for estimated ongoing clinical research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical clinical accrual estimates made by the Company have not been materially different from the actual costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-461" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more-likely-than-not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more-likely-than-not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="rnac:WarrantsPolicyTextBlock" id="f-462" continuedAt="f-462-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and then in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or may require settlement by issuing variable number of shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to&#160;its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-446-5" continuedAt="f-446-6"><ix:continuation id="f-462-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the statements of operations as a gain or loss.&#160;Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-463" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all stock-based compensation granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of estimated forfeitures. To the extent that actual forfeitures differ from the Company&#8217;s estimates, the differences are recorded as a cumulative adjustment in the period the estimates were adjusted. Stock-based compensation expense recognized in the consolidated financial statements is based on awards that ultimately vest.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-464" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company applies the two-class method to compute basic and diluted net income (loss) per share attributable to common stockholders when it has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company&#8217;s Series A Preferred Stock, Series B Preferred Stock and 2022 Warrants participate in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) per share attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase common stock and Series A Preferred Stock, forward contracts to issue Series A Preferred Stock, restricted stock units, warrants to purchase common stock, employee stock purchase plan stock, contingently issuable shares, Series A Preferred Stock, and Series B Preferred Stock are considered potential dilutive common shares.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-465" continuedAt="f-465-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Liabilities</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><ix:continuation id="f-465-1" continuedAt="f-465-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its contingent liabilities in accordance with ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies (ASC 450)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-465-2">. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-466" continuedAt="f-466-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases in accordance with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (ASC 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company elected not to recognize leases with an original term less than one year on its balance sheet. Operating lease right-of-use assets and their corresponding lease liabilities are recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 842, the fixed and in-substance fixed contract consideration must be allocated to lease and non-lease components based on their relative fair values. Non-components of a contract (e.g., administrative tasks that do not transfer a good or service to the Company, reimbursement or payment of a lessor&#8217;s cost, etc.) do not receive an allocation of the consideration in the contract. Although allocation of consideration of lease and non-lease components is required, the Company elected the practical expedient to not separate lease components (e.g. land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The lease component results in an operating right-of-use asset being recorded on the balance sheet and amortized on a straight-line basis as lease expense. Right-of-use assets and operating lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and the estimated incremental borrowing rate upon lease modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease agreements with terms generally ranging from <span style="-sec-ix-hidden:f-467">two</span> to <ix:nonNumeric contextRef="c-69" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-468">eight years</ix:nonNumeric>. Some of the Company&#8217;s lease agreements include Company options to either extend and/or early terminate the lease, the costs of which are included in </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-446-6" continuedAt="f-446-7"><ix:continuation id="f-466-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its operating lease liabilities to the extent that such options are reasonably certain of being exercised. Leases with renewal options allow the Company to extend the lease term typically between <span style="-sec-ix-hidden:f-469">one</span> and <ix:nonNumeric contextRef="c-69" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-470">five years</ix:nonNumeric>. When determining the lease term, renewal options reasonably certain of being exercised are included in the lease term. When determining if a renewal option is reasonably certain of being exercised, the Company considers several economic factors, including but not limited to, the significance of leasehold improvements incurred on the property, whether the asset is difficult to replace, underlying contractual obligations, or specific characteristics unique to that particular lease that would make it reasonably certain that the Company would exercise such option. Renewal and termination options were generally not included in the lease term for the Company&#8217;s existing operating leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-471" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations based on the fair value estimates as of the date of acquisition. In accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (ASC 805)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-472" continuedAt="f-472-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the amount of consideration paid in excess of the fair value of the identified net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-472-1">The Company evaluates goodwill for impairment at least annually on October 1 and whenever facts and circumstances indicate that their carrying amounts may not be recoverable.</ix:continuation> For the years ended December 31, 2024 and 2023, the Company determined that there was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-473"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-474">no</ix:nonFraction></ix:nonFraction> impairment to goodwill.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="f-475" continuedAt="f-475-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets consist of in-process research and development, or IPR&amp;D. The fair values of IPR&amp;D assets acquired in business combinations are capitalized. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry and recent and forecasted financial performance.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-475-1">The Company evaluates indefinite-lived intangible assets for impairment at least annually on October 1 and whenever facts and circumstances indicate that their carrying amounts may not be recoverable.</ix:continuation> For the years ended December 31, 2024 and 2023, the Company determined that there was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-476">no</ix:nonFraction> impairment to the IPR&amp;D assets.</span></div><ix:nonNumeric contextRef="c-1" name="rnac:TemporaryEquityPolicyPolicyTextBlock" id="f-477" continuedAt="f-477-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Preferred Stock</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-446-7" continuedAt="f-446-8"><ix:continuation id="f-477-1" continuedAt="f-477-2"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records its convertible preferred stock upon issuance at its fair value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value includes the original issuance price, the settlement of any related forward contract, and is less issuance costs. The Company classifies its convertible preferred stock outside of stockholders&#8217; deficit if the redemption of such shares is outside the Company&#8217;s control. For shares classified outside of stockholders&#8217; deficit, the Company does not adjust the carrying value of its convertible preferred stock to redemption value until it is probable of becoming redeemable. As of December 31, 2024, there were no conditions that could have required cash redemption of the convertible preferred stock and therefore, all convertible preferred stock were classified within stockholders&#8217; deficit.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Series A Preferred Stock Options </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><ix:continuation id="f-477-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies a portion of the fair value of the vested stock options for Series A Preferred Stock equal to the estimated redemption value on the measurement date outside of stockholders&#8217; deficit, if the redemption of the shares underlying the options are outside the Company&#8217;s control. Any fair value in excess of the estimated redemption value is recognized as additional paid-in capital. The estimated redemption value is based on the intrinsic value of the option. The Company does not adjust the carrying value of the stock options for Series A Preferred Stock until the underlying Series A Preferred Stock is probable of becoming redeemable. The Company records the stock options for Series A Preferred Stock based on the intrinsic value of the vested options.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="f-478" continuedAt="f-478-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable Interest Entities</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-478-1">The Company evaluates its variable interests in variable interest entities, or VIEs, and consolidates VIEs when the Company is the primary beneficiary. The Company determines whether it is the primary beneficiary of a VIE based on its assessment of whether the Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#8217;s economic performance and (ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary conclusion.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="rnac:ContingentValueRightLiabilityPolicyPolicyTextBlock" id="f-479" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Value Right Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CVRs distributed by the Company pursuant to the terms of the CVR Agreement (as defined below) represent financial instruments that are accounted for under the fair value option election in ASC Topic 825, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments (ASC 825).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the fair value option election, the CVRs are initially measured at the aggregate estimated fair value of the CVRs and will be subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the CVR liability was determined using a discounted cash flow methodology as of December 31, 2023 and a Monte Carlo simulation method as of December 31, 2024 to estimate future cash flows associated with the legacy assets, including the expected milestone and royalty payments under the Sobi License, net of deductions. Changes in fair value of the liability are presented in the consolidated statements of operations and comprehensive loss. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, expected volatilities of revenues (Monte Carlo simulation) and risk-adjustment discount rate (discounted cash flow methodology), which represent a Level 3 measurement within the fair value hierarchy.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-480" continuedAt="f-480-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Contract Liabilities</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-480-1">The Company accounts for contracts related to the future issuance of its convertible preferred stock as a liability if the underlying shares include a redemption feature that may require the Company to settle the instrument by transferring an asset. The forward contract liability is carried at fair value through the date the underlying shares are issued. The fair value of the Series A Preferred Stock forward contract liability was initially measured based on the fair value of the Series A Preferred Stock issued in the 2023 Private Placement (see Note 11), less the purchase price, if any. Subsequent measurement of the fair value of the Series A Preferred Stock forward contract liability was based on the market price of the Company&#8217;s common stock, which represented the redemption and conversion value of the Series A Preferred Stock, less the purchase price, if any, on an as-converted basis. The remeasurement of the forward contract liability is based on Level 2 inputs within the fair value hierarchy as it&#8217;s based on observable market data. Changes in fair value of the liability are presented within change in fair value of forward contract liabilities in the consolidated statements of operations and comprehensive loss.</ix:continuation>  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-481" continuedAt="f-481-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for the annual period beginning the year ended December 31, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company adopted the new standard during the year ended December 31, 2024 and the amendments have be applied retrospectively to all prior periods presented in the consolidated financial statements. See Note 21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-481-1"><ix:continuation id="f-446-8"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not Yet Adopted</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual period beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently in the process of evaluating the impact of the standard&#8217;s adoption on its consolidated financial statements and related disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement Reporting- Comprehensive Income- Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2024-03), which requires public companies to disclose, in interim and annual reporting periods, additional information about certain expenses in notes to financial statements, including purchases of inventory, employee compensation, depreciation, amortization of intangible assets, and selling expenses. This guidance will be effective for the annual period beginning the year ended December 31, 2027 and for interim periods beginning January 1, 2028, with early adoption permitted. The Company is currently in the process of evaluating the impact of the standard&#8217;s adoption on its consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div id="ida4b385316634ae2a3d2c21207c427f6_208"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-482" continuedAt="f-482-1" escape="true">Merger</ix:nonNumeric></span></div><ix:continuation id="f-482-1" continuedAt="f-482-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023, the Company merged with Old Cartesian in accordance with the terms of the Merger Agreement, by and among Selecta, Sakura Merger Sub I, Inc., a wholly owned subsidiary of Selecta, or First Merger Sub, Sakura Merger Sub II, LLC, a wholly owned subsidiary of Selecta, or Second Merger Sub, and Old Cartesian. Pursuant to the Merger Agreement, First Merger Sub merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corporation and became a wholly owned subsidiary of Selecta, or the First Merger. Immediately following the First Merger, Old Cartesian merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity, or the Second Merger and, together with the First Merger, the Merger. In connection with the Second Merger, Old Cartesian changed its name to Cartesian Bio, LLC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. As a result of the Merger, Selecta changed its corporate name to Cartesian Therapeutics, Inc. and its common stock began trading on the Nasdaq Global Market under the new trading symbol &#8220;RNAC&#8221; beginning on November 14, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement was unanimously approved by the board of directors, or the Board of Directors, of Selecta and the board of directors of Old Cartesian. The Merger was consummated substantially concurrently with the entry into the Merger Agreement and was not subject to approval of the Company&#8217;s stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merger Agreement, following the consummation of the Merger on November 13, 2023, or the Closing Date, in exchange for <ix:nonFraction unitRef="number" contextRef="c-70" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-483">100</ix:nonFraction>% of the outstanding shares of capital stock of Old Cartesian immediately prior to the effective time of the First Merger, the Company agreed to issue to the stockholders of Old Cartesian (i) <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-484">224,099</ix:nonFraction> shares of the Company&#8217;s common stock and (ii) <ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-485">384,930.724</ix:nonFraction> shares of Series A Preferred Stock. The issuance of the shares of common stock and Series A Preferred Stock occurred on December 5, 2023 which was after the December 4, 2023 record date for the distribution of the CVRs (see Note 6); as such, the Old Cartesian stockholders did not have rights as holders of common stock or holders of Series A Preferred Stock until such issuance on December 5, 2023. In addition, all outstanding stock options to purchase Old Cartesian common stock were assumed by the Company and converted into stock options to purchase (i) shares of the Company&#8217;s common stock or (ii) shares of the Company&#8217;s Series A Preferred Stock on terms substantially identical to those in effect prior to Merger Agreement, except for adjustments to the underlying number of shares and the exercise price based on the Merger Agreement exchange ratio. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, the Company agreed to hold a stockholders&#8217; meeting, or the Special Meeting, to submit the following proposals to a vote of its stockholders: (i) the approval of the conversion of shares of Series A Preferred Stock into shares of common stock, or the Conversion Proposal, and (ii) either or both of (A) the approval of an amendment to the Charter to increase the number of shares of common stock authorized under the Charter and (B) the approval of an amendment to the Charter to effect a reverse stock split of all outstanding shares of common stock, in either case (A) or (B) by a number of authorized shares or at a stock split ratio, as the case may be, sufficient to allow the conversion of all shares of Series A Preferred Stock issued in the Merger. The Special Meeting was held on March 27, 2024, during which the Company&#8217;s stockholders approved the Conversion Proposal, among other matters (see Note 11).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded the acquisition resulted in the Company obtaining a controlling financial interest in a VIE in accordance with ASC Topic 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation (ASC 810)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined that Old Cartesian was considered to be a VIE as it did not have sufficient equity to finance its activities without additional subordinated financial support. Prior to the Closing Date, the primary source of funding for Old Cartesian had been preferred stock financings. The Company acquired all of the outstanding shares of Old Cartesian and, therefore, is the sole equity holder and primary beneficiary. The Company has the obligation to absorb the losses and right to receive the benefits of Old Cartesian, and the power to direct the activities that most significantly affect the economic performance of Old Cartesian which the Company considers to be its development </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-482-2" continuedAt="f-482-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities. Therefore, the Company is the primary beneficiary. Further, the Company concluded the VIE qualified as a business and accounted for the transaction as the acquisition of a business in accordance with ASC 805. As the primary beneficiary, the Company was the acquirer in the transaction. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company exchanged the right to receive shares of common stock and Series A Preferred Stock for all of the outstanding equity of Old Cartesian. The Company determined the rights to receive shares exchanged in the Merger represent a forward contract. The fair value of the forward contracts was determined based on the fair value of shares of common stock and Series A Preferred Stock underlying the forward contracts as of the acquisition date. The total purchase price consists of the fair value of the forward contracts in addition to a portion of the fair value of options exchanged in the transaction related to prior service. Under the acquisition method, the total purchase price of the acquisition was allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the date of the acquisition.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-486" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The total fair value of the consideration of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-487">168.5</ix:nonFraction>&#160;million as of the Closing Date is summarized as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract to issue common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-488">2,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract to issue Series A Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-489">155,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options allocated to consideration paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-490">10,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-491">168,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the assets acquired and liabilities assumed as of the Closing Date based on the information available at that date. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-492" continuedAt="f-492-1" escape="true">The following table presents the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed as of the Closing Date (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><ix:continuation id="f-492-1"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of November 13, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-493">6,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="f-494">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="f-495">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset" scale="3" id="f-496">915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-497">150,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-498">48,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="f-499">206,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-500">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability" scale="3" id="f-501">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability" scale="3" id="f-502">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-503">34,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-504">38,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-505">168,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the IPR&amp;D assets were capitalized as of the Closing Date and are accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the carrying value of each respective IPR&amp;D asset will be amortized over its estimated useful life. Until that time, the IPR&amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the Merger is the excess of the fair value of the consideration transferred by the acquirer over the fair value of tangible assets, identifiable intangible assets and assumed liabilities as of the Closing Date and is not deductible for tax purposes. The goodwill balance is primarily attributable to the value of the assembled workforce and deferred tax liabilities associated with the transaction.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" id="f-506" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company&#8217;s intangible assets acquired in the Merger (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Date<br/>Fair Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for MG</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-507">93,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for SLE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-508">56,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total in-process research and development assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-509">150,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the intangible assets was estimated using the income approach in which the after-tax cash flows were discounted to present value. The cash flows are based on estimates used to price the transaction, and the discount rates applied </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-482-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were benchmarked with reference to the implied rate of return from the transaction model as well as the weighted average cost of capital. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period from November 13, 2023 to December 31, 2023, Old Cartesian&#8217;s revenue and net loss within the consolidated statements of operations and comprehensive loss were $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="f-510">0.0&#160;million</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="f-511">1.6</ix:nonFraction>&#160;million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="f-512" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information reflects the consolidated results of operations of the Company as if the Merger had taken place on January 1, 2022. The unaudited pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-513">26,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-514">232,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-515">4.9</ix:nonFraction>&#160;million were expensed as incurred and included in general and administrative expense in the consolidated statements of operations and comprehensive loss during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward contract related to the common stock was recorded as additional paid-in capital as the instrument is indexed to the Company&#8217;s common stock. The forward contract related to the Series A Preferred Stock was recorded as a liability as the underlying Series A Preferred Stock had a redemption feature that may have required the Company to settle the instrument by transferring an asset.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward contract was measured at fair value through the date of settlement through the issuance of the shares of Series A Preferred Stock on December 5, 2023.</span></div></ix:continuation><div id="ida4b385316634ae2a3d2c21207c427f6_220"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-516" continuedAt="f-516-1" escape="true">Net Loss Per Share Allocable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="f-516-1"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported a net loss for the years ended December 31, 2024 and 2023. The Company used the treasury stock method to determine the number of dilutive shares for the year ended December 31, 2024. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-517" continuedAt="f-517-1" escape="true">The following table sets forth the computation of basic and diluted net loss per share allocable to common stockholders (in thousands, except share and per-share data):</ix:nonNumeric></span></div><ix:continuation id="f-517-1"><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-518">77,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-519">219,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: CVR distribution to participating securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DistributedEarnings" format="ixt:fixed-zero" scale="3" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DistributedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-521">37,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss allocable to shares of common stock - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-522">77,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-523">257,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Change in fair value of forward contract liability settled in February 2024</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DilutiveSecurities" scale="3" id="f-524">446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DilutiveSecurities" format="ixt:fixed-zero" scale="3" id="f-525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss allocable to shares of common stock - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-526">77,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-527">257,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-528">17,276,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-529">5,170,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plus: Dilutive effect of forward contract liability settled in February 2024</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="f-530">81,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="f-531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding  - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-532">17,357,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-533">5,170,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-534">4.48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-535">49.76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-536">4.49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-537">49.76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:3pt;margin-top:1pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-538" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the potential dilutive shares of common stock excluded from the computation of the diluted net loss per share allocable to common stockholders for all periods presented, as the effect would have been anti-dilutive: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options and RSUs </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-539">2,150,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-540">776,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-80" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-541">692,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-542">1,040,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-543">4,026,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-544">14,503,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-545">437,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-85" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract to issue Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-548">3,304,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-550">470,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-551">7,307,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-552">20,096,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_223"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-553" continuedAt="f-553-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-553-1" continuedAt="f-553-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-554" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds (included in cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-555">39,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-556">39,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-559">39,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-560">39,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-563">3,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="f-564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-566">3,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contingent value right liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="rnac:ContingentValueRightLiability" format="ixt:num-dot-decimal" scale="3" id="f-567">395,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="rnac:ContingentValueRightLiability" format="ixt:fixed-zero" scale="3" id="f-568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="rnac:ContingentValueRightLiability" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="rnac:ContingentValueRightLiability" format="ixt:num-dot-decimal" scale="3" id="f-570">395,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-571">399,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-574">399,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds (included in cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-575">41,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-576">41,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-578">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-579">41,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-580">41,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-583">6,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="f-584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-586">6,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contingent value right liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="rnac:ContingentValueRightLiability" format="ixt:num-dot-decimal" scale="3" id="f-587">358,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="rnac:ContingentValueRightLiability" format="ixt:fixed-zero" scale="3" id="f-588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="rnac:ContingentValueRightLiability" format="ixt:fixed-zero" scale="3" id="f-589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="rnac:ContingentValueRightLiability" format="ixt:num-dot-decimal" scale="3" id="f-590">358,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forward contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-591">28,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-593">28,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-595">393,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-596">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-597">28,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-598">364,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" format="ixt:fixed-zero" scale="0" id="f-599"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="0" id="f-600"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="0" id="f-601"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" format="ixt:fixed-zero" scale="0" id="f-602">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers within the fair value hierarchy during the years ended December 31, 2024 or 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had restricted cash balances relating to secured letters of credit in connection with its real estate leases (see Note 9). <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-604" continuedAt="f-604-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-603" continuedAt="f-603-1" escape="true">The Company&#8217;s consolidated statement of cash flows includes the following as of December 31, 2024 and 2023 (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-604-1"><ix:continuation id="f-603-1"><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"/><td style="width:70.926%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.972%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-605">212,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-606">76,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-607">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-608">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-609">214,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-610">78,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants to Purchase Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company issued warrants to purchase common stock in connection with a private placement, or the 2019 Warrants. The outstanding 2019 Warrants expired on December 23, 2024 in accordance with their terms. Pursuant to the terms of the 2019 Warrants, the Company could have been required to settle the 2019 Warrants in cash in the event of certain acquisitions of the Company and, as a result, the 2019 Warrants were required to be measured at fair value and reported as a liability on the balance sheet.&#160;On December 20, 2022, the Company amended the terms of the outstanding 2019 Warrants held by certain members of the Board of Directors, or the Amended 2019 Warrants, to remove the cash settlement provision.  As a result, the Amended 2019 Warrants were remeasured at fair value on December 20, 2022 and reclassified from a liability to equity on the balance sheet. See Note 12 for further discussion on the equity-classified Amended 2019 Warrants. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company issued warrants in connection with an underwritten offering, or the 2022 Warrants. Pursuant to the terms of the 2022 Warrants, the Company could be required to settle the 2022 Warrants in cash in the event of an acquisition of the Company under certain circumstances and, as a result, the 2022 Warrants are required to be measured at fair value and reported as a liability on the balance sheet. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-553-2" continuedAt="f-553-3"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the fair value of the 2019 Warrants and the 2022 Warrants upon issuance using the Black-Scholes valuation model and is required to revalue the 2019 Warrants and the 2022 Warrants at each reporting date, with any changes in fair value recorded in the consolidated statements of operations and comprehensive loss. The valuations of the 2019 Warrants and the 2022 Warrants are classified as Level 3 of the fair value hierarchy due to the need to use assumptions in the valuations that are both significant to the fair value measurement and unobservable, including the stock price volatility and the expected life of the 2019 Warrants and the 2022 Warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The changes in the fair values of the&#160;warrants are reflected in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2024 and 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of the 2019 Warrants and the 2022 Warrants were determined using the following inputs to the Black-Scholes simulation valuation:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of the underlying stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of the common stock based on the closing stock price at the end of each reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is based on the U.S. Treasury at the valuation date commensurate with the expected remaining life assumption.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The dividend rate is based on the historical rate, which the Company anticipates will remain at <ix:nonFraction unitRef="number" contextRef="c-106" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="0" id="f-611">zero</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The expected life of the 2019 Warrants was assumed to be equivalent to their remaining contractual term which expired on December 23, 2024. The expected life of the 2022 Warrants is assumed to be equivalent to their remaining contractual term which expire on April 11, 2027. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company estimates stock price volatility based on the Company&#8217;s historical volatility for a period of time commensurate with the expected remaining life of the warrants.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 2019 Warrants expired on December 23, 2024 and therefore, there were no 2019 Warrants outstanding as of December 31, 2024. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-612" continuedAt="f-612-1" escape="true">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the 2019 Warrants liability as of December 31, 2023 is as follows:</ix:nonNumeric></span></div><ix:continuation id="f-612-1" continuedAt="f-612-2"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:22.877%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-613">4.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="3" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-109" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-615">0.98</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-110" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-616">83.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the 2022 Warrants liability is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-617">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-112" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-618">4.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-113" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="0" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-114" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="0" id="f-620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-115" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-621">2.28</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-116" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-622">3.28</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-623">92.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-624">84.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-625" continuedAt="f-625-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company&#8217;s Level 3 warrant liabilities (see Note 12), for the year ended December 31, 2024 (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-626">6,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-627">2,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-628">3,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Value Right</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2023, as contemplated by the Merger Agreement, the Company entered into a contingent value rights agreement, or the CVR Agreement, pursuant to which each holder of common stock or a 2022 Warrant as of December 4, 2023 was distributed a CVR, issued by the Company for each share of common stock held directly or underlying a 2022 Warrant held by such holder as of December 4, 2023. Holders of warrants other than the 2022 Warrants will be entitled to receive, upon </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-553-3" continuedAt="f-553-4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise of such warrants and in accordance with the terms of the warrants, <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="f-629">30</ix:nonFraction> CVRs per each share of common stock underlying such warrants.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each CVR entitles its holder to distributions of the following, pro-rated on a per-CVR basis, during the period ending on the date on which the Royalty Term (as defined in the Sobi License) ends, or the Termination Date: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="INF" name="rnac:ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" scale="-2" id="f-630">100</ix:nonFraction>% of all milestone payments, royalties and other amounts paid to the Company or its controlled affiliates, or the Company Entities, under the Sobi License or, following certain terminations of the Sobi License, any agreement a Company Entity enters into that provides for the development and commercialization of SEL-212; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="INF" name="rnac:ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" scale="-2" id="f-631">100</ix:nonFraction>% of all cash consideration and the actual liquidation value of any and all non-cash consideration of any kind that is paid to or is actually received by any Company Entity prior to the Termination Date pursuant to an agreement relating to a sale, license, transfer or other disposition of any transferable asset of the Company existing as of immediately prior to the Merger, other than those exclusively licensed under the Sobi License or which the Company Entities are required to continue to own in order to comply with the Sobi License.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The distributions in respect of the CVRs will be made on a semi-annual basis, and will be subject to a number of deductions, subject to certain exceptions or limitations, including for (i) certain taxes payable on the proceeds subject to the CVR distribution, (ii) certain out of pocket costs incurred by the Company Entities, including audit and accounting fees incurred in connection with reporting obligations relating to the CVRs and other expenses incurred in the performance of their obligations and other actions under the CVR Agreement, (iii) a fixed semi-annual amount of $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-4" name="rnac:ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead" format="ixt:num-dot-decimal" scale="6" id="f-632">0.75</ix:nonFraction>&#160;million for general and administrative overhead, (iv) payments made and remaining obligations on lease liabilities of Selecta immediately prior to the Merger and (v) amounts paid and remaining obligations with regard to the Xork product candidate. Each of the deductions described in (iv) and (v) will be made only if certain milestone payments under the Sobi License are made and are also subject to certain adjustments as contemplated in the CVR Agreement. Upon the achievement of a development milestone in June 2024, Sobi became obligated to make a $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-633">30.0</ix:nonFraction>&#160;million payment to the Company and made such payment in July 2024. The proceeds from this payment, net of deductions specified in the CVR Agreement, is expected to be included in the next scheduled distribution to the holders of the CVR in March 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CVRs represent financial instruments that are accounted for under the fair value option election in ASC 825.  Under the fair value option election, the CVRs are initially measured at the aggregate estimated fair value of the CVRs and will be subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The liability was recorded at the date of approval, November 13, 2023, as a dividend. The estimated fair value of the CVR liability was determined using a discounted cash flow methodology as of December 31, 2023 and a Monte Carlo simulation model as of December 31, 2024 to estimate future cash flows associated with the legacy assets, including the expected milestone and royalty payments under the Sobi License, net of deductions. Changes in fair value of the CVR liability are presented in the consolidated statements of operations and comprehensive loss.  The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, expected volatility of future revenues (Monte Carlo simulation model) and risk-adjustment discount rate (discounted cash flow methodology), which represent a Level 3 measurement within the fair value hierarchy. <ix:continuation id="f-612-2" continuedAt="f-612-3">The significant inputs used to estimate the fair value of the CVR liability, which represented a financial instrument being accounted for under the fair value option, were as follows:</ix:continuation></span><ix:continuation id="f-612-3" continuedAt="f-612-4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.877%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated cash flow dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2038</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated probability of success</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-125" decimals="3" name="rnac:ContingentValueRightLiabilityMeasurementInput" scale="-2" id="f-634">95.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-126" decimals="3" name="rnac:ContingentValueRightLiabilityMeasurementInput" scale="-2" id="f-635">100.0</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility of future revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" name="rnac:ContingentValueRightLiabilityMeasurementInput" scale="-2" id="f-636">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></ix:continuation></div><ix:continuation id="f-612-4"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:22.877%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated cash flow dates</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 - 2038</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated probability of success</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="3" name="rnac:ContingentValueRightLiabilityMeasurementInput" scale="-2" id="f-637">95.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-adjusted discount rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="3" name="rnac:ContingentValueRightLiabilityMeasurementInput" scale="-2" id="f-638">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:continuation id="f-625-1" continuedAt="f-625-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company&#8217;s Level 3 CVR liability for the year ended December 31, 2024 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CVR liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-639">358,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-640">36,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-641">395,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward Contract Liabilities </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-553-4"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Merger Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company entered into a contract for the issuance of <ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-642">384,930.724</ix:nonFraction> shares of Series A Preferred Stock as part of the consideration transferred. The fair value of the forward contract at the Closing Date was $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="f-643">155.3</ix:nonFraction>&#160;million. The non-cash settlement of this liability occurred on December 5, 2023 with the issuance of the Series A Preferred Stock for $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-644">261.8</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Private Placement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company entered into a contract for the issuance of <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-645">149,330.115</ix:nonFraction> shares of Series A Preferred Stock as part of the 2023 Private Placement which was settled in multiple tranches. The Company determined the obligation to issue <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="rnac:SettlementOfDerivativeLiabilityShares" format="ixt:num-dot-decimal" scale="0" id="f-646">148,710.488</ix:nonFraction> shares of Series A Preferred Stock to Dr. Timothy A. Springer, a member of the Company&#8217;s Board of Directors, and TAS Partners LLC, an affiliate of Dr. Springer, represented a forward contract. See Note 11. The initial fair value of the forward contract liability on November 13, 2023 was insignificant as the fair value of the underlying Series A Preferred Stock was equal to the purchase price of the Series A Preferred Stock as agreed upon in the 2023 Private Placement. Subsequent measurement of the fair value of the forward contract liability was based on the market price of the Company&#8217;s common stock, which represented the redemption and conversion value of the Series A Preferred Stock, less the purchase price, on an as-converted basis. The non-cash settlement of a portion of the liability occurred on December 13, 2023 with the issuance of the first tranche of the Series A Preferred Stock for $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="rnac:IssuanceOfStockForSettlementOfForwardContractLiability" format="ixt:num-dot-decimal" scale="6" id="f-647">14.8</ix:nonFraction>&#160;million. The non-cash settlement of the remaining second and third tranches occurred on January 12, 2024 and February 11, 2024, respectively, for a total of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="rnac:IssuanceOfStockForSettlementOfForwardContractLiability" format="ixt:num-dot-decimal" scale="6" id="f-648">35.2</ix:nonFraction>&#160;million.</span></div><ix:continuation id="f-625-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the forward contract liabilities for the periods presented (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward contract liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" format="ixt:num-dot-decimal" scale="3" id="f-649">28,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" format="ixt:num-dot-decimal" scale="3" id="f-650">35,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:f-651">Change in fair value</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-652">6,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" format="ixt:fixed-zero" scale="3" id="f-653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="ida4b385316634ae2a3d2c21207c427f6_226"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-654" continuedAt="f-654-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-654-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-655" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-656">7,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-657">6,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-658">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-659">702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-660">3,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-661">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-662">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-663">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-664">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-665">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-666">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-667">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-668">12,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-669">7,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-670">2,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-671">5,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-672">9,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-673">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9 for details regarding the impairment loss the Company recognized for certain furniture and fixtures during the year ended December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-674">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-675">0.7</ix:nonFraction> million for the years ended December 31, 2024 and 2023, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="ida4b385316634ae2a3d2c21207c427f6_229"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-676" continuedAt="f-676-1" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-677" escape="true"><ix:continuation id="f-676-1"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll and employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-678">3,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-679">4,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued patent fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:AccruedPatentFeesCurrent" scale="3" id="f-680">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:AccruedPatentFeesCurrent" scale="3" id="f-681">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued external research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-682">2,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-683">4,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:AccruedAuditFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-684">3,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:AccruedAuditFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-685">4,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:AccruedPropertyPlantAndEquipmentCurrent" scale="3" id="f-686">782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:AccruedPropertyPlantAndEquipmentCurrent" scale="3" id="f-687">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-688">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-689">516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-690">12,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-691">14,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:1pt;margin-top:6pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_235"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-692" continuedAt="f-692-1" escape="true">Leases </ix:nonNumeric></span></div><ix:continuation id="f-692-1" continuedAt="f-692-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">7495 New Horizon Way Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, the Company entered into a lease agreement with 7495 RP, LLC, or the Landlord, pursuant to which it agreed to lease from the Landlord the manufacturing space located at 7495 New Horizon Way, Frederick, Maryland, or the Frederick Lease Agreement. The space consists of <ix:nonFraction unitRef="sqft" contextRef="c-146" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-693">19,199</ix:nonFraction> leasable square feet of integrated manufacturing and office space. The lease commenced on May 1, 2024 which was the date the Landlord delivered full possession of the premises to the Company. The Frederick Lease Agreement will terminate approximately <ix:nonNumeric contextRef="c-147" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-694">7.2</ix:nonNumeric> years following the commencement date. The Company will have <ix:nonFraction unitRef="extension_option" contextRef="c-147" decimals="INF" name="rnac:LesseeOperatingLeaseNumberOfOptionsToExtend" format="ixt-sec:numwordsen" scale="0" id="f-695">one</ix:nonFraction> option to extend the term of the Frederick Lease Agreement for a period of <ix:nonNumeric contextRef="c-147" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-696">five years</ix:nonNumeric> at a cost of <ix:nonFraction unitRef="number" contextRef="c-148" decimals="2" name="rnac:OperatingLeaseCostPercentage" scale="-2" id="f-697">100</ix:nonFraction>% of the then-fair market value, not to exceed <ix:nonFraction unitRef="number" contextRef="c-149" decimals="2" name="rnac:OperatingLeaseCostPercentage" scale="-2" id="f-698">103</ix:nonFraction>% of the then-current base rent. Base rent, which was due beginning on July 1, 2024, is $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="rnac:LesseeOperatingLeaseMonthlyBaseRent" format="ixt:num-dot-decimal" scale="6" id="f-699">0.9</ix:nonFraction>&#160;million annually and is subject to an annual upward adjustment of <ix:nonFraction unitRef="number" contextRef="c-150" decimals="INF" name="rnac:LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" scale="-2" id="f-700">3</ix:nonFraction>% of the then-current rental rate. In addition, the Company is obligated to pay its share of operating costs and taxes related to the property. The Company paid the first month&#8217;s rent of $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="rnac:LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement" format="ixt:num-dot-decimal" scale="6" id="f-701">0.1</ix:nonFraction>&#160;million upon execution of the Frederick Lease Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the classification of the lease at the commencement date and concluded it should be accounted for as an operating lease. The Company recorded a lease liability and right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-702">3.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-703">3.7</ix:nonFraction>&#160;million, respectively, on the commencement date. The Frederick Lease Agreement includes a tenant improvement allowance of up to $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="rnac:OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-704">0.7</ix:nonFraction>&#160;million which was recognized as a reduction in the right-of-use asset and lease liability at the commencement date as the Company was reasonably certain to incur reimbursable costs related to alterations equal to or exceeding the amount. Additionally, the prepaid rent was included as an adjustment to the right-of-use asset. The discount rate of <ix:nonFraction unitRef="number" contextRef="c-147" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-705">14</ix:nonFraction>% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term, including any reasonably certain renewal periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 7, 2024, the Company and the Landlord entered into the first amendment to the Frederick Lease Agreement, or the First Frederick Lease Agreement Amendment, providing for the expansion of the premises leased pursuant to the Frederick Lease Agreement by approximately <ix:nonFraction unitRef="sqft" contextRef="c-152" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-706">7,842</ix:nonFraction> square feet. In connection with the expansion of the leased premises, the Company is obligated to pay $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="rnac:LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne" format="ixt:num-dot-decimal" scale="6" id="f-707">0.3</ix:nonFraction>&#160;million in additional annual base rent for the first year of the term, which is subject to an annual upward adjustment of <ix:nonFraction unitRef="number" contextRef="c-153" decimals="INF" name="rnac:LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" scale="-2" id="f-708">3</ix:nonFraction>% of the then-current rental rate, as well as its share of operating costs and taxes. The lease commenced on May 7, 2024 which was the date the Landlord delivered full possession of the premises to the Company and will be coterminous with the Frederick Lease Agreement. The rent commencement date was September 1, 2024. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the classification of the lease at the commencement date and concluded it should be accounted for as an operating lease. The Company recorded a lease liability and right-of-use asset each of $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-709"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-710">1.2</ix:nonFraction></ix:nonFraction>&#160;million on the commencement date. The First Frederick Lease Agreement Amendment includes a tenant improvement allowance of up to $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="rnac:OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-711">0.1</ix:nonFraction>&#160;million which was recognized as a reduction in the right-of-use asset and lease liability at the commencement date as the Company was reasonably certain to incur reimbursable costs related to alterations equal to or exceeding the amount. The discount rate of <ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-712">14</ix:nonFraction>% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective August 30, 2024, the Company and the Landlord entered into the second amendment to the Frederick Lease Agreement, or the Second Frederick Lease Agreement Amendment, providing for the expansion of the premises leased pursuant to the Frederick Lease Agreement and First Frederick Lease Agreement Amendment by approximately <ix:nonFraction unitRef="sqft" contextRef="c-154" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-713">2,009</ix:nonFraction> square feet. In connection with the expansion of the leased premises, the Company is obligated to pay $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="rnac:LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne" format="ixt:num-dot-decimal" scale="6" id="f-714">0.1</ix:nonFraction>&#160;million in additional annual base rent for the first year of the term, which is subject to an annual upward adjustment of <ix:nonFraction unitRef="number" contextRef="c-155" decimals="INF" name="rnac:LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" scale="-2" id="f-715">3</ix:nonFraction>% of the then-current rental rate, as well as its share of operating costs and taxes. The lease commenced on September 1, 2024, which was the date the Landlord delivered full possession of the premises to the Company and will be coterminous with the Frederick Lease Agreement. The rent commencement date was September 1, 2024. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-692-2" continuedAt="f-692-3"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the classification of the lease at the commencement date and concluded it should be accounted for as an operating lease. The Company recorded a lease liability and right-of-use asset each of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-716"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-717">0.3</ix:nonFraction></ix:nonFraction>&#160;million on the commencement date. The discount rate of <ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-718">14</ix:nonFraction>% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company secured a letter of credit from Silicon Valley Bank, a division of First-Citizens Bank &amp; Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), or SVB, for $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="f-719">0.3</ix:nonFraction> million for the Frederick Lease Agreement, the First Frederick Lease Agreement Amendment and the Second Frederick Lease Agreement Amendment, which is recognized as long-term restricted cash as of December 31, 2024 and renews automatically each year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">65 Grove Street Lease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into a lease with BRE-BMR Grove LLC for <ix:nonFraction unitRef="sqft" contextRef="c-157" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-720">25,078</ix:nonFraction> square feet of laboratory and office space located at 65 Grove Street, Watertown, Massachusetts, or the Watertown Lease Agreement. As part of the Watertown Lease Agreement, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-721">0.8</ix:nonFraction> million in non-reimbursable construction costs. The lease began in March 2020, when the Company took control of the office space, and the lease term is <ix:nonNumeric contextRef="c-157" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-722">8</ix:nonNumeric> years. The discount rate of <ix:nonFraction unitRef="number" contextRef="c-157" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-723">8.9</ix:nonFraction>% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term, including any reasonably certain renewal periods. In connection with the Watertown Lease Agreement, the Company secured a letter of credit from SVB for $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-724">1.6</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2022, the Company entered into an amendment, or the Watertown Lease Agreement Amendment, to its lease agreement with BRE-BMR Grove LLC, originally entered into on July 23, 2019 to expand the Company&#8217;s laboratory and office space located at 65 Grove Street, Watertown, Massachusetts by <ix:nonFraction unitRef="sqft" contextRef="c-160" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-725">7,216</ix:nonFraction> square feet. The lease term began on September 1, 2022, consistent with when the Company took control of the office space and the expected lease term is <ix:nonNumeric contextRef="c-160" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-726">5.7</ix:nonNumeric> years. The discount rate of <ix:nonFraction unitRef="number" contextRef="c-160" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-727">11.3</ix:nonFraction>% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods. Rent payments began in November 2022, and the base rent for the first year is $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="rnac:OperatingLeaseBaseRent" format="ixt:num-dot-decimal" scale="6" id="f-728">0.1</ix:nonFraction>&#160;million per month. The Company recorded the right-of-use asset and operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-729"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-730">3.2</ix:nonFraction></ix:nonFraction>&#160;million during the year ended December 31, 2022 as control of the premises was transferred to the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2022, the Company entered into a sublease agreement to sublease <ix:nonFraction unitRef="sqft" contextRef="c-163" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-731">7,216</ix:nonFraction> square feet of space currently rented by the Company at 65 Grove Street, Watertown, Massachusetts.  The sublease commenced on October 24, 2022, when the Company, the sublessee and BRE-BMR Grove LLC, executed a Consent to Sublease.  The term of the sublease expired on March 31, 2024 with no option to extend the sublease term. Sublease income is included within other income, net in the consolidated statements of operations and comprehensive loss.   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the sublease agreement and Consent to Sublease, rent payments to BRE-BMR Grove LLC for the lease of the office space increased.  The change of consideration in the contract was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of October 24, 2022.  The discount rate of <ix:nonFraction unitRef="number" contextRef="c-164" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-732">11.9</ix:nonFraction>% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods as of October 24, 2022, resulting in a decrease of less than $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-733"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-734">0.1</ix:nonFraction></ix:nonFraction>&#160;million to both the right-of-use asset and lease liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company received notice from BRE-BMR Grove LLC that the requirements to reduce the amount of the letter of credit for the Watertown Lease Agreement had been met. In connection therewith, in June 2023, the Company secured a letter of credit from JPMorgan Chase Bank, N.A. for $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-735"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-736">1.4</ix:nonFraction></ix:nonFraction>&#160;million, which is recognized as long-term restricted cash as of December 31, 2024 and 2023, and renews automatically each year. The $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-737">1.6</ix:nonFraction>&#160;million letter of credit with SVB was released from restriction and returned to the Company on July 17, 2023, and therefore was reclassified into cash and cash equivalents in the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2023, in connection with entering into Amendment No. 1 to the License and Development Agreement with Sobi as described in Note 14, the Company entered into a sublease agreement with Sobi to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="c-167" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-738">5,600</ix:nonFraction> square feet of space currently rented by the Company at 65 Grove Street, Watertown, Massachusetts for which Sobi paid $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="rnac:UpfrontRentalPayment" format="ixt:num-dot-decimal" scale="6" id="f-739">1.0</ix:nonFraction>&#160;million upfront rental payment.  The sublease commenced on November 6, 2023, when the Company, Sobi, and BRE-BMR Grove LLC, executed a Consent to Sublease.  The term of the sublease expired on November 5, 2024 with no option to extend the sublease term. As of December 31, 2023, deferred rent of $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:DeferredRentCreditCurrent" format="ixt:num-dot-decimal" scale="6" id="f-740">0.8</ix:nonFraction>&#160;million is included within accrued expenses and other current liabilities in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company determined that the right-of-use asset related to the operating lease for approximately <ix:nonFraction unitRef="sqft" contextRef="c-163" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-741">7,216</ix:nonFraction> square feet at 65 Grove Street was partially impaired as of November 30, 2023.  As a result, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-742">0.7</ix:nonFraction>&#160;million right-of-use asset impairment charge in impairment of long-lived assets on its consolidated statements of operations and comprehensive loss during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the expiration of the sublease to Sobi in November 2024 and the Company&#8217;s decision to cease use of its office and laboratory space at 65 Grove Street, Watertown, Massachusetts, the Company assessed the right-of-use assets and related furniture and fixtures associated with the Watertown Lease Agreement and Watertown Lease Agreement Amendment </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-692-3" continuedAt="f-692-4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for impairment. The carrying value of each asset group was compared against the future net undiscounted cash flows projected to be generated over the remaining lease terms. These projections included management's estimates of cash inflows from potential sublease income. The carrying amount of the asset groups was found to be unrecoverable, thus the Company assessed the fair value of each asset group. The fair value was determined using the income approach, whereby the Company discounted the estimated net cash flows using a rate commensurate with the Company&#8217;s estimated incremental borrowing rate. As a result of this assessment, which included unrecoverable operating and maintenance costs, the Company determined that each asset group was fully impaired. As such, an <span style="-sec-ix-hidden:f-743">impairment charge</span> of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-744">7.6</ix:nonFraction>&#160;million was recognized during the year ended December 31, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-745">7.4</ix:nonFraction>&#160;million of which related to the right-of-use assets and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-746">0.2</ix:nonFraction>&#160;million related to property and equipment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">704 Quince Orchard Road Leases</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company acquired <ix:nonFraction unitRef="operating_lease" contextRef="c-171" decimals="INF" name="rnac:NumberOfAcquiredOperatingLeases" format="ixt-sec:numwordsen" scale="0" id="f-747">two</ix:nonFraction> operating leases for office and laboratory space in Gaithersburg, Maryland. The leases expire in January 2027 and do not contain any renewal rights. The discount rate of <ix:nonFraction unitRef="number" contextRef="c-172" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-748">11.5</ix:nonFraction>% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the years ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-749">5.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-750">3.8</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-751" continuedAt="f-751-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024 and 2023, the components of lease costs were as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-752">3,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-753">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-754">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-755">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-756">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-757">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-758">1,099</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-759">1,172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-760">4,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-761">2,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-762" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2024 were as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-763">3,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-764">4,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-765">4,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-766">2,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-767">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-768">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-769">18,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-770">4,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-771">13,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="f-772" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-773">3,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-774">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the initial recording of the right-of-use assets and lease liabilities for the Frederick Lease Agreement, First Frederick Lease Agreement Amendment, and Second Frederick Lease Agreement Amendment during the year ended December 31, 2024, the impairments on the right-of-use assets for the Watertown Lease Agreement and Watertown Lease Agreement Amendment during the years ended December 31, 2024 and 2023, as applicable, and the assumption of the right-of-use assets and lease liabilities in connection with the Merger during the year ended December 31, 2023, which were non-cash, the changes in the Company&#8217;s right-of-use assets and lease liabilities for the years ended December 31, 2024 and 2023 are reflected in the non-cash lease expense and accrued expenses and other liabilities, respectively, in the consolidated statements of cash flows.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-751-1"><ix:continuation id="f-692-4"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to the Company&#8217;s operating leases:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-775">4.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-776">4.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-777">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-778">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_238"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-779" continuedAt="f-779-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-779-1" continuedAt="f-779-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020, the Company entered into a Loan and Security Agreement with Oxford Finance LLC, or Oxford, and Silicon Valley Bank, or the Loan and Security Agreement, and such facility, the 2020 Term Loan. On March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation, or the FDIC, was appointed as receiver. On March 13, 2023, the FDIC announced that all of Silicon Valley Bank&#8217;s deposits and substantially all of its assets had been transferred to a newly created, full-service, FDIC-operated bridge bank, Silicon Valley Bridge Bank, N.A., or SVBB. SVBB assumed all loans that were previously held by Silicon Valley Bank. On March 27, 2023, First-Citizens Bank &amp; Trust Company assumed all of SVBB&#8217;s customer deposits and certain other liabilities and acquired substantially all of SVBB&#8217;s loans and certain other assets from the FDIC, including the 2020 Term Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2023, the Company entered into a payoff letter with Oxford and SVB, pursuant to which the Company paid all outstanding amounts under the 2020 Term Loan, together with accrued interest and a prepayment penalty, resulting in the full extinguishment of the 2020 Term Loan. The total payoff amount was $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-780">22.3</ix:nonFraction>&#160;million, consisting of the remaining principal amount due of $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="f-781">19.8</ix:nonFraction>&#160;million, the final payment fee of $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-782">2.3</ix:nonFraction>&#160;million, the prepayment penalty of $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="rnac:DebtInstrumentPrepaymentFee" format="ixt:num-dot-decimal" scale="6" id="f-783">0.2</ix:nonFraction>&#160;million, and less than $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="rnac:DebtInstrumentAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-784">0.1</ix:nonFraction>&#160;million of accrued interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recorded a loss of $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-785">0.7</ix:nonFraction>&#160;million on the extinguishment of the 2020 Term Loan, consisting of the prepayment penalty of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="rnac:DebtInstrumentPrepaymentFee" format="ixt:num-dot-decimal" scale="6" id="f-786">0.2</ix:nonFraction>&#160;million and the write-off of $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="f-787">0.5</ix:nonFraction>&#160;million of unamortized debt issuance costs and venture debt termination fee, which was included within interest expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="c-179" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="f-788"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="f-789">no</ix:nonFraction></ix:nonFraction> outstanding borrowings.</span></div></ix:continuation><div style="margin-bottom:1pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-779-2">During the year ended December 31, 2024, the Company recognized <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="6" id="f-790">no</ix:nonFraction> interest expense. During the year ended December 31, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-791">2.1</ix:nonFraction> million of interest expense related to the 2020 Term Loan.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_244"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="rnac:TemporaryEquityDisclosureTextBlock" id="f-792" continuedAt="f-792-1" escape="true">Convertible Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="f-792-1" continuedAt="f-792-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Certificate of Designation of Preferences, Rights, and Limitations of the Series B Non-Voting Convertible Preferred Stock, or the Series B Certificate of Designation, was filed with the Secretary of State of the State of Delaware on July&#160;2, 2024, and provided for the designation of shares of Series B Preferred Stock and authorized the issuance of <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-793">2,937,903</ix:nonFraction> shares of Series B Preferred Stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on July 2, 2024, the Company entered into the 2024 Securities Purchase Agreement with certain institutional and accredited investors, or the Purchasers. The Purchasers included (i) Dr. Timothy A. Springer, a member of the Company&#8217;s Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Dr. Chafen Lu, Dr. Springer&#8217;s wife. Pursuant to the 2024 Securities Purchase Agreement, the Company agreed to issue and sell an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-794">3,563,247</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-795">2,937,903</ix:nonFraction> shares of Series B Preferred Stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="rnac:SaleOfStockGrossConsiderationReceivedOnTransaction" scale="6" id="f-796">130.0</ix:nonFraction> million in the 2024 Private Placement. Each share of Series B Preferred Stock is convertible into <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt-sec:numwordsen" scale="0" id="f-797">one</ix:nonFraction> share of the Company&#8217;s common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to stockholder approval of a proposal to issue such shares of common stock upon conversion of such shares of Series B Preferred Stock in accordance with the Listing Rules of the Nasdaq Stock Market LLC, or the Series B Conversion Proposal. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2024 Securities Purchase Agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-798">3,563,247</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-799">578,403</ix:nonFraction> shares of Series B Preferred Stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-800">82.8</ix:nonFraction> million to the Purchasers other than Dr. Springer, TAS Partners LLC, and Dr. Lu. The Company also issued (i) <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-801">1,636,832</ix:nonFraction> shares of Series B Preferred Stock to Dr. Springer, (ii) <ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-802">721,361</ix:nonFraction> shares of Series B Preferred Stock to TAS Partners LLC, and (iii) <ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-803">1,307</ix:nonFraction> shares of Series B Preferred Stock to Dr. Lu for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-804">47.2</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2024 Securities Purchase Agreement, the Company agreed to submit to its stockholders the approval of the Series B Conversion Proposal, at a special meeting of stockholders, which was held on September 20, 2024. On September 20, 2024, at such special meeting, the Company&#8217;s stockholders approved the Series B Conversion Proposal, among other matters. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-792-2" continuedAt="f-792-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2024, pursuant to the terms of the Series B Certificate of Designation, <ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-805">2,499,976</ix:nonFraction> shares of Series B Preferred Stock automatically converted into <ix:nonFraction unitRef="shares" contextRef="c-188" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-806">2,499,976</ix:nonFraction> shares of common stock; <ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="rnac:ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert" format="ixt:num-dot-decimal" scale="0" id="f-807">437,927</ix:nonFraction> shares of Series B Preferred Stock did not automatically convert at such time due to beneficial ownership limitations. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock were classified in permanent equity as there were no conditions that could have required cash redemption of the shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock has the following rights and preferences:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the stockholder approval of the Series B Conversion Proposal the Series B Preferred Stock were not convertible into shares of common stock. Following the stockholder approval of the Series B Conversion Proposal, each share of Series B Preferred Stock automatically converted into <ix:nonFraction unitRef="number" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockConvertibleConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-808">one</ix:nonFraction> share of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between <ix:nonFraction unitRef="number" contextRef="c-189" decimals="3" name="rnac:PreferredStockConvertibleBeneficialOwnershipPercentage" scale="-2" id="f-809">0.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-190" decimals="3" name="rnac:PreferredStockConvertibleBeneficialOwnershipPercentage" scale="-2" id="f-810">19.9</ix:nonFraction>%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion; provided, however, that such beneficial ownership limitation does not apply to Dr. Springer, TAS Partners LLC, or any of their respective affiliates. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock outstanding that was not automatically converted into common stock as a result of the stockholder approval of the Series B Conversion Proposal shall be convertible at any time at the option of the holder following stockholder approval of the Series B Conversion Proposal, only to the extent the beneficial ownership limitation does not apply to the shares of Series B Preferred Stock to be converted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock is not redeemable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock on an as-converted basis (without regard to the beneficial ownership limitation) equal to the dividends paid on shares of the common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then-outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the Series B Certificate of Designation, or (c) amend the Charter or other organizational documents in any manner that alters or changes the preferences, rights, privileges, or powers of, or restrictions provided for the benefit of the holders of Series B Preferred Stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Series B Preferred Stock shall rank on parity with the holders of common stock and the holders of Series A Preferred Stock as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, each holder of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B Preferred Stock were fully converted, which shall be paid pari passu with holders of common stock and holders of Series A Preferred Stock, plus an amount equal to any dividends declared but unpaid. If the assets available for distribution are not sufficient to pay the holders of the Series B Preferred Stock pursuant to the preceding sentence, all remaining assets will be distributed ratably to the holders of the Series A Preferred Stock, Series B Preferred Stock and common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Certificate of Designation of Preferences, Rights, and Limitations of the Series A Non-Voting Convertible Preferred Stock, or the Series A Certificate of Designation, was filed on November 13, 2023, which provided for the designation of shares of the Series A Preferred Stock and authorized the issuance of <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-811">548,375</ix:nonFraction> shares of Series A Preferred Stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally on November 13, 2023, the Company entered into the 2023 Securities Purchase Agreement with (i) Dr. Timothy A. Springer, a member of the Company&#8217;s Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Seven One Eight Three Four Irrevocable Trust, a trust associated with Dr. Murat Kalayoglu, a co-founder and the former chief executive officer of Old Cartesian, who joined the Company&#8217;s Board of Directors effective immediately after the effective </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-792-3" continuedAt="f-792-4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time of the Merger, or the Investors. Pursuant to the 2023 Securities Purchase Agreement, the Company agreed to issue and sell an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-812">149,330.115</ix:nonFraction> shares of Series A Preferred Stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-4" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-813">60.25</ix:nonFraction>&#160;million in the 2023 Private Placement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the 2023 Private Placement, Dr. Timothy A. Springer agreed to settle his purchases in three tranches of shares of Series A Preferred Stock, the first for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-814">10.0</ix:nonFraction>&#160;million and each thereafter for a purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-815"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-816">20.0</ix:nonFraction></ix:nonFraction>&#160;million, with the three tranches settling <ix:nonNumeric contextRef="c-191" name="rnac:SaleOfStockSettlementTerm" format="ixt-sec:durday" id="f-817">30</ix:nonNumeric>, <ix:nonNumeric contextRef="c-193" name="rnac:SaleOfStockSettlementTerm" format="ixt-sec:durday" id="f-818">60</ix:nonNumeric>, and <ix:nonNumeric contextRef="c-192" name="rnac:SaleOfStockSettlementTerm" format="ixt-sec:durday" id="f-819">90</ix:nonNumeric> days, respectively, following the Closing Date. TAS Partners LLC agreed to settle its purchase for approximately $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-820">10.0</ix:nonFraction>&#160;million within <ix:nonNumeric contextRef="c-191" name="rnac:SaleOfStockSettlementTerm" format="ixt-sec:durday" id="f-821">30</ix:nonNumeric> days following the Closing Date. The first, second and third tranches were settled on December 13, 2023, January 12, 2024 and February 11, 2024, respectively, under which (i) <ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-822">24,785.081</ix:nonFraction> shares of Series A Preferred Stock were issued to each of TAS Partners LLC and Dr. Timothy A. Springer in the first tranche, (ii) <ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-823">49,570.163</ix:nonFraction> shares of Series A Preferred Stock were issued to Dr. Timothy A. Springer in the second tranche, and (iii) <ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-824">49,570.163</ix:nonFraction> shares of Series A Preferred Stock were issued to Dr. Timothy A. Springer in the third tranche. On November 15, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="f-825">619.627</ix:nonFraction> shares of Series A Preferred Stock to Seven One Eight Three Four Irrevocable Trust for $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-4" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-826">0.25</ix:nonFraction>&#160;million.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company determined the obligation to issue <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="rnac:SettlementOfDerivativeLiabilityShares" format="ixt:num-dot-decimal" scale="0" id="f-827">148,710.488</ix:nonFraction> shares of Series A Preferred Stock to Dr. Springer and TAS Partners LLC represented a forward contract and was accounted for as a liability with changes in fair value recorded in earnings. A portion of the liability was settled with the initial issuance of <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="rnac:SettlementOfDerivativeLiabilityShares" format="ixt:num-dot-decimal" scale="0" id="f-828">49,570.162</ix:nonFraction> shares of Series A Preferred Stock on December 13, 2023. The remaining portion of the forward contract liability was settled upon the issuance of <ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="rnac:SettlementOfDerivativeLiabilityShares" format="ixt:num-dot-decimal" scale="0" id="f-829"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="rnac:SettlementOfDerivativeLiabilityShares" format="ixt:num-dot-decimal" scale="0" id="f-830">49,570.163</ix:nonFraction></ix:nonFraction> shares of Series A Preferred Stock each on January 12, 2024 and February 11, 2024, respectively (see Note 6).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-831">384,930.724</ix:nonFraction> shares of Series A Preferred Stock as part of its consideration transferred in connection with the Merger which settled the related forward contract liability (see Note 6).</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 26, 2024, the Company, with the consent of the requisite holders of Series A Preferred Stock, amended the Series A Certificate of Designation such that the automatic conversion of the Series A Preferred Stock into common stock, or the Automatic Conversion, would occur <ix:nonFraction unitRef="business_day" contextRef="c-201" decimals="INF" name="rnac:NumberOfBusinessDays" format="ixt-sec:numwordsen" scale="0" id="f-832">eight</ix:nonFraction> business days following stockholder approval of the Conversion Proposal. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2024, the Company&#8217;s stockholders approved the Conversion Proposal, among other matters, at the Special Meeting.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2024, pursuant to the terms of the Series A Certificate of Designation, as amended, <ix:nonFraction unitRef="shares" contextRef="c-202" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-833">367,919.247</ix:nonFraction> shares of Series A Preferred Stock automatically converted into <ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-834">12,263,951</ix:nonFraction> shares of common stock, including the non-cash reclassification of an amount equal to the increase in par value of common stock from additional paid-in capital; <ix:nonFraction unitRef="shares" contextRef="c-204" decimals="INF" name="rnac:ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert" format="ixt:num-dot-decimal" scale="0" id="f-835">166,341.592</ix:nonFraction> shares of Series A Preferred Stock did not automatically convert at such time due to beneficial ownership limitations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 11, 2024, pursuant to a Notice of Optional Conversion delivered to the Company by a holder of Series A Preferred Stock pursuant to the Series A Certificate of Designation, <ix:nonFraction unitRef="shares" contextRef="c-205" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-836">45,551.190</ix:nonFraction> shares of Series A Preferred Stock held by such holder were converted into <ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-837">1,518,373</ix:nonFraction> newly issued shares of common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with the guidance in ASC Topic 480,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Distinguishing Liabilities from Equity (ASC 480)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> the Series A Preferred Stock was classified outside of stockholders&#8217; deficit upon issuance and as of December 31, 2023 because the shares of Series A Preferred Stock contained redemption features that were not solely within the control of the Company. The Series A Preferred Stock was not currently redeemable, nor was it probable that the instrument would become redeemable, as it was only redeemable upon the occurrence of a contingent event. Accordingly, no accretion was recognized for the Series A Preferred Stock. As a result of the approval of the Conversion Proposal, all conditions that could have required cash redemption of the Series A Preferred Stock were removed. Since the Series A Preferred Stock was no longer redeemable, the associated balances of the Series A Preferred Stock were reclassified to permanent equity during the first quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock has the following rights and preferences:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the stockholder approval of the Conversion Proposal, the Series A Preferred Shares were not convertible. Following the stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock automatically converted into <ix:nonFraction unitRef="number" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="f-838">33.333</ix:nonFraction> shares of common stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between <ix:nonFraction unitRef="number" contextRef="c-68" decimals="2" name="rnac:PreferredStockConvertibleBeneficialOwnershipPercentage" scale="-2" id="f-839">0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-69" decimals="3" name="rnac:PreferredStockConvertibleBeneficialOwnershipPercentage" scale="-2" id="f-840">19.9</ix:nonFraction>%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion; provided, however, that such beneficial ownership limitation does not apply to Dr. Springer, TAS Partners LLC, or any of their respective affiliates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series A Preferred Stock outstanding that was not otherwise automatically converted into common stock as a result of the beneficial ownership limitation shall be convertible at any time at the option of the holder following stockholder approval of the Conversion Proposal, only to the extent the beneficial ownership limitation does not apply to the shares of Series A Preferred Stock to be converted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-792-4"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock was redeemable at the option of the holder at any time following the date that was <ix:nonNumeric contextRef="c-1" name="rnac:PreferredStockRedemptionTerm" format="ixt-sec:durmonth" id="f-841">18</ix:nonNumeric> months after the initial issuance date of the Series A Preferred Stock, other than any shares of Series A Preferred Stock that would not have been convertible into shares of common stock as a result of the beneficial ownership limitation referred to above. The amount payable upon redemption would have been equal to the average closing sale price of the common stock listed over the <ix:nonFraction unitRef="day" contextRef="c-1" decimals="INF" name="rnac:PreferredStockConvertibleThresholdConsecutiveTradingDays" format="ixt-sec:numwordsen" scale="0" id="f-842">ten</ix:nonFraction> consecutive trading days ending on, and including, the day immediately prior to the redemption date multiplied by the number of shares of common stock the Series A Preferred Stock would have been convertible into. Following the Conversion Proposal, the Series A Preferred Stock is not redeemable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock on an as-converted basis equal to the dividends paid on shares of the common stock; provided, however, that holders of Series A Preferred Stock (or any shares of common stock into which the Series A Preferred Stock are convertible) are not entitled to any CVRs or any amounts paid under the CVR Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then-outstanding shares of the Series A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (b) alter or amend the Series A Certificate of Designation, (c) amend the Charter or other organizational documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (d) issue further shares of Series A Preferred Stock (other than in connection with the exercise of the stock options to purchase Series A Preferred Stock) or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (e) prior to the stockholder approval of the Conversion Proposal or at any time while at least <ix:nonFraction unitRef="number" contextRef="c-8" decimals="INF" name="rnac:PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding" scale="-2" id="f-843">30</ix:nonFraction>% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate either (A) a Fundamental Transaction (as defined in the Series A Certificate of Designation) or (B) any merger or consolidation of the Company or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority of the capital stock of the Company immediately after such transaction, (f) amend or fail to comply with, in any manner that would be reasonably likely to prevent, impede or materially delay the conversion (or the stockholder approval thereof), or terminate, any of the stockholder support agreements entered into in connection with the Merger, or the Support Agreements, or agree to any transfer, sale or disposition of such shares subject to the Support Agreements (except for such transfers, sales or dispositions with respect to which the approval of the Company is not required pursuant to the applicable Support Agreement) or (g) enter into any agreement with respect to any of the foregoing. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The holders of Series A Preferred Stock shall rank on parity with the common stockholders and the holders of Series B Preferred Stock as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary each holder of Series A Preferred Stock shall be entitled to receive out the assets of the Company equal to of the same amount that a holder of common stock would receive if the Series A Preferred Stock were fully converted, which shall be paid pari passu with holders of common stock and holders of Series B Preferred Stock, plus an amount equal to any dividends declared but unpaid. If the assets available for distribution are not sufficient to pay the holders of the Series A Preferred Stock pursuant to the preceding sentence, the assets will be distributed ratably to the holders of the Series A Preferred Stock, Series B Preferred Stock and common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-844"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-845">120,790.402</ix:nonFraction></ix:nonFraction> shares of Series A Preferred Stock and <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-846"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-847">437,927</ix:nonFraction></ix:nonFraction> shares of Series B Preferred Stock issued and outstanding, respectively, which are convertible into a total of <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockConvertibleSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="f-848"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockConvertibleSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="f-849">4,464,273</ix:nonFraction></ix:nonFraction> shares of common stock.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_247"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-850" continuedAt="f-850-1" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="f-850-1" continuedAt="f-850-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Private Placement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 2, 2024, the Company and the Purchasers entered into the 2024 Securities Purchase Agreement for the 2024 Private Placement. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the 2024 Securities Purchase Agreement, the Purchasers agreed to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-851">3,563,247</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-852">2,937,903</ix:nonFraction> shares of Series B Preferred Stock, inclusive of <ix:nonFraction unitRef="shares" contextRef="c-207" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-853">2,359,500</ix:nonFraction> shares of Series B Preferred Stock purchased by directors and executive officers of the Company, and related parties thereto, each at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-854">20.00</ix:nonFraction>. The 2024 Private Placement resulted in gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="rnac:SaleOfStockGrossConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-855">130.0</ix:nonFraction>&#160;million before deducting placement agent fees and other offering expenses. See Note 11.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-850-2" continuedAt="f-850-3"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merger</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-208" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-856">224,099</ix:nonFraction> shares of common stock as part of its consideration transferred in connection with the Merger which settled the related equity-classified forward contract (see Note 4).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Underwritten Offering</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2022, the Company entered into an underwriting agreement with SVB Securities LLC (now known as Leerink Partners LLC), as representative of the several underwriters named therein, relating to an underwritten offering of <ix:nonFraction unitRef="shares" contextRef="c-209" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-857">914,285</ix:nonFraction> shares of the Company&#8217;s common stock and 2022 Warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-210" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-858">685,712</ix:nonFraction> shares of common stock, or the 2022 Offering. Each share and accompanying 2022 Warrant to purchase <ix:nonFraction unitRef="shares" contextRef="c-210" decimals="2" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="f-859">0.75</ix:nonFraction> shares of common stock was sold at a combined offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-210" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-860">42.30</ix:nonFraction>. The exercise price for the 2022 Warrants is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-210" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-861">46.50</ix:nonFraction> per share. The Company received net proceeds from the 2022 Offering of approximately $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-862">36.9</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company&#8217;s common stock and also upon any distributions for no consideration of assets to the Company&#8217;s stockholders. Each 2022 Warrant is exercisable at any time and from time to time after issuance. In the event of certain corporate transactions, the holders of the 2022 Warrants will be entitled to receive the kind and amount of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such transaction. Therefore, the Company is required to account for the 2022 Warrants as liabilities and record the 2022 Warrants at fair value. The 2022 Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which holders of common stock are entitled.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;At-the-Market&#8221; Offerings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Sales Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2024, the Company entered into a Sales Agreement, or the 2024 Sales Agreement, with Leerink Partners to sell shares of the Company&#8217;s common stock, from time to time, through an &#8220;at the market&#8221; equity offering program under which Leerink Partners will act as sales agent. The shares of common stock sold pursuant to the 2024 Sales Agreement will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-283803), filed on December 13, 2024 with the SEC and related prospectus supplement, filed on January 8, 2025 with the SEC, for aggregate gross sales proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="rnac:SaleOfStockAggregateMaximumGrossSalesProceeds" format="ixt:num-dot-decimal" scale="6" id="f-863">100.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Sales Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 25, 2021, the Company entered into a Sales Agreement, or the 2021 Sales Agreement, with Leerink Partners LLC (then known as SVB Leerink LLC), or Leerink Partners, pursuant to which the Company may sell shares of the Company&#8217;s common stock, from time to time, through an &#8220;at the market&#8221; equity offering program under which Leerink Partners will act as sales agent. The shares of common stock sold pursuant to the 2021 Sales Agreement, if any, would be issued and sold pursuant to a registration statement to be filed by the Company with the SEC, for aggregate remaining gross sales proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="rnac:SaleOfStockAggregateMaximumGrossSalesProceeds" scale="6" id="f-864">51.0</ix:nonFraction> million. During the years ended December 31, 2024 and 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-213" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-865"><ix:nonFraction unitRef="shares" contextRef="c-214" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-866">no</ix:nonFraction></ix:nonFraction> shares of its common stock pursuant to the 2021 Sales Agreement. The 2024 Sales Agreement supersedes the 2021 Sales Agreement, which is no longer in effect. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2020 Sobi Stock Purchase</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, the Company entered into a stock purchase agreement with Sobi, pursuant to which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-867">180,546</ix:nonFraction> shares of its common stock at a purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-216" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-868">138.4680</ix:nonFraction> per share, which represented <ix:nonFraction unitRef="number" contextRef="c-215" decimals="INF" name="rnac:SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" scale="-2" id="f-869">120</ix:nonFraction>% of the 10-day volume-weighted average price of the Company&#8217;s common stock prior to signing, for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-870">25.0</ix:nonFraction>&#160;million, or the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 815, this forward sale treatment qualified as equity classification as the shares are not within the scope of ASC 480. The gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-871">25.0</ix:nonFraction>&#160;million were determined to include a premium to the fair value of the Company&#8217;s shares as of July 28, 2020 of approximately $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:RedemptionPremium" format="ixt:num-dot-decimal" scale="6" id="f-872">14.5</ix:nonFraction>&#160;million. As a result, such amount was included in the transaction price for revenue recognition of the Sobi License. See Note 14 for details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on June 11, 2020, the Company entered into a registration rights agreement, as amended by that certain letter agreement, dated as of November 4, 2020, or the Sobi Registration Rights Agreement, with Sobi, pursuant to which the Company agreed to prepare and file a registration statement with respect to the resale of the shares of common stock acquired in the Sobi Private Placement. The Company will be required to file this resale registration statement within 30 days following receipt by the Company of a written request from Sobi to file such resale registration statement, and to have the registration statement declared effective within ten business days after the SEC informs the Company that no review of such resale registration statement will be made or that the SEC has no further comments on such resale registration statement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Financing</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-850-3" continuedAt="f-850-4"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 18, 2019, the Company entered into a securities purchase agreement, or the 2019 Securities Purchase Agreement, with a group of institutional investors and certain members of the Board of Directors. Pursuant to the 2019 Securities Purchase Agreement, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-218" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-873">1,254,496</ix:nonFraction> shares of its common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-219" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-874">43.80</ix:nonFraction> per share, warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-219" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-875">766,275</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-220" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-876">3.75</ix:nonFraction> per share underlying each common warrant, and pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-221" decimals="INF" name="rnac:ClassOfWarrantOrRightNumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-877">278,070</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-220" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-878">43.80</ix:nonFraction> per share, all with <ix:nonNumeric contextRef="c-220" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-879">five year</ix:nonNumeric> terms, or the 2019 Private Placement. The closing of the 2019 Private Placement occurred on December 23, 2019. The exercise price of the pre-funded warrants is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-222" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-880">0.003</ix:nonFraction> per share and the exercise price for the common warrants is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-220" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-881">43.80</ix:nonFraction> per share. In the event of a certain sale of the Company, the terms of the common warrants require us to make a payment to such common warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). This provision does not apply to the pre-funded warrants. Therefore, the Company is required to account for the common warrants as liabilities and record them at fair value, while the pre-funded warrants met the criteria to be classified as permanent equity. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the fair value of the 2019 Warrants of $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="rnac:WarrantIssued" scale="6" id="f-882">40.7</ix:nonFraction>&#160;million upon issuance using the Black-Scholes valuation model. Issuance costs were allocated between the equity component with an offset to additional paid-in capital and the liability component recorded as expense on a relative fair value basis. Total net proceeds from the equity offering was $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-883">65.6</ix:nonFraction> million, after deducting transaction costs and commissions of $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-884">4.4</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 6, the Company remeasured the Amended 2019 Warrants at the fair value of $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="rnac:WarrantIssued" format="ixt:num-dot-decimal" scale="6" id="f-885">0.8</ix:nonFraction>&#160;million on December 20, 2022 and reclassified this amount to additional paid-in capital. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding 2019 Warrants expired on December 23, 2024 in accordance with their terms. The remaining 2022 Warrants liability was revalued as of December 31, 2024 at $<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="f-886">3.8</ix:nonFraction> million. During the years ended December 31, 2024 and 2023, the Company recorded a decrease of $<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" sign="-" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="6" id="f-887">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" sign="-" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="6" id="f-888">12.7</ix:nonFraction> million, respectively, in the fair value of the warrants in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-889" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of warrant activity for the years ended December 31, 2024 and 2023: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>&#160;classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-227" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-890">74,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-228" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-891">966,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-892">1,040,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-893">46.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-229" decimals="0" name="rnac:StockIssuedDuringPeriodSharesWarrantsCanceled" scale="0" id="f-894">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-230" decimals="0" name="rnac:StockIssuedDuringPeriodSharesWarrantsCanceled" format="ixt:fixed-zero" scale="0" id="f-895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="rnac:StockIssuedDuringPeriodSharesWarrantsCanceled" scale="0" id="f-896">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="rnac:StockIssuedDuringWarrantedCanceledPricePerShare" scale="0" id="f-897">503.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-898">74,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-899">966,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-900">1,040,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-901">45.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-232" decimals="0" name="rnac:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-902">65,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="0" name="rnac:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="rnac:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-904">65,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="rnac:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" scale="0" id="f-905">43.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-232" decimals="0" name="rnac:StockIssuedDuringPeriodSharesWarrantsCanceled" format="ixt:num-dot-decimal" scale="0" id="f-906">1,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-120" decimals="0" name="rnac:StockIssuedDuringPeriodSharesWarrantsCanceled" format="ixt:num-dot-decimal" scale="0" id="f-907">280,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="rnac:StockIssuedDuringPeriodSharesWarrantsCanceled" format="ixt:num-dot-decimal" scale="0" id="f-908">282,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="rnac:StockIssuedDuringWarrantedCanceledPricePerShare" scale="0" id="f-909">44.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-233" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-910">6,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-911">685,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-912">692,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-913">46.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-914">350,000,000</ix:nonFraction> shares of common stock authorized for issuance, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-915">0.0001</ix:nonFraction> par value per share, with <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-916"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-917">25,767,369</ix:nonFraction></ix:nonFraction> shares issued and outstanding. The voting, dividend and liquidation rights of the common stockholders are subject to and qualified by the rights, powers and preferences of the preferred stock. The common stock has the following characteristics:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders are entitled to <ix:nonFraction unitRef="vote" contextRef="c-8" decimals="INF" name="rnac:CommonStockVotingRightsNumberOfVotes" format="ixt-sec:numwordsen" scale="0" id="f-918">one</ix:nonFraction> vote for each share of common stock held with respect to all matters voted on by the stockholders of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders are entitled to receive dividends, if and when declared by the Board of Directors. Through December 31, 2024, <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DividendsCommonStock" format="ixt:fixed-zero" scale="0" id="f-919">no</ix:nonFraction> cash dividends have been declared or paid on common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon liquidation of the Company, common stockholders are entitled to receive all assets of the Company available for distribution to such stockholders.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-850-4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserved Shares</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-920" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized shares of common stock for future issuance as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-233" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-921">692,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares available for future stock incentive awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-234" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-922">4,205,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-235" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-923">444,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-236" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-924">1,706,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-237" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-925">4,026,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-238" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-926">437,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-927">11,512,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_253"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-928" continuedAt="f-928-1" escape="true">Stock Incentive Plans</ix:nonNumeric></span></div><ix:continuation id="f-928-1" continuedAt="f-928-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintained the 2008 Stock Incentive Plan, or the 2008 Plan, for employees, consultants, advisors, and directors. The 2008 Plan provided for the granting of incentive and non-qualified stock option and restricted stock awards as determined by the Board of Directors. In connection with the Merger, all outstanding awards issued under the 2008 Plan were cancelled, and the Board of Directors formally terminated the 2008 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s stockholders approved the 2016 Incentive Award Plan, or the 2016 Plan, which authorized <ix:nonFraction unitRef="shares" contextRef="c-239" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-929">40,341</ix:nonFraction> shares of common stock for future issuance under the 2016 Plan and the Company ceased granting awards under the 2008 Plan. Upon the effective date of the 2016 Plan, awards issued under the 2008 Plan remained subject to the terms of the 2008 Plan. Awards granted under the 2008 Plan that expired, lapsed or terminated became available under the 2016 Plan as shares available for future grants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, pursuant to the terms of the 2016 Plan, the Board of Directors is authorized to grant awards with respect to common stock, and may delegate to a committee of one or more members of the Board of Directors or executive officers of the Company the authority to grant options and restricted stock units. On December 9, 2020, the Board of Directors established a Stock Option Committee authorized to grant awards to certain employees and consultants subject to conditions and limitations within the 2016 Plan. In January 2024 and 2023, the number of shares of common stock that may be issued under the 2016 Plan was increased by <ix:nonFraction unitRef="shares" contextRef="c-240" decimals="INF" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-930">215,903</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-241" decimals="INF" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-931">204,056</ix:nonFraction> shares, respectively. In June 2024, the Company&#8217;s stockholders approved an amendment and restatement of the 2016 Plan to reserve an additional <ix:nonFraction unitRef="shares" contextRef="c-242" decimals="INF" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-932">3,466,544</ix:nonFraction> shares of the Company&#8217;s common stock for issuance. As of December 31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-243" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-933">3,520,174</ix:nonFraction> shares remain available for future issuance under the 2016 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s 2018 Employment Inducement Incentive Award Plan, or the 2018 Inducement Incentive Award Plan was adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules, which authorized <ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-934">39,166</ix:nonFraction> shares of its common stock for issuance. In March 2019, the Board of Directors approved an amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional <ix:nonFraction unitRef="shares" contextRef="c-245" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-935">66,667</ix:nonFraction> shares of the Company&#8217;s common stock for issuance thereunder. In December 2023, the Board of Directors approved an amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional <ix:nonFraction unitRef="shares" contextRef="c-246" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-936">60,833</ix:nonFraction> shares of the Company&#8217;s common stock for issuance thereunder. In June and December 2024, the Board of Directors approved amendments and restatements of the 2018 Inducement Incentive Award Plan to reserve an additional <ix:nonFraction unitRef="shares" contextRef="c-247" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-937">360,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-248" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-938">450,000</ix:nonFraction> shares, respectively, of the Company&#8217;s common stock for issuance thereunder. As of December 31, 2024, there are <ix:nonFraction unitRef="shares" contextRef="c-248" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-939">611,960</ix:nonFraction> shares available for future grant under the 2018 Inducement Incentive Award Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Merger Agreement, the Company assumed Old Cartesian&#8217;s 2016 Stock Incentive Plan, or the Old Cartesian Plan. The Old Cartesian Plan permits the granting of options or restricted stock to employees, officers, directors, consultants and advisors to the Company. The unvested common stock options and Series A Preferred Stock options assumed by the Company in connection with the Merger generally vest over a <ix:nonNumeric contextRef="c-249" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-940">four-year</ix:nonNumeric> period. Additionally, the stock options granted have a contractual term of <ix:nonNumeric contextRef="c-249" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-941">ten years</ix:nonNumeric> and only full shares can be exercised as per the individual award agreements. As of December 31, 2024, there are <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-942">27,270</ix:nonFraction> shares available for future grant under the Old Cartesian Plan. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the outstanding stock options to purchase Old Cartesian common stock were converted into stock options to purchase <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-943">776,865</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-252" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-944">14,112.299</ix:nonFraction> shares of Series A Preferred Stock of the Company. These replacement awards were revalued at their acquisition-date fair value and then attributed to pre and post-combination service. This resulted in $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-945">2.6</ix:nonFraction>&#160;million attributed to post-combination service to be recognized as stock-based compensation expense over the remaining terms of the replacement awards, of which $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-946">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-947">0.2</ix:nonFraction> million was recognized as research and development expense in the consolidated statements of operations and comprehensive loss during the years ended December 31, 2024 and 2023, respectively. Following the Automatic Conversion, the options exercisable for shares of Series A Preferred Stock became exercisable for shares of common stock.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-928-2" continuedAt="f-928-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Settlement of Equity Compensation Awards</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the First Merger, the equity compensation awards of the Company outstanding as of the date of the Merger were settled as follows: (i) each unvested option to acquire shares of common stock and each unvested restricted stock unit award with respect to shares of common stock was accelerated and vested in full at the effective time of the First Merger; (ii) each option to acquire shares of common stock was canceled and in exchange therefore, former holders became entitled to receive an amount in cash equal to the product of (A) the total number of shares of common stock subject to the unexercised portion the stock option (determined after giving effect to the accelerated vesting) multiplied by (B) the excess, if any, of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" scale="0" id="f-948">61.80</ix:nonFraction>, or the Cash-out Amount, over the applicable exercise price per share of common stock under such stock option; and (iii) each restricted stock unit award with respect to shares of common stock was cancelled and the former holder of such canceled restricted stock unit became entitled, in exchange therefor, to receive an amount in cash equal to the product of (A) the total number of shares of common stock deliverable under such restricted stock unit (determined after giving effect to the accelerated vesting) multiplied by (B) the Cash-out Amount. Stock options with an exercise price in excess of the Cash-out Amount received no cash payment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The modification to accelerate the vesting of all awards upon the Merger resulted in full recognition of unrecognized compensation of $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-949">13.1</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-950">5.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-951">7.2</ix:nonFraction>&#160;million was classified as research and development expense and general and administrative expense, respectively, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. In addition, with the exception of any options with an exercise price greater than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" scale="0" id="f-952">61.80</ix:nonFraction> per share, all awards were settled in cash for an amount equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" scale="0" id="f-953">61.80</ix:nonFraction> less any exercise price associated with the awards. The total cash payment made to the holders of stock options and restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards" format="ixt:num-dot-decimal" scale="6" id="f-954">9.4</ix:nonFraction>&#160;million. The fair value of the awards prior to the settlement was recorded to additional paid-in capital in an amount of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="rnac:AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-955">6.2</ix:nonFraction>&#160;million and the amount in excess of fair value was recognized as additional stock-based compensation expense in an amount of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" format="ixt:num-dot-decimal" scale="6" id="f-956">3.2</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" format="ixt:num-dot-decimal" scale="6" id="f-957">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" format="ixt:num-dot-decimal" scale="6" id="f-958">1.7</ix:nonFraction>&#160;million was classified as research and development expense and general and administrative expense, respectively, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-959" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss, including $<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-960">1.5</ix:nonFraction>&#160;million recognized as stock-based compensation expense upon the achievement of a technical milestone by Ginkgo Bioworks Holdings, Inc., or Ginkgo, during the year ended December 31, 2023 as described in Note 16, was as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-961">3,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-962">12,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-963">3,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-964">12,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-965">6,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-966">25,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-967" continuedAt="f-967-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options assumed in connection with the Merger was calculated using a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes option pricing model based on the following </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A Preferred Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-263" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-968">4.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-264" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-969">4.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-263" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-264" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-263" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-972">3.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-264" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-973">3.29</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-263" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-974">83.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-264" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-975">83.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock or Series A Preferred Stock, as applicable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-263" decimals="2" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" scale="0" id="f-976">12.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-264" decimals="2" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" scale="0" id="f-977">403.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated grant date fair values of stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model based on the following weighted-average assumptions:</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-928-3" continuedAt="f-928-4"><ix:continuation id="f-967-1"><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-265" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-978">4.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-266" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-979">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-265" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-266" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-265" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-982">6.21</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-266" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-983">5.94</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-265" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-984">95.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-266" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-985">94.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-265" decimals="2" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" scale="0" id="f-986">19.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-266" decimals="2" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" scale="0" id="f-987">34.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of the Company&#8217;s stock options granted has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. Under the simplified method, the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data and the plain nature of its stock-based awards. Expected volatilities are based on the Company&#8217;s historical volatility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-988">15.63</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-989">26.90</ix:nonFraction>, respectively. The total intrinsic value of stock options exercised during the year ended December 31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-990">7.0</ix:nonFraction> million. <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-991">No</ix:nonFraction> stock options were exercised during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, total unrecognized compensation expense related to unvested common stock options was $<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-992">10.3</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-268" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-993">2.9</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-994" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the 2016 Plan, the 2018 Inducement Incentive Award Plan, and the Old Cartesian Plan for options for common stock:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual&#160;term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic&#160;value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-995">776,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-996">2.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-270" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-997">6.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-998">13,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-271" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-999">1,000,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1000">19.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Converted from options for Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-271" decimals="INF" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1001">470,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="2" name="rnac:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" scale="0" id="f-1002">2.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-271" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1003">458,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1004">2.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-271" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1005">82,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1006">17.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1007">1,706,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1008">11.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-271" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1009">7.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1010">12,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-271" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-1011">656,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="2" name="rnac:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" scale="0" id="f-1012">3.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-271" name="rnac:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-1013">5.36</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="rnac:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1014">9,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1015">1,564,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1016">11.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-271" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1017">7.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1018">11,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Old Cartesian Plan for options for Series A Preferred Stock:</span></div><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual&#160;term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic&#160;value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1019">14,112.299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-273" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1020">79.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-254" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1021">5.91</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1022">8,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Converted to options for common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-249" decimals="INF" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-1023">14,112.299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-249" decimals="2" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock" scale="0" id="f-1024">79.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-1025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-250" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonNumeric contextRef="c-249" xsi:nil="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="f-1027"></ix:nonNumeric></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-250" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="f-1028"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the approval of the Conversion Proposal on March 27, 2024, all conditions that could have required cash redemption of the Series A Preferred Stock underlying the stock options were removed. Since the Series A Preferred Stock was no longer redeemable, the associated balances of the stock options to purchase Series A Preferred Stock were reclassified to additional paid-in capital during the first quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Automatic Conversion, all options to purchase Series A Preferred Stock were converted into options to purchase common stock with adjustments to the underlying number of shares of common stock determined by multiplying the number of shares of Series A Preferred Stock by <ix:nonFraction unitRef="number" contextRef="c-274" decimals="3" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="f-1029">33.333</ix:nonFraction> and rounding down to the nearest whole number of shares and the per-share exercise price by dividing the per-share exercise price of Series A Preferred Stock by <ix:nonFraction unitRef="number" contextRef="c-274" decimals="3" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="f-1030">33.333</ix:nonFraction> and rounding the resulting exercise price up to the nearest whole cent. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-928-4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-275" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1031">477,037</ix:nonFraction> restricted stock unit awards with a weighted average fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-275" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1032">19.86</ix:nonFraction> per share based on the closing price of the Company&#8217;s common stock on the date of grant under the 2016 Plan and the Old Cartesian Plan, which generally vest over a <ix:nonNumeric contextRef="c-275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1033">four-year</ix:nonNumeric> term. Forfeitures are estimated at the time of grant and are adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has estimated a forfeiture rate of <ix:nonFraction unitRef="number" contextRef="c-275" decimals="2" name="rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" scale="-2" id="f-1034">10</ix:nonFraction>% for restricted stock unit awards based on historical experience. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-275" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-1035">No</ix:nonFraction> restricted stock unit awards vested during the year ended December 31, 2024. The aggregate fair value of restricted stock unit awards that vested during the year ended December 31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1036">0.7</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to the restricted stock unit awards was $<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-1037">5.4</ix:nonFraction> million as of December 31, 2024, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-275" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1038">2.9</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-1039" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock units under the 2016 Plan and the Old Cartesian Plan:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>grant date<br/>fair value ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-278" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-1040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-278" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-275" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1042">477,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-275" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1043">19.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-275" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1044">32,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-275" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1045">19.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1046">444,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-277" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1047">19.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_259"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-1048" continuedAt="f-1048-1" escape="true">Revenue Arrangements</ix:nonNumeric></span></div><ix:continuation id="f-1048-1" continuedAt="f-1048-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and license revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Astellas Gene Therapies</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2023, the Company entered into the License and Development Agreement, or the Astellas Agreement, with Audentes Therapeutics, Inc., or Astellas. Under the Astellas Agreement, the Company granted Astellas an exclusive license to the Company&#8217;s IdeXork technology arising from Xork, to develop and commercialize Xork for use in Pompe disease in combination with an Astellas gene therapy investigational or authorized product. Xork, Genovis&#8217; IgG Protease, was licensed pursuant to an Exclusive License Agreement, or the Genovis Agreement, with Genovis AB (publ.), or Genovis, as described in Note 16 to these consolidated financial statements. Astellas paid a $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="rnac:CollaborationAndLicenseAgreementsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1049">10.0</ix:nonFraction>&#160;million upfront payment to the Company upon signing of the Astellas Agreement, and the Company was entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="rnac:DevelopmentAndCommercialMilestonesPlusRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-1050">340.0</ix:nonFraction>&#160;million in future additional payments over the course of the partnership that were contingent on the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales where Xork is used as a pre-treatment for an Astellas investigational or authorized product. The Company was also eligible for tiered royalty payments ranging from low to high single digits. Any proceeds received from milestone payments or royalties relating to Xork would have been required to be distributed to holders of CVRs, net of certain deductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Astellas Agreement, the Company would have had the exclusive right and responsibility to complete research and development of Xork products and to conduct all preclinical studies and clinical trials for Xork for use in Pompe disease with an Astellas gene therapy investigational or authorized product, or the Xork Development Services. Astellas reimbursed the Company for <ix:nonFraction unitRef="number" contextRef="c-279" decimals="INF" name="rnac:ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment" scale="-2" id="f-1051">25</ix:nonFraction>% of all budgeted costs incurred to complete the development of Xork for use in Pompe disease with an Astellas gene therapy investigational or authorized product. The Company would have had control and responsibility over regulatory filings, including any investigational drug applications, biologics license applications, and marketing authorization applications relating to the licensed product. Astellas would have had the exclusive right and responsibility to research, develop, and commercialize Astellas products used in combination with Xork and would have had control and responsibility over all regulatory filings, including any investigational drug applications, biologics license applications, and marketing authorization applications, relating to Astellas products and Astellas products used in combination with Xork.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the Astellas Agreement represented a service arrangement under the scope of ASC 606. The Company determined that the sublicense of Xork to Astellas, the licensed know-how, and the Xork Development Services represented a single promise and performance obligation to be transferred to Astellas over time due to the nature of the promises in the contract. As such, the Company recognized the transaction price as revenue utilizing the input method to measure the progress of satisfying the single performance obligation to Astellas.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="rnac:CollaborationAndLicenseAgreementsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1052">10.0</ix:nonFraction>&#160;million and development cost reimbursements of $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="rnac:LicenseAndOptionAgreementDevelopmentCostReimbursements" format="ixt:num-dot-decimal" scale="6" id="f-1053">5.5</ix:nonFraction>&#160;million would be included in the initial transaction price. All other development milestones would be fully constrained and would only have been included in the transaction price when the applicable milestone was deemed probable of achievement. Each of these variable consideration items were evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should have been constrained until </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1048-2" continuedAt="f-1048-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they became probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt and timing of such development milestones was outside the control of the Company and probability of success criteria was estimated. The Company re-evaluated the transaction price in each reporting period, as uncertain events were resolved, or as other changes in circumstances occurred. In accordance with ASC 606, the Company would have only recognized revenue associated with sales-based milestones and royalties when the subsequent sales thresholds were reached and underlying sales occurred, respectively. The Company determined that a significant financing component did not exist in its arrangement with Astellas. The Company also determined the options to negotiate additional fields, enter into a clinical supply agreement, and enter into a commercial supply agreement did not represent material rights under the Astellas Agreement. Astellas had the right to terminate the Astellas Agreement in its entirety or on a field-by-field basis, upon <ix:nonNumeric contextRef="c-279" name="rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" format="ixt-sec:durday" id="f-1054">90</ix:nonNumeric> days&#8217; written notice to the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company was notified by Astellas of its intention to terminate the Astellas Agreement, which occurred effective June 6, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, there were <ix:nonFraction unitRef="usd" contextRef="c-280" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-1055">no</ix:nonFraction> unsatisfied performance obligations related to the Astellas Agreement. As of December&#160;31, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-1056">2.3</ix:nonFraction> million as a short-term contract liability and $<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-1057">3.5</ix:nonFraction> million as a long-term contract liability, representing deferred revenue associated with the Astellas Agreement. As of December 31, 2024 and 2023, the Company recorded a receivable of $<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-1058">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-1059">0.3</ix:nonFraction> million, respectively, representing billings for the Xork Development Services that were subject to reimbursement by Astellas. Revenue of $<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-5" name="rnac:CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" scale="6" id="f-1060">6.3</ix:nonFraction>&#160;million related to the Astellas Agreement was recognized during the year ended December 31, 2024, inclusive of $<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-1061">3.2</ix:nonFraction>&#160;million of revenue recognized from performance obligations related to prior periods as a result of the change in transaction price during the year ended December 31, 2024. Revenue of $<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="rnac:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" format="ixt:num-dot-decimal" scale="6" id="f-1062">5.5</ix:nonFraction>&#160;million related to the Astellas Agreement was recognized during the year ended December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Takeda Pharmaceuticals USA, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 1, 2021, the Company entered into a License Agreement, or the Takeda Agreement, with Takeda Pharmaceuticals USA, Inc., or Takeda. Under the Takeda Agreement, the Company granted Takeda an exclusive license to the Company&#8217;s ImmTOR technology initially for two specified disease indications within the field of lysosomal storage disorders. Takeda paid a $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="rnac:LicenseAndOptionAgreementUpfrontCashPayment" format="ixt:num-dot-decimal" scale="6" id="f-1063">3.0</ix:nonFraction>&#160;million upfront payment to the Company upon signing of the Takeda Agreement, and the Company was entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-6" name="rnac:LicenseAndOptionAgreementFutureAdditionalPaymentsExpected" format="ixt:num-dot-decimal" scale="9" id="f-1064">1.124</ix:nonFraction>&#160;billion in future additional payments over the course of the partnership that were contingent on the achievement of development or commercial milestones or Takeda&#8217;s election to continue its activities at specified development stages. The Company was also eligible for tiered royalties on future commercial sales of any licensed products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Takeda Agreement, the Company determined the Takeda Agreement represented a service arrangement under the scope of ASC 606, and given the reversion of the rights under the Takeda Agreement represented a penalty in substance for a termination by Takeda, the contract term would remain the stated term of the Takeda Agreement. The Company determined that the research license, the licensed know-how, and the manufactured supply and delivery of materials represented a single promise and performance obligation to be transferred to Takeda over time due to the nature of the promises in the contract. The delivery of the manufactured supply was the predominant promise within the arrangement, as it was essential to the utility of the licensed intellectual property. The material supplied by the Company to Takeda was unique to the Company and cannot be obtained by other vendors. As such, consideration in the initial transaction price was allocated to the single performance obligation and the recognition period would not extend beyond the initial contractual period. The Company recognized the revenue associated with the upfront payment and combined single performance obligation utilizing the output method over the term that manufactured supply was delivered to Takeda.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the payment associated with all the performance milestones was fully constrained and only included in the transaction price when the respective milestone was deemed probable of achievement. Each of these variable consideration items were evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt and timing of such study milestones is outside the control of the Company and probability of success criteria is estimated. The Company re-evaluated the transaction price in each reporting period, as uncertain events were resolved, or as other changes in circumstances occurred. Takeda had the right to exercise covenant release rights on a field-by-field basis. If Takeda exercised its covenant release rights, the Company could have received exercise payments per indication and would have been entitled to significant development and commercial milestone payments and tiered royalties on commercial sales. The Company determined that a significant financing component did not exist in its arrangement with Takeda. The Company also determined the options to negotiate additional fields, pursue other products, enter into a supply agreement explore additional fields, and pursue additional development under the initial fields did not represent material rights under the agreement. Takeda had the right to terminate the Takeda Agreement in its entirety or on a field-by-field basis, upon <ix:nonNumeric contextRef="c-284" name="rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" format="ixt-sec:durday" id="f-1065">90</ix:nonNumeric> days&#8217; written notice to the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company was notified by Takeda of the achievement of the milestone event related to the completion of a non-clinical milestone for one of the specified disease indications within the field of lysosomal storage </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1048-3" continuedAt="f-1048-4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disorders under the Takeda Agreement. Accordingly, the Company received a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:ContractWithCustomerAssetReclassifiedToReceivable" format="ixt:num-dot-decimal" scale="6" id="f-1066">0.5</ix:nonFraction>&#160;million during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Takeda Agreement was terminated effective July 25, 2023, following Takeda&#8217;s decision to discontinue discovery and preclinical activities in adeno-associated virus, or AAV, gene therapy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, there were <ix:nonFraction unitRef="usd" contextRef="c-286" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1067"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1068">no</ix:nonFraction></ix:nonFraction> unsatisfied performance obligations related to the Takeda Agreement. <ix:nonFraction unitRef="usd" contextRef="c-288" decimals="INF" name="rnac:CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" format="ixt:fixed-zero" scale="6" id="f-1069">No</ix:nonFraction> revenue and revenue of $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="rnac:CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" scale="6" id="f-1070">0.6</ix:nonFraction> million related to the Takeda Agreement was recognized during the years ended December 31, 2024 and 2023, respectively.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Swedish Orphan Biovitrum AB (publ.)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 11, 2020, the Company and Sobi entered into a License and Development Agreement. Pursuant to the Sobi License, the Company agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize the SEL-212 drug candidate, which is currently in development for the treatment of chronic refractory gout. The SEL-212 drug candidate is a pharmaceutical composition containing a combination of SEL-037, or the Compound, and ImmTOR. Pursuant to the Sobi License, in consideration of the license, Sobi agreed to pay the Company a one-time, upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="rnac:LicenseAndOptionAgreementUpfrontCashPayment" format="ixt:num-dot-decimal" scale="6" id="f-1071">75.0</ix:nonFraction>&#160;million. Sobi has also agreed to make milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="rnac:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-1072">630.0</ix:nonFraction>&#160;million to the Company upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier. Any proceeds received from milestone payments or royalties relating to the Sobi License would be required to be distributed to holders of CVRs, net of certain deductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sobi License, the Company agreed to supply (at cost) quantities of the Compound and ImmTOR as necessary for completion of the two Phase 3 clinical trials of SEL-212 (DISSOLVE I and DISSOLVE II) and a six-month placebo extension. The Company was required to supply quantities of the Compound until all rights to the Compound and any materials needed to manufacture the Compound were transferred to Sobi, which transfer occurred upon the execution of Amendment No. 1 to the License and Development Agreement on October 31, 2023. Sobi has agreed to reimburse the Company for all budgeted costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, except for any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212. Sobi will have control and responsibility over all regulatory filings, including any investigational drug applications (IND), biologics license applications (BLA), and marketing authorization applications (MAA) relating to the licensed product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transactions contemplated by the Sobi License were consummated on July 28, 2020. Sobi may terminate the Sobi License for any reason upon <ix:nonNumeric contextRef="c-289" name="rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" format="ixt-sec:durday" id="f-1073">180</ix:nonNumeric> days&#8217; written notice to the Company, whereby all rights granted under the Sobi License would revert back to the Company. In addition, if Sobi were to terminate the Sobi License, the Company has the option to obtain a license to all patents and know-how necessary to exploit SEL-212 in existence as of the termination date from Sobi in return for making an equitable royalty payment to Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June 11, 2020, the Company entered into the Sobi Purchase Agreement in connection with the Sobi License. The closing of the Sobi Private Placement occurred on July 31, 2020, following the closing of the transactions contemplated under the Sobi License. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 for details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sobi License represents a service arrangement under the scope of ASC 606. In addition, given the Sobi License and Sobi Purchase Agreement were executed contemporaneously and negotiated as a package with a single commercial objective, the Company will account for the two agreements as a single contract. The term of the Sobi License commenced upon the effective date of July 28, 2020 and will continue on a product-by-product basis until the royalty terms for each country have expired. The royalty term for a given product begins upon the first commercial sale of the product in a country and ends at the later of <ix:nonNumeric contextRef="c-289" name="rnac:EligiblePeriodToReceiveRoyalties" format="ixt-sec:durwordsen" id="f-1074">ten years</ix:nonNumeric> from the first commercial sale, expiration of the last valid patent claim covering the product and expiration of all regulatory exclusivity periods for the product in a country. Given the reversion of the rights under the Sobi License represents a penalty in substance for a termination by Sobi, the contract term would remain the stated term of the Sobi License.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sobi License contained <ix:nonFraction unitRef="obligation" contextRef="c-290" decimals="INF" name="rnac:RevenueNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-1075">three</ix:nonFraction> distinct performance obligations due to the nature of the promises in the contract, which includes conducting the Phase 3 DISSOLVE trials, Sobi&#8217;s option to set-up a second source supplier, and a combined obligation comprised of the delivery of the license to SEL-212, transfer of the know-how and the manufacturing and delivery of SEL-212 supply for development, or the Combined License Obligation. As the set-up of a second source supplier was optional for Sobi and the Company was to be reimbursed at cost for its efforts in the subsequent set-up and technology transfer, the option for this future service was determined to be at a significant and incremental discount to its standalone selling price and treated as a material right in the arrangement, namely a distinct performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="rnac:LicenseAndOptionAgreementUpfrontCashPayment" format="ixt:num-dot-decimal" scale="6" id="f-1076">75.0</ix:nonFraction>&#160;million and the $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="rnac:LicenseAndOptionAgreementDevelopmentMilestone" format="ixt:num-dot-decimal" scale="6" id="f-1077">5.0</ix:nonFraction>&#160;million development milestone associated with the dosing of the first patient in the Phase 3 DISSOLVE trials were included in the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1048-4" continuedAt="f-1048-5"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction price. All other development milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of the evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company and probability of success criteria is estimated. The Company re-evaluates the transaction price in each reporting period, as uncertain events are resolved. In accordance with ASC 606, the Company will only recognize revenue associated with sales-based milestones and royalties when the subsequent sales thresholds are reached and underlying sales occur, respectively. In connection with the Sobi Purchase Agreement, the Company determined that the gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1078">25.0</ix:nonFraction>&#160;million from the Sobi Private Placement included a premium to the fair value of the Company&#8217;s shares as of July 28, 2020 equal to approximately $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:RedemptionPremium" format="ixt:num-dot-decimal" scale="6" id="f-1079">14.5</ix:nonFraction>&#160;million. The premium amount is included in the transaction price for revenue recognition. The Company estimates and includes in the transaction price the total reimbursements to be received from Sobi for both the manufacturing and delivery of the Compound and ImmTOR as well as conducting the Phase 3 DISSOLVE trials. The Company determined that a significant financing component does not exist in its arrangement with Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the transaction price based on the relative standalone selling prices of the <ix:nonFraction unitRef="obligation" contextRef="c-290" decimals="INF" name="rnac:RevenueNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-1080">three</ix:nonFraction> distinct performance obligations. The Company estimated the standalone selling price of conducting the Phase 3 DISSOLVE trials by forecasting its anticipated costs and applying a margin reflective of the industry. The Company determined the standalone selling price of the second source supplier option by determining the discount given to Sobi multiplied by the likelihood that Sobi would have exercised the option in the future. Similar to the Phase 3 program estimate, the Company estimated the discount of the option by forecasting the set-up costs and applying a margin that is reflective of the industry. As the Company was to provide the set-up and technology transfer services and the future supply at cost, the discount of the option was equal to the margin amount. The Company considered discussions with Sobi as well as probability of regulatory success of SEL-212 in determining the likelihood of exercise. The Company estimated the standalone selling price of the Combined License Obligation by utilizing a discounted cash flow model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the delivery of the supply to Sobi best represented the pattern of delivery of the Combined License Obligation as the supply was essential to the utility of the license and know-how. The Company recognized the revenue allocated to the Combined License Obligation by utilizing the output method. The Company estimated the total supply of the Compound and ImmTOR required during the clinical trial period and recognized revenue as this supply was shipped for use in the clinical trials. The Company recognized the revenue allocated to the conducting of the Phase 3 DISSOLVE trials obligation by utilizing the input method. The Company estimated the total budgeted costs to be incurred over the Phase 3 DISSOLVE trials and recognized revenue as these costs were incurred. The Company&#8217;s costs best represented the pattern of transfer as these captured all performance of the trials completed to date and were readily able to be measured. The Company was to recognize the revenue allocated to the second source supplier option when the future services and goods were transferred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2022, the Company completed enrollment of the DISSOLVE II trial. The completion of enrollment of the DISSOLVE II trial resulted in the achievement of a development milestone and a $<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-5" name="rnac:CollaborativeArrangementPaymentObligation" format="ixt:num-dot-decimal" scale="6" id="f-1081">10.0</ix:nonFraction>&#160;million payment obligation from Sobi to the Company. This amount was added to the overall transaction price and payment was received during the year ended December 31, 2022.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 31, 2023, the Company and Sobi entered into Amendment No. 1 to the License and Development Agreement, pursuant to which the Company granted Sobi an exclusive license to manufacture ImmTOR solely in connection with Sobi&#8217;s development of SEL-212 under the License and Development Agreement and transferred certain contracts and manufacturing equipment to Sobi. Additionally, Sobi&#8217;s option to set-up a second source supplier was removed as a result of the amendment. Further, in connection with entry into the amendment, Sobi agreed to make employment offers to certain of the Company&#8217;s employees engaged in ImmTOR manufacturing activities on or prior to a specified date, and the Company agreed not to terminate the employment of such employees prior to such specified date. The Company maintains no responsibilities to Sobi to manufacture, or supply Sobi with, ImmTOR under the Sobi License.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2024, Sobi initiated a rolling biologics license application to the FDA for SEL-212 for the potential treatment of chronic refractory gout which resulted in the achievement of a development milestone and a $<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1082">30.0</ix:nonFraction>&#160;million payment obligation from Sobi to the Company. As a result, the development milestone was no longer constrained and $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1083">30.0</ix:nonFraction>&#160;million was recognized as revenue during the year ended December 31, 2024 as there were no remaining performance obligations under the Sobi License. The proceeds from the achievement of the development milestone were received from Sobi in July 2024 and are expected to be included, net of deductions as specified in the CVR Agreement, in the next scheduled distribution to holders of the CVRs in March 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, the Company recorded a total outstanding receivable of $<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-1084">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-1085">4.6</ix:nonFraction> million, respectively, representing billings for the Phase 3 DISSOLVE program that are subject to reimbursement by Sobi.  Additionally, as of December&#160;31, 2023, the Company recorded a total unbilled receivable of $<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-1086">3.0</ix:nonFraction> million representing revenue earned but not yet billed for the Phase 3 DISSOLVE program. As of December 31, 2024, there was <ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="0" id="f-1087">no</ix:nonFraction> unbilled receivable outstanding. Revenue of $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1088">31.9</ix:nonFraction> million, inclusive of the $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1089">30.0</ix:nonFraction>&#160;million development milestone, related to the Sobi License was </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1048-5" continuedAt="f-1048-6"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized during the year ended December 31, 2024, and $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="f-1090">1.9</ix:nonFraction> million of revenue recognized from performance obligations related to prior periods as a result of the change in transaction price during the year ended December 31, 2024. Revenue of $<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1091">19.4</ix:nonFraction> million related to the Sobi License was recognized during the year ended December 31, 2023, inclusive of $<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="f-1092">1.1</ix:nonFraction> million of revenue recognized from performance obligations related to prior periods as a result of the change in transaction price during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarepta Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research License and Option Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, the Company and Sarepta Therapeutics, Inc., or Sarepta, entered into a Research License and Option Agreement, or the Sarepta Agreement. Pursuant to the Sarepta Agreement, the Company agreed to grant Sarepta a license under the Company&#8217;s intellectual property rights covering the Company&#8217;s antigen-specific biodegradable nanoparticle encapsulating ImmTOR to research and evaluate ImmTOR in combination with Sarepta&#8217;s adeno-associated virus gene therapy technology, or gene editing technology, using viral or non-viral delivery, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Indications. Sarepta initially had an option term of <ix:nonNumeric contextRef="c-299" name="rnac:LicenseAndOptionAgreementOptionTerm" format="ixt-sec:durmonth" id="f-1093">24</ix:nonNumeric> months during which it could opt-in to obtain an exclusive license to further develop and commercialize the product to treat at least one Indication, with a potential to extend the option term for an additional fee. The Company agreed to supply ImmTOR to Sarepta for clinical supply on a cost-plus basis under the Sarepta Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sarepta paid a $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="rnac:LicenseAndOptionAgreementUpfrontCashPayment" scale="6" id="f-1094">2.0</ix:nonFraction> million upfront payment to the Company upon signing of the Sarepta Agreement, and the Company was eligible to receive additional preclinical payments during the option term. If Sarepta opted in to an exclusive license agreement, the Company could have received&#160;option exercise payments per Indication upon execution of the exclusive license, and the Company would have been entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sarepta Agreement, the Company determined the Sarepta Agreement represented a service arrangement under the scope of ASC 606, with a <ix:nonNumeric contextRef="c-299" name="rnac:LicenseAndOptionAgreementOptionTerm" format="ixt-sec:durmonth" id="f-1095">24</ix:nonNumeric>-month contract duration. Given the reversion of the rights under the Sarepta Agreement represents a penalty in substance for a termination by Sarepta, the contract term would remain the stated term of the Sarepta Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sarepta Agreement and supply obligation including the delivery of the research license, the licensed know-how, the manufactured supply and delivery of materials represented a single promise and performance obligation to be transferred to Sarepta over time due to the nature of the promises in the contract. The delivery of the manufactured supply was the predominant promise within the arrangement, as it was essential to the utility of the licensed intellectual property. As such, consideration in the initial transaction price was allocated to the single performance obligation based on the contractual price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the payment associated with all the performance milestones was fully constrained and would only be included in the transaction price when the respective milestone was deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should have been constrained until they became probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such study milestones was outside the control of the Company and probability of success criteria was estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also determined the option to enter into a future commercial license agreement and extend the term of the option did not represent a material right since it was not priced at an incremental discount. Sarepta had the right to terminate the Sarepta Agreement for any reason upon <ix:nonNumeric contextRef="c-299" name="rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" format="ixt-sec:durday" id="f-1096">30</ix:nonNumeric> days&#8217; written notice to the Company. The Sarepta Agreement contained other customary terms and conditions, including representations and warranties, covenants, termination, and indemnification obligations in favor of each party. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021, the Company was notified by Sarepta of the achievement of the milestone event related to the completion of a non-clinical study for Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies under the Sarepta Agreement. Accordingly, the Company received a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="rnac:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-1097">3.0</ix:nonFraction>&#160;million during the three months ended June 30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2022, the Company was notified by Sarepta that Sarepta would be extending their options under the Sarepta Agreement. In exchange for a <ix:nonNumeric contextRef="c-301" name="rnac:LicenseAndOptionAgreementExtensionTerm" format="ixt-sec:durwordsen" id="f-1098">nine-month</ix:nonNumeric> extension to Sarepta&#8217;s options to both Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies, the Company received a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-5" name="rnac:LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies" format="ixt:num-dot-decimal" scale="6" id="f-1099">2.0</ix:nonFraction>&#160;million during the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, the Company was notified by Sarepta of the achievement of a milestone event related to certain preclinical study milestones under the Sarepta Agreement. Accordingly, the Company received a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="rnac:LicenseAndOptionAgreementMilestoneReceivable" format="ixt:num-dot-decimal" scale="6" id="f-1100">4.0</ix:nonFraction>&#160;million during the year ended December 31, 2022.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1048-6" continuedAt="f-1048-7"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2023, the Company was notified by Sarepta that Sarepta would not be exercising its exclusive option under the Sarepta Agreement. The Sarepta Agreement terminated upon the expiration of the option in March 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, there were <ix:nonFraction unitRef="usd" contextRef="c-304" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1101"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1102">no</ix:nonFraction></ix:nonFraction> unsatisfied performance obligations related to the Sarepta Agreement. <ix:nonFraction unitRef="usd" contextRef="c-306" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1103">No</ix:nonFraction> revenue and revenue of $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1104">0.5</ix:nonFraction> million related to the Sarepta Agreement was recognized during the years ended December 31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to Future Performance Obligations</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Remaining performance obligations represent the transaction price of contracts for which work has not been performed, or has been partially performed. As of December 31, 2024, there were <ix:nonFraction unitRef="usd" contextRef="c-8" decimals="INF" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:fixed-zero" scale="6" id="f-1105">no</ix:nonFraction> unsatisfied performance obligations from contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances from Contracts with Customers</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-1106" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s contract liabilities during the year ended December 31, 2024 (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">end of period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:ContractwithCustomerLiabilityDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1107">5,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" format="ixt:fixed-zero" scale="3" id="f-1108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1109">5,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:ContractwithCustomerLiabilityDeferredRevenue" format="ixt:fixed-zero" scale="3" id="f-1110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-1111">5,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:ContractwithCustomerLiabilityIncreaseFromCashReceipts" format="ixt:fixed-zero" scale="3" id="f-1112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rnac:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" format="ixt:num-dot-decimal" scale="3" id="f-1113">5,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-1114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">National Institute of Neurological Disorders and Stroke of the National Institutes of Health</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Company received funding approval from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, or NINDS, for an award of $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:GovernmentAssistanceAwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1115">1.5</ix:nonFraction>&#160;million granted for the budget period, which runs from June 2024 through May 2025. Subject to the availability of funds and satisfactory progress of the project, an additional $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="rnac:GovernmentAssistancePotentialAdditionalAwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1116">1.5</ix:nonFraction>&#160;million has been recommended by NINDS to be awarded for the budget period June 2025 through May 2026. The initial $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:GovernmentAssistanceAwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1117">1.5</ix:nonFraction>&#160;million funding was provided by NINDS to further the Company&#8217;s use of RNA-based CAR-T cells to combat autoantibody-associated autoimmune disorders. Grant funding is to be used solely for manufacturing of RNA-based CAR-T cells and analysis of samples to inform mechanism of action. The award period runs through May 31, 2026. The Company will recognize grant revenue when expenses reimbursable under the grant have been incurred. </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1048-7">As of December 31, 2024, the Company recorded a <ix:nonNumeric contextRef="c-1" name="rnac:GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-1118">receivable</ix:nonNumeric> of $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:GovernmentAssistanceAmountCumulativeCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1119">0.6</ix:nonFraction>&#160;million that is subject to reimbursement by NINDS. Accordingly, the Company recognized grant revenue of $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-1120">0.6</ix:nonFraction>&#160;million during the year ended December 31, 2024.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_262"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-1121" continuedAt="f-1121-1" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-1121-1" continuedAt="f-1121-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Securities Purchase Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 2, 2024, the Company entered into the 2024 Securities Purchase Agreement with the Purchasers. The Purchasers included (i) Dr. Timothy A. Springer, a member of the Company&#8217;s Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Dr. Chafen Lu, Dr. Springer&#8217;s wife (see Note 11). <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="f-1122" continuedAt="f-1122-1" escape="true">The below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.</ix:nonNumeric></span><ix:continuation id="f-1122-1" continuedAt="f-1122-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Series B Preferred Stock purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total aggregate purchase price<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1123">1,636,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-1124">32,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TAS Partners LLC, affiliate of Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1125">721,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-1126">14,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chafen Lu, Ph.D., wife of Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1127">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="f-1128">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Securities Purchase Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 13, 2023, the Company entered into the 2023 Securities Purchase Agreement with (i) Dr. Timothy A. Springer, (ii) TAS Partners LLC, and (iii) Seven One Eight Three Four Irrevocable Trust, a trust associated with Dr. Murat Kalayoglu, in which the Company agreed to issue and sell an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-314" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1129">149,330.115</ix:nonFraction> shares of Series A Preferred Stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-4" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1130">60.25</ix:nonFraction>&#160;million (see Note 11). <ix:continuation id="f-1122-2" continuedAt="f-1122-3">The 2023 Private Placement included a delayed settlement mechanism, and as a result, the below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.</ix:continuation></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1121-2" continuedAt="f-1121-3"><ix:continuation id="f-1122-3"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Series A Preferred Stock purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total aggregate purchase price<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1131">99,140.326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-1132">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The below issuances and sales to related parties of the Company were made subject to the 2023 Private Placement during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Series A Preferred Stock purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total aggregate purchase price <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-316" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1133">24,785.081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-1134">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TAS Partners LLC (affiliate of Timothy A. Springer, Ph.D.)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-317" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1135">24,785.081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-1136">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Seven One Eight Three Four Irrevocable Trust (affiliate of Murat Kalayoglu, MD, Ph.D.)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-318" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="f-1137">619.627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="f-1138">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise of Amended 2019 Warrants</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1121-3">On March 26, 2024, TAS Partners LLC exercised <ix:nonFraction unitRef="shares" contextRef="c-319" decimals="INF" name="rnac:ClassOfWarrantOrRightExercisedDuringPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1139">65,681</ix:nonFraction> Amended 2019 Warrants, paid the per-share exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-320" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1140">43.80</ix:nonFraction> in cash for an aggregate exercise price of $<ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="f-1141">2.9</ix:nonFraction>&#160;million, and received <ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-1142">65,681</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="rnac:IssuanceOfContingentValueRightForExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1143">1,970,443</ix:nonFraction> CVRs.</ix:continuation>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_265"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="rnac:CollaborationAndLicenseAgreementsTextBlock" id="f-1144" continuedAt="f-1144-1" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="f-1144-1" continuedAt="f-1144-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 8, 2023, the Company entered into a non-exclusive, sublicensable, worldwide, perpetual patent license agreement, or the Biogen Agreement, with Biogen MA, Inc., or Biogen to research, develop, make, use, offer, sell and import products or processes containing or using an engineering T-cell modified with an mRNA comprising, or encoding a protein comprising, certain sequences licensed under the Biogen Agreement for the prevention, treatment, palliation and management of autoimmune diseases and disorders, excluding cancers, neoplastic disorders, and paraneoplastic disorders. The Company is not obligated to pay Biogen any expenses, fees, or royalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may terminate the Biogen Agreement for any reason or no reason, and Biogen may terminate the agreement after a notice-and-cure period of <ix:nonNumeric contextRef="c-322" name="rnac:CollaborativeArrangementWrittenNoticePeriodForTermination" format="ixt-sec:durday" id="f-1145">30</ix:nonNumeric> days if the Company fails to pay a fee owed to Biogen or for any other material breach of the agreement. The Biogen Agreement will otherwise expire when all claims of all issued patents within the patents and patent applications licensed to the Company under the Biogen Agreement have expired or been finally rendered revoked, invalid or unenforceable by a decision of a court or government agency.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biogen Agreement encompasses patents and patent applications in the PCT/US2010/026825 patent family, which was filed March 10, 2010. In general, all patents that issue in this family have an expected expiration date of March 10, 2030, subject to potential patent term adjustments and/or extensions. For the U.S. patents and applications in this family, U.S. Patent 9,034,324 was awarded 677 days of patent term adjustment, which would extend the expiration date of this patent to January 16, 2032, absent any challenges to the patent term. The other issued patent in this family was not awarded any patent term adjustment, so its expected expiration date is March 10, 2030.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">National Cancer Institute of the National Institutes of Health</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 16, 2019, the Company entered into a nonexclusive, worldwide license agreement, or the NCI Agreement, with the U.S. Department of Health and Human Services, represented by the National Cancer Institute of the National Institutes of Health, or NCI.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NCI Agreement, the Company was granted a license under certain NCI patents and patent applications designated in the agreement, to make, use, sell, offer and import products and processes within the scope of the patents and applications licensed under the NCI Agreement when developing and manufacturing anti-BCMA CAR-T cell products for the treatment of myasthenia gravis, pemphigus vulgaris, and immune thrombocytopenic purpura according to methods designated in the NCI Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s entry into the NCI Agreement, Old Cartesian paid to NCI a one-time $<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="rnac:LicenseAndOptionAgreementRoyaltyPayment" format="ixt:num-dot-decimal" scale="6" id="f-1146">0.1</ix:nonFraction>&#160;million license royalty payment. Under the NCI Agreement, the Company is further required to pay NCI a low five-digit annual royalty. The Company must also pay earned royalties on net sales in a low single-digit percentage and pay up to $<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="rnac:LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum" format="ixt:num-dot-decimal" scale="6" id="f-1147">0.8</ix:nonFraction>&#160;million in benchmark royalties upon the Company&#8217;s achievement of designated benchmarks that are based on the commercial development plan agreed between the parties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NCI Agreement, the Company must use reasonable commercial efforts to bring licensed products and licensed processes to the point of Practical Application (as defined in the NCI Agreement). Upon the Company&#8217;s first commercial sale, </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1144-2" continuedAt="f-1144-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company must use reasonable commercial efforts to make licensed products and licensed processes reasonably accessible to the United States public. After the Company&#8217;s first commercial sale, the Company must make reasonable quantities of licensed products or materials produced via licensed processes available to patient assistance programs and develop educational materials detailing the licensed products. Unless the Company obtains a waiver from NCI, the Company must have licensed products and licensed processes manufactured substantially in the United States. Prior to the first commercial sale, upon NCI&#8217;s request, the Company is obligated to provide NCI with commercially reasonable quantities of licensed products made through licensed processes to be used for in vitro research.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company must use reasonable commercial efforts to initiate a Phase 3 clinical trial of a licensed product by the fourth quarter of 2024, submit a BLA with respect to a licensed product by the fourth quarter of 2026, and make a first commercial sale of a licensed product by the fourth quarter of 2028.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NCI Agreement terminates upon the expiration of the last to expire of the patent rights licensed thereunder, if not sooner terminated. The NCI Agreement encompasses patents and patent applications in the PCT/US2013/032029 patent family, which was filed March 15, 2013. In general, all patents that issue in this family have an expected expiration of March 15, 2033, subject to potential patent term adjustments and/or extensions. For the U.S. patents and applications in this family, only two patents were awarded patent term adjustments. U.S. Patent 9,765,342 was awarded 297 days of patent term adjustment, which would extend the expiration date of this patent to January 6, 2034, absent any challenges to the patent term. The other patent, U.S. Patent 10,876,123, was awarded three days of patent term adjustment, but this patent is subject to terminal disclaimers filed against other family members, so this patent will not extend beyond the March 15, 2033 date. The other issued patents in this family were not awarded any patent term adjustment, so the expected expiration date for these patents also remains March 15, 2033. There is also a pending patent application which, if issued, will expire on March 15, 2033, but could also be subject to patent term adjustment and to any potential future terminal disclaimers.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NCI has the right to terminate the NCI Agreement, after giving written notice and providing a cure period in accordance with its terms, if the Company is in default of a material obligation. The Company has the unilateral right to terminate the agreement in any country or territory by giving NCI <ix:nonNumeric contextRef="c-323" name="rnac:CollaborativeArrangementWrittenNoticePeriodForTermination" format="ixt-sec:durday" id="f-1148">60</ix:nonNumeric> days&#8217; written notice. The Company agreed to indemnify NCI against any liability arising out of the Company&#8217;s, sublicensees&#8217; or third-parties&#8217; use of the licensed patent rights and licensed products or licensed processes developed in connection with the licensed patent rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 25, 2021, the Company entered into a Collaboration and License Agreement, or the First Ginkgo Agreement, with Ginkgo. Under the First Ginkgo Agreement, Ginkgo will design next generation IgA proteases with potentially transformative therapeutic potential. In return, Ginkgo is eligible to earn both upfront research and development fees and milestone payments, including certain milestone payments for fixed fair values in the form of the Company&#8217;s common stock, clinical and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="rnac:LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected" format="ixt:num-dot-decimal" scale="6" id="f-1149">85.0</ix:nonFraction>&#160;million in cash. The First Ginkgo Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company will expense costs related to the First Ginkgo Agreement as incurred until regulatory approval is received in accordance with ASC 730. The Company is accounting for the contingently issuable shares to be issued in exchange for the license obtained from Ginkgo as a liability classified stock-based compensation arrangement with a non-employee which will be recognized when achievement of the milestones is probable. The Company will assess the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, will amortize these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company is also obligated to pay Ginkgo tiered royalties ranging from low-single digit to high-single digit percentages of annual net sales of collaboration products which will be expensed as the commercial sales occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, the Company entered into a Collaboration and License Agreement, or the Second Ginkgo Agreement, with Ginkgo. Under this agreement, the Company will engage with Ginkgo to develop AAV capsids designed to enhance transduction efficiency and transgene expression. In return, Ginkgo is eligible to earn both upfront research and development fees and milestone payments, including certain milestone payments in the form of shares of the Company&#8217;s common stock, clinical and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-6" name="rnac:LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected" format="ixt:num-dot-decimal" scale="6" id="f-1150">207</ix:nonFraction>&#160;million in cash. The Second Ginkgo Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company will expense costs related to the Second Ginkgo Agreement as incurred until regulatory approval is received in accordance with ASC 730. The Company is accounting for the contingently issuable shares of common stock to be issued in exchange for the license obtained from Ginkgo as a liability-classified, stock-based compensation arrangement with a non-employee which will be recognized when achievement of the milestones is probable. The Company will assess the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, will amortize these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company is also obligated to pay Ginkgo tiered royalties ranging from low-single digit to high-single digit percentages of annual net sales of collaboration products which will be expensed as the commercial sales occur.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1144-3" continuedAt="f-1144-4"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 13, 2022, the Company was notified of the achievement of the midpoint of the technical development plan under the First Ginkgo Agreement by Ginkgo. This milestone resulted in the payment of $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="rnac:LicenseAndOptionAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1151">0.5</ix:nonFraction>&#160;million and issuance of <ix:nonFraction unitRef="shares" contextRef="c-327" decimals="INF" name="rnac:CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement" format="ixt:num-dot-decimal" scale="0" id="f-1152">29,761</ix:nonFraction> shares of the Company&#8217;s common stock then-valued at $<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="rnac:CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount" format="ixt:num-dot-decimal" scale="6" id="f-1153">1.0</ix:nonFraction>&#160;million to Ginkgo during the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2023, the Company and Ginkgo mutually agreed that the completion of the technical development plan&#8217;s midpoint task under the Second Ginkgo Agreement had been achieved as of June 30, 2023. This milestone resulted in the payment of $<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="rnac:LicenseAndOptionAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1154">1.0</ix:nonFraction>&#160;million and issuance of <ix:nonFraction unitRef="shares" contextRef="c-329" decimals="INF" name="rnac:CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement" format="ixt:num-dot-decimal" scale="0" id="f-1155">44,642</ix:nonFraction> shares of the Company&#8217;s common stock then-valued at $<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="rnac:CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount" format="ixt:num-dot-decimal" scale="6" id="f-1156">1.5</ix:nonFraction>&#160;million to Ginkgo during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genovis AB (publ.)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 21, 2021, the Company entered into the Genovis Agreement with Genovis. Under the Genovis Agreement, the Company paid to Genovis an upfront payment in exchange for an exclusive license to the Xork enzyme technology across all therapeutic uses in humans, excluding research, preclinical, diagnostic and other potential non-therapeutic applications of the enzyme. Genovis was eligible to earn from the Company development and sales-based milestones and sublicensing fees. The Genovis Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company was to expense costs related to the Genovis Agreement as incurred until regulatory approval was received in accordance with ASC 730. The Company would have assessed the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, would have amortized these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company was also obligated to pay Genovis tiered royalties of low double digit percentages of worldwide annual net sales of collaboration products which would have been expensed as the commercial sales occurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company made a $<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="rnac:LicenseAndOptionAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1157">4.0</ix:nonFraction>&#160;million payment to Genovis as a result of the sublicense of Xork to Astellas. See Note 14 to these consolidated financial statements for further discussion on the Astellas Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company notified Genovis of its intention to terminate the Genovis Agreement, which occurred effective September 13, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cyrus Biotechnology, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 7, 2021, the Company and Cyrus Biotechnology, Inc., or Cyrus, entered into a collaboration and license agreement, or the Cyrus Agreement. Pursuant to the Cyrus Agreement, Cyrus agreed to grant the Company an exclusive, worldwide license to certain intellectual property to form a protein engineering collaboration combining the Company&#8217;s ImmTOR platform with Cyrus&#8217; ability to redesign protein therapeutics. The lead program was a proprietary interleukin-2, or IL-2, protein agonist designed to selectively promote expansion of regulatory T cells for treatment of patients with autoimmune diseases and other deleterious immune conditions. In return for the licensed intellectual property, the Company made an upfront payment and was obligated to pay certain discovery, development, and sales-based milestones which could have potentially totaled up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-8" name="rnac:LicenseAndOptionAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-1158">1.5</ix:nonFraction>&#160;billion across multiple programs. The Cyrus Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company expensed costs related to the Cyrus Agreement as incurred until regulatory approval is received in accordance with ASC 730. The Company assessed the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, would have amortized these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company was also obligated to pay Cyrus tiered royalties ranging from mid-single digit to low-double digit percentages of annual net sales of collaboration products which would have been expensed as commercial sales occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 13, 2022, the Company and Cyrus mutually agreed that the preclinical key in-vitro success milestone had been achieved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Company notified Cyrus of its termination of the Cyrus Agreement, effective December 29, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Purchase Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on September 7, 2021, the Company entered into a stock purchase agreement, or the Series B Preferred Stock Purchase Agreement, in connection with the Cyrus Agreement. Pursuant to the Series B Preferred Stock Purchase Agreement, the Company purchased <ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="rnac:EquitySecuritiesStockPurchaseAgreementSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1159">2,326,934</ix:nonFraction> shares of Cyrus&#8217; Series B Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-332" decimals="4" name="rnac:EquitySecuritiesStockPurchaseAgreementParValuePerShare" scale="0" id="f-1160">0.0001</ix:nonFraction> per share, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-332" decimals="4" name="rnac:EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare" scale="0" id="f-1161">0.8595</ix:nonFraction> per share for $<ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-1162">2.0</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 810, the Company has a variable interest in Cyrus resulting from its equity investment. The Company will share in Cyrus&#8217; expected losses or receive a portion of its expected returns and absorb the variability associated with changes in the entity&#8217;s net assets. However, the Company is not the primary beneficiary as it does not have the power to direct the activities most significant to Cyrus, and therefore it is not required to consolidate Cyrus. The Company has recognized the $<ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-1163">2.0</ix:nonFraction> million investment of Cyrus&#8217; Series B Preferred Stock at cost on the purchase date.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1144-4"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2024, no impairment indicators are present and there were no observable price changes. Therefore, the carrying value of the investment in Cyrus is $<ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-1164">2.0</ix:nonFraction> million on the accompanying consolidated balance sheets. The Company&#8217;s maximum exposure to loss related to this VIE is limited to the carrying value of the investment. The Company has not provided financing to Cyrus other than the amount contractually required by the Series B Preferred Stock Purchase Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asklepios Biopharmaceutical, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Feasibility Study and License Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, the Company entered into a feasibility study and license agreement, or the AskBio Collaboration Agreement, with Asklepios Biopharmaceutical, Inc., or AskBio. Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to license intellectual property rights to each other as part of a collaboration to research, develop, and commercialize certain AAV gene therapy products utilizing the Company&#8217;s ImmTOR platform to enable re-dosing of such AAV gene therapy products to treat serious rare and orphan genetic diseases for which there is a significant unmet medical need.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to conduct proof of concept studies to potentially validate the use of ImmTOR in conjunction with AskBio&#8217;s AAV gene therapy, or SEL-302, (previously disclosed as MMA-101, in combination with ImmTOR) for the treatment of methylmalonic acidemia, or MMA, to mitigate the formation of neutralizing anti-AAV capsid antibodies. On April 29, 2021, the Company was notified by AskBio that it intended to opt-out of development of the MMA indication. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AskBio shared responsibility for the research, development and commercialization of products developed under the SEL-399 program collaboration. The parties also shared research, development, and commercialization costs equally for all collaboration products, but with a right of either party to opt out of certain products, and thereby not be required to share costs for such products. Each party would have received a percentage of net profits under the collaboration equal to the percentage of shared costs borne by such party in the development of such product. Pursuant to the AskBio Collaboration Agreement, AskBio was responsible for manufacturing the AAV capsids and AAV vectors and the Company was responsible for manufacturing ImmTOR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AskBio mutually agreed to the termination of the AskBio Collaboration Agreement, effective December 13, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024 and 2023, the Company recognized <ix:nonFraction unitRef="usd" contextRef="c-335" decimals="INF" name="us-gaap:OperatingExpenses" format="ixt:fixed-zero" scale="6" id="f-1165">no</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-1166">0.1</ix:nonFraction> million, respectively, of collaboration expense under the AskBio Collaboration Agreement in which actual costs incurred by both parties approximate a <ix:nonFraction unitRef="number" contextRef="c-336" decimals="2" name="rnac:CollaborativeArrangementCostSharePercentage" scale="-2" id="f-1167"><ix:nonFraction unitRef="number" contextRef="c-335" decimals="2" name="rnac:CollaborativeArrangementCostSharePercentage" scale="-2" id="f-1168">50</ix:nonFraction></ix:nonFraction>% cost share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shenyang Sunshine Pharmaceutical Co., Ltd</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the Company entered into a license agreement, or the 3SBio License, with Shenyang Sunshine Pharmaceutical Co., Ltd., or 3SBio. The Company has paid to 3SBio an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5" name="rnac:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" scale="6" id="f-1169">7.0</ix:nonFraction> million in upfront and milestone-based payments under the 3SBio License as of December 31, 2024. The Company is required to make future payments to 3SBio contingent upon the occurrence of events related to the achievement of clinical and regulatory approval milestones of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="rnac:AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" scale="6" id="f-1170">15.0</ix:nonFraction> million for products containing the Company&#8217;s ImmTOR platform.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_271"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1171" continuedAt="f-1171-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-1171-1" continuedAt="f-1171-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes under ASC 740. Under ASC 740, the Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023, the Company acquired, in accordance with the terms of the Merger Agreement, the assets of Old Cartesian. In accordance with ASC 805-740-25-3, recognition of deferred tax assets and liabilities is required for substantially all temporary differences and acquired tax carryforwards and credits. The Company has computed estimated temporary differences and acquired tax carryforwards and credits as of the transaction date. The Company will not have tax basis in IPR&amp;D booked as part of the purchase accounting. For accounting purposes, the IPR&amp;D will not be amortized and only subject to impairment review and testing. Though the tax effects may be delayed indefinitely, ASC 740-10-55-63 states that &#8220;deferred tax liabilities may not be eliminated or reduced because a reporting entity may be able to delay the settlement of those liabilities by delaying the events that would cause taxable temporary differences to reverse.&#8221; The Company can potentially only utilize indefinite-lived assets as it relates to this indefinite lived intangible deferred tax liability reversal. As such, the Company has booked a deferred tax liability for the portion of the liability that cannot be reduced based on scheduling. Additionally, a portion of this target deferred tax liability is offset with the Company&#8217;s pre-Merger deferred tax assets on a combined basis, and as such the portion of deferred tax liability reduced by the Company&#8217;s pre-Merger deferred tax assets has been charged to income rather than to goodwill.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1171-2" continuedAt="f-1171-3"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, the Company recognized a current tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1172">0.3</ix:nonFraction>&#160;million. For the year ended December 31, 2023, the Company recognized a current tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1173">19.0</ix:nonFraction>&#160;million. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1174" continuedAt="f-1174-1" escape="true">The following table reconciles the federal statutory income tax rate to the Company&#8217;s effective income tax rate:</ix:nonNumeric></span></div><ix:continuation id="f-1174-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Statutory U.S. federal rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1175">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1176">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">State income taxes - net of federal benefit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1177">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1178">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Permanent items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1179">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1180">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Research tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1181">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1182">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Change in fair value of contingent value right liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent" scale="-2" id="f-1183">127.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent" format="ixt:fixed-zero" scale="-2" id="f-1184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Change in fair value of forward contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent" scale="-2" id="f-1185">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent" scale="-2" id="f-1186">13.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Valuation allowance, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1187">160.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1188">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1189">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1190">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Effective income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1191">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1192">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1193" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to the Company&#8217;s net deferred tax assets are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1194">44,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1195">29,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1196">6,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1197">5,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1198">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="f-1199">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:fixed-zero" scale="3" id="f-1200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="3" id="f-1201">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-1202">75,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-1203">84,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1204">3,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1205">2,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Contingent value right liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" format="ixt:num-dot-decimal" scale="3" id="f-1206">108,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" format="ixt:fixed-zero" scale="3" id="f-1207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">R&amp;E Capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1208">26,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1209">19,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Patent and license costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1210">8,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1211">9,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1212">274,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1213">152,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1214">41,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1215">41,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-1216">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-1217">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1218">1,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1219">2,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1220">43,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1221">44,023</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Net deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="rnac:DeferredTaxAssetsNetOfDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1222">231,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="rnac:DeferredTaxAssetsNetOfDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1223">108,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1224">247,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1225">124,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Net deferred tax assets/(liabilities)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1226">16,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1227">15,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided a full valuation allowance against its net deferred tax assets, outside of the indefinite tax liability booked as part of the Merger. The Company believes that it is more likely than not that the net deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realization of future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded that it is more likely than not that the Company will not realize the benefit of its net deferred tax assets. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1228">123.6</ix:nonFraction>&#160;million for the year ended December 31, 2024, primarily as a result of tax loss in the current year and the recognition of a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1229">108.8</ix:nonFraction>&#160;million tax benefit related to the Company&#8217;s CVR liability. The valuation allowance decreased by $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1230">3.5</ix:nonFraction>&#160;million for the year ended December 31, 2023, primarily as a result of a tax benefit booked as part of the Merger. As of December 31, 2024, the Company is in the process of winding down operations in Russia and does not expect any tax liability relating to such operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December 31, 2024, the Company has federal net operating loss carryforward of $<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1231">152.6</ix:nonFraction>&#160;million, which can be carried forward indefinitely, subject to an 80% limitation and state net operating loss carryforward of $<ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1232">187.8</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="rnac:OperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-1233">74.4</ix:nonFraction>&#160;million has an unlimited carryforward and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="rnac:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-1234">113.4</ix:nonFraction>&#160;million will expire at various times through 2044. The Company has $<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1235">5.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1236">1.0</ix:nonFraction>&#160;million, respectively, of federal and state research and development tax credit carryforwards, which will expire at various times through 2044. Utilization of the NOL carryforwards and research and orphan drug credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, and similar state law due to ownership changes that could occur in the future.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1171-3"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. If the Company experiences a change of control, as defined by Section 382 of the Code and similar state law, utilization of the NOL carryforwards or research and orphan drug credit carryforwards may be subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL carryforwards or research and orphan drug credit carryforwards before utilization. The Company performed an analysis of ownership changes through December 31, 2023. Based on this analysis, the Company does not believe that any of its tax attributes through December 31, 2023 will expire unutilized due to Section 382 limitations. To the extent the Company enters into future equity transactions, there could be a limitation on the Company&#8217;s tax attributes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC 740, Income Taxes to uncertain tax positions. As of the adoption date on January 1, 2010 and through December 31, 2024, the Company had no unrecognized tax benefits or related interest and penalties accrued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company has not completed a detailed study of its research and development and orphan drug credits for the tax years ending December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 and December 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, the Company will adjust its deferred tax asset balances and include the impacts in the research tax credits and state income taxes &#8211; net of federal benefit lines in the effective rate reconciliation next year, once the updated study has been completed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act requires taxpayers to capitalize and amortize, rather than deduct, research and experimental, or R&amp;E, expenditures under Section 174 for tax years beginning after December 31, 2021. These rules became effective for the Company during the year ended December 31, 2022. As a result, the Company has capitalized R&amp;E costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="rnac:CapitalizedResearchAndExperimentalCostsTaxPurposes" format="ixt:num-dot-decimal" scale="6" id="f-1237">45.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="rnac:CapitalizedResearchAndExperimentalCostsTaxPurposes" format="ixt:num-dot-decimal" scale="6" id="f-1238">43.9</ix:nonFraction>&#160;million for the years ended December 31, 2024 and December 31, 2023, respectively. The Company will amortize these costs for tax purposes over five years if the R&amp;E was performed in the United States and over 15 years if the R&amp;E was performed outside the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as income tax expense in the accompanying statement of operations. As of December 31, 2024, the Company had no accrued interest related to uncertain tax positions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The statute of limitations for assessment by the Internal Revenue Service and state tax authorities is open for tax years 2020 to the present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, or state tax authorities to the extent utilized in a future period. The Company files income tax returns in the United States, Massachusetts, and Maryland. There are currently no federal, state or foreign audits in progress.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_274"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-1239" continuedAt="f-1239-1" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="f-1239-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Contribution Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution plan, or the 401(k) Plan, under Section&#160;401(k) of the Internal Revenue Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The 401(k) Plan provides for matching contributions on a portion of participant contributions pursuant to the 401(k) Plan&#8217;s matching formula. All matching contributions vest ratably over <ix:nonNumeric contextRef="c-1" name="rnac:DefinedContributionPlanEmployersMatchingContributionVestingPeriod" format="ixt-sec:durwordsen" id="f-1240">two years</ix:nonNumeric> and participant contributions vest immediately. Contributions by the Company totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1241">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1242">0.3</ix:nonFraction> million during the years ended December 31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company approved the 2016 Employee Stock Purchase Plan, or the ESPP, which initially authorized <ix:nonFraction unitRef="shares" contextRef="c-342" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1243">5,769</ix:nonFraction> shares of common stock for future issuance under the ESPP to participating employees. As of December 31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-343" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1244">45,795</ix:nonFraction> shares remain available for future issuance under the ESPP. In connection with the Merger, the Board of Directors suspended offerings under the ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized <ix:nonFraction unitRef="usd" contextRef="c-344" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1245">no</ix:nonFraction> stock-based compensation expense under the ESPP for the year ended December 31, 2024 and $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1246">0.1</ix:nonFraction> million of stock-based compensation expense under the ESPP for the year ended December 31, 2023.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_277"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1247" continuedAt="f-1247-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-1247-1" continuedAt="f-1247-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company was not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position, results of operations or cash flows. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1247-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December 31, 2024, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as permitted under Delaware law, the Company indemnifies its directors for certain events or occurrences while the director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is for the director&#8217;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; insurance coverage that limits its exposure and enables it to recover a portion of any future amounts paid. The Company also has indemnification arrangements under certain of its facility leases that require it to indemnify the landlord against certain costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from certain breaches, violations, or non-performance of any covenant or condition of the Company&#8217;s lease. The term of the indemnification is for the term of the related lease agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. To date, the Company had not experienced any material losses related to any of its indemnification obligations, and no material claims with respect thereto were outstanding.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party in various other contractual disputes and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect the Company&#8217;s business, financial position, results of operations or cash flows.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_283"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-1248" continuedAt="f-1248-1" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="f-1248-1"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, in light of current market conditions, the Board of Directors took steps to extend the Company&#8217;s cash runway by pausing further development of the Company&#8217;s product candidate, SEL-302, for the treatment of methylmalonic acidemia and conducting a targeted headcount reduction. On August 17, 2023, the Company announced additional steps to extend cash runway and maximize value for stockholders by continuing to prioritize development of the Company&#8217;s product candidate, SEL-212, and support of its collaboration with Astellas for Xork, and pausing further development of all of the Company&#8217;s other clinical and preclinical product candidates that it was no longer actively advancing. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these measures, the Company implemented a restructuring plan that resulted in an approximate <ix:nonFraction unitRef="number" contextRef="c-346" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-1249">90</ix:nonFraction>% reduction of the Company&#8217;s existing headcount as of December 31, 2024. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-1250" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in the Company&#8217;s accrued restructuring balance included in accrued expenses and other current liabilities on its consolidated balance sheets (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Severance liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-1251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-1252">6,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-1253">2,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-1254">3,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Severance liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-1255">3,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-1256">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-1257">4,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-1258">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized restructuring expenses consisting of one-time cash severance payments and other employee-related costs. The Company recorded these <span style="-sec-ix-hidden:f-1259"><span style="-sec-ix-hidden:f-1260"><span style="-sec-ix-hidden:f-1261"><span style="-sec-ix-hidden:f-1262">restructuring charges</span></span></span></span> based on each employee&#8217;s role to the respective research and development and general and administrative operating expense categories on its consolidated statements of operations and comprehensive loss. For the years ended December 31, 2024 and 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-1263">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-1264">5.6</ix:nonFraction> million in research and development expenses, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-1265">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-1266">0.8</ix:nonFraction> million in general and administrative expenses, respectively. Payments for the restructuring plan were substantially complete by June 30, 2024.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ida4b385316634ae2a3d2c21207c427f6_2241"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1267" continuedAt="f-1267-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-1267-1" continuedAt="f-1267-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors used in determining the reportable segment include the nature of the Company&#8217;s operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note 3. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1268" continuedAt="f-1268-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents selected financial information with respect to the Company&#8217;s single operating segment for the years ended December 31, 2024 and 2023 (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ida4b385316634ae2a3d2c21207c427f6_10">Table of Contents</a></span></div></div><ix:continuation id="f-1268-1"><ix:continuation id="f-1267-2"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and license revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1269">38,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1270">26,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="f-1271">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-1272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1273">38,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1274">26,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legacy Selecta programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-3" name="rnac:MedicalExpensesOperating" format="ixt:num-dot-decimal" scale="3" id="f-1275">6,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-3" name="rnac:MedicalExpensesOperating" format="ixt:num-dot-decimal" scale="3" id="f-1276">31,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for MG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-3" name="rnac:MedicalExpensesOperating" format="ixt:num-dot-decimal" scale="3" id="f-1277">12,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-3" name="rnac:MedicalExpensesOperating" scale="3" id="f-1278">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Early stage programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-3" name="rnac:MedicalExpensesOperating" format="ixt:num-dot-decimal" scale="3" id="f-1279">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-3" name="rnac:MedicalExpensesOperating" scale="3" id="f-1280">595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development employee expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="rnac:ResearchAndDevelopmentEmployeeExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1281">11,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="rnac:ResearchAndDevelopmentEmployeeExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1282">18,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="rnac:ResearchAndDevelopmentStockBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1283">3,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="rnac:ResearchAndDevelopmentStockBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1284">12,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development facilities and other expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="rnac:ResearchAndDevelopmentFacilitiesAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1285">10,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="rnac:ResearchAndDevelopmentFacilitiesAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1286">7,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1287">30,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1288">40,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="3" id="f-1289">7,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" id="f-1290">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense, net (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="us-gaap:OtherNonoperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1291">33,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="us-gaap:OtherNonoperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1292">133,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1293">77,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1294">219,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Includes impairment of long-lived assets, interest income, foreign currency transaction, net, interest expense, change in fair value of warrant liabilities, change in fair value of contingent value right liability, change in fair value of forward contract liabilities, other income, net, and income tax (expense) benefit.</span></div></ix:continuation></ix:continuation><div id="ida4b385316634ae2a3d2c21207c427f6_289"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1295" continuedAt="f-1295-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-1295-1"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date on which the consolidated financial statements were issued. The Company has concluded that no subsequent events have occurred that require disclosure, except as disclosed within these consolidated financial statements.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>exhibit41rnacspecimensto.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit41rnacspecimensto</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1365;"><!-- exhibit41rnacspecimensto001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit41rnacspecimensto001.jpg" title="slide1" width="1365" height="1055">
<DIV><FONT size="1" style="font-size:1pt;color:white">NUMBER SHARES COUNTERSIGNED: BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC TRANSFER AGENT BY: AUTHORIZED SIGNATURE DATED: INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE   CUSIP  816212  30  2 SEE REVERSE FOR CERTAIN DEFINITIONS This CerTifies ThaT: is The owner of C o M M o n  s T o C K GENERAL COUNSEL AND SECRETARY PRESIDENT AND CHIEF EXECUTIVE OFFICER FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF Cartesian therapeutiCs, inC. transferable on the books of the Corporation by the holder thereof in person or by duly authorized attorney upon surrender of  this certificate duly endorsed or assigned. This certificate and the shares represented hereby are subject to the laws of the State of  Delaware, and to the Certificate of Incorporation and Bylaws of the Corporation, as now or hereafter amended.  This certificate is not valid until countersigned by the Transfer Agent. WITNESS the facsimile seal of the Corporation and the facsimile signatures of its duly authorized officers. SPECIMEN SPECIMEN SPECIMEN - NOT NEGOTIABLE SPECIMEN not negotiable Exhibit 4.1 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit41rnacspecimensto002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit41rnacspecimensto002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">COLUMBIA PRINTING SERVICES, LLC - www.stockinformation.com   The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they  were written out in full according to applicable laws or regulations: TEN COM  - as tenants in common     UNIF GIFT MIN ACT - ....................Custodian.................... TEN ENT - as tenants by the entireties         (Cust)                     (Minor) JT TEN  - as joint tenants with right of          under Uniform Gifts to Minors    survivorship and not as tenants               Act ...................................................               in common                       (State)                Additional abbreviations may also be used though not in the above list. For Value Received,                                                                   hereby sell, assign and transfer unto  PLEASE INSERT SOCIAL SECURITY OR OTHER   IDENTIFYING NUMBER OF ASSIGNEE                                                                                                                                                                                                                                        (PLEASE PRINT OR TYPE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Shares  of the stock represented by the within Certificate, and do hereby irrevocably constitute and appoint                                                                                                                                                                                                                    Attorney to transfer the said stock on the books of the within named Corporation with full power of substitution in the premises. Dated                                                                                                                                                                                                              NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE  OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER.  Signature(s) Guaranteed By                                                                                                              The Signature(s) must be guaranteed by an eligible guarantor institution  (Banks, Stockbrokers, Savings and Loan Associations and Credit Unions  with membership in an approved Signature Guarantee Medallion Program),  pursuant to SEC Rule 17Ad-15. THE CORPORATION WILL FURNISH TO ANY STOCKHOLDER, UPON REQUEST AND WITHOUT CHARGE, A FULL STATEMENT OF THE DESIGNATIONS,  RELATIVE RIGHTS, PREFERENCES AND LIMITATIONS OF THE SHARES OF EACH CLASS AND SERIES AUTHORIZED TO BE ISSUED, SO FAR AS THE  SAME HAVE BEEN DETERMINED, AND OF THE AUTHORITY, IF ANY, OF THE BOARD TO DIVIDE THE SHARES INTO CLASSES OR SERIES AND TO  DETERMINE AND CHANGE THE RELATIVE RIGHTS, PREFERENCES AND LIMITATIONS OF ANY CLASS OR SERIES. SUCH REQUEST MAY BE MADE  TO THE SECRETARY OF THE CORPORATION OR TO THE TRANSFER AGENT NAMED ON THIS CERTIFICATE. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>3
<FILENAME>exhibit412descriptionofsec.htm
<DESCRIPTION>EX-4.12
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9a3204cf029a409b931c90cf85d9628c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.12</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2024, Cartesian Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended&#58; our common stock, par value $0.0001 per share (&#8220;common stock&#8221;), and contingent value rights (&#8220;CVRs&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following description of our securities is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our restated certificate of incorporation, as amended (the &#8220;Charter&#8221;), our amended and restated by-laws (the &#8220;Bylaws&#8221;), the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock, as amended (the &#8220;Series A Certificate of Designation&#8221;) governing the Company&#8217;s Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the &#8220;Series A Preferred Stock&#8221;), the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the &#8220;Series B Certificate of Designation&#8221;) governing the Company&#8217;s Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the &#8220;Series B Preferred Stock&#8221;), the Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) by and between the Company and Equiniti Trust Company, LLC (in such capacity, the &#8220;Trustee&#8221;), dated December 6, 2023, and applicable provisions of the Delaware General Corporation Law (&#8220;DGCL&#8221;). Our Charter, Bylaws, the Series A Certificate of Designation, the Series B Certificate of Designation, and the CVR Agreement are included as exhibits to the Annual Report on Form 10-K of which this Exhibit 4.12 forms a part. We encourage you to carefully read each of the foregoing documents and the applicable provisions of the DGCL for additional information.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF CAPITAL STOCK</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our authorized capital stock consists of 360,000,000 shares, comprised of 350,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share (&#8220;preferred stock&#8221;), of which 134,904.563 shares of preferred stock have been designated as Series A Preferred Stock, 437,927 shares of preferred stock have been designated as Series B Preferred Stock, and 9,427,168.437 shares of preferred stock remain undesignated. As of February&#160;28, 2025, there were 25,907,101 shares of our common stock outstanding, 120,790.402&#160;shares of Series&#160;A Preferred Stock outstanding, 437,927 shares of Series B Preferred Stock outstanding, no undesignated shares of preferred stock outstanding, and 177,746,054 CVRs outstanding, and an additional 204,397 CVRs held in nominee accounts and reserved for future distribution to holders of certain warrants to purchase common stock (and to be so distributed if and to the extend such warrants are exercised).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The transfer agent and registrar for our common stock, Series A Preferred Stock, and Series B Preferred Stock is Broadridge Corporate Issuer Solutions, Inc. Broadridge Corporate Issuer Solutions, Inc.&#8217;s address is P.O. Box 1342, Brentwood, New York 11717 and its telephone number is (877) 830-4932. Equiniti Trust Company, LLC acts as Trustee for the CVRs. Equiniti Trust Company, LLC&#8217;s address is Wall Street, Floor 23, New York, New York, 10005, and its telephone number is (800) 937-5449.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;RNAC.&#8221;  The outstanding shares of our common stock are duly authorized, validly issued, fully paid and nonassessable.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Voting Rights</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our Charter and Bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least a majority of the voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our Charter.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Rights Upon Liquidation</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Dividend Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock we may designate and issue in the future.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preferred Stock</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to our Charter, our board of directors is authorized, without stockholder approval, subject to limitations prescribed by law, to issue up to 10,000,000 shares of preferred stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware, to establish from time to time the number of shares to be included in each such series, and to fix the voting rights, if any, designations, powers, preferences and relative, participating, optional, special and other rights of the shares of each series, and any qualifications, limitations or restrictions thereof. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,904.563</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;shares of preferred stock have been designated as Series A Preferred Stock and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,927 shares of preferred stock have been designated as Series B Preferred Stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will fix the voting rights, designations, preferences and rights of the preferred stock of each series, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to such series. Any description of our securities that we file with the Securities and Exchange Commission (the &#8220;Commission&#8221;) describing any such certification of designation may include&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the title and stated value&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the number of shares offered&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the liquidation preference per share&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the purchase price per share&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the dividend rate(s), period(s) and&#47;or payment date(s) or method(s) of calculation for dividends&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether dividends are cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our right, if any, to defer payment of dividends and the maximum length of such deferral period&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the procedures for auction and remarketing, if any&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the provisions for a sinking fund, if any&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the provision for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any listing of the preferred stock on any securities exchange or market&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the terms and conditions, if applicable, upon which the preferred stock will be convertible into common stock, including the conversion price (or manner of calculation) and conversion period&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">voting rights, if any, of the preferred stock&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">preemptive rights, if any&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">restrictions on transfer, sale or other assignment, if any&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether interests in the preferred stock will be represented by depositary shares&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a discussion of any material and&#47;or special U.S. federal income tax considerations applicable to the preferred stock&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the liquidation, dissolution or winding up of our affairs&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any other specific terms, preferences, rights, limitations or restrictions of the preferred stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors could authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of discouraging a takeover or other transaction that might involve a premium price for holders of the shares or which holders might believe to be in their best interests. The issuance of preferred stock could adversely affect the voting power, conversion or other rights of holders of common stock and reduce the likelihood that holders of common stock will receive dividend payments and payments upon liquidation. We have no current plan to issue any shares of preferred stock other than the shares of our Series A Preferred Stock and Series B Preferred Stock that have been issued to date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The laws of the State of Delaware provide that the holders of preferred stock will have the right to vote separately as a class on any proposal involving fundamental changes to the rights of holders of such preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designations.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Series A Preferred Stock</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conversion</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. On March 27, 2024, we held a special meeting of stockholders at which our common stockholders approved a proposal (the &#8220;Conversion Proposal&#8221;) to issue shares of common stock upon conversion of shares of Series A Preferred Stock, subject to a beneficial ownership limitation described below.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to the stockholder approval of the Conversion Proposal, the shares of Series A Preferred Stock were not convertible into shares of common stock. Following the stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock automatically converted into 33.333 shares of common stock, subject to the beneficial ownership limitation that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock to the extent that, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set by the holder at a number up to 19.9% and thereafter adjusted, provided that no such adjustment exceeds 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. Such beneficial ownership limitation does not apply to any holder of Series A Preferred Stock who beneficially owned greater than 19.9% of our common stock immediately prior to our November 2023 merger (the &#8220;Merger&#8221;) with the private company then-known as Cartesian Therapeutics, Inc. (&#8220;Old Cartesian&#8221;).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each share of Series A Preferred Stock outstanding that was not otherwise automatically converted into common stock as a result of the beneficial ownership limitation shall be convertible at any time at the option of the holder, only to the extent the beneficial ownership limitation does not apply to the shares of Series A Preferred Stock to be converted.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Voting Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as otherwise required by law (e.g., voting on a change to the authorized shares of Series A Preferred Stock or the rights of such shares as required by the DGCL) and the Series A Certificate of Designation, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, we will not, without the affirmative vote of the hold</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ers of a majority of the then outstanding shares of the Series A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (b) alter or amend the Series A Certificate of Designation, (c) amend the Charter or other organizational documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (d) issue further shares of Series A Preferred Stock, (e) at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate either (A) a Fundamental Transaction (as defined in the Certificate of Designation) or (B) any merger or consolidation of the Company or other business combination in which our stockholders immediately before such transaction do not hold at least a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">majority of our capital stock immediately after such transaction, (f) amend or fail to comply with, in any manner that would be reasonably likely to prevent, impede or materially delay the conversion (or the stockholder approval thereof), or terminate, any of the stockholder support agreements entered into in connection with the Merger (the &#8220;Support Agreements&#8221;), or agree to any transfer, sale or disposition of such shares subject to the Support Agreements (except for such transfers, sales or dispositions with respect to which the approval of the Company is not required pursuant to the applicable Support Agreement) or (g) enter into any agreement with respect to any of the foregoing.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Dividends</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Holders of Series A Preferred Stock are entitled to receive non-cumulative dividends on shares of Series A Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the common stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liquidation and Dissolution</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Series A Preferred Stock ranks on parity with common stock and the Series B Preferred Stock upon any liquidation, dissolution or winding-up of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Preemptive Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Series A Preferred Stock does not have preemptive rights.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Transferability</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Series A Certificate of Designation does not contain any restrictions upon the transfer of the Series A Preferred Stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Redemption</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Series A Preferred Stock is not redeemable. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Series B Preferred Stock</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conversion</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. On September 20, 2024, we held a special meeting of stockholders at which our common stockholders approved a proposal (the &#8220;Series B Conversion Proposal&#8221;) to issue shares of common stock upon conversion of shares of Series B Preferred Stock, subject to a beneficial ownership limitation described below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to the stockholder approval of the Series B Conversion Proposal, the shares of Series B Preferred Stock were not convertible into shares of common stock. Following the stockholder approval of the Series B Conversion Proposal, each share of Series B Preferred Stock automatically converted into one share of common stock, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">subject to the beneficial ownership limitation that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock to the extent that, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set by the holder at a number up to 19.9% and thereafter adjusted, provided that no such adjustment exceeds 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. Such beneficial ownership limitation does not apply to TAS Partners LLC or any of its affiliates.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each share of Series B Preferred Stock outstanding that was not automatically converted into common stock as a result of the stockholder approval of the Series B Conversion Proposal shall be convertible at any time at the option of the holder, only to the extent the beneficial ownership limitation does not apply to the shares of Series B Preferred Stock to be converted.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Voting Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as otherwise required by law (e.g., voting on a change to the authorized shares of Series B Preferred Stock or the rights of such shares as required by the DGCL) and the Series B Certificate of Designation, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then-outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the Series B Certificate of Designation, or (c) amend the Charter or other organizational documents in any manner that alters or changes the preferences, rights, privileges, or powers of, or restrictions provided for the benefit of the holders of Series B Preferred Stock.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Dividends. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of Series B Preferred Stock are entitled to receive non-cumulative dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends paid on shares of the common stock.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liquidation and Dissolution</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Series B Preferred Stock ranks on parity with common stock and the Series A Preferred Stock upon any liquidation, dissolution or winding-up of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Preemptive Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Series B Preferred Stock does not have preemptive rights.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Transferability</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Series B Certificate of Designation does not contain any restrictions upon the transfer of the Series B Preferred Stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Redemption</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Series B Preferred Stock is not redeemable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Value Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each CVR entitles the holder thereof to distributions of the following, pro-rated on a per-CVR basis, during the period ending on the date on which the Royalty Term (as defined in our License and Development Agreement, as amended, with Swedish Orphan Biovitrum AB (publ.) (the &#8220;Sobi License&#8221;)) ends (the &#8220;Termination Date&#8221;)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;100% of all milestone payments, royalties and other amounts paid to us or our controlled affiliates (the &#8220;Company Entities&#8221;) prior to the Termination Date under the Sobi License or, following certain terminations of the Sobi License, any agreement a Company Entity enters into that provides for the development and commercialization of SEL-212 (a &#8220;New Applicable Agreement&#8221;)&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;100% of all cash consideration and the actual liquidation value of any and all non-cash consideration of any kind that is paid to or is actually received by any Company Entity prior to the Termination Date pursuant to an agreement between a Company Entity and any person who is not a Company Entity relating to a sale, license, transfer or other disposition of any transferable asset of the Company Entities existing as of immediately prior to the Merger (a &#8220;Disposition&#8221;) other than those exclusively licensed under the Sobi License or which the Company Entities are required to continue to own in order to comply with the Sobi License (a &#8220;Disposition Agreement&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The distributions in respect of the CVRs will be made on a semi-annual basis, and will be subject to a number of deductions, subject to certain exceptions or limitations, including for (A) certain taxes, (B) certain out-of-pocket expenses incurred by the Company Entities, including audit and accounting fees incurred in connection with reporting obligations relating to the CVRs, in respect of its performance of the Sobi License or any New Applicable Agreement, in connection with the entry into a Disposition Agreement and under any Disposition Agreement and performance of the Company Entities&#8217; related obligations thereunder, (C) a fixed amount of $750,000 for each Distribution Period (as defined below) to account for general and administrative overhead incurred by the Company Entities, (D) in the case of a distribution that includes payments for certain milestones under clause (ii) above and for the upfront portion, if any, of the consideration payable under a Disposition Agreement (a &#8220;Trigger Distribution&#8221;), the sum of payments made under any liabilities of the Company Entities arising under real property leases in effect as of immediately prior to the closing (the &#8220;Closing&#8221;) of the Merger (&#8220;Lease Liabilities&#8221;) after the Closing and the aggregate remaining payment obligations under the Lease Liabilities outstanding as of the applicable date of measurement (but subject to a positive adjustment in case amounts held back under this clause (D) exceed the liabilities actually incurred under the Lease Liabilities at the time such a lease expires or is terminated, assigned or subleased), and (E) in the case of a Trigger Distribution, the sum of payments made after the Closing under certain liabilities relating to our Xork product candidate (&#8220;Xork Liabilities&#8221;) after the Closing and the aggregate remaining payment obligations under Xork Liabilities outstanding as of the applicable date of measurement but subject to a positive adjustment in case amounts held back under this clause (E) exceed the liabilities actually incurred under the Xork Liabilities at such time as the development activities with respect to Xork are terminated, transferred or assigned by the Company Entities or otherwise completed in accordance with the development plan set forth in our License and Development Agreement with Audentes Therapeutics, Inc. (the &#8220;Astellas Agreement&#8221;), when such termination, transfer, assignment or completion occurs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will calculate the amount of any payment due on the CVRs for each six-month period from January 1 through June 30 and each six-month period from July 1 through December 31 of each year (each such period, a &#8220;Distribution Period&#8221;), except that the initial Distribution Period will commence on the date of the CVR Agreement and run through June 30, 2024. Payments on the CVRs will be cumulative and will be payable no later than the close of business on each March 15 (for Distribution Periods that end on December 31) and September 15 (for Distribution Periods that end on June 30), commencing on September 15, 2024 (each such date, a &#8220;Distribution Payment Date&#8221;), to holders of record of the CVRs as of the close of business on the first day of the month of the applicable Distribution Payment Date. If a Distribution Payment Date is not a business day, payment will be made on the immediately succeeding business day, without the accumulation of additional distributions. If the amount of any per-CVR distribution is less than $0.02, we may elect to defer such distribution until the next Distribution Payment Date when the aggregate per-CVR distribution would be $0.02 or greater.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the CVR Agreement, as long as any CVRs are outstanding, we will not&#58; (i) without the affirmative vote of the holders of at least 66 and 2&#47;3% of the then-outstanding CVRs modify in a manner adverse to the CVR holders any provision contained in the CVR Agreement with respect to the termination of the CVR Agreement or the CVRs, or the time for payment and amount of any distribution, or modify in any manner any provision of the CVR Agreement if such modification would reduce the amounts payable in respect of the CVRs or modify any other payment term or payment date, (ii) without the consent of each holder of each outstanding CVR affected thereby, reduce the number of CVRs, or modify any provision referenced in the preceding clause (i) or this clause (ii), except </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to increase the percentage of CVR holders from whom consent is required or to provide that certain other provisions of the CVR Agreement cannot be modified or waived without the consent of the holder of each CVR affected thereby, (iii) without the consent of the affirmative vote of the holders of a majority of the then-outstanding CVRs, alter, change, amend, or modify, in each case in any material respect or in any manner adverse to the CVR holders, the Sobi License, the Astellas Agreement, or our Exclusive License Agreement with Genovis AB (publ.), terminate the Sobi License, or sell, license, assign, transfer, enter into any monetization transaction, or otherwise dispose of or otherwise grant or suffer to exist a mortgage, pledge, lien, encumbrance or other security interest on all or a portion of (A) the patents or patent applications licensed under the Sobi License or (B) the Sobi License or any rights to receive any milestone payments, royalties or other amounts under the Sobi License, and (iv) subject to limited exceptions, issue any additional CVRs, other than pursuant to the Agreement and Plan of Merger between us, Old Cartesian, and the merger subsidiary parties thereto to former holders of Selecta&#8217;s common stock or to holders of warrants to purchase common stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additionally, in the event of certain terminations of the Sobi License at a time when any CVRs are outstanding, we will, and will cause our applicable related entities to, exercise our rights to obtain a &#8220;reversion license&#8221; and enforce any of our rights under the terminated Sobi License that survive the termination or expiration thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the CVR Agreement, the Trustee has, and holders of at least 20% of the CVRs then outstanding may also instruct the Trustee to exercise, certain rights to inspection, audit, and enforcement on behalf of all holders of the CVRs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CVR holders, solely by virtue of their holding of a CVR, are not entitled to dividends issued by us, do not have voting rights with respect to affairs of our Company, and shall have no rights upon a liquidation of our Company. The CVRs are not convertible or redeemable and do not constitute a debt or obligation of our Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The CVRs are transferable but are not expected to be listed on any securities exchange and no transaction involving the CVRs is expected to be registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registration Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain holders of our common stock or their transferees are entitled to the following rights with respect to the registration of such shares for public resale under the Securities Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These registration rights are granted pursuant to (i) a registration rights agreement we entered into on July 2, 2024 (the &#8220;2024 Registration Rights Agreement&#8221;), in connection with the private placement of 3,563,246 shares of our common stock and 2,937,903 shares of Series B Preferred Stock (the &#8220;2024 Private Placement&#8221;), (ii) a registration rights agreement we entered into on November 13, 2023 (the &#8220;2023 Registration Rights Agreement&#8221;), in connection with the Merger and the private placement of 149,330.115 shares of Series&#160;A Preferred Stock (the &#8220;2023 Private Placement&#8221;), and (iii) a registration rights agreement we entered into on June 11, 2020 (as amended, the &#8220;2020 Registration Rights Agreement&#8221;), we entered into in connection with the private placement of 5,416,390 shares of our common stock (the &#8220;2020 Private Placement&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">2024 Registration Rights Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On July 2, 2024, we entered into the 2024 Registration Rights Agreement with the purchasers party thereto. Pursuant to the 2024 Registration Rights Agreement, we agreed to prepare and file a resale registration statement with the Commission within 30 days of July 3, 2024 and to use our reasonable best efforts to cause this registration statement to be declared effective by the Commission within 90 calendar days of July 3, 2024 (or within 120 calendar days of July 3, 2024 if the Commission reviews the registration statement). We have filed a registration statement in satisfaction of such obligations, and for so long as such registration statement remains effective, the resale shares to which such registration statement relates will no longer constitute restricted securities and may be sold freely in the public markets, subject to lapse on any related contractual restrictions related thereto of any holder party thereto, and subject to any restrictions that may be applicable to any control securities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have also agreed, among other things, to indemnify the purchasers party thereto and each of their respective officers, directors, agents, partners, members, managers, stockholders, affiliates, investment advisers and employees, each person who controls any such purchaser party and the officers, directors, partners, members, managers, stockholders, agents, investment advisers and employees of each such controlling person from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the 2024 Registration Rights Agreement.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities of a holder cease to be registrable securities under the 2024 Registration Rights Agreement upon the earlier to occur of the following&#58; (A) a sale pursuant to a registration statement or Rule 144 under the Securities </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Act&#59; and (B) the time such shares become eligible for resale by such holder under Rule 144 without the requirement for the Company to be in compliance with the current public information required by Rule 144(c) and Rule 144(i)(2) and without volume or manner-of-sale restrictions, pursuant to a written opinion letter of counsel for the Company to such effect, addressed, delivered and reasonably acceptable to the Company&#8217;s transfer agent.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">2023 Registration Rights Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In connection with the Merger and the 2023 Private Placement, we entered into the 2023 Registration Rights Agreement, pursuant to which we agreed to prepare and file a resale registration statement with the Commission within 90 calendar days following November&#160;15, 2023, with respect to the shares of common stock underlying the Series&#160;A Preferred Stock issued in the 2023 Private Placement and the common stock and shares of common stock underlying the Series&#160;A Preferred Stock issued to the signatories to the 2023 Registration Rights Agreement in the Merger. We also agreed to use our commercially reasonable efforts to cause such registration statement to be declared effective by the Commission by March&#160;29, 2024 (or by May&#160;13, 2024 if the Commission reviews the registration statement). The parties to the 2023 Registration Rights Agreement previously waived these registration requirements during the period in which we were not eligible to use Form S-3 to register resales of the registrable securities under the 2023 Registration Rights Agreement, and one signatory to the 2023 Registration Rights Agreement has irrevocably waived such registration requirements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have filed a registration statement in satisfaction of our remaining obligations under the 2023 Registration Rights Agreement, and for so long as such registration statement remains effective, the resale shares to which such registration statement relates will no longer constitute restricted securities and may be sold freely in the public markets, subject to lapse on any related contractual restrictions related thereto of any holder party thereto, and subject to any restrictions that may be applicable to any control securities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We also agreed to, among other things, indemnify the holders of common stock and Series&#160;A Preferred Stock signatory thereto, their officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents under such registration statement from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the 2023 Registration Rights Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities of a holder cease to be registrable securities under the 2023 Registration Rights Agreement upon the earlier to occur of the following&#58; (A) a sale pursuant to a registration statement or Rule&#160;144 under the Securities Act&#59; and (B) the time such shares become eligible for resale by such holder under Rule&#160;144 without the requirement for us to be in compliance with the current public information required thereunder and without volume or manner-of-sale restrictions, pursuant to a written opinion letter of counsel for our Company to such effect, addressed, delivered and reasonably acceptable to our transfer agent.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">2020 Registration Rights Agreement</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of registrable securities under the 2020 Registration Rights Agreement have registration rights until the earlier of (i) such time as there are no longer any registrable securities held by the purchaser, its affiliates or permitted transferees and (ii) such time as all of the securities can otherwise be sold without regard to the volume or manner-of-sale restrictions pursuant to Rule 144. The registration of shares of common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Piggyback Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Any time we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities are entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Demand Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the holders of registrable securities request in writing that we effect a registration with respect to all of the registrable securities, we will be required to effect such registration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling security holders and blue sky fees and expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Termination of Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The registration rights terminate upon the earlier of (i) such time as there are no longer any registrable securities held by the purchaser, its affiliates or permitted transferees and (ii) such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">time as all of the securities can otherwise be sold without regard to the volume or manner-of-sale restrictions pursuant to Rule 144.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Anti-Takeover Effects of Delaware Law and Our Charter and Bylaws</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Some provisions of the DGCL, our Charter and our Bylaws could make the following transactions more difficult&#58; an acquisition of us by means of a tender offer&#59; an acquisition of us by means of a proxy contest or otherwise&#59; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interest, including transactions which provide for payment of a premium over the market price for our shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Undesignated Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to effect a change in control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our Company.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Stockholder Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Our Bylaws provide that a special meeting of stockholders may be called only by our chairman of the board of directors, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Requirements for Advance Notification of Stockholder Nominations and Proposals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Our Bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Elimination of Stockholder Action by Written Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Our Charter eliminates the right of stockholders to act by written consent without a meeting.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Staggered Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Removal of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Our Charter provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of common stock entitled to vote in the election of directors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Stockholders Not Entitled to Cumulative Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Our Charter does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Delaware Anti-Takeover Statute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. We are subject to Section 203 of the DGCL, which prohibits persons deemed to be&#160;&#8220;interested stockholders&#8221;&#160;from engaging in a&#160;&#8220;business combination&#8221;&#160;with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an&#160;&#8220;interested stockholder&#8221;&#160;is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a&#160;&#8220;business combination&#8221;&#160;includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this law may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Choice of Forum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Our Charter provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for&#58; (1) any derivative action or proceeding brought on our behalf&#59; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders&#59; (3) any action asserting a claim against us arising pursuant to any provision of the DGCL or our Charter or Bylaws&#59; or (4) any action asserting a claim governed by the internal affairs doctrine. Our Charter also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our Charter is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. Investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder and Section 22 of the Securities Act generally creates concurrent jurisdiction for the state and federal courts over suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amendment of Charter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The amendment of any of the above provisions in our Charter, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote thereon. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of the DGCL, our Charter and our Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interest.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103_employmentinduc.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5940c6df2b214e5cba09811280a63386_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;CARTESIAN THERAPEUTICS, INC.<br>AMENDED AND RESTATED 2018 EMPLOYMENT </font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INDUCEMENT INCENTIVE AWARD PLAN</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE I.<br>PURPOSE </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Plan&#8217;s purpose is to enhance the Company&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities.  Capitalized terms used in the Plan are defined in Article&#160;XI.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE II.<br>ELIGIBILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Eligible Individuals are eligible to be granted Awards under the Plan, subject to the limitations described herein.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE III.<br>ADMINISTRATION AND DELEGATION </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan is administered by the Administrator.  The Administrator has authority to determine which Eligible Individuals receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan.  The Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable.  The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan or any Award as it deems necessary or appropriate to administer the Plan and any Awards.  The Administrator may adopt procedures from time to time that are intended to ensure that an individual is an Eligible Individual prior to the granting of any Awards to such individual (including without limitation a requirement that each such individual certify to the Company prior to the receipt of an Award that he or she is not currently employed by the Company or a Subsidiary and, if previously so employed, has had a bona fide period of interruption of employment, and that the grant of Awards is an inducement material to his or her agreement to enter into employment with the Company or a Subsidiary). The Administrator&#8217;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any interest in the Plan or any Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appointment of Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  To the extent Applicable Laws permit, the Board may delegate any or all of its powers under the Plan to one or more Committees.  The Board may abolish any Committee or re-vest in itself any previously delegated authority at any time. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE IV.<br>STOCK AVAILABLE FOR AWARDS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Subject to adjustment under Article&#160;VIII and the terms of this Article&#160;IV, Awards may be made under the Plan covering up to the Overall Share Limit.  Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Share Recycling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If all or any part of an Award expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in any case, in a manner that results in the Company acquiring Shares covered by the Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award, the unused Shares covered by the Award will again be available for Award grants under the Plan.  Further, Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award and&#47;or to satisfy any applicable tax withholding obligation (including Shares retained by the Company from the Award being exercised or purchased and&#47;or creating the tax obligation) will again be available for Award grants under the Plan.  The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards shall not count against the Overall Share Limit.   </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE V.<br>STOCK OPTIONS AND STOCK APPRECIATION RIGHTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator may grant Non-Qualified Options or Stock Appreciation Rights to Eligible Individuals subject to the conditions and limitations in the Plan.  The Administrator will determine the number of Shares covered by each Option and Stock Appreciation Right, the exercise price of each Option and Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right.  A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator will establish each Option&#8217;s and Stock Appreciation Right&#8217;s exercise price and specify the exercise price in the Award Agreement.  The exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option or Stock Appreciation Right.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Duration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that the term of an Option or Stock Appreciation Right will not exceed ten years. Notwithstanding the foregoing and unless determined otherwise by the Company, in the event that on the last business day of the term of an Option or Stock Appreciation Right (i) the exercise of the Option or Stock Appreciation Right is prohibited by Applicable Law, as determined by the Company, or (ii) Shares may not be purchased or sold by the applicable Participant due to any Company insider trading policy (including blackout periods) or a &#8220;lock-up&#8221; agreement undertaken in connection with an issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be extended until the date that is thirty (30) days after the end of the legal prohibition, black-out period or lock-up agreement, as determined by the Company&#59; provided, however, in no event shall the extension last beyond the ten year term of the applicable Option or Stock Appreciation Right.  Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company otherwise determines.  In addition, if, prior to the end of the term of an Option or Stock Appreciation Right, the Participant is given notice by the Company or any of its Subsidiaries of the Participant&#8217;s Termination of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Service by the Company or any of its Subsidiaries for Cause, and the effective date of such Termination of Service is subsequent to the date of the delivery of such notice, the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#8217;s service as a Service Provider will not be terminated for Cause as provided in such notice or (ii) the effective date of the Participant&#8217;s Termination of Service by the Company or any of its Subsidiaries for Cause (in which case the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant will terminate immediately upon the effective date of such Termination of Service).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (i) as specified in Section&#160;5.5 for the number of Shares for which the Award is exercised and (ii) as specified in Section&#160;9.5 for any applicable taxes.  Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Upon Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Subject to Section&#160;10.9, any Company insider trading policy (including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;cash, wire transfer of immediately available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A) delivery (including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (B) the Participant&#8217;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price&#59; provided that such amount is paid to the Company at such time as may be required by the Administrator&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;to the extent permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their Fair Market Value&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#8217;s exercise valued at their Fair Market Value on the exercise date&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;to the extent permitted by the Administrator, delivery of a promissory note or any other property that the Administrator determines is good and valuable consideration&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;to the extent permitted by the Company, any combination of the above payment forms approved by the Administrator.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE VI.<br>RESTRICTED STOCK&#59; RESTRICTED STOCK UNITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Eligible Individual, subject to the Company&#8217;s right to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant (or to require </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">forfeiture of such shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award and subject to the conditions and limitations in the Plan.  In addition, subject to the conditions and limitations in the Plan, the Administrator may grant to Eligible Individuals Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement.  The Administrator will determine and set forth in the Award Agreement the terms and conditions for each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement.  In addition, unless the Administrator provides otherwise, if any dividends or distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may require that the Participant deposit in escrow with the Company (or its designee) any stock certificates issued in respect of shares of Restricted Stock, together with a stock power endorsed in blank.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Units.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#8217;s election, in a manner intended to comply with Section&#160;409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents.  Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE VII.<br>OTHER STOCK OR CASH BASED AWARDS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled.  Other Stock or Cash Based Awards </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">may be paid in Shares, cash or other property, as the Administrator determines.  Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock or Cash Based Award, including any purchase price, performance goal (which may be based on the Performance Criteria), transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE VIII.<br>ADJUSTMENTS FOR CHANGES IN COMMON STOCK <br>AND CERTAIN OTHER EVENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Restructuring</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;.  In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Article&#160;VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and&#47;or the Award&#8217;s exercise price or grant price (if applicable), granting new Awards to Participants (subject to Section 10.4), and making a cash payment to Participants.  The adjustments provided under this Section&#160;8.1 will be nondiscretionary and final and binding on the affected Participant and the Company&#59; provided that the Administrator will determine whether an adjustment is equitable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of time after such change) and either automatically or upon the Participant&#8217;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x) prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y) to facilitate such transaction or event or (z) give effect to such changes in Applicable Laws or accounting principles&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;To provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights under the vested portion of such Award, as applicable&#59; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights, in any case, is equal to or less than zero, then the Award may be terminated without payment&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To provide that such Award shall vest and, to the extent applicable, be exercisable as to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and&#47;or applicable exercise or purchase price, in all cases, as determined by the Administrator&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Awards and&#47;or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article&#160;IV hereof on the maximum number and kind of shares which may be issued) and&#47;or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;To replace such Award with other rights or property selected by the Administrator&#59; and&#47;or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of the Plan to the contrary, if a Change in Control occurs and an outstanding Award that is not subject to performance-based vesting conditions is not continued, converted, assumed, or replaced with a substantially similar award by (i) the Company, or (ii) a successor entity or its parent or subsidiary (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then, immediately prior to the Change in Control, such Award will become fully vested and exercisable and all forfeiture restrictions on such Award shall lapse.  The Administrator shall determine whether an Assumption of an Award has occurred in connection with a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Stand Still</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty days before or after such transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as expressly provided in the Plan or the Administrator&#8217;s action under the Plan, no Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation.  Except as expressly provided with respect to an Equity Restructuring under Section&#160;8.1 above or the Administrator&#8217;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#8217;s grant or exercise price.  The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in any way the Company&#8217;s right or power to make or authorize (i) any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business, (ii) any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii) any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares.  The Administrator may treat Participants and Awards (or portions thereof) differently under this Article&#160;VIII.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE IX.<br>GENERAL PROVISIONS APPLICABLE TO AWARDS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as the Administrator may determine or provide in an Award Agreement or otherwise, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of descent and distribution, or, subject to the Administrator&#8217;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant.  References to a Participant, to the extent relevant in the context, will include references to a Participant&#8217;s authorized transferee that the Administrator specifically approves.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines. Each Award may contain terms and conditions in addition to those set forth in the Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award.  The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator will determine how the disability, death, retirement, authorized leave of absence or any other change or purported change in a Participant&#8217;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#8217;s Awards by the date of the event creating the tax liability.  The Company may deduct an amount sufficient to satisfy such tax obligations based on the minimum statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment of any kind otherwise due to a Participant.  Subject to Section 10.9 and any Company insider trading policy (including blackout periods), Participants may satisfy such tax obligations (i) in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below is permitted, (ii) to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares retained from the Award creating the tax obligation, valued at their Fair Market Value, (iii) if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A) delivery (including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax withholding, provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv) to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator.  If any tax withholding obligation will be satisfied under clause (ii) of the immediately preceding sentence by the Company&#8217;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#8217;s behalf </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">some or all of the Shares retained and to remit the proceeds of the sale to the Company or its designee, and each Participant&#8217;s acceptance of an Award under the Plan will constitute the Participant&#8217;s authorization to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Award&#59; Repricing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type or changing the exercise or settlement date.  The Participant&#8217;s consent to such action will be required unless (i) the action, taking into account any related action, does not materially and adversely affect the Participant&#8217;s rights under the Award, or (ii) the change is permitted under Article&#160;VIII  or pursuant to Section&#160;10.7.  Notwithstanding the foregoing or anything in the Plan to the contrary, the Administrator may, without the approval of the stockholders of the Company, reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions on Delivery of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i)&#160;all Award conditions have been met or removed to the Company&#8217;s satisfaction, (ii)&#160;as determined by the Company, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii)&#160;the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws.  The Company&#8217;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator may at any time provide that any Award will become immediately vested and fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Action Required Upon Grant of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Promptly following the grant of an Award, the Company shall, in accordance with NASDAQ Rule 5635(c), (a) issue a press release disclosing the material terms of the Award, including the recipient(s) of the Award and the number of Shares involved and (b) provide written notice to the NASDAQ of the grant.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE X.<br>MISCELLANEOUS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Right to Employment or Other Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company.  The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Rights as Stockholder&#59; Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Subject to the Award Agreement, no Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares.  Notwithstanding any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provision of the Plan, unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator).  The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date and Term of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Unless earlier terminated by the Board, the Plan will become effective on the date it is approved by the Board and will remain in effect until the tenth anniversary of such date, but Awards previously granted may extend beyond that date in accordance with the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Approval Not Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. It is expressly intended that approval of the Company&#8217;s stockholders not be required as a condition of the effectiveness of the Plan, and the Plan&#8217;s provisions shall be interpreted in a manner consistent with such intent for all purposes. Specifically, NASDAQ Rule 5635(c) generally requires stockholder approval for equity-compensation plans adopted by companies whose securities are listed on the NASDAQ Stock Market that provide for the delivery of equity securities to any employees, directors or other service providers of such companies as compensation for services. NASDAQ Rule 5635(c)(4) provides an exemption in certain circumstances for employment inducement awards. Notwithstanding anything to the contrary herein, in accordance with NASDAQ Rule 5635(c)(4), Awards may only be granted as material inducements to Eligible Individuals being hired or rehired as Employees, as applicable, and must be approved by (a) the Board, acting through a majority of the Company&#8217;s Independent Directors or (b) the independent Compensation Committee of the Board. Accordingly, pursuant to NASDAQ Rule 5635(c)(4), the issuance of Awards and the Shares issuable upon exercise or vesting of such Awards pursuant to the Plan is not subject to the approval of the Company&#8217;s stockholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator may amend, suspend or terminate the Plan at any time&#59; provided that no amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#8217;s consent. No Awards may be granted under the Plan during any suspension period or after Plan termination.  Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination.  The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Provisions for Foreign Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company intends that all Awards be structured to comply with, or be exempt from, Section&#160;409A, such that no adverse tax consequences, interest, or penalties under Section&#160;409A apply.  Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#8217;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">actions intended to (A)&#160;exempt this Plan or any Award from Section&#160;409A, or (B)&#160;comply with Section&#160;409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#8217;s grant date.  The Company makes no representations or warranties as to an Award&#8217;s tax treatment under Section&#160;409A or otherwise.  The Company will have no obligation under this Section&#160;10.7 or otherwise to avoid the taxes, penalties or interest under Section&#160;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#8220;nonqualified deferred compensation&#8221; subject to taxes, penalties or interest under Section&#160;409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If an Award constitutes &#8220;nonqualified deferred compensation&#8221; under Section&#160;409A, any payment or settlement of such Award upon a termination of a Participant&#8217;s Service Provider relationship will, to the extent necessary to avoid taxes under Section&#160;409A, be made only upon the Participant&#8217;s &#8220;separation from service&#8221; (within the meaning of Section&#160;409A), whether such &#8220;separation from service&#8221; occurs upon or after the termination of the Participant&#8217;s Service Provider relationship.  For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms means a &#8220;separation from service.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payments to Specified Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s) of &#8220;nonqualified deferred compensation&#8221; required to be made under an Award to a &#8220;specified employee&#8221; (as defined under Section&#160;409A and as the Administrator determines) due to his or her &#8220;separation from service&#8221; will, to the extent necessary to avoid taxes under Section&#160;409A(a)(2)(B)(i) of the Code, be delayed for the six-month period immediately following such &#8220;separation from service&#8221; (or, if earlier, until the specified employee&#8217;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such six-month period or as soon as administratively practicable thereafter (without interest).  Any payments of &#8220;nonqualified deferred compensation&#8221; under such Award payable more than six months following the Participant&#8217;s &#8220;separation from service&#8221; will be paid at the time or times the payments are otherwise scheduled to be made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations on Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other employee or agent of the Company or any Subsidiary.  The Company will indemnify and hold harmless each director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#8217;s administration or interpretation, against any cost or expense (including attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#8217;s approval) arising from any act or omission concerning this Plan unless arising from such person&#8217;s own fraud or bad faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lock-Up Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may, at the request of any underwriter representative or otherwise, in connection with registering the offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring any Shares or other Company securities during a period of up to one hundred eighty days following the effective date of a Company registration statement filed under the Securities Act, or such longer period as determined by the underwriter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#8217;s participation in the Plan.  The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#8217;s name, address and telephone number&#59; birthdate&#59; social security, insurance number or other identification number&#59; salary&#59; nationality&#59; job title(s)&#59; any Shares held in the Company or its Subsidiaries and affiliates&#59; and Award details, to implement, manage and administer the Plan and Awards (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#8217;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management.  These recipients may be located in the Participant&#8217;s country, or elsewhere, and the Participant&#8217;s country may have different data privacy laws and protections than the recipients&#8217; country.  By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement, administer and manage the Participant&#8217;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares.  The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#8217;s participation in the Plan.  A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this Section&#160;10.10 in writing, without cost, by contacting the local human resources representative.  The Company may cancel Participant&#8217;s ability to participate in the Plan and, in the Administrator&#8217;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws the consents in this Section&#160;10.10.  For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If any contradiction occurs between the Plan and any Award Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan will not apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state&#8217;s choice-of-law principles requiring the application of a jurisdiction&#8217;s laws other than the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Claw-back Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  All Awards (including any proceeds, gains or other economic benefit the Participant actually or constructively receives upon receipt or exercise of any Award or the receipt or resale of any Shares underlying the Award) will be subject to any Company claw-back policy, including any claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder) as set forth in such claw-back policy or the Award Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Titles and Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#8217;s text, rather than such titles or headings, will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws.  Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws.  To the extent Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Relationship to Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in writing in such other plan or an agreement thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Broker-Assisted Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&#160;9.5&#58; (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable&#59; (b) such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an average price&#59; (c) the applicable Participant will be responsible for all broker&#8217;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale&#59; (d) to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable&#59; (e) the Company and its designees are under no obligation to arrange for such sale at any particular price&#59; and (f) in the event the proceeds of such sale are insufficient to satisfy the Participant&#8217;s applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#8217;s obligation.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE XI.<br>DEFINITIONS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As used in the Plan, the following words and phrases will have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.1&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Board or a Committee to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such Committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.2&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.3&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Other Stock or Cash Based Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.4&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.5&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.6&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (i) if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term &#8220;cause&#8221; is defined (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Relevant Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), &#8220;Cause&#8221; as defined in the Relevant Agreement, and (ii) if no Relevant Agreement exists, (A) the Administrator&#8217;s determination that the Participant failed to substantially perform the Participant&#8217;s duties (other than a failure resulting from the Participant&#8217;s Disability)&#59; (B) the Administrator&#8217;s determination that the Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or the Participant&#8217;s immediate supervisor&#59; (C) the occurrence of any act or omission by the Participant that could reasonably be expected to result in (or has resulted in) the Participant&#8217;s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for any felony or indictable offense or crime involving moral turpitude&#59; (D) the Participant&#8217;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participant&#8217;s duties and responsibilities for the Company or any of its Subsidiaries&#59; or (E) the Participant&#8217;s commission of an act of fraud, embezzlement, misappropriation, misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.7&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means and includes each of the following&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection&#160;(c) below) whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections&#160;13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the Directors then still in office who either were Directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x)&#160;a merger, consolidation, reorganization, or business combination or (y)&#160;a sale or other disposition of all or substantially all of the Company&#8217;s assets in any single transaction or series of related transactions or (z)&#160;the acquisition of assets or stock of another entity, in each case other than a transaction&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Successor Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section&#160;409A, to the extent required to avoid the imposition of additional taxes under Section&#160;409A, the transaction or event described in subsection&#160;(a), (b) or (c) with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &#8220;change in control event,&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto&#59; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#8220;change in control event&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5) shall be consistent with such regulation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.8&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.9&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means one or more committees or subcommittees of the Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit.  To the extent required to comply with the provisions of Rule 16b-3, it is intended that each member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule 16b-3, a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3&#59; however, a Committee member&#8217;s failure to qualify as a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3 will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.10&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the common stock of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.11&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Cartesian Therapeutics, Inc., a Delaware corporation, or any successor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.12&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render services to such entity if the consultant or adviser&#58; (i)&#160;renders bona fide services to the Company&#59; (ii)&#160;renders services not in connection with the offer or sale of securities in a capital-raising transaction and does not directly or indirectly promote or maintain a market for the Company&#8217;s securities&#59; and (iii)&#160;is a natural person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.13&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Designated Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rights if the Participant dies or becomes incapacitated.  Without a Participant&#8217;s effective designation, &#8220;Designated Beneficiary&#8221; will mean the Participant&#8217;s estate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.14&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Board member.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.15&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a permanent and total disability under Section&#160;22(e)(3) of the Code, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.16&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a right granted to a Participant under the Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.17&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Eligible Individual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any individual who was not previously an Employee or Director hired as a new Employee or rehired as an Employee following a bona fide period of interruption of employment if such person is granted an Award as a material inducement to his or her entering into employment with the Company or a Subsidiary (within the meaning of the NASDAQ Rule 5635(c)(4)).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.18&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any employee of the Company or its Subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.19&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Equity Restructuring</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of Shares (or other Company securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.20&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.21&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as of any date, the value of Common Stock determined as follows&#58; (i)&#160;if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable&#59; (ii)&#160;if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable&#59; or (iii) without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.22&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Incentive Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an Option intended to qualify as an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.23&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Independent Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Director who qualifies as &#8220;independent&#8221; within the meaning of NASDAQ Rule 5635(c)(4), or any successor rule, as such rule may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.24&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">NASDAQ Rule 5635(c)(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means NASDAQ Rule 5635(c)(4), or any successor rule, and all guidance and other interpretative authority thereunder, as such rule, guidance and other authority may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.25&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Non-Qualified Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an Option not intended to qualify as an Incentive Stock Option.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.26&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an option to purchase Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.27&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Other Stock or Cash Based Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.28&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Overall Share Limit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means 976,666.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.29&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an Eligible Individual who has been granted an Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.30&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Performance Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; mean the criteria (and adjustments) that the Administrator may select for an Award to establish performance goals for a performance period, which may include the following&#58; net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense)&#59; gross or net sales or revenue or sales or revenue growth&#59; net income (either before or after taxes) or adjusted net income&#59; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin&#59; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus)&#59; cash flow (including operating cash flow and free cash flow or cash flow return on capital)&#59; return on assets&#59; return on capital or invested capital&#59; cost of capital&#59; return on stockholders&#8217; equity&#59; total stockholder return&#59; return on sales&#59; costs, reductions in costs and cost control measures&#59; expenses&#59; working capital&#59; earnings or loss per share&#59; adjusted earnings or loss per share&#59; price per share or dividends per share (or appreciation in or maintenance of such price or dividends)&#59; regulatory achievements or compliance&#59; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments&#59; market share&#59; economic value or economic value added models&#59; division, group or corporate financial goals&#59; customer satisfaction&#47;growth&#59; customer service&#59; employee satisfaction&#59; recruitment and maintenance of personnel&#59; human resources management&#59; supervision of litigation and other legal matters&#59; strategic partnerships and transactions&#59; financial ratios (including those measuring liquidity, activity, profitability or leverage)&#59; debt levels or reductions&#59; sales-related goals&#59; financing and other capital raising transactions&#59; cash on hand&#59; acquisition activity&#59; investment sourcing activity&#59; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the Company&#8217;s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies.  The Committee may provide for exclusion of the impact of an event or occurrence which the Committee determines should appropriately be excluded, including (a) restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring or non-recurring charges or events, (b) asset write-downs, (c) litigation or claim judgments or settlements, (d) acquisitions or divestitures, (e) reorganization or change in the corporate structure or capital structure of the Company, (f) an event either not directly related to the operations of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control of management, (g) foreign exchange gains and losses, (h) a change in the fiscal year of the Company, (i) the refinancing or repurchase of bank loans or debt securities, (j) unbudgeted capital expenditures, (k) the issuance or repurchase of equity securities and other changes in the number of outstanding shares, (l) conversion of some or all of convertible securities to Common Stock, (m) any business interruption event, (n) the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted accounting principles, or (o) the effect of changes in other laws or regulatory rules affecting reported results.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.31&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means this 2018 Employment Inducement Incentive Award Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.32&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Shares awarded to a Participant under Article&#160;VI subject to certain vesting conditions and other restrictions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.33&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date, subject to certain vesting conditions and other restrictions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.34&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Rule 16b-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Rule 16b-3 promulgated under the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.35&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Section&#160;409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.36&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.37&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Service Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an Employee, Consultant or Director.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.38&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means shares of Common Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.39&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock Appreciation Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a stock appreciation right granted under Article&#160;V.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.40&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.41&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the date the Participant ceases to be a Service Provider.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">*&#160;*&#160;*&#160;*&#160;*</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="i5940c6df2b214e5cba09811280a63386_85"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CARTESIAN THERAPEUTICS, INC.<br>AMENDED AND RESTATED 2018 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT GRANT NOTICE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) have the meanings given to them in the Amended and Restated 2018 Employment Inducement Incentive Award Plan (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Cartesian Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has granted to the participant listed below (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) the Restricted Stock Units described in this Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), subject to the terms and conditions of the Plan and the Restricted Stock Unit Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), both of which are incorporated into this Grant Notice by reference.  </font></div><div style="padding-left:6.3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Number of RSUs&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Commencement Date&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;To be specified in individual award agreements&#93;</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By Participant&#8217;s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement.  Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CARTESIAN THERAPEUTICS, INC.</font></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PARTICIPANT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="6" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:-3.23pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Participant Name&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><div id="i5940c6df2b214e5cba09811280a63386_102"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE I.<br>GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Award of RSUs and Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Each RSU represents the right to receive one Share or, at the option of the Company, an amount of cash, in either case, as set forth in this Agreement.  Participant will have no right to the distribution of any Shares or payment of any cash until the time (if ever) the RSUs have vested.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Company hereby grants to Participant, with respect to each RSU, a Dividend Equivalent for ordinary cash dividends paid to substantially all holders of outstanding Shares with a record date after the Grant Date and prior to the date the applicable RSU is settled, forfeited or otherwise expires.  Each Dividend Equivalent entitles Participant to receive the equivalent value of any such ordinary cash dividends paid on a single Share.  The Company will establish a separate Dividend Equivalent bookkeeping account (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Dividend Equivalent Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for each Dividend Equivalent and credit the Dividend Equivalent Account (without interest) on the applicable dividend payment date with the amount of any such cash paid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incorporation of Terms of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Unsecured Promise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The RSUs and Dividend Equivalents will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Inducement Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The RSUs are intended to constitute an &#8220;employment inducement award&#8221; under NASDAQ Rule 5635(c)(4) that is exempt from the requirements of shareholder approval of equity-compensation plans under NASDAQ Rule 5635(c)(4).  This Agreement and the terms and conditions of the RSUs will be interpreted consistent with such intent.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE II.<br>VESTING&#59; FORFEITURE AND SETTLEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting&#59; Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The RSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated.  In the event of Participant&#8217;s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.  Dividend Equivalents (including any Dividend Equivalent Account balance) will vest or be forfeited, as applicable, upon the vesting or forfeiture of the RSU with respect to which the Dividend Equivalent (including the Dividend Equivalent Account) relates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;RSUs and Dividend Equivalents (including any Dividend Equivalent Account balance) will be paid in Shares or cash at the Company&#8217;s option as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than sixty (60) days after the RSU&#8217;s vesting date.  Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of taxes under Section&#160;409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If an RSU is paid in cash, the amount of cash paid with respect to the RSU will equal the Fair Market Value of a Share on the day immediately preceding the payment date.  If a Dividend Equivalent is paid in Shares, the number of Shares paid with respect to the Dividend Equivalent will equal the quotient, rounded down to the nearest whole Share, of the Dividend Equivalent Account balance divided by the Fair Market Value of a Share on the day immediately preceding the payment date.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE III.<br>TAXATION AND TAX WITHHOLDING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Representation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement.  Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company has the right and option, but not the obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the RSUs or Dividend Equivalents as Participant&#8217;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs and the Dividend Equivalents, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the RSUs or Dividend Equivalents.  Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the RSUs or the Dividend Equivalents or the subsequent sale of Shares.  The Company and the Subsidiaries do not commit and are under no obligation to structure the RSUs or Dividend Equivalents to reduce or eliminate Participant&#8217;s tax liability.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE IV.<br>OTHER PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participant acknowledges that the RSUs, the Shares subject to the RSUs and the Dividend Equivalents are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">principal office or the Secretary&#8217;s then-current email address or facsimile number.  Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files.  By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party.  Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, the RSUs and the Dividend Equivalents will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule.  To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement Severable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Participant&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs and Dividend Equivalents, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the RSUs and Dividend Equivalents, as and when settled pursuant to the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Not a Contract of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">*&#160;*&#160;*&#160;*&#160;*</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-4</font></div></div></div><div id="i5940c6df2b214e5cba09811280a63386_97"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CARTESIAN THERAPEUTICS, INC.<br>AMENDED AND RESTATED 2018 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">STOCK OPTION GRANT NOTICE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Capitalized terms not specifically defined in this Stock Option Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) have the meanings given to them in the Amended and Restated 2018 Employment Inducement Incentive Award Plan (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Cartesian Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has granted to the participant listed below (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) the stock option described in this Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), subject to the terms and conditions of the Plan and the Stock Option Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), both of which are incorporated into this Grant Notice by reference.</font></div><div style="padding-left:6.3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exercise Price per Share&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Shares Subject to the Option&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Final Expiration Date&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Commencement Date&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;To be specified in individual award agreements&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Type of Option</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Qualified Stock Option</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By Participant&#8217;s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement.  Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.  </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CARTESIAN THERAPEUTICS, INC.</font></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PARTICIPANT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="6" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:-3.23pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Participant Name&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><div id="i5940c6df2b214e5cba09811280a63386_92"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">STOCK OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE I.<br>GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company has granted to Participant the Option effective as of the grant date set forth in the Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incorporation of Terms of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Option is subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Inducement Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Option is intended to constitute an &#8220;employment inducement award&#8221; under NASDAQ Rule 5635(c)(4) that is exempt from the requirements of shareholder approval of equity-compensation plans under NASDAQ Rule 5635(c)(4). This Agreement and the terms and conditions of the Option will be interpreted consistent with such intent.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE II.<br>PERIOD OF EXERCISABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement of Exercisability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Option will vest and become exercisable according to the vesting schedule in the Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) except that any fraction of a Share as to which the Option would be vested or exercisable will be accumulated and will vest and become exercisable only when a whole Share has accumulated.  Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, unless the Administrator otherwise determines, the Option will immediately expire and be forfeited as to any portion that is not vested and exercisable as of Participant&#8217;s Termination of Service for any reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Duration of Exercisability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Vesting Schedule is cumulative.  Any portion of the Option which vests and becomes exercisable will remain vested and exercisable until the Option expires.  The Option will be forfeited immediately upon its expiration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Expiration of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Option may not be exercised to any extent by anyone after, and will expire on, the first of the following to occur&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The final expiration date in the Grant Notice&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Except as the Administrator may otherwise approve, the expiration of three (3) months from the date of Participant&#8217;s Termination of Service, unless Participant&#8217;s Termination of Service is for Cause or by reason of Participant&#8217;s death or Disability&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Except as the Administrator may otherwise approve, the expiration of one (1) year from the date of Participant&#8217;s Termination of Service by reason of Participant&#8217;s death or Disability&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Except as the Administrator may otherwise approve, Participant&#8217;s Termination of Service for Cause. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE III.<br>EXERCISE OF OPTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Person Eligible to Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During Participant&#8217;s lifetime, only Participant may exercise the Option.  After Participant&#8217;s death, any exercisable portion of the Option may, prior to the time the Option expires, be exercised by Participant&#8217;s Designated Beneficiary as provided in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Partial Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be exercised for whole Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company has the right and option, but not the obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the Option as Participant&#8217;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the Option, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Option.  Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares.  The Company and the Subsidiaries do not commit and are under no obligation to structure the Option to reduce or eliminate Participant&#8217;s tax liability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Exempt Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If Participant is an Employee in the United States who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option will not be first exercisable until at least six (6) months following the Grant Date (although the Option may vest prior to such date if provided for pursuant to the Vesting Schedule). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such Participant dies or suffers a Disability, (ii) upon a Change in Control, or (iii) upon the Participant&#8217;s retirement (as determined in accordance with the Company&#8217;s then current employment policies and guidelines), the vested portion of the Option may be exercised earlier than six (6) months following the Grant Date. The foregoing provision is intended to operate so that any income derived by a Participant who is a non-exempt Employee in connection with the exercise or vesting of an Option will be exempt from his or her regular rate of pay.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE IV.<br>OTHER PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number.  Any notice to be given </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files.  By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party.  Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are requirements for the application of such exemptive rule.  To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan, the Grant Notice and this Agreement (including any exhibit&#160;hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement Severable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Participant&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Not a Contract of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">*&#160;*&#160;*&#160;*&#160;*</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-4</font></div></div></div><div id="i5940c6df2b214e5cba09811280a63386_118"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CARTESIAN THERAPUETICS, INC.<br>AMENDED AND RESTATED 2018 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESTRICTED STOCK GRANT NOTICE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) have the meanings given to them in the Amended and Restated 2018 Employment Inducement Incentive Award Plan (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Cartesian Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has granted to the participant listed below (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the shares of Restricted Stock described in this Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), subject to the terms and conditions of the Plan and the Restricted Stock Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), both of which are incorporated into this Grant Notice by reference.  </font></div><div style="padding-left:6.3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Number of Restricted Shares&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Commencement Date&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;To be specified in individual award agreements&#93;</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By Participant&#8217;s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement.  Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CARTESIAN THERAPEUTICS, INC.</font></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PARTICIPANT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="6" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:-3.23pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Participant Name&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i5940c6df2b214e5cba09811280a63386_42"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESTRICTED STOCK AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE I.<br>GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance of Restricted Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company will issue the Restricted Shares to the Participant effective as of the grant date set forth in the Grant Notice and will cause (a) a stock certificate or certificates representing the Restricted Shares to be registered in Participant&#8217;s name or (b) the Restricted Shares to be held in book-entry form.  If a stock certificate is issued, the certificate will be delivered to, and held in accordance with this Agreement by, the Company or its authorized representatives and will bear the restrictive legends required by this Agreement.  If the Restricted Shares are held in book-entry form, then the book-entry will indicate that the Restricted Shares are subject to the restrictions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incorporation of Terms of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Restricted Shares are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Inducement Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Restricted Shares are intended to constitute an &#8220;employment inducement award&#8221; under NASDAQ Rule 5635(c)(4) that is exempt from the requirements of shareholder approval of equity-compensation plans under NASDAQ Rule 5635(c)(4).  This Agreement and the terms and conditions of the Restricted Shares will be interpreted consistent with such intent.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE II.<br>VESTING, FORFEITURE AND ESCROW</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Restricted Shares will become vested Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Vested Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) according to the vesting schedule in the Grant Notice except that any fraction of a Share that would otherwise become a Vested Share will be accumulated and will become a Vested Share only when a whole Vested Share has accumulated.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event of Participant&#8217;s Termination of Service for any reason, Participant will immediately and automatically forfeit to the Company any Shares that are not Vested Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unvested Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at the time of Participant&#8217;s Termination of Service, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.  Upon forfeiture of Unvested Shares, the Company will become the legal and beneficial owner of the Unvested Shares and all related interests and Participant will have no further rights with respect to the Unvested Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Escrow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Unvested Shares will be held by the Company or its authorized representatives until (i) they are forfeited, (ii) they become Vested Shares or (iii) this Agreement is no longer in effect.  By accepting this Award, Participant appoints the Company and its authorized representatives as Participant&#8217;s attorney(s)-in-fact to take all actions necessary to effect any transfer of forfeited Unvested Shares (and Retained Distributions (as defined below), if any, paid on such forfeited Unvested Shares) to the Company as may be required pursuant to the Plan or this Agreement and to execute such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">representations or other documents or assurances as the Company or such representatives deem necessary or advisable in connection with any such transfer.  The Company, or its authorized representative, will not be liable for any good faith act or omission with respect to the holding in escrow or transfer of the Restricted Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;All cash dividends and other distributions made or declared with respect to Unvested Shares (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Retained Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) will be held by the Company until the time (if ever) when the Unvested Shares to which such Retained Distributions relate become Vested Shares.  The Company will establish a separate Retained Distribution bookkeeping account (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Retained Distribution Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for each Unvested Share with respect to which Retained Distributions have been made or declared in cash and credit the Retained Distribution Account (without interest) on the date of payment with the amount of such cash made or declared with respect to the Unvested Share.  Retained Distributions (including any Retained Distribution Account balance) will immediately and automatically be forfeited upon forfeiture of the Unvested Share with respect to which the Retained Distributions were paid or declared.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;As soon as reasonably practicable following the date on which an Unvested Share becomes a Vested Share, the Company will (i) cause the certificate (or a new certificate without the legend required by this Agreement, if Participant so requests) representing the Share to be delivered to Participant or, if the Share is held in book-entry form, cause the notations indicating the Share is subject to the restrictions of this Agreement to be removed and (ii) pay to Participant the Retained Distributions relating to the Share.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Rights as Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as otherwise provided in this Agreement or the Plan, upon issuance of the Restricted Shares by the Company, Participant will have all the rights of a stockholder with respect to the Restricted Shares, including the right to vote the Restricted Shares and to receive dividends or other distributions paid or made with respect to the Restricted Shares.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE III.<br>TAXATION AND TAX WITHHOLDING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Representation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax consequences of the Restricted Shares and the transactions contemplated by the Grant Notice and this Agreement.  Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 83(b) Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If Participant makes an election under Section 83(b) of the Code with respect to the Restricted Shares, Participant will deliver a copy of the election to the Company promptly after filing the election with the Internal Revenue Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company has the right and option, but not the obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the Restricted Shares as Participant&#8217;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise deliverable under the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the Restricted Shares, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Restricted Shares.  Neither the Company nor any Subsidiary makes any representation or undertaking </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the Restricted Shares or the subsequent sale of the Restricted Shares.  The Company and the Subsidiaries do not commit and are under no obligation to structure this Award to reduce or eliminate Participant&#8217;s tax liability.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE IV.<br>RESTRICTIVE LEGENDS AND TRANSFERABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Any certificate representing a Restricted Share will bear the following legend until the Restricted Share becomes a Vested Share&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO FORFEITURE IN FAVOR OF THE COMPANY AND MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF A RESTRICTED STOCK AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Restricted Shares and any Retained Distributions are subject to the restrictions on transfer in the Plan and may not be sold, assigned or transferred in any manner unless and until they become Vested Shares.  Any attempted transfer or disposition of Unvested Shares or related Retained Distributions prior to the time the Unvested Shares become Vested Shares will be null and void.  The Company will not be required to (a)&#160;transfer on its books any Restricted Share that has been sold or otherwise transferred in violation of this Agreement or (b)&#160; treat as owner of such Restricted Share or accord the right to vote or pay dividends to any purchaser or other transferee to whom such Restricted Share has been so transferred.  The Company may issue appropriate &#8220;stop transfer&#8221; instructions to its transfer agent, if any, or make appropriate notations to the same effect in its records.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE V.<br>OTHER PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participant acknowledges that the Restricted Shares are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number.  Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files.  By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party.  Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer set forth in this Agreement or the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Restricted Shares will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule.  To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan, the Grant Notice and this Agreement (including any exhibit&#160;hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement Severable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Participant&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Not a Contract of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">*&#160;*&#160;*&#160;*&#160;*</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>exhibit105non-employeedire.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i3e2c4e321c6f493087717804467aa920_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.5</font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CARTESIAN THERAPEUTICS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-employee members of the board of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of Cartesian Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as amended by the Board effective December 12,2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) who is entitled to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company.  This Program shall remain in effect until it is revised or rescinded by further action of the Board.  This Program may be amended, modified or terminated by the Board at any time in its sole discretion.  The terms and conditions of this Program shall supersede any prior cash and&#47;or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors.  No Non-Employee Director shall have any rights hereunder, except with respect to stock options or restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) granted pursuant to the Program.  This Program shall become effective on the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.34pt">CASH COMPENSATION</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.28pt;text-decoration:underline">Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Non-Employee Director shall receive an annual retainer of $40,000 for service on the Board.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Additional Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition, each Non-Employee Director shall receive the following annual retainers&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:28.5pt">Chairperson of the Board or Lead Independent Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as Chairperson of the Board shall receive an additional annual retainer of $35,000 for such service, and a Non-Employee Director serving as Lead Independent Director shall receive an additional annual retainer of $25,000 for such service.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:28.5pt">Audit Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $20,000 for such service.  A Non-Employee Director serving as a member other than the Chairperson of the Audit Committee shall receive an additional annual retainer of $10,000 for such service.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:28.5pt">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $15,000 for such service.  A Non-Employee Director serving as a member other than the Chairperson of the Compensation Committee shall receive an additional annual retainer of $7,500 for such service.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:28.5pt">Nominating and Corporate Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $10,000 for such service.  A Non-Employee Director serving as a member other than the Chairperson of the Nominating and Corporate Governance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Committee shall receive an additional annual retainer of $5,000 for such service.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:28.5pt">Science and Technology Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as Chairperson of the Science and Technology Committee shall receive an additional annual retainer of $15,000 for such service.  A Non-Employee Director serving as a member other than the Chairperson of the Science and Technology Committee shall receive an additional annual retainer of $7,500 for such service.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Payment of Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The annual retainers described in Sections I(A) and I(B) shall be earned on a quarterly basis based on a calendar quarter and shall be paid in cash by the Company in arrears not later than the fifteenth day following the end of each calendar quarter.  In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section I(B), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.68pt">EQUITY COMPENSATION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-Employee Directors shall be granted the equity awards described below.  The awards described below shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s Amended and Restated 2016 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and shall be granted subject to award agreements, including attached exhibits, in substantially the form previously approved by the Board or its delegate.  All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options and RSUs hereby are subject in all respects to the terms of the Equity Plan and the applicable award agreement.  For the avoidance of doubt, the share numbers in Sections II(A) and II(B) shall be subject to adjustment as provided in the Equity Plan, including without limitation with respect to any stock dividend, stock split, reverse stock split or other similar event affecting the Company&#8217;s common stock that is effected prior to the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.28pt;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Non-Employee Director who is initially elected or appointed to the Board after the Effective Date shall receive an option to purchase 17,200 shares of the Company&#8217;s common stock and 5,800 RSUs on the date of such initial election or appointment, except that a Non-Employee Director serving as Lead Independent Director shall receive an option to purchase 17,866 shares of the Company&#8217;s common stock and 5,800 RSUs. The awards described in this Section II(A) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221; No Non-Employee Director shall be granted more than one Initial Award (consisting of both options and RSUs).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Non-Employee Director who (i) has been serving as a Non-Employee Director on the Board for at least six months as of the date of grant of any award made under this Program and (ii) will continue to serve as a Non- Employee Director immediately following such date, shall be automatically granted an option to purchase 7,800 shares of the Company&#8217;s common stock and 2,600 RSUs on the first business day of each new calendar year starting with January 2, 2025, provided, however that if such Non-Employee Director will serve as Chairperson of the Board as of immediately following the date of such date of grant, such Non-Employee Director shall receive an option to purchase 8,000 shares of the Company&#8217;s common stock and 2,600 RSUs on the first </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business day of each new calendar year. The awards described in this Section II(B) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221; For the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at an annual meeting of the Company's stockholders shall only receive an Initial Award in connection with such election, and shall not receive any Subsequent Award on the date of such meeting as well.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Termination of Employment of Employee Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section II(A) above, but to the extent that they are otherwise entitled, will receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section II(B) above.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.28pt;text-decoration:underline">Terms of Awards Granted to Non-Employee Directors</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:28.5pt">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The per share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a share of common stock on the date the option is granted.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:28.5pt">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Initial Award that is an option shall vest and become exercisable in thirty-six (36) substantially equal monthly installments following the date of grant, such that the Initial Award shall be fully vested on the third anniversary of the date of grant, subject to the Non-Employee Director continuing in service as a Non-Employee Director through each such vesting date.  Each Initial Award that is an RSU shall vest and become exercisable in three (3) substantially equal annual installments following the date of grant, such that the Initial Award shall be fully vested on the third anniversary of the date of grant, subject to the Non-Employee Director continuing in service as a Non-Employee Director through each such vesting date. Each Subsequent Award shall vest and become exercisable on the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through each such vesting date.  Unless the Board otherwise determines, any portion of an Initial Award or Subsequent Award which is unvested or unexercisable at the time of a Non-Employee Director&#8217;s termination of service on the Board as a Non-Employee Director shall be immediately forfeited upon such termination of service and shall not thereafter become vested and exercisable.  All of a Non-Employee Director&#8217;s Initial Awards and Subsequent Awards shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity Plan), to the extent outstanding at such time.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:28.5pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The maximum term of each stock option granted to a Non-Employee Director hereunder shall be ten (10) years from the date the option is granted.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.02pt">COMPENSATION LIMITS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in this Program, all compensation payable under this Program will be subject to any limits on the maximum amount of Non-Employee Director compensation set forth in the Equity Plan, as in effect from time to time.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">* * * * *</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>6
<FILENAME>exhibit191insidertradingpo.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iffad3a4d20c64e70acb35aa1fd6f74e0_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CARTESIAN THERAPEUTICS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSIDER TRADING POLICY</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I. &#160;&#160;&#160;&#160;PURPOSE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cartesian Therapeutics, Inc. (&#8220;Cartesian&#8221; or the &#8220;Company&#8221;) has adopted the following policies and procedures with respect to trading in Cartesian securities by members of Company&#8217;s board of directors, officers and employees.  These policies and procedures are designed to help you comply with insider trading laws, handle confidential information properly and avoid potentially embarrassing public disclosures and the appearance of impropriety.  You are receiving this policy because you are a Cartesian officer, director or employee, or an external contractor or consultant who has or may have access to material nonpublic information, and are subject to this policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All directors, officers and employees, and external contractors and consultants who have access to material nonpublic information, are responsible for reading these policies and procedures and complying with them.  Further, even after you are no longer employed by or affiliated with Cartesian, you must maintain the confidentiality of any confidential or proprietary information obtained during your employment or affiliation with Cartesian. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Penalties for violating these policies and procedures may involve any appropriate remedy, including termination of employment.  In addition, the Securities and Exchange Commission (the &#8220;SEC&#8221;) and criminal prosecutors vigorously enforce insider trading laws. Violation of insider trading laws could result in civil and criminal penalties under applicable federal securities laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you have any questions about the application of these policies and procedures, or if you would like to make a request for an exception, please contact the General Counsel.  Although the Chief Executive Officer, Chief Financial Officer and General Counsel generally are responsible for the implementation of these policies and procedures, the Company&#8217;s board of directors may designate employees to carry out any of the duties described below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II. &#160;&#160;&#160;&#160;PERSONS COVERED</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This policy applies to all (i) directors, officers, employees (permanent or temporary, salaried or hourly) and (ii) external contractors and consultants who have access to material nonpublic information, of Cartesian and its subsidiaries, both inside and outside the United States (collectively, &#8220;covered persons&#8221;).  This policy also applies to all immediate family members of covered persons, any other members of the covered person&#8217;s family, and other household members (other than tenants and household employees) of covered persons (collectively, &#8220;family members&#8221;). This policy further applies to all corporations, limited liability companies, partnerships, trusts or other entities controlled by covered persons or family members.</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.&#160;&#160;&#160;&#160;COVERED TRANSACTIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This policy applies to all transactions in all Cartesian securities, which may include common stock, preferred stock, debt securities, warrants or options to acquire common stock, derivative securities, units or any other type of securities that the Company may issue.  This policy also applies to securities of other companies about which you learn material nonpublic information during the course of your relationship with Cartesian. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.&#160;&#160;&#160;&#160;POLICY AGAINST INSIDER TRADING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;General Prohibition Against Insider Trading</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ederal and state laws prohibit &#8220;insider trading,&#8221; the purchase or sale of securities, in breach of a fiduciary duty or other relationship of trust and confidence, on the basis of material nonpublic information about the security.  Any covered person, or any other person designated by this policy, who has material nonpublic information relating to Cartesian may not, until the information becomes public or is no longer material&#58; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">engage in transactions in Cartesian securities, directly or indirectly, except as specifically noted herein&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">recommend the purchase or sale of any Cartesian securities&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">engage in any other action to take personal advantage of that information, including but not limited to, passing on or &#8220;tipping&#8221; that information to someone who uses it for personal gain, regardless of the quantity of securities traded&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">disclose material nonpublic information to persons within Cartesian whose jobs do not require them to have that information, or outside of Cartesian to other persons, including, but not limited to family, friends, business associates, investors and expert consulting firms, unless any such disclosure is made in express accordance with Cartesian&#8217;s policies regarding the protection or authorized external disclosure of information concerning the Company&#59; or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">assist anyone engaged in the above activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tipping arises when a covered person discloses material nonpublic information about Cartesian or another publicly-traded entity to another person or recommends another person to trade in the securities of a company while in possession of material nonpublic information about that company, and that person either (i) trades in a security of the company in respect of which you provided information or (ii) provides the information to a third person who then makes a trade in a related security.  Tipping is illegal even if you do not personally make a trade or otherwise benefit from disclosing the information.</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, any covered person who learns of material nonpublic information about another entity, including an entity with whom Cartesian does business, may not trade in that entity&#8217;s securities until the information becomes public.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Although you may believe it is necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) to engage in a transaction involving Cartesian&#8217;s securities, there are no exceptions to this policy&#8217;s prohibition against insider trading.  Even the appearance of impropriety must be avoided to preserve Cartesian&#8217;s reputation for adhering to the highest standards of conduct. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To ensure compliance with this policy, all covered persons must protect the confidentiality of material nonpublic information, by, for example, avoiding casual conversations about such information in public areas and storing files containing material nonpublic information in secure locations.  This policy also covers communications and postings made through the Internet.  You must not post any nonpublic or confidential information on the Internet, including through chatrooms, discussion groups, or social media platforms. This includes anonymous posts or discussion on the Internet.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Because insider trading law is complex, you should contact the General Counsel if you have any questions about whether information in your possession is material or nonpublic or if a proposed transaction or communication would violate the insider trading laws. You must also report any unauthorized disclosure of material nonpublic information, whether inadvertent or otherwise, immediately to the Chief Executive Officer, Chief Financial Officer and General Counsel.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;What Information is &#8220;Material&#8221;&#63;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the purposes of these policies and procedures, information is &#8220;material&#8221; if a reasonable investor would consider that information important in making a decision to trade securities.  It is also information that, if disclosed, is reasonably likely to affect the market price of Cartesian&#8217;s securities.  Both positive and negative information can be material.  Further, courts and the SEC have declined to identify all information that could be deemed to be material.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Some examples of material information include&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">quarterly or annual earnings information and guidance, including estimates or revisions&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">discussions, proposals or agreements for a significant merger, acquisition or divestiture&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">threatened litigation or administrative actions, or material developments in such matters&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant new or prospective contracts, licensing or collaboration agreements&#59;</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant developments or announcements involving the U.S. Food and Drug Administration and any Cartesian products, product candidates, regulatory applications, or clinical trials&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant changes in marketing, pricing strategies or market share&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant research and development initiatives, clinical studies, clinical data or new product prospects&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in business strategies&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in key members of management&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">a significant cybersecurity breach or incident&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in debt ratings&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">stock splits or changes in dividend policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The foregoing list does not include all of the information that could be deemed to be material. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;What Information is &#8220;Nonpublic&#8221;&#63;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information is &#8220;nonpublic&#8221; if it has not been widely disseminated to the public, such as through a press release carried over a major news service, a public filing with the SEC or materials sent to stockholders (e.g., a proxy statement or widely disseminated prospectus).  Information is also nonpublic if it has been widely disseminated to the public, but sufficient time has not elapsed to permit the investment community to absorb and evaluate the information.  In general, two full business days after public release is deemed sufficient for investor absorption and evaluation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The distribution of information through narrower channels may be insufficient to make it public.  For example, merely posting information on a website may not satisfy the &#8220;widely disseminated&#8221; standard to make such information public.  Also, the fact that nonpublic information is reflected in rumors in the marketplace does not mean that the information has been publicly disseminated.  It is important to note that even after information becomes public, many aspects relating to a matter may remain nonpublic.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">V.  &#160;&#160;&#160;&#160;RULES FOR SPECIFIC TRANSACTIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition to the general prohibition on insider trading described above, certain specific transaction types and related activities are prohibited by this policy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;Participation in Expert Networks or Similar Consulting Arrangements</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You are not permitted to provide information or services about or relating to Cartesian to &#8220;expert network firms&#8221; or similar consulting firms.  Expert network firms may seek to engage you as a consultant due to your knowledge of Cartesian, or your knowledge of our industry overall.  Your provision of such consulting services creates the risk that you may use or disclose, deliberately or inadvertently, Cartesian&#8217;s confidential information or engage, or assist another party in engaging, in activities that are detrimental to or competitive with the Company.  Such activity may also violate federal securities laws.  Accordingly, participation in such organizations is strictly prohibited.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;Derivatives Transactions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You may not engage in derivative transactions involving Cartesian&#8217;s securities.  Derivative transactions are speculative transactions that permit a person to leverage his or her investment using a relatively small amount of money.  Transactions in options (other than stock options issued by Cartesian) may create the appearance that a covered person is trading based on material nonpublic information and may focus a covered person&#8217;s attention on Cartesian&#8217;s short-term performance.  Examples of derivative transactions include, but are not limited to, purchases and sales of put and call options.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;Hedging, Pledging and Lending</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You are prohibited from hedging and lending Cartesian securities in any transaction, including by entering into any short sales, swaps, options, puts, calls, forward contracts or any other similar derivatives transaction. Unless authorized in advance by the Company&#8217;s board of directors, you are prohibited from pledging Cartesian securities in any transaction.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.&#160;&#160;&#160;&#160;Short Sales</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You may not engage in short selling of Cartesian securities.  Selling short includes transactions in which you borrow securities from a broker, sell them, and eventually buy securities on the market to cover the number of securities borrowed from the broker.  Profit is made if the price of the securities decreases during the period of borrowing.  Short sales may evidence an expectation on the part of the seller that the securities will decline in value, and therefore have the potential to signal to the market that the seller lacks confidence in the Company&#8217;s prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E.&#160;&#160;&#160;&#160;Margin Accounts</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You may not engage in purchasing Cartesian securities on margin.  Purchasing Cartesian securities on margin involves the use of borrowed money from a brokerage firm to purchase the securities.  Holding Cartesian securities in a margin account means that the securities can be sold to pay a loan to the brokerage firm.  Covered persons are prohibited from holding Cartesian securities in a margin account because a margin sale might occur at a time when the covered person is aware of material nonpublic information.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F.&#160;&#160;&#160;&#160;Post-Termination Transactions</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You may not engage in trading in Cartesian securities while in the possession of material nonpublic information after your relationship with the Company has ended.  This policy continues to apply to transactions in Cartesian securities even after termination of service to Cartesian.  If an individual is in possession of material non-public information when his or her service terminates, that individual may not trade in Cartesian securities until that information has become public or is no longer material.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VI.&#160;&#160;&#160;&#160;WHEN TRADING IS GENERALLY PERMITTED</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To help directors, officers and employees conduct trades in Cartesian securities in compliance with the general prohibition described above, Cartesian has established mechanisms for effecting trades in the Company&#8217;s securities in compliance with these policies and procedures.  If you are not certain whether a proposed transaction complies with the mechanisms described below, you should contact the General Counsel.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;Window Periods  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company requires that covered persons limit their trading in Company securities to prescribed &#8220;Window Periods.&#8221; The periods between Window Periods are considered &#8220;Blackout Periods&#8221;.  Covered persons may not engage in trades in Company securities during Blackout Periods.  The requirement to make trades during a Window Period does not apply to transactions described below under the headings &#8220;Rule 10b5-1 Plan Trading,&#8221; &#8220;Option Exercises,&#8221; &#8220;Estate Planning and Gifts,&#8221; &#8220;Employee Stock Purchase Plans,&#8221; &#8220;Tax Obligations&#8221; and &#8220;Transactions with the Company.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under this policy, a Window Period begins at market opening on the third business day after the Company has issued its usual press release announcing quarterly results and ends three calendar days prior to the end of the applicable fiscal quarter.  The Company retains the discretion to close a Window Period in the event of any major corporate development that has not been announced to the public.  The closing of any Window Period will be announced by email.  If you think you have any material nonpublic information during the Window Period, however, you must consult the General Counsel before trading Cartesian securities.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cartesian also strongly encourages employees, family members and close associates of any officer, employee or member of the board of directors to confine their trading in Cartesian securities to a Window Period.  While there is no violation of insider trading rules if it can be shown that a family member or other person associated with a director, officer or employee acted independently when trading and without knowledge of material nonpublic information, a strong presumption may arise that material nonpublic information has been shared with such person by the officer, employee or member of the board of directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;Special Blackout Periods</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may impose special periods during which certain covered persons will be prohibited from trading or otherwise effecting transactions in Cartesian securities (&#8220;special blackout periods&#8221;) even though the Window Period would otherwise be open.  This would be </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the case, for example, for Company employees working on a material merger or acquisition transaction, or another event that could involve material nonpublic information.  If a special blackout period is imposed, the Company will notify affected individuals by email.  The Company will also notify affected individuals at the end of such special blackout period.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Please note that special blackout periods may apply to all individuals working on material transactions or other matters that could involve material nonpublic information, even if those individuals only have a limited role in the transaction.  A special blackout period for these matters is not necessarily limited to individuals who are on any particular team or function.  The determination of whether a project or transaction is material will be made by the Chief Executive Officer, Chief Financial Officer and General Counsel.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;Rule 10b5-1 Plan Trading</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To avoid liability for insider trading, officers and members of the board of directors may wish to rely upon the affirmative defenses established by Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).  Rule 10b5-1 is available to an individual or entity who purchases or sells a security under a binding contract, specific instruction or written plan that the person or entity put into place before becoming aware of material nonpublic information (such a written plan, a &#8220;Rule 10b5-1 plan&#8221;).  If the trading plan meets all of the requirements of Rule 10b5-1, Cartesian securities may be purchased and sold under such plan without regard to certain insider trading considerations, and such trades would not be restricted to the window periods under this policy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company strongly encourages any of the following covered persons who wish to trade in Cartesian securities to limit such trading activity to Rule 10b5-1 plans adopted in accordance with this policy&#58; (i) members of the board of directors and (ii) officers appointed by the board of directors.  In addition, other covered persons who wish to trade in Cartesian securities may be encouraged to limit their trading activity to Rule 10b5-1 plans adopted in accordance with this policy, based on the determination of the Chief Executive Officer, Chief Financial Officer or General Counsel.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A covered person who enters into a Rule 10b5-1 plan is strongly discouraged from trading in any securities of the Company outside of the Rule 10b5-1 plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To create a Rule 10b5-1 plan, you must enter into a written plan for trading securities that must&#58; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">specify the amount, price and date of the transaction(s)&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">include a written formula, algorithm or computer program for determining the amount, price and date of the transaction(s)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">not permit the person for whom shares are being purchased or sold to exercise any subsequent influence over how, when or whether to effect purchases or sales, while </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">at the same time ensuring that the person effecting the trades is not aware of any material nonpublic information at the time of the trades.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In order to rely on the defense, a person must adopt a Rule 10b5-1 plan that meets all of the rule&#8217;s requirements.  These include a requirement that the plan include a representation certifying that the person adopting the plan is doing so in good faith, at a time when he or she is not in possession of material nonpublic information and not as part of a plan to evade the insider trading prohibitions.  Additionally, a director or officer adopting a new Rule 10b5-1 plan may not have any other outstanding Rule 10b5-1 plan, and may not subsequently enter into any additional Rule 10b5-1 plan, subject to certain exceptions. Frequent amendment of, or deviation from, a trading plan may make it difficult for an insider to demonstrate that he or she has satisfied the rule&#8217;s &#8220;good faith&#8221; requirement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A Rule 10b5-1 plan must provide for a &#8220;cooling off&#8221; period before purchases and sales can occur under the plan.  For a director or officer, no purchases or sales under the Rule 10b5-1 plan can occur until the later of (i) 90 days after the adoption of the Rule 10b5-1 plan and (ii) two business days following disclosure of the Company&#8217;s results in a Form 10-Q or Form 10-K for a completed fiscal quarter in which the plan was adopted&#59; provided, however, that in no event will the required cooling off period be longer than 120 days after adoption of the Rule 10b5-1 plan. No purchases or sales under a Rule 10b5-1 plan for a person other than a director or officer may be made until 30 days after adoption of the plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Any modification to the amount, pricing, or timing of purchases or sales of securities under a Rule 10b5-1 plan will constitute the termination of the plan and adoption of a new plan, which means that any such modification will trigger the need for the new trading plan to satisfy all of the elements of Rule 10b5-1, including a new cooling off period before trading can begin again.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Stock brokerage firms may assist directors, officers and employees in establishing Rule 10b5-1 plans.  To ensure that such arrangements comply with Rule 10b5-1, Cartesian requires that any covered person who wishes to establish a Rule 10b5-1 plan&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">enter into the required contract, provide the required instructions, or adopt the required plan, during a Window Period and otherwise while not in possession of material nonpublic information&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtain prior approval from the Chief Executive Officer, Chief Financial Officer or General Counsel for such Rule 10b5-1 plan, as well as any amendment of such plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">report promptly to the Chief Executive Officer, Chief Financial Officer and General Counsel all transactions made pursuant to the Rule 10b5-1 plan, as well as any termination of the plan&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">adopt a plan with a duration of at least six months.</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.&#160;&#160;&#160;&#160;Options Exercises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Directors, officers and employees who have stock options or other rights granted by Cartesian to purchase securities from the Company may exercise the options or purchase rights at any time permitted under the terms of the applicable option or other agreement so long as the exercise does not involve a broker-assisted cashless exercise.  This rule applies only to options or purchase rights granted by the Company.  Rules pertaining to options or purchase rights granted by third parties are described in the sections above captioned &#8220;Derivatives Transactions,&#8221; &#8220;Short Sales&#8221; and &#8220;Margin Accounts.&#8221;  Please be aware, however, that any subsequent sale of securities purchased by means of the exercise of stock options or other rights in accordance with this policy must be made during a Window Period, pursuant to a Rule 10b5-1 plan, or otherwise approved by the Chief Executive Officer, Chief Financial Officer or General Counsel.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E.&#160;&#160;&#160;&#160;Estate Planning and Gifts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Directors, officers and employees may at any time make bona fide gifts of Cartesian securities (such as charitable donations or family gifts or estate planning transfers).  Depending on the circumstances, recipients of gifts may be subject to restrictions on subsequent sales of securities.  Any such gifts made by directors and officers subject to Section 16 of the Exchange Act must be reported on Form 4 within two business days of the date of the transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gifts that are part of a plan to circumvent the insider trading rules are not permitted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F.&#160;&#160;&#160;&#160;Employee Stock Purchase Plans </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Purchases of Cartesian stock under the Company&#8217;s employee stock purchase plan, if any, resulting from periodic or lump sum contributions of money thereto, pursuant to an election made at the time of plan enrollment, are not subject to this policy.  Your initial election to participate in the plan, changes to that election for any enrollment period and sales of Cartesian stock purchased pursuant to the plan </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">are</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> subject to this policy and must comply therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">G.&#160;&#160;&#160;&#160;Tax Obligations</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Transactions between covered persons and Cartesian that are undertaken to satisfy tax obligations, such as upon the vesting of restricted stock units and the net issuance of shares, which effectively involves disposing of vested shares to the Company, are exempt under this policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">H. &#160;&#160;&#160;&#160;Transactions with the Company </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Purchases of Cartesian securities by a covered person from the Company, or sales of the Company&#8217;s securities by a covered person to the Company, may be made outside a Window Period with the prior approval of the Chief Executive Officer, Chief Financial Officer or General Counsel. </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VII.&#160;&#160;&#160;&#160;PRE-CLEARANCE PROCEDURES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following Company personnel may not trade or engage in any other transaction involving the Company&#8217;s securities (including a securities plan transaction such as an option exercise, a gift, a loan or pledge, a contribution to a trust or any other transfer) without first obtaining pre-clearance of the transaction from the Chief Executive Officer, Chief Financial Officer or General Counsel&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">all directors and executive officers who trade outside of a Rule 10b5-1 plan entered into in accordance with this policy&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">key financial or investor relations employees as designated by the Chief Executive Officer, Chief Financial Officer or General Counsel&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">all such other individuals as designated by the Chief Executive Officer, Chief Financial Officer or General Counsel.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This pre-clearance requirement applies regardless of whether (i) the individual subject to pre-clearance possesses material nonpublic information regarding the Company or its securities or (ii) the trade occurs during a Window Period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;A request for pre-clearance must be submitted to the Chief Executive Officer, Chief Financial Officer and General Counsel at least two business days prior to consummation of an intended transaction&#59; provided, however, that none of the Chief Executive Officer, Chief Financial Officer or General Counsel may provide pre-clearance for a proposed transaction by him or herself.  Notice may be given orally or in writing and should include in the request (i) the transaction type, (ii) the number and type of securities he or she intends to trade, (iii) the intended transaction date, (iv) a confirmation that he or she has reviewed this policy and (v) a confirmation that he or she is not aware of any material nonpublic information about the Company or its securities.  Approval or denial of the pre-clearance request will be provided to the insider in writing.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If a proposed transaction receives pre-clearance, the pre-cleared trade must be effected by the close of business on the second business day following receipt of pre-clearance unless (i) the insider becomes aware of material nonpublic information or (ii) the insider is advised by the Company that the pre-clearance has been revoked prior to that time.  In the case of either (i) or (ii), the trade must not be completed.  For example, if the pre-clearance were issued on a Friday, it would generally be effective through the close of business on the next Tuesday.  If the transaction order is not placed within this time period, clearance of the transaction must be re-requested.  Notice of a pre-cleared transaction must be provided by the applicable insider to the Chief Executive Officer, Chief Financial Officer and General Counsel on the same date of execution.  Please note that the date of execution is the trade date and not the settlement date.</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIII.&#160;&#160;&#160;&#160;SECTION 16 POLICY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Covered persons who are Company directors and officers subject to Section 16 of the Exchange Act must follow the additional policies and procedures set forth in Annex A to this policy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IX.&#160;&#160;&#160;&#160;INQUIRIES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Any person who has a question about this policy or its application to any proposed transaction may obtain additional guidance from the General Counsel, who can be reached by email at matt.bartholomae&#64;cartesiantx.com.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Adopted on March 20, 2024. </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ANNEX A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADDITIONAL POLICIES AND PROCEDURES ON TRADING CARTESIAN SECURITIES BY COMPANY DIRECTORS AND OFFICERS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I. &#160;&#160;&#160;&#160;INTRODUCTION </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cartesian, Inc. (&#8220;Cartesian&#8221; or the &#8220;Company&#8221;) has adopted the following policies and procedures with respect to trading in Cartesian securities by the Company&#8217;s directors and officers.  These policies and procedures supplement the Cartesian Insider Trading Policy and are designed to help directors and officers comply with the requirements of Section 16 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;All persons subject to this policy are responsible for reading these policies and procedures and complying with them.  You should direct any questions about the application of these policies and procedures or requests for exceptions, to the General Counsel.  Although the Chief Executive Officer, Chief Financial Officer and General Counsel generally are responsible for the implementation of these policies and procedures, the Chief Executive Officer, Chief Financial Officer or General Counsel may designate employees to carry out any of the duties described below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.&#160;&#160;&#160;&#160;PERSONS AFFECTED</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This policy applies to Cartesian&#8217;s directors and officers.  Cartesian&#8217;s board of directors has designated &#8220;officers&#8221; for purposes of Section 16, each of whom will be subject to the reporting requirements and &#8220;short-swing&#8221; profit provisions of Section 16 discussed below.  If you are a director of Cartesian or have been designated as an &#8220;officer&#8221; of Cartesian for the purposes of Section 16, you should read this Annex carefully.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.&#160;&#160;&#160;&#160;REPORTING AND OTHER TRADING RESTRICTIONS UNDER FEDERAL SECURITIES LAWS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 16(a) Reporting Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 16(a) of the Exchange Act requires that Cartesian&#8217;s insiders file electronic beneficial ownership reports in connection with their purchases and sales of the Company&#8217;s securities.  Securities and Exchange Commission (&#8220;SEC&#8221;) rules require that all filings be made with the SEC electronically and on Cartesian&#8217;s website.  Further, Cartesian is required to disclose in its annual proxy statement the names of all insiders who have failed to timely file all required Section 16(a) reports.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Form 3</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;An insider must file a Form 3 (entitled &#8220;Initial Statement of Beneficial Ownership of Securities&#8221;) with the SEC to report that he or she is an insider and his or her ownership interests </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in Cartesian.  Anyone becoming an insider in the future must file a Form 3 within ten days of becoming an insider.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Forms 4 and 5</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;An insider must file a Form 4 (entitled &#8220;Statement of Changes in Beneficial Ownership&#8221;) with the SEC to report a transaction within two business days after the date of such transaction if it results in a change in his or her beneficial ownership of Cartesian&#8217;s equity securities.  There are three general exceptions to the two-business-day reporting requirement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;First, the following types of transactions may be reported on a Form 4 within two business days following the date the insider receives </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">notice of the transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (but in no event later than five business days following the transaction), rather than two business days following the date on which the transaction occurs&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">a transaction pursuant to a Rule 10b5-1 plan under which the insider does not select the date on which the purchases or sales take place&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">a &#8220;discretionary transaction&#8221; (as defined in Rule 16b-3) pursuant to an employee benefit plan for which the insider does not select the date on which transactions take place (such as transfers in or out of, or cash withdrawals from, a company stock fund in a 401(k) plan or other employee benefit plan).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Second, certain transactions may, and in a few instances must, be reported on a year-end Form 5 (entitled &#8220;Annual Statement of Changes in Beneficial Ownership of Securities&#8221;).  A Form 5 must be filed with the SEC within 45 days after the end of such fiscal year by each person who was an insider for any part of a company&#8217;s fiscal year (unless he or she has no transactions to report on the Form 5).  There are certain limited types of stock transactions that the SEC has designated as eligible for Form 5 filing (rather than a Form 4 filing).  Insiders also must report on a Form 5 all transactions that occurred during the fiscal year that should have been, but were not, reported earlier on Form 4.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Third, the following types of transactions do not trigger any Form 4 or Form 5 filing requirement&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">an acquisition under an employee stock purchase plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">a transaction (other than a &#8220;discretionary transaction&#8221;) under certain employee benefit plans, such as pension plans, 401(k) plans, or related excess benefit plans&#59;  </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">an acquisition through a stock split, stock dividend or other pro rata distribution to stockholders of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">an acquisition under certain dividend or interest reinvestment plans&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">an acquisition or disposition as a result of a domestic relations orders (such as a divorce decree). </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Although these transactions do not require the filing of a Form 4 or Form 5, the next Form 4 or Form 5 filed after the occurrence of one of these transactions should reflect the effects of these transactions in the column reporting post-transaction security ownership.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Preparation of Forms 3, 4 and 5</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Although the responsibility for the timely filing of reports and compliance with trading restrictions rests with each individual required to report or comply, the General Counsel will prepare and file Forms 3, 4, and 5 on behalf of insiders who are Company directors and officers.   All Forms 3, 4, and 5 prepared on behalf of an insider will be based on information provided by the insider.  Accordingly, all insiders must fill out and deliver to the General Counsel a Form ID (a form to obtain access codes to file on the SEC&#8217;s electronic filing system).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;B.  &#160;&#160;&#160;&#160;Section 16(b) Short-Swing Profit Liability</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 16(b) of the Exchange Act allows the Company to recover any profit realized by one of its insiders resulting from any combination of purchases and sales of Cartesian&#8217;s equity securities within a period of less than six months.  Such liability arises without regard to whether any such transactions occur during the Window Period referred to above.  Profits are determined for this purpose by matching the highest sales price during the period with the lowest purchase price and are to be recovered even though the insider realized no actual profit for the period or he or she sustained a net loss.  Although the purpose of the statute is to prevent trading on the basis of material nonpublic information, the recovery provision operates without regard to the intent of the insider or the actual possession of material nonpublic information and may not be waived by the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The restrictions on &#8220;short-swing&#8221; trading apply not only to trading in Cartesian&#8217;s securities but also to any &#8220;derivative security.&#8221;  Thus, for example, a grant or exercise of options (other than grants or exercises made under a plan that is exempt from Section 16) would be considered to be a &#8220;purchase&#8221; or sales of Cartesian securities under Section 16.  Other transactions not necessarily thought to involve purchases, such as corporate mergers, also may be covered.  The SEC has exempted certain transactions, such as purchases under employee benefit plans that have been approved by stockholders or the board of directors, from the &#8220;short-swing&#8221; profit recovery provisions of Section 16 (but not the reporting provisions).  Directors and officers remain subject to these Section 16 requirements and restrictions for a period of up to six months after terminating their positions with Cartesian.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>exhibit211subsidiariesofca.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9adaf109534e4a1ea31eb855226d7000_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries of Cartesian Therapeutics, Inc.&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:47.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.858%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selecta (RUS) LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cartesian Bio, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>exhibit231_12312024.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i1a90d07056124acfa9674c80d3688e67_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.02pt">Registration Statement (Form S-8, File No. 333-212215) pertaining to the 2008 Stock Incentive Plan, as amended, the 2016 Incentive Award Plan and the 2016 Employee Stock Purchase Plan of Cartesian Therapeutics, Inc.,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.02pt">Registration Statement (Form S-8, File No. 333-224109) pertaining to the 2016 Incentive Awards Plan and the 2016 Employee Stock Purchase Plan of Cartesian Therapeutics, Inc.,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.02pt">Registration Statement (Form S-8, File No. 333-228264) pertaining to the 2018 Employment Inducement Incentive Award Plan of Cartesian Therapeutics, Inc.,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.02pt">Registration Statement (Form S-8, File No. 333-230501) pertaining to the 2018 Employment Inducement Incentive Award Plan of Cartesian Therapeutics, Inc.,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.02pt">Registration Statement (Form S-8, File No. 333-239075) pertaining to the 2016 Incentive Award Plan and the 2016 Employee Stock Purchase Plan of Cartesian Therapeutics, Inc.,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.02pt">Registration Statement (Form S-8, File No. 333-256061) pertaining to the 2016 Incentive Award Plan and the 2016 Employee Stock Purchase Plan of Cartesian Therapeutics, Inc.,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.02pt">Registration Statement (Form S-8, File No. 333-264691) pertaining to the 2016 Incentive Award Plan and the 2016 Employee Stock Purchase Plan of Cartesian Therapeutics, Inc., </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.02pt">Registration Statement (Form S-8, File No. 333-274036) pertaining to the 2016 Incentive Award Plan and the 2016 Employee Stock Purchase Plan of Cartesian Therapeutics, Inc.,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.02pt">Registration Statement (Form S-3, File No. 333-275171) of Cartesian Therapeutics, Inc., </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.02pt">Registration Statement (Form S-8, File No. 333-276486) pertaining to the 2016 Stock Incentive Plan and the 2018 Employment Inducement Incentive Award Plan of Cartesian Therapeutics, Inc., </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.02pt">Registration Statement (Form S-1, File No. 333-281204) of Cartesian Therapeutics, Inc.,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.02pt">Registration Statement (Form S-8, File No. 333-283049) pertaining to the Amended and Restated 2016 Incentive Award Plan and the Amended and Restated 2018 Employment Inducement Incentive Award Plan of Cartesian Therapeutics, Inc.,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(13)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.02pt">Registration Statement (Form S-3, File No. 333-283803) of Cartesian Therapeutics, Inc.,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(14)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.02pt">Registration Statement (Form S-3, File No. 333-283806) of Cartesian Therapeutics, Inc., and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.02pt">Registration Statement (Form S-3, File No. 333-283809) of Cartesian Therapeutics, Inc.&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of our report dated March&#160;13, 2025 with respect to the consolidated financial statements of Cartesian Therapeutics, Inc. included in this Annual Report (Form 10-K) of Cartesian Therapeutics, Inc. for the year ended December 31, 2024.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Boston, Massachusetts</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March&#160;13, 2025</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>exhibit311_12312024.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i58e015698afb40a48618e9240baad09a_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Carsten Brunn, Ph.D., certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Cartesian Therapeutics, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Carsten Brunn, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer, and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>exhibit312_12312024.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie893437b8f03402b9299f8be4ed8021b_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Blaine Davis, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Cartesian Therapeutics, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Blaine Davis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blaine Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>exhibit321_12312024.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i928286ea51c5447d9becc8185c279b9c_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:63pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Cartesian Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Annual Report on Form 10-K of the Company for the period ended December 31, 2024 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Carsten Brunn, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer, and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Blaine Davis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blaine Davis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>rnac-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f87b4d67-655c-40f8-bf99-5c1eb72d37a4,g:ec248d9b-f7a4-4998-8c2a-3c79ab383104-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rnac="http://www.cartesiantherapeutics.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cartesiantherapeutics.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rnac-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rnac-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rnac-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rnac-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cartesiantherapeutics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.cartesiantherapeutics.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>9952154 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals" roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals">
        <link:definition>9952155 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.cartesiantherapeutics.com/role/DescriptionoftheBusiness">
        <link:definition>9952157 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.cartesiantherapeutics.com/role/BasisofPresentation">
        <link:definition>9952158 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952159 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Merger" roleURI="http://www.cartesiantherapeutics.com/role/Merger">
        <link:definition>9952160 - Disclosure - Merger</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAllocabletoCommonStockholders" roleURI="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholders">
        <link:definition>9952161 - Disclosure - Net Loss Per Share Allocable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurements">
        <link:definition>9952162 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.cartesiantherapeutics.com/role/PropertyandEquipment">
        <link:definition>9952163 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.cartesiantherapeutics.com/role/AccruedExpenses">
        <link:definition>9952164 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cartesiantherapeutics.com/role/Leases">
        <link:definition>9952165 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.cartesiantherapeutics.com/role/Debt">
        <link:definition>9952166 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStock" roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStock">
        <link:definition>9952167 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.cartesiantherapeutics.com/role/Equity">
        <link:definition>9952168 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlans" roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlans">
        <link:definition>9952169 - Disclosure - Stock Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueArrangements" roleURI="http://www.cartesiantherapeutics.com/role/RevenueArrangements">
        <link:definition>9952170 - Disclosure - Revenue Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactions">
        <link:definition>9952171 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreements">
        <link:definition>9952172 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxes">
        <link:definition>9952173 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlans">
        <link:definition>9952174 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cartesiantherapeutics.com/role/CommitmentsandContingencies">
        <link:definition>9952175 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.cartesiantherapeutics.com/role/Restructuring">
        <link:definition>9952176 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.cartesiantherapeutics.com/role/SegmentReporting">
        <link:definition>9952177 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.cartesiantherapeutics.com/role/SubsequentEvents">
        <link:definition>9952178 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerTables" roleURI="http://www.cartesiantherapeutics.com/role/MergerTables">
        <link:definition>9955512 - Disclosure - Merger (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAllocabletoCommonStockholdersTables" roleURI="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersTables">
        <link:definition>9955513 - Disclosure - Net Loss Per Share Allocable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsTables">
        <link:definition>9955514 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentTables">
        <link:definition>9955515 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.cartesiantherapeutics.com/role/AccruedExpensesTables">
        <link:definition>9955516 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cartesiantherapeutics.com/role/LeasesTables">
        <link:definition>9955517 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.cartesiantherapeutics.com/role/EquityTables">
        <link:definition>9955518 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansTables" roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansTables">
        <link:definition>9955519 - Disclosure - Stock Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueArrangementsTables" roleURI="http://www.cartesiantherapeutics.com/role/RevenueArrangementsTables">
        <link:definition>9955520 - Disclosure - Revenue Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsTables">
        <link:definition>9955521 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesTables">
        <link:definition>9955522 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.cartesiantherapeutics.com/role/RestructuringTables">
        <link:definition>9955523 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.cartesiantherapeutics.com/role/SegmentReportingTables">
        <link:definition>9955524 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessDetails" roleURI="http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails">
        <link:definition>9955525 - Disclosure - Description of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationDetails" roleURI="http://www.cartesiantherapeutics.com/role/BasisofPresentationDetails">
        <link:definition>9955526 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9955527 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails">
        <link:definition>9955528 - Disclosure - Merger - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerScheduleofFairValueofConsiderationDetails" roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails">
        <link:definition>9955529 - Disclosure - Merger - Schedule of Fair Value of Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>9955530 - Disclosure - Merger - Schedule of Allocation of the Purchase Price to the Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerScheduleofIntangibleAssetsAcquiredDetails" roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails">
        <link:definition>9955531 - Disclosure - Merger - Schedule of Intangible Assets Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerScheduleofProFormaFinancialInformationDetails" roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofProFormaFinancialInformationDetails">
        <link:definition>9955532 - Disclosure - Merger - Schedule of Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails" roleURI="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails">
        <link:definition>9955533 - Disclosure - Net Loss Per Share Allocable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails" roleURI="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails">
        <link:definition>9955534 - Disclosure - Net Loss Per Share Allocable to Common Stockholders - Schedule of Potential Dilutive Shares of Common Stock Excluded from the Computation of the Diluted Net Loss Per Share Allocable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9955535 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9955536 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9955537 - Disclosure - Fair Value Measurements - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails" roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails">
        <link:definition>9955538 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for Warrants Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails" roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails">
        <link:definition>9955539 - Disclosure - Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Company&#8217;s Level 3 Warrant Liabilities and CVR Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails" roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails">
        <link:definition>9955540 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for CVR Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails" roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails">
        <link:definition>9955541 - Disclosure - Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Forward Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>9955542 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>9955543 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails">
        <link:definition>9955544 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases7495NewHorizonWayLeasesNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails">
        <link:definition>9955545 - Disclosure - Leases - 7495 New Horizon Way Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases65GroveStreetLeaseNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails">
        <link:definition>9955546 - Disclosure - Leases - 65 Grove Street Lease (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases704QuinceOrchardRoadLeasesNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails">
        <link:definition>9955547 - Disclosure - Leases - 704 Quince Orchard Road Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMoscowRussiaLeaseNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails">
        <link:definition>9955548 - Disclosure - Leases - Moscow, Russia Lease (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofLeaseCostsDetails" roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails">
        <link:definition>9955549 - Disclosure - Leases - Schedule of Components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails" roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails">
        <link:definition>9955550 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>9955550 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalDisclosurefortheStatementofCashFlowsRelatedtoOperatingLeasesDetails" roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofSupplementalDisclosurefortheStatementofCashFlowsRelatedtoOperatingLeasesDetails">
        <link:definition>9955551 - Disclosure - Leases - Schedule of Supplemental Disclosure for the Statement of Cash Flows Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails" roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails">
        <link:definition>9955552 - Disclosure - Leases - Schedule of Additional Information Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.cartesiantherapeutics.com/role/DebtDetails">
        <link:definition>9955553 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails">
        <link:definition>9955554 - Disclosure - Convertible Preferred Stock - Series B Preferred Stock (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails">
        <link:definition>9955555 - Disclosure - Convertible Preferred Stock - Series A Preferred Stock (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockConversionNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails">
        <link:definition>9955556 - Disclosure - Convertible Preferred Stock - Conversion (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockRedemptionNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockRedemptionNarrativeDetails">
        <link:definition>9955557 - Disclosure - Convertible Preferred Stock - Redemption (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockVotingNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockVotingNarrativeDetails">
        <link:definition>9955558 - Disclosure - Convertible Preferred Stock - Voting (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockLiquidationNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails">
        <link:definition>9955559 - Disclosure - Convertible Preferred Stock - Liquidation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity2024PrivatePlacementNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails">
        <link:definition>9955560 - Disclosure - Equity - 2024 Private Placement (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMergerNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails">
        <link:definition>9955561 - Disclosure - Equity - Merger (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityUnderwrittenOfferingNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails">
        <link:definition>9955562 - Disclosure - Equity - Underwritten Offering (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAttheMarketOfferingsNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails">
        <link:definition>9955563 - Disclosure - Equity - &#8220;At-the-Market&#8221; Offerings (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityJune2020SobiStockPurchaseNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails">
        <link:definition>9955564 - Disclosure - Equity - June 2020 Sobi Stock Purchase (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDecember2019FinancingNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails">
        <link:definition>9955565 - Disclosure - Equity - December 2019 Financing (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofWarrantActivityDetails" roleURI="http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails">
        <link:definition>9955566 - Disclosure - Equity - Schedule of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityCommonStockNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails">
        <link:definition>9955567 - Disclosure - Equity - Common Stock (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" roleURI="http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails">
        <link:definition>9955568 - Disclosure - Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails">
        <link:definition>9955569 - Disclosure - Stock Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9955570 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails" roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails">
        <link:definition>9955571 - Disclosure - Stock Incentive Plans - Schedule of Weighted Average Assumptions Used (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansScheduleofStockOptionActivityDetails" roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails">
        <link:definition>9955572 - Disclosure - Stock Incentive Plans - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails" roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails">
        <link:definition>9955573 - Disclosure - Stock Incentive Plans - Schedule of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueArrangementsNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails">
        <link:definition>9955574 - Disclosure - Revenue Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" roleURI="http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails">
        <link:definition>9955575 - Disclosure - Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails" roleURI="http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails">
        <link:definition>9955576 - Disclosure - Related-party Transactions - Schedule of Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>9955577 - Disclosure - Related-Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails">
        <link:definition>9955578 - Disclosure - Collaboration and License Agreements - Biogen M.A., Inc. (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails">
        <link:definition>9955579 - Disclosure - Collaboration and License Agreements - National Cancer Institute of the National Institutes of Health (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails">
        <link:definition>9955580 - Disclosure - Collaboration and License Agreements - Ginkgo Bioworks Holdings, Inc. (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails">
        <link:definition>9955581 - Disclosure - Collaboration and License Agreements - Genovis AB (publ.) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails">
        <link:definition>9955582 - Disclosure - Collaboration and License Agreements - Cyrus Biotechnology, Inc. (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails">
        <link:definition>9955583 - Disclosure - Collaboration and License Agreements - Asklepios Biopharmaceutical, Inc. (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails">
        <link:definition>9955584 - Disclosure - Collaboration and License Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955585 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9955586 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955587 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails">
        <link:definition>9955588 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails">
        <link:definition>9955589 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails" roleURI="http://www.cartesiantherapeutics.com/role/RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails">
        <link:definition>9955590 - Disclosure - Restructuring - Schedule of Change in Accrued Restructuring Balance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingDetails" roleURI="http://www.cartesiantherapeutics.com/role/SegmentReportingDetails">
        <link:definition>9955591 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rnac_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rnac_WarrantsAndRightsOutstandingCurrent" abstract="false" name="WarrantsAndRightsOutstandingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ContingentValueRightLiabilityCurrent" abstract="false" name="ContingentValueRightLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_WarrantsAndRightsOutstandingNoncurrent" abstract="false" name="WarrantsAndRightsOutstandingNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ContingentValueRightLiabilityNoncurrent" abstract="false" name="ContingentValueRightLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent" abstract="false" name="TemporaryEquityOptionsCarryingAmountAttributableToParent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_FairValueAdjustmentOfContingentValueRightLiability" abstract="false" name="FairValueAdjustmentOfContingentValueRightLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_PrivatePlacementOneMember" abstract="true" name="PrivatePlacementOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_PrivatePlacementTwoMember" abstract="true" name="PrivatePlacementTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_TemporaryEquityStockIssuedDuringPeriodShares" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares" abstract="false" name="TemporaryEquityTransferOfPreferredStockToPermanentEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity" abstract="false" name="TemporaryEquityTransferOfPreferredStockToPermanentEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward" abstract="true" name="IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger" abstract="false" name="TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition" abstract="false" name="TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity" abstract="false" name="TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_TransferOfTemporaryEquityToPermanentEquityShares" abstract="false" name="TransferOfTemporaryEquityToPermanentEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_TransferOfTemporaryEquityToPermanentEquity" abstract="false" name="TransferOfTemporaryEquityToPermanentEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement" abstract="false" name="StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement" abstract="false" name="StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesCommonWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueCommonWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent" abstract="false" name="IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ProceedsFromIssuanceOfCommonStockAndWarrants" abstract="false" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination" abstract="false" name="PaymentForSettlementOfEquityAwardsInBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_EquityOfferingCostsInAccruedLiabilities" abstract="false" name="EquityOfferingCostsInAccruedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_TemporaryEquityDisclosureTextBlock" abstract="false" name="TemporaryEquityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rnac_CollaborationAndLicenseAgreementsTextBlock" abstract="false" name="CollaborationAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" abstract="false" name="CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rnac_ClinicalTrialCostsPolicyTextBlock" abstract="false" name="ClinicalTrialCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rnac_WarrantsPolicyTextBlock" abstract="false" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rnac_TemporaryEquityPolicyPolicyTextBlock" abstract="false" name="TemporaryEquityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock" abstract="false" name="ContingentValueRightLiabilityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rnac_OldCartesianMember" abstract="true" name="OldCartesianMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_SecuritiesPurchaseAgreement2023Member" abstract="true" name="SecuritiesPurchaseAgreement2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_SecuritiesPurchaseAgreement2024Member" abstract="true" name="SecuritiesPurchaseAgreement2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_SaleOfStockGrossConsiderationReceivedOnTransaction" abstract="false" name="SaleOfStockGrossConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" abstract="false" name="ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rnac_AstellasGeneTherapiesMember" abstract="true" name="AstellasGeneTherapiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment" abstract="false" name="ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_Descartes08ForMGMember" abstract="true" name="Descartes08ForMGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_Descartes08ForSLEMember" abstract="true" name="Descartes08ForSLEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_ForwardContractToIssueSharesMember" abstract="true" name="ForwardContractToIssueSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_SeriesAPreferredStockOptionsMember" abstract="true" name="SeriesAPreferredStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_ContingentValueRightLiability" abstract="false" name="ContingentValueRightLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_A2022WarrantsMember" abstract="true" name="A2022WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_ContingentValueRightMember" abstract="true" name="ContingentValueRightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_SOBIPurchaseAgreementMember" abstract="true" name="SOBIPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead" abstract="false" name="ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_SettlementOfDerivativeLiabilityShares" abstract="false" name="SettlementOfDerivativeLiabilityShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_IssuanceOfStockForSettlementOfForwardContractLiability" abstract="false" name="IssuanceOfStockForSettlementOfForwardContractLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_A2019WarrantsMember" abstract="true" name="A2019WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_ProbabilityOfSuccessMember" abstract="true" name="ProbabilityOfSuccessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_MeasurementInputRevenueVolatilityMember" abstract="true" name="MeasurementInputRevenueVolatilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_ContingentValueRightLiabilityMeasurementInput" abstract="false" name="ContingentValueRightLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="rnac_LaboratoryEquipmentMember" abstract="false" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_AccruedPatentFeesCurrent" abstract="false" name="AccruedPatentFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_AccruedAuditFeesCurrent" abstract="false" name="AccruedAuditFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_AccruedPropertyPlantAndEquipmentCurrent" abstract="false" name="AccruedPropertyPlantAndEquipmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LeaseArrangementAxis" abstract="true" name="LeaseArrangementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="rnac_LeaseArrangementDomain" abstract="true" name="LeaseArrangementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_A7495NewHorizonWayLeaseMember" abstract="true" name="A7495NewHorizonWayLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_LesseeOperatingLeaseNumberOfOptionsToExtend" abstract="false" name="LesseeOperatingLeaseNumberOfOptionsToExtend" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rnac_OperatingLeaseCostPercentage" abstract="false" name="OperatingLeaseCostPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rnac_LesseeOperatingLeaseMonthlyBaseRent" abstract="false" name="LesseeOperatingLeaseMonthlyBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" abstract="false" name="LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement" abstract="false" name="LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability" abstract="false" name="OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne" abstract="false" name="LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_A65GroveStreetWatertownMAMember" abstract="true" name="A65GroveStreetWatertownMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_OperatingLeaseBaseRent" abstract="false" name="OperatingLeaseBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_UpfrontRentalPayment" abstract="false" name="UpfrontRentalPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_A704QuinceOrchardRoadLeasesMember" abstract="true" name="A704QuinceOrchardRoadLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_NumberOfAcquiredOperatingLeases" abstract="false" name="NumberOfAcquiredOperatingLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rnac_MoscowRussiaLeaseMember" abstract="true" name="MoscowRussiaLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_A2020TermLoansMember" abstract="true" name="A2020TermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_DebtInstrumentPrepaymentFee" abstract="false" name="DebtInstrumentPrepaymentFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_DebtInstrumentAccruedInterest" abstract="false" name="DebtInstrumentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_Dr.TimothyA.SpringerMember" abstract="true" name="Dr.TimothyA.SpringerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_TASPartnersLLCMember" abstract="true" name="TASPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_Dr.ChafenLuMember" abstract="true" name="Dr.ChafenLuMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert" abstract="false" name="ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_PrivatePlacement2023Member" abstract="true" name="PrivatePlacement2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_PrivatePlacement2023TrancheOneMember" abstract="true" name="PrivatePlacement2023TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_PrivatePlacement2023TrancheThreeMember" abstract="true" name="PrivatePlacement2023TrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_PrivatePlacement2023TrancheTwoMember" abstract="true" name="PrivatePlacement2023TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_SaleOfStockSettlementTerm" abstract="false" name="SaleOfStockSettlementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rnac_NumberOfBusinessDays" abstract="false" name="NumberOfBusinessDays" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rnac_PreferredStockConvertibleBeneficialOwnershipPercentage" abstract="false" name="PreferredStockConvertibleBeneficialOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rnac_PreferredStockRedemptionTerm" abstract="false" name="PreferredStockRedemptionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays" abstract="false" name="PreferredStockConvertibleThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding" abstract="false" name="PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rnac_DirectorsAndExecutiveOfficersMember" abstract="true" name="DirectorsAndExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_A2022OfferingMember" abstract="true" name="A2022OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_SaleOfStockAggregateMaximumGrossSalesProceeds" abstract="false" name="SaleOfStockAggregateMaximumGrossSalesProceeds" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" abstract="false" name="SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rnac_DecemberTwoThousandNineteenFinancingMember" abstract="true" name="DecemberTwoThousandNineteenFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_CommonWarrantMember" abstract="true" name="CommonWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_WarrantIssued" abstract="false" name="WarrantIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ClassOfWarrantOrRightRollForward" abstract="true" name="ClassOfWarrantOrRightRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rnac_StockIssuedDuringPeriodSharesWarrantsCanceled" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rnac_StockIssuedDuringWarrantedCanceledPricePerShare" abstract="false" name="StockIssuedDuringWarrantedCanceledPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rnac_CommonStockVotingRightsNumberOfVotes" abstract="false" name="CommonStockVotingRightsNumberOfVotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rnac_RestrictedStockUnitsUnvestedMember" abstract="true" name="RestrictedStockUnitsUnvestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_StockIncentivePlan2016Member" abstract="false" name="StockIncentivePlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_EmploymentInducementIncentiveAwardPlanMember" abstract="true" name="EmploymentInducementIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_OldCartesianPlanMember" abstract="true" name="OldCartesianPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_OldCartestianMember" abstract="true" name="OldCartestianMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rnac_GinkgoBioworksHoldingsIncMember" abstract="true" name="GinkgoBioworksHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" abstract="true" name="A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_TakedaAgreementMember" abstract="true" name="TakedaAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_SareptaTherapeuticsInc.Member" abstract="true" name="SareptaTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_SwedishOrphanBiovitrumABSOBIMember" abstract="true" name="SwedishOrphanBiovitrumABSOBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember" abstract="true" name="NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_CollaborationAndLicenseAgreementsUpfrontPayment" abstract="false" name="CollaborationAndLicenseAgreementsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_DevelopmentAndCommercialMilestonesPlusRoyalties" abstract="false" name="DevelopmentAndCommercialMilestonesPlusRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements" abstract="false" name="LicenseAndOptionAgreementDevelopmentCostReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" abstract="false" name="LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" abstract="false" name="CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementUpfrontCashPayment" abstract="false" name="LicenseAndOptionAgreementUpfrontCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected" abstract="false" name="LicenseAndOptionAgreementFutureAdditionalPaymentsExpected" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" abstract="false" name="LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_EligiblePeriodToReceiveRoyalties" abstract="false" name="EligiblePeriodToReceiveRoyalties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rnac_RevenueNumberOfPerformanceObligations" abstract="false" name="RevenueNumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementDevelopmentMilestone" abstract="false" name="LicenseAndOptionAgreementDevelopmentMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_CollaborativeArrangementPaymentObligation" abstract="false" name="CollaborativeArrangementPaymentObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementOptionTerm" abstract="false" name="LicenseAndOptionAgreementOptionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementExtensionTerm" abstract="false" name="LicenseAndOptionAgreementExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies" abstract="false" name="LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementMilestoneReceivable" abstract="false" name="LicenseAndOptionAgreementMilestoneReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_GovernmentAssistancePotentialAdditionalAwardAmount" abstract="false" name="GovernmentAssistancePotentialAdditionalAwardAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rnac_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rnac_ContractwithCustomerLiabilityDeferredRevenue" abstract="false" name="ContractwithCustomerLiabilityDeferredRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" abstract="false" name="ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" abstract="false" name="ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts" abstract="false" name="ContractwithCustomerLiabilityIncreaseFromCashReceipts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_SevenOneEightThreeFourIrrevocableTrustMember" abstract="true" name="SevenOneEightThreeFourIrrevocableTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_ClassOfWarrantOrRightExercisedDuringPeriod" abstract="false" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_IssuanceOfContingentValueRightForExerciseOfWarrants" abstract="false" name="IssuanceOfContingentValueRightForExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_BiogenM.A.Inc.Member" abstract="true" name="BiogenM.A.Inc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_CollaborativeArrangementWrittenNoticePeriodForTermination" abstract="false" name="CollaborativeArrangementWrittenNoticePeriodForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rnac_NationalCancerInstituteAgreementMember" abstract="true" name="NationalCancerInstituteAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementRoyaltyPayment" abstract="false" name="LicenseAndOptionAgreementRoyaltyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum" abstract="false" name="LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_GinkgoAgreementMember" abstract="true" name="GinkgoAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected" abstract="false" name="LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_LicenseAndOptionAgreementMilestonePayments" abstract="false" name="LicenseAndOptionAgreementMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement" abstract="false" name="CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount" abstract="false" name="CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_GenovisABMember" abstract="true" name="GenovisABMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_CyrusBiotechnologyIncMember" abstract="true" name="CyrusBiotechnologyIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_SeriesBPreferredStockPurchaseAgreementMember" abstract="true" name="SeriesBPreferredStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased" abstract="false" name="EquitySecuritiesStockPurchaseAgreementSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare" abstract="false" name="EquitySecuritiesStockPurchaseAgreementParValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare" abstract="false" name="EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="rnac_AskBioLicenseMember" abstract="true" name="AskBioLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_CollaborativeArrangementCostSharePercentage" abstract="false" name="CollaborativeArrangementCostSharePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" abstract="false" name="LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" abstract="false" name="AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" abstract="false" name="AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes" abstract="false" name="CapitalizedResearchAndExperimentalCostsTaxPurposes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rnac_DeferredTaxAssetsLeasingArrangements" abstract="false" name="DeferredTaxAssetsLeasingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities" abstract="false" name="DeferredTaxAssetsNetOfDeferredTaxLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" abstract="false" name="DefinedContributionPlanEmployersMatchingContributionVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rnac_EmployeeStockPurchasePlan2016Member" abstract="false" name="EmployeeStockPurchasePlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rnac_ReportingSegmentsMember" abstract="true" name="ReportingSegmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_LegacySelectaProgramsMember" abstract="true" name="LegacySelectaProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_EarlyStageProgramsMember" abstract="true" name="EarlyStageProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rnac_MedicalExpensesOperating" abstract="false" name="MedicalExpensesOperating" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ResearchAndDevelopmentEmployeeExpenses" abstract="false" name="ResearchAndDevelopmentEmployeeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ResearchAndDevelopmentStockBasedCompensationExpense" abstract="false" name="ResearchAndDevelopmentStockBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses" abstract="false" name="ResearchAndDevelopmentFacilitiesAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rnac_ChristopherJewellMember" abstract="true" name="ChristopherJewellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>rnac-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f87b4d67-655c-40f8-bf99-5c1eb72d37a4,g:ec248d9b-f7a4-4998-8c2a-3c79ab383104-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b56fde59-d551-4e5d-8a4d-a3b9f249f96c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b06318dc-5506-4550-b797-1c71ea6786db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b56fde59-d551-4e5d-8a4d-a3b9f249f96c" xlink:to="loc_us-gaap_AssetsCurrent_b06318dc-5506-4550-b797-1c71ea6786db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8243eccf-a418-415c-8b06-ba249adf8177" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b56fde59-d551-4e5d-8a4d-a3b9f249f96c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8243eccf-a418-415c-8b06-ba249adf8177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_87be619a-92e7-4d28-8d74-4f82b4283cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b56fde59-d551-4e5d-8a4d-a3b9f249f96c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_87be619a-92e7-4d28-8d74-4f82b4283cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b3d92536-26c5-47a5-a55f-4582290313a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b56fde59-d551-4e5d-8a4d-a3b9f249f96c" xlink:to="loc_us-gaap_Goodwill_b3d92536-26c5-47a5-a55f-4582290313a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_972f50b2-f924-41f9-a284-b8ec5105bd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b56fde59-d551-4e5d-8a4d-a3b9f249f96c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_972f50b2-f924-41f9-a284-b8ec5105bd1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e3823338-e517-4cf1-bd2b-65062c7ce981" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b56fde59-d551-4e5d-8a4d-a3b9f249f96c" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e3823338-e517-4cf1-bd2b-65062c7ce981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4cdb7b55-6d0f-41ed-aa9a-be7728602ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b56fde59-d551-4e5d-8a4d-a3b9f249f96c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4cdb7b55-6d0f-41ed-aa9a-be7728602ec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4980a269-9bb9-42f1-85ad-113c3150d6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b56fde59-d551-4e5d-8a4d-a3b9f249f96c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4980a269-9bb9-42f1-85ad-113c3150d6b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f9f18533-f08f-4176-8f91-6d2b2cd981d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_17bbf3bb-b4aa-4800-ab16-7475a8d8475b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9f18533-f08f-4176-8f91-6d2b2cd981d0" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_17bbf3bb-b4aa-4800-ab16-7475a8d8475b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2b4d2e84-3bc4-4d7c-99a5-b3cdc30d43fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9f18533-f08f-4176-8f91-6d2b2cd981d0" xlink:to="loc_us-gaap_AccountsPayableCurrent_2b4d2e84-3bc4-4d7c-99a5-b3cdc30d43fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_40b3cc7e-a67a-4d8e-9fd5-7204d62b739b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9f18533-f08f-4176-8f91-6d2b2cd981d0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_40b3cc7e-a67a-4d8e-9fd5-7204d62b739b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantsAndRightsOutstandingCurrent_352c1114-9072-4fe0-89ec-78cca70e8c7e" xlink:href="rnac-20241231.xsd#rnac_WarrantsAndRightsOutstandingCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9f18533-f08f-4176-8f91-6d2b2cd981d0" xlink:to="loc_rnac_WarrantsAndRightsOutstandingCurrent_352c1114-9072-4fe0-89ec-78cca70e8c7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b07774c5-09b4-467c-9daa-90b062383ede" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9f18533-f08f-4176-8f91-6d2b2cd981d0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b07774c5-09b4-467c-9daa-90b062383ede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityCurrent_381eada3-b0b5-4ba7-95a0-6b5f5f8b44fc" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9f18533-f08f-4176-8f91-6d2b2cd981d0" xlink:to="loc_rnac_ContingentValueRightLiabilityCurrent_381eada3-b0b5-4ba7-95a0-6b5f5f8b44fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_d9bf956d-8b78-4aeb-9a71-05ee01ed73e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9f18533-f08f-4176-8f91-6d2b2cd981d0" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_d9bf956d-8b78-4aeb-9a71-05ee01ed73e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1eba56c9-5d84-4b05-8ad2-d3de3136c1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_ce44bcf2-1ad0-4b72-a79c-248990e7b674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1eba56c9-5d84-4b05-8ad2-d3de3136c1c6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_ce44bcf2-1ad0-4b72-a79c-248990e7b674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cd15a5ef-aa15-4644-b00e-ba3294a496dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1eba56c9-5d84-4b05-8ad2-d3de3136c1c6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cd15a5ef-aa15-4644-b00e-ba3294a496dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8dd8916b-6e6b-4943-824e-72ec5440a282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1eba56c9-5d84-4b05-8ad2-d3de3136c1c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8dd8916b-6e6b-4943-824e-72ec5440a282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_438b7c4e-3ec6-4898-9370-170ec3b77bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1eba56c9-5d84-4b05-8ad2-d3de3136c1c6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_438b7c4e-3ec6-4898-9370-170ec3b77bc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_179eaaff-7eaa-45a2-a921-3ee493961223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8e5e6658-2d41-40c4-b04a-9eb7e58ee5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_179eaaff-7eaa-45a2-a921-3ee493961223" xlink:to="loc_us-gaap_Liabilities_8e5e6658-2d41-40c4-b04a-9eb7e58ee5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_48613300-ea9d-45a8-8c18-cc642e59cae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_179eaaff-7eaa-45a2-a921-3ee493961223" xlink:to="loc_us-gaap_StockholdersEquity_48613300-ea9d-45a8-8c18-cc642e59cae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_00cdf542-c487-46c2-9f0d-51ca23432898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_179eaaff-7eaa-45a2-a921-3ee493961223" xlink:to="loc_us-gaap_CommitmentsAndContingencies_00cdf542-c487-46c2-9f0d-51ca23432898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_49f84e71-c608-4125-8fec-ab0140424354" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_179eaaff-7eaa-45a2-a921-3ee493961223" xlink:to="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_49f84e71-c608-4125-8fec-ab0140424354" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fb8cc107-f1a2-4482-a677-5ff7a301a57d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_179eaaff-7eaa-45a2-a921-3ee493961223" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fb8cc107-f1a2-4482-a677-5ff7a301a57d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3df0261e-7d6c-42a2-97eb-cfd9d1b45e34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d6f40d4c-a5d7-441a-a395-b86478ef79bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3df0261e-7d6c-42a2-97eb-cfd9d1b45e34" xlink:to="loc_us-gaap_CommonStockValue_d6f40d4c-a5d7-441a-a395-b86478ef79bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a64d3e64-7c7e-4ec5-aa18-b01bbc0be3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3df0261e-7d6c-42a2-97eb-cfd9d1b45e34" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a64d3e64-7c7e-4ec5-aa18-b01bbc0be3fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd6a3eb4-0ff5-41f5-9967-4c02030dc299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3df0261e-7d6c-42a2-97eb-cfd9d1b45e34" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd6a3eb4-0ff5-41f5-9967-4c02030dc299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1373dc13-662f-4023-bca6-36c0d00e2855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3df0261e-7d6c-42a2-97eb-cfd9d1b45e34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1373dc13-662f-4023-bca6-36c0d00e2855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4ec9d49e-f62e-4d05-b4b2-43fa33ef0fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3df0261e-7d6c-42a2-97eb-cfd9d1b45e34" xlink:to="loc_us-gaap_PreferredStockValue_4ec9d49e-f62e-4d05-b4b2-43fa33ef0fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e09e130c-3f72-46ef-bcd3-451009af46e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_905511bf-ee17-45f8-9939-528d0b728124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e09e130c-3f72-46ef-bcd3-451009af46e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_905511bf-ee17-45f8-9939-528d0b728124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_32a5b73e-b012-4f17-98e5-b1bbad014ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e09e130c-3f72-46ef-bcd3-451009af46e0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_32a5b73e-b012-4f17-98e5-b1bbad014ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_59c188a0-262f-4166-a782-d66212be04ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e09e130c-3f72-46ef-bcd3-451009af46e0" xlink:to="loc_us-gaap_LiabilitiesCurrent_59c188a0-262f-4166-a782-d66212be04ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityNoncurrent_99b5d63c-92b5-4f40-b001-cf73399ef508" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e09e130c-3f72-46ef-bcd3-451009af46e0" xlink:to="loc_rnac_ContingentValueRightLiabilityNoncurrent_99b5d63c-92b5-4f40-b001-cf73399ef508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_92e746e1-437a-48e8-ab67-8c4ea0868ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e09e130c-3f72-46ef-bcd3-451009af46e0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_92e746e1-437a-48e8-ab67-8c4ea0868ef0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantsAndRightsOutstandingNoncurrent_a8f72777-67d6-42c8-8d4b-cb25bf240f54" xlink:href="rnac-20241231.xsd#rnac_WarrantsAndRightsOutstandingNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e09e130c-3f72-46ef-bcd3-451009af46e0" xlink:to="loc_rnac_WarrantsAndRightsOutstandingNoncurrent_a8f72777-67d6-42c8-8d4b-cb25bf240f54" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6f5c842-b9e0-427d-bea1-33c2440a5f82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c1f1bb2a-a6e2-4591-aa6d-496aea11f1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e6f5c842-b9e0-427d-bea1-33c2440a5f82" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c1f1bb2a-a6e2-4591-aa6d-496aea11f1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7216c18-8297-49f9-a65e-90538facf3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e6f5c842-b9e0-427d-bea1-33c2440a5f82" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7216c18-8297-49f9-a65e-90538facf3f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_314675f4-04a9-45fc-b413-e7e4975bbcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_161cdef8-7e73-47ca-b4d9-2832bbcddf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_314675f4-04a9-45fc-b413-e7e4975bbcc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_161cdef8-7e73-47ca-b4d9-2832bbcddf7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b0cc33a1-f785-4cf2-b814-ac4b81cd2d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_314675f4-04a9-45fc-b413-e7e4975bbcc6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b0cc33a1-f785-4cf2-b814-ac4b81cd2d72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_64c18cc7-8e13-4833-b761-5ecef048411f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_314675f4-04a9-45fc-b413-e7e4975bbcc6" xlink:to="loc_us-gaap_AssetImpairmentCharges_64c18cc7-8e13-4833-b761-5ecef048411f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7a56439-1e14-4252-82c3-0e28626a4312" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d9340e0b-3157-4f26-a120-34fd31c6db10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7a56439-1e14-4252-82c3-0e28626a4312" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d9340e0b-3157-4f26-a120-34fd31c6db10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_85a0ce65-7eac-4fc9-ae55-d4add67787ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7a56439-1e14-4252-82c3-0e28626a4312" xlink:to="loc_us-gaap_InvestmentIncomeInterest_85a0ce65-7eac-4fc9-ae55-d4add67787ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2899ee19-1029-4a4f-93b8-6526db104de6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7a56439-1e14-4252-82c3-0e28626a4312" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2899ee19-1029-4a4f-93b8-6526db104de6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f38d3b91-1746-4024-a9b2-5964686282a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7a56439-1e14-4252-82c3-0e28626a4312" xlink:to="loc_us-gaap_OperatingIncomeLoss_f38d3b91-1746-4024-a9b2-5964686282a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3d340e27-ee45-423f-b5f4-e9e63526f8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7a56439-1e14-4252-82c3-0e28626a4312" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3d340e27-ee45-423f-b5f4-e9e63526f8d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_56d980d0-d34c-4873-8444-224819ed30e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7a56439-1e14-4252-82c3-0e28626a4312" xlink:to="loc_us-gaap_InterestExpenseNonoperating_56d980d0-d34c-4873-8444-224819ed30e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_FairValueAdjustmentOfContingentValueRightLiability_67e6022b-bd74-4156-b182-a97802314905" xlink:href="rnac-20241231.xsd#rnac_FairValueAdjustmentOfContingentValueRightLiability"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7a56439-1e14-4252-82c3-0e28626a4312" xlink:to="loc_rnac_FairValueAdjustmentOfContingentValueRightLiability_67e6022b-bd74-4156-b182-a97802314905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_b6155870-eb38-4bca-9fb6-a78d8d4a7b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7a56439-1e14-4252-82c3-0e28626a4312" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_b6155870-eb38-4bca-9fb6-a78d8d4a7b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6935d047-d89f-4d22-99f3-cc24e40b2ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c461dd0e-e014-4e6f-928e-4da57c8ebf44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6935d047-d89f-4d22-99f3-cc24e40b2ccb" xlink:to="loc_us-gaap_NetIncomeLoss_c461dd0e-e014-4e6f-928e-4da57c8ebf44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70d1e734-5163-44d2-b111-b01083ad48a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6935d047-d89f-4d22-99f3-cc24e40b2ccb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70d1e734-5163-44d2-b111-b01083ad48a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7ac41d5d-ce13-423e-be9a-d9431aec2e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6935d047-d89f-4d22-99f3-cc24e40b2ccb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7ac41d5d-ce13-423e-be9a-d9431aec2e41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bc4df8e6-1346-48c7-9153-4f6b95cf1c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2b143d00-c549-40b3-b2ac-4fc33b164543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bc4df8e6-1346-48c7-9153-4f6b95cf1c9f" xlink:to="loc_us-gaap_Revenues_2b143d00-c549-40b3-b2ac-4fc33b164543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a605371e-73da-469e-99bd-1d1e4b3e10f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bc4df8e6-1346-48c7-9153-4f6b95cf1c9f" xlink:to="loc_us-gaap_OperatingExpenses_a605371e-73da-469e-99bd-1d1e4b3e10f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8e0229bc-4106-4c14-adb2-b4f508b2ec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6f6905f-d0ea-4ce2-a06b-4ffbd07c6073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_8e0229bc-4106-4c14-adb2-b4f508b2ec7d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6f6905f-d0ea-4ce2-a06b-4ffbd07c6073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_003e5b77-a0cc-4c0c-b408-529a772ff9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_8e0229bc-4106-4c14-adb2-b4f508b2ec7d" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_003e5b77-a0cc-4c0c-b408-529a772ff9ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8bd87fc-0aff-4ede-afef-c8f01109ef3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3ac4b1de-cd75-4af7-a2be-d6db07377b77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8bd87fc-0aff-4ede-afef-c8f01109ef3d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3ac4b1de-cd75-4af7-a2be-d6db07377b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants_1d957d8b-c625-413f-bdc8-36c80401a224" xlink:href="rnac-20241231.xsd#rnac_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8bd87fc-0aff-4ede-afef-c8f01109ef3d" xlink:to="loc_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants_1d957d8b-c625-413f-bdc8-36c80401a224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_cb257bdf-2dac-4bb9-9205-d5e4d3a49167" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8bd87fc-0aff-4ede-afef-c8f01109ef3d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_cb257bdf-2dac-4bb9-9205-d5e4d3a49167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_a3a63f37-b0a4-4092-8766-fbb5f2250a35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8bd87fc-0aff-4ede-afef-c8f01109ef3d" xlink:to="loc_us-gaap_ProceedsFromStockPlans_a3a63f37-b0a4-4092-8766-fbb5f2250a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_ca589cb5-d1e7-4937-988e-53e4cfadb1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8bd87fc-0aff-4ede-afef-c8f01109ef3d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_ca589cb5-d1e7-4937-988e-53e4cfadb1f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination_5d9e68ed-e681-42b4-926b-27c28eccfe27" xlink:href="rnac-20241231.xsd#rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8bd87fc-0aff-4ede-afef-c8f01109ef3d" xlink:to="loc_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination_5d9e68ed-e681-42b4-926b-27c28eccfe27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_8781f757-1323-4910-b21d-15d881224c32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8bd87fc-0aff-4ede-afef-c8f01109ef3d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_8781f757-1323-4910-b21d-15d881224c32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_18629cd9-0747-469e-acbe-2b34e78be14c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8bd87fc-0aff-4ede-afef-c8f01109ef3d" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_18629cd9-0747-469e-acbe-2b34e78be14c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_908cd3f5-74df-49f2-970d-06e587f77c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_908cd3f5-74df-49f2-970d-06e587f77c9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e6ffbc3f-a472-42e5-b343-6571ae023c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e6ffbc3f-a472-42e5-b343-6571ae023c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_edb2a00a-1fe3-46f5-b422-aa0731c98865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_PaidInKindInterest_edb2a00a-1fe3-46f5-b422-aa0731c98865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_445a3c95-5d06-4ec5-a78a-8555361242e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_445a3c95-5d06-4ec5-a78a-8555361242e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4474d61a-0d1f-4700-9f15-a0d2338f99bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4474d61a-0d1f-4700-9f15-a0d2338f99bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8b0e50dc-5877-4152-b631-32c937da3187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_ShareBasedCompensation_8b0e50dc-5877-4152-b631-32c937da3187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent_4c8d5d99-21a2-4098-89ea-eb82997b145f" xlink:href="rnac-20241231.xsd#rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent_4c8d5d99-21a2-4098-89ea-eb82997b145f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_cd9b8578-5a6e-4094-820a-01babb8c2bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_cd9b8578-5a6e-4094-820a-01babb8c2bdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f957fbf1-5634-4d70-a46c-9ed5549b1b29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f957fbf1-5634-4d70-a46c-9ed5549b1b29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_44925485-8bc5-4da8-9f79-44a79542185f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_44925485-8bc5-4da8-9f79-44a79542185f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f4e2f4b-ac37-4f95-a56c-d5a0fab31237" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f4e2f4b-ac37-4f95-a56c-d5a0fab31237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d6e42c49-8d9d-47ee-8c2e-3fe5555c2c09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_NetIncomeLoss_d6e42c49-8d9d-47ee-8c2e-3fe5555c2c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_410bb4ff-84e2-4e54-be00-661ded7afa2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_410bb4ff-84e2-4e54-be00-661ded7afa2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0e158a78-27e6-499f-a596-fb713b49ca36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0e158a78-27e6-499f-a596-fb713b49ca36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2c62af1e-26b9-4287-a7bc-b46d347ad0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2c62af1e-26b9-4287-a7bc-b46d347ad0b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_FairValueAdjustmentOfContingentValueRightLiability_cfa35942-6264-4599-885d-3298a5e87b28" xlink:href="rnac-20241231.xsd#rnac_FairValueAdjustmentOfContingentValueRightLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_rnac_FairValueAdjustmentOfContingentValueRightLiability_cfa35942-6264-4599-885d-3298a5e87b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_601aeb51-0a35-4653-88ee-a781d8dca1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_601aeb51-0a35-4653-88ee-a781d8dca1d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c4b9c586-e999-49d4-bf13-3b19acbeb537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_AssetImpairmentCharges_c4b9c586-e999-49d4-bf13-3b19acbeb537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_fd7b4c35-be57-44d7-9634-fdba291a0857" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_267e9b0e-a4b1-4106-8734-99f195f1b729" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_fd7b4c35-be57-44d7-9634-fdba291a0857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d9e4c0c8-a7fb-4c40-87c1-273a2cf34576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_dc943be8-3036-4876-8f0e-be15cfe6a5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d9e4c0c8-a7fb-4c40-87c1-273a2cf34576" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_dc943be8-3036-4876-8f0e-be15cfe6a5eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_126cfdb5-2633-4d34-b648-f96e3ce03d23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d9e4c0c8-a7fb-4c40-87c1-273a2cf34576" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_126cfdb5-2633-4d34-b648-f96e3ce03d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_bb87c754-46ef-46bc-abe3-69f950ccf1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d9e4c0c8-a7fb-4c40-87c1-273a2cf34576" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_bb87c754-46ef-46bc-abe3-69f950ccf1b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f839e0f6-130c-4f95-8778-2acad7fb3141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d9e4c0c8-a7fb-4c40-87c1-273a2cf34576" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f839e0f6-130c-4f95-8778-2acad7fb3141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3780fa75-46b9-40af-b13a-a1e798438a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80164f21-67c7-4ab2-9996-5ddc280a6a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3780fa75-46b9-40af-b13a-a1e798438a6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80164f21-67c7-4ab2-9996-5ddc280a6a9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b42ae30e-6353-45ff-9149-474489d393fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3780fa75-46b9-40af-b13a-a1e798438a6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b42ae30e-6353-45ff-9149-474489d393fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28a4c9fa-2162-4d8c-a1ba-56b2b7891277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3780fa75-46b9-40af-b13a-a1e798438a6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28a4c9fa-2162-4d8c-a1ba-56b2b7891277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1300abc3-b487-41c1-a07a-95669604ae1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3780fa75-46b9-40af-b13a-a1e798438a6b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1300abc3-b487-41c1-a07a-95669604ae1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerScheduleofFairValueofConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d824b337-c569-4181-a61a-8065d1af554c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a351066b-96f2-48b6-8faa-c19435f6d062" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d824b337-c569-4181-a61a-8065d1af554c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a351066b-96f2-48b6-8faa-c19435f6d062" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_73426915-8703-4883-86f6-9f4872c2689f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_8bd95347-bc1a-423f-9174-7822cf6a8ada" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_73426915-8703-4883-86f6-9f4872c2689f" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_8bd95347-bc1a-423f-9174-7822cf6a8ada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3b46455e-8fe4-48ae-b818-5ba80b26d562" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_73426915-8703-4883-86f6-9f4872c2689f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3b46455e-8fe4-48ae-b818-5ba80b26d562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability_81a36a0c-b99d-43af-9108-84c7d1596f9a" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_73426915-8703-4883-86f6-9f4872c2689f" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability_81a36a0c-b99d-43af-9108-84c7d1596f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability_2ef45439-fb75-46e3-9a7b-163bda88c037" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_73426915-8703-4883-86f6-9f4872c2689f" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability_2ef45439-fb75-46e3-9a7b-163bda88c037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7f2c8641-f36f-444b-94f9-710112f73615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2db7216a-2440-40f6-87d4-221d59ba6ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7f2c8641-f36f-444b-94f9-710112f73615" xlink:to="loc_us-gaap_Goodwill_2db7216a-2440-40f6-87d4-221d59ba6ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_aa6a7ce6-4839-4522-b982-305a0b44066b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7f2c8641-f36f-444b-94f9-710112f73615" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_aa6a7ce6-4839-4522-b982-305a0b44066b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8da4c08e-ef36-4a41-8dfc-efa3f6e4823b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7f2c8641-f36f-444b-94f9-710112f73615" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8da4c08e-ef36-4a41-8dfc-efa3f6e4823b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset_b458e14b-60e5-443d-adf4-843030859b0d" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7f2c8641-f36f-444b-94f9-710112f73615" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset_b458e14b-60e5-443d-adf4-843030859b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_fbae5037-27cf-45cd-b49d-924853e711f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7f2c8641-f36f-444b-94f9-710112f73615" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_fbae5037-27cf-45cd-b49d-924853e711f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cb89eaaf-8310-4b66-baca-9e99a540cadf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7f2c8641-f36f-444b-94f9-710112f73615" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cb89eaaf-8310-4b66-baca-9e99a540cadf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b5bdf452-75c1-4cbe-ab64-69bb6cd2e02e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_b57fca4d-e8d5-4ef3-aad6-ebd8d3317a06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b5bdf452-75c1-4cbe-ab64-69bb6cd2e02e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_b57fca4d-e8d5-4ef3-aad6-ebd8d3317a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c37fb4da-399c-4aae-a19a-8da66fc43c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b5bdf452-75c1-4cbe-ab64-69bb6cd2e02e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c37fb4da-399c-4aae-a19a-8da66fc43c2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a457a583-090e-4e87-b0a0-29e16156a07d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca8a5ef1-0cd1-44a8-912a-6282c5e4e2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a457a583-090e-4e87-b0a0-29e16156a07d" xlink:to="loc_us-gaap_NetIncomeLoss_ca8a5ef1-0cd1-44a8-912a-6282c5e4e2d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributedEarnings_942fbdd1-705c-4c82-a6ca-3c28d3aac6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributedEarnings"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a457a583-090e-4e87-b0a0-29e16156a07d" xlink:to="loc_us-gaap_DistributedEarnings_942fbdd1-705c-4c82-a6ca-3c28d3aac6ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3bf02a7e-e913-4059-ade2-e69a31a66725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecurities_99ebd862-948a-4d8c-a489-b1f0e3bb64b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3bf02a7e-e913-4059-ade2-e69a31a66725" xlink:to="loc_us-gaap_DilutiveSecurities_99ebd862-948a-4d8c-a489-b1f0e3bb64b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a86372f2-a2db-4856-91e8-8545ebe1a2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3bf02a7e-e913-4059-ade2-e69a31a66725" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a86372f2-a2db-4856-91e8-8545ebe1a2e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62e1956d-15e7-4c44-a442-de14d15be011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6f3b3303-a9b0-4a47-a7e4-f5acabd48445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62e1956d-15e7-4c44-a442-de14d15be011" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6f3b3303-a9b0-4a47-a7e4-f5acabd48445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5aa19fc5-8a4f-4cc5-9b8c-4aa18aff806e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62e1956d-15e7-4c44-a442-de14d15be011" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5aa19fc5-8a4f-4cc5-9b8c-4aa18aff806e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c3d3f393-3c0b-483c-9731-84d69ed477be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiability_8330e36d-b1c1-4eca-9de2-5224b6fd8666" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c3d3f393-3c0b-483c-9731-84d69ed477be" xlink:to="loc_rnac_ContingentValueRightLiability_8330e36d-b1c1-4eca-9de2-5224b6fd8666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_d9e18a5e-2f3f-4414-9876-4a47c77c11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c3d3f393-3c0b-483c-9731-84d69ed477be" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_d9e18a5e-2f3f-4414-9876-4a47c77c11e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_f046602f-4dce-4d6b-bc9d-29f851b5613e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c3d3f393-3c0b-483c-9731-84d69ed477be" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_f046602f-4dce-4d6b-bc9d-29f851b5613e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5fbbe746-e022-4a54-86de-ca65de0b0aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_55b8f8c8-cacc-4122-9811-c86273e9d928" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_5fbbe746-e022-4a54-86de-ca65de0b0aca" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_55b8f8c8-cacc-4122-9811-c86273e9d928" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddc1746f-dbb2-4a9a-a421-456221482a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9ba3d1f9-6545-4a59-b27f-070993550f50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddc1746f-dbb2-4a9a-a421-456221482a10" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9ba3d1f9-6545-4a59-b27f-070993550f50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bfd0f48-edfb-419c-a5ab-f4fa80cf1232" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddc1746f-dbb2-4a9a-a421-456221482a10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bfd0f48-edfb-419c-a5ab-f4fa80cf1232" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2f4b1624-a325-4604-8112-3a574b7cc0db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4db132cf-b78b-4f28-9284-a64c97255e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2f4b1624-a325-4604-8112-3a574b7cc0db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4db132cf-b78b-4f28-9284-a64c97255e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_be1dec1a-dbde-4319-9d72-62a5b3e60fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2f4b1624-a325-4604-8112-3a574b7cc0db" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_be1dec1a-dbde-4319-9d72-62a5b3e60fc1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5447dd00-f83c-4cce-aaa9-509fdad099af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedResearchAndDevelopmentCostsCurrent_66210fee-7e60-482c-8664-32fc4e19611a" xlink:href="rnac-20241231.xsd#rnac_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5447dd00-f83c-4cce-aaa9-509fdad099af" xlink:to="loc_rnac_AccruedResearchAndDevelopmentCostsCurrent_66210fee-7e60-482c-8664-32fc4e19611a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_14ba3155-1c93-46d7-9c3a-6737d67f600e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5447dd00-f83c-4cce-aaa9-509fdad099af" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_14ba3155-1c93-46d7-9c3a-6737d67f600e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedPropertyPlantAndEquipmentCurrent_f0df4054-6b34-4fd2-95c2-0103f7e41e92" xlink:href="rnac-20241231.xsd#rnac_AccruedPropertyPlantAndEquipmentCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5447dd00-f83c-4cce-aaa9-509fdad099af" xlink:to="loc_rnac_AccruedPropertyPlantAndEquipmentCurrent_f0df4054-6b34-4fd2-95c2-0103f7e41e92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b39301ed-21ba-4f37-a463-92afc260785f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5447dd00-f83c-4cce-aaa9-509fdad099af" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b39301ed-21ba-4f37-a463-92afc260785f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedAuditFeesCurrent_5dd17071-fb49-4434-83b8-b86892a9bf01" xlink:href="rnac-20241231.xsd#rnac_AccruedAuditFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5447dd00-f83c-4cce-aaa9-509fdad099af" xlink:to="loc_rnac_AccruedAuditFeesCurrent_5dd17071-fb49-4434-83b8-b86892a9bf01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedPatentFeesCurrent_67caaa0b-e9a1-4239-bfea-810b3cb4db24" xlink:href="rnac-20241231.xsd#rnac_AccruedPatentFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5447dd00-f83c-4cce-aaa9-509fdad099af" xlink:to="loc_rnac_AccruedPatentFeesCurrent_67caaa0b-e9a1-4239-bfea-810b3cb4db24" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#Leases65GroveStreetLeaseNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_43a1ff3e-26ad-4095-ac8f-d077f5734a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_7826d37b-9bff-4d29-8aba-2937173de0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetImpairmentCharges_43a1ff3e-26ad-4095-ac8f-d077f5734a8a" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_7826d37b-9bff-4d29-8aba-2937173de0a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3b954840-93c6-417f-9b82-6f0567e28d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetImpairmentCharges_43a1ff3e-26ad-4095-ac8f-d077f5734a8a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3b954840-93c6-417f-9b82-6f0567e28d1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#LeasesScheduleofComponentsofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_15c2ab98-ab36-47b2-b6c3-60833c41a244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_52a7561b-bc90-4bb5-a51b-b934375c489c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_15c2ab98-ab36-47b2-b6c3-60833c41a244" xlink:to="loc_us-gaap_VariableLeaseCost_52a7561b-bc90-4bb5-a51b-b934375c489c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_f229d817-2fc5-43ed-bbe5-db78ee5b601d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_15c2ab98-ab36-47b2-b6c3-60833c41a244" xlink:to="loc_us-gaap_SubleaseIncome_f229d817-2fc5-43ed-bbe5-db78ee5b601d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_97dd66a7-a62d-49eb-9934-ed595655987b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_15c2ab98-ab36-47b2-b6c3-60833c41a244" xlink:to="loc_us-gaap_OperatingLeaseCost_97dd66a7-a62d-49eb-9934-ed595655987b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_ff711664-ffd2-491d-8051-c4eea3a04253" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_15c2ab98-ab36-47b2-b6c3-60833c41a244" xlink:to="loc_us-gaap_ShortTermLeaseCost_ff711664-ffd2-491d-8051-c4eea3a04253" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13a74822-d7e4-4fca-af74-5f7c93fb41fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_166759d5-2eac-435f-9337-20e28ba0db7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13a74822-d7e4-4fca-af74-5f7c93fb41fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_166759d5-2eac-435f-9337-20e28ba0db7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b0bbcacd-9026-430f-8bcd-1ae682ea6b25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13a74822-d7e4-4fca-af74-5f7c93fb41fb" xlink:to="loc_us-gaap_OperatingLeaseLiability_b0bbcacd-9026-430f-8bcd-1ae682ea6b25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="rnac-20241231.xsd#LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1657b8c-5e93-4100-9153-5598405bed7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_295278ec-16de-46f7-82f6-dd39a9954492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1657b8c-5e93-4100-9153-5598405bed7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_295278ec-16de-46f7-82f6-dd39a9954492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1bd751c0-1076-463f-af83-4de137ac068e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1657b8c-5e93-4100-9153-5598405bed7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1bd751c0-1076-463f-af83-4de137ac068e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_35695c00-45d0-4c2e-9f65-84a8735cc9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1657b8c-5e93-4100-9153-5598405bed7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_35695c00-45d0-4c2e-9f65-84a8735cc9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0a3d2e49-c8b0-4146-a8e5-6a130fc08571" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1657b8c-5e93-4100-9153-5598405bed7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0a3d2e49-c8b0-4146-a8e5-6a130fc08571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_63d84dfa-3aa4-4cae-8e8a-fba7dbd9c36a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1657b8c-5e93-4100-9153-5598405bed7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_63d84dfa-3aa4-4cae-8e8a-fba7dbd9c36a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_edcf2c2e-fa46-4f7a-aa08-725572cf6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1657b8c-5e93-4100-9153-5598405bed7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_edcf2c2e-fa46-4f7a-aa08-725572cf6e06" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ea96b3a4-77c4-4092-9bf1-8c8e90f767c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityDeferredRevenue_d20c6946-2f38-4605-a853-5e0352361caa" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityDeferredRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_ea96b3a4-77c4-4092-9bf1-8c8e90f767c6" xlink:to="loc_rnac_ContractwithCustomerLiabilityDeferredRevenue_d20c6946-2f38-4605-a853-5e0352361caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts_3b185c21-79d2-455d-9de9-12368821bbe6" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_c5d323f5-cc90-441e-af4e-eef0173dac09" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts_3b185c21-79d2-455d-9de9-12368821bbe6" xlink:to="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_c5d323f5-cc90-441e-af4e-eef0173dac09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_eea9f83e-1ec7-4be1-aaf1-58ff68869863" xlink:href="rnac-20241231.xsd#rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_3e5e26fd-5144-47c6-a9c0-607894115645" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_eea9f83e-1ec7-4be1-aaf1-58ff68869863" xlink:to="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_3e5e26fd-5144-47c6-a9c0-607894115645" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d5af0d2-430b-449c-afc9-f0ea89d5019b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_58dd7574-c7ea-4e16-852e-fab47dda250e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d5af0d2-430b-449c-afc9-f0ea89d5019b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_58dd7574-c7ea-4e16-852e-fab47dda250e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_774605e2-ad39-4501-9044-fca61d1d3cef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d5af0d2-430b-449c-afc9-f0ea89d5019b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_774605e2-ad39-4501-9044-fca61d1d3cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_12f7e02f-de17-464b-8623-d20a4af0ecfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d5af0d2-430b-449c-afc9-f0ea89d5019b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_12f7e02f-de17-464b-8623-d20a4af0ecfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5811491f-cfcb-4a19-a74e-573649602b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d5af0d2-430b-449c-afc9-f0ea89d5019b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5811491f-cfcb-4a19-a74e-573649602b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_764c1039-46a2-4497-965b-469f99ed018f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d5af0d2-430b-449c-afc9-f0ea89d5019b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_764c1039-46a2-4497-965b-469f99ed018f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_f6476e05-6048-4e27-815e-b8ec799f9521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d5af0d2-430b-449c-afc9-f0ea89d5019b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_f6476e05-6048-4e27-815e-b8ec799f9521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent_a2443683-00c8-4184-a334-56a6c82b06b6" xlink:href="rnac-20241231.xsd#rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d5af0d2-430b-449c-afc9-f0ea89d5019b" xlink:to="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent_a2443683-00c8-4184-a334-56a6c82b06b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent_f08612d3-2683-4487-8905-ed6b4f727989" xlink:href="rnac-20241231.xsd#rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d5af0d2-430b-449c-afc9-f0ea89d5019b" xlink:to="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent_f08612d3-2683-4487-8905-ed6b4f727989" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities_d6724cae-66ac-4025-8382-4abf777ad1e4" xlink:href="rnac-20241231.xsd#rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d76e9d90-89ad-4641-92ad-d4bbe8224a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities_d6724cae-66ac-4025-8382-4abf777ad1e4" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d76e9d90-89ad-4641-92ad-d4bbe8224a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a31e0a7e-ca2a-44e1-831b-3e6fa4826968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities_d6724cae-66ac-4025-8382-4abf777ad1e4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a31e0a7e-ca2a-44e1-831b-3e6fa4826968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_e19dd70d-e0f9-452b-b77d-ef9159061a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities_0555b452-e19c-4260-8833-15ab6eca5613" xlink:href="rnac-20241231.xsd#rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_e19dd70d-e0f9-452b-b77d-ef9159061a4c" xlink:to="loc_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities_0555b452-e19c-4260-8833-15ab6eca5613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5103d794-9b04-4ece-a133-4fa75026c462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_e19dd70d-e0f9-452b-b77d-ef9159061a4c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5103d794-9b04-4ece-a133-4fa75026c462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f0a6e002-38f3-4c6a-bc1b-6b608409b64f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e581037f-8716-4d43-aae1-424e9b9a87c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0a6e002-38f3-4c6a-bc1b-6b608409b64f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e581037f-8716-4d43-aae1-424e9b9a87c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DeferredTaxAssetsLeasingArrangements_2f937f19-0922-4c9a-b723-12b6984107c4" xlink:href="rnac-20241231.xsd#rnac_DeferredTaxAssetsLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0a6e002-38f3-4c6a-bc1b-6b608409b64f" xlink:to="loc_rnac_DeferredTaxAssetsLeasingArrangements_2f937f19-0922-4c9a-b723-12b6984107c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b35d454b-c12b-4e44-9958-2d83a7d36b37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0a6e002-38f3-4c6a-bc1b-6b608409b64f" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b35d454b-c12b-4e44-9958-2d83a7d36b37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0e0f376f-a984-464f-8689-0f138c89de80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0a6e002-38f3-4c6a-bc1b-6b608409b64f" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0e0f376f-a984-464f-8689-0f138c89de80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_40f617b3-ef52-4ec3-aee9-b42fe220a580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0a6e002-38f3-4c6a-bc1b-6b608409b64f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_40f617b3-ef52-4ec3-aee9-b42fe220a580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_43626831-4261-48db-938f-938e0e155cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0a6e002-38f3-4c6a-bc1b-6b608409b64f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_43626831-4261-48db-938f-938e0e155cae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_6c5a5d1e-bcd0-4168-ae9f-bef55bfbfcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0a6e002-38f3-4c6a-bc1b-6b608409b64f" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_6c5a5d1e-bcd0-4168-ae9f-bef55bfbfcd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_71cda274-9209-479a-bbdb-f72bd25df69a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0a6e002-38f3-4c6a-bc1b-6b608409b64f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_71cda274-9209-479a-bbdb-f72bd25df69a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_417ccfee-5559-4c98-aba7-9ddd94ae33f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0a6e002-38f3-4c6a-bc1b-6b608409b64f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_417ccfee-5559-4c98-aba7-9ddd94ae33f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_43b0e843-5bda-4db5-858e-d230bf51d55c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9371fbe5-6169-46fa-816b-6febe8c69036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_43b0e843-5bda-4db5-858e-d230bf51d55c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9371fbe5-6169-46fa-816b-6febe8c69036" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f9a8c160-75e4-4524-960c-df60e2012fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_43b0e843-5bda-4db5-858e-d230bf51d55c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f9a8c160-75e4-4524-960c-df60e2012fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3bd28e04-a11f-4245-a786-978d698110e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_43b0e843-5bda-4db5-858e-d230bf51d55c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3bd28e04-a11f-4245-a786-978d698110e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#SegmentReportingDetails"/>
  <link:calculationLink xlink:role="http://www.cartesiantherapeutics.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fa1f0b22-8387-4ac8-bab6-359d3ee86093" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses_4981b15f-8a55-4e79-ad6e-bd7ed2bffa9d" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fa1f0b22-8387-4ac8-bab6-359d3ee86093" xlink:to="loc_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses_4981b15f-8a55-4e79-ad6e-bd7ed2bffa9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_f59897ea-34f2-4bcf-bee1-7a8482486bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fa1f0b22-8387-4ac8-bab6-359d3ee86093" xlink:to="loc_us-gaap_OtherNonoperatingExpense_f59897ea-34f2-4bcf-bee1-7a8482486bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_MedicalExpensesOperating_5ebc64c5-3c09-4c97-a466-62eea5a9b75a" xlink:href="rnac-20241231.xsd#rnac_MedicalExpensesOperating"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fa1f0b22-8387-4ac8-bab6-359d3ee86093" xlink:to="loc_rnac_MedicalExpensesOperating_5ebc64c5-3c09-4c97-a466-62eea5a9b75a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentEmployeeExpenses_df4a0d8c-4e45-42f8-ac4c-3d241cac12f0" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentEmployeeExpenses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fa1f0b22-8387-4ac8-bab6-359d3ee86093" xlink:to="loc_rnac_ResearchAndDevelopmentEmployeeExpenses_df4a0d8c-4e45-42f8-ac4c-3d241cac12f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_6b45ae21-82aa-42d5-b1b6-ea382c0a8cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fa1f0b22-8387-4ac8-bab6-359d3ee86093" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_6b45ae21-82aa-42d5-b1b6-ea382c0a8cb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fb5ae357-f158-44b5-b1ef-4a2ea7fc4339" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fa1f0b22-8387-4ac8-bab6-359d3ee86093" xlink:to="loc_us-gaap_Revenues_fb5ae357-f158-44b5-b1ef-4a2ea7fc4339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1623bde4-c68e-4179-ba2d-d1fb1ebce603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fa1f0b22-8387-4ac8-bab6-359d3ee86093" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1623bde4-c68e-4179-ba2d-d1fb1ebce603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentStockBasedCompensationExpense_f2825b10-fa50-40f9-8eaf-5fc3d9837e6f" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentStockBasedCompensationExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fa1f0b22-8387-4ac8-bab6-359d3ee86093" xlink:to="loc_rnac_ResearchAndDevelopmentStockBasedCompensationExpense_f2825b10-fa50-40f9-8eaf-5fc3d9837e6f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>rnac-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f87b4d67-655c-40f8-bf99-5c1eb72d37a4,g:ec248d9b-f7a4-4998-8c2a-3c79ab383104-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f5a2abbe-0763-4140-884c-ff14cacf74e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_af192cea-417b-4030-9820-28a447206c24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f5a2abbe-0763-4140-884c-ff14cacf74e7" xlink:to="loc_us-gaap_StatementTable_af192cea-417b-4030-9820-28a447206c24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1965d02b-ca99-4ad0-b391-076ef1329b06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_af192cea-417b-4030-9820-28a447206c24" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1965d02b-ca99-4ad0-b391-076ef1329b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1965d02b-ca99-4ad0-b391-076ef1329b06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1965d02b-ca99-4ad0-b391-076ef1329b06" xlink:to="loc_us-gaap_ClassOfStockDomain_1965d02b-ca99-4ad0-b391-076ef1329b06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2dcee0ac-d7e5-4bda-b706-9fcc92bd962c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1965d02b-ca99-4ad0-b391-076ef1329b06" xlink:to="loc_us-gaap_ClassOfStockDomain_2dcee0ac-d7e5-4bda-b706-9fcc92bd962c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_d29245c3-eae4-4ba4-8ac5-cf4df37f0720" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2dcee0ac-d7e5-4bda-b706-9fcc92bd962c" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_d29245c3-eae4-4ba4-8ac5-cf4df37f0720" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_3cdf34c7-a34c-47b2-9632-907f5e9b174c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2dcee0ac-d7e5-4bda-b706-9fcc92bd962c" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_3cdf34c7-a34c-47b2-9632-907f5e9b174c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_43cc2de4-b3c6-44b8-8afb-b6107e8a8358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5a2abbe-0763-4140-884c-ff14cacf74e7" xlink:to="loc_us-gaap_AssetsAbstract_43cc2de4-b3c6-44b8-8afb-b6107e8a8358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_43cc2de4-b3c6-44b8-8afb-b6107e8a8358" xlink:to="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f89f13b-ce0e-49bf-902c-87143e208a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f89f13b-ce0e-49bf-902c-87143e208a75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f1c45e38-c415-4ad0-acfe-729ddb0087b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f1c45e38-c415-4ad0-acfe-729ddb0087b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5b61d0fd-575f-4834-a89c-67851709fda0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5b61d0fd-575f-4834-a89c-67851709fda0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37491621-c321-4f3c-875c-555c5ffde63a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37491621-c321-4f3c-875c-555c5ffde63a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b68a166c-e39f-4516-9e5e-fba0439719f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:to="loc_us-gaap_AssetsCurrent_b68a166c-e39f-4516-9e5e-fba0439719f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_43cc2de4-b3c6-44b8-8afb-b6107e8a8358" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c962cbc4-6d48-4c46-af18-ef15241e254c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c962cbc4-6d48-4c46-af18-ef15241e254c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f162d1c-c8a1-4255-a2c5-21b7a7915beb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f162d1c-c8a1-4255-a2c5-21b7a7915beb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_eba6e427-79e7-4e92-9f5d-abde1a1e60cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_eba6e427-79e7-4e92-9f5d-abde1a1e60cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_803c9c53-58a1-4126-93c5-ba185411fbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_Goodwill_803c9c53-58a1-4126-93c5-ba185411fbfe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f1c6a586-8d18-4b3d-abd3-f32b65657f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f1c6a586-8d18-4b3d-abd3-f32b65657f2f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1851874a-04d0-4d33-bd3b-acd2f2abf875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1851874a-04d0-4d33-bd3b-acd2f2abf875" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4852bd76-a666-4ed4-879d-df36cd5e1061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4852bd76-a666-4ed4-879d-df36cd5e1061" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4afc226c-c4c6-4788-91aa-dd50a42bb601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_43cc2de4-b3c6-44b8-8afb-b6107e8a8358" xlink:to="loc_us-gaap_Assets_4afc226c-c4c6-4788-91aa-dd50a42bb601" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5a2abbe-0763-4140-884c-ff14cacf74e7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a03a332b-26dc-4684-9434-55bca1e6112d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_AccountsPayableCurrent_a03a332b-26dc-4684-9434-55bca1e6112d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_d019a3d3-4eed-4f6b-b940-4eb53aed9594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_d019a3d3-4eed-4f6b-b940-4eb53aed9594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_34c45bbc-7264-4034-9ad2-7a1fda36ea96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_34c45bbc-7264-4034-9ad2-7a1fda36ea96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d46cb7ea-e19b-4990-a09e-1a4f8f464fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d46cb7ea-e19b-4990-a09e-1a4f8f464fb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantsAndRightsOutstandingCurrent_0a3f4a90-ae44-487d-ba49-033d8fd1987c" xlink:href="rnac-20241231.xsd#rnac_WarrantsAndRightsOutstandingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_rnac_WarrantsAndRightsOutstandingCurrent_0a3f4a90-ae44-487d-ba49-033d8fd1987c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityCurrent_f5b392fc-68c9-4642-b644-903c7c04d3b3" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_rnac_ContingentValueRightLiabilityCurrent_f5b392fc-68c9-4642-b644-903c7c04d3b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_fd8f58f3-d95d-453c-bf9e-03ceb5ad3c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_fd8f58f3-d95d-453c-bf9e-03ceb5ad3c49" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_15f97b0f-7221-4b0b-901a-07791cf0718b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_LiabilitiesCurrent_15f97b0f-7221-4b0b-901a-07791cf0718b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_772c5e0b-9961-4050-861a-3f02e2fea16c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_772c5e0b-9961-4050-861a-3f02e2fea16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c4fb384-5af7-456b-87db-5e2e9d9b4094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c4fb384-5af7-456b-87db-5e2e9d9b4094" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantsAndRightsOutstandingNoncurrent_2955661b-8a8c-44e8-adb7-e038a28564a6" xlink:href="rnac-20241231.xsd#rnac_WarrantsAndRightsOutstandingNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:to="loc_rnac_WarrantsAndRightsOutstandingNoncurrent_2955661b-8a8c-44e8-adb7-e038a28564a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityNoncurrent_e244776a-72fa-457d-99eb-7c567424115e" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:to="loc_rnac_ContingentValueRightLiabilityNoncurrent_e244776a-72fa-457d-99eb-7c567424115e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5a19cee6-e730-46be-b48d-2475d7debfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5a19cee6-e730-46be-b48d-2475d7debfcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_21c09e67-8f74-40e4-bacd-2715ae63f753" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_Liabilities_21c09e67-8f74-40e4-bacd-2715ae63f753" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7254616f-5947-43d5-ba65-56e808693d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7254616f-5947-43d5-ba65-56e808693d77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e3ee050a-b419-46a3-a6b9-2ee39293d3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e3ee050a-b419-46a3-a6b9-2ee39293d3c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_a1280cb8-1ca2-4d4f-bee9-fed72395523c" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_a1280cb8-1ca2-4d4f-bee9-fed72395523c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c0a3d4bd-944f-41fe-899d-6cb73d6711b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_PreferredStockValue_c0a3d4bd-944f-41fe-899d-6cb73d6711b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_853402d6-e21c-4262-8534-c98ee1cc4525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_CommonStockValue_853402d6-e21c-4262-8534-c98ee1cc4525" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ba380616-0d88-4bea-9f7d-6dc7ff9d5aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ba380616-0d88-4bea-9f7d-6dc7ff9d5aa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bbae2f11-bae0-4b95-8fdc-430ab574e302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bbae2f11-bae0-4b95-8fdc-430ab574e302" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cb4bb74c-2517-4e57-a23c-f51d01df4873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cb4bb74c-2517-4e57-a23c-f51d01df4873" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0d67d66-66b1-4383-8687-6065c8bdab87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_StockholdersEquity_c0d67d66-66b1-4383-8687-6065c8bdab87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ed46011-d5d8-4b85-97e4-13d62feb42ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ed46011-d5d8-4b85-97e4-13d62feb42ba" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffebd99e-13d0-44f8-a8f3-27aa8b1df612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_StatementTable_ffebd99e-13d0-44f8-a8f3-27aa8b1df612" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2ae75085-9fd6-43e6-9911-e795ee2b0273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ffebd99e-13d0-44f8-a8f3-27aa8b1df612" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2ae75085-9fd6-43e6-9911-e795ee2b0273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ae75085-9fd6-43e6-9911-e795ee2b0273_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ae75085-9fd6-43e6-9911-e795ee2b0273" xlink:to="loc_us-gaap_ClassOfStockDomain_2ae75085-9fd6-43e6-9911-e795ee2b0273_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa5bda28-4171-4baf-9dec-8fef82b188d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ae75085-9fd6-43e6-9911-e795ee2b0273" xlink:to="loc_us-gaap_ClassOfStockDomain_aa5bda28-4171-4baf-9dec-8fef82b188d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b8dbc6cc-673c-47c6-a5be-a3c33924ff12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_aa5bda28-4171-4baf-9dec-8fef82b188d0" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b8dbc6cc-673c-47c6-a5be-a3c33924ff12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_bedea882-5fdb-439a-bf28-2f3e82a46e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_aa5bda28-4171-4baf-9dec-8fef82b188d0" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_bedea882-5fdb-439a-bf28-2f3e82a46e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3c34d4c7-fba6-4fe9-8af4-c6eb0abc886b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3c34d4c7-fba6-4fe9-8af4-c6eb0abc886b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_63e3e9fe-5a0f-4193-b90c-878453df0fab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_63e3e9fe-5a0f-4193-b90c-878453df0fab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_4b85f802-6e2a-43c1-9cb3-6a198c719c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_4b85f802-6e2a-43c1-9cb3-6a198c719c02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_aee98e35-5c74-4c3b-8760-c009b98b9503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_aee98e35-5c74-4c3b-8760-c009b98b9503" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9058dcf3-d73d-4b74-84e0-e391001920d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9058dcf3-d73d-4b74-84e0-e391001920d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_af68361b-9b51-44d0-a454-6cb79c629bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_af68361b-9b51-44d0-a454-6cb79c629bea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ee6cca43-7f2b-4719-8aae-682c6d541dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ee6cca43-7f2b-4719-8aae-682c6d541dae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a85ee156-06dd-4c01-a1fe-23780d079f76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a85ee156-06dd-4c01-a1fe-23780d079f76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_135259fd-5be0-4a19-a426-2032e284c00c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_135259fd-5be0-4a19-a426-2032e284c00c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9ab659c2-dff5-4baa-bedf-9cd2c57e4734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9ab659c2-dff5-4baa-bedf-9cd2c57e4734" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c57a31c6-ddb3-49f0-8858-f2b8d63d8607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_CommonStockSharesIssued_c57a31c6-ddb3-49f0-8858-f2b8d63d8607" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cb9e6e34-b969-4187-b82d-4ebfe1abaaef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cb9e6e34-b969-4187-b82d-4ebfe1abaaef" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_717f60e9-d8b5-4dc4-9a47-a62d1069a978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_717f60e9-d8b5-4dc4-9a47-a62d1069a978" xlink:to="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6c823b6b-cc5a-429f-b455-10c905a37b26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6c823b6b-cc5a-429f-b455-10c905a37b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c823b6b-cc5a-429f-b455-10c905a37b26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6c823b6b-cc5a-429f-b455-10c905a37b26" xlink:to="loc_us-gaap_EquityComponentDomain_6c823b6b-cc5a-429f-b455-10c905a37b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6c823b6b-cc5a-429f-b455-10c905a37b26" xlink:to="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_034a35f9-4279-4a48-89ba-742b0c63c7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:to="loc_us-gaap_PreferredStockMember_034a35f9-4279-4a48-89ba-742b0c63c7b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9d6cf825-aa6a-4c52-8479-108244f931ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:to="loc_us-gaap_CommonStockMember_9d6cf825-aa6a-4c52-8479-108244f931ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1b948ab2-e5c4-4b9b-bfd0-167d94dd7dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1b948ab2-e5c4-4b9b-bfd0-167d94dd7dc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_eca76048-f935-42b5-ac10-55e620fcb5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:to="loc_us-gaap_RetainedEarningsMember_eca76048-f935-42b5-ac10-55e620fcb5c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_205a182a-891c-4881-9c4b-21540e211b37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_205a182a-891c-4881-9c4b-21540e211b37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ce59b78f-e6af-4454-9209-2eb7b837ca12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ce59b78f-e6af-4454-9209-2eb7b837ca12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce59b78f-e6af-4454-9209-2eb7b837ca12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ce59b78f-e6af-4454-9209-2eb7b837ca12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce59b78f-e6af-4454-9209-2eb7b837ca12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_109b8f19-fe2c-46aa-ad84-a9102ea6df8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ce59b78f-e6af-4454-9209-2eb7b837ca12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_109b8f19-fe2c-46aa-ad84-a9102ea6df8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacementOneMember_0c58a1e9-355c-4f19-bf4f-4e380b41a3df" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacementOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_109b8f19-fe2c-46aa-ad84-a9102ea6df8e" xlink:to="loc_rnac_PrivatePlacementOneMember_0c58a1e9-355c-4f19-bf4f-4e380b41a3df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacementTwoMember_4f572093-11db-4871-b34c-0fe1d1c251d6" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacementTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_109b8f19-fe2c-46aa-ad84-a9102ea6df8e" xlink:to="loc_rnac_PrivatePlacementTwoMember_4f572093-11db-4871-b34c-0fe1d1c251d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1c353221-9650-43bf-99cd-285f9323a1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1c353221-9650-43bf-99cd-285f9323a1c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1c353221-9650-43bf-99cd-285f9323a1c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c353221-9650-43bf-99cd-285f9323a1c8" xlink:to="loc_us-gaap_ClassOfStockDomain_1c353221-9650-43bf-99cd-285f9323a1c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_402e94d8-b98e-4435-8bf0-6a284c2b5bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c353221-9650-43bf-99cd-285f9323a1c8" xlink:to="loc_us-gaap_ClassOfStockDomain_402e94d8-b98e-4435-8bf0-6a284c2b5bc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_6f315a21-16e5-43ef-960e-9b3c84045fde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_402e94d8-b98e-4435-8bf0-6a284c2b5bc6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_6f315a21-16e5-43ef-960e-9b3c84045fde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_340e0353-f1ad-4de7-a77a-2ea8c53e60f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_402e94d8-b98e-4435-8bf0-6a284c2b5bc6" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_340e0353-f1ad-4de7-a77a-2ea8c53e60f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_717f60e9-d8b5-4dc4-9a47-a62d1069a978" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_c5bc7b98-221e-49b4-9a99-cd09afb8a3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_c5bc7b98-221e-49b4-9a99-cd09afb8a3e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6ef81634-4893-435c-8783-e89631751987" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6ef81634-4893-435c-8783-e89631751987" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityStockIssuedDuringPeriodShares_1ac24c69-3629-4cd8-b0ac-dfa0161a985b" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityStockIssuedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_rnac_TemporaryEquityStockIssuedDuringPeriodShares_1ac24c69-3629-4cd8-b0ac-dfa0161a985b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5b795f8d-5218-4f87-86cd-8e3d04221404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5b795f8d-5218-4f87-86cd-8e3d04221404" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares_e6fd4111-7d2d-4c18-b6a9-4192ff0bd1dc" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares_e6fd4111-7d2d-4c18-b6a9-4192ff0bd1dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue_152d9a78-46b1-4037-9e65-d9a5a458a5b0" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue_152d9a78-46b1-4037-9e65-d9a5a458a5b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares_b10c963b-7cfa-483d-be98-786036f6d58e" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares_b10c963b-7cfa-483d-be98-786036f6d58e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity_921bcefa-337c-4366-904e-c50e5f7b533e" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity_921bcefa-337c-4366-904e-c50e5f7b533e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_a9f8e79a-543e-46ee-8aa3-82e934711238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_21d4d863-5ff2-4281-866f-ac0caea2b7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:href="rnac-20241231.xsd#rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_717f60e9-d8b5-4dc4-9a47-a62d1069a978" xlink:to="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_c7bb6705-d57c-4022-b69f-a97fa4f711e0" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:to="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_c7bb6705-d57c-4022-b69f-a97fa4f711e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger_464e97ac-55e7-44e7-9590-539e9e408c4d" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:to="loc_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger_464e97ac-55e7-44e7-9590-539e9e408c4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition_6f60e4f8-d14c-4299-b3ef-8d006e5b123e" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:to="loc_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition_6f60e4f8-d14c-4299-b3ef-8d006e5b123e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity_cc37122a-4f4c-43e2-a179-a20f64c164d1" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:to="loc_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity_cc37122a-4f4c-43e2-a179-a20f64c164d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_f48e71b6-a86d-494b-a4ea-80614b10588b" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_717f60e9-d8b5-4dc4-9a47-a62d1069a978" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4c4d4b57-c26e-4616-8954-c0d698379302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4c4d4b57-c26e-4616-8954-c0d698379302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_62dd9431-22af-4427-b96f-4dff5a771c74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockholdersEquity_62dd9431-22af-4427-b96f-4dff5a771c74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a6dca682-4b25-4f14-8884-b337cfd41deb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a6dca682-4b25-4f14-8884-b337cfd41deb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TransferOfTemporaryEquityToPermanentEquityShares_5072c3ab-95d3-4d65-bfd8-cf90bce2847f" xlink:href="rnac-20241231.xsd#rnac_TransferOfTemporaryEquityToPermanentEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_TransferOfTemporaryEquityToPermanentEquityShares_5072c3ab-95d3-4d65-bfd8-cf90bce2847f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TransferOfTemporaryEquityToPermanentEquity_aa3c4b84-dc2a-4cb2-8765-e1d4b701b16f" xlink:href="rnac-20241231.xsd#rnac_TransferOfTemporaryEquityToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_TransferOfTemporaryEquityToPermanentEquity_aa3c4b84-dc2a-4cb2-8765-e1d4b701b16f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ca92aaca-1d1b-4536-a027-e66eb2ec3a96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ca92aaca-1d1b-4536-a027-e66eb2ec3a96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ff170475-d1a0-4164-9bb0-ff065a3f0c27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ff170475-d1a0-4164-9bb0-ff065a3f0c27" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a17a7280-5b45-4d5e-b19d-7dd4b15e5c90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a17a7280-5b45-4d5e-b19d-7dd4b15e5c90" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e032d827-ea2f-48da-830b-ca538abbad94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e032d827-ea2f-48da-830b-ca538abbad94" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_61cd1e7c-983e-4045-adef-997ffcb84e45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_61cd1e7c-983e-4045-adef-997ffcb84e45" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_af5f863e-e651-4cf8-8577-8644ac3a7438" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_af5f863e-e651-4cf8-8577-8644ac3a7438" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b2cbcf5c-1c01-4a45-b193-04cabb3985e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b2cbcf5c-1c01-4a45-b193-04cabb3985e2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b1771d2-9fc6-442b-a702-af60d0af74d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b1771d2-9fc6-442b-a702-af60d0af74d1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_593c9f4b-20fd-4880-9316-a0a7c6b8a0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_593c9f4b-20fd-4880-9316-a0a7c6b8a0a9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger_5753cca4-e5b0-4d3e-b09d-fd776a4380e8" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger_5753cca4-e5b0-4d3e-b09d-fd776a4380e8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_883d7ea2-1026-459a-bec6-6a5dcee70691" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_883d7ea2-1026-459a-bec6-6a5dcee70691" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger_0bd1d0ed-37f1-46a7-a5a2-a5ce391e454a" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger_0bd1d0ed-37f1-46a7-a5a2-a5ce391e454a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement_e86f0b0d-eeb5-4b0e-a8db-521fa05f4a82" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement_e86f0b0d-eeb5-4b0e-a8db-521fa05f4a82" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement_216954b3-1114-467b-a5d5-61c4ea50d094" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement_216954b3-1114-467b-a5d5-61c4ea50d094" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_80d9558d-e3a8-49b0-9fd1-02b5567ece18" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_80d9558d-e3a8-49b0-9fd1-02b5567ece18" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights_8be9aac3-7f6b-4864-b5bb-732446aa17d6" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights_8be9aac3-7f6b-4864-b5bb-732446aa17d6" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised_52d545b3-d521-4eff-a1aa-d4bdf10a67f8" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised_52d545b3-d521-4eff-a1aa-d4bdf10a67f8" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised_6fd9da21-64e6-4d7e-a5a9-d6fb98d57485" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised_6fd9da21-64e6-4d7e-a5a9-d6fb98d57485" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3c89e0ee-ef4d-4f14-82b2-5e6a87b89f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3c89e0ee-ef4d-4f14-82b2-5e6a87b89f8b" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6720fc69-d961-482b-858e-d004b4b00a21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6720fc69-d961-482b-858e-d004b4b00a21" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c43ff4c5-f8be-49b5-a7ad-a381a026edfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c43ff4c5-f8be-49b5-a7ad-a381a026edfa" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79c6885d-a593-40bd-9248-5e4ade2cb5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_NetIncomeLoss_79c6885d-a593-40bd-9248-5e4ade2cb5cf" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5e90df10-ead9-4177-87c6-75d541768e68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2d5a9e54-8e5d-4f68-9683-2e9b4ed2218b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f5f96479-4583-4c4c-9445-97356b4d3763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b88cb5da-f43a-489e-90fa-0fdd595f2dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_270b7e5e-30e0-485d-9d7b-57f04648e687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b88cb5da-f43a-489e-90fa-0fdd595f2dd1" xlink:to="loc_us-gaap_StatementTable_270b7e5e-30e0-485d-9d7b-57f04648e687" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_151422ba-2417-45f9-8c5b-c758490fb091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_270b7e5e-30e0-485d-9d7b-57f04648e687" xlink:to="loc_us-gaap_StatementClassOfStockAxis_151422ba-2417-45f9-8c5b-c758490fb091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_151422ba-2417-45f9-8c5b-c758490fb091_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_151422ba-2417-45f9-8c5b-c758490fb091" xlink:to="loc_us-gaap_ClassOfStockDomain_151422ba-2417-45f9-8c5b-c758490fb091_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ce1adf5e-53f7-41b9-9749-86ab9635dd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_151422ba-2417-45f9-8c5b-c758490fb091" xlink:to="loc_us-gaap_ClassOfStockDomain_ce1adf5e-53f7-41b9-9749-86ab9635dd8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0d4f42d7-9413-43d0-a05a-049751e21852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ce1adf5e-53f7-41b9-9749-86ab9635dd8c" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0d4f42d7-9413-43d0-a05a-049751e21852" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d49ef37b-1dc2-4807-b1b6-3d6c6b0fe28b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_270b7e5e-30e0-485d-9d7b-57f04648e687" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d49ef37b-1dc2-4807-b1b6-3d6c6b0fe28b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d49ef37b-1dc2-4807-b1b6-3d6c6b0fe28b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d49ef37b-1dc2-4807-b1b6-3d6c6b0fe28b" xlink:to="loc_us-gaap_EquityComponentDomain_d49ef37b-1dc2-4807-b1b6-3d6c6b0fe28b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c2a24acf-cc55-44de-a759-653b0c39f15a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d49ef37b-1dc2-4807-b1b6-3d6c6b0fe28b" xlink:to="loc_us-gaap_EquityComponentDomain_c2a24acf-cc55-44de-a759-653b0c39f15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c5760a5d-d162-4011-9991-0e695809daa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c2a24acf-cc55-44de-a759-653b0c39f15a" xlink:to="loc_us-gaap_PreferredStockMember_c5760a5d-d162-4011-9991-0e695809daa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fea739c2-433f-46a0-accd-01fc6283fb65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b88cb5da-f43a-489e-90fa-0fdd595f2dd1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fea739c2-433f-46a0-accd-01fc6283fb65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_496a5a99-fa46-4e8a-a382-1c844b694b09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b88cb5da-f43a-489e-90fa-0fdd595f2dd1" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_496a5a99-fa46-4e8a-a382-1c844b694b09" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#DescriptionoftheBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3800911a-6cee-4990-b2d7-50b0cd41aac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3800911a-6cee-4990-b2d7-50b0cd41aac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3800911a-6cee-4990-b2d7-50b0cd41aac1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3800911a-6cee-4990-b2d7-50b0cd41aac1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3800911a-6cee-4990-b2d7-50b0cd41aac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d88e089f-bdea-4f1e-b3bc-3478f0b4e136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3800911a-6cee-4990-b2d7-50b0cd41aac1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d88e089f-bdea-4f1e-b3bc-3478f0b4e136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_bf84b743-2050-41be-bc52-a0b7dd6e88cf" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d88e089f-bdea-4f1e-b3bc-3478f0b4e136" xlink:to="loc_rnac_OldCartesianMember_bf84b743-2050-41be-bc52-a0b7dd6e88cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_232a7c66-e450-4067-b0a7-03542ce9d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_232a7c66-e450-4067-b0a7-03542ce9d26d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_232a7c66-e450-4067-b0a7-03542ce9d26d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_232a7c66-e450-4067-b0a7-03542ce9d26d" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_232a7c66-e450-4067-b0a7-03542ce9d26d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_245fdd1b-12f1-4b25-8410-6fa8d8b0245d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_232a7c66-e450-4067-b0a7-03542ce9d26d" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_245fdd1b-12f1-4b25-8410-6fa8d8b0245d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3dd32863-8574-4bad-b546-224ee2fa948c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_245fdd1b-12f1-4b25-8410-6fa8d8b0245d" xlink:to="loc_us-gaap_CommonStockMember_3dd32863-8574-4bad-b546-224ee2fa948c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_9b5f616a-0217-4cbb-990a-db11888a4e35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_245fdd1b-12f1-4b25-8410-6fa8d8b0245d" xlink:to="loc_us-gaap_PreferredStockMember_9b5f616a-0217-4cbb-990a-db11888a4e35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cc95703f-aa94-4244-9e05-aa3e3f868ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cc95703f-aa94-4244-9e05-aa3e3f868ef3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc95703f-aa94-4244-9e05-aa3e3f868ef3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cc95703f-aa94-4244-9e05-aa3e3f868ef3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc95703f-aa94-4244-9e05-aa3e3f868ef3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c921441-231f-4b78-b566-284cc9a40aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cc95703f-aa94-4244-9e05-aa3e3f868ef3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c921441-231f-4b78-b566-284cc9a40aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member_ea0be4de-eda6-4895-8151-14986aca5e62" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c921441-231f-4b78-b566-284cc9a40aaf" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2023Member_ea0be4de-eda6-4895-8151-14986aca5e62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2024Member_aace665a-57f2-433e-8606-48cd4f03bef0" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c921441-231f-4b78-b566-284cc9a40aaf" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2024Member_aace665a-57f2-433e-8606-48cd4f03bef0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ea134afc-d912-416e-9e0a-dc648e68f734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ea134afc-d912-416e-9e0a-dc648e68f734" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ea134afc-d912-416e-9e0a-dc648e68f734_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea134afc-d912-416e-9e0a-dc648e68f734" xlink:to="loc_us-gaap_ClassOfStockDomain_ea134afc-d912-416e-9e0a-dc648e68f734_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4af6873f-7bd1-4e5e-a2ad-09b831db0388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea134afc-d912-416e-9e0a-dc648e68f734" xlink:to="loc_us-gaap_ClassOfStockDomain_4af6873f-7bd1-4e5e-a2ad-09b831db0388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_ce456701-802e-4973-a388-598ed4d7a71b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4af6873f-7bd1-4e5e-a2ad-09b831db0388" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_ce456701-802e-4973-a388-598ed4d7a71b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7c3b73e2-11e2-41d9-862f-e370ed34c253" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4af6873f-7bd1-4e5e-a2ad-09b831db0388" xlink:to="loc_us-gaap_CommonStockMember_7c3b73e2-11e2-41d9-862f-e370ed34c253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0e0bc9a1-ba6a-47fa-8825-3fb772929392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4af6873f-7bd1-4e5e-a2ad-09b831db0388" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0e0bc9a1-ba6a-47fa-8825-3fb772929392" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea6f08d4-454b-43a0-ae2d-24c06013ecb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_srt_RangeAxis_ea6f08d4-454b-43a0-ae2d-24c06013ecb8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea6f08d4-454b-43a0-ae2d-24c06013ecb8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ea6f08d4-454b-43a0-ae2d-24c06013ecb8" xlink:to="loc_srt_RangeMember_ea6f08d4-454b-43a0-ae2d-24c06013ecb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c580563-c11d-4747-8a88-eb0408bce857" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ea6f08d4-454b-43a0-ae2d-24c06013ecb8" xlink:to="loc_srt_RangeMember_9c580563-c11d-4747-8a88-eb0408bce857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f0d62d0e-28e8-43c3-b345-606a24780d33" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c580563-c11d-4747-8a88-eb0408bce857" xlink:to="loc_srt_MinimumMember_f0d62d0e-28e8-43c3-b345-606a24780d33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d7c8da9d-6ed4-4c7f-80da-60023af86973" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c580563-c11d-4747-8a88-eb0408bce857" xlink:to="loc_srt_MaximumMember_d7c8da9d-6ed4-4c7f-80da-60023af86973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d46a935e-0bbb-4ef9-bb21-0a8afe5eb840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d46a935e-0bbb-4ef9-bb21-0a8afe5eb840" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0c3fe800-d8e9-494c-acf5-b77b6522972b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0c3fe800-d8e9-494c-acf5-b77b6522972b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_8b24cc92-ce14-4826-8884-5d24a3b7d170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_8b24cc92-ce14-4826-8884-5d24a3b7d170" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_15c45f28-3b9e-412f-a1cd-7030ac05028d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_15c45f28-3b9e-412f-a1cd-7030ac05028d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6fa216ef-120f-4fe3-a942-12cd9aaa9541" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6fa216ef-120f-4fe3-a942-12cd9aaa9541" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_24d185da-823f-42e1-9478-cab9628ef6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_24d185da-823f-42e1-9478-cab9628ef6cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4646a2f2-9b4f-4529-942e-0c8bd4f1415d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4646a2f2-9b4f-4529-942e-0c8bd4f1415d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_88bb1e01-d549-445b-8cd3-6b03f6621c80" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_88bb1e01-d549-445b-8cd3-6b03f6621c80" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f48e91a7-ecbe-4936-a81b-1040f82979ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f48e91a7-ecbe-4936-a81b-1040f82979ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_25e095bf-5986-42ff-bc10-5d7100ce7d0e" xlink:href="rnac-20241231.xsd#rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_25e095bf-5986-42ff-bc10-5d7100ce7d0e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_100dadc7-ce91-48fd-96ed-9dd9e7563f24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_100dadc7-ce91-48fd-96ed-9dd9e7563f24" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_3e437e40-b012-4c52-80cf-7b273f4ae961" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_3e437e40-b012-4c52-80cf-7b273f4ae961" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_770ed044-1d24-467b-a2f9-1ec32631f285" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:to="loc_srt_RangeAxis_770ed044-1d24-467b-a2f9-1ec32631f285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_770ed044-1d24-467b-a2f9-1ec32631f285_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_770ed044-1d24-467b-a2f9-1ec32631f285" xlink:to="loc_srt_RangeMember_770ed044-1d24-467b-a2f9-1ec32631f285_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6fa19118-5dc7-4310-ba68-a63c2eb9e5f3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_770ed044-1d24-467b-a2f9-1ec32631f285" xlink:to="loc_srt_RangeMember_6fa19118-5dc7-4310-ba68-a63c2eb9e5f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2f2a3546-1ca3-454c-a7c5-caea9d90dd9a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6fa19118-5dc7-4310-ba68-a63c2eb9e5f3" xlink:to="loc_srt_MinimumMember_2f2a3546-1ca3-454c-a7c5-caea9d90dd9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c97298ba-cdc0-405d-a9f7-cf752e1dcc16" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6fa19118-5dc7-4310-ba68-a63c2eb9e5f3" xlink:to="loc_srt_MaximumMember_c97298ba-cdc0-405d-a9f7-cf752e1dcc16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2f8157e7-6997-4c33-9d18-3099e9290741" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2f8157e7-6997-4c33-9d18-3099e9290741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2f8157e7-6997-4c33-9d18-3099e9290741_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2f8157e7-6997-4c33-9d18-3099e9290741" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2f8157e7-6997-4c33-9d18-3099e9290741_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4c2be6c2-6b8c-4dbb-b4ac-6a82864e459a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2f8157e7-6997-4c33-9d18-3099e9290741" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4c2be6c2-6b8c-4dbb-b4ac-6a82864e459a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AstellasGeneTherapiesMember_d50a1b38-814e-4c17-9d1f-251840700b4d" xlink:href="rnac-20241231.xsd#rnac_AstellasGeneTherapiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4c2be6c2-6b8c-4dbb-b4ac-6a82864e459a" xlink:to="loc_rnac_AstellasGeneTherapiesMember_d50a1b38-814e-4c17-9d1f-251840700b4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b79f78-8055-4cc8-ac51-8dd20b649b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b79f78-8055-4cc8-ac51-8dd20b649b50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84b79f78-8055-4cc8-ac51-8dd20b649b50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b79f78-8055-4cc8-ac51-8dd20b649b50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84b79f78-8055-4cc8-ac51-8dd20b649b50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc536bd-428c-406e-9de2-ae696e447ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b79f78-8055-4cc8-ac51-8dd20b649b50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc536bd-428c-406e-9de2-ae696e447ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c65de031-cf53-4e05-992f-c7bda750b157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc536bd-428c-406e-9de2-ae696e447ff4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c65de031-cf53-4e05-992f-c7bda750b157" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_5389db4b-4b78-46a6-a454-adc8d29c263c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc536bd-428c-406e-9de2-ae696e447ff4" xlink:to="loc_us-gaap_EquipmentMember_5389db4b-4b78-46a6-a454-adc8d29c263c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0da1a555-15a4-472e-b1ed-fbc4ac495bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc536bd-428c-406e-9de2-ae696e447ff4" xlink:to="loc_us-gaap_ComputerEquipmentMember_0da1a555-15a4-472e-b1ed-fbc4ac495bf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_092d41ad-3af7-49ec-b0e2-457d9817ee2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_092d41ad-3af7-49ec-b0e2-457d9817ee2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_62b90804-9e64-4136-87f7-acc63879ee74" xlink:href="rnac-20241231.xsd#rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_62b90804-9e64-4136-87f7-acc63879ee74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_09bb93f3-f821-42e8-8a4e-ab92adfcb46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_09bb93f3-f821-42e8-8a4e-ab92adfcb46d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4d8392e7-29c4-4212-8700-1d73eece6598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4d8392e7-29c4-4212-8700-1d73eece6598" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_acdcbb71-cc83-4c82-be4c-48de4051191f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_acdcbb71-cc83-4c82-be4c-48de4051191f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8b8e9cb2-e622-44b1-bcd7-3d3c78e33903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8b8e9cb2-e622-44b1-bcd7-3d3c78e33903" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1f9443af-f576-4ed5-aa64-e5298b9287ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1f9443af-f576-4ed5-aa64-e5298b9287ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f9443af-f576-4ed5-aa64-e5298b9287ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1f9443af-f576-4ed5-aa64-e5298b9287ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f9443af-f576-4ed5-aa64-e5298b9287ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39d8af61-3564-4ff1-98ba-9565ab7f1be9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1f9443af-f576-4ed5-aa64-e5298b9287ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39d8af61-3564-4ff1-98ba-9565ab7f1be9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_61fc6bb1-403a-4f25-a254-315497fa3375" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39d8af61-3564-4ff1-98ba-9565ab7f1be9" xlink:to="loc_rnac_OldCartesianMember_61fc6bb1-403a-4f25-a254-315497fa3375" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_8017c0fd-ef5c-4514-83c1-475d4550a184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_8017c0fd-ef5c-4514-83c1-475d4550a184" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_8017c0fd-ef5c-4514-83c1-475d4550a184_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_8017c0fd-ef5c-4514-83c1-475d4550a184" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_8017c0fd-ef5c-4514-83c1-475d4550a184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_6159352c-5270-4ffa-a620-b3860997906b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_8017c0fd-ef5c-4514-83c1-475d4550a184" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_6159352c-5270-4ffa-a620-b3860997906b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf8d15b2-2852-40ae-b4d5-383d89489849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_6159352c-5270-4ffa-a620-b3860997906b" xlink:to="loc_us-gaap_CommonStockMember_cf8d15b2-2852-40ae-b4d5-383d89489849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_11d0e9d8-ab07-4e23-83d5-0500af820f06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_6159352c-5270-4ffa-a620-b3860997906b" xlink:to="loc_us-gaap_PreferredStockMember_11d0e9d8-ab07-4e23-83d5-0500af820f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b1e14126-e524-4fc6-a56a-8ec00ef88b35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b1e14126-e524-4fc6-a56a-8ec00ef88b35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b1e14126-e524-4fc6-a56a-8ec00ef88b35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b1e14126-e524-4fc6-a56a-8ec00ef88b35" xlink:to="loc_us-gaap_ClassOfStockDomain_b1e14126-e524-4fc6-a56a-8ec00ef88b35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_72e97fab-5fe8-4530-9677-0504aa2839d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b1e14126-e524-4fc6-a56a-8ec00ef88b35" xlink:to="loc_us-gaap_ClassOfStockDomain_72e97fab-5fe8-4530-9677-0504aa2839d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5580c7cd-7890-4802-8d89-fa1ffc8c3982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_72e97fab-5fe8-4530-9677-0504aa2839d6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5580c7cd-7890-4802-8d89-fa1ffc8c3982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_eed6abea-7b77-44f6-a7e8-2f47cd8c18df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_eed6abea-7b77-44f6-a7e8-2f47cd8c18df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_555a0f10-d842-495f-951a-3d85a1d02e21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_555a0f10-d842-495f-951a-3d85a1d02e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f5737145-0172-4a3b-946f-4a14d42deef9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f5737145-0172-4a3b-946f-4a14d42deef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_b3b0dcc3-a8c3-4d2d-96d3-c43ffad113ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_b3b0dcc3-a8c3-4d2d-96d3-c43ffad113ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_7ce8970e-3291-4b43-b16b-5d2287e931ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_7ce8970e-3291-4b43-b16b-5d2287e931ed" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerScheduleofFairValueofConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7196be18-ea99-40af-aec3-a667da4bf99d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7410e024-b75d-45dd-81d1-813d4f474e70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7196be18-ea99-40af-aec3-a667da4bf99d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7410e024-b75d-45dd-81d1-813d4f474e70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4eb2ce46-f4ec-42b9-994d-41544434563e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7410e024-b75d-45dd-81d1-813d4f474e70" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4eb2ce46-f4ec-42b9-994d-41544434563e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4eb2ce46-f4ec-42b9-994d-41544434563e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4eb2ce46-f4ec-42b9-994d-41544434563e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4eb2ce46-f4ec-42b9-994d-41544434563e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904b1c61-632a-4a57-8d6f-ca0178bbb372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4eb2ce46-f4ec-42b9-994d-41544434563e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904b1c61-632a-4a57-8d6f-ca0178bbb372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_bc5c743a-9731-41e3-bea1-c249f2498a18" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904b1c61-632a-4a57-8d6f-ca0178bbb372" xlink:to="loc_rnac_OldCartesianMember_bc5c743a-9731-41e3-bea1-c249f2498a18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_b5a7935d-c7d3-4943-88d9-819cfba8ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7410e024-b75d-45dd-81d1-813d4f474e70" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_b5a7935d-c7d3-4943-88d9-819cfba8ef9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_b5a7935d-c7d3-4943-88d9-819cfba8ef9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_b5a7935d-c7d3-4943-88d9-819cfba8ef9c" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_b5a7935d-c7d3-4943-88d9-819cfba8ef9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2d962db1-b181-415f-a8eb-7ab0e74aa65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_b5a7935d-c7d3-4943-88d9-819cfba8ef9c" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2d962db1-b181-415f-a8eb-7ab0e74aa65b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6dac3498-256d-4c35-9c72-3b320b8f31ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2d962db1-b181-415f-a8eb-7ab0e74aa65b" xlink:to="loc_us-gaap_CommonStockMember_6dac3498-256d-4c35-9c72-3b320b8f31ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_88e74b62-eea0-4a2c-99c9-6f86ffccef49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2d962db1-b181-415f-a8eb-7ab0e74aa65b" xlink:to="loc_us-gaap_PreferredStockMember_88e74b62-eea0-4a2c-99c9-6f86ffccef49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_06470d35-8397-4b9b-a9ea-050ad0f4ba84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2d962db1-b181-415f-a8eb-7ab0e74aa65b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_06470d35-8397-4b9b-a9ea-050ad0f4ba84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_24b7e429-5efc-4cc8-90bc-70f36b37cb09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7196be18-ea99-40af-aec3-a667da4bf99d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_24b7e429-5efc-4cc8-90bc-70f36b37cb09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ef56145d-6dfe-48e3-9168-fc387c06d5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7196be18-ea99-40af-aec3-a667da4bf99d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ef56145d-6dfe-48e3-9168-fc387c06d5b2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a92a047b-3c21-46c3-8a10-8de85a3b702a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17fdc1d5-0dcb-42b5-836f-a4838cffa25b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a92a047b-3c21-46c3-8a10-8de85a3b702a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17fdc1d5-0dcb-42b5-836f-a4838cffa25b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_da443d41-3313-4be4-9c0d-d4943272581b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17fdc1d5-0dcb-42b5-836f-a4838cffa25b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_da443d41-3313-4be4-9c0d-d4943272581b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da443d41-3313-4be4-9c0d-d4943272581b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da443d41-3313-4be4-9c0d-d4943272581b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da443d41-3313-4be4-9c0d-d4943272581b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9d10e8-b8a8-4112-b898-6ecb55e806e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da443d41-3313-4be4-9c0d-d4943272581b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9d10e8-b8a8-4112-b898-6ecb55e806e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_f3de1544-1b2b-4425-b359-7670f43af9ac" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9d10e8-b8a8-4112-b898-6ecb55e806e9" xlink:to="loc_rnac_OldCartesianMember_f3de1544-1b2b-4425-b359-7670f43af9ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a92a047b-3c21-46c3-8a10-8de85a3b702a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4d947eb0-346a-4709-a8d5-30035475f36f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4d947eb0-346a-4709-a8d5-30035475f36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8e266879-a8df-4fb6-a34d-42d68c8731bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8e266879-a8df-4fb6-a34d-42d68c8731bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f156ca29-d80b-4119-8bca-ca7701df1d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f156ca29-d80b-4119-8bca-ca7701df1d4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset_fe704486-f1c6-4bf4-bfa0-105865463076" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset_fe704486-f1c6-4bf4-bfa0-105865463076" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6df6a5ce-ad87-4101-9d24-7a827b187aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6df6a5ce-ad87-4101-9d24-7a827b187aa9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_924f2413-00e0-4ef6-be8b-2e3e3ea481d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_Goodwill_924f2413-00e0-4ef6-be8b-2e3e3ea481d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f70dde56-d1d5-4a36-8fe1-67ce2905731f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f70dde56-d1d5-4a36-8fe1-67ce2905731f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a92a047b-3c21-46c3-8a10-8de85a3b702a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_4762a128-8930-4f02-b4b9-8af73fe6eff3" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_4762a128-8930-4f02-b4b9-8af73fe6eff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability_7417322d-dc47-4031-8bc1-d6435ab58ed2" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability_7417322d-dc47-4031-8bc1-d6435ab58ed2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability_1677bee6-c4f4-4706-9e20-be0dde9a9211" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability_1677bee6-c4f4-4706-9e20-be0dde9a9211" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_834018d7-c079-4782-894d-359121251db5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_834018d7-c079-4782-894d-359121251db5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_82f6fec6-db35-456d-ac04-59acbb678bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_82f6fec6-db35-456d-ac04-59acbb678bdc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_333a77cf-197f-41f0-aba8-ea344ecadef3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a92a047b-3c21-46c3-8a10-8de85a3b702a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_333a77cf-197f-41f0-aba8-ea344ecadef3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerScheduleofIntangibleAssetsAcquiredDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a6afda63-d307-4056-829b-d1be299b868c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b7187ba-a129-4e2a-833c-a31894547a54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6afda63-d307-4056-829b-d1be299b868c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b7187ba-a129-4e2a-833c-a31894547a54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fd3000af-1059-4281-9756-a7f9a19e3155" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b7187ba-a129-4e2a-833c-a31894547a54" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fd3000af-1059-4281-9756-a7f9a19e3155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd3000af-1059-4281-9756-a7f9a19e3155_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fd3000af-1059-4281-9756-a7f9a19e3155" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd3000af-1059-4281-9756-a7f9a19e3155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62e26-8015-4a99-9bf4-35a68b2e4bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fd3000af-1059-4281-9756-a7f9a19e3155" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62e26-8015-4a99-9bf4-35a68b2e4bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_fceec744-fb54-488b-93de-c7a3c7a200ef" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62e26-8015-4a99-9bf4-35a68b2e4bbb" xlink:to="loc_rnac_OldCartesianMember_fceec744-fb54-488b-93de-c7a3c7a200ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1da74bc9-afbc-497f-bf98-ea1e2867c666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b7187ba-a129-4e2a-833c-a31894547a54" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1da74bc9-afbc-497f-bf98-ea1e2867c666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1da74bc9-afbc-497f-bf98-ea1e2867c666_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1da74bc9-afbc-497f-bf98-ea1e2867c666" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1da74bc9-afbc-497f-bf98-ea1e2867c666_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_24d2660c-96e2-48c4-a1ab-b20f5e7dd6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1da74bc9-afbc-497f-bf98-ea1e2867c666" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_24d2660c-96e2-48c4-a1ab-b20f5e7dd6de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Descartes08ForMGMember_a3461472-f457-4f71-913e-7be413902b44" xlink:href="rnac-20241231.xsd#rnac_Descartes08ForMGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_24d2660c-96e2-48c4-a1ab-b20f5e7dd6de" xlink:to="loc_rnac_Descartes08ForMGMember_a3461472-f457-4f71-913e-7be413902b44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Descartes08ForSLEMember_cf1bf6de-7476-4c5e-b9b1-383d814df7c8" xlink:href="rnac-20241231.xsd#rnac_Descartes08ForSLEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_24d2660c-96e2-48c4-a1ab-b20f5e7dd6de" xlink:to="loc_rnac_Descartes08ForSLEMember_cf1bf6de-7476-4c5e-b9b1-383d814df7c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d7003181-63f5-4335-8383-da88a66fa87b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6afda63-d307-4056-829b-d1be299b868c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d7003181-63f5-4335-8383-da88a66fa87b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e70c7d62-70d9-4be6-9e91-e604f6358d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6afda63-d307-4056-829b-d1be299b868c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e70c7d62-70d9-4be6-9e91-e604f6358d02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6ec6a5d0-8ba0-43f1-a95b-5f710108a4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6afda63-d307-4056-829b-d1be299b868c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6ec6a5d0-8ba0-43f1-a95b-5f710108a4e2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e41e310e-6abb-40fb-a747-18a9d8539d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8da6e31-10ac-48cb-9eb1-c8babc2c51de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e41e310e-6abb-40fb-a747-18a9d8539d1d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8da6e31-10ac-48cb-9eb1-c8babc2c51de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_80994fe2-def2-4ac0-99a4-04f01b3b4cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8da6e31-10ac-48cb-9eb1-c8babc2c51de" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_80994fe2-def2-4ac0-99a4-04f01b3b4cbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_80994fe2-def2-4ac0-99a4-04f01b3b4cbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_80994fe2-def2-4ac0-99a4-04f01b3b4cbc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_80994fe2-def2-4ac0-99a4-04f01b3b4cbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_80994fe2-def2-4ac0-99a4-04f01b3b4cbc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_7b556813-6113-4827-a095-a0a76714e7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:to="loc_us-gaap_StockCompensationPlanMember_7b556813-6113-4827-a095-a0a76714e7d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b1caa41f-55e1-4407-b341-287c314c7bba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:to="loc_us-gaap_WarrantMember_b1caa41f-55e1-4407-b341-287c314c7bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_817fb3d4-09f5-4c20-afe6-17cffbeb9f63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:to="loc_us-gaap_PreferredStockMember_817fb3d4-09f5-4c20-afe6-17cffbeb9f63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ForwardContractToIssueSharesMember_0cebc113-d34e-4780-b55f-d8e8250c48b0" xlink:href="rnac-20241231.xsd#rnac_ForwardContractToIssueSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:to="loc_rnac_ForwardContractToIssueSharesMember_0cebc113-d34e-4780-b55f-d8e8250c48b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SeriesAPreferredStockOptionsMember_7dbe6f68-e6ee-4d1d-ac47-c9feb0f3511a" xlink:href="rnac-20241231.xsd#rnac_SeriesAPreferredStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:to="loc_rnac_SeriesAPreferredStockOptionsMember_7dbe6f68-e6ee-4d1d-ac47-c9feb0f3511a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ff085094-d09d-4709-81f3-91f82ad3b119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8da6e31-10ac-48cb-9eb1-c8babc2c51de" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ff085094-d09d-4709-81f3-91f82ad3b119" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ff085094-d09d-4709-81f3-91f82ad3b119_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ff085094-d09d-4709-81f3-91f82ad3b119" xlink:to="loc_us-gaap_ClassOfStockDomain_ff085094-d09d-4709-81f3-91f82ad3b119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a36e4dd3-c8ae-44a2-867f-9af68fd2e557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ff085094-d09d-4709-81f3-91f82ad3b119" xlink:to="loc_us-gaap_ClassOfStockDomain_a36e4dd3-c8ae-44a2-867f-9af68fd2e557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2ea2df4c-225d-4e8e-b1b7-36b5c5868c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a36e4dd3-c8ae-44a2-867f-9af68fd2e557" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2ea2df4c-225d-4e8e-b1b7-36b5c5868c2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_b8202f0f-df01-4184-b8df-c46ac4c5b1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a36e4dd3-c8ae-44a2-867f-9af68fd2e557" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_b8202f0f-df01-4184-b8df-c46ac4c5b1eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_139a25a0-f321-4572-b9c9-cb805d01948b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e41e310e-6abb-40fb-a747-18a9d8539d1d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_139a25a0-f321-4572-b9c9-cb805d01948b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fa3a06f0-07bd-45d2-8c48-7ce55c7f2f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fa3a06f0-07bd-45d2-8c48-7ce55c7f2f3d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32d37e49-341d-4ea6-822f-08b8510f5041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32d37e49-341d-4ea6-822f-08b8510f5041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_32d37e49-341d-4ea6-822f-08b8510f5041_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32d37e49-341d-4ea6-822f-08b8510f5041" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_32d37e49-341d-4ea6-822f-08b8510f5041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c1763540-ddc2-4c4c-b41f-46b1f7386802" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32d37e49-341d-4ea6-822f-08b8510f5041" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c1763540-ddc2-4c4c-b41f-46b1f7386802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_652c1854-d842-44dc-b9bf-c4197db68d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c1763540-ddc2-4c4c-b41f-46b1f7386802" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_652c1854-d842-44dc-b9bf-c4197db68d4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_18805806-bc97-4778-9dc6-cc86901ede40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_18805806-bc97-4778-9dc6-cc86901ede40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_18805806-bc97-4778-9dc6-cc86901ede40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_18805806-bc97-4778-9dc6-cc86901ede40" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_18805806-bc97-4778-9dc6-cc86901ede40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b285cb00-c013-40a8-949d-025940d8697e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_18805806-bc97-4778-9dc6-cc86901ede40" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b285cb00-c013-40a8-949d-025940d8697e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_51b3abed-1480-4ede-90aa-fea19b9cef62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b285cb00-c013-40a8-949d-025940d8697e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_51b3abed-1480-4ede-90aa-fea19b9cef62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17360b21-fac7-4a5d-8ce6-3079f089b676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17360b21-fac7-4a5d-8ce6-3079f089b676" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17360b21-fac7-4a5d-8ce6-3079f089b676_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17360b21-fac7-4a5d-8ce6-3079f089b676" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17360b21-fac7-4a5d-8ce6-3079f089b676_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24b35713-f719-4065-a44f-6b04d940a373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17360b21-fac7-4a5d-8ce6-3079f089b676" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24b35713-f719-4065-a44f-6b04d940a373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_589b5bf6-bc78-498c-a9de-38e3c7222d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24b35713-f719-4065-a44f-6b04d940a373" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_589b5bf6-bc78-498c-a9de-38e3c7222d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_99c7b77b-ef9d-41ca-a3ba-370ba5d404e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24b35713-f719-4065-a44f-6b04d940a373" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_99c7b77b-ef9d-41ca-a3ba-370ba5d404e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_979b0f2a-2497-4226-803b-856887c9a507" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24b35713-f719-4065-a44f-6b04d940a373" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_979b0f2a-2497-4226-803b-856887c9a507" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_f2985129-4a9d-452d-8b3c-7ad872e5e798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fa3a06f0-07bd-45d2-8c48-7ce55c7f2f3d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_f2985129-4a9d-452d-8b3c-7ad872e5e798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7338b79a-81f1-45fc-94a2-2a2ff15c1d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f2985129-4a9d-452d-8b3c-7ad872e5e798" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7338b79a-81f1-45fc-94a2-2a2ff15c1d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ed2ebd4d-6d20-4453-82a0-925b92218b61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f2985129-4a9d-452d-8b3c-7ad872e5e798" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ed2ebd4d-6d20-4453-82a0-925b92218b61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fa3a06f0-07bd-45d2-8c48-7ce55c7f2f3d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_a89a8bb4-9890-4eef-830c-ffb52779c89b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_a89a8bb4-9890-4eef-830c-ffb52779c89b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiability_0b56c3d0-8711-4753-937e-00279a36183a" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:to="loc_rnac_ContingentValueRightLiability_0b56c3d0-8711-4753-937e-00279a36183a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_74fc1b22-eca6-47ee-97ee-f0762ef68ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_74fc1b22-eca6-47ee-97ee-f0762ef68ef6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_34db10f8-db28-4e81-927d-a6cb6fb5c4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_34db10f8-db28-4e81-927d-a6cb6fb5c4a6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1421a63e-2cfb-4645-96c7-cfe0045eb6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1421a63e-2cfb-4645-96c7-cfe0045eb6a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1421a63e-2cfb-4645-96c7-cfe0045eb6a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1421a63e-2cfb-4645-96c7-cfe0045eb6a3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1421a63e-2cfb-4645-96c7-cfe0045eb6a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6e646340-a1ed-4a3b-aafc-1b182961c601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1421a63e-2cfb-4645-96c7-cfe0045eb6a3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6e646340-a1ed-4a3b-aafc-1b182961c601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2f67638d-d900-473a-84e1-c01e4572ed77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6e646340-a1ed-4a3b-aafc-1b182961c601" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2f67638d-d900-473a-84e1-c01e4572ed77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_d244e75e-134e-411c-af76-07ce142d02cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_ValuationTechniqueAxis_d244e75e-134e-411c-af76-07ce142d02cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_d244e75e-134e-411c-af76-07ce142d02cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_d244e75e-134e-411c-af76-07ce142d02cb" xlink:to="loc_us-gaap_ValuationTechniqueDomain_d244e75e-134e-411c-af76-07ce142d02cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_2628a7d7-3316-477a-a91d-e9e84085324f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_d244e75e-134e-411c-af76-07ce142d02cb" xlink:to="loc_us-gaap_ValuationTechniqueDomain_2628a7d7-3316-477a-a91d-e9e84085324f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_776b6f02-b09d-447d-b24f-5bfcb8fa1f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_2628a7d7-3316-477a-a91d-e9e84085324f" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_776b6f02-b09d-447d-b24f-5bfcb8fa1f0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01fda84c-3ce5-4708-822a-c97df4d182d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01fda84c-3ce5-4708-822a-c97df4d182d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01fda84c-3ce5-4708-822a-c97df4d182d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01fda84c-3ce5-4708-822a-c97df4d182d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01fda84c-3ce5-4708-822a-c97df4d182d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1482b21d-bf1f-41a6-8ced-e5b920241553" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01fda84c-3ce5-4708-822a-c97df4d182d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1482b21d-bf1f-41a6-8ced-e5b920241553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_f51b1f29-f943-48eb-9283-bb9c1a85948b" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1482b21d-bf1f-41a6-8ced-e5b920241553" xlink:to="loc_rnac_OldCartesianMember_f51b1f29-f943-48eb-9283-bb9c1a85948b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_85513935-3951-45be-8e56-f1a3a88aa060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_85513935-3951-45be-8e56-f1a3a88aa060" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_85513935-3951-45be-8e56-f1a3a88aa060_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_85513935-3951-45be-8e56-f1a3a88aa060" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_85513935-3951-45be-8e56-f1a3a88aa060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_12e2349d-0ecc-41c1-86da-ee18ba85f041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_85513935-3951-45be-8e56-f1a3a88aa060" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_12e2349d-0ecc-41c1-86da-ee18ba85f041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2022WarrantsMember_14bfa608-374b-4b7a-be4e-31901deb5fda" xlink:href="rnac-20241231.xsd#rnac_A2022WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_12e2349d-0ecc-41c1-86da-ee18ba85f041" xlink:to="loc_rnac_A2022WarrantsMember_14bfa608-374b-4b7a-be4e-31901deb5fda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9299da9b-b7e0-4220-a3f6-32ab11038c45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9299da9b-b7e0-4220-a3f6-32ab11038c45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9299da9b-b7e0-4220-a3f6-32ab11038c45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9299da9b-b7e0-4220-a3f6-32ab11038c45" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9299da9b-b7e0-4220-a3f6-32ab11038c45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a146391f-17e9-4863-b3bb-f3a82796d425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9299da9b-b7e0-4220-a3f6-32ab11038c45" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a146391f-17e9-4863-b3bb-f3a82796d425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightMember_b8d5a359-434e-4787-aa65-d8e340ec7609" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a146391f-17e9-4863-b3bb-f3a82796d425" xlink:to="loc_rnac_ContingentValueRightMember_b8d5a359-434e-4787-aa65-d8e340ec7609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_859a8aaf-8b13-4b47-9629-aa888f827af0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_859a8aaf-8b13-4b47-9629-aa888f827af0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_859a8aaf-8b13-4b47-9629-aa888f827af0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_859a8aaf-8b13-4b47-9629-aa888f827af0" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_859a8aaf-8b13-4b47-9629-aa888f827af0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_a28b3453-fb8a-464c-8007-0267a95f5a97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_859a8aaf-8b13-4b47-9629-aa888f827af0" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_a28b3453-fb8a-464c-8007-0267a95f5a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_508aaf67-f04c-4c79-902d-bec319c70b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_a28b3453-fb8a-464c-8007-0267a95f5a97" xlink:to="loc_us-gaap_PreferredStockMember_508aaf67-f04c-4c79-902d-bec319c70b19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ff85f5-9b53-4fe9-9b30-4284f5ef39d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ff85f5-9b53-4fe9-9b30-4284f5ef39d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5ff85f5-9b53-4fe9-9b30-4284f5ef39d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ff85f5-9b53-4fe9-9b30-4284f5ef39d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5ff85f5-9b53-4fe9-9b30-4284f5ef39d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f0c20e97-be6e-4f4a-a485-0de2dc530a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ff85f5-9b53-4fe9-9b30-4284f5ef39d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f0c20e97-be6e-4f4a-a485-0de2dc530a3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member_01de8263-910a-4833-842e-c6fa16b73543" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f0c20e97-be6e-4f4a-a485-0de2dc530a3e" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2023Member_01de8263-910a-4833-842e-c6fa16b73543" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2ce0e954-9b0a-4f03-bc24-347235234883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2ce0e954-9b0a-4f03-bc24-347235234883" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ce0e954-9b0a-4f03-bc24-347235234883_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ce0e954-9b0a-4f03-bc24-347235234883" xlink:to="loc_us-gaap_ClassOfStockDomain_2ce0e954-9b0a-4f03-bc24-347235234883_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_90ffa84a-3ec9-4518-9caf-94b2aefd2373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ce0e954-9b0a-4f03-bc24-347235234883" xlink:to="loc_us-gaap_ClassOfStockDomain_90ffa84a-3ec9-4518-9caf-94b2aefd2373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_693e6ceb-b93d-4a48-9dd6-c605914cda85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_90ffa84a-3ec9-4518-9caf-94b2aefd2373" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_693e6ceb-b93d-4a48-9dd6-c605914cda85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8e28a22a-bb4f-4f7b-802f-b5b5a8b0804c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_srt_CounterpartyNameAxis_8e28a22a-bb4f-4f7b-802f-b5b5a8b0804c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e28a22a-bb4f-4f7b-802f-b5b5a8b0804c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8e28a22a-bb4f-4f7b-802f-b5b5a8b0804c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e28a22a-bb4f-4f7b-802f-b5b5a8b0804c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_01eb0595-6f1a-4f2e-8ab8-7b0814e0465d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8e28a22a-bb4f-4f7b-802f-b5b5a8b0804c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_01eb0595-6f1a-4f2e-8ab8-7b0814e0465d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SOBIPurchaseAgreementMember_f91243d1-8080-4212-9613-00f9264b16dd" xlink:href="rnac-20241231.xsd#rnac_SOBIPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_01eb0595-6f1a-4f2e-8ab8-7b0814e0465d" xlink:to="loc_rnac_SOBIPurchaseAgreementMember_f91243d1-8080-4212-9613-00f9264b16dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_855ce65e-d2d5-4952-a7d7-34c91771459e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_855ce65e-d2d5-4952-a7d7-34c91771459e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_855ce65e-d2d5-4952-a7d7-34c91771459e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_855ce65e-d2d5-4952-a7d7-34c91771459e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_855ce65e-d2d5-4952-a7d7-34c91771459e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a2c1c2f-a400-493f-aff9-7e76cd931304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_855ce65e-d2d5-4952-a7d7-34c91771459e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a2c1c2f-a400-493f-aff9-7e76cd931304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4dd9f39d-cbbe-4232-9e66-5db53ebe9e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a2c1c2f-a400-493f-aff9-7e76cd931304" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4dd9f39d-cbbe-4232-9e66-5db53ebe9e56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f010cec1-7a72-4a85-acc0-89beb37ca53d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f010cec1-7a72-4a85-acc0-89beb37ca53d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6a04fe42-84e0-4a59-ba29-1102790b700d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6a04fe42-84e0-4a59-ba29-1102790b700d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_a579e119-c983-43ba-9633-0029f0ab99a2" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_a579e119-c983-43ba-9633-0029f0ab99a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead_7c7036ef-e8a4-4a67-ab04-a74d86887fa4" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead_7c7036ef-e8a4-4a67-ab04-a74d86887fa4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dfcad98a-2556-42ea-8659-6db9b6024e34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dfcad98a-2556-42ea-8659-6db9b6024e34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_9ec0f8cc-c4df-436e-aa5e-f4dd6cb7c51f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_9ec0f8cc-c4df-436e-aa5e-f4dd6cb7c51f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c71ed4f7-3f2f-44ec-9559-6fd1621fc355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c71ed4f7-3f2f-44ec-9559-6fd1621fc355" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_55dd23dc-63fe-4846-b1fc-9b8b7bb6be4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_55dd23dc-63fe-4846-b1fc-9b8b7bb6be4a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_febdc202-655c-449c-b6e9-a3c158d92d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_febdc202-655c-449c-b6e9-a3c158d92d90" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SettlementOfDerivativeLiabilityShares_37d89aec-dbbf-4f62-ba9d-3287d522f072" xlink:href="rnac-20241231.xsd#rnac_SettlementOfDerivativeLiabilityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_rnac_SettlementOfDerivativeLiabilityShares_37d89aec-dbbf-4f62-ba9d-3287d522f072" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IssuanceOfStockForSettlementOfForwardContractLiability_d1caa97f-8089-4b49-a261-3cab6b05ca32" xlink:href="rnac-20241231.xsd#rnac_IssuanceOfStockForSettlementOfForwardContractLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_rnac_IssuanceOfStockForSettlementOfForwardContractLiability_d1caa97f-8089-4b49-a261-3cab6b05ca32" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_dbde944c-de8a-4c33-b0fa-d9a824ebb423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_dbde944c-de8a-4c33-b0fa-d9a824ebb423" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_adb28cae-7b59-45e3-b6b3-c298af51e99f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:to="loc_us-gaap_ValuationTechniqueAxis_adb28cae-7b59-45e3-b6b3-c298af51e99f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_adb28cae-7b59-45e3-b6b3-c298af51e99f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_adb28cae-7b59-45e3-b6b3-c298af51e99f" xlink:to="loc_us-gaap_ValuationTechniqueDomain_adb28cae-7b59-45e3-b6b3-c298af51e99f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_359b0049-9717-4711-a6b5-b1fd114fff29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_adb28cae-7b59-45e3-b6b3-c298af51e99f" xlink:to="loc_us-gaap_ValuationTechniqueDomain_359b0049-9717-4711-a6b5-b1fd114fff29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_e92c056a-f657-48e8-99df-3d5bb50d08f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_359b0049-9717-4711-a6b5-b1fd114fff29" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_e92c056a-f657-48e8-99df-3d5bb50d08f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_62f52111-1b09-4cac-baff-f9d97f739b81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_62f52111-1b09-4cac-baff-f9d97f739b81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_62f52111-1b09-4cac-baff-f9d97f739b81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_62f52111-1b09-4cac-baff-f9d97f739b81" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_62f52111-1b09-4cac-baff-f9d97f739b81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_62f52111-1b09-4cac-baff-f9d97f739b81" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6d0d4a2c-401b-4dd9-a880-0f100aa8b7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6d0d4a2c-401b-4dd9-a880-0f100aa8b7b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b96ecea6-e7e8-45e0-b1e5-cd944f0f3246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b96ecea6-e7e8-45e0-b1e5-cd944f0f3246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_c36e4a1b-1c64-43d6-8ae7-ad269b7085d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_c36e4a1b-1c64-43d6-8ae7-ad269b7085d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_4b350f8f-d989-491e-9b22-91650566b245" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_4b350f8f-d989-491e-9b22-91650566b245" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_139ffe9a-90d8-4438-99f0-b801fdc26e01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_139ffe9a-90d8-4438-99f0-b801fdc26e01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_139ffe9a-90d8-4438-99f0-b801fdc26e01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_139ffe9a-90d8-4438-99f0-b801fdc26e01" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_139ffe9a-90d8-4438-99f0-b801fdc26e01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ad417133-e5b8-4e6d-96ba-a03f546d6a71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_139ffe9a-90d8-4438-99f0-b801fdc26e01" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ad417133-e5b8-4e6d-96ba-a03f546d6a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2019WarrantsMember_1b7f6607-0689-4494-839d-6ca976722077" xlink:href="rnac-20241231.xsd#rnac_A2019WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad417133-e5b8-4e6d-96ba-a03f546d6a71" xlink:to="loc_rnac_A2019WarrantsMember_1b7f6607-0689-4494-839d-6ca976722077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2022WarrantsMember_d87390db-e98f-4846-b4ef-935d05e53860" xlink:href="rnac-20241231.xsd#rnac_A2022WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad417133-e5b8-4e6d-96ba-a03f546d6a71" xlink:to="loc_rnac_A2022WarrantsMember_d87390db-e98f-4846-b4ef-935d05e53860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f169cd3e-36be-46f5-be19-6f0489352532" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_dbde944c-de8a-4c33-b0fa-d9a824ebb423" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f169cd3e-36be-46f5-be19-6f0489352532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f4513049-d84a-4376-a6c5-12246ad15488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_dbde944c-de8a-4c33-b0fa-d9a824ebb423" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f4513049-d84a-4376-a6c5-12246ad15488" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_923c008a-33cc-4a8f-9c19-38c72407f1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ec70468-be53-4384-a4fc-91f5e3040e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_923c008a-33cc-4a8f-9c19-38c72407f1d2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ec70468-be53-4384-a4fc-91f5e3040e3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_6a08a28a-732f-45d0-9fe3-7bbc49b375ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ec70468-be53-4384-a4fc-91f5e3040e3f" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_6a08a28a-732f-45d0-9fe3-7bbc49b375ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a08a28a-732f-45d0-9fe3-7bbc49b375ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_6a08a28a-732f-45d0-9fe3-7bbc49b375ef" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a08a28a-732f-45d0-9fe3-7bbc49b375ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fe3f0aee-1bdf-4158-8639-1a49825a1697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_6a08a28a-732f-45d0-9fe3-7bbc49b375ef" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fe3f0aee-1bdf-4158-8639-1a49825a1697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_82491ae3-46de-4df4-a0fa-dd3dc1132698" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fe3f0aee-1bdf-4158-8639-1a49825a1697" xlink:to="loc_us-gaap_WarrantMember_82491ae3-46de-4df4-a0fa-dd3dc1132698" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightMember_f183496e-bf6c-428d-9d6b-6db2e7a5ce42" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fe3f0aee-1bdf-4158-8639-1a49825a1697" xlink:to="loc_rnac_ContingentValueRightMember_f183496e-bf6c-428d-9d6b-6db2e7a5ce42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37f43ac0-99aa-4e72-b9e2-16d689ff1ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_923c008a-33cc-4a8f-9c19-38c72407f1d2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37f43ac0-99aa-4e72-b9e2-16d689ff1ad2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_53015746-ef14-47b5-b422-cb24a4a4e895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37f43ac0-99aa-4e72-b9e2-16d689ff1ad2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_53015746-ef14-47b5-b422-cb24a4a4e895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_997f4c23-5e9c-4951-9d74-7592a40af13c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37f43ac0-99aa-4e72-b9e2-16d689ff1ad2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_997f4c23-5e9c-4951-9d74-7592a40af13c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e9fe9160-0c1b-4a2b-aef7-3af1025315c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_899e6bd9-0a7d-4b00-97cb-eebc9929292b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_899e6bd9-0a7d-4b00-97cb-eebc9929292b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ff894ed-da5a-4e0e-85a0-6db833b894e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ff894ed-da5a-4e0e-85a0-6db833b894e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ff894ed-da5a-4e0e-85a0-6db833b894e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ff894ed-da5a-4e0e-85a0-6db833b894e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ff894ed-da5a-4e0e-85a0-6db833b894e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97df625c-73c0-469b-8117-06ffbdb51cff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ff894ed-da5a-4e0e-85a0-6db833b894e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97df625c-73c0-469b-8117-06ffbdb51cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5f2a34f5-7d93-4f6b-8909-affbd84c7b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97df625c-73c0-469b-8117-06ffbdb51cff" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5f2a34f5-7d93-4f6b-8909-affbd84c7b91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e7156c50-2c00-4284-8706-b34f15b91cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e7156c50-2c00-4284-8706-b34f15b91cc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e7156c50-2c00-4284-8706-b34f15b91cc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e7156c50-2c00-4284-8706-b34f15b91cc3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e7156c50-2c00-4284-8706-b34f15b91cc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5a64aba6-b1d5-42fb-a0d2-c6c80ec3dcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e7156c50-2c00-4284-8706-b34f15b91cc3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5a64aba6-b1d5-42fb-a0d2-c6c80ec3dcbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ProbabilityOfSuccessMember_a27bdc7c-cdac-48ac-a67c-43ed66ad00b3" xlink:href="rnac-20241231.xsd#rnac_ProbabilityOfSuccessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5a64aba6-b1d5-42fb-a0d2-c6c80ec3dcbc" xlink:to="loc_rnac_ProbabilityOfSuccessMember_a27bdc7c-cdac-48ac-a67c-43ed66ad00b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_MeasurementInputRevenueVolatilityMember_b9d80c86-7fed-4189-9098-f36f33880ca9" xlink:href="rnac-20241231.xsd#rnac_MeasurementInputRevenueVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5a64aba6-b1d5-42fb-a0d2-c6c80ec3dcbc" xlink:to="loc_rnac_MeasurementInputRevenueVolatilityMember_b9d80c86-7fed-4189-9098-f36f33880ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_ba80b9fc-cefc-481e-9df2-3c876f0cfe42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5a64aba6-b1d5-42fb-a0d2-c6c80ec3dcbc" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_ba80b9fc-cefc-481e-9df2-3c876f0cfe42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e24e5276-6e37-4395-b68c-c01e80a31cbf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:to="loc_srt_RangeAxis_e24e5276-6e37-4395-b68c-c01e80a31cbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e24e5276-6e37-4395-b68c-c01e80a31cbf_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e24e5276-6e37-4395-b68c-c01e80a31cbf" xlink:to="loc_srt_RangeMember_e24e5276-6e37-4395-b68c-c01e80a31cbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_12e06aa8-a664-4f73-9bf0-dcfa4d5e7b4f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e24e5276-6e37-4395-b68c-c01e80a31cbf" xlink:to="loc_srt_RangeMember_12e06aa8-a664-4f73-9bf0-dcfa4d5e7b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d444faa-1f97-4cd4-9bd1-5426d2950089" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_12e06aa8-a664-4f73-9bf0-dcfa4d5e7b4f" xlink:to="loc_srt_MinimumMember_9d444faa-1f97-4cd4-9bd1-5426d2950089" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3881cb74-c5a8-4af4-bbff-cae209a3fa8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_12e06aa8-a664-4f73-9bf0-dcfa4d5e7b4f" xlink:to="loc_srt_MaximumMember_3881cb74-c5a8-4af4-bbff-cae209a3fa8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityMeasurementInput_22c91bfe-42cd-4dbd-8add-c5ae91225953" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_899e6bd9-0a7d-4b00-97cb-eebc9929292b" xlink:to="loc_rnac_ContingentValueRightLiabilityMeasurementInput_22c91bfe-42cd-4dbd-8add-c5ae91225953" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d217edc7-051c-46a7-8104-679336c892e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_50a106e6-de49-490d-a70e-58659e2f76e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d217edc7-051c-46a7-8104-679336c892e9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_50a106e6-de49-490d-a70e-58659e2f76e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_48e644bc-7851-4e19-b08a-0b3a5b204936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_50a106e6-de49-490d-a70e-58659e2f76e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_48e644bc-7851-4e19-b08a-0b3a5b204936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48e644bc-7851-4e19-b08a-0b3a5b204936_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_48e644bc-7851-4e19-b08a-0b3a5b204936" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48e644bc-7851-4e19-b08a-0b3a5b204936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_48e644bc-7851-4e19-b08a-0b3a5b204936" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LaboratoryEquipmentMember_e21e59b9-c867-4043-80a3-995dbb155fe4" xlink:href="rnac-20241231.xsd#rnac_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_rnac_LaboratoryEquipmentMember_e21e59b9-c867-4043-80a3-995dbb155fe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d5bb91c2-83e3-48c7-9264-ab1bc7c57c96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_us-gaap_ComputerEquipmentMember_d5bb91c2-83e3-48c7-9264-ab1bc7c57c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_eaff684b-9b2f-4c64-970b-5db01d5c4797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_eaff684b-9b2f-4c64-970b-5db01d5c4797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ed9d6e2d-dd78-4009-9053-8112ecc9e7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ed9d6e2d-dd78-4009-9053-8112ecc9e7b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_59cc9c92-7174-4daf-a9e5-0595b7d66c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_us-gaap_OfficeEquipmentMember_59cc9c92-7174-4daf-a9e5-0595b7d66c1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_8c32c61d-2fd1-48c3-a6ee-9fbe1626bfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_us-gaap_ConstructionInProgressMember_8c32c61d-2fd1-48c3-a6ee-9fbe1626bfaa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_36864527-eebe-4b48-8fc3-4d82aafea5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d217edc7-051c-46a7-8104-679336c892e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_36864527-eebe-4b48-8fc3-4d82aafea5c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_04e8e6c6-cd9f-4f1e-88ad-cd401f527ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d217edc7-051c-46a7-8104-679336c892e9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_04e8e6c6-cd9f-4f1e-88ad-cd401f527ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4229a6b0-24af-4c1d-b905-ea09f8d951f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d217edc7-051c-46a7-8104-679336c892e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4229a6b0-24af-4c1d-b905-ea09f8d951f2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#Leases7495NewHorizonWayLeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2d951e21-b6e8-4b0a-9851-c78e66ee74c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2d951e21-b6e8-4b0a-9851-c78e66ee74c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementAxis_08c1b591-3796-431a-93e9-c66aac116464" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2d951e21-b6e8-4b0a-9851-c78e66ee74c4" xlink:to="loc_rnac_LeaseArrangementAxis_08c1b591-3796-431a-93e9-c66aac116464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_08c1b591-3796-431a-93e9-c66aac116464_default" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rnac_LeaseArrangementAxis_08c1b591-3796-431a-93e9-c66aac116464" xlink:to="loc_rnac_LeaseArrangementDomain_08c1b591-3796-431a-93e9-c66aac116464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_35754239-1d7b-4fcd-aaab-a07627cfd860" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rnac_LeaseArrangementAxis_08c1b591-3796-431a-93e9-c66aac116464" xlink:to="loc_rnac_LeaseArrangementDomain_35754239-1d7b-4fcd-aaab-a07627cfd860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A7495NewHorizonWayLeaseMember_d17d0d22-aed6-4152-9175-84d4efec42cc" xlink:href="rnac-20241231.xsd#rnac_A7495NewHorizonWayLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_LeaseArrangementDomain_35754239-1d7b-4fcd-aaab-a07627cfd860" xlink:to="loc_rnac_A7495NewHorizonWayLeaseMember_d17d0d22-aed6-4152-9175-84d4efec42cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d8290023-5490-48c6-a7eb-c3dad2321c6d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2d951e21-b6e8-4b0a-9851-c78e66ee74c4" xlink:to="loc_srt_RangeAxis_d8290023-5490-48c6-a7eb-c3dad2321c6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d8290023-5490-48c6-a7eb-c3dad2321c6d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d8290023-5490-48c6-a7eb-c3dad2321c6d" xlink:to="loc_srt_RangeMember_d8290023-5490-48c6-a7eb-c3dad2321c6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f323a234-14e4-48bc-bcf5-170a1f5e3425" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d8290023-5490-48c6-a7eb-c3dad2321c6d" xlink:to="loc_srt_RangeMember_f323a234-14e4-48bc-bcf5-170a1f5e3425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a78d5749-40fb-4f38-9c27-41713c7c8378" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f323a234-14e4-48bc-bcf5-170a1f5e3425" xlink:to="loc_srt_MinimumMember_a78d5749-40fb-4f38-9c27-41713c7c8378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4270227d-7890-45a5-bc21-f27f0a1a6022" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f323a234-14e4-48bc-bcf5-170a1f5e3425" xlink:to="loc_srt_MaximumMember_4270227d-7890-45a5-bc21-f27f0a1a6022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_fdd65c30-e21c-4868-bae6-7b3b46c53680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_fdd65c30-e21c-4868-bae6-7b3b46c53680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7a88b7b3-7b17-4a95-9a17-f5a14469bdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7a88b7b3-7b17-4a95-9a17-f5a14469bdcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend_2b724a58-0c02-4d22-81eb-9a0dea2362bd" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseNumberOfOptionsToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend_2b724a58-0c02-4d22-81eb-9a0dea2362bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ae3f8c54-17a6-4028-8623-839f085a21f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ae3f8c54-17a6-4028-8623-839f085a21f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLeaseCostPercentage_07460ff1-3c0c-4614-a11f-17c023b31332" xlink:href="rnac-20241231.xsd#rnac_OperatingLeaseCostPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_OperatingLeaseCostPercentage_07460ff1-3c0c-4614-a11f-17c023b31332" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseMonthlyBaseRent_69ae43d9-7ab7-445d-a9e0-5d1798eb4685" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseMonthlyBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_LesseeOperatingLeaseMonthlyBaseRent_69ae43d9-7ab7-445d-a9e0-5d1798eb4685" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne_22d1aa82-222b-4782-8bbf-9f08b1cd35b8" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne_22d1aa82-222b-4782-8bbf-9f08b1cd35b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement_7f5601c0-9a33-4685-a831-581b761e19a6" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement_7f5601c0-9a33-4685-a831-581b761e19a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4ff5430b-2d1d-4097-a84f-6d2daa5e7b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_OperatingLeaseLiability_4ff5430b-2d1d-4097-a84f-6d2daa5e7b8f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_684f1c54-05d6-450a-bbff-735c812290bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_684f1c54-05d6-450a-bbff-735c812290bc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability_a15ee0f9-afe3-4a38-8781-4ea06b35c790" xlink:href="rnac-20241231.xsd#rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability_a15ee0f9-afe3-4a38-8781-4ea06b35c790" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fff31d18-ff51-43c6-9d81-22716b6db51a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fff31d18-ff51-43c6-9d81-22716b6db51a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne_22111bcb-5933-4fa3-9e38-3acb7ae22289" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne_22111bcb-5933-4fa3-9e38-3acb7ae22289" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b6f9f375-68f6-4ea7-b7bc-f7ceb24fd64e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b6f9f375-68f6-4ea7-b7bc-f7ceb24fd64e" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#Leases65GroveStreetLeaseNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementAxis_10dbff29-2671-4b18-846e-ecedfe463264" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:to="loc_rnac_LeaseArrangementAxis_10dbff29-2671-4b18-846e-ecedfe463264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_10dbff29-2671-4b18-846e-ecedfe463264_default" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rnac_LeaseArrangementAxis_10dbff29-2671-4b18-846e-ecedfe463264" xlink:to="loc_rnac_LeaseArrangementDomain_10dbff29-2671-4b18-846e-ecedfe463264_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_ab300fe8-7257-4100-8a94-d6719ac64418" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rnac_LeaseArrangementAxis_10dbff29-2671-4b18-846e-ecedfe463264" xlink:to="loc_rnac_LeaseArrangementDomain_ab300fe8-7257-4100-8a94-d6719ac64418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A65GroveStreetWatertownMAMember_f1a77de4-6662-497e-a476-8c68e3c36c1f" xlink:href="rnac-20241231.xsd#rnac_A65GroveStreetWatertownMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_LeaseArrangementDomain_ab300fe8-7257-4100-8a94-d6719ac64418" xlink:to="loc_rnac_A65GroveStreetWatertownMAMember_f1a77de4-6662-497e-a476-8c68e3c36c1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9b1cbc6d-79ff-4607-a033-9f7e2e611782" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:to="loc_us-gaap_CreditFacilityAxis_9b1cbc6d-79ff-4607-a033-9f7e2e611782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9b1cbc6d-79ff-4607-a033-9f7e2e611782_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9b1cbc6d-79ff-4607-a033-9f7e2e611782" xlink:to="loc_us-gaap_CreditFacilityDomain_9b1cbc6d-79ff-4607-a033-9f7e2e611782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e2c33f3e-b9ad-4fb7-bd9b-54c88c93bd20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9b1cbc6d-79ff-4607-a033-9f7e2e611782" xlink:to="loc_us-gaap_CreditFacilityDomain_e2c33f3e-b9ad-4fb7-bd9b-54c88c93bd20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_928ff8ad-0a4e-4611-a163-0ccd0e0fc701" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_e2c33f3e-b9ad-4fb7-bd9b-54c88c93bd20" xlink:to="loc_us-gaap_LetterOfCreditMember_928ff8ad-0a4e-4611-a163-0ccd0e0fc701" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5bedfc35-d1c4-4902-bc88-1a65d1e1de2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5bedfc35-d1c4-4902-bc88-1a65d1e1de2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5bedfc35-d1c4-4902-bc88-1a65d1e1de2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5bedfc35-d1c4-4902-bc88-1a65d1e1de2f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5bedfc35-d1c4-4902-bc88-1a65d1e1de2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2eed2426-e4a5-497d-88e4-16c53bdd8765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5bedfc35-d1c4-4902-bc88-1a65d1e1de2f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2eed2426-e4a5-497d-88e4-16c53bdd8765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2da0c482-d8fc-432c-84db-3cb1eaea3caf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2eed2426-e4a5-497d-88e4-16c53bdd8765" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2da0c482-d8fc-432c-84db-3cb1eaea3caf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_77cd287d-0c01-4b40-a1c2-c1df526393e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2eed2426-e4a5-497d-88e4-16c53bdd8765" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_77cd287d-0c01-4b40-a1c2-c1df526393e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_3d99909b-863d-4203-ba1e-9b243b9c1c79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_3d99909b-863d-4203-ba1e-9b243b9c1c79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_17bc9f6a-0b1f-4570-abbe-9afb991d763e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_LeaseCost_17bc9f6a-0b1f-4570-abbe-9afb991d763e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_91f7a860-a877-4e3d-9c2a-3f0f2c6c023a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_91f7a860-a877-4e3d-9c2a-3f0f2c6c023a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_995c021b-c371-4d6e-94b4-c7b9635045b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_995c021b-c371-4d6e-94b4-c7b9635045b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d526e59e-8816-4804-8b0e-db2336cc8878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_RestrictedCash_d526e59e-8816-4804-8b0e-db2336cc8878" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLeaseBaseRent_26c5e0cb-f2c4-480f-8b9b-937053db7e74" xlink:href="rnac-20241231.xsd#rnac_OperatingLeaseBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_rnac_OperatingLeaseBaseRent_26c5e0cb-f2c4-480f-8b9b-937053db7e74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c855e348-b0bf-4380-86e4-c4f95cdc938f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c855e348-b0bf-4380-86e4-c4f95cdc938f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b2310a6c-fcb9-401d-920b-1149f21f1d86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_OperatingLeaseLiability_b2310a6c-fcb9-401d-920b-1149f21f1d86" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5b0760d6-30ef-49ce-831c-038c4ad0a3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5b0760d6-30ef-49ce-831c-038c4ad0a3e1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_41d5b9ff-3809-45f7-afba-bb39ccb859b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_41d5b9ff-3809-45f7-afba-bb39ccb859b9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_UpfrontRentalPayment_d40e13f3-74d3-4b9d-8d30-a4be4ebbe6c4" xlink:href="rnac-20241231.xsd#rnac_UpfrontRentalPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_rnac_UpfrontRentalPayment_d40e13f3-74d3-4b9d-8d30-a4be4ebbe6c4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_7267ae33-724c-4226-928c-20cf6810f84f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_7267ae33-724c-4226-928c-20cf6810f84f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3f0c6ede-445b-4150-99f5-15c219b0ebe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_AssetImpairmentCharges_3f0c6ede-445b-4150-99f5-15c219b0ebe9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_8ff401a1-d7ab-4335-b5b3-5e09cf45c964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_8ff401a1-d7ab-4335-b5b3-5e09cf45c964" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_da8ad8ba-a727-4a1b-8b77-1a1d78601d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_da8ad8ba-a727-4a1b-8b77-1a1d78601d3b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_19b3981d-d996-4f30-94d0-ffec5d6a3521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_da8ad8ba-a727-4a1b-8b77-1a1d78601d3b" xlink:to="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_19b3981d-d996-4f30-94d0-ffec5d6a3521" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#Leases704QuinceOrchardRoadLeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_1454d5ad-e710-4253-9355-5c3fcfdb783e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_36f42d3e-af08-4b82-8261-87e0b286adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1454d5ad-e710-4253-9355-5c3fcfdb783e" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_36f42d3e-af08-4b82-8261-87e0b286adb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementAxis_18487010-23d4-4488-aeb7-b7f7fcf55e04" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_36f42d3e-af08-4b82-8261-87e0b286adb2" xlink:to="loc_rnac_LeaseArrangementAxis_18487010-23d4-4488-aeb7-b7f7fcf55e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_18487010-23d4-4488-aeb7-b7f7fcf55e04_default" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rnac_LeaseArrangementAxis_18487010-23d4-4488-aeb7-b7f7fcf55e04" xlink:to="loc_rnac_LeaseArrangementDomain_18487010-23d4-4488-aeb7-b7f7fcf55e04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_a830ee3c-4c4c-419c-b5f5-55fff3072803" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rnac_LeaseArrangementAxis_18487010-23d4-4488-aeb7-b7f7fcf55e04" xlink:to="loc_rnac_LeaseArrangementDomain_a830ee3c-4c4c-419c-b5f5-55fff3072803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A704QuinceOrchardRoadLeasesMember_cca5b1a7-9ac3-4d58-8060-1c08abcc4790" xlink:href="rnac-20241231.xsd#rnac_A704QuinceOrchardRoadLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_LeaseArrangementDomain_a830ee3c-4c4c-419c-b5f5-55fff3072803" xlink:to="loc_rnac_A704QuinceOrchardRoadLeasesMember_cca5b1a7-9ac3-4d58-8060-1c08abcc4790" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NumberOfAcquiredOperatingLeases_36a4b9fd-54e9-4035-b25a-05e1ea330b6f" xlink:href="rnac-20241231.xsd#rnac_NumberOfAcquiredOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1454d5ad-e710-4253-9355-5c3fcfdb783e" xlink:to="loc_rnac_NumberOfAcquiredOperatingLeases_36a4b9fd-54e9-4035-b25a-05e1ea330b6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_658f6df3-2cbb-42e5-847f-f2f2c7362b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1454d5ad-e710-4253-9355-5c3fcfdb783e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_658f6df3-2cbb-42e5-847f-f2f2c7362b6b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#LeasesMoscowRussiaLeaseNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_4861ec46-59a7-4b35-9743-57ce11459030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_18e767a8-46af-4a84-9f7c-8d6292a0c8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_4861ec46-59a7-4b35-9743-57ce11459030" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_18e767a8-46af-4a84-9f7c-8d6292a0c8bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementAxis_90dcae23-fc75-4007-836b-93c583ba9193" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_18e767a8-46af-4a84-9f7c-8d6292a0c8bb" xlink:to="loc_rnac_LeaseArrangementAxis_90dcae23-fc75-4007-836b-93c583ba9193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_90dcae23-fc75-4007-836b-93c583ba9193_default" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rnac_LeaseArrangementAxis_90dcae23-fc75-4007-836b-93c583ba9193" xlink:to="loc_rnac_LeaseArrangementDomain_90dcae23-fc75-4007-836b-93c583ba9193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_354f64ac-b132-4f66-a277-2bcebda2e5a2" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rnac_LeaseArrangementAxis_90dcae23-fc75-4007-836b-93c583ba9193" xlink:to="loc_rnac_LeaseArrangementDomain_354f64ac-b132-4f66-a277-2bcebda2e5a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_MoscowRussiaLeaseMember_c2b514e3-33a2-4f57-97ae-da45df9f3f09" xlink:href="rnac-20241231.xsd#rnac_MoscowRussiaLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_LeaseArrangementDomain_354f64ac-b132-4f66-a277-2bcebda2e5a2" xlink:to="loc_rnac_MoscowRussiaLeaseMember_c2b514e3-33a2-4f57-97ae-da45df9f3f09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0046237e-8312-4414-8727-5fd71580f5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_4861ec46-59a7-4b35-9743-57ce11459030" xlink:to="loc_us-gaap_LeaseCost_0046237e-8312-4414-8727-5fd71580f5e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/DebtDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_4d5508db-39c7-40d4-8630-cbe839fc874c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_4d5508db-39c7-40d4-8630-cbe839fc874c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_44a98055-cd2a-4871-837b-c2f9f6c4bf78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4d5508db-39c7-40d4-8630-cbe839fc874c" xlink:to="loc_us-gaap_CreditFacilityAxis_44a98055-cd2a-4871-837b-c2f9f6c4bf78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_44a98055-cd2a-4871-837b-c2f9f6c4bf78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_44a98055-cd2a-4871-837b-c2f9f6c4bf78" xlink:to="loc_us-gaap_CreditFacilityDomain_44a98055-cd2a-4871-837b-c2f9f6c4bf78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b6b41879-fca4-4f76-bb11-ff912563287a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_44a98055-cd2a-4871-837b-c2f9f6c4bf78" xlink:to="loc_us-gaap_CreditFacilityDomain_b6b41879-fca4-4f76-bb11-ff912563287a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2020TermLoansMember_43b5a4e8-182c-4f1f-b5d2-e3240c105bd4" xlink:href="rnac-20241231.xsd#rnac_A2020TermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b6b41879-fca4-4f76-bb11-ff912563287a" xlink:to="loc_rnac_A2020TermLoansMember_43b5a4e8-182c-4f1f-b5d2-e3240c105bd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5e5f908f-7698-422a-9926-f112df8a9b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5e5f908f-7698-422a-9926-f112df8a9b2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_4033d0be-3476-431d-b5d4-c56f90ef86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_4033d0be-3476-431d-b5d4-c56f90ef86c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_9a82f923-275f-43e6-96aa-aa37c3f95157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_9a82f923-275f-43e6-96aa-aa37c3f95157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DebtInstrumentPrepaymentFee_8e7ed69d-634e-42ac-83db-81c915b21d03" xlink:href="rnac-20241231.xsd#rnac_DebtInstrumentPrepaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_rnac_DebtInstrumentPrepaymentFee_8e7ed69d-634e-42ac-83db-81c915b21d03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DebtInstrumentAccruedInterest_9cb198de-b9b6-4633-b972-b8f74e62fcc7" xlink:href="rnac-20241231.xsd#rnac_DebtInstrumentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_rnac_DebtInstrumentAccruedInterest_9cb198de-b9b6-4633-b972-b8f74e62fcc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8ab7405-e7d3-4f62-84cb-81fc577b30db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8ab7405-e7d3-4f62-84cb-81fc577b30db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_ad2526e2-6c53-486a-9c0a-e84694ad6904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_ad2526e2-6c53-486a-9c0a-e84694ad6904" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_b6de6441-c512-4c8e-a6a0-9dcaa67e2696" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_LineOfCredit_b6de6441-c512-4c8e-a6a0-9dcaa67e2696" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c1df7389-5517-4ed1-b56a-f92412e692b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_InterestExpenseDebt_c1df7389-5517-4ed1-b56a-f92412e692b8" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cb92e6e4-dfa6-4795-81e5-9e83d48b8e90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cb92e6e4-dfa6-4795-81e5-9e83d48b8e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cb92e6e4-dfa6-4795-81e5-9e83d48b8e90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cb92e6e4-dfa6-4795-81e5-9e83d48b8e90" xlink:to="loc_us-gaap_ClassOfStockDomain_cb92e6e4-dfa6-4795-81e5-9e83d48b8e90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_61e8c3d8-f140-48b1-bda4-3acbef8154a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cb92e6e4-dfa6-4795-81e5-9e83d48b8e90" xlink:to="loc_us-gaap_ClassOfStockDomain_61e8c3d8-f140-48b1-bda4-3acbef8154a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_f94ee0d6-9285-42f2-bced-b01488294f85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e8c3d8-f140-48b1-bda4-3acbef8154a2" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_f94ee0d6-9285-42f2-bced-b01488294f85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ceab3ea8-6506-4860-b2c4-680d530a2803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e8c3d8-f140-48b1-bda4-3acbef8154a2" xlink:to="loc_us-gaap_CommonStockMember_ceab3ea8-6506-4860-b2c4-680d530a2803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_be1c11b1-444e-495a-abd6-e70c8fa350bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_be1c11b1-444e-495a-abd6-e70c8fa350bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_be1c11b1-444e-495a-abd6-e70c8fa350bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_be1c11b1-444e-495a-abd6-e70c8fa350bd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_be1c11b1-444e-495a-abd6-e70c8fa350bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_284fef8b-79e0-42f7-bd91-a58e7a67af54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_be1c11b1-444e-495a-abd6-e70c8fa350bd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_284fef8b-79e0-42f7-bd91-a58e7a67af54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2024Member_d99ced57-af38-4704-b641-00adaaa30b50" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_284fef8b-79e0-42f7-bd91-a58e7a67af54" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2024Member_d99ced57-af38-4704-b641-00adaaa30b50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member_c80c62b8-143f-48f5-9b95-e4267a17be8d" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_284fef8b-79e0-42f7-bd91-a58e7a67af54" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2023Member_c80c62b8-143f-48f5-9b95-e4267a17be8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e02dfe84-13de-48d6-86ec-ac92a9f05e72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e02dfe84-13de-48d6-86ec-ac92a9f05e72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e02dfe84-13de-48d6-86ec-ac92a9f05e72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e02dfe84-13de-48d6-86ec-ac92a9f05e72" xlink:to="loc_us-gaap_EquityComponentDomain_e02dfe84-13de-48d6-86ec-ac92a9f05e72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e40ebc27-f0b2-40c0-8b21-5d6c074243c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e02dfe84-13de-48d6-86ec-ac92a9f05e72" xlink:to="loc_us-gaap_EquityComponentDomain_e40ebc27-f0b2-40c0-8b21-5d6c074243c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e9060e07-7b90-4440-9aef-f1d2d7023abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e40ebc27-f0b2-40c0-8b21-5d6c074243c2" xlink:to="loc_us-gaap_CommonStockMember_e9060e07-7b90-4440-9aef-f1d2d7023abe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b6beccbf-763f-4af8-be83-e2c6431649ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_srt_CounterpartyNameAxis_b6beccbf-763f-4af8-be83-e2c6431649ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6beccbf-763f-4af8-be83-e2c6431649ab_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b6beccbf-763f-4af8-be83-e2c6431649ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6beccbf-763f-4af8-be83-e2c6431649ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c865fc8-6eb8-445a-a55a-6d4df7074e83" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b6beccbf-763f-4af8-be83-e2c6431649ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c865fc8-6eb8-445a-a55a-6d4df7074e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Dr.TimothyA.SpringerMember_c2a2e185-6ea3-4ffa-b380-0e84900760cc" xlink:href="rnac-20241231.xsd#rnac_Dr.TimothyA.SpringerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c865fc8-6eb8-445a-a55a-6d4df7074e83" xlink:to="loc_rnac_Dr.TimothyA.SpringerMember_c2a2e185-6ea3-4ffa-b380-0e84900760cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TASPartnersLLCMember_029c681d-6f6e-4f77-8e8f-3b49f212c2f7" xlink:href="rnac-20241231.xsd#rnac_TASPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c865fc8-6eb8-445a-a55a-6d4df7074e83" xlink:to="loc_rnac_TASPartnersLLCMember_029c681d-6f6e-4f77-8e8f-3b49f212c2f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Dr.ChafenLuMember_06a7339d-2360-4d21-a9b8-438142572153" xlink:href="rnac-20241231.xsd#rnac_Dr.ChafenLuMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c865fc8-6eb8-445a-a55a-6d4df7074e83" xlink:to="loc_rnac_Dr.ChafenLuMember_06a7339d-2360-4d21-a9b8-438142572153" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4d1fccd-35c0-4f78-8740-ec8541b8bb04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4d1fccd-35c0-4f78-8740-ec8541b8bb04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e4d1fccd-35c0-4f78-8740-ec8541b8bb04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4d1fccd-35c0-4f78-8740-ec8541b8bb04" xlink:to="loc_us-gaap_RelatedPartyDomain_e4d1fccd-35c0-4f78-8740-ec8541b8bb04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_89b273d3-f733-47c2-bc61-3bfb8ca1be2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4d1fccd-35c0-4f78-8740-ec8541b8bb04" xlink:to="loc_us-gaap_RelatedPartyDomain_89b273d3-f733-47c2-bc61-3bfb8ca1be2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_bb043881-de35-4402-ae5a-f3dbce16b576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_89b273d3-f733-47c2-bc61-3bfb8ca1be2a" xlink:to="loc_us-gaap_RelatedPartyMember_bb043881-de35-4402-ae5a-f3dbce16b576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_602bfdb6-962d-4834-a86c-a27188c49084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_602bfdb6-962d-4834-a86c-a27188c49084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_44e4479a-3755-47d5-939f-72722ef3ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_44e4479a-3755-47d5-939f-72722ef3ff5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_6bf94dfc-00d2-4caa-b174-01a4e40a0088" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_6bf94dfc-00d2-4caa-b174-01a4e40a0088" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d5837cee-dac3-4b56-bef0-9e91875f5bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d5837cee-dac3-4b56-bef0-9e91875f5bc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_61ffe137-41b9-4023-8e2a-5348657a2bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_61ffe137-41b9-4023-8e2a-5348657a2bb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c185d703-0730-41b2-a5b9-32c62e0f6f46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c185d703-0730-41b2-a5b9-32c62e0f6f46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_3db1c75e-fa12-4ac1-9ce1-ba75e7074fc0" xlink:href="rnac-20241231.xsd#rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_3db1c75e-fa12-4ac1-9ce1-ba75e7074fc0" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_82ce430c-4b66-4e22-9265-3a2785c048db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_82ce430c-4b66-4e22-9265-3a2785c048db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82ce430c-4b66-4e22-9265-3a2785c048db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_82ce430c-4b66-4e22-9265-3a2785c048db" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82ce430c-4b66-4e22-9265-3a2785c048db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8ad6a648-5b92-463d-a7fa-24237b596441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_82ce430c-4b66-4e22-9265-3a2785c048db" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8ad6a648-5b92-463d-a7fa-24237b596441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member_785cc984-b208-44d1-9073-fefd7295ac57" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8ad6a648-5b92-463d-a7fa-24237b596441" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2023Member_785cc984-b208-44d1-9073-fefd7295ac57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023Member_d3add33c-b0f6-44b5-bd61-d9c1fd8e886d" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8ad6a648-5b92-463d-a7fa-24237b596441" xlink:to="loc_rnac_PrivatePlacement2023Member_d3add33c-b0f6-44b5-bd61-d9c1fd8e886d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023TrancheOneMember_a1cd02c7-5a3b-4429-8907-d9f35910a0b0" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_PrivatePlacement2023Member_d3add33c-b0f6-44b5-bd61-d9c1fd8e886d" xlink:to="loc_rnac_PrivatePlacement2023TrancheOneMember_a1cd02c7-5a3b-4429-8907-d9f35910a0b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023TrancheThreeMember_87e85e43-b850-4eb0-b51f-470c3daf055a" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_PrivatePlacement2023Member_d3add33c-b0f6-44b5-bd61-d9c1fd8e886d" xlink:to="loc_rnac_PrivatePlacement2023TrancheThreeMember_87e85e43-b850-4eb0-b51f-470c3daf055a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023TrancheTwoMember_52f6cc58-57e7-4943-aea5-db5f5f21f8ad" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_PrivatePlacement2023Member_d3add33c-b0f6-44b5-bd61-d9c1fd8e886d" xlink:to="loc_rnac_PrivatePlacement2023TrancheTwoMember_52f6cc58-57e7-4943-aea5-db5f5f21f8ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3ae99973-e462-443d-afb3-3879fb8888ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3ae99973-e462-443d-afb3-3879fb8888ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ae99973-e462-443d-afb3-3879fb8888ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3ae99973-e462-443d-afb3-3879fb8888ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ae99973-e462-443d-afb3-3879fb8888ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_905215a0-f94c-4b3c-abf8-86adc6f8d47d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3ae99973-e462-443d-afb3-3879fb8888ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_905215a0-f94c-4b3c-abf8-86adc6f8d47d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_cb3e07a4-2a09-460b-be66-2bc1d47c2acb" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_905215a0-f94c-4b3c-abf8-86adc6f8d47d" xlink:to="loc_rnac_OldCartesianMember_cb3e07a4-2a09-460b-be66-2bc1d47c2acb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f15958b0-e4a5-4114-a297-64f741edcf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f15958b0-e4a5-4114-a297-64f741edcf5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_f15958b0-e4a5-4114-a297-64f741edcf5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f15958b0-e4a5-4114-a297-64f741edcf5f" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_f15958b0-e4a5-4114-a297-64f741edcf5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_ff41521c-af9a-4ba7-a76b-52e7d3f4f625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f15958b0-e4a5-4114-a297-64f741edcf5f" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_ff41521c-af9a-4ba7-a76b-52e7d3f4f625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_8fc4c83e-e65e-4f87-81cd-eacb9988cd43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_ff41521c-af9a-4ba7-a76b-52e7d3f4f625" xlink:to="loc_us-gaap_PreferredStockMember_8fc4c83e-e65e-4f87-81cd-eacb9988cd43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_087f0e49-c918-4f71-b7ca-4fd8c09285f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_StatementClassOfStockAxis_087f0e49-c918-4f71-b7ca-4fd8c09285f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_087f0e49-c918-4f71-b7ca-4fd8c09285f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_087f0e49-c918-4f71-b7ca-4fd8c09285f9" xlink:to="loc_us-gaap_ClassOfStockDomain_087f0e49-c918-4f71-b7ca-4fd8c09285f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6fac3965-5c34-44a9-948e-2114a351d238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_087f0e49-c918-4f71-b7ca-4fd8c09285f9" xlink:to="loc_us-gaap_ClassOfStockDomain_6fac3965-5c34-44a9-948e-2114a351d238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b8b0f7a5-1054-48a6-9b00-bf8090b70851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6fac3965-5c34-44a9-948e-2114a351d238" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b8b0f7a5-1054-48a6-9b00-bf8090b70851" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_62917792-4bbd-4ca4-939f-fd89bcab4662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_62917792-4bbd-4ca4-939f-fd89bcab4662" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62917792-4bbd-4ca4-939f-fd89bcab4662_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62917792-4bbd-4ca4-939f-fd89bcab4662" xlink:to="loc_us-gaap_EquityComponentDomain_62917792-4bbd-4ca4-939f-fd89bcab4662_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ddd7dc98-b46a-495d-ba60-56a76a60151b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62917792-4bbd-4ca4-939f-fd89bcab4662" xlink:to="loc_us-gaap_EquityComponentDomain_ddd7dc98-b46a-495d-ba60-56a76a60151b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_28a5e1aa-58a3-4a32-af6d-ec5909543bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ddd7dc98-b46a-495d-ba60-56a76a60151b" xlink:to="loc_us-gaap_CommonStockMember_28a5e1aa-58a3-4a32-af6d-ec5909543bbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a051033e-dcdc-44c9-bff9-6f8eaa24a86b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a051033e-dcdc-44c9-bff9-6f8eaa24a86b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a051033e-dcdc-44c9-bff9-6f8eaa24a86b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a051033e-dcdc-44c9-bff9-6f8eaa24a86b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a051033e-dcdc-44c9-bff9-6f8eaa24a86b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9127edbd-8b69-4f4a-a286-0f8cbecc2aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a051033e-dcdc-44c9-bff9-6f8eaa24a86b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9127edbd-8b69-4f4a-a286-0f8cbecc2aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bb9a00da-895f-4028-91cb-5a518d0fa367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9127edbd-8b69-4f4a-a286-0f8cbecc2aa5" xlink:to="loc_us-gaap_SubsequentEventMember_bb9a00da-895f-4028-91cb-5a518d0fa367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_a6bd7c51-7cb4-424e-a3c3-e708c5b52874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_a6bd7c51-7cb4-424e-a3c3-e708c5b52874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ac18e82b-bf9a-4157-8668-a286314eabf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ac18e82b-bf9a-4157-8668-a286314eabf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_76e067cf-4fe0-40e5-b314-f051ebd1226d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_76e067cf-4fe0-40e5-b314-f051ebd1226d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockSettlementTerm_911a9969-b554-4eb6-8a5e-512852c6bb5c" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockSettlementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_rnac_SaleOfStockSettlementTerm_911a9969-b554-4eb6-8a5e-512852c6bb5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SettlementOfDerivativeLiabilityShares_175b1155-218c-42d6-870d-dde69a06362f" xlink:href="rnac-20241231.xsd#rnac_SettlementOfDerivativeLiabilityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_rnac_SettlementOfDerivativeLiabilityShares_175b1155-218c-42d6-870d-dde69a06362f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_decdc840-7921-4fab-97de-fa2ff57345e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_decdc840-7921-4fab-97de-fa2ff57345e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NumberOfBusinessDays_65b68d7e-a11c-491d-873c-217a91bb4429" xlink:href="rnac-20241231.xsd#rnac_NumberOfBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_rnac_NumberOfBusinessDays_65b68d7e-a11c-491d-873c-217a91bb4429" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7a934058-06bc-4b58-953f-2c1bbd49c447" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7a934058-06bc-4b58-953f-2c1bbd49c447" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_6c11dedf-8227-4ca9-9029-dd0f75986d98" xlink:href="rnac-20241231.xsd#rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_6c11dedf-8227-4ca9-9029-dd0f75986d98" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStockConversionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_56096b32-ea0e-4428-98cc-4787092c6b68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_aa6c80a1-2c03-4f4b-ae65-6656eecccdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_56096b32-ea0e-4428-98cc-4787092c6b68" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_aa6c80a1-2c03-4f4b-ae65-6656eecccdc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f730d710-76e9-4ee8-a582-9c9b85ecc05f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa6c80a1-2c03-4f4b-ae65-6656eecccdc2" xlink:to="loc_srt_RangeAxis_f730d710-76e9-4ee8-a582-9c9b85ecc05f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f730d710-76e9-4ee8-a582-9c9b85ecc05f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f730d710-76e9-4ee8-a582-9c9b85ecc05f" xlink:to="loc_srt_RangeMember_f730d710-76e9-4ee8-a582-9c9b85ecc05f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82edf12d-bcd3-4d05-bbef-1394e5844f94" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f730d710-76e9-4ee8-a582-9c9b85ecc05f" xlink:to="loc_srt_RangeMember_82edf12d-bcd3-4d05-bbef-1394e5844f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_32242da8-8833-45fb-8004-ad97138f6b6f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82edf12d-bcd3-4d05-bbef-1394e5844f94" xlink:to="loc_srt_MinimumMember_32242da8-8833-45fb-8004-ad97138f6b6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9924ecc7-1865-42c8-be28-74732299b2c6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82edf12d-bcd3-4d05-bbef-1394e5844f94" xlink:to="loc_srt_MaximumMember_9924ecc7-1865-42c8-be28-74732299b2c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12f8774b-9853-43f1-899b-9b07d8098c51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa6c80a1-2c03-4f4b-ae65-6656eecccdc2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12f8774b-9853-43f1-899b-9b07d8098c51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_12f8774b-9853-43f1-899b-9b07d8098c51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12f8774b-9853-43f1-899b-9b07d8098c51" xlink:to="loc_us-gaap_ClassOfStockDomain_12f8774b-9853-43f1-899b-9b07d8098c51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f95b92e7-8f94-4183-a88c-da5e84206a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12f8774b-9853-43f1-899b-9b07d8098c51" xlink:to="loc_us-gaap_ClassOfStockDomain_f95b92e7-8f94-4183-a88c-da5e84206a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_00626385-d262-4e7d-8102-6783a656c61d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f95b92e7-8f94-4183-a88c-da5e84206a5a" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_00626385-d262-4e7d-8102-6783a656c61d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_a13ed10a-da9e-473b-b860-a7b97b24649c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_56096b32-ea0e-4428-98cc-4787092c6b68" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_a13ed10a-da9e-473b-b860-a7b97b24649c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage_8fe7b87f-a6a6-4178-8bce-657c59a37acb" xlink:href="rnac-20241231.xsd#rnac_PreferredStockConvertibleBeneficialOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_56096b32-ea0e-4428-98cc-4787092c6b68" xlink:to="loc_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage_8fe7b87f-a6a6-4178-8bce-657c59a37acb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStockLiquidationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f2cb1f14-66d0-4359-9825-b4a295abb5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_210f6460-ecfe-4ebf-a73d-face22b0e4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2cb1f14-66d0-4359-9825-b4a295abb5e7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_210f6460-ecfe-4ebf-a73d-face22b0e4e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c2abe43e-0ef9-464c-88ea-5d1c096910a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_210f6460-ecfe-4ebf-a73d-face22b0e4e6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c2abe43e-0ef9-464c-88ea-5d1c096910a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c2abe43e-0ef9-464c-88ea-5d1c096910a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2abe43e-0ef9-464c-88ea-5d1c096910a5" xlink:to="loc_us-gaap_ClassOfStockDomain_c2abe43e-0ef9-464c-88ea-5d1c096910a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e9a3977a-534b-4fb6-a6d4-567f8008c1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2abe43e-0ef9-464c-88ea-5d1c096910a5" xlink:to="loc_us-gaap_ClassOfStockDomain_e9a3977a-534b-4fb6-a6d4-567f8008c1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_dadbe721-564c-415f-8196-5cef5161485b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e9a3977a-534b-4fb6-a6d4-567f8008c1fd" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_dadbe721-564c-415f-8196-5cef5161485b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0f88c48e-f432-44f4-abd8-01fa14867c78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e9a3977a-534b-4fb6-a6d4-567f8008c1fd" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0f88c48e-f432-44f4-abd8-01fa14867c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4366700e-2ed5-48e7-accb-7b3fd2aa8b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2cb1f14-66d0-4359-9825-b4a295abb5e7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4366700e-2ed5-48e7-accb-7b3fd2aa8b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_52c6b910-8c99-4eae-a847-da9bb219f7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2cb1f14-66d0-4359-9825-b4a295abb5e7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_52c6b910-8c99-4eae-a847-da9bb219f7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable_27e70b07-a7a0-4959-9544-da39a228a729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2cb1f14-66d0-4359-9825-b4a295abb5e7" xlink:to="loc_us-gaap_PreferredStockConvertibleSharesIssuable_27e70b07-a7a0-4959-9544-da39a228a729" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#Equity2024PrivatePlacementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_96d3af04-1eb2-4389-810e-d8cf3a49f7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:to="loc_us-gaap_StatementClassOfStockAxis_96d3af04-1eb2-4389-810e-d8cf3a49f7d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_96d3af04-1eb2-4389-810e-d8cf3a49f7d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96d3af04-1eb2-4389-810e-d8cf3a49f7d3" xlink:to="loc_us-gaap_ClassOfStockDomain_96d3af04-1eb2-4389-810e-d8cf3a49f7d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7233bbda-31a9-4c4f-9af2-d2fe4c6f24c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96d3af04-1eb2-4389-810e-d8cf3a49f7d3" xlink:to="loc_us-gaap_ClassOfStockDomain_7233bbda-31a9-4c4f-9af2-d2fe4c6f24c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d3a7154c-b448-4011-af75-a0b82645d849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7233bbda-31a9-4c4f-9af2-d2fe4c6f24c5" xlink:to="loc_us-gaap_CommonStockMember_d3a7154c-b448-4011-af75-a0b82645d849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_61405be1-c73a-49a0-8466-75d0067c122f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7233bbda-31a9-4c4f-9af2-d2fe4c6f24c5" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_61405be1-c73a-49a0-8466-75d0067c122f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_78e30cf4-c949-4a79-9f98-3f86ca01ae8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_78e30cf4-c949-4a79-9f98-3f86ca01ae8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78e30cf4-c949-4a79-9f98-3f86ca01ae8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_78e30cf4-c949-4a79-9f98-3f86ca01ae8d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78e30cf4-c949-4a79-9f98-3f86ca01ae8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_530df919-23ca-499d-9c18-c63e4213588d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_78e30cf4-c949-4a79-9f98-3f86ca01ae8d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_530df919-23ca-499d-9c18-c63e4213588d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2024Member_6bc5fd61-ccb3-457c-9100-23bcc225ccae" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_530df919-23ca-499d-9c18-c63e4213588d" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2024Member_6bc5fd61-ccb3-457c-9100-23bcc225ccae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_12094d7d-0814-45eb-a713-d95260869694" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:to="loc_srt_TitleOfIndividualAxis_12094d7d-0814-45eb-a713-d95260869694" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_12094d7d-0814-45eb-a713-d95260869694_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_12094d7d-0814-45eb-a713-d95260869694" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_12094d7d-0814-45eb-a713-d95260869694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6d52331-6f0c-4f69-84e5-505f2606fc3d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_12094d7d-0814-45eb-a713-d95260869694" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6d52331-6f0c-4f69-84e5-505f2606fc3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DirectorsAndExecutiveOfficersMember_1daf3fab-e6c2-4ad2-a03f-cafbb83e713b" xlink:href="rnac-20241231.xsd#rnac_DirectorsAndExecutiveOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6d52331-6f0c-4f69-84e5-505f2606fc3d" xlink:to="loc_rnac_DirectorsAndExecutiveOfficersMember_1daf3fab-e6c2-4ad2-a03f-cafbb83e713b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbde958a-dace-4f40-8825-2d7b39ae551d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbde958a-dace-4f40-8825-2d7b39ae551d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_556ce58b-0e9f-4a0b-9140-46764af7a061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_556ce58b-0e9f-4a0b-9140-46764af7a061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_14bc3c5c-4d7d-4563-be55-39f422776c50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_14bc3c5c-4d7d-4563-be55-39f422776c50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_e0080c25-c393-4470-8dec-d86a520720bb" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:to="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_e0080c25-c393-4470-8dec-d86a520720bb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityMergerNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0460036f-37da-4e00-a380-f857a3d1376d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e0471a76-b033-40f4-8f6e-9b1a70d32eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0460036f-37da-4e00-a380-f857a3d1376d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e0471a76-b033-40f4-8f6e-9b1a70d32eae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fbf5f85e-184a-4aa2-acdf-ff36b2b9bad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e0471a76-b033-40f4-8f6e-9b1a70d32eae" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fbf5f85e-184a-4aa2-acdf-ff36b2b9bad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbf5f85e-184a-4aa2-acdf-ff36b2b9bad0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fbf5f85e-184a-4aa2-acdf-ff36b2b9bad0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbf5f85e-184a-4aa2-acdf-ff36b2b9bad0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6439e12f-f33f-421b-ae2c-911cb6b1ca35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fbf5f85e-184a-4aa2-acdf-ff36b2b9bad0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6439e12f-f33f-421b-ae2c-911cb6b1ca35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_1c307bb1-ca50-4591-874f-c935213e72ec" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6439e12f-f33f-421b-ae2c-911cb6b1ca35" xlink:to="loc_rnac_OldCartesianMember_1c307bb1-ca50-4591-874f-c935213e72ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_03749881-31ab-4a15-9689-fb8c169930a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e0471a76-b033-40f4-8f6e-9b1a70d32eae" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_03749881-31ab-4a15-9689-fb8c169930a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_03749881-31ab-4a15-9689-fb8c169930a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_03749881-31ab-4a15-9689-fb8c169930a4" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_03749881-31ab-4a15-9689-fb8c169930a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_c05a4d30-677b-4d00-bb91-4c5baadf02af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_03749881-31ab-4a15-9689-fb8c169930a4" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_c05a4d30-677b-4d00-bb91-4c5baadf02af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5bf56117-8473-47d3-b0a9-38eede9a46d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_c05a4d30-677b-4d00-bb91-4c5baadf02af" xlink:to="loc_us-gaap_CommonStockMember_5bf56117-8473-47d3-b0a9-38eede9a46d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_9939a498-1db0-4c4a-81cd-9ec215bea6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0460036f-37da-4e00-a380-f857a3d1376d" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_9939a498-1db0-4c4a-81cd-9ec215bea6f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityUnderwrittenOfferingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f4a1b066-e765-495e-b749-eeea4cc52d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f4a1b066-e765-495e-b749-eeea4cc52d27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9406a09c-d3e8-4f44-821a-7796f67add89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4a1b066-e765-495e-b749-eeea4cc52d27" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9406a09c-d3e8-4f44-821a-7796f67add89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9406a09c-d3e8-4f44-821a-7796f67add89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9406a09c-d3e8-4f44-821a-7796f67add89" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9406a09c-d3e8-4f44-821a-7796f67add89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_260b306b-fc59-447a-9ec4-fd7463951a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9406a09c-d3e8-4f44-821a-7796f67add89" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_260b306b-fc59-447a-9ec4-fd7463951a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2022OfferingMember_1d36c125-c751-4f17-9e47-882548d81ea3" xlink:href="rnac-20241231.xsd#rnac_A2022OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_260b306b-fc59-447a-9ec4-fd7463951a9f" xlink:to="loc_rnac_A2022OfferingMember_1d36c125-c751-4f17-9e47-882548d81ea3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dbe4453c-c896-4bf5-a363-22f4e5eda953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dbe4453c-c896-4bf5-a363-22f4e5eda953" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_52468a97-52fb-4ece-9d7f-ed5bd76bf50e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_52468a97-52fb-4ece-9d7f-ed5bd76bf50e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6f8fceb4-3bf9-4cbc-a299-2e85ad8839a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6f8fceb4-3bf9-4cbc-a299-2e85ad8839a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_298147b1-3910-44e1-b095-225a5ce6dd87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_298147b1-3910-44e1-b095-225a5ce6dd87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22f451d4-21a3-4d19-a20b-4d995710a87b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22f451d4-21a3-4d19-a20b-4d995710a87b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_646da864-913f-462c-92db-c809854a2ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_646da864-913f-462c-92db-c809854a2ba3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityAttheMarketOfferingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_bca3690e-37d4-4cdb-b14e-de69b77cb3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_501ed183-4e0b-4de6-b5f6-7985170b6ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_bca3690e-37d4-4cdb-b14e-de69b77cb3bd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_501ed183-4e0b-4de6-b5f6-7985170b6ac5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8df2a347-f1f9-4412-a378-39adc2e7c20f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_501ed183-4e0b-4de6-b5f6-7985170b6ac5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8df2a347-f1f9-4412-a378-39adc2e7c20f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8df2a347-f1f9-4412-a378-39adc2e7c20f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8df2a347-f1f9-4412-a378-39adc2e7c20f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8df2a347-f1f9-4412-a378-39adc2e7c20f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb396c70-60e9-467d-a1c8-bcb380c9d0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8df2a347-f1f9-4412-a378-39adc2e7c20f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb396c70-60e9-467d-a1c8-bcb380c9d0b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AtTheMarketOfferingMember_903b40f7-f2c1-4b71-8332-7271b55c69c7" xlink:href="rnac-20241231.xsd#rnac_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb396c70-60e9-467d-a1c8-bcb380c9d0b3" xlink:to="loc_rnac_AtTheMarketOfferingMember_903b40f7-f2c1-4b71-8332-7271b55c69c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds_ae00736e-86e4-485c-8ba6-8475b43d740d" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockAggregateMaximumGrossSalesProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bca3690e-37d4-4cdb-b14e-de69b77cb3bd" xlink:to="loc_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds_ae00736e-86e4-485c-8ba6-8475b43d740d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76f3e948-8bb3-4711-9cd8-1d5b06fd1a89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bca3690e-37d4-4cdb-b14e-de69b77cb3bd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76f3e948-8bb3-4711-9cd8-1d5b06fd1a89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityJune2020SobiStockPurchaseNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ca614af4-2406-4c7a-9f74-17fc91cd382d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ca614af4-2406-4c7a-9f74-17fc91cd382d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e622f327-3280-4ea1-96f6-537061bf0ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ca614af4-2406-4c7a-9f74-17fc91cd382d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e622f327-3280-4ea1-96f6-537061bf0ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e622f327-3280-4ea1-96f6-537061bf0ca5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e622f327-3280-4ea1-96f6-537061bf0ca5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e622f327-3280-4ea1-96f6-537061bf0ca5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bccb6bc-14d8-4b5d-be80-ab5f4a5ef967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e622f327-3280-4ea1-96f6-537061bf0ca5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bccb6bc-14d8-4b5d-be80-ab5f4a5ef967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SOBIPurchaseAgreementMember_23d7a54a-5b2d-4de8-8843-48410d093b7a" xlink:href="rnac-20241231.xsd#rnac_SOBIPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bccb6bc-14d8-4b5d-be80-ab5f4a5ef967" xlink:to="loc_rnac_SOBIPurchaseAgreementMember_23d7a54a-5b2d-4de8-8843-48410d093b7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d91d4105-adc2-4f1c-b134-ab0d2a8c1177" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d91d4105-adc2-4f1c-b134-ab0d2a8c1177" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d23a8ede-5863-44c0-8dbc-efc225d9b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d23a8ede-5863-44c0-8dbc-efc225d9b9dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_3949051e-982c-4593-9178-fbbf1f2a6860" xlink:href="rnac-20241231.xsd#rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_3949051e-982c-4593-9178-fbbf1f2a6860" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_acebc20c-27b1-49a4-b271-81f0709c4d97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_acebc20c-27b1-49a4-b271-81f0709c4d97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium_4cd60258-ee0b-4e21-bad4-069bec91c328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedemptionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_us-gaap_RedemptionPremium_4cd60258-ee0b-4e21-bad4-069bec91c328" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityDecember2019FinancingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a3679518-180f-49d0-879e-678cfb1b53c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a3679518-180f-49d0-879e-678cfb1b53c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a3679518-180f-49d0-879e-678cfb1b53c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a3679518-180f-49d0-879e-678cfb1b53c4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a3679518-180f-49d0-879e-678cfb1b53c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f2d84d-0218-440f-9539-b63f48625e09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a3679518-180f-49d0-879e-678cfb1b53c4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f2d84d-0218-440f-9539-b63f48625e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DecemberTwoThousandNineteenFinancingMember_aa6edb17-7cf5-401e-b34a-a819abafdd9d" xlink:href="rnac-20241231.xsd#rnac_DecemberTwoThousandNineteenFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f2d84d-0218-440f-9539-b63f48625e09" xlink:to="loc_rnac_DecemberTwoThousandNineteenFinancingMember_aa6edb17-7cf5-401e-b34a-a819abafdd9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8207ca9e-de3c-49ba-aa27-ef98efaa56f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8207ca9e-de3c-49ba-aa27-ef98efaa56f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8207ca9e-de3c-49ba-aa27-ef98efaa56f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8207ca9e-de3c-49ba-aa27-ef98efaa56f3" xlink:to="loc_us-gaap_EquityComponentDomain_8207ca9e-de3c-49ba-aa27-ef98efaa56f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_855e3bb6-d0ad-4f2e-9729-f05c35db82f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8207ca9e-de3c-49ba-aa27-ef98efaa56f3" xlink:to="loc_us-gaap_EquityComponentDomain_855e3bb6-d0ad-4f2e-9729-f05c35db82f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CommonWarrantMember_92c4ac03-f6b4-41cf-8120-b08f7eaf9fd0" xlink:href="rnac-20241231.xsd#rnac_CommonWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_855e3bb6-d0ad-4f2e-9729-f05c35db82f6" xlink:to="loc_rnac_CommonWarrantMember_92c4ac03-f6b4-41cf-8120-b08f7eaf9fd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreFundedWarrantMember_b9044392-276d-4789-8be7-995af785ac8d" xlink:href="rnac-20241231.xsd#rnac_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_855e3bb6-d0ad-4f2e-9729-f05c35db82f6" xlink:to="loc_rnac_PreFundedWarrantMember_b9044392-276d-4789-8be7-995af785ac8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_42547feb-8792-43a9-ab47-11366685cba0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_42547feb-8792-43a9-ab47-11366685cba0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_42547feb-8792-43a9-ab47-11366685cba0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_42547feb-8792-43a9-ab47-11366685cba0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_42547feb-8792-43a9-ab47-11366685cba0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_45bbce14-2a4b-4237-a598-fd60b2923a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_42547feb-8792-43a9-ab47-11366685cba0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_45bbce14-2a4b-4237-a598-fd60b2923a4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2019WarrantsMember_2fc14dd3-9eae-4718-a11e-b2f36d799f29" xlink:href="rnac-20241231.xsd#rnac_A2019WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_45bbce14-2a4b-4237-a598-fd60b2923a4f" xlink:to="loc_rnac_A2019WarrantsMember_2fc14dd3-9eae-4718-a11e-b2f36d799f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d7694ab2-beab-455d-b86b-6a0b7ead56ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d7694ab2-beab-455d-b86b-6a0b7ead56ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b4c23048-89c0-4d75-94bd-3b9a98578fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b4c23048-89c0-4d75-94bd-3b9a98578fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e29dc946-e7de-4c5c-b5b1-494c2a6f1539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e29dc946-e7de-4c5c-b5b1-494c2a6f1539" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised_2a0d8e72-8783-4cc2-9160-ced98aae6198" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised_2a0d8e72-8783-4cc2-9160-ced98aae6198" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f31a19e4-5baf-41c9-aa3f-4da1d7d61a15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f31a19e4-5baf-41c9-aa3f-4da1d7d61a15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_ea2f6e01-708f-48b1-b920-a9349e9f6da1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_ea2f6e01-708f-48b1-b920-a9349e9f6da1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantIssued_daf0afd1-143e-416f-b69e-1963e7a11a85" xlink:href="rnac-20241231.xsd#rnac_WarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_rnac_WarrantIssued_daf0afd1-143e-416f-b69e-1963e7a11a85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cab1be52-80ff-434d-ab2e-8ff82db90265" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cab1be52-80ff-434d-ab2e-8ff82db90265" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_fa0a16ae-5542-456d-baaf-f895103a423b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_fa0a16ae-5542-456d-baaf-f895103a423b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_bc236297-17d1-4010-b14b-043a2dfbda26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_bc236297-17d1-4010-b14b-043a2dfbda26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_df296fb7-d428-4c92-80ec-89c2285646c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_df296fb7-d428-4c92-80ec-89c2285646c3" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityScheduleofWarrantActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9ab5ffe4-5825-4c23-ac71-3e0729a50a86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_b5a6dc62-0519-4454-885c-e145cedba83f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9ab5ffe4-5825-4c23-ac71-3e0729a50a86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_b5a6dc62-0519-4454-885c-e145cedba83f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_da76abaf-18a1-48ba-a05a-2e746c1ff779" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b5a6dc62-0519-4454-885c-e145cedba83f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_da76abaf-18a1-48ba-a05a-2e746c1ff779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_da76abaf-18a1-48ba-a05a-2e746c1ff779_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_da76abaf-18a1-48ba-a05a-2e746c1ff779" xlink:to="loc_us-gaap_EquityComponentDomain_da76abaf-18a1-48ba-a05a-2e746c1ff779_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cdd3d87b-7293-478b-8263-bb48976e8bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_da76abaf-18a1-48ba-a05a-2e746c1ff779" xlink:to="loc_us-gaap_EquityComponentDomain_cdd3d87b-7293-478b-8263-bb48976e8bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_dcb829eb-81b8-434b-96f3-a6bb2c771dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cdd3d87b-7293-478b-8263-bb48976e8bf2" xlink:to="loc_us-gaap_WarrantMember_dcb829eb-81b8-434b-96f3-a6bb2c771dcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_10e3212f-5c0a-4245-8d5f-14d49e7d76a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b5a6dc62-0519-4454-885c-e145cedba83f" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_10e3212f-5c0a-4245-8d5f-14d49e7d76a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10e3212f-5c0a-4245-8d5f-14d49e7d76a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_10e3212f-5c0a-4245-8d5f-14d49e7d76a5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10e3212f-5c0a-4245-8d5f-14d49e7d76a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_755e65ca-2974-4599-a6d8-d5c8ed0d7ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_10e3212f-5c0a-4245-8d5f-14d49e7d76a5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_755e65ca-2974-4599-a6d8-d5c8ed0d7ad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e0e7c8cb-f8bc-4cde-9c24-a9ec2a130e09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_755e65ca-2974-4599-a6d8-d5c8ed0d7ad3" xlink:to="loc_us-gaap_WarrantMember_e0e7c8cb-f8bc-4cde-9c24-a9ec2a130e09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9ab5ffe4-5825-4c23-ac71-3e0729a50a86" xlink:to="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6b9d4d47-fc7f-434f-a156-de50133e7866" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6b9d4d47-fc7f-434f-a156-de50133e7866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled_aa82cbf6-ad59-4d9e-b05f-c8641b4d11af" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodSharesWarrantsCanceled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:to="loc_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled_aa82cbf6-ad59-4d9e-b05f-c8641b4d11af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodSharesWarrantsExercised_2242ab40-d09d-4d84-a68c-de88cc7343c0" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:to="loc_rnac_StockIssuedDuringPeriodSharesWarrantsExercised_2242ab40-d09d-4d84-a68c-de88cc7343c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_59a2699e-b702-456c-9b49-e0ffa1880e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9ab5ffe4-5825-4c23-ac71-3e0729a50a86" xlink:to="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5ca78592-ff15-4389-8195-66a58507b506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5ca78592-ff15-4389-8195-66a58507b506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringWarrantedCanceledPricePerShare_3df98410-1d23-48c2-bef4-8e1bbcbc699d" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringWarrantedCanceledPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:to="loc_rnac_StockIssuedDuringWarrantedCanceledPricePerShare_3df98410-1d23-48c2-bef4-8e1bbcbc699d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_f1cf8cf4-2e35-4949-82c8-d87b4cb6f80a" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:to="loc_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_f1cf8cf4-2e35-4949-82c8-d87b4cb6f80a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4da77cb6-6b79-4845-8060-59989e75927c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1f4833a3-d0a8-48d4-a6ed-d4e7385016c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_75866852-7e69-420c-84e8-4e75e99d403f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1f4833a3-d0a8-48d4-a6ed-d4e7385016c9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_75866852-7e69-420c-84e8-4e75e99d403f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e6da1274-76f8-4482-b553-02eb404821eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75866852-7e69-420c-84e8-4e75e99d403f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e6da1274-76f8-4482-b553-02eb404821eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e6da1274-76f8-4482-b553-02eb404821eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6da1274-76f8-4482-b553-02eb404821eb" xlink:to="loc_us-gaap_EquityComponentDomain_e6da1274-76f8-4482-b553-02eb404821eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56365e37-c829-423c-ac4e-837a0503ddd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6da1274-76f8-4482-b553-02eb404821eb" xlink:to="loc_us-gaap_EquityComponentDomain_56365e37-c829-423c-ac4e-837a0503ddd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2a960e97-a0d8-436e-9e58-31c8b2cbf9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56365e37-c829-423c-ac4e-837a0503ddd0" xlink:to="loc_us-gaap_WarrantMember_2a960e97-a0d8-436e-9e58-31c8b2cbf9b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_733a5a80-a745-4b38-946f-646f5f0ef3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75866852-7e69-420c-84e8-4e75e99d403f" xlink:to="loc_us-gaap_AwardTypeAxis_733a5a80-a745-4b38-946f-646f5f0ef3f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_733a5a80-a745-4b38-946f-646f5f0ef3f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_733a5a80-a745-4b38-946f-646f5f0ef3f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_733a5a80-a745-4b38-946f-646f5f0ef3f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_733a5a80-a745-4b38-946f-646f5f0ef3f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_c485b62f-e52c-4425-bc09-ae626c5ed0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:to="loc_us-gaap_StockCompensationPlanMember_c485b62f-e52c-4425-bc09-ae626c5ed0bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_RestrictedStockUnitsUnvestedMember_87b92570-ac4b-4c0f-b705-ead6ac9dfde2" xlink:href="rnac-20241231.xsd#rnac_RestrictedStockUnitsUnvestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:to="loc_rnac_RestrictedStockUnitsUnvestedMember_87b92570-ac4b-4c0f-b705-ead6ac9dfde2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df8bc200-f56a-4346-b3f6-8572fe26e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df8bc200-f56a-4346-b3f6-8572fe26e89f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_e6098391-a32b-48ce-b1ab-99c2cf0e9b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_e6098391-a32b-48ce-b1ab-99c2cf0e9b9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_b1d23da5-0f6c-4965-971c-4304222ba825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_b1d23da5-0f6c-4965-971c-4304222ba825" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59802363-a966-45ad-913b-f428e0c4da5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1f4833a3-d0a8-48d4-a6ed-d4e7385016c9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59802363-a966-45ad-913b-f428e0c4da5b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_77278cd8-ff37-4496-9c36-6bdede5d0261" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_PlanNameAxis_77278cd8-ff37-4496-9c36-6bdede5d0261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_77278cd8-ff37-4496-9c36-6bdede5d0261_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_77278cd8-ff37-4496-9c36-6bdede5d0261" xlink:to="loc_us-gaap_PlanNameDomain_77278cd8-ff37-4496-9c36-6bdede5d0261_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_725de654-c5c6-4911-a85a-0970bd5a0e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_77278cd8-ff37-4496-9c36-6bdede5d0261" xlink:to="loc_us-gaap_PlanNameDomain_725de654-c5c6-4911-a85a-0970bd5a0e88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIncentivePlan2016Member_9527d595-1262-4af4-bce0-8d7d74c7435f" xlink:href="rnac-20241231.xsd#rnac_StockIncentivePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_725de654-c5c6-4911-a85a-0970bd5a0e88" xlink:to="loc_rnac_StockIncentivePlan2016Member_9527d595-1262-4af4-bce0-8d7d74c7435f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EmploymentInducementIncentiveAwardPlanMember_1dbfc4ad-ba51-4312-92ae-ffd2ab0415b8" xlink:href="rnac-20241231.xsd#rnac_EmploymentInducementIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_725de654-c5c6-4911-a85a-0970bd5a0e88" xlink:to="loc_rnac_EmploymentInducementIncentiveAwardPlanMember_1dbfc4ad-ba51-4312-92ae-ffd2ab0415b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianPlanMember_d070ac11-899e-4f3b-8eb0-f8409fc5e7e9" xlink:href="rnac-20241231.xsd#rnac_OldCartesianPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_725de654-c5c6-4911-a85a-0970bd5a0e88" xlink:to="loc_rnac_OldCartesianPlanMember_d070ac11-899e-4f3b-8eb0-f8409fc5e7e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f37c8e48-3804-46dd-a877-1dbc2fba78bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f37c8e48-3804-46dd-a877-1dbc2fba78bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f37c8e48-3804-46dd-a877-1dbc2fba78bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f37c8e48-3804-46dd-a877-1dbc2fba78bf" xlink:to="loc_us-gaap_EquityComponentDomain_f37c8e48-3804-46dd-a877-1dbc2fba78bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d44f6611-5fbc-4640-9c64-bc1e3af93b24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f37c8e48-3804-46dd-a877-1dbc2fba78bf" xlink:to="loc_us-gaap_EquityComponentDomain_d44f6611-5fbc-4640-9c64-bc1e3af93b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8cfc86a2-f06f-422e-925c-034190dc4a08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d44f6611-5fbc-4640-9c64-bc1e3af93b24" xlink:to="loc_us-gaap_CommonStockMember_8cfc86a2-f06f-422e-925c-034190dc4a08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_6ff5d3ca-1d13-480f-95b4-df02b1250c95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d44f6611-5fbc-4640-9c64-bc1e3af93b24" xlink:to="loc_us-gaap_PreferredStockMember_6ff5d3ca-1d13-480f-95b4-df02b1250c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b9727476-239b-4153-a35e-88d5aa8d5fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_AwardTypeAxis_b9727476-239b-4153-a35e-88d5aa8d5fd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9727476-239b-4153-a35e-88d5aa8d5fd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b9727476-239b-4153-a35e-88d5aa8d5fd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9727476-239b-4153-a35e-88d5aa8d5fd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88640dd2-0313-4fba-a35d-8b71b0d0cd19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b9727476-239b-4153-a35e-88d5aa8d5fd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88640dd2-0313-4fba-a35d-8b71b0d0cd19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b62334d9-1a46-42e9-9b56-3d5a1b535448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88640dd2-0313-4fba-a35d-8b71b0d0cd19" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b62334d9-1a46-42e9-9b56-3d5a1b535448" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6b589000-37ab-455d-aa50-cd8e8b110e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88640dd2-0313-4fba-a35d-8b71b0d0cd19" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6b589000-37ab-455d-aa50-cd8e8b110e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6abbbee9-0d97-4b4f-9777-deafb9a8d3d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_srt_RangeAxis_6abbbee9-0d97-4b4f-9777-deafb9a8d3d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6abbbee9-0d97-4b4f-9777-deafb9a8d3d5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6abbbee9-0d97-4b4f-9777-deafb9a8d3d5" xlink:to="loc_srt_RangeMember_6abbbee9-0d97-4b4f-9777-deafb9a8d3d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac3a4123-7b58-4318-943e-ecd61acc4278" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6abbbee9-0d97-4b4f-9777-deafb9a8d3d5" xlink:to="loc_srt_RangeMember_ac3a4123-7b58-4318-943e-ecd61acc4278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d9896ebd-d86b-46ca-acc3-0d40f3e01385" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac3a4123-7b58-4318-943e-ecd61acc4278" xlink:to="loc_srt_MinimumMember_d9896ebd-d86b-46ca-acc3-0d40f3e01385" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dffd58f6-b217-4edc-bec8-ec07d3e90160" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac3a4123-7b58-4318-943e-ecd61acc4278" xlink:to="loc_srt_MaximumMember_dffd58f6-b217-4edc-bec8-ec07d3e90160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_563cd329-fa4a-4da1-a640-bed1b3443918" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_563cd329-fa4a-4da1-a640-bed1b3443918" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_563cd329-fa4a-4da1-a640-bed1b3443918_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_563cd329-fa4a-4da1-a640-bed1b3443918" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_563cd329-fa4a-4da1-a640-bed1b3443918_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74424749-236e-419f-8102-cd1a4725e2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_563cd329-fa4a-4da1-a640-bed1b3443918" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74424749-236e-419f-8102-cd1a4725e2e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartestianMember_c82544da-b25e-4233-af56-ff6f2d4ffb95" xlink:href="rnac-20241231.xsd#rnac_OldCartestianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74424749-236e-419f-8102-cd1a4725e2e1" xlink:to="loc_rnac_OldCartestianMember_c82544da-b25e-4233-af56-ff6f2d4ffb95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_670d246d-7217-41f9-a589-259ef2a3b3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_670d246d-7217-41f9-a589-259ef2a3b3a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_670d246d-7217-41f9-a589-259ef2a3b3a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_670d246d-7217-41f9-a589-259ef2a3b3a0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_670d246d-7217-41f9-a589-259ef2a3b3a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_381785ad-3a3d-4ae0-b7d7-5c8ad14ee6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_670d246d-7217-41f9-a589-259ef2a3b3a0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_381785ad-3a3d-4ae0-b7d7-5c8ad14ee6de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d4c4cd-bdc6-4fff-948c-8fcb620261d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_381785ad-3a3d-4ae0-b7d7-5c8ad14ee6de" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d4c4cd-bdc6-4fff-948c-8fcb620261d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e6659255-8ec7-4d17-a8ec-440c0a6b47e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_381785ad-3a3d-4ae0-b7d7-5c8ad14ee6de" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e6659255-8ec7-4d17-a8ec-440c0a6b47e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2f5ce66a-230c-4e4a-ab9a-2d8a17da50f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2f5ce66a-230c-4e4a-ab9a-2d8a17da50f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_ede700d0-1b11-4440-b6c5-162afb1d305c" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_ede700d0-1b11-4440-b6c5-162afb1d305c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8343d4d1-c202-4127-a919-7a1c236427a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8343d4d1-c202-4127-a919-7a1c236427a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2f975c8d-4066-429b-a199-9e72cfd1d533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2f975c8d-4066-429b-a199-9e72cfd1d533" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3614b8b5-0549-40a8-ad37-144cc310fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3614b8b5-0549-40a8-ad37-144cc310fe36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7671188d-ea88-4e7f-95d1-36653af50afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7671188d-ea88-4e7f-95d1-36653af50afa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b4f167c4-9b35-4e7e-b6f0-8d419be90b38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b4f167c4-9b35-4e7e-b6f0-8d419be90b38" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_669ca712-f54f-4c41-8666-24ae3869bf41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_669ca712-f54f-4c41-8666-24ae3869bf41" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount_2b60136f-e2c6-4096-a97f-0f48569f0f99" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount_2b60136f-e2c6-4096-a97f-0f48569f0f99" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c109612e-c20e-4381-90de-1d7c6c971750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c109612e-c20e-4381-90de-1d7c6c971750" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards_2e79e227-2572-4bcb-80cc-a56510a091c3" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards_2e79e227-2572-4bcb-80cc-a56510a091c3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_60c1d9f9-4cbb-4ac7-843b-7bcb7c0a20cc" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_60c1d9f9-4cbb-4ac7-843b-7bcb7c0a20cc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement_b0c49c0c-4d75-4e39-b4f4-a092db382f5b" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement_b0c49c0c-4d75-4e39-b4f4-a092db382f5b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa101078-9da4-4dfa-a084-93a385d589d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa101078-9da4-4dfa-a084-93a385d589d2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9be693cf-a311-43c1-a8ab-9faba7caa97f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9be693cf-a311-43c1-a8ab-9faba7caa97f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c00e85cb-50ad-4eb7-94e2-87779dbb8fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c00e85cb-50ad-4eb7-94e2-87779dbb8fe9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b5c37fd-d39a-4181-9f4d-8b4046dbb5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b5c37fd-d39a-4181-9f4d-8b4046dbb5d3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_58fbd575-04ba-46b8-b490-0df15f08433e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_58fbd575-04ba-46b8-b490-0df15f08433e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_593502f7-60ae-4bec-9ae5-533d13ac1881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_593502f7-60ae-4bec-9ae5-533d13ac1881" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbf6a399-d312-4527-acef-585889ba8c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbf6a399-d312-4527-acef-585889ba8c2d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_57c09642-b20b-4b6c-a538-b432b6090529" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_57c09642-b20b-4b6c-a538-b432b6090529" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3ce65bcc-7b7a-4f58-90b1-b274e5aaa76d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3ce65bcc-7b7a-4f58-90b1-b274e5aaa76d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c9c03f1a-06f6-4fd9-8301-451023b2bf01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c9c03f1a-06f6-4fd9-8301-451023b2bf01" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c2c96693-1505-477d-8407-c8b66ed699da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c2c96693-1505-477d-8407-c8b66ed699da" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_607ffb06-6f63-47bc-8e3d-8b7b172fcdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eb84462c-842b-45df-be60-247e5e5668b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_607ffb06-6f63-47bc-8e3d-8b7b172fcdf1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eb84462c-842b-45df-be60-247e5e5668b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e89af17e-cb98-4e96-9cb0-8de314aa8ade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eb84462c-842b-45df-be60-247e5e5668b8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e89af17e-cb98-4e96-9cb0-8de314aa8ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e89af17e-cb98-4e96-9cb0-8de314aa8ade_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e89af17e-cb98-4e96-9cb0-8de314aa8ade" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e89af17e-cb98-4e96-9cb0-8de314aa8ade_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8b1a3a7-876c-4489-a0d7-03fc3ce5c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e89af17e-cb98-4e96-9cb0-8de314aa8ade" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8b1a3a7-876c-4489-a0d7-03fc3ce5c23a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ace6ba5-4753-4c20-b5d4-5ec67dccdead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8b1a3a7-876c-4489-a0d7-03fc3ce5c23a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ace6ba5-4753-4c20-b5d4-5ec67dccdead" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f369d319-ea59-4cb9-9608-c3c752778989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8b1a3a7-876c-4489-a0d7-03fc3ce5c23a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f369d319-ea59-4cb9-9608-c3c752778989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_db8e7c0d-776b-47bc-a2cd-114124b421e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eb84462c-842b-45df-be60-247e5e5668b8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_db8e7c0d-776b-47bc-a2cd-114124b421e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db8e7c0d-776b-47bc-a2cd-114124b421e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_db8e7c0d-776b-47bc-a2cd-114124b421e8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db8e7c0d-776b-47bc-a2cd-114124b421e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9928ff3a-44e4-4404-8d3f-de50e3c05fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_db8e7c0d-776b-47bc-a2cd-114124b421e8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9928ff3a-44e4-4404-8d3f-de50e3c05fe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GinkgoBioworksHoldingsIncMember_4f410436-2081-43df-a607-50d0cf38a78d" xlink:href="rnac-20241231.xsd#rnac_GinkgoBioworksHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9928ff3a-44e4-4404-8d3f-de50e3c05fe8" xlink:to="loc_rnac_GinkgoBioworksHoldingsIncMember_4f410436-2081-43df-a607-50d0cf38a78d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_103062aa-df57-4c2d-9199-c7ddee1a8a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_607ffb06-6f63-47bc-8e3d-8b7b172fcdf1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_103062aa-df57-4c2d-9199-c7ddee1a8a56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6380a525-1717-4e08-8c72-a985cbe7cf12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6380a525-1717-4e08-8c72-a985cbe7cf12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6380a525-1717-4e08-8c72-a985cbe7cf12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6380a525-1717-4e08-8c72-a985cbe7cf12" xlink:to="loc_us-gaap_EquityComponentDomain_6380a525-1717-4e08-8c72-a985cbe7cf12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a5b5199e-c2b2-4a3d-8bae-61fac982776d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6380a525-1717-4e08-8c72-a985cbe7cf12" xlink:to="loc_us-gaap_EquityComponentDomain_a5b5199e-c2b2-4a3d-8bae-61fac982776d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0382716-8a5e-4348-8137-73a69dfbbe4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5b5199e-c2b2-4a3d-8bae-61fac982776d" xlink:to="loc_us-gaap_CommonStockMember_c0382716-8a5e-4348-8137-73a69dfbbe4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c933b44e-4d16-418a-9eeb-f61e3052f627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5b5199e-c2b2-4a3d-8bae-61fac982776d" xlink:to="loc_us-gaap_PreferredStockMember_c933b44e-4d16-418a-9eeb-f61e3052f627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ba526f1e-654f-4e25-baa7-a7e54034d59d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:to="loc_us-gaap_AwardTypeAxis_ba526f1e-654f-4e25-baa7-a7e54034d59d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba526f1e-654f-4e25-baa7-a7e54034d59d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ba526f1e-654f-4e25-baa7-a7e54034d59d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba526f1e-654f-4e25-baa7-a7e54034d59d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09d9ec30-7cb6-4f8b-8d01-ea094a340e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ba526f1e-654f-4e25-baa7-a7e54034d59d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09d9ec30-7cb6-4f8b-8d01-ea094a340e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5ed0a936-30f0-41e7-a62b-f5fada44dd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09d9ec30-7cb6-4f8b-8d01-ea094a340e9e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5ed0a936-30f0-41e7-a62b-f5fada44dd0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b0bc9260-3cce-4674-b438-af859f263e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b0bc9260-3cce-4674-b438-af859f263e3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b0bc9260-3cce-4674-b438-af859f263e3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b0bc9260-3cce-4674-b438-af859f263e3b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b0bc9260-3cce-4674-b438-af859f263e3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeeab1e1-38c5-4fd2-a68b-74f6d495a578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b0bc9260-3cce-4674-b438-af859f263e3b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeeab1e1-38c5-4fd2-a68b-74f6d495a578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartestianMember_1c17a8b4-61ec-4557-8d60-07a7db5902b4" xlink:href="rnac-20241231.xsd#rnac_OldCartestianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeeab1e1-38c5-4fd2-a68b-74f6d495a578" xlink:to="loc_rnac_OldCartestianMember_1c17a8b4-61ec-4557-8d60-07a7db5902b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_153ebb6f-90e1-4425-961f-30d422cd9064" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_153ebb6f-90e1-4425-961f-30d422cd9064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5a1e1cd2-a6ca-4982-a499-9b7fdebb10e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5a1e1cd2-a6ca-4982-a499-9b7fdebb10e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2fb2ae52-dba4-4c32-89dc-be0afebc81ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2fb2ae52-dba4-4c32-89dc-be0afebc81ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_657fa5c4-76be-4a9d-a154-302ef1f71a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_657fa5c4-76be-4a9d-a154-302ef1f71a5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_173e0f26-673c-482a-a667-b77bab98ae11" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_173e0f26-673c-482a-a667-b77bab98ae11" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c5957aa-e9f5-481b-836e-9da9f5df5fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c5957aa-e9f5-481b-836e-9da9f5df5fe9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f02b2bd8-f4a9-4a6f-9d17-1a0c60e6c7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c5957aa-e9f5-481b-836e-9da9f5df5fe9" xlink:to="loc_us-gaap_PlanNameAxis_f02b2bd8-f4a9-4a6f-9d17-1a0c60e6c7e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f02b2bd8-f4a9-4a6f-9d17-1a0c60e6c7e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f02b2bd8-f4a9-4a6f-9d17-1a0c60e6c7e8" xlink:to="loc_us-gaap_PlanNameDomain_f02b2bd8-f4a9-4a6f-9d17-1a0c60e6c7e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8b49f31e-2c98-4705-826b-a156db45181f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f02b2bd8-f4a9-4a6f-9d17-1a0c60e6c7e8" xlink:to="loc_us-gaap_PlanNameDomain_8b49f31e-2c98-4705-826b-a156db45181f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_94706f75-2b56-4948-abee-020c2a374f34" xlink:href="rnac-20241231.xsd#rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8b49f31e-2c98-4705-826b-a156db45181f" xlink:to="loc_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_94706f75-2b56-4948-abee-020c2a374f34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianPlanMember_7373f2bf-030d-48aa-855f-f57d9decdf45" xlink:href="rnac-20241231.xsd#rnac_OldCartesianPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8b49f31e-2c98-4705-826b-a156db45181f" xlink:to="loc_rnac_OldCartesianPlanMember_7373f2bf-030d-48aa-855f-f57d9decdf45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6eb6b58-554a-4890-9652-427eda0d4d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6eb6b58-554a-4890-9652-427eda0d4d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f617f236-ab35-46bc-ad94-752953e34879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f617f236-ab35-46bc-ad94-752953e34879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_759f5205-338a-4792-a688-f9f687ad01f6" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_759f5205-338a-4792-a688-f9f687ad01f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d29d514-72dc-42a3-bf97-f92efd3f0cba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d29d514-72dc-42a3-bf97-f92efd3f0cba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0c3e7337-4412-405b-92c7-86842b6a6989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0c3e7337-4412-405b-92c7-86842b6a6989" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock_0aede337-522c-4c42-adec-ed1de0da21d5" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock_0aede337-522c-4c42-adec-ed1de0da21d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_34700dd3-6b63-40ae-bdcd-7fed45e70e59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_99b723d1-9557-404a-8f56-acefbe8b76cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_99b723d1-9557-404a-8f56-acefbe8b76cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ed44354a-03ae-41ad-b5af-34531c4b04c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ed44354a-03ae-41ad-b5af-34531c4b04c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_def9e57f-82b4-4bc2-ad15-f19ed279ae83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_def9e57f-82b4-4bc2-ad15-f19ed279ae83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26eeef4b-0fb6-4d4f-950b-9d1bf9798ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26eeef4b-0fb6-4d4f-950b-9d1bf9798ea2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_cbe8a649-db63-48b8-a0e0-db9e7515b6c4" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_cbe8a649-db63-48b8-a0e0-db9e7515b6c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60e77259-dec7-46bb-bc9a-6e65ba794e65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60e77259-dec7-46bb-bc9a-6e65ba794e65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_145ddbdd-1ee5-4249-be39-3034cb9c0063" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_145ddbdd-1ee5-4249-be39-3034cb9c0063" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock_6fad8551-45f2-43f6-989e-c47ca02990af" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock_6fad8551-45f2-43f6-989e-c47ca02990af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b332cda7-360c-46e5-b8de-eb1077a09738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_bf28c773-fdf8-4418-9c9d-2505bdcfcf8b" xlink:href="rnac-20241231.xsd#rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_bf28c773-fdf8-4418-9c9d-2505bdcfcf8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5eedd699-280b-4841-9116-e8a3f2d138bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5eedd699-280b-4841-9116-e8a3f2d138bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_9cff121e-a712-4478-84e3-643d348d7496" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_9cff121e-a712-4478-84e3-643d348d7496" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a5855ea-1cd9-4324-84f1-a83db4a4f156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_9cff121e-a712-4478-84e3-643d348d7496" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a5855ea-1cd9-4324-84f1-a83db4a4f156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_cf4aa2d5-ee51-431b-a144-d9bdb541d003" xlink:href="rnac-20241231.xsd#rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_9cff121e-a712-4478-84e3-643d348d7496" xlink:to="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_cf4aa2d5-ee51-431b-a144-d9bdb541d003" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_770e7d36-5a7e-4913-baf8-947122637888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_9cff121e-a712-4478-84e3-643d348d7496" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_770e7d36-5a7e-4913-baf8-947122637888" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_7e01eed5-3963-4dfe-a3dd-e5a9cff14a88" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_7e01eed5-3963-4dfe-a3dd-e5a9cff14a88" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a947a9e9-a6da-46e3-971b-e83bf9b74139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_7e01eed5-3963-4dfe-a3dd-e5a9cff14a88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a947a9e9-a6da-46e3-971b-e83bf9b74139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_b7bfa20d-fa95-4f72-937c-b121ff26c75f" xlink:href="rnac-20241231.xsd#rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_7e01eed5-3963-4dfe-a3dd-e5a9cff14a88" xlink:to="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_b7bfa20d-fa95-4f72-937c-b121ff26c75f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_625fe468-b2a5-4845-945c-dceef1a73875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_7e01eed5-3963-4dfe-a3dd-e5a9cff14a88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_625fe468-b2a5-4845-945c-dceef1a73875" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89077c84-7f7f-4569-b567-56ca59586f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebcb169c-827f-46d4-beb9-d586f10b8ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89077c84-7f7f-4569-b567-56ca59586f55" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebcb169c-827f-46d4-beb9-d586f10b8ac8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ee0aeb90-19c3-4f9b-b15f-265e09cc2744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebcb169c-827f-46d4-beb9-d586f10b8ac8" xlink:to="loc_us-gaap_AwardTypeAxis_ee0aeb90-19c3-4f9b-b15f-265e09cc2744" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0aeb90-19c3-4f9b-b15f-265e09cc2744_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ee0aeb90-19c3-4f9b-b15f-265e09cc2744" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0aeb90-19c3-4f9b-b15f-265e09cc2744_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a64f0bae-a7ee-4298-a776-914a12164344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ee0aeb90-19c3-4f9b-b15f-265e09cc2744" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a64f0bae-a7ee-4298-a776-914a12164344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_92c41abe-1944-464b-8b41-82db6cb54b09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a64f0bae-a7ee-4298-a776-914a12164344" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_92c41abe-1944-464b-8b41-82db6cb54b09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89077c84-7f7f-4569-b567-56ca59586f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_600dcc50-8a79-47a7-9c41-4b5341654588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_600dcc50-8a79-47a7-9c41-4b5341654588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_387919d7-e520-4997-a450-db8c83403d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_387919d7-e520-4997-a450-db8c83403d3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50328fc8-d20a-4170-9c7c-aea4a6acdad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50328fc8-d20a-4170-9c7c-aea4a6acdad2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0e7cfc85-4865-499a-b389-8532d0f59c62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89077c84-7f7f-4569-b567-56ca59586f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9ecb7da3-3036-4425-b0b4-e291675855d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9ecb7da3-3036-4425-b0b4-e291675855d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4675077-6820-42dd-8b10-b725acfbcd60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4675077-6820-42dd-8b10-b725acfbcd60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_26176e45-009b-4094-a405-69c69189570d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_26176e45-009b-4094-a405-69c69189570d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e66a92e6-9b3a-4da5-9cd7-00694ceeeeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RevenueArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2db9d1bd-7c99-4d33-a862-f619e81f79de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2db9d1bd-7c99-4d33-a862-f619e81f79de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2db9d1bd-7c99-4d33-a862-f619e81f79de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2db9d1bd-7c99-4d33-a862-f619e81f79de" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2db9d1bd-7c99-4d33-a862-f619e81f79de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f981109f-3f5a-4114-92fe-a9d9c7d316de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2db9d1bd-7c99-4d33-a862-f619e81f79de" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f981109f-3f5a-4114-92fe-a9d9c7d316de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TakedaAgreementMember_cd28e73f-696e-42a5-a9bc-acbd55713052" xlink:href="rnac-20241231.xsd#rnac_TakedaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f981109f-3f5a-4114-92fe-a9d9c7d316de" xlink:to="loc_rnac_TakedaAgreementMember_cd28e73f-696e-42a5-a9bc-acbd55713052" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_a0662cce-ff4d-4ebf-8582-67fd60c1a9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f981109f-3f5a-4114-92fe-a9d9c7d316de" xlink:to="loc_us-gaap_CollaborativeArrangementMember_a0662cce-ff4d-4ebf-8582-67fd60c1a9c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_054e81b6-b68d-446c-9603-f6190d23d641" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_054e81b6-b68d-446c-9603-f6190d23d641" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_054e81b6-b68d-446c-9603-f6190d23d641_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_054e81b6-b68d-446c-9603-f6190d23d641" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_054e81b6-b68d-446c-9603-f6190d23d641_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fdcf81ac-2d2f-4190-8023-8f7a0135f781" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_054e81b6-b68d-446c-9603-f6190d23d641" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fdcf81ac-2d2f-4190-8023-8f7a0135f781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AstellasGeneTherapiesMember_c1923b03-f981-4101-85b0-a5748d093eb9" xlink:href="rnac-20241231.xsd#rnac_AstellasGeneTherapiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fdcf81ac-2d2f-4190-8023-8f7a0135f781" xlink:to="loc_rnac_AstellasGeneTherapiesMember_c1923b03-f981-4101-85b0-a5748d093eb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SareptaTherapeuticsInc.Member_a4ebe56c-2c50-4467-b134-1210c76384b7" xlink:href="rnac-20241231.xsd#rnac_SareptaTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fdcf81ac-2d2f-4190-8023-8f7a0135f781" xlink:to="loc_rnac_SareptaTherapeuticsInc.Member_a4ebe56c-2c50-4467-b134-1210c76384b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3a66e1b5-54e3-48a0-9060-892e6a8a5238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3a66e1b5-54e3-48a0-9060-892e6a8a5238" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3a66e1b5-54e3-48a0-9060-892e6a8a5238_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3a66e1b5-54e3-48a0-9060-892e6a8a5238" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3a66e1b5-54e3-48a0-9060-892e6a8a5238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a39fce4-4013-4ba7-a466-3ada6d7ffad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3a66e1b5-54e3-48a0-9060-892e6a8a5238" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a39fce4-4013-4ba7-a466-3ada6d7ffad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SOBIPurchaseAgreementMember_b0b04618-2940-4fdc-b31f-d7fc19a63492" xlink:href="rnac-20241231.xsd#rnac_SOBIPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a39fce4-4013-4ba7-a466-3ada6d7ffad2" xlink:to="loc_rnac_SOBIPurchaseAgreementMember_b0b04618-2940-4fdc-b31f-d7fc19a63492" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_af40dc07-519d-4ed6-9535-68cbc76a1b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_af40dc07-519d-4ed6-9535-68cbc76a1b4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain_af40dc07-519d-4ed6-9535-68cbc76a1b4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_af40dc07-519d-4ed6-9535-68cbc76a1b4c" xlink:to="loc_us-gaap_ReceivablesBillingStatusDomain_af40dc07-519d-4ed6-9535-68cbc76a1b4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain_37e2af2e-67f5-4b47-a65d-fa98d356d5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_af40dc07-519d-4ed6-9535-68cbc76a1b4c" xlink:to="loc_us-gaap_ReceivablesBillingStatusDomain_37e2af2e-67f5-4b47-a65d-fa98d356d5c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledRevenuesMember_6fb3ca78-aa87-4914-a291-747622427293" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BilledRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain_37e2af2e-67f5-4b47-a65d-fa98d356d5c0" xlink:to="loc_us-gaap_BilledRevenuesMember_6fb3ca78-aa87-4914-a291-747622427293" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a89dc9f5-50cf-4916-a976-3414c95bbd8a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_srt_CounterpartyNameAxis_a89dc9f5-50cf-4916-a976-3414c95bbd8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a89dc9f5-50cf-4916-a976-3414c95bbd8a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a89dc9f5-50cf-4916-a976-3414c95bbd8a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a89dc9f5-50cf-4916-a976-3414c95bbd8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47425ba3-0b4d-44b5-a539-ff9f27cc9d2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a89dc9f5-50cf-4916-a976-3414c95bbd8a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47425ba3-0b4d-44b5-a539-ff9f27cc9d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SwedishOrphanBiovitrumABSOBIMember_77a7ffef-f155-4d26-8b61-bbb5da7fce3f" xlink:href="rnac-20241231.xsd#rnac_SwedishOrphanBiovitrumABSOBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47425ba3-0b4d-44b5-a539-ff9f27cc9d2d" xlink:to="loc_rnac_SwedishOrphanBiovitrumABSOBIMember_77a7ffef-f155-4d26-8b61-bbb5da7fce3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis_712a11bd-a2fc-4d51-bb04-07621de4afe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_GovernmentAssistanceTypeAxis_712a11bd-a2fc-4d51-bb04-07621de4afe5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_712a11bd-a2fc-4d51-bb04-07621de4afe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_712a11bd-a2fc-4d51-bb04-07621de4afe5" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_712a11bd-a2fc-4d51-bb04-07621de4afe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_396cad65-b687-40c0-892e-234856905a91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_712a11bd-a2fc-4d51-bb04-07621de4afe5" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_396cad65-b687-40c0-892e-234856905a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember_97f7ebcd-1360-4655-a5da-be74bd8ec5f1" xlink:href="rnac-20241231.xsd#rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_396cad65-b687-40c0-892e-234856905a91" xlink:to="loc_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember_97f7ebcd-1360-4655-a5da-be74bd8ec5f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborationAndLicenseAgreementsUpfrontPayment_7f535edb-e737-4b65-ad50-a0f200039227" xlink:href="rnac-20241231.xsd#rnac_CollaborationAndLicenseAgreementsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_CollaborationAndLicenseAgreementsUpfrontPayment_7f535edb-e737-4b65-ad50-a0f200039227" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties_5e3f7e2c-f5c1-4f55-9a0d-b925552bcd90" xlink:href="rnac-20241231.xsd#rnac_DevelopmentAndCommercialMilestonesPlusRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties_5e3f7e2c-f5c1-4f55-9a0d-b925552bcd90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_79dd2a7a-1c2d-43bc-a6e4-2be3f425a441" xlink:href="rnac-20241231.xsd#rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_79dd2a7a-1c2d-43bc-a6e4-2be3f425a441" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements_93b63d71-9dd3-4ca4-b3b7-cc5c3a89725b" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements_93b63d71-9dd3-4ca4-b3b7-cc5c3a89725b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation_91fd5024-0ece-44e5-8ab7-20203a2bd78c" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation_91fd5024-0ece-44e5-8ab7-20203a2bd78c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_959cd1da-37c4-4735-8eef-be45c559eb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_959cd1da-37c4-4735-8eef-be45c559eb1d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_d252e6a2-b735-4eba-b2b7-c925f3d41eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_d252e6a2-b735-4eba-b2b7-c925f3d41eeb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46db4196-9d48-413b-a8fb-7c1daf6a87c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46db4196-9d48-413b-a8fb-7c1daf6a87c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_92233bd7-3651-43f5-8225-bfad8c68cf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_92233bd7-3651-43f5-8225-bfad8c68cf9a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance_1c88f464-29a4-4060-9904-9f53efc9fdde" xlink:href="rnac-20241231.xsd#rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance_1c88f464-29a4-4060-9904-9f53efc9fdde" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_8bc6fcda-3a6e-4c52-8fff-fb7000ab47b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_8bc6fcda-3a6e-4c52-8fff-fb7000ab47b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_3b423df3-eb86-4f1e-aff6-8a61a1f7b1ae" xlink:href="rnac-20241231.xsd#rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_3b423df3-eb86-4f1e-aff6-8a61a1f7b1ae" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementUpfrontCashPayment_39df7284-334e-4dfc-8b3c-0d79bfa33d4e" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementUpfrontCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementUpfrontCashPayment_39df7284-334e-4dfc-8b3c-0d79bfa33d4e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected_3abd8398-e7b7-4c75-bee3-7b94d827636a" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected_3abd8398-e7b7-4c75-bee3-7b94d827636a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_9ca5f133-3dbd-4aa5-8f84-9d176664cd75" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_9ca5f133-3dbd-4aa5-8f84-9d176664cd75" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EligiblePeriodToReceiveRoyalties_b3ea5f94-476a-4629-8296-b767cdb6d06b" xlink:href="rnac-20241231.xsd#rnac_EligiblePeriodToReceiveRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_EligiblePeriodToReceiveRoyalties_b3ea5f94-476a-4629-8296-b767cdb6d06b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_RevenueNumberOfPerformanceObligations_d17d7fb5-5bb5-4305-9b4a-ac4d4c0f59de" xlink:href="rnac-20241231.xsd#rnac_RevenueNumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_RevenueNumberOfPerformanceObligations_d17d7fb5-5bb5-4305-9b4a-ac4d4c0f59de" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementDevelopmentMilestone_5c3e1026-879f-452b-bfbb-184fff117ba2" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementDevelopmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementDevelopmentMilestone_5c3e1026-879f-452b-bfbb-184fff117ba2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d0ed762d-5d46-4b4a-b6ea-7c5ccf56cb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d0ed762d-5d46-4b4a-b6ea-7c5ccf56cb8d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium_8ccbda50-63cd-4b19-9f5e-45bb87d25895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedemptionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_RedemptionPremium_8ccbda50-63cd-4b19-9f5e-45bb87d25895" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementPaymentObligation_af662402-4073-4f6b-b2f9-719117fdbe23" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementPaymentObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_CollaborativeArrangementPaymentObligation_af662402-4073-4f6b-b2f9-719117fdbe23" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0ff9fcb1-e946-4a4b-9de7-69266f157049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0ff9fcb1-e946-4a4b-9de7-69266f157049" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6319f117-067d-4e4c-8f07-0bad81a7b724" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6319f117-067d-4e4c-8f07-0bad81a7b724" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementOptionTerm_1cd6626b-5b96-4d6d-98b3-eb0b1d95e092" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementOptionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementOptionTerm_1cd6626b-5b96-4d6d-98b3-eb0b1d95e092" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementExtensionTerm_24152f52-515d-4082-b061-6be5519eca58" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementExtensionTerm_24152f52-515d-4082-b061-6be5519eca58" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies_03caac83-37e1-49a0-a51d-b1d56d4835d2" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies_03caac83-37e1-49a0-a51d-b1d56d4835d2" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestoneReceivable_8154b7b8-f4bf-458d-9467-018f15a6a955" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestoneReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementMilestoneReceivable_8154b7b8-f4bf-458d-9467-018f15a6a955" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_5da2ce28-8786-46c8-b2e5-28759691d111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_5da2ce28-8786-46c8-b2e5-28759691d111" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAwardAmount_a8e165c5-fb57-4d3c-b7b4-724718842853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_GovernmentAssistanceAwardAmount_a8e165c5-fb57-4d3c-b7b4-724718842853" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GovernmentAssistancePotentialAdditionalAwardAmount_b9db0449-1d82-4918-a74e-046281ee76a7" xlink:href="rnac-20241231.xsd#rnac_GovernmentAssistancePotentialAdditionalAwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_GovernmentAssistancePotentialAdditionalAwardAmount_b9db0449-1d82-4918-a74e-046281ee76a7" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_630fb1ee-08a4-42f0-bd64-9af2b396d881" xlink:href="rnac-20241231.xsd#rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_630fb1ee-08a4-42f0-bd64-9af2b396d881" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent_88f0dee1-17b7-46ab-94bb-b5a4bc4866ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmountCumulativeCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent_88f0dee1-17b7-46ab-94bb-b5a4bc4866ed" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_f0da6b12-2304-4980-913d-a11bedb5e052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_f0da6b12-2304-4980-913d-a11bedb5e052" xlink:type="arc" order="32"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2614102a-6a14-4cf8-a790-bf76f590f39b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2614102a-6a14-4cf8-a790-bf76f590f39b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c00685a-5dd5-4e43-9cb0-3f82c7deea71" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:to="loc_srt_CounterpartyNameAxis_0c00685a-5dd5-4e43-9cb0-3f82c7deea71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c00685a-5dd5-4e43-9cb0-3f82c7deea71_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0c00685a-5dd5-4e43-9cb0-3f82c7deea71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c00685a-5dd5-4e43-9cb0-3f82c7deea71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0c00685a-5dd5-4e43-9cb0-3f82c7deea71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Dr.TimothyA.SpringerMember_889a1ae6-f02f-4819-9ff2-9f115ec93efe" xlink:href="rnac-20241231.xsd#rnac_Dr.TimothyA.SpringerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:to="loc_rnac_Dr.TimothyA.SpringerMember_889a1ae6-f02f-4819-9ff2-9f115ec93efe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TASPartnersLLCMember_1a2b5dae-ad0a-4909-8458-0bcfc50b1f2b" xlink:href="rnac-20241231.xsd#rnac_TASPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:to="loc_rnac_TASPartnersLLCMember_1a2b5dae-ad0a-4909-8458-0bcfc50b1f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Dr.ChafenLuMember_ac0e920f-a6b5-4740-b5c4-e84222157e47" xlink:href="rnac-20241231.xsd#rnac_Dr.ChafenLuMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:to="loc_rnac_Dr.ChafenLuMember_ac0e920f-a6b5-4740-b5c4-e84222157e47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SevenOneEightThreeFourIrrevocableTrustMember_8f7415e8-2366-49c0-ac6b-f4ec39865c3d" xlink:href="rnac-20241231.xsd#rnac_SevenOneEightThreeFourIrrevocableTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:to="loc_rnac_SevenOneEightThreeFourIrrevocableTrustMember_8f7415e8-2366-49c0-ac6b-f4ec39865c3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6d56caf-f60d-4598-bf77-b5bd1c462b22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6d56caf-f60d-4598-bf77-b5bd1c462b22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b6d56caf-f60d-4598-bf77-b5bd1c462b22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6d56caf-f60d-4598-bf77-b5bd1c462b22" xlink:to="loc_us-gaap_RelatedPartyDomain_b6d56caf-f60d-4598-bf77-b5bd1c462b22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6331f329-eb32-49b8-b651-46d009dda493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6d56caf-f60d-4598-bf77-b5bd1c462b22" xlink:to="loc_us-gaap_RelatedPartyDomain_6331f329-eb32-49b8-b651-46d009dda493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_adfe159b-d205-448f-a851-c7bcd10917c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6331f329-eb32-49b8-b651-46d009dda493" xlink:to="loc_us-gaap_RelatedPartyMember_adfe159b-d205-448f-a851-c7bcd10917c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3bde5344-4996-4bc8-bba0-038a11a1dc96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3bde5344-4996-4bc8-bba0-038a11a1dc96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bde5344-4996-4bc8-bba0-038a11a1dc96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3bde5344-4996-4bc8-bba0-038a11a1dc96" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bde5344-4996-4bc8-bba0-038a11a1dc96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ec2abde-5b37-4968-8cbd-96cba5b2755e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3bde5344-4996-4bc8-bba0-038a11a1dc96" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ec2abde-5b37-4968-8cbd-96cba5b2755e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2024Member_67d9ae6d-60f2-4cf6-839f-9653cdbfa90f" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ec2abde-5b37-4968-8cbd-96cba5b2755e" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2024Member_67d9ae6d-60f2-4cf6-839f-9653cdbfa90f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023Member_5bf18031-be74-4e0a-a825-91d82fee5bbb" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ec2abde-5b37-4968-8cbd-96cba5b2755e" xlink:to="loc_rnac_PrivatePlacement2023Member_5bf18031-be74-4e0a-a825-91d82fee5bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_63deab1b-e784-4f6e-a9c4-efdfafa16b85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2614102a-6a14-4cf8-a790-bf76f590f39b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_63deab1b-e784-4f6e-a9c4-efdfafa16b85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_09b39b25-5021-42a0-903a-e883c79254e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2614102a-6a14-4cf8-a790-bf76f590f39b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_09b39b25-5021-42a0-903a-e883c79254e0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9d061645-0b28-4b7a-bfb0-53987844ca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9d061645-0b28-4b7a-bfb0-53987844ca9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d061645-0b28-4b7a-bfb0-53987844ca9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9d061645-0b28-4b7a-bfb0-53987844ca9a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d061645-0b28-4b7a-bfb0-53987844ca9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0089f567-1f42-4750-bb93-6c04448806aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9d061645-0b28-4b7a-bfb0-53987844ca9a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0089f567-1f42-4750-bb93-6c04448806aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member_8728a16b-878f-47b7-b6fe-4130703fa5ee" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0089f567-1f42-4750-bb93-6c04448806aa" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2023Member_8728a16b-878f-47b7-b6fe-4130703fa5ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d3b41a06-7997-4d61-a3b8-8fec8754ef84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d3b41a06-7997-4d61-a3b8-8fec8754ef84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d3b41a06-7997-4d61-a3b8-8fec8754ef84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d3b41a06-7997-4d61-a3b8-8fec8754ef84" xlink:to="loc_us-gaap_RelatedPartyDomain_d3b41a06-7997-4d61-a3b8-8fec8754ef84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_46f7148d-3877-4be8-a2b7-9c0432a62424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d3b41a06-7997-4d61-a3b8-8fec8754ef84" xlink:to="loc_us-gaap_RelatedPartyDomain_46f7148d-3877-4be8-a2b7-9c0432a62424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_711dc858-69de-4f7b-82ea-d32322bbfdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_46f7148d-3877-4be8-a2b7-9c0432a62424" xlink:to="loc_us-gaap_RelatedPartyMember_711dc858-69de-4f7b-82ea-d32322bbfdf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c6892fc8-82f3-447d-bc56-525c45e58449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c6892fc8-82f3-447d-bc56-525c45e58449" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c6892fc8-82f3-447d-bc56-525c45e58449_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c6892fc8-82f3-447d-bc56-525c45e58449" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c6892fc8-82f3-447d-bc56-525c45e58449_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5dfb2a20-d906-4f24-bef3-b59ef002cde7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c6892fc8-82f3-447d-bc56-525c45e58449" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5dfb2a20-d906-4f24-bef3-b59ef002cde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2019WarrantsMember_0d1b465e-dadd-44f1-af84-1e7c408c27bc" xlink:href="rnac-20241231.xsd#rnac_A2019WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5dfb2a20-d906-4f24-bef3-b59ef002cde7" xlink:to="loc_rnac_A2019WarrantsMember_0d1b465e-dadd-44f1-af84-1e7c408c27bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8d229f7b-b687-406b-8018-77e89ffafb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8d229f7b-b687-406b-8018-77e89ffafb7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b57b38a5-63a4-4fe4-b93d-66ffc0c8b94b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b57b38a5-63a4-4fe4-b93d-66ffc0c8b94b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightExercisedDuringPeriod_b621a551-590d-40c4-8d78-831941fd1a4d" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightExercisedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_rnac_ClassOfWarrantOrRightExercisedDuringPeriod_b621a551-590d-40c4-8d78-831941fd1a4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b9eae096-1240-4a43-a1fd-5d1a4fdb20be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b9eae096-1240-4a43-a1fd-5d1a4fdb20be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_9829fe7f-b739-4930-9144-0a44d5ee19a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_9829fe7f-b739-4930-9144-0a44d5ee19a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71bc1005-1235-4a05-ad60-4c6b1772bf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71bc1005-1235-4a05-ad60-4c6b1772bf6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants_bb76fa71-0432-4a97-879a-efa433487815" xlink:href="rnac-20241231.xsd#rnac_IssuanceOfContingentValueRightForExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants_bb76fa71-0432-4a97-879a-efa433487815" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c859f183-19b0-41c9-b484-c46cd0927baf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5287f67-4155-4049-aecf-78fe0376285f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c859f183-19b0-41c9-b484-c46cd0927baf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5287f67-4155-4049-aecf-78fe0376285f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f857256-f11d-45c6-85ca-1087a17eeecf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5287f67-4155-4049-aecf-78fe0376285f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f857256-f11d-45c6-85ca-1087a17eeecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f857256-f11d-45c6-85ca-1087a17eeecf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f857256-f11d-45c6-85ca-1087a17eeecf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f857256-f11d-45c6-85ca-1087a17eeecf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dee251b2-0f1b-4848-a460-bfca4f527464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f857256-f11d-45c6-85ca-1087a17eeecf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dee251b2-0f1b-4848-a460-bfca4f527464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BiogenM.A.Inc.Member_7a0ad2a7-d656-4d94-91fe-23f42ce28bf0" xlink:href="rnac-20241231.xsd#rnac_BiogenM.A.Inc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dee251b2-0f1b-4848-a460-bfca4f527464" xlink:to="loc_rnac_BiogenM.A.Inc.Member_7a0ad2a7-d656-4d94-91fe-23f42ce28bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_11523d7f-1d33-4ec9-b0b1-a26fa18ba96f" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementWrittenNoticePeriodForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c859f183-19b0-41c9-b484-c46cd0927baf" xlink:to="loc_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_11523d7f-1d33-4ec9-b0b1-a26fa18ba96f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b9a6acf-a49c-405a-9938-16d4b8c5c2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd174749-4b76-43fd-a17a-f44c2eb42a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b9a6acf-a49c-405a-9938-16d4b8c5c2a9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd174749-4b76-43fd-a17a-f44c2eb42a3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9a3d5356-a0a0-424d-a0ee-23bd9f2d2d74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd174749-4b76-43fd-a17a-f44c2eb42a3b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9a3d5356-a0a0-424d-a0ee-23bd9f2d2d74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9a3d5356-a0a0-424d-a0ee-23bd9f2d2d74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9a3d5356-a0a0-424d-a0ee-23bd9f2d2d74" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9a3d5356-a0a0-424d-a0ee-23bd9f2d2d74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ea066ef-cd96-4874-aebc-c8300e524fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9a3d5356-a0a0-424d-a0ee-23bd9f2d2d74" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ea066ef-cd96-4874-aebc-c8300e524fc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NationalCancerInstituteAgreementMember_20dac9af-8ec1-40a4-92e9-d97dbd6c649c" xlink:href="rnac-20241231.xsd#rnac_NationalCancerInstituteAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ea066ef-cd96-4874-aebc-c8300e524fc5" xlink:to="loc_rnac_NationalCancerInstituteAgreementMember_20dac9af-8ec1-40a4-92e9-d97dbd6c649c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementRoyaltyPayment_9177b7c9-7f04-401d-85c9-d91683d5be38" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementRoyaltyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b9a6acf-a49c-405a-9938-16d4b8c5c2a9" xlink:to="loc_rnac_LicenseAndOptionAgreementRoyaltyPayment_9177b7c9-7f04-401d-85c9-d91683d5be38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum_58945be8-5b1f-4e4a-a0f3-60838e7f2046" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b9a6acf-a49c-405a-9938-16d4b8c5c2a9" xlink:to="loc_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum_58945be8-5b1f-4e4a-a0f3-60838e7f2046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_b036089f-25a1-428d-b0b1-be03112941a0" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementWrittenNoticePeriodForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b9a6acf-a49c-405a-9938-16d4b8c5c2a9" xlink:to="loc_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_b036089f-25a1-428d-b0b1-be03112941a0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc77731-df5b-4e32-805a-5ae1520e2232" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc77731-df5b-4e32-805a-5ae1520e2232" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_988968a8-88ad-42e0-92e3-1eb999b997c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc77731-df5b-4e32-805a-5ae1520e2232" xlink:to="loc_us-gaap_TypeOfArrangementAxis_988968a8-88ad-42e0-92e3-1eb999b997c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_988968a8-88ad-42e0-92e3-1eb999b997c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_988968a8-88ad-42e0-92e3-1eb999b997c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_988968a8-88ad-42e0-92e3-1eb999b997c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93ec8b9-d9b5-46c0-beed-7dcb83c68268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_988968a8-88ad-42e0-92e3-1eb999b997c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93ec8b9-d9b5-46c0-beed-7dcb83c68268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GinkgoAgreementMember_0a6b8098-e174-44d6-a006-5f1b3215bc3e" xlink:href="rnac-20241231.xsd#rnac_GinkgoAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93ec8b9-d9b5-46c0-beed-7dcb83c68268" xlink:to="loc_rnac_GinkgoAgreementMember_0a6b8098-e174-44d6-a006-5f1b3215bc3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected_ba81b189-e083-4d4f-88ce-990860729fd5" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:to="loc_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected_ba81b189-e083-4d4f-88ce-990860729fd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestonePayments_5aad7060-ea66-47f6-a379-12d4cf9af667" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:to="loc_rnac_LicenseAndOptionAgreementMilestonePayments_5aad7060-ea66-47f6-a379-12d4cf9af667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement_d545164f-73e5-4e2c-b7b1-616daee96ee4" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:to="loc_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement_d545164f-73e5-4e2c-b7b1-616daee96ee4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount_fe96b0d9-6032-4e6e-85cf-241164fd45cc" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:to="loc_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount_fe96b0d9-6032-4e6e-85cf-241164fd45cc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fbbc4d6f-c2b6-4dc9-a67a-a4f9661107ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ad80e57-bcc5-4ebf-bd5c-cb10adfc92dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fbbc4d6f-c2b6-4dc9-a67a-a4f9661107ec" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ad80e57-bcc5-4ebf-bd5c-cb10adfc92dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d65a5e45-3c5c-4d4b-ae37-a153441ace9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ad80e57-bcc5-4ebf-bd5c-cb10adfc92dd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d65a5e45-3c5c-4d4b-ae37-a153441ace9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65a5e45-3c5c-4d4b-ae37-a153441ace9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d65a5e45-3c5c-4d4b-ae37-a153441ace9b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65a5e45-3c5c-4d4b-ae37-a153441ace9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7767ca4-8d09-465e-9ef7-c37deea91834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d65a5e45-3c5c-4d4b-ae37-a153441ace9b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7767ca4-8d09-465e-9ef7-c37deea91834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GenovisABMember_c33f62df-3acd-433e-8fdf-35cfc788e805" xlink:href="rnac-20241231.xsd#rnac_GenovisABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7767ca4-8d09-465e-9ef7-c37deea91834" xlink:to="loc_rnac_GenovisABMember_c33f62df-3acd-433e-8fdf-35cfc788e805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestonePayments_6b0b2a59-3e24-4340-8807-eb2395abbb0e" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fbbc4d6f-c2b6-4dc9-a67a-a4f9661107ec" xlink:to="loc_rnac_LicenseAndOptionAgreementMilestonePayments_6b0b2a59-3e24-4340-8807-eb2395abbb0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_96051af9-0ab2-4e59-8f09-19dcf1543b06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_96051af9-0ab2-4e59-8f09-19dcf1543b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96051af9-0ab2-4e59-8f09-19dcf1543b06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_96051af9-0ab2-4e59-8f09-19dcf1543b06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96051af9-0ab2-4e59-8f09-19dcf1543b06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2124a4-2bc9-453e-b0a8-4253566a0026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_96051af9-0ab2-4e59-8f09-19dcf1543b06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2124a4-2bc9-453e-b0a8-4253566a0026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CyrusBiotechnologyIncMember_ff16e197-151c-451c-9468-a0411887c929" xlink:href="rnac-20241231.xsd#rnac_CyrusBiotechnologyIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2124a4-2bc9-453e-b0a8-4253566a0026" xlink:to="loc_rnac_CyrusBiotechnologyIncMember_ff16e197-151c-451c-9468-a0411887c929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f0fa33ae-207e-423d-afb2-3dce6c640ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f0fa33ae-207e-423d-afb2-3dce6c640ee1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f0fa33ae-207e-423d-afb2-3dce6c640ee1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f0fa33ae-207e-423d-afb2-3dce6c640ee1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f0fa33ae-207e-423d-afb2-3dce6c640ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_959626d2-47d4-4ae1-a858-93795e488e67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f0fa33ae-207e-423d-afb2-3dce6c640ee1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_959626d2-47d4-4ae1-a858-93795e488e67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SeriesBPreferredStockPurchaseAgreementMember_7babb1ec-4aeb-447f-b60a-d12f992dc5db" xlink:href="rnac-20241231.xsd#rnac_SeriesBPreferredStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_959626d2-47d4-4ae1-a858-93795e488e67" xlink:to="loc_rnac_SeriesBPreferredStockPurchaseAgreementMember_7babb1ec-4aeb-447f-b60a-d12f992dc5db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a5ee0de1-8ad5-4e6a-9a70-886765b7257b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:to="loc_srt_OwnershipAxis_a5ee0de1-8ad5-4e6a-9a70-886765b7257b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a5ee0de1-8ad5-4e6a-9a70-886765b7257b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_a5ee0de1-8ad5-4e6a-9a70-886765b7257b" xlink:to="loc_srt_OwnershipDomain_a5ee0de1-8ad5-4e6a-9a70-886765b7257b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bb80fccb-cf7a-4999-894f-73693076fdc0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_a5ee0de1-8ad5-4e6a-9a70-886765b7257b" xlink:to="loc_srt_OwnershipDomain_bb80fccb-cf7a-4999-894f-73693076fdc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CyrusBiotechnologyIncMember_26ea46c0-f8ac-4ddf-b83e-2b8fc6b1c1d1" xlink:href="rnac-20241231.xsd#rnac_CyrusBiotechnologyIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_bb80fccb-cf7a-4999-894f-73693076fdc0" xlink:to="loc_rnac_CyrusBiotechnologyIncMember_26ea46c0-f8ac-4ddf-b83e-2b8fc6b1c1d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestonePayments_d56ad4a7-18e7-41bc-99c1-02b90fc3b9c8" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_rnac_LicenseAndOptionAgreementMilestonePayments_d56ad4a7-18e7-41bc-99c1-02b90fc3b9c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased_0495084e-01db-4655-b5e7-8a81bdc2e195" xlink:href="rnac-20241231.xsd#rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased_0495084e-01db-4655-b5e7-8a81bdc2e195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare_32edc273-2714-47c4-8f62-4a5b800ce86c" xlink:href="rnac-20241231.xsd#rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare_32edc273-2714-47c4-8f62-4a5b800ce86c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare_c2a5167a-89e0-4e83-b4b1-887f22f970e7" xlink:href="rnac-20241231.xsd#rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare_c2a5167a-89e0-4e83-b4b1-887f22f970e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_263c9a01-5b3c-4b1c-a5b0-c91407070da5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_263c9a01-5b3c-4b1c-a5b0-c91407070da5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47b2647e-eb87-4729-a4f1-b20d1f62d31f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e739f3b-9dd4-4296-8b7a-22f12982c3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47b2647e-eb87-4729-a4f1-b20d1f62d31f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e739f3b-9dd4-4296-8b7a-22f12982c3b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_39cf9131-7b3a-4653-85a7-1a6633779908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e739f3b-9dd4-4296-8b7a-22f12982c3b3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_39cf9131-7b3a-4653-85a7-1a6633779908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39cf9131-7b3a-4653-85a7-1a6633779908_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_39cf9131-7b3a-4653-85a7-1a6633779908" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39cf9131-7b3a-4653-85a7-1a6633779908_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_618e0e96-5132-4196-b2ca-6606466777c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_39cf9131-7b3a-4653-85a7-1a6633779908" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_618e0e96-5132-4196-b2ca-6606466777c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AskBioLicenseMember_ba256260-e8a3-4c42-9cda-51e2cfcfb226" xlink:href="rnac-20241231.xsd#rnac_AskBioLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_618e0e96-5132-4196-b2ca-6606466777c7" xlink:to="loc_rnac_AskBioLicenseMember_ba256260-e8a3-4c42-9cda-51e2cfcfb226" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f829a2b5-ca0d-4027-bdd6-22a16116f578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47b2647e-eb87-4729-a4f1-b20d1f62d31f" xlink:to="loc_us-gaap_OperatingExpenses_f829a2b5-ca0d-4027-bdd6-22a16116f578" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementCostSharePercentage_76b67288-bdc3-48ff-9b0f-24dccf8eecb1" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementCostSharePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47b2647e-eb87-4729-a4f1-b20d1f62d31f" xlink:to="loc_rnac_CollaborativeArrangementCostSharePercentage_76b67288-bdc3-48ff-9b0f-24dccf8eecb1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d05db94b-0e9f-4353-a3e0-3330ba87d129" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e73aa570-9c22-4552-b45a-da19344cc2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d05db94b-0e9f-4353-a3e0-3330ba87d129" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e73aa570-9c22-4552-b45a-da19344cc2fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0280df0f-02a0-4ded-9284-5d2d983d7ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e73aa570-9c22-4552-b45a-da19344cc2fc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0280df0f-02a0-4ded-9284-5d2d983d7ce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0280df0f-02a0-4ded-9284-5d2d983d7ce7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0280df0f-02a0-4ded-9284-5d2d983d7ce7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0280df0f-02a0-4ded-9284-5d2d983d7ce7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4a381ed-a88d-449c-8349-329488e4aac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0280df0f-02a0-4ded-9284-5d2d983d7ce7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4a381ed-a88d-449c-8349-329488e4aac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_38845781-ec25-4515-a0f6-1dd077f03e66" xlink:href="rnac-20241231.xsd#rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4a381ed-a88d-449c-8349-329488e4aac4" xlink:to="loc_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_38845781-ec25-4515-a0f6-1dd077f03e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_b2144e9c-7a46-47fc-8b6f-615a33e5e671" xlink:href="rnac-20241231.xsd#rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d05db94b-0e9f-4353-a3e0-3330ba87d129" xlink:to="loc_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_b2144e9c-7a46-47fc-8b6f-615a33e5e671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_03190dc8-9966-45fb-9a6a-8d4b59ada737" xlink:href="rnac-20241231.xsd#rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d05db94b-0e9f-4353-a3e0-3330ba87d129" xlink:to="loc_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_03190dc8-9966-45fb-9a6a-8d4b59ada737" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_695bfc91-838d-439f-a68f-22f3be523316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_695bfc91-838d-439f-a68f-22f3be523316" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3802fa21-8bde-4334-b867-9f495a1602dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_695bfc91-838d-439f-a68f-22f3be523316" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3802fa21-8bde-4334-b867-9f495a1602dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3802fa21-8bde-4334-b867-9f495a1602dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3802fa21-8bde-4334-b867-9f495a1602dd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3802fa21-8bde-4334-b867-9f495a1602dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e8afe70b-e6dd-49f6-86e9-6e8764343e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3802fa21-8bde-4334-b867-9f495a1602dd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e8afe70b-e6dd-49f6-86e9-6e8764343e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_ec065a0d-704c-490a-be35-b1e7ebea19e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e8afe70b-e6dd-49f6-86e9-6e8764343e0e" xlink:to="loc_us-gaap_DomesticCountryMember_ec065a0d-704c-490a-be35-b1e7ebea19e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_38ebb19c-024f-4139-98a1-a3262d89b831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e8afe70b-e6dd-49f6-86e9-6e8764343e0e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_38ebb19c-024f-4139-98a1-a3262d89b831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ddf4edda-e53f-4a37-b12a-c5561d9fc5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ddf4edda-e53f-4a37-b12a-c5561d9fc5f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0aefc812-7a8c-4685-8263-53105abd9bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0aefc812-7a8c-4685-8263-53105abd9bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_edb65625-dbe8-4993-b824-5ce47ca43421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_edb65625-dbe8-4993-b824-5ce47ca43421" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1cbb7b3b-615e-4ba5-b679-c7607a46f14c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1cbb7b3b-615e-4ba5-b679-c7607a46f14c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLossCarryforwardsNotSubjectToExpiration_4fe05fe4-9ae6-4a34-8a4d-76bb4524471f" xlink:href="rnac-20241231.xsd#rnac_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_rnac_OperatingLossCarryforwardsNotSubjectToExpiration_4fe05fe4-9ae6-4a34-8a4d-76bb4524471f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLossCarryforwardsSubjectToExpiration_4dc3b3f6-cb6d-4f0f-a342-a5ac5d72af3e" xlink:href="rnac-20241231.xsd#rnac_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_rnac_OperatingLossCarryforwardsSubjectToExpiration_4dc3b3f6-cb6d-4f0f-a342-a5ac5d72af3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9a98e519-52d4-4329-ad83-dcf7ccaa2b27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_9a98e519-52d4-4329-ad83-dcf7ccaa2b27" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes_148ff073-86ca-4725-931d-97d61f96b652" xlink:href="rnac-20241231.xsd#rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes_148ff073-86ca-4725-931d-97d61f96b652" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EmployeeBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e062caff-c0a2-4f3c-83cc-a706d14b289d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51cdd20e-a29d-409e-a172-6b53e38cfbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e062caff-c0a2-4f3c-83cc-a706d14b289d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51cdd20e-a29d-409e-a172-6b53e38cfbd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9f353f23-b919-4611-a5d6-87480a5c956d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51cdd20e-a29d-409e-a172-6b53e38cfbd4" xlink:to="loc_us-gaap_PlanNameAxis_9f353f23-b919-4611-a5d6-87480a5c956d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9f353f23-b919-4611-a5d6-87480a5c956d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9f353f23-b919-4611-a5d6-87480a5c956d" xlink:to="loc_us-gaap_PlanNameDomain_9f353f23-b919-4611-a5d6-87480a5c956d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d3efccf5-3360-45cf-9ec4-8a65aef11f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9f353f23-b919-4611-a5d6-87480a5c956d" xlink:to="loc_us-gaap_PlanNameDomain_d3efccf5-3360-45cf-9ec4-8a65aef11f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EmployeeStockPurchasePlan2016Member_2014cddd-1681-4517-8e5c-3c67b78e3dda" xlink:href="rnac-20241231.xsd#rnac_EmployeeStockPurchasePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d3efccf5-3360-45cf-9ec4-8a65aef11f8c" xlink:to="loc_rnac_EmployeeStockPurchasePlan2016Member_2014cddd-1681-4517-8e5c-3c67b78e3dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8640adc1-1537-4d50-99be-f9e17dc17b43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e062caff-c0a2-4f3c-83cc-a706d14b289d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8640adc1-1537-4d50-99be-f9e17dc17b43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_58fd78b6-6135-488b-b869-a9b1b0426b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e062caff-c0a2-4f3c-83cc-a706d14b289d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_58fd78b6-6135-488b-b869-a9b1b0426b8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ecc17397-be80-4b35-a467-920520ca864f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f3508ae-4ed5-440e-af11-24a8f15d99c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ecc17397-be80-4b35-a467-920520ca864f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f3508ae-4ed5-440e-af11-24a8f15d99c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c12fa0fe-0ba5-4680-960c-8cf5ad3e4228" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f3508ae-4ed5-440e-af11-24a8f15d99c5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c12fa0fe-0ba5-4680-960c-8cf5ad3e4228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c12fa0fe-0ba5-4680-960c-8cf5ad3e4228_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c12fa0fe-0ba5-4680-960c-8cf5ad3e4228" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c12fa0fe-0ba5-4680-960c-8cf5ad3e4228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e0df1aa5-b61c-4612-84a7-1d3983c345cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c12fa0fe-0ba5-4680-960c-8cf5ad3e4228" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e0df1aa5-b61c-4612-84a7-1d3983c345cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_54ffeca3-ae56-4a83-be62-4f51c1b78e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0df1aa5-b61c-4612-84a7-1d3983c345cf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_54ffeca3-ae56-4a83-be62-4f51c1b78e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c9b5701-27c4-4f51-91b9-6ee73037227c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0df1aa5-b61c-4612-84a7-1d3983c345cf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c9b5701-27c4-4f51-91b9-6ee73037227c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8e77c896-7aa7-4283-90b8-371c2a0ba740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ecc17397-be80-4b35-a467-920520ca864f" xlink:to="loc_us-gaap_RestructuringCharges_8e77c896-7aa7-4283-90b8-371c2a0ba740" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_66a71407-cf21-48b3-bfd5-d67ea788fa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ecc17397-be80-4b35-a467-920520ca864f" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_66a71407-cf21-48b3-bfd5-d67ea788fa2c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#SegmentReportingDetails"/>
  <link:definitionLink xlink:role="http://www.cartesiantherapeutics.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3759ad9-9f50-48f6-b456-8d5cda200a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3759ad9-9f50-48f6-b456-8d5cda200a0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d3503eeb-fc4c-450c-ab63-1c64179a5b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3759ad9-9f50-48f6-b456-8d5cda200a0d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d3503eeb-fc4c-450c-ab63-1c64179a5b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d3503eeb-fc4c-450c-ab63-1c64179a5b0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d3503eeb-fc4c-450c-ab63-1c64179a5b0d" xlink:to="loc_us-gaap_SegmentDomain_d3503eeb-fc4c-450c-ab63-1c64179a5b0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c557f66c-9ce1-477c-974b-558cfd850941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d3503eeb-fc4c-450c-ab63-1c64179a5b0d" xlink:to="loc_us-gaap_SegmentDomain_c557f66c-9ce1-477c-974b-558cfd850941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ReportingSegmentsMember_1d828199-7eb6-4abf-b836-22b785685516" xlink:href="rnac-20241231.xsd#rnac_ReportingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c557f66c-9ce1-477c-974b-558cfd850941" xlink:to="loc_rnac_ReportingSegmentsMember_1d828199-7eb6-4abf-b836-22b785685516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f45a97a5-285d-49ab-8b9c-16817544df27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3759ad9-9f50-48f6-b456-8d5cda200a0d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f45a97a5-285d-49ab-8b9c-16817544df27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f45a97a5-285d-49ab-8b9c-16817544df27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f45a97a5-285d-49ab-8b9c-16817544df27" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f45a97a5-285d-49ab-8b9c-16817544df27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11e5b0ad-8e3d-4586-a922-6cbd956fe997" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f45a97a5-285d-49ab-8b9c-16817544df27" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11e5b0ad-8e3d-4586-a922-6cbd956fe997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LegacySelectaProgramsMember_6a30cca9-156d-4508-ae0f-aa62b3df15b7" xlink:href="rnac-20241231.xsd#rnac_LegacySelectaProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11e5b0ad-8e3d-4586-a922-6cbd956fe997" xlink:to="loc_rnac_LegacySelectaProgramsMember_6a30cca9-156d-4508-ae0f-aa62b3df15b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Descartes08ForMGMember_35ffb7eb-f02c-42ca-a55f-09bac48cd6d0" xlink:href="rnac-20241231.xsd#rnac_Descartes08ForMGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11e5b0ad-8e3d-4586-a922-6cbd956fe997" xlink:to="loc_rnac_Descartes08ForMGMember_35ffb7eb-f02c-42ca-a55f-09bac48cd6d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EarlyStageProgramsMember_ef8b066d-12b7-4f52-a821-9fe20e021c4b" xlink:href="rnac-20241231.xsd#rnac_EarlyStageProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11e5b0ad-8e3d-4586-a922-6cbd956fe997" xlink:to="loc_rnac_EarlyStageProgramsMember_ef8b066d-12b7-4f52-a821-9fe20e021c4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1a0f9425-aa66-497a-8505-771fc30ee33f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:to="loc_us-gaap_RevenuesAbstract_1a0f9425-aa66-497a-8505-771fc30ee33f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e11217c-87d3-43ba-8108-d95a12b7b2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1a0f9425-aa66-497a-8505-771fc30ee33f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e11217c-87d3-43ba-8108-d95a12b7b2b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_a0b59f7e-d171-4806-a347-223df80aa9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1a0f9425-aa66-497a-8505-771fc30ee33f" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_a0b59f7e-d171-4806-a347-223df80aa9f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2b376349-e728-4584-bc0a-b689e462dedf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1a0f9425-aa66-497a-8505-771fc30ee33f" xlink:to="loc_us-gaap_Revenues_2b376349-e728-4584-bc0a-b689e462dedf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:to="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_MedicalExpensesOperating_b57e85e8-c6b8-4275-9978-e7782304288c" xlink:href="rnac-20241231.xsd#rnac_MedicalExpensesOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_rnac_MedicalExpensesOperating_b57e85e8-c6b8-4275-9978-e7782304288c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentEmployeeExpenses_ce7256fc-e09c-4594-83f7-905aaf3f6f55" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentEmployeeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_rnac_ResearchAndDevelopmentEmployeeExpenses_ce7256fc-e09c-4594-83f7-905aaf3f6f55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentStockBasedCompensationExpense_8d373714-a688-4d8f-8f5d-73d31e534cb4" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentStockBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_rnac_ResearchAndDevelopmentStockBasedCompensationExpense_8d373714-a688-4d8f-8f5d-73d31e534cb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses_b081b135-3214-424d-8b33-4a3f85657072" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses_b081b135-3214-424d-8b33-4a3f85657072" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9f7c88f7-8b3d-4400-a794-dd77d0798663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9f7c88f7-8b3d-4400-a794-dd77d0798663" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_648dc4c9-7710-4102-a828-0c5776c4cc82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_648dc4c9-7710-4102-a828-0c5776c4cc82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_a990a52b-8fa9-428f-828f-a4c6a7044d34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:to="loc_us-gaap_OtherNonoperatingExpense_a990a52b-8fa9-428f-828f-a4c6a7044d34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71b60f76-2c41-482e-9ef3-032c0d2f6bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:to="loc_us-gaap_NetIncomeLoss_71b60f76-2c41-482e-9ef3-032c0d2f6bdb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ChristopherJewellMember_64d404bd-26ab-4848-be7a-20db302be683" xlink:href="rnac-20241231.xsd#rnac_ChristopherJewellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rnac_ChristopherJewellMember_64d404bd-26ab-4848-be7a-20db302be683" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="691"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="692"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="693"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>rnac-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f87b4d67-655c-40f8-bf99-5c1eb72d37a4,g:ec248d9b-f7a4-4998-8c2a-3c79ab383104-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_rnac_DirectorsAndExecutiveOfficersMember_7108442f-8351-48f7-8a46-1b13b8b0faab_terseLabel_en-US" xlink:label="lab_rnac_DirectorsAndExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Directors and Executive Officers</link:label>
    <link:label id="lab_rnac_DirectorsAndExecutiveOfficersMember_label_en-US" xlink:label="lab_rnac_DirectorsAndExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors And Executive Officers [Member]</link:label>
    <link:label id="lab_rnac_DirectorsAndExecutiveOfficersMember_documentation_en-US" xlink:label="lab_rnac_DirectorsAndExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Directors And Executive Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DirectorsAndExecutiveOfficersMember" xlink:href="rnac-20241231.xsd#rnac_DirectorsAndExecutiveOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_DirectorsAndExecutiveOfficersMember" xlink:to="lab_rnac_DirectorsAndExecutiveOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_A65GroveStreetWatertownMAMember_b442d8e5-dcf8-4134-b65b-d97880e9d086_terseLabel_en-US" xlink:label="lab_rnac_A65GroveStreetWatertownMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">65 Grove Street, Watertown,MA</link:label>
    <link:label id="lab_rnac_A65GroveStreetWatertownMAMember_label_en-US" xlink:label="lab_rnac_A65GroveStreetWatertownMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">65 Grove Street, Watertown, MA [Member]</link:label>
    <link:label id="lab_rnac_A65GroveStreetWatertownMAMember_documentation_en-US" xlink:label="lab_rnac_A65GroveStreetWatertownMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">65 Grove Street, Watertown, MA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A65GroveStreetWatertownMAMember" xlink:href="rnac-20241231.xsd#rnac_A65GroveStreetWatertownMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_A65GroveStreetWatertownMAMember" xlink:to="lab_rnac_A65GroveStreetWatertownMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_59a50752-8378-4361-b519-ba438924f081_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_14890170-7898-463a-9ecc-cd5afde974c9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ddf6e02-c9f0-44e4-8f01-fafa6b9798c2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_6ccf97d2-65ea-4d67-ab00-c672ffb85bd4_terseLabel_en-US" xlink:label="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_label_en-US" xlink:label="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value</link:label>
    <link:label id="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_documentation_en-US" xlink:label="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:href="rnac-20241231.xsd#rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:to="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e0eb6b75-a5fd-44e5-81eb-90f299f046ef_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_2272b2ef-eb2c-45f2-8555-9d7ac5dd79a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of principal, final payment fee, and prepayment penalty on debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_88b5e121-6fac-42b9-9d71-c00f81c50baf_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total payoff amount of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_OperatingLossCarryforwardsNotSubjectToExpiration_f7c3ac86-bf11-4f20-a416-399417820b37_terseLabel_en-US" xlink:label="lab_rnac_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_rnac_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_rnac_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:label id="lab_rnac_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_rnac_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="rnac-20241231.xsd#rnac_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_rnac_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8a75ad48-a192-4918-a5dc-d59650af9c37_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_1eb43b73-a4ed-40d5-a749-bbeb65756747_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Converted from options for Series A preferred stock (in shares)</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Assumed in Period</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Assumed in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_af1dc9f3-066e-4a01-99cf-95df8a4f4938_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c611f2f2-aef5-4172-b3c4-1cf6605f12c7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants_c6629b0d-5cc6-4e55-9024-6368543551d2_terseLabel_en-US" xlink:label="lab_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of CVRs upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants_label_en-US" xlink:label="lab_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Contingent Value Right for Exercise of Warrants</link:label>
    <link:label id="lab_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants_documentation_en-US" xlink:label="lab_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of Contingent Value Right for Exercise of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants" xlink:href="rnac-20241231.xsd#rnac_IssuanceOfContingentValueRightForExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants" xlink:to="lab_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_a4ce1ac1-8405-4754-9058-30aadbdfa64f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-adjusted discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fed07d06-5877-46cd-ae71-e41b8383c209_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e897ac20-4b35-4228-b563-553b0f83a42e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8e2628ca-9a6c-4434-984e-112ddea8e60a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bda5eae4-f9fb-4296-82b4-11f48e90a9df_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_205e75ac-6dda-448b-ab99-1e7aeac65448_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c673c5f1-c7a8-4578-8711-9345ed6e3138_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CollaborativeArrangementPaymentObligation_2e1f0f58-1e10-4001-b3ec-4fb80ac39326_terseLabel_en-US" xlink:label="lab_rnac_CollaborativeArrangementPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, payment obligation</link:label>
    <link:label id="lab_rnac_CollaborativeArrangementPaymentObligation_label_en-US" xlink:label="lab_rnac_CollaborativeArrangementPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Payment Obligation</link:label>
    <link:label id="lab_rnac_CollaborativeArrangementPaymentObligation_documentation_en-US" xlink:label="lab_rnac_CollaborativeArrangementPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Payment Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementPaymentObligation" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementPaymentObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CollaborativeArrangementPaymentObligation" xlink:to="lab_rnac_CollaborativeArrangementPaymentObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PrivatePlacement2023TrancheOneMember_be4642ec-a58c-4ead-b2df-a4a307d92c73_terseLabel_en-US" xlink:label="lab_rnac_PrivatePlacement2023TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Private Placement, Tranche One</link:label>
    <link:label id="lab_rnac_PrivatePlacement2023TrancheOneMember_label_en-US" xlink:label="lab_rnac_PrivatePlacement2023TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement 2023, Tranche One [Member]</link:label>
    <link:label id="lab_rnac_PrivatePlacement2023TrancheOneMember_documentation_en-US" xlink:label="lab_rnac_PrivatePlacement2023TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement 2023, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023TrancheOneMember" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PrivatePlacement2023TrancheOneMember" xlink:to="lab_rnac_PrivatePlacement2023TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledRevenuesMember_6a9c5c8a-91e2-45c0-9ad3-7e01a10bcdc3_terseLabel_en-US" xlink:label="lab_us-gaap_BilledRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Billed Revenues</link:label>
    <link:label id="lab_us-gaap_BilledRevenuesMember_label_en-US" xlink:label="lab_us-gaap_BilledRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledRevenuesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BilledRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledRevenuesMember" xlink:to="lab_us-gaap_BilledRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_NumberOfBusinessDays_36a3d3ca-1a11-4097-adec-2c4e15e6de63_terseLabel_en-US" xlink:label="lab_rnac_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of business days</link:label>
    <link:label id="lab_rnac_NumberOfBusinessDays_label_en-US" xlink:label="lab_rnac_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Business Days</link:label>
    <link:label id="lab_rnac_NumberOfBusinessDays_documentation_en-US" xlink:label="lab_rnac_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Business Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NumberOfBusinessDays" xlink:href="rnac-20241231.xsd#rnac_NumberOfBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_NumberOfBusinessDays" xlink:to="lab_rnac_NumberOfBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_UpfrontRentalPayment_e62c1a18-0305-4ee8-859d-47e96ac4b94c_terseLabel_en-US" xlink:label="lab_rnac_UpfrontRentalPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront rental payment</link:label>
    <link:label id="lab_rnac_UpfrontRentalPayment_label_en-US" xlink:label="lab_rnac_UpfrontRentalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Rental Payment</link:label>
    <link:label id="lab_rnac_UpfrontRentalPayment_documentation_en-US" xlink:label="lab_rnac_UpfrontRentalPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Rental Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_UpfrontRentalPayment" xlink:href="rnac-20241231.xsd#rnac_UpfrontRentalPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_UpfrontRentalPayment" xlink:to="lab_rnac_UpfrontRentalPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_7fd967fa-05ba-4f77-aba2-a4a7e32c7ccb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_ef2b06b7-b442-4f6a-873c-ae9f2e124429_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1382e4e9-bed4-4e3e-94e8-ba55cffd81aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3fc9f533-e2ce-48cb-a216-4e6e117783b9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ef7711e0-d246-4957-87c0-2f1a2621f7b6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PrivatePlacementOneMember_16eeaaa2-34ff-4b7c-92d6-faaa6e341197_terseLabel_en-US" xlink:label="lab_rnac_PrivatePlacementOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement One</link:label>
    <link:label id="lab_rnac_PrivatePlacementOneMember_label_en-US" xlink:label="lab_rnac_PrivatePlacementOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement One [Member]</link:label>
    <link:label id="lab_rnac_PrivatePlacementOneMember_documentation_en-US" xlink:label="lab_rnac_PrivatePlacementOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacementOneMember" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacementOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PrivatePlacementOneMember" xlink:to="lab_rnac_PrivatePlacementOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AccruedPropertyPlantAndEquipmentCurrent_164c3775-38b4-4838-8261-449b7c92df3f_terseLabel_en-US" xlink:label="lab_rnac_AccruedPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_rnac_AccruedPropertyPlantAndEquipmentCurrent_label_en-US" xlink:label="lab_rnac_AccruedPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Property, Plant And Equipment, Current</link:label>
    <link:label id="lab_rnac_AccruedPropertyPlantAndEquipmentCurrent_documentation_en-US" xlink:label="lab_rnac_AccruedPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Property, Plant And Equipment, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedPropertyPlantAndEquipmentCurrent" xlink:href="rnac-20241231.xsd#rnac_AccruedPropertyPlantAndEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AccruedPropertyPlantAndEquipmentCurrent" xlink:to="lab_rnac_AccruedPropertyPlantAndEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e1a08950-bac7-41a0-84d4-b73ecc7e9918_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_4f34b37e-f54e-423e-9c73-55f8480d777c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_b5acb9e5-c371-47bb-83aa-e1462f367774_negatedLabel_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlement of outstanding equity awards at Merger</link:label>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_ef228043-f1ee-4750-b774-e67d6dde8309_terseLabel_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to additional paid in capital, settlement of outstanding equity awards at merger</link:label>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_label_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Settlement Of Outstanding Equity Awards</link:label>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_documentation_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Settlement Of Outstanding Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" xlink:to="lab_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4d7bdbac-9656-46de-908e-66a9fdaf29fd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_39124ae6-7fca-4a9d-abda-c15a89e4fe50_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized, increase (in shares)</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts_a3d1e210-789f-441f-bbda-780d037b8aeb_totalLabel_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts_label_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Increase From Cash Receipts</link:label>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts_documentation_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Increase From Cash Receipts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:to="lab_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_770046f7-b3c2-4358-9e3d-86975f71326e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33e2395e-151a-4a0e-9da3-6aff04c00b0c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_4b337bdc-b0e7-4f46-92d9-0f0540abbd17_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_162a95ce-e39a-4b01-894e-a53398fb0088_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8bd092a2-8f51-4e2c-9fbe-fd4736556735_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_5fc171db-2622-4716-b28f-dd5aa0e98a02_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_4a3ddf72-f002-4801-bea9-d57c1ba33c6b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bddcbddb-24d6-4ad8-bda1-3ef69f9e12ab_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plus: dilutive effect of forward contract liability settled in February 2024 (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1b27e7ac-580f-4481-b212-0615d32cb6b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_1b4e8db2-9532-4042-ad96-d3fd2b4eed50_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_e5a621c1-064d-4184-9f2f-d6d14d898b42_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_b9c81dcb-85ea-4d47-bb02-286a39dd4eb7_terseLabel_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercises (in dollars per share)</link:label>
    <link:label id="lab_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_label_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercises</link:label>
    <link:label id="lab_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_documentation_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:to="lab_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_924784f6-5562-41e2-9715-981993166d85_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_746b1a4b-95b6-4529-ab16-201b8cb6a96e_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value of common stock and preferred stock (in dollars per share)</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighed-average fair value relating to the share-based payment award.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5a4f787c-fa97-4059-9014-abf03c141e72_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_OperatingLossCarryforwardsSubjectToExpiration_6579fe7e-6c19-4ade-bd4c-1648c9ea83e8_terseLabel_en-US" xlink:label="lab_rnac_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_rnac_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_rnac_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:label id="lab_rnac_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_rnac_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="rnac-20241231.xsd#rnac_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_rnac_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c34c37da-5d65-46ff-9835-208484cf143c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare_53568b5e-6cdc-495f-bd27-74654589e0a4_terseLabel_en-US" xlink:label="lab_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, stock purchase agreement, par value per share (in dollars per share)</link:label>
    <link:label id="lab_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare_label_en-US" xlink:label="lab_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Stock Purchase Agreement, Par Value Per Share</link:label>
    <link:label id="lab_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare_documentation_en-US" xlink:label="lab_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Stock Purchase Agreement, Par Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare" xlink:href="rnac-20241231.xsd#rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare" xlink:to="lab_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CollaborationAndLicenseAgreementsTextBlock_fb88b50a-f242-4279-bb51-f588c8d2257a_terseLabel_en-US" xlink:label="lab_rnac_CollaborationAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_rnac_CollaborationAndLicenseAgreementsTextBlock_label_en-US" xlink:label="lab_rnac_CollaborationAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements [Text Block]</link:label>
    <link:label id="lab_rnac_CollaborationAndLicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_rnac_CollaborationAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborationAndLicenseAgreementsTextBlock" xlink:href="rnac-20241231.xsd#rnac_CollaborationAndLicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CollaborationAndLicenseAgreementsTextBlock" xlink:to="lab_rnac_CollaborationAndLicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_OldCartesianMember_34ca0ea2-015f-42cd-94d4-fd5ccc92511d_terseLabel_en-US" xlink:label="lab_rnac_OldCartesianMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Old Cartesian</link:label>
    <link:label id="lab_rnac_OldCartesianMember_label_en-US" xlink:label="lab_rnac_OldCartesianMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Old Cartesian [Member]</link:label>
    <link:label id="lab_rnac_OldCartesianMember_documentation_en-US" xlink:label="lab_rnac_OldCartesianMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Old Cartesian</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_OldCartesianMember" xlink:to="lab_rnac_OldCartesianMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne_418150a1-ca0a-4108-b03d-91e6629a41e3_terseLabel_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, base rent, annual upward adjustment percentage after year one</link:label>
    <link:label id="lab_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne_label_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rent, Annual Upward Adjustment Percentage After Year One</link:label>
    <link:label id="lab_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne_documentation_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rent, Annual Upward Adjustment Percentage After Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" xlink:to="lab_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties_46340244-1218-4e06-991e-bee4d12a8dc2_terseLabel_en-US" xlink:label="lab_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and commercial milestones plus royalties</link:label>
    <link:label id="lab_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties_label_en-US" xlink:label="lab_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Commercial Milestones Plus Royalties</link:label>
    <link:label id="lab_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties_documentation_en-US" xlink:label="lab_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Commercial Milestones Plus Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties" xlink:href="rnac-20241231.xsd#rnac_DevelopmentAndCommercialMilestonesPlusRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties" xlink:to="lab_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_193f95e1-df1b-4e81-919a-6c451e44e49e_terseLabel_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Expenses And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ff969e25-5c91-4e82-a167-fb2a6f2dbe66_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability_367fef28-3f85-483c-866c-4c66e4032b6f_terseLabel_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability_label_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Lease Liability</link:label>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability_documentation_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability" xlink:to="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_5026e821-ba26-445c-a7fc-23870bfd8e80_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_90edc94c-95c2-425a-bb7a-eee411c7e56f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SwedishOrphanBiovitrumABSOBIMember_89d37578-4d16-4110-af03-85db8474a96e_terseLabel_en-US" xlink:label="lab_rnac_SwedishOrphanBiovitrumABSOBIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB (SOBI)</link:label>
    <link:label id="lab_rnac_SwedishOrphanBiovitrumABSOBIMember_label_en-US" xlink:label="lab_rnac_SwedishOrphanBiovitrumABSOBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB (SOBI) [Member]</link:label>
    <link:label id="lab_rnac_SwedishOrphanBiovitrumABSOBIMember_documentation_en-US" xlink:label="lab_rnac_SwedishOrphanBiovitrumABSOBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB (SOBI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SwedishOrphanBiovitrumABSOBIMember" xlink:href="rnac-20241231.xsd#rnac_SwedishOrphanBiovitrumABSOBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SwedishOrphanBiovitrumABSOBIMember" xlink:to="lab_rnac_SwedishOrphanBiovitrumABSOBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ad0510bd-149e-4b81-be18-153b2cda8245_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c7ca916f-966f-4b14-83b0-63c4b6473c9f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_e0ac29c1-e0b1-4cf8-aa32-84ca1fd14682_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2a5080b6-1876-479f-9ec2-0ad63457bb68_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8494e80b-5aa1-44b7-92aa-51864a7521b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f814aa89-6559-4ad7-91d4-dc1056860e8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_72cd4581-2b4c-4f04-b27b-4d7438ff3cca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_OldCartesianPlanMember_0e7d3ac3-05b6-4c41-aae0-396d147e2fc1_terseLabel_en-US" xlink:label="lab_rnac_OldCartesianPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Old Cartesian Plan</link:label>
    <link:label id="lab_rnac_OldCartesianPlanMember_label_en-US" xlink:label="lab_rnac_OldCartesianPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Old Cartesian Plan [Member]</link:label>
    <link:label id="lab_rnac_OldCartesianPlanMember_documentation_en-US" xlink:label="lab_rnac_OldCartesianPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Old Cartesian Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianPlanMember" xlink:href="rnac-20241231.xsd#rnac_OldCartesianPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_OldCartesianPlanMember" xlink:to="lab_rnac_OldCartesianPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c48e9b88-7315-49e9-8d47-a2bdb6439d31_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1defd194-4bec-4af8-87e0-dbdd7ce7506a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_DecemberTwoThousandNineteenFinancingMember_5e52c501-bd27-4b44-a884-103c0f7a4d52_terseLabel_en-US" xlink:label="lab_rnac_DecemberTwoThousandNineteenFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2019 Financing</link:label>
    <link:label id="lab_rnac_DecemberTwoThousandNineteenFinancingMember_label_en-US" xlink:label="lab_rnac_DecemberTwoThousandNineteenFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December Two Thousand Nineteen Financing [Member]</link:label>
    <link:label id="lab_rnac_DecemberTwoThousandNineteenFinancingMember_documentation_en-US" xlink:label="lab_rnac_DecemberTwoThousandNineteenFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December Two Thousand Nineteen Financing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DecemberTwoThousandNineteenFinancingMember" xlink:href="rnac-20241231.xsd#rnac_DecemberTwoThousandNineteenFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_DecemberTwoThousandNineteenFinancingMember" xlink:to="lab_rnac_DecemberTwoThousandNineteenFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleSharesIssuable_37a54392-65b7-4766-bdeb-29444a34a3b0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, common stock issuable upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleSharesIssuable_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_2af107ce-2c8e-4d29-a51b-bf7cb140f01d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Disclosure for the Statement of Cash Flows Related to Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9ed472ad-0c78-4516-a9a4-727f648d451b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ae7190df-d52f-4566-a903-fff0aef0a979_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_56e4f5de-ee34-42ab-af17-3c37b48d64f7_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_08d847e8-b535-4fd5-bd16-671c91daab81_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5f2a794e-cd23-4065-b9a5-23440c5368d8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_94cfaa0c-d515-4db2-a956-1a335ce36356_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityDeferredRevenue_4fe67a04-72c4-4c77-9a62-ea868c15f9f7_periodStartLabel_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, beginning of period</link:label>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityDeferredRevenue_22385079-6d7f-462e-8321-0a314d815d3c_periodEndLabel_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, end of period</link:label>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityDeferredRevenue_label_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue</link:label>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityDeferredRevenue_documentation_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityDeferredRevenue" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContractwithCustomerLiabilityDeferredRevenue" xlink:to="lab_rnac_ContractwithCustomerLiabilityDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b5fee418-aee3-47d9-b0ed-777ff79a0341_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_83222b42-b0df-41d8-a588-dc3eaf2642cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5611153f-365d-4833-bdda-ee463aceca23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_020dc7af-4e27-4d34-a66c-1b5c1a671a69_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_d320be18-8c03-40c0-a671-f4c4b546f1d2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d9b1a9ca-7e4c-488b-9b1f-b03a3e9412fa_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_c4c6f43c-9a27-40bc-9ad2-4ba4caae2c81_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets/(liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_691cf2dd-531a-4f8d-be08-0f897e14121c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_e3121c0a-05ae-4949-a053-aeacaf58797c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_71a24834-9960-4c42-989b-a12c10c78b60_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred debt issuance cost, writeoff</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Debt Issuance Cost, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b0d1e3d8-4b04-4cc7-918c-070abd842d90_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_86a3c58d-d7b9-4749-a357-056c6a6877b6_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_8f9521c1-7307-484e-be4e-32470e372f0a_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_edbfb4a7-b788-4362-8050-329360a7f363_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_9cae99ce-5fff-4dfb-a32c-6f992021f207_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0ab1cc16-9573-4c27-b7c3-426a51f47002_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fbc4c922-fd5a-4f15-8951-afeb10a6af82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_c7b6e4f7-98dd-4a42-aa80-003a95932011_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Converted from options for Series A preferred stock (in dollars per share)</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Assumed in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Assumed in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" xlink:to="lab_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SecuritiesPurchaseAgreement2024Member_d48836db-cf77-4a9b-a546-f95b158c705f_terseLabel_en-US" xlink:label="lab_rnac_SecuritiesPurchaseAgreement2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Securities Purchase Agreement</link:label>
    <link:label id="lab_rnac_SecuritiesPurchaseAgreement2024Member_label_en-US" xlink:label="lab_rnac_SecuritiesPurchaseAgreement2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement 2024 [Member]</link:label>
    <link:label id="lab_rnac_SecuritiesPurchaseAgreement2024Member_documentation_en-US" xlink:label="lab_rnac_SecuritiesPurchaseAgreement2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2024Member" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SecuritiesPurchaseAgreement2024Member" xlink:to="lab_rnac_SecuritiesPurchaseAgreement2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_GenovisABMember_65d324d9-c58c-4103-b156-cb4cf54759b8_terseLabel_en-US" xlink:label="lab_rnac_GenovisABMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genovis AB</link:label>
    <link:label id="lab_rnac_GenovisABMember_label_en-US" xlink:label="lab_rnac_GenovisABMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genovis AB [Member]</link:label>
    <link:label id="lab_rnac_GenovisABMember_documentation_en-US" xlink:label="lab_rnac_GenovisABMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genovis AB</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GenovisABMember" xlink:href="rnac-20241231.xsd#rnac_GenovisABMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_GenovisABMember" xlink:to="lab_rnac_GenovisABMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_DebtInstrumentAccruedInterest_04b4b241-6988-49bb-bbbd-7a7a0364f4ac_terseLabel_en-US" xlink:label="lab_rnac_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, accrued interest</link:label>
    <link:label id="lab_rnac_DebtInstrumentAccruedInterest_label_en-US" xlink:label="lab_rnac_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:label id="lab_rnac_DebtInstrumentAccruedInterest_documentation_en-US" xlink:label="lab_rnac_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DebtInstrumentAccruedInterest" xlink:href="rnac-20241231.xsd#rnac_DebtInstrumentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_DebtInstrumentAccruedInterest" xlink:to="lab_rnac_DebtInstrumentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_00cc7502-b16a-4896-b266-68a7801d943e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, number of securities called by each warrant or right (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_aa64c5a0-872f-4520-ae9d-af918d5d353d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, asset, reclassified to receivable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Reclassified to Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:to="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_0e1f532e-af87-446a-8537-435fd8cea886_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Not from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_7d7e1a56-69c6-4e25-822e-0c13551237e9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4ceb1022-03f1-428d-8e57-cbcdad2106fe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ChristopherJewellMember_label_en-US" xlink:label="lab_rnac_ChristopherJewellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Christopher Jewell [Member]</link:label>
    <link:label id="lab_rnac_ChristopherJewellMember_documentation_en-US" xlink:label="lab_rnac_ChristopherJewellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Christopher Jewell</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ChristopherJewellMember" xlink:href="rnac-20241231.xsd#rnac_ChristopherJewellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ChristopherJewellMember" xlink:to="lab_rnac_ChristopherJewellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_2d949b34-e367-4fde-8f38-665525231a91_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Software and Office Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_11760e9e-386b-4cb2-94c4-cc92430c5f39_terseLabel_en-US" xlink:label="lab_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3SBio License</link:label>
    <link:label id="lab_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement With Shenyang Sunshine Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to License agreement with Shenyang Sunshine Pharmaceutical co., ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:href="rnac-20241231.xsd#rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:to="lab_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_d186e319-3af0-4b9a-a41b-65ea8a6b2e76_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SettlementOfDerivativeLiabilityShares_964779f1-447d-4720-96d3-7693fbe6de2e_terseLabel_en-US" xlink:label="lab_rnac_SettlementOfDerivativeLiabilityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, shares (in shares)</link:label>
    <link:label id="lab_rnac_SettlementOfDerivativeLiabilityShares_label_en-US" xlink:label="lab_rnac_SettlementOfDerivativeLiabilityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Of Derivative Liability, Shares</link:label>
    <link:label id="lab_rnac_SettlementOfDerivativeLiabilityShares_documentation_en-US" xlink:label="lab_rnac_SettlementOfDerivativeLiabilityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement Of Derivative Liability, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SettlementOfDerivativeLiabilityShares" xlink:href="rnac-20241231.xsd#rnac_SettlementOfDerivativeLiabilityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SettlementOfDerivativeLiabilityShares" xlink:to="lab_rnac_SettlementOfDerivativeLiabilityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_Descartes08ForSLEMember_01c800c1-30f4-4e16-a5ba-60911eb53ee2_terseLabel_en-US" xlink:label="lab_rnac_Descartes08ForSLEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Descartes-08 for SLE</link:label>
    <link:label id="lab_rnac_Descartes08ForSLEMember_label_en-US" xlink:label="lab_rnac_Descartes08ForSLEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Descartes-08 For SLE [Member]</link:label>
    <link:label id="lab_rnac_Descartes08ForSLEMember_documentation_en-US" xlink:label="lab_rnac_Descartes08ForSLEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Descartes-08 For SLE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Descartes08ForSLEMember" xlink:href="rnac-20241231.xsd#rnac_Descartes08ForSLEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_Descartes08ForSLEMember" xlink:to="lab_rnac_Descartes08ForSLEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20a59db2-4535-476a-83d3-8dd3ade50d2d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6712c288-6513-417d-adf3-d8456e1a9f1c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aba4238b-9f6f-46dc-ae7d-4ce53aaa1ea8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a9c7c6b1-6367-40db-930d-450b8ee2ea4e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_31881c72-e0cb-4115-bfab-db2a2175e668_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b73d2dc3-7d14-4ad4-b0ea-1b278dd0a051_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_3a1c126b-701f-4657-a4a7-b51bb4ade9cb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_05714714-cd63-4c2b-aaa9-c2a632b6e8a4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ba51765a-073d-42ec-9123-a6e8d0e77a83_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_03c301b6-48b9-4bc1-97e0-e808b758b9ba_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1d37fc7c-f610-45bf-9fbb-ec41650d9d8a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7a0f140b-4d29-4c6c-93f3-d1278a0e9f4d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_StockIncentivePlan2016Member_8a7db396-a9db-4fb6-8920-c0bc30c09db0_terseLabel_en-US" xlink:label="lab_rnac_StockIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_rnac_StockIncentivePlan2016Member_label_en-US" xlink:label="lab_rnac_StockIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2016 [Member]</link:label>
    <link:label id="lab_rnac_StockIncentivePlan2016Member_documentation_en-US" xlink:label="lab_rnac_StockIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the 2016 stock incentive plan, which provides for the granting of stock based awards to employees, directors, and consultants under terms and provisions established by the board of directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIncentivePlan2016Member" xlink:href="rnac-20241231.xsd#rnac_StockIncentivePlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_StockIncentivePlan2016Member" xlink:to="lab_rnac_StockIncentivePlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_2caa4b5f-1330-4590-91f4-3cf3e9b8d8da_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementMilestonePayments_8bd90110-6f92-4e06-91df-5b2042723b05_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementMilestonePayments_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Milestone Payments</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementMilestonePayments_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestonePayments" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementMilestonePayments" xlink:to="lab_rnac_LicenseAndOptionAgreementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_a998e136-8014-4100-9ba0-87650065da6f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contribution made</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1b1b827d-11a0-49eb-9c19-2d9e0572a5f0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ef6e7872-7ee5-4de7-8167-ed72d6cffafa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f7bd2320-d72a-45ff-88ee-e5754e88604a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_4ee9ed9f-6f66-4c58-a0e2-dfd01fc98490_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Change in Accrued Restructuring Balance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected_4ef7e2a8-620c-4745-abb9-de3509823fb1_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical and commercial milestone payment, expected</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Clinical And Commercial Milestone Payment, Expected</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Clinical And Commercial Milestone Payment, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected" xlink:to="lab_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_953bb28d-276b-4ac4-b5f7-1a6c6e6144c5_terseLabel_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, additions</link:label>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_label_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts</link:label>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_documentation_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:to="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6ba92799-194e-4089-bb8c-655a14a6ea32_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_089618b9-543f-4416-9c14-0c4c087fa4fd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LegacySelectaProgramsMember_3e261e85-bfee-413e-a6f4-71d7ab4ca2bc_terseLabel_en-US" xlink:label="lab_rnac_LegacySelectaProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legacy Selecta programs</link:label>
    <link:label id="lab_rnac_LegacySelectaProgramsMember_label_en-US" xlink:label="lab_rnac_LegacySelectaProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legacy Selecta Programs [Member]</link:label>
    <link:label id="lab_rnac_LegacySelectaProgramsMember_documentation_en-US" xlink:label="lab_rnac_LegacySelectaProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legacy Selecta Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LegacySelectaProgramsMember" xlink:href="rnac-20241231.xsd#rnac_LegacySelectaProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LegacySelectaProgramsMember" xlink:to="lab_rnac_LegacySelectaProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_908f959f-06b3-4378-99d6-04909f6a6b1c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_60efb92f-acce-4350-bfe4-f4f0c02a8c9e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_A7495NewHorizonWayLeaseMember_b5d40624-208c-44cb-b116-f4c78b888bd1_terseLabel_en-US" xlink:label="lab_rnac_A7495NewHorizonWayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">7495 New Horizon Way Lease</link:label>
    <link:label id="lab_rnac_A7495NewHorizonWayLeaseMember_label_en-US" xlink:label="lab_rnac_A7495NewHorizonWayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">7495 New Horizon Way Lease [Member]</link:label>
    <link:label id="lab_rnac_A7495NewHorizonWayLeaseMember_documentation_en-US" xlink:label="lab_rnac_A7495NewHorizonWayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">7495 New Horizon Way Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A7495NewHorizonWayLeaseMember" xlink:href="rnac-20241231.xsd#rnac_A7495NewHorizonWayLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_A7495NewHorizonWayLeaseMember" xlink:to="lab_rnac_A7495NewHorizonWayLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_4f879ac5-71f6-48a2-a1f7-5cf0860105f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_4c1eb57a-6c95-4460-8c6c-c65084e7decd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2e691bf8-65da-4d1e-adce-f0000c9e617a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_WarrantsAndRightsOutstandingNoncurrent_28917f44-ec96-4e83-bcc4-62e3ea83aea2_terseLabel_en-US" xlink:label="lab_rnac_WarrantsAndRightsOutstandingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liabilities, net of current portion</link:label>
    <link:label id="lab_rnac_WarrantsAndRightsOutstandingNoncurrent_label_en-US" xlink:label="lab_rnac_WarrantsAndRightsOutstandingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants And Rights Outstanding, Noncurrent</link:label>
    <link:label id="lab_rnac_WarrantsAndRightsOutstandingNoncurrent_documentation_en-US" xlink:label="lab_rnac_WarrantsAndRightsOutstandingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants And Rights Outstanding, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantsAndRightsOutstandingNoncurrent" xlink:href="rnac-20241231.xsd#rnac_WarrantsAndRightsOutstandingNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_WarrantsAndRightsOutstandingNoncurrent" xlink:to="lab_rnac_WarrantsAndRightsOutstandingNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_043e9d51-0074-4d17-ae7b-0a61155c3429_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_da9acbf6-d36e-4bd9-a5ce-400e1b0602af_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6ed5178b-5b79-4f2b-9a73-4a5d0d334b0a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_0c61f477-5f4a-4b12-996d-7751bd3b2962_terseLabel_en-US" xlink:label="lab_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written notice for agreement termination</link:label>
    <link:label id="lab_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_label_en-US" xlink:label="lab_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Written Notice Period For Termination</link:label>
    <link:label id="lab_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_documentation_en-US" xlink:label="lab_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Written Notice Period For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementWrittenNoticePeriodForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination" xlink:to="lab_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6c97a4b7-cb21-4105-b9da-ed68073ddae5_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_20c60b45-d614-49e4-8350-62598fb53265_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8bdcb5a9-2ec0-4fb9-aee2-7e33e0c2d82d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_280c1684-e812-4506-8599-f429a2bdc801_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d9cfce30-d434-4610-b5b7-d62704fb809d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_a27cbf2c-4f56-4ed1-b114-7527b86d2037_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee-paid construction costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_2fc109c6-4ea1-47ca-8dbc-61c0fba29ad3_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_f72359b3-b6f5-4503-bca2-91cc94ad4a90_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Technique, Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Option Pricing Model [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_daf289a1-9d71-40f7-836b-5ebb93a51533_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9f7783e6-14f8-437f-bd79-687cd8bde57e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_891a7841-d4df-4cf4-9b3d-912b61d2437a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d618d0d9-caae-4050-b9b5-18777ed2ae4f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_082fb1e6-7ee0-4544-bea2-a67b0b2da99f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_f1c26413-6483-4251-8d62-744a945f973f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_bbe54af8-d217-4e7a-8525-d8b2237a4e81_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61cff39b-dd8c-4411-a2f4-60110139386a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potential Dilutive Shares of Common Stock Excluded from the Computation of the Diluted Net Loss Per Share Allocable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_fb98daf7-4f5f-49a7-ab71-8de59f198c9a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c273fc2c-1dc3-4212-976f-67d85a52aee4_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ProbabilityOfSuccessMember_89993e5b-f8e4-41ed-a7d4-5e972f593b62_terseLabel_en-US" xlink:label="lab_rnac_ProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated probability of success</link:label>
    <link:label id="lab_rnac_ProbabilityOfSuccessMember_label_en-US" xlink:label="lab_rnac_ProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probability Of Success [Member]</link:label>
    <link:label id="lab_rnac_ProbabilityOfSuccessMember_documentation_en-US" xlink:label="lab_rnac_ProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probability Of Success</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ProbabilityOfSuccessMember" xlink:href="rnac-20241231.xsd#rnac_ProbabilityOfSuccessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ProbabilityOfSuccessMember" xlink:to="lab_rnac_ProbabilityOfSuccessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_a450196d-3ed0-47f8-a4a6-ffd599214ed9_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement_44b39043-c93e-4b02-ab3f-b0630e25ba06_terseLabel_en-US" xlink:label="lab_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, license agreement</link:label>
    <link:label id="lab_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement_label_en-US" xlink:label="lab_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During The Period, Values, Common Stock License Agreement</link:label>
    <link:label id="lab_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement_documentation_en-US" xlink:label="lab_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During The Period, Values, Common Stock License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement" xlink:to="lab_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_cd3a1b2a-3837-41c6-a32a-2ab14b783b4b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_58283e99-483b-44e5-8dea-5abcc34cdc40_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead_11a7d364-7978-4d15-b89c-bde8de9635c5_terseLabel_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed semi annual amount</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead_label_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability, Deduction From Distribution, General And Administrative Overhead</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead_documentation_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability, Deduction From Distribution, General And Administrative Overhead</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead" xlink:to="lab_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_14971ca0-9fe8-489b-9935-947b36180438_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, noncurrent</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cce19b37-6540-4787-ba6f-1026106ddb11_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b5ad4764-2b70-4748-9585-a4c4b00e7947_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series A Preferred Stock in connection with the Merger and settlement of related forward contract</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_5960de13-af64-492f-b1a7-2d0b21c0379b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ed8ca06a-36fc-4856-9310-9d0b4d7cb917_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_9c2dd2e1-5535-4d83-b1a6-0b50af4492d8_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d3d729d9-a05a-45e2-9d62-5911b2e0675a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_f4bfcb3f-fc30-4ce4-87f7-63671bd06aa5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_b77a681c-caca-4f1b-8de9-7e3738104256_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger_bb7333e3-ef65-4c76-ba32-8ce1371b8c67_terseLabel_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of replacement options in Merger</link:label>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger_label_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Issuance Of Replacement Options In Merger</link:label>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger_documentation_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Issuance Of Replacement Options In Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger" xlink:to="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_c3224a7e-1762-4483-a71c-13398b70867d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee workforce, termination percentage</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_7481c49f-0459-402c-8dc3-7cec0d8fc6ab_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_80c21276-65f9-4b84-a618-a65002110543_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_bb9286a3-0951-44da-bba2-047e92273f54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liabilities revaluation</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_5208ac81-3df5-4ad4-946b-caa6457e5147_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e15db757-4f6e-4075-a9f2-7458fbaaa4a6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency transaction, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_725f0b38-b35d-4212-813f-28b96a825cf4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_95bd012c-ef19-498c-bf17-9ea2424c4728_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f904c7a4-0991-4e56-be5e-811b1a8c4cd1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_de4ebbf7-1470-4c86-b095-f2588ab8241d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate fair value of RSU awards vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5cc2acb6-eb7d-48c9-ad5d-b32ab4c503ea_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4203b842-fb65-4ec0-9d51-eb46458d5015_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation_875dcbc7-90c9-4baf-80bd-8ea43f49f96d_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and option agreement, written notice period before cancellation</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Written Notice Period Before Cancellation</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Written Notice Period Before Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" xlink:to="lab_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecurities_3cc8955e-a378-4f5d-907c-350e7ac9ed6a_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Change in fair value of forward contract liability settled in February 2024</link:label>
    <link:label id="lab_us-gaap_DilutiveSecurities_label_en-US" xlink:label="lab_us-gaap_DilutiveSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities" xlink:to="lab_us-gaap_DilutiveSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e4914b5-b794-4bd9-9a18-15152ea6c44a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_35b2c126-25ae-439a-8dd9-73d71309d919_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and license revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4f4ce474-0aee-4830-b105-8eaddfd61f72_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected_7af234e4-88a9-431c-b6b0-2ae37ca28df5_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future additional payments, expected</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Future Additional Payments, Expected</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Future Additional Payments, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected" xlink:to="lab_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_57b41f39-71b3-44b9-bfd2-af552cb0d48b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_4a226826-b97d-423e-b53b-3cec6bc0e90d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_00a5656a-b570-4e46-b9f6-ea3c7f03703c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4127df3e-d8a6-43fd-9315-aa011b7ef87c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability_785e1d63-6808-42ca-8993-a23b6c5f555d_terseLabel_en-US" xlink:label="lab_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability_label_en-US" xlink:label="lab_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Tenant Improvement Allowance Recognized as Reduction in Right of Use Asset and Lease Liability</link:label>
    <link:label id="lab_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability_documentation_en-US" xlink:label="lab_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Tenant Improvement Allowance Recognized as Reduction in Right of Use Asset and Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability" xlink:href="rnac-20241231.xsd#rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability" xlink:to="lab_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_37cd0f25-e6f6-48f8-a781-c51a2e801fb0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll and employee related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_326bf874-eb12-499c-bd6b-9298e85f070f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_0df46321-9019-4b40-b8ca-843102ad20ad_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_212498cf-b74b-41fa-802e-988c9973d39b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_160f7225-eb8e-42f6-8ead-fc4f277c6ba5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2a23bef0-ed71-474e-b040-5be00fe8aa01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9ed57c0a-3436-48a0-a665-bcdd8045ef0f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_b099eb06-d37c-488b-805a-087372b96483_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fa521523-91a5-4553-af65-899c3649f1fe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_6cbd177b-fd07-4438-882b-0002a3471449_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb30bf6d-7441-4fe0-9f83-9ce9ec0b8335_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_062770f8-cde7-412d-a040-4d8ce39d2ad5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a7487394-4ed3-4c3f-a241-2f61b31c2ae5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9add7ddd-3b4b-4afa-8aa5-a254fee459c6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, convertible preferred stock, and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_f0cfb985-8319-4355-8653-7a7300afea2a_terseLabel_en-US" xlink:label="lab_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and marketable securities</link:label>
    <link:label id="lab_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale</link:label>
    <link:label id="lab_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:href="rnac-20241231.xsd#rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:to="lab_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b9e6aff8-ce58-4f5d-9b67-724d8aa983f0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7de94611-f33d-4c46-8da5-3d5d265b0041_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AccruedAuditFeesCurrent_5673196d-7c06-4f54-8a18-3d393e5d614a_terseLabel_en-US" xlink:label="lab_rnac_AccruedAuditFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional and consulting services</link:label>
    <link:label id="lab_rnac_AccruedAuditFeesCurrent_label_en-US" xlink:label="lab_rnac_AccruedAuditFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Audit Fees, Current</link:label>
    <link:label id="lab_rnac_AccruedAuditFeesCurrent_documentation_en-US" xlink:label="lab_rnac_AccruedAuditFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Audit Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedAuditFeesCurrent" xlink:href="rnac-20241231.xsd#rnac_AccruedAuditFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AccruedAuditFeesCurrent" xlink:to="lab_rnac_AccruedAuditFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmountCumulativeCurrent_28a567a2-83db-42d6-b70c-cef33c49ba4e_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government assistance, asset, current</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmountCumulativeCurrent_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmountCumulativeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:to="lab_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0dd63879-3046-444b-a6a7-eec2daddaea9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_07143bf4-bfb9-4a8c-87f4-721bd3918b90_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b54df60-134e-4fa6-b316-2e5576194251_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e4087067-ba7b-4d1c-8f35-333b15fa5e9b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a51f1404-3eb1-448c-ae23-39767ff050b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_effdd877-fcf0-460e-b55c-a0938bf569f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_79c2c26c-5bbf-4dac-baaf-15395d254e9c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ClinicalTrialCostsPolicyTextBlock_c96c5b9c-87ea-4d16-9442-ed23cc59543c_terseLabel_en-US" xlink:label="lab_rnac_ClinicalTrialCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial Costs</link:label>
    <link:label id="lab_rnac_ClinicalTrialCostsPolicyTextBlock_label_en-US" xlink:label="lab_rnac_ClinicalTrialCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Costs [Policy Text Block]</link:label>
    <link:label id="lab_rnac_ClinicalTrialCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_rnac_ClinicalTrialCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClinicalTrialCostsPolicyTextBlock" xlink:href="rnac-20241231.xsd#rnac_ClinicalTrialCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ClinicalTrialCostsPolicyTextBlock" xlink:to="lab_rnac_ClinicalTrialCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ClassOfWarrantOrRightRollForward_bddd9d7d-d7d3-4513-af05-e7725274a6d5_terseLabel_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Warrants</link:label>
    <link:label id="lab_rnac_ClassOfWarrantOrRightRollForward_label_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right [Roll Forward]</link:label>
    <link:label id="lab_rnac_ClassOfWarrantOrRightRollForward_documentation_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightRollForward" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ClassOfWarrantOrRightRollForward" xlink:to="lab_rnac_ClassOfWarrantOrRightRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_NumberOfAcquiredOperatingLeases_39525e84-e377-4366-bc41-50edb77b94bc_terseLabel_en-US" xlink:label="lab_rnac_NumberOfAcquiredOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of acquired operating leases</link:label>
    <link:label id="lab_rnac_NumberOfAcquiredOperatingLeases_label_en-US" xlink:label="lab_rnac_NumberOfAcquiredOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Acquired Operating Leases</link:label>
    <link:label id="lab_rnac_NumberOfAcquiredOperatingLeases_documentation_en-US" xlink:label="lab_rnac_NumberOfAcquiredOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Acquired Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NumberOfAcquiredOperatingLeases" xlink:href="rnac-20241231.xsd#rnac_NumberOfAcquiredOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_NumberOfAcquiredOperatingLeases" xlink:to="lab_rnac_NumberOfAcquiredOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ClassOfWarrantOrRightExercisedDuringPeriod_4c2c319f-64a1-4db9-9979-191288216f19_terseLabel_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_rnac_ClassOfWarrantOrRightExercisedDuringPeriod_label_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right, Exercised During Period</link:label>
    <link:label id="lab_rnac_ClassOfWarrantOrRightExercisedDuringPeriod_documentation_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right, Exercised During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightExercisedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="lab_rnac_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_35193e86-0337-4ebd-a714-aacb54faaa3a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5b476fe7-5061-4223-8664-837745bc63e7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share Allocable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_GinkgoBioworksHoldingsIncMember_eafb1f0a-7cf9-40ca-b99b-fd3eed1d10ce_terseLabel_en-US" xlink:label="lab_rnac_GinkgoBioworksHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ginkgo Bioworks Holdings, Inc</link:label>
    <link:label id="lab_rnac_GinkgoBioworksHoldingsIncMember_label_en-US" xlink:label="lab_rnac_GinkgoBioworksHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ginkgo Bioworks Holdings, Inc [Member]</link:label>
    <link:label id="lab_rnac_GinkgoBioworksHoldingsIncMember_documentation_en-US" xlink:label="lab_rnac_GinkgoBioworksHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ginkgo Bioworks Holdings, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GinkgoBioworksHoldingsIncMember" xlink:href="rnac-20241231.xsd#rnac_GinkgoBioworksHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_GinkgoBioworksHoldingsIncMember" xlink:to="lab_rnac_GinkgoBioworksHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2e62c7b0-d2f2-4041-b0c3-1e0cbf835fa0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_2b4d1b3f-3418-43a4-a591-846dc81762c4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_38f35cbc-fa32-4729-a745-453fcf74a2c4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_56647662-6e59-41cd-8949-655b0660272f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants in period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PrivatePlacement2023Member_4e3664f9-f03b-4617-bedc-8f8944ef2d0c_terseLabel_en-US" xlink:label="lab_rnac_PrivatePlacement2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Private Placement</link:label>
    <link:label id="lab_rnac_PrivatePlacement2023Member_label_en-US" xlink:label="lab_rnac_PrivatePlacement2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement 2023 [Member]</link:label>
    <link:label id="lab_rnac_PrivatePlacement2023Member_documentation_en-US" xlink:label="lab_rnac_PrivatePlacement2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023Member" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PrivatePlacement2023Member" xlink:to="lab_rnac_PrivatePlacement2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_911d69c4-2b84-402d-93c5-17d394dc449d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_585af349-656b-45aa-a794-2975089eb083_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_56036dd3-46e9-4c6c-bd9b-28fd5e3b4138_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContingentValueRightLiabilityNoncurrent_4d35d408-3bc1-4f5c-91b4-8eeebf52843b_terseLabel_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent value right liability, net of current portion</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiabilityNoncurrent_label_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability, Noncurrent</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiabilityNoncurrent_documentation_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityNoncurrent" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContingentValueRightLiabilityNoncurrent" xlink:to="lab_rnac_ContingentValueRightLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_5cbdb29d-8ee1-4912-a379-8a282350d899_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_GinkgoAgreementMember_a1af0e6d-4f1f-42cf-b100-47f3eeec186f_terseLabel_en-US" xlink:label="lab_rnac_GinkgoAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ginkgo Agreement</link:label>
    <link:label id="lab_rnac_GinkgoAgreementMember_label_en-US" xlink:label="lab_rnac_GinkgoAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ginkgo Agreement [Member]</link:label>
    <link:label id="lab_rnac_GinkgoAgreementMember_documentation_en-US" xlink:label="lab_rnac_GinkgoAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ginkgo Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GinkgoAgreementMember" xlink:href="rnac-20241231.xsd#rnac_GinkgoAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_GinkgoAgreementMember" xlink:to="lab_rnac_GinkgoAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01939ee2-095e-4255-8584-e62957b6d0be_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_3d92e05d-ba06-43e7-86ad-70b1ab78cfdf_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares_f3729e52-98f4-4358-ad57-9bcbb5bf9ffe_negatedTerseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfer of Series A preferred stock and options for Series A preferred stock to permanent equity (in shares)</link:label>
    <link:label id="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares_label_en-US" xlink:label="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Transfer Of Preferred Stock To Permanent Equity, Shares</link:label>
    <link:label id="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Transfer Of Preferred Stock To Permanent Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares" xlink:to="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4b9b439a-9e15-44e9-9492-28113f8bbbe1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a14ce358-c9d5-44ea-b536-88653c056b59_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized and reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_1d22f1a5-332d-4c79-8c0f-0c39b2d8a7a2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19eac569-ecf0-4e26-846b-fc9db4f3c802_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds (included in cash equivalents)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock_cf074d26-32c2-4fde-a94b-c72d2da1a67b_negatedTerseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Converted to options for common stock (in shares)</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Converted To Options For Common Stock</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Converted To Options For Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock_5c043610-6b30-4737-b637-bca1dc6aaee3_terseLabel_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock_label_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability, Policy [Policy Text Block]</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock" xlink:to="lab_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f9de6459-5533-4e27-9fe4-f3e4496f2747_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_35c1f1ae-96b5-4dce-9b91-d2e64d2faa63_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_73c0d8e5-6b37-457f-9f3a-381bd7786b61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c0c7735b-9976-498e-bbc6-ffac809b0e71_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_67b9a136-b5f9-4e03-8c30-f1ce04bbbb5a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CollaborativeArrangementCostSharePercentage_55937479-a41e-4626-a508-1915f0c82e01_terseLabel_en-US" xlink:label="lab_rnac_CollaborativeArrangementCostSharePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost share percentage</link:label>
    <link:label id="lab_rnac_CollaborativeArrangementCostSharePercentage_label_en-US" xlink:label="lab_rnac_CollaborativeArrangementCostSharePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Cost Share Percentage</link:label>
    <link:label id="lab_rnac_CollaborativeArrangementCostSharePercentage_documentation_en-US" xlink:label="lab_rnac_CollaborativeArrangementCostSharePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Cost Share Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementCostSharePercentage" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementCostSharePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CollaborativeArrangementCostSharePercentage" xlink:to="lab_rnac_CollaborativeArrangementCostSharePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c55ef0a-f410-4cfb-8790-911bae38a666_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_79721e8a-3643-45db-a4ca-27ad031dc49a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_7153ee7e-455b-4149-9727-75491e1e8410_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_97c63252-50cd-4727-857d-00e849e8e24a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a5cd5242-3709-4cd3-bc29-3532fe204bdd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_76f6e514-9f71-4f19-98cb-b6b985009c02_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SeriesBPreferredStockPurchaseAgreementMember_46ae2765-4f93-4389-9dcb-22a8e8509647_terseLabel_en-US" xlink:label="lab_rnac_SeriesBPreferredStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock Purchase Agreement</link:label>
    <link:label id="lab_rnac_SeriesBPreferredStockPurchaseAgreementMember_label_en-US" xlink:label="lab_rnac_SeriesBPreferredStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_rnac_SeriesBPreferredStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_rnac_SeriesBPreferredStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SeriesBPreferredStockPurchaseAgreementMember" xlink:href="rnac-20241231.xsd#rnac_SeriesBPreferredStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SeriesBPreferredStockPurchaseAgreementMember" xlink:to="lab_rnac_SeriesBPreferredStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4d764809-5337-4b3b-b084-e18be4ddc849_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f5ece118-043a-4c80-b876-77574ed593f1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common&#160;stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6f2d81f2-99a0-4b56-8ac7-4a779fa91ed0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_039be4aa-c5d8-4939-bd37-bc47a93f3c3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40ffe752-c843-4e25-b465-49122106788f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Roll-Forward of Fair Value for the Company&#8217;s Level 3 Warrant Liabilities, CVR Liability and Forward Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DistributedEarnings_14a393ee-c686-4660-9977-6b42422a8ec6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DistributedEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: CVR distribution to participating securities</link:label>
    <link:label id="lab_us-gaap_DistributedEarnings_label_en-US" xlink:label="lab_us-gaap_DistributedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributed Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributedEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributedEarnings" xlink:to="lab_us-gaap_DistributedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_957e073c-b266-4620-9f18-8a3cf4fb0e85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, accelerated cost</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_15901382-9fa0-4408-b926-adab8080edff_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0cd960d5-3681-4e6b-8c23-5f6a8f822b74_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_cafd8ed8-7993-451e-bf34-c7c993d5bf13_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_f37766ce-525c-48b4-bf86-152846ce8f83_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3f5cfab2-1049-4791-8471-0a69c559e815_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a353e554-5a61-4157-a5b2-4f373572972a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_f3c7260a-5bc4-4863-b84b-a28bf7669b13_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_WarrantsAndRightsOutstandingCurrent_aed665f2-1f3a-4527-856c-e2d44d0ac11b_terseLabel_en-US" xlink:label="lab_rnac_WarrantsAndRightsOutstandingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_rnac_WarrantsAndRightsOutstandingCurrent_label_en-US" xlink:label="lab_rnac_WarrantsAndRightsOutstandingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants And Rights Outstanding, Current</link:label>
    <link:label id="lab_rnac_WarrantsAndRightsOutstandingCurrent_documentation_en-US" xlink:label="lab_rnac_WarrantsAndRightsOutstandingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants And Rights Outstanding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantsAndRightsOutstandingCurrent" xlink:href="rnac-20241231.xsd#rnac_WarrantsAndRightsOutstandingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_WarrantsAndRightsOutstandingCurrent" xlink:to="lab_rnac_WarrantsAndRightsOutstandingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementMilestoneReceivable_ac31f229-6b69-4f18-804b-3d84b74f56a6_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone receivable</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementMilestoneReceivable_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Milestone Receivable</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementMilestoneReceivable_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Milestone Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestoneReceivable" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestoneReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementMilestoneReceivable" xlink:to="lab_rnac_LicenseAndOptionAgreementMilestoneReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1a5297e5-ef83-4511-baef-222f12a5d636_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c9bfbd7d-30fb-455c-82c4-2468a5ced3d9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_34a0a58a-a3c9-4396-ae40-a3edaec5ad83_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_88aeea9e-6227-4f23-a9cc-42b0e84d78a3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_9b98c233-6889-4584-a626-d7477f78fe63_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a8f47562-c1b7-4a19-ad91-76e24e29b5be_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_bef89d42-d6e2-440c-b78a-6ab47e6a34e2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_b2957ee9-940c-405b-b1c8-c8b915b9488e_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_0f291aa5-8bfb-4438-a2fd-4eac42f29aab_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_e821a55f-5fbd-4808-9779-5ece841eb8f8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1bd824f-c166-40d7-8968-26b20f23bb30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_99378075-81b8-4345-a871-57532f749313_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Measurement Inputs and Valuation Techniques for 2019 Warrants Liability and CVR Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a1bc0c1d-b228-4bfc-b587-de066c7be098_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value ($)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_892e364d-f514-4eac-aaec-aef5db5aa4f3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_a4d47fbd-7197-48a8-b32a-189821c1f992_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_5cf56e94-a145-4ab2-addc-ab0db6660511_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_75812a91-ca9a-433f-ac46-213f9dd3db95_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share allocable to common stockholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_f6895e18-adfa-4c31-9c9a-e95fdb1b6fb3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes_c4e3fa3e-4164-4887-aea5-7fac3ddd5456_terseLabel_en-US" xlink:label="lab_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and experimental costs, tax purposes</link:label>
    <link:label id="lab_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes_label_en-US" xlink:label="lab_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Research And Experimental Costs, Tax Purposes</link:label>
    <link:label id="lab_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes_documentation_en-US" xlink:label="lab_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capitalized Research And Experimental Costs, Tax Purposes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes" xlink:href="rnac-20241231.xsd#rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes" xlink:to="lab_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8a300f7c-2082-4a53-9d38-d47596685ee0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_043d5a4d-83ed-4c2c-8c30-5bbd6f263b96_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_a82e6f95-15d4-49da-9dac-de46a3aa552e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_042275ca-f60d-44a7-b087-be18249572fd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_6829f603-4c84-4b49-b366-9884825acb87_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0e0ba432-5a27-4fd5-a24a-f6b2e05af213_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_A2022WarrantsMember_9347d569-edb4-402c-ae6e-09bf5f339745_terseLabel_en-US" xlink:label="lab_rnac_A2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Warrants</link:label>
    <link:label id="lab_rnac_A2022WarrantsMember_label_en-US" xlink:label="lab_rnac_A2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Warrants [Member]</link:label>
    <link:label id="lab_rnac_A2022WarrantsMember_documentation_en-US" xlink:label="lab_rnac_A2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2022WarrantsMember" xlink:href="rnac-20241231.xsd#rnac_A2022WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_A2022WarrantsMember" xlink:to="lab_rnac_A2022WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d26e3278-c8a5-4f53-b6b2-abd3a70ed516_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e8d42035-86b8-4aea-9de5-fafb35b8e203_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_EmploymentInducementIncentiveAwardPlanMember_7edaf47f-3dbd-4684-8408-682e8e1f5e3b_terseLabel_en-US" xlink:label="lab_rnac_EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Inducement Incentive Award Plan</link:label>
    <link:label id="lab_rnac_EmploymentInducementIncentiveAwardPlanMember_label_en-US" xlink:label="lab_rnac_EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Inducement Incentive Award Plan [Member]</link:label>
    <link:label id="lab_rnac_EmploymentInducementIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_rnac_EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employment Inducement Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EmploymentInducementIncentiveAwardPlanMember" xlink:href="rnac-20241231.xsd#rnac_EmploymentInducementIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_EmploymentInducementIncentiveAwardPlanMember" xlink:to="lab_rnac_EmploymentInducementIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_e66a01ab-22e3-42e7-ac89-33ecbba6ad58_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, fee amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_152f2f52-66a9-4877-84b8-53a5cde6c8a1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d6f15cd5-914a-44ae-a6ce-2d3eaca06e2b_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6ad9a9c2-44d3-4e8a-966d-cbbbffb14f55_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_b422742f-6ccc-4ded-a082-c50b83dbb9b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_c723a020-5174-4291-82aa-ff596c1f4d7b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_078ca477-7d53-4fa5-ba3f-b42c1c0ce8a6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_530dde52-ec71-42c1-86e7-c029b2d9e6a1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_97558980-4e86-42b0-99fc-f00a7c544caa_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c87a55f4-1749-4ab3-8d00-a0d8737b0429_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e4bb2014-352b-4e2e-a875-575a2e01d05c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ForwardContractToIssueSharesMember_e2fc77c1-8f70-442f-8df8-1f306d7107eb_terseLabel_en-US" xlink:label="lab_rnac_ForwardContractToIssueSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward contract to issue Series A Preferred Stock</link:label>
    <link:label id="lab_rnac_ForwardContractToIssueSharesMember_label_en-US" xlink:label="lab_rnac_ForwardContractToIssueSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Contract To Issue Shares [Member]</link:label>
    <link:label id="lab_rnac_ForwardContractToIssueSharesMember_documentation_en-US" xlink:label="lab_rnac_ForwardContractToIssueSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Contract To Issue Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ForwardContractToIssueSharesMember" xlink:href="rnac-20241231.xsd#rnac_ForwardContractToIssueSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ForwardContractToIssueSharesMember" xlink:to="lab_rnac_ForwardContractToIssueSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0af9bf79-7e83-4684-af30-2d4d6baf4b6b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2af7531b-5624-457b-880b-e367db6015d4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock_8a26b887-a1e5-43bb-bfdb-7eecb8948197_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Converted to options for common stock (in dollars per share)</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Converted To Options For Common Stock</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Converted To Options For Common Stock, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_9583a0c7-5960-4339-ab1d-66452e6613eb_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_7b04c676-cc93-4f78-afdc-46cb82eebb55_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger_470b92b5-14d5-4696-881b-ca3336ef46d4_terseLabel_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock forward in connection with the Merger</link:label>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger_label_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Issuance Of Common Stock Forward In Connection With The Merger</link:label>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger_documentation_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Issuance Of Common Stock Forward In Connection With The Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger" xlink:to="lab_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_247ef237-af78-408b-bf58-38df5c1e18b6_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2004f916-2436-4402-b689-86ecff3d007d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0c35e389-1686-40c6-846f-f67a34273835_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f1e65ad4-ac3d-4543-bb04-59aedaae786c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_4c99a40b-9bb1-40e4-b6fc-a3170673cd16_negatedLabel_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, deductions</link:label>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_label_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue, Revenue Recognized</link:label>
    <link:label id="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_documentation_en-US" xlink:label="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:to="lab_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_1efaa123-d2ed-4a7c-b738-9f629cbdb5a6_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_462167d2-c8be-4d2d-8b91-4433773301a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited in period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_117f77f3-a004-435c-8357-e17180c15f77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity_b2b02a99-41c6-4e3c-83d6-7f5a7f44ca09_negatedTerseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity</link:label>
    <link:label id="lab_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity_label_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Options, Transfer Of Preferred Stock To Permanent Equity</link:label>
    <link:label id="lab_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Options, Transfer Of Preferred Stock To Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity" xlink:to="lab_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_668e366e-fbde-46a5-8683-f72efa928871_verboseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock options and RSUs</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_355bf618-3864-4989-b24b-35d0a8d17e7a_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future stock incentive awards</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c1bcf703-64e7-4230-9de1-32ad55854d83_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c00d5e89-0911-4484-bb0e-396e701d3a17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesBillingStatusDomain_5588adab-3071-4305-8e46-99f0fbee9afd_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesBillingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivablesBillingStatusDomain_label_en-US" xlink:label="lab_us-gaap_ReceivablesBillingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain" xlink:to="lab_us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_08744e59-c348-4f16-810b-e629612ece29_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_1eba583c-7204-4085-b945-c30d942aac12_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_0a58b590-d818-4598-a07b-001d83bddca7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash assumed in acquisition of Old Cartesian</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent_6bd771c7-0573-403f-945c-3fc472db3494_terseLabel_en-US" xlink:label="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of forward contract liabilities</link:label>
    <link:label id="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent_label_en-US" xlink:label="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Fair Value Of Contract Liabilities, Percent</link:label>
    <link:label id="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent_documentation_en-US" xlink:label="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Fair Value Of Contract Liabilities, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent" xlink:href="rnac-20241231.xsd#rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent" xlink:to="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_6bd8d518-ea5a-4a29-bef5-86ae688cb379_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement_f148ad71-4d78-4d00-afcf-f92e64eeb0d8_terseLabel_en-US" xlink:label="lab_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, number of shares issued for milestone achievement (in shares)</link:label>
    <link:label id="lab_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement_label_en-US" xlink:label="lab_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number Of Shares Issued For Milestone Achievement</link:label>
    <link:label id="lab_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement_documentation_en-US" xlink:label="lab_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number Of Shares Issued For Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement" xlink:to="lab_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AccruedPatentFeesCurrent_23a20ce8-2b6c-4886-b254-fe2b3f5b980d_terseLabel_en-US" xlink:label="lab_rnac_AccruedPatentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued patent fees</link:label>
    <link:label id="lab_rnac_AccruedPatentFeesCurrent_label_en-US" xlink:label="lab_rnac_AccruedPatentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Patent Fees Current</link:label>
    <link:label id="lab_rnac_AccruedPatentFeesCurrent_documentation_en-US" xlink:label="lab_rnac_AccruedPatentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of patent fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedPatentFeesCurrent" xlink:href="rnac-20241231.xsd#rnac_AccruedPatentFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AccruedPatentFeesCurrent" xlink:to="lab_rnac_AccruedPatentFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_21bb87bc-8f67-42b2-8944-d48752b35867_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss allocable to shares of common stock - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_97599791-1f60-40a9-bf8c-7b3eaab130ae_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Revenue</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_cfdccc58-5adc-4147-ae94-d46a863e73c5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LesseeOperatingLeaseMonthlyBaseRent_b14b6f77-9951-4b30-9a2d-f097345a0183_terseLabel_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease agreement, monthly base rent</link:label>
    <link:label id="lab_rnac_LesseeOperatingLeaseMonthlyBaseRent_label_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Base Rent</link:label>
    <link:label id="lab_rnac_LesseeOperatingLeaseMonthlyBaseRent_documentation_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseMonthlyBaseRent" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseMonthlyBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LesseeOperatingLeaseMonthlyBaseRent" xlink:to="lab_rnac_LesseeOperatingLeaseMonthlyBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e04b38b2-9305-4cc5-af17-756a0e0e0077_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_8cefbe69-bea5-45a3-860c-91f7db4c56ca_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_71f1e81d-e358-4c9e-a419-cf41bd888f26_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a7593f91-dece-4cb8-8d7d-b6ccf599dc1c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_773104c9-8ecd-4fb5-973d-f3c82582495f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_01eca5d9-2f4b-45d2-ac57-7124cef838fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 19)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_96b53b0a-3962-40c7-a465-7a22ec8e0e6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_23f1ce30-a3dd-48e6-b02a-79d046ffe9cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_A2020TermLoansMember_3a644d9a-b0cc-4a5a-95e1-309f9b2f9a0e_terseLabel_en-US" xlink:label="lab_rnac_A2020TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Term Loans</link:label>
    <link:label id="lab_rnac_A2020TermLoansMember_label_en-US" xlink:label="lab_rnac_A2020TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Term Loans [Member]</link:label>
    <link:label id="lab_rnac_A2020TermLoansMember_documentation_en-US" xlink:label="lab_rnac_A2020TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2020TermLoansMember" xlink:href="rnac-20241231.xsd#rnac_A2020TermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_A2020TermLoansMember" xlink:to="lab_rnac_A2020TermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance_20796cd1-c860-41f7-84ac-f5178698d837_terseLabel_en-US" xlink:label="lab_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer, liability, revenue recognized, including opening balance</link:label>
    <link:label id="lab_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance_label_en-US" xlink:label="lab_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer, Liability, Revenue Recognized, Including Opening Balance</link:label>
    <link:label id="lab_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance_documentation_en-US" xlink:label="lab_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer, Liability, Revenue Recognized, Including Opening Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:href="rnac-20241231.xsd#rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:to="lab_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e06dc89b-6848-4144-aeb5-d548a435a183_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2dcb637c-04cf-4773-bc6a-4b98477f8bd6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5ecada5d-d82f-4672-86ab-390c612b0848_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_15c5bef9-a5c1-4e59-abe3-79031e954591_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_eb2c7cc4-1ed6-4c07-8925-928cc717e6a5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_EarlyStageProgramsMember_16f903a2-8347-44f4-9227-094d596c0a1b_terseLabel_en-US" xlink:label="lab_rnac_EarlyStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early stage programs</link:label>
    <link:label id="lab_rnac_EarlyStageProgramsMember_label_en-US" xlink:label="lab_rnac_EarlyStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Early Stage Programs [Member]</link:label>
    <link:label id="lab_rnac_EarlyStageProgramsMember_documentation_en-US" xlink:label="lab_rnac_EarlyStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Early Stage Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EarlyStageProgramsMember" xlink:href="rnac-20241231.xsd#rnac_EarlyStageProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_EarlyStageProgramsMember" xlink:to="lab_rnac_EarlyStageProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_89f471cc-cab4-4c02-9968-8fec99317049_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_37c3d009-ec73-4c9d-b9e0-e3fddec6f1ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of the Purchase Price to the Estimated Fair Values of the Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e7064967-1023-4d06-bdc4-fd3eec5122b8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d8b5a3b7-1024-47a5-9c0a-442bfc7c4089_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_02f0f302-f819-4f97-a571-2252405647a8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_183db560-c11f-4486-b3bc-04ab088728a5_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ChangeInContractWithCustomerLiabilityRollForward_445739c4-7fe0-499a-a01a-9abc9e45eaca_terseLabel_en-US" xlink:label="lab_rnac_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_rnac_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_rnac_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_rnac_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_rnac_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="rnac-20241231.xsd#rnac_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_rnac_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement_c31ae66c-9a9c-4d4c-89ef-591e5ebe7a96_terseLabel_en-US" xlink:label="lab_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, license agreement (in shares)</link:label>
    <link:label id="lab_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement_label_en-US" xlink:label="lab_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During The Period, Shares, Common Stock License Agreement</link:label>
    <link:label id="lab_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement_documentation_en-US" xlink:label="lab_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During The Period, Shares, Common Stock License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement" xlink:to="lab_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset_038a8c8a-40d3-4c46-ae86-1cf1596b6552_terseLabel_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset, net</link:label>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset_label_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right Of Use Asset</link:label>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset_documentation_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset" xlink:to="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2791a15d-78a4-4d9a-b2ac-5727d4b0604f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_fd5326e3-55c9-45d7-9134-74a0d8dde0a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="lab_us-gaap_OtherNonoperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AtTheMarketOfferingMember_23f79789-c312-439e-ab06-d60d8672daa2_terseLabel_en-US" xlink:label="lab_rnac_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:label id="lab_rnac_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_rnac_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:label id="lab_rnac_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_rnac_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AtTheMarketOfferingMember" xlink:href="rnac-20241231.xsd#rnac_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AtTheMarketOfferingMember" xlink:to="lab_rnac_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_02adebfd-5238-4e73-b1c7-432dfe513b2a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PreferredStockRedemptionTerm_1b2d12af-6173-4ccf-af0c-00ac1afd593e_terseLabel_en-US" xlink:label="lab_rnac_PreferredStockRedemptionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, redemption term</link:label>
    <link:label id="lab_rnac_PreferredStockRedemptionTerm_label_en-US" xlink:label="lab_rnac_PreferredStockRedemptionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Redemption Term</link:label>
    <link:label id="lab_rnac_PreferredStockRedemptionTerm_documentation_en-US" xlink:label="lab_rnac_PreferredStockRedemptionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Redemption Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreferredStockRedemptionTerm" xlink:href="rnac-20241231.xsd#rnac_PreferredStockRedemptionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PreferredStockRedemptionTerm" xlink:to="lab_rnac_PreferredStockRedemptionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_cb45efe8-5bd9-48d2-ad16-d4848b377a69_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of debt, amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ed11f58-f4d3-4f43-9964-62bbb93a2f4b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_MedicalExpensesOperating_2a15c610-a5e0-4b49-874e-3fa541d9e52c_terseLabel_en-US" xlink:label="lab_rnac_MedicalExpensesOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical expenses, operating</link:label>
    <link:label id="lab_rnac_MedicalExpensesOperating_label_en-US" xlink:label="lab_rnac_MedicalExpensesOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Expenses, Operating</link:label>
    <link:label id="lab_rnac_MedicalExpensesOperating_documentation_en-US" xlink:label="lab_rnac_MedicalExpensesOperating" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Expenses, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_MedicalExpensesOperating" xlink:href="rnac-20241231.xsd#rnac_MedicalExpensesOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_MedicalExpensesOperating" xlink:to="lab_rnac_MedicalExpensesOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_ef3b8dd6-ad5e-4ab8-af88-2006b78ff2db_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends declared or paid on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_45901f86-86de-4592-ab74-0022ec9fc346_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_a8bc1fb7-2417-4348-8238-eba1aa24e83d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_03bcf6de-6fb2-44f8-b067-12c5e38da0bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_f991d5f7-33b5-4bea-8712-f961f1f412fc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_5de44f80-c3a6-44f1-9c29-a957e2e929bc_terseLabel_en-US" xlink:label="lab_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Gross Consideration Received On Transaction</link:label>
    <link:label id="lab_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Gross Consideration Received On Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:to="lab_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AuditInformationAbstract_label_en-US" xlink:label="lab_rnac_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_rnac_AuditInformationAbstract_documentation_en-US" xlink:label="lab_rnac_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AuditInformationAbstract" xlink:href="rnac-20241231.xsd#rnac_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AuditInformationAbstract" xlink:to="lab_rnac_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_07f54e19-6a79-411f-89cc-566112414e7f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_bc409975-98ad-487a-b870-ec94cf0c0e1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Authorized Shares of Common Stock for Future Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount_dc5dcfea-c707-43e7-b9a4-d4a02cdae1a5_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award, settlement of awards, amount (in dollars per share)</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards, Amount</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_0e874f5d-e71d-484c-a6db-579bc2b0fbb3_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_06247a19-3b08-4412-bc7b-b383c9ef284f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_9f8097db-26a1-4430-9deb-5317a8b6f9e4_terseLabel_en-US" xlink:label="lab_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, percentage of ten-day volume weighted average price of common stock</link:label>
    <link:label id="lab_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_label_en-US" xlink:label="lab_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock</link:label>
    <link:label id="lab_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_documentation_en-US" xlink:label="lab_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:href="rnac-20241231.xsd#rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:to="lab_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0a96e6ba-e400-4b09-a3cf-baa7d5efcde8_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c39c5d35-24a8-4531-b1c3-7bfbf9a92daf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SaleOfStockSettlementTerm_f1292587-989c-49cd-b1d3-b319ca320b83_terseLabel_en-US" xlink:label="lab_rnac_SaleOfStockSettlementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, settlement term</link:label>
    <link:label id="lab_rnac_SaleOfStockSettlementTerm_label_en-US" xlink:label="lab_rnac_SaleOfStockSettlementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Settlement Term</link:label>
    <link:label id="lab_rnac_SaleOfStockSettlementTerm_documentation_en-US" xlink:label="lab_rnac_SaleOfStockSettlementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Settlement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockSettlementTerm" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockSettlementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SaleOfStockSettlementTerm" xlink:to="lab_rnac_SaleOfStockSettlementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_065311d4-ec82-4f55-bedc-11cc62f74353_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_386017fa-53f5-45fe-a867-45675a0b6a67_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContingentValueRightLiabilityCurrent_a396e2ee-794c-434e-886b-983a33482646_terseLabel_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent value right liability</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiabilityCurrent_label_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability, Current</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiabilityCurrent_documentation_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityCurrent" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContingentValueRightLiabilityCurrent" xlink:to="lab_rnac_ContingentValueRightLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_WarrantsPolicyTextBlock_db70bbbc-af80-4f0e-ba54-36c4789a8d81_terseLabel_en-US" xlink:label="lab_rnac_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_rnac_WarrantsPolicyTextBlock_label_en-US" xlink:label="lab_rnac_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
    <link:label id="lab_rnac_WarrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_rnac_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantsPolicyTextBlock" xlink:href="rnac-20241231.xsd#rnac_WarrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_WarrantsPolicyTextBlock" xlink:to="lab_rnac_WarrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_EquityOfferingCostsInAccruedLiabilities_42f32dc2-9a04-47f5-99ae-b89e60535307_terseLabel_en-US" xlink:label="lab_rnac_EquityOfferingCostsInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity offering costs in accrued liabilities</link:label>
    <link:label id="lab_rnac_EquityOfferingCostsInAccruedLiabilities_label_en-US" xlink:label="lab_rnac_EquityOfferingCostsInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Offering Costs In Accrued Liabilities</link:label>
    <link:label id="lab_rnac_EquityOfferingCostsInAccruedLiabilities_documentation_en-US" xlink:label="lab_rnac_EquityOfferingCostsInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Offering Costs In Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquityOfferingCostsInAccruedLiabilities" xlink:href="rnac-20241231.xsd#rnac_EquityOfferingCostsInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_EquityOfferingCostsInAccruedLiabilities" xlink:to="lab_rnac_EquityOfferingCostsInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9336bd4b-a974-4636-949e-8b46b6b4f212_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c0641ebe-a7fd-413b-93a1-c7bc693cba21_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9e8c9cdf-26b8-432d-8bec-0dd63d008a57_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7496102a-6a78-42e5-8c4b-bfa50a7e3377_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_182335a5-bb34-479f-b3af-a7e944a09019_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisition Date Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_fd3c872f-8e08-463e-ab4b-c3c647d0bd39_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_49832a33-7b50-4a65-ae61-4b88911adea2_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_e0ad6a10-7b26-4c2f-ac28-2e805045739d_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e4321e6f-8a81-432b-b600-23163dd4b2f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a0a5a53b-77eb-42e0-bb77-1d6084bd4647_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_579cc367-75d9-4986-9dd3-3191dac899f2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_388a5351-8667-412c-95d9-94120be61373_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c5f0ea9a-4fb9-48ed-9198-74a2d5a97ef6_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_97524a20-7175-4419-885d-b44c1db62380_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Lease Costs and Additional Information Related to Operating Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_3f12aa7f-0733-4de4-b118-4a0baed3a04c_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unbilled receivables</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_GovernmentAssistancePotentialAdditionalAwardAmount_5e875411-f108-48ee-a86c-41c563479aff_terseLabel_en-US" xlink:label="lab_rnac_GovernmentAssistancePotentialAdditionalAwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government assistance, potential additional award amount</link:label>
    <link:label id="lab_rnac_GovernmentAssistancePotentialAdditionalAwardAmount_label_en-US" xlink:label="lab_rnac_GovernmentAssistancePotentialAdditionalAwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Potential Additional Award Amount</link:label>
    <link:label id="lab_rnac_GovernmentAssistancePotentialAdditionalAwardAmount_documentation_en-US" xlink:label="lab_rnac_GovernmentAssistancePotentialAdditionalAwardAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Assistance, Potential Additional Award Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GovernmentAssistancePotentialAdditionalAwardAmount" xlink:href="rnac-20241231.xsd#rnac_GovernmentAssistancePotentialAdditionalAwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_GovernmentAssistancePotentialAdditionalAwardAmount" xlink:to="lab_rnac_GovernmentAssistancePotentialAdditionalAwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities_f8db79c7-2c4c-4fae-8e7f-fd566ccb2de0_totalLabel_en-US" xlink:label="lab_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities_label_en-US" xlink:label="lab_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net Of Deferred Tax Liabilities</link:label>
    <link:label id="lab_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities_documentation_en-US" xlink:label="lab_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net Of Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:href="rnac-20241231.xsd#rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:to="lab_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount_bd75a391-4853-4da0-ac48-67f96d5f5c87_terseLabel_en-US" xlink:label="lab_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, shares issued for milestone achievement, amount</link:label>
    <link:label id="lab_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount_label_en-US" xlink:label="lab_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Shares Issued For Milestone Achievement, Amount</link:label>
    <link:label id="lab_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount_documentation_en-US" xlink:label="lab_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Shares Issued For Milestone Achievement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount" xlink:to="lab_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_RevenueNumberOfPerformanceObligations_fd64cc13-12ec-489e-8687-33ead1f5ba99_terseLabel_en-US" xlink:label="lab_rnac_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of obligations</link:label>
    <link:label id="lab_rnac_RevenueNumberOfPerformanceObligations_label_en-US" xlink:label="lab_rnac_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Number Of Performance Obligations</link:label>
    <link:label id="lab_rnac_RevenueNumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_rnac_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_RevenueNumberOfPerformanceObligations" xlink:href="rnac-20241231.xsd#rnac_RevenueNumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_RevenueNumberOfPerformanceObligations" xlink:to="lab_rnac_RevenueNumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_9863bab6-e1a5-4c18-893a-dfdd00a8fd59_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability_25f770b3-49c6-43df-9e6e-57696e5feca0_terseLabel_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability_label_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Lease Liability</link:label>
    <link:label id="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability_documentation_en-US" xlink:label="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability" xlink:to="lab_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bf652e69-283f-4e25-86d5-ce7e565b5aab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2970ada8-ab44-4b4b-854e-e4c751bbd19b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_a32b9765-5c69-4f9f-b20b-5afc92e3397f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_41491a91-a39c-44dd-b8dd-3d9f3a2f5e60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c76b8357-7aba-4494-ab28-bde105b2d240_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series A and Series B preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementOptionTerm_0635b115-e795-4c3a-9267-fbce71e43c04_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementOptionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option term</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementOptionTerm_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementOptionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Option Term</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementOptionTerm_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementOptionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Option Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementOptionTerm" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementOptionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementOptionTerm" xlink:to="lab_rnac_LicenseAndOptionAgreementOptionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger_f379710c-1ec5-494d-a7c4-2288fa9283a0_terseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of replacement options in Merger</link:label>
    <link:label id="lab_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger_label_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Options, Issuance Of Replacement Options In Merger</link:label>
    <link:label id="lab_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Options, Issuance Of Replacement Options In Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger" xlink:to="lab_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_7bd63813-913f-4757-af5c-256e4692e243_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of Series A Preferred Stock, gross in private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_15d5df4b-035c-407a-b667-350260979e61_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4cd68ea5-bd30-4233-8af4-2b89559fe7c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3047b4ca-2da9-4ccb-b222-86f0adae051a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4d700c8e-4c6a-4882-aee3-ec5bba3ff2b8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_f3dc75b6-389b-4092-b036-b56c0ff449ae_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_75776788-703d-4540-b8de-e4c9a09eb835_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_4d62ac24-18b0-4254-a9ec-d8d002af2a33_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_98209472-99ec-4280-a972-0998430233d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized for grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CommonStockVotingRightsNumberOfVotes_292807f5-d6df-4b48-8716-c3b1302014f0_terseLabel_en-US" xlink:label="lab_rnac_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes per share that common stockholders are entitled to</link:label>
    <link:label id="lab_rnac_CommonStockVotingRightsNumberOfVotes_label_en-US" xlink:label="lab_rnac_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes</link:label>
    <link:label id="lab_rnac_CommonStockVotingRightsNumberOfVotes_documentation_en-US" xlink:label="lab_rnac_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CommonStockVotingRightsNumberOfVotes" xlink:href="rnac-20241231.xsd#rnac_CommonStockVotingRightsNumberOfVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CommonStockVotingRightsNumberOfVotes" xlink:to="lab_rnac_CommonStockVotingRightsNumberOfVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a8737621-948f-487c-af36-9b6c4137af90_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1c7c202d-a395-40bb-9cc2-92816af35c5b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SevenOneEightThreeFourIrrevocableTrustMember_aa808626-fa6e-4a6b-97f7-b29845eb0ff7_terseLabel_en-US" xlink:label="lab_rnac_SevenOneEightThreeFourIrrevocableTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seven One Eight Three Four Irrevocable Trust (affiliate of Murat Kalayoglu, MD, Ph.D.)</link:label>
    <link:label id="lab_rnac_SevenOneEightThreeFourIrrevocableTrustMember_label_en-US" xlink:label="lab_rnac_SevenOneEightThreeFourIrrevocableTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seven One Eight Three Four Irrevocable Trust [Member]</link:label>
    <link:label id="lab_rnac_SevenOneEightThreeFourIrrevocableTrustMember_documentation_en-US" xlink:label="lab_rnac_SevenOneEightThreeFourIrrevocableTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seven One Eight Three Four Irrevocable Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SevenOneEightThreeFourIrrevocableTrustMember" xlink:href="rnac-20241231.xsd#rnac_SevenOneEightThreeFourIrrevocableTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SevenOneEightThreeFourIrrevocableTrustMember" xlink:to="lab_rnac_SevenOneEightThreeFourIrrevocableTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_f4992f52-76ae-4c65-b06a-1b7af0ebda3f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_25ecad64-0e50-43eb-8003-fecb7f489bc7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f4fb35f9-365e-4d70-8d8a-8d90da8be303_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses_9c4183fd-6017-488c-bf94-b4f50f721d7f_terseLabel_en-US" xlink:label="lab_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development facilities and other expenses</link:label>
    <link:label id="lab_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses_label_en-US" xlink:label="lab_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development, Facilities And Other Expenses</link:label>
    <link:label id="lab_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses_documentation_en-US" xlink:label="lab_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development, Facilities And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses" xlink:to="lab_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AskBioLicenseMember_01eb7deb-997b-480e-b4e1-fbc71e7c52d6_terseLabel_en-US" xlink:label="lab_rnac_AskBioLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AskBio License</link:label>
    <link:label id="lab_rnac_AskBioLicenseMember_label_en-US" xlink:label="lab_rnac_AskBioLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AskBio License [Member]</link:label>
    <link:label id="lab_rnac_AskBioLicenseMember_documentation_en-US" xlink:label="lab_rnac_AskBioLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AskBio License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AskBioLicenseMember" xlink:href="rnac-20241231.xsd#rnac_AskBioLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AskBioLicenseMember" xlink:to="lab_rnac_AskBioLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_ad69c78e-893d-4131-baac-360e999be19e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_10bc8e4e-ccf8-4620-aee2-b2ac4cd8cbd3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PrivatePlacement2023TrancheThreeMember_0f4c9df4-c08d-445e-b0fa-1d8f902e24d3_terseLabel_en-US" xlink:label="lab_rnac_PrivatePlacement2023TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Private Placement, Tranche Three</link:label>
    <link:label id="lab_rnac_PrivatePlacement2023TrancheThreeMember_label_en-US" xlink:label="lab_rnac_PrivatePlacement2023TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement 2023, Tranche Three [Member]</link:label>
    <link:label id="lab_rnac_PrivatePlacement2023TrancheThreeMember_documentation_en-US" xlink:label="lab_rnac_PrivatePlacement2023TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement 2023, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023TrancheThreeMember" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023TrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PrivatePlacement2023TrancheThreeMember" xlink:to="lab_rnac_PrivatePlacement2023TrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityPolicyPolicyTextBlock_b7f0c9e8-fb5f-48c9-90e0-0545771e6db0_terseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock and Series A Preferred Stock Options</link:label>
    <link:label id="lab_rnac_TemporaryEquityPolicyPolicyTextBlock_label_en-US" xlink:label="lab_rnac_TemporaryEquityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Policy [Policy Text Block]</link:label>
    <link:label id="lab_rnac_TemporaryEquityPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityPolicyPolicyTextBlock" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityPolicyPolicyTextBlock" xlink:to="lab_rnac_TemporaryEquityPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_10876bed-01d4-453c-adcc-7f5903bb5c71_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds (included in cash equivalents)</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3b6551cd-ceca-47ed-8fe2-88088fc6513e_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale common stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dca4529e-c2db-4d07-95ce-4e81494d9692_netLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_de978f15-5406-4a78-ad8d-adf20a036d0b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TransferOfTemporaryEquityToPermanentEquity_31283621-959f-44c4-bd49-8502ee6290b3_terseLabel_en-US" xlink:label="lab_rnac_TransferOfTemporaryEquityToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity</link:label>
    <link:label id="lab_rnac_TransferOfTemporaryEquityToPermanentEquity_label_en-US" xlink:label="lab_rnac_TransferOfTemporaryEquityToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer Of Temporary Equity To Permanent Equity</link:label>
    <link:label id="lab_rnac_TransferOfTemporaryEquityToPermanentEquity_documentation_en-US" xlink:label="lab_rnac_TransferOfTemporaryEquityToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transfer Of Temporary Equity To Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TransferOfTemporaryEquityToPermanentEquity" xlink:href="rnac-20241231.xsd#rnac_TransferOfTemporaryEquityToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TransferOfTemporaryEquityToPermanentEquity" xlink:to="lab_rnac_TransferOfTemporaryEquityToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ba999288-2c5d-4db6-a327-2ff2bb8b9c72_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4d590144-275c-437e-a62a-6fc6e02bfcb2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_9ef42dea-88ca-4b0c-8ca9-ab43af0ec9ea_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_8eb0fc59-1756-4303-bb3b-abaea274143b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum_34a96194-04ba-4bb6-9c7b-edef199c6ea2_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and option agreement, benchmark royalties, maximum</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Benchmark Royalties, Maximum</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Benchmark Royalties, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum" xlink:to="lab_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementRoyaltyPayment_0452ffe7-3633-45d7-a552-21d28ae974c4_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementRoyaltyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and option agreement, royalty payment</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementRoyaltyPayment_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementRoyaltyPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Royalty Payment</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementRoyaltyPayment_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementRoyaltyPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Royalty Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementRoyaltyPayment" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementRoyaltyPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementRoyaltyPayment" xlink:to="lab_rnac_LicenseAndOptionAgreementRoyaltyPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_8eb45afb-12b0-4e6d-95f7-01e054ff14c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5abd5803-0f15-4e86-88fe-293ad76faa43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e29ae539-8d34-4547-bacd-1c86bd2a0c03_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Settlement of forward contract liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ad000dfb-4e3b-43a0-950e-c6eafcd547ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9b487b60-cb4c-45b5-a477-70f7651913f0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_250313b0-757f-4ae1-9fbf-421b4f2783a9_terseLabel_en-US" xlink:label="lab_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate amount for future payments upon achievement of clinical and regulatory approval milestones for products containing ImmTOR platform</link:label>
    <link:label id="lab_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_label_en-US" xlink:label="lab_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform</link:label>
    <link:label id="lab_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_documentation_en-US" xlink:label="lab_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:href="rnac-20241231.xsd#rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:to="lab_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1c9b4184-7621-47ff-ae74-f3ec926deddf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ef51d45d-dcb7-4be5-a148-8c24c1f58d78_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance, deferred tax asset, increase (decrease), amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares_41d85f56-9000-4b4a-af0d-c7d5126c30fa_terseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series A preferred stock in connection with the merger and settlement of related forward contract (in shares)</link:label>
    <link:label id="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares_label_en-US" xlink:label="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Acquisitions, Shares</link:label>
    <link:label id="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Acquisitions, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares" xlink:to="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SeriesAPreferredStockOptionsMember_f3a31783-7492-4fcb-9b6d-68c0f6effa07_terseLabel_en-US" xlink:label="lab_rnac_SeriesAPreferredStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock options</link:label>
    <link:label id="lab_rnac_SeriesAPreferredStockOptionsMember_label_en-US" xlink:label="lab_rnac_SeriesAPreferredStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock Options [Member]</link:label>
    <link:label id="lab_rnac_SeriesAPreferredStockOptionsMember_documentation_en-US" xlink:label="lab_rnac_SeriesAPreferredStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SeriesAPreferredStockOptionsMember" xlink:href="rnac-20241231.xsd#rnac_SeriesAPreferredStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SeriesAPreferredStockOptionsMember" xlink:to="lab_rnac_SeriesAPreferredStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2a6322ff-92d0-485d-b9b1-f0e17faff577_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_ed3d17c2-d753-4e1c-8fdc-f202c34f80d1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d082f2d0-faf2-461b-8ddb-0313f44a4e5c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_c60728a9-51de-4eec-88e3-7b370c8d1de2_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_7087ebe0-181a-4eb7-ba3d-ecd5ce4f32f1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_3e03d196-52c3-4e55-9bdb-1f87365e3193_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_fffeb86d-f181-4353-b275-0f534d6a5ce2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_Dr.ChafenLuMember_30ea6f0a-ff3f-4cd0-b934-1b23155d05a8_terseLabel_en-US" xlink:label="lab_rnac_Dr.ChafenLuMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dr. Chafen Lu</link:label>
    <link:label id="lab_rnac_Dr.ChafenLuMember_label_en-US" xlink:label="lab_rnac_Dr.ChafenLuMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Chafen Lu [Member]</link:label>
    <link:label id="lab_rnac_Dr.ChafenLuMember_documentation_en-US" xlink:label="lab_rnac_Dr.ChafenLuMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dr. Chafen Lu</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Dr.ChafenLuMember" xlink:href="rnac-20241231.xsd#rnac_Dr.ChafenLuMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_Dr.ChafenLuMember" xlink:to="lab_rnac_Dr.ChafenLuMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember_aeca4b82-520f-46b1-a388-033595388495_terseLabel_en-US" xlink:label="lab_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">National Institute of Neurological Disorders and Stroke of the National Institutes of Health Funding</link:label>
    <link:label id="lab_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember_label_en-US" xlink:label="lab_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute Of Neurological Disorders And Stroke Of The National Institutes Of Health Funding [Member]</link:label>
    <link:label id="lab_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember_documentation_en-US" xlink:label="lab_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">National Institute Of Neurological Disorders And Stroke Of The National Institutes Of Health Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember" xlink:href="rnac-20241231.xsd#rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember" xlink:to="lab_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8acbde17-1884-451d-bb7d-6671f8cef431_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b227ba1a-31b7-4bc5-b05d-2cc89abe7b72_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6fd28430-f6cb-47f1-93cc-0f48d9bbd375_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LeaseArrangementDomain_102de2b8-7cb2-4d59-82b9-73f1395a803f_terseLabel_en-US" xlink:label="lab_rnac_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_rnac_LeaseArrangementDomain_label_en-US" xlink:label="lab_rnac_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_rnac_LeaseArrangementDomain_documentation_en-US" xlink:label="lab_rnac_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Lease Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LeaseArrangementDomain" xlink:to="lab_rnac_LeaseArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a3b5608e-c85a-4606-85b5-27239dabaa7a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContingentValueRightLiability_256d9419-acc4-4c82-b4d8-08ddbd8585da_terseLabel_en-US" xlink:label="lab_rnac_ContingentValueRightLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent value right liability</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiability_label_en-US" xlink:label="lab_rnac_ContingentValueRightLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiability_documentation_en-US" xlink:label="lab_rnac_ContingentValueRightLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiability" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContingentValueRightLiability" xlink:to="lab_rnac_ContingentValueRightLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_99baa796-986e-4108-bd77-07adfdc90de3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3a9763fe-0169-40d4-989b-890841185ab3_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9ea7a663-ae7e-4949-90fe-4dc28f6792aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_77567c20-a036-451c-a7ea-7f32f2f2e3c9_verboseLabel_en-US" xlink:label="lab_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_label_en-US" xlink:label="lab_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price</link:label>
    <link:label id="lab_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:href="rnac-20241231.xsd#rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:to="lab_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementExtensionTerm_a045a4fe-107d-40c1-a661-593151267daa_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension term</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementExtensionTerm_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Extension Term</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementExtensionTerm_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementExtensionTerm" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementExtensionTerm" xlink:to="lab_rnac_LicenseAndOptionAgreementExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_d0491855-6752-4c2f-84b4-b226195da689_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b4f284a4-56fb-4668-abbc-b78cbdc96a4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList_8c7345e3-c5d4-4552-97f6-185277c07716_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AstellasGeneTherapiesMember_49392cbf-010d-43d2-a742-eb8ea55fbce3_terseLabel_en-US" xlink:label="lab_rnac_AstellasGeneTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Astellas Gene Therapies</link:label>
    <link:label id="lab_rnac_AstellasGeneTherapiesMember_label_en-US" xlink:label="lab_rnac_AstellasGeneTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Astellas Gene Therapies [Member]</link:label>
    <link:label id="lab_rnac_AstellasGeneTherapiesMember_documentation_en-US" xlink:label="lab_rnac_AstellasGeneTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Astellas Gene Therapies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AstellasGeneTherapiesMember" xlink:href="rnac-20241231.xsd#rnac_AstellasGeneTherapiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AstellasGeneTherapiesMember" xlink:to="lab_rnac_AstellasGeneTherapiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_40d57d64-e929-4e8f-a486-edc8bc73d1e1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_838276a0-fce8-49e2-89a1-8c2b3e4f572a_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c16c281c-1e3d-4f2e-a5b8-cec9c0564325_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_5106ae50-7f16-42d9-93fc-acf02acb7fa9_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_852b2654-696b-42d7-8792-6856b836010c_netLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_us-gaap_WarrantMember_5c381e94-1645-4457-9b81-e70e58888a69_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a78ebd52-1960-4592-88d7-9fa6fb15db99_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_1bf19868-050b-43f1-a5ee-e0eca2a61d05_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_ac8d97f2-837d-4a54-87b2-0b58d9a2c83f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent value right liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4372813b-5412-456b-953a-2755225ffc05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7862f605-8eca-47e3-9b4e-7c9d15931727_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_NationalCancerInstituteAgreementMember_2ca234ab-e636-43b1-b831-f63f9f6055d0_terseLabel_en-US" xlink:label="lab_rnac_NationalCancerInstituteAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NCI Agreement</link:label>
    <link:label id="lab_rnac_NationalCancerInstituteAgreementMember_label_en-US" xlink:label="lab_rnac_NationalCancerInstituteAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Cancer Institute Agreement [Member]</link:label>
    <link:label id="lab_rnac_NationalCancerInstituteAgreementMember_documentation_en-US" xlink:label="lab_rnac_NationalCancerInstituteAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">National Cancer Institute Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NationalCancerInstituteAgreementMember" xlink:href="rnac-20241231.xsd#rnac_NationalCancerInstituteAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_NationalCancerInstituteAgreementMember" xlink:to="lab_rnac_NationalCancerInstituteAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_cce01658-cf78-4f4b-a635-980bbc22dfe7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c5fe86bc-5155-4d49-b080-53477a86305c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_StockIssuedDuringPeriodSharesWarrantsExercised_174b4284-c83f-40b6-bbc6-3cc6fc9bbfde_negatedTerseLabel_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercises (in shares)</link:label>
    <link:label id="lab_rnac_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_rnac_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants exercised during the current period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_rnac_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8c78cdc7-6ac2-4c0e-9d3b-fd77fb6be781_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4a17a083-5db3-41ad-8411-0455a91f1a31_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CollaborationAndLicenseAgreementsUpfrontPayment_06441d02-524d-43f0-92fc-1c4e3c398285_terseLabel_en-US" xlink:label="lab_rnac_CollaborationAndLicenseAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and license agreements upfront payment</link:label>
    <link:label id="lab_rnac_CollaborationAndLicenseAgreementsUpfrontPayment_label_en-US" xlink:label="lab_rnac_CollaborationAndLicenseAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements Upfront Payment</link:label>
    <link:label id="lab_rnac_CollaborationAndLicenseAgreementsUpfrontPayment_documentation_en-US" xlink:label="lab_rnac_CollaborationAndLicenseAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborationAndLicenseAgreementsUpfrontPayment" xlink:href="rnac-20241231.xsd#rnac_CollaborationAndLicenseAgreementsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CollaborationAndLicenseAgreementsUpfrontPayment" xlink:to="lab_rnac_CollaborationAndLicenseAgreementsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_68da75f9-13d5-4d37-a1b9-c13065c0184a_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b0ce23f3-4664-4286-9315-85283aa82eb0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination_9a9790e0-9ebb-4b73-864d-74572f063aa9_negatedTerseLabel_en-US" xlink:label="lab_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlement of outstanding equity awards at Merger</link:label>
    <link:label id="lab_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination_label_en-US" xlink:label="lab_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Settlement Of Equity Awards In Business Combination</link:label>
    <link:label id="lab_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination_documentation_en-US" xlink:label="lab_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Settlement Of Equity Awards In Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination" xlink:href="rnac-20241231.xsd#rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination" xlink:to="lab_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_87a9e116-7925-407b-8afd-cdca8680617b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c33984d9-5d7f-48d5-9b5b-45f26c58e1d6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_fac4c869-a25f-42e8-9df6-b1808d80db33_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_3001a3ef-878b-4702-b597-b9b4c4aee2e1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent and license costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_745bc92b-61c9-4fde-a7fe-f804ad8be2ac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_013d8e6f-4f32-4cee-a29b-448e4be269df_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_f6ca2918-3604-41af-bd31-0edfc91ca4c9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_fe32aa7e-6a7b-466d-9c2c-8dfdefb2e15b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_e6e23740-5c84-4efc-91b6-14a2a2dc76c9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne_c6c4b270-d010-4fe0-b753-093da5afada6_terseLabel_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, additional annual base rent, year one</link:label>
    <link:label id="lab_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne_label_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Additional Annual Base Rent, Year One</link:label>
    <link:label id="lab_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne_documentation_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Additional Annual Base Rent, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne" xlink:to="lab_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_d5fd25ec-a97d-4189-b8ad-fa74e76b75f7_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_45ba2006-9991-4b60-9930-9761bd2e2f31_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision (benefit) for deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cd6eab5d-ce96-47e7-af7b-c686e7523b2a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_A2022OfferingMember_183525db-ff13-4339-a168-7f18080fb49b_terseLabel_en-US" xlink:label="lab_rnac_A2022OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Offering</link:label>
    <link:label id="lab_rnac_A2022OfferingMember_label_en-US" xlink:label="lab_rnac_A2022OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Offering [Member]</link:label>
    <link:label id="lab_rnac_A2022OfferingMember_documentation_en-US" xlink:label="lab_rnac_A2022OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2022OfferingMember" xlink:href="rnac-20241231.xsd#rnac_A2022OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_A2022OfferingMember" xlink:to="lab_rnac_A2022OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_8206c514-86c4-448a-b7ac-3757eb0dc0eb_terseLabel_en-US" xlink:label="lab_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Temporary Equity, Option, Roll Forward [Roll Forward]</link:label>
    <link:label id="lab_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_label_en-US" xlink:label="lab_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Temporary Equity, Option, Roll Forward [Roll Forward]</link:label>
    <link:label id="lab_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_documentation_en-US" xlink:label="lab_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Temporary Equity, Option, Roll Forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward" xlink:href="rnac-20241231.xsd#rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward" xlink:to="lab_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_132c166f-cabb-4034-9795-41571f676e9d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Pro Forma Financial Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b239f6ea-09ff-47ba-a335-55ff131b84f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_78a169b5-9aed-4814-9dd1-252a90a21be8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ed35a3e2-e56a-405c-a32a-88a624ad2808_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3f048036-12c1-4a89-ae60-f57a538bfe4b_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential common shares</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_8f218e52-afc9-43d6-a808-03b43a379205_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_80bd10c2-64ca-45ac-8454-e906dd5a542f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_4fde7cc2-668c-4cb9-8881-7d4c8768a127_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_d1b558ad-47cf-4808-8436-d9d265d5b658_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of common warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_0b361d7d-bcd9-4d1f-b06d-4d0999d763e6_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_905bdedb-fade-4256-bf66-f1f0d76dacf9_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of forward contract liabilities</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6894467b-b1fb-41b2-95b8-ed093dba1ce1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forward contract liabilities revaluation</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_45eab34f-5f71-43c6-a3b9-6c1faad105a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_841e62f3-c15d-47df-a607-22a7398cf4b3_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TransferOfTemporaryEquityToPermanentEquityShares_32b6691f-7d4f-4667-9c66-33460b800fd9_terseLabel_en-US" xlink:label="lab_rnac_TransferOfTemporaryEquityToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of Series A preferred stock and options for Series A preferred stock to permanent equity (in shares)</link:label>
    <link:label id="lab_rnac_TransferOfTemporaryEquityToPermanentEquityShares_label_en-US" xlink:label="lab_rnac_TransferOfTemporaryEquityToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer Of Temporary Equity To Permanent Equity, Shares</link:label>
    <link:label id="lab_rnac_TransferOfTemporaryEquityToPermanentEquityShares_documentation_en-US" xlink:label="lab_rnac_TransferOfTemporaryEquityToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transfer Of Temporary Equity To Permanent Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TransferOfTemporaryEquityToPermanentEquityShares" xlink:href="rnac-20241231.xsd#rnac_TransferOfTemporaryEquityToPermanentEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TransferOfTemporaryEquityToPermanentEquityShares" xlink:to="lab_rnac_TransferOfTemporaryEquityToPermanentEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8415b27c-ace9-4c1b-aacb-958635f5c771_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_524d8b68-5e98-4a41-b406-825fae3ade16_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_583dffa3-83b3-434d-acdd-f7387abdadea_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dba63880-19a5-4b9f-bd66-245af6134b27_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_8fad9195-7e4d-413b-b8eb-b48969007093_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities, beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ca2f155b-24ef-4022-b990-644a941d0298_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities, end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_65f5928f-f90d-488a-ac21-7c5e2d278c62_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_027bbd32-6f9b-4e96-980f-82039b977ed7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_a13536aa-6beb-4d79-ae59-53e90f20a225_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Liabilities</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_89d64db6-03e9-4566-88a7-f446f89827c1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityDisclosureTextBlock_0d6bda07-d7ab-456f-908e-f6873479cd21_terseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_rnac_TemporaryEquityDisclosureTextBlock_label_en-US" xlink:label="lab_rnac_TemporaryEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Disclosure [Text Block]</link:label>
    <link:label id="lab_rnac_TemporaryEquityDisclosureTextBlock_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for temporary equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityDisclosureTextBlock" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityDisclosureTextBlock" xlink:to="lab_rnac_TemporaryEquityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5b84130a-621d-487c-a7c3-d054e60d82aa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_768ab009-91b7-4ad5-8457-f9a3e65b544c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9dfec485-7efd-4547-b3bd-9c2c39bfbb31_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1fd6d402-ad68-49ff-89f4-697810354d07_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_f27bfdb4-73fb-4c7d-a6a3-567574feee91_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7a999f01-96c1-463c-be50-7eff48f1cb1b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52c1d697-5430-4d24-8242-767a3cb8cfd4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_79e84b86-09f2-4ea1-929b-305ad697f4ab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_96de5847-dd8b-43b7-8d60-5226212f448f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_05b7c82d-927f-461a-954a-fdfb57c61718_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets, location</link:label>
    <link:label id="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_e4740f66-ac58-434c-8325-31593922f53d_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_b7a4b64c-ac1b-4906-bc2b-859d9e04106a_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_007ee2f7-ab03-412c-bf23-83083eb544a1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue_51db1b6f-8f37-45af-8836-3b319b354a80_terseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series A Preferred Stock in connection with the Merger and settlement of related forward contract</link:label>
    <link:label id="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue_label_en-US" xlink:label="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Acquisitions, Value</link:label>
    <link:label id="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Acquisitions, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue" xlink:to="lab_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ReportingSegmentsMember_9f0b661a-81f4-439a-b4c0-c24361342ab7_terseLabel_en-US" xlink:label="lab_rnac_ReportingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Segments</link:label>
    <link:label id="lab_rnac_ReportingSegmentsMember_label_en-US" xlink:label="lab_rnac_ReportingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Segments [Member]</link:label>
    <link:label id="lab_rnac_ReportingSegmentsMember_documentation_en-US" xlink:label="lab_rnac_ReportingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reporting Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ReportingSegmentsMember" xlink:href="rnac-20241231.xsd#rnac_ReportingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ReportingSegmentsMember" xlink:to="lab_rnac_ReportingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_5f63af4f-9e88-4a2b-97ba-e7779f397c4b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e4791771-bf2f-4f8c-8589-4a50a6064376_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ad8f6a76-78c1-407d-a76d-09e2161206be_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_79cfaf23-9c76-4bc2-80af-f18d96d77d62_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_31f4a4fe-7623-4987-806d-a25d3ea66397_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9764c2c5-032f-44a7-91d2-6543a2cc2756_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_00c18826-3aab-429c-ba76-f50bc8d0e6ff_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_a19f72d6-fd27-4307-8ac5-d50292889e95_terseLabel_en-US" xlink:label="lab_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement percentage, budgeted costs incurred to complete the development</link:label>
    <link:label id="lab_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_label_en-US" xlink:label="lab_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Percentage, Budgeted Costs Incurred To Complete The Development</link:label>
    <link:label id="lab_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_documentation_en-US" xlink:label="lab_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement Percentage, Budgeted Costs Incurred To Complete The Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment" xlink:href="rnac-20241231.xsd#rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment" xlink:to="lab_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1a9a7738-1fc3-4267-a69b-ff721b02f029_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0aa72411-9452-4eae-8cb8-a1e8597029fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeAxis_864f74c1-6570-4fba-b7fc-ff7c808e3771_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeAxis_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis" xlink:to="lab_us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_565e3745-87f6-446f-b68e-cde0a9e702e5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_DeferredTaxAssetsLeasingArrangements_83eb584b-a1b4-4980-baf2-a2988292446c_terseLabel_en-US" xlink:label="lab_rnac_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_rnac_DeferredTaxAssetsLeasingArrangements_label_en-US" xlink:label="lab_rnac_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:label id="lab_rnac_DeferredTaxAssetsLeasingArrangements_documentation_en-US" xlink:label="lab_rnac_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DeferredTaxAssetsLeasingArrangements" xlink:href="rnac-20241231.xsd#rnac_DeferredTaxAssetsLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_DeferredTaxAssetsLeasingArrangements" xlink:to="lab_rnac_DeferredTaxAssetsLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_45ad829a-eba5-4ebc-a738-ca6bb1f89ead_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_97a72a8c-7885-4020-b920-acded56e0da2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TASPartnersLLCMember_41ea5922-c46d-457c-8709-ce7e72a8145e_terseLabel_en-US" xlink:label="lab_rnac_TASPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TAS Partners, LLC</link:label>
    <link:label id="lab_rnac_TASPartnersLLCMember_label_en-US" xlink:label="lab_rnac_TASPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TAS Partners, LLC [Member]</link:label>
    <link:label id="lab_rnac_TASPartnersLLCMember_documentation_en-US" xlink:label="lab_rnac_TASPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TAS Partners, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TASPartnersLLCMember" xlink:href="rnac-20241231.xsd#rnac_TASPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TASPartnersLLCMember" xlink:to="lab_rnac_TASPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_OperatingLeaseCostPercentage_9cfd64a6-3239-4d75-ba0e-983a636ab87b_terseLabel_en-US" xlink:label="lab_rnac_OperatingLeaseCostPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, cost percentage</link:label>
    <link:label id="lab_rnac_OperatingLeaseCostPercentage_label_en-US" xlink:label="lab_rnac_OperatingLeaseCostPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost Percentage</link:label>
    <link:label id="lab_rnac_OperatingLeaseCostPercentage_documentation_en-US" xlink:label="lab_rnac_OperatingLeaseCostPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLeaseCostPercentage" xlink:href="rnac-20241231.xsd#rnac_OperatingLeaseCostPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_OperatingLeaseCostPercentage" xlink:to="lab_rnac_OperatingLeaseCostPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6ba084bd-f8fe-4917-982d-2e907a2553b2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_159395d4-b241-43c1-9653-09baacc8bd6c_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated forfeitures rate</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Forfeitures Rate</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of forfeitures rate of the stock options based on the historical trends.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage_1706ce04-f4e1-4cf7-a9a1-e5cda79876c5_terseLabel_en-US" xlink:label="lab_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficially holders owned percentage</link:label>
    <link:label id="lab_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage_label_en-US" xlink:label="lab_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Beneficial Ownership Percentage</link:label>
    <link:label id="lab_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage_documentation_en-US" xlink:label="lab_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Beneficial Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage" xlink:href="rnac-20241231.xsd#rnac_PreferredStockConvertibleBeneficialOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage" xlink:to="lab_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_477f274e-1c03-44aa-aa4d-2d9c8443fc01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_2edf5e82-9f80-4111-85fb-91acac6d4e5b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2aff3579-c08b-4045-acf0-0cf643210882_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplement cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c16113ad-41d5-4be0-91ef-89e88914515e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss allocable to shares of common stock - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_Dr.TimothyA.SpringerMember_c4bd0f25-8b14-4768-a666-f727f26bc7b1_terseLabel_en-US" xlink:label="lab_rnac_Dr.TimothyA.SpringerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timothy A. Springer, Ph.D.</link:label>
    <link:label id="lab_rnac_Dr.TimothyA.SpringerMember_label_en-US" xlink:label="lab_rnac_Dr.TimothyA.SpringerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Timothy A. Springer [Member]</link:label>
    <link:label id="lab_rnac_Dr.TimothyA.SpringerMember_documentation_en-US" xlink:label="lab_rnac_Dr.TimothyA.SpringerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dr. Timothy A. Springer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Dr.TimothyA.SpringerMember" xlink:href="rnac-20241231.xsd#rnac_Dr.TimothyA.SpringerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_Dr.TimothyA.SpringerMember" xlink:to="lab_rnac_Dr.TimothyA.SpringerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_29cecd98-8e68-4612-8c73-6ef5ee001e2e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;E Capitalization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_9ed042be-2f5f-4da3-a21b-0b45e8b9d79c_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f0b07367-bbaf-48a4-a9fd-246655f389e9_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c399215e-f816-4b9e-8de9-a95846104805_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements_699a6f31-82df-4fe6-aceb-659977eb4275_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and option agreement, development cost reimbursements</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Development Cost Reimbursements</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Development Cost Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements" xlink:to="lab_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_37247694-950f-4afc-99e6-19ff38114ea9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit related to the CVR liability</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_438802e7-e234-4216-9e90-958ba65eb54f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, convertible preferred stock, and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_9fa52088-5d16-4fdb-8afe-27a3e6475c21_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc018991-f79f-4161-8256-73f69823b9a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_89a985dc-939b-45c0-a18d-df9466a05db9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset impairment expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_9ca7dc6a-5052-4b43-9fd9-584ba5d73c9a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward contract liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_27fb0aa0-a8d9-447b-a7c4-1f6dd861a4d0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_A704QuinceOrchardRoadLeasesMember_d1a37e1a-df4b-4c7a-8c13-c90e0eb9e6e2_terseLabel_en-US" xlink:label="lab_rnac_A704QuinceOrchardRoadLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">704 Quince Orchard Road Leases</link:label>
    <link:label id="lab_rnac_A704QuinceOrchardRoadLeasesMember_label_en-US" xlink:label="lab_rnac_A704QuinceOrchardRoadLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">704 Quince Orchard Road Leases [Member]</link:label>
    <link:label id="lab_rnac_A704QuinceOrchardRoadLeasesMember_documentation_en-US" xlink:label="lab_rnac_A704QuinceOrchardRoadLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">704 Quince Orchard Road Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A704QuinceOrchardRoadLeasesMember" xlink:href="rnac-20241231.xsd#rnac_A704QuinceOrchardRoadLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_A704QuinceOrchardRoadLeasesMember" xlink:to="lab_rnac_A704QuinceOrchardRoadLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_FairValueAdjustmentOfContingentValueRightLiability_492ab760-ac46-4fd6-87f6-a15e8391a3be_negatedTerseLabel_en-US" xlink:label="lab_rnac_FairValueAdjustmentOfContingentValueRightLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent value right liability</link:label>
    <link:label id="lab_rnac_FairValueAdjustmentOfContingentValueRightLiability_8cc2a259-500e-4fb6-83d5-44548fc48b46_terseLabel_en-US" xlink:label="lab_rnac_FairValueAdjustmentOfContingentValueRightLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent value right liability revaluation</link:label>
    <link:label id="lab_rnac_FairValueAdjustmentOfContingentValueRightLiability_label_en-US" xlink:label="lab_rnac_FairValueAdjustmentOfContingentValueRightLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment Of Contingent Value Right Liability</link:label>
    <link:label id="lab_rnac_FairValueAdjustmentOfContingentValueRightLiability_documentation_en-US" xlink:label="lab_rnac_FairValueAdjustmentOfContingentValueRightLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment Of Contingent Value Right Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_FairValueAdjustmentOfContingentValueRightLiability" xlink:href="rnac-20241231.xsd#rnac_FairValueAdjustmentOfContingentValueRightLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_FairValueAdjustmentOfContingentValueRightLiability" xlink:to="lab_rnac_FairValueAdjustmentOfContingentValueRightLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TakedaAgreementMember_0fa05a9d-4bab-40c5-8356-4f8a222f7005_terseLabel_en-US" xlink:label="lab_rnac_TakedaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda Agreement</link:label>
    <link:label id="lab_rnac_TakedaAgreementMember_label_en-US" xlink:label="lab_rnac_TakedaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Agreement [Member]</link:label>
    <link:label id="lab_rnac_TakedaAgreementMember_documentation_en-US" xlink:label="lab_rnac_TakedaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Takeda Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TakedaAgreementMember" xlink:href="rnac-20241231.xsd#rnac_TakedaAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TakedaAgreementMember" xlink:to="lab_rnac_TakedaAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_398d8912-454b-47b7-abf1-c67126b8173c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ResearchAndDevelopmentEmployeeExpenses_034808dd-a3a3-4f83-9495-6749701355c8_terseLabel_en-US" xlink:label="lab_rnac_ResearchAndDevelopmentEmployeeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development employee expenses</link:label>
    <link:label id="lab_rnac_ResearchAndDevelopmentEmployeeExpenses_label_en-US" xlink:label="lab_rnac_ResearchAndDevelopmentEmployeeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Employee Expenses</link:label>
    <link:label id="lab_rnac_ResearchAndDevelopmentEmployeeExpenses_documentation_en-US" xlink:label="lab_rnac_ResearchAndDevelopmentEmployeeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Employee Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentEmployeeExpenses" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentEmployeeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ResearchAndDevelopmentEmployeeExpenses" xlink:to="lab_rnac_ResearchAndDevelopmentEmployeeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3a5296ff-ba7a-44d3-a107-c2ddc0793c35_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f853d54d-8f78-4aa8-9b94-a3969c78a6f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_67d87b54-1258-47d8-9192-9b58685af362_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward contract to issue stock and options</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_98d1a49b-7abf-45ea-91aa-1d35482084e2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forward contract to issue stock</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6dca08d6-6475-4e88-9990-57a2bbf5ab57_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3decb180-960f-41b1-9969-431141fdca60_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0e733855-d448-42e8-80ef-2bf4e607e4c1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_6c7755f6-d32a-48cc-a32d-863e91279edf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_3f490159-fc01-4fb9-a81e-a71107bbb49b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_Descartes08ForMGMember_49696694-e34d-4c69-990f-85b26920347d_terseLabel_en-US" xlink:label="lab_rnac_Descartes08ForMGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Descartes-08 for MG</link:label>
    <link:label id="lab_rnac_Descartes08ForMGMember_label_en-US" xlink:label="lab_rnac_Descartes08ForMGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Descartes-08 For MG [Member]</link:label>
    <link:label id="lab_rnac_Descartes08ForMGMember_documentation_en-US" xlink:label="lab_rnac_Descartes08ForMGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Descartes-08 For MG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Descartes08ForMGMember" xlink:href="rnac-20241231.xsd#rnac_Descartes08ForMGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_Descartes08ForMGMember" xlink:to="lab_rnac_Descartes08ForMGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SOBIPurchaseAgreementMember_e9109621-2543-484c-b0d3-a216994e6033_terseLabel_en-US" xlink:label="lab_rnac_SOBIPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOBI Purchase Agreement</link:label>
    <link:label id="lab_rnac_SOBIPurchaseAgreementMember_label_en-US" xlink:label="lab_rnac_SOBIPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOBI Purchase Agreement [Member]</link:label>
    <link:label id="lab_rnac_SOBIPurchaseAgreementMember_documentation_en-US" xlink:label="lab_rnac_SOBIPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SOBI Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SOBIPurchaseAgreementMember" xlink:href="rnac-20241231.xsd#rnac_SOBIPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SOBIPurchaseAgreementMember" xlink:to="lab_rnac_SOBIPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_495d073b-c0c1-4857-b88e-9be2a83ba7b2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_RestrictedStockUnitsUnvestedMember_97f0b9d1-d081-4f11-9435-b73399c02391_terseLabel_en-US" xlink:label="lab_rnac_RestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_rnac_RestrictedStockUnitsUnvestedMember_label_en-US" xlink:label="lab_rnac_RestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units, Unvested [Member]</link:label>
    <link:label id="lab_rnac_RestrictedStockUnitsUnvestedMember_documentation_en-US" xlink:label="lab_rnac_RestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units, Unvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_RestrictedStockUnitsUnvestedMember" xlink:href="rnac-20241231.xsd#rnac_RestrictedStockUnitsUnvestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_RestrictedStockUnitsUnvestedMember" xlink:to="lab_rnac_RestrictedStockUnitsUnvestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_04d9f5fa-ad9f-4282-886d-c322e53e003c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_39e9114c-d241-41a6-a178-3876a051e76e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_41441935-5e79-483d-9a00-3faaf2399a77_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity_45a56f83-2c13-446c-80d5-59fd33cabc03_negatedTerseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity</link:label>
    <link:label id="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity_label_en-US" xlink:label="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Transfer Of Preferred Stock To Permanent Equity</link:label>
    <link:label id="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Transfer Of Preferred Stock To Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity" xlink:to="lab_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ff710014-2082-4711-8bd7-675ddddb4d26_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_327e6506-43f0-4f4a-8405-3adc6a9930d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b365ca72-88c1-482e-b085-a46c6a11bc0e_terseLabel_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="lab_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_22df991b-74ad-49a8-b54b-5e06b2438340_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_8a3e4141-a9f0-49c2-bb7d-4c1a48cca366_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_fe4a86c4-0fbb-47bb-8d5e-5786527fb3da_terseLabel_en-US" xlink:label="lab_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_label_en-US" xlink:label="lab_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Employers Matching Contribution Vesting Period</link:label>
    <link:label id="lab_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_documentation_en-US" xlink:label="lab_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period which an employee's right to exercise a plan is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:href="rnac-20241231.xsd#rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:to="lab_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContingentValueRightLiabilityMeasurementInput_396d4d9b-13a1-49f5-87b4-d0b1c495717e_terseLabel_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent value right liability, measurement input</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiabilityMeasurementInput_label_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability, Measurement Input</link:label>
    <link:label id="lab_rnac_ContingentValueRightLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_rnac_ContingentValueRightLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityMeasurementInput" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContingentValueRightLiabilityMeasurementInput" xlink:to="lab_rnac_ContingentValueRightLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_7e150c58-d2ae-437c-af68-827bbb5b221d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding_e6350d4e-84b8-482a-91ef-667eb3c43bbb_terseLabel_en-US" xlink:label="lab_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, convertible, transaction restrictions, percentage of originally issued stock issued and outstanding</link:label>
    <link:label id="lab_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding_label_en-US" xlink:label="lab_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Transaction Restrictions, Percentage Of Originally Issued Stock Issued And Outstanding</link:label>
    <link:label id="lab_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding_documentation_en-US" xlink:label="lab_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Transaction Restrictions, Percentage Of Originally Issued Stock Issued And Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding" xlink:href="rnac-20241231.xsd#rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding" xlink:to="lab_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_IssuanceOfStockForSettlementOfForwardContractLiability_64c56fd7-feb8-4340-b338-be78611d2cdb_terseLabel_en-US" xlink:label="lab_rnac_IssuanceOfStockForSettlementOfForwardContractLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock for settlement of liability</link:label>
    <link:label id="lab_rnac_IssuanceOfStockForSettlementOfForwardContractLiability_label_en-US" xlink:label="lab_rnac_IssuanceOfStockForSettlementOfForwardContractLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Stock For Settlement Of Forward Contract Liability</link:label>
    <link:label id="lab_rnac_IssuanceOfStockForSettlementOfForwardContractLiability_documentation_en-US" xlink:label="lab_rnac_IssuanceOfStockForSettlementOfForwardContractLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Stock For Settlement Of Forward Contract Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IssuanceOfStockForSettlementOfForwardContractLiability" xlink:href="rnac-20241231.xsd#rnac_IssuanceOfStockForSettlementOfForwardContractLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_IssuanceOfStockForSettlementOfForwardContractLiability" xlink:to="lab_rnac_IssuanceOfStockForSettlementOfForwardContractLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3ea06458-0648-4406-9aa3-11d8f25963b4_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_1655d2b6-3508-4cc3-88c4-f50fd32f17d5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_4ef1355b-f009-485c-9f20-a4bca94fa828_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_51105eaa-17d6-4dbd-b0fe-f6e06346f56f_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PrivatePlacement2023TrancheTwoMember_50ff5296-6c5e-4116-8163-e5947246aa55_terseLabel_en-US" xlink:label="lab_rnac_PrivatePlacement2023TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Private Placement, Tranche Two</link:label>
    <link:label id="lab_rnac_PrivatePlacement2023TrancheTwoMember_label_en-US" xlink:label="lab_rnac_PrivatePlacement2023TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement 2023, Tranche Two [Member]</link:label>
    <link:label id="lab_rnac_PrivatePlacement2023TrancheTwoMember_documentation_en-US" xlink:label="lab_rnac_PrivatePlacement2023TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement 2023, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023TrancheTwoMember" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PrivatePlacement2023TrancheTwoMember" xlink:to="lab_rnac_PrivatePlacement2023TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_6636d249-4ac5-4eca-9666-fff27cdb1170_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_d452fc85-4332-4aee-8c02-b139cbad1626_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_fda7b152-802b-44bd-b57e-1661f70a85f0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_560c8d39-de5c-46c9-8806-8cff96eaedff_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory U.S. federal rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b8dca09c-c1fd-4406-8bbf-7df651d018de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_658e279f-c03d-4c63-b69b-24fa59f3d57f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9f9ef730-055d-4fe1-a6a3-daa855509059_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_d4c3a0d3-7999-491e-92e3-17d099556aee_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ResearchAndDevelopmentStockBasedCompensationExpense_c9c1cc7c-678c-460a-8bde-3c34b7217db3_terseLabel_en-US" xlink:label="lab_rnac_ResearchAndDevelopmentStockBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development stock-based compensation expense</link:label>
    <link:label id="lab_rnac_ResearchAndDevelopmentStockBasedCompensationExpense_label_en-US" xlink:label="lab_rnac_ResearchAndDevelopmentStockBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development, Stock-Based Compensation Expense</link:label>
    <link:label id="lab_rnac_ResearchAndDevelopmentStockBasedCompensationExpense_documentation_en-US" xlink:label="lab_rnac_ResearchAndDevelopmentStockBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development, Stock-Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentStockBasedCompensationExpense" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentStockBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ResearchAndDevelopmentStockBasedCompensationExpense" xlink:to="lab_rnac_ResearchAndDevelopmentStockBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContingentValueRightMember_7719f18a-7ef6-4c29-88ee-2d3f8d0aaddd_terseLabel_en-US" xlink:label="lab_rnac_ContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CVR liability</link:label>
    <link:label id="lab_rnac_ContingentValueRightMember_label_en-US" xlink:label="lab_rnac_ContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Right [Member]</link:label>
    <link:label id="lab_rnac_ContingentValueRightMember_documentation_en-US" xlink:label="lab_rnac_ContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightMember" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContingentValueRightMember" xlink:to="lab_rnac_ContingentValueRightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement_2eb75983-d7d9-4ea5-8b5c-48f51347f919_terseLabel_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, first month rent paid on execution of lease agreement</link:label>
    <link:label id="lab_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement_label_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, First Month Rent Paid on Execution of Lease Agreement</link:label>
    <link:label id="lab_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement_documentation_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, First Month Rent Paid on Execution of Lease Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement" xlink:to="lab_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1ffb828b-63f4-4ca0-9907-e95406d96dc6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_445227db-1728-453e-ae8b-1e699ffe883f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7e82e28a-c94c-4350-8a8f-ffeeca74282e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare_9378d5e1-cb81-414e-a3a3-45b54560297f_terseLabel_en-US" xlink:label="lab_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, stock purchase agreement, purchase price per share (in dollars per share)</link:label>
    <link:label id="lab_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare_label_en-US" xlink:label="lab_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Stock Purchase Agreement, Purchase Price Per Share</link:label>
    <link:label id="lab_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare_documentation_en-US" xlink:label="lab_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Stock Purchase Agreement, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare" xlink:href="rnac-20241231.xsd#rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare" xlink:to="lab_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_41d60648-5705-4a26-8797-ff59d47e6271_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled_345a2af9-db55-434c-83ef-3fe1e3410fc2_negatedTerseLabel_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled_label_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Warrants Canceled</link:label>
    <link:label id="lab_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled_documentation_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodSharesWarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled" xlink:to="lab_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PrivatePlacementTwoMember_f050dfd0-ce7d-4e46-9f17-2930ae47d4d4_terseLabel_en-US" xlink:label="lab_rnac_PrivatePlacementTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement Two</link:label>
    <link:label id="lab_rnac_PrivatePlacementTwoMember_label_en-US" xlink:label="lab_rnac_PrivatePlacementTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Two [Member]</link:label>
    <link:label id="lab_rnac_PrivatePlacementTwoMember_documentation_en-US" xlink:label="lab_rnac_PrivatePlacementTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacementTwoMember" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacementTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PrivatePlacementTwoMember" xlink:to="lab_rnac_PrivatePlacementTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_d30aa9dd-1cc2-4b36-b0c9-144b7a45da9b_terseLabel_en-US" xlink:label="lab_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan</link:label>
    <link:label id="lab_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_label_en-US" xlink:label="lab_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan [Member]</link:label>
    <link:label id="lab_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:href="rnac-20241231.xsd#rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:to="lab_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_36e93e8f-35f6-4f77-b037-ff3c345e4f6e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_64bf1b3a-e4ad-4c26-bcc2-7b74db5c7320_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, license agreement in stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7fdcc414-00a4-45e5-9248-9d34c6fd5272_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_b2f0c49a-be5a-4241-b9dd-6c9a71038c55_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_1b0d4236-b977-4f9f-9b8d-e1a789e06f2e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_d2a891f3-5b1a-48de-9696-5f7d7850c236_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement_176791a8-62ed-4fab-9ad0-3402be6ec8ae_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess over fair value recognized as additional stock-based compensation expense</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards, Stock Based Compensation Expense Recognized On Settlement</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards, Stock Based Compensation Expense Recognized On Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_DebtInstrumentPrepaymentFee_11c6a62e-8a46-4d81-b406-c83bb46dee38_terseLabel_en-US" xlink:label="lab_rnac_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, prepayment fee</link:label>
    <link:label id="lab_rnac_DebtInstrumentPrepaymentFee_label_en-US" xlink:label="lab_rnac_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee</link:label>
    <link:label id="lab_rnac_DebtInstrumentPrepaymentFee_documentation_en-US" xlink:label="lab_rnac_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DebtInstrumentPrepaymentFee" xlink:href="rnac-20241231.xsd#rnac_DebtInstrumentPrepaymentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_DebtInstrumentPrepaymentFee" xlink:to="lab_rnac_DebtInstrumentPrepaymentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_70560ea5-2af2-4934-a0e0-241ac4551fca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_25873af4-4a87-47aa-a6c6-9c6f42bf0823_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_d5d7d00c-9fd2-4c8c-87fa-ba074a7fe683_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_85941d15-b6b7-4804-a5c6-67ba74db82f2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_a70447c0-0422-42c7-a485-7f1ca3cb5edf_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionRatio_0e17c5d2-fe9e-443f-b8c7-b062c1db7071_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionRatio_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c10b5d5e-2ed6-4ea8-9f81-032d2d41b50e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_38f6e326-7195-4f96-8a79-069b0ec4412d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_315c674a-b56e-4a06-a9bd-ef2d958ccfb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_15db4848-931e-43ea-8623-ae4be11d83f4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fed0bc8e-5408-40c8-9762-ba901d70ce34_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants_c3317e9f-fc37-4a05-988e-d78ca8616daf_terseLabel_en-US" xlink:label="lab_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock and Series B Preferred Stock in private placement</link:label>
    <link:label id="lab_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants_label_en-US" xlink:label="lab_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:href="rnac-20241231.xsd#rnac_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1431e6ae-c352-4e29-9291-6c986de82fa5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays_1ec5ec17-55ea-41cc-bba7-dc09b802cb8a_terseLabel_en-US" xlink:label="lab_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:href="rnac-20241231.xsd#rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:to="lab_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a387fbe5-bf22-4681-a79f-1791bfce6968_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_73f4d082-c11b-4a05-a010-eab05db1afc1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series B preferred stock and common stock in connection with private placement, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition_d110dffc-310a-41fe-8286-d93b330bdffc_terseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition_label_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Options, Share-Based Payment Arrangement, Increase For Cost Recognition</link:label>
    <link:label id="lab_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Options, Share-Based Payment Arrangement, Increase For Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:to="lab_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cb057224-7256-473b-8abe-ddc3cbf69c21_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8b0b658b-6db1-4d52-8284-fdaa18539af2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_1fe86273-4b85-4bdc-be48-57c6274e45b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax, Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_01bfd9a4-4786-4be0-bb6e-68a33e27c304_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights_897db1ac-59a7-4f5d-823b-c5459a597f8e_negatedTerseLabel_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Distribution of contingent value rights</link:label>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights_label_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Distribution Of Contingent Value Rights</link:label>
    <link:label id="lab_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights_documentation_en-US" xlink:label="lab_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Distribution Of Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights" xlink:to="lab_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_a92c9c63-88da-4238-a571-96ca8fc9cbe3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised_49621d29-c228-4823-94d2-307e35f121c6_terseLabel_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised_label_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Common Warrants Exercised</link:label>
    <link:label id="lab_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised_documentation_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Common Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised" xlink:to="lab_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend_c123f488-494b-46f1-b23f-8e4b3029dce8_terseLabel_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to extend lease</link:label>
    <link:label id="lab_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend_label_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Options To Extend</link:label>
    <link:label id="lab_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend_documentation_en-US" xlink:label="lab_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Options To Extend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseNumberOfOptionsToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:to="lab_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c247e3fc-f6e2-4503-82f6-ce1ab18a57c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LeaseArrangementAxis_fd2b333c-1fe0-41fd-8bf9-5ff41bbf0d97_terseLabel_en-US" xlink:label="lab_rnac_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_rnac_LeaseArrangementAxis_label_en-US" xlink:label="lab_rnac_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_rnac_LeaseArrangementAxis_documentation_en-US" xlink:label="lab_rnac_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementAxis" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LeaseArrangementAxis" xlink:to="lab_rnac_LeaseArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_MeasurementInputRevenueVolatilityMember_d054d569-ae07-4cdd-a006-52f40560aaad_terseLabel_en-US" xlink:label="lab_rnac_MeasurementInputRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility of future revenues</link:label>
    <link:label id="lab_rnac_MeasurementInputRevenueVolatilityMember_label_en-US" xlink:label="lab_rnac_MeasurementInputRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Revenue Volatility [Member]</link:label>
    <link:label id="lab_rnac_MeasurementInputRevenueVolatilityMember_documentation_en-US" xlink:label="lab_rnac_MeasurementInputRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Revenue Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_MeasurementInputRevenueVolatilityMember" xlink:href="rnac-20241231.xsd#rnac_MeasurementInputRevenueVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_MeasurementInputRevenueVolatilityMember" xlink:to="lab_rnac_MeasurementInputRevenueVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3b428aba-090e-450c-be7c-696e1e570953_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_37fd48ad-65e6-4d5b-b33d-923223aa8491_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_331c1799-45ad-4280-b647-306309fcd74b_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_aba77f1b-f02b-41c2-9522-dc6f02ed581e_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_986fa3a8-6ea2-4273-8464-21aa100aa1e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1ececff2-138a-4214-a7e2-32bbd5eb1463_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fc153724-63a1-4120-84c2-1e97c4c9d4de_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_efb5d0c7-5329-4d2a-b72b-3027f5d445aa_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_51848538-7aba-4095-a8c6-d99bcd5a5792_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9000b732-3244-4e25-9874-a4bcafd2ea08_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_e49e2f1d-6c62-4182-8114-12c8419d338f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense related to term loans</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_8c07fd92-113b-4fb3-baa7-4d9c845ed480_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b07e5f7e-2fa4-4430-adcc-1f8427c0b0df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SecuritiesPurchaseAgreement2023Member_bf786db5-d90d-4d2b-a7e2-929c3108ceb0_terseLabel_en-US" xlink:label="lab_rnac_SecuritiesPurchaseAgreement2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Securities Purchase Agreement</link:label>
    <link:label id="lab_rnac_SecuritiesPurchaseAgreement2023Member_label_en-US" xlink:label="lab_rnac_SecuritiesPurchaseAgreement2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement 2023 [Member]</link:label>
    <link:label id="lab_rnac_SecuritiesPurchaseAgreement2023Member_documentation_en-US" xlink:label="lab_rnac_SecuritiesPurchaseAgreement2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SecuritiesPurchaseAgreement2023Member" xlink:to="lab_rnac_SecuritiesPurchaseAgreement2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c090f2b9-623f-4c93-bedf-44086eea19de_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased_d8f9c64f-eeb2-4be2-aea4-bd4ee3e6e275_terseLabel_en-US" xlink:label="lab_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, stock purchase agreement, shares purchased (in shares)</link:label>
    <link:label id="lab_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased_label_en-US" xlink:label="lab_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Stock Purchase Agreement, Shares Purchased</link:label>
    <link:label id="lab_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased_documentation_en-US" xlink:label="lab_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Stock Purchase Agreement, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased" xlink:href="rnac-20241231.xsd#rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased" xlink:to="lab_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceAwardAmount_762b591e-ea5f-4f7f-8bde-4dab330702c0_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government assistance, award amount</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceAwardAmount_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Award Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAwardAmount" xlink:to="lab_us-gaap_GovernmentAssistanceAwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_782a522d-eed7-471b-917a-6ff50abd87b7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_34c31614-ce24-4b58-8f13-8ed858bfc20c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_27b5859d-4684-49af-94a4-f9f1d8e7fe1e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_137789b6-12ab-4433-8e87-58a069b93d66_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a0263074-7e29-4f72-a04c-d8f83aac91af_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b710dab7-d317-4490-8255-b625e8e702dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_700628d2-f71a-49f1-b39e-b26e47707d55_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_768c0c40-121e-47fd-8702-852d5a59e1b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_710282a7-a9f7-45cf-b821-e700274d27e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of stock options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_cf531ca0-cf3a-4e78-9d44-19986fa782da_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c3449485-a53a-41d1-afa7-02a2591b065d_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity securities without readily determinable fair value, amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_f5c4135d-e550-4303-acc5-908ae61d3d5a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised_d088a4c8-5248-4f2b-be67-fa4badd44ab1_terseLabel_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of common warrants (in shares)</link:label>
    <link:label id="lab_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised_label_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Common Warrants Exercised</link:label>
    <link:label id="lab_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised_documentation_en-US" xlink:label="lab_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Common Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised" xlink:to="lab_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_228b1f1c-7281-44c2-9768-c1bf78b5830f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5703df17-032d-42c4-beb6-ef180cf15c7d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_b3a17cc9-abf9-4606-b2c9-3a89eb5df35e_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales milestone payments</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Sales Milestone Payments That May Be Received</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Sales Milestone Payments That May Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:to="lab_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_a65897ab-3eae-4756-b6dd-5578056575e0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedemptionPremium_9b5898bc-ca65-4081-900f-0ea4bd8ee38e_terseLabel_en-US" xlink:label="lab_us-gaap_RedemptionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption premium</link:label>
    <link:label id="lab_us-gaap_RedemptionPremium_label_en-US" xlink:label="lab_us-gaap_RedemptionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedemptionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedemptionPremium" xlink:to="lab_us-gaap_RedemptionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1beeea83-5dbd-497d-be06-ca449891047a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_e7bf3739-b1ef-4e22-a6b2-fc452f9925e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_da6e12e3-415d-4687-ba88-42a949b44c88_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_89322b2f-dbad-4236-a4f3-05ab6a3999ec_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent_cb6fe9da-7d76-45f6-8a50-7776727e5cc9_negatedLabel_en-US" xlink:label="lab_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unbilled receivable</link:label>
    <link:label id="lab_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Contract With Customer, Asset, Allowance For Credit Loss, Current</link:label>
    <link:label id="lab_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent_documentation_en-US" xlink:label="lab_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Contract With Customer, Asset, Allowance For Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:href="rnac-20241231.xsd#rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:to="lab_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_2339777a-9a14-49b3-be5d-3c04402257fd_terseLabel_en-US" xlink:label="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, term</link:label>
    <link:label id="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:href="rnac-20241231.xsd#rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_5813ce75-2c46-492a-885f-cea6e5751d66_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_aab4d058-784e-4eea-8356-03db516fa352_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_16f60b70-113f-425b-b068-8dd481d85b10_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementUpfrontCashPayment_95dc6ca2-4e8c-43ab-b25e-e86e2e547de4_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementUpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementUpfrontCashPayment_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementUpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Upfront Cash Payment</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementUpfrontCashPayment_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementUpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Upfront Cash Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementUpfrontCashPayment" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementUpfrontCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementUpfrontCashPayment" xlink:to="lab_rnac_LicenseAndOptionAgreementUpfrontCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CyrusBiotechnologyIncMember_f0ac3840-4cec-47a0-8418-18564a0129c4_terseLabel_en-US" xlink:label="lab_rnac_CyrusBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cyrus Biotechnology, Inc.</link:label>
    <link:label id="lab_rnac_CyrusBiotechnologyIncMember_label_en-US" xlink:label="lab_rnac_CyrusBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cyrus Biotechnology, Inc. [Member]</link:label>
    <link:label id="lab_rnac_CyrusBiotechnologyIncMember_documentation_en-US" xlink:label="lab_rnac_CyrusBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cyrus Biotechnology, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CyrusBiotechnologyIncMember" xlink:href="rnac-20241231.xsd#rnac_CyrusBiotechnologyIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CyrusBiotechnologyIncMember" xlink:to="lab_rnac_CyrusBiotechnologyIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityStockIssuedDuringPeriodShares_9db80038-257a-4e3b-a795-e1dcddcd9081_terseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityStockIssuedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series A preferred stock forward in connection with private placement and settlement of related forward contract (in shares)</link:label>
    <link:label id="lab_rnac_TemporaryEquityStockIssuedDuringPeriodShares_label_en-US" xlink:label="lab_rnac_TemporaryEquityStockIssuedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares</link:label>
    <link:label id="lab_rnac_TemporaryEquityStockIssuedDuringPeriodShares_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityStockIssuedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityStockIssuedDuringPeriodShares" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityStockIssuedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityStockIssuedDuringPeriodShares" xlink:to="lab_rnac_TemporaryEquityStockIssuedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ae03ef85-6527-4de3-bc5d-4ae4dd990c85_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_34ca5041-d034-4017-8adf-df36308d2ad8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4878ea89-5835-40f4-9aec-21b13030402f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series B Preferred Stock and common stock in connection with private placement, net of issuance costs of $5,585</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_1d3d7911-c672-424e-9d6e-a205a8de009d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Warrant, increase (decrease) in equity, amount</link:label>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_label_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e4088608-5cc4-4ffd-8626-c8bf9636294f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_215d9722-571f-4e98-89cb-079dded2a182_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_917c0945-babc-452d-80e3-7cdf36f141d3_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_32f43756-9790-4028-a6a7-0f523cabb459_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_063be076-c90c-4e1b-b949-13a80330d864_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 350,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 25,767,369 and 5,397,597 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_343495e6-0df7-40cb-a5ba-8f77acab7cb3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3b18d1bc-0930-404f-9337-3bfd4fcf8b5e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges, location</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_4405d3dd-5045-4936-903b-544491381393_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_67b2ae67-e2d9-4e8e-b614-3fa56efa6a02_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95f469ef-be32-4e12-b606-7af596981832_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_37e6f30d-5745-452c-9eab-7c382e790cc5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the merger and settlement of related forward contract (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9a79d3f2-bea2-41c3-9f08-f941549487d9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes - net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8475b46b-e160-456f-b634-b476d1bd9bc4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_968d78ee-1241-4472-8dbc-b19df05ae3e3_terseLabel_en-US" xlink:label="lab_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent value right, percentage of milestone payments, royalties and other amounts to be distributed</link:label>
    <link:label id="lab_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_label_en-US" xlink:label="lab_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Right, Percentage Of Milestone Payments, Royalties And Other Amounts To Be Distributed</link:label>
    <link:label id="lab_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_documentation_en-US" xlink:label="lab_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Value Right, Percentage Of Milestone Payments, Royalties And Other Amounts To Be Distributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" xlink:to="lab_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d012d5e0-e787-4999-8de6-a09256cd86ac_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, value, issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3dd819bc-47f1-4037-9393-c628eb2ca7f3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_4ba2c565-9eac-42dd-a095-93d70aa4e10b_terseLabel_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options for Series A Preferred Stock</link:label>
    <link:label id="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_14a85e01-b8df-4c0b-8f23-bd32b2541740_periodStartLabel_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_da0a7cee-c50d-4c84-95bf-be256058efac_periodEndLabel_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Options, Carrying Amount, Attributable To Parent</link:label>
    <link:label id="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_documentation_en-US" xlink:label="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Options, Carrying Amount, Attributable To Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent" xlink:to="lab_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_8137d0c9-2d12-49fb-af80-534bc6e51c46_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_366f18ef-5e29-4358-a1b4-042d039b270b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_be26a9ed-db06-46ec-8fcf-a0b0933a40d8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_71742a97-fc2c-4e88-bea2-f589901befc6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies_1f853200-9a6c-4cdb-97d7-aa5129b6d77d_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone receivable for certain dystrophies</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Milestone Receivable For Certain Dystrophies</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Milestone Receivable For Certain Dystrophies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies" xlink:to="lab_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SareptaTherapeuticsInc.Member_0859e6af-7838-4cc6-a322-48949f335d19_terseLabel_en-US" xlink:label="lab_rnac_SareptaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sarepta Therapeutics, Inc.</link:label>
    <link:label id="lab_rnac_SareptaTherapeuticsInc.Member_label_en-US" xlink:label="lab_rnac_SareptaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sarepta Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_rnac_SareptaTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_rnac_SareptaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sarepta Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SareptaTherapeuticsInc.Member" xlink:href="rnac-20241231.xsd#rnac_SareptaTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SareptaTherapeuticsInc.Member" xlink:to="lab_rnac_SareptaTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1f93cb8f-c3c1-4f1d-ad3c-e0594b289df3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award expiration term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_PreFundedWarrantMember_de561815-9e64-4b23-ab9a-768f850b4187_terseLabel_en-US" xlink:label="lab_rnac_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant</link:label>
    <link:label id="lab_rnac_PreFundedWarrantMember_label_en-US" xlink:label="lab_rnac_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:label id="lab_rnac_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_rnac_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreFundedWarrantMember" xlink:href="rnac-20241231.xsd#rnac_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_PreFundedWarrantMember" xlink:to="lab_rnac_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_EligiblePeriodToReceiveRoyalties_2a47e1a1-6654-4b50-b4f1-89bd475c1d9c_terseLabel_en-US" xlink:label="lab_rnac_EligiblePeriodToReceiveRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period after first commercial sale when the Company is eligible to receive royalties</link:label>
    <link:label id="lab_rnac_EligiblePeriodToReceiveRoyalties_label_en-US" xlink:label="lab_rnac_EligiblePeriodToReceiveRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eligible Period To Receive Royalties</link:label>
    <link:label id="lab_rnac_EligiblePeriodToReceiveRoyalties_documentation_en-US" xlink:label="lab_rnac_EligiblePeriodToReceiveRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eligible Period To Receive Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EligiblePeriodToReceiveRoyalties" xlink:href="rnac-20241231.xsd#rnac_EligiblePeriodToReceiveRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_EligiblePeriodToReceiveRoyalties" xlink:to="lab_rnac_EligiblePeriodToReceiveRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_7b1adbe6-753c-4625-8c04-e3020696468a_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_29a5b184-c7c7-4106-840c-70d1db9e21dc_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment not yet paid</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LaboratoryEquipmentMember_56c72b48-8f2b-4267-8098-1c38ec1ac1bb_terseLabel_en-US" xlink:label="lab_rnac_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_rnac_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_rnac_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_rnac_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_rnac_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LaboratoryEquipmentMember" xlink:href="rnac-20241231.xsd#rnac_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LaboratoryEquipmentMember" xlink:to="lab_rnac_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_381e539f-b01b-4b62-8926-3d60b9a4269f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ba7a1111-7e0b-4202-b50a-26ce76293e3d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_53a483f2-c91c-4bfe-a831-87a568cdaa7c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c119161c-e602-497f-a374-afe4fda4007e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock, $0.0001 par value; no and 548,375 shares authorized as of December 31, 2024 and December 31, 2023, respectively; no and 435,120.513 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4e32bb45-2a5e-44c6-93a1-658166752aec_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_29ef6fea-412d-4a7e-af17-2ef75bda3659_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e384677b-0aa2-4612-9c38-463d856eacef_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to unvested employee stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards_c3b59a1b-874c-4481-b564-48c29e78527c_terseLabel_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash payment made to the holders of stock options and restricted stock units</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards_label_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards</link:label>
    <link:label id="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards_documentation_en-US" xlink:label="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards" xlink:to="lab_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_18a3a445-208f-4f8e-8094-bd57479b19fb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_a0c4a3ed-ff30-4253-a2ce-5aa350f5d4cc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_13cc99cf-67c8-4811-b3f0-cc02f7247b7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_811e8756-d921-444a-8f8e-8ea9087881a0_terseLabel_en-US" xlink:label="lab_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_5ba363bf-dec1-4341-b363-37598585111b_negatedTotalLabel_en-US" xlink:label="lab_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_label_en-US" xlink:label="lab_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized, Including Opening Balance</link:label>
    <link:label id="lab_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_documentation_en-US" xlink:label="lab_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized, Including Opening Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:href="rnac-20241231.xsd#rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:to="lab_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_8bf8b6d9-bdbd-4aa6-a0aa-7c3c57023ec0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_b491af26-2304-445d-9f42-94754e1c46d5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_58bf8917-54cb-41b2-838d-9e022fd3bf03_terseLabel_en-US" xlink:label="lab_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares that did not automatically convert (in shares)</link:label>
    <link:label id="lab_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_label_en-US" xlink:label="lab_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares That Did Not Automatically Convert</link:label>
    <link:label id="lab_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_documentation_en-US" xlink:label="lab_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares That Did Not Automatically Convert</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert" xlink:href="rnac-20241231.xsd#rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert" xlink:to="lab_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e4603f9-3fa3-403f-8991-e33067a5c3c9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50273947-9fab-46b9-a41b-d54aa083b73b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fa824fa6-e95b-470c-b4b4-538c608e7eeb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_4aa578d7-2dc0-4e27-bb8c-2211078a54d3_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_b631bb70-da2e-4f36-933a-a13bfc3d263e_terseLabel_en-US" xlink:label="lab_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate amount of upfront and milestone-based payments</link:label>
    <link:label id="lab_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_label_en-US" xlink:label="lab_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Amount Of Upfront And Milestone Based Payments Paid</link:label>
    <link:label id="lab_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_documentation_en-US" xlink:label="lab_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Amount Of Upfront And Milestone Based Payments Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:href="rnac-20241231.xsd#rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:to="lab_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_97ee69b4-3566-4e3f-9a09-02170479a5d1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CommonWarrantMember_99f569dc-570e-4388-bed5-8736d5c613a1_terseLabel_en-US" xlink:label="lab_rnac_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Warrant</link:label>
    <link:label id="lab_rnac_CommonWarrantMember_label_en-US" xlink:label="lab_rnac_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Warrant [Member]</link:label>
    <link:label id="lab_rnac_CommonWarrantMember_documentation_en-US" xlink:label="lab_rnac_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CommonWarrantMember" xlink:href="rnac-20241231.xsd#rnac_CommonWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CommonWarrantMember" xlink:to="lab_rnac_CommonWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock_6d1f4cfb-1a5a-4f41-a9d6-301ba1309415_terseLabel_en-US" xlink:label="lab_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents, Marketable Securities and Investments</link:label>
    <link:label id="lab_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments [Policy Text Block]</link:label>
    <link:label id="lab_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" xlink:href="rnac-20241231.xsd#rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" xlink:to="lab_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3c5c9fdc-7f72-4602-93f9-ef91f07056e9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_OldCartestianMember_df53699a-0f10-4d10-ade1-b417c68b59f9_terseLabel_en-US" xlink:label="lab_rnac_OldCartestianMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Old Cartestian</link:label>
    <link:label id="lab_rnac_OldCartestianMember_label_en-US" xlink:label="lab_rnac_OldCartestianMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Old Cartestian [Member]</link:label>
    <link:label id="lab_rnac_OldCartestianMember_documentation_en-US" xlink:label="lab_rnac_OldCartestianMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Old Cartestian</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartestianMember" xlink:href="rnac-20241231.xsd#rnac_OldCartestianMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_OldCartestianMember" xlink:to="lab_rnac_OldCartestianMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_c23ca075-55ae-419c-b902-c971d4289885_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6760ffe0-020d-476d-9a2d-8f295b685f9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_OperatingLeaseBaseRent_cffe7417-908d-4349-9fa8-0050e102d695_terseLabel_en-US" xlink:label="lab_rnac_OperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base rent</link:label>
    <link:label id="lab_rnac_OperatingLeaseBaseRent_label_en-US" xlink:label="lab_rnac_OperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Base Rent</link:label>
    <link:label id="lab_rnac_OperatingLeaseBaseRent_documentation_en-US" xlink:label="lab_rnac_OperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLeaseBaseRent" xlink:href="rnac-20241231.xsd#rnac_OperatingLeaseBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_OperatingLeaseBaseRent" xlink:to="lab_rnac_OperatingLeaseBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c6f2ee27-b6cf-4a59-82f8-29ee73cc1358_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_LicenseAndOptionAgreementDevelopmentMilestone_4b9be148-013f-44e4-bccb-eaf1b8384847_terseLabel_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development milestone</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementDevelopmentMilestone_label_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Development Milestone</link:label>
    <link:label id="lab_rnac_LicenseAndOptionAgreementDevelopmentMilestone_documentation_en-US" xlink:label="lab_rnac_LicenseAndOptionAgreementDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement, Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementDevelopmentMilestone" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementDevelopmentMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_LicenseAndOptionAgreementDevelopmentMilestone" xlink:to="lab_rnac_LicenseAndOptionAgreementDevelopmentMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_A2019WarrantsMember_9510671b-ff97-48b6-b8e7-7b9e7429ee37_terseLabel_en-US" xlink:label="lab_rnac_A2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Warrants</link:label>
    <link:label id="lab_rnac_A2019WarrantsMember_label_en-US" xlink:label="lab_rnac_A2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Warrants [Member]</link:label>
    <link:label id="lab_rnac_A2019WarrantsMember_documentation_en-US" xlink:label="lab_rnac_A2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2019WarrantsMember" xlink:href="rnac-20241231.xsd#rnac_A2019WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_A2019WarrantsMember" xlink:to="lab_rnac_A2019WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0759b711-7d99-409d-a84c-9bc2e75b698c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock&#8209;based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7538cd81-1d5b-4c80-8860-2a4ac9fe0ba4_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_41a9daa9-ad23-4cac-9d5d-c55628706b04_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series A Preferred Stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e92d230a-27e5-4c29-9e64-63139436dbf7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ce77343c-ddf1-4b4c-ad0c-cd56d49bd5be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_cc03cc8f-0210-410c-8751-a1e662aeb02e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_c78d5f67-ea77-40c9-a98b-8f2986ae7336_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of office space leased</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised_242908c9-89dd-4929-b59b-1787f685f271_terseLabel_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, number of warrants exercised (in shares)</link:label>
    <link:label id="lab_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised_label_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:label id="lab_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="lab_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_31abb34f-0f8e-4816-8205-5797b740765b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_AccruedResearchAndDevelopmentCostsCurrent_8a6f361c-6364-4998-a8d0-b2ba3272f9cc_terseLabel_en-US" xlink:label="lab_rnac_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued external research and development costs</link:label>
    <link:label id="lab_rnac_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_rnac_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Costs Current</link:label>
    <link:label id="lab_rnac_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_rnac_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="rnac-20241231.xsd#rnac_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_rnac_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_0015f51a-0427-4e6d-a7ff-20aa380be5cb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_820d8c9a-278d-4761-87fa-57918c3d8ae2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_ed3c6efc-4704-45d6-9bd3-f2cc917724cc_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_7a679692-9b24-422c-8bce-9daface94b02_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Arrangements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bda047d1-6c01-4eb5-ba56-e4c7d1c2279f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeDomain_557f7d8d-4aa3-43ac-a11b-7c13a2edea24_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeDomain_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain" xlink:to="lab_us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_MoscowRussiaLeaseMember_578df173-e790-425b-a4d1-68e643aa099d_terseLabel_en-US" xlink:label="lab_rnac_MoscowRussiaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moscow Russia Lease</link:label>
    <link:label id="lab_rnac_MoscowRussiaLeaseMember_label_en-US" xlink:label="lab_rnac_MoscowRussiaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Moscow Russia Lease [Member]</link:label>
    <link:label id="lab_rnac_MoscowRussiaLeaseMember_documentation_en-US" xlink:label="lab_rnac_MoscowRussiaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Moscow Russia Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_MoscowRussiaLeaseMember" xlink:href="rnac-20241231.xsd#rnac_MoscowRussiaLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_MoscowRussiaLeaseMember" xlink:to="lab_rnac_MoscowRussiaLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_722608dc-9547-430f-8f2e-2e57c53042e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_60b30dae-a2dd-4029-8c0c-2877c7817893_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds_e6d7fa31-3ef7-4b67-8ff7-e98cf0395cec_terseLabel_en-US" xlink:label="lab_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate maximum gross sales proceeds</link:label>
    <link:label id="lab_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds_label_en-US" xlink:label="lab_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Maximum Gross Sales Proceeds</link:label>
    <link:label id="lab_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds_documentation_en-US" xlink:label="lab_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Maximum Gross Sales Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockAggregateMaximumGrossSalesProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds" xlink:to="lab_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_fc096e00-7972-4b36-a082-7ef2abbf4606_terseLabel_en-US" xlink:label="lab_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance Current Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance Current Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Assistance Current Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="rnac-20241231.xsd#rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a59ddfa7-6a0f-47d9-b2a9-18c477a3c67f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_065a478d-55c8-4e16-b935-5a35bb93c77d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e50a554-db04-4961-b25e-3907cca8a544_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67e4bffb-5574-42dd-bae5-a7b691e08e71_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2b6b82e4-06de-4757-9a89-dc6fb1bf13a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c3f6dfc1-8fce-46e4-bdf5-4243b0a97556_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_2aaeb7aa-ca8b-4921-a06a-f7987b342570_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e3c16865-fee0-4a6b-8664-1eeb65fcaec0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_874fdcc2-4c6e-472e-9cd5-265188c0cd22_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_18c73f2d-7c67-4ac0-a863-bc3559cd596c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_WarrantIssued_8aef6fe7-e5a7-4d00-9346-d4a7d38df9f2_terseLabel_en-US" xlink:label="lab_rnac_WarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant issued</link:label>
    <link:label id="lab_rnac_WarrantIssued_label_en-US" xlink:label="lab_rnac_WarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Issued</link:label>
    <link:label id="lab_rnac_WarrantIssued_documentation_en-US" xlink:label="lab_rnac_WarrantIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantIssued" xlink:href="rnac-20241231.xsd#rnac_WarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_WarrantIssued" xlink:to="lab_rnac_WarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_EmployeeStockPurchasePlan2016Member_ac254880-8e11-4aef-83f6-da1e3577d14e_terseLabel_en-US" xlink:label="lab_rnac_EmployeeStockPurchasePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_rnac_EmployeeStockPurchasePlan2016Member_label_en-US" xlink:label="lab_rnac_EmployeeStockPurchasePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan 2016 [Member]</link:label>
    <link:label id="lab_rnac_EmployeeStockPurchasePlan2016Member_documentation_en-US" xlink:label="lab_rnac_EmployeeStockPurchasePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent information pertaining to the 2016 Employee Stock Purchase Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EmployeeStockPurchasePlan2016Member" xlink:href="rnac-20241231.xsd#rnac_EmployeeStockPurchasePlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_EmployeeStockPurchasePlan2016Member" xlink:to="lab_rnac_EmployeeStockPurchasePlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_db18c124-211d-403c-a68f-70a3b833f0d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_BiogenM.A.Inc.Member_6a178be5-4aed-4455-8a64-5ab3519366b7_terseLabel_en-US" xlink:label="lab_rnac_BiogenM.A.Inc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen M.A., Inc.</link:label>
    <link:label id="lab_rnac_BiogenM.A.Inc.Member_label_en-US" xlink:label="lab_rnac_BiogenM.A.Inc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen M.A., Inc. [Member]</link:label>
    <link:label id="lab_rnac_BiogenM.A.Inc.Member_documentation_en-US" xlink:label="lab_rnac_BiogenM.A.Inc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen M.A., Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BiogenM.A.Inc.Member" xlink:href="rnac-20241231.xsd#rnac_BiogenM.A.Inc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_BiogenM.A.Inc.Member" xlink:to="lab_rnac_BiogenM.A.Inc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8976fc6a-b343-4b94-86c7-6fbdb49a014c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8a933b53-bb27-4125-84c0-c7c8108b2727_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a17fc33e-eea7-4476-96c4-2ec4bb71ff8a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_StockIssuedDuringWarrantedCanceledPricePerShare_46b076c7-5dba-4d99-bcb0-d48c948ab805_terseLabel_en-US" xlink:label="lab_rnac_StockIssuedDuringWarrantedCanceledPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_rnac_StockIssuedDuringWarrantedCanceledPricePerShare_label_en-US" xlink:label="lab_rnac_StockIssuedDuringWarrantedCanceledPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During, Warranted Canceled, Price Per Share</link:label>
    <link:label id="lab_rnac_StockIssuedDuringWarrantedCanceledPricePerShare_documentation_en-US" xlink:label="lab_rnac_StockIssuedDuringWarrantedCanceledPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During, Warranted Canceled, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringWarrantedCanceledPricePerShare" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringWarrantedCanceledPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_StockIssuedDuringWarrantedCanceledPricePerShare" xlink:to="lab_rnac_StockIssuedDuringWarrantedCanceledPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8c0af422-616c-41f6-93e9-ee4ca04f7c19_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b5361b27-a3f0-4ff4-8eb9-a8a6b7898457_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent_b6ba96fc-0d26-49b0-b286-18a2bd49bf6f_terseLabel_en-US" xlink:label="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent value right liability</link:label>
    <link:label id="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent_label_en-US" xlink:label="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Fair Value Of Contingent Value Right Liability, Percent</link:label>
    <link:label id="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent_documentation_en-US" xlink:label="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Fair Value Of Contingent Value Right Liability, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent" xlink:href="rnac-20241231.xsd#rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent" xlink:to="lab_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf464d12-2b07-4b44-b692-e4cf22dbf776_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_c8ec6491-350c-40c1-9315-3b4badeac1ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_2e76ce47-1ca8-4efe-a361-7c2aa12af20c_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_fb3cbff6-e27d-4a30-9aa1-fdcae6fcbaee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_905b8220-6c01-47e3-9f38-b15a531c75be_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>rnac-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f87b4d67-655c-40f8-bf99-5c1eb72d37a4,g:ec248d9b-f7a4-4998-8c2a-3c79ab383104-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="rnac-20241231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_05dacb60-1e1c-4e86-8487-4d9e44adee5a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_DocumentType_05dacb60-1e1c-4e86-8487-4d9e44adee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6173b865-c6cb-4eae-afc2-bdcd07c663ec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_DocumentAnnualReport_6173b865-c6cb-4eae-afc2-bdcd07c663ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a10fdccf-53be-469b-918f-6720ea9e8c56" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_DocumentPeriodEndDate_a10fdccf-53be-469b-918f-6720ea9e8c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_32b1ae1b-9014-4b90-ba59-efdc00b46713" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_CurrentFiscalYearEndDate_32b1ae1b-9014-4b90-ba59-efdc00b46713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d5ae9102-d32e-4b0d-8ee8-f64a1c131152" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_DocumentTransitionReport_d5ae9102-d32e-4b0d-8ee8-f64a1c131152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a7b5c6d1-8df3-42a3-9deb-eceb2c2de677" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityFileNumber_a7b5c6d1-8df3-42a3-9deb-eceb2c2de677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2b034656-0094-4506-80db-0430973932cb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityRegistrantName_2b034656-0094-4506-80db-0430973932cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a408701d-ac2e-4392-8c9b-483cf6a0440e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a408701d-ac2e-4392-8c9b-483cf6a0440e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_606e9753-0f46-4872-86d4-38eaeeb52b49" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityTaxIdentificationNumber_606e9753-0f46-4872-86d4-38eaeeb52b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_30454cc5-93b7-4103-8cd2-dad69f912c64" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityAddressAddressLine1_30454cc5-93b7-4103-8cd2-dad69f912c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b0105b8d-504b-4317-a54b-50d450766d25" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityAddressCityOrTown_b0105b8d-504b-4317-a54b-50d450766d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9af961f8-1a4d-4fc6-be53-01f141e3f4a3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityAddressStateOrProvince_9af961f8-1a4d-4fc6-be53-01f141e3f4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_946cd51d-10e2-4a4d-a0c8-e05a7dbe546c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityAddressPostalZipCode_946cd51d-10e2-4a4d-a0c8-e05a7dbe546c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_55b1176f-48a9-4dd5-afbd-1d93e8c2cc10" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_CityAreaCode_55b1176f-48a9-4dd5-afbd-1d93e8c2cc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_26b29184-2f8f-402d-afd2-048503094967" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_LocalPhoneNumber_26b29184-2f8f-402d-afd2-048503094967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d872a952-10ad-455f-9482-45960a2ad83f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_Security12bTitle_d872a952-10ad-455f-9482-45960a2ad83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b72846a8-26b9-42fb-b6bb-57fcc2497a7e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_TradingSymbol_b72846a8-26b9-42fb-b6bb-57fcc2497a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d2239de5-e7da-47f7-9598-d4d82ead6efe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_SecurityExchangeName_d2239de5-e7da-47f7-9598-d4d82ead6efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0a2756b0-0899-40d3-b3b0-ac68229d28d8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0a2756b0-0899-40d3-b3b0-ac68229d28d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_2e23bc0f-bc2e-4790-82f5-e70083fe6cf9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityVoluntaryFilers_2e23bc0f-bc2e-4790-82f5-e70083fe6cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e36fede3-ebe4-4495-996a-fa96ac56040c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityCurrentReportingStatus_e36fede3-ebe4-4495-996a-fa96ac56040c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3f2d8d59-879b-4278-ad5e-7ebb81f016ae" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityInteractiveDataCurrent_3f2d8d59-879b-4278-ad5e-7ebb81f016ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0477c186-30ce-4a9a-a96c-95dee4a50ce5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityFilerCategory_0477c186-30ce-4a9a-a96c-95dee4a50ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9b1cb5dd-5e6b-4d58-96bd-8962d7d6f0c4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntitySmallBusiness_9b1cb5dd-5e6b-4d58-96bd-8962d7d6f0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_407a1b99-19ea-4f09-8c3f-62415aa7042f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityEmergingGrowthCompany_407a1b99-19ea-4f09-8c3f-62415aa7042f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_625b52d5-8e37-4621-a690-1eb6c3d86be8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_IcfrAuditorAttestationFlag_625b52d5-8e37-4621-a690-1eb6c3d86be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_75dce67e-0560-4110-850c-4eaad467a89f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_75dce67e-0560-4110-850c-4eaad467a89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8403c7cd-ca1b-4bd8-b89e-dae3c6118073" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityShellCompany_8403c7cd-ca1b-4bd8-b89e-dae3c6118073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_b3bff86f-b776-4686-a766-155733690cb9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityPublicFloat_b3bff86f-b776-4686-a766-155733690cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e69c5ca1-e068-4158-9636-41e3989d0338" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e69c5ca1-e068-4158-9636-41e3989d0338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2c480dd3-d82e-4027-b9e4-fbf1c79d899a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2c480dd3-d82e-4027-b9e4-fbf1c79d899a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c5bd76f2-bc36-4f47-81a8-4b190d072bc6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_AmendmentFlag_c5bd76f2-bc36-4f47-81a8-4b190d072bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3788f0a2-0ecd-42c4-9aa7-0c8f6781609d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_DocumentFiscalYearFocus_3788f0a2-0ecd-42c4-9aa7-0c8f6781609d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ee886062-bb35-4dc1-a4b2-6b13d5671225" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ee886062-bb35-4dc1-a4b2-6b13d5671225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0a87cd87-1dd6-4fd8-83d9-2dfc74c83644" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f94fac4a-b664-45f5-a575-b18c49840371" xlink:to="loc_dei_EntityCentralIndexKey_0a87cd87-1dd6-4fd8-83d9-2dfc74c83644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/AuditInformation" xlink:type="simple" xlink:href="rnac-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AuditInformationAbstract_bc5fcb04-1723-478c-b45b-04c24d9208f3" xlink:href="rnac-20241231.xsd#rnac_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_be3f6c9d-f18b-4f5e-8074-37ae064ac12f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_AuditInformationAbstract_bc5fcb04-1723-478c-b45b-04c24d9208f3" xlink:to="loc_dei_AuditorFirmId_be3f6c9d-f18b-4f5e-8074-37ae064ac12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_5a1425f8-3199-4d08-a334-424ae91206a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_AuditInformationAbstract_bc5fcb04-1723-478c-b45b-04c24d9208f3" xlink:to="loc_dei_AuditorName_5a1425f8-3199-4d08-a334-424ae91206a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_27083c7f-01f1-43b5-8769-8f22fc32e62d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_AuditInformationAbstract_bc5fcb04-1723-478c-b45b-04c24d9208f3" xlink:to="loc_dei_AuditorLocation_27083c7f-01f1-43b5-8769-8f22fc32e62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4791ccee-a732-4ea3-a4db-d5327ba7c3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_af192cea-417b-4030-9820-28a447206c24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4791ccee-a732-4ea3-a4db-d5327ba7c3bb" xlink:to="loc_us-gaap_StatementTable_af192cea-417b-4030-9820-28a447206c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1965d02b-ca99-4ad0-b391-076ef1329b06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_af192cea-417b-4030-9820-28a447206c24" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1965d02b-ca99-4ad0-b391-076ef1329b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2dcee0ac-d7e5-4bda-b706-9fcc92bd962c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1965d02b-ca99-4ad0-b391-076ef1329b06" xlink:to="loc_us-gaap_ClassOfStockDomain_2dcee0ac-d7e5-4bda-b706-9fcc92bd962c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_d29245c3-eae4-4ba4-8ac5-cf4df37f0720" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2dcee0ac-d7e5-4bda-b706-9fcc92bd962c" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_d29245c3-eae4-4ba4-8ac5-cf4df37f0720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_3cdf34c7-a34c-47b2-9632-907f5e9b174c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2dcee0ac-d7e5-4bda-b706-9fcc92bd962c" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_3cdf34c7-a34c-47b2-9632-907f5e9b174c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f5a2abbe-0763-4140-884c-ff14cacf74e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_af192cea-417b-4030-9820-28a447206c24" xlink:to="loc_us-gaap_StatementLineItems_f5a2abbe-0763-4140-884c-ff14cacf74e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_43cc2de4-b3c6-44b8-8afb-b6107e8a8358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5a2abbe-0763-4140-884c-ff14cacf74e7" xlink:to="loc_us-gaap_AssetsAbstract_43cc2de4-b3c6-44b8-8afb-b6107e8a8358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_43cc2de4-b3c6-44b8-8afb-b6107e8a8358" xlink:to="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f89f13b-ce0e-49bf-902c-87143e208a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f89f13b-ce0e-49bf-902c-87143e208a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f1c45e38-c415-4ad0-acfe-729ddb0087b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f1c45e38-c415-4ad0-acfe-729ddb0087b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5b61d0fd-575f-4834-a89c-67851709fda0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5b61d0fd-575f-4834-a89c-67851709fda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37491621-c321-4f3c-875c-555c5ffde63a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37491621-c321-4f3c-875c-555c5ffde63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b68a166c-e39f-4516-9e5e-fba0439719f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_749303f8-9181-42e5-bd98-178de9f87966" xlink:to="loc_us-gaap_AssetsCurrent_b68a166c-e39f-4516-9e5e-fba0439719f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_43cc2de4-b3c6-44b8-8afb-b6107e8a8358" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c962cbc4-6d48-4c46-af18-ef15241e254c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c962cbc4-6d48-4c46-af18-ef15241e254c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f162d1c-c8a1-4255-a2c5-21b7a7915beb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f162d1c-c8a1-4255-a2c5-21b7a7915beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_eba6e427-79e7-4e92-9f5d-abde1a1e60cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_eba6e427-79e7-4e92-9f5d-abde1a1e60cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_803c9c53-58a1-4126-93c5-ba185411fbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_Goodwill_803c9c53-58a1-4126-93c5-ba185411fbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f1c6a586-8d18-4b3d-abd3-f32b65657f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f1c6a586-8d18-4b3d-abd3-f32b65657f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1851874a-04d0-4d33-bd3b-acd2f2abf875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1851874a-04d0-4d33-bd3b-acd2f2abf875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4852bd76-a666-4ed4-879d-df36cd5e1061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0dc02613-8053-44ed-95f3-28e6dee52773" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4852bd76-a666-4ed4-879d-df36cd5e1061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4afc226c-c4c6-4788-91aa-dd50a42bb601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_43cc2de4-b3c6-44b8-8afb-b6107e8a8358" xlink:to="loc_us-gaap_Assets_4afc226c-c4c6-4788-91aa-dd50a42bb601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5a2abbe-0763-4140-884c-ff14cacf74e7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a03a332b-26dc-4684-9434-55bca1e6112d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_AccountsPayableCurrent_a03a332b-26dc-4684-9434-55bca1e6112d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_d019a3d3-4eed-4f6b-b940-4eb53aed9594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_d019a3d3-4eed-4f6b-b940-4eb53aed9594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_34c45bbc-7264-4034-9ad2-7a1fda36ea96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_34c45bbc-7264-4034-9ad2-7a1fda36ea96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d46cb7ea-e19b-4990-a09e-1a4f8f464fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d46cb7ea-e19b-4990-a09e-1a4f8f464fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantsAndRightsOutstandingCurrent_0a3f4a90-ae44-487d-ba49-033d8fd1987c" xlink:href="rnac-20241231.xsd#rnac_WarrantsAndRightsOutstandingCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_rnac_WarrantsAndRightsOutstandingCurrent_0a3f4a90-ae44-487d-ba49-033d8fd1987c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityCurrent_f5b392fc-68c9-4642-b644-903c7c04d3b3" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_rnac_ContingentValueRightLiabilityCurrent_f5b392fc-68c9-4642-b644-903c7c04d3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_fd8f58f3-d95d-453c-bf9e-03ceb5ad3c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_fd8f58f3-d95d-453c-bf9e-03ceb5ad3c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_15f97b0f-7221-4b0b-901a-07791cf0718b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cbad051d-7c3c-42c2-adb7-3ebc406481ea" xlink:to="loc_us-gaap_LiabilitiesCurrent_15f97b0f-7221-4b0b-901a-07791cf0718b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_772c5e0b-9961-4050-861a-3f02e2fea16c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_772c5e0b-9961-4050-861a-3f02e2fea16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c4fb384-5af7-456b-87db-5e2e9d9b4094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c4fb384-5af7-456b-87db-5e2e9d9b4094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantsAndRightsOutstandingNoncurrent_2955661b-8a8c-44e8-adb7-e038a28564a6" xlink:href="rnac-20241231.xsd#rnac_WarrantsAndRightsOutstandingNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:to="loc_rnac_WarrantsAndRightsOutstandingNoncurrent_2955661b-8a8c-44e8-adb7-e038a28564a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityNoncurrent_e244776a-72fa-457d-99eb-7c567424115e" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:to="loc_rnac_ContingentValueRightLiabilityNoncurrent_e244776a-72fa-457d-99eb-7c567424115e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5a19cee6-e730-46be-b48d-2475d7debfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_d1b75054-a9c8-4d7b-bf5f-11acf40c4baa" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5a19cee6-e730-46be-b48d-2475d7debfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_21c09e67-8f74-40e4-bacd-2715ae63f753" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_Liabilities_21c09e67-8f74-40e4-bacd-2715ae63f753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7254616f-5947-43d5-ba65-56e808693d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7254616f-5947-43d5-ba65-56e808693d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e3ee050a-b419-46a3-a6b9-2ee39293d3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e3ee050a-b419-46a3-a6b9-2ee39293d3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_a1280cb8-1ca2-4d4f-bee9-fed72395523c" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_a1280cb8-1ca2-4d4f-bee9-fed72395523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c0a3d4bd-944f-41fe-899d-6cb73d6711b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_PreferredStockValue_c0a3d4bd-944f-41fe-899d-6cb73d6711b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_853402d6-e21c-4262-8534-c98ee1cc4525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_CommonStockValue_853402d6-e21c-4262-8534-c98ee1cc4525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ba380616-0d88-4bea-9f7d-6dc7ff9d5aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ba380616-0d88-4bea-9f7d-6dc7ff9d5aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bbae2f11-bae0-4b95-8fdc-430ab574e302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bbae2f11-bae0-4b95-8fdc-430ab574e302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cb4bb74c-2517-4e57-a23c-f51d01df4873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cb4bb74c-2517-4e57-a23c-f51d01df4873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0d67d66-66b1-4383-8687-6065c8bdab87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_434f7a66-7d02-458d-bfc7-ffcb27a1c8cd" xlink:to="loc_us-gaap_StockholdersEquity_c0d67d66-66b1-4383-8687-6065c8bdab87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ed46011-d5d8-4b85-97e4-13d62feb42ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ddadedb-b41e-4709-8a2a-c534a74550cc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ed46011-d5d8-4b85-97e4-13d62feb42ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1b9136fe-7585-4e83-8ca0-5fd48d14ec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffebd99e-13d0-44f8-a8f3-27aa8b1df612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1b9136fe-7585-4e83-8ca0-5fd48d14ec3c" xlink:to="loc_us-gaap_StatementTable_ffebd99e-13d0-44f8-a8f3-27aa8b1df612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2ae75085-9fd6-43e6-9911-e795ee2b0273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffebd99e-13d0-44f8-a8f3-27aa8b1df612" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2ae75085-9fd6-43e6-9911-e795ee2b0273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa5bda28-4171-4baf-9dec-8fef82b188d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ae75085-9fd6-43e6-9911-e795ee2b0273" xlink:to="loc_us-gaap_ClassOfStockDomain_aa5bda28-4171-4baf-9dec-8fef82b188d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b8dbc6cc-673c-47c6-a5be-a3c33924ff12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_aa5bda28-4171-4baf-9dec-8fef82b188d0" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b8dbc6cc-673c-47c6-a5be-a3c33924ff12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_bedea882-5fdb-439a-bf28-2f3e82a46e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_aa5bda28-4171-4baf-9dec-8fef82b188d0" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_bedea882-5fdb-439a-bf28-2f3e82a46e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffebd99e-13d0-44f8-a8f3-27aa8b1df612" xlink:to="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3c34d4c7-fba6-4fe9-8af4-c6eb0abc886b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3c34d4c7-fba6-4fe9-8af4-c6eb0abc886b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_63e3e9fe-5a0f-4193-b90c-878453df0fab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_63e3e9fe-5a0f-4193-b90c-878453df0fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_4b85f802-6e2a-43c1-9cb3-6a198c719c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_4b85f802-6e2a-43c1-9cb3-6a198c719c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_aee98e35-5c74-4c3b-8760-c009b98b9503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_aee98e35-5c74-4c3b-8760-c009b98b9503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9058dcf3-d73d-4b74-84e0-e391001920d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9058dcf3-d73d-4b74-84e0-e391001920d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_af68361b-9b51-44d0-a454-6cb79c629bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_af68361b-9b51-44d0-a454-6cb79c629bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ee6cca43-7f2b-4719-8aae-682c6d541dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ee6cca43-7f2b-4719-8aae-682c6d541dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a85ee156-06dd-4c01-a1fe-23780d079f76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a85ee156-06dd-4c01-a1fe-23780d079f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_135259fd-5be0-4a19-a426-2032e284c00c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_135259fd-5be0-4a19-a426-2032e284c00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9ab659c2-dff5-4baa-bedf-9cd2c57e4734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9ab659c2-dff5-4baa-bedf-9cd2c57e4734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c57a31c6-ddb3-49f0-8858-f2b8d63d8607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_CommonStockSharesIssued_c57a31c6-ddb3-49f0-8858-f2b8d63d8607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cb9e6e34-b969-4187-b82d-4ebfe1abaaef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0aa48d35-2d19-45c3-b578-d29116454823" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cb9e6e34-b969-4187-b82d-4ebfe1abaaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_515ff7a2-ddaa-462d-8960-9b18cbf89a61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_RevenuesAbstract_515ff7a2-ddaa-462d-8960-9b18cbf89a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6f38826-8d9c-45ec-be5c-d4ec79396934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_515ff7a2-ddaa-462d-8960-9b18cbf89a61" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6f38826-8d9c-45ec-be5c-d4ec79396934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_73c334f5-041c-4b20-ad39-8e9af64a6def" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_515ff7a2-ddaa-462d-8960-9b18cbf89a61" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_73c334f5-041c-4b20-ad39-8e9af64a6def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d960195c-d970-4ccb-9e31-e897d01bcec3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_515ff7a2-ddaa-462d-8960-9b18cbf89a61" xlink:to="loc_us-gaap_Revenues_d960195c-d970-4ccb-9e31-e897d01bcec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_70d9f661-fedc-4a32-b83d-c674dcfcf2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_CostOfRevenueAbstract_70d9f661-fedc-4a32-b83d-c674dcfcf2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4f25a087-4741-4bbc-9300-6fcfb15079d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70d9f661-fedc-4a32-b83d-c674dcfcf2e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4f25a087-4741-4bbc-9300-6fcfb15079d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0cf2362f-f3f2-40d8-9144-85389d04f766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70d9f661-fedc-4a32-b83d-c674dcfcf2e9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0cf2362f-f3f2-40d8-9144-85389d04f766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0f8ce645-e67f-45e3-b1f1-cc2367f49eba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70d9f661-fedc-4a32-b83d-c674dcfcf2e9" xlink:to="loc_us-gaap_AssetImpairmentCharges_0f8ce645-e67f-45e3-b1f1-cc2367f49eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9d9b6415-f479-4e7e-87d2-f2fe6556a3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70d9f661-fedc-4a32-b83d-c674dcfcf2e9" xlink:to="loc_us-gaap_OperatingExpenses_9d9b6415-f479-4e7e-87d2-f2fe6556a3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2e8f1be4-3ace-4099-9fd4-b4bef3258199" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_OperatingIncomeLoss_2e8f1be4-3ace-4099-9fd4-b4bef3258199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_af3a11be-b5b1-4a4b-9d4f-f3fcbfa9c597" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_af3a11be-b5b1-4a4b-9d4f-f3fcbfa9c597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a09013cb-138f-4ea2-897d-275817d8a2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a09013cb-138f-4ea2-897d-275817d8a2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_7759e96d-090d-476d-806d-57706d794029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_InterestExpenseNonoperating_7759e96d-090d-476d-806d-57706d794029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_f0860cb3-8e47-4a4e-909e-a7734d01acc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_f0860cb3-8e47-4a4e-909e-a7734d01acc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_FairValueAdjustmentOfContingentValueRightLiability_ff73660e-5238-4f8c-ae7b-1135f4a2c406" xlink:href="rnac-20241231.xsd#rnac_FairValueAdjustmentOfContingentValueRightLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_rnac_FairValueAdjustmentOfContingentValueRightLiability_ff73660e-5238-4f8c-ae7b-1135f4a2c406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2cabe85e-e6e8-4917-a89c-3a7c26416390" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2cabe85e-e6e8-4917-a89c-3a7c26416390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c666be8e-2d80-4177-80d1-b7f00736c43d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c666be8e-2d80-4177-80d1-b7f00736c43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a4d434c5-db15-49bf-a719-2080e6dda976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a4d434c5-db15-49bf-a719-2080e6dda976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a26f1ce7-ede4-4232-9411-748b66a6063d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a26f1ce7-ede4-4232-9411-748b66a6063d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_22bb0ec1-5375-483f-88d1-e35b7eed23fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_NetIncomeLoss_22bb0ec1-5375-483f-88d1-e35b7eed23fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_95541380-6f0e-4625-a4e4-526f93c7e717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_95541380-6f0e-4625-a4e4-526f93c7e717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d3cd223c-5b09-4b26-a445-8d901b858021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_95541380-6f0e-4625-a4e4-526f93c7e717" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d3cd223c-5b09-4b26-a445-8d901b858021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5c2ad1b6-e8a4-45e2-a8e2-283f169a6eac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_95541380-6f0e-4625-a4e4-526f93c7e717" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5c2ad1b6-e8a4-45e2-a8e2-283f169a6eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1f10cf70-1114-4a7d-84cb-f28bfdab085d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1f10cf70-1114-4a7d-84cb-f28bfdab085d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_74422d08-825f-41c5-a2b8-7412a2e4d18c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_EarningsPerShareAbstract_74422d08-825f-41c5-a2b8-7412a2e4d18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7fad02fb-5fe8-46c0-af30-f160d53f3e52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_74422d08-825f-41c5-a2b8-7412a2e4d18c" xlink:to="loc_us-gaap_EarningsPerShareBasic_7fad02fb-5fe8-46c0-af30-f160d53f3e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_da481eaa-c537-4768-8ed5-c17478502940" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_74422d08-825f-41c5-a2b8-7412a2e4d18c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_da481eaa-c537-4768-8ed5-c17478502940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_882b046c-9ee2-4e34-9135-9ac8f39184de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4dd9f34f-3cfb-4167-8bed-60eb476020f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_882b046c-9ee2-4e34-9135-9ac8f39184de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9fe3827c-9623-491c-b8f1-49c2d42a503e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_882b046c-9ee2-4e34-9135-9ac8f39184de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9fe3827c-9623-491c-b8f1-49c2d42a503e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c360e29d-84a5-4c2d-a711-67a7c730262e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_882b046c-9ee2-4e34-9135-9ac8f39184de" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c360e29d-84a5-4c2d-a711-67a7c730262e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f9b64d6c-022a-49fc-8c13-01bd643e1097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f9b64d6c-022a-49fc-8c13-01bd643e1097" xlink:to="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6c823b6b-cc5a-429f-b455-10c905a37b26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6c823b6b-cc5a-429f-b455-10c905a37b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6c823b6b-cc5a-429f-b455-10c905a37b26" xlink:to="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_034a35f9-4279-4a48-89ba-742b0c63c7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:to="loc_us-gaap_PreferredStockMember_034a35f9-4279-4a48-89ba-742b0c63c7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9d6cf825-aa6a-4c52-8479-108244f931ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:to="loc_us-gaap_CommonStockMember_9d6cf825-aa6a-4c52-8479-108244f931ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1b948ab2-e5c4-4b9b-bfd0-167d94dd7dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1b948ab2-e5c4-4b9b-bfd0-167d94dd7dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_eca76048-f935-42b5-ac10-55e620fcb5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:to="loc_us-gaap_RetainedEarningsMember_eca76048-f935-42b5-ac10-55e620fcb5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_205a182a-891c-4881-9c4b-21540e211b37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d2b75f0a-8f49-4207-a924-9c51cdb298d8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_205a182a-891c-4881-9c4b-21540e211b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ce59b78f-e6af-4454-9209-2eb7b837ca12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ce59b78f-e6af-4454-9209-2eb7b837ca12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_109b8f19-fe2c-46aa-ad84-a9102ea6df8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ce59b78f-e6af-4454-9209-2eb7b837ca12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_109b8f19-fe2c-46aa-ad84-a9102ea6df8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacementOneMember_0c58a1e9-355c-4f19-bf4f-4e380b41a3df" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacementOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_109b8f19-fe2c-46aa-ad84-a9102ea6df8e" xlink:to="loc_rnac_PrivatePlacementOneMember_0c58a1e9-355c-4f19-bf4f-4e380b41a3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacementTwoMember_4f572093-11db-4871-b34c-0fe1d1c251d6" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacementTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_109b8f19-fe2c-46aa-ad84-a9102ea6df8e" xlink:to="loc_rnac_PrivatePlacementTwoMember_4f572093-11db-4871-b34c-0fe1d1c251d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1c353221-9650-43bf-99cd-285f9323a1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1c353221-9650-43bf-99cd-285f9323a1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_402e94d8-b98e-4435-8bf0-6a284c2b5bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c353221-9650-43bf-99cd-285f9323a1c8" xlink:to="loc_us-gaap_ClassOfStockDomain_402e94d8-b98e-4435-8bf0-6a284c2b5bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_6f315a21-16e5-43ef-960e-9b3c84045fde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_402e94d8-b98e-4435-8bf0-6a284c2b5bc6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_6f315a21-16e5-43ef-960e-9b3c84045fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_340e0353-f1ad-4de7-a77a-2ea8c53e60f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_402e94d8-b98e-4435-8bf0-6a284c2b5bc6" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_340e0353-f1ad-4de7-a77a-2ea8c53e60f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_717f60e9-d8b5-4dc4-9a47-a62d1069a978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_64ef1e7e-72ea-48e3-86ea-1cd22637b859" xlink:to="loc_us-gaap_StatementLineItems_717f60e9-d8b5-4dc4-9a47-a62d1069a978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_717f60e9-d8b5-4dc4-9a47-a62d1069a978" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_c5bc7b98-221e-49b4-9a99-cd09afb8a3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_c5bc7b98-221e-49b4-9a99-cd09afb8a3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6ef81634-4893-435c-8783-e89631751987" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6ef81634-4893-435c-8783-e89631751987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityStockIssuedDuringPeriodShares_1ac24c69-3629-4cd8-b0ac-dfa0161a985b" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityStockIssuedDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_rnac_TemporaryEquityStockIssuedDuringPeriodShares_1ac24c69-3629-4cd8-b0ac-dfa0161a985b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5b795f8d-5218-4f87-86cd-8e3d04221404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5b795f8d-5218-4f87-86cd-8e3d04221404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares_e6fd4111-7d2d-4c18-b6a9-4192ff0bd1dc" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares_e6fd4111-7d2d-4c18-b6a9-4192ff0bd1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue_152d9a78-46b1-4037-9e65-d9a5a458a5b0" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue_152d9a78-46b1-4037-9e65-d9a5a458a5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares_b10c963b-7cfa-483d-be98-786036f6d58e" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares_b10c963b-7cfa-483d-be98-786036f6d58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity_921bcefa-337c-4366-904e-c50e5f7b533e" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity_921bcefa-337c-4366-904e-c50e5f7b533e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_a9f8e79a-543e-46ee-8aa3-82e934711238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_a9f8e79a-543e-46ee-8aa3-82e934711238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_21d4d863-5ff2-4281-866f-ac0caea2b7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7a7d60b9-f5e2-4a0b-9a2e-a0ef0610dfec" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_21d4d863-5ff2-4281-866f-ac0caea2b7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:href="rnac-20241231.xsd#rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_717f60e9-d8b5-4dc4-9a47-a62d1069a978" xlink:to="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_c7bb6705-d57c-4022-b69f-a97fa4f711e0" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:to="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_c7bb6705-d57c-4022-b69f-a97fa4f711e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger_464e97ac-55e7-44e7-9590-539e9e408c4d" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:to="loc_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger_464e97ac-55e7-44e7-9590-539e9e408c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition_6f60e4f8-d14c-4299-b3ef-8d006e5b123e" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:to="loc_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition_6f60e4f8-d14c-4299-b3ef-8d006e5b123e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity_cc37122a-4f4c-43e2-a179-a20f64c164d1" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:to="loc_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity_cc37122a-4f4c-43e2-a179-a20f64c164d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_f48e71b6-a86d-494b-a4ea-80614b10588b" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward_bded37cc-d194-4298-a4ba-8201d17a49cf" xlink:to="loc_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent_f48e71b6-a86d-494b-a4ea-80614b10588b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_717f60e9-d8b5-4dc4-9a47-a62d1069a978" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4c4d4b57-c26e-4616-8954-c0d698379302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4c4d4b57-c26e-4616-8954-c0d698379302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_62dd9431-22af-4427-b96f-4dff5a771c74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockholdersEquity_62dd9431-22af-4427-b96f-4dff5a771c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a6dca682-4b25-4f14-8884-b337cfd41deb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a6dca682-4b25-4f14-8884-b337cfd41deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TransferOfTemporaryEquityToPermanentEquityShares_5072c3ab-95d3-4d65-bfd8-cf90bce2847f" xlink:href="rnac-20241231.xsd#rnac_TransferOfTemporaryEquityToPermanentEquityShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_TransferOfTemporaryEquityToPermanentEquityShares_5072c3ab-95d3-4d65-bfd8-cf90bce2847f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TransferOfTemporaryEquityToPermanentEquity_aa3c4b84-dc2a-4cb2-8765-e1d4b701b16f" xlink:href="rnac-20241231.xsd#rnac_TransferOfTemporaryEquityToPermanentEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_TransferOfTemporaryEquityToPermanentEquity_aa3c4b84-dc2a-4cb2-8765-e1d4b701b16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ca92aaca-1d1b-4536-a027-e66eb2ec3a96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ca92aaca-1d1b-4536-a027-e66eb2ec3a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ff170475-d1a0-4164-9bb0-ff065a3f0c27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ff170475-d1a0-4164-9bb0-ff065a3f0c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a17a7280-5b45-4d5e-b19d-7dd4b15e5c90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a17a7280-5b45-4d5e-b19d-7dd4b15e5c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e032d827-ea2f-48da-830b-ca538abbad94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e032d827-ea2f-48da-830b-ca538abbad94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_61cd1e7c-983e-4045-adef-997ffcb84e45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_61cd1e7c-983e-4045-adef-997ffcb84e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_af5f863e-e651-4cf8-8577-8644ac3a7438" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_af5f863e-e651-4cf8-8577-8644ac3a7438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b2cbcf5c-1c01-4a45-b193-04cabb3985e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b2cbcf5c-1c01-4a45-b193-04cabb3985e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b1771d2-9fc6-442b-a702-af60d0af74d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b1771d2-9fc6-442b-a702-af60d0af74d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_593c9f4b-20fd-4880-9316-a0a7c6b8a0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_593c9f4b-20fd-4880-9316-a0a7c6b8a0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger_5753cca4-e5b0-4d3e-b09d-fd776a4380e8" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger_5753cca4-e5b0-4d3e-b09d-fd776a4380e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_883d7ea2-1026-459a-bec6-6a5dcee70691" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_883d7ea2-1026-459a-bec6-6a5dcee70691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger_0bd1d0ed-37f1-46a7-a5a2-a5ce391e454a" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger_0bd1d0ed-37f1-46a7-a5a2-a5ce391e454a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement_e86f0b0d-eeb5-4b0e-a8db-521fa05f4a82" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement_e86f0b0d-eeb5-4b0e-a8db-521fa05f4a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement_216954b3-1114-467b-a5d5-61c4ea50d094" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement_216954b3-1114-467b-a5d5-61c4ea50d094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_80d9558d-e3a8-49b0-9fd1-02b5567ece18" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_80d9558d-e3a8-49b0-9fd1-02b5567ece18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights_8be9aac3-7f6b-4864-b5bb-732446aa17d6" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights_8be9aac3-7f6b-4864-b5bb-732446aa17d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised_52d545b3-d521-4eff-a1aa-d4bdf10a67f8" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised_52d545b3-d521-4eff-a1aa-d4bdf10a67f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised_6fd9da21-64e6-4d7e-a5a9-d6fb98d57485" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised_6fd9da21-64e6-4d7e-a5a9-d6fb98d57485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3c89e0ee-ef4d-4f14-82b2-5e6a87b89f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3c89e0ee-ef4d-4f14-82b2-5e6a87b89f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6720fc69-d961-482b-858e-d004b4b00a21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6720fc69-d961-482b-858e-d004b4b00a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c43ff4c5-f8be-49b5-a7ad-a381a026edfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c43ff4c5-f8be-49b5-a7ad-a381a026edfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79c6885d-a593-40bd-9248-5e4ade2cb5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_NetIncomeLoss_79c6885d-a593-40bd-9248-5e4ade2cb5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5e90df10-ead9-4177-87c6-75d541768e68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5e90df10-ead9-4177-87c6-75d541768e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2d5a9e54-8e5d-4f68-9683-2e9b4ed2218b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_StockholdersEquity_2d5a9e54-8e5d-4f68-9683-2e9b4ed2218b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f5f96479-4583-4c4c-9445-97356b4d3763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_596814a2-3c32-41b3-9f8c-6c509af98d4b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f5f96479-4583-4c4c-9445-97356b4d3763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a2ffaad1-f081-43d0-8f83-b516378ed8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_270b7e5e-30e0-485d-9d7b-57f04648e687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a2ffaad1-f081-43d0-8f83-b516378ed8ba" xlink:to="loc_us-gaap_StatementTable_270b7e5e-30e0-485d-9d7b-57f04648e687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_151422ba-2417-45f9-8c5b-c758490fb091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_270b7e5e-30e0-485d-9d7b-57f04648e687" xlink:to="loc_us-gaap_StatementClassOfStockAxis_151422ba-2417-45f9-8c5b-c758490fb091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ce1adf5e-53f7-41b9-9749-86ab9635dd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_151422ba-2417-45f9-8c5b-c758490fb091" xlink:to="loc_us-gaap_ClassOfStockDomain_ce1adf5e-53f7-41b9-9749-86ab9635dd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0d4f42d7-9413-43d0-a05a-049751e21852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ce1adf5e-53f7-41b9-9749-86ab9635dd8c" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0d4f42d7-9413-43d0-a05a-049751e21852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d49ef37b-1dc2-4807-b1b6-3d6c6b0fe28b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_270b7e5e-30e0-485d-9d7b-57f04648e687" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d49ef37b-1dc2-4807-b1b6-3d6c6b0fe28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c2a24acf-cc55-44de-a759-653b0c39f15a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d49ef37b-1dc2-4807-b1b6-3d6c6b0fe28b" xlink:to="loc_us-gaap_EquityComponentDomain_c2a24acf-cc55-44de-a759-653b0c39f15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c5760a5d-d162-4011-9991-0e695809daa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c2a24acf-cc55-44de-a759-653b0c39f15a" xlink:to="loc_us-gaap_PreferredStockMember_c5760a5d-d162-4011-9991-0e695809daa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b88cb5da-f43a-489e-90fa-0fdd595f2dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_270b7e5e-30e0-485d-9d7b-57f04648e687" xlink:to="loc_us-gaap_StatementLineItems_b88cb5da-f43a-489e-90fa-0fdd595f2dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fea739c2-433f-46a0-accd-01fc6283fb65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b88cb5da-f43a-489e-90fa-0fdd595f2dd1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fea739c2-433f-46a0-accd-01fc6283fb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_496a5a99-fa46-4e8a-a382-1c844b694b09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b88cb5da-f43a-489e-90fa-0fdd595f2dd1" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_496a5a99-fa46-4e8a-a382-1c844b694b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ac8e4f92-2e8e-453c-8cac-843de4bc4084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e65fc561-88ed-4768-b378-4da079f2f1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac8e4f92-2e8e-453c-8cac-843de4bc4084" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e65fc561-88ed-4768-b378-4da079f2f1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b5ee93f0-ee3b-4eb7-8490-34b509f38629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e65fc561-88ed-4768-b378-4da079f2f1a5" xlink:to="loc_us-gaap_NetIncomeLoss_b5ee93f0-ee3b-4eb7-8490-34b509f38629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e65fc561-88ed-4768-b378-4da079f2f1a5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_1753c5d4-3b71-45fc-8f1c-25f76a1a6c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_1753c5d4-3b71-45fc-8f1c-25f76a1a6c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a1da6f06-2975-4f75-a3a8-df5a41dcbac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a1da6f06-2975-4f75-a3a8-df5a41dcbac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b863108e-5778-47c7-b712-58cbfd146c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b863108e-5778-47c7-b712-58cbfd146c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e7c37cbc-e464-49f6-8deb-801e654ba368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_AssetImpairmentCharges_e7c37cbc-e464-49f6-8deb-801e654ba368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d1f9bd36-d532-4516-86ca-fcd4085bf09c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d1f9bd36-d532-4516-86ca-fcd4085bf09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_11232933-4345-4c14-9df7-0dc74840c0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_ShareBasedCompensation_11232933-4345-4c14-9df7-0dc74840c0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_cc9c03ea-871d-4b2b-b54f-8302b0217445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_PaidInKindInterest_cc9c03ea-871d-4b2b-b54f-8302b0217445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_bc8cd1e3-ffef-48c7-bda9-3142e3c1229f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_bc8cd1e3-ffef-48c7-bda9-3142e3c1229f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_FairValueAdjustmentOfContingentValueRightLiability_e65d5483-a61c-4a9c-b42d-a59c2c209471" xlink:href="rnac-20241231.xsd#rnac_FairValueAdjustmentOfContingentValueRightLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_rnac_FairValueAdjustmentOfContingentValueRightLiability_e65d5483-a61c-4a9c-b42d-a59c2c209471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_4a3067cb-4541-4416-8325-65aa06c806ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_4a3067cb-4541-4416-8325-65aa06c806ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7e2150cb-b280-4bc9-99b9-9388928d8f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7e2150cb-b280-4bc9-99b9-9388928d8f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_51dd8f77-2d8c-479a-8293-dec357a4eb16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_51dd8f77-2d8c-479a-8293-dec357a4eb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6abe5eaa-4b73-4e9b-90a8-8ecd4bae7c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc8c06fb-c257-4b51-ae62-26121c57fba8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6abe5eaa-4b73-4e9b-90a8-8ecd4bae7c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f2f49f29-3543-4785-84a2-5632522c3b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6abe5eaa-4b73-4e9b-90a8-8ecd4bae7c2d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f2f49f29-3543-4785-84a2-5632522c3b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent_64d39fdc-9020-41c4-876f-ef4ba5070c89" xlink:href="rnac-20241231.xsd#rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6abe5eaa-4b73-4e9b-90a8-8ecd4bae7c2d" xlink:to="loc_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent_64d39fdc-9020-41c4-876f-ef4ba5070c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99bf70fb-9e9b-4e16-8018-726c23367fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6abe5eaa-4b73-4e9b-90a8-8ecd4bae7c2d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99bf70fb-9e9b-4e16-8018-726c23367fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ef4b29a0-baaf-4155-ad6c-b5a2e7dabd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6abe5eaa-4b73-4e9b-90a8-8ecd4bae7c2d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ef4b29a0-baaf-4155-ad6c-b5a2e7dabd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8552b628-d850-457d-8864-e9162bbe25ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6abe5eaa-4b73-4e9b-90a8-8ecd4bae7c2d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8552b628-d850-457d-8864-e9162bbe25ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_053a9f8e-e38a-4fed-acb0-47578e174073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6abe5eaa-4b73-4e9b-90a8-8ecd4bae7c2d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_053a9f8e-e38a-4fed-acb0-47578e174073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94da2e52-8d1f-44fb-8c24-b4b8364e921a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e65fc561-88ed-4768-b378-4da079f2f1a5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94da2e52-8d1f-44fb-8c24-b4b8364e921a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ef86d5-05f0-43b5-af10-88bac22a0ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac8e4f92-2e8e-453c-8cac-843de4bc4084" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ef86d5-05f0-43b5-af10-88bac22a0ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_f5d73ba6-a5eb-4848-a85f-4037f23f9ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ef86d5-05f0-43b5-af10-88bac22a0ec5" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_f5d73ba6-a5eb-4848-a85f-4037f23f9ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_f8b71c6d-dce5-43ee-aecb-67244e82ca18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ef86d5-05f0-43b5-af10-88bac22a0ec5" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_f8b71c6d-dce5-43ee-aecb-67244e82ca18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_40e5f76d-80fb-447c-8653-59d1ef865c53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ef86d5-05f0-43b5-af10-88bac22a0ec5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_40e5f76d-80fb-447c-8653-59d1ef865c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_bf2f4be6-6541-4623-89ba-edfdea01aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ef86d5-05f0-43b5-af10-88bac22a0ec5" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_bf2f4be6-6541-4623-89ba-edfdea01aa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d01ec81-39dd-44fb-8ddc-d468b9cf9a20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ef86d5-05f0-43b5-af10-88bac22a0ec5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d01ec81-39dd-44fb-8ddc-d468b9cf9a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac8e4f92-2e8e-453c-8cac-843de4bc4084" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_a06bd63a-456c-4ffc-b763-28635f440987" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_a06bd63a-456c-4ffc-b763-28635f440987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_948c021e-2f08-409a-a085-934875abd53b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_948c021e-2f08-409a-a085-934875abd53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants_c69f8952-57a5-4c33-a66d-c59aa08a75d7" xlink:href="rnac-20241231.xsd#rnac_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:to="loc_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants_c69f8952-57a5-4c33-a66d-c59aa08a75d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a94b2a51-f4a2-4c42-96b8-3cef44375920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a94b2a51-f4a2-4c42-96b8-3cef44375920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_44f66cdc-437d-4305-8a5c-0844ce5c0b35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_44f66cdc-437d-4305-8a5c-0844ce5c0b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination_bf0d4f73-dda1-41c6-b383-49e309a73ccd" xlink:href="rnac-20241231.xsd#rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:to="loc_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination_bf0d4f73-dda1-41c6-b383-49e309a73ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d3211cad-0503-449f-9c52-d82ecb02b556" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d3211cad-0503-449f-9c52-d82ecb02b556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_59062f4e-039d-4f00-b7d1-2d9e3fa4747b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:to="loc_us-gaap_ProceedsFromStockPlans_59062f4e-039d-4f00-b7d1-2d9e3fa4747b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f17ff650-d7fa-4b65-a3c4-6f345680158e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f2ab7ec3-3bb5-4ea3-acb7-f8ef091d8700" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f17ff650-d7fa-4b65-a3c4-6f345680158e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fd6de3b8-11cd-48b2-96d5-a8df1e52345f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac8e4f92-2e8e-453c-8cac-843de4bc4084" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fd6de3b8-11cd-48b2-96d5-a8df1e52345f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d662ff38-bf94-4599-bb53-84f5dc14443e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac8e4f92-2e8e-453c-8cac-843de4bc4084" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d662ff38-bf94-4599-bb53-84f5dc14443e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eadb13f2-0895-41a4-aa90-89108ea32c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac8e4f92-2e8e-453c-8cac-843de4bc4084" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eadb13f2-0895-41a4-aa90-89108ea32c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ea06fd1-da73-461a-a889-ff6d81786059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac8e4f92-2e8e-453c-8cac-843de4bc4084" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ea06fd1-da73-461a-a889-ff6d81786059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_cbe9febe-e072-4a07-a413-69cfb2971a08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac8e4f92-2e8e-453c-8cac-843de4bc4084" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_cbe9febe-e072-4a07-a413-69cfb2971a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4b39f33b-b414-4294-b58f-3248c466cc80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_cbe9febe-e072-4a07-a413-69cfb2971a08" xlink:to="loc_us-gaap_InterestPaidNet_4b39f33b-b414-4294-b58f-3248c466cc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2807efad-7c22-4cac-b07d-d240e00fa6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac8e4f92-2e8e-453c-8cac-843de4bc4084" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2807efad-7c22-4cac-b07d-d240e00fa6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_91a8d247-2d49-47fd-a97d-e48aaad622c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2807efad-7c22-4cac-b07d-d240e00fa6ba" xlink:to="loc_us-gaap_StockIssued1_91a8d247-2d49-47fd-a97d-e48aaad622c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_62890c8f-61b4-4bfe-9ea2-e08e9f19ff80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2807efad-7c22-4cac-b07d-d240e00fa6ba" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_62890c8f-61b4-4bfe-9ea2-e08e9f19ff80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquityOfferingCostsInAccruedLiabilities_efdb1348-e937-47f7-965c-5206ac88e882" xlink:href="rnac-20241231.xsd#rnac_EquityOfferingCostsInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2807efad-7c22-4cac-b07d-d240e00fa6ba" xlink:to="loc_rnac_EquityOfferingCostsInAccruedLiabilities_efdb1348-e937-47f7-965c-5206ac88e882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="rnac-20241231.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_419432a0-2943-47b0-a581-6d0491802a43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_77285b16-e1c7-4685-9723-8dfe288988ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_419432a0-2943-47b0-a581-6d0491802a43" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_77285b16-e1c7-4685-9723-8dfe288988ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/BasisofPresentation" xlink:type="simple" xlink:href="rnac-20241231.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5775df57-51fd-4dad-ac5a-939c04552a43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_a832d6a0-06d0-4dd4-8c7f-f4a3b6ac7347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5775df57-51fd-4dad-ac5a-939c04552a43" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_a832d6a0-06d0-4dd4-8c7f-f4a3b6ac7347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="rnac-20241231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_15796484-31f3-4ed9-89af-3a58403e7e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c8f1e908-3f78-42f7-998e-14e442b65a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15796484-31f3-4ed9-89af-3a58403e7e4b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c8f1e908-3f78-42f7-998e-14e442b65a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Merger" xlink:type="simple" xlink:href="rnac-20241231.xsd#Merger"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/Merger" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_24774aca-7b99-4abe-a2cf-e65d1fa135e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9b823792-b029-47e6-be88-ec862f47522f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_24774aca-7b99-4abe-a2cf-e65d1fa135e3" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9b823792-b029-47e6-be88-ec862f47522f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholders" xlink:type="simple" xlink:href="rnac-20241231.xsd#NetLossPerShareAllocabletoCommonStockholders"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_047c8160-ea76-48a3-81d2-298891fe887d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0a31beb3-ad05-483e-a3f9-0ba381eaf9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047c8160-ea76-48a3-81d2-298891fe887d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0a31beb3-ad05-483e-a3f9-0ba381eaf9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3cb89430-ae1e-4fc8-a682-cba561875e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b0ae6f2f-ca46-4408-b8a4-fe7afdd04325" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3cb89430-ae1e-4fc8-a682-cba561875e64" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b0ae6f2f-ca46-4408-b8a4-fe7afdd04325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="rnac-20241231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_425e8b6c-ca37-4b4a-9de6-4d8946193dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3b34b2bf-d4e1-4b7e-aec6-a98160c6c16a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_425e8b6c-ca37-4b4a-9de6-4d8946193dab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3b34b2bf-d4e1-4b7e-aec6-a98160c6c16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/AccruedExpenses" xlink:type="simple" xlink:href="rnac-20241231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_15364455-f810-4310-a5ef-e9abc5e08b27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1ff41f6e-8e77-43cb-89f5-f73861159607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_15364455-f810-4310-a5ef-e9abc5e08b27" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1ff41f6e-8e77-43cb-89f5-f73861159607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Leases" xlink:type="simple" xlink:href="rnac-20241231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_27a048bf-0c86-4ea3-8c60-5380f1311c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_fdfd286d-a9f2-48aa-a439-127c9438ea86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27a048bf-0c86-4ea3-8c60-5380f1311c3c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_fdfd286d-a9f2-48aa-a439-127c9438ea86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Debt" xlink:type="simple" xlink:href="rnac-20241231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fb8bfad2-feaa-4818-9db1-544be7d637a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5c44a92e-7681-4340-8c76-3421439c570a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fb8bfad2-feaa-4818-9db1-544be7d637a8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5c44a92e-7681-4340-8c76-3421439c570a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStock" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_8bf7984e-ba7a-4eb4-9064-674f214d7fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityDisclosureTextBlock_bcae5736-c4d5-4728-969d-abeaddf7ae97" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_8bf7984e-ba7a-4eb4-9064-674f214d7fbe" xlink:to="loc_rnac_TemporaryEquityDisclosureTextBlock_bcae5736-c4d5-4728-969d-abeaddf7ae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Equity" xlink:type="simple" xlink:href="rnac-20241231.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_91067993-64ea-43ce-8d16-fd9f6bf60f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_258018c6-d67b-4f94-9b74-7f7dd2752209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_91067993-64ea-43ce-8d16-fd9f6bf60f19" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_258018c6-d67b-4f94-9b74-7f7dd2752209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlans" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c9fbdec-a555-4192-b603-e12471469b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ad1df121-96b0-471f-8090-02e7bfc15fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c9fbdec-a555-4192-b603-e12471469b2e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ad1df121-96b0-471f-8090-02e7bfc15fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RevenueArrangements" xlink:type="simple" xlink:href="rnac-20241231.xsd#RevenueArrangements"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RevenueArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bc7cc11a-9884-4a3f-b8bc-3c27261a86c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7dcedeaa-1e57-4f0d-849d-defe673095c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bc7cc11a-9884-4a3f-b8bc-3c27261a86c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7dcedeaa-1e57-4f0d-849d-defe673095c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="rnac-20241231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ece8c31b-cdd1-4800-b099-b8baebfc4722" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a7b04492-37f1-4c0c-ac0b-9bc63b21c6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ece8c31b-cdd1-4800-b099-b8baebfc4722" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a7b04492-37f1-4c0c-ac0b-9bc63b21c6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cfb84c03-1108-4014-8100-9f562b98eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborationAndLicenseAgreementsTextBlock_ab18122c-e92c-42f1-b529-371afe600a8d" xlink:href="rnac-20241231.xsd#rnac_CollaborationAndLicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cfb84c03-1108-4014-8100-9f562b98eda6" xlink:to="loc_rnac_CollaborationAndLicenseAgreementsTextBlock_ab18122c-e92c-42f1-b529-371afe600a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="rnac-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_724ab7f9-65ee-48d3-8c21-a2a3f066c90e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f149db0d-d72e-42ba-ac17-1a52c1ba2058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_724ab7f9-65ee-48d3-8c21-a2a3f066c90e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f149db0d-d72e-42ba-ac17-1a52c1ba2058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="rnac-20241231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_827cf52d-61fb-4e74-b755-2e034a700dee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_752ac79e-6f75-415e-a835-924f5aef6f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_827cf52d-61fb-4e74-b755-2e034a700dee" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_752ac79e-6f75-415e-a835-924f5aef6f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="rnac-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0a8d0caf-1570-48e7-a0e5-9fa4e8e9bbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7d99988c-ce72-4128-b3fd-4488f51637f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0a8d0caf-1570-48e7-a0e5-9fa4e8e9bbfe" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7d99988c-ce72-4128-b3fd-4488f51637f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Restructuring" xlink:type="simple" xlink:href="rnac-20241231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3bbfd9fc-add1-448f-9c1a-b350077b6841" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_c25d50d8-0198-45ae-8b48-07a6b420b9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3bbfd9fc-add1-448f-9c1a-b350077b6841" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_c25d50d8-0198-45ae-8b48-07a6b420b9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/SegmentReporting" xlink:type="simple" xlink:href="rnac-20241231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2d318d88-172c-42d2-9b78-54f4937114b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_f8a9c045-714e-4b09-985c-efccc1d69de5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2d318d88-172c-42d2-9b78-54f4937114b8" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_f8a9c045-714e-4b09-985c-efccc1d69de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="rnac-20241231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_35539bc1-2a51-45db-91db-d17ac1614885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_54122327-6952-4471-807e-27a754745d84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_35539bc1-2a51-45db-91db-d17ac1614885" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_54122327-6952-4471-807e-27a754745d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="rnac-20241231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_51613c83-7181-484b-9156-60244d375972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_51613c83-7181-484b-9156-60244d375972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_2ebed6c9-ae3e-41e7-85ff-41cb09d8d79f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_UseOfEstimates_2ebed6c9-ae3e-41e7-85ff-41cb09d8d79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6ef8f0a6-ff29-42c7-a6b0-5ff954f9b2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6ef8f0a6-ff29-42c7-a6b0-5ff954f9b2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock_36682a7d-b2a7-4d21-b209-273cbcc87a9f" xlink:href="rnac-20241231.xsd#rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock_36682a7d-b2a7-4d21-b209-273cbcc87a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9a818f1f-4182-4311-acd0-7d050c1634b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_9a818f1f-4182-4311-acd0-7d050c1634b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_b3a9a235-a15e-40e9-8847-76d5a1eabd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_b3a9a235-a15e-40e9-8847-76d5a1eabd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9d1408eb-de11-48d8-a241-8d18bc264a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9d1408eb-de11-48d8-a241-8d18bc264a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d58e70b4-5c2f-4e04-b66a-cb369e6fee25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d58e70b4-5c2f-4e04-b66a-cb369e6fee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_e83e15ed-1565-43c7-923f-9f62e7c67729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_DebtPolicyTextBlock_e83e15ed-1565-43c7-923f-9f62e7c67729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c774cdb3-9ec6-416f-b03a-4a581571d742" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c774cdb3-9ec6-416f-b03a-4a581571d742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9ff137dc-9886-4cbc-9cb0-b65202ecefdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9ff137dc-9886-4cbc-9cb0-b65202ecefdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock_2f4bd09d-6d8a-4380-b2fe-d31440fcc6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_GovernmentAssistancePolicyTextBlock_2f4bd09d-6d8a-4380-b2fe-d31440fcc6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3dcc3363-e7a7-4d98-a796-a0525b5d431a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3dcc3363-e7a7-4d98-a796-a0525b5d431a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClinicalTrialCostsPolicyTextBlock_6ccfa394-3dc1-46d1-bdda-c98d07ac732b" xlink:href="rnac-20241231.xsd#rnac_ClinicalTrialCostsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_rnac_ClinicalTrialCostsPolicyTextBlock_6ccfa394-3dc1-46d1-bdda-c98d07ac732b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6f1aeb98-af2a-4e0b-9954-c2c7242d5b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6f1aeb98-af2a-4e0b-9954-c2c7242d5b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantsPolicyTextBlock_5cd4a507-1cf1-4832-833d-6302fe9a365f" xlink:href="rnac-20241231.xsd#rnac_WarrantsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_rnac_WarrantsPolicyTextBlock_5cd4a507-1cf1-4832-833d-6302fe9a365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4a1102c0-a0ba-40a3-94a1-5d06c2f0d2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4a1102c0-a0ba-40a3-94a1-5d06c2f0d2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_62468fe2-ae54-4cd3-b978-bf0d2e9b0669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_62468fe2-ae54-4cd3-b978-bf0d2e9b0669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13885abc-0930-4066-a013-b1920920af84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13885abc-0930-4066-a013-b1920920af84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_b2849264-68a2-49a7-9bab-1350f308bbea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_b2849264-68a2-49a7-9bab-1350f308bbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_4fcc0d05-5654-4c49-90e2-e01c3e780702" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_4fcc0d05-5654-4c49-90e2-e01c3e780702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_02b38fa4-03c9-4d0f-90ef-f062b4f8f4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_02b38fa4-03c9-4d0f-90ef-f062b4f8f4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_e744744a-96d8-4521-a558-d7081c0626f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_e744744a-96d8-4521-a558-d7081c0626f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TemporaryEquityPolicyPolicyTextBlock_501b6e02-9307-43ed-8d24-72ec968e4e0b" xlink:href="rnac-20241231.xsd#rnac_TemporaryEquityPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_rnac_TemporaryEquityPolicyPolicyTextBlock_501b6e02-9307-43ed-8d24-72ec968e4e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_ce4caaf8-99e0-4771-91ec-85e2764690e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_ce4caaf8-99e0-4771-91ec-85e2764690e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock_59067db5-ffb3-4891-8401-ac9fb443e2df" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock_59067db5-ffb3-4891-8401-ac9fb443e2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_eaafe6a8-c3d9-4e07-90b7-3585e87e225a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_eaafe6a8-c3d9-4e07-90b7-3585e87e225a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7f5941e7-9a97-4991-a275-c7761410640b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e566562-c4bf-4c7a-afe5-f89569fe73d4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7f5941e7-9a97-4991-a275-c7761410640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_09e7220f-40d2-44d7-bd08-5cb41f775557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9ef906c5-22f7-4ab2-825a-007c111691d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_09e7220f-40d2-44d7-bd08-5cb41f775557" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9ef906c5-22f7-4ab2-825a-007c111691d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_6d3caad0-b497-4acd-ab0d-6c1c561d587e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_09e7220f-40d2-44d7-bd08-5cb41f775557" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_6d3caad0-b497-4acd-ab0d-6c1c561d587e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_e53d9775-2e7b-4563-9125-4e7aa3362fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_09e7220f-40d2-44d7-bd08-5cb41f775557" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_e53d9775-2e7b-4563-9125-4e7aa3362fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_d90f813e-4d83-46ce-ac59-44c3b5d37f84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_09e7220f-40d2-44d7-bd08-5cb41f775557" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_d90f813e-4d83-46ce-ac59-44c3b5d37f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#NetLossPerShareAllocabletoCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9afe674d-6259-40f6-87cf-5bfba24f0141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a8eac50e-f6af-42d8-b1dc-ee65eae07649" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9afe674d-6259-40f6-87cf-5bfba24f0141" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a8eac50e-f6af-42d8-b1dc-ee65eae07649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0a0325c7-19cf-49d7-b42d-71040056fafb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9afe674d-6259-40f6-87cf-5bfba24f0141" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0a0325c7-19cf-49d7-b42d-71040056fafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_552d3cd1-6970-4091-bc31-e3fc0297812b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c63ba71e-058d-4169-af2b-63802dcedf56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_552d3cd1-6970-4091-bc31-e3fc0297812b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c63ba71e-058d-4169-af2b-63802dcedf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5146fcfb-a081-4c2a-ad41-b0d88efda4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_552d3cd1-6970-4091-bc31-e3fc0297812b" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5146fcfb-a081-4c2a-ad41-b0d88efda4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_b6bb5f74-603d-4f31-a76d-4ec4e8419f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_552d3cd1-6970-4091-bc31-e3fc0297812b" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_b6bb5f74-603d-4f31-a76d-4ec4e8419f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2e2289a4-7b65-4d17-abd2-39789354c801" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_552d3cd1-6970-4091-bc31-e3fc0297812b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2e2289a4-7b65-4d17-abd2-39789354c801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f51d63ae-78e3-40cf-91cd-c41b1054e139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_552d3cd1-6970-4091-bc31-e3fc0297812b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f51d63ae-78e3-40cf-91cd-c41b1054e139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_22deb29f-958d-4e1f-b6a0-c9b2b762d86d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_780c5130-2ed6-4cea-bc55-4ab063448b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_22deb29f-958d-4e1f-b6a0-c9b2b762d86d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_780c5130-2ed6-4cea-bc55-4ab063448b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3f2fb4cc-c13a-4ed6-beca-7458dd4be0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_43ab660a-908d-4969-b628-02e05191d573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3f2fb4cc-c13a-4ed6-beca-7458dd4be0f3" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_43ab660a-908d-4969-b628-02e05191d573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/LeasesTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a901a5f1-b57d-4f12-84a5-f50ef10042cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_183b2b0e-6e8d-4467-9a37-f68d5e45e608" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a901a5f1-b57d-4f12-84a5-f50ef10042cf" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_183b2b0e-6e8d-4467-9a37-f68d5e45e608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_218b7395-3f7c-4cd1-b12f-82319ba7254a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a901a5f1-b57d-4f12-84a5-f50ef10042cf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_218b7395-3f7c-4cd1-b12f-82319ba7254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_5e8ec4b2-5198-4ea5-8f41-ca33d23eebbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a901a5f1-b57d-4f12-84a5-f50ef10042cf" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_5e8ec4b2-5198-4ea5-8f41-ca33d23eebbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7e8835be-fb4d-44d7-979f-e9385d2dcd77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d5663f21-5138-438a-83d8-4f819a45ed4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7e8835be-fb4d-44d7-979f-e9385d2dcd77" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d5663f21-5138-438a-83d8-4f819a45ed4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_be6458fe-332f-41b5-ad01-f7d4ed32a578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7e8835be-fb4d-44d7-979f-e9385d2dcd77" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_be6458fe-332f-41b5-ad01-f7d4ed32a578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7512b121-0bd8-46c8-a9fe-823526995371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_76f972bd-567a-4007-9f4d-f3c1fff92168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7512b121-0bd8-46c8-a9fe-823526995371" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_76f972bd-567a-4007-9f4d-f3c1fff92168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_20ccd108-e35c-474f-bdb4-dd3fe827be0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7512b121-0bd8-46c8-a9fe-823526995371" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_20ccd108-e35c-474f-bdb4-dd3fe827be0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4bd01516-0ea5-4270-b21a-f7c9ea50307c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7512b121-0bd8-46c8-a9fe-823526995371" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4bd01516-0ea5-4270-b21a-f7c9ea50307c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_438df460-8ca4-4a6b-bcb4-b745aa5f6e60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7512b121-0bd8-46c8-a9fe-823526995371" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_438df460-8ca4-4a6b-bcb4-b745aa5f6e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RevenueArrangementsTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#RevenueArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RevenueArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_79e16618-327b-4dd0-8062-35d6c7daf66a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e97fe1ce-7fdd-48c5-909c-4348ab5db846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_79e16618-327b-4dd0-8062-35d6c7daf66a" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e97fe1ce-7fdd-48c5-909c-4348ab5db846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f641d8d0-9fb3-452d-aa37-6e91c8af0cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_da3aaa85-dbe1-4350-938a-03a2e2f22679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f641d8d0-9fb3-452d-aa37-6e91c8af0cae" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_da3aaa85-dbe1-4350-938a-03a2e2f22679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bfdc299a-b2ba-403d-9e10-4c8d6da3631f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8f2f4679-c1f1-4a97-a963-c015bc6bb024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bfdc299a-b2ba-403d-9e10-4c8d6da3631f" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8f2f4679-c1f1-4a97-a963-c015bc6bb024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_493caf34-5659-40eb-b785-f983f7f905c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bfdc299a-b2ba-403d-9e10-4c8d6da3631f" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_493caf34-5659-40eb-b785-f983f7f905c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RestructuringTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3e2914de-f736-46f6-b227-5446f443849c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ca0b292e-8edf-41b0-b274-e149bf9c667d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3e2914de-f736-46f6-b227-5446f443849c" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ca0b292e-8edf-41b0-b274-e149bf9c667d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="rnac-20241231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6bfccf5c-9d5b-4adb-9143-6552ede5b7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_dc70fd93-ac34-4aac-841f-f98db3f63a61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6bfccf5c-9d5b-4adb-9143-6552ede5b7a8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_dc70fd93-ac34-4aac-841f-f98db3f63a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#DescriptionoftheBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_733cf4ad-63fd-4fb1-a162-d49b1e655860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_733cf4ad-63fd-4fb1-a162-d49b1e655860" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3800911a-6cee-4990-b2d7-50b0cd41aac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3800911a-6cee-4990-b2d7-50b0cd41aac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d88e089f-bdea-4f1e-b3bc-3478f0b4e136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3800911a-6cee-4990-b2d7-50b0cd41aac1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d88e089f-bdea-4f1e-b3bc-3478f0b4e136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_bf84b743-2050-41be-bc52-a0b7dd6e88cf" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d88e089f-bdea-4f1e-b3bc-3478f0b4e136" xlink:to="loc_rnac_OldCartesianMember_bf84b743-2050-41be-bc52-a0b7dd6e88cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_232a7c66-e450-4067-b0a7-03542ce9d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_232a7c66-e450-4067-b0a7-03542ce9d26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_245fdd1b-12f1-4b25-8410-6fa8d8b0245d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_232a7c66-e450-4067-b0a7-03542ce9d26d" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_245fdd1b-12f1-4b25-8410-6fa8d8b0245d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3dd32863-8574-4bad-b546-224ee2fa948c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_245fdd1b-12f1-4b25-8410-6fa8d8b0245d" xlink:to="loc_us-gaap_CommonStockMember_3dd32863-8574-4bad-b546-224ee2fa948c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_9b5f616a-0217-4cbb-990a-db11888a4e35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_245fdd1b-12f1-4b25-8410-6fa8d8b0245d" xlink:to="loc_us-gaap_PreferredStockMember_9b5f616a-0217-4cbb-990a-db11888a4e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cc95703f-aa94-4244-9e05-aa3e3f868ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cc95703f-aa94-4244-9e05-aa3e3f868ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c921441-231f-4b78-b566-284cc9a40aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cc95703f-aa94-4244-9e05-aa3e3f868ef3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c921441-231f-4b78-b566-284cc9a40aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member_ea0be4de-eda6-4895-8151-14986aca5e62" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c921441-231f-4b78-b566-284cc9a40aaf" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2023Member_ea0be4de-eda6-4895-8151-14986aca5e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2024Member_aace665a-57f2-433e-8606-48cd4f03bef0" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c921441-231f-4b78-b566-284cc9a40aaf" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2024Member_aace665a-57f2-433e-8606-48cd4f03bef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ea134afc-d912-416e-9e0a-dc648e68f734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ea134afc-d912-416e-9e0a-dc648e68f734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4af6873f-7bd1-4e5e-a2ad-09b831db0388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea134afc-d912-416e-9e0a-dc648e68f734" xlink:to="loc_us-gaap_ClassOfStockDomain_4af6873f-7bd1-4e5e-a2ad-09b831db0388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_ce456701-802e-4973-a388-598ed4d7a71b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4af6873f-7bd1-4e5e-a2ad-09b831db0388" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_ce456701-802e-4973-a388-598ed4d7a71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7c3b73e2-11e2-41d9-862f-e370ed34c253" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4af6873f-7bd1-4e5e-a2ad-09b831db0388" xlink:to="loc_us-gaap_CommonStockMember_7c3b73e2-11e2-41d9-862f-e370ed34c253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0e0bc9a1-ba6a-47fa-8825-3fb772929392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4af6873f-7bd1-4e5e-a2ad-09b831db0388" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0e0bc9a1-ba6a-47fa-8825-3fb772929392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea6f08d4-454b-43a0-ae2d-24c06013ecb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_srt_RangeAxis_ea6f08d4-454b-43a0-ae2d-24c06013ecb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c580563-c11d-4747-8a88-eb0408bce857" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ea6f08d4-454b-43a0-ae2d-24c06013ecb8" xlink:to="loc_srt_RangeMember_9c580563-c11d-4747-8a88-eb0408bce857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f0d62d0e-28e8-43c3-b345-606a24780d33" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c580563-c11d-4747-8a88-eb0408bce857" xlink:to="loc_srt_MinimumMember_f0d62d0e-28e8-43c3-b345-606a24780d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d7c8da9d-6ed4-4c7f-80da-60023af86973" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c580563-c11d-4747-8a88-eb0408bce857" xlink:to="loc_srt_MaximumMember_d7c8da9d-6ed4-4c7f-80da-60023af86973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_07aed5b4-fa85-44ed-ac36-e435a39fadde" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d46a935e-0bbb-4ef9-bb21-0a8afe5eb840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d46a935e-0bbb-4ef9-bb21-0a8afe5eb840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0c3fe800-d8e9-494c-acf5-b77b6522972b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0c3fe800-d8e9-494c-acf5-b77b6522972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_8b24cc92-ce14-4826-8884-5d24a3b7d170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_8b24cc92-ce14-4826-8884-5d24a3b7d170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_15c45f28-3b9e-412f-a1cd-7030ac05028d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_15c45f28-3b9e-412f-a1cd-7030ac05028d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6fa216ef-120f-4fe3-a942-12cd9aaa9541" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6fa216ef-120f-4fe3-a942-12cd9aaa9541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_24d185da-823f-42e1-9478-cab9628ef6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_24d185da-823f-42e1-9478-cab9628ef6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4646a2f2-9b4f-4529-942e-0c8bd4f1415d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4646a2f2-9b4f-4529-942e-0c8bd4f1415d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_88bb1e01-d549-445b-8cd3-6b03f6621c80" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_88bb1e01-d549-445b-8cd3-6b03f6621c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f48e91a7-ecbe-4936-a81b-1040f82979ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f48e91a7-ecbe-4936-a81b-1040f82979ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_25e095bf-5986-42ff-bc10-5d7100ce7d0e" xlink:href="rnac-20241231.xsd#rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_25e095bf-5986-42ff-bc10-5d7100ce7d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_100dadc7-ce91-48fd-96ed-9dd9e7563f24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_100dadc7-ce91-48fd-96ed-9dd9e7563f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_3e437e40-b012-4c52-80cf-7b273f4ae961" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2c9fc9ce-7b23-497b-9ffe-4bf4162a0551" xlink:to="loc_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_3e437e40-b012-4c52-80cf-7b273f4ae961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/BasisofPresentationDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#BasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/BasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09f5b4d0-2816-41e5-b2fc-e3b09e2df095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ef50396f-915d-46a5-ab4d-a479b9cbcd70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09f5b4d0-2816-41e5-b2fc-e3b09e2df095" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ef50396f-915d-46a5-ab4d-a479b9cbcd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3382d31d-3134-488b-98f2-a605f9ebe869" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3382d31d-3134-488b-98f2-a605f9ebe869" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_770ed044-1d24-467b-a2f9-1ec32631f285" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:to="loc_srt_RangeAxis_770ed044-1d24-467b-a2f9-1ec32631f285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6fa19118-5dc7-4310-ba68-a63c2eb9e5f3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_770ed044-1d24-467b-a2f9-1ec32631f285" xlink:to="loc_srt_RangeMember_6fa19118-5dc7-4310-ba68-a63c2eb9e5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2f2a3546-1ca3-454c-a7c5-caea9d90dd9a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6fa19118-5dc7-4310-ba68-a63c2eb9e5f3" xlink:to="loc_srt_MinimumMember_2f2a3546-1ca3-454c-a7c5-caea9d90dd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c97298ba-cdc0-405d-a9f7-cf752e1dcc16" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6fa19118-5dc7-4310-ba68-a63c2eb9e5f3" xlink:to="loc_srt_MaximumMember_c97298ba-cdc0-405d-a9f7-cf752e1dcc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2f8157e7-6997-4c33-9d18-3099e9290741" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2f8157e7-6997-4c33-9d18-3099e9290741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4c2be6c2-6b8c-4dbb-b4ac-6a82864e459a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2f8157e7-6997-4c33-9d18-3099e9290741" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4c2be6c2-6b8c-4dbb-b4ac-6a82864e459a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AstellasGeneTherapiesMember_d50a1b38-814e-4c17-9d1f-251840700b4d" xlink:href="rnac-20241231.xsd#rnac_AstellasGeneTherapiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4c2be6c2-6b8c-4dbb-b4ac-6a82864e459a" xlink:to="loc_rnac_AstellasGeneTherapiesMember_d50a1b38-814e-4c17-9d1f-251840700b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b79f78-8055-4cc8-ac51-8dd20b649b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b79f78-8055-4cc8-ac51-8dd20b649b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc536bd-428c-406e-9de2-ae696e447ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b79f78-8055-4cc8-ac51-8dd20b649b50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc536bd-428c-406e-9de2-ae696e447ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c65de031-cf53-4e05-992f-c7bda750b157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc536bd-428c-406e-9de2-ae696e447ff4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c65de031-cf53-4e05-992f-c7bda750b157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_5389db4b-4b78-46a6-a454-adc8d29c263c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc536bd-428c-406e-9de2-ae696e447ff4" xlink:to="loc_us-gaap_EquipmentMember_5389db4b-4b78-46a6-a454-adc8d29c263c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0da1a555-15a4-472e-b1ed-fbc4ac495bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc536bd-428c-406e-9de2-ae696e447ff4" xlink:to="loc_us-gaap_ComputerEquipmentMember_0da1a555-15a4-472e-b1ed-fbc4ac495bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cc1b179b-3b38-44b4-9751-f48f7f816209" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_092d41ad-3af7-49ec-b0e2-457d9817ee2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_092d41ad-3af7-49ec-b0e2-457d9817ee2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_62b90804-9e64-4136-87f7-acc63879ee74" xlink:href="rnac-20241231.xsd#rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_62b90804-9e64-4136-87f7-acc63879ee74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_09bb93f3-f821-42e8-8a4e-ab92adfcb46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_09bb93f3-f821-42e8-8a4e-ab92adfcb46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4d8392e7-29c4-4212-8700-1d73eece6598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4d8392e7-29c4-4212-8700-1d73eece6598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_acdcbb71-cc83-4c82-be4c-48de4051191f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_acdcbb71-cc83-4c82-be4c-48de4051191f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8b8e9cb2-e622-44b1-bcd7-3d3c78e33903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4b0ff0cb-00a5-4e24-90c5-f9e2b0547639" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8b8e9cb2-e622-44b1-bcd7-3d3c78e33903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_080b4716-64e4-4250-bbeb-5b7f35cbd67e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_080b4716-64e4-4250-bbeb-5b7f35cbd67e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1f9443af-f576-4ed5-aa64-e5298b9287ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1f9443af-f576-4ed5-aa64-e5298b9287ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39d8af61-3564-4ff1-98ba-9565ab7f1be9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1f9443af-f576-4ed5-aa64-e5298b9287ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39d8af61-3564-4ff1-98ba-9565ab7f1be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_61fc6bb1-403a-4f25-a254-315497fa3375" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39d8af61-3564-4ff1-98ba-9565ab7f1be9" xlink:to="loc_rnac_OldCartesianMember_61fc6bb1-403a-4f25-a254-315497fa3375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_8017c0fd-ef5c-4514-83c1-475d4550a184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_8017c0fd-ef5c-4514-83c1-475d4550a184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_6159352c-5270-4ffa-a620-b3860997906b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_8017c0fd-ef5c-4514-83c1-475d4550a184" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_6159352c-5270-4ffa-a620-b3860997906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf8d15b2-2852-40ae-b4d5-383d89489849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_6159352c-5270-4ffa-a620-b3860997906b" xlink:to="loc_us-gaap_CommonStockMember_cf8d15b2-2852-40ae-b4d5-383d89489849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_11d0e9d8-ab07-4e23-83d5-0500af820f06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_6159352c-5270-4ffa-a620-b3860997906b" xlink:to="loc_us-gaap_PreferredStockMember_11d0e9d8-ab07-4e23-83d5-0500af820f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b1e14126-e524-4fc6-a56a-8ec00ef88b35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b1e14126-e524-4fc6-a56a-8ec00ef88b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_72e97fab-5fe8-4530-9677-0504aa2839d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b1e14126-e524-4fc6-a56a-8ec00ef88b35" xlink:to="loc_us-gaap_ClassOfStockDomain_72e97fab-5fe8-4530-9677-0504aa2839d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5580c7cd-7890-4802-8d89-fa1ffc8c3982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_72e97fab-5fe8-4530-9677-0504aa2839d6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5580c7cd-7890-4802-8d89-fa1ffc8c3982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65f42497-749a-46a4-9960-3166391918c4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_eed6abea-7b77-44f6-a7e8-2f47cd8c18df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_eed6abea-7b77-44f6-a7e8-2f47cd8c18df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_555a0f10-d842-495f-951a-3d85a1d02e21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_555a0f10-d842-495f-951a-3d85a1d02e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f5737145-0172-4a3b-946f-4a14d42deef9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f5737145-0172-4a3b-946f-4a14d42deef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_b3b0dcc3-a8c3-4d2d-96d3-c43ffad113ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_b3b0dcc3-a8c3-4d2d-96d3-c43ffad113ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_7ce8970e-3291-4b43-b16b-5d2287e931ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33ee6b23-c573-4e03-9d27-4c3b56b5eddb" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_7ce8970e-3291-4b43-b16b-5d2287e931ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerScheduleofFairValueofConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c905f12e-1199-4ad9-af43-f3668773d771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7410e024-b75d-45dd-81d1-813d4f474e70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c905f12e-1199-4ad9-af43-f3668773d771" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7410e024-b75d-45dd-81d1-813d4f474e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4eb2ce46-f4ec-42b9-994d-41544434563e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7410e024-b75d-45dd-81d1-813d4f474e70" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4eb2ce46-f4ec-42b9-994d-41544434563e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904b1c61-632a-4a57-8d6f-ca0178bbb372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4eb2ce46-f4ec-42b9-994d-41544434563e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904b1c61-632a-4a57-8d6f-ca0178bbb372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_bc5c743a-9731-41e3-bea1-c249f2498a18" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904b1c61-632a-4a57-8d6f-ca0178bbb372" xlink:to="loc_rnac_OldCartesianMember_bc5c743a-9731-41e3-bea1-c249f2498a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_b5a7935d-c7d3-4943-88d9-819cfba8ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7410e024-b75d-45dd-81d1-813d4f474e70" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_b5a7935d-c7d3-4943-88d9-819cfba8ef9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2d962db1-b181-415f-a8eb-7ab0e74aa65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_b5a7935d-c7d3-4943-88d9-819cfba8ef9c" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2d962db1-b181-415f-a8eb-7ab0e74aa65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6dac3498-256d-4c35-9c72-3b320b8f31ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2d962db1-b181-415f-a8eb-7ab0e74aa65b" xlink:to="loc_us-gaap_CommonStockMember_6dac3498-256d-4c35-9c72-3b320b8f31ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_88e74b62-eea0-4a2c-99c9-6f86ffccef49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2d962db1-b181-415f-a8eb-7ab0e74aa65b" xlink:to="loc_us-gaap_PreferredStockMember_88e74b62-eea0-4a2c-99c9-6f86ffccef49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_06470d35-8397-4b9b-a9ea-050ad0f4ba84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2d962db1-b181-415f-a8eb-7ab0e74aa65b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_06470d35-8397-4b9b-a9ea-050ad0f4ba84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7196be18-ea99-40af-aec3-a667da4bf99d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7410e024-b75d-45dd-81d1-813d4f474e70" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7196be18-ea99-40af-aec3-a667da4bf99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_24b7e429-5efc-4cc8-90bc-70f36b37cb09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7196be18-ea99-40af-aec3-a667da4bf99d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_24b7e429-5efc-4cc8-90bc-70f36b37cb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ef56145d-6dfe-48e3-9168-fc387c06d5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7196be18-ea99-40af-aec3-a667da4bf99d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ef56145d-6dfe-48e3-9168-fc387c06d5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_08aedcd7-7e4f-4e7d-b46c-99545586e0af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17fdc1d5-0dcb-42b5-836f-a4838cffa25b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_08aedcd7-7e4f-4e7d-b46c-99545586e0af" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17fdc1d5-0dcb-42b5-836f-a4838cffa25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_da443d41-3313-4be4-9c0d-d4943272581b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17fdc1d5-0dcb-42b5-836f-a4838cffa25b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_da443d41-3313-4be4-9c0d-d4943272581b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9d10e8-b8a8-4112-b898-6ecb55e806e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da443d41-3313-4be4-9c0d-d4943272581b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9d10e8-b8a8-4112-b898-6ecb55e806e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_f3de1544-1b2b-4425-b359-7670f43af9ac" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9d10e8-b8a8-4112-b898-6ecb55e806e9" xlink:to="loc_rnac_OldCartesianMember_f3de1544-1b2b-4425-b359-7670f43af9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a92a047b-3c21-46c3-8a10-8de85a3b702a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17fdc1d5-0dcb-42b5-836f-a4838cffa25b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a92a047b-3c21-46c3-8a10-8de85a3b702a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a92a047b-3c21-46c3-8a10-8de85a3b702a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4d947eb0-346a-4709-a8d5-30035475f36f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4d947eb0-346a-4709-a8d5-30035475f36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8e266879-a8df-4fb6-a34d-42d68c8731bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8e266879-a8df-4fb6-a34d-42d68c8731bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f156ca29-d80b-4119-8bca-ca7701df1d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f156ca29-d80b-4119-8bca-ca7701df1d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset_fe704486-f1c6-4bf4-bfa0-105865463076" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset_fe704486-f1c6-4bf4-bfa0-105865463076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6df6a5ce-ad87-4101-9d24-7a827b187aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6df6a5ce-ad87-4101-9d24-7a827b187aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_924f2413-00e0-4ef6-be8b-2e3e3ea481d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_Goodwill_924f2413-00e0-4ef6-be8b-2e3e3ea481d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f70dde56-d1d5-4a36-8fe1-67ce2905731f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a9b9bba-f371-4470-81e7-319a4fa81ebd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f70dde56-d1d5-4a36-8fe1-67ce2905731f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a92a047b-3c21-46c3-8a10-8de85a3b702a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_4762a128-8930-4f02-b4b9-8af73fe6eff3" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_4762a128-8930-4f02-b4b9-8af73fe6eff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability_7417322d-dc47-4031-8bc1-d6435ab58ed2" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability_7417322d-dc47-4031-8bc1-d6435ab58ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability_1677bee6-c4f4-4706-9e20-be0dde9a9211" xlink:href="rnac-20241231.xsd#rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:to="loc_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability_1677bee6-c4f4-4706-9e20-be0dde9a9211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_834018d7-c079-4782-894d-359121251db5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_834018d7-c079-4782-894d-359121251db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_82f6fec6-db35-456d-ac04-59acbb678bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_da3c7c26-a0cc-4b35-8291-7ace0a63d0b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_82f6fec6-db35-456d-ac04-59acbb678bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_333a77cf-197f-41f0-aba8-ea344ecadef3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a92a047b-3c21-46c3-8a10-8de85a3b702a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_333a77cf-197f-41f0-aba8-ea344ecadef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerScheduleofIntangibleAssetsAcquiredDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e4256191-91c1-4b08-9f07-90028daef216" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b7187ba-a129-4e2a-833c-a31894547a54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e4256191-91c1-4b08-9f07-90028daef216" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b7187ba-a129-4e2a-833c-a31894547a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fd3000af-1059-4281-9756-a7f9a19e3155" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b7187ba-a129-4e2a-833c-a31894547a54" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fd3000af-1059-4281-9756-a7f9a19e3155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62e26-8015-4a99-9bf4-35a68b2e4bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fd3000af-1059-4281-9756-a7f9a19e3155" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62e26-8015-4a99-9bf4-35a68b2e4bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_fceec744-fb54-488b-93de-c7a3c7a200ef" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62e26-8015-4a99-9bf4-35a68b2e4bbb" xlink:to="loc_rnac_OldCartesianMember_fceec744-fb54-488b-93de-c7a3c7a200ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1da74bc9-afbc-497f-bf98-ea1e2867c666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b7187ba-a129-4e2a-833c-a31894547a54" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1da74bc9-afbc-497f-bf98-ea1e2867c666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_24d2660c-96e2-48c4-a1ab-b20f5e7dd6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1da74bc9-afbc-497f-bf98-ea1e2867c666" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_24d2660c-96e2-48c4-a1ab-b20f5e7dd6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Descartes08ForMGMember_a3461472-f457-4f71-913e-7be413902b44" xlink:href="rnac-20241231.xsd#rnac_Descartes08ForMGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_24d2660c-96e2-48c4-a1ab-b20f5e7dd6de" xlink:to="loc_rnac_Descartes08ForMGMember_a3461472-f457-4f71-913e-7be413902b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Descartes08ForSLEMember_cf1bf6de-7476-4c5e-b9b1-383d814df7c8" xlink:href="rnac-20241231.xsd#rnac_Descartes08ForSLEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_24d2660c-96e2-48c4-a1ab-b20f5e7dd6de" xlink:to="loc_rnac_Descartes08ForSLEMember_cf1bf6de-7476-4c5e-b9b1-383d814df7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a6afda63-d307-4056-829b-d1be299b868c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b7187ba-a129-4e2a-833c-a31894547a54" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a6afda63-d307-4056-829b-d1be299b868c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d7003181-63f5-4335-8383-da88a66fa87b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6afda63-d307-4056-829b-d1be299b868c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d7003181-63f5-4335-8383-da88a66fa87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e70c7d62-70d9-4be6-9e91-e604f6358d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6afda63-d307-4056-829b-d1be299b868c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e70c7d62-70d9-4be6-9e91-e604f6358d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6ec6a5d0-8ba0-43f1-a95b-5f710108a4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6afda63-d307-4056-829b-d1be299b868c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6ec6a5d0-8ba0-43f1-a95b-5f710108a4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/MergerScheduleofProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#MergerScheduleofProFormaFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/MergerScheduleofProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bf62514d-dfd5-425a-adf1-e1d674fa513e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_94a3c6f9-643c-41a3-a240-d2ec3c5b2fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bf62514d-dfd5-425a-adf1-e1d674fa513e" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_94a3c6f9-643c-41a3-a240-d2ec3c5b2fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_3f6b1ee7-0f02-465e-8536-5f87d377c5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bf62514d-dfd5-425a-adf1-e1d674fa513e" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_3f6b1ee7-0f02-465e-8536-5f87d377c5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dd0c3295-b35e-4e22-b446-0bc75e0565ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_83ad48a6-07d1-48fd-bf7c-c097c3a0a9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dd0c3295-b35e-4e22-b446-0bc75e0565ee" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_83ad48a6-07d1-48fd-bf7c-c097c3a0a9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd256df4-8003-4f96-943d-bf0f3dd0bd29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_83ad48a6-07d1-48fd-bf7c-c097c3a0a9a7" xlink:to="loc_us-gaap_NetIncomeLoss_fd256df4-8003-4f96-943d-bf0f3dd0bd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributedEarnings_d9ddf027-4d71-42bb-9091-338b7a64eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributedEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_83ad48a6-07d1-48fd-bf7c-c097c3a0a9a7" xlink:to="loc_us-gaap_DistributedEarnings_d9ddf027-4d71-42bb-9091-338b7a64eaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_55df1f9e-41ad-41c8-83d9-5a7041fb6eda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_83ad48a6-07d1-48fd-bf7c-c097c3a0a9a7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_55df1f9e-41ad-41c8-83d9-5a7041fb6eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecurities_8c1778e6-e8a5-42bf-8641-6e7555aa53e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_83ad48a6-07d1-48fd-bf7c-c097c3a0a9a7" xlink:to="loc_us-gaap_DilutiveSecurities_8c1778e6-e8a5-42bf-8641-6e7555aa53e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1e75b806-09d7-40d4-a833-6e6e6cebebb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_83ad48a6-07d1-48fd-bf7c-c097c3a0a9a7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1e75b806-09d7-40d4-a833-6e6e6cebebb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_949d1d6a-e4ae-4e16-8750-43d89041e6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dd0c3295-b35e-4e22-b446-0bc75e0565ee" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_949d1d6a-e4ae-4e16-8750-43d89041e6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_55561376-c872-4460-86a3-bf134b41e890" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_949d1d6a-e4ae-4e16-8750-43d89041e6c9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_55561376-c872-4460-86a3-bf134b41e890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2e68e1e1-4c47-4d61-809a-1b2d707034a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_949d1d6a-e4ae-4e16-8750-43d89041e6c9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2e68e1e1-4c47-4d61-809a-1b2d707034a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_af4376ab-c293-40f5-bc67-7f733121cfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_949d1d6a-e4ae-4e16-8750-43d89041e6c9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_af4376ab-c293-40f5-bc67-7f733121cfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_8137e75e-52ab-4de2-accf-70c3a06d8c08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dd0c3295-b35e-4e22-b446-0bc75e0565ee" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_8137e75e-52ab-4de2-accf-70c3a06d8c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_65505e50-9e6c-4248-b914-df32a707b19a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8137e75e-52ab-4de2-accf-70c3a06d8c08" xlink:to="loc_us-gaap_EarningsPerShareBasic_65505e50-9e6c-4248-b914-df32a707b19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7de17475-2eba-428a-a4ff-d408d20d65dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8137e75e-52ab-4de2-accf-70c3a06d8c08" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7de17475-2eba-428a-a4ff-d408d20d65dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_85104b20-e1ea-48b7-9691-a0394fdfbd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8da6e31-10ac-48cb-9eb1-c8babc2c51de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_85104b20-e1ea-48b7-9691-a0394fdfbd3f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8da6e31-10ac-48cb-9eb1-c8babc2c51de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_80994fe2-def2-4ac0-99a4-04f01b3b4cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8da6e31-10ac-48cb-9eb1-c8babc2c51de" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_80994fe2-def2-4ac0-99a4-04f01b3b4cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_80994fe2-def2-4ac0-99a4-04f01b3b4cbc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_7b556813-6113-4827-a095-a0a76714e7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:to="loc_us-gaap_StockCompensationPlanMember_7b556813-6113-4827-a095-a0a76714e7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b1caa41f-55e1-4407-b341-287c314c7bba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:to="loc_us-gaap_WarrantMember_b1caa41f-55e1-4407-b341-287c314c7bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_817fb3d4-09f5-4c20-afe6-17cffbeb9f63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:to="loc_us-gaap_PreferredStockMember_817fb3d4-09f5-4c20-afe6-17cffbeb9f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ForwardContractToIssueSharesMember_0cebc113-d34e-4780-b55f-d8e8250c48b0" xlink:href="rnac-20241231.xsd#rnac_ForwardContractToIssueSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:to="loc_rnac_ForwardContractToIssueSharesMember_0cebc113-d34e-4780-b55f-d8e8250c48b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SeriesAPreferredStockOptionsMember_7dbe6f68-e6ee-4d1d-ac47-c9feb0f3511a" xlink:href="rnac-20241231.xsd#rnac_SeriesAPreferredStockOptionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1730e5af-8c05-475d-a819-c1c045563ef7" xlink:to="loc_rnac_SeriesAPreferredStockOptionsMember_7dbe6f68-e6ee-4d1d-ac47-c9feb0f3511a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ff085094-d09d-4709-81f3-91f82ad3b119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8da6e31-10ac-48cb-9eb1-c8babc2c51de" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ff085094-d09d-4709-81f3-91f82ad3b119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a36e4dd3-c8ae-44a2-867f-9af68fd2e557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ff085094-d09d-4709-81f3-91f82ad3b119" xlink:to="loc_us-gaap_ClassOfStockDomain_a36e4dd3-c8ae-44a2-867f-9af68fd2e557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2ea2df4c-225d-4e8e-b1b7-36b5c5868c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a36e4dd3-c8ae-44a2-867f-9af68fd2e557" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2ea2df4c-225d-4e8e-b1b7-36b5c5868c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_b8202f0f-df01-4184-b8df-c46ac4c5b1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a36e4dd3-c8ae-44a2-867f-9af68fd2e557" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_b8202f0f-df01-4184-b8df-c46ac4c5b1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e41e310e-6abb-40fb-a747-18a9d8539d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8da6e31-10ac-48cb-9eb1-c8babc2c51de" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e41e310e-6abb-40fb-a747-18a9d8539d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_139a25a0-f321-4572-b9c9-cb805d01948b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e41e310e-6abb-40fb-a747-18a9d8539d1d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_139a25a0-f321-4572-b9c9-cb805d01948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_92f9f7c4-59be-4b16-9696-1cadd09182c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_92f9f7c4-59be-4b16-9696-1cadd09182c6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32d37e49-341d-4ea6-822f-08b8510f5041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32d37e49-341d-4ea6-822f-08b8510f5041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c1763540-ddc2-4c4c-b41f-46b1f7386802" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32d37e49-341d-4ea6-822f-08b8510f5041" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c1763540-ddc2-4c4c-b41f-46b1f7386802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_652c1854-d842-44dc-b9bf-c4197db68d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c1763540-ddc2-4c4c-b41f-46b1f7386802" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_652c1854-d842-44dc-b9bf-c4197db68d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_18805806-bc97-4778-9dc6-cc86901ede40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_18805806-bc97-4778-9dc6-cc86901ede40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b285cb00-c013-40a8-949d-025940d8697e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_18805806-bc97-4778-9dc6-cc86901ede40" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b285cb00-c013-40a8-949d-025940d8697e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_51b3abed-1480-4ede-90aa-fea19b9cef62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b285cb00-c013-40a8-949d-025940d8697e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_51b3abed-1480-4ede-90aa-fea19b9cef62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17360b21-fac7-4a5d-8ce6-3079f089b676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17360b21-fac7-4a5d-8ce6-3079f089b676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24b35713-f719-4065-a44f-6b04d940a373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17360b21-fac7-4a5d-8ce6-3079f089b676" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24b35713-f719-4065-a44f-6b04d940a373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_589b5bf6-bc78-498c-a9de-38e3c7222d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24b35713-f719-4065-a44f-6b04d940a373" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_589b5bf6-bc78-498c-a9de-38e3c7222d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_99c7b77b-ef9d-41ca-a3ba-370ba5d404e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24b35713-f719-4065-a44f-6b04d940a373" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_99c7b77b-ef9d-41ca-a3ba-370ba5d404e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_979b0f2a-2497-4226-803b-856887c9a507" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24b35713-f719-4065-a44f-6b04d940a373" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_979b0f2a-2497-4226-803b-856887c9a507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fa3a06f0-07bd-45d2-8c48-7ce55c7f2f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1720a3d1-dd05-4a0e-85f9-e83506046149" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fa3a06f0-07bd-45d2-8c48-7ce55c7f2f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_f2985129-4a9d-452d-8b3c-7ad872e5e798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fa3a06f0-07bd-45d2-8c48-7ce55c7f2f3d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_f2985129-4a9d-452d-8b3c-7ad872e5e798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7338b79a-81f1-45fc-94a2-2a2ff15c1d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f2985129-4a9d-452d-8b3c-7ad872e5e798" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7338b79a-81f1-45fc-94a2-2a2ff15c1d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ed2ebd4d-6d20-4453-82a0-925b92218b61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f2985129-4a9d-452d-8b3c-7ad872e5e798" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ed2ebd4d-6d20-4453-82a0-925b92218b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fa3a06f0-07bd-45d2-8c48-7ce55c7f2f3d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_a89a8bb4-9890-4eef-830c-ffb52779c89b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_a89a8bb4-9890-4eef-830c-ffb52779c89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiability_0b56c3d0-8711-4753-937e-00279a36183a" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:to="loc_rnac_ContingentValueRightLiability_0b56c3d0-8711-4753-937e-00279a36183a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_74fc1b22-eca6-47ee-97ee-f0762ef68ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_74fc1b22-eca6-47ee-97ee-f0762ef68ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_34db10f8-db28-4e81-927d-a6cb6fb5c4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3a1f905a-6162-47b5-b990-0287aab1153b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_34db10f8-db28-4e81-927d-a6cb6fb5c4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b8025850-8c9f-460c-b866-5f916d445006" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c864c781-a748-4feb-bb69-61a12f667b01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b8025850-8c9f-460c-b866-5f916d445006" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c864c781-a748-4feb-bb69-61a12f667b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_77d8b2aa-6867-472c-9b34-05dc33aa9025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b8025850-8c9f-460c-b866-5f916d445006" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_77d8b2aa-6867-472c-9b34-05dc33aa9025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b8025850-8c9f-460c-b866-5f916d445006" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1421a63e-2cfb-4645-96c7-cfe0045eb6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1421a63e-2cfb-4645-96c7-cfe0045eb6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6e646340-a1ed-4a3b-aafc-1b182961c601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1421a63e-2cfb-4645-96c7-cfe0045eb6a3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6e646340-a1ed-4a3b-aafc-1b182961c601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2f67638d-d900-473a-84e1-c01e4572ed77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6e646340-a1ed-4a3b-aafc-1b182961c601" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2f67638d-d900-473a-84e1-c01e4572ed77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_d244e75e-134e-411c-af76-07ce142d02cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_ValuationTechniqueAxis_d244e75e-134e-411c-af76-07ce142d02cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_2628a7d7-3316-477a-a91d-e9e84085324f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_d244e75e-134e-411c-af76-07ce142d02cb" xlink:to="loc_us-gaap_ValuationTechniqueDomain_2628a7d7-3316-477a-a91d-e9e84085324f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_776b6f02-b09d-447d-b24f-5bfcb8fa1f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_2628a7d7-3316-477a-a91d-e9e84085324f" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_776b6f02-b09d-447d-b24f-5bfcb8fa1f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01fda84c-3ce5-4708-822a-c97df4d182d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01fda84c-3ce5-4708-822a-c97df4d182d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1482b21d-bf1f-41a6-8ced-e5b920241553" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01fda84c-3ce5-4708-822a-c97df4d182d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1482b21d-bf1f-41a6-8ced-e5b920241553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_f51b1f29-f943-48eb-9283-bb9c1a85948b" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1482b21d-bf1f-41a6-8ced-e5b920241553" xlink:to="loc_rnac_OldCartesianMember_f51b1f29-f943-48eb-9283-bb9c1a85948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_85513935-3951-45be-8e56-f1a3a88aa060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_85513935-3951-45be-8e56-f1a3a88aa060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_12e2349d-0ecc-41c1-86da-ee18ba85f041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_85513935-3951-45be-8e56-f1a3a88aa060" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_12e2349d-0ecc-41c1-86da-ee18ba85f041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2022WarrantsMember_14bfa608-374b-4b7a-be4e-31901deb5fda" xlink:href="rnac-20241231.xsd#rnac_A2022WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_12e2349d-0ecc-41c1-86da-ee18ba85f041" xlink:to="loc_rnac_A2022WarrantsMember_14bfa608-374b-4b7a-be4e-31901deb5fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9299da9b-b7e0-4220-a3f6-32ab11038c45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9299da9b-b7e0-4220-a3f6-32ab11038c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a146391f-17e9-4863-b3bb-f3a82796d425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9299da9b-b7e0-4220-a3f6-32ab11038c45" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a146391f-17e9-4863-b3bb-f3a82796d425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightMember_b8d5a359-434e-4787-aa65-d8e340ec7609" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a146391f-17e9-4863-b3bb-f3a82796d425" xlink:to="loc_rnac_ContingentValueRightMember_b8d5a359-434e-4787-aa65-d8e340ec7609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_859a8aaf-8b13-4b47-9629-aa888f827af0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_859a8aaf-8b13-4b47-9629-aa888f827af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_a28b3453-fb8a-464c-8007-0267a95f5a97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_859a8aaf-8b13-4b47-9629-aa888f827af0" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_a28b3453-fb8a-464c-8007-0267a95f5a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_508aaf67-f04c-4c79-902d-bec319c70b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_a28b3453-fb8a-464c-8007-0267a95f5a97" xlink:to="loc_us-gaap_PreferredStockMember_508aaf67-f04c-4c79-902d-bec319c70b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ff85f5-9b53-4fe9-9b30-4284f5ef39d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ff85f5-9b53-4fe9-9b30-4284f5ef39d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f0c20e97-be6e-4f4a-a485-0de2dc530a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ff85f5-9b53-4fe9-9b30-4284f5ef39d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f0c20e97-be6e-4f4a-a485-0de2dc530a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member_01de8263-910a-4833-842e-c6fa16b73543" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f0c20e97-be6e-4f4a-a485-0de2dc530a3e" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2023Member_01de8263-910a-4833-842e-c6fa16b73543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2ce0e954-9b0a-4f03-bc24-347235234883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2ce0e954-9b0a-4f03-bc24-347235234883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_90ffa84a-3ec9-4518-9caf-94b2aefd2373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ce0e954-9b0a-4f03-bc24-347235234883" xlink:to="loc_us-gaap_ClassOfStockDomain_90ffa84a-3ec9-4518-9caf-94b2aefd2373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_693e6ceb-b93d-4a48-9dd6-c605914cda85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_90ffa84a-3ec9-4518-9caf-94b2aefd2373" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_693e6ceb-b93d-4a48-9dd6-c605914cda85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8e28a22a-bb4f-4f7b-802f-b5b5a8b0804c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_srt_CounterpartyNameAxis_8e28a22a-bb4f-4f7b-802f-b5b5a8b0804c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_01eb0595-6f1a-4f2e-8ab8-7b0814e0465d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8e28a22a-bb4f-4f7b-802f-b5b5a8b0804c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_01eb0595-6f1a-4f2e-8ab8-7b0814e0465d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SOBIPurchaseAgreementMember_f91243d1-8080-4212-9613-00f9264b16dd" xlink:href="rnac-20241231.xsd#rnac_SOBIPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_01eb0595-6f1a-4f2e-8ab8-7b0814e0465d" xlink:to="loc_rnac_SOBIPurchaseAgreementMember_f91243d1-8080-4212-9613-00f9264b16dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_855ce65e-d2d5-4952-a7d7-34c91771459e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_855ce65e-d2d5-4952-a7d7-34c91771459e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a2c1c2f-a400-493f-aff9-7e76cd931304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_855ce65e-d2d5-4952-a7d7-34c91771459e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a2c1c2f-a400-493f-aff9-7e76cd931304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4dd9f39d-cbbe-4232-9e66-5db53ebe9e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a2c1c2f-a400-493f-aff9-7e76cd931304" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4dd9f39d-cbbe-4232-9e66-5db53ebe9e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_76079788-cb3a-4105-91ee-f6c695d1fefd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f010cec1-7a72-4a85-acc0-89beb37ca53d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f010cec1-7a72-4a85-acc0-89beb37ca53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6a04fe42-84e0-4a59-ba29-1102790b700d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6a04fe42-84e0-4a59-ba29-1102790b700d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_a579e119-c983-43ba-9633-0029f0ab99a2" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed_a579e119-c983-43ba-9633-0029f0ab99a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead_7c7036ef-e8a4-4a67-ab04-a74d86887fa4" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead_7c7036ef-e8a4-4a67-ab04-a74d86887fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dfcad98a-2556-42ea-8659-6db9b6024e34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dfcad98a-2556-42ea-8659-6db9b6024e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_9ec0f8cc-c4df-436e-aa5e-f4dd6cb7c51f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_9ec0f8cc-c4df-436e-aa5e-f4dd6cb7c51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c71ed4f7-3f2f-44ec-9559-6fd1621fc355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c71ed4f7-3f2f-44ec-9559-6fd1621fc355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_55dd23dc-63fe-4846-b1fc-9b8b7bb6be4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_55dd23dc-63fe-4846-b1fc-9b8b7bb6be4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_febdc202-655c-449c-b6e9-a3c158d92d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_febdc202-655c-449c-b6e9-a3c158d92d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SettlementOfDerivativeLiabilityShares_37d89aec-dbbf-4f62-ba9d-3287d522f072" xlink:href="rnac-20241231.xsd#rnac_SettlementOfDerivativeLiabilityShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_rnac_SettlementOfDerivativeLiabilityShares_37d89aec-dbbf-4f62-ba9d-3287d522f072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IssuanceOfStockForSettlementOfForwardContractLiability_d1caa97f-8089-4b49-a261-3cab6b05ca32" xlink:href="rnac-20241231.xsd#rnac_IssuanceOfStockForSettlementOfForwardContractLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ab5adfd1-dc31-4799-be6c-1e6a6e9a3f0e" xlink:to="loc_rnac_IssuanceOfStockForSettlementOfForwardContractLiability_d1caa97f-8089-4b49-a261-3cab6b05ca32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1c99453c-ec5c-40e4-83c1-fb95fcc47c72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d9edc5c-6bf5-40da-b669-bccfb2a933a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1c99453c-ec5c-40e4-83c1-fb95fcc47c72" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d9edc5c-6bf5-40da-b669-bccfb2a933a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_555bbe79-e352-4ce7-abd1-eecdb45ea567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1c99453c-ec5c-40e4-83c1-fb95fcc47c72" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_555bbe79-e352-4ce7-abd1-eecdb45ea567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d601d111-d416-493c-8847-b45ce5c91832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1c99453c-ec5c-40e4-83c1-fb95fcc47c72" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d601d111-d416-493c-8847-b45ce5c91832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4e517de2-bffa-491e-a9db-f88dff5ebbca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4e517de2-bffa-491e-a9db-f88dff5ebbca" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_adb28cae-7b59-45e3-b6b3-c298af51e99f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:to="loc_us-gaap_ValuationTechniqueAxis_adb28cae-7b59-45e3-b6b3-c298af51e99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_359b0049-9717-4711-a6b5-b1fd114fff29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_adb28cae-7b59-45e3-b6b3-c298af51e99f" xlink:to="loc_us-gaap_ValuationTechniqueDomain_359b0049-9717-4711-a6b5-b1fd114fff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_e92c056a-f657-48e8-99df-3d5bb50d08f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_359b0049-9717-4711-a6b5-b1fd114fff29" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_e92c056a-f657-48e8-99df-3d5bb50d08f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_62f52111-1b09-4cac-baff-f9d97f739b81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_62f52111-1b09-4cac-baff-f9d97f739b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_62f52111-1b09-4cac-baff-f9d97f739b81" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6d0d4a2c-401b-4dd9-a880-0f100aa8b7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6d0d4a2c-401b-4dd9-a880-0f100aa8b7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b96ecea6-e7e8-45e0-b1e5-cd944f0f3246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b96ecea6-e7e8-45e0-b1e5-cd944f0f3246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_c36e4a1b-1c64-43d6-8ae7-ad269b7085d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_c36e4a1b-1c64-43d6-8ae7-ad269b7085d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_4b350f8f-d989-491e-9b22-91650566b245" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_282bdf75-b321-4749-ad4a-2777ab43712e" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_4b350f8f-d989-491e-9b22-91650566b245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_139ffe9a-90d8-4438-99f0-b801fdc26e01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_139ffe9a-90d8-4438-99f0-b801fdc26e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ad417133-e5b8-4e6d-96ba-a03f546d6a71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_139ffe9a-90d8-4438-99f0-b801fdc26e01" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ad417133-e5b8-4e6d-96ba-a03f546d6a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2019WarrantsMember_1b7f6607-0689-4494-839d-6ca976722077" xlink:href="rnac-20241231.xsd#rnac_A2019WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad417133-e5b8-4e6d-96ba-a03f546d6a71" xlink:to="loc_rnac_A2019WarrantsMember_1b7f6607-0689-4494-839d-6ca976722077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2022WarrantsMember_d87390db-e98f-4846-b4ef-935d05e53860" xlink:href="rnac-20241231.xsd#rnac_A2022WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad417133-e5b8-4e6d-96ba-a03f546d6a71" xlink:to="loc_rnac_A2022WarrantsMember_d87390db-e98f-4846-b4ef-935d05e53860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_dbde944c-de8a-4c33-b0fa-d9a824ebb423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ea87cd09-a053-4881-8514-0bbcad7b17d7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_dbde944c-de8a-4c33-b0fa-d9a824ebb423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f169cd3e-36be-46f5-be19-6f0489352532" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_dbde944c-de8a-4c33-b0fa-d9a824ebb423" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f169cd3e-36be-46f5-be19-6f0489352532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f4513049-d84a-4376-a6c5-12246ad15488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_dbde944c-de8a-4c33-b0fa-d9a824ebb423" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f4513049-d84a-4376-a6c5-12246ad15488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_959dd026-9bd5-4207-a233-aa2abb47a587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ec70468-be53-4384-a4fc-91f5e3040e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_959dd026-9bd5-4207-a233-aa2abb47a587" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ec70468-be53-4384-a4fc-91f5e3040e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_6a08a28a-732f-45d0-9fe3-7bbc49b375ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ec70468-be53-4384-a4fc-91f5e3040e3f" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_6a08a28a-732f-45d0-9fe3-7bbc49b375ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fe3f0aee-1bdf-4158-8639-1a49825a1697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_6a08a28a-732f-45d0-9fe3-7bbc49b375ef" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fe3f0aee-1bdf-4158-8639-1a49825a1697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_82491ae3-46de-4df4-a0fa-dd3dc1132698" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fe3f0aee-1bdf-4158-8639-1a49825a1697" xlink:to="loc_us-gaap_WarrantMember_82491ae3-46de-4df4-a0fa-dd3dc1132698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightMember_f183496e-bf6c-428d-9d6b-6db2e7a5ce42" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fe3f0aee-1bdf-4158-8639-1a49825a1697" xlink:to="loc_rnac_ContingentValueRightMember_f183496e-bf6c-428d-9d6b-6db2e7a5ce42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_923c008a-33cc-4a8f-9c19-38c72407f1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ec70468-be53-4384-a4fc-91f5e3040e3f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_923c008a-33cc-4a8f-9c19-38c72407f1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37f43ac0-99aa-4e72-b9e2-16d689ff1ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_923c008a-33cc-4a8f-9c19-38c72407f1d2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37f43ac0-99aa-4e72-b9e2-16d689ff1ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_53015746-ef14-47b5-b422-cb24a4a4e895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37f43ac0-99aa-4e72-b9e2-16d689ff1ad2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_53015746-ef14-47b5-b422-cb24a4a4e895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_997f4c23-5e9c-4951-9d74-7592a40af13c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37f43ac0-99aa-4e72-b9e2-16d689ff1ad2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_997f4c23-5e9c-4951-9d74-7592a40af13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e9fe9160-0c1b-4a2b-aef7-3af1025315c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37f43ac0-99aa-4e72-b9e2-16d689ff1ad2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e9fe9160-0c1b-4a2b-aef7-3af1025315c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b78cf8c3-6402-4293-b40c-10f3166f8ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b78cf8c3-6402-4293-b40c-10f3166f8ccf" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ff894ed-da5a-4e0e-85a0-6db833b894e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ff894ed-da5a-4e0e-85a0-6db833b894e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97df625c-73c0-469b-8117-06ffbdb51cff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ff894ed-da5a-4e0e-85a0-6db833b894e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97df625c-73c0-469b-8117-06ffbdb51cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5f2a34f5-7d93-4f6b-8909-affbd84c7b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97df625c-73c0-469b-8117-06ffbdb51cff" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5f2a34f5-7d93-4f6b-8909-affbd84c7b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e7156c50-2c00-4284-8706-b34f15b91cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e7156c50-2c00-4284-8706-b34f15b91cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5a64aba6-b1d5-42fb-a0d2-c6c80ec3dcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e7156c50-2c00-4284-8706-b34f15b91cc3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5a64aba6-b1d5-42fb-a0d2-c6c80ec3dcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ProbabilityOfSuccessMember_a27bdc7c-cdac-48ac-a67c-43ed66ad00b3" xlink:href="rnac-20241231.xsd#rnac_ProbabilityOfSuccessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5a64aba6-b1d5-42fb-a0d2-c6c80ec3dcbc" xlink:to="loc_rnac_ProbabilityOfSuccessMember_a27bdc7c-cdac-48ac-a67c-43ed66ad00b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_MeasurementInputRevenueVolatilityMember_b9d80c86-7fed-4189-9098-f36f33880ca9" xlink:href="rnac-20241231.xsd#rnac_MeasurementInputRevenueVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5a64aba6-b1d5-42fb-a0d2-c6c80ec3dcbc" xlink:to="loc_rnac_MeasurementInputRevenueVolatilityMember_b9d80c86-7fed-4189-9098-f36f33880ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_ba80b9fc-cefc-481e-9df2-3c876f0cfe42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5a64aba6-b1d5-42fb-a0d2-c6c80ec3dcbc" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_ba80b9fc-cefc-481e-9df2-3c876f0cfe42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e24e5276-6e37-4395-b68c-c01e80a31cbf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:to="loc_srt_RangeAxis_e24e5276-6e37-4395-b68c-c01e80a31cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_12e06aa8-a664-4f73-9bf0-dcfa4d5e7b4f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e24e5276-6e37-4395-b68c-c01e80a31cbf" xlink:to="loc_srt_RangeMember_12e06aa8-a664-4f73-9bf0-dcfa4d5e7b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d444faa-1f97-4cd4-9bd1-5426d2950089" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_12e06aa8-a664-4f73-9bf0-dcfa4d5e7b4f" xlink:to="loc_srt_MinimumMember_9d444faa-1f97-4cd4-9bd1-5426d2950089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3881cb74-c5a8-4af4-bbff-cae209a3fa8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_12e06aa8-a664-4f73-9bf0-dcfa4d5e7b4f" xlink:to="loc_srt_MaximumMember_3881cb74-c5a8-4af4-bbff-cae209a3fa8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_899e6bd9-0a7d-4b00-97cb-eebc9929292b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_39494b2b-b015-4749-9a2d-67590d35f6be" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_899e6bd9-0a7d-4b00-97cb-eebc9929292b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContingentValueRightLiabilityMeasurementInput_22c91bfe-42cd-4dbd-8add-c5ae91225953" xlink:href="rnac-20241231.xsd#rnac_ContingentValueRightLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_899e6bd9-0a7d-4b00-97cb-eebc9929292b" xlink:to="loc_rnac_ContingentValueRightLiabilityMeasurementInput_22c91bfe-42cd-4dbd-8add-c5ae91225953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1c3e4154-8d71-4deb-9059-35f67ccfba8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c021c342-1e3a-47bc-b8aa-6adff6651437" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1c3e4154-8d71-4deb-9059-35f67ccfba8e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c021c342-1e3a-47bc-b8aa-6adff6651437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_a03968b3-261b-44b5-b582-82ff6b3e1de1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c021c342-1e3a-47bc-b8aa-6adff6651437" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_a03968b3-261b-44b5-b582-82ff6b3e1de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_29246700-fc82-4501-8d95-795622fe82ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c021c342-1e3a-47bc-b8aa-6adff6651437" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_29246700-fc82-4501-8d95-795622fe82ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_99ac39f4-7f6c-4c9c-b8d8-8ad530606400" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c021c342-1e3a-47bc-b8aa-6adff6651437" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_99ac39f4-7f6c-4c9c-b8d8-8ad530606400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_49d7bfd4-b463-4712-9d46-6cecfaa31746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c021c342-1e3a-47bc-b8aa-6adff6651437" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_49d7bfd4-b463-4712-9d46-6cecfaa31746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList_95355f44-e8e2-40fe-aa3a-68d61374e960" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c021c342-1e3a-47bc-b8aa-6adff6651437" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList_95355f44-e8e2-40fe-aa3a-68d61374e960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_10b89b26-e4f8-4ac8-ac4b-0df8532286d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_50a106e6-de49-490d-a70e-58659e2f76e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_10b89b26-e4f8-4ac8-ac4b-0df8532286d8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_50a106e6-de49-490d-a70e-58659e2f76e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_48e644bc-7851-4e19-b08a-0b3a5b204936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_50a106e6-de49-490d-a70e-58659e2f76e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_48e644bc-7851-4e19-b08a-0b3a5b204936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_48e644bc-7851-4e19-b08a-0b3a5b204936" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LaboratoryEquipmentMember_e21e59b9-c867-4043-80a3-995dbb155fe4" xlink:href="rnac-20241231.xsd#rnac_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_rnac_LaboratoryEquipmentMember_e21e59b9-c867-4043-80a3-995dbb155fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d5bb91c2-83e3-48c7-9264-ab1bc7c57c96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_us-gaap_ComputerEquipmentMember_d5bb91c2-83e3-48c7-9264-ab1bc7c57c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_eaff684b-9b2f-4c64-970b-5db01d5c4797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_eaff684b-9b2f-4c64-970b-5db01d5c4797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ed9d6e2d-dd78-4009-9053-8112ecc9e7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ed9d6e2d-dd78-4009-9053-8112ecc9e7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_59cc9c92-7174-4daf-a9e5-0595b7d66c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_us-gaap_OfficeEquipmentMember_59cc9c92-7174-4daf-a9e5-0595b7d66c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_8c32c61d-2fd1-48c3-a6ee-9fbe1626bfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c07fe185-ae0c-4806-9d66-3f8d75e873e3" xlink:to="loc_us-gaap_ConstructionInProgressMember_8c32c61d-2fd1-48c3-a6ee-9fbe1626bfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d217edc7-051c-46a7-8104-679336c892e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_50a106e6-de49-490d-a70e-58659e2f76e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d217edc7-051c-46a7-8104-679336c892e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_36864527-eebe-4b48-8fc3-4d82aafea5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d217edc7-051c-46a7-8104-679336c892e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_36864527-eebe-4b48-8fc3-4d82aafea5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_04e8e6c6-cd9f-4f1e-88ad-cd401f527ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d217edc7-051c-46a7-8104-679336c892e9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_04e8e6c6-cd9f-4f1e-88ad-cd401f527ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4229a6b0-24af-4c1d-b905-ea09f8d951f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d217edc7-051c-46a7-8104-679336c892e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4229a6b0-24af-4c1d-b905-ea09f8d951f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_12cf1a79-33c7-4a95-98ed-1912fc1de2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5f23e264-b518-4ac8-846d-5329a34c8c88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_12cf1a79-33c7-4a95-98ed-1912fc1de2bc" xlink:to="loc_us-gaap_Depreciation_5f23e264-b518-4ac8-846d-5329a34c8c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_abeb9e9d-051a-46ac-a6b6-3c4d79398ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7d2c0e1c-5885-4819-bb50-e4897d37d6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_abeb9e9d-051a-46ac-a6b6-3c4d79398ab5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7d2c0e1c-5885-4819-bb50-e4897d37d6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedPatentFeesCurrent_74d2b351-a095-44bb-95a4-148b9d1bd9cf" xlink:href="rnac-20241231.xsd#rnac_AccruedPatentFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_abeb9e9d-051a-46ac-a6b6-3c4d79398ab5" xlink:to="loc_rnac_AccruedPatentFeesCurrent_74d2b351-a095-44bb-95a4-148b9d1bd9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedResearchAndDevelopmentCostsCurrent_b777db0e-c1ac-43e9-ace0-2e60281ee827" xlink:href="rnac-20241231.xsd#rnac_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_abeb9e9d-051a-46ac-a6b6-3c4d79398ab5" xlink:to="loc_rnac_AccruedResearchAndDevelopmentCostsCurrent_b777db0e-c1ac-43e9-ace0-2e60281ee827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedAuditFeesCurrent_2df2ed5a-4de9-419b-9305-d4d2ec78ec79" xlink:href="rnac-20241231.xsd#rnac_AccruedAuditFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_abeb9e9d-051a-46ac-a6b6-3c4d79398ab5" xlink:to="loc_rnac_AccruedAuditFeesCurrent_2df2ed5a-4de9-419b-9305-d4d2ec78ec79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AccruedPropertyPlantAndEquipmentCurrent_4a6494fa-1d94-4fcb-b019-3ae65faeee8d" xlink:href="rnac-20241231.xsd#rnac_AccruedPropertyPlantAndEquipmentCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_abeb9e9d-051a-46ac-a6b6-3c4d79398ab5" xlink:to="loc_rnac_AccruedPropertyPlantAndEquipmentCurrent_4a6494fa-1d94-4fcb-b019-3ae65faeee8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_567bc72f-1f98-4dec-a4ae-1f655c89023a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_abeb9e9d-051a-46ac-a6b6-3c4d79398ab5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_567bc72f-1f98-4dec-a4ae-1f655c89023a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7835a2fc-3245-4df2-987e-c61ad9c1f7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_abeb9e9d-051a-46ac-a6b6-3c4d79398ab5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7835a2fc-3245-4df2-987e-c61ad9c1f7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#Leases7495NewHorizonWayLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9cae2e2e-eefd-43d6-a6b2-5450abee276d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2d951e21-b6e8-4b0a-9851-c78e66ee74c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9cae2e2e-eefd-43d6-a6b2-5450abee276d" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2d951e21-b6e8-4b0a-9851-c78e66ee74c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementAxis_08c1b591-3796-431a-93e9-c66aac116464" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2d951e21-b6e8-4b0a-9851-c78e66ee74c4" xlink:to="loc_rnac_LeaseArrangementAxis_08c1b591-3796-431a-93e9-c66aac116464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_35754239-1d7b-4fcd-aaab-a07627cfd860" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_LeaseArrangementAxis_08c1b591-3796-431a-93e9-c66aac116464" xlink:to="loc_rnac_LeaseArrangementDomain_35754239-1d7b-4fcd-aaab-a07627cfd860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A7495NewHorizonWayLeaseMember_d17d0d22-aed6-4152-9175-84d4efec42cc" xlink:href="rnac-20241231.xsd#rnac_A7495NewHorizonWayLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_LeaseArrangementDomain_35754239-1d7b-4fcd-aaab-a07627cfd860" xlink:to="loc_rnac_A7495NewHorizonWayLeaseMember_d17d0d22-aed6-4152-9175-84d4efec42cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d8290023-5490-48c6-a7eb-c3dad2321c6d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2d951e21-b6e8-4b0a-9851-c78e66ee74c4" xlink:to="loc_srt_RangeAxis_d8290023-5490-48c6-a7eb-c3dad2321c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f323a234-14e4-48bc-bcf5-170a1f5e3425" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d8290023-5490-48c6-a7eb-c3dad2321c6d" xlink:to="loc_srt_RangeMember_f323a234-14e4-48bc-bcf5-170a1f5e3425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a78d5749-40fb-4f38-9c27-41713c7c8378" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f323a234-14e4-48bc-bcf5-170a1f5e3425" xlink:to="loc_srt_MinimumMember_a78d5749-40fb-4f38-9c27-41713c7c8378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4270227d-7890-45a5-bc21-f27f0a1a6022" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f323a234-14e4-48bc-bcf5-170a1f5e3425" xlink:to="loc_srt_MaximumMember_4270227d-7890-45a5-bc21-f27f0a1a6022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2d951e21-b6e8-4b0a-9851-c78e66ee74c4" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_fdd65c30-e21c-4868-bae6-7b3b46c53680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_fdd65c30-e21c-4868-bae6-7b3b46c53680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7a88b7b3-7b17-4a95-9a17-f5a14469bdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7a88b7b3-7b17-4a95-9a17-f5a14469bdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend_2b724a58-0c02-4d22-81eb-9a0dea2362bd" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseNumberOfOptionsToExtend"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend_2b724a58-0c02-4d22-81eb-9a0dea2362bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ae3f8c54-17a6-4028-8623-839f085a21f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ae3f8c54-17a6-4028-8623-839f085a21f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLeaseCostPercentage_07460ff1-3c0c-4614-a11f-17c023b31332" xlink:href="rnac-20241231.xsd#rnac_OperatingLeaseCostPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_OperatingLeaseCostPercentage_07460ff1-3c0c-4614-a11f-17c023b31332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseMonthlyBaseRent_69ae43d9-7ab7-445d-a9e0-5d1798eb4685" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseMonthlyBaseRent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_LesseeOperatingLeaseMonthlyBaseRent_69ae43d9-7ab7-445d-a9e0-5d1798eb4685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne_22d1aa82-222b-4782-8bbf-9f08b1cd35b8" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne_22d1aa82-222b-4782-8bbf-9f08b1cd35b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement_7f5601c0-9a33-4685-a831-581b761e19a6" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement_7f5601c0-9a33-4685-a831-581b761e19a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4ff5430b-2d1d-4097-a84f-6d2daa5e7b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_OperatingLeaseLiability_4ff5430b-2d1d-4097-a84f-6d2daa5e7b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_684f1c54-05d6-450a-bbff-735c812290bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_684f1c54-05d6-450a-bbff-735c812290bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability_a15ee0f9-afe3-4a38-8781-4ea06b35c790" xlink:href="rnac-20241231.xsd#rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability_a15ee0f9-afe3-4a38-8781-4ea06b35c790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fff31d18-ff51-43c6-9d81-22716b6db51a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fff31d18-ff51-43c6-9d81-22716b6db51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne_22111bcb-5933-4fa3-9e38-3acb7ae22289" xlink:href="rnac-20241231.xsd#rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne_22111bcb-5933-4fa3-9e38-3acb7ae22289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b6f9f375-68f6-4ea7-b7bc-f7ceb24fd64e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_db774100-d75e-4cd0-9676-ea3b4055203f" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b6f9f375-68f6-4ea7-b7bc-f7ceb24fd64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#Leases65GroveStreetLeaseNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_18bbc95e-f150-4367-97f7-5f391ca7bf59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_18bbc95e-f150-4367-97f7-5f391ca7bf59" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementAxis_10dbff29-2671-4b18-846e-ecedfe463264" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:to="loc_rnac_LeaseArrangementAxis_10dbff29-2671-4b18-846e-ecedfe463264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_ab300fe8-7257-4100-8a94-d6719ac64418" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_LeaseArrangementAxis_10dbff29-2671-4b18-846e-ecedfe463264" xlink:to="loc_rnac_LeaseArrangementDomain_ab300fe8-7257-4100-8a94-d6719ac64418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A65GroveStreetWatertownMAMember_f1a77de4-6662-497e-a476-8c68e3c36c1f" xlink:href="rnac-20241231.xsd#rnac_A65GroveStreetWatertownMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_LeaseArrangementDomain_ab300fe8-7257-4100-8a94-d6719ac64418" xlink:to="loc_rnac_A65GroveStreetWatertownMAMember_f1a77de4-6662-497e-a476-8c68e3c36c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9b1cbc6d-79ff-4607-a033-9f7e2e611782" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:to="loc_us-gaap_CreditFacilityAxis_9b1cbc6d-79ff-4607-a033-9f7e2e611782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e2c33f3e-b9ad-4fb7-bd9b-54c88c93bd20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9b1cbc6d-79ff-4607-a033-9f7e2e611782" xlink:to="loc_us-gaap_CreditFacilityDomain_e2c33f3e-b9ad-4fb7-bd9b-54c88c93bd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_928ff8ad-0a4e-4611-a163-0ccd0e0fc701" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_e2c33f3e-b9ad-4fb7-bd9b-54c88c93bd20" xlink:to="loc_us-gaap_LetterOfCreditMember_928ff8ad-0a4e-4611-a163-0ccd0e0fc701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5bedfc35-d1c4-4902-bc88-1a65d1e1de2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5bedfc35-d1c4-4902-bc88-1a65d1e1de2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2eed2426-e4a5-497d-88e4-16c53bdd8765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5bedfc35-d1c4-4902-bc88-1a65d1e1de2f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2eed2426-e4a5-497d-88e4-16c53bdd8765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2da0c482-d8fc-432c-84db-3cb1eaea3caf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2eed2426-e4a5-497d-88e4-16c53bdd8765" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2da0c482-d8fc-432c-84db-3cb1eaea3caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_77cd287d-0c01-4b40-a1c2-c1df526393e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2eed2426-e4a5-497d-88e4-16c53bdd8765" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_77cd287d-0c01-4b40-a1c2-c1df526393e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7d3263d4-885d-4025-aa36-9071ef217716" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_3d99909b-863d-4203-ba1e-9b243b9c1c79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_3d99909b-863d-4203-ba1e-9b243b9c1c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_17bc9f6a-0b1f-4570-abbe-9afb991d763e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_LeaseCost_17bc9f6a-0b1f-4570-abbe-9afb991d763e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_91f7a860-a877-4e3d-9c2a-3f0f2c6c023a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_91f7a860-a877-4e3d-9c2a-3f0f2c6c023a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_995c021b-c371-4d6e-94b4-c7b9635045b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_995c021b-c371-4d6e-94b4-c7b9635045b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d526e59e-8816-4804-8b0e-db2336cc8878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_RestrictedCash_d526e59e-8816-4804-8b0e-db2336cc8878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLeaseBaseRent_26c5e0cb-f2c4-480f-8b9b-937053db7e74" xlink:href="rnac-20241231.xsd#rnac_OperatingLeaseBaseRent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_rnac_OperatingLeaseBaseRent_26c5e0cb-f2c4-480f-8b9b-937053db7e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c855e348-b0bf-4380-86e4-c4f95cdc938f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c855e348-b0bf-4380-86e4-c4f95cdc938f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b2310a6c-fcb9-401d-920b-1149f21f1d86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_OperatingLeaseLiability_b2310a6c-fcb9-401d-920b-1149f21f1d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5b0760d6-30ef-49ce-831c-038c4ad0a3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5b0760d6-30ef-49ce-831c-038c4ad0a3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_41d5b9ff-3809-45f7-afba-bb39ccb859b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_41d5b9ff-3809-45f7-afba-bb39ccb859b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_UpfrontRentalPayment_d40e13f3-74d3-4b9d-8d30-a4be4ebbe6c4" xlink:href="rnac-20241231.xsd#rnac_UpfrontRentalPayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_rnac_UpfrontRentalPayment_d40e13f3-74d3-4b9d-8d30-a4be4ebbe6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_7267ae33-724c-4226-928c-20cf6810f84f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_7267ae33-724c-4226-928c-20cf6810f84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3f0c6ede-445b-4150-99f5-15c219b0ebe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_AssetImpairmentCharges_3f0c6ede-445b-4150-99f5-15c219b0ebe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_8ff401a1-d7ab-4335-b5b3-5e09cf45c964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_8ff401a1-d7ab-4335-b5b3-5e09cf45c964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_da8ad8ba-a727-4a1b-8b77-1a1d78601d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5e218a01-987b-4f94-b471-81f0b82f3589" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_da8ad8ba-a727-4a1b-8b77-1a1d78601d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_19b3981d-d996-4f30-94d0-ffec5d6a3521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_da8ad8ba-a727-4a1b-8b77-1a1d78601d3b" xlink:to="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_19b3981d-d996-4f30-94d0-ffec5d6a3521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#Leases704QuinceOrchardRoadLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_259c081f-b76f-47ff-8a5a-2f7faa853acc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_36f42d3e-af08-4b82-8261-87e0b286adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_259c081f-b76f-47ff-8a5a-2f7faa853acc" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_36f42d3e-af08-4b82-8261-87e0b286adb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementAxis_18487010-23d4-4488-aeb7-b7f7fcf55e04" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_36f42d3e-af08-4b82-8261-87e0b286adb2" xlink:to="loc_rnac_LeaseArrangementAxis_18487010-23d4-4488-aeb7-b7f7fcf55e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_a830ee3c-4c4c-419c-b5f5-55fff3072803" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_LeaseArrangementAxis_18487010-23d4-4488-aeb7-b7f7fcf55e04" xlink:to="loc_rnac_LeaseArrangementDomain_a830ee3c-4c4c-419c-b5f5-55fff3072803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A704QuinceOrchardRoadLeasesMember_cca5b1a7-9ac3-4d58-8060-1c08abcc4790" xlink:href="rnac-20241231.xsd#rnac_A704QuinceOrchardRoadLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_LeaseArrangementDomain_a830ee3c-4c4c-419c-b5f5-55fff3072803" xlink:to="loc_rnac_A704QuinceOrchardRoadLeasesMember_cca5b1a7-9ac3-4d58-8060-1c08abcc4790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_1454d5ad-e710-4253-9355-5c3fcfdb783e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_36f42d3e-af08-4b82-8261-87e0b286adb2" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_1454d5ad-e710-4253-9355-5c3fcfdb783e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NumberOfAcquiredOperatingLeases_36a4b9fd-54e9-4035-b25a-05e1ea330b6f" xlink:href="rnac-20241231.xsd#rnac_NumberOfAcquiredOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1454d5ad-e710-4253-9355-5c3fcfdb783e" xlink:to="loc_rnac_NumberOfAcquiredOperatingLeases_36a4b9fd-54e9-4035-b25a-05e1ea330b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_658f6df3-2cbb-42e5-847f-f2f2c7362b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1454d5ad-e710-4253-9355-5c3fcfdb783e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_658f6df3-2cbb-42e5-847f-f2f2c7362b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#LeasesMoscowRussiaLeaseNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_16fb877f-6c30-426e-8ec5-d0fb2217763e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_18e767a8-46af-4a84-9f7c-8d6292a0c8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16fb877f-6c30-426e-8ec5-d0fb2217763e" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_18e767a8-46af-4a84-9f7c-8d6292a0c8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementAxis_90dcae23-fc75-4007-836b-93c583ba9193" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_18e767a8-46af-4a84-9f7c-8d6292a0c8bb" xlink:to="loc_rnac_LeaseArrangementAxis_90dcae23-fc75-4007-836b-93c583ba9193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LeaseArrangementDomain_354f64ac-b132-4f66-a277-2bcebda2e5a2" xlink:href="rnac-20241231.xsd#rnac_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_LeaseArrangementAxis_90dcae23-fc75-4007-836b-93c583ba9193" xlink:to="loc_rnac_LeaseArrangementDomain_354f64ac-b132-4f66-a277-2bcebda2e5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_MoscowRussiaLeaseMember_c2b514e3-33a2-4f57-97ae-da45df9f3f09" xlink:href="rnac-20241231.xsd#rnac_MoscowRussiaLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_LeaseArrangementDomain_354f64ac-b132-4f66-a277-2bcebda2e5a2" xlink:to="loc_rnac_MoscowRussiaLeaseMember_c2b514e3-33a2-4f57-97ae-da45df9f3f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_4861ec46-59a7-4b35-9743-57ce11459030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_18e767a8-46af-4a84-9f7c-8d6292a0c8bb" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_4861ec46-59a7-4b35-9743-57ce11459030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0046237e-8312-4414-8727-5fd71580f5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_4861ec46-59a7-4b35-9743-57ce11459030" xlink:to="loc_us-gaap_LeaseCost_0046237e-8312-4414-8727-5fd71580f5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#LeasesScheduleofComponentsofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9763c2da-5a64-4fe6-89b0-07a96639b089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a49b5c05-fa2f-458f-88ee-4ffd9c7fc694" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9763c2da-5a64-4fe6-89b0-07a96639b089" xlink:to="loc_us-gaap_OperatingLeaseCost_a49b5c05-fa2f-458f-88ee-4ffd9c7fc694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_a4b7bb5c-b49d-4706-9d97-ec59515bf066" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9763c2da-5a64-4fe6-89b0-07a96639b089" xlink:to="loc_us-gaap_VariableLeaseCost_a4b7bb5c-b49d-4706-9d97-ec59515bf066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_4cd7ea78-ea4d-4cf5-a2a4-1518f7be2b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9763c2da-5a64-4fe6-89b0-07a96639b089" xlink:to="loc_us-gaap_ShortTermLeaseCost_4cd7ea78-ea4d-4cf5-a2a4-1518f7be2b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_f3e1fa0e-96b8-4193-a5cc-13180c60c4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9763c2da-5a64-4fe6-89b0-07a96639b089" xlink:to="loc_us-gaap_SubleaseIncome_f3e1fa0e-96b8-4193-a5cc-13180c60c4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_4a445438-1dcf-4905-a487-5b9ed2583ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9763c2da-5a64-4fe6-89b0-07a96639b089" xlink:to="loc_us-gaap_LeaseCost_4a445438-1dcf-4905-a487-5b9ed2583ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f15603b1-4cdb-48fb-9709-5dd955fc240d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_41ca2b21-8d01-4e53-a254-bc3221d6987e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f15603b1-4cdb-48fb-9709-5dd955fc240d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_41ca2b21-8d01-4e53-a254-bc3221d6987e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dd79fcbb-752b-4d91-8632-177fec052ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f15603b1-4cdb-48fb-9709-5dd955fc240d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dd79fcbb-752b-4d91-8632-177fec052ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c0bb50eb-fd57-4f9f-8232-7a04e6631cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f15603b1-4cdb-48fb-9709-5dd955fc240d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c0bb50eb-fd57-4f9f-8232-7a04e6631cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b4102ea3-d262-4463-b68d-c42c67ae9ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f15603b1-4cdb-48fb-9709-5dd955fc240d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b4102ea3-d262-4463-b68d-c42c67ae9ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_80051bee-3bdd-4067-8aca-f8993c52de26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f15603b1-4cdb-48fb-9709-5dd955fc240d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_80051bee-3bdd-4067-8aca-f8993c52de26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4acf6d3f-d964-4302-a8cc-1c33809f1a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f15603b1-4cdb-48fb-9709-5dd955fc240d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4acf6d3f-d964-4302-a8cc-1c33809f1a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_710e6403-8593-4035-af06-e259218eaf25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f15603b1-4cdb-48fb-9709-5dd955fc240d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_710e6403-8593-4035-af06-e259218eaf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e83173de-86f8-4a5a-8258-52bf47761869" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f15603b1-4cdb-48fb-9709-5dd955fc240d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e83173de-86f8-4a5a-8258-52bf47761869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_46221f00-5de4-4913-9734-f2dfd6e6434f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f15603b1-4cdb-48fb-9709-5dd955fc240d" xlink:to="loc_us-gaap_OperatingLeaseLiability_46221f00-5de4-4913-9734-f2dfd6e6434f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofSupplementalDisclosurefortheStatementofCashFlowsRelatedtoOperatingLeasesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#LeasesScheduleofSupplementalDisclosurefortheStatementofCashFlowsRelatedtoOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/LeasesScheduleofSupplementalDisclosurefortheStatementofCashFlowsRelatedtoOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c5eed229-ca93-496c-9495-1a54a58181f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_53e310b1-9102-4293-b30a-ea5322d63be3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5eed229-ca93-496c-9495-1a54a58181f9" xlink:to="loc_us-gaap_OperatingLeasePayments_53e310b1-9102-4293-b30a-ea5322d63be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0f82cd4d-ca9a-494f-93da-818d20871a13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_87f6100f-ed95-498a-91c2-e2b73e059173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f82cd4d-ca9a-494f-93da-818d20871a13" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_87f6100f-ed95-498a-91c2-e2b73e059173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7a08538f-83bb-4b8e-a580-17d0501f8f85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f82cd4d-ca9a-494f-93da-818d20871a13" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7a08538f-83bb-4b8e-a580-17d0501f8f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/DebtDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bb704018-1fac-49b6-90de-ea814b643f34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_4d5508db-39c7-40d4-8630-cbe839fc874c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb704018-1fac-49b6-90de-ea814b643f34" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_4d5508db-39c7-40d4-8630-cbe839fc874c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_44a98055-cd2a-4871-837b-c2f9f6c4bf78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4d5508db-39c7-40d4-8630-cbe839fc874c" xlink:to="loc_us-gaap_CreditFacilityAxis_44a98055-cd2a-4871-837b-c2f9f6c4bf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b6b41879-fca4-4f76-bb11-ff912563287a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_44a98055-cd2a-4871-837b-c2f9f6c4bf78" xlink:to="loc_us-gaap_CreditFacilityDomain_b6b41879-fca4-4f76-bb11-ff912563287a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2020TermLoansMember_43b5a4e8-182c-4f1f-b5d2-e3240c105bd4" xlink:href="rnac-20241231.xsd#rnac_A2020TermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b6b41879-fca4-4f76-bb11-ff912563287a" xlink:to="loc_rnac_A2020TermLoansMember_43b5a4e8-182c-4f1f-b5d2-e3240c105bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4d5508db-39c7-40d4-8630-cbe839fc874c" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5e5f908f-7698-422a-9926-f112df8a9b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5e5f908f-7698-422a-9926-f112df8a9b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_4033d0be-3476-431d-b5d4-c56f90ef86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_4033d0be-3476-431d-b5d4-c56f90ef86c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_9a82f923-275f-43e6-96aa-aa37c3f95157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_9a82f923-275f-43e6-96aa-aa37c3f95157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DebtInstrumentPrepaymentFee_8e7ed69d-634e-42ac-83db-81c915b21d03" xlink:href="rnac-20241231.xsd#rnac_DebtInstrumentPrepaymentFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_rnac_DebtInstrumentPrepaymentFee_8e7ed69d-634e-42ac-83db-81c915b21d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DebtInstrumentAccruedInterest_9cb198de-b9b6-4633-b972-b8f74e62fcc7" xlink:href="rnac-20241231.xsd#rnac_DebtInstrumentAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_rnac_DebtInstrumentAccruedInterest_9cb198de-b9b6-4633-b972-b8f74e62fcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8ab7405-e7d3-4f62-84cb-81fc577b30db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8ab7405-e7d3-4f62-84cb-81fc577b30db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_ad2526e2-6c53-486a-9c0a-e84694ad6904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_ad2526e2-6c53-486a-9c0a-e84694ad6904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_b6de6441-c512-4c8e-a6a0-9dcaa67e2696" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_LineOfCredit_b6de6441-c512-4c8e-a6a0-9dcaa67e2696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c1df7389-5517-4ed1-b56a-f92412e692b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1aeeb44d-f60d-4669-9212-251adb125443" xlink:to="loc_us-gaap_InterestExpenseDebt_c1df7389-5517-4ed1-b56a-f92412e692b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_26a56d17-559b-4b72-9cdd-0d1f785c8ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_26a56d17-559b-4b72-9cdd-0d1f785c8ce3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cb92e6e4-dfa6-4795-81e5-9e83d48b8e90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cb92e6e4-dfa6-4795-81e5-9e83d48b8e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_61e8c3d8-f140-48b1-bda4-3acbef8154a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cb92e6e4-dfa6-4795-81e5-9e83d48b8e90" xlink:to="loc_us-gaap_ClassOfStockDomain_61e8c3d8-f140-48b1-bda4-3acbef8154a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_f94ee0d6-9285-42f2-bced-b01488294f85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e8c3d8-f140-48b1-bda4-3acbef8154a2" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_f94ee0d6-9285-42f2-bced-b01488294f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ceab3ea8-6506-4860-b2c4-680d530a2803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e8c3d8-f140-48b1-bda4-3acbef8154a2" xlink:to="loc_us-gaap_CommonStockMember_ceab3ea8-6506-4860-b2c4-680d530a2803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_be1c11b1-444e-495a-abd6-e70c8fa350bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_be1c11b1-444e-495a-abd6-e70c8fa350bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_284fef8b-79e0-42f7-bd91-a58e7a67af54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_be1c11b1-444e-495a-abd6-e70c8fa350bd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_284fef8b-79e0-42f7-bd91-a58e7a67af54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2024Member_d99ced57-af38-4704-b641-00adaaa30b50" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_284fef8b-79e0-42f7-bd91-a58e7a67af54" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2024Member_d99ced57-af38-4704-b641-00adaaa30b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member_c80c62b8-143f-48f5-9b95-e4267a17be8d" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_284fef8b-79e0-42f7-bd91-a58e7a67af54" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2023Member_c80c62b8-143f-48f5-9b95-e4267a17be8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e02dfe84-13de-48d6-86ec-ac92a9f05e72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e02dfe84-13de-48d6-86ec-ac92a9f05e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e40ebc27-f0b2-40c0-8b21-5d6c074243c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e02dfe84-13de-48d6-86ec-ac92a9f05e72" xlink:to="loc_us-gaap_EquityComponentDomain_e40ebc27-f0b2-40c0-8b21-5d6c074243c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e9060e07-7b90-4440-9aef-f1d2d7023abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e40ebc27-f0b2-40c0-8b21-5d6c074243c2" xlink:to="loc_us-gaap_CommonStockMember_e9060e07-7b90-4440-9aef-f1d2d7023abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b6beccbf-763f-4af8-be83-e2c6431649ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_srt_CounterpartyNameAxis_b6beccbf-763f-4af8-be83-e2c6431649ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c865fc8-6eb8-445a-a55a-6d4df7074e83" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b6beccbf-763f-4af8-be83-e2c6431649ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c865fc8-6eb8-445a-a55a-6d4df7074e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Dr.TimothyA.SpringerMember_c2a2e185-6ea3-4ffa-b380-0e84900760cc" xlink:href="rnac-20241231.xsd#rnac_Dr.TimothyA.SpringerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c865fc8-6eb8-445a-a55a-6d4df7074e83" xlink:to="loc_rnac_Dr.TimothyA.SpringerMember_c2a2e185-6ea3-4ffa-b380-0e84900760cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TASPartnersLLCMember_029c681d-6f6e-4f77-8e8f-3b49f212c2f7" xlink:href="rnac-20241231.xsd#rnac_TASPartnersLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c865fc8-6eb8-445a-a55a-6d4df7074e83" xlink:to="loc_rnac_TASPartnersLLCMember_029c681d-6f6e-4f77-8e8f-3b49f212c2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Dr.ChafenLuMember_06a7339d-2360-4d21-a9b8-438142572153" xlink:href="rnac-20241231.xsd#rnac_Dr.ChafenLuMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c865fc8-6eb8-445a-a55a-6d4df7074e83" xlink:to="loc_rnac_Dr.ChafenLuMember_06a7339d-2360-4d21-a9b8-438142572153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4d1fccd-35c0-4f78-8740-ec8541b8bb04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4d1fccd-35c0-4f78-8740-ec8541b8bb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_89b273d3-f733-47c2-bc61-3bfb8ca1be2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4d1fccd-35c0-4f78-8740-ec8541b8bb04" xlink:to="loc_us-gaap_RelatedPartyDomain_89b273d3-f733-47c2-bc61-3bfb8ca1be2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_bb043881-de35-4402-ae5a-f3dbce16b576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_89b273d3-f733-47c2-bc61-3bfb8ca1be2a" xlink:to="loc_us-gaap_RelatedPartyMember_bb043881-de35-4402-ae5a-f3dbce16b576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6168e6c-cb80-45d4-bb76-6bdddea47144" xlink:to="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_602bfdb6-962d-4834-a86c-a27188c49084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_602bfdb6-962d-4834-a86c-a27188c49084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_44e4479a-3755-47d5-939f-72722ef3ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_44e4479a-3755-47d5-939f-72722ef3ff5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_6bf94dfc-00d2-4caa-b174-01a4e40a0088" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_6bf94dfc-00d2-4caa-b174-01a4e40a0088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d5837cee-dac3-4b56-bef0-9e91875f5bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d5837cee-dac3-4b56-bef0-9e91875f5bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_61ffe137-41b9-4023-8e2a-5348657a2bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_61ffe137-41b9-4023-8e2a-5348657a2bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c185d703-0730-41b2-a5b9-32c62e0f6f46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c185d703-0730-41b2-a5b9-32c62e0f6f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_3db1c75e-fa12-4ac1-9ce1-ba75e7074fc0" xlink:href="rnac-20241231.xsd#rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_76475220-e01a-42a7-bccf-12138798fa12" xlink:to="loc_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_3db1c75e-fa12-4ac1-9ce1-ba75e7074fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_4af4dd0c-f5d4-4d9a-9e54-5304ea929606" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_4af4dd0c-f5d4-4d9a-9e54-5304ea929606" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_82ce430c-4b66-4e22-9265-3a2785c048db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_82ce430c-4b66-4e22-9265-3a2785c048db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8ad6a648-5b92-463d-a7fa-24237b596441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_82ce430c-4b66-4e22-9265-3a2785c048db" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8ad6a648-5b92-463d-a7fa-24237b596441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member_785cc984-b208-44d1-9073-fefd7295ac57" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8ad6a648-5b92-463d-a7fa-24237b596441" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2023Member_785cc984-b208-44d1-9073-fefd7295ac57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023Member_d3add33c-b0f6-44b5-bd61-d9c1fd8e886d" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8ad6a648-5b92-463d-a7fa-24237b596441" xlink:to="loc_rnac_PrivatePlacement2023Member_d3add33c-b0f6-44b5-bd61-d9c1fd8e886d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023TrancheOneMember_a1cd02c7-5a3b-4429-8907-d9f35910a0b0" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_PrivatePlacement2023Member_d3add33c-b0f6-44b5-bd61-d9c1fd8e886d" xlink:to="loc_rnac_PrivatePlacement2023TrancheOneMember_a1cd02c7-5a3b-4429-8907-d9f35910a0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023TrancheThreeMember_87e85e43-b850-4eb0-b51f-470c3daf055a" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023TrancheThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_PrivatePlacement2023Member_d3add33c-b0f6-44b5-bd61-d9c1fd8e886d" xlink:to="loc_rnac_PrivatePlacement2023TrancheThreeMember_87e85e43-b850-4eb0-b51f-470c3daf055a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023TrancheTwoMember_52f6cc58-57e7-4943-aea5-db5f5f21f8ad" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023TrancheTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_PrivatePlacement2023Member_d3add33c-b0f6-44b5-bd61-d9c1fd8e886d" xlink:to="loc_rnac_PrivatePlacement2023TrancheTwoMember_52f6cc58-57e7-4943-aea5-db5f5f21f8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3ae99973-e462-443d-afb3-3879fb8888ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3ae99973-e462-443d-afb3-3879fb8888ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_905215a0-f94c-4b3c-abf8-86adc6f8d47d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3ae99973-e462-443d-afb3-3879fb8888ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_905215a0-f94c-4b3c-abf8-86adc6f8d47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_cb3e07a4-2a09-460b-be66-2bc1d47c2acb" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_905215a0-f94c-4b3c-abf8-86adc6f8d47d" xlink:to="loc_rnac_OldCartesianMember_cb3e07a4-2a09-460b-be66-2bc1d47c2acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f15958b0-e4a5-4114-a297-64f741edcf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f15958b0-e4a5-4114-a297-64f741edcf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_ff41521c-af9a-4ba7-a76b-52e7d3f4f625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f15958b0-e4a5-4114-a297-64f741edcf5f" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_ff41521c-af9a-4ba7-a76b-52e7d3f4f625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_8fc4c83e-e65e-4f87-81cd-eacb9988cd43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_ff41521c-af9a-4ba7-a76b-52e7d3f4f625" xlink:to="loc_us-gaap_PreferredStockMember_8fc4c83e-e65e-4f87-81cd-eacb9988cd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_087f0e49-c918-4f71-b7ca-4fd8c09285f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_StatementClassOfStockAxis_087f0e49-c918-4f71-b7ca-4fd8c09285f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6fac3965-5c34-44a9-948e-2114a351d238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_087f0e49-c918-4f71-b7ca-4fd8c09285f9" xlink:to="loc_us-gaap_ClassOfStockDomain_6fac3965-5c34-44a9-948e-2114a351d238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b8b0f7a5-1054-48a6-9b00-bf8090b70851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6fac3965-5c34-44a9-948e-2114a351d238" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b8b0f7a5-1054-48a6-9b00-bf8090b70851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_62917792-4bbd-4ca4-939f-fd89bcab4662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_62917792-4bbd-4ca4-939f-fd89bcab4662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ddd7dc98-b46a-495d-ba60-56a76a60151b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62917792-4bbd-4ca4-939f-fd89bcab4662" xlink:to="loc_us-gaap_EquityComponentDomain_ddd7dc98-b46a-495d-ba60-56a76a60151b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_28a5e1aa-58a3-4a32-af6d-ec5909543bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ddd7dc98-b46a-495d-ba60-56a76a60151b" xlink:to="loc_us-gaap_CommonStockMember_28a5e1aa-58a3-4a32-af6d-ec5909543bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a051033e-dcdc-44c9-bff9-6f8eaa24a86b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a051033e-dcdc-44c9-bff9-6f8eaa24a86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9127edbd-8b69-4f4a-a286-0f8cbecc2aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a051033e-dcdc-44c9-bff9-6f8eaa24a86b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9127edbd-8b69-4f4a-a286-0f8cbecc2aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bb9a00da-895f-4028-91cb-5a518d0fa367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9127edbd-8b69-4f4a-a286-0f8cbecc2aa5" xlink:to="loc_us-gaap_SubsequentEventMember_bb9a00da-895f-4028-91cb-5a518d0fa367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f6a5ee4c-20b9-4332-bf8b-d8fe56fc5638" xlink:to="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_a6bd7c51-7cb4-424e-a3c3-e708c5b52874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_a6bd7c51-7cb4-424e-a3c3-e708c5b52874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ac18e82b-bf9a-4157-8668-a286314eabf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ac18e82b-bf9a-4157-8668-a286314eabf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_76e067cf-4fe0-40e5-b314-f051ebd1226d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_76e067cf-4fe0-40e5-b314-f051ebd1226d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockSettlementTerm_911a9969-b554-4eb6-8a5e-512852c6bb5c" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockSettlementTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_rnac_SaleOfStockSettlementTerm_911a9969-b554-4eb6-8a5e-512852c6bb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SettlementOfDerivativeLiabilityShares_175b1155-218c-42d6-870d-dde69a06362f" xlink:href="rnac-20241231.xsd#rnac_SettlementOfDerivativeLiabilityShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_rnac_SettlementOfDerivativeLiabilityShares_175b1155-218c-42d6-870d-dde69a06362f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_decdc840-7921-4fab-97de-fa2ff57345e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_decdc840-7921-4fab-97de-fa2ff57345e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NumberOfBusinessDays_65b68d7e-a11c-491d-873c-217a91bb4429" xlink:href="rnac-20241231.xsd#rnac_NumberOfBusinessDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_rnac_NumberOfBusinessDays_65b68d7e-a11c-491d-873c-217a91bb4429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7a934058-06bc-4b58-953f-2c1bbd49c447" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7a934058-06bc-4b58-953f-2c1bbd49c447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_6c11dedf-8227-4ca9-9029-dd0f75986d98" xlink:href="rnac-20241231.xsd#rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31a72a56-3662-421e-b3f1-d97ce63d6a1d" xlink:to="loc_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert_6c11dedf-8227-4ca9-9029-dd0f75986d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStockConversionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_7074682d-ae64-455f-bf52-163b5bdabbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_aa6c80a1-2c03-4f4b-ae65-6656eecccdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_7074682d-ae64-455f-bf52-163b5bdabbdd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_aa6c80a1-2c03-4f4b-ae65-6656eecccdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f730d710-76e9-4ee8-a582-9c9b85ecc05f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa6c80a1-2c03-4f4b-ae65-6656eecccdc2" xlink:to="loc_srt_RangeAxis_f730d710-76e9-4ee8-a582-9c9b85ecc05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82edf12d-bcd3-4d05-bbef-1394e5844f94" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f730d710-76e9-4ee8-a582-9c9b85ecc05f" xlink:to="loc_srt_RangeMember_82edf12d-bcd3-4d05-bbef-1394e5844f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_32242da8-8833-45fb-8004-ad97138f6b6f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82edf12d-bcd3-4d05-bbef-1394e5844f94" xlink:to="loc_srt_MinimumMember_32242da8-8833-45fb-8004-ad97138f6b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9924ecc7-1865-42c8-be28-74732299b2c6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82edf12d-bcd3-4d05-bbef-1394e5844f94" xlink:to="loc_srt_MaximumMember_9924ecc7-1865-42c8-be28-74732299b2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12f8774b-9853-43f1-899b-9b07d8098c51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa6c80a1-2c03-4f4b-ae65-6656eecccdc2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12f8774b-9853-43f1-899b-9b07d8098c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f95b92e7-8f94-4183-a88c-da5e84206a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12f8774b-9853-43f1-899b-9b07d8098c51" xlink:to="loc_us-gaap_ClassOfStockDomain_f95b92e7-8f94-4183-a88c-da5e84206a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_00626385-d262-4e7d-8102-6783a656c61d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f95b92e7-8f94-4183-a88c-da5e84206a5a" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_00626385-d262-4e7d-8102-6783a656c61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_56096b32-ea0e-4428-98cc-4787092c6b68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa6c80a1-2c03-4f4b-ae65-6656eecccdc2" xlink:to="loc_us-gaap_ClassOfStockLineItems_56096b32-ea0e-4428-98cc-4787092c6b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_a13ed10a-da9e-473b-b860-a7b97b24649c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_56096b32-ea0e-4428-98cc-4787092c6b68" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_a13ed10a-da9e-473b-b860-a7b97b24649c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage_8fe7b87f-a6a6-4178-8bce-657c59a37acb" xlink:href="rnac-20241231.xsd#rnac_PreferredStockConvertibleBeneficialOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_56096b32-ea0e-4428-98cc-4787092c6b68" xlink:to="loc_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage_8fe7b87f-a6a6-4178-8bce-657c59a37acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockRedemptionNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStockRedemptionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockRedemptionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_84bfacec-2c73-41d1-9c97-38b786815800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreferredStockRedemptionTerm_1fde199c-9819-4cf9-955f-e30f31e8f46f" xlink:href="rnac-20241231.xsd#rnac_PreferredStockRedemptionTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_84bfacec-2c73-41d1-9c97-38b786815800" xlink:to="loc_rnac_PreferredStockRedemptionTerm_1fde199c-9819-4cf9-955f-e30f31e8f46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays_3be5bcfa-be29-429d-ae9e-7006dd44bded" xlink:href="rnac-20241231.xsd#rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_84bfacec-2c73-41d1-9c97-38b786815800" xlink:to="loc_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays_3be5bcfa-be29-429d-ae9e-7006dd44bded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockVotingNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStockVotingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockVotingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_315ebf5e-c612-41bf-bade-62bb9acca926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding_553be532-39d2-4fd7-a447-eb9e18ce69d0" xlink:href="rnac-20241231.xsd#rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_315ebf5e-c612-41bf-bade-62bb9acca926" xlink:to="loc_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding_553be532-39d2-4fd7-a447-eb9e18ce69d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#ConvertiblePreferredStockLiquidationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0bd8bec3-3e97-4243-bb15-d9fb84f986e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_210f6460-ecfe-4ebf-a73d-face22b0e4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0bd8bec3-3e97-4243-bb15-d9fb84f986e9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_210f6460-ecfe-4ebf-a73d-face22b0e4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c2abe43e-0ef9-464c-88ea-5d1c096910a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_210f6460-ecfe-4ebf-a73d-face22b0e4e6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c2abe43e-0ef9-464c-88ea-5d1c096910a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e9a3977a-534b-4fb6-a6d4-567f8008c1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2abe43e-0ef9-464c-88ea-5d1c096910a5" xlink:to="loc_us-gaap_ClassOfStockDomain_e9a3977a-534b-4fb6-a6d4-567f8008c1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_dadbe721-564c-415f-8196-5cef5161485b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e9a3977a-534b-4fb6-a6d4-567f8008c1fd" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_dadbe721-564c-415f-8196-5cef5161485b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0f88c48e-f432-44f4-abd8-01fa14867c78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e9a3977a-534b-4fb6-a6d4-567f8008c1fd" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0f88c48e-f432-44f4-abd8-01fa14867c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f2cb1f14-66d0-4359-9825-b4a295abb5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_210f6460-ecfe-4ebf-a73d-face22b0e4e6" xlink:to="loc_us-gaap_ClassOfStockLineItems_f2cb1f14-66d0-4359-9825-b4a295abb5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4366700e-2ed5-48e7-accb-7b3fd2aa8b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2cb1f14-66d0-4359-9825-b4a295abb5e7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4366700e-2ed5-48e7-accb-7b3fd2aa8b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_52c6b910-8c99-4eae-a847-da9bb219f7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2cb1f14-66d0-4359-9825-b4a295abb5e7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_52c6b910-8c99-4eae-a847-da9bb219f7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable_27e70b07-a7a0-4959-9544-da39a228a729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2cb1f14-66d0-4359-9825-b4a295abb5e7" xlink:to="loc_us-gaap_PreferredStockConvertibleSharesIssuable_27e70b07-a7a0-4959-9544-da39a228a729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#Equity2024PrivatePlacementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3207313f-db6f-41c4-936c-007da8e21f21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3207313f-db6f-41c4-936c-007da8e21f21" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_96d3af04-1eb2-4389-810e-d8cf3a49f7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:to="loc_us-gaap_StatementClassOfStockAxis_96d3af04-1eb2-4389-810e-d8cf3a49f7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7233bbda-31a9-4c4f-9af2-d2fe4c6f24c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96d3af04-1eb2-4389-810e-d8cf3a49f7d3" xlink:to="loc_us-gaap_ClassOfStockDomain_7233bbda-31a9-4c4f-9af2-d2fe4c6f24c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d3a7154c-b448-4011-af75-a0b82645d849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7233bbda-31a9-4c4f-9af2-d2fe4c6f24c5" xlink:to="loc_us-gaap_CommonStockMember_d3a7154c-b448-4011-af75-a0b82645d849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_61405be1-c73a-49a0-8466-75d0067c122f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7233bbda-31a9-4c4f-9af2-d2fe4c6f24c5" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_61405be1-c73a-49a0-8466-75d0067c122f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_78e30cf4-c949-4a79-9f98-3f86ca01ae8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_78e30cf4-c949-4a79-9f98-3f86ca01ae8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_530df919-23ca-499d-9c18-c63e4213588d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_78e30cf4-c949-4a79-9f98-3f86ca01ae8d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_530df919-23ca-499d-9c18-c63e4213588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2024Member_6bc5fd61-ccb3-457c-9100-23bcc225ccae" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_530df919-23ca-499d-9c18-c63e4213588d" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2024Member_6bc5fd61-ccb3-457c-9100-23bcc225ccae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_12094d7d-0814-45eb-a713-d95260869694" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:to="loc_srt_TitleOfIndividualAxis_12094d7d-0814-45eb-a713-d95260869694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6d52331-6f0c-4f69-84e5-505f2606fc3d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_12094d7d-0814-45eb-a713-d95260869694" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6d52331-6f0c-4f69-84e5-505f2606fc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DirectorsAndExecutiveOfficersMember_1daf3fab-e6c2-4ad2-a03f-cafbb83e713b" xlink:href="rnac-20241231.xsd#rnac_DirectorsAndExecutiveOfficersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6d52331-6f0c-4f69-84e5-505f2606fc3d" xlink:to="loc_rnac_DirectorsAndExecutiveOfficersMember_1daf3fab-e6c2-4ad2-a03f-cafbb83e713b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0084d014-a6b1-4ce0-8adc-dd17bbb80211" xlink:to="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbde958a-dace-4f40-8825-2d7b39ae551d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbde958a-dace-4f40-8825-2d7b39ae551d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_556ce58b-0e9f-4a0b-9140-46764af7a061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_556ce58b-0e9f-4a0b-9140-46764af7a061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_14bc3c5c-4d7d-4563-be55-39f422776c50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_14bc3c5c-4d7d-4563-be55-39f422776c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_e0080c25-c393-4470-8dec-d86a520720bb" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_03c6e2d6-4678-4202-bf56-65e5d9efa00d" xlink:to="loc_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction_e0080c25-c393-4470-8dec-d86a520720bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityMergerNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7b996f20-82ab-4562-b8a9-230c24ab9e20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e0471a76-b033-40f4-8f6e-9b1a70d32eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7b996f20-82ab-4562-b8a9-230c24ab9e20" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e0471a76-b033-40f4-8f6e-9b1a70d32eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fbf5f85e-184a-4aa2-acdf-ff36b2b9bad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e0471a76-b033-40f4-8f6e-9b1a70d32eae" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fbf5f85e-184a-4aa2-acdf-ff36b2b9bad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6439e12f-f33f-421b-ae2c-911cb6b1ca35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fbf5f85e-184a-4aa2-acdf-ff36b2b9bad0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6439e12f-f33f-421b-ae2c-911cb6b1ca35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianMember_1c307bb1-ca50-4591-874f-c935213e72ec" xlink:href="rnac-20241231.xsd#rnac_OldCartesianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6439e12f-f33f-421b-ae2c-911cb6b1ca35" xlink:to="loc_rnac_OldCartesianMember_1c307bb1-ca50-4591-874f-c935213e72ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_03749881-31ab-4a15-9689-fb8c169930a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e0471a76-b033-40f4-8f6e-9b1a70d32eae" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_03749881-31ab-4a15-9689-fb8c169930a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_c05a4d30-677b-4d00-bb91-4c5baadf02af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_03749881-31ab-4a15-9689-fb8c169930a4" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_c05a4d30-677b-4d00-bb91-4c5baadf02af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5bf56117-8473-47d3-b0a9-38eede9a46d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_c05a4d30-677b-4d00-bb91-4c5baadf02af" xlink:to="loc_us-gaap_CommonStockMember_5bf56117-8473-47d3-b0a9-38eede9a46d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0460036f-37da-4e00-a380-f857a3d1376d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e0471a76-b033-40f4-8f6e-9b1a70d32eae" xlink:to="loc_us-gaap_ClassOfStockLineItems_0460036f-37da-4e00-a380-f857a3d1376d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_9939a498-1db0-4c4a-81cd-9ec215bea6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0460036f-37da-4e00-a380-f857a3d1376d" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_9939a498-1db0-4c4a-81cd-9ec215bea6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityUnderwrittenOfferingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_52066365-7cdd-4fca-9bb6-f92dca66c452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f4a1b066-e765-495e-b749-eeea4cc52d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_52066365-7cdd-4fca-9bb6-f92dca66c452" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f4a1b066-e765-495e-b749-eeea4cc52d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9406a09c-d3e8-4f44-821a-7796f67add89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4a1b066-e765-495e-b749-eeea4cc52d27" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9406a09c-d3e8-4f44-821a-7796f67add89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_260b306b-fc59-447a-9ec4-fd7463951a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9406a09c-d3e8-4f44-821a-7796f67add89" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_260b306b-fc59-447a-9ec4-fd7463951a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2022OfferingMember_1d36c125-c751-4f17-9e47-882548d81ea3" xlink:href="rnac-20241231.xsd#rnac_A2022OfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_260b306b-fc59-447a-9ec4-fd7463951a9f" xlink:to="loc_rnac_A2022OfferingMember_1d36c125-c751-4f17-9e47-882548d81ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4a1b066-e765-495e-b749-eeea4cc52d27" xlink:to="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dbe4453c-c896-4bf5-a363-22f4e5eda953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dbe4453c-c896-4bf5-a363-22f4e5eda953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_52468a97-52fb-4ece-9d7f-ed5bd76bf50e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_52468a97-52fb-4ece-9d7f-ed5bd76bf50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6f8fceb4-3bf9-4cbc-a299-2e85ad8839a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6f8fceb4-3bf9-4cbc-a299-2e85ad8839a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_298147b1-3910-44e1-b095-225a5ce6dd87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_298147b1-3910-44e1-b095-225a5ce6dd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22f451d4-21a3-4d19-a20b-4d995710a87b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22f451d4-21a3-4d19-a20b-4d995710a87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_646da864-913f-462c-92db-c809854a2ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aed52344-6701-4227-b85f-f549be7224b0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_646da864-913f-462c-92db-c809854a2ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityAttheMarketOfferingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a63bcffc-2ee8-4067-b786-15765ec43692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_501ed183-4e0b-4de6-b5f6-7985170b6ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a63bcffc-2ee8-4067-b786-15765ec43692" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_501ed183-4e0b-4de6-b5f6-7985170b6ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8df2a347-f1f9-4412-a378-39adc2e7c20f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_501ed183-4e0b-4de6-b5f6-7985170b6ac5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8df2a347-f1f9-4412-a378-39adc2e7c20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb396c70-60e9-467d-a1c8-bcb380c9d0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8df2a347-f1f9-4412-a378-39adc2e7c20f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb396c70-60e9-467d-a1c8-bcb380c9d0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AtTheMarketOfferingMember_903b40f7-f2c1-4b71-8332-7271b55c69c7" xlink:href="rnac-20241231.xsd#rnac_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb396c70-60e9-467d-a1c8-bcb380c9d0b3" xlink:to="loc_rnac_AtTheMarketOfferingMember_903b40f7-f2c1-4b71-8332-7271b55c69c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_bca3690e-37d4-4cdb-b14e-de69b77cb3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_501ed183-4e0b-4de6-b5f6-7985170b6ac5" xlink:to="loc_us-gaap_ClassOfStockLineItems_bca3690e-37d4-4cdb-b14e-de69b77cb3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds_ae00736e-86e4-485c-8ba6-8475b43d740d" xlink:href="rnac-20241231.xsd#rnac_SaleOfStockAggregateMaximumGrossSalesProceeds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bca3690e-37d4-4cdb-b14e-de69b77cb3bd" xlink:to="loc_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds_ae00736e-86e4-485c-8ba6-8475b43d740d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76f3e948-8bb3-4711-9cd8-1d5b06fd1a89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bca3690e-37d4-4cdb-b14e-de69b77cb3bd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76f3e948-8bb3-4711-9cd8-1d5b06fd1a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityJune2020SobiStockPurchaseNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5e93b58e-6f64-4e5f-adfd-4afe5ec652f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ca614af4-2406-4c7a-9f74-17fc91cd382d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5e93b58e-6f64-4e5f-adfd-4afe5ec652f0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ca614af4-2406-4c7a-9f74-17fc91cd382d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e622f327-3280-4ea1-96f6-537061bf0ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ca614af4-2406-4c7a-9f74-17fc91cd382d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e622f327-3280-4ea1-96f6-537061bf0ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bccb6bc-14d8-4b5d-be80-ab5f4a5ef967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e622f327-3280-4ea1-96f6-537061bf0ca5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bccb6bc-14d8-4b5d-be80-ab5f4a5ef967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SOBIPurchaseAgreementMember_23d7a54a-5b2d-4de8-8843-48410d093b7a" xlink:href="rnac-20241231.xsd#rnac_SOBIPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bccb6bc-14d8-4b5d-be80-ab5f4a5ef967" xlink:to="loc_rnac_SOBIPurchaseAgreementMember_23d7a54a-5b2d-4de8-8843-48410d093b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ca614af4-2406-4c7a-9f74-17fc91cd382d" xlink:to="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d91d4105-adc2-4f1c-b134-ab0d2a8c1177" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d91d4105-adc2-4f1c-b134-ab0d2a8c1177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d23a8ede-5863-44c0-8dbc-efc225d9b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d23a8ede-5863-44c0-8dbc-efc225d9b9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_3949051e-982c-4593-9178-fbbf1f2a6860" xlink:href="rnac-20241231.xsd#rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_3949051e-982c-4593-9178-fbbf1f2a6860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_acebc20c-27b1-49a4-b271-81f0709c4d97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_acebc20c-27b1-49a4-b271-81f0709c4d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium_4cd60258-ee0b-4e21-bad4-069bec91c328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedemptionPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aba91379-02d4-490b-97c8-7da51ce001a9" xlink:to="loc_us-gaap_RedemptionPremium_4cd60258-ee0b-4e21-bad4-069bec91c328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityDecember2019FinancingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1e98eee7-5ea0-4ffe-b388-dd11d2e0035e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1e98eee7-5ea0-4ffe-b388-dd11d2e0035e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a3679518-180f-49d0-879e-678cfb1b53c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a3679518-180f-49d0-879e-678cfb1b53c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f2d84d-0218-440f-9539-b63f48625e09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a3679518-180f-49d0-879e-678cfb1b53c4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f2d84d-0218-440f-9539-b63f48625e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DecemberTwoThousandNineteenFinancingMember_aa6edb17-7cf5-401e-b34a-a819abafdd9d" xlink:href="rnac-20241231.xsd#rnac_DecemberTwoThousandNineteenFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f2d84d-0218-440f-9539-b63f48625e09" xlink:to="loc_rnac_DecemberTwoThousandNineteenFinancingMember_aa6edb17-7cf5-401e-b34a-a819abafdd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8207ca9e-de3c-49ba-aa27-ef98efaa56f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8207ca9e-de3c-49ba-aa27-ef98efaa56f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_855e3bb6-d0ad-4f2e-9729-f05c35db82f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8207ca9e-de3c-49ba-aa27-ef98efaa56f3" xlink:to="loc_us-gaap_EquityComponentDomain_855e3bb6-d0ad-4f2e-9729-f05c35db82f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CommonWarrantMember_92c4ac03-f6b4-41cf-8120-b08f7eaf9fd0" xlink:href="rnac-20241231.xsd#rnac_CommonWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_855e3bb6-d0ad-4f2e-9729-f05c35db82f6" xlink:to="loc_rnac_CommonWarrantMember_92c4ac03-f6b4-41cf-8120-b08f7eaf9fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PreFundedWarrantMember_b9044392-276d-4789-8be7-995af785ac8d" xlink:href="rnac-20241231.xsd#rnac_PreFundedWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_855e3bb6-d0ad-4f2e-9729-f05c35db82f6" xlink:to="loc_rnac_PreFundedWarrantMember_b9044392-276d-4789-8be7-995af785ac8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_42547feb-8792-43a9-ab47-11366685cba0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_42547feb-8792-43a9-ab47-11366685cba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_45bbce14-2a4b-4237-a598-fd60b2923a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_42547feb-8792-43a9-ab47-11366685cba0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_45bbce14-2a4b-4237-a598-fd60b2923a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2019WarrantsMember_2fc14dd3-9eae-4718-a11e-b2f36d799f29" xlink:href="rnac-20241231.xsd#rnac_A2019WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_45bbce14-2a4b-4237-a598-fd60b2923a4f" xlink:to="loc_rnac_A2019WarrantsMember_2fc14dd3-9eae-4718-a11e-b2f36d799f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_05b25c82-ee25-47a6-99a2-d0175c2b5cd8" xlink:to="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d7694ab2-beab-455d-b86b-6a0b7ead56ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d7694ab2-beab-455d-b86b-6a0b7ead56ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b4c23048-89c0-4d75-94bd-3b9a98578fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b4c23048-89c0-4d75-94bd-3b9a98578fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e29dc946-e7de-4c5c-b5b1-494c2a6f1539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e29dc946-e7de-4c5c-b5b1-494c2a6f1539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised_2a0d8e72-8783-4cc2-9160-ced98aae6198" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised_2a0d8e72-8783-4cc2-9160-ced98aae6198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f31a19e4-5baf-41c9-aa3f-4da1d7d61a15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f31a19e4-5baf-41c9-aa3f-4da1d7d61a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_ea2f6e01-708f-48b1-b920-a9349e9f6da1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_ea2f6e01-708f-48b1-b920-a9349e9f6da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_WarrantIssued_daf0afd1-143e-416f-b69e-1963e7a11a85" xlink:href="rnac-20241231.xsd#rnac_WarrantIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_rnac_WarrantIssued_daf0afd1-143e-416f-b69e-1963e7a11a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cab1be52-80ff-434d-ab2e-8ff82db90265" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cab1be52-80ff-434d-ab2e-8ff82db90265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_fa0a16ae-5542-456d-baaf-f895103a423b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_fa0a16ae-5542-456d-baaf-f895103a423b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_bc236297-17d1-4010-b14b-043a2dfbda26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_bc236297-17d1-4010-b14b-043a2dfbda26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_df296fb7-d428-4c92-80ec-89c2285646c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_38ee7abc-7209-4adf-aaa0-3c7b1e468e02" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_df296fb7-d428-4c92-80ec-89c2285646c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityScheduleofWarrantActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bcbad0bf-1079-4ad7-a401-31b273edf2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_b5a6dc62-0519-4454-885c-e145cedba83f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bcbad0bf-1079-4ad7-a401-31b273edf2b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_b5a6dc62-0519-4454-885c-e145cedba83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_da76abaf-18a1-48ba-a05a-2e746c1ff779" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b5a6dc62-0519-4454-885c-e145cedba83f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_da76abaf-18a1-48ba-a05a-2e746c1ff779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cdd3d87b-7293-478b-8263-bb48976e8bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_da76abaf-18a1-48ba-a05a-2e746c1ff779" xlink:to="loc_us-gaap_EquityComponentDomain_cdd3d87b-7293-478b-8263-bb48976e8bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_dcb829eb-81b8-434b-96f3-a6bb2c771dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cdd3d87b-7293-478b-8263-bb48976e8bf2" xlink:to="loc_us-gaap_WarrantMember_dcb829eb-81b8-434b-96f3-a6bb2c771dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_10e3212f-5c0a-4245-8d5f-14d49e7d76a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b5a6dc62-0519-4454-885c-e145cedba83f" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_10e3212f-5c0a-4245-8d5f-14d49e7d76a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_755e65ca-2974-4599-a6d8-d5c8ed0d7ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_10e3212f-5c0a-4245-8d5f-14d49e7d76a5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_755e65ca-2974-4599-a6d8-d5c8ed0d7ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e0e7c8cb-f8bc-4cde-9c24-a9ec2a130e09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_755e65ca-2974-4599-a6d8-d5c8ed0d7ad3" xlink:to="loc_us-gaap_WarrantMember_e0e7c8cb-f8bc-4cde-9c24-a9ec2a130e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9ab5ffe4-5825-4c23-ac71-3e0729a50a86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b5a6dc62-0519-4454-885c-e145cedba83f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_9ab5ffe4-5825-4c23-ac71-3e0729a50a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9ab5ffe4-5825-4c23-ac71-3e0729a50a86" xlink:to="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6b9d4d47-fc7f-434f-a156-de50133e7866" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6b9d4d47-fc7f-434f-a156-de50133e7866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled_aa82cbf6-ad59-4d9e-b05f-c8641b4d11af" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodSharesWarrantsCanceled"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:to="loc_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled_aa82cbf6-ad59-4d9e-b05f-c8641b4d11af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringPeriodSharesWarrantsExercised_2242ab40-d09d-4d84-a68c-de88cc7343c0" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:to="loc_rnac_StockIssuedDuringPeriodSharesWarrantsExercised_2242ab40-d09d-4d84-a68c-de88cc7343c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_59a2699e-b702-456c-9b49-e0ffa1880e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ClassOfWarrantOrRightRollForward_da979561-18be-4d50-9117-1a922ac88442" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_59a2699e-b702-456c-9b49-e0ffa1880e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9ab5ffe4-5825-4c23-ac71-3e0729a50a86" xlink:to="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5ca78592-ff15-4389-8195-66a58507b506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5ca78592-ff15-4389-8195-66a58507b506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIssuedDuringWarrantedCanceledPricePerShare_3df98410-1d23-48c2-bef4-8e1bbcbc699d" xlink:href="rnac-20241231.xsd#rnac_StockIssuedDuringWarrantedCanceledPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:to="loc_rnac_StockIssuedDuringWarrantedCanceledPricePerShare_3df98410-1d23-48c2-bef4-8e1bbcbc699d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_f1cf8cf4-2e35-4949-82c8-d87b4cb6f80a" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:to="loc_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_f1cf8cf4-2e35-4949-82c8-d87b4cb6f80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4da77cb6-6b79-4845-8060-59989e75927c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_b8af1392-7f97-4695-8fba-3e25ded83c60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4da77cb6-6b79-4845-8060-59989e75927c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityCommonStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_20bb7a96-cb6e-4b90-a42c-f4410d8da32a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f2f04196-8450-4c29-b41e-d63dd387979f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_20bb7a96-cb6e-4b90-a42c-f4410d8da32a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f2f04196-8450-4c29-b41e-d63dd387979f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1fd20f68-1965-40f5-a06c-0a939f8b32c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_20bb7a96-cb6e-4b90-a42c-f4410d8da32a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1fd20f68-1965-40f5-a06c-0a939f8b32c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_99d49715-0263-44ce-907d-7857a0cf01d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_20bb7a96-cb6e-4b90-a42c-f4410d8da32a" xlink:to="loc_us-gaap_CommonStockSharesIssued_99d49715-0263-44ce-907d-7857a0cf01d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_215981f7-464c-4ed5-b7e4-3839e061592f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_20bb7a96-cb6e-4b90-a42c-f4410d8da32a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_215981f7-464c-4ed5-b7e4-3839e061592f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CommonStockVotingRightsNumberOfVotes_c2773796-3379-4dd3-bd53-b9774fe546dd" xlink:href="rnac-20241231.xsd#rnac_CommonStockVotingRightsNumberOfVotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_20bb7a96-cb6e-4b90-a42c-f4410d8da32a" xlink:to="loc_rnac_CommonStockVotingRightsNumberOfVotes_c2773796-3379-4dd3-bd53-b9774fe546dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_e3572d88-39b9-4689-8533-aab6530f5682" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_20bb7a96-cb6e-4b90-a42c-f4410d8da32a" xlink:to="loc_us-gaap_DividendsCommonStock_e3572d88-39b9-4689-8533-aab6530f5682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_752df28e-c507-4103-b6a2-0d13eabbe28b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_75866852-7e69-420c-84e8-4e75e99d403f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_752df28e-c507-4103-b6a2-0d13eabbe28b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_75866852-7e69-420c-84e8-4e75e99d403f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e6da1274-76f8-4482-b553-02eb404821eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75866852-7e69-420c-84e8-4e75e99d403f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e6da1274-76f8-4482-b553-02eb404821eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56365e37-c829-423c-ac4e-837a0503ddd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6da1274-76f8-4482-b553-02eb404821eb" xlink:to="loc_us-gaap_EquityComponentDomain_56365e37-c829-423c-ac4e-837a0503ddd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2a960e97-a0d8-436e-9e58-31c8b2cbf9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56365e37-c829-423c-ac4e-837a0503ddd0" xlink:to="loc_us-gaap_WarrantMember_2a960e97-a0d8-436e-9e58-31c8b2cbf9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_733a5a80-a745-4b38-946f-646f5f0ef3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75866852-7e69-420c-84e8-4e75e99d403f" xlink:to="loc_us-gaap_AwardTypeAxis_733a5a80-a745-4b38-946f-646f5f0ef3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_733a5a80-a745-4b38-946f-646f5f0ef3f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_c485b62f-e52c-4425-bc09-ae626c5ed0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:to="loc_us-gaap_StockCompensationPlanMember_c485b62f-e52c-4425-bc09-ae626c5ed0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_RestrictedStockUnitsUnvestedMember_87b92570-ac4b-4c0f-b705-ead6ac9dfde2" xlink:href="rnac-20241231.xsd#rnac_RestrictedStockUnitsUnvestedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:to="loc_rnac_RestrictedStockUnitsUnvestedMember_87b92570-ac4b-4c0f-b705-ead6ac9dfde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df8bc200-f56a-4346-b3f6-8572fe26e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df8bc200-f56a-4346-b3f6-8572fe26e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_e6098391-a32b-48ce-b1ab-99c2cf0e9b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_e6098391-a32b-48ce-b1ab-99c2cf0e9b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_b1d23da5-0f6c-4965-971c-4304222ba825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f9ce3b8-d12d-48d0-9285-c040612efe2f" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_b1d23da5-0f6c-4965-971c-4304222ba825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1f4833a3-d0a8-48d4-a6ed-d4e7385016c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75866852-7e69-420c-84e8-4e75e99d403f" xlink:to="loc_us-gaap_ClassOfStockLineItems_1f4833a3-d0a8-48d4-a6ed-d4e7385016c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59802363-a966-45ad-913b-f428e0c4da5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1f4833a3-d0a8-48d4-a6ed-d4e7385016c9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59802363-a966-45ad-913b-f428e0c4da5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90b58129-aa04-42d8-bf8c-70d901a31f49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90b58129-aa04-42d8-bf8c-70d901a31f49" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_77278cd8-ff37-4496-9c36-6bdede5d0261" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_PlanNameAxis_77278cd8-ff37-4496-9c36-6bdede5d0261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_725de654-c5c6-4911-a85a-0970bd5a0e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_77278cd8-ff37-4496-9c36-6bdede5d0261" xlink:to="loc_us-gaap_PlanNameDomain_725de654-c5c6-4911-a85a-0970bd5a0e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_StockIncentivePlan2016Member_9527d595-1262-4af4-bce0-8d7d74c7435f" xlink:href="rnac-20241231.xsd#rnac_StockIncentivePlan2016Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_725de654-c5c6-4911-a85a-0970bd5a0e88" xlink:to="loc_rnac_StockIncentivePlan2016Member_9527d595-1262-4af4-bce0-8d7d74c7435f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EmploymentInducementIncentiveAwardPlanMember_1dbfc4ad-ba51-4312-92ae-ffd2ab0415b8" xlink:href="rnac-20241231.xsd#rnac_EmploymentInducementIncentiveAwardPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_725de654-c5c6-4911-a85a-0970bd5a0e88" xlink:to="loc_rnac_EmploymentInducementIncentiveAwardPlanMember_1dbfc4ad-ba51-4312-92ae-ffd2ab0415b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianPlanMember_d070ac11-899e-4f3b-8eb0-f8409fc5e7e9" xlink:href="rnac-20241231.xsd#rnac_OldCartesianPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_725de654-c5c6-4911-a85a-0970bd5a0e88" xlink:to="loc_rnac_OldCartesianPlanMember_d070ac11-899e-4f3b-8eb0-f8409fc5e7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f37c8e48-3804-46dd-a877-1dbc2fba78bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f37c8e48-3804-46dd-a877-1dbc2fba78bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d44f6611-5fbc-4640-9c64-bc1e3af93b24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f37c8e48-3804-46dd-a877-1dbc2fba78bf" xlink:to="loc_us-gaap_EquityComponentDomain_d44f6611-5fbc-4640-9c64-bc1e3af93b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8cfc86a2-f06f-422e-925c-034190dc4a08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d44f6611-5fbc-4640-9c64-bc1e3af93b24" xlink:to="loc_us-gaap_CommonStockMember_8cfc86a2-f06f-422e-925c-034190dc4a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_6ff5d3ca-1d13-480f-95b4-df02b1250c95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d44f6611-5fbc-4640-9c64-bc1e3af93b24" xlink:to="loc_us-gaap_PreferredStockMember_6ff5d3ca-1d13-480f-95b4-df02b1250c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b9727476-239b-4153-a35e-88d5aa8d5fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_AwardTypeAxis_b9727476-239b-4153-a35e-88d5aa8d5fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88640dd2-0313-4fba-a35d-8b71b0d0cd19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b9727476-239b-4153-a35e-88d5aa8d5fd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88640dd2-0313-4fba-a35d-8b71b0d0cd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b62334d9-1a46-42e9-9b56-3d5a1b535448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88640dd2-0313-4fba-a35d-8b71b0d0cd19" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b62334d9-1a46-42e9-9b56-3d5a1b535448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6b589000-37ab-455d-aa50-cd8e8b110e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88640dd2-0313-4fba-a35d-8b71b0d0cd19" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6b589000-37ab-455d-aa50-cd8e8b110e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6abbbee9-0d97-4b4f-9777-deafb9a8d3d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_srt_RangeAxis_6abbbee9-0d97-4b4f-9777-deafb9a8d3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac3a4123-7b58-4318-943e-ecd61acc4278" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6abbbee9-0d97-4b4f-9777-deafb9a8d3d5" xlink:to="loc_srt_RangeMember_ac3a4123-7b58-4318-943e-ecd61acc4278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d9896ebd-d86b-46ca-acc3-0d40f3e01385" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac3a4123-7b58-4318-943e-ecd61acc4278" xlink:to="loc_srt_MinimumMember_d9896ebd-d86b-46ca-acc3-0d40f3e01385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dffd58f6-b217-4edc-bec8-ec07d3e90160" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac3a4123-7b58-4318-943e-ecd61acc4278" xlink:to="loc_srt_MaximumMember_dffd58f6-b217-4edc-bec8-ec07d3e90160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_563cd329-fa4a-4da1-a640-bed1b3443918" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_563cd329-fa4a-4da1-a640-bed1b3443918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74424749-236e-419f-8102-cd1a4725e2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_563cd329-fa4a-4da1-a640-bed1b3443918" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74424749-236e-419f-8102-cd1a4725e2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartestianMember_c82544da-b25e-4233-af56-ff6f2d4ffb95" xlink:href="rnac-20241231.xsd#rnac_OldCartestianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74424749-236e-419f-8102-cd1a4725e2e1" xlink:to="loc_rnac_OldCartestianMember_c82544da-b25e-4233-af56-ff6f2d4ffb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_670d246d-7217-41f9-a589-259ef2a3b3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_670d246d-7217-41f9-a589-259ef2a3b3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_381785ad-3a3d-4ae0-b7d7-5c8ad14ee6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_670d246d-7217-41f9-a589-259ef2a3b3a0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_381785ad-3a3d-4ae0-b7d7-5c8ad14ee6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d4c4cd-bdc6-4fff-948c-8fcb620261d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_381785ad-3a3d-4ae0-b7d7-5c8ad14ee6de" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d4c4cd-bdc6-4fff-948c-8fcb620261d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e6659255-8ec7-4d17-a8ec-440c0a6b47e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_381785ad-3a3d-4ae0-b7d7-5c8ad14ee6de" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e6659255-8ec7-4d17-a8ec-440c0a6b47e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d027c33-43dd-4984-9be5-7994ca43104e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2f5ce66a-230c-4e4a-ab9a-2d8a17da50f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2f5ce66a-230c-4e4a-ab9a-2d8a17da50f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_ede700d0-1b11-4440-b6c5-162afb1d305c" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_ede700d0-1b11-4440-b6c5-162afb1d305c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8343d4d1-c202-4127-a919-7a1c236427a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8343d4d1-c202-4127-a919-7a1c236427a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2f975c8d-4066-429b-a199-9e72cfd1d533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2f975c8d-4066-429b-a199-9e72cfd1d533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3614b8b5-0549-40a8-ad37-144cc310fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3614b8b5-0549-40a8-ad37-144cc310fe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7671188d-ea88-4e7f-95d1-36653af50afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7671188d-ea88-4e7f-95d1-36653af50afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b4f167c4-9b35-4e7e-b6f0-8d419be90b38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b4f167c4-9b35-4e7e-b6f0-8d419be90b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_669ca712-f54f-4c41-8666-24ae3869bf41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_669ca712-f54f-4c41-8666-24ae3869bf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount_2b60136f-e2c6-4096-a97f-0f48569f0f99" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount_2b60136f-e2c6-4096-a97f-0f48569f0f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c109612e-c20e-4381-90de-1d7c6c971750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c109612e-c20e-4381-90de-1d7c6c971750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards_2e79e227-2572-4bcb-80cc-a56510a091c3" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards_2e79e227-2572-4bcb-80cc-a56510a091c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_60c1d9f9-4cbb-4ac7-843b-7bcb7c0a20cc" xlink:href="rnac-20241231.xsd#rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards_60c1d9f9-4cbb-4ac7-843b-7bcb7c0a20cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement_b0c49c0c-4d75-4e39-b4f4-a092db382f5b" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement_b0c49c0c-4d75-4e39-b4f4-a092db382f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa101078-9da4-4dfa-a084-93a385d589d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa101078-9da4-4dfa-a084-93a385d589d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9be693cf-a311-43c1-a8ab-9faba7caa97f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9be693cf-a311-43c1-a8ab-9faba7caa97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c00e85cb-50ad-4eb7-94e2-87779dbb8fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c00e85cb-50ad-4eb7-94e2-87779dbb8fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b5c37fd-d39a-4181-9f4d-8b4046dbb5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b5c37fd-d39a-4181-9f4d-8b4046dbb5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_58fbd575-04ba-46b8-b490-0df15f08433e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_58fbd575-04ba-46b8-b490-0df15f08433e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_593502f7-60ae-4bec-9ae5-533d13ac1881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_593502f7-60ae-4bec-9ae5-533d13ac1881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbf6a399-d312-4527-acef-585889ba8c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbf6a399-d312-4527-acef-585889ba8c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_57c09642-b20b-4b6c-a538-b432b6090529" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_57c09642-b20b-4b6c-a538-b432b6090529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3ce65bcc-7b7a-4f58-90b1-b274e5aaa76d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3ce65bcc-7b7a-4f58-90b1-b274e5aaa76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c9c03f1a-06f6-4fd9-8301-451023b2bf01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c9c03f1a-06f6-4fd9-8301-451023b2bf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c2c96693-1505-477d-8407-c8b66ed699da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504613e9-e78e-4012-9040-631ea21e7174" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c2c96693-1505-477d-8407-c8b66ed699da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ac50128-7cfa-4cf4-bd06-d04eea737164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eb84462c-842b-45df-be60-247e5e5668b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ac50128-7cfa-4cf4-bd06-d04eea737164" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eb84462c-842b-45df-be60-247e5e5668b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e89af17e-cb98-4e96-9cb0-8de314aa8ade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eb84462c-842b-45df-be60-247e5e5668b8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e89af17e-cb98-4e96-9cb0-8de314aa8ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8b1a3a7-876c-4489-a0d7-03fc3ce5c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e89af17e-cb98-4e96-9cb0-8de314aa8ade" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8b1a3a7-876c-4489-a0d7-03fc3ce5c23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ace6ba5-4753-4c20-b5d4-5ec67dccdead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8b1a3a7-876c-4489-a0d7-03fc3ce5c23a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ace6ba5-4753-4c20-b5d4-5ec67dccdead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f369d319-ea59-4cb9-9608-c3c752778989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8b1a3a7-876c-4489-a0d7-03fc3ce5c23a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f369d319-ea59-4cb9-9608-c3c752778989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_db8e7c0d-776b-47bc-a2cd-114124b421e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eb84462c-842b-45df-be60-247e5e5668b8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_db8e7c0d-776b-47bc-a2cd-114124b421e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9928ff3a-44e4-4404-8d3f-de50e3c05fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_db8e7c0d-776b-47bc-a2cd-114124b421e8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9928ff3a-44e4-4404-8d3f-de50e3c05fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GinkgoBioworksHoldingsIncMember_4f410436-2081-43df-a607-50d0cf38a78d" xlink:href="rnac-20241231.xsd#rnac_GinkgoBioworksHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9928ff3a-44e4-4404-8d3f-de50e3c05fe8" xlink:to="loc_rnac_GinkgoBioworksHoldingsIncMember_4f410436-2081-43df-a607-50d0cf38a78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_607ffb06-6f63-47bc-8e3d-8b7b172fcdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eb84462c-842b-45df-be60-247e5e5668b8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_607ffb06-6f63-47bc-8e3d-8b7b172fcdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_103062aa-df57-4c2d-9199-c7ddee1a8a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_607ffb06-6f63-47bc-8e3d-8b7b172fcdf1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_103062aa-df57-4c2d-9199-c7ddee1a8a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4808c86-2c85-4cb5-aa51-6eac39146f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4808c86-2c85-4cb5-aa51-6eac39146f8d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6380a525-1717-4e08-8c72-a985cbe7cf12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6380a525-1717-4e08-8c72-a985cbe7cf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a5b5199e-c2b2-4a3d-8bae-61fac982776d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6380a525-1717-4e08-8c72-a985cbe7cf12" xlink:to="loc_us-gaap_EquityComponentDomain_a5b5199e-c2b2-4a3d-8bae-61fac982776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0382716-8a5e-4348-8137-73a69dfbbe4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5b5199e-c2b2-4a3d-8bae-61fac982776d" xlink:to="loc_us-gaap_CommonStockMember_c0382716-8a5e-4348-8137-73a69dfbbe4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c933b44e-4d16-418a-9eeb-f61e3052f627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5b5199e-c2b2-4a3d-8bae-61fac982776d" xlink:to="loc_us-gaap_PreferredStockMember_c933b44e-4d16-418a-9eeb-f61e3052f627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ba526f1e-654f-4e25-baa7-a7e54034d59d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:to="loc_us-gaap_AwardTypeAxis_ba526f1e-654f-4e25-baa7-a7e54034d59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09d9ec30-7cb6-4f8b-8d01-ea094a340e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ba526f1e-654f-4e25-baa7-a7e54034d59d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09d9ec30-7cb6-4f8b-8d01-ea094a340e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5ed0a936-30f0-41e7-a62b-f5fada44dd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09d9ec30-7cb6-4f8b-8d01-ea094a340e9e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5ed0a936-30f0-41e7-a62b-f5fada44dd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b0bc9260-3cce-4674-b438-af859f263e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b0bc9260-3cce-4674-b438-af859f263e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeeab1e1-38c5-4fd2-a68b-74f6d495a578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b0bc9260-3cce-4674-b438-af859f263e3b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeeab1e1-38c5-4fd2-a68b-74f6d495a578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartestianMember_1c17a8b4-61ec-4557-8d60-07a7db5902b4" xlink:href="rnac-20241231.xsd#rnac_OldCartestianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeeab1e1-38c5-4fd2-a68b-74f6d495a578" xlink:to="loc_rnac_OldCartestianMember_1c17a8b4-61ec-4557-8d60-07a7db5902b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_713100c8-d2a8-4a73-83cc-800ce310c230" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_153ebb6f-90e1-4425-961f-30d422cd9064" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_153ebb6f-90e1-4425-961f-30d422cd9064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5a1e1cd2-a6ca-4982-a499-9b7fdebb10e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5a1e1cd2-a6ca-4982-a499-9b7fdebb10e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2fb2ae52-dba4-4c32-89dc-be0afebc81ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2fb2ae52-dba4-4c32-89dc-be0afebc81ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_657fa5c4-76be-4a9d-a154-302ef1f71a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_657fa5c4-76be-4a9d-a154-302ef1f71a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_173e0f26-673c-482a-a667-b77bab98ae11" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b73acce5-0a41-40ef-8a64-be3cfab43da2" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_173e0f26-673c-482a-a667-b77bab98ae11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf496720-2f33-4984-94dc-5685b792a7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c5957aa-e9f5-481b-836e-9da9f5df5fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf496720-2f33-4984-94dc-5685b792a7a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c5957aa-e9f5-481b-836e-9da9f5df5fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f02b2bd8-f4a9-4a6f-9d17-1a0c60e6c7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c5957aa-e9f5-481b-836e-9da9f5df5fe9" xlink:to="loc_us-gaap_PlanNameAxis_f02b2bd8-f4a9-4a6f-9d17-1a0c60e6c7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8b49f31e-2c98-4705-826b-a156db45181f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f02b2bd8-f4a9-4a6f-9d17-1a0c60e6c7e8" xlink:to="loc_us-gaap_PlanNameDomain_8b49f31e-2c98-4705-826b-a156db45181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_94706f75-2b56-4948-abee-020c2a374f34" xlink:href="rnac-20241231.xsd#rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8b49f31e-2c98-4705-826b-a156db45181f" xlink:to="loc_rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_94706f75-2b56-4948-abee-020c2a374f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OldCartesianPlanMember_7373f2bf-030d-48aa-855f-f57d9decdf45" xlink:href="rnac-20241231.xsd#rnac_OldCartesianPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8b49f31e-2c98-4705-826b-a156db45181f" xlink:to="loc_rnac_OldCartesianPlanMember_7373f2bf-030d-48aa-855f-f57d9decdf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c5957aa-e9f5-481b-836e-9da9f5df5fe9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6eb6b58-554a-4890-9652-427eda0d4d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6eb6b58-554a-4890-9652-427eda0d4d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f617f236-ab35-46bc-ad94-752953e34879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f617f236-ab35-46bc-ad94-752953e34879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_759f5205-338a-4792-a688-f9f687ad01f6" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_759f5205-338a-4792-a688-f9f687ad01f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d29d514-72dc-42a3-bf97-f92efd3f0cba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d29d514-72dc-42a3-bf97-f92efd3f0cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0c3e7337-4412-405b-92c7-86842b6a6989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0c3e7337-4412-405b-92c7-86842b6a6989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock_0aede337-522c-4c42-adec-ed1de0da21d5" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock_0aede337-522c-4c42-adec-ed1de0da21d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_34700dd3-6b63-40ae-bdcd-7fed45e70e59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e94677b-2e83-4402-a8e6-5b92f3ebb247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_34700dd3-6b63-40ae-bdcd-7fed45e70e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_99b723d1-9557-404a-8f56-acefbe8b76cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_99b723d1-9557-404a-8f56-acefbe8b76cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ed44354a-03ae-41ad-b5af-34531c4b04c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ed44354a-03ae-41ad-b5af-34531c4b04c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_def9e57f-82b4-4bc2-ad15-f19ed279ae83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_def9e57f-82b4-4bc2-ad15-f19ed279ae83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26eeef4b-0fb6-4d4f-950b-9d1bf9798ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26eeef4b-0fb6-4d4f-950b-9d1bf9798ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_cbe8a649-db63-48b8-a0e0-db9e7515b6c4" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_cbe8a649-db63-48b8-a0e0-db9e7515b6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60e77259-dec7-46bb-bc9a-6e65ba794e65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60e77259-dec7-46bb-bc9a-6e65ba794e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_145ddbdd-1ee5-4249-be39-3034cb9c0063" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_145ddbdd-1ee5-4249-be39-3034cb9c0063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock_6fad8551-45f2-43f6-989e-c47ca02990af" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock_6fad8551-45f2-43f6-989e-c47ca02990af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b332cda7-360c-46e5-b8de-eb1077a09738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2666bd6e-b1fa-4864-98db-b09dcc2bac9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b332cda7-360c-46e5-b8de-eb1077a09738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_bf28c773-fdf8-4418-9c9d-2505bdcfcf8b" xlink:href="rnac-20241231.xsd#rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_bf28c773-fdf8-4418-9c9d-2505bdcfcf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5eedd699-280b-4841-9116-e8a3f2d138bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5eedd699-280b-4841-9116-e8a3f2d138bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_9cff121e-a712-4478-84e3-643d348d7496" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_9cff121e-a712-4478-84e3-643d348d7496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a5855ea-1cd9-4324-84f1-a83db4a4f156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_9cff121e-a712-4478-84e3-643d348d7496" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a5855ea-1cd9-4324-84f1-a83db4a4f156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_cf4aa2d5-ee51-431b-a144-d9bdb541d003" xlink:href="rnac-20241231.xsd#rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_9cff121e-a712-4478-84e3-643d348d7496" xlink:to="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_cf4aa2d5-ee51-431b-a144-d9bdb541d003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_770e7d36-5a7e-4913-baf8-947122637888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_9cff121e-a712-4478-84e3-643d348d7496" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_770e7d36-5a7e-4913-baf8-947122637888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_7e01eed5-3963-4dfe-a3dd-e5a9cff14a88" xlink:href="rnac-20241231.xsd#rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3de3f5e6-e835-4f32-8d6d-23ad2b4f167e" xlink:to="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_7e01eed5-3963-4dfe-a3dd-e5a9cff14a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a947a9e9-a6da-46e3-971b-e83bf9b74139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_7e01eed5-3963-4dfe-a3dd-e5a9cff14a88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a947a9e9-a6da-46e3-971b-e83bf9b74139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_b7bfa20d-fa95-4f72-937c-b121ff26c75f" xlink:href="rnac-20241231.xsd#rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_7e01eed5-3963-4dfe-a3dd-e5a9cff14a88" xlink:to="loc_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_b7bfa20d-fa95-4f72-937c-b121ff26c75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_625fe468-b2a5-4845-945c-dceef1a73875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_7e01eed5-3963-4dfe-a3dd-e5a9cff14a88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_625fe468-b2a5-4845-945c-dceef1a73875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d2907444-d013-4661-bb57-069c2bf4dc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebcb169c-827f-46d4-beb9-d586f10b8ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d2907444-d013-4661-bb57-069c2bf4dc1a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebcb169c-827f-46d4-beb9-d586f10b8ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ee0aeb90-19c3-4f9b-b15f-265e09cc2744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebcb169c-827f-46d4-beb9-d586f10b8ac8" xlink:to="loc_us-gaap_AwardTypeAxis_ee0aeb90-19c3-4f9b-b15f-265e09cc2744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a64f0bae-a7ee-4298-a776-914a12164344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ee0aeb90-19c3-4f9b-b15f-265e09cc2744" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a64f0bae-a7ee-4298-a776-914a12164344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_92c41abe-1944-464b-8b41-82db6cb54b09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a64f0bae-a7ee-4298-a776-914a12164344" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_92c41abe-1944-464b-8b41-82db6cb54b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89077c84-7f7f-4569-b567-56ca59586f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebcb169c-827f-46d4-beb9-d586f10b8ac8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89077c84-7f7f-4569-b567-56ca59586f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89077c84-7f7f-4569-b567-56ca59586f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_600dcc50-8a79-47a7-9c41-4b5341654588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_600dcc50-8a79-47a7-9c41-4b5341654588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_387919d7-e520-4997-a450-db8c83403d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_387919d7-e520-4997-a450-db8c83403d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50328fc8-d20a-4170-9c7c-aea4a6acdad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50328fc8-d20a-4170-9c7c-aea4a6acdad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0e7cfc85-4865-499a-b389-8532d0f59c62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8c293-d93e-4643-a7d3-bd1f19c8c48f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0e7cfc85-4865-499a-b389-8532d0f59c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89077c84-7f7f-4569-b567-56ca59586f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9ecb7da3-3036-4425-b0b4-e291675855d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9ecb7da3-3036-4425-b0b4-e291675855d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4675077-6820-42dd-8b10-b725acfbcd60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4675077-6820-42dd-8b10-b725acfbcd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_26176e45-009b-4094-a405-69c69189570d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_26176e45-009b-4094-a405-69c69189570d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e66a92e6-9b3a-4da5-9cd7-00694ceeeeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c697ef15-d0e5-4872-9ddd-0eb57f42fe41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e66a92e6-9b3a-4da5-9cd7-00694ceeeeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RevenueArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_690d3aef-4358-4c1a-a5a4-b17e0480a1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_690d3aef-4358-4c1a-a5a4-b17e0480a1e9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2db9d1bd-7c99-4d33-a862-f619e81f79de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2db9d1bd-7c99-4d33-a862-f619e81f79de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f981109f-3f5a-4114-92fe-a9d9c7d316de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2db9d1bd-7c99-4d33-a862-f619e81f79de" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f981109f-3f5a-4114-92fe-a9d9c7d316de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TakedaAgreementMember_cd28e73f-696e-42a5-a9bc-acbd55713052" xlink:href="rnac-20241231.xsd#rnac_TakedaAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f981109f-3f5a-4114-92fe-a9d9c7d316de" xlink:to="loc_rnac_TakedaAgreementMember_cd28e73f-696e-42a5-a9bc-acbd55713052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_a0662cce-ff4d-4ebf-8582-67fd60c1a9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f981109f-3f5a-4114-92fe-a9d9c7d316de" xlink:to="loc_us-gaap_CollaborativeArrangementMember_a0662cce-ff4d-4ebf-8582-67fd60c1a9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_054e81b6-b68d-446c-9603-f6190d23d641" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_054e81b6-b68d-446c-9603-f6190d23d641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fdcf81ac-2d2f-4190-8023-8f7a0135f781" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_054e81b6-b68d-446c-9603-f6190d23d641" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fdcf81ac-2d2f-4190-8023-8f7a0135f781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AstellasGeneTherapiesMember_c1923b03-f981-4101-85b0-a5748d093eb9" xlink:href="rnac-20241231.xsd#rnac_AstellasGeneTherapiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fdcf81ac-2d2f-4190-8023-8f7a0135f781" xlink:to="loc_rnac_AstellasGeneTherapiesMember_c1923b03-f981-4101-85b0-a5748d093eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SareptaTherapeuticsInc.Member_a4ebe56c-2c50-4467-b134-1210c76384b7" xlink:href="rnac-20241231.xsd#rnac_SareptaTherapeuticsInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fdcf81ac-2d2f-4190-8023-8f7a0135f781" xlink:to="loc_rnac_SareptaTherapeuticsInc.Member_a4ebe56c-2c50-4467-b134-1210c76384b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3a66e1b5-54e3-48a0-9060-892e6a8a5238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3a66e1b5-54e3-48a0-9060-892e6a8a5238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a39fce4-4013-4ba7-a466-3ada6d7ffad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3a66e1b5-54e3-48a0-9060-892e6a8a5238" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a39fce4-4013-4ba7-a466-3ada6d7ffad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SOBIPurchaseAgreementMember_b0b04618-2940-4fdc-b31f-d7fc19a63492" xlink:href="rnac-20241231.xsd#rnac_SOBIPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a39fce4-4013-4ba7-a466-3ada6d7ffad2" xlink:to="loc_rnac_SOBIPurchaseAgreementMember_b0b04618-2940-4fdc-b31f-d7fc19a63492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_af40dc07-519d-4ed6-9535-68cbc76a1b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_af40dc07-519d-4ed6-9535-68cbc76a1b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain_37e2af2e-67f5-4b47-a65d-fa98d356d5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_af40dc07-519d-4ed6-9535-68cbc76a1b4c" xlink:to="loc_us-gaap_ReceivablesBillingStatusDomain_37e2af2e-67f5-4b47-a65d-fa98d356d5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledRevenuesMember_6fb3ca78-aa87-4914-a291-747622427293" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BilledRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain_37e2af2e-67f5-4b47-a65d-fa98d356d5c0" xlink:to="loc_us-gaap_BilledRevenuesMember_6fb3ca78-aa87-4914-a291-747622427293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a89dc9f5-50cf-4916-a976-3414c95bbd8a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_srt_CounterpartyNameAxis_a89dc9f5-50cf-4916-a976-3414c95bbd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47425ba3-0b4d-44b5-a539-ff9f27cc9d2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a89dc9f5-50cf-4916-a976-3414c95bbd8a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47425ba3-0b4d-44b5-a539-ff9f27cc9d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SwedishOrphanBiovitrumABSOBIMember_77a7ffef-f155-4d26-8b61-bbb5da7fce3f" xlink:href="rnac-20241231.xsd#rnac_SwedishOrphanBiovitrumABSOBIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47425ba3-0b4d-44b5-a539-ff9f27cc9d2d" xlink:to="loc_rnac_SwedishOrphanBiovitrumABSOBIMember_77a7ffef-f155-4d26-8b61-bbb5da7fce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis_712a11bd-a2fc-4d51-bb04-07621de4afe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_GovernmentAssistanceTypeAxis_712a11bd-a2fc-4d51-bb04-07621de4afe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_396cad65-b687-40c0-892e-234856905a91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_712a11bd-a2fc-4d51-bb04-07621de4afe5" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_396cad65-b687-40c0-892e-234856905a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember_97f7ebcd-1360-4655-a5da-be74bd8ec5f1" xlink:href="rnac-20241231.xsd#rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_396cad65-b687-40c0-892e-234856905a91" xlink:to="loc_rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember_97f7ebcd-1360-4655-a5da-be74bd8ec5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4835292e-2f20-4896-9ec7-974734afdd11" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborationAndLicenseAgreementsUpfrontPayment_7f535edb-e737-4b65-ad50-a0f200039227" xlink:href="rnac-20241231.xsd#rnac_CollaborationAndLicenseAgreementsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_CollaborationAndLicenseAgreementsUpfrontPayment_7f535edb-e737-4b65-ad50-a0f200039227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties_5e3f7e2c-f5c1-4f55-9a0d-b925552bcd90" xlink:href="rnac-20241231.xsd#rnac_DevelopmentAndCommercialMilestonesPlusRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties_5e3f7e2c-f5c1-4f55-9a0d-b925552bcd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_79dd2a7a-1c2d-43bc-a6e4-2be3f425a441" xlink:href="rnac-20241231.xsd#rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment_79dd2a7a-1c2d-43bc-a6e4-2be3f425a441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements_93b63d71-9dd3-4ca4-b3b7-cc5c3a89725b" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements_93b63d71-9dd3-4ca4-b3b7-cc5c3a89725b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation_91fd5024-0ece-44e5-8ab7-20203a2bd78c" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation_91fd5024-0ece-44e5-8ab7-20203a2bd78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_959cd1da-37c4-4735-8eef-be45c559eb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_959cd1da-37c4-4735-8eef-be45c559eb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_d252e6a2-b735-4eba-b2b7-c925f3d41eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_d252e6a2-b735-4eba-b2b7-c925f3d41eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46db4196-9d48-413b-a8fb-7c1daf6a87c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46db4196-9d48-413b-a8fb-7c1daf6a87c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_92233bd7-3651-43f5-8225-bfad8c68cf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_92233bd7-3651-43f5-8225-bfad8c68cf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance_1c88f464-29a4-4060-9904-9f53efc9fdde" xlink:href="rnac-20241231.xsd#rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance_1c88f464-29a4-4060-9904-9f53efc9fdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_8bc6fcda-3a6e-4c52-8fff-fb7000ab47b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_8bc6fcda-3a6e-4c52-8fff-fb7000ab47b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_3b423df3-eb86-4f1e-aff6-8a61a1f7b1ae" xlink:href="rnac-20241231.xsd#rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_3b423df3-eb86-4f1e-aff6-8a61a1f7b1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementUpfrontCashPayment_39df7284-334e-4dfc-8b3c-0d79bfa33d4e" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementUpfrontCashPayment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementUpfrontCashPayment_39df7284-334e-4dfc-8b3c-0d79bfa33d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected_3abd8398-e7b7-4c75-bee3-7b94d827636a" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected_3abd8398-e7b7-4c75-bee3-7b94d827636a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_9ca5f133-3dbd-4aa5-8f84-9d176664cd75" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_9ca5f133-3dbd-4aa5-8f84-9d176664cd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EligiblePeriodToReceiveRoyalties_b3ea5f94-476a-4629-8296-b767cdb6d06b" xlink:href="rnac-20241231.xsd#rnac_EligiblePeriodToReceiveRoyalties"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_EligiblePeriodToReceiveRoyalties_b3ea5f94-476a-4629-8296-b767cdb6d06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_RevenueNumberOfPerformanceObligations_d17d7fb5-5bb5-4305-9b4a-ac4d4c0f59de" xlink:href="rnac-20241231.xsd#rnac_RevenueNumberOfPerformanceObligations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_RevenueNumberOfPerformanceObligations_d17d7fb5-5bb5-4305-9b4a-ac4d4c0f59de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementDevelopmentMilestone_5c3e1026-879f-452b-bfbb-184fff117ba2" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementDevelopmentMilestone"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementDevelopmentMilestone_5c3e1026-879f-452b-bfbb-184fff117ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d0ed762d-5d46-4b4a-b6ea-7c5ccf56cb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d0ed762d-5d46-4b4a-b6ea-7c5ccf56cb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium_8ccbda50-63cd-4b19-9f5e-45bb87d25895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedemptionPremium"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_RedemptionPremium_8ccbda50-63cd-4b19-9f5e-45bb87d25895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementPaymentObligation_af662402-4073-4f6b-b2f9-719117fdbe23" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementPaymentObligation"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_CollaborativeArrangementPaymentObligation_af662402-4073-4f6b-b2f9-719117fdbe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0ff9fcb1-e946-4a4b-9de7-69266f157049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0ff9fcb1-e946-4a4b-9de7-69266f157049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6319f117-067d-4e4c-8f07-0bad81a7b724" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6319f117-067d-4e4c-8f07-0bad81a7b724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementOptionTerm_1cd6626b-5b96-4d6d-98b3-eb0b1d95e092" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementOptionTerm"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementOptionTerm_1cd6626b-5b96-4d6d-98b3-eb0b1d95e092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementExtensionTerm_24152f52-515d-4082-b061-6be5519eca58" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementExtensionTerm"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementExtensionTerm_24152f52-515d-4082-b061-6be5519eca58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies_03caac83-37e1-49a0-a51d-b1d56d4835d2" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies_03caac83-37e1-49a0-a51d-b1d56d4835d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestoneReceivable_8154b7b8-f4bf-458d-9467-018f15a6a955" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestoneReceivable"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_LicenseAndOptionAgreementMilestoneReceivable_8154b7b8-f4bf-458d-9467-018f15a6a955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_5da2ce28-8786-46c8-b2e5-28759691d111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_5da2ce28-8786-46c8-b2e5-28759691d111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAwardAmount_a8e165c5-fb57-4d3c-b7b4-724718842853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_GovernmentAssistanceAwardAmount_a8e165c5-fb57-4d3c-b7b4-724718842853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GovernmentAssistancePotentialAdditionalAwardAmount_b9db0449-1d82-4918-a74e-046281ee76a7" xlink:href="rnac-20241231.xsd#rnac_GovernmentAssistancePotentialAdditionalAwardAmount"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_GovernmentAssistancePotentialAdditionalAwardAmount_b9db0449-1d82-4918-a74e-046281ee76a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_630fb1ee-08a4-42f0-bd64-9af2b396d881" xlink:href="rnac-20241231.xsd#rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_630fb1ee-08a4-42f0-bd64-9af2b396d881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent_88f0dee1-17b7-46ab-94bb-b5a4bc4866ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmountCumulativeCurrent"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent_88f0dee1-17b7-46ab-94bb-b5a4bc4866ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_f0da6b12-2304-4980-913d-a11bedb5e052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9dbd5b95-a3d0-4ab9-919d-f4a36fb6c37a" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_f0da6b12-2304-4980-913d-a11bedb5e052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c010fef9-3869-4e27-94ac-53694f4aab5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward_76c763ff-28df-49af-bd77-b0063e635bc1" xlink:href="rnac-20241231.xsd#rnac_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c010fef9-3869-4e27-94ac-53694f4aab5a" xlink:to="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward_76c763ff-28df-49af-bd77-b0063e635bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityDeferredRevenue_285f9f0c-2b2f-458e-8200-33eb3cb660b5" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityDeferredRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward_76c763ff-28df-49af-bd77-b0063e635bc1" xlink:to="loc_rnac_ContractwithCustomerLiabilityDeferredRevenue_285f9f0c-2b2f-458e-8200-33eb3cb660b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_c1b4ead2-8d9a-443a-ac0a-223f363a1ddb" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward_76c763ff-28df-49af-bd77-b0063e635bc1" xlink:to="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_c1b4ead2-8d9a-443a-ac0a-223f363a1ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_dffb96cb-e320-4b69-ae1e-4117c7a603f6" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward_76c763ff-28df-49af-bd77-b0063e635bc1" xlink:to="loc_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_dffb96cb-e320-4b69-ae1e-4117c7a603f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityDeferredRevenue_2e42574c-0ce1-4aa8-b0e2-109c9d19096f" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityDeferredRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward_76c763ff-28df-49af-bd77-b0063e635bc1" xlink:to="loc_rnac_ContractwithCustomerLiabilityDeferredRevenue_2e42574c-0ce1-4aa8-b0e2-109c9d19096f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a3f9c328-e160-4f91-826b-ef167c1cd873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward_76c763ff-28df-49af-bd77-b0063e635bc1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a3f9c328-e160-4f91-826b-ef167c1cd873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts_f7163daa-bd54-44b8-8ceb-070cc84e4bd2" xlink:href="rnac-20241231.xsd#rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward_76c763ff-28df-49af-bd77-b0063e635bc1" xlink:to="loc_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts_f7163daa-bd54-44b8-8ceb-070cc84e4bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_2ef27c36-a557-4e70-9763-8daa74071447" xlink:href="rnac-20241231.xsd#rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward_76c763ff-28df-49af-bd77-b0063e635bc1" xlink:to="loc_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_2ef27c36-a557-4e70-9763-8daa74071447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4a00f9e1-43df-4cdd-ad8b-d2b900c0fa47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rnac_ChangeInContractWithCustomerLiabilityRollForward_76c763ff-28df-49af-bd77-b0063e635bc1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4a00f9e1-43df-4cdd-ad8b-d2b900c0fa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bb42582d-04e7-45ec-9e49-aecdb05a173b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bb42582d-04e7-45ec-9e49-aecdb05a173b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c00685a-5dd5-4e43-9cb0-3f82c7deea71" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:to="loc_srt_CounterpartyNameAxis_0c00685a-5dd5-4e43-9cb0-3f82c7deea71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0c00685a-5dd5-4e43-9cb0-3f82c7deea71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Dr.TimothyA.SpringerMember_889a1ae6-f02f-4819-9ff2-9f115ec93efe" xlink:href="rnac-20241231.xsd#rnac_Dr.TimothyA.SpringerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:to="loc_rnac_Dr.TimothyA.SpringerMember_889a1ae6-f02f-4819-9ff2-9f115ec93efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_TASPartnersLLCMember_1a2b5dae-ad0a-4909-8458-0bcfc50b1f2b" xlink:href="rnac-20241231.xsd#rnac_TASPartnersLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:to="loc_rnac_TASPartnersLLCMember_1a2b5dae-ad0a-4909-8458-0bcfc50b1f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Dr.ChafenLuMember_ac0e920f-a6b5-4740-b5c4-e84222157e47" xlink:href="rnac-20241231.xsd#rnac_Dr.ChafenLuMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:to="loc_rnac_Dr.ChafenLuMember_ac0e920f-a6b5-4740-b5c4-e84222157e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SevenOneEightThreeFourIrrevocableTrustMember_8f7415e8-2366-49c0-ac6b-f4ec39865c3d" xlink:href="rnac-20241231.xsd#rnac_SevenOneEightThreeFourIrrevocableTrustMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ce6e0d5-813c-4d60-99d3-1b766320f83a" xlink:to="loc_rnac_SevenOneEightThreeFourIrrevocableTrustMember_8f7415e8-2366-49c0-ac6b-f4ec39865c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6d56caf-f60d-4598-bf77-b5bd1c462b22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6d56caf-f60d-4598-bf77-b5bd1c462b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6331f329-eb32-49b8-b651-46d009dda493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6d56caf-f60d-4598-bf77-b5bd1c462b22" xlink:to="loc_us-gaap_RelatedPartyDomain_6331f329-eb32-49b8-b651-46d009dda493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_adfe159b-d205-448f-a851-c7bcd10917c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6331f329-eb32-49b8-b651-46d009dda493" xlink:to="loc_us-gaap_RelatedPartyMember_adfe159b-d205-448f-a851-c7bcd10917c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3bde5344-4996-4bc8-bba0-038a11a1dc96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3bde5344-4996-4bc8-bba0-038a11a1dc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ec2abde-5b37-4968-8cbd-96cba5b2755e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3bde5344-4996-4bc8-bba0-038a11a1dc96" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ec2abde-5b37-4968-8cbd-96cba5b2755e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2024Member_67d9ae6d-60f2-4cf6-839f-9653cdbfa90f" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ec2abde-5b37-4968-8cbd-96cba5b2755e" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2024Member_67d9ae6d-60f2-4cf6-839f-9653cdbfa90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_PrivatePlacement2023Member_5bf18031-be74-4e0a-a825-91d82fee5bbb" xlink:href="rnac-20241231.xsd#rnac_PrivatePlacement2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ec2abde-5b37-4968-8cbd-96cba5b2755e" xlink:to="loc_rnac_PrivatePlacement2023Member_5bf18031-be74-4e0a-a825-91d82fee5bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2614102a-6a14-4cf8-a790-bf76f590f39b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4fe7e1bd-a140-4bd8-a191-defd756323ad" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2614102a-6a14-4cf8-a790-bf76f590f39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_63deab1b-e784-4f6e-a9c4-efdfafa16b85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2614102a-6a14-4cf8-a790-bf76f590f39b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_63deab1b-e784-4f6e-a9c4-efdfafa16b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_09b39b25-5021-42a0-903a-e883c79254e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2614102a-6a14-4cf8-a790-bf76f590f39b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_09b39b25-5021-42a0-903a-e883c79254e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bba61053-9c36-4865-b5e6-1e7194d0e7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bba61053-9c36-4865-b5e6-1e7194d0e7e7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9d061645-0b28-4b7a-bfb0-53987844ca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9d061645-0b28-4b7a-bfb0-53987844ca9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0089f567-1f42-4750-bb93-6c04448806aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9d061645-0b28-4b7a-bfb0-53987844ca9a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0089f567-1f42-4750-bb93-6c04448806aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SecuritiesPurchaseAgreement2023Member_8728a16b-878f-47b7-b6fe-4130703fa5ee" xlink:href="rnac-20241231.xsd#rnac_SecuritiesPurchaseAgreement2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0089f567-1f42-4750-bb93-6c04448806aa" xlink:to="loc_rnac_SecuritiesPurchaseAgreement2023Member_8728a16b-878f-47b7-b6fe-4130703fa5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d3b41a06-7997-4d61-a3b8-8fec8754ef84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d3b41a06-7997-4d61-a3b8-8fec8754ef84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_46f7148d-3877-4be8-a2b7-9c0432a62424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d3b41a06-7997-4d61-a3b8-8fec8754ef84" xlink:to="loc_us-gaap_RelatedPartyDomain_46f7148d-3877-4be8-a2b7-9c0432a62424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_711dc858-69de-4f7b-82ea-d32322bbfdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_46f7148d-3877-4be8-a2b7-9c0432a62424" xlink:to="loc_us-gaap_RelatedPartyMember_711dc858-69de-4f7b-82ea-d32322bbfdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c6892fc8-82f3-447d-bc56-525c45e58449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c6892fc8-82f3-447d-bc56-525c45e58449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5dfb2a20-d906-4f24-bef3-b59ef002cde7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c6892fc8-82f3-447d-bc56-525c45e58449" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5dfb2a20-d906-4f24-bef3-b59ef002cde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_A2019WarrantsMember_0d1b465e-dadd-44f1-af84-1e7c408c27bc" xlink:href="rnac-20241231.xsd#rnac_A2019WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5dfb2a20-d906-4f24-bef3-b59ef002cde7" xlink:to="loc_rnac_A2019WarrantsMember_0d1b465e-dadd-44f1-af84-1e7c408c27bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fff565d-88d2-42e9-9a04-47b3262bfb9b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8d229f7b-b687-406b-8018-77e89ffafb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8d229f7b-b687-406b-8018-77e89ffafb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b57b38a5-63a4-4fe4-b93d-66ffc0c8b94b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b57b38a5-63a4-4fe4-b93d-66ffc0c8b94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ClassOfWarrantOrRightExercisedDuringPeriod_b621a551-590d-40c4-8d78-831941fd1a4d" xlink:href="rnac-20241231.xsd#rnac_ClassOfWarrantOrRightExercisedDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_rnac_ClassOfWarrantOrRightExercisedDuringPeriod_b621a551-590d-40c4-8d78-831941fd1a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b9eae096-1240-4a43-a1fd-5d1a4fdb20be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b9eae096-1240-4a43-a1fd-5d1a4fdb20be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_9829fe7f-b739-4930-9144-0a44d5ee19a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_9829fe7f-b739-4930-9144-0a44d5ee19a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71bc1005-1235-4a05-ad60-4c6b1772bf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71bc1005-1235-4a05-ad60-4c6b1772bf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants_bb76fa71-0432-4a97-879a-efa433487815" xlink:href="rnac-20241231.xsd#rnac_IssuanceOfContingentValueRightForExerciseOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4543677c-8e0a-4620-a168-b92c360edf86" xlink:to="loc_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants_bb76fa71-0432-4a97-879a-efa433487815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26ec2a66-f8e8-4f31-8a7f-4c4cbaa27216" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5287f67-4155-4049-aecf-78fe0376285f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26ec2a66-f8e8-4f31-8a7f-4c4cbaa27216" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5287f67-4155-4049-aecf-78fe0376285f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f857256-f11d-45c6-85ca-1087a17eeecf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5287f67-4155-4049-aecf-78fe0376285f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f857256-f11d-45c6-85ca-1087a17eeecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dee251b2-0f1b-4848-a460-bfca4f527464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f857256-f11d-45c6-85ca-1087a17eeecf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dee251b2-0f1b-4848-a460-bfca4f527464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_BiogenM.A.Inc.Member_7a0ad2a7-d656-4d94-91fe-23f42ce28bf0" xlink:href="rnac-20241231.xsd#rnac_BiogenM.A.Inc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dee251b2-0f1b-4848-a460-bfca4f527464" xlink:to="loc_rnac_BiogenM.A.Inc.Member_7a0ad2a7-d656-4d94-91fe-23f42ce28bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c859f183-19b0-41c9-b484-c46cd0927baf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5287f67-4155-4049-aecf-78fe0376285f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c859f183-19b0-41c9-b484-c46cd0927baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_11523d7f-1d33-4ec9-b0b1-a26fa18ba96f" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementWrittenNoticePeriodForTermination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c859f183-19b0-41c9-b484-c46cd0927baf" xlink:to="loc_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_11523d7f-1d33-4ec9-b0b1-a26fa18ba96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2d213a69-8117-45a7-85a4-6b9a7cd2093f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd174749-4b76-43fd-a17a-f44c2eb42a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2d213a69-8117-45a7-85a4-6b9a7cd2093f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd174749-4b76-43fd-a17a-f44c2eb42a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9a3d5356-a0a0-424d-a0ee-23bd9f2d2d74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd174749-4b76-43fd-a17a-f44c2eb42a3b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9a3d5356-a0a0-424d-a0ee-23bd9f2d2d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ea066ef-cd96-4874-aebc-c8300e524fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9a3d5356-a0a0-424d-a0ee-23bd9f2d2d74" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ea066ef-cd96-4874-aebc-c8300e524fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_NationalCancerInstituteAgreementMember_20dac9af-8ec1-40a4-92e9-d97dbd6c649c" xlink:href="rnac-20241231.xsd#rnac_NationalCancerInstituteAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ea066ef-cd96-4874-aebc-c8300e524fc5" xlink:to="loc_rnac_NationalCancerInstituteAgreementMember_20dac9af-8ec1-40a4-92e9-d97dbd6c649c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b9a6acf-a49c-405a-9938-16d4b8c5c2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd174749-4b76-43fd-a17a-f44c2eb42a3b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b9a6acf-a49c-405a-9938-16d4b8c5c2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementRoyaltyPayment_9177b7c9-7f04-401d-85c9-d91683d5be38" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementRoyaltyPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b9a6acf-a49c-405a-9938-16d4b8c5c2a9" xlink:to="loc_rnac_LicenseAndOptionAgreementRoyaltyPayment_9177b7c9-7f04-401d-85c9-d91683d5be38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum_58945be8-5b1f-4e4a-a0f3-60838e7f2046" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b9a6acf-a49c-405a-9938-16d4b8c5c2a9" xlink:to="loc_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum_58945be8-5b1f-4e4a-a0f3-60838e7f2046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_b036089f-25a1-428d-b0b1-be03112941a0" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementWrittenNoticePeriodForTermination"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b9a6acf-a49c-405a-9938-16d4b8c5c2a9" xlink:to="loc_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination_b036089f-25a1-428d-b0b1-be03112941a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_817bead5-a8b3-42e2-9746-140999dd583e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc77731-df5b-4e32-805a-5ae1520e2232" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_817bead5-a8b3-42e2-9746-140999dd583e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc77731-df5b-4e32-805a-5ae1520e2232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_988968a8-88ad-42e0-92e3-1eb999b997c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc77731-df5b-4e32-805a-5ae1520e2232" xlink:to="loc_us-gaap_TypeOfArrangementAxis_988968a8-88ad-42e0-92e3-1eb999b997c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93ec8b9-d9b5-46c0-beed-7dcb83c68268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_988968a8-88ad-42e0-92e3-1eb999b997c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93ec8b9-d9b5-46c0-beed-7dcb83c68268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GinkgoAgreementMember_0a6b8098-e174-44d6-a006-5f1b3215bc3e" xlink:href="rnac-20241231.xsd#rnac_GinkgoAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93ec8b9-d9b5-46c0-beed-7dcb83c68268" xlink:to="loc_rnac_GinkgoAgreementMember_0a6b8098-e174-44d6-a006-5f1b3215bc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc77731-df5b-4e32-805a-5ae1520e2232" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected_ba81b189-e083-4d4f-88ce-990860729fd5" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:to="loc_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected_ba81b189-e083-4d4f-88ce-990860729fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestonePayments_5aad7060-ea66-47f6-a379-12d4cf9af667" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:to="loc_rnac_LicenseAndOptionAgreementMilestonePayments_5aad7060-ea66-47f6-a379-12d4cf9af667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement_d545164f-73e5-4e2c-b7b1-616daee96ee4" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:to="loc_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement_d545164f-73e5-4e2c-b7b1-616daee96ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount_fe96b0d9-6032-4e6e-85cf-241164fd45cc" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84240aa1-2212-42dd-94d8-5a86083f3848" xlink:to="loc_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount_fe96b0d9-6032-4e6e-85cf-241164fd45cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c4beb49d-5a25-4678-8ad2-488e0173fff2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ad80e57-bcc5-4ebf-bd5c-cb10adfc92dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c4beb49d-5a25-4678-8ad2-488e0173fff2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ad80e57-bcc5-4ebf-bd5c-cb10adfc92dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d65a5e45-3c5c-4d4b-ae37-a153441ace9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ad80e57-bcc5-4ebf-bd5c-cb10adfc92dd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d65a5e45-3c5c-4d4b-ae37-a153441ace9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7767ca4-8d09-465e-9ef7-c37deea91834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d65a5e45-3c5c-4d4b-ae37-a153441ace9b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7767ca4-8d09-465e-9ef7-c37deea91834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_GenovisABMember_c33f62df-3acd-433e-8fdf-35cfc788e805" xlink:href="rnac-20241231.xsd#rnac_GenovisABMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7767ca4-8d09-465e-9ef7-c37deea91834" xlink:to="loc_rnac_GenovisABMember_c33f62df-3acd-433e-8fdf-35cfc788e805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fbbc4d6f-c2b6-4dc9-a67a-a4f9661107ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ad80e57-bcc5-4ebf-bd5c-cb10adfc92dd" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fbbc4d6f-c2b6-4dc9-a67a-a4f9661107ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestonePayments_6b0b2a59-3e24-4340-8807-eb2395abbb0e" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fbbc4d6f-c2b6-4dc9-a67a-a4f9661107ec" xlink:to="loc_rnac_LicenseAndOptionAgreementMilestonePayments_6b0b2a59-3e24-4340-8807-eb2395abbb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b0728277-a964-4be9-9ddb-3a3ca1e5b12c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b0728277-a964-4be9-9ddb-3a3ca1e5b12c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_96051af9-0ab2-4e59-8f09-19dcf1543b06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_96051af9-0ab2-4e59-8f09-19dcf1543b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2124a4-2bc9-453e-b0a8-4253566a0026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_96051af9-0ab2-4e59-8f09-19dcf1543b06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2124a4-2bc9-453e-b0a8-4253566a0026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CyrusBiotechnologyIncMember_ff16e197-151c-451c-9468-a0411887c929" xlink:href="rnac-20241231.xsd#rnac_CyrusBiotechnologyIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2124a4-2bc9-453e-b0a8-4253566a0026" xlink:to="loc_rnac_CyrusBiotechnologyIncMember_ff16e197-151c-451c-9468-a0411887c929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f0fa33ae-207e-423d-afb2-3dce6c640ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f0fa33ae-207e-423d-afb2-3dce6c640ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_959626d2-47d4-4ae1-a858-93795e488e67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f0fa33ae-207e-423d-afb2-3dce6c640ee1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_959626d2-47d4-4ae1-a858-93795e488e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_SeriesBPreferredStockPurchaseAgreementMember_7babb1ec-4aeb-447f-b60a-d12f992dc5db" xlink:href="rnac-20241231.xsd#rnac_SeriesBPreferredStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_959626d2-47d4-4ae1-a858-93795e488e67" xlink:to="loc_rnac_SeriesBPreferredStockPurchaseAgreementMember_7babb1ec-4aeb-447f-b60a-d12f992dc5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a5ee0de1-8ad5-4e6a-9a70-886765b7257b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:to="loc_srt_OwnershipAxis_a5ee0de1-8ad5-4e6a-9a70-886765b7257b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bb80fccb-cf7a-4999-894f-73693076fdc0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_a5ee0de1-8ad5-4e6a-9a70-886765b7257b" xlink:to="loc_srt_OwnershipDomain_bb80fccb-cf7a-4999-894f-73693076fdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CyrusBiotechnologyIncMember_26ea46c0-f8ac-4ddf-b83e-2b8fc6b1c1d1" xlink:href="rnac-20241231.xsd#rnac_CyrusBiotechnologyIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_bb80fccb-cf7a-4999-894f-73693076fdc0" xlink:to="loc_rnac_CyrusBiotechnologyIncMember_26ea46c0-f8ac-4ddf-b83e-2b8fc6b1c1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4b3f924e-5b02-4172-aee3-709a2d5f962e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAndOptionAgreementMilestonePayments_d56ad4a7-18e7-41bc-99c1-02b90fc3b9c8" xlink:href="rnac-20241231.xsd#rnac_LicenseAndOptionAgreementMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_rnac_LicenseAndOptionAgreementMilestonePayments_d56ad4a7-18e7-41bc-99c1-02b90fc3b9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased_0495084e-01db-4655-b5e7-8a81bdc2e195" xlink:href="rnac-20241231.xsd#rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased_0495084e-01db-4655-b5e7-8a81bdc2e195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare_32edc273-2714-47c4-8f62-4a5b800ce86c" xlink:href="rnac-20241231.xsd#rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare_32edc273-2714-47c4-8f62-4a5b800ce86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare_c2a5167a-89e0-4e83-b4b1-887f22f970e7" xlink:href="rnac-20241231.xsd#rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare_c2a5167a-89e0-4e83-b4b1-887f22f970e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_263c9a01-5b3c-4b1c-a5b0-c91407070da5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb3a53cc-f952-48b5-9873-e711af7fda45" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_263c9a01-5b3c-4b1c-a5b0-c91407070da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5dd3bf94-d337-4907-8be3-dcb2b87490fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e739f3b-9dd4-4296-8b7a-22f12982c3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5dd3bf94-d337-4907-8be3-dcb2b87490fb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e739f3b-9dd4-4296-8b7a-22f12982c3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_39cf9131-7b3a-4653-85a7-1a6633779908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e739f3b-9dd4-4296-8b7a-22f12982c3b3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_39cf9131-7b3a-4653-85a7-1a6633779908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_618e0e96-5132-4196-b2ca-6606466777c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_39cf9131-7b3a-4653-85a7-1a6633779908" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_618e0e96-5132-4196-b2ca-6606466777c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AskBioLicenseMember_ba256260-e8a3-4c42-9cda-51e2cfcfb226" xlink:href="rnac-20241231.xsd#rnac_AskBioLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_618e0e96-5132-4196-b2ca-6606466777c7" xlink:to="loc_rnac_AskBioLicenseMember_ba256260-e8a3-4c42-9cda-51e2cfcfb226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47b2647e-eb87-4729-a4f1-b20d1f62d31f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e739f3b-9dd4-4296-8b7a-22f12982c3b3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47b2647e-eb87-4729-a4f1-b20d1f62d31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f829a2b5-ca0d-4027-bdd6-22a16116f578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47b2647e-eb87-4729-a4f1-b20d1f62d31f" xlink:to="loc_us-gaap_OperatingExpenses_f829a2b5-ca0d-4027-bdd6-22a16116f578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CollaborativeArrangementCostSharePercentage_76b67288-bdc3-48ff-9b0f-24dccf8eecb1" xlink:href="rnac-20241231.xsd#rnac_CollaborativeArrangementCostSharePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47b2647e-eb87-4729-a4f1-b20d1f62d31f" xlink:to="loc_rnac_CollaborativeArrangementCostSharePercentage_76b67288-bdc3-48ff-9b0f-24dccf8eecb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e74f44ce-b368-42de-9648-07f7832e9c18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e73aa570-9c22-4552-b45a-da19344cc2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e74f44ce-b368-42de-9648-07f7832e9c18" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e73aa570-9c22-4552-b45a-da19344cc2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0280df0f-02a0-4ded-9284-5d2d983d7ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e73aa570-9c22-4552-b45a-da19344cc2fc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0280df0f-02a0-4ded-9284-5d2d983d7ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4a381ed-a88d-449c-8349-329488e4aac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0280df0f-02a0-4ded-9284-5d2d983d7ce7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4a381ed-a88d-449c-8349-329488e4aac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_38845781-ec25-4515-a0f6-1dd077f03e66" xlink:href="rnac-20241231.xsd#rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4a381ed-a88d-449c-8349-329488e4aac4" xlink:to="loc_rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_38845781-ec25-4515-a0f6-1dd077f03e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d05db94b-0e9f-4353-a3e0-3330ba87d129" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e73aa570-9c22-4552-b45a-da19344cc2fc" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d05db94b-0e9f-4353-a3e0-3330ba87d129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_b2144e9c-7a46-47fc-8b6f-615a33e5e671" xlink:href="rnac-20241231.xsd#rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d05db94b-0e9f-4353-a3e0-3330ba87d129" xlink:to="loc_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_b2144e9c-7a46-47fc-8b6f-615a33e5e671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_03190dc8-9966-45fb-9a6a-8d4b59ada737" xlink:href="rnac-20241231.xsd#rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d05db94b-0e9f-4353-a3e0-3330ba87d129" xlink:to="loc_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_03190dc8-9966-45fb-9a6a-8d4b59ada737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_340e54a2-eea9-49f0-9b9a-b738d91e6f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_695bfc91-838d-439f-a68f-22f3be523316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_340e54a2-eea9-49f0-9b9a-b738d91e6f7e" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_695bfc91-838d-439f-a68f-22f3be523316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3802fa21-8bde-4334-b867-9f495a1602dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_695bfc91-838d-439f-a68f-22f3be523316" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3802fa21-8bde-4334-b867-9f495a1602dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e8afe70b-e6dd-49f6-86e9-6e8764343e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3802fa21-8bde-4334-b867-9f495a1602dd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e8afe70b-e6dd-49f6-86e9-6e8764343e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_ec065a0d-704c-490a-be35-b1e7ebea19e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e8afe70b-e6dd-49f6-86e9-6e8764343e0e" xlink:to="loc_us-gaap_DomesticCountryMember_ec065a0d-704c-490a-be35-b1e7ebea19e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_38ebb19c-024f-4139-98a1-a3262d89b831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e8afe70b-e6dd-49f6-86e9-6e8764343e0e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_38ebb19c-024f-4139-98a1-a3262d89b831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_695bfc91-838d-439f-a68f-22f3be523316" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ddf4edda-e53f-4a37-b12a-c5561d9fc5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ddf4edda-e53f-4a37-b12a-c5561d9fc5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0aefc812-7a8c-4685-8263-53105abd9bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0aefc812-7a8c-4685-8263-53105abd9bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_edb65625-dbe8-4993-b824-5ce47ca43421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_edb65625-dbe8-4993-b824-5ce47ca43421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1cbb7b3b-615e-4ba5-b679-c7607a46f14c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1cbb7b3b-615e-4ba5-b679-c7607a46f14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLossCarryforwardsNotSubjectToExpiration_4fe05fe4-9ae6-4a34-8a4d-76bb4524471f" xlink:href="rnac-20241231.xsd#rnac_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_rnac_OperatingLossCarryforwardsNotSubjectToExpiration_4fe05fe4-9ae6-4a34-8a4d-76bb4524471f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_OperatingLossCarryforwardsSubjectToExpiration_4dc3b3f6-cb6d-4f0f-a342-a5ac5d72af3e" xlink:href="rnac-20241231.xsd#rnac_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_rnac_OperatingLossCarryforwardsSubjectToExpiration_4dc3b3f6-cb6d-4f0f-a342-a5ac5d72af3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9a98e519-52d4-4329-ad83-dcf7ccaa2b27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_9a98e519-52d4-4329-ad83-dcf7ccaa2b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes_148ff073-86ca-4725-931d-97d61f96b652" xlink:href="rnac-20241231.xsd#rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_a9fb550e-0eb1-4c1e-a414-1dd02f5a6db7" xlink:to="loc_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes_148ff073-86ca-4725-931d-97d61f96b652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8c58dd5a-52b1-474e-b942-bbb5ff30519a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4b383def-9276-4070-8d24-0a2d40f1562f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c58dd5a-52b1-474e-b942-bbb5ff30519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4b383def-9276-4070-8d24-0a2d40f1562f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9874431a-a6c4-4964-80a6-fe3981673a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c58dd5a-52b1-474e-b942-bbb5ff30519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9874431a-a6c4-4964-80a6-fe3981673a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_95ac4670-38c5-46ec-9a10-713d57674bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c58dd5a-52b1-474e-b942-bbb5ff30519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_95ac4670-38c5-46ec-9a10-713d57674bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_e3e09b0c-f7e3-4cc5-9957-2f91274a238c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c58dd5a-52b1-474e-b942-bbb5ff30519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_e3e09b0c-f7e3-4cc5-9957-2f91274a238c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent_45ad86ba-a62e-4c04-9e66-52c447d34ea2" xlink:href="rnac-20241231.xsd#rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c58dd5a-52b1-474e-b942-bbb5ff30519a" xlink:to="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent_45ad86ba-a62e-4c04-9e66-52c447d34ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent_3f86c435-a27d-4eeb-82e0-779b9efbf1fc" xlink:href="rnac-20241231.xsd#rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c58dd5a-52b1-474e-b942-bbb5ff30519a" xlink:to="loc_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent_3f86c435-a27d-4eeb-82e0-779b9efbf1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_45059b68-e70d-445d-bf16-cadae5e005b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c58dd5a-52b1-474e-b942-bbb5ff30519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_45059b68-e70d-445d-bf16-cadae5e005b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_503ca1f7-612d-473e-961d-d6fd8a892a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c58dd5a-52b1-474e-b942-bbb5ff30519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_503ca1f7-612d-473e-961d-d6fd8a892a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d224836c-a8f0-4458-8b70-75bee3a0cd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c58dd5a-52b1-474e-b942-bbb5ff30519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d224836c-a8f0-4458-8b70-75bee3a0cd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e092b1d1-bed5-40f3-a214-b5443731a973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e092b1d1-bed5-40f3-a214-b5443731a973" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_19fd9de6-c885-4172-8688-a754253a3531" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_19fd9de6-c885-4172-8688-a754253a3531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6a91fdef-f0f6-46f0-bda0-5967b78b4f18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6a91fdef-f0f6-46f0-bda0-5967b78b4f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c2419df7-223b-456a-ac09-d191f3279354" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c2419df7-223b-456a-ac09-d191f3279354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_32fda8c5-b5f2-476f-908b-1e1d29189d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_32fda8c5-b5f2-476f-908b-1e1d29189d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3d58aeeb-bdf6-4fd8-9611-0846402798f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3d58aeeb-bdf6-4fd8-9611-0846402798f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DeferredTaxAssetsLeasingArrangements_34f8b475-bf45-4e47-9032-0b6ca21ace9b" xlink:href="rnac-20241231.xsd#rnac_DeferredTaxAssetsLeasingArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:to="loc_rnac_DeferredTaxAssetsLeasingArrangements_34f8b475-bf45-4e47-9032-0b6ca21ace9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_5cf8668c-897e-4475-b169-f9d2bedca564" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_5cf8668c-897e-4475-b169-f9d2bedca564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_49870b61-f2f0-4904-ade1-fc48672bca7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_49870b61-f2f0-4904-ade1-fc48672bca7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d52f5bb7-3091-4dde-96da-c29bf05fc480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d52f5bb7-3091-4dde-96da-c29bf05fc480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d0783a3b-1348-4f36-9edd-651ea1869431" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ded1df09-be6b-4847-ba86-b6275d6d793b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d0783a3b-1348-4f36-9edd-651ea1869431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9e5e9881-45e7-4333-93dc-f5747c52a2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e092b1d1-bed5-40f3-a214-b5443731a973" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9e5e9881-45e7-4333-93dc-f5747c52a2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7a936836-1947-4d39-8421-42d104433d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9e5e9881-45e7-4333-93dc-f5747c52a2f8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7a936836-1947-4d39-8421-42d104433d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2c01f25a-1b79-43b4-b6c3-faf3fde4e06b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9e5e9881-45e7-4333-93dc-f5747c52a2f8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2c01f25a-1b79-43b4-b6c3-faf3fde4e06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_9bfb2dfe-51f0-4bd0-a3bb-a164ed94a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9e5e9881-45e7-4333-93dc-f5747c52a2f8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_9bfb2dfe-51f0-4bd0-a3bb-a164ed94a6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_599f60ac-b633-4f78-add1-a3051338abd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9e5e9881-45e7-4333-93dc-f5747c52a2f8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_599f60ac-b633-4f78-add1-a3051338abd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities_15c762b0-8dd8-451b-86cc-87b4c481f912" xlink:href="rnac-20241231.xsd#rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e092b1d1-bed5-40f3-a214-b5443731a973" xlink:to="loc_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities_15c762b0-8dd8-451b-86cc-87b4c481f912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6f25ada3-6fc4-46b8-bc90-de6d053dee0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e092b1d1-bed5-40f3-a214-b5443731a973" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6f25ada3-6fc4-46b8-bc90-de6d053dee0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_8b810a61-1772-483c-b0fa-6827461f6b69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e092b1d1-bed5-40f3-a214-b5443731a973" xlink:to="loc_us-gaap_DeferredTaxLiabilities_8b810a61-1772-483c-b0fa-6827461f6b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_422c9466-1c50-4a0a-aae8-774141edd17a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_f16d48df-3cad-48b2-931e-905f770f8db0" xlink:href="rnac-20241231.xsd#rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_422c9466-1c50-4a0a-aae8-774141edd17a" xlink:to="loc_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_f16d48df-3cad-48b2-931e-905f770f8db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_7982e0eb-dc75-472c-b589-c8e2b7f66a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_422c9466-1c50-4a0a-aae8-774141edd17a" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_7982e0eb-dc75-472c-b589-c8e2b7f66a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51cdd20e-a29d-409e-a172-6b53e38cfbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_422c9466-1c50-4a0a-aae8-774141edd17a" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51cdd20e-a29d-409e-a172-6b53e38cfbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9f353f23-b919-4611-a5d6-87480a5c956d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51cdd20e-a29d-409e-a172-6b53e38cfbd4" xlink:to="loc_us-gaap_PlanNameAxis_9f353f23-b919-4611-a5d6-87480a5c956d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d3efccf5-3360-45cf-9ec4-8a65aef11f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9f353f23-b919-4611-a5d6-87480a5c956d" xlink:to="loc_us-gaap_PlanNameDomain_d3efccf5-3360-45cf-9ec4-8a65aef11f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EmployeeStockPurchasePlan2016Member_2014cddd-1681-4517-8e5c-3c67b78e3dda" xlink:href="rnac-20241231.xsd#rnac_EmployeeStockPurchasePlan2016Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d3efccf5-3360-45cf-9ec4-8a65aef11f8c" xlink:to="loc_rnac_EmployeeStockPurchasePlan2016Member_2014cddd-1681-4517-8e5c-3c67b78e3dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e062caff-c0a2-4f3c-83cc-a706d14b289d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51cdd20e-a29d-409e-a172-6b53e38cfbd4" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e062caff-c0a2-4f3c-83cc-a706d14b289d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8640adc1-1537-4d50-99be-f9e17dc17b43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e062caff-c0a2-4f3c-83cc-a706d14b289d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8640adc1-1537-4d50-99be-f9e17dc17b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_58fd78b6-6135-488b-b869-a9b1b0426b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e062caff-c0a2-4f3c-83cc-a706d14b289d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_58fd78b6-6135-488b-b869-a9b1b0426b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d72fda80-a813-480f-98c2-6c7c279523b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_80f480bd-2227-42bc-95a6-ead70351f6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d72fda80-a813-480f-98c2-6c7c279523b7" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_80f480bd-2227-42bc-95a6-ead70351f6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f3508ae-4ed5-440e-af11-24a8f15d99c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d72fda80-a813-480f-98c2-6c7c279523b7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f3508ae-4ed5-440e-af11-24a8f15d99c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c12fa0fe-0ba5-4680-960c-8cf5ad3e4228" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f3508ae-4ed5-440e-af11-24a8f15d99c5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c12fa0fe-0ba5-4680-960c-8cf5ad3e4228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e0df1aa5-b61c-4612-84a7-1d3983c345cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c12fa0fe-0ba5-4680-960c-8cf5ad3e4228" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e0df1aa5-b61c-4612-84a7-1d3983c345cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_54ffeca3-ae56-4a83-be62-4f51c1b78e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0df1aa5-b61c-4612-84a7-1d3983c345cf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_54ffeca3-ae56-4a83-be62-4f51c1b78e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c9b5701-27c4-4f51-91b9-6ee73037227c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0df1aa5-b61c-4612-84a7-1d3983c345cf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c9b5701-27c4-4f51-91b9-6ee73037227c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ecc17397-be80-4b35-a467-920520ca864f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f3508ae-4ed5-440e-af11-24a8f15d99c5" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_ecc17397-be80-4b35-a467-920520ca864f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8e77c896-7aa7-4283-90b8-371c2a0ba740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ecc17397-be80-4b35-a467-920520ca864f" xlink:to="loc_us-gaap_RestructuringCharges_8e77c896-7aa7-4283-90b8-371c2a0ba740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_66a71407-cf21-48b3-bfd5-d67ea788fa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ecc17397-be80-4b35-a467-920520ca864f" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_66a71407-cf21-48b3-bfd5-d67ea788fa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0b2f2b43-d1e9-4f8e-b3d7-4f32edecd4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_d683875c-7cec-47c1-bc84-a7affdd7833f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0b2f2b43-d1e9-4f8e-b3d7-4f32edecd4c4" xlink:to="loc_us-gaap_RestructuringReserveRollForward_d683875c-7cec-47c1-bc84-a7affdd7833f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_8d335769-213f-4c29-a150-7a64d2e0df61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d683875c-7cec-47c1-bc84-a7affdd7833f" xlink:to="loc_us-gaap_RestructuringReserve_8d335769-213f-4c29-a150-7a64d2e0df61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_49ec6876-238e-48de-bdff-3a3728b7f006" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d683875c-7cec-47c1-bc84-a7affdd7833f" xlink:to="loc_us-gaap_RestructuringCharges_49ec6876-238e-48de-bdff-3a3728b7f006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_338239d9-90e8-4edc-8d2c-96a159dd5f18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d683875c-7cec-47c1-bc84-a7affdd7833f" xlink:to="loc_us-gaap_PaymentsForRestructuring_338239d9-90e8-4edc-8d2c-96a159dd5f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7de2dda0-9ff4-405d-a07e-38caccce2db1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d683875c-7cec-47c1-bc84-a7affdd7833f" xlink:to="loc_us-gaap_RestructuringReserve_7de2dda0-9ff4-405d-a07e-38caccce2db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cartesiantherapeutics.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="rnac-20241231.xsd#SegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://www.cartesiantherapeutics.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e482a4be-599b-43cb-8dea-f69ae748d86b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3759ad9-9f50-48f6-b456-8d5cda200a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e482a4be-599b-43cb-8dea-f69ae748d86b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3759ad9-9f50-48f6-b456-8d5cda200a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d3503eeb-fc4c-450c-ab63-1c64179a5b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3759ad9-9f50-48f6-b456-8d5cda200a0d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d3503eeb-fc4c-450c-ab63-1c64179a5b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c557f66c-9ce1-477c-974b-558cfd850941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d3503eeb-fc4c-450c-ab63-1c64179a5b0d" xlink:to="loc_us-gaap_SegmentDomain_c557f66c-9ce1-477c-974b-558cfd850941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ReportingSegmentsMember_1d828199-7eb6-4abf-b836-22b785685516" xlink:href="rnac-20241231.xsd#rnac_ReportingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c557f66c-9ce1-477c-974b-558cfd850941" xlink:to="loc_rnac_ReportingSegmentsMember_1d828199-7eb6-4abf-b836-22b785685516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f45a97a5-285d-49ab-8b9c-16817544df27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3759ad9-9f50-48f6-b456-8d5cda200a0d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f45a97a5-285d-49ab-8b9c-16817544df27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11e5b0ad-8e3d-4586-a922-6cbd956fe997" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f45a97a5-285d-49ab-8b9c-16817544df27" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11e5b0ad-8e3d-4586-a922-6cbd956fe997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_LegacySelectaProgramsMember_6a30cca9-156d-4508-ae0f-aa62b3df15b7" xlink:href="rnac-20241231.xsd#rnac_LegacySelectaProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11e5b0ad-8e3d-4586-a922-6cbd956fe997" xlink:to="loc_rnac_LegacySelectaProgramsMember_6a30cca9-156d-4508-ae0f-aa62b3df15b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_Descartes08ForMGMember_35ffb7eb-f02c-42ca-a55f-09bac48cd6d0" xlink:href="rnac-20241231.xsd#rnac_Descartes08ForMGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11e5b0ad-8e3d-4586-a922-6cbd956fe997" xlink:to="loc_rnac_Descartes08ForMGMember_35ffb7eb-f02c-42ca-a55f-09bac48cd6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_EarlyStageProgramsMember_ef8b066d-12b7-4f52-a821-9fe20e021c4b" xlink:href="rnac-20241231.xsd#rnac_EarlyStageProgramsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11e5b0ad-8e3d-4586-a922-6cbd956fe997" xlink:to="loc_rnac_EarlyStageProgramsMember_ef8b066d-12b7-4f52-a821-9fe20e021c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3759ad9-9f50-48f6-b456-8d5cda200a0d" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1a0f9425-aa66-497a-8505-771fc30ee33f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:to="loc_us-gaap_RevenuesAbstract_1a0f9425-aa66-497a-8505-771fc30ee33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e11217c-87d3-43ba-8108-d95a12b7b2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1a0f9425-aa66-497a-8505-771fc30ee33f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e11217c-87d3-43ba-8108-d95a12b7b2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_a0b59f7e-d171-4806-a347-223df80aa9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1a0f9425-aa66-497a-8505-771fc30ee33f" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_a0b59f7e-d171-4806-a347-223df80aa9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2b376349-e728-4584-bc0a-b689e462dedf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1a0f9425-aa66-497a-8505-771fc30ee33f" xlink:to="loc_us-gaap_Revenues_2b376349-e728-4584-bc0a-b689e462dedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:to="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_MedicalExpensesOperating_b57e85e8-c6b8-4275-9978-e7782304288c" xlink:href="rnac-20241231.xsd#rnac_MedicalExpensesOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_rnac_MedicalExpensesOperating_b57e85e8-c6b8-4275-9978-e7782304288c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentEmployeeExpenses_ce7256fc-e09c-4594-83f7-905aaf3f6f55" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentEmployeeExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_rnac_ResearchAndDevelopmentEmployeeExpenses_ce7256fc-e09c-4594-83f7-905aaf3f6f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentStockBasedCompensationExpense_8d373714-a688-4d8f-8f5d-73d31e534cb4" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentStockBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_rnac_ResearchAndDevelopmentStockBasedCompensationExpense_8d373714-a688-4d8f-8f5d-73d31e534cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses_b081b135-3214-424d-8b33-4a3f85657072" xlink:href="rnac-20241231.xsd#rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses_b081b135-3214-424d-8b33-4a3f85657072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9f7c88f7-8b3d-4400-a794-dd77d0798663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9f7c88f7-8b3d-4400-a794-dd77d0798663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_648dc4c9-7710-4102-a828-0c5776c4cc82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28892e2c-1d39-4633-aa85-09871d15df84" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_648dc4c9-7710-4102-a828-0c5776c4cc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_a990a52b-8fa9-428f-828f-a4c6a7044d34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:to="loc_us-gaap_OtherNonoperatingExpense_a990a52b-8fa9-428f-828f-a4c6a7044d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71b60f76-2c41-482e-9ef3-032c0d2f6bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54eff562-e86d-40dd-802d-bb6c53a9f6ed" xlink:to="loc_us-gaap_NetIncomeLoss_71b60f76-2c41-482e-9ef3-032c0d2f6bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rnac_ChristopherJewellMember" xlink:href="rnac-20241231.xsd#rnac_ChristopherJewellMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rnac_ChristopherJewellMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exhibit41rnacspecimensto001.jpg
<TEXT>
begin 644 exhibit41rnacspecimensto001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0?!54# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% !7%_$[PIJ?C'PU!IFEO9I*EW'.S74C(N%SP-JMR<UVE%
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M3+#;?:V6 J=.*.6/RG).3DC&>5].1UNAZA)>)<Q3F0RPR':9H_+=XC]URO&
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MEO<+-9I.WR@KE@01M(Z@@],'-<3<^(+F^GCN+>T-Y< 3+!8"$X>!\!9\MU&
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M6>1W\R.5EX.[CG@$KMPP YJ[I-C&F+:VLI_M$+++-)'M+J0S-$DK,V68 Y8
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M(/G1P6#,@+LH503ELX+8''>SK4!@M9[6Q2XM[FTME$D;?ZWR",*P9#\P7E2
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M,9D41I&7W1;U8*I&/X@V6;H*IZD(9%,VK-+=2QO<1JQF<*D8D6+HF#R3D\D
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MDY%:6I2P:I/;W5R[N5EC2*.))#Y)=$.<H5(R&/S%L +T)S61K5K/=SRF".<
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MB)$+AH]RE0N-H^]NR3T (J#5H8KA5N-6,EP899TC)FD55B\Q(R2%P1DN">P
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M2NYW_P _Z_KH)-V4;:?U_7_#DEU% TUI=ZG%-)J4L,23$7#'9DLZ+A>.=O\
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MQR^T8//KQFJUSIVFR7#C3K8BZ5HWF-LH5QSO0,6(XR 2N<X XP:(U%J[:/\
MK4;IO17U7]:'-Z;)I^GW[W&EK<%HHGG25W9_.5LDYW<<E-I*A2"5'-6_$/V)
M[F:\OA<3!H[B,M%O4*D?F93<K*%^[_'NR6Z 5O>(;)O[)C2PM(Q<FY25(T4
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MZPPVEQ&"T1A3."WR_P"K'#;N%(QST]*X;6=*T^.%II+B2QNHY91 (UV+--(
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MMJ26WH:6B7L]WK&HF=-Y2XF@60# C1"FU?J=Y/OCVHT.3&M:W9/AE\\7"#G
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M2JY/6DZD7'E6WS&J<E+F?Z%&+4F:QA>\CENY)X6GDD5<J[F3R5.,_P (V\9
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M;B6:)Y))$CR'D$H@1@H(R0""!G'S9R,"L"W2_MKN:2]+7=C;-\UK(7VLK8)
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M^]BS'G ' 'N0*?M(2LG^OXZ"]G.-VOT_S*FL+]I:6RAC,$ZSFV@F92WEQQ[
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M4)9$2 2O8F1HWP.-P8+GI@$$_6EM[6^T>+RUU6Q"+'\S_9'D>&+^$9#X(&"
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M>",*QW]23Z9ZY&H27VGZF=4TZ&*XE?\ ULD(\M(XV5<!Y"HW/OQC() )S@'
M]%2Y_A?]=CSW'E^)?UW+FHRW.AV*745M:26;7?V5+8[OFDR5\R0Y&\EACH0
M 0#6=IQ\K0KC4IDF_>PL@:6#R@6:-E*LS(H"%BIW%B"0.,\5?M;>*]5[Z]L5
M2$2NBF1MEO<#@&0$9$3D C^ZV!SSD5;V>"QL+V:YE 5E>-(O-BF9P4,8R$!*
MQ\JS;B=I10,TX_R]1/\ FZ'1ZG-=V.BRQ1);S?;HU59;I]@YC52&7:2QXSCC
MKC(HM(KSPYI5N-L5U/\ 9Q%F>?9@J>#P&)!SDXSS^8-1TO2]819[^\NXD>$/
M;2Q3/&NW:IW#'\77"M[X'6LX6L\,>AVU^!-=>645Y$?:K-B,MC'^T2 0....
M:PC9QM]YN[J5_N)M$@N-*LHKJ:6UN)T:5C LVT#>68%>> -VW&,[>V>*BTJS
MNEO+W5;JXM4DFNA.+2&;"L!L&,MC)PF<D#DU';7$:3W)73;=00^V6X9%V\J%
M8D*HY;&5SQ@8)Z!]VUM:@I'8Z<^[8%>T W+\I.,$$C+;L':< ]"35N]WW9"M
M9=D*EG<:MX@O=3O)[2TCDM?LT<*39###<L2!D_-C@8QWJS=F[U?Q-93O-;6=
MG9!]I68,[EL=21@ 8! &>0,U7LWLY+5!_9\222Q"4N\2EE0MY>WC:K?,%P3@
M;<$CCFM9S6\E_P#9FL7MT:'S1<2I&\9.6/[P*BXP0>C=6YYHL[M]M NK6[ZE
MG4UO;J#2],C%@(K*6)WG:;)DV#' QA0W.<MG!(P<U)KRW-QH-QH=J;-UN&8-
M=--DX+;LA0/O9..2!T.?1LD*OI5K'+IVFVDCJKRQ1J9"J% "&C*97D@?1<9&
M<@U/6-#LXT<:?IZ;?F4W,H4YR3E-H8-S_M#GZ4E>ZLMOZ[@[6=WO_78MSW%S
MIVGW$-J+2ZEN(P TMQ\J'!!4X!) [8&#D\CO#I,,WA_3;=EN8;V:.V\D(\X4
M*?E&>-QP<<XST%4!J^D/=FT&FQ/.1MB1K#8"I&%&YI,$$<#'7IBDGUC2XF=)
M=+1%@W>8LNG,$1AW+[\!=R@9QU'M3Y':U@YU>]RYH-E-IUL;RYGLI;DW$EQ]
MG60*B%M_"9&0!O[\X+>PINFV]Q)J6IZM=S6B2SRQO';)* A";<#+8.2%&20!
MD+Z4EOJFC:E9L\6GV#R[2(7BD5U1MIQN+A0.IX!)Y/O4JF+R(B;#3%N-RB66
M<G>H+*-X3:NY0,?,"!\H_!/FN[K5@N6RL]$,,=YJOB66_FFM+*+[(ULH6;<>
MI(9B=N3R1@9P"W//,E\UWJVNZ<S+9VMK9AB2+C+DLNWKC  SD8)R0.G44K=H
M'U*YMQIDY\IU E*PH96._(52@! P3][.&Z]35EI++$\*Z; LL*JLCP0@-)O0
MLH4,< ;%YSNYX --JS^0)W7S(]4@N[NRT[1HGM/)MITDDNGGRS[&)! Q@$]R
M3W/![S:M'=+X?GT2TDM)_M.8VNYI@3M( )V@'+#D#) X'-5;>6,75]MTU(9K
M=28GD5'BGZ, &54(9BW&"PR#C-7KFWM8+B"#[!IT:H-MQ#;GS 5QC:<H ORY
M&&*CGJ<8)JFE\PW3?R)UEN='TTBUEL[VX:%(PTTP !!;[VT$D?,.!WW<CBJN
MB03:#I-HXDM[JXCC>-HVG5<;MI!R < ;=H&"<;?0U%=:UH-O<");"QB9I N)
M6'F;L@Y"#AN1U#=0*BL]1T^[/V.VTA))LD&)K#R1T.0 TG)"L<CW/K2Y7RZK
M<?,N;1[$^BVUQ9I+?7$EF\S7CW7V:.4*N&!&U<XX4G<,@9);CD&F6EK=76K:
MGJMS/:6[3M"T=O%/PPB.=I+8^]T)QC@=>U)_$.BB$RMI\*VZCY?M&GM$@8D'
M!<N0"< CCL*T3>Z3J-MMM;*P-P"!')'(LB#!.0"P&3@G[H;J:;4E=M;DIQ=D
MGL-N+>YUSQ*;V>X@L+>*W:",QS R')SN8G R,< 9')Y]9-12ZU2_TRU#65K9
M61WEUF!9CLV@#C 7D]"2>.G97BMY1:VYL-+16!29F4F1?EZ"(J,9VJ!DD=.N
M!G.MKFWOI&9M.FA$4KHKW$<39"8.]EVJ<98XVMU/7) (D]UT&VMGU+NNK>76
MEIH]J;-5\T2&[$PW'#[P5 & QP,DD<D]N3/JCW$6DW>F68LIA=IL,\L_"@H$
M/R@$DC'L.G/6H+A[28^8FFI Z2&%Q%&A<NI5'.Y@0$&X#ID@$\ 5#IDR78DG
MCTR*"\2Z$+Q7B "3+\E'5%;/5CE3UI):)VV_,&];=_R-"R>?0]*B6%K>\G%J
MD(\VX  92W+8W'D-DXSR#SWJOHEK/HVGV4[W%M<3012H;=9@JY=@P8=2,8V=
M,[?RIS)80WB[[/3TM$B\N6"W D5SM(VAR%'M@D< C!W<5Y]9T>*^6*'3[$2L
M&*J@,D_J1Y8"\Y"]&.?PHLW?3?5_U_D.Z5KO;8=H6G30W-QJ=[=6HEEO'NOL
MD<HV'<,8RV#D?>R0.?3J7VT%SJ&NWVJ7<ME;[X5AC@63*,%!QO) ))+$9 P
M,<U5M=6TJ:WE-KI<<B1H3.%L0AV+D,0ADR0"2/Q/KS"_B#1H8\2:=:K$\H %
MU:-;*3CD9);+ A<\>GI5.,VWIJ2I126NAI7?VO6/$]G=.]O9VMJKI\LX+N&P
M?GZ# VC !;DYSQFHM32[U!M)L%6QBM[)U>23S^7VJ5P.,!3WY)P<8SQ2RW6G
MWMK;_8M.M=ZR"1]@#JRG=G9D;FY)Y"<Y/(SFI+K[&^0=.T]+80%E2("25^%R
MF& "$#&00>%]N)5TUIL4[-/7<BUV*[O-%FT*W>UV3SL[7;SY8*9-X*@?Q#IR
M1TJY?RW%IIEY:V7V*XDNU"AI9ODC'EA"N "2!C.. <GD5GZ<Z:A%%.^E;)6P
M%2X5'&=[!=P"JPR02",@9SSS3OM&GZA8P7MKIL7E2H?(CQ&GR8=0&+!CSL(
M5>X'/2BS6C6WY_TA73U77\OZ9>TU)M TN+RKBWOITMEA59)PNTJ3SP&/S9&<
M9^ZO7DU!H=O-I5BMW(]G/=%Y)&@$@15+EFRG4@#=M Z[<_[M0Z9(M]%:W2:7
M 9YG/FPWH"O& -^[>JCY0V!DKG<:LQ_V=%J$TDEA;2V^ (EMT!P<;20Q"AN"
M1\I8_-C P<J5]4_F-6T:*^E6UTNH:CJMS-:*\\RS+:)/\AP5X&['S80') !)
M'I2?9KO5_$%YJ-Q/:6<;V;6J(D^2>&PS$@<Y;L,8[^L+Z[I'VAQ;V6GB0(6S
M AN) "PSN0;2.F3SV!YH&J:4+)[R+1D:R4*)'2Q^8;LA?D$F2#N/YGUJ[2WM
MY$WCM?S+EY]JUKQ+I]Q(UM9VEB&((G!D<MMR#QM &,\$\@=.T6I07=Y:Z5H\
M<EG';6DD;RW+3 O)LZ8XPN[N<YP2,'O337]$B=(Y+*P7S-Q'VB$V@9<#D9+$
MCC'3^&M$RV%P\$MCI\"P@DS1B,$R#.0< %P.6.2HY.>>A5I1MIML.ZE?7?<-
M;%T^A3Z-:O92BY9@UT\V2%8YR% ^\,X&2.@.?2U)<W.F:>\=JMG=S31@%YKC
MA#@Y5L D@=1@8.3TXS2O1:0V=W*]A8_9DC#QPV($KS<8/++C& !]TGH/3++1
M[>2)+J?3<1J@E:"9$;'R[V"D*K!QDG!!YX^7(J;>[Y#O[Q8T>*;P_I5L1/'?
M7"0>45DN -I^7!XSP=O8$C"^]0Z):W&GP&]N);22<W3W!MHI0JKNW\+GL"_L
M>O'K!J4MM!;O<+I(E,<)98840+LV(0@8JS,VQ^P X8= 2+UK#!.T4WV*PEA>
M(R3&]Q%+'AARQ52I!Y8<#./R;O9M]1*UTET(-,L9YM6U/5KVYM(6NI(G6VCF
M!7$90CE@"20G)P.WX2>5=:KXGEO[FXM;.".V-O$J2ABV23N8D#)[ #( )Y]7
M12:9"LDM[86TBCF%50#RQEAW )&#C*ANYSS@4)=?T4O-.+.R86Y&^2WA:YVK
MU))!4KT7MP<>E"YFW9>07BDKOS+VHR7FJ:SIP"V5K;6;,2ZS@LVY2I[ !1G.
M 23@=.T.L1W5Y8V>D0BQCBAN$E>X6;EMK;@5&, GN2WKP>,QOJNG0QFY_LE5
MB9S$)5L=["3!)#*LF1@%C]":@@U_15G%O)IVGHY0,RSH;9^>#A,.3D!<<\_A
M349:66PG*.MWN7]56[30[S1K5[6X^UJ8S=37&<*452< $[A@XR0.G/4"U')<
M:-8$6TEK>SO"D8,L^%4@N3NQDG[W;OGD56\VQ-^LL&GVPLF7#JR 8?).7*AM
MHSSDXZ]*I:C/#96,TRZ1!.^[8+73D# K@ ;W93D,#@849 -)*]HV*;M>5R[H
M5I-H&EVSF[M[R>*-U,33*@&[9TP#@#81C!."*;HEO<6@GU*YDLFNI;IK@VT<
M@1>01A2>>,[N0,DMZYIBW-A9P333Z:)(UD^9'C4EB7PI5D 'W\<,,]3G((JO
MJ;PV09%TT3+O6*3R5B14!9HV9$*NQ Y!W<8/OR[.3?F*ZBEY%FTAO+K6M2U2
MXELH!.L>R!9LJVS^%B0"2PZG&. .:?/'<ZSXE6[FF@L;>&W:%&BN/WAW$'+'
M '&W@#/4G-20);KYBRZ=I\EG'&C^9<'R65GRWED8*EQM0D<=5]*CCFTRTL5&
MH6-K+/'DB5T\M% R!G(W+PQ_@P,XYZE7=[I>0[*UF_,CU&.[U:YTJS_T*VMK
M$AFE\X,S,$*8'&T+R>Y)XX%.UV.[OM+71+:2UCB>??)=^>"X DW@J ,;NG)(
MYS]:I/KNCR-YSV-FZ!S$QM[4W(). %\P,H!) [<@"I+C5;"-4:72%42DF"4:
M>9E;:W4[9.#N8]^IJE&2:TV)YHM/7<T=2>YMM&N["S:QN7NUV&267Y4!C5"-
MH!)Q@XS@8QS3[1Y]#TR(0-;WL_V=8B9KD#!4GDX#$YW9. ><\]ZS;?7=#ENV
MBET^Q,B$#:X*3 E0,>7ACGC'7H!5V'[*NH372V5EY$F#&96"*AR"=TB!@"22
M>3R?2H<6ERM?\$M23=T_^ 1Z)!/I%A;SRRVUS-&)<Q";:/G.X,.> ,[<8)VX
MXS\M1:/9W4-Q=:I<W%LLLMX;G[)#, K [1C+8R0!GD#)/;K4,QAA^RC^S87D
MN9/)D@M8U6*)<E#O9D8MA?8#!';FKMM':+# 6TV&26Y98XS<(@97;YP6*#!4
M[<] <J.N013OJ^Y,;:+L00V=QJFNZAJEY/:6RRP"".!)LA@ ?OE@,D[L'C&.
MYJS<_:M6\4VMU)-;6=G9JZIMF#/(6(^\2,8&T$ 9Y )-9TTUI#)&L>E3R0SL
M$=H8H@0OEAP FPY4ABN"V<DCUQI-#!':72-9Z2T7F%(I4!4R-\O(CP=Q&.Q/
M*=.P3NFG]WY K/3[_P RMJ2WMX-)T]!8)#8RQN\QFR9-HP0!C"J1G/S9QD8R
M<4_Q MU=Z-/HEJ;3RYY"3=M/EL%]^0H&-W;D@9YIS7>CV-C#'=6-DTR$_/(R
MI$&R>X!*GYCR57.2<#.*H_VWHT@@<Z? T,D9$?EV)D3ID@2%P,!5&1@=!3BG
MHTM@;6J;W-6\GNK+3+JVM19W,MT@ >2X^2/*;2I !) QQP <GIW9IT<^@:?"
MT=S#?3):K $DG"A&7'/&X_-U.,]!]:H7&J6,<T<4NCXG8)*@33C,'0DE2K+)
MC)^8_G2V&L^'KT[&T[395#% L39? &.4(P!M '+>W:ER/EVT'SKFWU+&@6,N
ME6<=U//9S7*O++]G64*BERQ^7.2,;L#O@GZ4:3;W!O\ 4M4O)K1)+B=)%MHY
M!LPI7H6P=Q"#)( )QZ4L(0274K66G32.Q>V:3Y 0#D ,JL&;.#@'KW]*%U<0
M0WD,7]F^;Y\#22W%O&B11XC_ (2R-G@[<L0,\>U/63?=_P##BTBEV7_#%P17
MFI^)+C4)Y;.TB:S:U1%FW GDAF)"DGYB!@<#=SSS+>/=ZKXCTZ9UM+6ULP_2
MX!<EE Y.  %Z@ G) Z=0)+8QOY9L($G82MYKPC<@3YI P!P3D)@@C.>@VFJ$
M+0'4DL_[.ECBE+Q^=LB< JY3:ZJ@&T9+<-G;D]^1*^O9 W;3NR74K>[O+/2=
M&C>T$%E-&\ET\^7D\O."!C W=\G/)X/>;5X[HZ!-H-K):3"X9E>\EE!.UB#D
M*,_,,D#)'W0<^CWAB?2\?V?ID4DI_=O&"2X#<MY>PG:0BX.3U![4V\U/0K&U
M)^P6"LB\F=UB5C@M\N-W/).TD'D^M)-W5EL_Q[@TK.[W7X=BXTUUI6G2K:R6
M5[/+&JAIY@ N >&"@DCD'\6Z<56T:*;0-(MF62"[N$B,;))<!2/N\Y /'RXP
M 3]WWQGKK>C!Q UC!ME4-&HL-J$8 )WM( PZ#/'2I9M4T^&X%M<:1Y<D+;I4
M.FLRK_$6#!\  MDGWS1R.UK;ASJ][[$^AV]SI\$MY</9R3-=M<?9TE"J P;A
M<] "W<?WN.13;&UNI]3U75;J>TA>Y>%TMXI^#Y14XRV.6VX)P!TZ]F:?K.@Z
MC&JOIVG/\F%\F0/M&,'=N"JHQQC=R*G0QQ6C/+8:>]X/F,LN5+<@Y4!1O4'D
MD'C&>:;YKNZU8+ELK/1$<]K<ZYXCFO;BZ@T^!;5K6,Q39?!).XD@#([ 9')Y
M]9M1%SJVKZ=%FRM+*R)?<LP+LQ3:!G  49/ ))P.G:A(UJ-:DL/[.>9<(QN%
MCB1&8L$"J"AZ@GJQ.TUH-)8M<"'^SX&G6-)/.6)=Y1V55 !; ;<.3D@;5/<"
MAW5O30%9W]=2'6Q>W6G6VD6QLE2.5)&NA,-S%7W!E&,!C@9)(Y+<'J9]6-S'
MHUSI%E]CF%TGEFZEGZ H%)V@'+#'? Z<]<4+.:";4GB.G_9V6!9%NIT1XF!4
MGYRJJ1@[A\K8RWOBKT]LJPVR"PTRUE;#S)&#(=A X8;1MZ#KQ\H&1P:5N5I/
MU#=-KT)K>6?1=,18#;7DYMDBS+<  $,Q^?&X\ANP/(//0U6T6UFT/3;*4W%M
M<SP0R1F$3!1ERI![D ;=O3."..U-OM7T&R<1+IUC$<A<3N%;.[C:%R&Y8G[P
MZ_6JT.I:9++):P:3$\S$*J-8>4K Y"#+2<Y"G&.PZ4*,FFVMQ\T4TK[$^@:=
M-:R3ZC>75J9I;U[O[+'* GS C W<\9SD@<^G4OLK>YO-;U#5KR>RA,JHD=NL
MF48(.C$@$DYP3C@8'/:D^O:/%YV=/2-(RWF>;I[(JN&ZL^_ &X=>>:M1ZAHU
M_I[Q6MAIYD*?(89%>-"00-Q8* <9&!N//0]*<E+5M;DQ<=$GL/NA=ZSXE@NI
M)+>QMH(GB!2<,[!B#E^@.-HP 3@G.?5FJ)=ZI/I5F%L8+:S8,[K/\Q(0IA>,
M!><]2<=L\5.%MWBAA-EI:/Y@29[@-N4$@[O+VC@D+SD#.*SHKFTN)YHO[)N1
M';N%5IH8AO\ D=CA2@X R.&SSR1G)(WZ+8<K=7N6]=CN[[2FT2!K01R7'F/=
MM/EMOF^8"H QN[')'?KUJSJ3W-MI%Y869LKA[M GF2S?(@\I4(P 2?NYP<#G
MK45U]CFBF/\ 9L D@!21HHU+N=F_Y=_ &U02""<X&.,U3A:.2XOR-.B2YMV"
MHEPBO'<8/R[65%(9MYQ]X=?J4EHO(&]33L5GT'2HQ!<6]].MLL($LX7:5)Y.
M QYW#.,_='UJ#1()M'TZ*X=[.XN09&>$2A I<ELIU( SMQUV_E3[J&TCOX"U
MEIZ1Q$^>L.)1Z ;BJA3A0.2.#WQBH+K6=$@O8@EC81N[<%VS-DDGA .><G(;
MJ?>E9R6U[[E747O:VP:1;W<5W?ZG<36F^:Y\\6B3 (>@P"V.1MSD@98_C2+;
M76JZW?ZE<S6EHLMK]GCCCGSG ;!8D#)^?' P!W-066JZ9=2-:VFE1R7."LD7
MV'RC@*-PP9,DA2!BH3XAT>*%ICIT*6[,IS<6+0+N+ G+EB,_Q#CWJ^65W9:D
M<T;*[T-*[%SK7BBQNY9+>RM;(-M*S@R.6*D[CC;@;>,$\U#J,%Y?0Z3I*/91
M6UF\;R3F8,TFQ<8'&%![_-G!QCL0W&EW^FD6.FV"7#8 :,K)'CI@%@"QPS=%
M;N.]3N;68JD>G:?#!("\NT%YMP 8(8V5=KG'&<_=^E2KJVFWX#T=]=Q-=6ZG
MT671;5[-UN)&W73398 ONR% QN&>I(Z9^EFZN;BQTZ>"T6SN)+E "\UQQ&2N
M"I"@E@.W !R>1WR--DAOE2(Z6\2B5HXQ,D3J?F50[)M0X)D/W3_>ZGBK#SZ?
M>I'Y>FQQA6,01408*M&CY9P0$W,HX4D@ Y' HY;>ZT/FO[R+.E)/H&FP,L\5
M].MN(MLEP 488YR-W!QS@$_*OU$.AVMQI=JMY-+:2S^?+,UM%,%5=Y<_+GL"
M^/7&>.QKZ=/]NC$_]CQI=&=8C;WB#YAN891U53\OS,<J<!O>KS16 U!WFT^R
MDM5BV^5" X+8 X=@JGCC&<X7&WG()7U3^81MHU\BOI5C,^HZEJU[<6L<EU/'
M*MK%*"N$*8Y;!R0G)('.*>8+O5O$-SJ%Q=6EG$+4VL2)*&SU.YB0,GG& ",%
MN<U6N-<T0WACAL+$S8+($4S3$YW#]W\I!W'/4^M+#JVFRQ/<P:2)(XE9I7%C
MM8!?E)"F3<1U'TS3M+>Q-X[7+E])>:IK^GOBSM;:T+Y83AG;<N.N  !P< G)
M Z8X@U>.[O;33M*B%BD5K/'*\PFSOV'(VC&%SW);/7@]Z8\0Z- X=K&T3S)"
M$-S;-:ANY^8ELD,!GCK6@\NG7,2'3M.M,=) @#"5!GA1C<PY(^Z!\W7KDLXV
MTV'=2OKN&L+=MH-QH=J]K-]IRC7DUQD[2!EL#.6'(Y(' Y]+337&DV,HM7M+
MR>6)4!FFPJGYLAL DCG\<GD57N!9NDQ6TT]+8Q^9BU_>RR-D=F4!2,*3D$CC
MTJIIODW\4,JZ2$WHKBWN$CVY)DPIPJLK'#'."!NSC!)I6]W78=_>TW+6B6<O
MA_2[5_M4%[<0P-%L>95QG9T(!X^3&.> OO3=#M[BQAFU"XDLGNY+IK@V\<@1
M?F##"D\X&XD9 .2_J*BN&M985N(-,7RGB\V*W1$7*E&*AR58Y(C P!Q\HR:D
MTMH;VTM+B'3[4K)ODD@OQY3Q8^;<&5<;<G&2N<GK0[M-OJ)632702QANY]8U
M35+B6SB^T>4R6Z3?*?+Q\I)P26 Y.,<+UQ2SPW6M>(Y+N>X@L($M6MHVBN/G
MY.=Q.!R,8 &>IY]9$_LN.6>2YLK.6U V00QHI"@#:<,0,K@#INX],8JG/KFD
MO<3%;.P:6+!W01M=.OSGE@-A7&,^QYIJ[=TO^ #LE9O_ ()/J"W>L:EI<)^Q
M6MM8Y9I/.#.S%-N!QM"\YZDG X'8UN*\OM.M]%MY+2.$3*\EWYX+D*^X%1C
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MJ$6(G/(.3*006([G#CID\UI:%X7TJ2T>SDOM,U>"X?S+=GCVS-W8B8<D@@=
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MZ>E85O)J]M?PV]SK1M;!',D!#>>'8'<R^=L.-IQ\I!&#C)ZUO7/AG7(+>/\
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MVD.V_D$9..PK.C74+R/4//9+\%V^QVD%QYXZC ?)V@?>R6/TVD<S%K<<D]C
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MPOI$@GC.KV&L6EW_ *O[1'NEWCC"RYRIQV )Y_/>_LB2ZMIL:=,D:._EM/(
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MK":SMV>X,/GS;6=8(O*13@# 7)Y]3GFN?$0BM=F;X><GINC2HHHKE.H****
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MP[',)X(LT1$&HZ@0@4 EHR3A"G/R<\,3]0#U%._X0NU".HU&_P#F!&?W61E
MG'R<<#/UR>M=+11[>IW#V,.QSLGA""1F/]I7JEMV=JPC[VWI^[XQM&/Q]30W
MA"W;.=0O<%BV L/=P_\ SS]1CZ''2NBHH]M/N/V,.QS"^"+-71AJ.H$JP8 M
M'@X<OS\G(R<?3 Z"FIX%LD55&I:D=NW&7C/W0P&?D_VCGUP/05U-%'MZG<7L
M*?8Y8^!+(J5_M+4L%-GWX\X\OR_[G7'.?[W/6I&\%VK!Q_:-^-^[./*'W@HX
M_=\?=X],D]372T4>WJ=P]C3['-GP;;,[,=2O^23@"' RX;_GGZC'TR.AI/\
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MZ"HAX)M J#^T=0^4*!S%SA"G/R>C$_4 ]17344>VGW#V,.QS#>"+-T=#J.H
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M+$?0 =!38_ UG$$"ZEJ)V;<;FC.=JLHSE.?O$GU(![5U-%'MZG</84^QS/\
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M/8P[',R^"K6975M2U ;PP)4Q*1N"@XQ'Q]T$>A)]:1_!%F[NQU'4 7+$@-&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUK7\66D9TVTM+2)4GVP6[7&P%9(^<H#US@9^A-=',E:/?_@?Y?B8<K=Y=O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#0$B_[^/\ _%4?\*T\'_\ 0$B_[^/_ /%4 >=_V?\ $'_HF/A'_P !X?\
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M_"M?!_\ T!(O^_C_ /Q5 'G?]G_$'_HF/A'_ ,!X?_CM']G_ !!_Z)CX1_\
M >'_ ..UZ)_PK3P?_P! 2+_OX_\ \51_PK3P?_T!(O\ OX__ ,50!YW_ &?\
M0?\ HF/A'_P'A_\ CM']G_$'_HF/A'_P'A_^.UZ)_P *T\'_ /0$B_[^/_\
M%4?\*T\'_P#0$B_[^/\ _%4 ><36OCVW@DGE^&?A%8XU+L?L\)P ,G_EK5:U
MOQK>B^$=<M=-T_2=0DUEXFDTS3R2$5&SA%#,QQGCD>O%=?>>'M*\/>,A%I-H
MMJDV@WK2*K,0Q#1X/)/J:\^\/QW4OP]\(1V/D&Z?7)EC%PK&-F*,,-MY /3(
MZ9SQB@#O;O6KS1]>N;[^T+*$QI/(MK=R/";F)CE7D#KN4JVU5P"#D@8P<^@Z
M+?G4M*AG?R1<!0L\<+[ECD ^90>^#7"0V$]_K^HZ';V]I@1N)9Y;17^SH>D9
M/!D#?(PYR-ISS@#O=(TY-*TNWLT$.Y$'F/%"L0D?'S/M7@$GF@"[1110 444
M4 %%%% !1110!P>F1W5UI\@M;T)$;GRB%*N2Y2+!^50!MY/J".2>:Q=/MK33
M?$VKBX8VUEJ-B9RR]1L(:1!GN5SGW!]*T([_ &Z?<R&![PVDL3QP*6EW.Z!
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MQ\I(&%)(VMT&Y"W!4UZ35G?S/.3NK>0^>%1?VX5%E2(M)'>!%\F)@?OXV[L
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M//\ ^F]Q_P!_O_MU'G_]-[C_ +_?_;J #SO^FUQ_W]_^VT>=_P!-KC_O[_\
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M547*J-RA ,@]>O('HE<]X5T[1TTZSU6P*W%Q=6<6^]88DG7:N"P[=!QVKH:
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M]Q_W^_\ MU !YW_3:X_[^_\ VVCSO^FUQ_W]_P#MM'GC_GO<?]_O_MU'G_\
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MYC@X//3@USQ:MO\ U;H;R3OM_5^ID,BV!U75'M9[9H+GR[:X2$NY4@?*')P
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M,QMAEGD+AU:7"KGRVVR\!OEZD8((XFZV_P#" _#S:RNO]L3X95V@C[0>0,#
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MO_3Y!_X%_P#W70 ?;/\ I\M__ K_ .ZJ/MG_ $^6_P#X%?\ W51]M_Z?(/\
MP+_^ZZ/MO_3Y!_X%_P#W70 ?;/\ I\M__ K_ .ZJ/MG_ $^6_P#X%?\ W51]
MM_Z?(/\ P+_^ZZ/MO_3Y!_X%_P#W70 ?;/\ I\M__ K_ .ZJ/MG_ $^6_P#X
M%?\ W51]M_Z?(/\ P+_^ZZ/MO_3Y!_X%_P#W70 ?;/\ I\M__ K_ .ZJ/MG_
M $^6_P#X%?\ W51]M_Z?(/\ P+_^ZZ/MO_3Y!_X%_P#W70 ?;/\ I\M__ K_
M .ZJ/MG_ $^6_P#X%?\ W51]M_Z?(/\ P+_^ZZ/MO_3Y!_X%_P#W70 ?;/\
MI\M__ K_ .ZJIZO=YT6_'VNW.;>3@76?X3_T\G^1JY]M_P"GR#_P+_\ NNJ>
MKWF=%OQ]LA.;>3@76?X3_P!/1_D: .6T_P#Y*K\-O^Q=C_\ 1,U.\(^1/X)M
M85:&1DO&:,71A%LEQYG&_9^^!Y7D\<CMBFZ?_P E5^&W_8NQ_P#HF:H_"[6
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M#]<^-VHWM[]A\+Z:/F?9'+*IDDD/;:@Z?K5F.7XTR6WVD)$,\B%EMPV/I_\
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MO_3Y!_X%_P#W71]M_P"GR#_P+_\ NN@ ^V?]/EO_ .!7_P!U4?;/^GRW_P#
MK_[JH^V_]/D'_@7_ /=='VW_ *?(/_ O_P"ZZ #[9_T^6_\ X%?_ '51]L_Z
M?+?_ ,"O_NJC[;_T^0?^!?\ ]UT?;?\ I\@_\"__ +KH /MG_3Y;_P#@5_\
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MKVFB2.!(C07"0X.Z-1GY]WIV^H]^*6KVR7&E6TMI&5GB$<XBD1XRDB8X 8#
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M()CC\R16WV<;,BAMJ/PF,$_+R5YS@GI0!RO_  FGAW_H'>.O_!E+_P#%T?\
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M>M KE3(LEG&66,P1N9!M3HK.0=V!@=10!SG_  FGAW_H'>.O_!E+_P#%T?\
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MC,?C8Z5)/!X]6YN\XAA2T51*"W$@)CR5VACP",J<,>P!SW_":>'?^@=XZ_\
M!E+_ /%T?\)IX=_Z!WCK_P &4O\ \771SKXR^S*]OXZ?S&++$);6/$S"0J N
MU"?F4;A@'@'MS3KM/&,%P!!X\>YMA#)(TJ6D0.X*&5-NP@'&6.3G':@#FO\
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M[>"!C&.,R.PGUC7+NW2VOH5DU-2\]O<1>98A8B,GY28V)4@!.-KYSR"WJM%
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M\2R7F8L @[!YD@9L8?@[<DGDCU&B@#SRQ\%17'A 37$6HPWI0RI9M,H$/!S
MJ[-@C;H5VD'/>L@V=SJ>KWEFFFWD+,UA%*D$T/F68*8$FW:1'L#?*4].<=O6
MJ* .%U7PW!H=Y;:G9VM]?9WBX!E1]A\MLS_.IPYP%8J02".#@"LKPGX>&K-9
M&\ANUM+>PC4S17*-!>G<P*%E7<Z C<-QZL>HP3Z?10!Y=JFEMH=W!916UTT9
MU:V:&\FN(U>X.PX&[9EV4_* ^1C&3UQ(-$EM/"T$S17MK<W=WL^SSN"MFH).
M$1  %8QH6 SG)Z]_3:* /(S;06VG%K:UD$LMNTD\^P,]RD;NN %<'>5W<_,
MI."I KT+PKL&A1K'%+$%=P8Y3\R'<>/_ -?UR<Y.U10 4444 %%%% !1110
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M(+%;32EL;9C$$B\M' Y!Q][ZYYKB3X*\0%B?[60^YFD_PKJO$5SJMKIPDTF
M33;P&&W<0OJ!WKE?[:\:_P#/@_\ X#5UXKV-U"<7IV.+!*ORN<)1U[[B?\(5
MX@_Z"R?]_G_PK<\,Z!J>D74TM[?B='3:L:NS#.>O/^>:Q/[:\:_\^#_^ U6+
M'5_&$E_ DU@?*9P'+0;0%SSSVXK"D\/":E&,K_,Z*RQ4Z;C*<+?([FBBBO8/
M!"BJ&F:Q9ZN]\EH[,;*Y:UFRI&)% ) ]>HYJK/KC0^,K+0?(!6YLIKHS;N5*
M.BXQ[[_TH UW1)%VNBL/1AFJXTVP5MPLK8-ZB)<_RJU10 BJJ#"J /0"EHHH
M **** "BBB@ HHHH **** "BJ]]>PZ=I]S?7+%8+:)II& R0J@D\?05);SI=
M6T5Q$28Y4#J2,<$9% $E%9>C:U'K)U$1PO%]BO9+-MY'S%,98>W-:E !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'F_V9YM)O5^V?8VN)H4BFGD=55XU5P,R#()#-@@;?D&.U/GOH+"VL
MUNVA\V-MGF.N2\C$-N (/\6) I[NO0 U=L;];#342:WFW/=+,KK&5"A$B)^\
MQ/*ENG! 8X%8UKY.L^)-5BO!_HUI8.\L@^ZTKGYB.#Q@MCN-Q'I7IK6]]E_P
MQYKTM;=_\.:$YC,]C=BZ2PMK=UEF1L'S@NT@*2"6);<1CG]X&_BJ#3]+MY[;
M4["^BS.\\8$,/R MDY .[ 4''((Z#J>K/".JSZEH$;0$23N4:6)B?G=&SU'=
ME5O7 51CL9TLAJ?]L%Y6L[XW,3;8SN9),[@JE022"H.<'@'MT'>+<7I;_,%:
M24EK?_(M7%@FE^%M5CN(YH[IX#GS9S(9$) (5R6(/09/0X./7!UPS^1)$)H6
MN=XCG6%&WR$OM8+\_4L"-VQ02&QW!V;Z/48/!NJ27D]S?ZB(0GE2Q'*JS 94
M*J^F01G!').,"M"EQ=RQ:DNE75Q/(B/'+!<1V\4K$Y+;)0'7GG@$$\CGFBFV
MO>;Z_P"7<)I/W4NG^?8?H!2"TM1=13Q:K )6OYRNP*IR%W,V%"GA@I!Z'Y>:
MM1AOM<KQ7<4=Q+*OFEK:Y2)FRH/#.4W#(&2O!QD53\1!6TVW$4X\YF<2:;&1
M#Z,SDR#[P Y=^H8D8)&6:191,L4\5Q;ZA]F11)="&16C(<R%658VY#,20&4G
M #=*35USC3L^0CB9;DQC1%NY'\F9-4BWX=P#APAESAMQR0".H]J[O1A<&"1Y
M'N# Y#0"Y*F0+M&<D=L^N3U]L5-.\,:0D$<K*+]7S*CW!$BY<[F90>!N//%;
MV,# KEK55+1'31I..K"BBBN<Z HHHH **** "BBB@ HHHH *R]6O+A$>SLHV
M>[>(NI#JNP9QG+=_P-:E4=4TFSU>T:"[MX9>#L:1 VP]B*J#2EJ3--K0X1(&
MO98-8@=ELK6]/F27KF2Y5=NPI\NXX5OF )]Z@@TZVN+:W/VV.6VN'C\N23=(
MS2*I5<1-& HP[GYCU(.[CG2U'P_J<6J1WLL-O*5G61[J+,<:(%*HIBR<A7(8
MDD\9^E4-1N;[2-4>]LL7$D[,'2$O.JH5&#(/,VEB^ N2,Y/'05Z49<VD7_7]
M?\,>=*/+\2_K^O\ AR:^-QH5HLL-C;-IC78MC"'Q).^2H,K+@8R-H4 J,8Z=
M*&FW-LFE378D@:::"2-DCA5'D)C8%#@#/SX.3P-O'7 O6T4&KN6NXIUBBFDC
M,+L(XI7(VEX7;)1L=4W#DG!X.:UPXL;*]>]0VL$D7E+'=-&OF#RRBHN&)9=Q
M5MQ "A>,\FFK6Y7N)[\RV.MDAL6M4?4+2#4#<6Z_O-J;RNP @[B."1G/OSC%
M5-/M8]%FTB'>72&TE82>867:%&,D<<@ ]/7'>IM3TC1]8C$NJQ37$3H'MYH3
M(RX*K\PV_P 61QQTQCO65+#=:;86J7+M)=1Z;=-ODQNR$Y)'7D_-^/-<T=5:
M_P#5CHEH[V_JY4T^\>]O+[3YB5ANK=8S</$62&8*Y8!L #YE5_SJ/Q3*J6NG
MZG9RK,I:WFCC\M=\,(4HS,W7DL!@<<'W-,U)VT_3-=NC/#<.]RL@4VSOY )
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M2Y@@MI(Y!D,(QS2H5ZF)@O9SLUOI?YE8C#4L)4?M(<T7MK:WD<K_ ,+(M_\
MH'2?]_1_A6OX?\5PZ_<RP):R0NB;\E@P(SBMG^S[+_GT@_[]BI(K>&#/DPQQ
MYZ[% S713IXA23G.Z]#DJU<+*#4*;3[W)*BN8I)K:2**X>WD=2%F0*60^H#
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MW1[GVK!OKV^U&W-K#)+%),5\RV:<SB9"K,RE&D8KA@J\;2<D;>#4MO=P6/\
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M#G[F<<>N>,'TNO/=2NWNX= <PR(HD15;+_O%\ZV(<X X.>_RY[DXKT*N*O\
M#&_G^9V4/BE;R_(****YCI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[1MN032/(JGUVLQ'Z5U=% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY'CVK\F#RA(/<$=,\27WB_R=,EU.RM(KJR6T2Z5S.49MS;=NW8<$8.>>O&*
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M#*PXQD'N<AUIX&B?PT+&^N+AKHVLL*DSL\<#2(R%D7.,[6(Z=SZU?_M'5?\
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M ?EQ\H/-3W7A[4KN/3XY;?3/LUC>^=%9AV\L0B%HPF2G)RY/3   J_M\6_\
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MG_TBSTV'(B^S2,L;(6VH0 N'++ALDDEB>, T0;:?5W_R%-)-=%;_ ##4+?\
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M7_D'_P"2:/M=O_TY?^0?_DF@ ^QI_P ^T?\ X#K_ /(M'V-/^?:/_P !U_\
MD6C[7;_].7_D'_Y)H^UV_P#TY?\ D'_Y)H /L<?_ #[1_P#@.O\ \BT?8T_Y
M]H__  '7_P"1:/M=O_TY?^0?_DFC[7;_ /3E_P"0?_DF@ ^QI_S[1_\ @.O_
M ,BT?8X_^?:/_P !U_\ D6C[7;_].7_D'_Y)H^UV_P#TY?\ D'_Y)H /L:?\
M^T?_ (#K_P#(M'V-/^?:/_P'7_Y%H^UV_P#TY?\ D'_Y)H^U6_\ TY?^0?\
MY)H /L<?_/M'_P" Z_\ R+1]C3_GVC_\!U_^1:/M=O\ ].7_ )!_^2:/M5O_
M -.7_D'_ .2: #[&G_/M'_X#K_\ (M'V-/\ GVC_ / =?_D6C[7;_P#3E_Y!
M_P#DFC[5;_\ 3E_Y!_\ DF@ ^QI_S[1_^ Z__(M'V./_ )]H_P#P'7_Y%H^U
MV_\ TY?^0?\ Y)H^UV__ $Y?^0?_ ))H /L:?\^T?_@.O_R+1]C3_GVC_P#
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MX!M<XPXJU_8FK_\ 0&L?_ B#_P"1:W_#^B3:.+YKBY@GENYQ,WD0&)%Q&B8
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M-RC6,@9H1YV%C=T.UQ&W\04\9P/YUT%<E><F[-6.NC"*5T[A1117.;A1110
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MO9[DE22G"_:(=OWN?NX^[\WX9KT>N/$.\8OU_,Z\.K2DO3\@HHHKE.H****
M"BBB@ KF]22Y;6)S$+C;M3_5M(!T/]V11^E=)7)ZQ;F36YV%OYGR)SY&_L>_
MD/\ SH /*O?2[_[[F_\ CU'E7OI=_P#?<W_QZJ?V1O\ GS/_ ("?_<E'V1O^
M?,_^ G_W)0!<\J]]+O\ [[F_^/4>5>^EY_WW-_\ 'JI_9&_Y\S_X"?\ W)1]
MD;_GS/\ X"?_ ')0!<\J]]+O_ON;_P"/4>5>^EW_ -]S?_'JI_9&_P"?,_\
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MRKWTN_\ ON;_ ./4>5>^EW_WW-_\>JG]D;_GS/\ X"?_ ')1]D;_ )\S_P"
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M_CU'E7OI=_\ ?<W_ ,>JG]D;_GS/_@)_]R4OV1O^?,_^ G_W)0!;\J]]+O\
M[[F_^/4>5>^EW_WW-_\ 'JI_9&_Y\S_X"?\ W)1]D;_GS/\ X"?_ ')0!!JE
MOK+W=F(FUQ+7Y_/-A*!)G V_ZV1ACKTYJC;:3K@UZ>ZMK_Q);1-:I'YEY]GE
M=F#.<#&< 9'YUJ_9&_Y\S_X"?_<E'V1O^?,_^ G_ -R4 :?A&?4';6+;4;V>
M[:VO%CC>>-$8*88WQA1CJQKI:\ZDT"*2XDG$-]$\I!?R&FB5B !G:EL!G  Z
M=J3_ (1Y/75__ JY_P#D>@#T:BO.?^$?3UU?_P ";G_Y'H_X1Y/75_\ P*N?
M_D>@#T:BO.?^$?3UU?\ \";G_P"1Z/\ A'T]=7_\";G_ .1Z /1JS=?T6U\1
MZ!>Z/>;OL]W$8V*]5]"/<'!_"N+_ .$>3UU?_P "KG_Y'H_X1]/75_\ P)N?
M_D>@#1\*^&_%6CV5CI.HZW93:9I^U8GMX&2>9%^XCDMA0.,X!) QGKF[KWA1
M[[Q-I7B;3IHHM4TY7BVS ^7/$P(*,1RI&201GGL:P?\ A'D]=7_\"KG_ .1Z
M/^$?3UU?_P ";G_Y'H Z#PYX5.E:WK&OWTL<VK:LZ&4Q A(HT4*J+GD\#D\9
M]!BHK/PDUQ=QW>N"UGGM-2DO[,VX8!"ZD8;/7&0>,<J/2L3_ (1Y/75__ JY
M_P#D>C_A'T]=7_\  FY_^1Z -;P+X4U#PI!K:75S:SG4+^2^3RE8!&?JISV&
M!S]:DTOPC)&UGJ&J"TFUC3Y+M[26$,L8\]BQW \\$D?3ZUB_\(\GKJ__ (%7
M/_R/1_PCZ>NK_P#@3<__ "/0!L?#[PC<^$/"S:+?7%O=+YTCAHU(!5^2"#^-
M9"?#F^MO"=YX.M-0@30;F9F65E8W$,3.&:,#[K<Y 8GOT-)_PCR>NK_^!5S_
M /(]'_"/IZZO_P"!-S_\CT =1JVASGPQ!H^B&VMQ!Y*Q>>&952-E(''/\(%9
M<_@1'^(^F^,89DAGC@>.]A4';.VPJK#W&XCGL!67_P (^GKJ_P#X$W/_ ,CT
M?\(\GKJ__@5<_P#R/0!Z-7/WNG:W_:MY-;SV5WIUU$B&PO0V$<9!96&1@C&5
MV\D9R._,_P#"/IZZO_X$W/\ \CT?\(\GKJ__ (%7/_R/0!U7A#PW%X4\.0:3
M%(K['>1BJ[5W.Q8A1DX49P!Z"LKPOX2U#0_&/B36KFZM98=9='$<:L&C*9 Y
M/7(8Y]ZRO^$?3UU?_P ";G_Y'H_X1Y/75_\ P*N?_D>@#?\ $/A1]1\1:1XC
MT^:.'5=,WHHE!,<\3@AD;'(ZD@C.#V-'A[PJVF^(=7\1W\L<NJZH45_*!\N&
M-%"JBYY/0$DXR>PK _X1]/75_P#P)N?_ )'H_P"$>3UU?_P*N?\ Y'H L?\
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MGD_^2J/M7C'_ )^]._\ !/)_\E5!]D;_ )\S_P" G_W)1]D;_GS/_@)_]R4
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MM)J.E1&&.-\MI4F6W%QT^T?['ZU4^R-_SYG_ ,!/_N2M'PS&8M7U)3'Y?[F
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M]>11<LRW(MF)P/E#?+OQLZC;]WCD5'XBC'V.+RKE"K.WFZ?&/GWX!,C%QEF
M&27V\$$88#,6D6<&Z"9KBTU"2!2&N8 ZA,N9<.JQD(=Q.>5) &0.*'JG/O\
MU]P+1J'8;#(DT"RZ6+JX)AE34D _> ;CYAB\P?>W=0!SQP#7:Z%)=2V9><W3
M1'!A-V$$I7 Z[./Z^M5;/PMI?D1--F^'SR*TC93,AS(0!V8G)!R.W2MX *
M  . !7+6JQEHCIHTY1U8M%%%<YT!1110 4444 %%%% !1110 5E:QJ$\$4EK
M86TUS>M$7"Q,BE5SC=ESCUQP?I6K5'5-*M=5M'AN(HV;:0CLN2A]1W_6J@TI
M>\3--QT.$8WEQ>6^HQS3FPAU ))+?2,EP/E"[/+  (5R& QDG'U-:*RM+_R8
MI=3M;J">1#&[2;R\@1E!6,+NS\Q8Y.2<?-\M:5_I6IV5X+I[2"*(3!Y98'VV
MZQA,(K(.6PYW,2,8'IP*6H:A=Z?K7G!I+I;C(-O"[7 \LH"'=-^S=N^4#(!W
M<#@5Z47?X>QYTE;XBS+(?#UJ;E-/Q9M<?9OW<@$ES*,KF1A]U<C:%7@$<\5E
MZ-<VCZ7<3QS0,]S&Z>5;H-TKF-B4V@Y)#8;)4!=IP<'C2MXX-7WI<0W/E+<2
M9M]VP/(, R0,_0_[!(*G.#QRS4 UGI%XNHEX;1E:!8KF,1A\H55$^<Y^?8P;
M:NT*?4T)KX7NP:?Q+8UM8@UO4[>'^S;:SN#!&A>>9E!F^4,0,JW7/? ^O9EM
MJ-SJ2Z-=65M%'>/:L8D(VQJI"D@<]@1VQD=NAFUN[N3M?2[&\N?+C0S36<NU
M73&>#N ;@\8R?H,$P#4K>Z.D26:I"+B%HT;<2R&0J >1DD[PQR>O7/48J[BM
M/ZMU-G;F>O\ 5^AA>,;![N""XFE9(&=&E,)(4PN<O[D;@S8/95J[J#7-_P"-
MG@M9RUG;P1!(MX*^>5P&QWPKC/L<]J6WN;;4+6>VMTO/LEM'(BB<L^54HI W
M 9SN5M@R/E '4BG062>&[)Y=LVZ.4I*4=G8N5+'+8)Z8&X#.&; X!K:]E9[J
M]OF8VN^9;:7^1!K"3PKX8^UW 9I;E&C7>HV R0?NQ\OS8P>F#[X!!]+KS#4K
MKS)O#XA:9899UG42.^X!YXBR' YPZM][ Z=P,^GURXCX8W\_S.G#_%*WE^04
M445RG4%%%% !1110 5R>LR6Z:U,)1:%MB?ZT19[_ -^13^E=97,ZHMP=8F,3
M3!=B?<=@._I,G\J ,SSK/^[IW_?-O_\ ':/.L_[NG?\ ?-O_ /':M>7>?W[G
M_OZ__P E4>7>?W[G_OZ__P E4 5?.L_[NG?]\V__ ,=H\ZS_ +NG?]\V_P#\
M=JPQN4.&FG4D9P9G'_MU2 W#,%$\Q)["9_\ Y*H @\^S_NZ=_P!\V_\ \=H\
M^S_NZ=_WS;__ !VK7EWG]^Y_[^O_ /)5'EWG]^Y_[^O_ /)5 %7S[/\ NZ=_
MWS;_ /QVCS[/^[IW_?-O_P#':M>7>?W[G_OZ_P#\E4C+=HI9I+@*!DDRO@?^
M35 %;S[/^[IW_?-O_P#'://L_P"[IW_?-O\ _':E@FEN4#V]U)*AZ-'.[ XZ
M]+JI?+O/[]S_ -_7_P#DJ@"KY]G_ '=._P"^;?\ ^.T>?9_W=._[YM__ ([5
MKR[S^_<_]_7_ /DJCR[S^_<_]_7_ /DJ@"KY]G_=T[_OFW_^.T>?9_W=._[Y
MM_\ X[5KR[S^_<_]_7_^2J/+O/[]S_W]?_Y*H J^?9_W=._[YM__ ([1YUG_
M '=._P"^;?\ ^.U:\N\_OW/_ ']?_P"2J/+O/[]S_P!_7_\ DJ@"KY]G_=T[
M_OFW_P#CM'G6?]W3O^^;?_X[5KR[S^_<_P#?U_\ Y*IF^?G_ $B;@X_US_\
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M:\N\_OW/_?U__DJCR[S^_<_]_7_^2J *OGV?]W3O^^;?_P".T>?9_P!W3O\
MOFW_ /CM6O+O/[]S_P!_7_\ DJCR[S^_<_\ ?U__ )*H J^?9_W=._[YM_\
MX[1Y]G_=T[_OFW_^.U:\N\_OW/\ W]?_ .2J/+O/[]S_ -_7_P#DJ@"KY]G_
M '=._P"^;?\ ^.T>?9_W=._[YM__ ([5KR[S^_<_]_7_ /DJCR[S^_<_]_7_
M /DJ@"KY]G_=T[_OFW_^.T>?9_W=._[YM_\ X[5KR[S^_<_]_7_^2J/+O/[]
MS_W]?_Y*H J^?9_W=._[YM__ ([1YUG_ '=._P"^;?\ ^.U:\N\_OW/_ ']?
M_P"2J/+O/[]S_P!_7_\ DJ@"KY]G_=T[_OFW_P#CM'G6?]W3O^^;?_X[5KR[
MS^_<_P#?U_\ Y*H\N\_OW/\ W]?_ .2J *OGV?\ =T[_ +YM_P#X[1Y]G_=T
M[_OFW_\ CM6O+O/[]S_W]?\ ^2J/+O/[]S_W]?\ ^2J *OGV?]W3O^^;?_X[
M1Y]G_=T[_OFW_P#CM6O+O/[]S_W]?_Y*H\N\_OW/_?U__DJ@"KYUG_=T[_OF
MW_\ CM'GV?\ =T[_ +YM_P#X[5KR[S^_<_\ ?U__ )*H\N\_OW/_ ']?_P"2
MJ *OGV?]W3O^^;?_ ..T>?9_W=._[YM__CM6O+O/[]S_ -_7_P#DJCR[S^_<
M_P#?U_\ Y*H J^?9_P!W3O\ OFW_ /CM'GV?]W3O^^;?_P".U:\N\_OW/_?U
M_P#Y*H\N\_OW/_?U_P#Y*H J^=9_W=._[YM__CM'GV?]W3O^^;?_ ..U:\N\
M_OW/_?U__DJCR[S^_<_]_7_^2J *OGV?]W3O^^;?_P".T>?9_P!W3O\ OFW_
M /CM6O+O/[]S_P!_7_\ DJCR[S^_<_\ ?U__ )*H J^?9_W=._[YM_\ X[1Y
M]G_=T[_OFW_^.U:\N\_OW/\ W]?_ .2J/+O/[]S_ -_7_P#DJ@"KY]G_ '=.
M_P"^;?\ ^.T>=9_W=._[YM__ ([5KR[S^_<_]_7_ /DJCR[S^_<_]_7_ /DJ
M@"KYUG_=T[_OFW_^.T>=9_W=._[YM_\ X[5KR[S^_<_]_7_^2J/+O/[]S_W]
M?_Y*H J^?9_W=._[YM__ ([1Y]G_ '=._P"^;?\ ^.U:\N\_OW/_ ']?_P"2
MJ/+O/[]S_P!_7_\ DJ@"KYUG_=T[_OFW_P#CM'GV?]W3O^^;?_X[5KR[S^_<
M_P#?U_\ Y*H\N\_OW/\ W]?_ .2J *OGV?\ =T[_ +YM_P#X[1Y]G_=T[_OF
MW_\ CM6O+O/[]S_W]?\ ^2J/+O/[]S_W]?\ ^2J *OGV?]W3O^^;?_X[1Y]G
M_=T[_OFW_P#CM6O+O/[]S_W]?_Y*H\N\_OW/_?U__DJ@"KY]G_=T[_OFW_\
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M::XC@\B26)W'&Y2&4G:<!3Z =.F ,59U'6XO#XA\R[MI!.J!TG98R&"@%LY
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M3_P';_Y%H\B3_GTD_P# =O\ Y%J/9IW]V#_OFS_^)HV:=_=@_P"^;/\ ^)H
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M_P# =O\ Y%J/9IW]V#_OFS_^)HV:=_=@_P"^;/\ ^)H D\B3_GTD_P# =O\
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M_P"^;/\ ^)H D\B3_GTD_P# =O\ Y%H\B3_GTD_\!V_^1:CV:=_=@_[YL_\
MXFC9IW]V#_OFS_\ B: )/(D_Y])/_ =O_D6CR)/^?23_ ,!V_P#D6H]FG?W8
M/^^;/_XFC9IW]V#_ +YL_P#XF@"3R)/^?23_ ,!V_P#D6CR)/^?23_P';_Y%
MJ/9IW]V#_OFS_P#B:-FG?W8/^^;/_P")H D\B3_GTD_\!V_^1:/(D_Y])/\
MP';_ .1:CV:=_=@_[YL__B:-FG?W8/\ OFS_ /B: )/(D_Y])/\ P';_ .1:
M/(D_Y])/_ =O_D6H]FG?W8/^^;/_ .)HV:=_=@_[YL__ (F@"3R)/^?23_P'
M;_Y%H\B3_GTD_P# =O\ Y%J/9IW]V#_OFS_^)HV:=_=@_P"^;/\ ^)H D\B3
M_GTD_P# =O\ Y%H\B3_GTD_\!V_^1:CV:=_=@_[YL_\ XFC9IW]V#_OFS_\
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M;6^F>6D\4BROL2_:,E"A* #J3_"<Y('>N^T*RDL[+#Q);HX4I;1NS)$,=!D
M_A@#]:YZ].,=5H=%"I*6CU-2BBBN4Z0HHHH **** "BBB@ HHHH ***Y_P 3
M:B]M ;;[1;V<<T9S<W.[83G&P8(YQ[CVSSBH1<G9$SDHJ[%U>/07OP9S:C6
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MAB0<ALC=D$X)ZYQ7.FK;_P!6Z'0T[[?U?J9.K74MG8B5IY+N^95@7S J@S.
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M/3'4U1O?!5Q=ZO>ZE'XAU2VEO&C:01/!_P LR"@R9R3@@=2:Z[9-_P \I_\
MOS-_\8HV3?\ /*?_ +\S?_&* ,'_ (1V8>+!XA&J7@G^S_9FB$D>UD]"WVC?
M][YOO=1Z<5'H_A5M)TS4K ZE>74.H.\DOFR1J=SC#'"7"@Y]P>E=%LF_YY3_
M /?F;_XQ1LF_YY3_ /?F;_XQ0!B^&= _X1?1(],M;F>1%9G+M*J%B3GHET!^
ME;&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/
M_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\
MWYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_X
MQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_
M )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\
M@2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\
M)=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/
M_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\
MWYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_X
MQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_
M )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\
M@2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\
M)=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/
M_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\
MWYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_X
MQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_
M )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\
M@2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\
M)=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/
M_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\
MWYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_X
MQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_
M )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\
M@2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\
M)=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/
M_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\
MWYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_X
MQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_
M )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\
M@2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\
M)=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/
M_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\
MWYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_X
MQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_
M )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\
M@2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\
M)=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/
M_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\
MWYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_X
MQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_
M )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\
M@2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\
M)=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/
M_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\
MWYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_X
MQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_
M )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\
M@2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\
M)=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/
M_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\
MWYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_X
MQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_
M )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\
M@2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\
M)=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/
M_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\
MWYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_ )Y3_P#?F;_X
MQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\ @2?_ )+IVR;_
M )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\ )=&ZY_YZR_\
M@2?_ )+IVR;_ )Y3_P#?F;_XQ1LF_P">4_\ WYF_^,4 -W7/_/67_P "3_\
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M ($+_P#)= !Y%G_<B_[XM_\ XS1]GLO^><7_ 'Q;_P#QFC[:G_/S#_X$+_\
M)='VU/\ GYB_\"%_^2Z #[/9_P#/.+_OBW_^,T>19?\ /.+_ +XM_P#XS1]M
M3_GYA_\  A?_ )+H^VI_S\Q?^!"__)= !Y%G_P \XO\ OBW_ /C-'D67_/.+
M_OBW_P#C-'VU/^?F+_P(7_Y+H^VI_P _,/\ X$+_ /)= !Y%G_SSB_[XM_\
MXS1Y%G_SSB_[XM__ (S1]M3_ )^8O_ A?_DNC[:G_/S%_P"!"_\ R70 >19_
MW(O^^+?_ .,T>19_\\XO^^+?_P",T?;4_P"?F+_P(7_Y+H^VI_S\P_\ @0O_
M ,ET 'V>R_YYQ?\ ?%O_ /&:/(L_[D7_ 'Q;_P#QFC[:G_/S%_X$+_\ )='V
MU/\ GYA_\"%_^2Z #R++_GG%_P!\6_\ \9H\BS_N1?\ ?%O_ /&:/MJ?\_,7
M_@0O_P ET?;4_P"?F+_P(7_Y+H /(L_^><7_ 'Q;_P#QFCR+/^Y%_P!\6_\
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M+_OBW_\ C-'D6?\ <B_[XM__ (S1]M3_ )^8O_ A?_DNC[:G_/S#_P"!"_\
MR70 >19_\\XO^^+?_P",T?9[/_GG%_WQ;_\ QFC[:G_/S%_X$+_\ET?;4_Y^
M8O\ P(7_ .2Z #R+/_GG%_WQ;_\ QFCR+/\ YYQ?]\6__P 9H^VI_P _,7_@
M0O\ \ET?;4_Y^8?_  (7_P"2Z #[/9?\\XO^^+?_ .,T>19_\\XO^^+?_P",
MT?;4_P"?F'_P(7_Y+H^VI_S\Q?\ @0O_ ,ET 'D6?_/.+_OBW_\ C-'D6?\
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M_/S%_P"!"_\ R71]M3_GYA_\"%_^2Z #R++_ )YQ?]\6_P#\9H\BS_YYQ?\
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M+/\ YYQ?]\6__P 9H^VI_P _,7_@0O\ \ET?;4_Y^8?_  (7_P"2Z #R+/\
MYYQ?]\6__P 9H\BS_P"><7_?%O\ _&:/MJ?\_,7_ ($+_P#)='VU/^?F'_P(
M7_Y+H /L]G_<B_[XM_\ XS1Y%G_<B_[XM_\ XS1]M3_GYB_\"%_^2Z/MJ?\
M/S#_ .!"_P#R70 >19?\\XO^^+?_ .,T>19_W(O^^+?_ .,T?;4_Y^8O_ A?
M_DNC[:G_ #\P_P#@0O\ \ET 'D67_/.+_OBW_P#C-'D6?]R+_OBW_P#C-'VU
M/^?F'_P(7_Y+H^VI_P _,/\ X$+_ /)= !Y%G_<B_P"^+?\ ^,T>19_W(O\
MOBW_ /C-'VU/^?F'_P "%_\ DNC[:G_/S%_X$+_\ET 'V>S_ .><7_?%O_\
M&:/(L_[D7_?%O_\ &:/MJ?\ /S#_ .!"_P#R71]M3_GYB_\  A?_ )+H /(L
M_P#GG%_WQ;__ !FC[/9?\\XO^^+?_P",T?;4_P"?F'_P(7_Y+H^VI_S\Q?\
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M_I]_\C_X4;K[_I]_\C_X51^QQ_\ /&W_ ._2?_(M'V./_GC;_P#?I/\ Y%H
MO;K[_I]_\C_X4;K[_I]_\C_X51^QQ_\ /&W_ ._2?_(M'V./_GC;_P#?I/\
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MYSPC&)-.\1DJAVZ<Y&Y0<<-TS&W\U^M'-).*?F'L,/*G6G3U2<;?-ZG3Z/\
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MNOO6]_\ (_\ A5'[''_SQM_^_2?_ "+1]CC_ .>-O_WZ3_Y%H O;K[_I]_\
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MK[_I]_\ (_\ A5'[''_SQM_^_2?_ "+1]CC_ .>-M_WZ3_Y%H O;K[_I]_\
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MKN>0?ED7@]*OVPL+:YU6RN3'()+J.+S+D%@IR4!;YN2=P'&W[Q]Z4K7?5?\
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MFM6%S!B2[$1B"&0J60EN<8'7'4&FZ5\/M>L]#UFWEM\7-VD<<04OMPK;CDC
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M19/&!93&1Y,?W""._I(X_P#'ORKUG[9#_?L_^^X__DJN-\6^"/$&M>(_M]M
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M^E[^<_\ \<H H_;(?[]G_P!]Q_\ R51]LA_OV?\ WW'_ /)57O*O_2]_.?\
M^.4>5?\ I>_G/_\ '* */VR'^_9_]]Q__)5'VR'^_9_]]Q__ "55[RK_ -+W
M\Y__ (Y1Y5_Z7OYS_P#QR@"C]LA_OV?_ 'W'_P#)5'VR'^_9_P#?<?\ \E5>
M\J_]+W\Y_P#XY1Y5_P"E[^<__P <H H_;(?[]G_WW'_\E4?;(?[]G_WW'_\
M)57O*O\ TO?SG_\ CE'E7_I>_G/_ /'* */VR'^_9_\ ?<?_ ,E4?;(?[]G_
M -]Q_P#R55[RK_TO?SG_ /CE'E7_ *7OYS__ !R@"C]LA_OV?_?<?_R51]LA
M_OV?_?<?_P E5>\J_P#2]_.?_P".4>5?^E[^<_\ \<H H_;(?[]G_P!]Q_\
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M !E*2G:3N.-^">6)VD8QF>\NX;[3_+L([=&N3LC5PKPJ%!W1G^$C=M8<X8L
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M0_Y]$_\  4?_ ")1YUA_>B_[ZM?_ ([1YUA_>B_[ZM?_ ([0 ?8E_P"?1/\
MP%'_ ,B4?8A_SZ)_X"C_ .1*/.L/[T7_ 'U:_P#QVCSK#^]%_P!]6O\ \=H
M/L2_\^B?^ H_^1*/L2_\^B?^ H_^1*/.L/[T7_?5K_\ ':/.L/[T7_?5K_\
M': #[$O_ #Z)_P" H_\ D2C[$O\ SZ)_X"C_ .1*/.L/[T7_ 'U:_P#QVCSK
M#^]%_P!]6O\ \=H /L0_Y]$_\!1_\B4?8A_SZ)_X"C_Y$H\ZP_O1?]]6O_QV
MCSK#^]%_WU:__': #[$/^?1/_ 4?_(E'V(?\^B?^ H_^1*/.L/[T7_?5K_\
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MK#^]%_WU:_\ QV@ ^Q#_ )]$_P# 4?\ R)1]B'_/HG_@*/\ Y$H\ZP_O1?\
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M$_\  4?_ ")1]B'_ #Z)_P" H_\ D2CSK#^]%_WU:_\ QVCSK#^]%_WU:_\
MQV@ ^Q+_ ,^B?^ H_P#D2C[$O_/HG_@*/_D2CSK#^]%_WU:__':/.L/[T7_?
M5K_\=H /L0_Y]$_\!1_\B4?8A_SZ)_X"C_Y$H\[3_P"]%_WU:_\ QVCSK#^]
M%_WU:_\ QV@ ^Q#_ )]$_P# 4?\ R)1]B'_/HG_@*/\ Y$H\ZP_O1?\ ?5K_
M /':/.L/[T7_ 'U:_P#QV@ ^Q#_GT3_P%'_R)1]B7_GT3_P%'_R)1YUA_>B_
M[ZM?_CM'G6']Z+_OJU_^.T 'V(?\^B?^ H_^1*/L2_\ /HG_ ("C_P"1*/.L
M/[T7_?5K_P#':/.L/[T7_?5K_P#': #[$O\ SZ)_X"C_ .1*/L2_\^B?^ H_
M^1*/.L/[T7_?5K_\=H\ZP_O1?]]6O_QV@ ^Q+_SZ)_X"C_Y$H^Q#_GT3_P !
M1_\ (E'G6']Z+_OJU_\ CM'G6']Z+_OJU_\ CM !]B7_ )]$_P# 4?\ R)1]
MB7_GT3_P%'_R)1YUA_>B_P"^K7_X[1YUA_>B_P"^K7_X[0 ?8A_SZ)_X"C_Y
M$H^Q#_GT3_P%'_R)1YUA_>B_[ZM?_CM'G6']Z+_OJU_^.T 'V)?^?1/_  %'
M_P B4?8A_P ^B?\ @*/_ )$H\ZP_O1?]]6O_ ,=H\ZP_O1?]]6O_ ,=H /L0
M_P"?1/\ P%'_ ,B4?8E_Y]$_\!1_\B4>=I_]Z+_OJU_^.T>=8?WHO^^K7_X[
M0 ?8A_SZ)_X"C_Y$H^Q#_GT3_P !1_\ (E'G6']Z+_OJU_\ CM'G6']Z+_OJ
MU_\ CM !]B7_ )]$_P# 4?\ R)1]B'_/HG_@*/\ Y$H\ZP_O1?\ ?5K_ /':
M/.L/[T7_ 'U:_P#QV@ ^Q+_SZ)_X"C_Y$H^Q+_SZ)_X"C_Y$H\ZP_O1?]]6O
M_P =H\ZP_O1?]]6O_P =H /L2_\ /HG_ ("C_P"1*/L2_P#/HG_@*/\ Y$H\
MZP_O1?\ ?5K_ /':/.L/[T7_ 'U:_P#QV@ ^Q#_GT3_P%'_R)1]B'_/HG_@*
M/_D2CSK#^]%_WU:__':/.L/[T7_?5K_\=H /L2_\^B?^ H_^1*/L0_Y]$_\
M 4?_ ")1YUA_>B_[ZM?_ ([1YUA_>B_[ZM?_ ([0 ?8A_P ^B?\ @*/_ )$H
M^Q#_ )]$_P# 4?\ R)1YUA_>B_[ZM?\ X[1YUA_>B_[ZM?\ X[0 ?8A_SZ)_
MX"C_ .1*/L0_Y]$_\!1_\B4>=I_]Z+_OJU_^.T>=8?WHO^^K7_X[0 ?8E_Y]
M$_\  4?_ ")1]B'_ #Z)_P" H_\ D2CSK#^]%_WU:_\ QVCSK#^]%_WU:_\
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M0_Y]$_\  4?_ ")1YUA_>B_[ZM?_ ([1YUA_>B_[ZM?_ ([0 ?8E_P"?1/\
MP%'_ ,B4?8A_SZ)_X"C_ .1*/.L/[T7_ 'U:_P#QVCSK#^]%_P!]6O\ \=H
M/L2_\^B?^ H_^1*/L0_Y]$_\!1_\B4>=8?WHO^^K7_X[1YUA_>B_[ZM?_CM
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MN(/&,D]!GMGBLS[=>R:5:7-X@,O]FW#N#DC<(_NG/H=PY.>._)K!7E&U[_\
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M_P"?B;_O_)_\DT>;+_S\3?\ ?^3_ .2:=F[_ .><_P#WX;_Y$HS=_P#/.?\
M[\-_\B4 -\V7_GXF_P"_\G_R31YLO_/Q-_W_ )/_ ))IV;O_ )YS_P#?AO\
MY$HS=_\ /.?_ +\-_P#(E #?-E_Y[S?]_P"3_P"2:/-E_P">\W_?^3_Y)IV;
MO_GG/_WX;_Y$HS=_\\Y_^_#?_(E #?-E_P"?B;_O_)_\DT>;+_S\3?\ ?^3_
M .2:=F[_ .><_P#WX;_Y$HS=_P#/.?\ [\-_\B4 )YLO_/>;_O\ R?\ R32>
M;+_SWF_[_P G_P DT[-W_P \Y_\ OPW_ ,B49N_^><__ 'X;_P"1* &^;+_S
M\3?]_P"3_P"2:/-E_P">\W_?^3_Y)IV;O_GG/_WX;_Y$HS=_\\Y_^_#?_(E
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M_P"?B;_O_)_\DT>;+_S\3?\ ?^3_ .2:=F[_ .><_P#WX;_Y$HS=_P#/.?\
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MG9N_^><__?AO_D2C-W_SSG_[\-_\B4 -\V7_ )[S?]_Y/_DFCS9?^?B;_O\
MR?\ R33LW?\ SSG_ ._#?_(E&;O_ )YS_P#?AO\ Y$H ;YLO_/Q-_P!_Y/\
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M^2:/-E_Y[S?]_P"3_P"2:=F[_P"><_\ WX;_ .1*,W?_ #SG_P"_#?\ R)0
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M;O\ YYS_ /?AO_D2@!OFR_\ />;_ +_R?_)-+YLO_/>;_O\ R?\ R32YN_\
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MWDN;B[\Q86#1H!+B4)@MLSC(/)<D@+GKFII7VVU_R'4MOOI_F6]4>?5(%TV
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M_G[?_P "C_\ )= #/^);_P!._P#Y)T?\2W_IW_\ ).G_ &F3_G[?_P "C_\
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M2W_IW_\ ).G_ &F3_G[?_P "C_\ )='VF3_G[?\ \"C_ /)= #/^);_T[_\
MDG1_Q+?^G?\ \DZ?]ID_Y^W_ / H_P#R71]ID_Y^W_\  H__ "70 S_B6_\
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M71]ID_Y^W_\  H__ "70 S_B6_\ 3O\ ^2='_$M_Z=__ "3I_P!ID_Y^W_\
M H__ "71]ID_Y^W_ / H_P#R70 S_B6_].__ ))T?\2W_IW_ /).G_:9/^?M
M_P#P*/\ \ET?:9/^?M__  */_P ET ,_XEO_ $[_ /DG1_Q+?^G?_P DZ?\
M:9/^?M__  */_P ET?:9/^?M_P#P*/\ \ET ,_XEO_3O_P"2='_$M_Z=_P#R
M3I_VF3_G[?\ \"C_ /)='VF3_G[?_P "C_\ )= #/^);_P!._P#Y)T?\2W_I
MW_\ ).G_ &F3_G[?_P "C_\ )='VF3_G[?\ \"C_ /)= #/^);_T[_\ DG1_
MQ+?^G?\ \DZ?]ID_Y^W_ / H_P#R71]ID_Y^W_\  H__ "70 S_B6_\ 3O\
M^2='_$M_Z=__ "3I_P!ID_Y^W_\  H__ "71]ID_Y^W_ / H_P#R70 S_B6_
M].__ ))T?\2W_IW_ /).G_:9/^?M_P#P*/\ \ET?:9/^?M__  */_P ET ,_
MXEO_ $[_ /DG1_Q+?^G?_P DZ?\ :9/^?M__  */_P ET?:9/^?M_P#P*/\
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MF3_G[?\ \"C_ /)='VF3_G[?_P "C_\ )= #/^);_P!._P#Y)T?\2W_IW_\
M).G_ &F3_G[?_P "C_\ )='VF3_G[?\ \"C_ /)= #/^);_T[_\ DG1_Q+?^
MG?\ \DZ?]ID_Y^W_ / H_P#R71]ID_Y^W_\  H__ "70 S_B6_\ 3O\ ^2='
M_$M_Z=__ "3I_P!ID_Y^W_\  H__ "71]ID_Y^W_ / H_P#R70 S_B6_].__
M ))T?\2W_IW_ /).G_:9/^?M_P#P*/\ \ET?:9/^?M__  */_P ET ,_XEO_
M $[_ /DG1_Q+?^G?_P DZ?\ :9/^?M__  */_P ET?:9/^?M_P#P*/\ \ET
M,_XEO_3O_P"2='_$M_Z=_P#R3I_VF3_G[?\ \"C_ /)='VF3_G[?_P "C_\
M)= #/^);_P!._P#Y)T?\2W_IW_\ ).G_ &F3_G[?_P "C_\ )='VF3_G[?\
M\"C_ /)= #/^);_T[_\ DG1_Q+?^G?\ \DZ?]ID_Y^W_ / H_P#R71]ID_Y^
MW_\  H__ "70 S_B6_\ 3O\ ^2='_$M_Z=__ "3I_P!ID_Y^W_\  H__ "71
M]ID_Y^W_ / H_P#R70 S_B6_].__ ))T?\2W_IW_ /).G_:9/^?M_P#P*/\
M\ET?:9/^?M__  */_P ET ,_XEO_ $[_ /DG1_Q+?^G?_P DZ?\ :9/^?M__
M  */_P ET?:9/^?M_P#P*/\ \ET ,_XEO_3O_P"2='_$M_Z=_P#R3I_VF3_G
M[?\ \"C_ /)='VF3_G[?_P "C_\ )= #/^);_P!._P#Y)T?\2W_IW_\ ).G_
M &F3_G[?_P "C_\ )='VF3_G[?\ \"C_ /)= #/^);_T[_\ DG1_Q+?^G?\
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M /)= #/^);_T[_\ DG1_Q+?^G?\ \DZ?]ID_Y^W_ / H_P#R71]ID_Y^W_\
M H__ "70 S_B6_\ 3O\ ^2='_$M_Z=__ "3I_P!ID_Y^W_\  H__ "71]ID_
MY^W_ / H_P#R70 S_B6_].__ ))T?\2W_IW_ /).G_:9/^?M_P#P*/\ \ET?
M:9/^?M__  */_P ET ,_XEO_ $[_ /DG1_Q+?^G?_P DZ?\ :9/^?M__  */
M_P ET?:9/^?M_P#P*/\ \ET ,_XEO_3O_P"2='_$M_Z=_P#R3I_VF3_G[?\
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M&Y2"!E85/.,=1UK.M+'^W/%=EJ\UHEC;V%LR>7<^2A>9^#@"(@@#/)!Y(P:
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M]+K_ +]R_P#R-53[-:>MC^=O_P#&*/LUIZV/YV__ ,8H M^;>^EU_P!^Y?\
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M_P C4>;>^EU_W[E_^1JJ?9K3UL?SM_\ XQ1]FM/6P_.W_P#C% %OS;WTNO\
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M4?9K3UL/SM__ (Q0!;\V]]+K_OW+_P#(U'FWOI=?]^Y?_D:JGV:T];'\[?\
M^,4?9K3UL?SM_P#XQ0!;\V]]+K_OW+_\C4>;>^EU_P!^Y?\ Y&JI]FM/6P_.
MW_\ C%'V:T];'\[?_P",4 6_-O?2Z_[]R_\ R-1YM[Z77_?N7_Y&JI]FM/6Q
M_.W_ /C%'V:T];'\[?\ ^,4 6_-O?2Z_[]R__(U'FWOI=?\ ?N7_ .1JJ?9K
M3UL?SM__ (Q1]FM/6Q_.W_\ C% %OS;WTNO^_<O_ ,C4>;>^EU_W[E_^1JJ?
M9K3UL?SM_P#XQ1]FM/6Q_.W_ /C% %OS;WTNO^_<O_R-1YM[Z77_ '[E_P#D
M:JGV:T];'\[?_P",4?9K3UL?SM__ (Q0!;\V]]+K_OW+_P#(U'FWOI=?]^Y?
M_D:JGV:T];'\[?\ ^,4?9K3UL?SM_P#XQ0!;\V]]+K_OW+_\C4>;>^EU_P!^
MY?\ Y&JI]FM/6Q_.#_XQ1]FM/6Q_.W_^,4 6_-O?2Z_[]R__ "-1YM[Z77_?
MN7_Y&JI]FM/[UC^=O_\ &*/LUIZV/YV__P 8H M^;>^EU_W[E_\ D:CS;WTN
MO^_<O_R-53[-:>MC^=O_ /&*/LUIZV'YV_\ \8H M^;>^EU_W[E_^1J/-O?2
MZ_[]R_\ R-53[-:>MC^=O_\ &*/LUIZV/YV__P 8H M^;>^EU_W[E_\ D:CS
M;WTNO^_<O_R-53[-:>MC^=O_ /&*/LUIZV/YV_\ \8H M^;>^EU_W[E_^1J/
M-O?2Z_[]R_\ R-53[-:>MC^=O_\ &*/LUIZV/YV__P 8H M^;>^EU_W[E_\
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MW/(.5!WX&1C)[54BTJ:Q71H&Q-=6]JSQJ^TL2@0@=3C)09QD GKT)PC:V_\
M5C>5[[?U<;8_NGN[W3\)*6(62897!X!(*_*I.#E, 9&01R73P2RV$EK>PEX(
MVS#'&OV=P#S@E 2&."<+CY02V <51BL[/2WGNXTEBLY8WGF%T<;UD*$*<$\?
M)@GNJOQQDN@NV\2:=)"Z2D/*8[F*4!)-P4@?+D $@X/(R H_BS6C6O,MC)/3
ME>XFJ7$3RZ%$J^6@>.2%65%(#3P_*00/F!#@[<-P,]Z]'KS2Y@CMCHZVJO%;
MI*+5%=MI<1W,.YB #DERQQD< '.>*]+K#$6Y8V\SHP][ROY!1117*=(4444
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M[^7?_P 31NN?^>5[_P!_+O\ ^)H H_;1_P _:?\ @4/_ )+H^VC_ )^T_P#
MH?\ R75[=<_\\KW_ +^7?_Q-&ZY_YY7O_?R[_P#B: */VT?\_:?^!0_^2Z/M
MH_Y^T_\  H?_ "75[=<_\\KW_OY=_P#Q-&ZY_P">5[_W\N__ (F@"C]M'_/V
MG_@4/_DNC[:/^?M/_ H?_)=7MUS_ ,\KW_OY=_\ Q-&ZY_YY7O\ W\N__B:
M*/VT?\_:?^!0_P#DNC[:/^?M/_ H?_)=7MUS_P \KW_OY=__ !-&ZY_YY7O_
M '\N_P#XF@"C]M'_ #]I_P"!0_\ DNC[:/\ G[3_ ,"A_P#)=7MUS_SRO?\
MOY=__$T;KG_GE>_]_+O_ .)H H_;1_S]I_X%#_Y+H^VC_G[3_P "A_\ )=7M
MUS_SRO?^_EW_ /$T;KG_ )Y7O_?R[_\ B: */VT?\_:?^!0_^2Z/MH_Y^T_\
M"A_\EU>W7/\ SRO?^_EW_P#$T;KG_GE>_P#?R[_^)H H_;1_S]I_X%#_ .2Z
M/MH_Y^T_\"A_\EU>W7/_ #RO?^_EW_\ $T;KG_GE>_\ ?R[_ /B: */VT?\
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M"C]M'_/VG_@4/_DNC[:/^?M/_ H?_)=7MUS_ ,\KW_OY=_\ Q-&ZY_YY7O\
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M_;1_S]I_X%#_ .2Z/MH_Y^T_\"A_\EU>W7/_ #RO?^_EW_\ $T;KG_GE>_\
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M_P \KW_OY=__ !-&ZY_YY7O_ '\N_P#XF@"C]M'_ #]I_P"!0_\ DNC[:/\
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M4/\ Y+H^VC_G[3_P*'_R75[=<_\ /*]_[^7?_P 31NN?^>5[_P!_+O\ ^)H
MH_;1_P _:?\ @4/_ )+H^VC_ )^T_P# H?\ R75[=<_\\KW_ +^7?_Q-&ZY_
MYY7O_?R[_P#B: */VT?\_:?^!0_^2Z/MH_Y^T_\  H?_ "75[=<_\\KW_OY=
M_P#Q-&ZY_P">5[_W\N__ (F@"C]M'_/VG_@4/_DNM+PL[3ZAJEP'WH!##NW[
MOF4,QY\Q^TB]_P *J7=[+:1*S17C22,$AB\ZZ!E<]%&0!D^_ &2< &NBT;3W
MT[3ECF?S+F1C+.^XMEVZ\GD@<*,\X44 :%%%% !1110 4444 %%%% 'GMK<Q
M-H5Y;$B6!95,PC=-Y9E15 *#Y>=Q)QN&WKGI,PNHM/@M+%8M@/F -;><69?E
M/4 \G*G=\RDC)(.16-C'J.C7"744ES#<SQP2"%_,<%%1X^NW ^^"O^T,'O4=
MYJ3Z6D,"J[I#N0)%\Q11PY<\]%7:S#H0^.HKTK7=EN>=>RNR],4GU:UNFB:2
MZD=5$T63$K$_*2FT@KD !C\Q'((^7-6"#^UXM6O(+J2SN))XY(BP.4?=N  /
M4Y4< <\COD336\5ZUKJ5Q;R7,EBZM;F+"@R'8JAAGY?NIG&>=PZ@9K6FFWEL
MNKM8W47VRUGC9I7 PS!N2^"3@@$'OAN,]Q6MOK_P0=[[:?\  -"\CU-O"^IW
M&I7:7ES%'\J" 1^5RIW%3GIMW<Y!Y[5@:WIT$UVUA'Y%M)%.%1I+G!3Y_O,F
M\9!3YN@7!P"".>AU!]4U?PUJ5U>-:V6R#Y)+=GDQAE8],,2-IXQ_$!SS6?%)
M?P-:64%W=PRK$(\6L$<Z0$?*5,DK;S@\?+QG@<T4VUKUO_EV"HD].EOZW%L)
MY=!TRSL[EX%M;02"V&[][/N) ;YPHC3YBNY@<Y'<@F&WEMKJYMK26W+V+2+)
M#%$\QVCS-@)D\W:3N#8 7D+GY>*FUZ9?L]G']F8/N<G4%'F!R!S&RR<[V(7Y
M'SC QD@830;NRET]4MK:'3H7W@6[7,K&0*=CM\I_=@G@GGU-/[//;5_U_7Z"
M^UR7T7]?U^HR&\GU)K8RCS)[!IX[?[# TY5D;:AER20K 9!)&>N0.3WFG6;V
MT1>9]]Q*%,A"A0"!C  JCI_B/2)56V646C1GRA',IC7<IVE$8X5RIX.TG%;=
M<E:;>EK'71@EK>X4445SFX4444 %%%% !1110 4444 %8/B-[GRC&7O(;,Q$
MM-9Q+(X?/ *D'Y<<Y ^I'?>ILD:2QM'(H9'!5E/0@]150ERNY,X\RL>;R1[M
M05]5#KKT=\CQ1Q B-P5"_-@LH+(/FY' '05:M889KBWMFL+99GC#"(W,K(5P
M%8H&C59!@@<.>#C)!YUM0\)6D.;N"ZEBAA8S&VEEQ"6*;&8L06!*$C.2!UQ7
M.ZE9O/<^=9W8M'W&699) T\Y($>U8UP"IX)&?F.!CI7?&49[/^O\CAE&4-T&
MN.(+<W-E>7::BEV;>7;N'D0= ,  (,;7 Q\QX^;I52RBN+;19Y%MHH93"4D*
MDR%<1D%@-B[V",WR^9QEB!Q@:VFF:#31JMQ<+,$FDC@VC_28%SCRBI/S\C[A
MY7L:SM4G33+*[G>V<32@X>:T%H!E2F1N),D@1F"]N23FM(O[",Y+[;.CU#3-
M/N0@U2\N;#9&B6OE3F-%.T8VL,;F!!PI^N.:KZ;::G%%HL)F\N\6V<#<A"]!
MD]."<-C/3=TX(%F[L[OQ%"AMM5%ALACFCB"++D%006)X*YR,@<X/.*KZ;>7!
M&D75ZK&Z2SF8_-NSA06Y)Y^;@=>!U]<$WRVO\ODS=I<U[?/YHP]<CNGBMX#"
M;BW2=#>B'[L<*L%P >@.W(]I&J74Y)X/&XF2%X;74K6+]\J_*EP%++S[  X[
M[13K5Y8-2OEO0JV#1+:7D:/^]9PC*"%''.]!]0*I^(KVUU31XM4TYMLL:6]Y
M= 2$K%&I*!$P,9.3GV SVK>-[J/3_.W]?<<\K6<NO^7]?F:FJ)=(=$\Z0O$T
MB-"1OSL,UN?GP.OJ&XSWSMKT.O.-4::6+PZ9(SN6Z8\*3A#<PE?ND #!7KD=
ML9P1Z/7'7^&/S_,[*'Q2^7Y!1117,=(4444 %%%% !1110!S%]X0A\UY]*:W
MM6=M\D,EM')&Y[XW*2A/MQWQFJHT*[3B32XV/K ;5A_X]"I_2NQHH X_^Q9O
M^@3)_P!\V?\ \;H_L6;_ *!,G_?-G_\ &Z["B@#C_P"Q9O\ H$R?]\V?_P ;
MH_L6;_H$R?\ ?-G_ /&Z["B@#C_[%F_Z!,G_ 'S9_P#QNC^Q9O\ H$R?]\V?
M_P ;KL** ./_ +%F_P"@3)_WS9__ !NC^Q9O^@3)_P!\V?\ \;KH=3UJPT?R
M/MTS1?:)!%%B)WWN>BC:#R<'BJTWBG2+:"ZFN+B6&.U57G,MM*AC5L@,05SC
MY3STXH Q_P"Q9O\ H$R?]\V?_P ;H_L6;_H$R?\ ?-G_ /&ZZ.?5K.VTP:C-
M(Z6I ;?Y3Y /0E<9'Y5&-=T\ZLFE>=(+YXO.$)A<'R\XW=, 9XSZT 8']BS?
M] F3_OFS_P#C=']BS?\ 0)D_[YL__C==%JNL6&BVRW.H3F&%G"!]C,-Q. .
M>I.!2:EK-AI&FG4+^9H+1<;I&C;Y<_W@!D?C0!SW]BS?] F3_OFS_P#C=']B
MS?\ 0)D_[YL__C==#<ZS86FG1:A/*ZVTI0(_E.22Q 7@#/)( X[BKN\>7YF&
MQC.-IS^77\* .1_L6;_H$R?]\V?_ ,;H_L6;_H$R?]\V?_QNM6W\7Z%<R(D=
M^HWS&W1I(WC5I0<% S #=GC&<UIS7UM;W=M:RSHD]R6$,9/+[1EL?04 <O\
MV+-_T"9/^^;/_P"-T?V+-_T"9/\ OFS_ /C==%J>L6&CK U_,8EGE6&,^6S;
MG;HO /)["J\WB32X-1;3WFF^V+&)3"MM*S!"<!L!3QGC- &+_8LW_0)D_P"^
M;/\ ^-T?V+-_T"9/^^;/_P"-UTNGZG8ZK;F>PNHKB(,49HVSM8=5/H1Z'FK=
M ''_ -BS?] F3_OFS_\ C=']BS?] F3_ +YL_P#XW73VE_:W]I]KM)EG@RRA
MX^02I*G'K@@BHM.UBPU9)VL;D3?9Y#%,NTAHW'564@$'\* .=_L6;_H$R?\
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M=:L-7-P+&9I?L\K0R_NF4(Z]5.0.1W% '/?V+-_T"9/^^;/_ .-T?V+-_P!
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MC29;NWNS!,D]M#Y$+Q7,L?EQ\?*-K# X'Y5<L=-M=.$WV99-TS[Y'DE>1F.
M.68D] .* ,+Q1H]]?:E87^AZE%9ZW9Q2>5'.NZ*>)BN]' Y R$Y'(KE/$6LR
M:M\,?$RW>FC3]4MKJ**]A#[T,F^+#*W<%=O^>3Z)>Z/9:A<PW-Q')]HA5DCE
MBF>-E5L;@"I!P<#\JK3^%M&N=*ETR:T9[2:3S9D,SYE?(.YVW;F.0.I/0>E
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M;8W5[<P0,);TYN2\KN)3C'(8D=./I0 _1;2VL-#T^SLY3+:P6\<<,A;=O0*
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MWZ -&R*#(>0  O?.=ON#BN0UZ.QVPR7MX\4BO^Y%JNQ6E(VA9)%>1E(7.,D
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MQ5,D#C.,G.202<$]:PC:VC_JWZ&\KWU_K7]2"S1I)+RVTMDDNH"6CA88V'J
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MSGUXK:H QO[+UC_H89?_  %B_P */[+UC_H89?\ P%B_PK9I'+!&* %L< G
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MHK6J&*[MI9UG$IR#&5!!7;_MCG- '+V/PHT_3_"NIZ/%J-RUSJC*;R_< R2
M-DJ!V!Y]3R>M7$^&>C6.OPZIHX&FA;66VF@A3*S*X(R<GJ#@_@*[6B@#B+/X
M<6]C:^&$@U&5;C0)':.?RQF9')+(PSP#G%;47AF*+QQ/XG%RYEFL19F#:-H
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M,,&4\$'T_P :;'\-$M='B@L=?U&VU-+M[U]15@6FE<88NG1A@#C_ !.>[HH
M\SUOX>FT\":U:0W][?:OJ=Q'/+=! 'EEW *,+PJ9/)[#)KT'2[,Z?I-G9-(9
M#;P)$7/\6U0,_I5NB@#A[3X;6UH_BUAJ,K?\)&)!)F,?N-Q<\<\_?_2K;> ;
M ^)]"U])W2[TJW^SG"#$Z["HW>A&3_D5UM% 'GC_  GM&NW@76;U= DN_MCZ
M0 OEF3.<;NNW/;]>];NF^$%T[QOJ?B4:A-(U_$(S;,OR1XV\@Y_V/UKIJ* "
MLV[L=1GN6DM]8DMHCC$0MT8#\2,UI5B^)-;FT*VLYX[5+A)[R&U?=*4*>8X0
M,!M.<9Z<4 +_ &7K'_0PR_\ @+%_A1_9>L?]##+_ . L7^%;-% &-_9>L?\
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MLD0.N1@X(R* ,K^R]8_Z&&7_ ,!8O\*/[+UC_H89?_ 6+_"MFB@#&_LO6/\
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M7[>L,2:?.JR6<BR$O(ASRRE1M[$#)ZT :M%%% !1110 4444 %%%% 'GMG;
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M:M+IODVZ-% $#D?*,%B^=P!R.QSG)/%1645SJK:/_:JC<]N_F*K9!; .1U!
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M08N;AMA$D4I+9/S9)R.-H( KT<6\ E\T0QB3KOVC/YTQ;.U2>2=;:%99!AY
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MRB+2R4"*%@""P&XX+<9Z?=JKK$RO\0=*L-356TN:QF,"2C,<ER&7@@\$A,D
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M'J0#Z5V<5M!!!Y,,,<<738B@+^0IL5G:P0&"&VACB)R8T0!3^ H \C72[/\
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ML(IK)]#@DL8Y@&BD?)$I /!<#9[@?4UB31LNDZ1%<7$HM!XJ,-BYG92UIN;
M#9R5R" ?0#':O5);&TFA6&6U@DB4Y5&C!4'U ITEO!, )88W"C W*#B@#D-
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MCNT[1J,PMCD$8)/Y]*[6.&*%2L4:("<D*H'-)+!%.H6:)) K!@'4'!'0\]Z
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M=O+'Q7::C.LE[!JET+:$W!,\7 V>4N=V21QCKC';%>HI96L2*D5K"BH=R*J
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ME1D+U.0,>U5[BY?P[;^.;+2GD@MK*YM)%BA8EH(9$C,[(.H^4N>.G45Z>UM
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MK>5)8F&5>-@P/T(KDK^TO[_]?U_PQU4/9V]TDHHHKG.@**** "BBB@ HHHH
M**** "LK5M/FG#W=I*%N5A9 CQB17'7&TD8)(QG/US6K2,RHA=V"JHR23@ 5
M49-.Z%))JS/-(KA--G_LJTWPVMQ>%C;RP[+D@1[V< %< X"C(//UP)1J$%A?
MI!<S3FP4A(Y&N9FS(%#JOS.R."N>2%&1T&0:Z?4M=TB>-+4.+IIW"PM%N\LR
M## >:HPI'WNN0 37':I?6]Z%EEA;4YD$:1RQYD:WW@L#Y1 #!E1L_P 6.#C/
M'?!N>Z:_K<\^:4-FG_6Q=OUDUVS6T6:V%M'>F=+EE(VRYSY4F3F-@6([AA@
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MK/1XCJ!5M1N/W]VRC@RL!D#V PH]E% #KK68X=1.G6]O+=WJP_:'BB*C:A.
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M11K!9H"DS-L/DB,!OD&/NYXSUH U3XAM99+2&R22[GN[;[7%''@?N>,.2Q
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M46-U;0VZ!)F,B^67.2NS'._UXQWK)\->$KG0"MA)I.C7=M#<-)!J#'$X0N6
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M!EF=E7S>@;Y 1CV!J]_8VKQ>*-)U>..S9(M/:QNHS.P*9=&W(=GS?=/!"]:
M+#>+[%8;>[$,YTZXNA:)>#;L\PN4!QG=M+#&['OTYK+\:ZX+CP9KQL+2]N([
M>">-KJVD5!%(BD$_?#$*W7 /0]<&F>&/"5SX?6/3Y=)T:ZM[>=G@U G$X0N6
M&Y?+.7&<9W=A44GA?Q'%H.N^'+6336TZ^^TM;7,LCB2(3%F*,@4@_,Q&[=P#
MG!Z4 =AI)+Z)8EB23;1Y.>?NBN&T/Q,/#VF:[/=6>I7=E:ZS=)+<JPD$$8<
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MK2[B"&"WG>1=ODW/^KD'=6X/!&1T- &9J?BE='T>\U*]TN^6&U",P3RWW*W
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M  Y&P#:@"@.-P)/3GM4LTD@T&:5++R;CR")6,A?D1%=P&T;F",QV;OEW'/3
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M'O9@N>3C)..>:X"SUC7O$!\(9U6XT_\ MC3KB2Y6&./AD"8=,J<$[B><C!X
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MA() L;8CC'!4@\D]26X(%;-S;0M\7'D:283#14EB1;ET#,)F&,!@".F5Z>U
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MH ]!K U7Q5:V/A[5-7LXS?)IK21SQJVS#1_?&2.WM6CI&G?V7I-O9&:29XT
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M?ZK<6]K;B2TMF:&:Y\P#;, IV!<<\-R<]1BM.O)#+-HOA3QCJ>GSW2SQ:W+
MSFZD(CB,L0=L9(#!2?GQN%='=:;<I:ZMJ$=Y#:V<NE.5MK&[=MTBY83AQM*G
M'!QUR,GB@#N*R_$.O6OAO19M4O [0Q8RL8RQR><#V&2?8&LWP1IR6_AZQU)K
MJ[N+F_L+9YFGG:09"9RH/"_>[=<#ODENJ07&OZ^]E:S6JV^GPD3BX@,RO)*I
M&W =<%8\]^DM '3(ZR1K(C!D8 JP.00>].KS.WO[ZR^&FMZ.VH+#J7AXFVDG
M9BFZ%2&1@1DKNB^4'J#5N*+?<ZKKVC,8%CTS?;:=#>!@]PH8[VCC<H>"B\YR
M?PR >@T5P/AFWNM7M/#VL17UO&CP?Z5)%=O))>[H^5<87#!OFSDE<$#BN?,3
MP_#2;7EOKXZC9:E)Y$S7<AVJ+PIM(+88%>#G.?RH ]4&I6AU5M+$P-ZL N&B
MP>(RQ4'/3J#^56JXA;6W?XP73RS3K(-)@D11<NH8^;("-H;!'3Y>G/3FNPL[
MVUU"U2ZLKB*XMWSLEB<,K8.#@CCJ"* )Z*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#S6"&].E:A';1LTKO#)#&RS*2$*%R"27(YC.%ZA>*O-<Q_9;=KM9O-
M"[9@'(7=]T*S$Y('SJ6/55YR=M.TO[##I02[$44GV]9HU*^7D;(U9N&/\+]<
MC)(X&<5CR6L?B/Q'/I@80I:6K7/"[1%)D*@ ']T8]CM4X/?TE:3=]D>:[Q2M
MNS5N#<R7]A]G!FC6X2:[ED9E\H#:69E4[?\ GH/FX&S Z50TM-0CM[QM/MF=
M[2XB=+>5CP <[23P/EW+GG!.>,'$FC:A9ZEX?69K;S(Y=C2 N-RJ'42 ^JX
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MP. <Y73;ZZU"ZTBYOH3&SVTAE1AT.T'!&.V2.W0\>C-2_MJY@A_LBS2Y2*!
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MA65]JE6:UGEMHI;B1!*CS:B; SL1@N("6P??*YK>U5(;'PYJ=A#+'./LI(P
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M#'<KH1;6YVY*,R\,>IV;@HSCL*I+Y6HV%['+"EO');%T,, MR L9?G:WSQ\
M'('WQ@\U2WUV_0E[:;_J=%J^L3VP6;2[6_G3R5DEGM$5@R@ Y(?C.&'3YC]
M*A9K35+>Q^PC%O-I]PJH&RQW)GJ1GOGMU&1Z2:AKL6@V]MY-PT!DAC:6.:!I
M_+ 4 D[2&! VY)XZ=R:?:2:?:W&BS6\H6Q6UDP7(Z8 'W?E/& .O;%8)6BFE
M_5C9N\K-_P!7.3OXX[Z34-.4---J=PGV4,%#0Q9_UF<9/.\  ^M6;ZWU#2/"
MMW-=SEKK4+>(+=LP'S[<*@4G/ RN>2=V>,&H-=N%T/41J%M +N\,36EBZ@8@
M8\1GWRN6S_MCUK7\475O=:C#H<OF!XXX;DQE,QQJFXE_7.<+CTKIN_=MMO\
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M1S1K)$ZNC#*LIR#^-<E=U+^\=5!4[>Z.HHHKG.@**** "BBB@ HHHH ****
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MLS&UOK*>&*06H6<*3$R%8QL_U>6^0_>W#/!#'OD5K>RY?Q,K7=_P(]54 :)
MMOY36LPAD3RSD;9[< G!XRNTY.[KCW'H->97L;"?0/.61Y%CMPS2A-P;SH3@
MY/#!67.T9Y';./3:Y\0K1C\SHH.\I?(****Y3I"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBD#JS,H8%EZ@'D4 +1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:[;_ )^(O^^Q0!-14/VNV_Y^(O\ OL4?:[;_ )^(O^^Q0!-14/VNV_Y^(O\
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M_P"^!_\ %T;;?_GK%_WP/_BZF^T?]/OZ?_94?:?^GW]/_LJ (=MO_P ]8O\
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M5);\%I),9'RJQ#8*E@%/&""!G@.TK29)Y"^A^'/M'FL9)-9\0?*)G8[BZP
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MALL=H"J<[3\H/.TD'!HOM,;1K"&:99Q>I$B1R6B,9(E'E^9(QW8)RO0A@I&
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MGD87C Z@'+T[%WX@U:XU!2=-M-.D1)F4JDA+ R,I[\YW>A)'>M*"5]/\*3J
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M!%]H_P"GP_\ ?/\ ]E1]H/\ S^'_ +Y_^RJ7-Q_SQE_[[/\ \11FX_YXR_\
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M=G*/'$(O,CPPZJ!PW<5(_BJ_O8I+G3G0V\;3,VV)6D14V8+HS*=H)8-MRP(
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M[F6ZN[6VG-Q% R!1YF2<L1%D\D\9Q[5U'V3_ *<?_'?_ +52_9/^G$_]\_\
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M7#$I=FP3P!D\#D\ ]*XO6([+Q)KJ+I6I-;7"6^V9E@VK*' 9=SLAW857& >
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M.NH^+K2/*_VD*S*?ILB)Q]0*[BB@#A_L:?\ /D__ ("R_P#R/2_9$_Y\G_\
M 67_ .1Z[>B@#A_L:?\ /D__ ("R_P#R/2_8T_Y\G_\  67_ .1Z[>B@#B/L
M:?\ /D__ ("R_P#R/2?8T_Y\G_\  67_ .1Z[BB@#A_L:?\ /D__ ("R_P#R
M/2_8T_Y\G_\  67_ .1Z[>B@#B/L:?\ /D__ ("R_P#R/2?8T_Y\G_\  67_
M .1Z[BB@#B/L:?\ /D__ ("R_P#R/2?8T_Y\G_\  67_ .1Z[BB@#B/L:?\
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M'KN** .(^QI_SY/_ . LO_R/1]C3_GR?_P !9?\ Y'KMZ* .(^QI_P ^3_\
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M\0_%K2?#WB>?P_+I>J75[%MXM8D<-N0/P-P)X/I0!W]%>;_\+AM?^A2\3_\
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M"3Q_7T7POX>A\+Z!!I,$\LZQ,[&67[SLS%B3CW-5].\':5INNMK,9NYK[RC
MDEQ<O)LC)SL&3R,^N:VY[F"UC,EQ/'#&.K2.%'YF@#D/$=K%;>,;%Y 4M->M
MI-+NF7@B0*7A;_>QY@'U%<QIUW>P^&4A,BV#Z3<202WL(>3R55E+N1@\ F1=
MC'& #C!!'8>.W27P3-JMJRS&P>+48'C(8'RG#D@]""H8?C7,3Z=YOC?5E6^\
MFQEMUU&/+G*D[260@Y1B5?G:V>?0@@'3^%?$E[K%Y=074#LG$L,RVS0JL952
M 0YR<DMAL8.TXKJZY;PA!IVRXN1<1W.JI-+!<S,A21,N9!$0>< ,.W.,UU-
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M\._]^6_^-UT7B;Q(W@_P-)JFI20R7T4"H O"RW!&,*..-V3] :YW_A3.E?\
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MG2I'*@<2[\?=)'W@@X)H W/#6KZKK/Q&\3)/=B/3M+$=K#9!>K-\WF$^O!_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0O;S;SOD:93Y!=Q(<C=V9LX*@C<,DX%;.H6-OH'@S4TO(9$G\D,7\[S0?G4
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MI H(LKMA@2GMM?@'/ 8 GJ: -?7O%5MHDT=K%:W.HZ@X\S['9KOD6,?>=AV
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M;GRY]Q!3,G*[ N5*DYXXY(IUI)/X<MK>VN+U#;VRR-;6@C\N3!/WI&RQ11N
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M2,%51ZDGI7+>&_'UAXK\07VG:5:W,EK:1!VOG7;&[$C"@'GD<@GK@T =;02
M,DX%%0W=W;6%K)=7<\<%O$NYY96"JH]230!1E\2:' P235[$.PRJ"=2S<9X
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MC0855'  '85B>#-+ETOPS;"[YO[HM=WC]VFD.YL_3.T>RBM^@ HHHH ****
M"BH9[NVM6A6XN(H3-((HA(X7>YZ*N>IX/ J:@ KSJQL3XL^+%UKDGS:9X?7[
M%:]P]P1F1O\ @.['U ]*TOB/XKG\.^'Y8=- ?5;B&1HAN \F-5R\I]AP!ZL0
M*O?#_1O["\"Z59N")VA$TY/),C_,V3WP3C\* .EHHHH ***QO%NMKX<\)ZGJ
MQ(W6T#-&#T+GA!^+$"@#D;C5V\?^-+CPU:QC^P=(E634I]W_ !\2*3MA'^SN
M&3Z[#^/H]<A\-?#)\,^#K:*X#?VA=_Z5>,_WC(PS@_08'U!]:O\ BGQIHOA"
MS,VIW/[TJ6CMHANED'J%[#W.![T 5/#LOVCQQXOD4?)'+:P@^I6')_\ 0JZN
MO-O!^G>.SI<]Q))I.E_VC/)?.9H7N)]TAR 5W*J@+M &21C\MVRU/7-'\0V6
MD:_/:7L.H*XM;VV@,)$J#<8W4LPY4$@@_P )&* .LHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /.(M0:/3[R5X9+\VDT;)!&WF[FD15!  7)55?Y/5NIX-2_P!E
MKJ\,8N[=0R/)<()"69 CD'( R2.HS]X[P?O4ZT1+G0[B0;KAVF\L6PD8M(52
M-@5,@X*E21G*<D=",+<R"+2D-Q=0V<IV)Y=P2S+G[DFY5 RO. @" YY)KTKZ
M^[HSSK::ZH6X+1W-O9RV,D\5ZR1EH6)6U0A1&V0<9Y^]SN*'U-5+!]4NTU"^
MM(83>P7$<K#C:[#);!&3@@,F?1O3FM&='%[%LMUEMHF+K? *(T(/+!=I;@Y)
MVG9GG*\BJ6V?3?[36VLA<6EK=1A8">'0-R#D 'C=C.1G'>DGI;^MP:U_KL7M
M3-WXB\(:A<:E;+81-;?<C_?,<,K#K@$_*<=ANSGKC-MBT,D.G17EUN*%"EE>
MK!'$RG81'&<D@-\N3@9%:>H:E%>^&M7FM+"2RMU@*2)(JQLSG;QM&=K8) )]
MB1C&>?UKS4@<1W$/VOS%2:.%7+NQ?#!/GZEP06VJ"0Q7G(+IJZY=E?\ R"H[
M/FWT-+5WN(;2T@AM"L5M(SM=6S>1.DFW.Q^H0OGER2K>V14&DW<;P1K<6MOI
MSR>8)+2&(['6,B-C*N\*>W #$#N<U-X?EC%I;+.)DU>W$S7\NW:%7)P&8X 7
M."%(.,'BK**S7<SPW$4=S)*GFEK:Y2(OE1_$^S=R!DKP<9%#=KQ!*]I(W;'Q
M582#RKE&L=K/&K2X$<C(=KA#GD*>,D"M^O,;0?:_).E3WK.;:6'4X1@L0&.\
MQM*#AMS<@<'(/7KWFBBX^S,TLET\+8,/VK89 N!U*]1]>>OM7-7I1CJCIHU9
M2T9I4445S'0%%%% !1110 4444 %%%% !2,JNI5E#*PP01D$4M9FK7EPB/:6
M43O=M$7!5U78N<9RV>?P-.*;=D*325V9NH^%=(A4WL2K:"$[UB!(MP2-IS$#
MC+*2N0,\^M<IK&GQRO')<SQ:?.S"9$4.)+I\!/ORHB[@I^[C/=B.HL".6^EM
M=4BED>UM;[;)+=,6N%4H%*80'(5OF&>.A]ZACT^SGMXX1?VTL,HCVN7,K%PI
M12L9C&!\[GDYR02W'/HTU*.\K_UL>?-J6RM_6Y=T?,>D_:([I[F8W$GE6:KB
M:V/'RQD @ #&008SGKCK2UE[K3M*O)3:7,.X,F^[\MMN1M*)]G#88J2H9S\H
M.!@&K-VTWA^V6:.QA;2WNOLIA63$D\G*AI' X 8;0H&!CTQC/L);>/3)[I7M
MI9IX)$:*WA =R4.4P!ECOP23PNS@X.!45KS=/ZT)D].7K_6IU$MKJVO0QSV.
MJI8[8(V2(1&12Q16!^;'&21NQGCL0:HQW-Y>IH=Q>KY;E5$RL3P-R;@><\?,
MISGH<GUM:G;ZYJ<,0TY=.N5@B3<]SUD;:K<8!^]D=>..0<\10ZA;:H-)NKN,
MP6\UG(C(?[KJN  !R?F XQSV],8WM_5UI^IL]_ZL]?T,_3Y[F5[JUOK(QS2/
M*L9E(Q(0RA@V,?*0[$CG 7<.>:N7TD*64TEJC73N^8DF(S+\K99MP^\"F"2/
ME0<8SDT-6OC%8H;9S->S+%:1/-(9 [G;G!/4?,OU'F4EB1H>L76CW<S70MME
MU#,S?O&B8?,<^V"?JJ5IRW][\/Z_K<RYK>[^/]?UL5K_ .TO<>'#/#(DG[DR
M+\S;?WT8!8I@9VA,[ACIQG%>IUYEJZPM-H+*[RS/?F:4R+N96:>' )+<87"Y
M&>F,=<>FUAB7>,?G^9T8?XI?+\@HHHKD.HJ:I?#3-)O;]HS(+6!YB@.-VU2<
M9_"N=;QE<1*L<VD!+J4Q&WC^V(4F20D!@^,<$#C_ &AZUU%TBR6DR.H9&1@R
ML,@C'0UY/8)=W2Z?& "8/L,D&1G='Y5MYR?@3$_X&LYR:>AW82E3J1?,MOZ_
MX<[,>--VFP31V >[E>8&#[2@2-(F*L[2GY0N< 'N2*5?&+&QD<Z</MJO$$@6
MY1DE61MJNL@^4C.0?0BN9:*/^R-+3RUV-8+N7'!S=PYS]:OZ-I-GJ=W+8W$;
M"W$<Y58G,97;>RD8*X(Q@=*A2DW8WE0H1BY-:7\^_K_7<OS>-;V"T-R='M7C
M\MY5\O58F+J@);:!][ !Z5TFHZBNGZ)=:F8RZV]NTY0'!.%SC-<'IGAS3-1U
M)-,N(6^RVXOA$J2,A4"XVXR"#C:2#ZYKT&ZB0Z?-$RAH_*92K#((QT-7!R:=
MSGQ$:,9145Z[[7]6<V_C*YB"Q3:0$NY6B\B+[8A299-P#!\8ZKC'N/6F)XVG
MFCM_(TJ-Y9$G=U:^1%01.48AB,,.,Y':N3L4N[J33XP 3 UC)"2,[HO+MO.3
M\#Y3_G6C<0VJ^%-&:5"D9TR\\QHD&_:8B6QZGJ?K4*<NYURPU&-ERZOU[-]S
MH;/QB9)O]-LH;:U\B6;[3%>I.N(]NX?+W^84V#QE)]J1+S2_LT!95D?[4DDD
M&[A3)&/F0$D YZ$UR]G;Z?'X>\1M<):QZR(Y55"(4G$/EI]Y(R0/FS^E0ZG!
MYFL7+BVM3Y4]Q.7D23=*!<*K+N1UZ90X(-'/*P+"T7)JWY_AKY_\ [*]\721
M:A+;66G)<I'(81))>)!YDH^\B!N6P2!QWXIEQXS^: V-BD\4D*REY[I+?8S,
MR["&_B!1@1[5S5W%')<7#/&C,DURR%ADJ?MZ#(]*MWFAV%UX4N-5FC=KJWGN
M1&?,8+Q<RXRN<$C<V"1QFCFD]B?84(J/,NMNO^?^1JR^-;BU,_VO28T$,4SM
MY5\DI#1H6*$*/E/'>M+1/$$VJ7\]G<6*6TD4,<X*7*S!E?..5Z=,_0BLK1=
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MTL,]WLDWI<LI3 ("J=RA6&> V[)'8=_110 4444 %%%% !1110 5R7Q*+_\
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M3O!FI,S=&O;B"!5^H#LV/PH ZFBFQ%S$AE"B3:-P4Y /?%.H **** "BBB@
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M[I>A^>4A8T//3)([BM+2_"VK:;']FT.UT;PW9.H+/$C75T3Z%FPN?KOKN:*
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M7FH21Q^2AZE45F9FQG'09QS7<T4 ,AC\F".+<S[%"[F.2<#J?>GT44 %%%%
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M?-\V6[N%BL=H(8*#N+ON/"CD9 _IAUPFHV7AR^NKZ-&U"\LXS'($S$@ 550
MC.['4D]=M)K<MMX<U:/5WA>:XCM7MK$0\J) 2%+#W^=AQWK7\5W5I>36F@RN
MPD0P7$<84YB50<N6QC';K^'-=5W[J2T_RM?]#FLO>;>O^=_^"4[A/*@T,),T
MB-<J =S9&);92#@8."IX.!^.!7IM>>:RT.SPZL+%B)P9 @=@KM/ S D' &6[
MY'0=2*]#KCQ#O&+]?S.R@K2DO3\@HHHKE.D**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K)U?4+J"ZL+"P$(NKQWQ+.I9(T
M1<L=H(+'H ,CKG/%:U4M2TNWU1(A*TL<L+^9#-"^QXVP1D'Z$@@Y!SR* .5G
M\77BQVL4-]ILKR7CP/<V]I+<+M$6\?ND?<K9XQN/'/?BS_PE-U9ZGIT-X(IK
M&> O/=+;R6YB8R;$)C<DA<X4Y[D'IFKY\)69*2"[OUNA,9S="?\ >,Y39R2,
M8V\8  JVF@6GS&Y>:\+V[6TAN6#;XV.2#P/I]* .8C\7ZE=7,40FMK4&RCN"
M1ID]WN9I)5(_=N-H C'7KD^E.O\ Q=J-KJ>H6L4MH\MM<QV]O:?89B]TS11R
M8$@?:A)=NH. ,GUK8M_!]E9"$65[J%KY=NEMF*?ED1G9=V0<G+MS[U;E\.V$
M]G?6THE<7LJS2N7^82*B*KJ>Q'EJ0?49H H?\)4H\:?V.3;_ &;_ (]]V_\
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M,KM]H:%I5W?*WE-N0$>F>H[TUO#NG'5$U!8C',K(^V,[4+('"DCUQ(P_+TH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[\<<-U'!J_+:6'A/3X+VSMH9'E4/=16L/FQ7(R/N;S\O&3@$@<C%5=7W;O\
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M\H'!!R/<#)XYZYK*^PW.F6WVF'Q-IMWI_/E1W.8I%!/(5N6!S@9^][BH3O\
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M!K=GI-N,^=#&C2W:C/1U^]G@'DDCUJDW+6]E_7;_ "):4=+7?]=S3GTCPS9
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MS,^2;P[!(K32F-P5";KTC.TDCK$!P6/YUIV6E>%;F*/RWU$1X 0B16W +L&
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MO/;<R)P%!(1N<X&<[N<^N*O7D\L%U9VMMJVK7-Q=1_+%'(Q;.W!)Y(!7.3G
MSCKR [4IGTRT3S=8U3[4TOE^0LC,Y<D$* "<Y ...F[.".&F[JW7U!I-._3T
M*I\*WE]I26VM75S>6MF3)NGC\I!C(X.!)TS_ 'A[=,7;.PT^PL=T4$MJA<1H
MXMRJ(N0K.SCOUY^3..1Q3KSSK/3);O4-6U*T:%0[PL['<"#CG/J<8]0!Z96V
MBF2Q%S=ZGJ5A&8C(D,C,/E!4'N-O8_\  C^$N4FM7H-1BGHM15EOS.T3VMRL
M$! MIXXX@FPYRVX87' /7!!Y7N)7-RK3 1&2VQ_H<:/M#@JWF!"V/X\  '.P
M_+67I>E6NHQC4Y9+JWAE??%<2I@R'#$,#PW(Z'O@?C+9^;K$=QNOM4DT]6\E
MYW8^7G(4]2,X/4\CKUH:5_0:;MZDK3ZC)->RWMM)9V\";;=F1%:?Y01'M ^;
M.6 49 (_B[T]8\.Z;J-XD,UG(9)L^3<>2\3<$  @XSU ^\B_,.!THL+5(]:N
MH=*:]D^S@>?)""@"Y+!<C&3@\+GH1G!S5BX$IU&WTZTU34[^X>+>DBNW[M2N
MWS"1T&3U/4CI5*\9>Z[$OWH^\KC[ZU\0L]O%'</;V\!13"+=AO )R"4P@!P.
MA) /6H8[:6Z@F@DT[3!!Y3Q1!YXRT)8]Q\N<#/.<Y)YJ?4+B2QEM(TU35;B[
MN6.RU5FWY#98<$CC:0?0'KSFDU&5])T]7N-9U0W1?R1!O8R%R, #!P3\ZD<>
MGH123=DD-I7;9E7.D7]]-*D<5C97./+2>QW.RHSEMI"-CN>=O' ]:N7/AR2_
MLK>[\1-/>?95"H]PHB#%B.,*N_.<##*>O:KEQYUIILD]]K&I6DL2"5HWE.=I
M/7KVV," ,\GKD410W-Q8BZO;[5;2)XS*L<KGY\=B&;@G<".G3M@T_:2W3_KR
M%R1VM_7F$%CI\5O9J%DA2;@%H#'"%VDK\W*_-@#DE?\ 9[4D-UJT\KR7^FB'
M8[P[Y@B1-$-NW<W (.2,#=TR,$8:/3!<:I9^>-1U:'3WRBW3NVUA@#=AB/E^
M7@XZL>/2K865M+J%Q/8->1PV;E9;N&,@*=Q+ 'J>OS 'HOYJV]QWVL;$K7(.
MZ6VEFE+@1Q2<NT(9=AP2-V 7)7KN"YXJO!+=W)EGU));.>2<0K$T2N;B/=C)
M0+DE1AMQ4=<<=:@EA;4=8FT>.]U&^CC7]_DL8T!7 W9/4XR.>^>E-6&"PU>.
MSTF]NYYKH"9HK<,@"$@AVQ_#@A<DYQQS225K=1MN]^A#<>'-/O\ 5XRUDRW^
MY7B=D*%P,L"4<\_=(.YCT/!QBIM0M]<GU%9KB2:2T7(>R:-XQ( O0OPG<\@8
M]<TNHEK(6L0U;4[B]GS!'&KGS0PW*<%202""3_#QGT!FOI9=+M3=7FJZFLRO
MM^S&1OF)*D8P<MGA0/\ :.1P2*YI::W)Y8Z]")+>2[@:6;3]+DG18TMY6GC(
M*K_"R_* .W Z8]!67/H^IWTGVJ!H+&\5@LDUBCR[]B\#"DC(X_A&2*W$2YMM
M-DGU'5]3M&$7F*)I&R%PV3U'(SDC!QA<9[IIZW5Y8)<W&IZM:1S9:%I68,^
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MG-06@DF@A%YYD-U.#)+9K;^88FV_>VIR@.".H)X.1R*J:W;PVVGI)J5_?2W
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MS/9EYOM1A.TPF[5!*5P/O;>/Z^M<U:DHZHZ:-5RT9JT445S'0%%%% !1110
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M(56.,+C<^""<#'4Y/I8>[T3^U-/O$U%_MULSC#PR(9'D!+*05)!.<[<9P!C
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MWL>CQI%+%>&T0("K"'8TJJ".0OF,V=I!(7 R:?(D]6[_ "_R\Q<[:T2M\_\
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MO9<C2=_ZU["]KSIM6_K3N:6JW^A:I%)'J-R\<SQ/"@^S2C"'E]N5&\8&21T
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MBO$@"Q?*4C>-I=BD8P#,2IP1D+@<XINFDVFW_7R$JC:32-#S]$&KV-]!?/\
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MB0PLQ^8E3*@<?-\VT9 //6II+.:9HK74HD8)=VML"-S%DD4&6([LL%R@89Y
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M=DD(:(EP7VQ_-\V!E@#CC@ YI\UK>&YBM8WN/M.Q6^TX*L81<LPCSCAPH!(
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M53.[))R..*EGL'EU%;YK=A=2-&MS''#(3%& F$4)G;W8;@03D$\8H3CHWO\
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M@+L(_G((5BN#@D?A1IHD]/Z_I!KJVM2./Q(W]EPO)9PRWKN9YY6W>5)&Q"8
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MDCIA3S7;:KH\5QX8DTT1HRI$-JA, E<'@+TSCMTS5RQTY;-Y9&FDGED"J9)
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MTL=M\JRW=RTQF.G)*%0@L^<MC.1Q@#G@5ZM5&ZTN*ZN#*9'0.$65%"XD56+
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M2TTV:Y:(1O?/YS1DER@VA0N]N6'!(S_>K@=4TV'2=?-K+ +J.WNO,@LF9O\
M28Y 3\BD[0(QE>!CU P:]?JCJFEIJ<4(,TMO-!)YL,\6-T;8(SR"#P2,$=ZJ
MEB'&;;ZBJ8=2@DNAY_X/TRPOO$,5ZMO9F599;P[&8RP<>7Y4BE1@[B6!//R9
M[DUN>-=&,J_;X7DC65?L]WL9U&TD$2ML(R5P1SQAN<8KIM-TZ'2[,6\+.^7:
M1Y)""TCL2S,<=R2:MD!@00"#P0:4\0W5YUT"&'2I\CZGBVFK;-8)9PV,POBY
M>2]4HD<L&T!L9VG;ME'T'<#./1/!$KG1[BWD#QO;7+Q"!WW^2N 54-W&""#T
M^;CBIY?!VDL(S;K<VLT/$$L-P^Z$9SA Q*@'TQCVJ]I.DC2TFS<//)*5)9D1
M,!5"@ *   !6E>O"I%I$4*$Z<DV:-%%%<1V!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit41rnacspecimensto002.jpg
<TEXT>
begin 644 exhibit41rnacspecimensto002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]ND\FQKB7R8A@G<^"<<>RG\J +%%%4GUC3T"G[4C W(M 4RW[W.-G'?U].]
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ME9W1/W,@5RN=VUBN& P>02*V: "BBH;6ZM[VW6XM9DFA?.V2-LJV#@X/?D4
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MS6W#IEE;R220VL4;R1)"S*N"47.U?H,G'UI]O9VUI91V<$$<=M&@C2)5^55
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M6U@T)M1O;BT/B/[/;R^>=\D$48ED#-_'M=64,<G('<5Z1J>BZ;K,<::C9Q7
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M%,JAC'(CAU.#U&5''<5B7G@VYUF+49-8U99;RZL7L87MK?RH[>-^6(0LQ))
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M%&<CD T_0_#-SH<;"#4(4-Q>M=W:0V@2-@4"[(UW'RQD*2<DDY]: .DHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "H;NZBL;26ZG+"*)2S%$+G'LJ@D_0"IJ* .9M_'_AVZNS:PW-V\
MX949/[/N,J6Z;ODXS[TY_'GAY)IHA<W4C0R-$YBL)Y%#J2&&Y4(."".#6?X6
MO(X=*\3>))N8Y[^YG#^L4(\I?TB/YU1\&Z7XHMO"FF>5KNEPI-$+EHI-/9W5
MI29&!;S1DY8\XH Z^+Q!I<NI6FG+=8O+NV^U0PNC*S1^N"!@^QYX/'%68=1M
M)]1NM/BEW75JJ/,@4_('SMYQCG::\^U6UN-1U_Q)XALE,EYH<MLEGC^/RD,D
MT8_WEF9?KBMSP)<1ZN^O>((FWQ:AJ!6!_P"]%$BQK^JL?QH V=6\2:5HL\5O
M>7#FYE4M';P0O-*RCJ=B MCWQBGV_B'2;K1Y-6BOXA81[O,F<[!&5ZA@V"I'
MH<&L+PH\)\2>+KBZ=!J"WX1MYPR6RQH8OHO+'ZDUDZO=:/J+Z%>P1"/1;S7"
MUY,Z[8[B1$98W/8H71,$\' H ZG3O&&B:I>Q6=O=2K/,"T*SVTL(F Y)0NH#
M^O&:O6VM:=>:O?:5;W*O?6(0W$04@QAQE><8.1Z5SWC26.\O_#^DVQ634FU.
M"Z55Y:**,[I)#Z#;E??=BN0TG5O[%UNX\3&-ICKOV[[/$OWIG2>..!!]1_C0
M!ZA#K6G7&M7.CPW*O?VT:RS0A3\BMTR<8R?3.:OUP/P[TN2VU?Q+>7$HGNFN
M8[:>?_GI*J;Y"/;?*5'LH':NIO\ 4=4MM2@M[30Y+RV?;YETMS&@CR<'Y6.X
MX'/ H U:*YOQ?>RI#8Z7:M>"\U"?;&MI(L;LB#>X\QON# ZCYO2N2T^^U*6P
M\1Z=;:FUH[7L5CIXN+][C$^P/+&)B"P)''?:<XH ]1J 7EN;UK(3(;E8Q*T0
M/S!"2 2.P)!_(^E<UX*E9I-5@D;489;>9(Y;&]N3<_9WV!LI*22RL&4\GC'0
M9KE=2FNK.^\4ZYIL]P+NXU*WT>!VN#LC!V!VPQVC#2.%R,*3]<@'JU%>6W&H
M:MH<'B$127,0ATS'DSZF;N1+J1ML3 GE,Y/&<<# %7[F>3PIKL+W&KZC<I:Z
M+/=:BTLS2K(5*+&5C)VJ<[\8QGN>IH ]#HKS"QNM3TKQ7HT=W-?QF2WN+J_^
MU:EY_F1)']XQ#Y(_G*XVXZ$<T[3%U067@R]GU74)-3U2[$LD;7#>6MNR22LA
M3.TX7:,D$@XP0 !0!Z-#>6]S-/##,DDENX295.=C$ X/O@@X]Q4]>4Z3:S-X
M9,NF:A.-0US49KM+>6^D1KF".1AL23DHQC"?,.3@<^G8^"9Q<:3<E9K\B.[D
MB-O?2>;);,N T?F9.\ @D$D\'VH W8;V"XNKFVC<F6V*B4;" I8;AR1@\>E6
M*\TM+[4];O=,MXM4NX(M1U6^NBT4A#+:0YB5!Z*25/U.>M='X*,IBUI#<W,]
MK%JDL-J;B9I65$"JPWL22-X?J: .HHKSZ)VUA+W5K[Q!>Z=.-6>QL4AF8)'L
MDV*AB!Q(SD$G<#PW8"J-[>WESX0O_%)U6]CU4WDD6GVL5PRQHRS&..$Q [7+
M;?FW GD],4 >GT5Y?KTVH7EGXLU:/5=0A%O>1V.FP07+1HLP")NX^]F1R,'@
MXY![/UNYOM OM?%KJE_<21:*I<S3LP^US2%(F5>B'Y3PH Y% 'IM%>>1Z5<1
M>+/[,F\0:N]K;Z0)]1<WCCS7+X0@@_N^$<_)@GN3SFMX9FO]>71],U+4KZ.V
M32%U%RERT<MQYDC! TBD-A$ S@C)89H ],HKS'2K[4M;N-$TN+5KT6INK^;[
M4DF)9[.)O+CW-WR7'S=3M!Z\UT_@=YGL-3W7-Q<6R:G<16C7$K2L(T(3&]B2
M1N5\9)ZT =/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 55&I6C:LVEB;-XD N&BVGB,L5!SC'4'C.>*M5R.@S12>-O%]Y/(B- ]O
M; .P!2-(M^X^@+2-S[4 ;%[XGT?3H]2DN[T1II@C-V2C'RMX!7H.<Y'3/6K5
MUJUC9V]M//<*L5U+'# P!8.[G"@8]?7I7FL2C6+:W9EWQ^(_$OV@!A_K+2 9
M4_[I$"G_ (%4U@9$\3:)X/N"2NBWD]VK,?O6R1_N&)]O."_6,T =Q=>*=&LK
M:\N)[S$5G<K:3%8G8B4[<(  2Q^9>F>M+I?B;3-9N6M[)[II%0N?-LYHAC('
M5T [CC.:\XM([S5=-\,16<L4%YJ^K76ML\T1D550LR94$$CYHNX[5Z7I,&MP
MF7^U[^RN@<>7]EM&AV]<YR[9[>E !JVOZ9H8A%_<E))B1%#'&TLDA'7:B L<
M>PING^(]*U2SN;JUNLQVN?M"R1M&\.!GYD8!EXYY%8&G-))X^\6./);4X8+>
M.Q2X8@"$Q[LC&3M,A;) ["L#4M8NK[P]XQ:2TTZ._9X=(%U8NSB=Y %QD@9V
M^=C\Z .UNO&>A6:632W<I^VP"YMUBM99&:+CYMJJ2!\PZXZTC^,]%2Q6]:6\
M$#.T8/\ 9]QG( )^79D#D<XQ^5<Y;V.JW/CS4VT.\LK6+2K*VTU?M-JTP.09
M"!M=<8!3/7MZ5M>)[R_TCX=ZK/>3PSWXM9(Q)!$8U+O\J84LQ'++W- %[1?%
MFC^() FF3SS9C\T.UI+&A7CD,R@'J.]6QK6G'7CH8N5_M(6_VHP;3GR]VW=G
M&.O;.:?I%@NE:+8Z>F-MK;QPC'^RH']*\TFU"'3O'=WXNNF*VB:A-I;$#)V1
MVN[ ]<R(P ]: /1Y-;TZ+6X]&>Z4:A)";A8-I)\L'!8G& ,^IJO%XJT28:5L
MOT_XFV[[#E&'G;1DXR./QQG(Q7FA:\L;OQ?X@O@1JD>D*KKG/E37!)2(?[BK
M"ON<GO6I<>&GU'5#HUHX2;P_H5O':R?\\[HN'5O_ " N?9C0!Z*=1M!JHTSS
M?],,!N!%M/\ JPP7.<8ZG'K4.LZWIOA[37U#5;I;:U0A2Y4MR>@  )/X"N5\
M$ZF/$WB'6/$'EE MO:V2H?\ EFX0R2I]0T@!_P!VLSQ#)>^+-:U".VT6[U+2
M=/@GLH7@EA5&NW0K(Y#NI.Q6VC /):@#T._U.RTS3WO[VYC@M4 +2N<#GI]2
M>P[U0TSQ5I&K736MM/*MPL?FB*XMI('9/[RAU!8>XS7'6U_'JO\ PKB:^8?9
M)8'E8.?D:Z6%0@/N#YA'N*[*2\TF[\4P6)B$^IV<#3B15R+=6PN">Q;L.X!/
M:@#/_P"%A^&O/\C[3>>=MW^7_9USNVYQG'EYQGO72Q2+-"DJ9VNH894@X/L>
M17+Z+_IWQ \27YY2TCM]/C;TPIE<?G(OY5LZQ?:C8Q1-IVCR:D[$AU2>.+8/
M7+D9_"@#2HJ)9MMJDUP%@)4%U9AA">V>G7BE:>%2X:5 8QN?+#Y1ZGTH DHI
MGG1;MOFIG;OQN'W?7Z>](L\3% LJ$NNY &'S#U'J.: )**C6XA<1E9HV\S.S
M# [L=<>M N(2%(FCPS; =PY;T^O!XH DHJ/[1" 29H\!MA.X<-Z?7VH:XA02
M%IHU\O&_+ ;<],^E $E%1M/$I<-*@,:[GRP^4>I]!Q2^=%NV^:F=N_&X?=]?
MI[T /J&ZNK>QM9;JZFCAMXE+R22-M50.Y-.6>)B@65"9!N3##YAZCU%<EXXE
M@G_X1Q+B1&TJ;5HQ<MD%&PKE%;MM,@7KWQ0!J:=XPT35;V*TMKF433*6A$]M
M+")@.24+J _'/&>*W:P]7U+1DU6RLKV,3W<0>]B"KN, C4YD;^Z.2H/<G%<M
M9ZM>OX?\%V<FH3?VCJMPM[.1*2_D -.P)Z[<;4QZ'% 'HM06]Y;W3SI!,DC0
M2>5+M.=CX!VGWP1^=>>V=U<GQ'97=SJ5Z]KJ=Z\FGW]M>,]M-#AG$#P$@(0@
M(W $Y&<@U1\-6\K6FA6<5_?6\7B&:[U"YE%T_F.BG,:*Q.5+*ZEB,,0AYH ]
M7JA=ZS86-R]O<3[9DMGNV0(S$1(0&;@>I''4]JX%=1O?[3F\/V6J78TRXUE;
M**]>8O+&JVYEEC61LDG<NT$DD9(SP*IW"R6^K:^-.U.[E9KJQT6TG>X:1X2S
MAYE$A.XX#'J21C':@#U:*19HDE0DHZAER"#@^QZ4^O)_$FK7]S97^M:?-J2A
MKP6FGS'4/(C602"+"P+GS!O#$[QDC/05?UJ>YNX?&NJRZIJ$5GIJ_9[2&VN&
MB'G)"&+94@_?<#'0XY!P, 'I-%4K&5H=-A2]N$:YA@3[0Q8##;>2?3)S5HS1
M!BIE0%5WD%APOK]* 'T4P31,RJ)4)9=Z@,.5]1[4BW$+^7MFC;S 2F&!W8]/
M6@"2BHQ<0L%(FC(=MJD,/F/H/?@T?:(<9\Z/&_R_O#[WI]?:@"2BHVN(5#EI
MHP$(#DL/E)Z ^G44-/"GF;I4'EC+Y8?*/4^E $E%,,T08J94!"[R-PX7U^GO
M0LT3%0LJ$NNY0&'S#U'M0 ^BHUN(7\O;-&WF9V88'=CKCUJ2@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBH;NUBO;26UGW^5*I5MDC(V#Z,I!'X&@")=+L$TQM-6S@6Q9&1K<(-
MA5L[AMZ8.3GZUEQ>!_"D$J2Q>'=+21&#*RVJ J1R".*YKPQX<TR[U'7KZ62_
M^R6>HF"U5M1N"J")%WD_/\V7W=<]*QO#IL-5TF/4-5T?Q5=7=[+)<&6"2X6+
M:[LR!=L@&T*5' H ]7M[2VM/-^SP1Q>=(99-B@;W/5CZDX'--LK&TTVT2TL;
M:*VMTSMBB0*JY))P![DFO/=3O[K2?&LE]:W$RZ/H,-I9W<#2,RE)=VYSDDDH
M#"V3S@'UKH_#D\M_XF\3WAE=K:.ZBLH4+$JOEQ@N0.@RTA_+VH TM3\,Z'K-
MPEQJ6DV=W,@VK)-"K''ID]1[5=FL;2YL6L9[6&2T9=A@>,%"OIMZ8KSF^N+;
M5/&^O&_L->OK6T,-I;C3FF6-&";Y,^6Z\YD Y]*?KMK<&RT'2/#;:AIUQ=3S
MWZK=32-(##&=JOO8G:7,8(SC!H [G2_#^CZ()!I>FVMIYGWS#$%+?4]34B:-
MID:6:)I]LJV1)M0(A^Y)&#L]./2N5M=9'BKQ+X>-N\L5M_9D][<Q*Y7#,5B"
M-CNI\S\5]JHZ9X5TR^\::Y:[]1^P6$5O$L8U.Y_US!G8Y\S/W2@QG% 'H%M:
M6]F)!;01Q"61I7V*!N=CEF/J2>]34B*$147HHP.<U2NM:TJQNXK2\U.SM[F7
M'EPS3JCODX&%)R<GB@!VI:3I^L0)#J-G#=1HV]5E0-M;U'H:@/AS1382V']D
MV0M)7$CP"!0C,  &QC&0%'/L*;XAU=]%THW4<=N[F18P;FY6"),G[SNW0#KP
M"3V%<Y;^/I'T?7;K[-9WDFE>5^\T^X,L$H?ONVY&WJV < 9YH Z[3],L=)MO
MLVGVD-M#N+%(D"@L>I/J?>H#H&D'[<#IEH1?D&[!B&)R.A<=^M5/#>L7FL0S
M27$5DT VF"[L;GS89P0<XX!!4C!!]1[XYJ]\67VD>(?$FHWWDMI6G+!9P0K<
M%=T[X8=0%!(D3<2?E"]^: .OMO#VCVEB;&WTRUCM3()6B6(;6<$$,?4@@')]
M!5F73K*>6:6:TADDFA\B5G0$O'R=A]5Y/'N:XZW^(2*FJ"Y?2KE[/3GU!6TV
M]\]"%X,;' VMDKCUS[5?LO$NJG5[&TU+2H+=+VREND2.X+2Q>7LR) 0%&=X'
M!X(H U+;PMH-FA6WT>RB#1O$=L*Y*, &4GN" !CV%7_L%IYEM)]FBWVJE8&V
M#,0(P0OIP *X_2?'<M]KNG6$RZ2POS(!%9:@)YK8JA?]Z -O1<'!X/KUI;#Q
MKJ=Y;Z-J#:3;Q:=J=Y]ECS<$S$$OMD"[<;<+GKG% '0'PMH!L/L!T>R^R^:9
MA$(0%5SU8>A]Q6A9V-KIUHEK96\5O;Q_=BB0*H[]!7 V7BO6;'1]7UN_CMI(
M)M5-M;,9W\FW16\IF8[/EC!0G(');G%=AH&HWFIV+S7EO;QD28CEM9Q+#<)@
M$.C=<<D8(Z@]: +-MI6GV;0M;64$+0Q&&(I&!L0D$J/0$@''M4UM:6]E#Y-M
M#'#'N9]L:@#<Q+,?J223]:X!/$6KZ?=>)=?^R1W&D0ZB(&\RX8.(XPL;&)<$
M<-O)R1DY%;MYXN-DFMH]IONK&ZCM;6!7YNGD1&C'3C)8@]<!2: -== TA-5.
MJKIEJ+\G)N!$-^<8SGUQQGKBFKX>T9-4.IKI=H+XL6,XA&_<>"V?7WZUE^-]
M0U33_!LSZ>8H]1G,5LC!R-CRL$!0XY(+#'2L&?6-=M?$.N7<$%O+'H^EP).)
MKMQ"'"M+)M^4EF(*#) XZ^E '<_V5I_D^3]B@\KS_M.SRQCS=V[?C^]NYSZT
M2Z5I\\DLDUE!(\S1M(S1@ES&<H3Z[3R/2N2O/B%&+Q+.V;2K6=+6*YG_ +4O
MQ %,B[EC7@EFQR3T&1US71:=XAM+[PI#XA<&"T>U^U.&Y,:A<MTZXP: +S:?
M9O)<R-;1%[E!'.Q09D49 5O4#<?S-5;WP[HNHPV\-[I=I/';KLA62($1KC&T
M>@P!QTXKF-'^(::EJ.F1N=*,.IN4BAMK]9;F ["RF5 ,#(7!P?E) YI]KXUU
M.ZM]-U$:5;IIM]J'V*-C<'S7!D95D5=N,87<<G/7V) .OCL+.&=)XK6%)8XO
M(1U0 K'G.P>@R!Q[4ZUM+>RMQ!:PQPP@DA(UP 222<>Y)/XUY[!K.J78U(ZD
MB2VVH:XFFVB073J45&VN5( P!L=N.O(X%7)_']U;Z?<:M+IUK'I:WDEE;22W
M6QKB02%%897:J<$EB> #P<<@'>45YY=_$"X_L77E@DTFXOK*Q%S%-87GG0G<
M2NTG;D.".!C!R.G."7Q(WAP+_;2>=>:1I<(ED2\;;)--)L56W #)\L,7;[N3
MVS0!Z'17&:7XY-U=7MI(NG7L\%B]\@TB\^T!@IP8SP,-DKCUSVQ5OPKXEO?$
M!$CP6#VCP^8+BRNO,$3Y&8I%8!@W.>G8].X!U%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5DZEX8T+6+E+G4M(LKJ=1@230JS8]">X]C6M10!7
M-C:--;2FVB\RV!$#;!F($8(7TR..*:^FV4EZUX]I"UTT)MVF*#>8R<[,]=N>
M<5:HH J0Z786SVSPV<$;6T/D0%4 ,<?'RKZ#Y1Q["K=%% &9JOAW1M<:-M4T
MRUNVC&$::(,RCT!ZX]JECT72X;.&TBTZUCMH)%EBA2%0B.IR&  P"#SFKU%
M$,%I;6KSO!!'$\\GF2LB@%WP!N/J< #\*+JTMKZ#R+J".>+<K;)%##*D$'!]
M" ?PJ:B@ JBVBZ8\*PMI]LT2W'VI4,0($V2V_'][))SUYJ]10!2ETC3IQ<"6
MQMW%RZ23[HP?,9<;2WJ1M7'T%3Q6EO#<SW$4$:37!4S2*H#2;1@9/? XJ:B@
M"O:6-I8B86EM% )I6FE\M N]VZL<=2?6EL[.VT^U2VL[>."!,E8XU"J,G)X'
MJ234]% &?+H6DSZ4-+ETVU>P'2V:(%!SG('0<DFGZ9H^FZ-;FWTRQM[2)CN9
M88PNX^IQU/UJ[10!#;VEM:&8V\$<1GD,LI10-[D %CZG '/M4U%% $%W9VU_
M;-;7<$<\#$%HY%#*2"".#Z$ _A44VDZ=<&[,UE;R?;$6.YW1@^<H! #>H )Z
M^M7** *CZ98R2R2O9P-))!]F=B@RT7/R'_9Y/'O1'IEA#)!)%9P(]O#]GA94
M ,<?'R+Z#@<>PJW10!A2R>'-(V!XK6W72HP8RL7%N)/E"K@<,W3:.3QQR*32
MI/#^HE;6TLEBDLI/M*V\]FT#Q,^[]X%=0>27^8=\^]<_%;W$NG66J_9I;LPZ
M_<W-[#$-SL%::%"!_%LQ'QUPG'(J[JMW?:E'%<KH]U%9I>VV9/*/VB2)&,C$
MQCY@FY4&.O+$C% '2'1]-*,AL+<JUQ]J(\L8,V<^9_O9 .?:J6H#P_!]NAO8
M+4^=Y4]VC1;MX+!$=^.>5&"?[OM7(:C::E=VLMS<Z;=B2XOKBZ2"6W-Q&=H$
M4<<L:G(W*NX,#A3SGU9-I3);:W'+ITL&HW\5IIEL9"9"RF)=Q$A^_M/F%CG.
M(\GM0!Z!-I6GW!NS-902&\01W):,'SD ("MZ@9/!]:5M,L7F>5K. R/!]F9B
M@R8N3L_W>3Q5NB@"I%IEA!);R16<"/;0^1 RH 8X^/E7T'RCCV%-_LC3?[*_
MLO[!;'3]NS[*8AY>WKC;TJ[10!G:9H&D:+%)'INFVMJLO^L$407?]3WIEAX;
MT32Y%DL-*L[:1"2K10JI&1@X/TXK4HH R[7PWHEC?->VNDV<-RV[,J0J#\WW
ML>F>^.M-/A?03IJZ=_9%G]C20R)"(1M5C_$!V/TK6HH SI= TB?2DTN33+1K
M!""EOY0V*1R"!V/O2V^A:3:QQQV^FVD21S"=%2)5"R!=N\ =]O&?2M"B@#)/
MA?03=R79T>Q-Q*XD>0P+DN"&W=.N0#GU%6FTK3WMIK9K* P3R&66,QC:[D[B
MQ'<Y .:N44 4IM(TVY%X)K&WD%Z%%SNC!\X*, -ZX'K3I=,L9I+B26S@=[B'
MR)F9 3)'S\A]5Y/'N:MT4 5%TRQ25)4LX%DC@^S(P0 K%Q\@]%X''M65+>>&
MM*N+&)DMH'MIUT^T*PG$4DJ\1*0/ER ,]@,9KH*\O?2[[5O"^A3PVTDLD-C-
MJSL!G?>DHRK_ +Q+2_E0!V4TOAS3+VTTQH($N;:*6^M[>*W+M&HSO=0H."=Q
M'J23C-:"Z1IAC4"PM]OVC[6 8@/WV<^9C^]GG/6N#DT/5[W6;G4+BUF6XO8[
M:)V'_+*.2<-)&#Z)%$@/8LQ/>ICHFK^1:7]I;3)K$KW]XTLA/[LLD@BA.> N
M9$.WIE,T =N^CZ;+'<1R6%NR7$JS3*8P1)(,89O4C:O/L*@DM-'N[[4+&6TM
MY)[B&-[Q'B!\Z,[E3<<?,/E88[?C7%R:/<W">5I-AJ%G;36T5I=R2ADDF=YH
M]\ASR62,29?N7X)Q71Z1901>*[XV,0CLK.UCM>.C2L[2.,]R RDGU<T ;4FF
M6,LLTLEG TD\/V>5B@)>+GY#ZKR>/<T)IEC'+%*EG LD4'V>-@@!2+CY!Z+P
M./:K=% %.'2=.M_LGDV-O']C5DMML8'DJ1@A?0$ =*N444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 <_9^&39>$;K0X[UO-N5N-]WY?.^5F8MMSV+>O:JVF>'O$.F6UG:1^
M)8#:6R)$L8TT E% &,[_ $'6K$^LZA/XFO\ 1M-CM=UK81SF6?=@2N[!5..V
MU"?Q%9FAZQXMU;4;Z)ET1;:PO?LLSJLN7(56?;SVW8Y[B@#9M/#=O%'KD=T_
MVI=7G>2<,N,(R+&$]P%7K[T>%?#R^&-"33A=/=R>;)+)<2+AI&=B<D?B!^%.
M\27>JZ?IDE[IK6"I;Q237!O Y^51GY=OT/6N=;Q+XHL_"*Z]?6^E9N((3;6T
M0D#>;*R*JL2>@W<XH NV?A77=-FOFL/$L44=Y=RW;*^G!R&<YQG?S@8'X5J6
M^A2KKUMK%W>_:+B"Q-I@1! 69PS..3C.U1CVZU'9CQ;]LB^VOHAMMW[SR%EW
MX]LG&:SO"OC8:[!JDEY EM]E9YX=I/[VUW,%DY[Y1@?H/6@"]HGA*VT/Q!J^
MJPSN_P#:!7;"5P(!N9F"GT9W9OQJ[HVBKI$NIR^>9I+^]>Z=BN-N0JA>O( 4
M"CPWJ-SJ_AK3M2NX4AGNX%G:-,X4,,@<^Q%:E !4$ME:3SK/+:PR3)C;(\8+
M+CD8-3T4 8>OZ!+J]QIMW;7<=O=6$K21^=!YT;;E*G*;EYP>"",5GP>#[VVA
MNY(=?G74+C4!?&Y\H8)$:IY;H" T> <#(QQSD9KHM0U&STJS>[OKA(($P"[G
MN3@ >I)X ')JE;^*-%N;"ZO4OT6"TP+@R*T;19Z;E8!AGMQSVH C\.^'_P"P
MS?RR3QS7-_/Y\QAA$,0;:%^5,G' R2223SFLZ7P4TT.JQMJ9'VO44U*V<0#=
M;S*5(SDX=?E48P.,CWK<TO6].UD3?8+CS&A8+*C(R.A(R,JP!&1TXYJM<:];
M6=_J'VN]LXK*RBB\TL6\Q)')(!XQ@C;@#))/TH SI_"-UJ&F7UMJ6LM/+>F)
M7,<'EQ)&CABB1[C@MR"Q)//MBK&M^$XM<N[Z:>[DC6ZTQM.547F,,Q9F![Y^
M7C_9]ZED\4Z;-HFH7UC>P;K1=K?:5=!&Y'R!UQO )([<]J+GQ?HFG226]_J4
M$=S RI<*BL1$Q4'+8!VK\PY/'/6@#.'@^^ENX+J[UJ-I;>SGM8$M[(111F0*
M-X7<3N&WUP>V.^A%X7AA'AV-)R(-$0K''L_UA\KRPQYXP"Q_&BV\46UWXQNO
M#\*$M:VZRR2X;[[$_)TQP!G.><C'0TDWBJTB\8Q^'L8D^RO<S2L& 3&-J],<
MC<<YP-N.IH H6/A#4M,TBPL[37RLME)*49[;,4R/R5EC#C><DG<".3TK7\-Z
M#'X>TQ[1)1*TL\EQ(RQB- SG)"(.%7T'-+IOB;1M7N3;V-\DLNPR*-K+O0'!
M9"0 Z\CE<CD5%9>+] U&[M[6TU**:6Y!,.U6VN0,D!L8W8&<9SCM0!CVG@6X
MBLXM,NM;>YTD7'VJ6V-N%>60OYA!?=]PO\VW&>V<4S2-*.L^.KSQ-+;7=O9Q
M(D5M#=1&,R3!65IMAY&%;8,]<L?2MR/Q9H4NI#3TU&-KAI3"ORML:0=4#XVE
MN#QG-)+XOT""[-K)J40F6?[.X"L0DF< ,0,+D\ G )H ?XBT277+6S2&\%K+
M:W<=VCM%YBL4R0"N1QDYZ]0*I7'A%;C1=>T\WS!M9N'EEF$?*JP5=@&>?D4+
MFB#QKILFLZW9RR"&WTE4\VX<, 6/WATQQE .23NXK5TO6].UE9C87'F-"P65
M&1D="1D;E8 C(Z<<T 8][X3NGU.^NM,U?[!%J"H+I!;+(X*KL#1,2-AV@#D-
MTS6W=:5;WFB3:3,9&MIK=K9R7)8J5VGD]\=ZAN?$6D6=K=75S?110VDXMYW;
M/R2';A?K\R_G46J:[!:M):6UW:KJ"R01[)]VT&5L*#M'4@-@>PS@<T 4;#PS
MJ5N4-WKS3^1;M!;+%;"%02,;Y &/F,.W0=>*E@\*0V]IX;M%N"8-$PRIL_US
M")HPQYX^\6[\UC2_$:VDTV[N[58T2+58M/C>?<JLK, TAR!C $G'^SSUKJ]+
MUK3]:CF?3[CS1"_ER*49&1L X*L 1P0>G- &%IG@R2P73$EU3STTVZN+F$?9
M]NYI0P&[YCD@R.<\9ST&*E;P<@\*Z7I$-ZT=QIKQS071C#9E7.69,\AMS9&>
M_6K]YXIT6QOI+&XOXTNH^7BPQ*#;NR< X&.<GCFJT?BS3;.SLAJVH6B7<\"S
ML( Y15;HYR,JG^TV* *MWX0O+_1;ZUN];:2[NY8I#*(,0QB-U8*L6[A3MY^;
M)SUZ4Z\\&"^_M*:74&%[=W%O<QSK$,0O J[/E).X9#$@_P!XCWIMYXXT^WU?
M2X8[B)[&\M);II@K,Q"E50(H&6R2QZ'A2:EN?&VFKJ>@V=I(+D:N2R2H&*K&
M <-P.[87'&,Y/2@!P\-7\ME?"ZU^Y^VW(0)/:1^0EOL.X;(\GJ?O9)W#CI4N
MB^'9M/UF]UB]O(;B^NHDA<V]MY";5)()7<Q9OFZD]  ,5I:GJ]AH\"37]PL*
MN^R,8+,[>BJ 2Q]@*P/$'CFQT_PVNI:;-%<S7$ZVUNK(Y7S"X5@X W#;DD@X
M/&* .LHJMI[7#Z? ]V\+SL@+M"C(ASZ!B2/QJS0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.GNJV\BDYE&65\_1EQQ6?9^.Y]4O=?6T6SALK)X+>SN;@OB>61BG.W)VDCC
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M'O\ 4;I;(NVGZ1;Z?I^ /WNQ&=]OU8J/^ U#X:T6^TG7- AN;*<PVNA>3YX
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M4,=QX/\ = ->F.ZQQL[L%102S$X  [U':W4%[:0W=M()()D$D;CHRD9!'U%
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M[L1)+M:1MF%*]P>#5_5]#U,6/B\V5E*QELK?3;%5QN:%4^<KSZR/]=M>AT4
M>?:_;W[W4<^GZ5JUI=062)IMU9;&SD9,,Z,=H 8+UXZX(-;^K6VHQ_#Z[M;.
MSB&I'3FC2WM@%02E,$(.F 2<5T5% '"6L-SHFMVVHKHFH7-H='@L[9(D4R0,
MC,61E+?+N!3G./EYZ5N^$]-N])T B^15O)YYKN:&,[A&TDC/L![XSCZUO44
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M_P >ZO;J1#_NC''0=/04 <%:7U]XBFT^.WU6\BM]5UB[N5DAF8$6<"F,*O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?NL<G<K<^_'%;]87A[1;_1--L;!]0@GAMED63;;E6E).5;)8X/WL^I/;%;M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^M9_\'-W_P#':/\ A$M._P"?K6?_  <W?_QV@#=HK"_X1+3O^?K6?_!S=_\
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M!+?RQ$TC!5,;9)(#$ ALY&3Q5A/"B3S;]7U*ZU55MY+9$N5C4*D@ ?.Q5R2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS)#JMCI6H"X$+%!*RI&8IU ]1DCT.X=JZ9[A7TP::?".HBR"A1 OV=5 !!
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M23L&E#2P[)" %&Y//VGA0.1VI;FQLKN\FNY?".L^?,09&CN8TW$*%!(6<#H
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MO/\ H6]6_P"^K?\ ^.T ;-%8W]N7G_0MZM_WU;__ !VC^W+S_H6]6_[ZM_\
MX[0!LT5C?VY>?]"WJW_?5O\ _':/[<O/^A;U;_OJW_\ CM &S161;:ZTVHPV
M5QI5_9R3*[1M/Y15MN,CY'8]QVK7H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *QM:_Y"WAS_L(O_P"DMQ6S6-K7_(6\
M.?\ 81?_ -);B@#9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH QM0
M_P"1HT7_ *YW'\EK9K&U#_D:-%_ZYW'\EK9H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO^A=UK_OU'_\71_PDDW_ $+NM?\ ?J/_ .+H W:*PO\ A))O^A=UK_OU'_\
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M%W6O^_4?_P 71_PDDW_0NZU_WZC_ /BZ -VBL+_A))O^A=UK_OU'_P#%T?\
M"23?]"[K7_?J/_XN@#=HK"_X22;_ *%W6O\ OU'_ /%T?\))-_T+NM?]^H__
M (N@#=HK"_X22;_H7=:_[]1__%T?\))-_P!"[K7_ 'ZC_P#BZ -VBL+_ (22
M;_H7=:_[]1__ !='_"23?]"[K7_?J/\ ^+H W:*PO^$DF_Z%W6O^_4?_ ,71
M_P ))-_T+NM?]^H__BZ -VBL+_A))O\ H7=:_P"_4?\ \71_PDDW_0NZU_WZ
MC_\ BZ -VBL+_A))O^A=UK_OU'_\71_PDDW_ $+NM?\ ?J/_ .+H W:*PO\
MA))O^A=UK_OU'_\ %T?\))-_T+NM?]^H_P#XN@#=HK"_X22;_H7=:_[]1_\
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M23?]"[K7_?J/_P"+H W:*PO^$DF_Z%W6O^_4?_Q='_"23?\ 0NZU_P!^H_\
MXN@#=HK"_P"$DF_Z%W6O^_4?_P 71_PDDW_0NZU_WZC_ /BZ -VBL+_A))O^
MA=UK_OU'_P#%T?\ "23?]"[K7_?J/_XN@#=HK"_X22;_ *%W6O\ OU'_ /%T
M?\))-_T+NM?]^H__ (N@#=HK"_X22;_H7=:_[]1__%T?\))-_P!"[K7_ 'ZC
M_P#BZ -VBL+_ (22;_H7=:_[]1__ !='_"23?]"[K7_?J/\ ^+H W:*@L[DW
M=HD[6\UN6S^ZG #KSCD D?K4] !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4=7O)+'3GEA"F9
MGCABW= \CJBD^P+ GVJ]45S;17<0BF7<H=''.,,K!E/X$ T <0FK>(8K&>^,
MUPUO%+-&\MRD CPLVQ=@3YLX'.X8Z^U:6JZM<MX@2UM;R=;;[,LA-L]O]XNP
M.3+UX ^[73-!$\31-$C1MG<A4$'/7(J Z5IS*JFPM2J_=!A7 ^G% '+3^*;M
M;_4U61(;5HYH[&>>%EB66)>27QA@3YAXS@19[U6;7]2\V"S%Y>>9]H99,"U\
MP+Y6X /_ *LC//16QU'<]UY,6U5\I-JG*C:,#Z?F?SJ#^S+ P"#[%;>2IW"/
MREV@^N,=: ,75[W4(H-%BM);QI+ERLI@%N96 B9NK_N^H&<?A6-)K/B&WN"E
MT\\;Q-;1NRK#]G0OC/FG[_/3*< GKCFNZ2&*-45(D58_N * %[<>E#0QN'#1
MHP<8<%0=P]_6@#@;SQ9J]E#JMTSHUI;6LWS",;H9//N$C<^J_ND4_4'IFNDL
MC?'Q1>02:G<26T5O#,L+1Q 9D:4$9"!L#8N.<^N:V?L\.UU\F/:XPPVCYAR<
M'UZG\S3PBARP4!B "<<D#I_,T <;-KM_';"]6_5IY+J:W.G[$Q&%W\CC=N4*
M&))((SP,C%CPSJ6I7MW);WLMTO\ H<4P%TL(<LV?GC\OY2G;GD'''KTWV6W\
M]Y_(B\YUVM)L&YAZ$]Q3Q'&&5@BAE7:IQR!Z#VX'Y4 <E]MU6PTW5-3;4IKQ
M--N'+P2QQ+YD*+E@"JC#8)(YQD =":9<77B;^U)+.&262YCLX9]L*PB!9)))
M<JY?#E $497G )ZFNO,491T,:E7SN&.&SUSZTX*H<N%&X@ MCD@=/YG\Z .8
M\-ZC>W][.UU<W+*)9T5&-OY>%E91@+^\S@=_?VK/3Q;>65S&FILHA:]O&21(
M_P#66\0GRO\ OJ8T^H(]Z[".QM(9S/':P),V<R+& QSUYJ1K>%U"M#&P!+ %
M0<$]3^I_.@#A!XKU>"VLUNOW=U#>JUZLD!3=;-$\C$ @$!=K@'OY7O38_$>K
MWFI>5]IFC@DDN)(A;B!'$82V:,$R\=)FSWR?05WKP0R-N>)&;&,E03CGC]3^
M9J.:PL[@ 36D$F#D;XP>< =_8#\J .?\1:]=:8MDEF)9G5/M5SMA\TM"N 5.
MT84MDX/3Y36>_BG4(KED:2-K>YOFCLIT08**#F,^^ &![C/]WGM5BC3[D:+\
MH7A0/E'0?3DTT6\"HJ+#&$4Y"A1@&@#F] U>X>:U2XU,7L<VG"[G=@@-NWR\
M$H ,-N;&1GY#S69!XHO[J(Q33RV+W-S#+!*UN(RMO(Q&T;UPQ7 RV"/G%=M%
M9VL$310VT,<;_>1$ !^H%$UK;W*A9[>*50, .@;CCU^@_*@#CX]9O)]0-K)K
MRV]M MR5O0D6V?88L%LC'&]U.W&2IZ57M/$>M75S#-*+BW22ZM(6!2(6T?F0
MPR.C$_O0Q+L%/3<4%=L]C:2"(/:P,(O]7F,'9]/2I3#$P8-&A#D%@5')XY/Y
M#\J .(L-:U2?P^;U]0D2XDCBP;A[81@LZ@[-H+*<$A=XQDC--G\0Z@+0;-0E
M5K<3F<%;<397:02"?+D503NV,IY'0YKLTTZQC+E+*W4R*5?;$HW ]0>.12FP
MLS#'";2 Q1',:&,80^H&.* *.JZD\.A/>6DB[P8\';TW,H.0>G!Z&N5D\7:O
M:6VR98WN&:[E@;R_EEB19, @=T95SCJ"I[G'=K;PJ) (EQ(V]^,[FXY/Y#\J
M<(HQMQ&@VDE?E'&>N* .:_M5[+5+"V_MV.]BFN%$I=$!16AG8?,H"X+1J1QG
M@\D&G3Z[,DM_%'<Q>8FJVEO G!)AD$!; [\/*<^Q]*W?[.L?),/V*W\HMO*>
M4NW=ZXQU]Z<MG:K+'*MM")(UV(X095?0'L/:@#B8?$6I1:787"ZF+N:[L!<R
MHR1YMVW1]-H'RG>PPV3TYX-)+XMU>TA*2HDEPTMY);E8^)HHUFPI _B5D0''
M4%>Y-=O%96D"NL5M#&KG+!(P WUJ011@J1&@VDE?E'!/4C\S0!@Z1J1;5IK)
M]3DO4^S+.LK+#M(SR5,9^[R.&&>#R:RK?6+\@7D&KM=64URD-NLJ1;V3#;I/
MD48#'&/89[X'816EM;AQ#;Q1B0Y<(@&X^IQUID6G6,!)AL[>,GND2C^0H Y_
MPU>ZY<:>+V\2YEADLDF47 A#/*1DA/*_A(_O<]/>JHUNYCTJVN1KD,TMW#"\
MBF),6P>1%:1<8PJASP^>0#G :NR5510J@*H&  , "HDM+:(RF.WB0S',FU -
MY]_6@#DY-4O1K*:6-;86XGVM?!8MW,3.8R2NS((4\ <,/J:]AKVIW^J)$]W.
M(5AC8/;?9U24&:9/,/F?-AEC5@%['Z5V)T^R,"0&SMS"ARL?E+M4^H&,"EEL
M+.>19)K2"1U "L\8) '3!- %'6[^2WM;;[/<+ D]RL$ESP1"#GGGC)("C/&6
M'!Z5SS:MJ\VL#3+:[NKF*)YU^T6JVX>4*L!Y+C9\IE93M Y ]#79+:P+ T B
M3RF+%D(R#N))R/<DTL=O#"J+%#&BH"J!5 "CT'IT% '-^(M?N-)O;6*#S)(K
M=!<WS"$O^ZW!>2!A>/,?/'^KQWJC/X@OX;J]/]I1!6^TK;L1&UNA0,5W8Q(A
M7;\Q8,O7&,BNT,:$L2BDN,-QU'H?S-1K:6R3-*EO$LCKM9P@!8>A/I0!Q3^)
M=2M+:4))+<7$+2DQSI&Q.+=I%&Z+Y6&Y<\!6QP1W+[S6]2MYC9Z=J?VVX<V[
MQ23QQ&-PS@$!HSD*V<<KD<D$UV4-I;6Z*D%O%$JDE51 H!/4C%$5G:P;O*MH
M8]S;VV(!EO4^_O0!PW_"47^HZFB6\]U! S7(,<0@21#&+<;6\WC*M)(#CG/L
M*U-.U"^O-?N[>2]NQ#%.8DVFVV8\M2,C&\G)SQQ^%='-86=QCS[2"7!)^>,-
MR>IY'L/RIITVR,AD%K"LN,"58P''&.#U'% $>C7DFH:-:74H DDB!?;TW=R/
M;/2KU1P016UO%;PH$BB0(BCHJ@8 J2@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^,4 ;M%87VGQ7_T"=&_\&<O_ ,8H^T^*_P#H$Z-_X,Y?_C% &[16%]I\5_\
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MC'85/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M24D1JP +D#) '?@$U':RZ=>M<+;>1*;>4PR[5!V. "5/O@C\Z *G_"6^&_\
MH8=)_P# V/\ QH_X2WPW_P!##I/_ (&Q_P"-:?V:#_GA'_WP*/LT'_/"/_O@
M4 9G_"6^&_\ H8=)_P# V/\ QH_X2WPW_P!##I/_ (&Q_P"-:?V:#_GA'_WP
M*C*V0N%MR+<3LA<1X&XJ" 3CKC)'/N* *'_"6^&_^AATG_P-C_QH_P"$M\-_
M]##I/_@;'_C6G]F@_P">$?\ WP*/LT'_ #PC_P"^!0!F?\);X;_Z&'2?_ V/
M_&C_ (2WPW_T,.D_^!L?^-6S+IPU!; ^1]K:(S"':-VP$ M],D"K'V:#_GA'
M_P!\"@#,_P"$M\-_]##I/_@;'_C1_P );X;_ .AATG_P-C_QK3^S0?\ /"/_
M +X%'V:#_GA'_P!\"@#,_P"$M\-_]##I/_@;'_C1_P );X;_ .AATG_P-C_Q
MK3^S0?\ /"/_ +X%'V:#_GA'_P!\"@#,_P"$M\-_]##I/_@;'_C1_P );X;_
M .AATG_P-C_QK3^S0?\ /"/_ +X%'V:#_GA'_P!\"@#,_P"$M\-_]##I/_@;
M'_C1_P );X;_ .AATG_P-C_QK3^S0?\ /"/_ +X%'V:#_GA'_P!\"@#,_P"$
MM\-_]##I/_@;'_C1_P );X;_ .AATG_P-C_QK3^S0?\ /"/_ +X%1P+97,0E
M@%O+&21N0!AD$@C(]""/PH H?\);X;_Z&'2?_ V/_&C_ (2WPW_T,.D_^!L?
M^-:?V:#_ )X1_P#? JO<RZ=9M;K<^1$UQ*(80RCYW()"CWP#^5 %3_A+?#?_
M $,.D_\ @;'_ (T?\);X;_Z&'2?_  -C_P :MWLNG:;92WE[Y$%O$-SR.H 4
M>]6/LT'_ #PC_P"^!0!F?\);X;_Z&'2?_ V/_&C_ (2WPW_T,.D_^!L?^-:?
MV:#_ )X1_P#? J.=;*V@>>=;>*&,%GD<!54>I)Z4 4/^$M\-_P#0PZ3_ .!L
M?^-'_"6^&_\ H8=)_P# V/\ QJV9=.6_CL3Y'VJ2(S+%M&XH" 6^F2!^-6/L
MT'_/"/\ [X% &9_PEOAO_H8=)_\  V/_ !H_X2WPW_T,.D_^!L?^-:?V:#_G
MA'_WP*/LT'_/"/\ [X% &9_PEOAO_H8=)_\  V/_ !H_X2WPW_T,.D_^!L?^
M-:?V:#_GA'_WP*IQWFD2K,R2VI6&?[-(3@!9>!L^N2!CWH @_P"$M\-_]##I
M/_@;'_C1_P );X;_ .AATG_P-C_QJVDNG27TMBGD-=0HLDD04956SM)^N#^5
M$\NG6UQ;6\WD)-<L4A0J,R$ L0/H 30!4_X2WPW_ -##I/\ X&Q_XT?\);X;
M_P"AATG_ ,#8_P#&M/[-!_SPC_[X%'V:#_GA'_WP* ,S_A+?#?\ T,.D_P#@
M;'_C1_PEOAO_ *&'2?\ P-C_ ,:J7?BSPE8:@UC=:IIT5RC;71F'R'T8]%/U
M(K=%O;L 1#$0>00HYH S?^$M\-_]##I/_@;'_C1_PEOAO_H8=)_\#8_\:T_L
MT'_/"/\ [X%1R+90M&LHMT:5MD88 %VQG ]3@'\J *'_  EOAO\ Z&'2?_ V
M/_&C_A+?#?\ T,.D_P#@;'_C4DNI:)!!?32SVB16!VW3M@"(X!P??!'YBF:7
MJVAZUD:=/;7!""0A4Y"DE02"..58?A0 G_"6^&_^AATG_P #8_\ &C_A+?#?
M_0PZ3_X&Q_XUI_9H/^>$?_? H^S0?\\(_P#O@4 9G_"6^&_^AATG_P #8_\
M&C_A+?#?_0PZ3_X&Q_XU?1;*262*,6[21$"15 )3(R,CMQ4GV:#_ )X1_P#?
M H S/^$M\-_]##I/_@;'_C1_PEOAO_H8=)_\#8_\:T_LT'_/"/\ [X%'V:#_
M )X1_P#? H S/^$M\-_]##I/_@;'_C1_PEOAO_H8=)_\#8_\:T_LT'_/"/\
M[X%'V:#_ )X1_P#? H S/^$M\-_]##I/_@;'_C1_PEOAO_H8=)_\#8_\:MW$
MNG6L]M!/Y$<MRYCA1E&9& +$#\ 3^%6/LT'_ #PC_P"^!0!F?\);X;_Z&'2?
M_ V/_&C_ (2WPW_T,.D_^!L?^-6WETZ._BL7\@74J-(D6T;F52 3]!D?G5C[
M-!_SPC_[X% &9_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\ 0PZ3_P"!L?\ C5^Y
M%E:6LMS<+#%!"ADD=E "J!DD_A2PI:7$$<T4<3QR*'1@HP01D&@#/_X2WPW_
M -##I/\ X&Q_XT?\);X;_P"AATG_ ,#8_P#&M/[-!_SPC_[X%'V:#_GA'_WP
M* ,S_A+?#?\ T,.D_P#@;'_C1_PEOAO_ *&'2?\ P-C_ ,:T_LT'_/"/_O@5
M7$NG-J#6 \@W:Q"9HMHW!"2 WTR"/PH J?\ "6^&_P#H8=)_\#8_\:/^$M\-
M_P#0PZ3_ .!L?^-:?V:#_GA'_P!\"C[-!_SPC_[X% &9_P );X;_ .AATG_P
M-C_QH_X2WPW_ -##I/\ X&Q_XU;$NG-J#V \@W:1"9H@HW!"2 WT)!_*K'V:
M#_GA'_WP* ,S_A+?#?\ T,.D_P#@;'_C1_PEOAO_ *&'2?\ P-C_ ,:T_LT'
M_/"/_O@4?9H/^>$?_? H S/^$M\-_P#0PZ3_ .!L?^-'_"6^&_\ H8=)_P#
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MN;C[0&W>;N(Y;(],8XQBIM)\+V^E:O<:L][>WM_<0)!)-=.I^522,!5 7KT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BJ]]>V^G6%Q>W<@BM[>-I)'/15 R367X7\30>
M*-'?4(K::T$<K1217& R%<'G'L0: -RBL*W\6Z;=6.D7<7G%-6F\JT4IAFX8
M[B,\+M4M],=^*W-R[@N1N/;- "T4A('4@4;AD#(R>@SUH 6BD+ $ D GID]:
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBJFH6D]Y;B.#4+FQ<,&\VW6,L1SQ^\1AC\,\=: +=%87]@ZE_T-NL_P#?
MJT_^,4?V#J7_ $-NL_\ ?JT_^,4 ;M%87]@ZE_T-NL_]^K3_ .,4?V#J7_0V
MZS_WZM/_ (Q0!NT5A?V#J7_0VZS_ -^K3_XQ1_8.I?\ 0VZS_P!^K3_XQ0!N
MT5A?V#J7_0VZS_WZM/\ XQ1_8.I?]#;K/_?JT_\ C% &[16%_8.I?]#;K/\
MWZM/_C%']@ZE_P!#;K/_ 'ZM/_C% &[16%_8.I?]#;K/_?JT_P#C%']@ZE_T
M-NL_]^K3_P",4 ;M%87]@ZE_T-NL_P#?JT_^,4?V#J7_ $-NL_\ ?JT_^,4
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M%']@ZE_T-NL_]^K3_P",4 ;M%87]@ZE_T-NL_P#?JT_^,4?V#J7_ $-NL_\
M?JT_^,4 ;M%87]@ZE_T-NL_]^K3_ .,4?V#J7_0VZS_WZM/_ (Q0!NT5A?V#
MJ7_0VZS_ -^K3_XQ1_8.I?\ 0VZS_P!^K3_XQ0!NT5A?V#J7_0VZS_WZM/\
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M&Z5=Z3X?\O4$5;ZXN9[JX"L&&^21FZCK@$#\* .3U;QEJ\4?CBX^S3V]GIL
MM;23='A+C'7@EB29(R.P P<$XK>TOQ6;::VTO5[&\LR+!KE+N[9#YJ1!0[,
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M$.YMH?9NW["Q W8[YQBJK>*?L?BW7FFDN+B*$V]C8V,'S--/L,C[5]<.N2>
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M6HMW+:ZSIT^D2I:O>*;B1'5XDQO.Y"0"N1D>_>N?USQC?7^G:?;6FF:EIO\
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M5M]J@Q,< EF("^O/TZFL>'2?$^GZ)J7ARRL(&6[N+@QZJUPNQ(YG9BS)]XN
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M+>&TC\P$[40LP)[?.Y'X9KDU\"WUG8^')[C2TU62TM)8KRS%R(F$LKB0NC9
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MGW&EP"YG@<K(6C.=K(5)#9*D=L$<U8TCQ%/J&H"RO-&N["22#[1"[LDD<B9
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M/XU-10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%<K'\1_"4A7&KA49MHE>"5(\YQ]
M\J%Z]\UU((90000>01WH 6BH+N\MK"U>YNYTA@3&YW. ,G _,D#ZFIZ "BBJ
MMOJ5I=7UY903![BS*+.@!^0LNY1GH>.>* +5%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7_R+0!NT5A?\59_U!?\ R+1_Q5G_ %!?_(M &[16%_Q5G_4%_P#(M'_%6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX?\ $/AK3-4U*UO$U"2[:XEBM?*Q''$K* ,GD')SWS0!I?\ "1^)?^A'O/\
MP/MO_BZ/^$C\2_\ 0CWG_@?;?_%U@Z1J_COQ%I,'B;3)M,6TGE)ATF6(@M"'
M*Y:;/#8!/3'\JSM<\=ZA:^.=;TF7Q1IVB6MD8/(6YL3,TF^,,W((Z$_K0!U_
M_"1^)?\ H1[S_P #[;_XNC_A(_$O_0CWG_@?;?\ Q=:&EZN9!IEI*9KV6ZM!
M<?;X;8K;N,#G.?E)SD"K5_K5EIMQ#!<_:!),<1B.UED#'!. 54C.%8XZX&:
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MS$^PLH)90^-I88.0#G@^AH R/^$C\2_]"/>?^!]M_P#%T?\ "1^)?^A'O/\
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M"/QI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$CQ,WV:)<F3!4#>&SSV- %C_ (1C41+:O_:$;31JBM=?O%F4*Y8KD-^\7!P
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M]9KFS$-OYZVD+QED#/N7&]BQY4D#DJ",'.*DLS<:?JPO5M;]='WS)!$(9'=
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M)/%;IBDC\*"2RAD>:UE6X$45K);M)L<,RJCDMEERO7DF@!+/P?"MQ-+J$S7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D9@HRQ  [FEKB/B
M_P#\DLUO_=B_]&I0!VJNC_=96^AS3J\8TO2Y_#_Q#T,'1K7P\;ZVN(8?L-P9
MUN)-@(\T'& O4<'G'X=#X8\;:MX@UC1])*PQWD$=P^MJ$_U9C?RU5?3<W/TH
M ]&HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*QM+N/$=_<:%!+XCG7^U=):^E9+:$&)U\K CRF #YO.[=]WC&: -G^Q/%_\
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MZC#;!UD5E4,JQ=%.X\/SQ0!T_P#8GB__ *'&#_P4I_\ %T?V)XO_ .AQ@_\
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M?_%TR32O%<*[I?&MJBY RVE(!DG _C[GBJMSK6H:=8>*T.H&1M+TR.:VEE1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK.EVLJ6=E=V+XN(-T"LGS?-O (X)SG/O2C4M)LI?[/66&%DD2'R57 #."57
M&.0":\JBU0KX5T^VCO)X9+30+:5=^J/9(K,K89%0%IF^4#!^7@#J36A;7,E[
MJUG=3/OEGO-(D=O[S&!R3^M 'HFD6.B1QF^TBQLX5N!DRV]NL9?GO@ GGUJS
M+IFGW%@MA-8VTEFH %N\2F, =!M(QQ7FVCZDM_';)XBUZ[LK9=,$]O(+UH#+
M)YLHD<N""Y4+'\IR.>G-)92ZKK6GZE<ZEJ6I07%IH-M=1I!</ !,RS'S"JD<
MG8I*GCU'H =KK5QX8TJRM=/U>&R2UD)\BV>VWI\O7"!2!C/IWJSI$^@ZI;&;
M2A9RQQ%XCY48!C+$,ZD8RN>"1WX-<QJ<NJ7NL^"Y[*:U2]EL[B1GN8F=#F.,
MGY593^M1ZIH>H6=Y9RW6KR"[UK5HH[M[ -;+Y2P2@(OS%NW)SGIC&!0!W45C
M:068LX;6".U"E1 D8"8/4;1QCDU#9Z-I>G12Q66FV=M'+_K$A@5 _P!0!S7G
MEW?/:VVJR_VU>KKUEJ MK&R:\<[XPRB-3$3B3>O)8@GDG(QPV;51YMK-/KMW
M#KS^(([:6P6[8 0_:0H3R<X"&/:=V.<]3G% 'I3V-G(BH]K RI&8E#1@@(0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZP]'U2,Z[I%KI.O/KUL9&#V]W;JTUBGEM^\\P*I4@X7#C)W8H Z&S\9:%?"
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MS-Y=M'] "I/N6-9MK8:[X/O;(>19JEW8'3E>WE:3?<HK/%(^Y1@L=XSSRPH
M]"GO+.&]M+&5@)[@,T";"0=@!//08R*CU>\TS2[%]3U5X(K>U!<S2@'9].^?
M8<FO.]&:Q?7/#LFCW$EQJPL;@W:W,TC!9S&O^NSG8V[.1C..V *Z3Q197-]X
M UF36[*P>^@LKEX?LY:14/E, 5+*"&Z]J -;5M:T;36M)+\,TEPK>0([22=V
M4 $X"*Q Y'YU?C:UU6QCE,7FP2 ,JSPE3^*N 0?J*Y+7AI":EI,^K:I?Z9LL
M)$AN(I1%$2Q0LI?KO^52%[@'KTK7\*:I/<:+IL&J2M_:<T#R[9(]CO&KX#L,
M8!(*$CCD]* -FXM(KBU>W.Z-6C:,-$=C(",?*1RI]Q65IOAF*QOFO;F^NM0N
M/)-NC7(C 2,D%AA%4$DJN2<DX%;E% #&BC?.]%;<NTY&<CT^E-6UMUC\M8(@
MFW;M"#&/3'I4M% $7V6WW[_(BW[0N[8,X'0?2G^5&49-B[6SN7'!SUS3J* &
M111P1B.*-8T'14& /PIHMH%G,X@C$Q&#($&X_CUJ6B@",V\#2F5H8S(0 7*C
M. <CGZT@MK<2-(((@[D%FV#)(Z9-2T4 1/;P2Q>5)#&\?78R@C\J<(8U;<L:
M YSD*/3'\J?10!&8(CC,2':V\94<-Z_6B."&*1WCBC1W.795 +?7UJ2B@".*
M"&$N8HHXRYRQ10-Q]3ZTHBC&W$:C:25P.A/7'YT^B@"*2V@EB\J2"-X\YV,@
M(SUSBE>"*4()(D<(05#*#M([CTJ2B@"(VUN6C8P1%HQA"4&5'MZ4H@B7&(D&
M,8PHXQTJ2B@")[:WD1%>"-E0Y4,@(4^H]*>8T)8E%RPPW'4>A_.G44 -\M,J
M=BY484XZ?2E*JQ!90=IR,CH:6B@",P0M,LQB0RJ,!RHW >F:PV\*12ZDES/J
M=_/ ES]J2TD9"BR [A\VW>5#'(4M@<=@!7044 1O;P20F%X8VB/)1E!'KTI1
M#$I!6- 1R"%'IC^7%/HH 9Y48  1>#N''0^OUY-4++0[.S@MDPTKP3/<"5S\
MS2ONW.<<$G>WL,\=!6E10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !534M.M]5M!:W08Q
MB6.7Y3@[D=77]5%6Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***JZA<W%K;>9:V,E[)N \J-T0
MX]<L0/UH M45R]AXR-WIUKJ$NCW=M:W4\4$+O)&VYI'V#A6) !ZYJWK7BBVT
M22Z26WFE:WLC>'R\?,H8+M&3UR: -VBLS3M1U"[N&CN]$N;&,*2)99HG!.1Q
MA&)__55*Z\3.ES>1V&D7FH16+;+F6 H K !BJAF!=@",@>N,YXH Z"BL&?Q*
M7NQ:Z7IEUJ,PA2>4(5B$2ORH8N1\QP?EZ^N.*@/C".;[ EAIMW=7%V9E,&Y(
MWA:(@.K[F !!.."?RH Z6BN7D\9*D6P:1>&_%\MB]F7C#"1H_,!W;MI4KSG-
M2?\ "8P1)=1WFG7EO?V[Q1BR.QY)6ESY>PJQ4YVMU(QM.< 9H Z2BN<D\6BR
M2[75-+NK&X@LY;Q(V='$\<8RVQE)&X9&0<=1U%/MO$TC7EA;WVCW=DM^Q2WF
M>2)U9]A?:=K$@E58],<4 =!16%#XH@NM7U/2[6UGENK)-R@%56X( W*A)QE2
MR@YP,M5.W\83RQ:G--H%[!!IOF"YD::$[62,2%0 Y)R".1QS0!U-%8$OB5I+
MD6VF:7<ZA.L*33"-T18@XRJEF8 L1S@?CC(J#_A.=*%QI$3I<1_VE)+"#(@'
MV>2-E0I)S\IWL%[C)'J* .FHK+&MQNFLF.WE=]+<HZ#&93Y2RX7\' Y[U5'B
MRQ;5=(L425SJ<'G12@#8@*ED#<]6"OC_ '30!O45R\OCBRBMKFX-K<&."TN[
ML$;?G2WD\ML<_P 1.1[5LZGJL6EVD%Q+&[K-<0VX"XR#(ZH#] 6&: +]%5-4
MOX]*TB]U&5&>.T@>=U7J0JEB![\5CR>*+JUTNYU*^T&\M;6"#SM[30ONZ8 "
MN3GG//I0!T=%9FIZU#I=U:P2Q2.UPDSJ5Q@"--QS]169:>+GF73)KK1KRTM=
M29$@N&DB==SKN0,%8L,_3KUQ0!TU%<S9^.--O="O-4BBG LY_(F@8 2*=X4'
MKC!R"#_45-<>+((FFBBLYY[E=0_LZ*%2J^;+Y0ESDD #;GKZ=.E '045@Q^)
M@! EWIUW:W$EZMD8I IVLR%PP8$AEP.H/7C&0:T$U2)]=GTD(_FPVT=R7XVE
M79U ^N8S^8H O45S5MXHOKC6GTM_#E[%+$D<LS-<0%8XW9E#'#\_<;@<\4T>
M,T^R+J9TJ\&B,1C4"4V["<"39NW>7[XZ<XQS0!T]%9/B'7[?PYI?VZXAFGRX
M18H0"[G!)P#Z*K-]%-0ZAXJT_3M5TBQF+E=55S!<+@QKC8!N/;<74 ^I [T
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M5SK-U/$=$NK6."5X9999HB%D7&1A6)/7KC%3P^([2;Q/-H2I()XH]_FD#8S
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MXC@;&)",;<@$,5SP,\DBG0>--]YK]G-:>5-IPF>V);Y;I(U!;![$$C(]&!H
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MTY=5,Z#-Q?S7$85@<HV,?0\5S<7A'6+>TL]5%_/)J\=[]OELR8A#ND.)4#;
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M/#4EM+% (I;K[<)%R%P3MW'J1Z=ZLVGB;4)+.XNY)=#F2*T>X\JTNV>3Y5R
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M03R0M"\L:NT3]4)&2I]QTJ:H;5Y);.&24Q&1D5F,+;D)(YVGN/2IJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*\1:0=<T=K
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M>SO+<2PRR2J I)2/RF'L'0L#_O'%<[<ZO<31:79VU]K=VHU.:WF2./[/=[1
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M\MG,JV\),414-N( &]B26&,$4 =E9>%K6QN;"X2XGDFM7GE>20@M/)*/F9L
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M"'!66TSU7MN089?4 CO73Z(NH1Z;+>ZF[/=W+&<VX;*P+CY8E^@ R>[$GTH
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M0R!QNSG# G:& !R35>+XAZ;+87E^;*]2UM59FD9H/FPX3 42%AR>K #')(H
MC_X6IX._Z"<__@ON?_C='_"U/!W_ $$Y_P#P7W/_ ,;KHM&U:/6M/%Y';SP
ML5V3!<\=P5)5AZ%20:J_\)/8C0VU?9/]G6Z-H1M&[?Y_D=,]-WOT_*@#'_X6
MIX._Z"<__@ON?_C='_"U/!W_ $$Y_P#P7W/_ ,;K8U;Q)#I=\+)+"^O[D0_:
M)([.-7,<6<;B"PSD@X"Y)P<"ME2&4,,X(SR,&@#CO^%J>#O^@G/_ ."^Y_\
MC='_  M3P=_T$Y__  7W/_QNK<GC_0(;M+6:XDCF9[I"KIC8;<$R;O3@9'K3
M(?B%H,KVD;23PRW5REM''-'M8.\:R*2.P(=>?4XH K_\+4\'?]!.?_P7W/\
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M8&BV1.K-O4]#POOCN*GG\=VEO*ES,LD6GG2WU$K) PFVB15!QG !#9P>>10
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU>ZCBF#8,<,*NA+[_OA,L,\88D$'!%=;10!@:!X;;P\WEVUZSVTC2S7$9B1
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MM2"G&"\JE2O3[H!X[UTM% &;H&C0^'M#MM*MY))(K<,%>3&XY8MSCZUI444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>rnac-20241231_g1.jpg
<TEXT>
begin 644 rnac-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (@!/\# 2(  A$! Q$!_\0
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M;$G ]S4'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
M"BL__CE'_#2_P@_Z*KX(_P#"BL__ (Y1R2[!='I-%>;?\-+_  @_Z*KX(_\
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M<58R_BQ]'^A:^%GS11116Q 4444 %%%% !1110 4444 %%%% !1110 4444
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M.JCU"BBBO'.D*_$O_@HO_P GD_$'_N'_ /INMJ_;2OQ+_P""B_\ R>3\0?\
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M?9'P@^.'PS\<?"[XJ?"7QGJ,GP\T'Q-KDFN:)J<5FUS#8DRJZP.D?.%$: =
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M*2^2=_ZMT*562G*?5N_SM8^F?VZOC'X1^,OB_P #WG@_5_[8M--\-6]A=/\
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MQ?O %;'&UC@8 R2,'7_'7P/_ &J?!7PQO_'WQ!G\ Z]X0L$TW5M,?3)K@:C
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MS\ >#/!7@Z30?CYKGP[ATY%.O>$?$.F-J\-PP(+BU;9B)6.[&S)^8$@$'+O
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MO\C[ET_XS_"O5?VHOBGXFA^)OB#P6^MM')X?\7Z/%,+53Y:[X[JU:,/(H8#
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M_14=0_\  "+_ .+H_P"'3'@W_HJ.H?\ @!%_\77K_6Z7?\&<O*S\S**_3/\
MX=,>#?\ HJ.H?^ $7_Q='_#ICP;_ -%1U#_P B_^+H^MTN_X,.5GYF45^F?_
M  Z8\&_]%1U#_P  (O\ XNC_ (=,>#?^BHZA_P" $7_Q='UNEW_!ARL_,RBO
MTS_X=,>#?^BHZA_X 1?_ !='_#ICP;_T5'4/_ "+_P"+H^MTN_X,.5GYF45^
MF?\ PZ8\&_\ 14=0_P# "+_XNC_ATQX-_P"BHZA_X 1?_%T?6Z7?\&'*S\S*
M*_3/_ATQX-_Z*CJ'_@!%_P#%T?\ #ICP;_T5'4/_   B_P#BZ/K=+O\ @PY6
M?F917Z9_\.F/!O\ T5'4/_ "+_XNC_ATQX-_Z*CJ'_@!%_\ %T?6Z7?\&'*S
M\S**_3/_ (=,>#?^BHZA_P" $7_Q='_#ICP;_P!%1U#_ , (O_BZ/K=+O^##
ME9^9E%?IG_PZ8\&_]%1U#_P B_\ BZ/^'3'@W_HJ.H?^ $7_ ,71];I=_P &
M'*S\S**_3/\ X=,>#?\ HJ.H?^ $7_Q='_#ICP;_ -%1U#_P B_^+H^MTN_X
M,.5GYF45^F?_  Z8\&_]%1U#_P  (O\ XNC_ (=,>#?^BHZA_P" $7_Q='UN
MEW_!ARL_,RBOTS_X=,>#?^BHZA_X 1?_ !='_#ICP;_T5'4/_ "+_P"+H^MT
MN_X,.5GYF45^F?\ PZ8\&_\ 14=0_P# "+_XNC_ATQX-_P"BHZA_X 1?_%T?
M6Z7?\&'*S\S**_3/_ATQX-_Z*CJ'_@!%_P#%T?\ #ICP;_T5'4/_   B_P#B
MZ/K=+O\ @PY6?G]\&/\ DL/@7_L/6'_I0E=G^V1_R=+\3O\ L-S_ ,Z^Y?!W
M_!+?PCX4\7:'K</Q*O[J;3;Z"\2!K&,"1HY%<*3OXR5Q70_%O_@F+X?^*_Q+
M\1^,+GQYJ.GSZS>/>/:Q6,;K$6_A!+ FL7BJ2J*5^G8M0;6A^2E%?I[_ ,.@
M_#'_ $4C5?\ P71?_%T?\.@_#'_12-5_\%T7_P 76GURCW_ 7LY'YA45^GO_
M  Z#\,?]%(U7_P %T7_Q='_#H/PQ_P!%(U7_ ,%T7_Q='URCW_ /9R/S"HK]
M/?\ AT'X8_Z*1JO_ (+HO_BZ/^'0?AC_ **1JO\ X+HO_BZ/KE'O^ >SD?F%
M17Z>_P##H/PQ_P!%(U7_ ,%T7_Q='_#H/PQ_T4C5?_!=%_\ %T?7*/?\ ]G(
M_,*BOT]_X=!^&/\ HI&J_P#@NB_^+H_X=!^&/^BD:K_X+HO_ (NCZY1[_@'L
MY'YA45^GO_#H/PQ_T4C5?_!=%_\ %T?\.@_#'_12-5_\%T7_ ,71]<H]_P
M]G(_,*BOT]_X=!^&/^BD:K_X+HO_ (NC_AT'X8_Z*1JO_@NB_P#BZ/KE'O\
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M+H_X=!^&/^BD:K_X+HO_ (NCZY1[_@'LY'YA45^GO_#H/PQ_T4C5?_!=%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#'J\#'YW@\MJJCB&[M7T5]/Z1]1EG#F/S>BZ^%2Y4[:NVNC_4^Q:*^.O\
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M^@9H/_@/-_\ 'J/]:\M[O[@_U(SC^6/_ ($?8M%?'7_#8WC/_H&:#_X#S?\
MQZC_ (;&\9_] S0?_ >;_P"/4?ZUY;W?W!_J1G'\L?\ P(^Q:*^.O^&QO&?_
M $#-!_\  >;_ ./4?\-C>,_^@9H/_@/-_P#'J/\ 6O+>[^X/]2,X_EC_ .!'
MV+17QU_PV-XS_P"@9H/_ (#S?_'J/^&QO&?_ $#-!_\  >;_ ./4?ZUY;W?W
M!_J1G'\L?_ C[%HKXZ_X;&\9_P#0,T'_ ,!YO_CU'_#8WC/_ *!F@_\ @/-_
M\>H_UKRWN_N#_4C./Y8_^!'V+17QU_PV-XS_ .@9H/\ X#S?_'J/^&QO&?\
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MJ/\ AL;QG_T#-!_\!YO_ (]1_K7EO=_<'^I&<?RQ_P# C[%HKXZ_X;&\9_\
M0,T'_P !YO\ X]1_PV-XS_Z!F@_^ \W_ ,>H_P!:\M[O[@_U(SC^6/\ X$?8
MM%?'7_#8WC/_ *!F@_\ @/-_\>H_X;&\9_\ 0,T'_P !YO\ X]1_K7EO=_<'
M^I&<?RQ_\"/L6BOCK_AL;QG_ - S0?\ P'F_^/4?\-C>,_\ H&:#_P" \W_Q
MZC_6O+>[^X/]2,X_EC_X$?8M%?'7_#8WC/\ Z!F@_P#@/-_\>H_X;&\9_P#0
M,T'_ ,!YO_CU'^M>6]W]P?ZD9Q_+'_P(^Q:*^.O^&QO&?_0,T'_P'F_^/4?\
M-C>,_P#H&:#_ . \W_QZC_6O+>[^X/\ 4C./Y8_^!'V+17QU_P -C>,_^@9H
M/_@/-_\ 'J/^&QO&?_0,T'_P'F_^/4?ZUY;W?W!_J1G'\L?_  (^Q:*^.O\
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MKA_$G_(:N/\ @/\ Z"*Z*'Q')B?@7J9E%%%=IYH4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 367_ !^0?]=%
M_G7>/]]OK7!V7_'Y!_UT7^==X_WV^M<M;=';A]F-HHHKG.L*YQOB5X13QBOA
M)O%6B+XJ8;AH1U&'[<1MWY\C=OQM^;ITYZ5T=?DM^TY>R^ _^"A'BGXI0NR1
M>"+[PW<WS*>!93QK!/G\'4?C4Q:=:%-Z*3W[#:?LYS6\5?UU6A^HT7Q*\(S^
M,)/"<?BK1)/%48W/H::C";Y1MWY,&[>!M(;IT.>E='7Y!?L\C6_B'^VU9?$;
M2[]M.UCQ_;^*+[1KV1%D6"*-9+>U;:P(8*8^A&"!7N_@/]LGXC_$[P_\$O!&
MG:E#I_Q2U7Q/>Z9XPF^Q0L;>UL"3<GRRI5"Z,A! '((%5"\XT[Z2DDVNUVT_
ME&WO=KBJ>Y*=M5%M7]%?\=;=['Z#45^7OC7]M;XH>&_']GK6B_$Y?&6A/XMC
MTBYT?1_!FWP_!;/+M\K^U)461Y\#^'()R0Q KI/VE?VH?C)\-/CGXLL=6\97
M_P */"EG/ OAR>7P8FJ:+J<) WO<W@#3(22<B)3CIP1S,9*48RVYO\D_RDMK
M]>Q<H.,I1ZK_ #:_1[VZ=S]&I+F*&2*.25$DE)6-&8 N0"2 ._ )_"LWPYXN
MT+QA;7%QH.M:?K=O;3O:SRZ==1W"13+C=&Q0D*XR,J>1FO@SQT?&7CC_ (*%
M?!'4M(^(=C%9:GX3.JVCV.FK<6J6VPFYCCWL"XGVMME8!D#C@[:\7^&WC+XO
M_"#]G#XO?$WP1XXL-#T#PWX]O&E\.RZ+%=-JC27$,<GF3R$F-0'3 C /#9;D
M8=[?'I\7RM-0^[7U\K:DI<VD-=8_/FBY6]=/3SZ'ZXT5^=?QD_;$^(/B+XS>
M(O"_A7QO_P *UL?#6@6>H1I;^$I=>DUB^N($G$$A6*3R(L.%W\'J>>VWK7[4
M/QD\?7G[-.E^'KRV^'VM?$*UU&'6XM1T<3BVF@ 4RI%+AQC:[HI8 Y4-D=6D
MVTDM6[?^E?+[+_"]DR;I*[>EK_@G^3_/L?<OB7Q3HO@S1YM6\0:O8:%I4)42
MWVI7*6\$98A5W.Y"C)( R>2:THI4GB22-UDC<!E=3D,#T(-?F/\ $OX\_$9O
MV;/VD/#/CK5=(\=:S\/_ !)I^G6VK7^AVPBO(9;A<&6UVF+(V9'RY!/4X!KN
M/VJ?VC_'G@_Q3+H_@OXH-H4^D^&H=17PQX5\'?VW>O+Y6_?>R2)Y5M#C'*MD
M+\Q7I4<Z4>;II]SAS^NQIR/F4>NOWJ2C^;/T"KBO''QN^'GPSOX+'Q=XZ\.>
M&+V<!HK;5]5@M9'4_P 05V!Q[]*Y_P#9<^)NJ_&+]GCP+XTUI(5UC5],2>Z%
MNNR-I02K,%[ E<X[9KXD_9>\(>%OB'\)OC+\6_''PS3XS_$B?Q5=V5UHT]M'
M=7D40:)%A@60$1;5D8Y7!"I@'Y15U%*G4E3?V4V_DU'3YO?HB*;4X1FOM-)?
M--_DC])M+U6RUS3K?4-.O(-0L+E!)#=6LJR12H>C*RDA@?45:K\N?#G[1#_!
M?]B_Q--\%M-U[P=>Z!XZBTA]-\7S0Z@\$DQ!F@4; $0'C&-P.XYR<UZK\8/B
M)\9_@UX?\'^&_%?QUL+?Q?K=W=WDC>&_!@U35IX B>5;VEFL7E[$;?NDE(8Y
M&"=I!)-;K;3YW2EIWT=_Z0)/9^?X-K7MJOQ]6?>-9WB#Q'I/A+1[G5M<U2RT
M;2K8!I[[4+A(((@2 "SN0J\D#D]2*_/'PE^V)\8I?V7M.^*5_J7VL>#_ !T=
M&\5QS:1#;SW^E;HU+R1!3Y$J&0*1'C&><XJU\=/VB?%GQ/\ AU^TYXATJZTS
M4?A;X42RT71K.\TRWN[>]O1-";F9O,1O,5<X"G*_.IQD5$Y<L6UT5_E:+3^?
M,DO._9EPCS2C%]7;Y\SBU\K-ORUZGZ(6EW!?VL-S;31W%M,@DBFB8,DBD9#*
M1P00<@BI:_.7]H/]HKXO_#C4O!\5MKVJ?#3X</X1L;JU\1Z)X.@UFTGOFB4O
M'<EO^/>->@$:DXY"D'C[5_9\\?R?$SX+>%?$UQKND^)KF]LPT^JZ)')':W$B
MDJS(DBJZ'*G*L 0<C'%;2C;G?2+:^YM?H8J6D+_:2?X)_J=#KOQ+\(>%VU(:
MSXKT32#IB127PO\ 488/LB2G$32[F&P.00I;&X],TV[^)_@VP\(P^*[GQ;H5
MOX7FQY6MRZE"ME)D[1MG+;#D@@8/6OS%\>7;^._V /C[\2-1)FUKQ=XY#S2,
M<LEO!>0PV\(_V44$ >]>7^,M7O=4^"Z?LSO+*9_!OB#Q!JUR,G/]FVEG)=6S
M'V=I7Q_NBN;G?(Y6UM%_)J,I?^ J7X,Z732FHWT;DOG&Z7WM6^:/V0NOB%X6
ML?"2^*KGQ+H]OX8>,3+K4M_$MDR'HPF+;"#V.<52\"?%SP/\4(;F7P?XPT+Q
M2EMCSSH^HPW7DYZ;PC';^-?FQX)T>Q^*_C#]C/X;>-$^U^ )/!TFK#2YV(M[
M^^1)=JR#H^T1I\I[,1T8Y]1T"]^'/PW_ &\O"MCIWP7\1?##7=1:]T33[[36
MM['1=7@C5MT[6R(-X("D$$<E"<D5U.%JOL^[DE_VZVM?5K;MJ<W-^[Y^RBW\
MU?\ !=>^A]Z:%X@TOQ3I4&IZ-J5GJ^FSY\J\L)UGADP2IVNI(."".#U!J_7R
M=^QQ?2>%OC=^T9\-8"?[#T+Q)#J^G1#[MNM_&99(E]%#KD#_ &CZU]8UFM8Q
MDOM)/[TG^&Q;TG*'9M?=_FM0HHHH \J_:>_Y(OK?_72W_P#1Z5\,U]S?M/?\
MD7UO_KI;_P#H]*^&:_'.+_\ D81_P+\Y'[_P%_R*Y_XW_P"DQ"BBBOAS])"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^8?\^)?<P_M_*O\ H)A_X$CR"BO7_P#AE7X@?\^5G_X&)1_PRK\0/^?*S_\
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M (95^('_ #Y6?_@8E'_#*OQ _P"?*S_\#$H_L?,/^?$ON8?V_E7_ $$P_P#
MD>045Z__ ,,J_$#_ )\K/_P,2C_AE7X@?\^5G_X&)1_8^8?\^)?<P_M_*O\
MH)A_X$CR"BO7_P#AE7X@?\^5G_X&)1_PRK\0/^?*S_\  Q*/['S#_GQ+[F']
MOY5_T$P_\"1Y!17K_P#PRK\0/^?*S_\  Q*/^&5?B!_SY6?_ (&)1_8^8?\
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MCYA_SXE]S#^W\J_Z"8?^!(\@HKU__AE7X@?\^5G_ .!B4?\ #*OQ _Y\K/\
M\#$H_L?,/^?$ON8?V_E7_03#_P "1Y!17K__  RK\0/^?*S_ / Q*/\ AE7X
M@?\ /E9_^!B4?V/F'_/B7W,/[?RK_H)A_P"!(\@HKU__ (95^('_ #Y6?_@8
ME'_#*OQ _P"?*S_\#$H_L?,/^?$ON8?V_E7_ $$P_P# D>05ZS^RY_R672?^
MN-Q_Z*:IO^&5?B!_SY6?_@8E>Q? #]GN^^'FL2:_K\\#ZCY30V]K;MO$0;[S
M,V!EL< #C!//IZ^4Y/CUCJ4YTG%1DFVU;1.YX.>Y_ECRVO3IUXRE*+22=W=J
MW0]ZHHHK]M/YS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "K=5*MU+*B%%%%(L*X?Q)_R&KC_ (#_ .@BNXKA_$G_ "&KC_@/_H(KHH?$
M<F)^!>IF4445VGFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!-9?\?D'_71?YUWC_?;ZUP=E_P ?D'_71?YU
MWC_?;ZURUMT=N'V8VBBBN<ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** %7HWTI*5>C?2DI %%%%, H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5MUB5MUG,VI]0HHHK,U"N'\2?\AJX_P"
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M*  .IK>TW4(=5TZUOH"?(N8DFC+#!VL 1D?0TEK>W0;TM?K^G_#EFBBC(]:
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M_A=.N?\ /M8?]^W_ /BZ/[<P?=_<'^K>/[+[SVJBO%?^%TZY_P ^UA_W[?\
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M[.HFME;U:4.2WEWOOK8TJ5?:0DGN[_)N7->_EM;;0]FHHHK0YPHHHH ****
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MAOMD7D3O'"R@DQF58RA<8/R!BV01C/%;7Q _:=^&/PM\/:%K?B;Q9;Z=8Z[
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M$?VZ/$OBK7O&G@V\^&$6C^/=)\.3:_I^G6/BBTU**Y5" 8I)455AD!8$HV>
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M3^X/[4P/_/Z/WHXRBNS_ .%1^(O^>,'_ '^%'_"H_$7_ #Q@_P"_PH^H8O\
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MC7WV5T)X?"QA45GJ?EV=8FGBL;.I2=XZ*_H@HHHKUCPPHHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBNXKA_$G_(:N/^ _^@BNBA\1R8GX%ZF91117:>:%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $UE_Q^0?]=%_
MG7>/]]OK7!V7_'Y!_P!=%_G7>/\ ?;ZURUMT=N'V8VBBBN<ZPHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** %7HWTI*5>C?2DI %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN%P-3V=>5G:^S9[V!R3&YE2=;#1O%.VZ6OS]3[BHKX=_X>#^(?\ H4],_P#
MB2C_ (>#^(?^A3TS_P ")*X_]8<O_G?W/_(]#_53-?\ GVO_  )?YGW%17P[
M_P /!_$/_0IZ9_X$24?\/!_$/_0IZ9_X$24?ZPY?_._N?^0?ZJ9K_P ^U_X$
MO\S[BHKX=_X>#^(?^A3TS_P(DH_X>#^(?^A3TS_P(DH_UAR_^=_<_P#(/]5,
MU_Y]K_P)?YGW%17P[_P\'\0_]"GIG_@1)1_P\'\0_P#0IZ9_X$24?ZPY?_._
MN?\ D'^JF:_\^U_X$O\ ,^XJ*^'?^'@_B'_H4],_\")*/^'@_B'_ *%/3/\
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MQ>6.*Q4+7VU37X$U%%%>B>4%%%% !1110 4444 %%%% !1110 4444 %%%%
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MS1LK,-Q#D$\E1G->):+X#L]$_9 \,_%.'4-7?QQH'Q$CT72=3EU.=OL-BDQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5;JI5NI940HHHI%A7#^)/^0U<?\
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M1OBU_P!"A)_X'6O_ ,=H_L_&?\^9?^ O_(/[4P'_ $$0_P# H_YGC]%>P?\
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M%Q-.E2H5%)IMNSNE\T:%%%%?>'YD%%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6BS#F1/14'VG_9_6C[3_ +/ZT68<R)Z*@^T_[/ZT?:?]G]:+,.9$]%0?:?\
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MBH/M/^S^M'VG_9_6BS#F1/14'VG_ &?UH^T_[/ZT68<R)Z*@^T_[/ZT?:?\
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MN>KNCJI?"R.BBBLC8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!\723_=_J*93XNDG^[_44RD/H%%%%
M,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7/5W1U4OA9'11161L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTG_P 7_&C_AOCXK_ //UI/\ X +_ (T>RD'M8GZ945^9O_#?'Q7_ .?K2?\
MP 7_ !H_X;X^*_\ S]:3_P" "_XT>RD'M8GZ945^9O\ PWQ\5_\ GZTG_P
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MPSM;W!R#[@U$H..Y<9*6QMT445!84444 %%%% !1110 4444 %%%% !1110
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MOQ;?FQTJW*Q@(A>6:1ONQQH.6<]A[$G !->6?#3]MGPGX^\?:;X.U/POXO\
M &MZO&9=)3Q=I7V--14#/[I@[9)&<9P#T!)XIIJ5=S7Q7O\ .VZ\[?YCM*-'
MEM[MK?+K\CZ&HKQCXN_M:> O@G\2O"7@?Q'+?#6/$;(()+:)&@ME>01H\[,Z
ME5+9Y ;[IJS\?_VFO#G[.S^&HM<T;Q!KEUXAGDMK&T\/6:7,SR(%)&QI$))W
MC 7)/-3SQY>:^E[?/L+DES<MM;7^7<]>HKP?X3_ME>#/BOX_3P2-&\4^#_$\
MUNUU;:=XKTHV4ES&N2QC^9LX )YQP#C.#7;?&CXS6OP4T.QU2[\+^*/%27=Q
M]G%OX6TW[;-&=I;>Z[EVKQC.>I%5*2C'F>W_  ;?F)1;ERVU_IGH5%?.'P;_
M &Y?"OQR\3Z?H_A[P/X^BANYY+?^U[W146P@D12S++,DS!3QC&,Y('>OH^FM
M4I=&2TXOE>Y-9?\ 'Y!_UT7^==C<?Z]_K7'67_'Y!_UT7^==C<?Z]_K7/5W1
MU4OA9'11161L%>??%;X^^ /@A-H47CCQ);^'Y-<N#:Z>LT4LGG2#;D?(K;0-
MRY9L*,CFO0:_([]LOQ]X=^//[1_Q(TW6=-\1:SH_A'0)?#_AY] TV2\CBUDL
MLCRR%3A0'!0]20HXXK*=3EDE:^[?HE=V\WHEYM&M.GSIMNVR^;=OPU;\DS]<
M <C(Y%5=5U6RT+3;G4=2O(-/L+6-I9[JZD6.*) ,EF9B H ZDU^=&@?M3>(_
MB!\,_P!E"_LO$%_I6H3>,(O#7B>""X:+[2\(1"DX!^8.I5]I_OFH?VD/$VO^
M/?%G[8WAF?QAK:>'O#WAS3;RRTZTO2((G$"M+%L.0$=LAP ">>155G[/G4=;
M<WW1C&5_1J2%1A[3EYM+\OWN3C;U31^C6AZY8>)M&L=6TJ[BO],OH4N;:ZA;
M<DT; ,KJ>X(((-97Q#^(?A[X4^#=2\5^*M1&DZ!IR*]U>-%)*(U9@H.U%9C\
MS < ]:_/GPN?%7V+]F#X)V'Q*\5^'/#?C#P^VO:CKEOJ"QZBY%LKI86TX4&*
M--N%49.'&<XJKXM^+'CWP-\(/VJ_A^/'.L^)H? $NG_V+XJO;GS-1C6>5-\$
MLXP79,$9//WN@P ZS]GS\O3FM_VZU%_B_G;TNJ,?:<E^O+?_ +>V_KI?R=OT
MHTG5+77-*L]2L9?/LKR%+B"4*5WQNH96P0",@@\U;K\X+B[\=_%KXW>,O"Y^
M*?C'POH6D_#/3=>C@T#4S;L]Y]EB(;?@E068L^S:6X!-<E\/_'GQ.T[P1^S+
M\5K_ .*WBS6-3\7^*X?#^I:-=W@_LQ[/S7A , 4!I"L9)D8EB6SG(K5Q3J."
MT7,E]\Y07XQ^[7R,]534WVO]T%-_@_O/U,HK\P_B-K7Q#\52?M9>((OBSXTT
M*'X=:L)M#TS2-4:"!6.25DX+-'M0 1@A<DD@UV/PQ\1_$#P9^T)^SS=:C\3/
M$_BJ'XG^&KK4=<TS5KI7L8IEM?.3[- JJD(!91\HS\O7DUC"?,D^Z3^^+DOP
MB_P[FE2'(I/M?_R5I/\ -?B?H717Y@R_'KQW%_P3;UKQ4WCC65\6IXQ:PBU8
MW\GVL1B[0>4),[L>7GY?3->A^)K3QM\8OVL/C'X-'Q3\9>$O#6A^%K'5+:U\
M.ZD;9A<FW0J0V"40LS,P3:7.,GBDYV5_*_\ Y(I_D_O*]F^;DOW_ /2^3\]?
M0^^Z*_*C3_VC_B9\1_A7^S7X5OO$'C-AXI759-9U+P;-'%KNHBTFDCBBBFD=
M &VJ"YW9(Y.X\'ZW_80\8>-]=\,>-]#\8W>JZG!X?UV2TTG4/$%S;S:H]J1D
M179AD<><A!#;CGGVK91NY+M?YV:3_%_@S%Z)7W?X;_Y?EYV[SXO?M@?"'X#>
M)X?#WCOQC'H&L36RW:6SV%U.3$S,JMNBB9>J-QG/%;7A;]I'X:>-_AQJ_CW0
M?%UEJOA72(I)M0OK99&:U5%W-YD6WS%.T9P5R1T!KYW\0V]I=?\ !5#24O8H
M)H/^%=N2MPH9<_:7['BO(M2U"W\*_M"?MB7?P[GCTW0K3P)]HGET9@D$.J")
M"&4I\HD'[\G'.=_?-<SJ.-/F>[4VO+D<M_7E[K5HZ524JG*NC@O7FY=O_ NS
MT1^B_@_Q=I/CWPMI7B/0;P7^BZI;I=V=T$9!+$XRK;6 89!Z$ UL5^6_BOQ'
M\7O%7A;X0W=CK?C;Q'X</@.TN[[2_ASXGCL==AO6Y:[G@PTMQ&04P,;<_P 0
M/WM;QM^TMXC\9_"3]GGPYX8\9>.M5L?%>H7MGK>N:3;0V'B2Y^RE1]E0F78D
MIWX+B3YMH.220>B>DY0CNI<MOFU?TTWMK=6UT.>*O&,F]&K_ /DO-;^ORU/T
MRHK\X-'^-WC#P1\ _C#H_B_QGXVT2QTO7+73?#FMW0M=0\4;9RV;.39.56<&
M,C>[@@,2.@ YWX9>/_B]X8\<_&;P-;^)O%'AJ9/!(U;2(_B?XFM[^YL;II8T
M25K@_) 7#MA&.%)4MVK-S2O;M?\ \EYK>MNF]_+4T4'HF^MO_)N6_I?^KZ'Z
M@T5^;7[+_P 5?%GP[^+>EZ-XXU7XJ6&N:OH-U/!HGC#4$US2=;N(83*9K.[4
MKY0PN0J*ZD'!?D9X'X5?&OXO:UI7@3XK6_B#XA:EKNM^*/L^I66IWUG%X3N+
M)IG1K6UA:8,LRJO&$#9#8Z G1+FFH+K;7UDXK\5KV7GH9M<L7)]/QTYO^!YO
M;34_6.N:OOB3X9TSQ;:>&+K6+>'7+J"2XBM6S]R-HE?<^-JG,\("L03O& :_
M-/XG?$'XG>!_B9XQ\8>+?%_Q&C\,V/B0_8O%?@+6K?4_#UA9^:H2VNM-4A58
M!E5O,<-EA\K'[WU_KW[&O@3XF_&G1_C'--%<79-I>):?V9;FVNE6-LM*K)EW
M<M"PD;+IY2A2.T4VZD8SZ/?NKJZ_X/H[7W+J15-RCU6W9V>O]>>MMCVW0?B1
MX9\3Z_JFBZ7K%O>:GICQI<P)D8,D0E78Q 63Y&#90MC/.*Z6OGGX+_L4^#/@
ME\6-6\>Z2Z3ZCJ"W"BW;3K:**T,DI9?L^Q 80L9\HA,!Q\S9-?0U4OABWO;7
MR9#LI-+;IYA1110!X1^V_P#\FU^*/^NEG_Z515^7%?J/^V__ ,FU^*/^NEG_
M .E45?EQ771^%G+5W"BBBN@Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OUE_90_Y-W\#_\
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MU0>7N,M_92EI >^2(MK9^7Y<+]/_ /!2JXGM?V4-=DMYY+>8:A8;98F*LO\
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MG_DW[6O^QJU'^<=?6]9'ACP?H/@G3WL/#NB:=H-B\K3O;:9:1VT32-]YRJ
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MD@L1TXX&.X^$GP:\'_ SPFOASP5HZ:/I?FM<2*)'EDGE;&Z221R6=C@<DG@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPY\4_C!\1-5\:R>&)?!<%IX=>SBBTS4],NS->O+I]O=L/M*706(%IRH/E-@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<C\3? '_  L71])L?M_]G_8-<TS6?,\G
MS?,^R7D5SY>-RXW^5MW<[=V<'&#P/B2'XX_\)GXX?1KK01X=;2PGAV.>RW2"
M[7!S(?M"X#>85W'(_<@[%Q^\F\7^)?'O@/\ 90\2Z]KM]:1?$'2/#=Y=R7EE
M;KY*744+LCJC%U;E5//#==JYVB)-*'M'TL_/1M_A;\4:04O:*,=WI^7^?X,P
MO'_[(>G^/_A?XP\*W'B&6RU+6-=O]>T[7+:TQ+I<MSD,@7?^\78SQN,J'5V&
M%[/T_P#9[\?>%M1\5CPO\2=)T?2O$9M6N1-X7>XOK=HK*&T+0S_;5C4E8 PW
M0OM+?Q8K/U#QAXP^"&I_#[5_$?CZ\\9^%O$D[6.HP:OIUG#/8N;.:Y6>%[6&
M+*CR&5E=6X8$$8YO?\-;+IFB)J^O^ M;T>PU'0KGQ!H>R:"YEU&WA1'9&1&_
M<R[)$?:Q(VELL"I%4XJ"E'HERO\ [=6B?R7SMU:,XR=1QEU>J_[>>K7S^[R3
MU[?7O@=IEW^S_<_"G1KM](TMM%_L6VNY(_/>) FP.RY7>W<\C))Z5R>I?LN_
MVAXPU;7?^$F\O[?>ZA>?9_L&=GVK2X;#;N\WG;Y/F9P,[MN!C<<W3OVH$\6:
M)X9U:UMOLEO=>(TTPR:-JMEJ=I>(;.:? F3=A1LPPPCAE'.W.6:)^V1:MX=L
M]>\2>"M5\.:9J?AJ3Q/I3?:H+F2\AC,*M%L5ALD+7,.P,<,'Y*D$!S7M'/FU
M;NG\US?BE?OHP@^3DY>FJ^_E_/Y%ZR_95^Q^ ?$_AK_A*-_]M_V+_I7]GX\G
M^SX+6+[OF_-YGV7/4;=^/FQD^<6?@/QNWQ5\.>%M-M=8M?!VC^.KGQ');7^A
MA(H86-Q*9%U(3E)HWDFRD2Q"5?,PYPE>[?#;XOZMXQ\=:YX2U[P9=^$=6TK3
MK34V$U]#=1S17#S(NQH^ZF!@<XYR!D ,?.M)_:DU53/INF^$M4\8ZA#%K.IS
M327EK:^5;6>HRVS)]U03\@"#&2,;CG+4Y3M4C4D]=_\ P&SO\N77T8E']VZ<
M5IHO_ DTOO4M/5'=_$CX#_\ "PM4\=7G]N?8/^$G\('PIL^R>9]FR\[>?G>-
M_P#K_N?+]W[W/'._$;]F"Z\<:OJ>HVOBU=/-[!I$$EE<:>\UK<)8FY)CN$2>
M)I8I?M.2@9,&-22P.*F^/_Q@NM-_9LL_'GA;5[KP\FJ2:--#J*6D<]Q;VMW=
M6ZNPB=)%+^5*W&UN>@->0:[\=_'OAG3/%-]X8\4>(/'WAJRM=,DCUK6?#D.G
MSI>RZG#"]G"3;6\4WF0.^3L^0[?G&X82C[WLVMG;YKWOSD_5Z=D-RO'G[K\^
M5?\ MJ]$K]ST#P7^R)J/PX,.I>&/%VE:3XBMM8OM2MGC\-A=-BANX((I[;[(
MEPIV[K='1A*K @!M_P Q;(N?V&()=/T"277/#FOZ_86-YI]U?>*_!\&JV\Z3
MWDUT)8K=IE\B9'G<!@S*P/S(1@#N[C]I6YTW1_$G]J>#9],\0:%J-OI]W8W.
MK6J6D2SPB:.X>[9@B1;#@DC<&&T*V03QK_MWZ%+HFAW=KH4<MQJ,U_;D3Z[9
M06;RVDJQO%;7;N(KB1]P:-5(W+DDK2^)J/:UO+2WY/7S>NHU>*;Z/_._YK_+
M0];\0?!J#5_AWX2\)VVHK8P>'[[2KQ)TL8D$HLIHY=@BB\N./?Y>/D 5<\+@
M8KB=/_9@U"U;1]&N/&:7'@70M5N=9TK1ETG9=QSR^<42:Z\XB6*-KARJB)&.
M%#.V.<SQS^W%X.\"^.+S0+N& )IDEI#J;7&L6<%Y#)<)&X$-FTGF7 194+E.
MG(7>5('HW[1/B?Q?X/\ @]XFUKP2FFC6;&PN+K[5JCMY=K''"[F18U4^:^5
M5"57+9)P,&:K7)*I+9MOYZ:_@K/INATU>2IQWLE\M=/Q=UOT9I^#OAK_ ,(E
M\&=(\ _VC]J^P:''HW]H>1L\S; (O,\O<<9QG;N/IGO69X0^!^E>#O@Y;^![
M/[''=)H"Z'-K,%@D3SD0>4960')R?FVEC]>]7M3^)=MX(^"R>-]?\ZYBM-(B
MOKE;:-3+.[1J=J+P-S,P ' R1T%>/1_M+^+M#^*GB#1O$/@V^M+J6ST6VT/P
MQ'=6LIN+RZDOB\GVD8 3R[8;]Q^7R7VAL@MK6C>I4ISU<G9^>^WWO;N9TIVI
MPJQT4=5Y7Y?^!OV.D\3_ ++]SKN@:586?C.XTBXT_P '+X36[MK1@SXFM9#,
M=LJD(PM2C1A@2LK8<8S7,Z7^Q?)I.G^+X8-;\*1KXCDT^2XTL>"XFTAOLHF!
M26UDN'>19!*"6\U9 R B3!VC4\2_MC67A.QCM]5\,/I'B*/5Y=%OK+5]6MK.
MRM)T@CG7=>N?+(ECEC,8X+$D$*5-5?B#^W-X4^'U]!:WEA%%<Q:/;:WJ-I?Z
MW8V=S!%,K,L4$;R_Z5,%5B5B)7[N&)8 RWS:M[O\VY_<[M]NGD4DTDET_2T?
MT2,N;]A>R&F^'6&K>']7U;28KZVV>*/"RZOI:07,PF$=O:2W&Z 1,,1_OFPI
M8-N!X]:UOX2:U#\"8_A_X0\61^$]3BLHK&/7H=(B C4$>8R6UNT"1EQN \LK
MLW97D TSXQ_M!^'O@_X,T/7[R2"=->N8K331=7L-C!([QM*&EGF*I$@1&8DY
M/0 $D"O-)_VZ_#<GAG1-2L-+M[B?4+V]T]S<:[9P6$<]MY9:-+XN897D$J&(
M*1O&[.TJ0!ZJ5-]'JOZ]=?74([QJ+KL_Z]-/30]9^#?P[UKX8^#SX?U"_P##
MMW86RA;&'P[H4VF)$.2YD$MY<F5V8[B^X$DDG<3FO#?A?^RMKWCCX.^$]&^)
MNNO_ &?8:#>:=::%;Z8+6ZLGNH6@=IYC*XE9(W94 CC W9;>>:]4L/V@;[Q!
MXDGLM \ ZQK&EZ=/9VNKW\=S;J]E-<112[%BWDR^4DT;2,IP 3MWX-<?K7[7
M<)\0ZMX5CTE='UB:PU6337.JVES=Q2VD$DFZYLU9GA5A&64MNSP&"DXJ*LDE
M.4];I_<D_P T]'UW3*I+6*AIJOO;T_X*^\K:%^Q9;Z9I&H0MJGAC2M3,=E_9
MU]X5\%VFDF&>UN$N([BXVN[W#&2*/<@>.,@'"*2&&PG[,7B#5==O-=\0_$"*
M[UJ[U^VUQY]*T4V20^382V:Q0JUQ(5XD#AV9B"N,'/&3/^V!'X(T;P:OB32D
MG:_L=(-WJ$VJ6=K<7,UVD69+6S+!YE5I,OM"XPVT-M-5] _:7URS\3Z@_C2'
M^R-&L/$'B"T!T^2*:.2TL+5ICYH,>_*A<@HPW$\\#%:U%RN49/2-V_\ MV4;
M_BX^J\M#.G[RBXKXK+_P*+LON3]'YZE/0/V&&TXWSWWBO3);B\\*:CX5N;S3
M_#QM[J\6Z6(?:[F9[F5YIE,63DA3N.%3)SVS?LTZAJ/@?Q_HNJ^++>XU'Q>+
M$SWUII+0Q6[6UO!#E8FG<D-Y&[!?C=C)QS0UC]K>7PGH-WJ'B7X?ZMHLSZ*=
M?TJS-Y;S/J%LLL,;H2C$13+]HA)1LC#\,<''H'P\^*VH>--6\5:%J7A:?PYX
MCT!+>:2PGO(IXYHKA':!A+'D DQNK#'RE?X@0:&W&]^WY2>G_@5]-_N!6DTU
M_5TOT2UV,CPA\%?$'@OQ)LT_QP8?!"ZQ=ZVNA1:8%NFEN&DDDADN_-(: 2RN
MX01*^=H+D#!Q_B#^SEK?C;Q/XYGMO&\6E^&O&MG:Z?K.E'1_.G\B%&1A!<><
MHC>1792S1N ",#(S7+?"#]IWQ?XQTCPOIVJ^#A<:[JFEW6LW=_97\26]K:1W
M1@+[67)89&$ .=IR:CN_VS;/P1X$\(ZOK.E2W=G>Z+IVHW.H:EJUC9W=Q]H5
M<_9[?*&XD7.7$:HO.%R>!,5=)+962_%?^VM:]BVW&3EUW?X/_P!N3T[EO5?V
M-Y=5^(L'B:7Q3I\XM/$MOXAM)KS0C<:G D4BL+);M[G"P *541Q(1QDN 0U*
M[_8FEU*7Q>]SXLTVUDU_1[_29;C1_#BV$MX;DC]_J"Q3B*[DC ^5ECASDD]:
M]$\%_$75]1\*?%O4=2O'F/A[6]3M;)H8HU>&"&"-T4?+AB"S'+@YSSD5QJ_M
M:W&E:--='P=JFM:5H>BZ1JVMZT;NVC:.&\A#[Q%A?,D7YF95"C .,<+2@KQ2
M6UD_E./7Y1LP=X2OU3?WPET^<M"'Q!^Q/I=_;V]CINHZ,FA:7JIU?0_#^N>'
M8]2TRP>6%H[N%H&E0/!(6\U44QF)\E6(.T=3X'_9OG\!:QX$U+3-;TFVD\/K
MJ<5[:V/AR&RM+N*]>*1T@A@=%MRC01A6;S25!W%B=U=3\5?BS>_#[7?">AZ5
MX7N/%&L>))KF&U@ANX[9(S#"96:1WX"[0>1DYQP<UYYH'[7-QK^D6VHI\.]7
MMH=2T"_US2(I;V!I;TV907$!5"WEMF0;"<A@/X>E-2Y6Y7V_1?Y(2A>T4O3Y
MO_-_J;_CW]GB\\9?$:^\10^)H;#3[^31)[G3Y-,,TIETV]-Q&4F$RA5=6="I
M1B"58'@J<KQS^RW=>+-2UB\@\4VR0ZEXD.OS:5JFE/=:?<*;&*T\BXA2YB,P
M4Q>8K%P Q&4;&:@\<?MI>$O"+1M##%>6ES%IWV34+G48+*TDN+R*6X2*2:4A
M(PD$7FLQ)XDC 5BP%<T?VT=-U*[\/>)+65D\+V]EKHUG3K&2WOC-=VAM!$L$
M\9*R!OM'R,K@-Y@W8(("4;7BEM>_X-^?V8_AT8<W,U+O:WW-+\&_QZHW?AU^
MS#K7P.TJ_OO"WB&PU+7+?1M3LM,M7T9;:U6:YOFO$S&DP4(C-Y>Q=HV\@C&*
M]9\>_#N3Q[<>#+B74%L9?#^L1ZNZK!Y@N"L$T1C'S#:#YV=W/W<8YR/-M>_:
MGO/!T=[8>(?A]J>G>*8FTUK;18K^WG^V0WMT+6-TF!"!EE.'5L8XPQ!S3M#_
M &H[Z]\06^G:M\/M1T:!/$2^%;^].H6\Z6^H.@DB"*IW2QLK1Y?"X+@;3@D.
MW.E'>ST]>9/_ -*DK^;2\A2LN:3ZWO\ ./\ \BG;RNT4]4_8^L]=^'G@GPE?
M^)IFM?#FBW^D-<6]F(Y+@W"(%F7+L(S&T8;:=X;IQ71?\*0\6:_K?A_5_%WQ
M CUJZT?5[;48;:QT;[':!(K>XA*K&9Y&620W.YY"Y'[M0$453\ ?M2Z?XU^*
MEMX'N-&72K^]MKJYM4&KVMU=1K RAENK>)R]LS!@5#9Z$$@C%;7BC]H"S\,P
M^/I'T>><>$M2T[390LP'VAKL6Y5EX^4+]H&0<YVGUI_&U+OK]TO\_P"K#>S@
M_-?>M?P/-Y/V+K[5M'T?P_K7CT7?AK0M*O\ 2-)M;/1Q;W,4=P4*22S&9Q))
M$8H\$(BL!RO.:N^*?V2-7^)4GB2\\=>-=,\0:GJ4.DI:"/PRL=E;/83SS1F6
MVDN)1.DAG8.C,N<M@KD!=[3_ -J$S^)DMKWP;?V'AM_$MWX577FO(64WD)E^
M;R0=_E-Y)&[J&.,$?-7'W?[66IKXD\(^(]0T&_\ #'PRO= U?7_M<[V\[ZA:
MP1121.44EX7VL6"9Y#C)R"!%U**GT6M^VG-?U:U75E-.[I]6[6[ZV^ZZMV1I
M/^Q_GP3/HB7?@:,W6J?VC<Z<GP^M(]$D40^6B"T259@RGYUE^TEPQ/.W"BW\
M0_A=J7A#]G'PW\.M+;5?%VI#5-+@2[$+OA4U"*XD>0DMY4*(C@;F.%5%RQQG
M"TS]O30=7M;N*QT&+5M;4V#6NFZ+K]E?B9+NZ2U4/+"[)%*CRIN1^,,"&89(
MZ?5/VL[3PQJ=CI'B+PS<Z7KLOB:U\.W5E'=I.MJL\$4JW9< !H@9HT) ^\:T
M5[JW>/S:<4E^*3]=>IF[6]$_QN_^#Y[+H2Z#^S7K.B^,/#=V?&T,_A;P]XCU
M#Q%8Z.-&VW#27B70DCEN?/(95:[<J5B4X&&W<$85Q^Q%H=UX4\7:/<:RM\=4
MUFWU/2SJ&F1W-OID%O,TUO8M [%9X%>6?*DKN64CY2 :;XN_;:TWPCX;'B*Y
M\,F+0?*GNUNK[6K2S>[MDN)8E:TCE8-<2,L7F>6H'$B#<2<5W3?M$V(UNYT,
M:-<'74\2VOA^&P\Y=T\<\"W*W8..(Q!YKD>L++G/-1%*227E]]XI?.]M=]^E
MRYNS;EY_=[S?RU;?35>1A>!?V68O!VJ>'-2&H:!9W&E:]+K<EIX:\+0:192!
MK&6T6%(HW9EQYI<O))*Q.0-H(QE:U^QW_;%G>P?\)=Y/VE-:3=_9N[;_ &AJ
MD-__ ,]AGR_)\O\ VMV[Y<;3](455WS*75?Y6_(EI-6_K1M_FV?.<7['.EV?
MQ4N_%-K-X9^QW>O#Q%*;WPA:W>L+.6#O%%J$C'9$SC=_JC(N2$D7C'I'Q \
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M%8.D]JTP\Q7$?F JZ,C;<$X)/U%1222;?>U_D[HIR;MY7_'<\K\.? R+P_\
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M[)WAW0+.TM/"WB;Q5X-METJWT:]30[Z*,ZA;0EO+\UWA=HW'F./,@,3@-@,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>rnac-20241231_g2.jpg
<TEXT>
begin 644 rnac-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )X!5P# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK(\3>+-)\':<U]J]['9
MP#.W=RSGT51R3]*\1U7X^>*?&M[)I_@'0)& X^US1^8X]#C[B?\  B17;0P=
M;$+FBK175Z+[SDK8JE0?+)Z]EJSZ%JI/JUC;-MFO+>)O1Y5!_4U\]'X%_$CQ
MM^]\3^,6M$?K;I*TN/7Y%*H/P-3Q?L9Z.RYN/$=])(>K1PJF?S)KK^J82&E3
M$:^46_Q.?ZQB)ZPHZ>;2_ ^@K>]M[L9@GBF'_3-PW\JGKYJO/V+[:(F72O%M
MU:3C[K2VP;GZJPK-F\!_'/X7?O\ 1->/B:QCY^SM-YQ*^GERC(^B'-4L%AJN
ME'$*_P#>3C^(_K-:&M2D[>33/J>BOG3P-^UW:/J T?QWI,OAK4E8(UPJ-Y0;
M_;0_/'_X][XKZ$LKZWU*TANK2>.ZMIE#QS0N'1U/0@C@BN'$X2MA':K&U]GT
M?HSJHUZ==7INY/1117&= 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1W!*P2$'!"G!'T
MK$^TS?\ /5_^^C6U<_\ 'M+_ +A_E6#0!)]IF_YZO_WT:/M,W_/5_P#OHU'1
M0!)]IF_YZO\ ]]&C[3-_SU?_ +Z-1T4 2?:9O^>K_P#?1H^TS?\ /5_^^C4=
M% $GVF;_ )ZO_P!]&C[3-_SU?_OHU'10!)]IF_YZO_WT:/M,W_/5_P#OHU'1
M0!)]IF_YZO\ ]]&C[3-_SU?_ +Z-1T4 2?:9O^>K_P#?1H^TS?\ /5_^^C4=
M% $GVF;_ )ZO_P!]&C[3-_SU?_OHU'10!)]IF_YZO_WT:/M,W_/5_P#OHU'1
M0!)]IF_YZO\ ]]&C[3-_SU?_ +Z-1T4 2?:9O^>K_P#?1H^TS?\ /5_^^C4=
M% $GVF;_ )ZO_P!]&C[3-_SU?_OHU'10!)]IF_YZO_WT:/M,W_/5_P#OHU'1
M0!)]IF_YZO\ ]]&C[3-_SU?_ +Z-1T4 2?:9O^>K_P#?1H^TS?\ /5_^^C4=
M% $GVF;_ )ZO_P!]&C[3-_SU?_OHU'10!T=%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QOQ*^)-E\/=+WN
M!<ZC,"+>U!ZG^\WHH_7\R-[Q+X@MO"^B76I71_=P+D*#@NW91]37D?PW\(7'
MQ"\0S^,?$2^=!YG^BP/RK$=./[J],=SUZ'/HX6C!IUZWP1_%]O\ ,\[%5YJ2
MH4?CE^"[_P"1G^%?A/J_Q/U!?$GC>YF^S2?-#9 [69>H&/X$]AR>O'4^Z:3H
M]CH5C'9Z=:16=JGW8H4"CZ^Y]ZN45EB,54Q#L](K9+9&V'PT,.M-9/=O=A11
M7G'QA^,%G\--+,4.R[UR=?\ 1[7.0@_OO[>@[_F1C1HSKS5.FKMFU6K"C!SF
M[)'H]0WEY!I]K-<W,R6]O"A>261@JHH&223T%<!\'_%/B#5/ <FL^,6BM<NT
ML4\BK%FWP#O8#  SG!XR,'W/B'Q)^(.N_M >)T\'^$$D310^9)#E1, >9)#_
M  H.P^G4X [Z&7SJUI4Y-*,?BET1R5,9"%.,TG>6RZGKUU9_#K]I72+^)%34
M7LF\DWB1-#<0$Y*E6(!*G!X.0<<BN5\0>)_#O[)7PZ31-.GDU?7;@M+!;SR$
MEG/'F.H/R(,=!]['U(-7UGPY^REX#&F:;LU+Q/>J'(?K*^"/,<#[L8YPO?G_
M &C7&_!CX':C\4->/CWQ^9+JWG?SK>TN.MT>S,.T8XPO? _AZ^K3I4XPE4JS
M?U=/W4]Y/R\OZ]..523DH0BO;-:M;)'<_LM7'Q!UZQU;Q%XOU">?3=2*O86]
MU][J<NB_P(00 !P>H&,$^\UX;\0_CMJ'PR^,.BZ'J>G16?@^ZA""\')8M@>8
M#_"$/!7T)/=:]Q5@ZAE(92,@CH:\C'QJ2FL1**C&:NK;6V^_N>AAG%1=)2;<
M=[BT445YAV!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% $5S_Q[2_[A_E6#6]<_\>TO^X?Y5@T
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M2R0)=+#+"=Z'#*4E574@^H&001P0: .QHHHH **** "BBB@ HHHH Z.BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8>RJQYBJE^1V/:/@9\&-!^!/PYTOPOH=K%%Y$2F\NE4"2[N,#?*YZDDYQZ#
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MCQ!XN^)'AW3/&&O:AKVL:>!K$"W)TFWM;Z>TAMK7=G[/B.%7)BV,SN7)+'-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=!)$L%JB&>1RAW[%C+!0Q( 5L8\E3^?\$>E]9PG_ $#_ /DTOZ_I>=^ \/\
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M[S2W#0VD*Q(TLCM))(0H +.[,S'J68DY)J[110 445Q7_"YO!WE^9_;'R?\
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MM+\2)MQ@VCGI/V[?AU'^SQ%\8S9ZY_PCDFH?V8+ 6\'V_P _>5V[/.V=!O\
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MEINEO?1ZWMV*AB.>2C;?S\KGVQ1117CG:%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 (RAU*L RD8(/>N2UZ_M? >E>5I]L!<7#,4XSSZGUQG@5UU0
M7-C;WNS[1!'/L.Y?,0-M/J,UM2FH2]_6/5=SEQ%*52#]FTI=';:^YY]X1\%-
M<S-KNNDR.<RK'+SGON;V]O\ )R/$&K:E\2]7&E::K1:=&V6+< X_B?\ H/ZU
MVOC$Z];RQ76FE9;6)3O@5<EO7([CZ?\ UZSO"GC30[9&MWMETB9SE^/D8_7M
M^/ ]:]>-2<D\0ES/HE]GY'STZ5*G)8-RY(_:;WGZ,Z/PQX7L_"NG+:VB98\R
M2D?-(WJ?\*=KVC:/?)'>:M;P2)9YD66;H@[Y]1QT-:4%Q%=1B2&5)HST:-@P
M/XBL3QKX7/B[1&L%NC:$NK[PNX'&>",CU_,"O*C-RJ\U235]V?0SA&%#EI03
M26BZ'D_BKQ#JGQ:UM-#T1'BTI&RS'@,!_&_H!V']<5ZOX+\%6'@G2EM+- TK
M8,UPP^:5O?T'H/\ ZYJ7PIX3L?"&FK:VB N<&68CYI&]3[>@JWJVOZ;H47F:
MA>PVB]0)' )^@ZG\*ZJ^(]JE0H*T%][\V<F&PWLF\1B7>;Z]%Y(T*X7XH?%&
MS\ ::R1E;G6)5_<6P.=O^V_H/;O^9',^)/C1=ZO/_9G@^QENKJ3Y1=/'DCW5
M/ZMT]*L> O@R;;4/[=\4R_VEJ[MY@A=MZQMZL?XF_0>_&-*>%A02JXO3M'J_
M\D3/%RQ#]EA->\NB_P V4?@O\-;L7\OC+Q(&EUB[)DMTF^]&&ZN1V)' '8?I
M[-117%B*\\34<Y_\,NQWT*$</!0C_P .^X4445S'0%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4=:** /G3Q)\#/AVG[0?@S3U\$: +&[T+6+B
MXMAIT7ERR)-8A'9=N"P$CX)Z;CZUO_M/Z=I6D?!:QT]M+$VA0:WHEN^EVEJ9
M0]N-0MU,*0J/F!7Y0@'/3%>F7_@NSU#QSH_BF269;[3+&ZL(HE(\MDG>%G+#
M&<@P+C![GKQ1XV\%V?CO2K6POI9H8K?4+/45: @,9+>X2= <@_*6C /?!."*
MW536+;V,^71V/&_@)'HUW\5/%-SX$T&\\*^#+.RCL-1TRZMFLE?50PD#I:-A
MHBL+@,Q5=^],;MN:[+X/R._CSXPAF9@OB>(*"<X']F6/2NMM_ =C9?$"[\76
MLT]M>WUBEC>VT9 @NMC;HI77&?,0%U# _=<@YPN'^&_!-GX8U;Q1J%K/.T_B
M"_74+@2%2(Y!;Q0 )QTVPJ><\D]N*4IIW]!I-'SE\2OB-"WQ0U?XA0^(;>WT
M_P"'-Y%I*Z5]L13>POC^UG\LG+%%DBV\?>M6 ZUZO^TU=A_@5K=Q;391Y+!D
MEC;@J;R#!!'8@UK^&?@-X(\.^&;;1Y= T_62B,L]_J=G%-<W3N2TDDK[<EF9
MF)/'7C%-U+X,6&H_!F/X<MJ^I+I\-M#:PZB6C>ZC6%U>(Y92K%=B#E3D#G-7
MSPO&W3\OZ_,FSL_,]#HKB/"O@;Q+H6LI>:G\1-8\1V@1E-A>6-C%&Q/1MT,"
M/Q[-CUKMZYVK;,T04444AA1110!%<_\ 'M+_ +A_E6#6]<_\>TO^X?Y5@T %
M%%% '@WPH'QY'[1GQ+_X3DZ:WPDVH?"Y@\CS=VY<;=G[W[F_S/._CV^7\N:W
MOVN_^36/BY_V*NI?^DSUZW535]'L/$&E7FF:I96VI:;>1-!<V=Y$LL,\;##(
MZ,"&4@D$$8(- 'Q]?W\B_;?@?\WD>9)XS"DDM_8GE"\YR/N_VHQ@"@D>4-O0
M;1?^!%S;Z'J'[,NHZZZ6^E7OPLM])T:YN3B%=3>*QD:%23A9I88SMXRRPR $
M\BOJMO#6D/>&[;2K)KHVGV SFW0N;;.?)W8SY>>=G3VJM>^!O#>I>$E\*W?A
M_2KKPNMO':+HDUE&]D(8\>7$(2NS8NU<+C VC'2@#YE^+OBWQ!:^.O'GA36+
MWP9XBF?X;:_?/>:/H<EIJFEPKY(AMYI6NY\QR^8S8VQAFAR!QQZA\!-.^(-A
MX#\&7>O>+/"UYX:30[5S9V?ARXM+E4^SKLS<OJ$B?+QN/E<X. N>.^\-_"[P
M9X-T"_T+0/".A:'HE^7-WINFZ;#;VUR70(YDC10K[E 4Y!R  >*V_P"QK#^R
M/[*^PVW]E^1]E^P^2OD>3MV^7LQMV;>-N,8XH ^"O$7B/Q1K?A+Q3\;-*^''
MB;4=1C\3P^+M$\0P3:9]D;1+%#;I%L:[%SLFLC=L5$).ZZ8J#PU?3/[2EQ)\
M0/V3O&UYX9,^J6^J^'7NX5L 6DO+1XQ)(D8!!8R0EU !R=V!R:]<M-&T^PT>
M'2;:QMK;2H8%M8K&*%5@CA"[1&J ;0@4 !0,8XHT;1=/\.:3::7I-A;:7IEG
M$L-M964*PPP1J,*B(H 50.  ,"@#S?XB?$KX<V/PGT;7-0@L?%7A?5KJPM]$
MT^PBAN3J5S)*GV1+2-B%>16 D7!!01,_&PD>"MKZ6>J_%#0(D\2WNJ^(/BK<
M6NGZ5X8U1=)EU":/0K.X\J>^+H]O;@1%G:%A*=JJH<%HW^H-(^#_ (#\/^++
MGQ3I?@GPYIOB>YDEEGUJTTFWBO97D),K-,J!V+DDL2><G.:FUSX6>"_$VFZA
MI^L>$-!U;3]0O!J%Y:WVF0S17-T$5!/(C*0\FU$7>P+84#. * /D7P'K'C+Q
M1H7Q(\&P>,K*PN-(^(-IIEO87OCR^E%U']EBDGTJ#6FB%X)#(LI^5#(I22/&
MW<:W-,U;Q!XO\!Q>$=+U'6O#'B?2/%2V^K>$?%WCMDN;TO8FZ_LZRUNU,MRZ
M*9(YE))EQ&Z/LC^4?2Y^#O@$Z!?Z$? _APZ)?I;QW>F_V3;_ &:Y6 *(%DCV
M;7$81 @(.W:N,8%*?@_X#;P8OA ^"?#A\)+)YHT$Z3;_ & /NW[O(V;,[CNS
MCKSUH X_]F+Q4OB+P'J5C);^)+#4]"U:;3-1T[Q1J<6J7-C<[(YWMTO(W?[3
M%&)U5)'9I,##X92!X5_S#?\ NO\ _P"W-?8'AOPQHW@W1+;1O#^DV.A:1:AA
M!I^FVR6]O""Q8[(T 5<LQ)P.I)[U!_PA'AS;M_L#2]O]H?VMC[''C[;G/VG[
MO^NSSYGWL]Z / _VL_&&K:]^S+\9K&^\#:_X<M;;P_=^5J>ISZ>]O=8X'EBW
MNI9!D?,-Z)QUP>*B^-_BZU_9C^,<GQ/GB9O#_BW0Y=(U&WB!W3:O9QR7&G8'
M=YHQ<VX'=O) ]_HW6]#TWQ-I%WI6L:?:ZKI=W&8KFROH5FAF0]5=&!5@?0C%
M-UOP]I7B6UBMM7TRSU6VBGCN8X;VW29$EC8/'( P(#*P#*W4$ B@#BOV?OAU
M=?#'X5:/I6JLLOB.Y\S5-<N%.[S]2N7,]T^<G(\V1P#_ '0M>BT44 %%%% !
M1110 4444 %%%% !1110 4444 ='1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%>??M 6?A_4O@MXQLO%>JW&A^'+O3I+:^U*VB:5[:)_D,FU5
M;*C=ELC&W.[ R:N$>:2CW$W9-FMX.^+/@?XB75Q;>%/&7A_Q/<6R"2:'1M4@
MNWB4G 9A&[$#/&36_I&LZ?X@TV#4=+OK;4M/G&Z*[LYEEBD&<95U)!Y!'![5
M\]0/XC\,_%WX7Q>.;3PGXPM)Y9K#PKXC\,)<:;>63-82O<&6R\V6.6W>.%!N
M638A$;% =A7Q;7?B?XN\+_"3X8>(-%\::Q-XBUW2;RSU^&ZFGOUL=)61_.US
MRRQ"2VA*8?'SB0*=P3 ]!8-5&E![_P#!_P NRUZ=3F=;E7O+^M/\S[ZHKR+X
MQZ5J.A_L[:B_A#5M5N=0T&QAU2PO!J<LMS>BU9)RLDY;=*)DC9&W$A@YSUKP
M[PE\6_$/CSQI>V5KK^IG3/B;J\-SX9D2Y9#::=8W<L5^8,,/+66TM8W!7!WW
M.[DL,XT\,ZD'-/1?U^5W\F7*JHM1:_K^OS/LZBOC/PQK?Q%\67%WXV_MW1]!
MO;3QI-IL]QK/CJ]M[:WACOC --?2/LOV7>]OM5"7\UGE24."0H/#&M_$7Q9<
M7?C;^W='T&]M/&DVFSW&L^.KVWMK>&.^, TU](^R_9=[V^U4)?S6>5)0X)"C
M1X-J]Y+3\_\ +\?(GVZ?3^OZ_P"'/L#2]9T_7(II=.OK;4(H)Y;65[699%CF
MC<I)&Q4G#HRE64\@@@X(HTC6=/\ $&FP:CI=];:EI\XW17=G,LL4@SC*NI(/
M((X/:OCKX%:YJ\OQLOM"\27MYHGA&;Q?XHN?#@TR^>%-6U*+5)VGBO&0JQVQ
MMNC@),<@29FWE55,;P+XSU[X7_##P#<:;J-ZT?C7PQ<>'M*LS.SP6VN"\(M)
M4C)PI=+B8N4'(MESTR+E@FFXIZZ6_'_+]!*OI=K^M/\ ,^ZJI#6]..M'1_M]
MK_:PMQ=FP\Y?/$.[;YOEYW;-P*[L8SQ7FWQ[UC4_AG^SUK]WH>I7D-YI=A#"
M-5F;[1<P1!XXY;EF<'<Z1EY"S \J2<\U\[?$H+\&_B;X[N_"'B[5KNZ@^'UK
M(UWJFK2:K<::DFI(DEP);AI& \HM*%8E%*E@ &Q6-'#>V5[^GX;_ 'ESJ\G3
M^OZ1]OT5\G>,$U+P7XH\6^"O!_Q'NK'3;WP?#J+ZCXK\17%U'IMXUY'!"1>S
M/));_:HWE4;2=K('C4-UYOQ#\0?$?A'PMXA\(6\?B'PSKR^)-)LM7BUSQE)?
MV5E97<DT4<MIK#)+=0QW MD!,J+)"T^46,D-51P;G9Q>_P#P/\_ZNKRZR6Z/
MH?X[_L^>&_V@M$TBRUV\U;2+S1[]-2TS5]!NQ;7ME.G1XY"K 'IS@D$ C! -
M+\#OV?O#_P !=/UJ/2=1UK7M3UJ[^V:GK?B*]^UW]Y(!A?,DVJ"%&0..YSG-
M>-S:'X_L=.\2^%Y?&OAS1FDUC1OL7AZ;XA7]U>A9"YGLVU.2W6\@-R(U:+:)
M'^64+A3@>I?LS>)#K/@_6M,N+;Q'IVJZ%JTEAJ&F^)-535I;&X:**X:"*]5F
M:XA43KM:5C( =K;0%45452%%P4[Q[>NOY_*_4(N,IWY=?Z_KN>OT445YITA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C:SX1TO7<M<VRB4
M_P#+6/Y6_'U_'-;-%7&<H/FB[,SJ4X58\M177F>=7'PKN+60R:7J\EN3V;*M
M_P!]+_A4!\+^.H/ECUE'7L3.S']17IE%=BQM7[5GZI'F_P!F8=?P[Q]&SRR3
MP/XWU$E;G7Q#&>NRXD'Z 8J33_@79&;SM5U&>_<G+*@V _4G)/Z5Z?13>.KV
MM%J/HDBHY;A[WFG+U;9G:+X=TWP[;^3IUG%:H>I0?,WU8\G\:T:**X92<G>3
MNSTHQ4%RQ5D%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[^YGUV?7;:SU3SU$4<-[-)*VYX?,9X1(0NR-MJ;R6 /HFBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .CHHHH **** "BBB@ HHHH ****
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MM#HI*2@E/<****Y#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-NMZ_/X^TR3QQ#'X,\;ZJNH:KI/]C;KI(_)MXI(8+GS\)YBV^UV:)_E;Y C
MN;'BO]G"_P#$,GBS1;?Q<MCX!\6WXU'6M%;3/,O'=@@N(X+OS5$44PC7<K12
M,-TFUEW#;[C15+$U5:SV\EY>6^BUW%[*'8****Y34**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<L)>4AV(-BX08%?6]UX&\-WUOK-O<^']+N(-:18]4BELHV6_58Q&JS@KB4!
M$ ;/R@#I1J_@?PYX@:Y.J>']+U(W-DVF3F\LHY?-M&.6MVW*=T1(R4/RD]J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMW(/"7B-/%6APWZQ&W=B4DA8YV.IP1GO6K<*7@D51EBI 'X5Q7P>&WPE( $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCV/:EHHKT#RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5^/GBC6=*T+79;'5KVRDC\C8]M</&4R\><;2,9R?S-?-7_"TO&?_ $-VO?\
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M5<O11]:Q'_/Q_>P^I87_ )]1^Y?Y'4?\+2\9_P#0W:]_X,YO_BJ/^%I>,_\
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M57+T4?6L1_S\?WL/J6%_Y]1^Y?Y'4?\ "TO&?_0W:]_X,YO_ (JC_A:7C/\
MZ&[7O_!G-_\ %5R]%'UK$?\ /Q_>P^I87_GU'[E_D=1_PM+QG_T-VO?^#.;_
M .*H_P"%I>,_^ANU[_P9S?\ Q5<O11]:Q'_/Q_>P^I87_GU'[E_D=1_PM+QG
M_P!#=KW_ (,YO_BJ/^%I>,_^ANU[_P &<W_Q5<O11]:Q'_/Q_>P^I87_ )]1
M^Y?Y'4?\+2\9_P#0W:]_X,YO_BJ/^%I>,_\ H;M>_P#!G-_\57+T4?6L1_S\
M?WL/J6%_Y]1^Y?Y'4?\ "TO&?_0W:]_X,YO_ (JC_A:7C/\ Z&[7O_!G-_\
M%5R]%'UK$?\ /Q_>P^I87_GU'[E_D=1_PM+QG_T-VO?^#.;_ .*H_P"%I>,_
M^ANU[_P9S?\ Q5<O11]:Q'_/Q_>P^I87_GU'[E_D=1_PM+QG_P!#=KW_ (,Y
MO_BJ/^%I>,_^ANU[_P &<W_Q5<O11]:Q'_/Q_>P^I87_ )]1^Y?Y'4?\+2\9
M_P#0W:]_X,YO_BJ/^%I>,_\ H;M>_P#!G-_\57+T4?6L1_S\?WL/J6%_Y]1^
MY?Y'4?\ "TO&?_0W:]_X,YO_ (JC_A:7C/\ Z&[7O_!G-_\ %5R]%'UK$?\
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MN6HH^M5_^?C^]A]2PO\ SZC]R_R.I_X6KXU_Z'#7_P#P9S__ !5'_"U?&O\
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M*:3LMKM:A1117U!\:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUW:7S[=MM/ R2MGIA2,G/:N_^&OP/\6^)?%NG1SZ%?Z;81SI)<75[;O"B(K
MM@L!N;'0#GGTYK\ZI9EFF+B\&[S3=MM5\U^I^L5LGR7 S681M3<4WHU9_)W_
M  LS[XHHHK]N/YR"BBB@ HHHH I6C,?M&YX7Q,P'D]AZ-_M>M.EI+1"OVC,4
M<>9F(\L_>'J?>EEJ9[E0V15EZ&JLM6I>AJK+7+([8'@7[1?_ "+GB'_MW_\
M0XJ^5:^JOVB_^1<\0_\ ;O\ ^AQ5\JU^-<1?[[\OU9_0/"?_ "+OG_[;$]B_
M9[_YC_\ V[_^U*\=KV+]GO\ YC__ &[_ /M2O':\_$_[EA_^WOS/5P?_ ",,
M7_VY_P"DFSX,_P"1PT+_ *_X/_1BUV'QZ_Y'"S_Z\$_]&25Q_@S_ )'#0O\
MK_@_]&+78?'K_D<+/_KP3_T9)12_W"I_B05O^1I2_P ,CS:O8OB1_P D@\+?
M]NO_ *3M7CM>Q?$C_DD'A;_MU_\ 2=J,%_!K_P"']0S'_>,-_B_0\=KV+X;_
M /)(/%/_ &]?^DZUX[7L7PW_ .20>*?^WK_TG6C+/XS_ ,+_ "#.?]WC_BC^
M9X[78_"'_DHFD_\ ;;_T2]<=78_"'_DHFD_]MO\ T2]<>#_WFG_B7YG?C_\
M<ZW^&7Y,/B]_R435O^V/_HE*XZNQ^+W_ "435O\ MC_Z)2N.HQG^\U/\3_,,
M!_N='_#'\D%%%%<AWA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '065IJC^#+^XBNHTTI)@)K<
M_>9\I@CCW7OVKGZV+:PLY/#5W=/J'EWB2A4L]P_>#*_-C\3_ -\UCUO5VAZ=
M[]_N]#EH;S]>UNB^_P!?\CV+XD?\D@\+?]NO_I.U>.U[%\2/^20>%O\ MU_]
M)VKQVO0S/^,O\*_(\O)O]WE_BE^9[%^SW_S'_P#MW_\ :E>.U[%^SW_S'_\
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M $9'6.7?[W3]3HS;_<:OH<?XS_Y'#7?^O^?_ -&-6-6SXS_Y'#7?^O\ G_\
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M]J3-<)(%$C+N#$%.!T;J.G>LGPGKWC7Q-XGAL=+\2:HFI7VV-IVU&6/Y(PS
MN^[.U%WGO@9P.:]FUWXB'3M6FEM?%4"M<>.8YVDM=31]^GF),;F5S^YP "I^
M4;<$9&!YOX2U[2?#WQJUIT;3TTBYEU&SMY)/^/5%D61(CE>!&24!(X"DGI6U
M>C"G7IQ59\O,D[O7UO?MY:'/AL14JX:K*6'CS*+:LM/2UNCVUU\CGM4U37?"
M>HC4].\:&_GU-"\NH:3J$RRN0Q!68.$E!R ?G7!!!!-3>%?"WB7XA:%XB^R:
MFTMGI@.JW-G<W$A\^4JV71 "&E(5ADX)SC-:OCO28-7TW0(K5=&E\3P6-U<Z
MO_9$ELD'EHY>/'DD1-((PQ(CRV ,YQ5CX->,+7P9HGB:\FNHHIA-ISK;NZ[[
MB-;D&554\M\F[..QKCA2C]:5.M)JG9O=_P MWOUONM==+L[ZE:2P3K8>*=5-
M+9?S\J>BV:U3LM-4EL<^OA3Q%J/PM;Q!)J.?#FGWGV:*QFN),B1L%GCCQM R
MW)R.0?2L'2_%FMZ'93V>FZSJ&GVD^3-!:W3Q1R9&#N52 >..:]UUGQ!X0T6R
MU/PY;:C;7OAK2KK2 B"=91=H;B:>Y9!DE\"0*V,XV@5I:3XML8/%NG2Z]XCT
MR]<>)[FZTZ<W\4ZVVGFWE!&\,1#&S&'$3;?NGY1BNUY?#G@H5N5V2;O?6[B]
M;K333OY'GK-:GLZCJ8?FBVY15K-KE4EI9W>MY=O,\*\*7GBS5;NUT[0=1U 3
M644\UO##>M$($VEIBF6 7*@DXZ^]3ZZWB;P9HVFZ5)KMTNE:M81Z@EC:WDH@
M,<I/#IPN[Y3D8(]S7K/@KXDO<Q^"KO4?$J_VQ+!K=M<W-Q?JCQAD1K=969AL
M4N/DW8 (&.G$=YXXAGL1I%UK]O/IW_"!O'+:M>(\+7XW$ C<0TP*KCJW3%3'
M!TO8W59W>W;6,7:U_.SU>VVA4\?7^L6>'CRK5][J4U>_+W5UHM]]3R[PC::_
MJ^D7,\/B-M$T30I([DW%S=3K#;3R,5C,:1*[>8QW<JO 5B2*Q?%VD:EH7B74
M;+5Y#-J22EIIC+YGG%OF\S?_ !;@P;)Y.>:Z+X:7=T]GKNEQRZ!+97B0-<:?
MX@NFM8Y]DGRNDH>/#)N)(\P$JS85L<6/C+<1>*/&FN^(=+>&YT:.>WL!<1.H
M!=;<*"$SNVMY+D-C''6O-G2C+!QJ)MROM_X%?Y)*/I=WTL>O3K3AF$J4DE&S
MULO[EDWW;<O)V5M5(;?Z;XS?X2VNM3:_=77A:6X%B-,^VS.(MI.TM$?D" H
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MM^S[XD\.^!]6T*XN=-ENK\S".6&9S&N^(*-Q* \%23@'BOHRHY3\\/\ O?\
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M_P#XS1_PQGXU_P"@IH'_ ($3_P#QFOLRBI_U5RWL_O*_UVS?^:/_ ("?&?\
MPQGXU_Z"F@?^!$__ ,9H_P"&,_&O_04T#_P(G_\ C-?9E%'^JN6]G]X?Z[9O
M_-'_ ,!/C/\ X8S\:_\ 04T#_P ")_\ XS1_PQGXU_Z"F@?^!$__ ,9K[,HH
M_P!5<M[/[P_UVS?^:/\ X"?&?_#&?C7_ *"F@?\ @1/_ /&:/^&,_&O_ $%-
M _\  B?_ .,U]F44?ZJY;V?WA_KMF_\ -'_P$^,_^&,_&O\ T%- _P# B?\
M^,T?\,9^-?\ H*:!_P"!$_\ \9K[,HH_U5RWL_O#_7;-_P":/_@)\9_\,9^-
M?^@IH'_@1/\ _&:D@_8Z\=6L\<T.L:'#-&P=)([J=65@<@@B'@@]Z^R**?\
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M_&O_ $%- _\  B?_ .,U]F44?ZJY;V?WA_KMF_\ -'_P$^,_^&,_&O\ T%-
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M;N0\=O;:-;VNEZ<(BI>>28(SIM#87#;WR0.XKT$?!7Q=\/-%B\1^%-;77?B
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MF?)E7$GS-QC/WN_\(KKZNI]GT,Z/VO7R\NWZZA1116)TA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?4JH>TB?J[?N8[21EE2$C'SR#*CD58K\F)/^"L7Q;E0J_AKP0ZGJK6%V0?\
MR:IW_#V;XN_]"YX)_P# &\_^2J?U.K8.=7/UEHK\FO\ A[-\7?\ H7/!/_@#
M>?\ R51_P]F^+O\ T+G@G_P!O/\ Y*I?4JH>TB?K+17Y-?\ #V;XN_\ 0N>"
M?_ &\_\ DJC_ (>S?%W_ *%SP3_X WG_ ,E4?4JH>TB?K+17Y-?\/9OB[_T+
MG@G_ , ;S_Y*H_X>S?%W_H7/!/\ X WG_P E4?4JH>TB?K+17Y-?\/9OB[_T
M+G@G_P  ;S_Y*H_X>S?%W_H7/!/_ ( WG_R51]2JA[2)^LM%?DU_P]F^+O\
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M?^'MOQ?_ .A<\$?^ -Y_\E4OJ-8/:Q/ULHK\D_\ A[;\7_\ H7/!'_@#>?\
MR51_P]M^+_\ T+G@C_P!O/\ Y*H^I5@]K$_6RBOR3_X>V_%__H7/!'_@#>?_
M "51_P /;?B__P!"YX(_\ ;S_P"2J/J58/:Q/ULHK\D_^'MOQ?\ ^A<\$?\
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M_DJCZE6#VL3];**_)/\ X>V_%_\ Z%SP1_X WG_R51_P]M^+_P#T+G@C_P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKXQ_P""@_CF3PAX
MQ^#%M>^//$O@#PIJ-[J":UJ'AF^GMI_)5;?#8B#%RI8XRC8W'CFM*<'4ERHF
M3Y5<^SJ*_/OX _$.]U#X\ZMI_P +_B9X[^*/PQ7PS//K6I^+9)YAI]Z%E\@1
M32QQE&)"X557<-QR^SY.U_9O^/GC#PY^Q;X-\2MH7B+XK^+M1U&YM$22[=CM
M%W*#+=WL@=8(41?OR<#Y1PN67:6'E'\/Q_X8E33/L^BOE;X>_M]:!XB^&/Q%
M\6^)?#S:!)X(F@BO+32]5M]7BNO/.V#R+B/;'(S.&4X^4<'<><=3\+?VD_&/
MB+5U@^('P?UGX=:5<:2VL6NMB]&IV7E*I=EN)(HU^SOL&0C_ #'!! . <W1F
MKW6Q7,F?0%%?&O@[_@I)H?B;QKH5G=>%H=-\):[J/]FZ?K"^)+.XOP[.4C>Y
MTU#YUNA(Y9C@ J>=PKF?"O[17Q-\%_%W]H:/1_!>O?%:PT76//\ (EUP6]MI
M-I&DI981*')9L#$,29(7UP#?U>>M]">='WA17S=XA_;9T0_#SX=ZSX-\-W_C
M'Q-X_=H]"\-1SQVSL\<@2X\^8[EB6,[P6PP)7LNYEZKX%?M%R_%7Q+XE\'>)
M/"-YX!\?>'1'+?Z'=727<9AD^Y+%.@"R#!7/ QN&"W6LW2FE=HKF6Q[/7QX?
M"6C_ !:_X*&^+;+QAIMKXBTSPSX3MCIFGZC$)[>%Y'C9I/+;*EOWC\X[CT%?
M8=?GQ\3?VE/#?[,?[='Q+U_Q'9ZCJ"7WAVPL[6VTZ-&=Y=D3_,690JX7KR>>
MAK2@I2<E'>W^1,VE:Y]H?\*.^''_ $3_ ,+?^"6V_P#B*^.OV\_!UI\--;\
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M6-?J=^WM_P D4\=?]N/_ *4V]?EC7U5+^''T1Y\OB9]G?\$Z/^:@_P#</_\
M;FOC&OL[_@G1_P U!_[A_P#[<U\8UJ]B3M/@I_R67P'_ -A^P_\ 2B.O9O\
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MT?\ -0?^X?\ ^W-?&-#V ]G_ &.O^3CO"/\ V^?^D<]'[8O_ "<=XN_[<_\
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M-MXDTW0/[/\ #OBS4M-GCU.WTR0,D9@/F+#(H4R*DK1.0"^&Y-0H58MV>_\
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MW-G%*K&R3\ON17NO<^+Z**GLK*XU*\@M+2"6ZN[B18H8($+R2.QPJJHY))(
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M)(MT )Q^_;)F]>/N_P"SZ5!<P-%U&1ZU:T^19/M.V9YML[*=XQM/'RCV%6B
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M $2OQM_X3MY_\;H_X9K^+O\ T2OQM_X3MY_\;HYX]PLSS>BO2/\ AFOXN_\
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M(YP64XD5550_4!0 <"L3_A1'QS_M[^W/^%>?$+^VOM/VW^TO[$OOM/VC?O\
M-\S9NW[OFW9SGG.:(P2BX\VZ!N[O8O?&WPI9Z7\,OA5X@T>_\00Z#K=KJ#6?
MAS7]06];3#%=%7>&18XE\N8D/Q$OS*^2W6O4?V&?$=CX8\)?%2?5HTET6[;1
M-+U))2-OV2[O3;3DYX.(YG.#Z=NM<3!X1_:/?6]5UC5/ WQ&\0ZKJ6D7&B37
MFLZ7J=S)]FF0HR[B,L &;"ON4$[MN0".5L_@+\<=/TS4-.M?AU\0;;3]0$8O
M+2'0[Y(KD(VY!(@3#[6Y&X'!Y%6[2AR-K^F)73O8^LM0^%]KX,^#&K? ;4=1
M@C^PZYX;?7=0M1L9+K4;^X#,P)(!2TCL\$Y_*N=\%?L__#;QWX^MK6Z\#C0K
M+2_B1>^#I;.VU&[VZC:)9W,JM,9)G=9XWMTW-$40^=R@XKY^U3X2?M"ZX=5.
MI>#/B9J!U9H7U#[5I6HR_;&A&(3-N0^84!(7=G:.F*TK[P3^TYJFIZ3J-[H/
MQ:N]0T@,NG7<]GJ;RV08!6$+E<QY  .TC( K)0:3]_<J_D>[_ *Q\&66H_#G
MQOH_@C2M"NO$NC>,;.XTY+Z^F@(M+96B93)<%]YC>1'PV"K,556"E:OCGP[X
M4^(WAS0=)U3PK:KJ&G?!)/$5EK4%W=+<6TMN'>*%4\WRFBX<'>C.=Y^<8%>!
M:1\*?VB- ;2&TOP=\3M-;1WFDTTVFEZC$;)Y0!,T.U1Y9< !BN-V!G-.N/A;
M^T7=7+W$_A'XH37#V#:4TLFFZBSM9-G=;$E<F(Y.8_NG)XYI\BYK\WX^H7TM
M8/@CK]H/A;\3_"FK:9XD_L77CI)FU[PYIHOVL9H;EC##-$TD2E)B[ 9E4[XT
MP&[6_P!N%+:+]J#QE%;,S");".4NX=_.6QMQ-O(ZOY@?=_M9K.\(_"#]H/P!
MJ4FH>%_!7Q+\-ZA+$;=[K2-*U"UE>,E6*%XT!*DJIQG&5![59F^$_P =KGP;
MJ'AJX^&'CBYL[_5H]9N)I]!U!Y7N4CEC#<KMY$SECMW,<98@ 5K[JGS)K^K?
MY$ZVL>\?"CPH?C!^RIX%^$\<MM;ZAXD?7-0TF6X4-MO[*YM7 4=<FVEO5R.<
M$\'D'JOBKHWA7XM6W@ZYGT]=4\.>$O#/BN;1M&BGD2/48M,N%M[6(LC"0*T<
M2R,$8-A6P>]?*VE_"3]H70VTDZ;X,^)FGG2'EDTXVNE:C%]B:4 2M#M0>67
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M>E=P7D=JL57U!BMI(5>)#Q\T_P!P<CK36XI;,L4444B@HHHH **** "BBB@
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M"J7235[W]/\ -'=45X_8_$?6]$\'Z5<WDUE+-J,TIANKH2L$16.\R!1G.2
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MCA?]GTJW3>Y,=@HHHI%&<J@:A=D1R*3LR[?=;C^'^M35"I4ZC=@/*Q&S*O\
M<7C^'^M35HS%$<YP@_WE_P#0A[C_ #Z]*DJ.?.P8S]Y>GU%24N@=0J. Y0_[
MS?\ H1]S_GTZ5)4<&=ASG[S=?J: ZDE1J?\ 2''^RO\ ,^_]/S[25&N?/?KC
M:O\ ,T 25'*?GA_WO_93[_X_U$E1R9WQ8S][G\C0#)*K:DH:RD#1R2CCY(OO
M'D=*LU5U(@64A9Y8QQ\T/WQR.E-;H4MF6J***104444 %%%% !1110 4444
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M  GC^'_#6D2W"07+?V;;W$C7%\$GEW*-Q1,,SG@DDX'N><2IXEOM(U?Q'/+
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M0 4444 %%%% !1110 4444 %%%% !1110!%<_P#'M+_N'^58-;US_P >TO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% $5S_Q[2_[A_E6#6]<_\>TO^X?Y5@T %%%% 'R%_P %5_\
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M3NO^":'C;X:^)6"^+?AIXFM_#M['NR3"MWF!QP/DP'C4X&1"#7ZX44 ?FO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.3J1IMJ[5^^U^WH2ZRY7)+K8^X:*^0_"/QBB^ 'P6TJ\M=-^+'C3Q/XMU_\
ML[1?#?Q,NECUB2X("[2[ B&WPF[<0W+YZ$D<U\>?VJO$7B/]G3XR:/=Z%K'P
ME^*7A2'3IY[.VU43.D$]W"$E@NX-NX%25;;C&[&3S@C@JDII1VO:_P [7MO:
M_4'6BE=[GW#17Q=IO[04OPJ^-OQJU[Q;K6KW_A/PYX4T*\CTS[2\J+--%&O[
MJ-VV*\DCJ">,ELDUV'AO]L+Q:VL#P_XR^#M[X+\4:MHESK/A>QDUN*\BUCR(
M7EE@:2./=;R;0N%*,>3N"X :98.JM8ZJR[=K_A?7L-5H/<^H:*^4_#W[?WA[
M7?&_PGT%M#%I:>-]'CU&[U1]0'E:1.XG"6S_ +L!R9+>1-Q9#C#;>U=]\'OV
MKO"7Q&\&:#K6OZEHG@6^\02RG2-&U36X1=WEN)W@BF5'$;?O&C;"A3SP":B>
M%K4U>4?ZU_R94:L):)GMU%?'/P&\=^)=8_8C^*>NW_B'5;[6[/\ X2/[-J5S
M>RR7,'E1R&+9(6++LP-N#\N.,55\"?M5^-O"_@GX,^#M(\ ZC\4O&/B3P=%K
M/VBXUU;621EX<S2SHPP5#-YC-DL57!+9K1X.=Y*+O9V[=+WU(]M&R;ZGVA17
MF'[/'QRM_C[X$N=;&C7'AW5=-U&?1]6T>YE$K65Y#M\R/S  ' #J=V!UZ#%>
MGUQSA*G)PDM4;1:DKH****@H**** "BBB@ HHHH Y/Q+XAUZV\4:+HVC:*T\
M-RPFN]5N5/V6"%7'F1Y4[A,RYV9&W/6NLKA-7L!)\8] N_[(2<QZ;<)_:?\
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M_P K[3 \._&=NY2,X[]:74]3L]$TV[U'4;N"PT^TA>XN;NZD6.*&)%+.[NQ
M55 )))P ":I^$O%6E^.?#&E>(M$NOMNCZI;1WEG<^6\?FQ.H9&VN PR"." ?
M:DD[<Q6FQ\K^&/\ @GAI.AZG\%KZ\\5+J<OPZ$PD#:4$&J W4EU"#^^/E>7)
M*W]_=_LTZ+]@[6=$T+P@OAGXJS:#XD\,ZWJ>L6>J-H,5W ?MH 96M992A= ,
M+(2<;F^4':5^E_%_Q(\-> ;[0+3Q!JT6ESZ]?#3=.\]6VSW!5F$>X JI(4XW
M$ G !R0"[Q)\1/#OA#Q!X;T/5]4CL]7\1W$EKI5H4=GNI(T,C@;0<!5&2S8
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MN< CRXNC.2VXMGAFYX"D ]^HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUM$N)EC:XF^R[_+C!/S/M1VVC)PC'H#7LE4-3T.QUB?3IKR#SY-/N?M=MEF
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MPM+#I6LZU86=M$1E8(=2N4AA7<0 %15102  JC@"O(?AS/XFM?VM?!^H>*/
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M0+=SEY3%/]IC/[UI-C1N5PI"  ^EJ*^8_BC\3/B-X&\-^,?#/B^_T6;5-3\
MZUKFCZUX3MKC3VLKFSA43Q$23RLQ4W,#QS*4)*OE%(!KZ$\&3RW7@_0III'F
MFDL('>21BS,QC4DDGJ2>] &Q17@O[5-YXWTG3?#.HZ'XGCT#P]%XE\/PWEM9
M6["^OS-JL$4D+7&\".#8ZEE5"TARI8)N22C\<_#GCS6_B-=7]CX<U+5_!FE:
M"DJ_8_B!>^&FFNO-F:=8H[/)GD\M80OGF*,$X#\L5 /HBBOC+5_B?X*\3?%2
MZUCQ!K7Q'B\"R?#_ $'7=+3P]=^(0EM%.]\\D]T--8[&,20Y><Y/EG!.UJ]P
M_9=OM6U7X927UY=:G?:%=ZE<W/AJZUN=Y[Z;1W8-:O,[DR,64L5\P^9Y9CW_
M #;J /7:*\'_ &O-0\56?A;P/;^#=;N-!UZ_\66=I!<02%4=FAN"D<R]'B+J
MFY&X(%<;\3/C3J7COQ1\(Y?"FJ7VDZ"][H6J:M% [0R3?;[GR[>UEQ@D*D%Y
MYL1Q\WE;@. 0#ZJHKYTLTMOB7_PG_C#QEJ_C(:1HNOW.AZ;HOA&_U2V:VAMI
M%@>0PZ8RSW,DLNZ0EMX6/R]JH!(S;_PR^.G@;P_\/M&A\2_%>PO+AKN[TZWU
M#Q:@T&_NV@G,9BDM[GRW::(&..1@B[F&[:N[  /;**^+OVA/VD[#PM\:;K5(
M?B18:#:?#:ZT^"\\*OK$<$FNB[(.H9MBX,_D6TD#Q_*Q$JRA=I!!]3U_P_;?
M$S]IJ^TJ_P!=\1+H5MX,L-0M;;0O$VH:9 99+V\5I2+2>,.61$&6SPHQ0![]
M17RA<^+O$?AJ\N_!?_"1ZI?P>&OB9H6DVNI3W3F[GT^Z@MKG[+<RYW3%?/="
MSDLZ!"^YMS'ZOH **** "BBB@"2V_P"/F+_?'\ZWZP+;_CYB_P!\?SK?H BN
M?^/:7_</\JP:WKG_ (]I?]P_RK!H **** "BBB@#YL\0^%_#WQ/_ &M/$7AW
MXC:;8:_HNG>$K*]\/:+K<2SV;%[BX6^NDA?*-*I6V0R8W(K  @.<^,?#WP[H
M_CWQ7^S5J6NZ7:>)X1KGBFSTK5M:MTN[F[TJU^UMIK/+("TBHJQO&Q/97')W
M'[7\:_#;PC\2;2VM?%WA;1?%-M;.98(=:T^&\2)R,%E616"G'&16C+X9T>XO
M-*NY=*L9+K2=PT^=[9"]GN38WDMC,>4^4[<9''2@#R;]J#QEX4T/P]I>A^*]
M(\"ZQ;:O)))#%\1-;M--TM6A"Y8F9)9'D_>#;Y4+XYW-'E=V'\&O'_@WP+X4
M6&Z^-NG^/8]5UB#2+6[TN]DU"UL;N97\F$2RW%Y-&9-A.;FX9-VU4";@A^AZ
MH:[H&F>*='N])UG3K35]*NT,5Q8W\"SP3(>JNC JP]B* /#?@-"_AGX[_%WP
MN-4G\7/%'I>IWWB:_*&]:ZEBD3['/Y2I"/+BAB=$BCC"K,,J2VX\3=?#_P"&
M/C[]I_X\K\0[32]433]"TBX$.LLIBL;8VTWG7<8;B-UVJ#./FC 7#+N.[Z>\
M)^"_#_@+1TTGPQH6F>'-*1VD6QTFSCM8%9N68)& N3W..:\[F_9G\):Y\6/%
MWC7Q5I.B^+_[:33A:6.L:/#<?V:]K'(A>-Y-W+[P>%7&P=>P!\]_ #3C\:O%
MW@G2?C/9Q>*EB^'&FZGHNF>)XA<Q7<KW%PES>-#*"LEP(EM SL-Z"3MYA+9?
MPYU:XU?Q#\&7^W76J:+;GQ]::#?WDQGEN-*BD1+-S*Q)D'DJ@5R?F4*<GJ?M
M/QI\.?"?Q(LK>S\6^%]&\4VEO)YL-OK6GQ7D<3XQN59%8 X)&1S@U<F\):'<
M7&FSRZ-I\L^FPR6]C*]K&6M8G4+(D1QE%9552%P"% /2@#X>^%'@/P[X'^$O
M[(_BO2-'M[7Q+KFIV.EZKJZKF[U"TN-*O&>WN)3EI8@8H=D;DJBQ1J@4* &?
M#_X):5K'PAT_3/#T'@;3=77XCZ[(/"?B6W2+3?$Z6]Y>1"TF6(;G\B$F6+"2
MK&8$^3:,C[?B\#>&X-.T73X_#^EQV&AR)-I5JEE&(M/=$9$:!=N(F5'=04 (
M#$#@FLG4?@Q\/M7M]8@OO OAJ]@UFY6\U..XTBWD6^G4DK+."A$C@LV&;)&3
MSS0!PG[*VM:7-X;\7^'-,\(1>!Y/#'B2[TR\T?3]2-_IL4Y"3L;*0JFV%A.K
M^4(X_+9V78M?(?[1;/J?PH^+7Q0TRR\.:3<:1XDO8K7Q=XDF-]XI2_MKZ*&&
MTL2D< TZ*,Q,8U$DQ*<LF9)&K]%/#'A71?!.AVVB^'='L-!T>VW>1I^F6J6U
MO%N8NVV- %7+,S' Y+$]37/ZE\$OAWK.O:AKE_X!\,7VM:A$\%YJ5SHUM)<W
M,;)Y;I)(4+.I3Y2&)!7CI0!Y3\&O ^A:7^UM\>=7M]!TVUU)DT8I?0VD:S;9
MK9GG^<#</,D0,W/S,H)R0#7EG[027&D?'WXD^-;*-I;_ ,":#X9\4HB*"6@M
M[O41>+^-I)=+_P "K[!@\">&K7Q+'XBA\/:5#X@CM!IZ:K'91+=+; Y$ E"[
MA&#SLSCVJ:Y\(Z%>WFI7=QHNG3W>IVJV-]/+:QL]W;#=B&5B,O&/,DPC9'SM
MQR: /C(ZOJGB/XL?#OXCZ1&\^K>++7QAJ^BQE"Q-K'9VL.G (W]^*&*4KTW3
MMUSDKX1T3PKX?^%'[.GCKP>(7^(_B76M(@U'7K9P^I:T)VW:Q'>2_?G5%%P[
M+(2(W@3 7RP!]EV_@[0+671I(-$TV&318&M=+>.TC4V$+*J-' 0/W2E412JX
M!"J.@%9^D?"[P9X?\5WWBC2_".A:;XEOPXN]9L]-ABO+@.P9Q),JAWW,JDY)
MR0">E 'P_:^"- T+]G'7?B3;:5 /'.F_$^1K+7R,WMK&WBA8'@BE.6CA:.24
M-$I\LF:1BI9V);\4OA_H&G^$/VHI+31;+2KRX^('AVU:\TZ!;>X$,L^C2LJR
MQ@,N9)'DX/WV+?>)-?=;> ?##Z'-HK>'-);1IKG[;+IQL8OL\EQYPG\UH]NT
MOYH$FXC.\;LYYJMJ7PM\%ZSJ]_JM_P"$=!OM4U!(8[R]N=,ADFN5B=)(5D<J
M6<(\<;*"3M9%(P0* /&?A_X-T#X4_M<ZAX8\&Z+8^&/#VH>!H=1N=,TJ!;>W
MDN8KYHDF,:X7S-CE2^-S #).!7/_ +8%GXKU^76_MG@36]<\!:!X:OKZTN-,
MN]/$,NJ26\R">Y2>ZBD\NVCRR!8W+/*6 S$F[Z>_L'3/[=_MK^SK3^V?LWV/
M^T?(7[1Y&[?Y7F8W;-WS;<XSSC-6+^PM=5L;FRO;:*\L[F-H9[>X0/'+&P(9
M&4\,I!((/!!H \\_9KU*XU7X _#V:ZTJ[T>1="LHA;WKPL[*L"*L@,4CKM<
M,H)W88;E4Y ]*KDM1^'&F7OB+P9J,,%K8P>%1/\ 8;:WM$4H)(# (T<?ZN((
MS9C488K&>/+ /6T %%%% !1110 4444 ='1110 4444 %%%% !1110 4444
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MK95]PV^/^'OVZX-5LM"\72>,/AY-H&LZQ!8IX(M;P'Q%:6D]P+>*Y=_M)#R
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MDZK\<M;^'WQ!^(=R^C>&H]*T+Q9X>TOQ)JUGICPW-S:W>GVRM=R/YQYBEGB
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M7\+>%/%E[+J.I6\>E>9JEI<3G_2Y+"]6=%MVE^\"\,ICD9G7J%4 \Z\(7_Q
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M4_$6L^%[CPI97^EZ&;.UL+:<J\TIMVN9&DE=XXBQ\U5Q$@55^8MV7B;X*_\
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MM_Q\Q?[X_G6_6!;?\?,7^^/YUOT 17/_ ![2_P"X?Y5@UO7/_'M+_N'^58-
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M.T'B?Q1;:-I5EI\$BQ;1.MBKAS(VU(2D[%4=VF&-HZNS_:<\7?$3Q7\-=0\
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M=0O+*V5IR[:=.TJ"UD=;APV^.9&*QDH0I4@&$W[47B#Q&VE_\(5X!M]8CO?
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M6&RL590WEDR17:N2CL/+7:IYK*NOVF_'_ASP?X]O+[2?[9GT;PA>^(;369/
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MX?\ P?TCX=:S=:I87NH7EW<Z+I>A2&]>,@PV G$+X1%Q(WVF3>?NG"[57!R
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M2:"50\<D;!E=2,@@C@@CO5.Y\0Z59WOV.?4[."[S&OV>2=%DS(2L8VDYRQ!
M]2#B@#0HHJO!J%K=75S;0W,,MQ;%5GA20,\18;E# <KD$$9Z@T 6**KV.H6N
MIVPN+.YAN[<LR"6"0.I96*L,CC(8$'T((HM-0M;]KA;:YAN#;RF&812!O+D
M!*-CHP!!P>>10!8HHHH **** "BJ]CJ%KJELMS97,-W;L659H) Z$J2K $<<
M$$'T(-6* "BBB@ HHJE?:UI^F7-I;7E_;6EQ>.8[:*>94>=O[J G+'D<#UH
MNT5336=/DU633$OK9M2CB$SV:S*9EC)P'*9R%SQG&*IZ=XR\/ZQJ<NFV&N:;
M>ZC%N\RTM[N.29-IPV4!)&#P<CB@#8HJGJVLZ?H%B][J=];:=9H0&N+N98HU
M). "S$ 9-5'\7:%'HT6KOK6G+I4S;8[YKN,0.<D8$F=I.01P>HH UZ*J7.K6
M-G?V=C/>V\%[>;_LUM)*JR3[!E]BDY;:.3CH.M4I/&.@1:X-%?7--36"0O\
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M /'A1_9UQ_SS_P#'A6U10!B_V=<?\\__ !X4?V=<?\\__'A6U10!B_V=<?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME+\@()]\U+=?$G0[*VLII_[3B-[,]O;V[:/>"XE=4WL!#Y6_ 4$YVXX//!H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:EXFIVFKZ'8"]E>,01Q_9V!BE$>TQL 9 %(;((P<9[:%X(E&BQ6'A_6==O\
M4[--0^P0W.938, 4AN&EF5/LX.U1"6*DJ<*<N3!_9O@=[/1)+?PWKNI7FJ74
M]B-/:<+.1"K,]G/YTRJ8(_*.(MQ3Y> =QW1S5?Y5]_\ P#J]EE__ #^G_P"
M+_Y,[[X9W-]IGAG0M#\01BU\1BR>:6VC@1(PBR!>#$/*&-Z?*I[CBL._BNO"
M_CCQ7=7*ZO:VFNQ6CVNJZ+8->R0M"NQXF012[3SN!9"I#-@AA4]E+H?PN\*W
MFOS>']4T^8.L"VUU+%=7SJS*L<,3"5P(QP%C#@ *3CJ3WVEZE!K.F6E_:OYE
MK=0I/$_]Y&4,I_(BM5=K4\^HH*;5-MKNU;\+O\SY^U+PYXDO?"WA%O$FE^?I
MZP:@+BQET,WWES/*3;N]K:/&%<P[@''",QSM9LC-U?X>:M=6/B.XO-)U+5=5
MM?#NFKI][=61^T&X1V)*!"X\U0%SM9B,G)Y.?=K[X@Z=IWC[3O",T-S_ &C?
MVQN89@B^1@;SM)W9W8B<XQT'6H/#_P 3]$\1:WK&EQ2/:SZ;>C3R]V41+B8[
M_EB^8EB/*DXP#\IXX-49'F4_A76)OBU/=7,%S'>_V]#<VM_!HTLSFR"#,?VT
MS+%%%M\Q&C*[B6R%<D51TKP@='^'WAI;GPFC7%YJ=W)J4][H]Q?^7M:X\EIK
M2(J\P*E50ME4R".2#7M^I>-O#NC0B74-?TRQB,KP![F\CC4R(<.F2P^93U'4
M=ZEG\6:';:G::=-K.GQ:A=HLEO:/=(LLRG.UD0G+ X."!V- 'S;#X/\ $7_"
M)6<$FAZD+B+0S;&+[(^49=81A&!STC7< "?E&02.:Z^ST.SU_5M>U;3/#EUX
M;\2-:7MMHL,6A366R1HW'VB>Y\I4,CG[H+[5!'5F..TT_P"/7A&_^P2?;EMK
M2\GN[<7MQ-"D$36Y4-O??@!_,0IZA@>,BNNO?%FAZ;_9_P!KUG3[7^T<?8O.
MND3[3G;CR\GY_O+]W/WAZT ?/^G^#-77PCKZZ58WD$4VFV*7NFVVA3::D^R8
M&= )9F::<PB169%VN& W$FO2?@_I=O8:YXVFT_1;K1-'N;Z%[*&YLWM0RBW1
M69(W4%5W!L# QZ#H.T/C/P^-7&E'7=-_M0R&(6/VN/SRX )79G=G!!QCO53_
M (6'X>M]*M;_ %+5K#1X;IY4A^W7]NH<QN5;:RR%6P1T#$C(!P<@ 'S]H_PK
MDETKP\+OPM.TLN@ZK]M$MD^Y[@.?LXER.7 /[L-R,#;T&.OTW0-0;Q-X5TJ>
M.4QZYI^GZIJZ3C+I)91@-YBD@C>YM5.X?P-]*]C\2>(K'PGHEUJNHR-%9VX!
M8HA=B2P5551R69B !W)%<[HWB?26\1W,E_X<N/"^KSV1N3>:G#;JUS;QD!\S
M12./W>5)5V! 8$# ) !Y/INB:G/X[L+Y?#M[I4GF:O'?-IVF3Q7B;TE\K=?R
MN5N"Y4,C#"*=HR,H#3;P4)_!-_;1>%#/96MWH\V^/P_<6<MP$E(FW6CER\BQ
ML=\D:_.)".0M>[R_$;PG!91WDOB?1H[221HDG?4(A&SKC<H;=@D9&1VR*T'\
M2Z1'!<S/JMDL-M(D4\C7"!8G?;L5CGY2V]< ]=PQU% 'BNC>"[JU\06NN6^B
MW%OJTGC>]+7S6CB3[#)'-@MP#Y);8><+D\<GGD[;P3KZ^%M:1["^_MUM"OK;
M4X[?0I8S>SLV1YMR\S"YD+@LCQ(<AB"5! KZ%M?B%X?DM["2ZU6PTV6_9DMK
M>ZOH-\I#E,)LD96^88^4GK@X.14GC#QA#X/M].>2PO-2FU"\2QM[>R\O>TC*
MS#)D=% PAY)]* /&D\#WFCZ^D.G:%<VU@;_PW=,L%JXC+HTOVB0X&,@!"[=1
MP6ZT_P"'^G:D?BAH>I#PY+HJO_:2Z@R:3<Q2+O;=&MQ=R.WVHDH&# !0< =0
M![&OC"ULM(;4=?B/A2 2^4/[9N;=,G&0=R2NG/( W9X/%76\1Z2@8MJED MK
M]N)-PG%O_P ]NO\ J_\ ;Z>] 'A7QVTM%O?&%WJVE7-Z\UE8)HE\EJ\L=MB4
MB9!*!MA8DC.2-X(4;L[:O77A-[72O'=_+X7:^O;_ ,3"$S36<TK&Q+P$R>7&
M5DGA4[F,:'#D'.0#7HU[-\/[SQ5:37;^&I_$C-']FDF-NUX6P&CV$_/G#*5Q
MV((ZU=UCXB:%HVO6&BO>Q7.K7=VEG]BMI8WF@9HVD5I4W!E4JG7'\2\<T >'
MZ?H7B'PYX>N]8T?0[LZI8Z[=I9VEKIDEG&UI=6J*'C@;<T:"41.1D[=K;@""
M!?O_ (<+H%QJ6F/I]])I=M#HD<<L6E/J%M.\0NO,,T"D--'E@6"'<&=&/ KU
MO5?BEX5TO2-9OQKFGWHTB!Y[JWL[N*29=O&W;NX8MA0#C+$#O4VG_$30K[3[
MS4'O[6STVU2!WO;B\@$0$J*R9(D.S[X'SA<D\9!!(!#\++>:U\!:5%/IHTAU
M$F+-4D0(OF-M(21F:,%<,(R<H&V\;<5U=85[X\\,Z;;VUQ=^(M)M8+F+SH)9
MKZ)%ECR!O4EL,N2.1QR*UIK^VM[%[V6XBCLTC,S7#N!&J 9+%N@7'.>F* )Z
M*XOQ'\7O#7A_2M.OX]0M]6BU&Z^R6HT^[MV\U_XL,\BIA> 26X) [BM7QOXT
ML? 7A^75]0CN)XD=8U@M$#RR,QQA02 3C)//0&@#?HK%OO&GA_2[&TO+_6]/
ML+6[B\ZWEO+E(1*GR_,NXC(^=/\ OH>M2V'BO1-56]:RUC3[Q;$9NC!=(XMQ
M@G]Y@_+PIZXZ'TH U:*PAX\\--I/]J#Q%I1TSS##]M%]%Y/F 9*;]V-V!G&<
MXJ*/X@:"--N-1NM4L=/T^*Z-H+NYOH!%(X&1AUD(&1R%8AN.5% '145D77B_
M0K'4+.PN=;TZWOKP*UM;2W<:RSACA2BDY;)X&.IK7H **** "BBB@ HHHH *
M*** "O)OCAX4U#Q5JOAR.PMKB22"#4)8YX8R5AG6)7@W'&!F1%QG&>U>LUE>
M*/$=MX3T&ZU6[CFFAMPO[FV4-+(S,%1$!(!9F8 #(Y- 'A6F^#?$7B[4/$NH
MRZ?>Z7?^)_#U^<7<3H+>1YE2&W=CC#>5&F1QQDXQ742:AK6KZKX.MM+L-;LI
MK*ZA74=,O-*B6RM(HPR2NEQ)%\SG.%,,K97.!S7=77Q%TJW\*:7KT:W%W!JG
ME+96UN@:>>2096,#. W!SD@#:<D8K,O_ (OZ7H]I=2:KI^HZ5<VMU;6L]G<B
M'S(Q<'$4I99&0QDALD,2-C<9&* (_&UO=Z3X^\,^)C:7>HZ5:6]U9W$=G T\
MELTIC*S"- 78?(5.T$@$'IFO.KI-6\7Q^,-5DT#5+&UO+W1Y+_19K247%U9Q
M@>?L&T;PW(P#N*QD,JDA:]5U?XGZ18VVD3::K^)AJMTUG:_V--!*K2*C.P+M
M(J# 0_Q5?\+^,8/$UUJEF;*[TO4=,D2.ZLKWRS(F] Z-F-W0@@]F/0@XH \C
MT>RN= UC0-3&BZK:^&[?Q)J-Q9VT.F3N]K:/9M&I^SHA>)&F,A"E1C?G !KV
MNRO+/Q/I+/\ 9YGL[A6B>#4+.2 NO(8-%*JM@\]1@CVK,N_'VFV7CBR\*NEP
MVH7<)F65$!A3AV",V<AF6*1@,=$-1Z!\2-!\0ZS?Z1#>Q6^JVEW+9FQN98UG
MF,8RSQH&+,G7G'\)XXH \]T_PC!#X4\56&IZ5K5MI'_"6&Y2WT:!HY#;HT+1
MLJJ YB!0?ZD;L+\O3BK9:#XBUG5O#&)]>LM.A\0:@]A?W$1DN[:R-HX0RFX1
MR TAD5?.4MM91UQ7MD-_;7%U<6L5S%)<V^WSH4<%XMPRNX=1D D9ZU8H \R^
M'B2^#KOQ(OB/[=/K%QJD,<NM2VQ\K4%DQ';%/+0(@ VHRCA6Y)PPJG\</"FH
M>*M5\.1V%M<2200:A+'/#&2L,ZQ*\&XXP,R(N,XSVKKO"7C;1/B/IMU=6\+&
M"QN@"M_&H(*A9(YE&3\I!5U;@]^,5?C\<^&YM&EU>/Q!I3Z5%)Y4E\M[&8$?
MCY3)NV@_,.,]QZT >(Z;X-\1>+M0\2ZC+I][I=_XG\/7YQ=Q.@MY'F5(;=V.
M,-Y4:9''&3C%=1)J&M:OJO@ZVTNPUNRFLKJ%=1TR\TJ);*TBC#)*Z7$D7S.<
MX4PRME<X'-=IJ/Q5\,Z5X@TO2;G5;6-]1LFU""Z:XB$!A&,'<6_B!)4@$$(W
M/%:&N^-=,T"]L+2:0SW5W>PV/DV[*SPO*'*-("054B-N?;@&@#GO&UO=Z3X^
M\,^)C:7>HZ5:6]U9W$=G T\ELTIC*S"- 78?(5.T$@$'IFO-KD:IXFO]:\1G
MP]JNGE-;T*^ETV2RE-P8H,>9*B[1Y@Z@!<OB/YE4\#UWQ!\3O#N@:;J=V=1@
MU!M-FB@O+:PGCEF@:298AO7<-N&;G..A[C%:4?C/P_-HDNLIKNF/I$3;)-06
M\C-NC9 P9,[0<L!C/4CUH \2N+6[NK>[DN/"]S<Z??>*+V\5]4T2ZO(XXC;K
MY;M9(49]YX5GX0YR >F#9^$?$7_"-Z5#+HFI">'2+2W:,VDF49-:1]F.<;8U
MW8R<(,].:]WU3XFZ-IMU%"CF]273FU2*Y@G@%N\*RQQ\2O(JY)E4C)P0#SG
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M/->TT4 >!^,/!7C/5A>V5EX>_L^PE73#'::9-8BV*P%&=)I'43.R%=J;=JX
MYZ@^^444 %%%% !1110 4444 %%%% !7G'Q45M3U?0;&75%T/2+!I-:U#4EG
M@22!85Q$0LH8%?,<$DH0-HY!(KT>L[5?#NEZY/8S:A86][+8S"XMGGC#&&0=
M&7/0]#]0#U J9<UO=W-J7LN=>VOR^6_X_P!?D>(I:/X:MHX$U2QU*/PIJ?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8;.01110!UWB'P7=>)/AR/#UWJ6_4?LT"MJ#1Y#W$11Q(5ST+H"1GH36??\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>rnac-20241231_g3.jpg
<TEXT>
begin 644 rnac-20241231_g3.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %D!:(# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'O5KX5?M'>'/BEJUQI,"3:?JT6&%K.IRRD9!!QCIS0!ZS1110 4444 %%%%
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M)M7M;MMC,%'W@/2OLEU+=#7D?C[]E3X=?$?6GU;5M':._<8>6SD\DO[G YH
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MMS:?L3RV']WZ<4 >?:YXR\/:[\./A]IVF>(;[3=+FCF1]%LX&EEN77 )R/F
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M^*Y3$VF32 =%:'(% 'CW['GA.V\/>%-3O+2RGL[>]EWJ9PRM)@GG:>E?0B#
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MY_[]F@#?HKG_ /A*3_SX7/\ W[-'_"4G_GPN?^_9H Z"BN?_ .$I/_/A<_\
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M3*0;NY'OOK;HH YS3_"*V<;*U_=REF+ E^@JU_PCD?\ S]7/_?=;%+0!C?\
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MK7UT5;@*7XJU_P (U'S_ *7<_P#?=;-% %>RLULHMBN[CU<Y-3BEHH ****
M"BBB@ HHHH **** "BBB@ JAK):/3IF0D-C@CK5ZL[77VZ7.WH.U &'9^&CJ
M.FVDQOKI'/S-A^O-:O\ PCD7_/U<_P#?=2^'IEDT2T8?*"G0GWK3!R,BE<#(
M_P"$<C_Y^KG_ +[I#X<C_P"?JY_[[K8_BI:8'/7OAU(;.>1;B[D94+!$?EN.
M@JAX>T@:CIBS3&_LW/6*9L,*Z/565-+O"\AB00N3(.JC'6LCP-+!/X?B:VNV
MO8R?]:^<G\Z +8\-Q@#_ $JY_P"^Z/\ A'(_^?JY_P"^ZV!TI:0&-_PCD?\
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MBB@!I&<]QZ4#@<8^E.I* #K2T44 %%%% !1110 4444 %%%% !1110 4444
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M''.:D P*YI-R=V5:PM%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFEP#S0 K=
M#7->%Y1<:?>IC^)Q_.NB,BY//:L'PB%-O<@8R9&SCZTNH')?!>7RI-=L#_R[
MSC ^N37I]>4>"#_9_P 5_$MF/E61E8#Z+7JV>:TDK,2%J+:5!_&I*9DD'(_&
ML^HSRSQ+\,="^+5M>Z;K,LUU'#*CJ&(.S!SQ4NH_L_\ AF[\,R:596XLW9<?
M:(P V<=<UUGAL.=1U$M+#(-PP(DVD?7UKI$&T8K7VDULP/%=&_9\N+;23I=_
MK=Q=V*KM1&?.*L:S^S=I.K3M<_;9X;Q85BAE0X*8[U['B@C-/VU2^XK'G7PU
M^$$'@&WU5);^?4I=24+-)<-DX Q_(URT?[,6G#4ID?5+Q]%8ETL2XV(_8@8[
M5[<1FC'%3[2:=[C.,\-?#2T\.>%+_0HYY'MKMF)=C\PR.U<KX;_9[L=%U,75
MQ?SW85F*K(V< ]J]=&:0@T*I..S \)TG]E;2=+FO_+U&X6*9F>(JPW1DDDX_
M.H]+_94T_3=.N8EU2Y:XFF68S;OFW#IS7O6VE Q6JQ5;:XK(\=M?V=-.2WC6
M:^FEE%R+EF)SN;'>LK7/V4M&U1TN([V>.\68R;\]0>U>[;<<BEYI?6JR^T.Q
MY(_[.^D-:7-NL\L:SJ@;:>ZUI^ O@W;^ ?$$VH6=].T4JD- S?*3C&:](Y]J
M.:F5>I45I,! N!@<"E''%'- &#6("T444P"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXVW3)SC.!6A5#6R/[-FSZ4 9L&;WP6ZE<%[9UV_@:Y#X#71?0=2MF/S6]ZZ
M>@ %=[HT8DT6V0]&C(->9?!R7['XN\5:?T5;R1@/QJXZQ9+/7FZTZFY!ZTN:
MS115U,%M.NE"[\Q-\I.,\=*R?!B.FA(LEN+8@_ZM7W?K6KJNW^R[S=NV^2^=
MHR<8/05B^!3'_P (_'Y EV9P/.7:WY570#I%&!3J:#@#-+FI0"T4F11FF M%
M)FC- "T4FX'O10 M%)FC- "T4F:,B@!:*3</6C- "T4F>*,T +1110 44F11
MD4 +129%&: %HI,YI: "BDS1F@!:**3- "T4E&: %HI,T9H 6BDS1F@!:*3(
MHS0 M%)FC- "T4F:,T +129%&0* %HI.M+0 4444 %%%% " YKE/B1X\M/AM
MX6N]:O(WG6('9%&I)=L<#BN!^('Q:\<^%O$DUCI'@^/5K%/NW#.P)_*K>F_$
MP7O@#4?$'Q%T>WT*SL6+B*1B0V!GC=WH Y;PI^U+>7OB32=-\3^&'T"VUD@:
M?<-+O\S<,C(QQQ7LG@VT6V@N&&<O(3DGMFOFWP-.G[27Q#T[Q7J-]8V'A;1Y
M<Z3IZ3+YDK#@-MZ\@U]&^#OM96Z\P@0AR(QGL#0]@.+9OL'QS3' N8F)]\+7
MK9.&KQSXC[],^*OAV[C(4R(ZD_B!7KX+':3@FMJBT3)1-3&/RDCGKQ1\Q]*9
M\P!'UK#J4<_X8A\O4=1/V7[/EAEM^[=^':ND7KS7*^%L?VGJ?ERS2$L-PE3:
M!]/6NGCW\YQ5,"3.*,BF_-1AO6D [(HR*;AO6C#>M #LBC(IN&]:,-ZT .R*
M,BFX;UH^:@5QV11D4WYCWHPWK0,=D49%-PWK1AO6@!V11D4W#>M&&]: '9%&
M13<-ZT8;UH =D49%-PWK1AO6@!V11D4WYJ/F]:!7'9%&13<-ZT8;UH&.R*,B
MFX;UHPWK0 [(HR*;\WK1AO6@!V11D4W#>M&&]: '9%&13<-ZT8;UH =D49%-
MPWK1AO6@!V11D4W#>M&&]: '9%&13<-ZT8;UH =D49%-PWK1AO6@!V12TS#>
MM+\WM0 ZDSFFX;/6G#..: %HHHH **** "BBB@ HHHH **:W ZXK$\0^,]$\
M)B :SJD&G-<,$B$S8WL> !0!N9I:R],UW3];C=M/O8KH1G:QC.<&M,=!0 M%
M1Y(SDXQ7CGBK]J;PAX8\07NE#SK]K!]E[/!]RV.,G=^'- 'H.L&0>)[';C;@
M9S]:Z*7_ %;?2N/TWQ!8>+;C1M8TJX6[TZZA66*9.A!Z5V,AP*!,\&T%?[)^
M,GB&Q'RQ7*QLOO@9->Q^''S;NG]TUX_XR7^ROC/H5V/ECO!(KGZ+Q7K'AM]L
MTJ$]>:[ZVL$S&*]XZ&N3\5K&==T0O#/(5GRK1#*KQU;VKJZYCQ1*J:UHRF[6
MW9YL",Y_><=*X4;G2H,"GTB\ =J6D 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ=MS(O>NNI,#- 'B7@_]E'PAX'U>ROM-GO$-G@Q0[AL&.G:O2O!\OF0W0VL
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MIH\P_P!TT 245'YA_NFCS#_=- $E)C%,\P^E.#$]J '4444 (3B@&O/?C/\
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M'LAE@3/W)CEJYUL:'1)]T4ZFK]T>E.J4 4444P"BBB@ HHHH **** "BBB@
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M0 SS/]DTGF'^Z:>>!2;C2N WS#_=-+YGL:4$FESSBF T.2>E.%+24 +1110
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MI(23"A/7%<1%_KDKMX/]2GT%*K%)*PXDE%%%<YH%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZU7DY/6OG#X9_ W5M!^*=CJ,ME:Z=I6DVT826&/:]S(4VN6/?GFOI #+D]J
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M_P"PX_/,32D\^2H5?R%9*:FMM87<,@\Z-HF&W.,\=,UH>!C&OA^(1VWV1?\
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MN=EJ^7(]"#6]HOPS\/Z&PF:V%_==3//][/K749+'+'F@C-+F[!8,_*%  4<
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M]*#Q7F35]#HV-S5=7#6ZI"?F8<FL1<=^6/>D49.#TIX4#I41CRJPF[ABEHI
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MC2RT_5;Z35M*OW$<MO+V8G /X$U]'?&?]ENV\46 M7O)8M9MF+07]RWR2 ]
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M444 %9^M_+IDWTK0JAK@SIDX]J &^'VWZ-:D?W/ZUHUG>'5"Z+: ?W/ZUHT
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M?OW4HS(Q^M59(1R^F> -2\6S#4/&-R67.Z/3HSF-?3)ZUW]K:P6=NEO;1K!
M@P(T' %2[=Q))YI=H'2DY,!&  XJSI0S>QU7?I5C2?\ C^CK*6S*CN=@1S[T
MZD/]:6O/.D*0C-+10 A&:0( <]:=10 F.:6BB@!",TFP9SWIU% $7D(@;8BH
M2.2H KG_  7%+%;7(D;</-;'YUT;< _3I7/>#9FD@N0RE<2M_.@#HCS2T44
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M87//>G @@9)HKH22V,[MD>T F@+ZTK'G@?C4%[>0:?;-/=2K! O)D<X%7J]
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MV?Q)#:+9[%:-[>9'/([A>E 'JOAJ4S:':,5*?)T/UK4K.\/\Z-:_[O;ZUHT
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MP-/^W!MWFF/Y<^N:]3\+^%(_#R&23$ETPY9>B^P]J]3&8]58\L3&E1<=S>4
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M($MH%& B# K31$G*>%OAI9>'Y?M=W*VH:JW+W$O8_P JZTQ,6R7^E/ R<T$
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M<ES^5.S1CVJ;MFEAA4_WC2[#C[QIQ&1CI5BULI;M@J*<?WJF345<$KE4(Q(
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M#"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-^5&Q_[C?E7<?9X_[@_*D^SQ?\\U_*CV_D'LSA]LG]T_E1L?^X?RKN/LL/\
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M 4444 %%%% !1110 4444 '6D  Z#%+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%)B@!:*3;0!B@!:*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IK'%%%  #D4W><FBB@"2BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I.]%% "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>rnac-20241231_g4.jpg
<TEXT>
begin 644 rnac-20241231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (G!1\# 2(  A$! Q$!_\0
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MM"W_ .>G_CI_PK%HH VO[0M_^>G_ (Z?\*/[0M_^>G_CI_PK%HH VO[0M_\
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M^.G_  H_M"W_ .>G_CI_PK%HH VO[0M_^>G_ (Z?\*/[0M_^>G_CI_PK%HH
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MH VO[0M_^>G_ (Z?\*/[0M_^>G_CI_PK%HH VO[0M_\ GI_XZ?\ "C^T+?\
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MI_XZ?\*/[2MO^>G_ (Z?\*PZ*.1![1FY_:5M_P ]/_'3_A1_:5M_ST_\=/\
MA6'11R(/:,W/[2MO^>G_ (Z?\*LJP=0R\@C(KFJZ&U_X]HO]P?RJ)142X2<M
MR6BBBLS4R=6_X^%_W/ZFJ57=6_X^%_W/ZFJ5 !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M '!_*LJFQK3W):***Q.@R=6_X^%_W/ZFJ57=6_X^%_W/ZFJ5 !1110 4444
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MGX5>&_C(OQS\ WMFUSJ%S:W)O+2RAV2]'+RB%D*1G"2;3YBJ?F/ ![W\5O\
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M;57"]<]:^?\ ]HK_ ()_WMY\(]=U+1_B_P#%CQ9XDT*(ZSH^G>)?$@OK5KN
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MO?V*H_$GQ*^*GA[0?%]M,&^ FE7GAYI9-VRXU.:XDMXY%S]Y4LK=5!Y.9,C
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MI[Q^RI\7KKXQ?LMPW>L%D\5Z):W.@:]!(<RQWULAC<O_ +3KLD/_ %TKQ?\
MX)O_  %^&?CS]DCPQJ_B7X=^%/$&K3W5\DNH:IHEM<W#A;J15!D="QP  .>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M47A3X6^"_ >EWVF^&O"&@^'=.O\ F[L])TR&UAN,KM/F)&H#_+QR#QQ7444
M8G@_P-X;^'NDG2_"WA_2_#6F&1IC9:/91VD)D( +[(U"[B ,G&>!6/8_!7X>
M:9XG/B2S\!^&;3Q$7\PZO!H]NEV6X^;S@F_/ YSVKLZ* .:\9?#'P=\1?LO_
M  E?A/0_$_V1MUO_ &SIL-WY+>J>8IVGZ4VQ^%O@S2_$D'B*R\(Z#:>((+<6
MD6K0:9"EU'"%VB)90NX(%XV@XQQ73T4 <AXK^#O@+QYJL&I^)?!'ASQ%J4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCX;Z'XIGFM1J=IXFU<BQT[S9&'V>1HW#K.RC"!L;F!XQQ2=AJYZ'^S;\"V^
M_@C4M/O=8/B+Q)KNKW6OZYK'D>2+J^N&!D94R=J@*H SV)XSBO6*Q_%7C3P_
MX$TIM3\2Z[IOA[358(;S5;R.UA#'H-\A S^-'ASQGX?\8:&-9T'7=-UO1SNQ
MJ&FW<=Q;G R?WB$KQWYIB\S8HKAKGX\?#2RL]*NKCXA^%(+75E+:?-)K=LJ7
M@#%286+XD&X$?+GD$5V\<BS1JZ,KHPW*RG((/0@T .HK.\0>)-)\)Z3/JFN:
MI9:-ID S+>ZA<)!#&/5G<@#\367X?^)O@_Q;H%WKNA^*]#UK1+-6>YU+3]1A
MGMH54$L7D1BJ@ $G)XP: .EHKY*^"7[6WB3]H#X^>)-$\-ZQ\.K;P+H6KW&G
M+9S7TMQKNK00J0;RU"2",P,Q0A]K#!//0U[Q\?/B8?@W\%?&OC9$AEN-$TJ>
M[MHK@$QR7 0B%'P0=K2% <$'!.*+CL[V.]HKY4\):S^V1XBTO1=6GMO@G965
M]##=/;2KK"W,4;JK%& )4. <=2,CJ17U70&P45\M_$#XS?&WQ1^T1XI^'7P<
MM/ #6?A72K&ZU:[\9I?;EN;GS'2-&MF[QA&P5_O<]!7K_P %_P#A;?\ 96H_
M\+;_ .$+_M+SE^Q?\(7]K\GRMOS>;]IYW;NFWC%%PL>BT5C>,_%^E?#_ ,):
MQXEURY6ST?2;26]NYVYV1QJ6; [G X Y)P!7-? GQ?XF^(/PPTCQ1XKTRUT6
M_P!9#7]OIELKAK2SD8M;1REF.Z;RBA<@*-Q("C% COJ*X/X3_&71?C'_ ,)E
M_8MK?VO_  BOB2\\+WOV^-$\RZMMGF/%M=LQGS!@MM8X.5%<5^TQ^UIX5_9Q
MTB2VG6;Q!XWN;.2[TSPKIR-+=7"*'_>N%!\N$>6Y:1NT;X#%2*+CL]CW&BO-
MOV;?B5J?QB^!/@KQIK,%I;:IK6GI=W$-BC) KDD$(&9F X[L:[O7M>T[POHM
M]K&L7UOIFE6,+7%U>74@CBAC499V8\  "@1>HKY2^$G[<$/QR_:C_P"$!\*:
M0W_""KX?N-5AU^_M989M2D2=(A);!B!]GSYB[BI+,A^[MY]7^(?Q=U'X8_%[
MP/I6L6UI_P (/XN=M'MM21&6>TUCEX8I6+;6CG0,J84$/'R2&&"Z'9GJU%%%
M,04444 %%%% !70VO_'M%_N#^5<]70VO_'M%_N#^595-C6GN2T445B=!DZM_
MQ\+_ +G]35*MV:UBG8,Z[CC'4TS^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\
M?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*V
MO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_
M^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'
M_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK
M^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_
M (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\
M?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*V
MO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_
M^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'
M_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK
M^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_
M (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\
M?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*V
MO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_
M^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'
M_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK
M^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_
M (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\
M?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*V
MO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_
M^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'
M_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK
M^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_
M (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\
M?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*V
MO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_
M^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'
M_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK
M^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_
M (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*VO[/M_P#GG_X\
M?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H Q:*V
MO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_
M^/'_ !H Q:*VO[/M_P#GG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'
M_&C^S[?_ )Y_^/'_ !H DMO^/>+_ '!_*I:15"*% P ,"EH **** (KK_CVE
M_P!P_P JYZNANO\ CVE_W#_*N>K:GL85-T%%%%:F(4444 %?&7[:7@_2/'W[
M5W[*FA:]9IJ&DW-]KK7%I*,QS!(+60(X_B0E &4\,,@\&OLVO)OBA\!?^%D_
M&CX2^/\ ^W?[._X0*;49?[/^R>;]N^U0QQX\SS%\O9Y>?NMG..,4F.+LSYD_
M:\\/_9_C[\%_AMX:^&]EXJ\(>7J7B"?P'IUQ:Z3:ZG=(,!Y/,VQL$),A3^++
M9!S4^F_#;XES_M&?#/QKX7_9WB^$$&GW3V7B.\T_7]+>WOM-E4*RRV\#KO*8
MW*0"<@<'"X^DOC[^SKIWQR_X1S5(=<U'PAXR\,7+W>A^)-)VF:T=P Z,C#;)
M&X"[D.,XQG!(/*^#_P!E[Q)<_$O0?&_Q3^*-Y\2M2\."1M$L8=)ATBQLY74*
MTS11.WFR8'!9L#/3@8FVI7-H>7_L9_"?P=\;O#?Q)^(7C_PUIGBSQ9XB\5:E
M:7LFMVL=R]G;Q.(X[2,,#Y:JH' P>5Y(5<>.-X5L_ _["'[7?A_3YVN;'3/B
M'J5I#))(9'V))IX 9B<LP P2>20:^IM6_9-\2^'_ !OXHUSX4?%B^^&EAXJN
MFO\ 6M&_L:#4K=[I\"2XM_,9?(D<#D_,"2.,  3_  N_8MT#P#\$_B+\,-5U
M^_\ %.A>,M5NM1FN[I EY$)H8(_FDRPDE5H/,\S"@LWW1CDL/F1S7[8+!?\
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M_B;XA\<_"CXF77PQU/Q,$;7;-M(AU6RO)D!"SK%*R^7+@G+ D'GCDY[?X"?
M#2_@5I.L&/5+WQ-XGU^[.H:[XDU0@W6HS\A20.$1 2$0<*">Y))U"^AY5_P4
M@O';]GW3M"8N+'Q'XHTG2+WRVVL8'G\Q@#[F(#\:]@^,O@3Q]XRT?3+3X=_$
ME?AA=6TI:XN5T"WU47$6W"QA)B F#SD?2N?_ &POA/J/QE_9^\2Z'H19?$MJ
M(M5T<H0&-Y;2":-03T+["F?]NLZ75/&7[37P:\%>*OA=\2_^%83W\0N;V7^P
M;?5BS;=DELR3L!&T<H=21SE2*.H=#YD_9"^$?QJUF[^+TFA?'W_A'8-/^)FL
M6FK0_P#"&V5U_:UY&8?/N\NX\CS05'E)E4V\=:^S/CQH>FK\)_B/K T^U&K/
MX5O[5K_R5\\PK;S,L9DQNV!G<A<X!8GN:\7\+?LM?'7PA=W4FF?M(V%A!?W[
M:EJ,-A\,M*MOMMPY'FRRE&&Z1PH!D.6.!DG%?27CSPO_ ,)MX&\1>'?M/V+^
MU].N-/\ M/E^9Y7FQ-'OVY&[&[.,C..HH6PV]3R?]A;_ )-#^%?_ &!8_P#T
M)J]LU32[+6M/N+#4;2"_L;A#'-:W42R12J>JLK @CV-<3\%?A7)\&_@QX;\!
MPZQ_:4VBZ>+)-4^RB+S&&<2>46;')^[N/3K6O\,O#_B7PMX'TW2_&'BS_A./
M$4'F?:M>_LV+3_M6Z5V3]Q$2B;4*)P>=F3R331+/G"_@CM?^"HF@PPQK##'\
M*"B1QJ%55&I2@  = !70?\%'+%I/V1?&&J03?9-2T2>PU6PNE^]#/%>0[67W
MP6 _WJ[Z[^ OVK]J6R^,G]N[?LWA4^&/[%^R9W9N7G\_SO,X^_MV;.V=W:O/
M_P!MC3W^*UCX'^"=CF6Y\:ZS#/JJIDFVT>SD2>YG;'3YQ BYQEGP.14]&5U1
M]':/>/J.DV5VZJKSP)*RKT!902!^=6Z;'&L,:HBJB*-JJHP !T %.JR HHHH
M **** "NAM?^/:+_ '!_*N>KH;7_ (]HO]P?RK*IL:T]R6BBBL3H"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH BNO\ CVE_W#_*N>KH;K_CVE_W#_*N>K:GL85-T%%%%:F(4444 %%%
M?-O[4W[1WC;X,?%#X1>%/!GAG3_%-QXV?5+9[.[9XI!-#%#]G990P6.,/-ND
M+*QV(=N#S2V!*Y])45\SZ'\>/BE\-?B]X2\$_&;1/"QL?&3RVVB>(O!TEP+>
M*[1 _P!FN([@E@6'"NIY./E^]MK?\+Z^+?QH\<^,M+^"FB>$+?PWX1U*31KS
MQ%XTDNGCO[Z,?O8;>.VP0J$J"[$@@@@'.*5Q\I](>(O$FD>$=%NM8UW5++1=
M)M5#7%_J-PEO!""0 7D<A5&2!R>I%7;6ZAOK:*XMY8[BWF021S1,&1U(R&!'
M!!'.17QKX\_:NOM<_9G^-/\ PD_@70E\?_#^6"RUSPKK<?\ :.DW'F3)Y,P7
M*F2&1=SJ&P04[XR=GQI^TQ\1-!^+OPU^&W@;PAX?U6;Q3X/3584NC+:P6,X/
M+.ZLVVV2-&^0(7+;%##-%Q\K/K6J]KJ%K?274=M<PW$EK+Y$ZQ2!C#)M5MC@
M'Y6VNK8/.&![BOG#X>_'3XHV'QNO?A#\2M*\*1^)[W0)-=T'6O#;7 L)PKF,
MQ312L9%(;DX;HI]17B/[)_Q \?\ PB\+_M)^-?%$?AO4?"N@^-/$=]K%GH\%
MRM]/J\8@:06[.Q1;4\ ;P77.2<"BX<I^@M%?(6B_'[]H4^"?#OQ*?P;X)\:^
M"-7>UEDT+P5+>W.M6EM.R@.&.Z.9HPX+A57&#R "P^O:8K6"D=UC5F9@JJ,E
MF. !ZU\_>*OB!\>/%WQ#\1Z%\-_"'ASP]H&A-'!_PD'CZ.\V:K*R[F^R10;2
M8UZ&0L03T'8>2^+OCM\0_B]^RS^T/X?U+2/#F@>/?!=KJ&EZ_&DDT]C<61LY
M&DEML$.LCQB38') (!;J5"N/E/M:QOK;4[*WO+.XBN[2XC6:&X@</'(C#*LK
M#@@@@@C@@U@^+OB7X0^']QIL'BCQ5HGAN?4F9+&+5]1AM6NF4J&6(2,"Y!=,
MA<XWKZBO+/V(U\9K^S5X!_X2Z70I(#H.FG1O[%CF1EL/L</E"Y\QB#/C[Q3"
M^@KYY_X*:?#%OC)\5_@)X-B)6[U2W\3I:$,1BY2SMY("2.WF(F?;-%]+@EK8
M^_:Y_0_B)X4\3Z]JFAZ/XFT?5M;TIBFH:;8W\4US9L&*D31JQ:,[@1\P'(Q7
MCOPQ_:6M;W]C&R^+>M-FYTS0))=4BE)5VOK96BEC(/(9YHR #S\Z_6OE_P#8
M;TF3X'_'#XO:IXSNI(M0C\%V'BCQ%=3YWI/.K7ER6'8IO92!_<_&BX<NY^D5
M%?)'AKXW?M(_%#P2GQ*\'>!/!-OX,NHFO-,\-ZS=W7]N:C:C<4<2Q_N(GD4*
M54AASR>A-3Q[^W9J4GPW^"GC+X=>&(-?7Q_JSZ3)HE^Q2Y2X :/R%D#!8R)Q
MM,C*PV?-MHN@Y6?855X]0M9KZ>RCN87O($22:W60&2-'+!&9<Y 8H^">NUL=
M#7S(OQX^,/PK^+O@'PY\6-$\&3>'_'%V^FV-_P"$IKH2V%X%W)%,)S^]!^[N
M4+W.!@ \#^SG'\5/^&[?V@_M=QX/-DMQH/\ PD0A@NA(\'V"7[$+,E\*X3;Y
MOF9!;.W HN'*?9?AGQ=H7C733J/A[6M/U[3Q(\)N],NH[F+S%.&3>A(W \$9
MR*UJ_.;]A_7OCM=? W5K/X8Z!X-@TK3M>U)CJ'B^:Y9M1F:4N8H(X-NQ5!4>
M8[$%B1C@FOL/]F'XY#]HCX-Z1XR?3#HM_-)-:7VG^9Y@@N89#'(%;NI*[AWP
MPH3N#5CU:N:\.7W@[3=>U?PUH%QH=IK4,AU+4M(TUX4N4><[C<30I\P,A.=[
M#YLYR:YC]H#XS)\&/!*7EG8'7?%FK7":7X>T&,XDU&_DXC3J,(OWW;HJJ3UQ
MGY=_8U\ :O\ #?\ ;.^,6E^(M:E\1>)9_#^EW^K:E(>);R?$LH08&(U9BB#L
MJK1?45M+GW=1115""BBB@ K/7P[I2:])KBZ99KK<ELMF^I"W07+0*Q=8C)C<
M4#$L%SC))Q6A10 4444 %%%% !1110 5T-K_ ,>T7^X/Y5SU=#:_\>T7^X/Y
M5E4V-:>Y+1116)T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 177_'M+_N'^5<]70W7_'M+_N'^5<]6
MU/8PJ;H****U,0HHHH *^+_VVOB$OPJ_:C_9>\42Z9?:O;6,_B(7%MIUN\\X
MADM;:*618T!9O+1VD( SA#7VA7A_QE^!VN_$3]H+X'^.M-N].@TCP//JLNI0
MW4DBSRBY@BCC\E50JQ!C.[<RX!&,U+''?4\=\:?$S1/VR/C9\'=)^&AO-=\-
M^#]?7Q3KOB3[%<6UI:M A\FV#NJ[I'9B"@Z <Y&[&?\ !7XP>'/V*]:^)/@#
MXM2WGA:UNO%-[KV@:]+8SSVFJ6=SAE5'B1_WR[#N0\Y.!D@U]Q446ZCOT/S,
M^*6D:IXV^"G[7/QKN]'O]!T/QJFDVFA6VI0&"XGM+-HH?M+1M\RK(0I4$ \'
ML0:]>T?_ )/D^!W_ &2Q_P#T(U]JT4<H<Q\H>-?^4EWPZ_[$*^_]*'KA/@'\
M3+'P'=_M/^ Y]!?Q+X^F\;^(?$EKX'N$:*36--E6$ HS1LC"10V%P2V0,<U]
MU446"Y^4WC"X^"D/AW^U_P!G34?&_@'XY7#PO!X&\/+?;OM1=1)#=6\B&,1J
M"V3N"<#@@[3^I>@_;_[#T[^U/+_M/[/']J\K[GG;1OQ[;LU>HH2L#=S\YO$G
MQ%\.:U\=/BAI/[1'Q \=>$C8:U)!X7\*Z//?6=A?Z6,B&:-;5"T\KCJ2V?GP
M.X7+_9S\/P2> _VU_#7AOPSJN@O=:6_]E^'-3,CZB(9].NOL_F+(S2;Y RMA
MB2"^"<U^EM%+E'S'@W[$7Q/\,_$3]F_P+9:!J:WUYX;T/3M%U:W\MXWM+R*T
MB62)@P'((/(R#ZUPO[47_)Y_[)?_ %]^(O\ TDMZ^LZ*JVA-];GYR^(/".K6
MG[2GB#]FH64W_"%^,O%UI\0/,R6B&EA'N+VW(/W%:[MHD4#CEN,FNSUOP'/\
M4/VL/VJO"-I*L%YKG@&QL()6.%662VVH6]MQ&?;-?<]%*P^8^*O@U^VOX+^$
M/P-\,>!?&=CK>C_%#PMI$.B/X+_LFYDO;Z:VB\F/[.50HZR"($,&VC//&,^3
M:7\+=>^$G@O]D32_%%K_ &?XAOOB))JU[8GK;-<.76,^C!"F1V.1VK]+J*+!
MS'RA^VI_R5S]F+_L?8O_ $ 5G_#/QUHOP[_X*!_'70?$ETVD:EXX3PZ_AV.X
MA<+J0M]/D2;RW"[?E8XY(Y!'45]?T46"^ECY0_X)F_\ )M<W_8R:K_Z/-'_!
M,W_DVN;_ +&35?\ T>:^KZ*+"N?/GQD_9C\4?$CXSZ+\1O#WQ4N_!FHZ/IK:
M=86HT.UU&.W\QB9I4$^55W!52P7=M7&<'%>"? _X=_$2P_X* ?$>WO\ XLW.
MJ7FF:5I-SJUXV@641UFW*J5MF15VP #C?'AC7W]118?,%%%%42%%%% !1110
M 4444 %%%% !1110 5T-K_Q[1?[@_E7/5T-K_P >T7^X/Y5E4V-:>Y+1116)
MT!1110 4444 %%?)WA7XD?M ?%SQE\3H_!NK?#W2=%\)^*;KP];VNN:3>S3S
M"*.)P[R1W  R)0.%['BNV^%_[3ESKGPV\::EXQ\+WECXR\#ZD^CZ[H'AZ&34
M'FN/D,3VB@;I$F65&7.,9.XX4F@#WNBO$OV5/C9XD^.7AOQKJ7BCP_'X6O\
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MS\'OVJO$?C#]KCXC?"SQ%I^GVN@Z?-<0>';ZVC=);B6V2W>XBD)<AF"74;C
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M8$1DDCB*'+1L.O;WKU3]DOPGXB^W?$[XC^)]#NO"]]X^U\:A::'?@+=6MC#
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M2[O45B)M(WMXB)[-FQMW27T%G-M_NLYQ7U-_PEWBG_H1+O\ \&5K_P#%T?\
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M (3+Q/\ ]"+=?^#.U_\ BZ/^$R\3_P#0BW7_ (,[7_XN@#M:*XK_ (3+Q/\
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MU_X,[7_XN@#M:*XK_A,O$_\ T(MU_P"#.U_^+H_X3+Q/_P!"+=?^#.U_^+H
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MSM?_ (N@#X]\-_ KQ+)XN^'6F:G97$>M>)O /BNZU[43 _E0:IJDL$KI(^,
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M+H_X3+Q/_P!"+=?^#.U_^+H [6BN*_X3+Q/_ -"+=?\ @SM?_BZ/^$R\3_\
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M9+)X(4^14,$BJT8 7 ! XQ73U6TVXGO+"":YM6LIW4,]NSJYC/H64D'\*LT
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MFQS_ '6(^,/!L9C_ &#OV9HI%*NGQBM$=&&"#]HOL@BOK/\ X**?\BU\$/\
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M3Z* &?O/]C]:/WG^Q^M/HH 9^\_V/UH_>?['ZT^B@!G[S_8_6C]Y_L?K3Z*
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M(1XV[-N,;<<8Z8JQ10(XK3?@C\.M'M[2WT_P#X7L;>TU!=7MXK;1K:-8;U0
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M+\:?@SJWCKQ)X1\9>$/$,'A?QQX7:X2SN[VR-Y:7-M<*JSV\\0=&*MLC8,K
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/"_0:+XGO!&OI%(Y:/\ #:!^=>Y5Q8/2A&'\ON_^ NWZ'I9CKBIS7VK2_P#
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M@!GDK_M?]]'_ !H\E?\ :_[Z/^-/HH 9Y*_[7_?1_P :/)7_ &O^^C_C3Z*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 7(_]6OTIU-C_ -6OTIU !1110!%=
M?\>TO^X?Y5SU=#=?\>TO^X?Y5SU;4]C"IN@HHHK4Q"BBB@ KYC_:?^'WA[XA
M?%[X=P:3\3+CX8?&:SM[R7PY>PV?VA;NW8 3Q.C@1R8 ^YOSAB=I%?3E</\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 &T>E&T>E%% !M'I1M'I110 ;1Z4;1Z444 &T>E&T>E%% !M'I1M'I110
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M!37LJ?>7ZUWX?%0Q7,X)JW=;^:/-Q>#J8/E4Y)W71WMY/S+E%%%=AYX4444
M%<I\6/#%EXV^%_BWP_J5U;6.GZII-U9W%U>)OAAC>)E:1UW+E5!R1N7@=1UK
MJZX_XP^!1\3_ (3^,O"#7ITT:]I%WIOVP#/D>;$R;R.X&[)'H* /A#X??&C7
M]#L?#_AZQ_:=U:/PTIATO3/$FL?"=H]+GQB.)!?.X0@X"B1C@\?,<YK]'8PR
MQJ&;<P'+8QD^M?"'BKXD?$CXJ?!/3/A7J7A#P+X>TCQ9$/"L7CI/&%I<:/<;
M08I&L;=0)))L12>7%QM=0,_+7W596HL;."W5F=88UC#.<L<#&2?6@">BBB@#
MB?C';Q77@&X@GB2>&2]L$>.10RLIO(000>"#Z5V<4201)'&BQQH JHHP% X
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MN2T45\__ !8^(7QS\'^(M3ET3P[\.!X/CD5;/4O$7B2>RF<% 3YB^254[MP
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MTCM(%/4A1@LWJS'+$]R2:Z"BBLVVW=E#)O\ 5M52K<W^K:JE( HHHH ****
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M$\=*XGQ1\3-0\)Z;!+J&D:=87;1W$C17VM1PI+Y1 "P$(SRLX(('EKC(#8)
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MO0?&5YK?Q.T31M2\<:PZLVGVSW%UJM\X153;:P.7/RJH!V@<=:Q.@=JGPO\
M"'[._P"TU\(;[X96-OX6L?&5Y?Z)K^BZ4^RQO$2QEN(93 #L62-X>&4 D,0:
M^NJ^ _V6_AWX5\:?%[2?&OPR_9YTSX?^$-!U"\L[CQ)XEU"9=8,T:20R1P62
MR,(F#G:QE/0M@9%?=VO:K_8>B:AJ7V.[U#[';R7'V2PB\VXGV*6V1ID;G.,
M9Y)% %ZO+_B1^TU\,OA'X@71/%?BJ#3-4\@74MNMO-<&V@)P)9S$C"%"0?FD
M*C@\US.D?M6?VMJUE8_\*>^+%E]JG2#[3>>&/+ABW,%WR-YORJ,Y)[ &H_C%
MX,U'7M"^(T/P7D\%P_$#6E6S\37&K%II"!:,D*.(R=DOELNWS!M"MDJ<T =Q
MXBNFUCX@_#V\TF_M7LYH+R<3JGGI<0%(3\C*P W @A^1CL<UZ%7RS^SKXD@U
MSX0_L_WG@C2V-A%H5U8QVFN7QCDC6!8X)-TL<3AV#Q'&% (YXZ5]1[I/[J_]
M]'_"@!]<-\=/"_\ PFWP7\=:"%WOJ&B7EO&/]MH6"'_OK%=MND_NK_WT?\*1
M@[J59$*L,$%O_K4XOE:8'AO['?BD>)_A5',6RTGD7V/07-M%,?\ Q]I/RKV3
MQ%&TVB7B)#>3LR8$>GS"&=N>B.64*??<*^8_V)WE\/?VKX8< /I_VS32K-CY
MK+4+B$=O^>4D/X8KZ9\26\UYH=Y EE]N9TP+>.Z:W:3GH)!@K]:Y,*N12I_R
MRDOES.WX6/0S#WJBJ?S1B_FXJ_\ Y-<U%^Z.O3OUH9@BEF(50,DGH*8OF!0-
MBCCIO)_I5/6H8KK1[^"\=(+22"1)I3)MV(5(9LD<8&>:ZCSSX6^.7_!3_P (
M?9_$GA+P3;ZB;V57T^W\6.JBTMW9MCW"("9'5 693CYBHXP<U]F_"?POH/@O
MX9^&-%\,2)/X?L]/A2RN$.X3QE 1*3W+YWD]RQ-?CUX/_8&^*/Q)NK>\\(Z?
M!>^"KZYE33O$U[<1V\4UJLK(MP8BWFA6"[@ IR"".#FOV*^&W@T?#GX>^&O"
ML$OVJ'1=.M]/6=R09/*C5-Q&.,XSCWKT,3&E3BHTWZF%-RDVY'3T4S=)_=7_
M +Z/^%&Z3^ZO_?1_PKSS<)O]6U5*L3-)Y;?*O_?1_P *J;I/[J_]]'_"@!]%
M,W2?W5_[Z/\ A1ND_NK_ -]'_"@!]%,W2?W5_P"^C_A1ND_NK_WT?\* 'T4S
M=)_=7_OH_P"%&Z3^ZO\ WT?\* 'T4S=)_=7_ +Z/^%&Z3^ZO_?1_PH ?13-T
MG]U?^^C_ (4;I/[J_P#?1_PH ?13-TG]U?\ OH_X4;I/[J_]]'_"@!]%,W2?
MW5_[Z/\ A1ND_NK_ -]'_"@!]%,W2?W5_P"^C_A1ND_NK_WT?\* 'T4S=)_=
M7_OH_P"%&Z3^ZO\ WT?\* 'T4S=)_=7_ +Z/^%&Z3^ZO_?1_PH ?13-TG]U?
M^^C_ (4;I/[J_P#?1_PH ?13-TG]U?\ OH_X4;I/[J_]]'_"@!]%,W2?W5_[
MZ/\ A1ND_NK_ -]'_"@!]%,W2?W5_P"^C_A1ND_NK_WT?\* 'T4S=)_=7_OH
M_P"%&Z3^ZO\ WT?\* 'T4S=)_=7_ +Z/^%&Z3^ZO_?1_PH ?13-TG]U?^^C_
M (4;I/[J_P#?1_PH ?3D^\OUJ+=)_=7_ +Z/^%.C,F]<JO7^]_\ 6H OT444
M %%%% !7#?$SXT>%/A+<>'K7Q#?R1ZCX@OET[2]/M+=[BYNI21NVQH"=J [F
M8\*.IY&>YKYG_:!U?_A3?[0'@;XO:WI5]JG@>TT*_P##VI7FGVCW3Z))--!-
M'=M$@+>6PB>-F4$KE<\&@#U7XD?'?PI\)/$WA?1_%,UYIB>(IFMK35FM';3X
MY\J$BFG VQ,Y;"[L [3R,5Z'7Q9^T%^U!\/?VFOA+K_PK^%-S+\2?%WBJ :?
M;V^GZ?/]GT_>Z_Z7<S/&$A6+'F9)W;E&!W'V7I]N]G86UO)*9GBB6-I&ZN0
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MM#K?CO49_$URD@^:.*8@6L7T2W2$8[<U[76M3?E[:$QVN%4JNU2K(H2BBB@
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MP_\ $#7?!_A2X^'B:CK$>DW91A&NI2JTENK$I'<,PAC\X*7"%@*YOXX?L_\
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M]#J&J6(FFN7M2Q@C>69Y3'&6Y*KOVY.,X)P,XKV.K,WN%%%%, HHHH ****
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M_P#I;!794 ,\E?5O^^C_ (T>2OJW_?1_QI]% 'RQ\4M*?3_C[X^M+<LI\0>
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M?A'XB^"T\7>'/$-AJOAID>0ZE%,!%&$SOWEL;"N#D-@CO0%F=317AN@?MP?
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M'4D@,6W$/9W%NK'IG["^BZ%X=^)'[2.F^&HX8-&MO&S1PPVV/+B;ROWD:@<
M*^]=HX&,=JM?\%(/^21^!/\ L?=&_P#0Y*@_X)W?#)O!/A/XAZ[;:%?^&O#O
MB;Q+-=Z#INJI(ET-.10D,LBR?."_S'YLDC!YSD^Z?&SX(Z%\>/#NDZ-K]WJ%
MG:Z;J]MK,+Z;)&CM- 245BZ."AW'( !]"*.@?:/EG5OB@O['_P 2/VCM 5%C
MM=6TP>/_  O;\XEO;DK:30J,<EKLPX5>@)XK'\(_#&X^"_[37[,OA546?6K'
MP5K,MXSN3Y]_)&\MPQ8GG=,[\D]"*^I?C'^S#X+^.7C?P'XJ\2+?#4_!UY]L
MLELY42.Y_>1R"*X!1B\8>)&V@KWYY-;/B#X(Z%XD^-'A3XG7-WJ$>O>&[*YL
M+2WADC%J\<X(<R*4+%AGC# >H-%@NCP__@F;I^GW?[*MCJT\4<_B76]4U.X\
M233(#//>?:Y5(FR,[O*$?RG^][U\E_$Z*+2_V-OVH]$T4*/!>E_$W[/HT</,
M,(^U0&6*(]/+4[< <?,3SG-?<7B;]B?PCJOBC6M:\/>+/''P[_MV<W6KZ=X-
MUPV-G?RG&^22(HP5F Y9-I.3ZUK>+/V/?AWXF_9];X-6MM>^&_!S/%*?[(F5
M;HR)*LN]I)4DW,S+\S,"3[<85G:P^97N>4?\%*/#>E^$?V(]0M-'T^WT^#0;
MO3/[+2&)5%GLN(T4Q\?*0I(R.Q/K74>(/^4CWA/_ +)O>?\ I>M>M?'SX':%
M^T5\,=1\"^)+O4;+2+Z2&66;2I(XYP8I%D7:SHZXRHSE3QZ5D?%3]FW0_BEX
M_P##GC;_ (2'Q)X3\4:'"UK#J/AJ^2W>>W9P[03!XW#QEAG&!U/-58E/0\:_
M8J\/Z;_POK]I[6_L4)U<^-)+/[8RYD$(#-L![#<Q)QUXSG Q=_8?ACT_XE?M
M+Z?:QI;V,/C^X>*WB4*B%D^8@#IG _*O</A?\$="^$WB+QWK.D7>H7-UXQU=
MM9OTO9(V2*9A@K$%12$]F+'WH^%_P1T+X3>(O'>LZ1=ZA<W7C'5VUF_2]DC9
M(IF&"L05%(3V8L?>DEL%ST*OE#X4_P#*1;XY?]BWHW_HM:^KZ\]\/_!'0O#?
MQH\5_$ZVN]0DU[Q)96UA=V\TD9M4C@ "&-0@8,<<Y8CT JF)'&_M!?M*2?#C
M6+#P'X'T5_&_Q9UN$OIN@P'$5K'G;]KO'SB*!3ZD%L$ CEA/^S+^SW=?!FQ\
M0:]XIUO_ (2OXE>+;E;[Q#KFS8CNJD1P0K_#%&"0O SGH!M5>/\ %7[!.@>)
M/BEXG\?VGQ2^*/A;Q!XBD#WK>&]?BLD** $B&VWW&-  %5F. *]$^"O[/?\
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M-Z%"KBJL:-&/-*6R1V,W^K:JE>8_"G]H#1OBM?7&F1VMSI.J1QF5+>:0.LJ
MC)5AW&1D$?GS7IGE_P"V_P"=98;%4<9356A+FB;8S!XC 570Q,.62Z#J*;Y?
M^V_YT>7_ +;_ )UU'$.HIOE_[;_G1Y?^V_YT .HIOE_[;_G1Y?\ MO\ G0 Z
MBF^7_MO^='E_[;_G0 ZBF^7_ +;_ )T>7_MO^= #J*;Y?^V_YT>7_MO^= #J
M*;Y?^V_YT>7_ +;_ )T .HIOE_[;_G1Y?^V_YT .HIOE_P"V_P"='E_[;_G0
M ZBF^7_MO^='E_[;_G0 ZBF^7_MO^='E_P"V_P"= #J*;Y?^V_YT>7_MO^=
M#J*;Y?\ MO\ G1Y?^V_YT .HIOE_[;_G1Y?^V_YT .HIOE_[;_G1Y?\ MO\
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MP,#CI6G7EXFFL0K;-;-='_6]]ST,+B)8=O3FB]&GLU_6S6J>J,[P_P"(=/\
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M_B>'QYHOQ&OGNH3JW@5M%M=.MT@=@)1:WF\/NC!.#*QW8S@D!6Z#XA6/QO\
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M)IWUZ\W8MT445[9\X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEF *J%7D-GY3C'U?13L%SX/OOAOXM?2?VX$7POK3/XA _L91I\V=3_T25?\
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MY1I?[..K7GQZ3XC^,_B!?>,;72)+I_"WAZ33X;2WT7[1\KDM&<W#JA**[@$
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MV+I9V$(C3<U["68XZL3U8Y)[FO4J (]LG]]?^^?_ *]&V3^^O_?/_P!>I**
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M\_\ UZ-K_P!\?]\__7I]% #-K_WQ_P!\_P#UZ-K_ -\?]\__ %Z?10 S:_\
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MK;<47861]@_#/]KSX0_&#Q-%X>\*^-+>^UR:,RP6%U:W%E+<( 6+1+/&GFC
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M2L4>>I.223R23R2>36A117H1BH)1BK)'ERG*I)SF[M]0HHHJB HHHH ****
M"BBB@ IR?>7ZTVG)]Y?K0!<HHHH **** "BBB@ HHHH **** .(^,WGCX?W1
MM1$US]LL?*$Q(0M]LAQN(!(&>N!79V_F^1'YX03;1O$9)7=CG&>V:Y'XN?\
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M[X'TKSCQ9XTT'X@?"F'7?#.LV.OZ-=7U@8;[3KA9H7Q>P@@,I(R#P1V->ET
M%%%% !1110!E^&;06.CQ0BSM[ *\A^SVLYFC&78Y#%5R3G)XX)(YQFM2L?PF
ML*Z%"($TV.+?)A=)(-O_ *QL[< <YSN_VLUL4WN);!1112&%%%% !5*KM4J
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MVE_W#_*N>KH;K_CVE_W#_*N>K:GL85-T%%%%:F(4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %=#:_P#'M%_N#^5<]70VO_'M%_N#^595-C6GN2T4
M45B= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% $5U_Q[2_[A_E7/5T-U_Q[2_[A_E7/5M3V,*FZ"BBB
MM3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NAM?^/:+_<'\JYZ
MNAM?^/:+_<'\JRJ;&M/<EHHHK$Z HHKQ3]K+Q!JGAOX<Z=<Z3J5YI=RVJQQM
M-93O"Y4PS$J2I!QD X]A7'C,4L'AYXB2NHJYZ&7X.688JGA8NSF[7/:Z*_.+
M_A:GC7_H<->_\&<__P 57M?[)OC7Q#XD^(VHVVK:]J>J6RZ5)(L-[>23(&$T
M(# ,Q&<$C/N:^5P?%%'&8B&'C2:<G;='VN8<%XC+\+4Q4JR:@KVLSZRHHKQR
M3XW^)[S4_$T.B_#Y]9L=!O)K2XNH]7CC8^63DB,IN)(&=JY].:^KQ&+I86WM
M6]=K)O;T3/B<+@:^-YO8I>[O>48K71:R:6Y['17*:/\ %#PWJWA'3/$DFJ6^
MEZ7J (A?4IDMSN!(9#N;&X%6& 3T-:FJ>+M"T2UM;G4=:TZPMKH;H)KJ[CC2
M88!RA8@-P0>/45I'$491YU-6LGOT>S^9E+"UXS]FX.]VMGNMU\NIKT5E7_BK
M1-+TNWU*]UBPL].N=OD7EQ=(D,NY2R[7)PV5!(P>0,U'J'C/P_I%G9W=_KNF
MV5K>+OMI[B[CC2=< [D8G##!!R/453K4XWO):>9$:%65K0;OY,V:*Q+[QQX<
MTN*WEO/$&EVD=Q"+B%Y[V-!+$<8=26Y4Y'(XYK*\-_%KPMXLOM:MM.U:WE&D
M@M/.TJ+&T8&6D0YYC4G!?&W/0D8-9O$T8R4'-7?2_P S2.#Q$H.HJ;Y5N[.V
M]OS.PHK(MO&&@WFD3ZK;ZWIT^EP-MEOH[N-H(R,9#.#M!Y'4]Q4VB^(M)\26
M[SZ1J=GJD$;;'DLKA)E5L9P2I.#@CCWK15:<FDI+7S,I4:L4W*+26CTV-&BO
M,/B#\:)_"6O7>E:1X:G\1RZ;9?VAJDD=RL"VD.1@C()=L98@8P,=>=N)XB_:
M36RN9VT3PS/K>FV=A;ZC>WCWB6YABF567"$$N<.N0#UR.V:\ZIFF#HN49SUC
MH]&^^UEK:SO:]K:V/6HY+CZ\8RIT])*ZUBNUKW>E[JU[7OI<]JHJKI>HQ:QI
MEG?P;A!=0I/'O&#M90PR/7!JU7JIJ2NCQ)1<6T]T%%%?F#_P5 ^+WCOX?_'S
M0-/\+^-?$7AO3Y/#-O</:Z1JL]K$\ANKM2Y2-P"Q"J,XSA0.U=%&DZTN5,B4
MN57/T^HK\ O^&F/B_P#]%5\;?^%%>?\ QROT^_X)?^.?$GQ ^ >OZAXH\0:I
MXDU"/Q-<6Z76KWLEU*D8M;1@@>1B0H+,<9QEB>];UL)*C'F;,XU%)V/K^BL/
MQSXE_P"$+\$^(/$'V;[9_9.GW%_]GW[/-\J-GV;L';G;C.#C/0U\P>'_ -N+
MQBVB^#_%?BKX*7/AWX>>)+RWLX?$=KXDM[]HS/D1.;98UDVEASNVX'J<*W+&
MG*:O$T<DMSZ[HKQGX7_M-Z#XT\.^-];\1MIW@;3/#/BN\\+FZU358UAG: 1D
M2^8ZQA"_F<)SC;U-=^GQ1\&2>#Y/%J>+M";PK&VU]<74H38J=XCP9]VP'>0O
M7J0.M)PE%V:'='3T5S+?$_P<O@Y?%K>+=#'A1CA==.I0_82?,,>!/NV??!3K
M]X8ZUP7Q0_:6T3X?O\-[FP%AXBT+QEK"Z8NM6^J(MK:QD$M<!PK+(J[3D;E'
M!^:A0E)V2"Z/8Z*YO2?B5X0U[PS>>)-,\5:)J/AVSWFYU>TU&&6T@V ,^^96
M*+M!!.3P#S5CPCXY\-_$#39-0\+^(-+\2:?'*;=[K2+V.ZB20*K%"\;$!@&4
MXSG# ]ZFS[ ;E%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 177_'M+_N'^5<]70W7_'M+_N'^5<]6U/8PJ;H****U,0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** (KK_CVE_W#_*N>KH;K_CVE
M_P!P_P JYZMJ>QA4W04445J8A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOJ&KPQI]EM9&QE6RX=MNY2Q1&"AN2.<=+XAUZT\,:+=ZI?,RVULF]@@RS'.
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MN>;S,$$ D8 7+$DC@>I -#XUZ==ZK\.KVVLK6:\N6N[%A#;QEW(6[A9B !G
M4$GT )KR[Q-X.U^]TO6]+ETN\GL_#8CM-'Q"SFX26[CD#QX'S>5 B1G'3YN!
MS0![K<>+-$L]8BTBXUG3X-6EQY=C)=(L[YZ8C)W'.#VJ)?&WAUM672AKVEG5
M&<QK9"\C\XL"05";MV05(QCL:\>\1:'?MH_C7PV-!OY]?UC7/MEA?1V;M!L9
MT:*8W(&Q/*52,,P88P <U)?>&=3@T#59;;2+H7S^/4OU*VK%VB%RA$W3E H/
MS=,9[4 =I;_'?PE=>6R7Z^0VI2Z8UP9H?*B:-'?S7;?@1,(V*MW]*[G2]5LM
M;L8KW3KRWO[*7/EW%K*LD;X)!PRD@X((_"O$;+P_?7'B;2X)M(OF6U\;WVH2
M/)9R")8G29HI0Y7:5SMY!."0#@D5WWPKT^[T\^,!=6LUJLWB*\F@$T93S(VV
M$.N1RI.[D<'F@#3TWXC:'K7C2\\,6%R;S4;.!IKEX<-#$5=4:,MG_6 L,J.G
M?!XJCH?Q6T[7-0TN$:?J-G9:L9!IFI74<8M[TH"<)M<NNY0S+YBID*>^ 8&T
MR6R^,BW\=C+'IR^'YE:>&!C'YK72NRY Y<_,V.IY-8GA;7F\:>-+76=;L-:T
MY[5Y(M'TJ;1;R-+8,"K3SS&+89'7( W;$5L99B2 #T+6O$5MHMUI=K(DD]UJ
M-P+>"" *7/!9W()&$102Q^@&20#%IOC;P[K&H"PL-?TN^OBI86MM>1R2[1U.
MT,3BN<U@-#\:O#4MR&:UETF]@M#_  K<;X6?Z$QJ?^^37 ^'?">I:?X9^%J1
M:/<6US;ZQ=27@:T;,22+<*S2C (5@R@YQD$>U 'O=<MH'CE_$DVZS\/:J=-:
M2:./4Y&MEAD\MF7(7SO,PS+@90=03@<U@Z%\)_['UBTO?L/@J/R) ^ZQ\*_9
MYQC^Y)]H;8??!KF/#'AVUM]:\*+X<\'W?A+6;.[F.LS-!+Y8M<.'B:Z=0+H.
MYB*8+XP&^7;0!ZUX;\16OBC28[^T$D8+-'+!.NV6"525>)QDX96!!P2.,@D8
M-:E<#\+ED;5_'DR$?8)-?D$"X_B6&)92/;S%8?4-7?4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!%=?\ 'M+_ +A_E7/5T-U_Q[2_[A_E7/5M3V,*FZ"BBBM3$**** "BBB@
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M=*=10!1T31++PYI=OING0?9[.W!$<>YF/)))+,222222222235ZBB@ HHHH
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CBBB@ HHHH **** "BBB@ KH;7_CVB_W!_*BBLJFQK3W/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>rnac-20241231_g5.jpg
<TEXT>
begin 644 rnac-20241231_g5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (4!-4# 2(  A$! Q$!_\0
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MHKBX6V0,P)!..*K_ -K0_P!U_P A_C0!=HJE_:T/]U_R'^-']K0_W7_(?XT
M7:*I?VM#_=?\A_C1_:T/]U_R'^- %VBJ7]K0_P!U_P A_C1_:T/]U_R'^- %
MVBJ7]K0_W7_(?XT?VM#_ '7_ "'^- %VBJ7]K0_W7_(?XT?VM#_=?\A_C0!=
MHJE_:T/]U_R'^-']K0_W7_(?XT 7:*I?VM#_ '7_ "'^-']K0_W7_(?XT 7:
M*I?VM#_=?\A_C1_:T/\ =?\ (?XT 7:*I?VM#_=?\A_C1_:T/]U_R'^- %VB
MJ7]K0_W7_(?XT?VM#_=?\A_C0!=HJE_:T/\ =?\ (?XT?VM#_=?\A_C0!=HJ
ME_:T/]U_R'^-']K0_P!U_P A_C0!=HJE_:T/]U_R'^-']K0_W7_(?XT 7:*I
M?VM#_=?\A_C1_:T/]U_R'^- %VBJ7]K0_P!U_P A_C1_:T/]U_R'^- %VBJ7
M]K0_W7_(?XT?VM#_ '7_ "'^- %VBJ7]K0_W7_(?XT?VM#_=?\A_C0!=HJE_
M:T/]U_R'^-']K0_W7_(?XT 7:*I?VM#_ '7_ "'^-']K0_W7_(?XT 7:*I?V
MM#_=?\A_C1_:T/\ =?\ (?XT 7:*I?VM#_=?\A_C1_:T/]U_R'^- %VBJ7]K
M0_W7_(?XT?VM#_=?\A_C0!=HJE_:T/\ =?\ (?XT?VM#_=?\A_C0!=HJE_:T
M/]U_R'^-']K0_P!U_P A_C0!=HJE_:T/]U_R'^-']K0_W7_(?XT 7:*I?VM#
M_=?\A_C1_:T/]U_R'^- %VBJ7]K0_P!U_P A_C1_:T/]U_R'^- %VBJ7]K0_
MW7_(?XT?VM#_ '7_ "'^- %VBJ7]K0_W7_(?XT?VM#_=?\A_C0!=HJE_:T/]
MU_R'^-']K0_W7_(?XT 7:*I?VM#_ '7_ "'^-']K0_W7_(?XT 7:*I?VM#_=
M?\A_C1_:T/\ =?\ (?XT 7:*I?VM#_=?\A_C1_:T/]U_R'^- %VBJ7]K0_W7
M_(?XT?VM#_=?\A_C0!=HJE_:T/\ =?\ (?XT?VM#_=?\A_C0!=HJE_:T/]U_
MR'^-']K0_P!U_P A_C0!=HJE_:T/]U_R'^-']K0_W7_(?XT 7:*I?VM#_=?\
MA_C1_:T/]U_R'^- %VBJ7]K0_P!U_P A_C1_:T/]U_R'^- %VBJ7]K0_W7_(
M?XT?VM#_ '7_ "'^- %VBJ7]K0_W7_(?XT?VM#_=?\A_C0!=HJE_:T/]U_R'
M^-']K0_W7_(?XT 7:*I?VM#_ '7_ "'^-']K0_W7_(?XT 7:*I?VM#_=?\A_
MC1_:T/\ =?\ (?XT 7:*I?VM#_=?\A_C1_:T/]U_R'^- %VBJ7]K0_W7_(?X
MT?VM#_=?\A_C0!=HJE_:T/\ =?\ (?XT?VM#_=?\A_C0!=HJE_:T/]U_R'^-
M']K0_P!U_P A_C0!=HJE_:T/]U_R'^-']K0_W7_(?XT 7:*I?VM#_=?\A_C1
M_:T/]U_R'^- %VBJ7]K0_P!U_P A_C1_:T/]U_R'^- %VBJ7]K0_W7_(?XT?
MVM#_ '7_ "'^- %VBJ7]K0_W7_(?XU=H **** "BBJUS?QVKA'#$D9X%-*XF
M[;EFBJ/]KP_W9/R'^-']KP_W9/R'^-/E9/-'N7J*H_VO#_=D_(?XT?VO#_=D
M_(?XT<K#FCW+U%4?[7A_NR?D/\:/[7A_NR?D/\:.5AS1[EZBJ/\ :\/]V3\A
M_C1_:\/]V3\A_C1RL.:/<O451_M>'^[)^0_QH_M>'^[)^0_QHY6'-'N7J*H_
MVO#_ '9/R'^-']KP_P!V3\A_C1RL.:/<O451_M>'^[)^0_QH_M>'^[)^0_QH
MY6'-'N7J*H_VO#_=D_(?XT?VO#_=D_(?XT<K#FCW+U%4?[7A_NR?D/\ &C^U
MX?[LGY#_ !HY6'-'N7J*H_VO#_=D_(?XT?VO#_=D_(?XT<K#FCW+U%4?[7A_
MNR?D/\:/[7A_NR?D/\:.5AS1[EZBJ/\ :\/]V3\A_C1_:\/]V3\A_C1RL.:/
M<O451_M>'^[)^0_QH_M>'^[)^0_QHY6'-'N7J*H_VO#_ '9/R'^-']KP_P!V
M3\A_C1RL.:/<O451_M>'^[)^0_QH_M>'^[)^0_QHY6'-'N7J*H_VO#_=D_(?
MXT?VO#_=D_(?XT<K#FCW+U%4?[7A_NR?D/\ &C^UX?[LGY#_ !HY6'-'N7J*
MH_VO#_=D_(?XT?VO#_=D_(?XT<K#FCW+U%4?[7A_NR?D/\:/[7A_NR?D/\:.
M5AS1[EZBJ4>JQ2.J!7RQ &0/\:NTFFMRDT]@HHHI#"BBB@"EJW_'LO\ OC^1
MK)K6U;_CV7_?'\C630 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %='7
M.5T= !1110 5CZQ_Q\K_ +@_F:V*Q]8_X^5_W!_,U<-S.I\)1HHHKH.8****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0IJDVZX)DE5B2W10-Q)PHYJJ?OSI]I2MZVYK^FJ_X!,[QA-]8QOZ7Y7\]S]
MJ*_-KPTWQ;_:'_:V^._P[L_C%XC\%^%-%N6G0Z;*6GBP^V*&!MP,298EMI!.
MP"O.?@SJ'QS^/?[/7Q+UG4/CCXET:#X;)="Q.G2M'=:C-'&TS?:;E6$CJ H4
M D_>YSCG)33I^U>BY>;Y;/\ '2QHX_O'36ZER_.UT?K717YYV/QW\:_$#_@G
MSX*\4:I\7M.^&>K75[)8ZIXIOTD:[N88II$"VZQ*7,S*JDE1N.T\C)->9?LQ
M_M#:MIO[9/@OPEX3^+OC;XG> =?AEANY/&:R_/*(Y6W0>:Q8*"B'< I^\"#7
M0H-UG1ZWM^%_E?S,7.U+VO\ 6CL_7Y'ZLT5^77ANW^._[3/[37QM\"^'_C-K
M7@OP[X<UJ6X62*>5GC"SR)#;Q%'4HA&XD X^5<AL"O3O@I\=?$OP#_:"^.WP
M\^)GBO4_$6EZ+IC^)="NM8N3+(;2-#(8T9NI*2(,>L;5A&:<%4>EXN2]$KOY
M[_<:RBU-PCK:2B_5NR_-?>?>]>*_M+_M:>"_V5-/T*\\8VNL746LRRPVPTBW
MCF8-&%+;M\B8^\,8S7G'_!.'6?'OCWX,ZGX_\>^(-2UFX\3:K-<:=;WL[/':
M6B,4 B4\*"_F=.RK7CW_  5YGO+4_!&;3K=;O4(]=G>VMV; EE'D%%)R, G
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M;6)9RJ_O+DQ84;SN8!W'&T <DF;VA%RW;DONO_E;S>V@:2FU';E3^_\ SO\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z.N<KHZ
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M1@\D*.?K@C3^.'P3^+&H_M&>%OBC\,9O!9?2= FT:2S\5SW<:L9)2Q91!$W
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MQ,:@N6EX0?*,\UO6.N>)OV<?VFOB_JM]\-O&'C#0/'#Z??Z5J/A/3?MRK)#
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MPBJ,[C@$Y'I6Q^QEX0UWPM^SSXITW6=%U'2-1FU[6YH[2_M)()I$DF<QNJ,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:A5A-ZJ+3^Z,(_\ MK^_U/E?2KAY_CC^QG-/(7DE\&WY9W.2S'3H3U[FG_\
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M/SO?38\%_:&\-V7C+]MCX.Z#J40FT_5/"_B*RN(S_%')!L8?D37EGPFU^_\
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M 4444 2VO_'S#_OC^==#7/6O_'S#_OC^==#6-3<WI[!11161L%%%% !1110
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M "BBB@ HHKS3]I3XCZI\(?@+XY\9Z)':RZMHFERWELEZC/"SJ. ZJRDCZ$4
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M+_:0\3?"E/#%IX=\(7.IR7][I*:EKMW"5TVQ@N[Q+<JK;@99R6.$7.T$,W&
M>Q^)6K?%>_\ '=EX>\ VFB:-I"Z<U]>^*/$-I+>0F;S"B6D4,4T3;\ NSLV
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MA5E WI\K U]C:'JL6O:)I^IP@B&]MX[E >H5U##]#0!>HHHH **** "BBB@
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M)&:]7T[6/B%>W6I1266@6RVEP((Y)/M&+A?*C?S%XZ9=D^J&KWVCQ[Z>'/\
MR8H [6BN*^T>/?3PY_Y,4?:/'OIX<_\ )B@#M:*XK[1X]]/#G_DQ1]H\>^GA
MS_R8H [6OST7X%_%+PU\-_#-_P"%M O+3Q5J5_XB\*:K&V$DMM-U&]EDAOC[
M0L!(/:0^M?:WVCQ[Z>'/_)BC[1X]]/#G_DQ0!\@?$?\ 96UK55^*VG:3X2>_
MT73M9\+:EI&E2LL<>L6NGVZI/;(S$#)3>G. 6P#UKUGX/^';KQ/^TC>^/]'\
M!:E\.O"L'AA=&N8=4LDL)=3N_/$B'R%)RL* J)#U\S R!7K&GZQ\0KV[U*&2
MST"V2TN!#'))]HQ<*8HWWKQTR[)]4-7OM'CWT\.?^3% ':T5Q7VCQ[Z>'/\
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M5=EN;*XAR ?O?-*HP.>:ZDZ3XU!(_P"$MT[_ ,$A_P#C])_9/C7_ *&W3O\
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M^"0__'Z/[)\:_P#0VZ=_X)#_ /'Z .XHKA_[)\:_]#;IW_@D/_Q^C^R?&O\
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MV3XU_P"AMT[_ ,$A_P#C] '<45P_]D^-?^AMT[_P2'_X_1_9/C7_ *&W3O\
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M<MVE[$8HV/16?=@$Y'!-4Q\4_!;$ >+]!)/  U.#_P"*I@=117+^+?BEX,\
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MULW#D8V$ X'0''/7O3Z"ZFO14?D#^\__ 'T:/(']Y_\ OHTADE%1^0/[S_\
M?1H\@?WG_P"^C0!)4-ST6G>0/[S_ /?1J&XA  ^9_P#OHT 1T4SRA_>;_OHT
M>4/[S?\ ?1H ?13/*']YO^^C1Y0_O-_WT: 'T4SRA_>;_OHT>4/[S?\ ?1H
M?13/*']YO^^C1Y0_O-_WT: 'T4SRA_>;_OHT>4/[S?\ ?1H ?13/*']YO^^C
M1Y0_O-_WT: 'T4SRA_>;_OHT>4/[S?\ ?1H ?13/*']YO^^C1Y0_O-_WT: '
MT4SRA_>;_OHT>4/[S?\ ?1H ?13/*']YO^^C1Y0_O-_WT: 'T4SRA_>;_OHT
M>4/[S?\ ?1H ?13/*']YO^^C1Y0_O-_WT: 'T4SRA_>;_OHT>4/[S?\ ?1H
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MJ2BMN96>W25[_='IN[:=,:>L8R>]G=?^ VM][ZZI7UZ^X_"7X]^/+CXUZO\
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M=32HHHI#"BBB@ J&YZ+4U0W/1: *]%%% !1110 4444 %%%% !1110 4444
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MS(<[VSS@?-G[PQP<UW]#S.IL4444AA1110 5#<]%J:H;GHM %>BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH M0_ZI:DJ.'_5+4E !1110 4444 %%%% !1110!PG
MCZQM]0\:_#Q+F".X1-4GE59%#!76SF96&>A! (-=B-+M!*)!;Q^8)C<!MO(D
M*[2WUVDBN-^(-U):>-/AVT5I->%]4GC*PE 45K.<%SN8?*HY.,G X!/%=Y4N
M*>K12E)*R9BZUX2TW6=$N]-DM8EAGMI[487[JRCY\?4X/X5SWPL:'Q%X#LCJ
M%O')J$$)TJ^#+DEH'9"I]L@M_P "KNZX#PG_ ,4]\3O%6B'Y8-16+6[8=LL/
M*F _X%&K?\#K@JQC3KTYVT=XO[KK\K?,]2A.57#5:=]8VDOOL_S3_P"W3M7T
MNT=I&:WC+22K.Y*_>D4 *Q]QM7\A6?=Z5#'J^DO#:W 6.::8M;^6(D9T.6DW
M?,<DG&WN>>*VJS-1@,FKZ5((E<1M(2YNFC*90CB,#$F>F#TZCFO048WO8\MS
ME:UR1="T]81"+.$1"!K8)MX$3=4^AP.*?)I%E*SL]M&Q<1AB5ZA#N3\CR*N4
M5/)'L5[2?=E0Z5:&4R&WCWF87!;;SY@7;N^NWCZ4D>D647E[+:-?+\S9A?N[
MSE\?4\FKE%/DCV%SR[E$Z'IY@:$VD7E-;BU*;>#$,X3Z<GBGR:59RM(SVT;&
M21)7)7[SIC8Q]QM&/I5NBER1[#]I/NS)_LRT282+;QATF:=6"\AV!#-]2"1^
M-1KH]BB*BVL018GA4!>B,067Z' S]*NM]X_6DI\D>PN>7<J/I%E('#VT3!XT
MB;*]40DJOT!)(^M..F6C.SFWC+M,)V.WDR !0WU  'X59HHY8]@YY=RM'IEI
M"T3);QJ8F=T(7[K.27(^I)S]:C_L6P\CR?LD7E?9_LNS;QY7]SZ>U7:*7)'L
M'//N59-+M)6=GMHV+M&S$KU*'*'\" 12C3+591(+>,2"4SAL<B0J5+?7:2*L
MT4^6/8.>7<J)I-G&$"VT8"*Z+A>BN<N/Q(!-(VC6+QLAM8BC0K;E2O!C7.U?
MH,GCWJY12Y(]@]I/NRLVFVKL[-;QEI)5G8E>KJ %8^XVK^0H33;6-XV6WC5H
MY'E0A?NN^=S#W.XY^IJS13Y8[V#GEM<I#1;!81$+2(1B!K8+MX\H]4^AP.*>
M^E6<I<O;1L7$8;*]=ARGY'D5:HI<D>P>TGW96_LVU,ID^SQ^89?/W;>?,V[=
MWUV\9]*1-*LXS'MMHU\OS-N%^[O.7Q]3R:P/B/J=WIWA^!+.X:SDO+ZVLFND
MQN@26549QG@'!P#V)%<WXSTO_A"]*NY=.\1:A#)-$@%C=W\D\CL)X@98VD<N
MN Q#!?E.X<"N*K7C3<K0NH[[=K_Y?\'6WI8?#2KJ"<[.3LMWM;?MO^=[(]!.
MBV)A,/V2+RC +8IMX,0Z)].3Q3Y-,M)6D9[>-C)(DKDK]YTQL)]QM&/H*\ZT
M_P ;:W<:C+INEVUH[[]1F:6_GE8 0W(C '4\[NG 7MP,4RT^)=U?7L#V5FOV
MK5K?3OL\=S<.88FF2:1BP''RK&?N@%C@'MC&..P\E%I?%;IW3M;37M\S=Y;B
MM7?;S\[:ZZ;7^1Z0NF6B2)(MO&'25IU8+R'8$,WU(8C\:8NCV*1JBVL018F@
M "\!&(++]#@?E7!>(?B-K.@1&&6#2_[0@AEFECA>:Y,@0X7:D:ED! R6?A3Q
MSUK5\ :_/KUSXBNY'D,1FMY(89'+"%7M(7VCT&6)X[DUI#%T)S]G%:]=/Z[?
M@93P6)ITG6D_=]=]4OU.I?2+*0.&MHV#HD;97JJ$E!] 22/K3FTRT:1I#;QE
MVE6<MMY,@4*&^H  _"O-M,^(OBG4[739$T[28VU'3)=3BW328C6/8&5ACDMY
MBXQC'.<XY9:?&2_U6=9K#0YKBTC-LLT4=K<RR,9(XY&VR)&8UVB0<,03@_=R
M,YK'X5V6U_+U-O[+QMW;6V]FN]OS5OEVU/3(],M(C&4MXU,;.Z$+]UG)+D?4
MDD_6H_[%L/(\G[)%Y7V?[+LV\>5_<^GM7!77Q4N[;Q"MJL%I<6<EW-9CR!,Y
M1D1V#-+M\K),>"@.1GO@U0O/B1K+:!;3:C96L(U+3$U*W^PW$BO&/-A5D9N#
MR)@<@]B.>M'U_"R3Y=;>7E?\K?D$<LQC<;Z7MU[W_P F_P#AST^32[24R%[:
M-C(T;.2OWBA!0GZ$ BE&F6BRK(+>,2+*9PVWD2%2I;Z[21^-<+;_ !$U5+N*
MXN[*S72)-5N=+!BD<S@Q^;B3!&,'RL%??.>U87B7XA>)Y/"YN(X+"PCU31KK
M4;2:&5VFMU2-6 /0;MK@[AP#VXYF>88>--U4F[*^WDFOONK"IY9BIS5.Z5]-
M_6_W)._IZ'JJ:39QA MM&H171<+T5R"X_$@$TC:-8O&T;6L11HE@*E>#&N2J
M_09/'O7!Z9XMO/#WAK487CCGETJ[L[,/)-+(9?.$)9BSLS$CSCC)["K.C^++
MK2/AO)JDN[4+S[=/;Q">4_,S7C11AFY(497Z 5M]9HWY6MDV].UD9RP6(2YH
MRO>2BM=VUS)^73[SMFTRT=W9K>,L\JS,2O5U "L?<!5_(41Z9:Q-&R6\:M'(
M\J$+]UWSN8>YW-GZFO++GQ]KWAOQ)J]G?11W5_<7%K;VT=LL\\$0,,DC.(T5
MGZ)RH')Y) Y&UIWC_7=;DL=.M-)BL]6E6YED;44FAB,<3(H9$95?YS(N,@8P
M>N.8AC\/-N-O>3:M;71_\,_^&9<\MQ4(J5_=:3O?2W+?\%=':C1;!81$+2(1
MB VP7;QY1ZI]#@<4]]*LY-^ZVC;?Y8;*]=ARF?H>17G5W\4=9LX-5NI--LS!
M9S6UFL4$DD[O/,D1&"BG*J9#RH)8#@9J0?$[55LF2>QBL[O[4(([BZM;J))D
M,9?=' T8E=@1M*@8'7..*/KV%U7Z?(/[-QK7-^OH_P!4]/T/0O[-M?-\S[/'
MYGF^?NV\^9MV;OKMX^E(FE6<90K;1KL\S;A>F\Y?\SR:\UF^+>JG0=.U)=+B
MMX95N!<7,\5PT*212F/8=J%H@VTMND "]#S5F/XKWU[KDD=CI,EYIT-Y'9NT
M%M<RL^=NZ595C,05=^<%LD G(R!1''X6323U=NG?J#RO')/3:_7L[-'?_P!B
MV!B,1M(O*, MBFWCRAT3Z<GBMD=!5,=:N#I7J**6R/&<G+=BT444R0K'UC_C
MY7_<'\S6Q6/K'_'RO^X/YFKAN9U/A*-%%%=!S!1110 445\"?M#^&=0L/CUX
MNUKXM^ ?B%X^^'EQ%;CPWJ7@?4+@Q:(BQ8F,EM!+&0_F98R-D'C@UG*7*TOZ
M_P"'];+S+C'F3?\ 7]?U8^^Z*^!/%>HPM^R7X$^*?@;Q[JWQ%D^&>O+J+ZEJ
M*/#>S60EV75G<HQW%DC=<EN2$!Z'->C>(?$*_'C]J>S&DWKS^$?A[X4?697A
M<B.?4-0B/V<-C@[8!Y@]":<Y<BD^U_N4>:_SU2Z76XHQYK>?Y\W+;Y73?9/8
M^M:*_+OPG\&H;K_@GE_PM^[\3>)I/B!I6GS7^CZE'K=S&FFI!<LJ110JXCVD
M*2Q92Q+$YKT7XF_#EOA/X(^"_P 7M.\2^([KXC:MXAT6/6=6N]7GDCU&*\&9
MH6MRWE)'SA41%   YK2S53V;Z.*?_;SLOQ3OVZ7)?P<Z[2?_ ("KO\U;OUL?
M?]<_\0?'&G?#3P-KWBO5Q,VEZ-92WUR+= \ACC4LP4$C)P..17R/8_!JP^.7
M[:OQOT_Q5JNK3^%-+M=&D/A^SU*>TAN9WM3MDD,+JQ"!7PH(&7R<XKA/%NB>
M7\*OVJOA!K6H:CXF\._#^UAU?P[<ZC>RR7%H)K1YD@:4,&D6)AP')&#@@URS
MJ-47-:/E<EZ*U_GK=+JMVF;P@G54'JKQ3_[>M;\TGV[,^^?!/BFW\<^#="\1
MVD,EO:ZO8P7\44V-Z)+&KJ&QD9 89Q6U7Y^VWA2.W\/?LT?!;PSJ.I^$/#'C
MS3I->\1W&F7\RW-X8K*&1H4F9BT:R-]Y4(&.@'.>YU7P1!^R5^T?\(['P#J6
MKP>$/'-U=:1JOAF_U.>^MQ(D/F1W47GN[(X/WB#@CCBNV:2J\JT3DXKUO;[N
M;W4_FTD<L6W34NO+S/TW^^VMOE=L^R:*_.WX0_ 33?C-X!^.GB'Q5KOB*YGT
MCQ5KT.AP6FL7%M#ICQDR><B1NH>0LPY?<,*H %<_J?@*[U/]@FR^/>I^+_%-
M_P#%BRL(-1L]>;6KA1;JEPL2PK"K"(J4'S$J69BS%CDUS1G[GM):*T6_22NO
M5JSO^=]#H=/W_9Q>K<HKUB[?=K_P.I^F5%9OAJ_EU7PYI5[-CSKFTBF? P-S
M("?U-?GKXE\4S_'+X^?%-?&?@'XE?$7P[X8U8Z'H^D>#KTVMA8^6OSS2[+F%
MVF=OF!.0!@<\ :3O"I[/JK_@TOS:,J=JE/VG1V_'7\DS]'**^(?A=\+_ !C\
M7O@+\1_ GCV'Q9X1TW2M0%YX+U[Q7,%U2QA"%XC+*CG>(64J26Y1\9'&,7]C
M3QSK/[8?Q+C\9>.=:M)3\.;6+3[#0M/F;R[R\=2)-5D7 #*^W]V,$ @G@CEQ
M]Z?)Y)_)J_WIZ-=VM;7L-<L>;S:^=[?<UK?RVO:_WQ17P7^S9^S;HGQVLOBG
MJ_C;6_$&H)!XVUFRTBTL]9N+2/2]LV3-&L3J#*68<ON "J,8KA/%7C;Q=\1O
MV7?A[HFI^)]1.O:7\6XO"/\ PDD$Q2ZN(HY)8TG+CJ^UA\W<KD\UG"3FH::R
M47\I.*W\N9%RBHN6ND7)?.*D_P >5GZ7T5\$_M,Z#!\"M1^&?PB\!6/C-_#G
MC'4;W4M<L_#NJ2W&KW\=O#'F"&:XFRBN3N<*XX#8ZX,WP9T[Q5X%^/OA)?AW
M\,?B9X)^'^I)/:^)--\7W7VNQ0^7F"ZB+W$SI('&&Y ((%5&7.]-MOFOTOI?
MYM)$S7)&[[7^5_SMK;\6S[PHK\N-9T9? D.MR?'71?BKX5^(?V^::'XO:#>7
M=]I<"^:6B94AE$<<83:/*,9. ?N]![/^TOI>O^*_$/P\\3WVA>*OC-\%#X>4
MW-GX'OI+:XGOF(9;UX(9$>96CQM4, I+=.AE2O%2[V]%=-Z]MK:I:_.UN%IN
M/K\[-+3OO?1[?*_V/XSUC4O#WA/5]3T?1I/$6J6EL\UMI,4RPO=R 96(.P(4
ML>,G@58\-ZC>:OX>TR^U#3GT>_N;:.:XT^202-:R,H+1%APQ4DC(X.*^&/#'
MBKPG<?LC?M!V7@CQIXGU&TL--NI8_#7BN.:/4O#>ZW;$&^5B[(2I*G) P1G.
M:F\.VE[^T#\1?A1\)]=UO5;'P+I?PTT_Q)J.GZ;?26CZQ<.$B5)I8V#F-1S@
M$<_I2NYN"Z\OXQG)]^D?.^EO.6DH\SZ<WX."7XR\K:W/O*BOC;PWI4_[.O[3
MUU\+_#FKZI>> /$O@^[UFWT?4[Z6\_LFZA8J3#)*S.(W7^$L>>>U>/\ PB_9
M[T_QE^P<?B9K/B;Q3/XVL=$U"_T?48-<N8%TO[,TQBCAB1PF"8\L64L2Q.1Q
MB'42A*I]E*[[[R3^=XOKJNJV+5-N2AU;LOFDU\K/7S[[GZ4T5YY^SMXJU'QQ
M\!?AYX@U><W.J:GH-E=74Y&#)*\*EF/U))_&OF3X_2?#GQ+\?M?T[QQK7CGX
MI3VMG;I9_#SP-97_ )>BDKEI9WM955Y)#A@7*[1P01@UK53I5/9];O\ #^O\
MS&DU4AS^2?WGU]\0?'&G?#3P-KWBO5Q,VEZ-92WUR+= \ACC4LP4$C)P..14
MW@GQ3;^.?!NA>([2&2WM=7L8+^**;&]$EC5U#8R,@,,XK\ZO"<*^.?V0_P!I
MKPSKD/B)]$\'ZA=S:!IWB>[<ZAIBK;>9'%*RR$G82?D+,.3G-?:'[)/@30_
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M\-IK<=JWE.1YR-9/*0X[C<1Q["JOQ*\6:V-,\6VNBI! FDV >>Z>9XYMSHS
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M_L/ZG_Z5R5VE<)\))+E['Q(LT"10KXAU(0NLFXR#[3)DD8&WG(QD],^U=W0
M=:X'X-_\2_0=4T!N&T/4[BR5?2(MYD7X;)%_*N^K@=*_XDGQFUNTZ0ZUIL%_
M&.WFPL8I/_'6B_*N&O[E6E4\W'Y-?YI'I8;]Y0K4O)27K%V_])E)G?5F>'H'
MMM,"/$\+>9(=DEVUR>7)SO;GGT[=!TK3K%\(FW.BK]E_L[R?.E_Y!:[8,^8V
M<#^]G.[_ &LUW]#S.IM4444AA1110 5#<]%J:H;GHM %>BBB@ HHHH ****
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M1)WMI?9_?;F]&=/1117J'B!1110 4444 4F^\?K24K?>/UI* "BBB@ HHHH
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MC_YYI_WR* 'T4SR(_P#GFG_?(H\B/_GFG_?(H ?13/(C_P">:?\ ?(H\B/\
MYYI_WR* 'T4SR(_^>:?]\BCR(_\ GFG_ 'R* 'T4SR(_^>:?]\BCR(_^>:?]
M\B@!]%,\B/\ YYI_WR*/(C_YYI_WR* 'T4SR(_\ GFG_ 'R*/(C_ .>:?]\B
M@!]%,\B/_GFG_?(H\B/_ )YI_P!\B@!]%,\B/_GFG_?(H\B/_GFG_?(H ?13
M/(C_ .>:?]\BCR(_^>:?]\B@!]%,\B/_ )YI_P!\BCR(_P#GFG_?(H ?13/(
MC_YYI_WR*/(C_P">:?\ ?(H ?13/(C_YYI_WR*/(C_YYI_WR* 'T4SR(_P#G
MFG_?(H\B/_GFG_?(H ?13/(C_P">:?\ ?(H\B/\ YYI_WR* 'T4SR(_^>:?]
M\BCR(_\ GFG_ 'R* 'T4SR(_^>:?]\BCR(_^>:?]\B@"[#_JA4E16ZA85
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MNKCG,T:O&%=&Y#*X(/XUT4ZU.JKTY)^CN<M6A5H.U6#B_--?F2T4S<_]P?\
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M9"5@+; P/ 8 '!.:^@Z "BBB@#@_A(UT;'Q()TA6 >(=2\AHW)9E^TR9W @
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M048'H***[3S@P/048'H*** # ]!1@>@HHH ,#T%&!Z"BB@ P/048'H*** #
M]!1@>@HHH ,#T%&!Z"BB@ P/048'H*** # ]!1@>@HHH ,#T%&!Z"BB@ P/0
M48'H*** # ]!1@>@HHH ,#T%&!Z"BB@ P/048'H*** # ]!1@>@HHH M0<1+
M4E1P_P"J6I* "BBB@ HHHH **** "BBB@#@_B#+<P^-?AV;6W2Y<ZI.KJ\OE
M[4-G/N8'!R0,D#C/3(KO*XOQG_R/'P__ .PA=?\ I%/7:4 %%%% !63JBQ'6
M]&+QV;2!Y?+:>;;,O[LY\I<?.<=>1@<UK5F:C/Y>KZ3'YL*>8\@V26S2.^$)
M^1P0(\=R0<C@<TT)FG1112&%%%% !1110!2;[Q^M)2M]X_6DH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\B^(_[->@?$/Q&^M->W>E
MWD^W[2+<*RRX  ;!'#8 &>G'2O7:*Y,3A:&,A[.O'F6YW8/'8G 5/:X6;C*U
MM.QQGA_P?_PK>S2/2KJ>7P[96++_ &4(!+,\H)8R(PP2S9;*G.3C&*Z;1=7M
M]?TJUU&T,AM[A-Z>;&8V ]"I (/L:NUDWVA&XURRU:.]O(9+6-XVM(I<07"L
M.CJ01D'!##!XZXXIQI^P2C27N]NWIY)=/N%.M]9;E6?OO6_???35M]?O\M:B
MLOP[K,^LZ9%<7FG3Z/=EG1[.Y*EE*G!((X93U!'4&M2NB,E.*DNIRS@Z<G&6
MZ"BBBJ("BBB@ HHHH **** %'6K@Z53'6K@Z4 +1110 5CZQ_P ?*_[@_F:V
M*Q]8_P"/E?\ <'\S5PW,ZGPE&BBBN@Y@HHHH ***^=/%7[7&HV'QC\6_#'PK
M\,=:\;^*="BMKD)87D%O!)#+$)&DDEF*I%M+*H&6+$\ 8J7))VZC2;3?8^BZ
M*^3](_;PN_&?A34=7\'?!WQ9XBFT#S4\36K36]K_ &1+$6$D(:1O](D 4MMB
M!.TKG!.*[KQ'^UYX9T[X8^ _%FAZ/JWBF]\=,D7A_0-/C1;NZE*EF5RS!(PF
M#O8D@8[T[JU_3\=K=[]+;A9WMZ_AO?M;K?8]VHKP7X=?M/ZEKGQ7M?AQX[^&
M^K_#?Q1J-E+?Z8MW>V]_;7L4?^L"S0,0'4<[?0<D<9\R\"?M,^"O@G^S7>>-
M])\):E:>'_\ A-+G2KBQDU%KJ82O=%);A6*DD9!81@>P-%U=>:O_ .3*/YNW
MKT['*[.W1_\ MKE^2O\ UK]CT5\Z:+^UUJ$'Q"\*^'?&WPK\1^ -.\6SFUT'
M5]3N+:9;B;;N6.>.)V:W=AT5LG/XD<-\(_C#\0[_ /;3^,&D:WX;O8O"UA;V
M"2&XUR%[?1+=89G2=8@?F^T8#$(-RY&[I235TGY_*V]^SU6X->ZWVM\[NVG?
MY==-S[$HKY3N?VX]9NO"-[X^T'X*^*=<^%UIYDC^)UO;2&22"-B))X[1G\UH
MQM8YXX&3CG'0>./B1X)\4?%O]G/4QI-[J]QXE%]>>']4BO&MX[1&LUD9I81Q
M+N1@ #]T\TUJTO-+SUO;3Y=;":Y;WZ)O[M_NZG=?%+]EWX5_&G6(=6\9^"[#
M6=5BC$(OBTD$S1CHC/$REU'HQ(YKM_!G@G0/AWX<L] \,Z1::'HMHNV"RL8A
M'&F3DG ZDGDD\DG)KYZA_;/UKQ+XD\;:!X*^#WB'QGJ?A+5[C3M1:TOK>WMU
MCB.%D$LI7=(^&Q"@9L+UY%=)#^V=X(G^ NE_%!+35I(-4N_[+L_#\=N&U*?4
M=YC^QK&#@R;E;OC S[5,9+DO'9V?K?9VZW;^_3<J49<UI;JZ]+;J_31?<K['
MOE%> ^$_VIM2'CO0/"GQ&^&FM_#&\\1LT6AW=]>6U[:WDH7=Y#20,?*E(Y",
M.<$9SC,/B3]K*\?Q[XC\-> ?AEXA^),?A>00Z_J6ESV]O#:2XW-#%YSJ;B51
MU1.<\53:5OG^&]^UM+WVNNXK/^O/:W>_2W9]CZ$HKY4_X)S^(D\6?"?QQK$1
MN/L][XYU>XA6Z4K(D;O&RJRGE2 >1VKU+XW_ +0MC\'M1\.Z!9Z!J?C/QKXC
M>1-)\.:/L$TPC&9))'<A8HU!&78_A@$@;LHM[R2=O5)V^7_!"UY22Z-K[FU<
M]9HKXZ^,'[1\OQ!^!GQO\%^(?"&K?#OQ]H_A6XOY-(U">*=9;9T*K/!<0L4D
M4-P<8P?7G&KX.\0>'+;QQ^RUIVI:+>7WB:^\(3/IVJQW[1PVJK80F420])2X
MP 3]WK1'WI6]/G=3?X<FOSZJS)+EC?U_#E_/F_JY]845\K:9^VWK?B^7Q7%X
M+^#/B3Q>_A;5+O3M5EM+VWA@B$#E04>4J99& W>4BD@%><FCXF_'?X?_ !3^
M#WP>\<RZ)J6LZ-KWC'38=/MUNS9365[YLB!I=N0XC='#)G#>M*+4U%QV;C_Y
M,]'\^G3S023A=/IS?^2J[7]=-;,^J:*\#\<?M37EG\1M9\#_  \^'.M?$[7M
M!CCDUIM/NK>SM+ NNY(C-,P#2E>=BC/OD$"DW[;?A.7X4Z9XLL]!UZ\UO4M9
M;PW;^$$MU74O[44D/;,"VU=N,ER< $=^*%)-77]7=E;OK9775H;BT[/^M+Z]
MM-=>A]$T5\_^"/VI=6O/BOHOP]^(/PQUGX;ZYK\$\^C2W-_;7]M>>2N^1/-@
M8A7"\[3GWQD9^1_']]<K^SG^T@XN)0Z?&+8K!SE5^U6O ]![4)WG&/?_ .3C
M#\'+\+":LF^W_P C*7_MMO\ AC].**\P\-?'"#6/CQXH^%MYI$NF:GI&F6VK
MV=V\X=-1M9#M=T7:"NQ_E(R>:E^%_P :H/BIXW^(6BZ=I4D6F>$-2326U=I@
MR7EUY8:9$0#Y?+)"DY.2>U-/FM;JF_DG9_<]/43TW\OQ5U^&OH>E4444P"BB
MB@ HHHH **** );7_CYA_P!\?SKH:YZU_P"/F'_?'\ZZ&L:FYO3V"BBBLC8*
M*** "BBB@ HHHH XOX5_\@G7/^P_J?\ Z5R5VE<'\(TNUL?$IGEA> ^(=2\A
M(XBK(OVF3(<EB&.<G("\<8/6N\H **** "LWP^DL>FA9H[N*3S)#MOI5DDQO
M./F4D8QT&>!@'FM*LGPQ&D6DJJ16\*^;(=EK<&=/OGG>0#GU'8Y':GT%U-:B
MBBD,**** "H;GHM35#<]%H KU@>//"$'CSPCJ6A7$K01WD>T2J,E&!!5L=\$
M#BM^BLZD(U8.G-73T9K2JSHU(U:;M*+33\T?,/@;]D>^L/$\-UXBU*UGTRV?
M>(K)Y%DF(Z9. 4'?@Y_G7LG_  K;4=*YT'QCK&G@=+>^9+Z#Z8D&\?@]=U17
ME8;*,)A(.%*-O.[O]ZU/;QF?8_'S4Z\T[*UK*WW--7\SA?MWQ#T7_7Z;HWB6
M$?Q6,[64Q'^[)N7/_ A0/BW9:>0NO:-K7AUN\EW9-) /^VL6Y?S(KNJ",C!Y
M%=GL*L/X=1^CU7Z/\3@^LT:G\6BO6+<7^L?_ "4R=#\7Z'XF3?I.KV.HCN+:
MX5R/J <C\:UJYO7/AOX7\1R>9J&AV<T__/=8_+E'T=<-^M9'_"LKO2^= \6Z
MUI8'W;>YE6]@^FV4%OR84<^)A\4%+T=G]ST_\F#V>$J?!4<7_>5U]\;O_P E
M.[HKA?M/Q$T7_66>B^)H1WMI'L9R/H^],_B*K:C\9K7PW8SW'B+P_KFA>4I8
MM+:>=$Q[*)8BR9)X&XCK2>,I05ZMX^J:7W[?B4LOK5&E0M._\K3?_@/Q?@>A
MT5X7X"_:JTSQAXKMM&N]'ETI;R40VUP9Q("YX57&!C)XR,\FO=*>$QN'QT'/
M#RYDM/ZN3CLNQ66U%2Q<.5M76ST^5PHHHKM/."BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"U#_JEJ2HX?]4M24 %%%% !1110 44
MG2H!J-H3@74)/IY@H L45\R_MC>,/BAX4A\-W/A:\L-!\'IKFB0ZCJ"R,VH7
MK3ZE%"UM&N-L<85@S.22P;: .361^U5XW\1)\:O!_A33+[XAZ?HJ:'>:K??\
M*[LA-=W$AFBCA5V>-D55"S'!P3D 9) H ]U^(%G]M\:_#M?/FM]FJ3R[H'VE
MMMG.=I]5/0CN*[ROG3P'X_\ "MQX0^%>N6GC74_$.C?VG?1/K'BEU2^646]R
MK0W V1['1LIM*@C:.O4_0RW,3J&612I&00>M $M%1^?'_?7\Z//C_OK^= $E
M9U^T@U73 KWBH6DWK B&%OD./-)!('IM(YZ\5=\^/^^OYUG7^V75=,D$32K&
MTA,JW1C6+*$99 <29Z8(..M-"9JT5'Y\?]]?SH\^/^^OYTADE%1^?'_?7\Z/
M/C_OK^= $E%1^?'_ 'U_.CSX_P"^OYT 5F^\?K24UIDW'YQU]:3SD_OC\Z '
MT4SSD_OC\Z/.3^^/SH ?13/.3^^/SH\Y/[X_.@!]%,\Y/[X_.CSD_OC\Z 'T
M4SSD_OC\Z/.3^^/SH ?13/.3^^/SH\Y/[X_.@!]%,\Y/[X_.CSD_OC\Z 'T4
MSSD_OC\Z/.3^^/SH ?13/.3^^/SH\Y/[X_.@!]%,\Y/[X_.CSD_OC\Z 'T4S
MSD_OC\Z/.3^^/SH ?13/.3^^/SH\Y/[X_.@#/U?PUI^MWFG7=W"7N=/E\ZVF
M1V1D;&",@C((X(/![U4T_7;NR61/$8L=+EDO#;6;I<C9=*1N3 ;!#8R"OJI(
MX(K;\Y/[X_.JNI6&GZS;?9[^W@O(-ROY<Z!EW*<@X/<$ UA*FTW.GH_S]3IA
M532A5UC^*].GJO\ AR[17,76N3^$AJ^HZ_J-O)H8DC:V>&W?S+=6(5A)MSE0
M<'=@8!.>!711W4,T:R)*KHP#*RG((/0BKC44G;9]NOK\[:$3I2@E+=/KTO9-
MKU5]26BF><G]\?G1YR?WQ^=:&(^BF><G]\?G1YR?WQ^= #Z*9YR?WQ^='G)_
M?'YT 2#K5P=*H"9,_?'YU?'2@!:*** "L?6/^/E?]P?S-;%8^L?\?*_[@_F:
MN&YG4^$HT445T',%%%% !7R_\$T4_MS?M%OM&\6/A\ ]\?9G_P !7U!122M-
M3\FOO!ZP<>]OP:?Z'R%^R0H_X5K^T3P.?'7B+/O\BUXGX9^*WB?X>_LG?LUZ
M=;^)+WX?^ M9BNXO$7C33]/%W-8!9',,8RCB+S&)&_:2,>QS^E-%0H<L4NR@
MO7D37XWOY>:-'.[;MNYOTYVG^%O^&/S@^'>J^'+O]N+X/W_AWQIXX^(&BS6&
MK6R^)_&$\KV]S<&V),-GOCC3"C!;RUP2R\G%<ZBA_P!B*V5@&4_&  @]Q_:1
MK]0:*N'N2B_Y?_DXS_2WS\M8D^927?\ ^0E#];_+ST^8/VT1_P 5=^SL>_\
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M(T@76I6TWB?Q7/(]@;B2S8)!:;HHH]W=MBG[R DD<9?Q _Y-P_:3_P"RR?\
MMU:5^GU%7%<KB^W_ ,G"?_MMOGY:S)\W]>4U_P"W?AYZ?(O[<.HW?P0U_P
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M4(NS=MCO****[CS0HHHH **** "BBB@ HHHH **** +4/^J6I*CA_P!4M24
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M>/UI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?S-;%8^L?\?*_P"X/YFKAN9U/A*-%%%=!S!1110 5Y;XY_:A^%7PSU'5]/\
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M'XK:S97/_!0KX':9%<QR7UIH.M2SP*P+1K)$ A8=L[&Q]*]"HE[5P7\TH_\
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M%_!<V<[%(Y5; 9AU SWX/'M5*K!NR>O^1#HU(KF<7;3\=47_ #X_[XH\^/\
MOBGT5J8C//C_ +XH\^/^^*?10!:MV#0J0<BI*CA_U2U)0 4444 %%%% !111
M0 4444 <7XS_ .1X^'__ &$+K_TBGKM*X3X@627WC7X=H[S1A-4GE!AE:,DK
M9SD E2,J>ZG@C@BN[H **** "LZ_68ZIIA1+QH@TGF- Z"(?(<>:&.XC/3:#
MSUXK1K,U&'?J^DOY4;['D.]KEHV3*'[J 8DSTP>G6FA,TZ***0PHHHH ****
M *3?>/UI*5OO'ZTE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8^IYJ]110 4444 %%%% !1110 4444 %(0#U&:6B@!NQ?[H_*C8O]T?E3J*
M&[%_NC\J-B_W1^5.HH ;L7^Z/RHV+_='Y4ZB@!NQ?[H_*C8O]T?E3J* &[%_
MNC\J-B_W1^5.HH ;L7^Z/RHV+_='Y4ZB@!NQ?[H_*C8O]T?E3J* &[%_NC\J
M-B_W1^5.HH ;L7^Z/RHV+_='Y4ZB@!NQ?[H_*C8O]T?E3J* &[%_NC\J-B_W
M1^5.HH ;L7^Z/RHV+_='Y4ZB@!NQ?[H_*C8O]T?E3J* &[%_NC\J-B_W1^5.
MHH ;L7^Z/RHV+_='Y4ZB@!NQ?[H_*C8O]T?E3J* &[%_NC\J-B_W1^5.HH 0
M#'3BEHHH **** "BBB@!DRN\+K&_ER%2%?&=I[''>O%+7X5?&>*]BEF^.L<]
MNL@9X/\ A#K1=ZYY7=YF1D<9KVZB@#XR_:3^-LOBWXGZC\+-4A\5>&OAS8PQ
MC7M4T;P_?75SKID7<UE;RPQ,L4.T@229W'<47')K5B\4Z!\(/C?HOQ$BT/6+
M'X9^(/ EKH=A+9Z'<NUA-:7,TD<$MND9EBWQS87<HY0@XKZXHH ^=OV9_A1)
M?_"47WBG3=1T6_U;Q'JGB:VM!<RV=W9I=3R&-7,3*RL8F&Y<\;B#R*^AT4(H
M49( QR<FG44 %%%% !3'ACDD1VC5GCR48@$KD8.#VI]% !1110 4444 %%%%
M #/)0]J3R4]*DHH C\E/2CR4]*DHH C\E/2CR4]*DHH C\E/2CR4]*DHH C\
ME/2CR4]*DHH C\E/2CR4]*DHH C\E/2CR4]*DHH C\E/2CR4]*DHH C\E/2C
MR4]*DHH C\E/2CR4]*DHH C\E/2CR4]*DHH C\E/2CR4]*DHH C\E/2CR4]*
MDHH C\E/2CR4]*DHH C\E/2CR4]*DHH C\E/2CR4]*DHH C\E/2CR4]*DHH
MC\E/2I*** "BBB@ K'UC_CY7_<'\S6Q6/K'_ !\K_N#^9JX;F=3X2C11170<
MP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!+:_\?,/^^/YUT-<]:_\?,/^
M^/YUT-8U-S>GL%%%%9&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !6/K'_ !\K_N#^9K8K'UC_ (^5_P!P?S-7#<SJ?"4:
M***Z#F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** );7_CYA_WQ_.NAKGK7
M_CYA_P!\?SKH:QJ;F]/8****R-@HHHH *X+XZ^)]3\&_"K6]8T>Y^QZC;>1Y
M4WEJ^W=/&C?*P(/RL1R.]=[7EO[3G_)#O$O_ &[?^E,5>=F,I0P5><'9J,K/
MY,]7*81J9CAX35TYP33U37,M&?+O_#3GQ+_Z&7_R0MO_ (W7K?[,WQB\7_$'
MQY?Z=K^K_;[.+39+A(OLT,>)!+$H.40'HS<9QS7RE7O7[&?_ "5#5/\ L#R_
M^CX*_),FS#&5<PHPJ5I--[.3:_,_=>(,JP%'*Z]2EAX1DHZ-1BFOG8^R9I1!
M"\C9*HI8XZ\5Y)IG[3?AN_BL;J?1O$.F:3>3>1%JU[8JMGOR1@R*Y[@CC.,'
MT->KWRE[*X5068QL !U/%?*.GQ>(=6^!=A\-X?!7B*'6)K@![R\T]H;2)3<&
M7<9&]L#D#J?Q_1\RQN)P]=0H_P MTK7YI<R7+?I=7/Q_)L#AL7"3Q"^U%-\R
MCRQ:ES2UWM9'U2^KV$>HQV#7MNM](N]+4RJ)67U"YR1P>::-<TYM3.FC4+4Z
MB!N-H)E\T#&<[,YZ>U?)&J^ O$$?CG5+">QU)];EUN.XL=5ATIIV\E3\CK<F
M951%&,K@XXR>.+!\-ZOIGQB62Q\.7][,WB!KPPZAII4Q*7YF6\C;+1CD@,=H
M[@\YY5G==SBO8:.5M_3I;?7;]+M>E_JYAG&\<2F^3FVZV[WV\_)W:V/K%-9T
M^34GTY+ZV;4$7<UHLRF51ZE,Y _"H[;Q!I=Y<7-O;ZE9SSVP)GBCG1FB Z[@
M#E?QKYC\$Z0=$DCL=2^'FKZSX]M]1N;E]3S);H002)#<*1O4XQM/!R<<GGE_
M!?A779-?M+J'PUJ5E%_9FI6\\$&BR0102-!*%B,I+/*22N#(<@D*,XJ?[=K6
M@U2OS;VOIHM'>*U3=G:_R*7#=!^T_?VY5HWRVEOJK2;L[:72W^_ZHUSXI^%O
M#]UI]M<ZQ;/<7TZ6\,<$BR$%\89L'"K@@Y...F:Z#^V+#^T1I_VVV^WE-_V7
MS5\W;Z[<YQ[XKY-G^$]KX=\#_#?5[KPG>RW)U '7(A:R23M'O.%>,\@8&,8&
M>/44R+P7X@/Q EM[C3M1BU]O$?VZ+4H=(9R8,\/]I,JJ(L=4V\>N> 1SC%PJ
M^SJ44[M+1O1-1?5:OWG;_"UTN7+A_ 3A>EB&K*5VTM7&5M$F[+2[\FGU/K.W
MUS3;O4)K&#4+6:^AYDMHYE:1/]Y0<C\:Y[X@_$[2OAQ'8"^M[Z_N[]V2VLM-
M@\V>3:,L0I(X (SSWKYM^'OAC7=%^)NE1:=X?O7FAN;C?+JVF&"2Q#Y'F/<1
ML!.,=-^0>0HY!KM?%>G^._"/C/PCXM\4QCQ3:Z:]U$Z^'[0EX5DBVJ64XZD]
M>G'7D4_[8Q%7">U5-P?,DW:ZBKJ[\]^FG5VU2PED.&H8N--UE.+BVE?E<G:5
MDM[7:6]M]+Z-]WJ/[17A>STO2;VUM]5UC^T;:2\2WTZU$DL,2$AVD!8!0I5@
M>3]T]N:] \/:]9^*-#LM6T^0RV5Y$)HG(P<'U'8CH17QX_P^US1O#_AI==T?
M78+%]-O3&=&MLW,=Q+(VV&8XR$9=ORG^^P_O5]1_!^TU.P^&7ARVUBT6QU"*
MT5)+=8PFP G:"HZ-MVY'KFNO*\=B<55G'$1M91=K6LWNOZWW,L[RO X+#QJ8
M6?,^9J]T[J\K?=97]?,[&BBBOI3XH**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *Q]8_X^5_W!_,UL5CZQ_Q\K_N#^9JX;F=3X2C11170<P4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!+:_\ 'S#_ +X_G70USUK_ ,?,/^^/YUT-
M8U-S>GL%%%%9&P4444 %%%5=4N'M-,NYX\>9%"[KGID*2*F3Y4VQI<S21:HK
MQ?3?B]K4_P &I]6F6W/BM&6!4$>(R[H)4?;GIY3;S_NFNFL_BY9PZ3!/=V5_
M=+;VMO+J=_:0*;>T:2-7^?+!C@,&.P-M!&<5=M6NUOQ)3ND^_P"AZ%17%/\
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M6'Q!?^*+.YBTRWO?#MW%M87.LZ<6C(SR HD7)Q[C%#T!:G545Y)IWBGQ_?\
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MMBL?6/\ CY7_ '!_,U<-S.I\)1HHHKH.8**** "BBB@ HHHH **** "BBB@
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M^2*U;5M[_CK_ )LE\-?"O2_"GBVZUJPDN%66TCM4MI;B:41[6<ELO(V[(8
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M+:]=ECW!C$X<J!D8SC&>WH:Y6S^#,%HS_P#$S:1/[6COXT:#_50(SLML/FZ
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M+BTTW4[>ZUB.YFO=%BT;S8K,QA%C$H63:9&R<2C(R.5Z\X'?44FKWOU_X/\
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MG_8W_3;_ ,=_^O1_8W_3;_QW_P"O1SH.278S**T_[&_Z;?\ CO\ ]>C^QO\
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M[X_G70UG1:3Y<J/YN=I!QM_^O6C6<VGL;032U"BBBLS0**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>rnac-20241231_g6.jpg
<TEXT>
begin 644 rnac-20241231_g6.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )$!-(# 2(  A$! Q$!_\0
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MG9P*0-\LA!P,D#H?R!I_4J.K[>8O:R/TO_X>V_"#_H7/&_\ X V?_P E4?\
M#VWX0?\ 0N>-_P#P!L__ )*KX!MOV0_'/_":^*/#VI7.A:!'X;MX;O4-;U74
M1%IR0S$>0ZS '<),C;@?7!KSKXF?#?6_A+XVU+PKXAABBU6Q90_D2"2.164.
MCHP^\K*RD'T/:H6&P\FDGOKN5SU-7V/U#_X>V_"#_H7/&_\ X V?_P E4?\
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M/_Y*H_X>V_"#_H7/&_\ X V?_P E5^2=%'U*B'M9'ZV?\/;?A!_T+GC?_P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&LK')'YB1Z=*GFV6U VX)LY'S%NA_./^PM2_Z!]W_P!^&_PH_L+4O^@?=_\
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MT2^Y25__ ";[S3VS]I[3S;^_E=O_ "7\3]"OBW\0?#_C#]G#61K7C32[./\
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M=_\ ?AO\*/["U+_H'W?_ 'X;_"N=TH.[OJVW]ZDK?^3/UZC4K));))?=R_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO\+/[C=T^S[_ (67ZH^5Z*^O;[]F+P)>^)_"-]:33P^'[W1M2U;4+'2]534
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HJ"^E:&U=T.&&,'\:RO[2N?^>G_CH_PJU%LB4U%V9N45
MA_VE<_\ /3_QT?X4?VE<_P#/3_QT?X4^1D^T1N45A_VE<_\ /3_QT?X4?VE<
M_P#/3_QT?X4<C#VB-RBL/^TKG_GI_P".C_"C^TKG_GI_XZ/\*.1A[1&Y16'_
M &E<_P#/3_QT?X4?VE<_\]/_ !T?X4<C#VB-RBL/^TKG_GI_XZ/\*/[2N?\
MGI_XZ/\ "CD8>T1N45A_VE<_\]/_ !T?X4?VE<_\]/\ QT?X4<C#VB-RBL/^
MTKG_ )Z?^.C_  H_M*Y_YZ?^.C_"CD8>T1N45A_VE<_\]/\ QT?X4?VE<_\
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M[.J;!&R!=K#:<'<"3W.:_0C_ (8O^#?_ $)W_E3O/_CU'_#%_P &_P#H3O\
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M_!O_ *$[_P J=Y_\>H_X8O\ @W_T)W_E3O/_ (]5^UB3[*1^7=%?J)_PQ?\
M!O\ Z$[_ ,J=Y_\ 'J/^&+_@W_T)W_E3O/\ X]1[6(>RD? O@+]HKQ_\-M$7
M1]#UM4TR.0RPVUY:0W2V\AZM'YJ-L/4\8&23BLG6/C)XS\06_B2#4]>GOT\1
M- ^IFX1':<PG,0W%<H%/0(0.W2OT0_X8O^#?_0G?^5.\_P#CU'_#%_P;_P"A
M._\ *G>?_'JES@W=HI0FE9,^"[7]I?XBV7AZVT6'7D6QM[%M,4M86[RO:E2O
MDO(T99D )P">.O4"C2/VF/B/H6@V.D6/B$16MG;-90N]E;R3"W8$>29&C+%
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MBQC8)V0R8_X%D>M?<_\ PQ?\&_\ H3O_ "IWG_QZC_AB_P"#?_0G?^5.\_\
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M9?\ #?<VK^CZ!1112&%%%% !1110 4444 %%%% !5[1_^/EO]P_S%4:O:/\
M\?+?[A_F*F6Q4?B1L4445S'6%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHNPLB'['#_<_4T?8X?[GZFIJ*+L+(A^QP_W/U-'V.'^Y^IJ:BB["R(?L</\
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MM_:-O_ST_P#'31_:-O\ \]/_ !TT 6:*K?VC;_\ /3_QTT?VC;_\]/\ QTT
M6:*K?VC;_P#/3_QTT?VC;_\ /3_QTT 6:*K?VC;_ //3_P =-']HV_\ ST_\
M=- %FBJW]HV__/3_ ,=-']HV_P#ST_\ '30!9HJM_:-O_P ]/_'31_:-O_ST
M_P#'30!9HJM_:-O_ ,]/_'31_:-O_P ]/_'30!9HJM_:-O\ \]/_ !TT?VC;
M_P#/3_QTT 6:*K?VC;_\]/\ QTT?VC;_ //3_P =- %FBJW]HV__ #T_\=-'
M]HV__/3_ ,=- %FBJW]HV_\ ST_\=-']HV__ #T_\=- %FBJW]HV_P#ST_\
M'31_:-O_ ,]/_'30!9HJM_:-O_ST_P#'31_:-O\ \]/_ !TT 6:*K?VC;_\
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MP)R3)@';\WR_+@5XGI.E^-/$_P"S/\*K'2_",GBSPE)I4VK^)HXM2M[66[U
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M9OW21C.Q(T'0"O5-6OM-M_VG_&=SXJ:%=#T[X?021B[4-"+9[JY-\Q!X(Q%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ([5RBCF8613_L__ *:?^.T?V?\ ]-/_ !VKE%',PLBG_9__ $T_\=H_L_\
MZ:?^.U<HHYF%D4_[/_Z:?^.T?V?_ --/_':N44<S"R*?]G_]-/\ QVC^S_\
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M9_Y:?^.U<HHYF%D<5X6^#/@OP/K&H:MX=\+Z-H>IZAG[7>:?I\4$L^3N(9E
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M(P4,AR0&S@X%>ET47_K\1K1W1GVVC16=O%!!MBAB0(D:)@*H&  /0"I/[/\
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MF_T_%'W117ROXM_X*:_ #P?XLFT&?Q7<ZA)!(8I[[3;"6XM8V!P?WBCYP/5
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M;6M=@^+7BCXC:C+#9QZIIVO-<&'2;LHSR)"96._.[!=>NP>M533J<[Z1_/\
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M<4D0A.44&1)!@]R02>N<UZ'X!\&V7PZ\$:!X6TV6XGT_1;&'3[>6Z96E>.)
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M^"?@WQMX-^+?[1VNV:>$O#D]_P"%-4:X\)^&/$%O=S:??(@*'R$.]0'\SG:
MIDQ7UA^T)^P+X&^/GC.V\9C6-<\&>,XHUA?6= N%C>X55VJ9 5Y8+QN4J<<'
M( QU7[-/[(7@;]E_2M5B\/\ VW5]7U<@ZEK6L2++<W(&3LX4!4R2< <D\D\5
MS0A^Y5-O50E'UOI?]==;FDIWJ<Z6CE&5NUM;?HK:'RY_P2V\#_#[7OV2_&%S
MK>F:3?W%UJ-W!K<M]$CLMNL*%%<L,J@4LP[9+'K5/_@C*L">&/BRMLVZV&K6
MHB8]UV2X/Y5ZI?\ _!+'X63^/-0UJPUOQ/HGA_4I?-O_  MIM\(K*XYSY9(7
M?Y62?DR<9.".,>Q_LV_LG^#OV68/$T'@^[U>X@U^Z2[GBU2:*182H8*D7EQ)
MA0&(PVX\#FNI3O*51Z7BHV\TU^>MC!QM%06MI-W\FG_FK_(]HHHHK(T"BBB@
M HHHH **** "BBB@"SIW_'Y'^/\ (UM5BZ=_Q^1_C_(UM4 %%%% !1110!5U
M+_CRD_#^8K#K<U+_ (\I/P_F*PZWAL<]3<**_-GP)KGB+XB?&WXCV.KZU^T#
M>Q6OCV\TJSNO VH+_8=A;B90B3[WR@3<2P48";<"O8_'?[=&J>!/CW9^"IM(
M\,7>CS>(;?P^8+77&N-77S2%%U)'%&T42AC_ *J1Q)QT&>'3E[2--K>=K+UM
M_FO^&(G'D<^T;W^5_P#)GV'17YXP_M"_%'4=+\67'B^>6&TLOBU:>';63P_K
M+6LL \Q5:U.(,26X7:3GYI"S9QC)]%^(/[;_ (VT#3_B+XJ\/_#_ $K5/ /@
M[71X:FO;O5WAO9KL2QQO*L0B*^4&D"_>W<@\C(#A)3C%KK^JB_\ V^*^?8)0
M<9./;3\9+3_P%L^R:*^7/&/[9&H>%_"OQVU=/#-K._PWO;.T@B:Z8"^$ZQDL
MYV_)CS.V<XKBOB9_P48C\!_$#7]/ATGP])X?\,3V=KJL=_KJV^KWCS!3(UC:
ME3YJP[QNR1G!QBA-2:2ZV_&S7YH7*[7]5\UN?;%%,@G2Y@CFC.Z.10ZGU!&1
M3ZK;0E--704444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKQS]H
MSXL/X-TFV\+Z)J]GI/B[7X9OLUY=RHB:=;1KF:[.X@$J"%1?XI'0= V,ZDU3
MBY%PCSRL>QT5Y=^S;XL?Q'^SGX!UR^U5M8NY- M);V^DG\Z2280*9"[9)+YS
MG/.>M>8:'-<^-/@IH7Q'\8_$;5/"'A?4FNO$6K0V-[):R/%-@65O'<(P>)(X
MP@\N,9E<YZDAM:B]G*47]G?]/OL_N,X>_%-=?Z_R7S/J"BOD3P%/XY^(.K^
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MYU'1/"]]X)\1ZWJWANUO&>&62T&.1\H<@QML++D;J]EU;]C/PGJ.G?#1-/\
M$OB#PGJ/@C2#HEO>^'ITA>YM715F1]\;X+D$[EPPW'G.,5M-_8J\$>$/#OAZ
MVTB[U36IO"^A:QHNEV&N7,9M;J._W&2.Y,<*N1EMH9"I Z[CS53C*"ERN[5[
M/_MV:3MYMQ>V]]-+M0E&;C=63M=?]O1;7R2:\U;N[<?X;_; ^(VJZO\ #W3?
M%?@#2=!TSXAZ-J.L:7?Z5K;S3V]O#:&=$D4Q+MEP4)()'SCH017*6'[9NO?#
M7]F;X3:U9KH][=:YI-S>S7?CSQ.\MY*8I& B18H6GN9&Z;Q&$7"ACS7/_L__
M +*GQ!B^+7P_O_%>@:_X:\.^$M*U*P=]:\66^L)LN(3#%;V$<2YBB0,6S*-V
M, D[0*]Q/[!_@>SLO!=OI'C#QAH;>&=&G\/"ZL;R%9[[3Y9&D>&9O(P,LS?-
M&$.#ZX(JI%V?)U_).I:_WQO]]GLYA*-US]-_5\NWXV^[3I[-\"/BDGQL^#WA
M+QTE@=+&NV"7C61D\SR6.0RAL#< 0<' R.U=Y7$_!_X=:-\%?AIH'@C1;V]O
M=*T6W^S6T^HLKSLFXL-[(B*<;L<*. ._-=A]LA_O_H:UJ6<Y."TOIZ&,+J*4
MGJ345#]LA_O_ *&C[9#_ '_T-9V9=T345#]LA_O_ *&C[9#_ '_T-%F%T345
M#]LA_O\ Z&C[9#_?_0T6871-14/VR'^_^AH^V0_W_P!#19A=$U%0_;(?[_Z&
MC[9#_?\ T-%F%T345#]LA_O_ *&C[9#_ '_T-%F%T345#]LA_O\ Z&C[9#_?
M_0T6871-14/VR'^_^AH^V0_W_P!#19A=$U>,?M(_%M_!>D6OA70]8L](\8>(
M89OLM[=RHB:=;1KF>\;<0"5!"HO\4CH.@;'L/VR'^_\ H:YCQG\/?!OQ"CQX
MC\/:3K4JQ-#%/?V$4\D*MUV,Z';Z\=ZQJPE*#4?Z_K\C6G*,9)LYC]FCQ<_B
M7]F[X?:[?ZJVLWDGAZTEOKZ2?SI))A IE+MDDOG.<\YZUY;H4UUXV^"&@?$K
MQG\2-5\'>%=2:Z\1ZO#8WLEK*\4V!96T=PCAXHXXP@\N(9E<YZDAO=/AE\//
M#GPF^'FC^#-!A\O1],M$M$+QH))@%"F278JJSMC+-@9))KQ/2/V79-?\(^$/
M#VN>*/$7AM?A]J-RN@3Z-)8RPWD!/^BW$D5Q;SCS(HF\L;E4JRNR\%6KHK>_
M5FXK?;R5]?\ VVR\GYF5+W814GM_EI^MWYHYOP!/X[^(>K_#[P'XK\1>*-!L
M+G2-8\0&6*[:RUBYMDO(H=.2ZFCPP=89@[J,$MM#YPP.-_;'Q6\<_#WPYKEM
MJ6LWATF'4]+_ +8L=36QABO[35/*%]J""2-98C;02%EVNN2_R99:]YUCX$G5
M8-!NQ\2/%<7BW11<Q6_BHI8&]>WGV^;!(@M1 R?(A'[H,"BG.<YVK7X,^&++
MX36GPZM[B_B\.Q!%GQ*#/>KYOFS+,Y4[A,V[S, %@[ %<U-FK-;K\;MV;]$T
MNCNKK9%73NGL_P %U2]7JO+1G#?!7XWZ3XJ\9:JFK:CJ<>L>([P+IUA-;SBS
MLX%M_.M[4.1Y:W+VY^U.N=W[W!^X .J_9^\27U[;>-/"VI7<^H77A#Q!/I$=
MY<R&26:V:..XMR[GEF6*=$+'DF/)Y)JPGP2\-0?$K_A,TOM3\Y;PZHNCAXQ9
M"^^R_9/M(7R_,W^1\F/,V=]N[FE^"'A.\\*Z7XCU;7(Q:Z_XHUJXUJ]M0XD^
MS!@L4$)9<JQ2"*)6()&X-@D8HBM=M.6WSO&WX<VOWZL4GI\U^4K_ "^'Y^2/
M3J*A^V0_W_T-'VR'^_\ H:+,5T356U.*ZGTZZBLKA+2]>)U@N)(_,6*0@[6*
M9&X X.,C..HI_P!LA_O_ *&J6MP1ZSHU_8)?W.G-=0/ +RR(6> LI&^,LK ,
MN<@D$9 X-1.+<6DBHM<RU/GCX76VL:+\>=.\/Z'XZ\1>.[;2]+G7QU?:K>-<
M6"7[",VZ0J<K!.6\QC#$0J1D;ADJ3Z%<^(K_ ,2?M+0^&H;J>VTGPSX?76+F
M&*1D6ZNKJ62&$28^\J)!,=IR-TBGJHQ1^"_[/MO\#XK"RTGXB>+=5T*S20+H
MNJ)IOV:1GSF21H;*.5WW$L6,F6;EMU:]]X4O=+^/FG^,]-B^TZ=JFC-HFL*'
M56@,,C36L^"1N&9)XR%R<R(<8#$:6?-#MK?[I6T]6K=M.Q+:Y9VWTM]\;_A>
MYY*GQ$^(7P_OOVC]3\1Z];ZWJ/AWPW9:OIEC9P-'8V+&"^<1QHS$MS&A=VY<
MCH  HSK^P\?>"+[1_#7AGQIKOB#6_&_@;5+I7UN_\[R=6@CMVCN(&;B ,;AU
MV+B,80@#!S] 2?##PY<^(/&NJW9GO?\ A+["WTW4[.<@P&"%)D 0!0PW+.X;
M+'MC'?GOAI\"M.^'GB*VUJ[\6:]XNO=.TTZ-I)UQH"-.LBRLT:>5%'O9O+C#
M22;G(C49ZYSC!W:ELU;\)K\W%^=KO5*^TIKW91Z:_C%_A:7WV6C9XCI/C_7/
M!VJ0>%_$$WBO2M%&NPZHEC=7<NIZT+4Q1K:V!>.25V:>ZBNI=I=L00N&PK #
MUS4_B7"?B=\)_$6A:K-J'A/QW!<:4T)9Q%YBP/=VTZQMC8X$4\;< G>H;[@Q
MMZW\#O#^M07TAU?5[/6;G7%\0)KEN\1N[>Y5/*C";XFC\M(LQ!&1AM)SEB6K
M&LOA#%IGCCX::?8026_@OP%8SW%K//,))+J^EC-N@(^]\D;3NS$ %I4QG#8T
MC=I<RUNONY;._GI;S=GNS%V5^5Z6?WWT^5[/O:Z>B/:Z*A^V0_W_ -#1]LA_
MO_H:5F%T345#]LA_O_H:/MD/]_\ 0T6871-14/VR'^_^AH^V0_W_ -#19A=$
MU%0_;(?[_P"AH^V0_P!_]#19A=$U%0_;(?[_ .AH^V0_W_T-%F%T345#]LA_
MO_H:/MD/]_\ 0T6871-14/VR'^_^AH^V0_W_ -#19A=$U%0_;(?[_P"AH^V0
M_P!_]#19A=$U%0_;(?[_ .AH^V0_W_T-%F%T345#]LA_O_H:/MD/]_\ 0T68
M71-14/VR'^_^AH^V0_W_ -#19A=$U%0_;(?[_P"AH^V0_P!_]#19A=$U%0_;
M(?[_ .AH^V0_W_T-%F%T345#]LA_O_H:/MD/]_\ 0T6871-14/VR'^_^AH^V
M0_W_ -#19A=$U%0_;(?[_P"AH^V0_P!_]#19A=$U%0_;(?[_ .AH^V0_W_T-
M%F%T345#]LA_O_H:/MD/]_\ 0T6871-14/VR'^_^AH^V0_W_ -#19A=$U%0_
M;(?[_P"AH^V0_P!_]#19A=$U%0_;(?[_ .AH^V0_W_T-%F%T35+;_?/TJI]L
MA_O_ *&K%G.DLI"MDXSTI-,I/4N4445!N%8%S_Q\R_[Y_G6_6!<_\?,O^^?Y
MT 1T444 %%?&?_!3']HWXF?L[^ /"U[\.\:<NHWLL5_K9LTN?LNU5,<>)%9!
MYF7Y8'[F!7M/[(7Q)\6?%S]G?P?XK\;V T_Q%J$#M.!#Y(F59&6.8)_#O0*V
M!Q\V1P11#]Y&4E]EV_K^OP"?N.*?VM3V.O'_ -JO]H6+]F'X177CJ70G\1)!
M=P6OV%+H6Q;S&QNWE'Z>F*]@KXY_X*Q?\F?:K_V%K'_T8:QK2<(IKNOQ:1M2
MBI2L^S_)GMO[,G[1F@_M/?"JS\9Z)";&0N]O?:7)*))+*=>L;, ,@@JP; R&
M' Y%<K^R7^UM#^U.?&_D^&)/#?\ PC-^EBV^^%S]HW>9\PQ&FW_5].>M? '[
M/'B/5O\ @G_\8? MYK-S-+\*OB?H=C=RW4GW()9(D)<]MT,CD'UCDSUKL?V!
M_BH/@W\$_P!J'QU#"EZ^CWJ75O$3E)9")Q$"1_"69<X[5TU'&#G/[*B].THR
MBFOQ=O4YJ2E-1AU<HV?=2C)K\E?T\S]4:*_+KX&_LM?$?]K;X.W'QD\1_&CQ
M5IWC/5GN9M$@LKMH[6W\IV10RJ1L4NAPL>T*,'D\5]#?\$TOVCO$OQ[^$>LV
M'C*Y;4/$GA:^6PFU%\;[J)E)C:0CJXVNI/? )Y)-"@[RC+244FUY/3\]QN2L
MI1U3;5_-?\,['I_[7G[3D7[*'PQM/&$WAU_$RSZE%IWV-+P6I4NDC[]Y1^GE
MXQCOUKUGP=XA'BWPCHFN+ ;5=3L8+T0%MQC\R-7VYP,XW8S@5\7_ /!8;_DU
MW2?^QEM?_1%Q7SO^T1\$O'OP5_9N\"_&^+XP^*[GQB5TY7LTNC#9VD4L.8XH
M$0C:$ 52#D-SD#-8TYKEJ.>RE%7[77XZFLXOF@H;N,G]S_R/UOHK\W?VSOB#
MX[\)^#/V>OV@=(US5;6V:'3_ .W]+L[R6.TN&=$N%WPJP0AOWR'([J/2MG]K
M'XFZW\<_VI_@?\*? /B;4]+TJ]@CUS5KG1KV2W,EK*!)AVC8=((F8 _\]16R
M@^=4^O.X/RMK=^35V8\RY/:=.7F7GTMZWLOF?H317YA?$F+XB_%'_@I3XL^&
M&@?$CQ!X0\/7NG0B[-A>R'[/;+9022"!"VU)'8 ;P 1O8\Y(-[P _C']B;]N
MKPM\*_\ A-]8\9> /&D"/'!K4YEDA>0R(K\G"NLD?+* &5N1D#$4OWGL^G/M
MZZZ?.VY<_<4GORV;]';\K['Z7T5^8/@JQ\9?\%'OV@?B2NJ?$'7O!OPX\(7'
MV2QTK09S"TA+R)&Q'W2Q$3.S,&/(48'3K_V4OBKXW^ ?[4_C3]GOQIXHO?&^
M@V%E+J&D:E?N9+B)4A6<+N8D[6B8Y4D@,GRX!-3&2<5*6EXN2]$K_)VUL.:<
M9.,=;-1?J]/GKH?H?17Y5?LR_#[QY_P4#\2^.OB;XD^*_B?PBFF:A]ET6TT"
MZ:-+1R-ZA5S@(BE!@ ,Y));/7L/^"??C+XDZO\6?VB-(\4>-[C5->TB)X(KS
M5KAY;&VNDFG0S"(MM1-RABJX&!CBJ2?PR5GRN5O)*_I?7\?N3MJXNZ4E&_FW
M;[C]):*_$;XNZIX-\-^'M=U6^_::\6>//C(MP\MJWAE[@Z8I#?*#,X4 8SS$
M^%X 4@<^[_'#XY>.?$/_  2\^'/C*3Q/JEIXIN=7CM+G5K*[>WN)UC>ZC!=T
M())$:D^I&3S4N5J;J=G%?^!::/R*M[ZAWO\ @K[>9^H5%?D+^TQX!^)'P2^"
MOPS^/7_"X?%>I>-]8FL_M$#W12UMA+;M-''$@.-JA-K*V0^22!DYD_:D\&?$
MG]G7P?\ #'XY#XN^)]8\;^(+N&3489K@I:1-)#YXBBB4X$0 *%""I'8#BM>6
MTG&6EI*+\F]O7]"$W))Q^U'F7FEOZ'Z[45^;'[;WC+X@:C^U]\$/#G@WQIJO
MA%_$FEVT+-9W+B"-YYY$:4P[@KLJL2,CJHYXKS?X@?#GXD?L]_MD^&?A3X(^
M,GBMK?QY90K=ZIJER;B:-9I)$E?!.TR*(F9'&&&<;NYB"<N56UE*45ZK^MP;
M23E?114GZ/\ K8_6^BOS&^&>D>*/V4_^"C/AOX8V'CWQ#XJ\*^)+ SW<6NW1
MF:0O#,P9AG;O62'(< '!(]<UOVME\)2?'+Q5<?%_]I+4]/T^$;='\&^!A.]Q
M8_W4F4*T2-MP26(9BW4  5+DK1DMG?[T[->9=GS2B]U;[GL_+S/U"HK\L_V(
M_P!JKQ;X6_9M^/VI7>N:AXIMO!4$=SH$NML9)HS+YJ(KY9B%W)&Q3<0/F ZT
MG[/W[/OQ-^*_P&U']H%_C5XJLOB!<QWM_I]NMT6M'2%G4Q3(3RKF-@%7"J"/
ME.,4ZCY.9O:,5)OUVT[Z._ZB@N:RZN3BO5>?S1^@O[17QD3]G_X-^(_'TFDM
MKB:/'$YL$N/(,N^5(\;]K8QOST/2K/P$^*Z?'+X0>&/'<>F-HR:W;&Y%BT_G
M&'#LN-^U=WW<YP.M?F?\-_&6O^-_^"57QGOO$6MZCKUZFMI$MQJ=W)<R*@>R
M(4,Y) R2<=.378^+OVC?$?P#_P"":WP9M/!]RVG^)?$\3:?#J$>-]K$LDC2,
MA/1SE%![;B1R :IIP4[ZN\$O^WD]/OL*'[SEMI\=_P#MUK_@GZ?5\]?M=_M=
M0_LHVW@Z6;PO)XF_X2*]DLP$OA;>1M"'=S&^[._IQTKX_P#C7^RQ\1_V3_@Q
M!\9O#OQI\5:AXUTEK:YUJ"]NVDM;CS75&"JQ.\!W&1)N##)XZ5A_\%#?BC=?
M&_\ 9P_9P\;0PI9:EK4\\S1+]R.Y"QHX&?X?,4XSVQ2>C5M;3C%KU?3U5]0B
M^;T<9-/T77TT/U@1MRANF1FEK\K_ -JOX'?$K]C[PGX=^-.B_&;Q1K_BL:C!
M!K4>I7!-M-)(K-\D><&+*E?+8$8(QC&*[+]HKXR>)-=_:D_9/O\ 2];U31M)
M\4V6F:A=Z79WLL5O*)YT8K(BL%?AMOS \54$ISC!/5RY7Y-JZ]58F3<8.HUH
MH\R\];?)GZ/5\\>./VO(?!?[67A+X(MX6DNYM?M5NAK8O@BP;A,=OD^6=W^I
MZ[Q][VKPG_@H/XY\1^%_VF_V<M/T;Q!JFDV.H:HJ7EK8WLD,5ROVRV&)%5@'
M&"1@YX)K$^.G_*7#X1?]@F+_ - O*FE^\E2ETE.46O\ "F55]R-5=8P4E\VC
MZJ\,_M$:UK_[2VO_  MF^'.K:?H^F6QN(_&$KO\ 8[HA(VV*#$%S^\(XD/W#
M^'MU? 7PJ\<^)+W_ (*K_$CP[<>(-5G\/V^E.\.DRWLC6D3>3:G*Q%MH.6;D
M#N?6O%/V4/A[\0/VM_%GQ>\-ZW\7O%VA^$=(U0N]O87[O-/*\DRQ)O<G;$H1
MB4'!)7T!$P;G3IM+5PYON=OZL5-*,ZEWHI*/WJY^M%%?FA^PE\=?%OPP\*?M
M&:%XFUR\\6V/PWBFNK ZA,\C!HC<(R*6)*HYA0[<X&3CJ:\!\)^)(?C5\/?%
M7Q1\<_M,:CX5^*JRW$^BZ##J+01Q^6NY$V*1L#ME5";0O!.[.*'*.\=8\JE?
MR?9=7OH"B[N,M'S./S6N_1:H_:VBORD^*O[4WC7XH?\ !-7P_P"+6U_4-,\7
MV/BB+1K_ %33+E[66YV1R,&)C(^\C1[AT+ G%8'[3'@'XD?!+X*_#/X]?\+A
M\5ZEXWUB:S^T0/=%+6V$MNTT<<2 XVJ$VLK9#Y)(&3FI>XY<VT7%7_Q)-/\
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M7=OX=\13I$\.K2VP8R(D2.9$+!&V;E&_&!@\5!X-_;IT#6?&NH^'?$WA/5_
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M%]3CU._LTGU"T@T6XTQ8+.-_-@CTG[/=>4ID:<NY?,CX <X01FN[G^(MU?\
M[/VIZWX2\:V'B_Q+X;LQ>7M]9>4\5Y-"HFEA95&$25 RJ0 0KJP)ZF5)<GM'
MM9/T]?3KZHKD?/R+>[7]>O3OZ'ME%9OAG7[7Q7X;TG6[$EK+4K2*\@)ZF.1
MZ_HPK2K247%N+W1E%J24EU"BBBD4%%%% !1110 4444 %%%% !1110 4444
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M#^=^T/>_%"74VDCNO"X\--H_V0CC[093+YV_OG;MV>^[M7L]%.4N:W,MK_\
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MN?/?P%^ _C?X.3/#J'C+1/$=C=227.ISQ^&)K;4M2N6'^OFNGOI=S9QQY>
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M;UE=KLDM/S[=-7JS]AO%?B[1/ NA76M^(M7LM#TBU&Z:^U"=888QVRS$#D\
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M;!1112&%%%% !1110 4444 6=._X_(_Q_D:VJQ=._P"/R/\ '^1K:H ****
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MZGI7E_A[_@G9XILOV;?&7@[5/%&FW?CC4=8L;[3]22:?[.+6P5([*VE=521
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MO#6BM<>&+BWN+7199HX5D9]8-[<O#-+82>: (K=4$K$K)E6Y*##'>N=7\?\
MC*UT7QCX TWPQKNBZYH"VDVF^()GL9[&X+$EC*D$K2("61X&VX9.#DFK.G?
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MB>*-IX?"/B.QUZ[B09)M8V:.X8#OLBE>3_MG7G/B+]G7Q=J$7CGPKH2>&Y?
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M?^S?)^R;YDD_UWFMOQLQ]Q>N:^BZ*:=I*2Z)I>CW):NFGU:?S6WW'RM^U_\
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M0 4444 %%%% !1110!9T[_C\C_'^1K:K%T[_ (_(_P ?Y&MJ@ HHHH ****
M(YO]4U53P*M3?ZIJJU2,I;GRYJ/[?VA:;XX_X1"3X2?%I_$;0O<Q:?'X94S3
M0(^PSHGG[FCS_%C%?1T7BK2)-1@TU]1M8-6FC$JZ;-.BW.TC/,>=WZ=J^?\
M7_">N3?\%"/"OB./1M0?P]#X#NK.75EM7-I'.;O<(FEQL#D<A2<XYQ7R!\2/
M WC+Q+^TC-KMO\,]5TC5=+^)=G>2RZ5X0N+F2?3EF11?/JS.[,C+_P L(0J*
M 20 #12]]TX/>5[OM:?+^6O_  -4JBY?:2CM&UEWO'F_X'_!T?ZBG7]+75QI
M)U*T&J%/,%B9U\\K_>V9W8]\5Q'PH^/GA/XP6=]-I%Q)92VNJWFC_9-2,<4\
MTUL^V5HT#L63/0]<=0*^-_AAX'T_P[\7=6L/'?P6\3^+/BM-\0Y]6LO&%M:3
MPP16#-F"Y_M%2%\B-.# 6P3P5)XKE=,_9OU73O!>G>*8/AUJL/CY/C;]L_M$
M:1,+]-*^UL3(&V;Q:E3N+?<.<^]%+WW"^TDODVZ:_#F=_1Z[I.HE!3MO%OYI
M*;_'E5O7;9O]*AKNFFT2[&HVAM7?REG$Z[&?.-H;."<\8I(=?TNYU6;2X=2M
M)=3A7?+9).IFC7U9 <@<CDBOSRT3X7ZR_P"V-+\#8H5_X5_H?B*7XHQ$'*(L
MD0$%N5[*MV[G!Z@9J7]FGP=9^#]1\.Z7KWP+\4ZI\<M+U35KK5/&#03V4#%S
M*RSO?AE2YCD1D18R6&22!W,QE>*D^JO^2?W2YD_1/9Z.4;-I=';[[M?>N5_]
MO6W6OZ"VGB?1[^^N[*UU:QN;RS!-S;PW*-)!CKO4'*_C48\7:$8+J?\ MK3O
M)M462XD^UQ[85;[K.<_*#V)ZU^6/P)^''C!_B_X.\00_#;6/#"OI'B&RUBSL
M/!=QI]O93R6TIC@ENY&DEO"S8Q)*V,E57GBNFL?V7U\"_LI?!+5[CX::O>@:
M[9:C\1-"BT^:34;VVC,X3SK8_.ZQ&0?N]O0CC XKHF]/A7_@4FON25[]FNFH
MFE=I:_%^"3^]MVMW^X^U_P#AJSPM<:SXETS3]'\0:Q<:!KMCH-VVG6D<R&6Z
M0/',A$G,*J06<X([ UZL_B32(]932'U2R75G7>M@UP@G9>N1'G=CWQ7YC6'P
MBUZ6T\;R^%OA=XG\.>';[XK>'-5TK2YM#G@9+! Q>98@OR1+G)'2,$*VTC J
M_$CP-XR\2_M(S:[;_#/5=(U72_B79WDLNE>$+BYDGTY9D47SZLSNS(R_\L(0
MJ* 20 #54US.$'HW:_E>-._XS?W=KM347*IR72]O/6=OPBOO[V3_ %4HHHI"
M"BBB@ HHHH **** "BBB@ HHHH **** "N)^)'Q7L?AQ/H]DVD:QXBUG5Y)$
MLM)T.W66XE$:[I')=T144$9+,.6 &2<5VU>7_'3QA%X>TVRTO5=)\3/X9UE9
MK:^U[PH+E[O2W 5H_DM4:<"3YE\Q/ND '[V:B3:6A45=ZG7?#WQ[I'Q.\(:?
MXDT.25].O X5;B(Q2Q.CLDD;H>5='5E(]5-<CKO[1_@GPOX"\0^,]8OVT[PY
MI-[<6"7<P7.H30DJZVJ!BTA\Q9(P, DQL1\N&.)^RKX?USPY\ K/2;VRNM,$
M$]\FD1:E;BWO18F>0VKW2 #$S(59\@,2<M\Q:N-^&N@+KO[!EKI\.F&_UVU\
M*W]E]G$'FW"ZBL,T,ZJ,%O,,OF*<<DDCO2KMPC4E'HDU\[O[U:S7=E48J4XQ
MEU=K_A^.Z?9'J'B_X^Z-X3TKP==IHNO:]=>*XC-INF:-9K/=,@A$S,REU "J
M1DY/) K-\3?M,:)X1@TF35/#GB2U>[LFU.]@EM84ETFT6=(#-<JTH(&^1?EC
M\QL9.W KSCQ]X:\,0Z3\(9_B#X0\77NGZ?X<>T^WZ#]O;[!<-#;AH+BVLQYV
M7\O"L?E5DP0"0:JZ5\+M0UC]GG1=7\7>'=>U_P ;6@N++2+"]NKD74UI+>[K
M&#4O+;]Y&BK;/+YN=HC8MSNSO-*-25M4I/[M4EZMV?FKV>S,H>]3BWHVE_FW
MZ)77D[73U/HWP[XYLO%&N^(]-T^"XD70ITM+B\(4027!C$C11G.2R*R;N  7
MQDD, O@'QSI_Q#\.1ZOIZ36ZB::UN+2Z4+-:W$4C1RPR $@,KJP."0>H)!!K
MYZ^&6A_$+X=_&"P\+)<:[>:)#J+_ &N273@-,NK%[ S2WK7'EX^U2:BSY3S-
MP5L;-@!KOOV=$DE\1_&6]AS_ &1=>-;C[&?X6:.UMHK@K[>?'*#[JU1'5V_N
MW^:<5_[=\K6Z,<M%?S2^34G]^GW._5'M-%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5+;_?/TJ*
MI;?[Y^E)C6Y9HHHJ3<*P+G_CYE_WS_.M^L"Y_P"/F7_?/\Z (Z*** /G3]LS
M]LS2OV/_  [H%Y=>'KCQ/JFMSRQVMC%<BV0)&%,CO*4?&-Z  *<Y[8KT;]GS
MXUZ7^T/\)-!\>:1:3Z?::HC[K2Y(+P2([(Z$CA@&4X/<8.!TI?C5^S]X"_:&
M\/VNC>/= CURSM9O/MCYTD,L#XP2DD;*PR.",X/&1P*Z?P-X&T'X:^$]-\,^
M&=,AT?0M.B\FULH,[8UR2>222222222222231#2,N?>^GI_7_#K8)ZN/+\_Z
M_KTZF[7QS_P5B_Y,^U7_ +"UC_Z,-?8U?'/_  5B_P"3/M5_["UC_P"C#7-B
M/@7K'_TI'10^-^C_ "9\W?\ !-_XT:U^SW\1;?X,>/7-KHGBZTM]9\.W$C?N
MEFN(ED0(3_#*IVX[2)CJ374?\$RO'.E_#/P'^T;XKUJ0Q:5HVIK>W+*,L41;
M@D*.Y., >I%='^T/^S!/\:_V(?A7XP\,PNGC[P=X9L+VRDMN)KBW6WC:2$$<
M[AC>G^TI ^]7C/\ P3\^'VI_&O\ 93_:3\+6<F_6M:^SB!I&V^9<>7+(H8]M
MSJ 3[UV5W).NE\4(M>JYH\K_  L_0Y:*BU1;^&<HOT?++F7XW7J>J^%OVG/V
MN?CSX3U?XH?#KPOX6TWP+923?8](OE,MU?QQ$[PI+ R,,$$@Q@D$*"17U-^Q
MQ^U'8_M6_"@>)%L%TC6[&X-CJNG*Y9(IPH8,A/)1@01GD<CG&3\6_LR_M\>&
MOV7_ -G>?X8^//#FNZ9X_P##+74%MI1LBHNVDD>1 Q)'ED,Y!R.@!&[.*]P_
MX)5_!/Q+\+O@WK^O^*+";2;WQ;J"WUOI]PA22.W1"$=E/*EBSD \[0I[U<5&
M\U'6"2:?FWW]-;="&Y>ZY:2<FFO*SZ>MM>MSU/\ ;=_:G/[*7PDCUZQT^'5?
M$>IW0L-+M+DGRO,*EFDD"D$JH'0$$DJ,C.:^$OVRO&O[3,O[,4*_&/0O#TGA
MKQ#>6L]O=:5^[N],F&9$BG0$KAE##N01RV>#]'_\%9_A3X@\=?!3P]XD\/V,
MVI/X4U,WEY;0(7<6[IAI-HY(5E3/H"3T!KY]_;0_;B\-?M-?LN6V@>#]"UF2
M]@FL[[7Y[BTVVVEA3M"&3)#%Y64+CJ,]#Q7 ]83>[4HZ=EH[_??7RL=JTE#H
MG&6OGJK?=;3S.X_:B^)*_#C]D']FB9O"?AGQ7]KL;*+R_$M@UTD&+.([HP'7
M:WOS7%?\%2#\1]2_:,^'5A?:;HEQX>-Z$\*1R?,;J1C;"9;I2V-OF[5Z+\N:
M?^W9_P F;_LL?]>]G_Z115Z1_P %0/\ DO?[-G_88;_TJM*[YQYL:D^M9K\(
M_B<M-\N#37_/J_XL^=/VS=)^-5MXV^#^D>/?"?@G1YC>/_8FF:#"J6<]P\L'
MFB= Y&TOY8/3(+9KZK^*'[47Q/\ @1X9^&GPGT3P7X7A^.7BQG>>QTN$1Z78
MJ\[I&Z(K %G R26P-K$YZ5S_ /P5 _Y+W^S9_P!AAO\ TJM*Y[_@IM\.9O#7
M[1/PZ^+.LV6N7'P_6VBTW5[SP_*T5U9%))#E9!]PLLN5)(!*,,C-<\)7I4[Z
M*522?31>?2[M?Y&DH^_*V\8)KKKKTZZ7?WGK/PB_:J^,'P[_ &B]&^#?Q_TO
M1&O/$4'G:-KVA96-W.[:C#HP)1D^ZK!L9R"#7$?%7]MWX\G]J'QW\&OAGX6T
M7Q!J5NXAT<M#LE@ CCEDEE>241D!2X&[:,E>O0^>? 2R^%?QF_:S\))\./#G
MQ \;:=X?,6HR^+O$?B*14TUT8O@Q/"^Y20JA=Z%F)[#->@_ *)9/^"MOQC9@
M"4TJ8J?0XLQ_(FM(1YYPC+2\9OM>UK?JK]>AG*7)"<H]'#SLW>_Z.WWG0?$W
M]L3XU>$8/A;\)M+\/Z/=_'SQ39+<ZIYT>+33@[OL78'*[]B%F;<54*2 <@#H
M_@1^U5\5?#/[1D/P/^/.EZ/'K^IVIN]'US1,K#<?*S;6&<$$1R $!2&3!!R"
M/#?^"BGP]7P)^UOX-^*OBBU\0-\-[^TBL=1U+PW,T%U9R()$(60?<)5T8 D;
M@'44S]E_3?AE\7OVN]&OOAUX:\=^*M(\-1K=GQMXD\0R%+1PK$1F%X6W!F;:
M$\Q2<LV, T8=^TES-;RE==DKVMVLK-=PKKV<6D]HQL^[ZW[W>C70[7P3^V/^
MT;\;?BC\3?AU\/O#_A.34=!U*>*#6=062&"RM8YI(_W@WMYDKD(%P,#:Q*D=
M/2?V'OVP/&GQ9UWXC^"OBM8Z?8>)_!)9[F]L4\M&1'>.8.H)7*,GWEP"#TXR
M?-/^":@'_#4'[3)[_P!KM_Z6759/[(.@_P#"4_ME_M::+YGD_P!HKJ-GYG]W
MS+MTS^&:QIN7)325W*DY?-+3_@]S6JH\]2^BC4C'Y-ZFOX:_:P_:9_:FU#Q9
MXA^!^A>&]*\#:!<-;P+K"[[G4&4;@F2<%RNT[0%"[P-Q/->G7_[=?B7X??LC
MW'Q(^(GP[O\ PMXZBO!I,&A:A:S6<5[<LNY)D$@WB+:&8CDC8P!Y!KYH_8\_
M:HT7]@[PSX^^%_Q9T36-*\0V6J27]G';VF];LF-4V Y& 3$K*_W2&SGCGJOV
MC+OXJ_MJ_L,#QKJ'@,:#>Z3K::G9:79>;)-?6"Q/').(V&[@R9&,Y5&(XQEU
M;1I-TG>-H:^K5W?[].BU"%Y54JBL[RT[V3LK?=KU>AJ7W[7W[3WP,T#PE\3?
MBKX:\-ZA\-O$4T(ELM,0QWEA'*N]/XB58H"0&WCC:Q4FOT7TC5;77=)LM2L9
M1/97D"7$$J]'C=0RG\017XL7?B[X+_$3PEX*\,^&M#^*7Q%\;ZG+!;WOA.[\
M1RPVT$BIAC&QCE!PWW?EP%R6VXQ7[*^ _#L?A'P1X?T.&%K>+3=/M[-(7F\Y
MHQ'&JA3)A=^,8W8&<9P*ZI12C+LI67I;OUMW\]3F4FY1[M7?K?MT]/(^/M:^
M)*P_\%2] \'_ /")^&7:71WE_P"$A>P8ZJG^@SOM6??@+\NW&W[I(KFK_P#;
M(^/'B[]J+XD?!SX?>'?#.I7>F2R1Z;?:@LD,=C"A7?/<-O/F?>"@*!\S X.,
M&CX@_P"4RWAG_L O_P"FZXJ#]E( _P#!47X_'N+2Z_\ 2BVKEH+GG3B]N6H_
MND['77?)"4EO>FOO2N=_^QS^UC\3_&7Q[\:?!CXO:?I0\3Z%;O<QW^E1^6K;
M'0,C $JRE9596 4XSD<\?3OQWUKQ;X:^#_BO6/ T=I/XJTZQDO+*"^A:6*8Q
M_.T9564DLH8#!ZD5\1_!3_E+M\6/^P1)_P"BK.OT790RE2 01@@]Z<KU<-3D
MM)2C>_G=F:M3Q%2+U49;>5D['R%\(_VY1XM_8CU_XPZY'8Q>(] BN;:]L[=2
MD#7JD"W4*6+!7\R'O_$?2N=\,?M,?M$>(_V2="\=:1X!L?%7CSQ/?R+86^G6
M;I:V%B/E6>9#*68LRDC# 88$\#GXJ^-7P>\6^"_VD_$O[.'AXO;^%?'?B6QU
M:TC4':MN?,*D?[,8D<-_U[CTKZE_X*A'Q#\+/A#\+/#?AJ75M'^&%O.-.UM]
M$8I((8TB6&)F&!@H)2 WRLP&>@H<E.'MMN=Q26UK6<K]M7R^GF-1<*GLM^52
M;?=._+ZZ*_K^-*+]L#X__ 7X[>!?!_Q=N?!/B33O$]Y':30>'Y%-S8;Y$CRV
MW!5E+@X92& (!SR/2/VC?VM_B5<_M#VGP)^!NDZ5=>+5MQ<ZGJ^LY:&U!3S-
MH&< *A4LQ#9+A0N:^!/'H^"VE_$SX/:S\'O#WB*Q\)V>NVZZMXGU\2A+RX$T
M+^6I9MH,:!BVT+]_H1@U]-?%[79?V-_^"B]W\6O%>EW]Q\/?%EB85U6RA,HA
M9H(T9?3<KQ E<Y*-D9Z5HDFJ:J:*\UVNTDXKT=]^JL9W:<W#5VB^^[:D_5=N
MGR/H3]G#XW?'.V^(7B3P/\<_!(MK?2[5KRW\;:-8RKIDH50[(TN/+)*DD$;2
M"I4KFO&O#7[6'[3/[4VH>+/$/P/T+PWI7@;0+AK>!=87?<Z@RC<$R3@N5VG:
M H7>!N)YKTSX2?M=:O\ MC_$7QMX.\'>$WC^%:Z3/;/XNO5DAF$TD)0*$Y4D
MNQ(7((523CI7S5^QY^U1HO[!WAGQ]\+_ (LZ)K&E>(;+5)+^SCM[3>MV3&J;
M <C )B5E?[I#9SQSG>[]_3W+KS=[/3R73YEVLO<U]ZS\E:^C\WN^FQ[=\8?V
MBO&'BC]@3Q#XO\?_  KM]&\4V-]:VEWH'BS29Q8W69XMLZ0R%7*$-D L=K*>
M3QFM\7OVN/%?P _8G^"OC7PAH_AZQNM;2UMY].^Q/]C@B-N[E88Q("@!4 98
M\5R_[0WQJ\;_ !^_X)O>,?&'C/PA!X/%UJ5DNFP1/(6N;<7,7[XJXRH)) ]0
MN>A%><_MC_\ *-W]G/\ ZZ6?_I'+3ES*-72SYZ:^]*__  5TV'3492IJ]URU
M/P>G]?,]$^,_[8G[4/P4TWPQ\3O$?A;PKI_P[URYCC@T%"TUU%&Z&1%GD!!6
M1HU8@KE01RHZ'V#]J[]M+Q%X%U'X=^!OA3HMKK'Q"\=V\-W9_P!H\Q6D$IQ&
M2H(!9CNY)VJ$).:X/_@JR /V,_!8 P!K.GX_\!)Z\:_;8^',WAKQC\!?BSK-
MEKEQ\/U\.:;INKWGA^5HKJR*(3E9!]PLLN5)(!*,,C-4[<TJ;^&-11OY.+>K
M];:F<6W",U\4J;E;S32T7I<^AOA%^U5\8/AW^T7HWP;^/^EZ(UYXB@\[1M>T
M+*QNYW;48=&!*,GW58-C.00:^X*_*7X"67PK^,W[6?A)/AQX<^('C;3O#YBU
M&7Q=XC\12*FFNC%\&)X7W*2%4+O0LQ/89K]6JMK]W%RWU\M+Z?Y7V=B;_O))
M;:??;7_AN@4445F:!1110 4444 %%%% !1110 4444 %%%% !1110!9T[_C\
MC_'^1K:K%T[_ (_(_P ?Y&MJ@ HHHH **** *]^YCM)&4X(Q_,5C_;)O[_Z"
MM;4O^/*3\/YBL.MH)6.>IN3?;)O[_P"@H^V3?W_T%>.Z;^TYX4U3P1\3/%,-
MIJPT[X?W]]IVJH\$8EEEM5#2F$>9AE(/REBI/<"NP\-?%+PYXF\'Z-XD74H-
M-L=5LK>_ACU&:.&5(YU#1AQN(!.<8R><X)JU:2NO)_\ @6J^^QF[K1^:^[1_
M=<[+[9-_?_04?:YO[_Z"LG4O$.E:,KM?ZG9V(2/S6-S<)'A,XW')'&2!GU-+
MJ'B#2](LX;N^U*SLK69E6.>XG2-'+?="L2 2>V.M.R%=G,?#SX+>"_A5K_B+
M7/#&B+I^L>(9O/U.^DN);B:X8$D#=*[%4!8X1<*.PKO/MDW]_P#05E:AXATK
M2& OM3L[(E0X%Q.D?!8*#R1P20/J<4_4=:T_1T#W]_;6*%68-<S+&"%&6/)'
M ')]!2LDDNB'=MM]6:7VR;^_^@H^V3?W_P!!60OB/27OK:R75+)KRZC\Z"W%
MPGF2Q]=Z+G++[CBE_P"$CTG^V?[(_M2R_M;;O^P?:$\_;C.?+SNQCOBG9"N:
MWVR;^_\ H*/MDW]_]!6./$NCF]BLQJMB;N9WCCM_M">8[K]Y0N<DCN!TKG_#
M/Q3TOQ%?^([66TOM"&B:DVF//K");Q7;A0V^W;>=Z8/4X/!XI67]?+_-#U_K
M^O([C[9-_?\ T%'VR;^_^@K!;QEX?1[!&US35>_ -FINX\W(/ ,?/S_AFL;0
M?B[X4\3_ !#\1^"--U1+GQ'X?B@EU&U"D"+S0Q10QX8X7)VYVY&<'BG97L*[
MM?\ K4[?[9-_?_04?;)O[_Z"L>R\3:/J4%W/::K8W4-H2MQ)#<HZPD=0Y!^4
MCWI++Q/HVI7C6EGJUC=72]8(+E'<< _=!ST(/XT6079L_;)O[_Z"C[9-_?\
MT%9;ZS:?V?>7=O*M]':A_,6U82-N09*<'[WL:Y[P;\4=&\7>"M+\2S"?PW;W
M]NUTMEK^RUNH45BK&1-Y"XQZD<BE9:_U_6P]?Z_KS.U^V3?W_P!!1]LF_O\
MZ"O'?C'^TUX7^#=UX1LKBSU+Q-J?BF=H=,L?#ZPS22JJ[FD)DE10@'?=SVSS
M7IUOKVFW6I2Z='?VSZE$@DELEF4S1J>A9 <@<]::2>WH)MJU_7]#4^V3?W_T
M%'VR;^_^@K#N?%VAVEQ?6\VL6*7-C";BZ@^T(9(8P,EW3.0,=R*X+PU^T?X4
M\;6?@F_\-P:IK^E>+;FXMK34;*US#;&+=E[G<RM$K;?ERI)R,@9I))Z+R_'8
M>JU_K35GK/VR;^_^@H^V3?W_ -!67'KVF3:M)I<>HVCZG&GF/9+.IF5?[Q3.
M0.>N*C3Q/H\E[!9IJUBUW.76*W%RADD*_>"KG)QWQTIV0KLV/MDW]_\ 04?;
M)O[_ .@J&BBR"[)OMDW]_P#04?;)O[_Z"H:*+(+LF^V3?W_T%96@Z#8>%WU-
MM+MQ9C4KQ[^Y1&)1YW #N%)(7=M!(4 %B6(RQ)OT466X7>Q-]LF_O_H*/MDW
M]_\ 05#119!=DS74K @OP>.!BLOPOH=CX,T*UT?1K<66G6P81Q ESEF+,S,Q
M+,S,2Q9B2222235ZBBR"[)OMDW]_]!1]LF_O_H*AHHL@NR;[9-_?_04?;)O[
M_P"@J&BBR"[)OMDW]_\ 04?;)O[_ .@KSWXN?&[PE\$M'M+_ ,3ZAY#WMPEM
M9V, #W-U(SJN(X\C(&X%FX"CJ>E=IJ.H6VD:?<WU[.EM9VT33332'"QHH)9B
M>P !-2^5)R>R'JVD7OMDW]_]!1]LF_O_ *"O'=3_ &D-*L8/"PMO"OBG6=0\
M1Z=+JUIINEV,<MS':(T:B653(H0-YL9 R3\V" 015C5OVB-%T3Q%I6D7FAZ[
M!+=1:?)>3/!"J:4U[,T-K'<@R[]SR*RD1JX7&6(!S56U2MUM\]K?>FO705[*
M_E?Y?TT>M?;)O[_Z"C[9-_?_ $%<EX>\>VWBJS\076E65U=6^E7<UBD@"!;V
M6( 2"$EN0)-T66VC<C=AFKG@KQAIWC_PIIGB'27=[#4(1-&)%VNAZ,CK_"ZL
M"K#L5(I))Z^GX[#=U_78Z'[9-_?_ $%'VR;^_P#H*AHIV0KLF^V3?W_T%'VR
M;^_^@J&BBR"[)OMDW]_]!1]LF_O_ *"H:*+(+LF^V3?W_P!!1]LF_O\ Z"H:
M*+(+LF^V3?W_ -!1]LF_O_H*AHHL@NR;[9-_?_04?;)O[_Z"H:*+(+LF^V3?
MW_T%'VR;^_\ H*AHHL@NR;[9-_?_ $%'VR;^_P#H*AHHL@NR;[9-_?\ T%'V
MR;^_^@J&BBR"[)OMDW]_]!1]LF_O_H*AHHL@NR;[9-_?_04?;)O[_P"@J&BB
MR"[)OMDW]_\ 04?;)O[_ .@J&BBR"[)OMDW]_P#04?;)O[_Z"H:Q/&?C70_A
M[X<O->\1:G;Z3I-HNZ6YN'VCV4#JS$\!1DDD  FI?+%78U=NR.A^V3?W_P!!
M1]LF_O\ Z"N8^'GCG3OB9X&T+Q7I"3IIFLVD=[;+=($E$;C*[E!(!P>F37)Z
MQ^T!X>TFPO[I+/4]3,6M'P]96^GP++-JE\JYDCMEW $(1(K,Y508I,G"YJI+
ME?*UK_P4OS:7S$G=76W_  +_ ))OT1ZG]LF_O_H*/MDW]_\ 05XO>?M.Z':^
M'K._3PYXDFU2>\NK&3P^;6&*_MY+:(S7!<22K'M6,!LK(P;<NW<379^%_BCH
M_C/7(=.T83WL;Z3;ZP]ZJ 0Q13\P(V3D.ZAF"XX5<G&5R))[?U=77WI.W<;N
MM_ZL[/[FSM?MDW]_]!1]LF_O_H*YCP9XXL?&T6J_98YK6ZTK4)M-O;2Y $L,
MT9!YP2,,C)(ISRKJ>.@Z&BRLGW%=W:)OMDW]_P#04?;)O[_Z"H:*+(+LF^V3
M?W_T%'VR;^_^@J&BBR"[)OMDW]_]!1]LF_O_ *"H:*+(+LF^V3?W_P!!1]LF
M_O\ Z"H:*+(+LF^V3?W_ -!1]LF_O_H*AHHL@NR;[9-_?_05<TN=Y;A@S9&W
M/3W%9M7M'_X^6_W#_,5,DK%Q>J-BBBBN<Z@K N?^/F7_ 'S_ #K?K N?^/F7
M_?/\Z (Z*** "BBB@ HHKB_C#\8/#'P)\ ZAXQ\7WKV.BV6U7>*%I9'=CM1%
M51RS$@#.!ZD#FIE)15V-)R=D=I17AGQ'_:<F\*?L[:'\5O#7@?5O&4>L16=Q
M;Z%:DI="*X7<&;8DG*@C. 1[U-\3?VLO"?P5^"WAKX@>.;:_T9]=M;>2WT.*
M%I;K[1+")3;\A0&3)!9]H^4]#Q5M--I[IV?J]D$5S)./577H>P76B:=?7D%W
M<V%K<7<'^JGEA5I(_P#=8C(_"KM16MP+JUAG4%5D0. >HR,U+0U;0E-22DNH
M55T_2K+24D2QL[>S21R[K;Q+&&8]2<#D^]6J*0PHHHH *9-#'<PO%+&LL3@J
MR. 58'J"#UKY\_9F_:[@_:/\>?$GPU%X7DT!O!EZ+-KE[X7 N\RS1[@HC79_
MJ<XR?O>U?0U&\5+HU=>C!Z2<>J=GZE33-(L=%M_L^GV5O809W>5;1+&N?7"@
M"K=%<I\4OBAX=^#7@35?&'BN].GZ%IJ*\\ZQ-*V68*JJJ@DEF90/KS@<TI24
M5=C2<G9'3W-M#>0207$23PR#:\<BAE8>A!ZU#IVEV6CVHMK"T@L;<$D0VT2Q
MH#]  *YWX4?$C3OB_P##G0/&>D07%MIFM6PN[>*[55E5"2!N"D@'CH":ZRKE
M%Q;B]R4U))K8****D91U#0M-U:6&2^T^UO9(3F)[B!9#&?521Q^%7J** *-K
MH6FV%]->VVG6EO>3_P"MN(H%623_ 'F R?QJ]110 445\@_M2_\ !0*3]F_X
MP:?\/[/X;7WC;4;VPBO86L=0\J1R[2+Y:Q"%RQ'ED\'OTXJ7))I/KM^92BVF
M^Q]?45\%^&?^"L.B6WBS3](^)'PO\1_#:VO7")J%ZQF2/)QO=&BC;8,\E0Q'
MI7W?:7<%_:PW-M,EQ;3(LD4L;!E=2,A@1U!!SFM.5VYNAG=7Y>I+45U:07UO
M);W,,=Q!(-KQ2J&5AZ$'@U+14E$-G96^G6T=M:016MO&,)#"@1%'H .!27MA
M;:E:O;7EO%=6\@P\,Z!T;Z@\&IZ*-PV(+*PMM,MDMK.WBM+=.$A@0(B_0#@5
M!J&A:;JTL,E]I]K>R0G,3W$"R&,^JDCC\*O44 %%%<#\;_CAX3_9Z\ W7C#Q
ME=S6NDPR+"BV\+2RS2MG;&BC^(X/)( QR14RDHJ[&DY.R.^IDT,=S"\4L:RQ
M."K(X!5@>H(/6LGP9XGM_&W@_0_$5I%)!:ZM8P7\44V-Z)+&KJ&P2,@,,X-;
M-7*+BW&6Z)C)22E$J:9I%CHMO]GT^RM["#.[RK:)8USZX4 5;HHI#"BBOC7X
M_P#_  4L\-_!WXEZEX'\/>"]7^(.K:.A?5Y--D$<-G@ N,A'+% 1N. H/&<Y
MQ+DDTGNRE%M-H^RJ*\7^%/[6G@'XL? J^^*ME>2Z=X?TN*9]4AO%'GV+Q+N>
M-U4G)P05QG<&&.3BOG"+_@K%IWE1>(;CX.>,;?X;2WGV1/%Q ,1;./N[/++=
M?E$I/!JVK3]F]]/QVUVUZ=R$[QYUM_EO]W4^]Z*SO#?B'3_%WA_3=<TFY6]T
MO4K:.[M;A/NR1.H9&'U!%:-#3B[/<$U)76P4444AA1110 45\\_!;]KN#XQ?
MM!?$?X71^%Y-*E\'-*K:HU\)1=[)A%Q'Y:[,YS]XU]#4+6,9K:2NO0'I*4'N
MG9^H4444 %%%% %G3O\ C\C_ !_D:VJQ=._X_(_Q_D:VJ "BBB@ HHHH JZE
M_P >4GX?S%8==#<H)(&5AD''\ZH?8X?[GZFM8R21A45V?FQXBO\ Q/\ "KPM
M^TG\+[GX;^,]9UKQWKNIW_A^^T;1WNK&ZBO8U5"TZ_*FS&6STKC?%7@[0?"O
MQFU#PWX]^'6J>/KG3_A/I6F16FD:8VI&TOQ&T:ML3)0[@RK,!\I/4;J_5G['
M#_<_4USEI\+_  O8>/=0\:P:4D?B>_LH].N=0$LA:2WC8LB;2VT8))R!GWK/
ME7+&+[)/T4)15O/WM7\_(KG:;DN[?S<HR?R]W;Y'YFS>&X/!WQ,^!^E?&/P1
MJOCR33OAA*FH:/;:>VIS0/\ :&$9D@7)?8"J9P=K8;C;D<[<?!?XA^'_  C\
M)Y_''A'4M4\)6^@:K:VVD7OA>X\1MI4TUT[P1RVD<\+1RF QJDC,=A & 1E?
MU4G^%_A>Z\?VOC>72D?Q3:V#Z9#J/FR;DMF<.T>W=MP6 .2,^]=']CA_N?J:
MTDU.[ENW)^6KD_F[2T?3TWB-XV2V2CZZ12^2NM5U]3\Z/AI^S%>>)OB[\%++
MXB>&-9\1:%H?P^D66ZUS3WACBNA>%K>&?9)(BRI&RXC,C'Y <<<>O?M>?!T?
M&'XR? /3M1\-7GB'PG!JFH-K/DV\CVT,1ME*"=T&$5F4#YB >G-?7/V.'^Y^
MIH^QP_W/U-7*:DU=;2<O5N3E^MO1$)-7L]U;T]WET_/U/RD\9_ CQ79_'+Q7
MHP\-:I::Q<^++&Z\+Z]I?@Z6_DM=-B\L0"'4S=Q16T,2+L>)E/'KQMU-4^'/
MB#PU^UI)J.@^ =8UZ_N?' U&2#Q#X496@B=QOO+?7+=QF!5)*PRG:, %"<BO
MU'^QP_W/U-'V.'^Y^IJ:;]FX/?E_'X?_ )%7^]6TM4[S4U_-^'Q?_).R^6NM
M_P AYO"5OXS/Q8TGP[\.];U3XK77Q5N'T'Q?9::[P6"1WB/)NO!Q J+O+*2,
M^8IYQQWWC?X$>)O&GBC7],U;P9KM[HFI_&^VO;HC3IQ'/IIMBDMQN"_Z@Y*F
M0';SC-?HOX+^%_ACX>)K">'M*335U?49M6O@DLC^==2X\R0[F."<#@8'H*Z/
M['#_ '/U-32Y:<(1>ME&_;3V;_\ <?SO<=1N<I-:7<O77G7X<WRL?D_^U]\&
M]7N?&GCCPSX1^%%U86^E:7IL/AR?1/"4VJ2ZA#$ S^7>L[+9B([ALA4.YX.2
M:[+Q?\(?$#_$[]HN'PSX+U2Q\7>*O"MA<>'M9BTJ2))";<'4(A<[0L<LK94J
M2&9NO(K]+OL</]S]31]CA_N?J:5ER.+>Z?XK7]+]-^CTKF?,I);6_!Q:_P#2
M;?,_+E/AK/XA'B"Y^%7PI\2^!-%M?ACJ.C^(;.[T26Q;5=1:'$$"1$9N9E?)
M,B@DYQDY&>A^(?PCL_V5OV;?A)\8O"7AD:-XO\(BUN]>MIU:*XO?MELEO<I,
M'^;?YAC^4],'@5^DOV.'^Y^IKA?B3\ _ ?Q?OM"N_&&@+KDFB3_:;&.:ZG2%
M),J<O$CA)>44@2*P&.!R:J<N9Z:7:N^R4I2=O7F:MV2(BDK7U23T[WC&.O\
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MA1KFI_!_P)JGB'3-2O\ XNSV>GZ;+=^?,T<$R.TD5U?)&WE2&UW/*&D!!D&
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M-/-LJ-"@+"YV2LUPJQR<['7(&%QB:)X8^)7PT\7:'::?#JMM+J3:5>RVNE6
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MGV.'^Y^IJQ9P)%*2JX.,=:F4DT5%:HN4445B=(5@7/\ Q\R_[Y_G6_6!<_\
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M%+7Q/JD>DWLD*!KB2/B8(P#!?W2X.?OGU-?4O[+OP_\ B3XV_93\1?![XI^
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M@(.2J\A<MSZI_P $];VPC^(?B&U\%_'QOB)X#DM?,A\+>(%G35[-_E_>A90
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M]P,07<+P2%.&"LI4X/K@US/PD^'&C_!?P!H?A#0%EDTW2+86EO/>$/<-&&+
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M^"2?PT75!"?&/C-O"'VG[7_PC!OT^S%_3=LSCMG&['\6>:]S^.O['?@+X^^
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M!<_\?,O^^?YT 1T444 %%%% !2,JN,, P]"*6B@  P,#I1110 4444 %%%%
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MSM8XR1SBN\MOBE^TI<?&;P?\-F\0^"(M3US0)/$UW>KI4QBL[<3J!!&-^78
M[,G^]GJ*T2<I**Z_\&_W<LON]+YO2+E_7V?_ )*/WGV[17YH_!;XL?$OX/Z
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M_P")3IE_9ZO8Q]H!?0M)-$OH/.BEDQV\TU['26R?I_PWR&U9M!1113$%%%%
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MQ.P2U6&<P\,2 N5CVMZXYYJ8:??:E#&FEQ:_'I,QT\7/VIKA96E\\>:R%CN
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M9!/=,Y8#[0_EJYS@N(MF0><\GGFO3:?1/U_-H.K7I^284444@"BBB@ HHHH
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MGNKV\4L\.]Y"S29F<S.[N6+1H.=Q(]6^WQ^C?E5"BGRJUOG^2_))?(5[N_\
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MH%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV[ &.#4P<H4HQZJVGHD]?5KENNDG)J]BI\DZC;ZW_%Z?<FW;NDD[7/'O&?\
MP4#ETF2[BTK1]!BAO?%-SX;T/6-?UC[%ITD=K$CW5W<2[3M0.X10N2Q[YX,L
M_P"WM=ZI\%M$\6Z3IWA+3M3N-8N]$U"36_$.W3X9K< EK=HD::[60,A7RHS@
M,">.3Z4G[#7A'3/AAX)\(:#JWB#P_=>#;J6]T;Q)8W4(U*&:4L96=C'Y;A]Y
M# I@@#IBFZK^Q'I&HV/@IHO&_C6T\0^%I[N>#Q(-4CFO[C[4 +@2-)&R@,
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M^L"Y_P"/F7_?/\Z (Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML_N;2OUN)Z:^=OS:^])OR/4:***0!1110 4444 %%%% !1110 4444 %%%%
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MG'XY(,\.PWR1^6(_]3GR2.2N=V?XZ]IHJHP4+*/2UODTU]SBON(E-RO?K?\
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MUZ&U@-PDBA[%+9_,A%O\F%VRYE^8-ECSE0%'844^16M_7KZ^>X<SO?\ KO\
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M_"WY)+Y'!Z3\&M \'>-=0\9V$^K:E>*;Z[L]%>:(6T%Q=%&N6ARBL&E:-?\
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MA_O_ *&LVBCD0<S-+[9#_?\ T-'VR'^_^AK-HHY$',S2^V0_W_T-'VR'^_\
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M>VL474YXENGFB/F&Z4PF3)!)*DD!LY&3S7KL-U#<$B*5)" "=C XSTI!>0-
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MK?"*Y!7$*QX+97#-U)QU!H?AC4Q9?V?8P:AITD,&HL&D65$%R+J-X3N;A@5
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M?*QOROWON\<NFW[KEY-_=3O_ .Y/N\U<DHW:6VWRO/7_ -(_I:0_$G]NK2?
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M!DD[7P2\::CXFTWQ'H^MS_:]=\+ZU/HUW=[%0W*J$E@F*J  SPRQ%@ !NW8
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M!KMI86T<&DM=0BU$;V]W-!,Z W?F[0H\N,D+@A?N#IDXY]GHJ4K?UY6*;O\
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M **** +.G?\ 'Y'^/\C6U6+IW_'Y'^/\C6U0 4444 %%%% $<W^J:JM6IO\
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M* "BO(/!WQHUSQ1\?M>\#W7A6;0=#T_1AJ%I>Z@P%S?-]I:%I%16.R'Y3MW
M,WWL $9Z+QC\0+O3/B1X,\&:3'!)?ZO]HU"]EG4L+?3[<*)& !'SM)+"BYX&
MYC@[<%+51DOM;?)M/[K-OR0VK.47T_R3_5?,[VBOF#X*_M1:O\7/&4L,6O>
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ME3@<C<.>>M=M2Z)]TG]ZN'5KLW^#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** +.G?\?D?X_R-;58NG?\ 'Y'^/\C6U0 4444 %%%%
M %74O^/*3\/YBL.MS4O^/*3\/YBL.MX;'/4W/"? _P"U[X/UNS\6W?BJZL/
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M1*)(PX,D8P8&R0H1LEL@CK75_#CXK>$/B]H;ZSX,\16'B338Y3!)<6$P<1R
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MV.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *O:/_P ?+?[A_F*HU>T?_CY;_</\Q4RV*C\2-BBB
MBN8ZPK N?^/F7_?/\ZWZP+G_ (^9?]\_SH CHHHH **** (H[6**XEG5 )I0
MH=^Y S@?09/YFI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH LZ=_P ?D?X_R-;58NG?\?D?
MX_R-;5 !1110 4444 1W"AH6! (]#5+R8_\ GFOY5=F_U355/ ]:I.R,I[C/
M)C_YYK^5'DQ_\\U_*O%])_:X\#:I\'/&?Q(DCU33]'\(W=U8ZM8WD$:7L-Q
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M^BBX#/)C_P">:_E1Y,?_ #S7\J?11<!GDQ_\\U_*CR8_^>:_E3Z*+@,\F/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS'^%']D0_P!Z3\Q_A111=A9!_9$/]Z3\Q_A1_9$/]Z3\Q_A111=A9!_9$/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>rnac-20241231_g7.jpg
<TEXT>
begin 644 rnac-20241231_g7.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (U!-L# 2(  A$! Q$!_\0
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MA:\(N4H-);Z;;?YK[UW-RBBBN@Y0HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/EM:_GNV^B7?U[L****[SS HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQU%X;GM-.CT?5M,N-*6[%Y:+,9'1'+CRRX.W."5QD'M7&1_\$ZM'O/@S\1_
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M^CVD.I,S.;A8P&#-]YAV!/<CDTHX/$JUY_B]-M?.UGH[)WZ;#GF&#DY<M/\
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M<YXJ^/#FEBPN['[! UG=LSW$#("DK-]XL#US7GQR^LK_ +QW:WN[WUMVVO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-J$EVMQ/)$U_.8)9"#QYD8#KC (/'% 'TK1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %><?$CX&Z1\1/$&G^(H]7UOPKXGL;=K.+6O#UX+>X:W9MQAD
M#*R2)N&X!E.#R,9->CUPT_Q*O9-;UC3M+\&ZSK*Z7<K:3W5M-9QQF0Q1RX42
MSHQPLJ\XZYH Y,_LJ^$%\*Q:7%?:[!J\>JG75\4IJ+'5OMYC\MK@SD$$F/\
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MFC<DDM+MY;G ..@%=]7$?\)[XA_Z)QX@_P# O3O_ )*H_P"$]\0_]$X\0?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1EN?D3V-:BBBNHXPHHHH 0*!G  SR?>EHHH **** "BBB@ I" 001D'M2T4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKQ8X+.U\W/F73DY3C^%0"Q;T!KQ;QS^RI/X@":A;:F8M7<NU_/<'>ER^"QE
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M7QF5\-_V?B_K,JG,E>RM;?37Y'Z%G7%_]JX'ZI"ERN5N9WOL[Z?-'#?&GY/
MDTPZV]W:7 /ILN8V_D*Z"L3XT0F;X8>(]OWDL991]54M_2M>VF%Q;12K]UT#
M#Z$9KZ5_[U/_  Q_.1\@O]RI_P"*7Y0)*EMO^/B/ZU%4MM_Q\1_6NA;G&]C6
MHHHKJ.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*V.<;O/]UOTHWG^ZWZ4ZB@!N\_W6_2C>?[K?I3J* &[S_=;]*-Y_NM^E.HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4#ZDT)/'*S*DB.R@$A6!(!Z4 /HJ/[1%YWD^8GG8W>7N&['KBO*/CW^T%:?
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M/_#M[V&/4IL<&ZDF*L4'_//E2.,<DU]-4[^XD^[^[3_@NWG\A6]]M=E]^O\
MP%?R\C\\/V0_V4/ _P <;+XHZ[\0[2?Q39Q^-=7LM-TF>\ECMK']Z#+*B1LO
M[URP!8\@(N,5L_"'6-4\-_#;]I#X2WGQ-N/"&B>!-1%II/C34LW,VF6$X+"/
M)="S*%*+A@07&WH!7,_LB^'/CBEO\6-5^%7B+PB-.N_'.JVUUI'C"WN3';2J
MZD7$#P<EB& *,-OR ]Z]=O\ ]@>36?V;_&_@G4_&#7_CWQAJ:Z_JOB9[?$4U
M\L@=$\H'_4C!7'^T3CHHYXI^PC9:.G%6\WR.]NMES/SO;J[=#:]L[O55)._D
MG+3[[+Y7Z'R7\6]+_9WM/@?J>I_"SPA\0-9\:Z3:I>6_Q'L;#4(HUN$*EKJ>
M>9U558YZ+QN&T=*]H^/NB2?'/Q]^QMI^O7UT$\1Z7=2:K+:S-#)<1O96\D\>
M]""!(-RG!'#FO0_B+\ OVD_C=\(]3^'_ (K\6_#OPYI,EAY ;PQ:WC2Z@Z*/
M*CF:4!8(BRJ7\M&. 0!@XKJ%_9E\8W'BS]FC6+F]T1%^&FG3V>LI'<3,9W>T
MC@4VV8AN&4)._9@'O73&WM%S;<R?E:TT]-DGHFOO.9WY--'RR7S]VVN[>]G_
M ,$\0_:^_9-^$OP]U+X$:;H'@NSL++5/'5KIMY%YTTGG6TI9I(B7<G:3S@'Z
M5Z+:>'M,\$_\%&_"VC:-9I8:1IGPM:WM;2+.V*)+M@J#.3@ 8KU#]KKX$>*/
MC;X>\'7'@G5=+TKQ5X3\06^O6!UM9#:3/&&&R0Q@L!D@\ ]".,Y&;X7^!OQ
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MXA?#/Q);Z!\1/"=JVG0S:\LEU::G9L,&"Z8$R'DD[QELL3UP1=TFG+5<U_\
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M=4MS;7VGSC_EG-$<[3P>02#@\Y!Q,?>5X_UY^GF-^Z[/^O\ @^1Z316/XO\
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M]-AC\H"Q9MY\MXUR2JC: "<UU=U_P4+\,OI5SXAT?X9_$OQ'X'MB_F>+=-T
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M!--704444#"HY+>*62.1XT>2(DHS*"4)&"0>W!(J2B@ HHHH **** -;2?\
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MX?TFTTVPMTM[.UC6**-3PJ@<=J\D^,'[-=C\2]6.LV5Z-(U610LS%/,CFP,
MD<$-CC/MTKVJBO3Q."P^+I>PK0O'MV]+;'CX/,<5@*_UG#S:GU>][[WOO\SP
MCX>?LKZ?X/+WEYK%U<:R/^/>\LG-O]F/JHYR3T^;(QQBN[_M?Q9X-&-5L_\
MA*-,7_E_TY-MU&/62'H_U3G_ &:[RBL*.74,+!0PON6[=?6^_P"?9HZ<1FV)
MQM1U,:_:7[Z6]&K6^6G=,R/#_BG3?%-I]ITN\ANXP<.$8AXS_=92,J?8@&M7
M+_W5_/\ ^M7-^(/A]I>NW8U"/S=*UA1A-3T]_*G'LQZ./9@165_;OBCP;\NM
MV7_"1:8O_,3TJ+$Z#UEM^_UC)_W16_MITOX\=.ZV^:W7XKS.;ZO3KZX>6O\
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MUC4=;5P<$VLQBL/R:7\A7Z Z3\#O ^A_%?5_B78Z#';^-]6M5LKW51/*3+$
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M_#_["/P&\+ZXFK6'PXT\722&6..YN+BYMXW/\202R-$I]"%&.V*R<'*GR/\
MDC'RO%-/3K?3?;56-5/EGSK^:3^3:>_2VNV^CN?&4+[_ -@W]E#G./']@/\
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M5G?3[:2*2'=T1W#;@/KM!Q_C7TI7MY376+PL<3;6=V_6]ON5M/\ ,^<SS#/
M8V6#O>-.R7HU>[\W>[\_*P4445[!\^%%%% !1110 4V3_5M]#3J;)_JV^AH&
MMS&)P,U\%_%/XD:MX\\4WLUS=2K90S,MK:!B$B4$@<?WL=3UYK[TKYE^)O[+
M>IZAXBNM2\,SVS6MW(96M+AS&T3$Y.TX(*Y^F*^&XCPV+Q-""PR;2>J77MZV
M/TKA#&8'!XJ<L8TFU[K>R[^ESP+3].U?Q=?BWM(KG5;Q8B5C7,C[%'8=<#T%
M=_\ #/X!^*_&6NVZS:=<Z-I\;AY;V]@*!0.<*K8+$^@_.O=?@7\"'^&MQ/JV
MJW$5SJ\T?E(D&3'"A()P2!DG YQ7O-M_J(_I7EY9PPJL8UL8VGOR^72[/;SK
MC1T9SP^7I.-K*7GULNOE^J. UGQ+XS\#Z+>WNHZ5IVO65G \S7.G3&WD554G
M+1/D'ISM?\*^'_%'CK7?&.LS:GJFI3SW+L64>80L8[*@Z*![5^CM[9PZC9SV
MEP@EMYXVBD0]&5A@C\C7R+XJ_8]\1VVLRC0+RSO-,=R8VN93')&OHPP0<>HZ
M^E=W$> QM:--8=RG!7NNSZ>;^=['F<(YIEN'G5>+4:<W:TMDUU79?*U_D=]^
MR7\2=5\5Z9JNB:M<27KZ<(Y+>XE8L_EMD%&)ZX(&,^OM7T'7C7[-'@.S\#Z#
MK$$C%O$(NS;ZDC#'E%,^6J^J%6WAN^[VP/9:^ER:-:& I1KN\K?KHGYI:'QW
M$,\/4S.M+"JT+KR6RNUY-ZKON%%%%>T?.A1110 4444 %%%% !16)XQ\9:5X
M$T*?5]9N1;6<6!G&6=CT51W)]*\FT+]KWPAJVKI9W-I?Z9!(VU;NX52@]"P4
MDJ/SKSZ^887"S5*M449/H_ZT^9ZN%RK'8VG*MAZ3E%;M+^K_ "/=**;'(LL:
MNC!T8 JRG((]13J] \H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"MJ/_'G)^'\Q6+6UJ/_ !YR?A_,5BT %%%% !1110 4
M45\9^&/VB_CG\?=;\:W?PHA^'.G:+X:U2XTR/1_$TMU)JMXT)P7=8F"PJY^[
MD=<Y)QFIOK;RO\E;_-#MI?SM\W?_ "9]F45\G?$O]J#XC^ /@O\ #?XE:QX.
MC\*6\NMP:?XST34XFDFL[:20QF>%PPVC(!&X'_6*#TY[O]I;XWZ[\/;SX;>&
MO!"6%WXL\;:[%86WVV-IHHK-1ON9]JLI.U"O?'-:6UM_>Y?GI^&J_'L3?2[[
M.7R5[_/3\NY[M17QIX>_:"^/?Q9^+/Q7\#> -)\&6L7@_6GM1KOB);D0K 1B
M*$1Q,6DE)5R7R%  XR153X4_M)?M#_M :7K^D>%/"G@CPWXF\(WTVEZ_JFNS
M74EC<7:,0(K2*,[QPN69V(&X8SFHB^9*2ZI2^6FOXK[]+W137*VGT=OGKI^'
M^=C[6HKXQO?VU_%EU^Q#XJ^*\&BZ;I?CCPWJ?]C7U@ZO-9_:4NHHI"@WAMI2
M7(!;@]SCF?Q5\>OVC_ 7P]3XMZUX0\&2^!(XX[Z]\*VTMS_;5I8M@^89B?*,
MBJ0S*%P!]#3NM7?16UZ:I-/T:?\ F*ST5M7?3KIHU]Y]::SXGTCP[+I\6J:I
M::=+J%PMI9QW,RQM<S-]V.,$Y9CZ#)K3KX _;(UOQEX\^+/[,WB+P3J^@+HF
MLZG%=>'6U"UE=X[J2)7,EQM8;HBC1X5<,"&YKUGQG\?_ (J:S\5K?X/?#/2O
M#.H^-](TFWO_ !5XDUSSUTJQ>15PD449\QF8G<H)X!&<X)#2=FFO>YFK>B3?
MW:W\K=0;6C3TY4[^K:7Z?.Y]345\U_"3]H3QYI_QM?X/_&+1=$L/%5UI[:IH
MNM^&GE.GZI A(D4)*2Z2+@D@GL>!P6\L^$O[1W[2OQ\\":_KO@S0_ 5C#H&H
M7EG+=ZZMUG4I(F++%!%&_P F$V!G=N6;C !J7))7Z6;OY)V?W/0:3>G6Z7S:
MNOO1]ST5\0^#/VHOV@OCO\&Y/B3\/_"7@K0-'TNVD-W;>(YKF>?4[B!29Q;"
M(J(X\@JN\DDCJ ,U]-_L]_%J/XZ_!?PGX\2R_LXZU9^=):;MPBD5F210>X#H
MV#Z8K1Q:O?I;\;V?SLR+[>=_PM=>JN>AT5X=^TM^T%JGPENO"/A3P=HEMXC^
M(GC&Z>UT>QOIC%:Q+&H:6XG8<^6@(.!@GGGBO/V^/WQA^!WC?PA8_&BQ\%ZI
MX4\4ZBFD0:[X-:YC;3KR3/EI/'.3N1B" RXQ@D^AB'ONRZNR\WV_3UTW*E[J
MN^U_EW_!_F?6-%?+7B[]JO5O@#\?=8\-?%MM.L/A]JFG2ZGX7\1VMN\>3"I:
M:TGRS!I<?=V@;OEXRX P!^TQ\5XOV2_B%\;=2TG2-%0J+WPGHUQ:R&1+$RJB
M2W1\SYV=6R NT8 /.X 1SKD=3HE=_?:WKH]/)O8KE?.J?5NR\^M_3S[Z;GV)
M17QG?_'C]I;2_A5%\8)O"'@E_!D=FFJ3^%-]T-9^P;0S3>=GREDVY?9M.U>.
M2*T?C5^UWXNL]9^!,?PHTO2=<@^)EM<O;Q:R'01MY41B9W1LJL9D9I  20A
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M0 4444 %%%% !7D'[5NFZ5KGP8O]*UKQ3'X-TZ_O["WDU>:T-S'&3=Q%4=>
M%=@$+,=HW<\5Z_5/5]'L/$&F7.FZI96^HZ?=(8I[6ZB62*5#U5E8$$>QH \/
M^!7B;7++XO>.? =YXIC\>:3I6GV.HPZY]EMX9[>6=I@UI,;=5C8@1K(ORA@K
M\YX-=K\.O[5_X3SXC9-G_9']M+MX?S_-^PV><_P[<?C74^#O ?AOX>:4=,\+
MZ!IOAW3V<R&UTNU2WC+GJQ5  3QUK"^',3+XI^(\AE=E;7D C.-JXL+3D<9Y
M]R>E '<?/ZK^5'S^J_E3Z* *.H[_ "EY7KZ5XI\1OV;M$\>:Q+JT-W+H]_,=
MTYA0/'*?[Q4XPWN#SZ9KV[4?]4OUK/KS<9A*&,C[.O'F1[&7X[$Y?/VN%FXR
M\OZLSR3X%^ -,\!OX@LD3?K=I=&"XNI?O20$!XF4?PJ5(R/[RGT%<#XW_:TO
M[#7YK;PU8VDME;R%/M5V&8S$'!*@$87TZD^U>P>+$3P_XQTS6&?R;'5(CI%\
M^<!2<M!(3VPV],_]-!7Q'XH\.7'A77+K3KAHY3"Y"3PL&25<\,I'!!_3I7PF
M;XFOE>'AA\)[B3:;7R<?O3U?5IGZ;D.#PV=8JIB\?[\I132??52^YK1=$T?;
M'P-^.<?Q;MKJVN+:.PUFT4/+"A)21"<;TSR.>"#TR.>:]5^?U7\J^2OV1M"?
M2_&5SJ&HE]/:ZL3'8PW",ANP7!=HR1A@NWG'/-?5M[J]AISHEW>V]J[_ '%F
ME5"WTR>:^MR3%U<3@8U<2_>U5_RO_7F?"<1X&A@\RG1P:]W1VWMWMW7Y;="Q
M\_JOY4?/ZK^5.#!@"""#R"*6OH#Y49\_JOY4?/ZK^5/JGK&K6F@Z7=:C?3""
MTMHS++(W90/\\4FU%-O8J,7)J,5=L_.#QCI]_I7BO5[74U==0CNI!-OZEMQ)
M;\>N?>O7/V0-/U"?XE75W;*RV4%C(MR^/E.XKM4^Y(S_ ,!->[V/PBTCXD)/
MXB\9Z0)M2U%EDAMV=HVM+<#$<1*D9;'+9[L1T KT'PSX2T?P;IHL-%T^'3K4
M'<4A7&X^K'J3[FOSO+^'*M+&1Q<I^XG=;\S[7[>9^LYKQ=1K9?/ QI_O&N5O
M3E7>W5^6GF:GS^J_E1\_JOY4^BOT4_)!GS^J_E1\_JOY4^B@!GS^J_E1\_JO
MY4^B@!GS^J_E1\_JOY4^B@!GS^J_E1\_JOY4^B@".2,RHR.$=&&"I&01Z5X%
MXC_8\\/ZMK$EWI^J7.DVTK;FM$C$BKGJ$).0/8YKZ!HKAQ>!PV.2CB(*5MCT
M\#F>,RV3EA*CC??S^3T.9\ _#_2_AOH":3H\6R$-ODEDYDE<]68^O'TKH_G]
M5_*GT5U4Z<*4%3IJR6R.&K5J5ZCJU97D]6WU&?/ZK^5'S^J_E3Z*T,AGS^J_
ME1\_JOY4^B@!GS^J_E1\_JOY4^B@!GS^J_E39-_EMRO0]JEILG^K;Z&@:W,3
MY_5:/G]5IU%<AV#?G]5K6MM_D1\KT]*RZUK;_41_2M8;F538=\_JOY4?/ZK^
M5/HK8YS@O&L4O@_6X/&5L/\ 151;768D!^:VS\L^.YB))/\ L,WH*[B-S+&K
MHZ.C ,K+R"#T(ITT,=S#)%*BR12*5=&&0P/!!%<1X%FD\*ZM<^#+MV:*W0W.
MD3.<F6TS@QY[M$2%_P!TH?6N'^!5_NS_  E_P?S\V>E_O-#^_!??'_./_I/E
M$[?Y_5?RH^?U7\J?17<>:,^?U7\J/G]5_*GT4 ,^?U7\J/G]5_*GT4 ,^?U7
M\J/G]5_*GU3U?5[/0=-N-0U"X2UL[="\DLAP%'^>W>DVHJ[>A48N348J[9\^
M_MGZ?J$_AGP]=QAFT^WN9%N-H.%=E7RR?R<9]_>ODL L0 "2> !7W_9^'I_B
M;<IJOB6S,6@KDZ?H5POWP1CS[A>[$'Y4/"@\_-TGT/X%^!?#NK+J5CX>MX[M
M&WHTC-($/JJL2 ?PK\]S+(:V:XIXJE)1C*V][Z*UTO/L['ZKE'%&'R3!+ UH
M.4XW^&UKMMV;ONNK2?;H87PU^(-EX9\#Z#I/B9[K0]0MK2.%WU2VDBC; P,2
MD;#QCO7I]E?PZE;K/:7,%U WW987#J?H0<5/)$DR%)$61",%6&0:Y.]^%/AN
MXN&N;2S?1KQN?M.DS-:/GU.P@-^(-?9TZ=?#PC"+4DE;6Z>GWW_ _/:U7"XJ
MI*I).#DV]+26OE[K2^;.L^?U7\J/G]5_*N,_X1[QCHG.F>)(-8A'2WUNV&_'
MIYT6T_B5-'_">:OI'&O>$[^!!UNM*87T/UPN)!_WQ6GUE1_BQ<?577WJZ^^Q
ME]3E/^#.,_1V?W2LW\KG9_/ZK^5'S^J_E6%H?C_P[XCE\G3]7MI;D=;9V\N9
M?K&V&'Y5T%=$*D*BYH-->1R5*52C+EJ1:?FK#/G]5_*CY_5?RI]4YM9L+>[6
MUEOK:*Z;[L+S*'/T4G-6VENR%%RT2N6?G]5_*CY_5?RI]%,D9\_JOY4?/ZK^
M5/HH 9\_JOY4?/ZK^5/HH 9\_JOY4?/ZK^5/HH 9\_JOY4?/ZK^5/HH 09QS
MUI:** "BBB@ HHHH K:C_P ><GX?S%8M;6H_\><GX?S%8M !1110 4444 !Z
M5^9OQ*U+]G'Q;XW\43_&3PGKOP-^+%GJ,RQW7ATWK2ZBH/[NY@EAA,4C/UW%
M 23U/)K],J*AQO*_]=-4RE*RM_7S/C_]GCX>^-/CA^Q'KWA'XH3:I<S:V+VV
MTBZ\0H1J'V(X-I-.#\V\.-PW<X"]L5YO^P?/XC^.OQ<MO%?C"TFA?X4^'8_!
ML"3_ ,6I%G6XF_WO*15/^\*^R?C7>?$FQ\'J_P +-/T'4O$K7"HT7B*:2.W6
M$JV7!3DL&V'!X(S[5B?LP?!&;X#_  LAT34K^/5_$M_=SZMKFIQ A;J^G;=(
MRY .T<*,@$A0<#.*VC*]253R2]79J_G[LI7?>QG)?NU#NV_173:^^,;+M<\E
M_8O'_%\?VH3W_P"$T'_HMJ3]@7_D+_M"_P#92=3_ /9:^M:*B/NV\H*'W<FO
M_DNWGOH5+WK^<G+[^;3_ ,F_ _+&^8I_P3@_:#8#)'Q"NR!Z_P"GV=>P_%O]
MLS0/BQ^S_J?PW\+Z%K]]\7?$>EC1G\'MI%PDUC+*@CD>5V01B-068,&.1@\#
M./HG]KWX.ZU\?/V??$_@;P]<V-IJ^I_9O)FU*1XX%\NXCD;<R([#Y4.,*><5
MZMH=C)IFB:?9RE6EM[>.)RAR"54 X]N*B$$Z4J4]O=7JE!1?I>VOX&DIM5(U
M(;WF_2[37K_P#X3_ &D]!7]G/PA^R9>^(#.^@> M4MH-:U*V@>=+?;;HI<A0
M3MRC8XR<<<\5=M_BMH_[/'[4?BKXK:]'?3_"+XJZ-IM[I_BZSL)IX+66*(!8
MYU52Z!U)897/(XX;;]VT5KSRYY5.K;?_ ($DFOP37;S,5&*@J?1)+_P%W3_%
MI]_(^*?!OB<?M7_MG>$_B+X0T[4#\-O FC7=NOB*]LY+6+4KNX!39 )%5F50
M02<#&#G&5SL_\$XAC]FKQ)_V,^L?^C*^O:*R<4X."V<7'_P*7,W]_0N[<N9[
MW3^Z+BE^)\9?L%_\H_6_ZXZW_P"C9Z[[_@G5_P F7_#+_KTN?_2N>OH^BMI2
MO*4N_+_Y+?\ .Y/;UD__  )I_A8^(/\ @H;\);;6?'/PL^(WB#PA>>._ 'AZ
M2YLO$ND6 D:>*VF"[;A5C96(1@2<$=%SP:\T\-Z%^RWXV^)G@O1_@=\'7^(&
MJ2:A%/J6I_:-4L+30X$(8S2R3<%U(!"8P<8SD@']*J*BE^[:MLG?L^]K]K_/
M7?:SJ?O-]VK?\&W>WRT5T?!?[1.@WG_!0#XMZE\*O#5\FG>!O *R7&K>(EA6
M03:RT;)!;1D@_*A)WXZX<=E-9'CWX[7OQ._8'^+_ (1\6VZ:7\3/!%I'I&OZ
M=@+O*3QK'<HHXV2!<\<9SC@KG]"Z\K_:D^%FK?&SX ^,O!&A3V=MJVLVBP6\
MNH.R0*PE1OG959@,*>BFL*D6J$X+6ZU\Y=_NTMVMU5S:#3K0F]+-6\H]5]^M
M^]^CL?,.N_MM^&_%/[-!\ Z5H>OW7Q=U;P\NBQ>#5T>X\Y9I;<1>;OV>68<-
MO#!N5QQUQ4G^&]W\(OBQ^Q#X.U%UDU#2+/58+HH=RB;[(C. >X#,0#[5]P>
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MHW[)G[0?[,^GIHOPH^#_ (@\Z]F$DD=NVEWL<UY(J%Y)I9I855G*J222.@
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MI9&O1117MGS@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX;\$:%J%DZV'A[4VMIY)9+?Y564AC'$H5R43 9F!/2LX7G&/=J3_ / 9<O\
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M(AXN^))64M,==3?'YA(4?8+3!VYP,\\XYQ[4 =YA_P"\OY?_ %Z,/_>7\O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$^C:7K.G:1>:M8VFK:CO^Q6$]RB3W6P9?RHR=S[1R=H.!UH TZ*** "BBB@
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MW\OQ;7Z?U<]QHKR+X<?M<?!WXN>+I/"_A#X@:1KFO(&(LH'96E"\L8BR@28
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MZ;6WM#;R^+X?=6N_NV[*BBBO>/F HHHH **** "BBB@ HHHH **** "BBB@
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M5DK+:V]M=4DG\DD%%%%=QYH4444 %%%% !1110 4444 %%%% !1110 4444
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M4MIV)G>021HY!E#*XQLR21[C.2=XW>EE)V_[B27W125UUO=];Z2T>FMW%?\
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MVCC!WN>@ QD9%3?LF_\ )L'PH_[%?3O_ $G2O&_BI\ OCUJ?[35Y\3_!>O>
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MG'O0_BOYM_-R4ONTM9W[WOJ32;C%76MHKY)-;]]=]-DK6T/@/X1^']#\9_\
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MTO7=*G%UIFIVL=Y;3+T>*10RG\B*F.J;CLG^+7ZHJ6C2EU7X)_YF'?\ P=\
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MLKF,XDAF0_=9<CN00002"#75FYB6,.94"$9#%A@CZT 24444 %%%% !1110
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M9Z1<Q66K^(+73GDTO3+B0*5CGG'W3ATW$ A-PW%:]?!R,CI0 M%%% !1110
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M"\(:[X:^*?[1-WJ^BZCI5KJGC)KJPGO;22%+R'8?WD3, )$_VER*5+2,8O\
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MW[:?QF\<>#+3X2M\*-7LYM2\0^*H]*V'9-:W8:-@$D8 D('P3M(. >:?X/\
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M@^'M5NOADK^*)H;/5%E%A<$"P*M C'_CVWES&K #<A*C !K[?P",8X]* ,#
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M%H_X5WJ__11/$_\ WQ8?_(M=O10!Q'_"N]7_ .BB>)_^^+#_ .1:/^%=ZO\
M]%$\3_\ ?%A_\BUV]% '$?\ "N]7_P"BB>)_^^+#_P"1:S]<^'/BE]/(TGXC
M>($O?-B.;F.Q*>7YB^9TM>NS?CWQ7H]% '$?\*[U?_HHGB?_ +XL/_D6C_A7
M>K_]%$\3_P#?%A_\BUV]% '$?\*[U?\ Z*)XG_[XL/\ Y%H_X5WJ_P#T43Q/
M_P!\6'_R+7;T4 <1_P *[U?_ **)XG_[XL/_ )%H_P"%=ZO_ -%$\3_]\6'_
M ,BUV]% '$?\*[U?_HHGB?\ [XL/_D6C_A7>K_\ 11/$_P#WQ8?_ "+7;T4
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M7>K_ /11/$__ 'Q8?_(M=O10!Q'_  KO5_\ HHGB?_OBP_\ D6C_ (5WJ_\
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MUT-?)7A/]G+XI_%WXP>&_B)\>M6\/I:^%I#<:#X.\,"5[6*Y.,3SR2<LX(!
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MV[?KVIPUFT8@!VR6C7[AZN,KV_\ U4<\>X>SG_*R]16>VO6:1&0R-M$<TO\
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M61R&CAE'[MONRL5C[=R#].^*.>/</9S?V6:5%4AK%J7"[VR6D3[AZI][M_\
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MBN>%4M@'T-?0?P9_:5^''[0 U%/ _B--5N].(^V64UO+:W, )P"T4JJV,_Q
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M56W8;&" 0 !CBB'OP<ULG;^OZUU"7NR4>ZO_ %_75=SLZ*** "BBB@ HHHH
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M;O\ 8/Y4;O\ 8-/HH 9N_P!@_E1N_P!@T^B@!F[_ &#^5&[_ &#3Z* &;O\
M8/Y4;O\ 8-/HH 9N_P!@T;O]@_E3Z* &;O\ 8:C=_L'\J?10 S=_L&C=_L'\
MJ?10 S=_L&C=_L'\J?10 S=_L-1N_P!@T^B@!F[_ &#^5&[_ &#3Z* &;O\
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MKC3/ $-Q:/*@;R93<;"ZYZ-M9AGT8U;%I#IO_!47?:Q) U_\.3)=&,8\YUO
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M YH@T6_^)<R7FNP3:=X:4A[?19"1)=]Q)<^B]Q%_WUZ#OT@2-%1!M11@*I(
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH UM)_P"/9O\ ?/\
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MU<'\4I8H-1\!-.0(_P#A(HQ\PR,FUN0/UQ0!WE%%% %34?\ 5+]:\_\ '/\
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M !YR?A_,5BT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3^= #J*;N;^Z?SHW-_=/YT .HINYO[I_.C<W]T_G0 ZBF[F_NG\Z-S?W3^=
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M_!375PRI/$DJ'<CJ&4^H/2JVJ6:ZGIMW9RIF.XB>)AGLP(/\ZP_AGJ$M_P"
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M\C3B-V.!M2-MA"@'<Y SD= 322^-KJS\13R>8WV6V.I%H+BY"1N8Q 4RQ&$
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M>7D&GVLMS=3);V\2EY)96"JBCJ23T%4]?\0V'AC3)=0U*X6WMH\#)Y9F/15
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M _\ (-=K;?\ 'Q']:XL/I*<>TOS2?ZGI8O6%*?>/Y-Q_)&M1117JGB!1110
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MT 8M%;7]G6__ #S_ /'C1_9UO_SS_P#'C0!BT5M?V=;_ ///_P >-']G6_\
MSS_\>- &+16U_9UO_P \_P#QXT?V=;_\\_\ QXT 8M%;7]G6_P#SS_\ 'C1_
M9UO_ ,\__'C0!BT5M?V=;_\ //\ \>-']G6__//_ ,>- &+16U_9UO\ \\__
M !XT?V=;_P#//_QXT 8M%;7]G6__ #S_ /'C1_9UO_SS_P#'C0!BT5M?V=;_
M ///_P >-']G6_\ SS_\>- &+16U_9UO_P \_P#QXT?V=;_\\_\ QXT 8M%;
M7]G6_P#SS_\ 'C1_9UO_ ,\__'C0!BT5M?V=;_\ //\ \>-']G6__//_ ,>-
M &+16U_9UO\ \\__ !XT?V=;_P#//_QXT 8M%;7]G6__ #S_ /'C1_9UO_SS
M_P#'C0!BT5M?V=;_ ///_P >-']G6_\ SS_\>- &+16U_9UO_P \_P#QXT?V
M=;_\\_\ QXT 8M%;7]G6_P#SS_\ 'C1_9UO_ ,\__'C0!BT5M?V=;_\ //\
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MX"=E=A_PD48Q&A8\VMR.@KM+V_MM,MGN+RXBM;=/O2SN$1?J3Q7$_$RXQ?\
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MF-C'<ZI-G[%:'N,C_6N/[B_B17BWB;]C2:[OQ<:3XBC59?FF6[M\8<\L5V<
M9Z+CCUKZ7T[3K72+*&SLK>*TM85VQPPJ%51Z "K-?78C*Z./BOKGO/I:Z2]/
MUOOY;'P6$SK$99)_V>^1/>Z3<O6_X)6MY[GC7@?X4ZI\#;%YM!=?$D5P%;4;
M1T6*=RN<- W3@$_(QY[$&O2-%\;Z-KNDSZA!>I%!;9%TMS^Z>U(ZK*K8*$>]
M;M?-_P"V-I:VGA_2M2M;412W%P;:[NHLJ9$V[D1\?>&02,]".*QQ%LGPLJF'
M5X17P_Y/5^M[_(WPE^(,=&CBI6J3?QJWXK1/1635OGT]@T/XO>#/$FJC3=-\
M165U>L=JPARI<^BD@!OPS4GB'QXMGJ#:-HEJ=<\08!-K$VV*V!Z-/)T0>W+'
ML*_.N*5X)4DB=HY$(970X*D="#ZU^B_PQT:+1O NC(MFEE<S6L4UTH'S-,R
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M&T4>;B\77QU:6(Q$N:3W8F!Z"C ]!2T5TG()@>@HP/04M% "8'H*,#T%+10
MF!Z"O./C-\%K#XN:;;*]P=/U.TS]GNU3<,'JK+QD<#OQ^=>D45SXC#TL52=&
MM&\7T.O"XJM@JT<1AY<LH[,^=/AI^R3'X9\1VVK:_JL6I"TD$L-I;QE49P<J
M7)Z@'G 'XU]%T45SX+ 8?+X.GAXV3W.K,,SQ>:5%5Q<^9K1=$OD@HHHKT#R@
MHHHH **** "BBB@ HHHH **** "BBB@ JO??\>Y^HJQ5>^_X]S]14RV94=T9
ME<C\3OAMI_Q.\.G3+UVMY8W\VWN4&6B?&,X[@C@BNNHKAJTH5Z;I5%>+W1Z5
M"O4PU6-:C*THZIGS=X6_9#^RZY#-K>M17>GQ.&-O;1%6F /1B3\H]<9KZIBA
M2&-(T0(B *J@< #H*R$^^OUK:K'+\OPV C*.'C:^_7\SIS7-L9FDHRQ<^;EV
MV27R1X#\6_V68?''B*?6]%U*/2[JZ;?<V\\9:-W[NI'()[C!YKJ?@I\!K+X2
MI<W<MW_:>L7*>6]P$V)&F<[4&2>2!DGK@=*]5HJ:>48*EB7BX4_?^>_>VQ57
M/LQK8-8&=6]-:6TO9;*^]C&\7>%-/\;>'+[1=2C+V=VFQMIPRG.0P/J" 1]*
M^;?^&*[PZFP_X2: :?D[7^S$RX[ KNQ^.?PKZKHJL;E6$S"49XB%VO-KY:$Y
M?G>/RN$J>$J<JETLGKWU6YPGPMOH-)TN+PA<6::5JVCPJC6JL2D\?03Q$\LC
M'D]PQ(//7NZYWQAX0C\3P0303MIVLV3&6QU&,9>!^X(_B1NC*>"/?!'*W?QS
MT;PCITL7C%CH^N6S".:QC1I/.])8<#YHVP2">G0\BKC6C@H^SKM**V;T5ET?
M1-?CNNJ6<J$\QG[7#1<IR?O15V[OJNK3_!Z/HWZ97,^._$=KH^F"Q>T_M74-
M2#6UKI:'YKDD8;/]U #EF/ 'X5RNE_M$>%?$EA(=#DGU'5RPBM])\HI/,YZ8
MSQMXR6SA0,FNE\'^$9].N9]:UJ9+[Q'>*%FF4?N[>/J(80>B#UZL>3[/ZS#%
MKEPLE)/=K5)?Y]E\WYS]3G@9<^-@XM;1=TV_S2[OY+75?/EQ^Q=J,L\+Q>(;
M2&.0!IHS Y\HGJJ<_,!V)P:]>\'_  ]OO@OHZV_A\OK^F,?-O+*4(ER9, -)
M"W / '[MSVX8=#ZA17)A\EP>$DZF'BXR[W>GWZ'=B^(LPQ\%2Q4U*':R2?W6
M?SN9N@^(M/\ $MD;G3YQ*BL4DC92DD+CJCH<,C#N" :TJYW7O!T>HWHU33KE
MM'UU5"K?0*")5'1)DZ2I['D?PE3S69)\28/#,$R>,D30)X$W_:AN>TN5'&Z)
M\9SR/W; ,,\!AS7H^W=+3$:>?3_@?/Y-GD_5E7UPMV_Y?M?+^9>:U[I':T5Y
MYX1^/G@CQMJRZ9INKXOI#B**YA>+S3Z*6&"?;K[5Z'6E'$4<3'GHS4EW3N98
MC"U\)/V>(@X/LTU^84445T'*%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S_
M /&CPYI?Q"_:,^%GA7Q1I]MK/A<Z7K&J?V7?QB6VN+R+[+'&7C;*N42:8@$'
M&2>U<5\)S?Z/X(L='\/VMO>6>@_$_5-+T2UO+IH8$M(Q=[(A($D(5-SJH"G
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MQ2P>'J5E7G33FNMM3TX9ABZ5"6&IU6H/=7T_I]34R_\ =7\__K49?^ZOY_\
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MELYFFA"@G=AF5?FR<D8[BOMQ$6- J@*JC  & !61XI\':+XUT_[#KFG0ZC;
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M[J_G_P#6IU% #<O_ '5_/_ZU&7_NK^?_ -:G44 -R_\ =7\__K49?^ZOY_\
MUJ=10 W+_P!U?S_^M1E_[J_G_P#6IU% #<O_ '5_/_ZU&7_NK^?_ -:G44 -
MR_\ =7\__K49?^ZOY_\ UJ=10 W+_P!U?S_^M1E_[J_G_P#6IU% #<O_ '5_
M/_ZU&7_NK^?_ -:G44 -R_\ =7\__K49?^ZOY_\ UJ=10 W+_P!U?S_^M1E_
M[J_G_P#6IU% #<O_ '5_/_ZU&7_NK^?_ -:G44 -R_\ =7\__K49?^ZOY_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>rnac-20241231_g8.jpg
<TEXT>
begin 644 rnac-20241231_g8.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &B K8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXI\6?MB
M?%:]^)WQ"T_X?^%/#'B#2/ FHI:7WA:62YD\3:I"LJ1SW%I%'\OE@N!N*-MR
M#\V0*^UJ_-O]ISP?K?CCQ3XZM_$/P$\17?Q42_0>#/B#\/K*>.TDMUD3[-+>
MRB9D$RJ@5F8$JI 'E;%>O5R^%.<VJB3_ .']5\];K<X\3*48IQ?]?B?>%O\
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MZT74Z8SK*-DM4^O;Y7/M6BJ>C:1:>'](L=+L(O(L;*!+:WBW%MD:*%5<DDG
M &22:N5XK\CO"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD6:..1<E>59%P<C&,&O1J\J<'3DX2W1V1:DDUU"BBBH*"BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?E?\)!_9T/V_9LV;?M&WS,;?EQNZ<=* .EHHHH **** "BBB@ HHHH ****
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M4^*/PP\-_&3P)J_@_P 6:<FIZ'J<1BFA;AE/571NJNI 96'((!KY%M/VQ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWXZ\)^#/&]FSZ=KFD:IK=K:M'>0MLE>-7D&Z)R-ZLN1AL9)!KZ:K\KOVB_\
M@G/XOU?]M@^+_ /AK2]9\*WX'BJYLM:D>&PENXYD\^Q=U5L-,QW@$ 8D?& A
M( /U/1UE171@Z,,JRG((]13J^=/"7[:WAJ'7[?PK\5=$U+X+^,ICLBL_%&T:
M?>,.IM=07]Q*N<#DJ23@ U]$QR)-&LD;*Z, RLIR"#T(- #J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV5-.CC:]FU.YU&XN-2NKIF:.6X(08A8DY1$6.)L<>9'+]2 ?7-%%% !1110
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M#1--GD@YQ\ZJA*\@CGN*X>]_8)^&[_%[3KZW\(I!X471[D31P7KQI'>^="(
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MASX7^)_"_P"VQ\-;BZT[4-1TG1OA;!HMWXACM9&LVNXYI@RF;;M#MPVTD'#
MXYIW_!1?P5=^-/#?PO4>#M>\<:)8^+;>ZUK2_#ME-<W,EB$;SE B(*EERH.Y
M>6'S#K6L84'6HP2TMKYO7T^XERJ>SG)O6^GX&MX5^.WQC\%_M!>#?AM\5]*\
M$7R>+K6ZEL;OP1)=[[1H$+LTZW!)*$*0, =SDX(JC-^T!\<?B_J?C74/@IX6
M\'-X/\+WD^E1W?BV6Y:ZUNZA!,OV5(6547.U5\P@$L#O'SJGC_P?^&UA:_M*
M_#O5O@I\%_B'\*--LQ=_\)7>^,K6>VM+JQ81A8E\^:7>Y;HJD$':VU@I9.T^
M&GBSQM^Q;:^.O VH?"7QG\0;2?6+O6O#>L^$;#[9;7<4PRL5R5R;=E= "=KG
MYF(0A5,FTZ-).].*<K+1Z=7=VNUM;KMJ9QG-KWF[7W^2ZV]>GD:?[1O[9'Q,
M^%?P5^&_BS3/ -IH/B;Q++,M[X>\2QR3R6JI&7&T121,"0,[7 89VE0P(K'_
M &J?^"@'B+X5>$?AGJW@#2-&U27Q-H8\07ZZK#-,EI;R>2L6/+EC()DD=#NZ
M%0.N:V/C)X;^(OQ6A_9IO/&G@9H-:C\2K-XDT_14DN[6QA("L\CKN$2%>3EB
M%R1O;&:^3M5_9I^**_!7XI6VJ>%?$6K:IH%S8>$O#L,>ESR376GPWT\\DD*A
M3YD66C(=!M(YSWK?#4<+)0=1*Z;NK[W;7X;F=6I67,HM[?DK_B?>7[8/[1/B
MSX+0>%-%^'NDZ7KWC;7I+R>*PU-))$^R6ML\T[!(W1MW"A<MCAN#U'J7P+^)
M]O\ &CX0>$_&MNBQ?VQ8)/+%'G;%./EF09)X6177\*^9/%7PM^*_QO\ VP_%
M/B?P]XDU'X5Z9X,TV#1M&UG4/#2WL>H>:&:X,"3E48;MP,BYX"#H:/V8/V?[
MB#P?\4_@!\5-"O\ 7_!VFZS%?Z9JCV5QIUGJ4$I67$$D3!5V21JYC1SM,C#)
M ('GSH4%ATKKF5F[;V?W+2ZTOWO8Z8U*GM7IH[I=M/Q[]#Z/^#_QTT'XV3^,
M(M#M-1M6\+ZU/H5X=0BC023Q'#-'L=LH>Q;:?85J_%3XO^#O@EX6?Q%XWUZW
MT#2!*D*RS*\CRR,<!(XT#/(W4D(I(568X"DCYT_9@_8!\-_!;QMKOBK7=*TZ
M[UFWUVXN_"]SI^HWCFPL&4K'%(KE59PK,#N#]?O&MS]LOPIXB'B[X.?$72/"
M^H^-=)\$:Y)=ZKHFCPBXO7CE$2I/#"3^]:-DR .1D'*J&9<'1P\L2J=.3Y?D
MNFR>N[TN:*=54N:2U/3=(_:B^%FO?"K4/B19>,K*7P9I[M'=ZBR2HT$@('EM
M"R"4.2R[4V;FW*5!##-+P;^UQ\)/B#X.\3^*= \81:AHGAJ'[1JTPLKF.2UC
MVE@YB>,2,I"M@JIR00.0:^>OBWXE\=^-_@;X@\3>"O@)-X,FN?%EG<3Q7OA^
MUOM<U"V5F\R_.G20D?:%D,07>9&VL[AE5=]>7^#OAAXWFB_:;OG\*_$BXB\4
M^$(FT>;QK:-<:M?MY>WRW:)=GF@\+"/F1 B[>*ZH8*C*$I2=G?NGU6^F^O\
MP#&6(J*225].S\_Z_4^SO G[9'P:^)GC2R\)^&O'-IJ>OWL*S6UJMM<1B4&,
M2[1(\83>%/,>[>"&4@,K 2ZW^U_\'?#OQ*'@'4?'5A;>*OM"VC6ABF:*.9N!
M&\X0Q(V>"&<$'@X/%?/>I?"WQ!86?[$PT_PCJ<;>'TA;61#ILF=-:2UMC/\
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MLTZ0%D"F38!*V"%5P3@<JMA\.E4C%KF;DX[[+:W36SW?:P0J56X-WLK7^?\
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MJUUM=[+Y=_D:4:LY24)+I^B/H:BBBO&.X**** "BBB@ HHHH **** "BBB@
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M1DDC970XR#M89!(.02*\E^(G[87_  @5A\:+G_A$OMW_  KB\TBTV_VEY?\
M:/VYHANSY)\K9YO3Y]VWJN>/)/BY\>OB'\,?B-^T7<>'+]+Y-.U;PG865OJ]
MY(T&FQW5H!*UM$5= SNP)X Y+D.1M-T,)7<KQ?*]+._^'[OB3)J5J:5GJO\
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M6FE6,%A"2,92*-47]%%:]%%<S;;NS5*V@4444AA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!XI^U'\1?&WPUT#PIJ'A--+BL+KQ'
MI>GZM>7K,]PD-Q?VT'EP1;"K%Q+)N=F&P+PK%PR>.?$[]J3Q[X#D\<:]:7.F
M7UG9R>*+"RT&6V&+1M,LEF@N7=2)'WN&,BDA=LT87:1N;Z\U_P -Z5XJLH[/
M6-.MM3M8[B&Z2&ZC$B+-%(LD4@!_B5U5@>Q -9 ^%G@Q?$VI^(O^$4T7^WM4
M@:UOM2-A$;BZB945TD?;EE98XU(/41H#D*, 'E_PX^,FKZ.GQ#T_Q5+?^,SX
M8\10:1;:EX>T:2YGNHYM-M+S,D-LI V-<2)O  P$!^;EO1/AS\6=(^)UQKEO
MIMEJ^GW.C31P7=OK.FRV,JM)&)%(CE ;!5ASBM7PQX&T+P!X>DTCPEH^F^&K
M$%Y([>QM%B@65AR[(FW=T&>02!C(KRK]GI=43XD_%X:QK]CXEOO[0T[=J&G6
MGV6%A]ACP!'YDF".A.[GVH ]UHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH 9--';Q/+*ZQQ(I9G<X"@<DD]A7GJ_M'?"9F 'Q0\&$G@ >(+3G_P B4?'#
M3OB=JGA>U@^%FH>&-/UHW0^UOXJMYI[9[;8X956+G>6*=>,!J_('0O\ @FW\
M6+?]K*?PE':^% ^FV\7BC[7<QW,FA20--A(-NTR$&17C\MB"5C<Y(&2 ?N$#
MD9'(JCKNO:9X7T>\U;6=1M-)TJSC,US?7TZPP0(.K.[$*H'J3BN6^#UI\1++
MP>(_B??Z!J7B?[0Y,_AN&6*U\GC8-LOS;OO9[=*X_P#;/=8_V5?B@[L%1=$G
M)9C@ 8'- '>^!?BQX'^*'V[_ (0WQEX?\6_8=GVO^PM4@O?L^_=L\SRG;;NV
M/C.,[6QT-=77R?\ $_XCVGQ'^(EGXE^"&K:5XU\3>'/!_B$W.H>'IXK^&-I(
M8S8VDLD992\EU$CI"<DB&1L8!SY5X,\<ZQ?^!O%,T?Q3TZU\-BRT.>]G_P"$
MXUC5TANC=XGCN=6-G$VD&YC'E2(C$VQ*R>7&&^< _06BOB:+XAZ?=^%_AS'X
MK\9:QX3^%EU+XA6^\0_\)I<F*6\AFC%A%!K@\B>XMW1KQXBYW2^2H;?LP>5^
M)7QGN(_B7I*Z%XJU][[2]8\*6;SZ[XIO-,O)[*=[(SW T!+6.&2"1+EEEN+K
M:RRLZKM\N)* /O74-<TW2;K3[:^U"UL[G49C;64-Q,L;W4H1I#'&"<NP2-VV
MKD[48] :O5^?^A:;!J>H_!GQOXF\3>(+F]D^+VNZ?]HU3Q3?)9Q+&VL1V<"Q
M&;R4R\<,0 7+JQB.Y'*'(^&?Q#\<ZUH&N7&K?$>V\.ZU)X2U"7QA&?$NJZQ<
MZ3?B:+,L]FMHL>AF(FYC*Q2@",ET$GV?S% /T7JD=:T]=972#?VPU5K<W2V!
MF7SS"&"F01YW; Q"[L8R0.]?//[/GC3Q-J_A35O^$+L=.\56-OKQMY;O5?B%
M=ZOIRPFUMG+:;J;V,DUX@9W#K-C9,LR*^U5"U-3\(:;X;_:]\3W>F?:;2_U;
MX<WEW=7Q6XU&?S/MJ!2D>YI&5 !L@CP!]U%&: /<?!7Q=\"_$JZO+;PCXU\.
M^*KFR :ZAT358+QX 20"XC=BN2".<=#76U\N?LE>($TS6K3P'X3^(B?%;X>:
M+X2L=NL1VUHJZ7>(YB6T$EK&BC?$N_R9=\T7E@NY\Q:^HZ "BBB@ HHHH **
M** "BBB@ HHHH *^2?%?[0'Q-\->+?C?INH'0[%-#E\*V^@):!IULX=4U"6T
M>YG=U7S) @64IC8A4+E@&=OK:N>U+X=^%]9DUY]0\/:9?-K]M'9:M]IM4D%_
M!&'$<4P8'>JB23 .0-[>M 'R!XI_:A^(VAZ7XHCAUK2Y;CP38^(]2EN#:IOU
M_P#LW4HK:*!UQB/<DC+*8@#YI3;L'R'Z4^(GQ^T/X92:O_:NA>+;FWTJW:ZN
M;W3O#EW<VHC6/S&(G5/+("]3NP"""1@UKS?!/X?7.G:%83>"?#\MEH4OGZ7;
MOIL)2RD+AR\0*_*2ZJY(ZLH8\@&N0_:U36&^ _C0Z5XCT[P_$-#U'[2M_8_:
M6NT^RR?NHSYL>QCS\V&[<<<@'KMC>1ZA96]U"289XUE0D8.UAD?SJ>LGPG_R
M*NC?]>4/_H K6H **** "BBB@ HHHH **** "BBB@ HHHH *\Y^-O[0O@#]G
M30K#6?B'KK>'],OKC[)!<BPN;I6EVEMI$$;E>%)YP#@UZ-7R)^UK^P]XC_:4
MM?$^?BSK5OIMVJW6F^$[BVA?3K>ZCA"QX8C>H9P26'(\QNHXH ]2^"G[9/P?
M_:)\37?A_P"'OBX^(=7M+1KZ>W_LN\MMD(=$+[IH47[TB# .>>G6O::_-?\
M8<_X)X>/OAWX#LO%-[\2/$7PS\2:Q*LNH:!I]I#GR(I#Y4<S-DY898@8P' (
MR#7Z44 >5^+OCP_A[XAZEX-T?X?^*_&FJZ;I=MJUX^AMIR10PSR3I$/]*O(&
M9R;:7A%;H/6M>#X\?#X^"O#_ (LOO%VDZ%H>O;1I]QKEVFGF:0Y_=!9BI\P$
M,"F-P*D$<5Y_KR^,O ?[1OB[Q;IOPXUWQIHVL>&-)TZWGT6]TR()<6UQ?O(D
MBW5W"P&+F+#*K#D^E>1>(_V9_B!X;T?PN]O#K&N/)X=UC2]8T_PA<:.&2XU"
M]-Y+%NU:!D-HQD:)G0"7$41\M@2% /K:X^)7A&T\:VO@Z?Q5HD/BZZC,UOH$
MFHPK?S(%9BR6Y;S&&U';(7&%8]C447Q4\%3:CK^GQ^+]!DO_  ]"UQK-JNIP
M&738U&6>Y7=F%0 22X P*^??"_P=\8>#OB3X>L],\/:LFCQ7.ES:K>:AJ6EZ
MKHM^+738K8W<C2PQZA'?J(4C0P(L3&&*1MOF2J,V/X<_$71_@P_@BR^%ECJ7
MB+0;&]@A\5:G<Z;,MZ9[Z.60V,4IDWO*H:9A>"%!-##N$H^90#Z!C^/?PQE\
M+CQ*GQ&\)/X<-TUB-877+4V9N%C,K0^=YFSS!&I<KG(4$XP,UA^$/VI_A=XQ
M\':OXKB\9Z)IOAS2]8GT2;5-1U6UBMFGC<J"LHE*%9  \9)!9&!P,UX)X8^!
M/Q)OOB)IWB#7-&U>]AD^)&F^)I;OQ%=:4;Y;*'0KBS+SK9;(?,CF\E=L2L<,
MA#/AV$NK?!3XD66NV^KV>E>([1='\9^)K]1X;N-$>\N[74G,D-S;#4/,@^5<
MQ.LOE2 2OMW#A@#ZEU7XJ>"M"U;0]+U+Q?H.GZGKNPZ3976IP13:AN("_9T9
M@9<E@!L!R2/6IOB!\0M ^%_A>YU_Q)J":?IT)"#@O+/*QPD,,:Y:65SA5C0%
MF)  )KY8TSX#>,_!5AX0TOP_X3UF"X;2=)T_4))M5T?4])FBM[R6;[+J<4]O
M%(%MUFE\M]/C!/FD<>6A/TD_@G6;'P_XN@F\6:UXLEU2WF6TM-5CL8DLR4<"
M.$V]O"2IW*,RLY^5?F'S$@',2?M):?>:'\.;[0/"'B7Q3>>.]&.OZ9I6FBQB
MN8;-8K>1WG-Q=11*5^UP*0LC?,V!D<UZQ93O=6<$TMM+9R21J[6TY4R1$C)1
MBC,N1T.UB.."1S7R3J7P%9O@E\*='\5? Z/XD^(M$\ P^'<'5+,G1[TVUNL@
M*3RI$HWPC_2H&DF39A%(;)^FOAMH>L>&/AUX6T?Q#JAUS7]/TJUM-1U0LS&\
MN8X526;+<G>X9N>>>: .CHHHH **** "BBB@ HHHH **** "BBB@ HHK\Z_C
MS^U'\1?"7QJ\9^&+#XUZ;X3O;37;2PTGPA=>"FO+R:TF2 FY2;&QD422MRW(
MB.2I(% 'Z*45Y[^SWX\U/XH? _P/XMUF*&/4]9TF"]G-M&T<4A=0?,1&^95<
M8< \@,.37H5 $%_&DUC<));"\C:-E:V(4B4$<IAN.>G/'/->"_LR6,.G>//B
MY!!X*B^'\8U'3R-#A%L%CS8Q_/\ Z,S1_-UX.?6O>KYTCLKAI+@VB+&Q:X!
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M?$NJ3:C+J%V&D6[U2U=RXAMI2\(6 F)U(RUM &7=]44 %%%% !1110 4444
M%%%% !117G/[1?B?7?!/P*\=>(/#,SV^O:9I,]Y9S):?:MCHN[<8OX@ #D<\
M9.#C% 'HU%?G=\!OVM_'GB;X]^%= @^,&B_%WPQJEU#8W T[PC+IH$DMO=3/
MLE."'A6V1R""I20@[6 K]$: "O"_VR=.M[_X'>*6G^'\7CAH=&U%TGE6S/\
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M-O/I7S]^RQ#HT'C7XMIH.GZYI>F_VCI^VW\1+=K=AOL,>2PNB9<$],G&.G%
M'T11110 5Y)^U9>_$/2/@)XLU7X6WZ6/C/3+;[?:[[5+GSHXB'FB5'5@6:,/
MMX)+8 ZY'K=9^N7.HVFG/+I5C#J-X"-MO/<FW5AGD[]C8Q]* /S&_P""=?[:
M/QH_:*^/HT3QS\0-('AVRL9KB72YK&RMKC4)2-D<4.U5D)5F\PE<@"/!QN%?
MJ37Q5\*OV4/@]\2?#GB30F^%.BMHO_"2ZC+<ZI'JY>^L+O=G9:RQP1ND*XC"
M*KA=N"=QSGH_^%-_M ?L^_O/A;X]B^*OA2'[O@_XAR_Z=&@_@MM24 D] HE
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MW%=SVL5CY^H:I=ZA)%;1%C';PM<RR&&%2[$11[4&>G KNZ** "BBB@ HHHH
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MM.'09O@?XD_MK3?$6H2KI&HFS.@K?%(9?LSX>X^S$*(QQ_K<KU]Z /9O"?\
MR*NC?]>4/_H K6K)\)_\BKHW_7E#_P"@"M:@ HHHH R/$_A+1O&FG16&NZ9;
M:M9Q74%ZD%U&'59H9%EB< ]U=%(^GH37)?%[]GGX<?'G319>//"&F^(0JE(K
MF>+9=0 _\\YTQ(G_  %A7HE% 'R8/V;?C/\  K]]\%?BM)XAT&$Y3P1\20U[
M %_N07J8FB Y"KC'3<3BK.F_MV0> KZ#1_CSX!USX.:G(XACU6X0ZAH=R_\
MTSO800">N& V@C+=:^JJK:EIEGK-A/8ZA:07UE.ACFMKF,21R*>JLI!!'L:
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M/M7^ NM:_/+IVE:9XU\#^(-;\-R:&EQ::GHK6L6^$33F4B5VBD5B\:PF.12
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M*.Y)^8FN1_9DL8=.\>?%R"#P5%\/XQJ.GD:'"+8+'FQC^?\ T9FC^;KP<^M
M'T#1110 5Y_\>?$NM^%?A7KEWX<LKB^UR2,6UJMJI9XVD.WS<#GY 2PX/(%>
M@44 ?G=^S5XC^(OP.U^_F?P9K&J^'KU2VH6D=JZR)Y>3YT>1RRC=Q_$..P(^
M\? WCW0OB1X?@UKP]J$6HV$O&Y#AHV[HZGE6'<&N@KQOQQ\$[_2_$$_C3X9W
ML7AWQ4_S7FGR#_B7ZL!R5F0?=<\X<<Y)Z$[@ >C^-/ GASXC:#/HGBG0M/\
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MX9UNZMT?[3X;L;RSDAOD*A;N/_2&*R;5&3NP3R5))-?H+10!\B#Q=^T7^S
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M@>F1]:\._9Z75$^)/Q>&L:_8^);[^T-.W:AIUI]EA8?88\ 1^9)@CH3NY]J
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M>1CP9/\ @GQ\(%\11:D=&WVZ6?DG3VA@\E[G 7[6<1YW\;O+_P!3O^?R]W-
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MY/\ 5+OR!][*+\QQR ;5%8T'AZ:%[1CK>I2B"^GO2KO'B99!*! ^$YB3S1M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7FWQP^%^O?%+0]-LM!\8W7@^:UNC/++ UXJW"[
M&4*QM+NUERI(8#S2F1\R/QCTFB@#C/ 7PIT3X=L)M+66*[FMEBO6BD,4%Y,,
M%[E[9"(5F=MS-(J!FW').!CLZ** "O(?VK/^$G_X43XX_P"$=&D>3_8&I?;S
MJGF[O)^RR9\K9_'C/WN.E>O5X)^VG9Z)=_ [Q+_;'AK6/$+QZ1J#VKZ7'(Z6
M<HMGQ+-M=0%''+9Z'CK0![+X3_Y%71O^O*'_ - %:U9/A/\ Y%71O^O*'_T
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M4W@?_H3?#_\ X*X/_B* #_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\
M_@T@_P#BZX?X2? ;0?#FD:_#KG@S0A/<^(M5O;??8V\O^BRW<CP<A3@>6R_+
MVZ8&*[C_ (5-X'_Z$WP__P""N#_XB@ _X6SX'_Z'+P__ .#2#_XNC_A;/@?_
M *'+P_\ ^#2#_P"+H_X5-X'_ .A-\/\ _@K@_P#B*/\ A4W@?_H3?#__ (*X
M/_B* #_A;/@?_H<O#_\ X-(/_BZ/^%L^!_\ H<O#_P#X-(/_ (NC_A4W@?\
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M.7A__P &D'_Q='_"IO __0F^'_\ P5P?_$4?\*F\#_\ 0F^'_P#P5P?_ !%
M!_PMGP/_ -#EX?\ _!I!_P#%T?\ "V? _P#T.7A__P &D'_Q='_"IO __0F^
M'_\ P5P?_$4?\*F\#_\ 0F^'_P#P5P?_ !% !_PMGP/_ -#EX?\ _!I!_P#%
MT?\ "V? _P#T.7A__P &D'_Q=</\7_@-H/B3P[I%MH7@S0C=0>(M&O9MEC;Q
M'[+#J-O+<<E1D>4DF5_BZ8.<5W'_  J;P/\ ]";X?_\ !7!_\10 ?\+9\#_]
M#EX?_P#!I!_\71_PMGP/_P!#EX?_ /!I!_\ %T?\*F\#_P#0F^'_ /P5P?\
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MAR\/_P#@T@_^+H_X6SX'_P"AR\/_ /@T@_\ BZ/^%3>!_P#H3?#_ /X*X/\
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MX?\ _!I!_P#%T?\ "IO _P#T)OA__P %<'_Q%'_"IO __0F^'_\ P5P?_$4
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M.""/PJY5/2=&T_0+%++3+&VTZS0DK;VD*Q1J2<G"J !D\U<H **** "BBB@
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MI[J""SM1:6I55:18F1DF*1E"Y<Y)5W5ON2J5GHEAI^H7]];6<,%Y?LCW<\:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>rnac-20241231_g9.jpg
<TEXT>
begin 644 rnac-20241231_g9.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 8B#8H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z3^!7P*T3
MXQ>%M1U[7M1U9=0749("UM/& X$<;[FWHQ+$N><^E>C_ /#&O@K_ *"FO?\
M@1!_\9H_8U_Y)AJG_88E_P#1$%>\T >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P
M5_T%->_\"(/_ (S7O-% '@W_  QKX*_Z"FO?^!$'_P 9H_X8U\%?]!37O_ B
M#_XS7O-% '@W_#&O@K_H*:]_X$0?_&:/^&-?!7_04U[_ ,"(/_C->\T4 >#?
M\,:^"O\ H*:]_P"!$'_QFC_AC7P5_P!!37O_  (@_P#C->\T4 >#?\,:^"O^
M@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-% '@W_  QKX*_Z"FO?^!$'
M_P 9H_X8U\%?]!37O_ B#_XS7O-% '@W_#&O@K_H*:]_X$0?_&:/^&-?!7_0
M4U[_ ,"(/_C->\T4 >#?\,:^"O\ H*:]_P"!$'_QFC_AC7P5_P!!37O_  (@
M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
M'@W_  QKX*_Z"FO?^!$'_P 9H_X8U\%?]!37O_ B#_XS7O-% '@W_#&O@K_H
M*:]_X$0?_&:/^&-?!7_04U[_ ,"(/_C->\T4 >#?\,:^"O\ H*:]_P"!$'_Q
MFC_AC7P5_P!!37O_  (@_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P
M5_T%->_\"(/_ (S7O-% '@W_  QKX*_Z"FO?^!$'_P 9H_X8U\%?]!37O_ B
M#_XS7O-% '@W_#&O@K_H*:]_X$0?_&:/^&-?!7_04U[_ ,"(/_C->\T4 >#?
M\,:^"O\ H*:]_P"!$'_QFC_AC7P5_P!!37O_  (@_P#C->\T4 >#?\,:^"O^
M@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-% '@W_  QKX*_Z"FO?^!$'
M_P 9H_X8U\%?]!37O_ B#_XS7O-% '@W_#&O@K_H*:]_X$0?_&:/^&-?!7_0
M4U[_ ,"(/_C->\T4 >#?\,:^"O\ H*:]_P"!$'_QFC_AC7P5_P!!37O_  (@
M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
M'@W_  QKX*_Z"FO?^!$'_P 9H_X8U\%?]!37O_ B#_XS7O-% '@W_#&O@K_H
M*:]_X$0?_&:/^&-?!7_04U[_ ,"(/_C->\T4 >#?\,:^"O\ H*:]_P"!$'_Q
MFC_AC7P5_P!!37O_  (@_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P
M5_T%->_\"(/_ (S7O-% '@W_  QKX*_Z"FO?^!$'_P 9H_X8U\%?]!37O_ B
M#_XS7O-% '@W_#&O@K_H*:]_X$0?_&:/^&-?!7_04U[_ ,"(/_C->\T4 >#?
M\,:^"O\ H*:]_P"!$'_QFC_AC7P5_P!!37O_  (@_P#C->\T4 >#?\,:^"O^
M@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-% '@W_  QKX*_Z"FO?^!$'
M_P 9H_X8U\%?]!37O_ B#_XS7O-% '@W_#&O@K_H*:]_X$0?_&:/^&-?!7_0
M4U[_ ,"(/_C->\T4 >#?\,:^"O\ H*:]_P"!$'_QFC_AC7P5_P!!37O_  (@
M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
M'@W_  QKX*_Z"FO?^!$'_P 9H_X8U\%?]!37O_ B#_XS7O-% '@W_#&O@K_H
M*:]_X$0?_&:/^&-?!7_04U[_ ,"(/_C->\T4 >#?\,:^"O\ H*:]_P"!$'_Q
MFC_AC7P5_P!!37O_  (@_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P
M5_T%->_\"(/_ (S7O-% '@W_  QKX*_Z"FO?^!$'_P 9H_X8U\%?]!37O_ B
M#_XS7O-% '@W_#&O@K_H*:]_X$0?_&:/^&-?!7_04U[_ ,"(/_C->\T4 >#?
M\,:^"O\ H*:]_P"!$'_QFC_AC7P5_P!!37O_  (@_P#C->\T4 >#?\,:^"O^
M@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-% '@W_  QKX*_Z"FO?^!$'
M_P 9H_X8U\%?]!37O_ B#_XS7O-% '@W_#&O@K_H*:]_X$0?_&:/^&-?!7_0
M4U[_ ,"(/_C->\T4 >#?\,:^"O\ H*:]_P"!$'_QFC_AC7P5_P!!37O_  (@
M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M_P#C->\T4 >#?\,:^"O^@IKW_@1!_P#&:/\ AC7P5_T%->_\"(/_ (S7O-%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;XJ?\
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M8X'L  HP !7OMC\:/!6L?#75?'VC^(;+7O">FVUS=W&HZ3*+E D",\H&PG+
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M-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\
M_H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O
M^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51
M_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A
M'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[
M_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T
M4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF
M'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]
M!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R
M51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )
MA\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_
M +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\
ME5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#
M?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__
M .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_
M *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_P
MF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_
M /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I
M_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S
M10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A
M\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'
MT'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_
M "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q_
M_P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1
M]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)
M5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X
M-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\
M_H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O
M^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51
M_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A
M'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[
M_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T
M4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF
M'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]
M!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R
M51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )
MA\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_
M +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\
ME5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#
M?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__
M .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_
M *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_P
MF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_
M /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I
M_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S
M10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A
M\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'
MT'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_
M "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q_
M_P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1
M]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)
M5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X
M-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\
M_H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O
M^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51
M_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A
M'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[
M_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T
M4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF
M'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]
M!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R
M51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )
MA\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_
M +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\
ME5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#
M?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__
M .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_
M *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_P
MF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_
M /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I
M_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S
M10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A
M\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'
MT'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_
M "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q_
M_P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1
M]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)
M5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X
M-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\
M_H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O
M^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51
M_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A
M'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[
M_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T
M4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF
M'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]
M!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R
M51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )
MA\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_
M +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\
ME5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#
M?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__
M .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_
M *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_P
MF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_
M /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I
M_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S
M10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A
M\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'
MT'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_
M "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q_
M_P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1
M]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)
M5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X
M-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\
M_H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O
M^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51
M_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A
M'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[
M_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T
M4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF
M'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]
M!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R
M51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )
MA\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_
M +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\
ME5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#
M?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__
M .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_
M *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_P
MF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_
M /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I
M_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S
M10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A
M\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'
MT'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_
M "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q_
M_P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1
M]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)
M5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X
M-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\
M_H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O
M^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51
M_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A
M'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[
M_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T
M4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF
M'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]
M!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R
M51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )
MA\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_
M +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\
ME5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#
M?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__
M .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_
M *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_P
MF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_
M /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I
M_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S
M10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A
M\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'
MT'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_
M "51_P )A\?_ /H1]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q_
M_P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1
M]!_[_I_\E5[S10!X-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)
M5>\T4 >#?\)A\?\ _H1]!_[_ *?_ "51_P )A\?_ /H1]!_[_I_\E5[S10!X
M-_PF'Q__ .A'T'_O^G_R51_PF'Q__P"A'T'_ +_I_P#)5>\T4 >#?\)A\?\
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M>QT9Y<75Q;RJ7C3'4 7#<_@:]CHHH **** "BBB@#EOBI_R3#Q?_ -@>\_\
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MPQ%_Z(GKWF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH Y;XJ?\ ),/%_P#V![S_ -$/7YRU^C7Q4_Y)
MAXO_ .P/>?\ HAZ_.6@#[*_8U_Y)AJG_ &&)?_1$%>\UX-^QK_R3#5/^PQ+_
M .B(*]YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \&_
M;*_Y)AI?_88B_P#1$]>\UX-^V5_R3#2_^PQ%_P"B)Z]YH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M6^*G_),/%_\ V![S_P!$/7YRU^C7Q4_Y)AXO_P"P/>?^B'K\Y: /LK]C7_DF
M&J?]AB7_ -$05[S7@W[&O_),-4_[#$O_ *(@KWF@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#P;]LK_DF&E_]AB+_P!$3U[S7@W[97_)
M,-+_ .PQ%_Z(GKWF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH Y;XJ?\DP\7_\ 8'O/_1#U^<M?HU\5
M/^28>+_^P/>?^B'K\Y: /LK]C7_DF&J?]AB7_P!$05[S7@W[&O\ R3#5/^PQ
M+_Z(@KWF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P;
M]LK_ ))AI?\ V&(O_1$]>\UX-^V5_P DPTO_ +#$7_HB>O>: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#EOBI_R3#Q?_V![S_T0]?G+7Z-?%3_ ))AXO\ ^P/>?^B'K\Y: /LK]C7_
M ))AJG_88E_]$05[S7@W[&O_ "3#5/\ L,2_^B(*]YH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \&_;*_Y)AI?_ &&(O_1$]>\UX-^V
M5_R3#2_^PQ%_Z(GKWF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH Y;XJ?\ ),/%_P#V![S_ -$/7YRU
M^C7Q4_Y)AXO_ .P/>?\ HAZ_.6@#[*_8U_Y)AJG_ &&)?_1$%>\UX-^QK_R3
M#5/^PQ+_ .B(*]YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \&_;*_Y)AI?_88B_P#1$]>\UX-^V5_R3#2_^PQ%_P"B)Z]YH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** .6^*G_),/%_\ V![S_P!$/7YRU^C7Q4_Y)AXO_P"P/>?^B'K\Y: /
MLK]C7_DF&J?]AB7_ -$05[S7@W[&O_),-4_[#$O_ *(@KWF@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#P;]LK_DF&E_]AB+_P!$3U[S
M7@W[97_),-+_ .PQ%_Z(GKWF@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;XJ?\DP\7_\ 8'O/_1#U
M^<M?HU\5/^28>+_^P/>?^B'K\Y: /LK]C7_DF&J?]AB7_P!$05[S7@W[&O\
MR3#5/^PQ+_Z(@KWF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#P;]LK_ ))AI?\ V&(O_1$]>\UX-^V5_P DPTO_ +#$7_HB>O>: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#EOBI_R3#Q?_V![S_T0]?G+7Z-?%3_ ))AXO\ ^P/>?^B'K\Y:
M /LK]C7_ ))AJG_88E_]$05[S7@W[&O_ "3#5/\ L,2_^B(*]YH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \&_;*_Y)AI?_ &&(O_1$
M]>\UX-^V5_R3#2_^PQ%_Z(GKWF@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;XJ?\ ),/%_P#V![S_
M -$/7YRU^C7Q4_Y)AXO_ .P/>?\ HAZ_.6@#[*_8U_Y)AJG_ &&)?_1$%>\U
MX-^QK_R3#5/^PQ+_ .B(*]YH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \&_;*_Y)AI?_88B_P#1$]>\UX-^V5_R3#2_^PQ%_P"B)Z]Y
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .6^*G_),/%_\ V![S_P!$/7YRU^C7Q4_Y)AXO_P"P/>?^
MB'K\Y: /LK]C7_DF&J?]AB7_ -$05[S7@W[&O_),-4_[#$O_ *(@KWF@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P;]LK_DF&E_]AB+
M_P!$3U[S7@W[97_),-+_ .PQ%_Z(GKWF@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB)Z]YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'CS2W_JY]#T5Q/PA^*^E?&+P?'KNEQR6^)&@N+68@O!* "5)'!&""#W!'0Y
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MC<D%6'1E8$%6&3R#W-<Y\-O@7X,^$]Q<7/A[2O(O9UV/=SRM++LSG8"Q^49
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M,Q:9/-)->!?W$@0^7)&3TE#[=F.2Q '7% '8_#/XG>&?C%X)TSQ;X/U:'6M
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M1_PU]X%_YY:M_P" J?\ Q=>R_P!EV7_/G;_]^E_PH_LNR_Y\[?\ []+_ (4
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M_P#%U[+_ &79?\^=O_WZ7_"C^R[+_GSM_P#OTO\ A0!XU_PU]X%_YY:M_P"
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M^% 'C7_#7W@7_GEJW_@*G_Q='_#7W@7_ )Y:M_X"I_\ %U[+_9=E_P ^=O\
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M_@*G_P 71_PU]X%_YY:M_P" J?\ Q=>R_P!EV7_/G;_]^E_PH_LNR_Y\[?\
M[]+_ (4 >-?\-?>!?^>6K?\ @*G_ ,71_P -?>!?^>6K?^ J?_%U[+_9=E_S
MYV__ 'Z7_"C^R[+_ )\[?_OTO^% 'C7_  U]X%_YY:M_X"I_\71_PU]X%_YY
M:M_X"I_\77LO]EV7_/G;_P#?I?\ "C^R[+_GSM_^_2_X4 >-?\-?>!?^>6K?
M^ J?_%T?\-?>!?\ GEJW_@*G_P 77LO]EV7_ #YV_P#WZ7_"C^R[+_GSM_\
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MYY:M_P" J?\ Q='_  U]X%_YY:M_X"I_\77LO]EV7_/G;_\ ?I?\*/[+LO\
MGSM_^_2_X4 >-?\ #7W@7_GEJW_@*G_Q='_#7W@7_GEJW_@*G_Q=>R_V79?\
M^=O_ -^E_P */[+LO^?.W_[]+_A0!XU_PU]X%_YY:M_X"I_\71_PU]X%_P">
M6K?^ J?_ !=>R_V79?\ /G;_ /?I?\*/[+LO^?.W_P"_2_X4 >-?\-?>!?\
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MM_\ OTO^% 'C7_#7W@7_ )Y:M_X"I_\ %T?\-?>!?^>6K?\ @*G_ ,77LO\
M9=E_SYV__?I?\*/[+LO^?.W_ ._2_P"% 'C7_#7W@7_GEJW_ ("I_P#%T?\
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M  H_LNR_Y\[?_OTO^% 'C7_#7W@7_GEJW_@*G_Q='_#7W@7_ )Y:M_X"I_\
M%U[+_9=E_P ^=O\ ]^E_PH_LNR_Y\[?_ +]+_A0!XU_PU]X%_P">6K?^ J?_
M !='_#7W@7_GEJW_ ("I_P#%U[+_ &79?\^=O_WZ7_"C^R[+_GSM_P#OTO\
MA0!XU_PU]X%_YY:M_P" J?\ Q='_  U]X%_YY:M_X"I_\77LO]EV7_/G;_\
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MZ7_"C^R[+_GSM_\ OTO^% 'C7_#7W@7_ )Y:M_X"I_\ %T?\-?>!?^>6K?\
M@*G_ ,77LO\ 9=E_SYV__?I?\*/[+LO^?.W_ ._2_P"% 'C7_#7W@7_GEJW_
M ("I_P#%T?\ #7W@7_GEJW_@*G_Q=>R_V79?\^=O_P!^E_PH_LNR_P"?.W_[
M]+_A0!XU_P -?>!?^>6K?^ J?_%T?\-?>!?^>6K?^ J?_%U[+_9=E_SYV_\
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M[+LO^?.W_P"_2_X4 >-?\-?>!?\ GEJW_@*G_P 71_PU]X%_YY:M_P" J?\
MQ=>R_P!EV7_/G;_]^E_PH_LNR_Y\[?\ []+_ (4 >-?\-?>!?^>6K?\ @*G_
M ,71_P -?>!?^>6K?^ J?_%U[+_9=E_SYV__ 'Z7_"C^R[+_ )\[?_OTO^%
M'C7_  U]X%_YY:M_X"I_\71_PU]X%_YY:M_X"I_\77LO]EV7_/G;_P#?I?\
M"C^R[+_GSM_^_2_X4 >-?\-?>!?^>6K?^ J?_%T?\-?>!?\ GEJW_@*G_P 7
M7LO]EV7_ #YV_P#WZ7_"C^R[+_GSM_\ OTO^% 'C7_#7W@7_ )Y:M_X"I_\
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M?\*/[+LO^?.W_P"_2_X4 >-?\-?>!?\ GEJW_@*G_P 71_PU]X%_YY:M_P"
MJ?\ Q=>R_P!EV7_/G;_]^E_PH_LNR_Y\[?\ []+_ (4 >-?\-?>!?^>6K?\
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MW_[]+_A0!XU_PU]X%_YY:M_X"I_\71_PU]X%_P">6K?^ J?_ !=>R_V79?\
M/G;_ /?I?\*/[+LO^?.W_P"_2_X4 >-?\-?>!?\ GEJW_@*G_P 71_PU]X%_
MYY:M_P" J?\ Q=>R_P!EV7_/G;_]^E_PH_LNR_Y\[?\ []+_ (4 >-?\-?>!
M?^>6K?\ @*G_ ,71_P -?>!?^>6K?^ J?_%U[+_9=E_SYV__ 'Z7_"C^R[+_
M )\[?_OTO^% 'C7_  U]X%_YY:M_X"I_\71_PU]X%_YY:M_X"I_\77LO]EV7
M_/G;_P#?I?\ "C^R[+_GSM_^_2_X4 >-?\-?>!?^>6K?^ J?_%T?\-?>!?\
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M  U]X%_YY:M_X"I_\77LO]EV7_/G;_\ ?I?\*/[+LO\ GSM_^_2_X4 >-?\
M#7W@7_GEJW_@*G_Q='_#7W@7_GEJW_@*G_Q=>R_V79?\^=O_ -^E_P */[+L
MO^?.W_[]+_A0!XU_PU]X%_YY:M_X"I_\71_PU]X%_P">6K?^ J?_ !=>R_V7
M9?\ /G;_ /?I?\*/[+LO^?.W_P"_2_X4 >-?\-?>!?\ GEJW_@*G_P 71_PU
M]X%_YY:M_P" J?\ Q=>R_P!EV7_/G;_]^E_PH_LNR_Y\[?\ []+_ (4 >-?\
M-?>!?^>6K?\ @*G_ ,71_P -?>!?^>6K?^ J?_%U[+_9=E_SYV__ 'Z7_"C^
MR[+_ )\[?_OTO^% 'C7_  U]X%_YY:M_X"I_\71_PU]X%_YY:M_X"I_\77LO
M]EV7_/G;_P#?I?\ "C^R[+_GSM_^_2_X4 >-?\-?>!?^>6K?^ J?_%T?\-?>
M!?\ GEJW_@*G_P 77LO]EV7_ #YV_P#WZ7_"C^R[+_GSM_\ OTO^% 'C7_#7
MW@7_ )Y:M_X"I_\ %T?\-?>!?^>6K?\ @*G_ ,77LO\ 9=E_SYV__?I?\*/[
M+LO^?.W_ ._2_P"% 'C7_#7W@7_GEJW_ ("I_P#%T?\ #7W@7_GEJW_@*G_Q
M=>R_V79?\^=O_P!^E_PH_LNR_P"?.W_[]+_A0!XU_P -?>!?^>6K?^ J?_%T
M?\-?>!?^>6K?^ J?_%U[+_9=E_SYV_\ WZ7_  H_LNR_Y\[?_OTO^% 'C7_#
M7W@7_GEJW_@*G_Q='_#7W@7_ )Y:M_X"I_\ %U[+_9=E_P ^=O\ ]^E_PH_L
MNR_Y\[?_ +]+_A0!XU_PU]X%_P">6K?^ J?_ !='_#7W@7_GEJW_ ("I_P#%
MU[+_ &79?\^=O_WZ7_"C^R[+_GSM_P#OTO\ A0!XU_PU]X%_YY:M_P" J?\
MQ='_  U]X%_YY:M_X"I_\77LO]EV7_/G;_\ ?I?\*/[+LO\ GSM_^_2_X4 >
M-?\ #7W@7_GEJW_@*G_Q='_#7W@7_GEJW_@*G_Q=>R_V79?\^=O_ -^E_P *
M/[+LO^?.W_[]+_A0!XU_PU]X%_YY:M_X"I_\71_PU]X%_P">6K?^ J?_ !=>
MR_V79?\ /G;_ /?I?\*/[+LO^?.W_P"_2_X4 >-?\-?>!?\ GEJW_@*G_P 7
M1_PU]X%_YY:M_P" J?\ Q=>R_P!EV7_/G;_]^E_PH_LNR_Y\[?\ []+_ (4
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MP\7_ /8'O/\ T0]?G+7Z-?%3_DF'B_\ [ ]Y_P"B'K\Y: /LK]C7_DF&J?\
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M))Q@8%4O!?\ P2YU?Q=\0=.\6_'_ .+&I_%9M.8-;Z/)YOV=@#G8[R.Q\HD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <M\5/^28>+_\ L#WG_HAZ_.6OT:^*G_),
M/%__ &![S_T0]?G+0!]E?L:_\DPU3_L,2_\ HB"O>:\&_8U_Y)AJG_88E_\
M1$%>\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >#?ME
M?\DPTO\ [#$7_HB>O>:\&_;*_P"28:7_ -AB+_T1/7O- !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P;]LK_DF&E_\
M88B_]$3U[S7@W[97_),-+_[#$7_HB>O>: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Y;XJ?\DP\7_]@>\_]$/7YRU^C7Q4
M_P"28>+_ /L#WG_HAZ_.6@#[*_8U_P"28:I_V&)?_1$%>\UX-^QK_P DPU3_
M +#$O_HB"O>: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /!OVRO^28:7_P!AB+_T1/7O->#?ME?\DPTO_L,1?^B)Z]YH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[S_T0]?G+0!]E?L:_P#),-4_[#$O_HB"O>:\&_8U_P"28:I_V&)?_1$%>\T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >#?ME?\ ),-+
M_P"PQ%_Z(GKWFO!OVRO^28:7_P!AB+_T1/7O- !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP3G.!QP<\=%^S7^T$WQOTG48M1L8=/US32AF6V)\F5'SM= Q)7!4@@D]CGG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Y;XJ?\DP\7_\ 8'O/_1#U^<M?HU\5/^28>+_^P/>?^B'K\Y:
M/LK]C7_DF&J?]AB7_P!$05[S7@W[&O\ R3#5/^PQ+_Z(@KWF@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P;]LK_ ))AI?\ V&(O_1$]
M>\UX-^V5_P DPTO_ +#$7_HB>O>: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .6^*G_),/%__ &![S_T0]?G+7Z-?%3_DF'B__L#WG_HA
MZ_.6@#[*_8U_Y)AJG_88E_\ 1$%>\UX-^QK_ ,DPU3_L,2_^B(*]YH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \&_;*_P"28:7_ -AB
M+_T1/7O->#?ME?\ ),-+_P"PQ%_Z(GKWF@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;X
MJ?\ ),/%_P#V![S_ -$/7YRU^C7Q4_Y)AXO_ .P/>?\ HAZ_.6@#[*_8U_Y)
MAJG_ &&)?_1$%>\UX-^QK_R3#5/^PQ+_ .B(*]YH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \&_;*_Y)AI?_88B_P#1$]>\UX-^V5_R
M3#2_^PQ%_P"B)Z]YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK+\3>)-/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHJ%KR!;E+9IXUN'!982XWD#J0.N*!
M[DU%%? 7[:GC+7[KXM7.A3W-Q!HMC! UI;*Q6.3=&&:4CH6W%ESVV8]:YL16
M6'ASM7/8RG+99KB/81ERZ7OO^'S/OVO!/VR/B)KO@#X;V8T&>2QFU*\^RS7L
M)P\4>QF*J?X6;'4<X!K%_8<\9:]XF\#ZW9:O<3WMGIMS''9W%PQ9@&4EHMQZ
MA<*0.V_TQ7OGB[P?H_CO0;G1M=L8]0TZX WPR9&".C*1RI'8@YJ>9XBA>&C9
MI[*&49DH8A<Z@]?/^NWR/AG]D_XM>+8OBYI6B2ZI?:MI>JM)'<6MU,TP7",_
MF+N)VD$9)'49SVK[]=5D5E90RL,%6&01Z5Y_\-_@+X*^%-]/?>']*,5_,IC-
MU<2M+(J$YVJ6/RCITZX&<UZ%2PM*=&GRS=R\[QV'S#%>VPT.56MVN^^GW'AO
M_#&OPU_X2@ZQ]AO/*\SS?[+^T?Z)G.<;=N[;G^'=CMC'%>X(BQHJ(H5%& JC
M  ]*=171"G"G?D5KGE8C&8C%<OMYN5MKL****T.0**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M .6^*G_),/%__8'O/_1#U^<M?HU\5/\ DF'B_P#[ ]Y_Z(>OSEH ^ROV-?\
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M\,L?#K_H$W'_ (&R_P#Q5 '>_P#"?>&/^ACTG_P.B_\ BJ/^$^\,?]#'I/\
MX'1?_%5P7_#+'PZ_Z!-Q_P"!LO\ \51_PRQ\.O\ H$W'_@;+_P#%4 =[_P )
M]X8_Z&/2?_ Z+_XJC_A/O#'_ $,>D_\ @=%_\57!?\,L?#K_ *!-Q_X&R_\
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MQ_T,>D_^!T7_ ,57!?\ #+'PZ_Z!-Q_X&R__ !5'_#+'PZ_Z!-Q_X&R__%4
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M ,50!WO_  GWAC_H8])_\#HO_BJ/^$^\,?\ 0QZ3_P"!T7_Q5<%_PRQ\.O\
MH$W'_@;+_P#%4?\ #+'PZ_Z!-Q_X&R__ !5 '>_\)]X8_P"ACTG_ ,#HO_BJ
M/^$^\,?]#'I/_@=%_P#%5P7_  RQ\.O^@3<?^!LO_P 51_PRQ\.O^@3<?^!L
MO_Q5 '>_\)]X8_Z&/2?_  .B_P#BJ/\ A/O#'_0QZ3_X'1?_ !5<%_PRQ\.O
M^@3<?^!LO_Q5'_#+'PZ_Z!-Q_P"!LO\ \50!WO\ PGWAC_H8])_\#HO_ (JC
M_A/O#'_0QZ3_ .!T7_Q5<%_PRQ\.O^@3<?\ @;+_ /%4?\,L?#K_ *!-Q_X&
MR_\ Q5 '>_\ "?>&/^ACTG_P.B_^*H_X3[PQ_P!#'I/_ ('1?_%5P7_#+'PZ
M_P"@3<?^!LO_ ,51_P ,L?#K_H$W'_@;+_\ %4 =[_PGWAC_ *&/2?\ P.B_
M^*H_X3[PQ_T,>D_^!T7_ ,57!?\ #+'PZ_Z!-Q_X&R__ !5'_#+'PZ_Z!-Q_
MX&R__%4 =[_PGWAC_H8])_\  Z+_ .*H_P"$^\,?]#'I/_@=%_\ %5P7_#+'
MPZ_Z!-Q_X&R__%4?\,L?#K_H$W'_ (&R_P#Q5 '>_P#"?>&/^ACTG_P.B_\
MBJ/^$^\,?]#'I/\ X'1?_%5P7_#+'PZ_Z!-Q_P"!LO\ \51_PRQ\.O\ H$W'
M_@;+_P#%4 =[_P )]X8_Z&/2?_ Z+_XJC_A/O#'_ $,>D_\ @=%_\57!?\,L
M?#K_ *!-Q_X&R_\ Q5'_  RQ\.O^@3<?^!LO_P 50!WO_"?>&/\ H8])_P#
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MPZ_Z!-Q_X&R__%4 =[_PGWAC_H8])_\  Z+_ .*H_P"$^\,?]#'I/_@=%_\
M%5P7_#+'PZ_Z!-Q_X&R__%4?\,L?#K_H$W'_ (&R_P#Q5 '>_P#"?>&/^ACT
MG_P.B_\ BJ/^$^\,?]#'I/\ X'1?_%5P7_#+'PZ_Z!-Q_P"!LO\ \51_PRQ\
M.O\ H$W'_@;+_P#%4 =[_P )]X8_Z&/2?_ Z+_XJC_A/O#'_ $,>D_\ @=%_
M\57!?\,L?#K_ *!-Q_X&R_\ Q5'_  RQ\.O^@3<?^!LO_P 50!WO_"?>&/\
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MC_H8])_\#HO_ (JC_A/O#'_0QZ3_ .!T7_Q5<!)^RY\.(HV=]+F1%&69KZ4
M =S\U<KX=^&'P(\6:Q)I6CW]IJ.HIG_1[?59&=L9R5&[Y@,=5S4N23LV:QI5
M)IRC%M+?3;U/:?\ A/O#'_0QZ3_X'1?_ !5'_"?>&/\ H8])_P# Z+_XJN"_
MX98^'7_0)N/_  -E_P#BJ^*/CU?:9H/Q*U?0O#-A_9>GZ7,;4LTKRR32+P[$
ML3@;L@ =A6-:O&A'FD>CEN65\TJNE0LK*[;V/T4_X3[PQ_T,>D_^!T7_ ,56
M5XG^,?@OPCHMQJE_XCT\V\(Y2WN$FE<G@*J*26/T^O2O /V:?AIX'^,7PZ.J
M:GH4D.IV=T]E<-#=S+'*RJK!P-YQE7&1Z@]L5H_'C]DG3KKP.9O FG2#6K69
M93;O<LYN(L$,J[VP&Y!'K@CO1*HY4O:4U?30*6"C3QZPF,ERI2LW_P ']3T#
MX=_M5^ ?B/J$MC;WL^C7:*76/652 2*.NU@[+GV)!]N#7H?_  GWAC_H8])_
M\#HO_BJ^&?@+^R_XG\2>.+.?Q3H%[H_AVUW/<F]5K>28@$+&@.&Y;&3TP#SG
M /U3_P ,L?#K_H$W'_@;+_\ %5GA:E2I"]169UYYA,)@\2J>#GS1MKK>S[7/
M@_Q]\7/%GBSQS>ZW=:U?6UVEP_V=+>Y=%M%#$!(]I&T =QUZGDU]Y_ [XNVG
MB;X4^'=2\2:YIMOK<L++<+-=1QNQ61D5V4D8+*JMT_BK.N/V/OAA=7"S/HMP
M&!R0M[* WU^:KJ_LK_#E5 &D3@#@ 7LO_P 566'P]2C.4IRNF=N<9MA,?AJ5
M&A2Y7'TTTV7EUZ;'%?M/_#O0_C5INF7>C^+M"M=:TSS%2.ZOXQ%/&V"5)!.U
M@5X.,<D'U'._LO?"'3?A1KUWXD\2>+= ;47MVMK>SM-1C=8U9@6=VR,GY0 !
MD8)[]/6/^&6/AU_T";C_ ,#9?_BJ/^&6/AU_T";C_P #9?\ XJNAX>FZGM;:
MGEQSC%PP;P"E[C\M;;VOV.]_X3[PQ_T,>D_^!T7_ ,56?_;W@,:K_:@U'PZ-
M2V[?MGGP>=CTWYSC\:Y+_AECX=?] FX_\#9?_BJ/^&6/AU_T";C_ ,#9?_BJ
MZ#QU)QV9WO\ PGWAC_H8])_\#HO_ (JC_A/O#'_0QZ3_ .!T7_Q5<%_PRQ\.
MO^@3<?\ @;+_ /%4?\,L?#K_ *!-Q_X&R_\ Q5,D[W_A/O#'_0QZ3_X'1?\
MQ5'_  GWAC_H8])_\#HO_BJX+_AECX=?] FX_P# V7_XJC_AECX=?] FX_\
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MECX=?] FX_\  V7_ .*H_P"&6/AU_P! FX_\#9?_ (J@#O?^$^\,?]#'I/\
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M8^'7_0)N/_ V7_XJ@#O?^$^\,?\ 0QZ3_P"!T7_Q5'_"?>&/^ACTG_P.B_\
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M?]#'I/\ X'1?_%4?\)]X8_Z&/2?_  .B_P#BJX+_ (98^'7_ $";C_P-E_\
MBJ/^&6/AU_T";C_P-E_^*H [W_A/O#'_ $,>D_\ @=%_\51_PGWAC_H8])_\
M#HO_ (JN"_X98^'7_0)N/_ V7_XJC_AECX=?] FX_P# V7_XJ@#O?^$^\,?]
M#'I/_@=%_P#%4?\ "?>&/^ACTG_P.B_^*K@O^&6/AU_T";C_ ,#9?_BJ/^&6
M/AU_T";C_P #9?\ XJ@#O?\ A/O#'_0QZ3_X'1?_ !5'_"?>&/\ H8])_P#
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MECX=?] FX_\  V7_ .*H [W_ (3[PQ_T,>D_^!T7_P 51_PGWAC_ *&/2?\
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MP')[5K2J.=-3FK'!CL+##XR>'P\N=)V76_EIUZ'J'_"?>&/^ACTG_P #HO\
MXJC_ (3[PQ_T,>D_^!T7_P 57BO@7X8_ SXF?:/^$:F_M1[?F6);RXCD49QN
M*.0V,]\8KK?^&6/AU_T";C_P-E_^*K6,E)7B[G!4IU*,G"I%Q:Z-69WO_"?>
M&/\ H8])_P# Z+_XJC_A/O#'_0QZ3_X'1?\ Q5<%_P ,L?#K_H$W'_@;+_\
M%4?\,L?#K_H$W'_@;+_\55&9WO\ PGWAC_H8])_\#HO_ (JC_A/O#'_0QZ3_
M .!T7_Q5<%_PRQ\.O^@3<?\ @;+_ /%4?\,L?#K_ *!-Q_X&R_\ Q5 '>_\
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M#'_0QZ3_ .!T7_Q5<%_PRQ\.O^@3<?\ @;+_ /%4?\,L?#K_ *!-Q_X&R_\
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M+'PZ_P"@3<?^!LO_ ,51_P ,L?#K_H$W'_@;+_\ %4 =[_PGWAC_ *&/2?\
MP.B_^*H_X3[PQ_T,>D_^!T7_ ,57!?\ #+'PZ_Z!-Q_X&R__ !5'_#+'PZ_Z
M!-Q_X&R__%4 =[_PGWAC_H8])_\  Z+_ .*H_P"$^\,?]#'I/_@=%_\ %5P7
M_#+'PZ_Z!-Q_X&R__%4?\,L?#K_H$W'_ (&R_P#Q5 '>_P#"?>&/^ACTG_P.
MB_\ BJ/^$^\,?]#'I/\ X'1?_%5P7_#+'PZ_Z!-Q_P"!LO\ \51_PRQ\.O\
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MPRQ\.O\ H$W'_@;+_P#%4 =[_P )]X8_Z&/2?_ Z+_XJC_A/O#'_ $,>D_\
M@=%_\57!?\,L?#K_ *!-Q_X&R_\ Q5'_  RQ\.O^@3<?^!LO_P 50!WO_"?>
M&/\ H8])_P# Z+_XJC_A/O#'_0QZ3_X'1?\ Q5<%_P ,L?#K_H$W'_@;+_\
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M?_BJ/^&6/AU_T";C_P #9?\ XJ@#O?\ A/O#'_0QZ3_X'1?_ !5'_"?>&/\
MH8])_P# Z+_XJN"_X98^'7_0)N/_  -E_P#BJ/\ AECX=?\ 0)N/_ V7_P"*
MH [W_A/O#'_0QZ3_ .!T7_Q5'_"?>&/^ACTG_P #HO\ XJN"_P"&6/AU_P!
MFX_\#9?_ (JC_AECX=?] FX_\#9?_BJ .]_X3[PQ_P!#'I/_ ('1?_%4?\)]
MX8_Z&/2?_ Z+_P"*K@O^&6/AU_T";C_P-E_^*H_X98^'7_0)N/\ P-E_^*H
M[W_A/O#'_0QZ3_X'1?\ Q5'_  GWAC_H8])_\#HO_BJX+_AECX=?] FX_P#
MV7_XJC_AECX=?] FX_\  V7_ .*H [W_ (3[PQ_T,>D_^!T7_P 51_PGWAC_
M *&/2?\ P.B_^*K@O^&6/AU_T";C_P #9?\ XJC_ (98^'7_ $";C_P-E_\
MBJ .]_X3[PQ_T,>D_P#@=%_\51_PGWAC_H8])_\  Z+_ .*K@O\ AECX=?\
M0)N/_ V7_P"*H_X98^'7_0)N/_ V7_XJ@#O?^$^\,?\ 0QZ3_P"!T7_Q5'_"
M?>&/^ACTG_P.B_\ BJX+_AECX=?] FX_\#9?_BJ/^&6/AU_T";C_ ,#9?_BJ
M .]_X3[PQ_T,>D_^!T7_ ,51_P )]X8_Z&/2?_ Z+_XJN"_X98^'7_0)N/\
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M\51_PGWAC_H8])_\#HO_ (JN"_X98^'7_0)N/_ V7_XJC_AECX=?] FX_P#
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M?_%4?\)]X8_Z&/2?_ Z+_P"*K@O^&6/AU_T";C_P-E_^*H_X98^'7_0)N/\
MP-E_^*H [W_A/O#'_0QZ3_X'1?\ Q5'_  GWAC_H8])_\#HO_BJX+_AECX=?
M] FX_P# V7_XJC_AECX=?] FX_\  V7_ .*H [W_ (3[PQ_T,>D_^!T7_P 5
M1_PGWAC_ *&/2?\ P.B_^*K@O^&6/AU_T";C_P #9?\ XJC_ (98^'7_ $";
MC_P-E_\ BJ .]_X3[PQ_T,>D_P#@=%_\51_PGWAC_H8])_\  Z+_ .*K@O\
MAECX=?\ 0)N/_ V7_P"*H_X98^'7_0)N/_ V7_XJ@#O?^$^\,?\ 0QZ3_P"!
MT7_Q5'_"?>&/^ACTG_P.B_\ BJX+_AECX=?] FX_\#9?_BJ/^&6/AU_T";C_
M ,#9?_BJ .]_X3[PQ_T,>D_^!T7_ ,51_P )]X8_Z&/2?_ Z+_XJN"_X98^'
M7_0)N/\ P-E_^*H_X98^'7_0)N/_  -E_P#BJ .]_P"$^\,?]#'I/_@=%_\
M%4?\)]X8_P"ACTG_ ,#HO_BJX+_AECX=?] FX_\  V7_ .*H_P"&6/AU_P!
MFX_\#9?_ (J@#O?^$^\,?]#'I/\ X'1?_%4?\)]X8_Z&/2?_  .B_P#BJX+_
M (98^'7_ $";C_P-E_\ BJ/^&6/AU_T";C_P-E_^*H [W_A/O#'_ $,>D_\
M@=%_\51_PGWAC_H8])_\#HO_ (JN"_X98^'7_0)N/_ V7_XJC_AECX=?] FX
M_P# V7_XJ@#O?^$^\,?]#'I/_@=%_P#%4?\ "?>&/^ACTG_P.B_^*K@O^&6/
MAU_T";C_ ,#9?_BJ/^&6/AU_T";C_P #9?\ XJ@#O?\ A/O#'_0QZ3_X'1?_
M !5'_"?>&/\ H8])_P# Z+_XJN"_X98^'7_0)N/_  -E_P#BJ/\ AECX=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYJ_
M;D\(:]XD\#:+>:3!/>66FW4DE[;VZEB R@)*5'4+A@3VW^F:^E:*RJTU5@X/
MJ=^!Q<L#B88F*NX]/P/@+]BOP?X@NOBU;:[!:W$&BV5O.MW<LA6.3<A58P>A
M.XJV/]G-??A..3P*6N*^-.DZOKOPI\4V&A;SJMQ8R)"L9P[\?,B^[+E1]:QH
MT?JU-I:]3OS#'O.<;&I-*"=H][*^[>G<FTGXO^"=<UXZ)I_BC2[S5-Q06T-R
MK,[#J%/1C[ FNOK\E?"OA[7-8\6V.EZ-:W!UW[2J0QQJ5DBD5NI_N[2,DGIC
MFOUHCW"-0Y#/CYB!@$UGA<1+$)N2M8Z\]RBEE,J:I5.;F3WW5OT?Z#J*P-<^
M('ACPQJ$-CK'B+2]+O9L&.WO+R.)V!Z':Q!QQUK>5@ZAE(92,@CH:[KIZ(^9
ME"<4I25D]A:***9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>$>,OVRO
M ?@WQ7/H;QZEJ3VTIAN;NQA1H8W!PP!9P6P>N!CTS6<ZD*:O-V.S#8/$8R3C
MAX.378]WK@_BE\;/"OP?M;63Q#>2+/=9\BTM8_,FD ZMC(  SU)'M76:#KUA
MXHT6RU;2[E+S3[R)9H)X^C*1QUY!]0>0>#7R;^VA\&/%?BGQ=IWB?0M-NM<L
MOL2V<MO9QF66!E=V!"#DJ0_4 X(.<9%8XBI.%-SIJ[._*<)0Q6,5#%RY(Z^6
MJZ:['TE\,_BQX;^+6CRZAX=O&G2!Q'/!,A26%CR RGU .",@X//!KDOVI_ ^
MM>/O@_J&G:%&]S?13Q71M8S\UPB$Y0#N>0P'?;ZUYQ^Q7\(/$O@4:[KOB"RG
MTA;^*.WM[*Y79*P5BQ=T/*]@ >>6XZ9^I*5/FKT;5%9LO%^RRO,KX.7-&#37
M7SMI]Q^;O[/GPE\7ZM\6_#T\6D7^G6^EW\5W=W=S;O$D21N&926'WF *A??T
MS7Z1444\/AUAXN*=[BS;-IYM5C4G%1LK6"BBBNH\(**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#V]/VGL[ZGI_V;B_JOUSV?[OOIZ;;V\['HWC/QAI?@'PS?Z]K,_V?3K)-\C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@B4:9IMIIPF;=(+6!(MY]3M R:OT5V'SG,TK)Z!1113)"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#/UKP_I?B6R-GJ^FV>JVFX-]GO8$FCR.AVL",U+I>DV.AV,5EIU
MG;Z?9Q#$=O:Q+'&@] J@ 5;HI65[E\\N7DOIV/!/VT]8US2/@TQT=Y88+B^C
M@U"6$D,MN5?@D=%+A%)]\=Z^4_V4M4UO3_C=X?AT9YMEU*8[V%"=CV^TERXZ
M84<C/<"OTAO+.WU&TFM;N".ZMIE*2PS('1U(P593P0?0U@^%?AQX6\#RSRZ!
MH&GZ1+/Q+):P*C,,YP3UQGMTK@JX652M&JI:(^KP.=TL)EU3!2I7<KZ]->_I
M_5CI**QO&=]?Z7X/UV\TN+S]3M[">:UB"[M\RQL47'?+ <5^5J^-=?7Q,/$(
MUB]_MSS/-^W^<QFW9S][/Z=.U5B<4L.TFKW,,GR.>;QJ2C44>7RO=O\ )>9^
MM=%97A6\O=1\+Z/=ZE%Y&HSV<,MS%C&R5D!=<=L,36K7:G=7/FI1Y9.+Z!11
M13)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKFOB3XYM?
MAKX'U?Q+>Q-/!I\._P E#@R.S!43/;+,HSVS2DU%-LTITY59JG!7;=EZLZ6B
MOBOP3^W9KUYXRM8/$6D:9'H-S.L3FR619K=6. ^YG(;&<D8&<<8Z5]J5A1KP
MKIN'0]',,LQ.6RC'$*W-MU/DWXF?MQ2>%_&U[I&@:#;ZC8:?.UO-=74S*TSJ
M2'V #Y1D<$YSC..:^B?AE\0K#XI>"=-\2:<CPP7:G=#)]Z*16*NA]<$'GN,'
MO7S!\4OV(=<USQU?ZGX9U738]*U"X:X:&_>1)+=G)9E&U&#+DG'0\@=LU]+_
M  D^'%K\)_ 6F^&[:=KO[,&:6Y9=IED9BS-CL,G '8 =:YL.\1[67M=CV<TC
ME"P5)X)_O-+[[6UOYW_JQY/^U1^SCJGQ?NM-UWP_<0#5[.#[+):W+[%FBW%E
M*MCA@6;KP0>HQRW]E?\ 9PU3X0WFIZ[XAGMSJUY!]DBM;5]ZQ1;@S%FQRQ*K
MP. !U.>/HNBM_JU/VOM;:GF?VQB_J7U"ZY/36V]K]@HHHKJ/$"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%%%49!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA034#+,,RQ.9S4\0]M%;0****W/*"BBB@ HHHH **** "BBB@ HHHH ****
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M1]WT5^>EY^UY\4+HGR]<@M.<_N;" _A\R-6%>?M'?$N^!$GB^^7(Q^Y"1?\
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M/]CWX96S9DTFZN^<XFOI1^'RL*V[/]F7X8V( C\)6K8&/WTLLO\ Z$YI//\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!RWQ4_Y)AXO_P"P/>?^B'K\Y:_1KXJ?\DP\7_\
M8'O/_1#U^<M 'V5^QK_R3#5/^PQ+_P"B(*]YKP;]C7_DF&J?]AB7_P!$05[S
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X-^V5_R3#2
M_P#L,1?^B)Z]YKP;]LK_ ))AI?\ V&(O_1$]>\T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MASXLU''V3POK5UG@>3I\SYQUZ+7ZF(BQHJ(H55& JC  ]*=7/+B.7V:7X_\
M -XY''K4_#_@GYF6?P#^(M\ 8_!NKKD _OK8Q=?][%;MG^RE\4;PC'A@PKG!
M::]MUQ^'F9_2OT6HKGEQ#B/LPC^/^9M'):'63_#_ "/@6S_8O^(]R 9(M+M.
M,XFO,_A\JM6[9_L*>,)"/M6O:'",_P#+%II./QC6OMVBN>6>XQ[-+Y&\<HPJ
MWN_F?'MG^P3>2 ?:O&<$)QSY.G-)S^,BUO6?[!NB1D?:O%=_,,\^3;)'Q^):
MOJ2BN>6<8Z7_ "\_!?Y&T<LPD?L?B_\ ,^=[/]ASP)  9]2UVY;&#FXB5?J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#EOBI_R3#Q?_P!@>\_]$/7YRU^C7Q4_Y)AXO_[ ]Y_Z(>OSEH ^
MROV-?^28:I_V&)?_ $1!7O->#?L:_P#),-4_[#$O_HB"O>: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /!OVRO\ DF&E_P#88B_]$3U[
MS7@W[97_ "3#2_\ L,1?^B)Z]YH **** "BBB@ HHHH **** "BBB@ HHHH
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M'5/(U>V\VPD;%OJ4 )@F]L_PM_LGGZCFLOX=_$WQ#\+]:74M OFMW.!-;O\
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MU%5["_MM4LX;NSN(KNUF4/%/"X='4]""."*L5\WMHSZ(****0!1110 4444
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M^%=(N=4U>]AT[3[==TMQ</M5>P_$G  '))P*YWP+\8_!GQ+N)[?PWKUOJ5S
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_L,1?\ HB>O>:\&_;*_Y)AI?_88B_\ 1$]>\T %%%% !1110 4444 %%%%
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M .T;R-66 +%Y:1Y&"W4Y."1^->I45E3R? T:BJPIV:\W_F)4XIW2"BBBO8-
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MO<5965_);!1117:?,A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\8SUZ5]TT455"A'#QY8F69YI6S2JJM9)65DD%%%%=!Y 4444 %%%% !1110
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M?HI)'Y5]845\W2X9P\?XDV_N7^9@J"ZL^?-+_9?O9,'4=<@A]5M86D_5BO\
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MU>D_ 7P=IFTO8RW[C^*[G8_HN!^E?A%3*\XQ\KXNHW_BDW_F>Y#"\OPI(^4
M"Q  R:W]*^'_ (DUO:;+1+Z9&Z2>253_ +Z.!^M?8.E^&=(T/']GZ99V1Z;H
M(%0_F!6G772X76]6K]R_5_Y'0J'=GD7P/^%>I>";B\U35]D-U/%Y$=LCARJY
M#$L1QG('3->NT45]?A<+3P=)4:6R.B,5%604445UE!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2S8[98DX[9KHJ**W2459'EU)RJ3<YN[>K"BBBF0%%%% !1110 4444 %%%%
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M\26;_P =KR_Q%^W)XOU#<FD:3IFD1GHT@:XE'XDA?_':P[?2[.S7$%I#"/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <WX\^'N@_$G0WTK7[!+RW.3&_22%L?>1NJG^??(
MXKX9^-G[,NO?"F2;4;/?K7AK.1>QI^\@'83*.G^\.#[$XK]"J;)&LT;(ZAT8
M;65AD$'J"*]; YE6P+M'6/;^MCSL7@:6+7O:2[GY1>'_ !%J?A/5K?5-'OIM
M/OX#NCG@;##V]P>X/![U]I? _P#:YTSQE]GT;Q<8='UML)'>9VVUR>V<_P"K
M8^AX)Z$9 K)^.'['EKK7VC6O J1V-\<O+H[$+#*>_E'HA_V3\O\ NU\>:II5
M[H>H3V&H6LUE>V[%);>="CHP[$&OLG'!YU2NOB7WK_@?@?+IXK*JEGL_N9^L
MU%?!'P/_ &K-9^'/V?2->\[7/#BX106S<6J_],R?O*/[A/T(Z'[>\)>,=&\=
M:+#JVA7\6HV,O22(\J>ZLIY5AZ$ U\5C<OK8&7OJ\>CZ?\ ^JPN-I8M>Z[/L
M;-%%%>8=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !39(TF4JZ*Z_W6&13J* ,:[\%^'[\$7.AZ=/[
MO:H3^>*CTGP+X>T&\-WI^CV=K<]I8XAN7/7![?A6[16'L*7-S<BOZ(5D%%%%
M;C"N?\>>%5\:^%;[2#+Y#S*#')C(5U8,N?;(Y]C7045G4IQJP=.:NGHQ-75F
M?)E]\"/&ED[!=+6Z0?\ +2"XC(/T!8']*PKOX;^*K')E\/:C@=62V9P/Q4&O
MM"BODY\,X9_!.2^Y_H8>PCW/A6[TN\L,BYM)[8C@^=&R_P Q5:OO.LV[\-Z1
M?Y^U:597.>OG6Z-_,5Q3X7?V*OWK_@D>P[,^??V:?[0_X2Z]\DR?V<+4_:.N
MS=N&S_@77'MFOI2JNGZ79Z3;^18VD%E!G/EV\2QKGZ 5:KZK+<&\#AU1<KG1
M"/*K!1117IEG!?%3XJ0_#FWM8TM?MNH763'$S[551U9C]3P/KZ5YU:_M17:G
M_2/#\,H_Z9713^:FNX^,7PIF^(4=G=6%S';ZA:JR!9\A)$)SC(!P0?;O7C5W
M\ _&EMG9IT5R/^F-S'_[,17Q.9ULVIXF7U=/DZ62?Z,Y:CJ*6FQZ/:?M/:0^
M/M.C7L/KY+I)_,K6S:?M%>$+C'F/>VO_ %VM\X_[Y)KP6[^%GBZRSYGAZ^;'
M_/&(R?\ H.:Q;OP]JNGDBZTR\MB.OG6[K_,5Y7]M9I1_B1^^-O\ (CVE1;GU
MA9?&3P9?L%CUZ!">/WR/$/S9177PSQW,*2PR++$X#)(A!5@>A!'45\(5]5_
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MBRX592E9H]THHHK[8Z@KC_B!\4-)^'D<"WHEN;N<%H[6 #=M'&XDG &>/?\
M UV%>)_'CX8:QXHU6TUC2(?MI2 6\MNK .N&9@PR>1\Q&!Z>]>9F57$4<-*>
M&C>7W_@1-M1O$9+^U!8J1Y>@W#CONN%7^AJ"7]J2-2/+\-LX[[KT+_[3->9Q
M?!_QE-G;H-P,?WBB_P S5B+X(^-IL[=#<8_O7$*_S>OA_P"T,ZELI?\ @'_
M.7GJG>2_M1S,1Y?AQ$'?=>%O_9!47_#4-[YBG^P(/+_B7[2V3]#MX_*N0B^
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M_P"^A_A7J:_LNVVT;O$,I;N1: #_ -#JP/V8-,P,ZW=D]_W2US?V;G,MV_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Y;XJ?\ ),/%_P#V![S_ -$/7YRU^C7Q4_Y)AXO_ .P/>?\ HAZ_.6@#
M[*_8U_Y)AJG_ &&)?_1$%>\UX-^QK_R3#5/^PQ+_ .B(*]YH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R
MWQ4_Y)AXO_[ ]Y_Z(>OSEK]&OBI_R3#Q?_V![S_T0]?G+0!]E?L:_P#),-4_
M[#$O_HB"O>:\&_8U_P"28:I_V&)?_1$%>\T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >#?ME?\ ),-+_P"PQ%_Z(GKWFO!OVRO^28:7
M_P!AB+_T1/7O- !1110 4444 %%%% !116'XV\9:;\/_  KJ/B#5Y&BT^QC\
MR38NYF)("JH[EF( ]SVI-J*NRX0E4DH05V]$;E%?,W@+]N+0_%WC&UT;4/#\
M^B6MY,(+>_:[64;V.%\Q=B[ 3CD%L9].:^F:SIU85E>#N=F,P&)P$E#$PY6]
M5M^AY3X\_:<\ _#OQ&=#U74YI-0C($Z6D#2K;Y&<.1WQV&2/2O2-#URP\2:1
M::II=U'>Z?=1B6&XB.5=3W_^MU%?G=\;O@7XXTGXH:Z\>@:GK%MJ-]-=6U[9
M6SSK*LCE@"5!PPS@@\\>F#7V3^SGX-U#X6_!O2].\1RI:7:M+<RQRR#;;!W+
M!"W3(!R?<FN3#UJM2K*$HV2/?S3+,#A,#2KT*O-.5KZK735VZ6_K4\<_;\L]
M<ET_PO<1+,_AZ)Y1/Y>=BW!V["__  '<%)_VO6N-_8/L];;XC:M<VJS+H2V#
M)>/SY32;E,2_[WWB/;=ZU]1>+/CU\,]%MYK;5?$NF7B,-KVUO_IF[_9*QAA^
M=>5ZE^VIX)\,VGV/PQX9O+F*/[D:I'9P?AC<1_WS7H4\EQ5>NJT(O[K?BS@_
MUIP^'RMY=-*^JO?N[[=SZ;=%D1D=0R,,%6&01Z5YSH_[.?PYT'Q,NOV/A:UA
MU)9/-C8O(T4;YR&2(L44@XQA>,<8KYC\1?MQ>,M1WII.F:7H\9Z.R-/*/Q8A
M?_':YK2?B=XY^)!N9=;\6ZFUHA"FVM)OLR2$\X81;1CVKT,?EW]GX:6,QS48
M1^;N]%9=_F?'4<\Y9.EA92][>SLGZ_\ #'WGKOB[0_"\?F:QK%AI:8SF\N4B
MS]-Q&:\YUG]J;X?Z9N2SU"ZUZ=>L6DV<DO\ X\0J?^/5\L0^'].AD,@LXWE)
MR9)1YCD^NYLFKZJ%  &!Z"O@:O%&$AI1HREZM1_!*7YB=:M+:R_'_+\CV'6/
MVMM3N,KH/@IT4_=N-7O%CQ]8T!/_ (]7"Z]\</BEKT;K'KFFZ$&_Y9Z;9[OP
MWR;F'U&*YV"WENI!'#&\LC=$C4L3^ KJ=(^$_BW6F40:'=1JW\=RODKCU^?'
M'TKSUQ+F-:7^RT8KTCS?^E<WZ&3C4J:2FW^'Y6/GWQIXL\5ZMJ$UKXAUW4=2
M=3RMQ=/)'@\@JI. /H*Y>OO32?V0/"EX\5_XF>[U/4611+!%<&.W7'9=H#GZ
M[N?05Z3X=^#/@;PGM.F>%=,@D7[LTEN)91_P-\M^M?N&%X@A'"T_:T_WEES)
M:*]M?Q/(>3UJDVY2T\]6?F_X>\!^)/%A']C:#J6J G&^UM7D0?5@,#\37J'A
MO]C_ .)&N%'N+"TT2,\A]0NESCUVQ[R/H0*_0)5"J%4  #  [4M<]7B"O+2G
M!+\?\CMIY+2C\<F_P/E2[_9[\9V=PD*6MK?+@;KB"X58\]^'(;]*V])_9EUN
MXVG4-3L[)3U$0:9A^'RC]:^D**_,%P]@>=R:;OTOI^&OXGMJC%'D&E?LT^'[
M7#7U_>WS?W5*Q(?P )_6NRTKX3^$='V^1H5J[+T:X4S'/K\Y-=;17J4LNP='
MX*2^Z_YFBA%;(C@MXK6,1PQ)#&.B1J% _ 5)117H[;%A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B'QN_9=T/XH+/JFE^7HG
MB5LL;A5Q#<G_ *:J._\ MCGUW<5\.>-/ NN?#W6Y=*U[3Y+"[3E=PRDB_P!Y
M&'#+[C^=?JE7.>._A[H/Q)T1]+U^P2\MSDQOTDA;^\C=5/\ /OD<5]%E^<5,
M+:G5]Z'XKT_R/$QF60Q%YT])?@S\_O@[\?O$?P?O%2TE_M#1'?=/I5PQ\L^K
M(?X&]QP>X-?=WPO^+WASXM:3]LT2[_TB, W%A-A9X#_M+W'HPR#ZYXKXL^-O
M[,NO?"F2;4;+S-:\-9R+R-/WEN.PF4=/]X?*?;.*\I\/^(M3\)ZM;ZIH]]-I
M]_ =T<\#88>WN#W!X/>OHL3@,-FD/;T':7?_ #7],\2AC*^7S]E56G;_ "/U
M?HKYR^!_[7.F>,OL^C>+C#H^MMA([S.VVN3VSG_5L?0\$]",@5]&U\+B,-5P
ML_9U59_UL?74,13Q$>>F[A1117*= 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!RWQ4_Y)AXO_ .P/>?\ HAZ_.6OT:^*G_),/%_\ V![S_P!$/7YRT ?9
M7[&O_),-4_[#$O\ Z(@KWFO!OV-?^28:I_V&)?\ T1!7O- !1110 5PR?&_P
M/)\7)/A@NOPGQW'9#4&T?R9=X@(R'W[=G3G&[/(XY%>'?M<?M^>'OV9O$&F^
M#-)\.WWQ ^(VI(CV_A_37V"-7)">8ZJ[;V(^6-49B.NT$$_%5C\0/VE? O[4
M'B']HS6/V==9O#J>E)IK:/#%/MM( D W@JKR!ML!R63 ,C9 Z4 ?K_17FG[.
M/QOLOVC/@WH'Q L-*NM$AU03*VGWI#20213/#(NX<,-\;8.!D8R <@<7^U!^
MVU\./V6-/\K7[YM7\53IFS\,:61)>2DCY2XZ1(3CYFZ\[0Q&* /?Z*^&OV"?
MV\O&_P"U?\5O'/AOQ3X8T?PW9Z-9_:[:"RCG%U$WG",Q3-(Y#,,\D(G(Z=J^
MY: "BO@CXR?\%%_&&N?&+4/A7^SEX @^(_B32RZW^J7I=K-&1@L@14>/Y%8[
M#*\BKNX 88)XZ3_@HO\ ';]G7QKHVF?M)?".RT30-2?8NK:"&W( ?F=6$TT4
MQ7()C5D8 @^F0#]***HZ'K5AXDT73]7TNZCOM,U"WCN[6ZA.4FAD4,CJ>X*D
M$?6OA;XR?\%%_&&N?&+4/A7^SEX @^(_B32RZW^J7I=K-&1@L@14>/Y%8[#*
M\BKNX 88) /O>BOS7D_X*+_';]G7QKHVF?M)?".RT30-2?8NK:"&W( ?F=6$
MTT4Q7()C5D8 @^F?T:T/6K#Q)HNGZOI=U'?:9J%O'=VMU"<I-#(H9'4]P5((
M^M %ZBBB@ HHHH \&_;*_P"28:7_ -AB+_T1/7O->#?ME?\ ),-+_P"PQ%_Z
M(GKWF@ HHJ&WO+>[W^1/'-L.UO+<-M/H<=#0,FHJCJVN:=H-O]HU*_MM/@_Y
MZ74RQ+^;$"OSA\5_M0?$+Q!XLFUBU\1WVDP"8M;6%K)M@B3/RJR='XZE@<UR
MXC$+#I.2W/<RG**V;2G&E)+EM>_GM^1^EE?.G[4?[2VI?"'4M/T#P]:V\FK7
M-O\ :IKFZ4ND,99E4*H(RQ*L>>  .#GCC[?]O(1^&]/!\+O>:UY"K=2O<B&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 -DC61&1U#HPP589!'H:
M^7_CA^QY:ZU]HUKP*D=A?G+R:.2%@E/_ $R/2-O]D_+_ +M?45%=F%Q=;"3Y
MZ3M^3]3FQ&'IXF/)41^3.JZ3>Z'J-Q8:C:S65[;N4EMYT*.C#L0:]O\ @?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBLGXP? [P+\>_"Y\/^//#EIXATT$O$)P5E@<\;XI5(>-O=2,C@Y%?G7\=O\
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MG_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\
MA1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL
M7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G
M_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHK
MP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1W
MQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__
M 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QR
MC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ
M'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\
MWQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <
MH ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A
M1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z
M*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)
M_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1
MWQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*
MQ?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_
M\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]Y
MHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'
M_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_
M /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'
M*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_
M .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\
M_?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H
M]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;
M_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"B
ML7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$
MG_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\
MA1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL
M7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G
M_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHK
MP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1W
MQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__
M 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QR
MC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ
M'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\
MWQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <
MH ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A
M1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z
M*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)
M_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1
MWQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*
MQ?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_
M\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]Y
MHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'
M_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_
M /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'
M*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_
M .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\
M_?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H
M]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;
M_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"B
ML7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$
MG_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\
MA1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL
M7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G
M_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHK
MP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1W
MQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__
M 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QR
MC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ
M'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\
MWQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <
MH ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A
M1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z
M*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)
M_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1
MWQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*
MQ?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_
M\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]Y
MHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'
M_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_
M /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'
M*/\ A1WQ'_Z*Q?\ _?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_
M .BL7_\ WQ)_\<H ]YHKP;_A1WQ'_P"BL7__ 'Q)_P#'*/\ A1WQ'_Z*Q?\
M_?$G_P <H ]YHKP;_A1WQ'_Z*Q?_ /?$G_QRC_A1WQ'_ .BL7_\ WQ)_\<H
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M_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\
MZ*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]
M\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A
M1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z
M*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)
M_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WF
MBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%
M'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?
M_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_
M !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'
M_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_
M /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'
M* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O
M^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?
M_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?
M$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC
M_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"B
ML7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$
MG_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />
M:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?
M$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%
M_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_Q
MRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1W
MQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__
M 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR
M@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&
M_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\
MZ*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]
M\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A
M1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z
M*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)
M_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WF
MBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%
M'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?
M_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_
M !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'
M_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_
M /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'
M* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O
M^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?
M_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?
M$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC
M_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"B
ML7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$
MG_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />
M:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?
M$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%
M_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_Q
MRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1W
MQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__
M 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR
M@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&
M_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\
MZ*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]
M\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A
M1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z
M*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)
M_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WF
MBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%
M'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?
M_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_
M !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'
M_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_
M /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'
M* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O
M^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?
M_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?
M$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC
M_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"B
ML7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$
MG_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />
M:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?
M$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%
M_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_Q
MRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1W
MQ'_Z*Q?_ /?$G_QR@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__
M 'Q)_P#'* />:*\&_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR
M@#WFBO!O^%'?$?\ Z*Q?_P#?$G_QRC_A1WQ'_P"BL7__ 'Q)_P#'* />:*\&
M_P"%'?$?_HK%_P#]\2?_ !RC_A1WQ'_Z*Q?_ /?$G_QR@#WFBO'?"?PC\=:'
MXDT^_P!2^)%YJUC!*'FLI$<+,N/NG+G^5>Q4 %%%% !1110!RWQ4_P"28>+_
M /L#WG_HAZ_.6OT:^*G_ "3#Q?\ ]@>\_P#1#U^<M 'V5^QK_P DPU3_ +#$
MO_HB"O>:\&_8U_Y)AJG_ &&)?_1$%>\T %%%% 'P%\1/^"F_B#]GCXO>*_"W
MQ9^$FK6GAZVU6>'1->T=67[;9AV$,FV8A)&9 &+)(!G(VC!KDOB5_P %:+'X
MK>$]1\)?!3X;>,-;\9:Q;O8V\E]:1C[,9%*^8L=O)*TC#.0#M&>2<#!^WOVF
M/".N?$#]GOXB>&/#=I'?:[K6AW6G6EO-(L:N\L9CY9B .&)R3VKF_P!BGX/Z
MK\!_V8_!'@K7K2&SUZP@F>_B@=9 )I;B64C>N0Q <#()Z4 >:_\ !-/]E76_
MV8?@G>KXLC2V\6^)+M;^]LD96^QQJFR&%F4D,P!9C@X!DQSC)M_'#_@I;\(O
MV?\ XGZQX#\30>(Y=<TKR?M+:?IZ20_O84F4*S2J3\LBYXZYKZOK/N_#^EZA
M.9KK3;.YF;@R30(S''3DB@#\3?V-?VS_  !\!OVEOB[X\\2PZS)H?BJ2Z>P6
MQM4DF DO#,OF*9%"_*>Q/-?K!\*_BUX)_;.^!^KZCH4>H?\ "+ZU'>:)<Q:A
M L,V&0QRC:&88*OP<GK7IG_")Z'_ - ;3_\ P%C_ ,*T+2SM]/@$-K!';0KR
M(X4"J,]>!0!^0/[,WQXU?_@E]\2/&GPL^+OA_5I_"FHWGVW3]4TRW#+(Z@1_
M:8@[*)(I(Q'NPVY#& 1G('0_M<?MGS_MW:;I?P.^ _AS6M6&L7<,VJW]W;^2
M&CC<,BX!.R)7"2/(^T#8!BOU0\0>&='\66)LM;TFQUFR/)M]0MDGC/&/NN".
MA(_&HO#?@[0/!MJ]KX?T/3="MG(+0Z;:1VZ''3(0 =S^= ' _#']GW1OA_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M106S<6J_],R?O*/[A/T(Z'[>\)>,=&\=:+#JVA7\6HV,O22(\J>ZLIY5AZ$
MU\5C<OK8&7OJ\>CZ?\ ^JPN-I8M>Z[/L;-%%%>8=X4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '+?%3
M_DF'B_\ [ ]Y_P"B'K\Y:_1KXJ?\DP\7_P#8'O/_ $0]?G+0!]E?L:_\DPU3
M_L,2_P#HB"O>:\&_8U_Y)AJG_88E_P#1$%>\T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >#?ME?\DPTO_L,1?\ HB>O>:\&_;*_Y)AI
M?_88B_\ 1$]>\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!RWQ4_Y)AXO_P"P/>?^B'K\Y:_1KXJ?\DP\7_\ 8'O/_1#U^<M
M'V5^QK_R3#5/^PQ+_P"B(*]YKP;]C7_DF&J?]AB7_P!$05[S0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!X-^V5_R3#2_P#L,1?^B)Z]
MYKP;]LK_ ))AI?\ V&(O_1$]>\T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'B/QN_9>T/XHK/JFE^7HGB4Y8W"K^YN3Z2J._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .6^*G_ "3#Q?\ ]@>\_P#1#U^<M?HU\5/^28>+_P#L#WG_ *(>OSEH
M ^ROV-?^28:I_P!AB7_T1!7O->#?L:_\DPU3_L,2_P#HB"O>: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /!OVRO^28:7_V&(O\ T1/7
MO->#?ME?\DPTO_L,1?\ HB>O>: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ;)&LB,CJ'1A@JPR"/0U\O_ !P_8\M=:^T:
MUX%2.POSEY-')"P2G_ID>D;?[)^7_=KZBHKLPN+K82?/2=OR?J<V(P]/$QY*
MB/R9U72;W0]1N+#4;6:RO;=RDMO.A1T8=B#7M_P/_:JUGX;^1I.O>;K?AQ<*
MH+9N+5?^F;'[RC^X?P([_6GQ;^!OAOXP:?LU.#[+JD:[;?5+=0)H_0'^^O\
MLGU.,'FO@_XK_!7Q)\(=3\G5[;SK"1L6^I6X)@F]L_PMC^$\\<9'-?<X?&87
M-J?L:RM+M^J9\C6PN(RV?M:3T[_YGZ,^$?&6C>.M%AU;0K^+4+&7I)&>5/=6
M4\JP]#S6U7Y<?#SXF>(?A?K2ZEH%\ULYP)K=OFAG4?PNG<=>>HSP17W5\%?V
MD/#WQ;@CLG9=(\1A?GTZ9^)<#EH6_B'M]X<\8YKYK,,HJX2\Z?O0_%>O^9[V
M#S*GB;0GI+\_0]=HHHKY\]D**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .6^*G_),/%__ &![S_T0]?G+7Z-?%3_DF'B__L#WG_HA
MZ_.6@#[*_8U_Y)AJG_88E_\ 1$%>\UX-^QK_ ,DPU3_L,2_^B(*]YH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \&_;*_P"28:7_ -AB
M+_T1/7O->#?ME?\ ),-+_P"PQ%_Z(GKWF@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#EOBI_R3#Q?_P!@>\_]$/7YRU^C7Q4_Y)AX
MO_[ ]Y_Z(>OSEH ^ROV-?^28:I_V&)?_ $1!7O->#?L:_P#),-4_[#$O_HB"
MO>: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!OVRO\
MDF&E_P#88B_]$3U[S7@W[97_ "3#2_\ L,1?^B)Z]YH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '+?%3_DF'B__ + ]Y_Z(>OSEK]&OBI_R3#Q?
M_P!@>\_]$/7YRT ?97[&O_),-4_[#$O_ *(@KWFO!OV-?^28:I_V&)?_ $1!
M7O- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@W[97_)
M,-+_ .PQ%_Z(GKWFO!OVRO\ DF&E_P#88B_]$3U[S0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;XJ?\DP\7_]@>\_]$/7YRU^
MC7Q4_P"28>+_ /L#WG_HAZ_.6@#[*_8U_P"28:I_V&)?_1$%>\UX-^QK_P D
MPU3_ +#$O_HB"O>: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /!OVRO^28:7_P!AB+_T1/7O->#?ME?\DPTO_L,1?^B)Z]YH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#Q'XW?LOZ'\4EGU/3/+T3Q*06^THO[FY/I*H[
M_P"V.?7=P*^'/&W@/7/AWKDNDZ]826-VO*[N4E7^\C#AE]Q_.OU1KG/'7P^T
M'XD:&^E:_81WML>4?I)"W]Y&ZJ?IUZ'(XKZ++\XJ86U.K[T/Q7I_D>)C,LAB
M+SIZ2_!GY^_![X^^(_@_>JEG+_:&BNVZ?2KASY;>K(?X&]QP>X-?=_PO^,'A
MOXM:3]KT2[_TB-0;BPFPL\!_VE[C_:&0?7/%?%GQM_9DU[X4O-J-CYFM>&LY
M%Y&O[RW'I,HZ?[X^4^V<5Y3X?\1:GX4U:WU32+Z;3[^!MT<\#;6'M[@]P>#W
MKZ+$X'#9I#V]!VEW_P U_3/$H8ROE\_955IV_P C]7Z*^<?@?^UUIOC'[/HW
MB]H='UHX2.]^[;7)]\_ZMCZ'Y2>A' KZ.KX7$86KA9^SJJS_ *V/KJ&(IXB/
M/3=PHHHKE.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .6^*G_),/%__ &![S_T0]?G+7Z-?
M%3_DF'B__L#WG_HAZ_.6@#[*_8U_Y)AJG_88E_\ 1$%>\UX-^QK_ ,DPU3_L
M,2_^B(*]YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M&_;*_P"28:7_ -AB+_T1/7O->#?ME?\ ),-+_P"PQ%_Z(GKWF@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;XJ?\ ),/%_P#V![S_
M -$/7YRU^C7Q4_Y)AXO_ .P/>?\ HAZ_.6@#[*_8U_Y)AJG_ &&)?_1$%>\U
MX-^QK_R3#5/^PQ+_ .B(*]YH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \&_;*_Y)AI?_88B_P#1$]>\UX-^V5_R3#2_^PQ%_P"B)Z]Y
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6LZ+8>(M,N-.U.S
MAO[&X79+;SH&1A[@_P"15VBFFT[H32:LSXI^.'[']]X=^T:UX(274],&7DTL
MY>X@'_3/O(OM]X?[76OFF*66SN%DC=X)XFW*RDJR,#U![$&OULKQ'XW?LOZ'
M\4EGU/3/+T3Q*06^THO[FY/I*H[_ .V.?7=P*^PR_/'&U+%ZKO\ Y_YGS.,R
ME/\ >8??M_D>5? _]L:6S^SZ+X]=KB#A(M;5<NGIYRC[P_VQSZ@\FOKNPU"V
MU6R@O+*XBN[2= \4\+AT=3T((X(K\MO&W@/7/AWKDNDZ]826-VO*[N4E7^\C
M#AE]Q_.NL^#WQ]\1_!^]5+.7^T-%=MT^E7#GRV]60_P-[C@]P:ZL=DU/$+VV
M$:3?3H_3M^1SX3-)T7[+$[+KU7K_ %<_26BN)^%_Q@\-_%K2?M>B7?\ I$:@
MW%A-A9X#_M+W'^T,@^N>*[:OB*E.=*3A-6:/K(3C4BI0=TPHHHK,L**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .6^*
MG_),/%__ &![S_T0]?G+7Z-?%3_DF'B__L#WG_HAZ_.6@#[*_8U_Y)AJG_88
ME_\ 1$%>\UX-^QK_ ,DPU3_L,2_^B(*]YH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \&_;*_P"28:7_ -AB+_T1/7O->#?ME?\ ),-+
M_P"PQ%_Z(GKWF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\]^+7P/\-_&#3?+U.#[-J<:XM]4MU FB] ?[ZY_A/OC!YKT
M*BM:=6=&2G3=FC.I3C5BX35TS\S?BQ\$_$GPAU/R=6M_/T^1B+?4K<$PR^V?
MX6Q_">>#C(YK*^'GQ,\0_"_6EU+0+YK9S@36[?-#.H_A=.XZ\]1G@BOTZUC1
MK'Q#IEQIVIVD-]8W"[);>= R./<&OC?XX?L?WOAW[1K7@A)=2TP9>72B2]Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#EOBI_P DP\7_ /8'O/\ T0]?G+7Z-?%3_DF'B_\ [ ]Y_P"B'K\Y
M: /LK]C7_DF&J?\ 88E_]$05[S7@W[&O_),-4_[#$O\ Z(@KWF@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P;]LK_DF&E_]AB+_ -$3
MU[S7@W[97_),-+_[#$7_ *(GKWF@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q+XW?LOZ%\4EGU/3?+T3Q*0
M6^THO[JY/I*H[_[8Y]=V *^&_&W@/7/AWKDFDZ_826-TO*EAE)5S]]&Z,ON/
MIUK]4:YWQU\/]!^)&AOI6OV$=[;'E&/$D+?WD;JI^G7H<CBOHLOSBIA;4ZOO
M0_%>G^1XF,RR&(O.GI+\&?GY\'OC[XC^#]ZJ6<O]H:*[;I]*N'/EMZLA_@;W
M'![@U]W_  O^,'AOXM:3]KT2[_TB-0;BPFPL\!_VE[C_ &AD'USQ7Q;\;/V8
M]>^%3S:E8^9K?AH'/VR-/WEN/291T_WQP>^W.*\H\/\ B+4_"FK6^J:1?3:?
M?P-NCG@;:P]O<'N#P>]?18G X;-(>WH.TN_^:_IGB4,9B,OG[*JM.W^1^K]%
M?./P/_:ZTWQC]GT;Q>T.CZT<)'>_=MKD^^?]6Q]#\I/0C@5]'5\+B,+5PL_9
MU59_UL?74,13Q$>>F[A1117*= 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!RWQ4_Y)AXO_P"P/>?^B'K\Y:_1KXJ?\DP\7_\ 8'O/_1#U^<M
M'V5^QK_R3#5/^PQ+_P"B(*]YKP;]C7_DF&J?]AB7_P!$05[S0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!X-^V5_R3#2_P#L,1?^B)Z]
MYKP;]LK_ ))AI?\ V&(O_1$]>\T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5<)>=/WH?BO7_,][!YE3Q-H3TE^?H>NT445\^>R%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#EOBI_P DP\7_ /8'O/\ T0]?G+7Z-?%3_DF'B_\ [ ]Y_P"B'K\Y: /L
MK]C7_DF&J?\ 88E_]$05[S7@W[&O_),-4_[#$O\ Z(@KWF@ HHHH **** "O
MR/\ A/I/AGXT?\%8OB98_&&"VUAK*XU"#0-+U@K);32031I:Q^6WRN/LPDD$
M9!!.2<D<_KA7QM^V+_P3=\._M+>)E\<^'==E\"_$-%3?J$,1DM[QHQB-I54J
MRR* JB53D!1E6P, 'O7B[]F'X1^.]#;2-;^&WAB\L2GEJJZ7%"\0QC]W(BJ\
M9]U(-=?X!\"Z+\,?!>C>%/#MJUEH>D6R6EG;M*TA2-1@ LQ+'ZDU^7>L?'#]
ML3]@":S;XDP0?$[X>1RI!_:<\AN4()QM%X%$T3G& ;A6'H#7Z0_ +XX>'?VB
MOA7HOCOPP\@T_4$(DMY\"6UF4[9(9 /XE;(R.",$<$4 ?F]^P?X)\.^./^"@
M?[1EIXDT'2_$%K#=:O+'!JEG'<HC_P!J@;@KJ0#@D9'J:_2BW^ 7PQM9XYX/
MAQX2AFC8.DD>AVJLK Y!!$?!![U\7>(_^"3NKWOQ8\;^-_#OQYUKP?/XDU"\
MOO)TK2GBDA\^<S>6\J7:&55)Z;5S@'BO(/C19_M/?\$W;S1/%T?Q8O/BI\/[
MB[6REBUMYI4#E=PBDAE>0PA@C;7BDX*G.,X8 _1']K/XJW/P3_9O^(/C2Q;9
MJ.FZ6_V*3&=ES*1#"Q'<"21#CVKY,_X)'_LZZ%:?!Z3XO:]IL>K>,/$U]<?9
M=1U!!-)!;1R&,F,L"59Y5E+-G+ +Z<]A^WQ\2+7XO?\ !,_6_&NAH\6EZ]::
M/?F*8CS(HWOK8F-L<;E?"G'H:]&_X)LJB_L1_"T1XV_9+HG;Z_;)\_KF@#YO
M_P""P'[/^A:?\-M"^+OAO3(-$\4Z1JL-K>WVG1B!YX9 WER.4 R\<JQA6Z@.
M1G@8^WOV:?B-<_%S]G_X?>,+X[M0U?1;:XNV  !N/+ E( Z N&(]J\0_X*L1
MQM^P_P"."_WEN=-*<XY^W0#^1-=9_P $[8YX_P!BOX5"X_UG]FR,/]TW$I3_
M ,=(H ^C:*** "BJ^H23PV%S):QB:Y6)FBC/1G .!^)Q7AW_  L;XV?]$\L/
M^_P_^.T '[97_),-+_[#$7_HB>O>:^.OC_XL^(FN^#;.W\6^%;;0]-6_1X[B
M&3<6E$<@"??;C:6/3M7IG_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3
MRP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_  L;XV?]$\L/^_P_^.T?
M\+&^-G_1/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP
M_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0
M![S17@W_  L;XV?]$\L/^_P_^.T?\+&^-G_1/+#_ +_#_P".T >\T5X-_P +
M&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[
M_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_  L;XV?]$\L/^_P_^.T?\+&^
M-G_1/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_
MP_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S1
M7@W_  L;XV?]$\L/^_P_^.T?\+&^-G_1/+#_ +_#_P".T >\T5X-_P +&^-G
M_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X
M[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_  L;XV?]$\L/^_P_^.T?\+&^-G_1
M/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\
MCM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_
M  L;XV?]$\L/^_P_^.T?\+&^-G_1/+#_ +_#_P".T >\T5X-_P +&^-G_1/+
M#_O\/_CM'_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_P
ML;XV?]$\L/\ O\/_ ([0![S17@W_  L;XV?]$\L/^_P_^.T?\+&^-G_1/+#_
M +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\ CM '
MO-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_  L;
MXV?]$\L/^_P_^.T?\+&^-G_1/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\
M/_CM'_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV
M?]$\L/\ O\/_ ([0![S17@W_  L;XV?]$\L/^_P_^.T?\+&^-G_1/+#_ +_#
M_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\ CM 'O-%>
M#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_  L;XV?]
M$\L/^_P_^.T?\+&^-G_1/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM
M'_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\
ML/\ O\/_ ([0![S17@W_  L;XV?]$\L/^_P_^.T?\+&^-G_1/+#_ +_#_P".
MT >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\
M"QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_  L;XV?]$\L/
M^_P_^.T?\+&^-G_1/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"Q
MOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\
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M/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\
MCM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_
M  L;XV?]$\L/^_P_^.T?\+&^-G_1/+#_ +_#_P".T >\T5X-_P +&^-G_1/+
M#_O\/_CM'_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_P
ML;XV?]$\L/\ O\/_ ([0![S17@W_  L;XV?]$\L/^_P_^.T?\+&^-G_1/+#_
M +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\ CM '
MO-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_  L;
MXV?]$\L/^_P_^.T?\+&^-G_1/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\
M/_CM'_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV
M?]$\L/\ O\/_ ([0![S17@W_  L;XV?]$\L/^_P_^.T?\+&^-G_1/+#_ +_#
M_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\ CM 'O-%>
M#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_  L;XV?]
M$\L/^_P_^.T?\+&^-G_1/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM
M'_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\
ML/\ O\/_ ([0![S17@W_  L;XV?]$\L/^_P_^.T?\+&^-G_1/+#_ +_#_P".
MT >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\ CM 'O-%>#?\
M"QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\ O\/_ ([0![S17@W_  L;XV?]$\L/
M^_P_^.T?\+&^-G_1/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"Q
MOC9_T3RP_P"_P_\ CM 'O-%>#?\ "QOC9_T3RP_[_#_X[1_PL;XV?]$\L/\
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M/+#_ +_#_P".T >\T5X-_P +&^-G_1/+#_O\/_CM'_"QOC9_T3RP_P"_P_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KSWXM? _PW\8--\O4X/LVIQKBWU2W4":+T!_OKG^$^^,'FO0J*
MUIU9T9*=-V:,ZE.-6+A-73/S-^+'P3\2?"'4_)U:W\_3Y&(M]2MP3#+[9_A;
M'\)YX.,CFLKX>?$SQ#\+]:74M OFMG.!-;M\T,ZC^%T[CKSU&>"*_3K6-&L?
M$.F7&G:G:0WUC<+LEMYT#(X]P:^.?C9^QU?Z')+JW@6.74].)W/I+-NN(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '+?%3_DF'B__ + ]Y_Z(>OSEK]&OBI_R
M3#Q?_P!@>\_]$/7YRT ?97[&O_),-4_[#$O_ *(@KWFO!OV-?^28:I_V&)?_
M $1!7O- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@W[
M97_),-+_ .PQ%_Z(GKWFO!OVRO\ DF&E_P#88B_]$3U[S0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M['=QRY_[Y)K8KBE%Q=I*QUJ2DKIA1114C"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;XJ?\DP
M\7_]@>\_]$/7YRU^C7Q4_P"28>+_ /L#WG_HAZ_.6@#[*_8U_P"28:I_V&)?
M_1$%>\UX-^QK_P DPU3_ +#$O_HB"O>: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /!OVRO^28:7_P!AB+_T1/7O->#?ME?\DPTO_L,1
M?^B)Z]YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDU^3U.CD:)U=&9'4Y#*<$5SSX=IOX*C7JK_Y&T<[J+XX)_A_F?K=17Y<:/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?,?X8+V-V_(-FN">&KT_C@U\F=D:]*I\$T_F='129SR.12US&X4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY_A(KM=(_:0^)6B;?L_BZ^E _P"?P)<_^C%:OK/5_P!C/X;ZEG[/;:EI6?\
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MVT?_ )==*'V=,>FX'>1[,QKR]W:1V=V+,QR68Y)/K7T>'X>D]:\[>2_S_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKAFCN(UDB=9(VZ,A!!_&N"5.=/2:L=<9QGK%W'T445!84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%8/BKQ
MYX=\#VXGU[6K+2D(RJW$P5W_ -U?O-^ ->$>-OVX?#.D[X?#6EW6O3#@7$_^
MC0?49!<_0J/K7;0P>(Q/\*#?Y??L<M;%4:'\227]=CZ5KG/%OQ%\,^!83)K^
MN66E\;A'-*/,8?[*#+-^ -?"'C;]JKXA^,O,C75O[#LVX^SZ2ODG'_73)?\
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M917S>(S+%8C2<].RT1[E' 8>AK&.OGJ(JA5  P!P *6BBO,.\**** "BBB@
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M+_\ L#WG_HAZ_.6OT:^*G_),/%__ &![S_T0]?G+0!]E?L:_\DPU3_L,2_\
MHB"O>:\&_8U_Y)AJG_88E_\ 1$%>\T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >#?ME?\DPTO\ [#$7_HB>O>:\&_;*_P"28:7_ -AB
M+_T1/7O- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!AB7_T1!7O->#?L:_\DPU3_L,2_P#HB"O>: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /!OVRO^28:7_V&(O\ T1/7O->#?ME?\DPT
MO_L,1?\ HB>O>: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#EOBI_R3#Q?_ -@>\_\ 1#U^<M?HU\5/
M^28>+_\ L#WG_HAZ_.6@#[*_8U_Y)AJG_88E_P#1$%>\UX-^QK_R3#5/^PQ+
M_P"B(*]YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \&
M_;*_Y)AI?_88B_\ 1$]>\UX-^V5_R3#2_P#L,1?^B)Z]YH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.6^*G_),/%__ &![S_T0]?G+7Z-?%3_DF'B__L#WG_HAZ_.6@#[*_8U_Y)AJ
MG_88E_\ 1$%>\UX-^QK_ ,DPU3_L,2_^B(*]YH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \&_;*_P"28:7_ -AB+_T1/7O->#?ME?\
M),-+_P"PQ%_Z(GKWF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Y;XJ?\DP\7_]@>\_]$/7YRU^C7Q4
M_P"28>+_ /L#WG_HAZ_.6@#[*_8U_P"28:I_V&)?_1$%>\UX-^QK_P DPU3_
M +#$O_HB"O>: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /!OVRO^28:7_P!AB+_T1/7O->#?ME?\DPTO_L,1?^B)Z]YH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .6^*G_ "3#Q?\ ]@>\_P#1#U^<M?HU\5/^28>+_P#L#WG_ *(>OSEH ^RO
MV-?^28:I_P!AB7_T1!7O->#?L:_\DPU3_L,2_P#HB"O>: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /!OVRO^28:7_V&(O\ T1/7O->#
M?ME?\DPTO_L,1?\ HB>O>: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#EOBI_R3#Q?_ -@>\_\ 1#U^
M<M?HU\5/^28>+_\ L#WG_HAZ_.6@#[*_8U_Y)AJG_88E_P#1$%>\UX-^QK_R
M3#5/^PQ+_P"B(*]YH **** "BBB@ HHHH **** "BH;J[@L;>2XN9H[>",;G
MEE8*JCU)/ KY%_85_:<\5?M">/OCA!XAU?3[W1=#U_[)X=M[6*.-TM?,N >5
MYD&Q8?F.><\\T ?8%%%8/B[Q]X8^']BE[XH\1Z3X;LW)"W&KWT5K&V!DX:1@
M.!S0!O45SG@WXD>$?B);R7'A3Q3HOB>"/&^71M0ANU7/3)C8@5T= !1110 4
M444 >#?ME?\ ),-+_P"PQ%_Z(GKWFO!OVRO^28:7_P!AB+_T1/7O- !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
M >#_ ./4 >\T5X-_PV5X*_Z!>O?^ \'_ ,>H_P"&RO!7_0+U[_P'@_\ CU '
MO-%>#?\ #97@K_H%Z]_X#P?_ !ZC_ALKP5_T"]>_\!X/_CU 'O-%>#?\-E>"
MO^@7KW_@/!_\>H_X;*\%?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P
M?_'J/^&RO!7_ $"]>_\  >#_ ./4 >\T5X-_PV5X*_Z!>O?^ \'_ ,>H_P"&
MRO!7_0+U[_P'@_\ CU 'O-%>#?\ #97@K_H%Z]_X#P?_ !ZC_ALKP5_T"]>_
M\!X/_CU 'O-%>#?\-E>"O^@7KW_@/!_\>H_X;*\%?] O7O\ P'@_^/4 >\T5
MX-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\  >#_ ./4 >\T5X-_PV5X
M*_Z!>O?^ \'_ ,>H_P"&RO!7_0+U[_P'@_\ CU 'O-%>#?\ #97@K_H%Z]_X
M#P?_ !ZC_ALKP5_T"]>_\!X/_CU 'O-%>#?\-E>"O^@7KW_@/!_\>H_X;*\%
M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
M >#_ ./4 >\T5X-_PV5X*_Z!>O?^ \'_ ,>H_P"&RO!7_0+U[_P'@_\ CU '
MO-%>#?\ #97@K_H%Z]_X#P?_ !ZC_ALKP5_T"]>_\!X/_CU 'O-%>#?\-E>"
MO^@7KW_@/!_\>H_X;*\%?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P
M?_'J/^&RO!7_ $"]>_\  >#_ ./4 >\T5X-_PV5X*_Z!>O?^ \'_ ,>H_P"&
MRO!7_0+U[_P'@_\ CU 'O-%>#?\ #97@K_H%Z]_X#P?_ !ZC_ALKP5_T"]>_
M\!X/_CU 'O-%>#?\-E>"O^@7KW_@/!_\>H_X;*\%?] O7O\ P'@_^/4 >\T5
MX-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\  >#_ ./4 >\T5X-_PV5X
M*_Z!>O?^ \'_ ,>H_P"&RO!7_0+U[_P'@_\ CU 'O-%>#?\ #97@K_H%Z]_X
M#P?_ !ZC_ALKP5_T"]>_\!X/_CU 'O-%>#?\-E>"O^@7KW_@/!_\>H_X;*\%
M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
M >#_ ./4 >\T5X-_PV5X*_Z!>O?^ \'_ ,>H_P"&RO!7_0+U[_P'@_\ CU '
MO-%>#?\ #97@K_H%Z]_X#P?_ !ZC_ALKP5_T"]>_\!X/_CU 'O-%>#?\-E>"
MO^@7KW_@/!_\>H_X;*\%?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P
M?_'J/^&RO!7_ $"]>_\  >#_ ./4 >\T5X-_PV5X*_Z!>O?^ \'_ ,>H_P"&
MRO!7_0+U[_P'@_\ CU 'O-%>#?\ #97@K_H%Z]_X#P?_ !ZC_ALKP5_T"]>_
M\!X/_CU 'O-%>#?\-E>"O^@7KW_@/!_\>H_X;*\%?] O7O\ P'@_^/4 >\T5
MX-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\  >#_ ./4 >\T5X-_PV5X
M*_Z!>O?^ \'_ ,>H_P"&RO!7_0+U[_P'@_\ CU 'O-%>#?\ #97@K_H%Z]_X
M#P?_ !ZC_ALKP5_T"]>_\!X/_CU 'O-%>#?\-E>"O^@7KW_@/!_\>H_X;*\%
M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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M?] O7O\ P'@_^/4 >\T5X-_PV5X*_P"@7KW_ (#P?_'J/^&RO!7_ $"]>_\
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MQ7I\VK^%]8L;< W%U9S01AC@;F0J,GZF@#SG]EC_ )(OI/\ UVN/_1K5ZW7
M? SP;J7@'X;V&C:LL:7T,DS.L3[UPTC,.?H:[^@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#!\??\B)XC_[!MS_Z*:N"_98_Y(OI/_7:X_\ 1K5Z-XKT^;5_"^L6
M-N ;BZLYH(PQP-S(5&3]37*_ SP;J7@'X;V&C:LL:7T,DS.L3[UPTC,.?H:
M._HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \&_9&_P"18\4?]AB3_P! 2O>:
M\L_9_P#A[K'P[T36[76$A26[U%KF+R9 XV%5 SZ'@UZG0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@#EOBI_R3#Q?_ -@>\_\ 1#U^<M?HU\5/^28>+_\
ML#WG_HAZ_.6@#[*_8U_Y)AJG_88E_P#1$%>\UX-^QK_R3#5/^PQ+_P"B(*]Y
MH **** "BBB@ HHHH **** "BBB@ HHHH ***^:?VS/VNM3_ &:8_"6B>%O
MU]X^\<>+7N(]*TVU#F,>3Y>]F"*SN?WJ810,\DLN.0#Z6HK\Q?%G[5_[=?PV
MT6Y\:^)?@YH,7A6W0S7$"6AE^SQ Y9V6*[:9  >6<8 7)'!K[!_8Z_:VT']K
MSX9R>(M,LFT;6-/F%IJVCR2B0VTI7<K*^!NC<9*M@?=88RM 'O-%?,?[;'[;
MVC?LCZ!IEK;Z8?$_CK6\C2]#1RHV@[3-*0"0F[Y0H&YVR!C#,OSCKW[1/[>_
M@[P[-XYU?X2^&_\ A&X(S=7.FQ0K)-! /F+-$EV9QA3SP2H7+ 8.0#]*J*\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHD4L[L>P"@DGVK\Z6_;V^/G[3GC+7=-_9F^'&GW?A?2)?)E\0:]M#29!"O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** "H[BWBNH)(9XTFAD4J\<BAE93P00>HJ2B@ K\J_VF(+?XB?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  DVM?M%?%^-YOB+XL+SZ?:72;9+"WE'S2LI_P!6[KM14_Y9QC;_ !%5H_\
M!:S3VF_9F\)W:DXM_%L",N>,-9W?/YJ!^- 'TO\ L3^ [+X<_LH_"[2;*%8O
M-T*UU"XVIM+3W$8GE)]3ND(R>< 5\<?\%M/"44/A/X7^-[8?9]5L=3GTW[3'
M\LA5XQ,G/^RT+$>A<^M?=O[->H0ZM^SK\+KRW<20S>%M+=6&.]I'Q]:^+_\
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M93NN>0CQ2*IQ]8V_*OT,^*5]#IOPR\77EP_EV]OH]Y+(Q[*L+DG\A0!\,?\
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M#X[_ ."@7CO6OVB_C'X0_92\!W;1RZE/%J'BZ^A^9;2V7$JQO[*@\XJ>K&
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M-?\ DF&J?]AB7_T1!7O- !1110 4444 %%%% !1110 4444 %%%% !7YX_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[>'P(_9'^'_]GVG@;Q9JOB[4E636M>:.U#7$@Y$<>9LK$A)P.IY8\GC]F**
M/CS]FO\ X*:> _VFOBM8^ M#\+>)-*U*\@FGCN=02 P@1(78,4D)&0#CCK@=
MZX;_ (*M?LP^)_BAX;\+?$WP%97&H>*/!SL+BTLD+W$EJ6$BR1J!EFBD7.T<
MXD8_PU]^44 ?G)X3_P""TWP^C\"QMXM\'>)+7QO;P!+K3].@A-I+< 8.R1Y0
MR(6'(925!Q\Y'-+]@CX/^._CA^TQXG_:E^).BS:!'>B5?#]A<HR.V^,0*Z!@
M#Y45N/+#$#>6W#H<_HC<>$-!O-474Y]$TZ;4EX6\DM(VF'T<C/ZUKT %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M22.SNK+(ZAXRY9UDC)!WGC&#7ZY5G:UX=TKQ';K!JVF6>J0*<B.]MTF4=.S
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M\6[Z8]XA87/V>1I8(D<@"20S.TC,HVHHVY)VEOU7HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQH_X*;_M;ZGX^
M^.=W\'=2?4= ^&?AR_A75HM,16O-3<*KM)ARJ[5#?NT)VY^=L_*%_9>B@#\P
M/A?_ ,%9/@/\&O ND^#_  E\,O%FE:%IL7E001K:DL>K.[>=EG8Y+,>22:^Q
M?V2OVP?#/[7WA_7]6\-:-J^C1Z-=1VLT>JK&"Y="P*E'8'H<YQV]:]ZHH _(
M6>Z\3_\ !*_]KKQ3XAN?#%]K?P=\7/(([BQ7@0O(98T1SA!/"Q9-CD;D)(QN
M!'7?M*?\%*K?]ISX>WGPG^!?@SQ3JOB3Q7%]@NIKJTC5XK9\"1(TCDDR64E&
M9MJHK$Y/4?J1<6\5W"\,\231.,-'(H96'H0>M4-%\,Z/X;C>/2-)L=*C;EEL
MK9(0?J% H \+_9 ^!9_9#_9=L=!U%/MFM6T,^M:T+/Y_,NF7<\<?][:B)&#_
M !;,]Z_)'7?VQ= ^/_[2EO\ $+X[Z5JVM^#])W'1O!NB>6UO$H8%(Y3(Z;E.
M TC8S(0 <( H_?6B@#\YX?\ @M=\*+>&.*+P#XNBBC4*D:):!54#   FX%?8
M_@_7/!_[6_P#TO5M1\/&^\(>*[-9WT?6HE)*B3(#JI(R'0,"#V4BO4:* /G_
M /X8#_9Y_P"B3^'_ /OT_P#\57YZ_M1?L]_#SP;_ ,%(_@YX%T7PAI^F^#]8
MATMKW2(4807'F7EPDA89R<JB@\]J_8JH)+*WFNHKEX(GN(@1',R NF>#@]1F
M@#S.Z^%?A'X/? SQ?H'@KP_9>&]'_LV^N#:6,>Q&E:!@SGN6(51D]@!T KX/
MK]&OBI_R3#Q?_P!@>\_]$/7YRT ?97[&O_),-4_[#$O_ *(@KWFO!OV-?^28
M:I_V&)?_ $1!7O- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <M\5/^28>+_\ L#WG_HAZ_.6OT:^*G_),/%__
M &![S_T0]?G+0!]E?L:_\DPU3_L,2_\ HB"O>:\&_8U_Y)AJG_88E_\ 1$%>
M\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!RWQ4_Y)AXO_P"P/>?^B'K\Y:_1KXJ?\DP\7_\ 8'O/_1#U^<M
M'V5^QK_R3#5/^PQ+_P"B(*]YKP;]C7_DF&J?]AB7_P!$05[S0 4444 %%%%
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M<+E\CVQDT >RT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCVKZ)H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>E;F"[[S1KDKSW/EJ_% 'V)17+?#GXI>$?BYX=CUWP9XBT[Q+I+G;]IT^=9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **^&?VS/&WB";XE2^'I+JXMM#M;:)X;:-BL<^]<M(P_B.2R\]
M-I]\_.M?58;(98BC&K*I:^NU_P!4?.XC.%1JRIJ%[>=OT/UPHK\CZ*ZO]7/^
MGW_DO_!,/[<_Z=_C_P  _7"BOR/HH_U<_P"GW_DO_!#^W/\ IW^/_ /UPHK\
MCZ*/]7/^GW_DO_!#^W/^G?X_\ _7"BOR/HH_U<_Z??\ DO\ P0_MS_IW^/\
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MVGS97MW?C']YCTXH ^S/A3\2M(^,7P[T'QKH N%T?6K875L+N,1RA"2,,H)
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M@/V?_P#@II\&OVA/&%IX5T^?5O#&OWK;+.U\16\4*W4F<"..2.1U+GLI()/
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MMKW\CZ=HKA_C=XDU3P?\)_$^L:*/^)G:6A>%MN[R\D OC_94EN?[M?G)X/\
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MH [;2?\ @H5\&K_2/B!JE]K-WH%CX)U!=,U"35+8(;BX9IE1+9$9FE),$G
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M_93M;0>,M2N+G5[L;[?0]'C6>^>/G]X49E5$R,!G903D#.#CP?\ X>6?!O\
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M?B;]N;XF?%7X]ZY%!#IMS):^%K.\TVXO84"3-'$PCBBD :**,$%L#?*6&6Y
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M_P $Z?A5KGQ^^*GBC]JSXD0>9J.JW4UOX9M),LD"#,3RQY_AC0>0GTE)YP:
M/T?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA:YE\ ^/M$6/640%AMWA+J/'<H1#<(.,GY1P#7Z#?\%;/^3+?$'_ &$]/_\
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M9M9R^/;*Q_I7V!\!-6C\,_LM?#K4]<N%MHM/\&:=<WUQ)P(UCL8VD8^PPQH
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MP]T__@JAH>J? _4EE\!^,8&M-1M+&QFM(/-D@<R(L4L:,JB:**;@8!)P<9%
M'ZN?$#XB>&OA5X3OO$WB[6K30-"L5W3WMX^U%SP% ZLQ/ 5023P 37QA=?\
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MR1/'_JRHZ$0(V<@8::1F&"IK]-* "BBB@ HHHH **** "BBB@ HHHH ****
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M+P-)^;FOK'X-_!'P5\ ?!D7A;P+H<.AZ0LAF=$9I))Y2 &DD=B6=B% R3T
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ML5?J57B6B_LA> =!_:0U/XWVPU0^--0B:.59+H&T7=$L198]N<[$ Y8CD\4
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M\7W^-@AUO5M+N[N#0O#NM3;H,0W;1B%8SQ((HU&(^0=S,5/)K];Z^8?VAO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<=]D(;^+((R#FNE_X+=,$U/X#LQ"J)M8))Z#YM/K] /@;^SA\._V<?#\ND^
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MPR.K AE()!!X(- 'S_\ L\_MW?"7X_>#[#48/%FE>'=?>,"\\/ZS>Q6UU!*
M-X178>;'GHZ9&",X.5$GQ/\ V]/@S\,=;T70SXKM_%.OZM>PV,&E^&9([Z5&
MDD"!I&5MD8!8$AFW$=%->:^//^"2/[/WC;5Y]0M-/USPFTS;WM]!U$) &SD[
M4F20*#R-JX !X XQWOP+_P"">GP2_9^UJ#7-!\,R:KX@MVWV^K:].;N: YR#
M&I C1AV94#>] 'R#^W-=7'[,_P#P45^%OQNU*T<^$K^.&*YNX06*F-6M[H8
MR66"5' _BZ#H<?HYIWQJ\ :MX/'BJT\:Z#-X;\L2G5!J,0@12N[YF+84X['!
M&#Q4WQ2^$OA'XU^#[OPOXUT*UU_1;CEK>Y4[HV[/&XPT;C)PRD$9/-?'J_\
M!&;X$+JYO#JGC1K<ON_L\ZG;^0!_=S]G\S'_  //O0!Y#\"]67]L+_@J9JWQ
M3\-1M<^ ?!EML2_D5E68"U>VA(!&09)6DE4$ [4.>:Z__@MQ_P D7^'G_8P2
M?^DSU]T?"#X*^"O@+X0B\,^!- M] TA7\UXX2SO-(0 9))&)9V( &6)X '0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZUHEA
MXBT^2QU*UCO+63[T<@XSZCT/N.:O45,HJ2<9*Z8'!?\ "B_ _P#T!/\ R;G_
M /BZ/^%%^!_^@)_Y-S__ !==[17%_9^#_P"?,?\ P%?Y$<D>QP7_  HOP/\
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M ?BW^U9^S+8_\$V_C+\(?B1\/[_6]7T-;XRW!UB:*2430NK20[HXHP$EA=E
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M/OA_^T]KWA/4_'*ZI<_\(T\CVMG:W8CMY1(T;.LJ%3D'RE!P5..,], 'QO\
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M926W<C&^*52'C;'=2,]#D4 2:'\=/ASXDT*/6M,\>>&[W2G02"[BU6 H%/\
M>.[Y3UR#@@@@]*_-'_@I%^TYIW[5'BCP9\!/A!J$7BE[G5XWO;^RE!M+BZ.8
MX(4EZ.B[W=W&4^[@DJ<>\W?_  1I^ UQJ7VF/4/&5K!S_H<.J0&+G/=K<OQ_
MO=N]6/BS_P $DOA%XE^&]MI'@*&X\$>*M/8S6FOM<2W33OQE;A6?E3@8*;2A
MY'&58 ^L_@W\-K/X._"GPGX)L'\ZVT'38+ 3$8,K(@#R$>K-N;_@5=E7P_\
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MLC<8]*[2X^'^D77PWE\#LDPT&323HI19#YGV8P^3C=_>V=_6@#XO_P"",/\
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MLN>"?A#\5O''Q!\/I?IKWC!]^H)<7 :W3YRY$2!1M!8]R?;% 'YZ?M86.A_
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M&2>YH LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <M\5/^28>+_^P/>?^B'K\Y:_1KXJ?\DP\7_]@>\_]$/7YRT ?97[&O\
MR3#5/^PQ+_Z(@KWFO!OV-?\ DF&J?]AB7_T1!7O- !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .6^*G_),/%__ &![S_T0]?G+7Z-?%3_DF'B__L#WG_HAZ_.6
M@#[*_8U_Y)AJG_88E_\ 1$%>\UX-^QK_ ,DPU3_L,2_^B(*]YH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^*H_X6IX*_Z&_0?_  9P?_%4 =317+?\+4\%?]#?H/\ X,X/_BJ/^%J>"O\
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M5 '4T5RW_"U/!7_0WZ#_ .#.#_XJC_A:G@K_ *&_0?\ P9P?_%4 =317+?\
M"U/!7_0WZ#_X,X/_ (JC_A:G@K_H;]!_\&<'_P 50!U-%<M_PM3P5_T-^@_^
M#.#_ .*H_P"%J>"O^AOT'_P9P?\ Q5 '4T5RW_"U/!7_ $-^@_\ @S@_^*H_
MX6IX*_Z&_0?_  9P?_%4 =317+?\+4\%?]#?H/\ X,X/_BJ/^%J>"O\ H;]!
M_P#!G!_\50!U-%<M_P +4\%?]#?H/_@S@_\ BJ/^%J>"O^AOT'_P9P?_ !5
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MRW_"U/!7_0WZ#_X,X/\ XJC_ (6IX*_Z&_0?_!G!_P#%4 =317+?\+4\%?\
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MOT'_ ,&<'_Q5 '4T5RW_  M3P5_T-^@_^#.#_P"*H_X6IX*_Z&_0?_!G!_\
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M]#?H/_@S@_\ BJ/^%J>"O^AOT'_P9P?_ !5 '4T5RW_"U/!7_0WZ#_X,X/\
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M;]!_\&<'_P 50!U-%<M_PM3P5_T-^@_^#.#_ .*H_P"%J>"O^AOT'_P9P?\
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MX*_Z&_0?_!G!_P#%4 =317+?\+4\%?\ 0WZ#_P"#.#_XJC_A:G@K_H;]!_\
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MH/\ X,X/_BJ/^%J>"O\ H;]!_P#!G!_\50!U-%<M_P +4\%?]#?H/_@S@_\
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M/!7_ $-^@_\ @S@_^*H_X6IX*_Z&_0?_  9P?_%4 =317+?\+4\%?]#?H/\
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M>"O^AOT'_P &<'_Q5 '4T5RW_"U/!7_0WZ#_ .#.#_XJC_A:G@K_ *&_0?\
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M^#.#_P"*H_X6IX*_Z&_0?_!G!_\ %4 =317+?\+4\%?]#?H/_@S@_P#BJ/\
MA:G@K_H;]!_\&<'_ ,50!U-%<M_PM3P5_P!#?H/_ (,X/_BJ/^%J>"O^AOT'
M_P &<'_Q5 '4T5RW_"U/!7_0WZ#_ .#.#_XJC_A:G@K_ *&_0?\ P9P?_%4
M=317+?\ "U/!7_0WZ#_X,X/_ (JC_A:G@K_H;]!_\&<'_P 50!U-%<M_PM3P
M5_T-^@_^#.#_ .*H_P"%J>"O^AOT'_P9P?\ Q5 '4T5RW_"U/!7_ $-^@_\
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M^*H_X6IX*_Z&_0?_  9P?_%4 =317+?\+4\%?]#?H/\ X,X/_BJ/^%J>"O\
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M5 '4T5RW_"U/!7_0WZ#_ .#.#_XJC_A:G@K_ *&_0?\ P9P?_%4 =317+?\
M"U/!7_0WZ#_X,X/_ (JC_A:G@K_H;]!_\&<'_P 50!U-%<M_PM3P5_T-^@_^
M#.#_ .*H_P"%J>"O^AOT'_P9P?\ Q5 '4T5RW_"U/!7_ $-^@_\ @S@_^*H_
MX6IX*_Z&_0?_  9P?_%4 =317+?\+4\%?]#?H/\ X,X/_BJ/^%J>"O\ H;]!
M_P#!G!_\50!U-%<M_P +4\%?]#?H/_@S@_\ BJ/^%J>"O^AOT'_P9P?_ !5
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MRW_"U/!7_0WZ#_X,X/\ XJC_ (6IX*_Z&_0?_!G!_P#%4 =317+?\+4\%?\
M0WZ#_P"#.#_XJC_A:G@K_H;]!_\ !G!_\50!U-%<M_PM3P5_T-^@_P#@S@_^
M*H_X6IX*_P"AOT'_ ,&<'_Q5 !\5/^28>+_^P/>?^B'K\Y:^]_B5\2O"-]\.
MO%-M;>*=%N+F;2KJ.*&+486=V,+ *H#9)). !7P10!I^)XD@\2ZM%$BQQI=S
M*J*,!0'(  ["LRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O9M!T'3)M#TZ233K1Y&MHV9F@4DDJ,DG%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333120880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cartesian Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1622110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7495 New Horizon Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Frederick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">348-8698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RNAC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,901,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,907,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive Proxy Statement relating to its 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001453687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150335539504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333262416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 212,610<span></span>
</td>
<td class="nump">$ 76,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">5,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Unbilled receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,144<span></span>
</td>
<td class="nump">4,967<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">216,626<span></span>
</td>
<td class="nump">90,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,912<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">5,535<span></span>
</td>
<td class="nump">10,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">In-process research and development assets</a></td>
<td class="nump">150,600<span></span>
</td>
<td class="nump">150,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">48,163<span></span>
</td>
<td class="nump">48,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investments</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">435,023<span></span>
</td>
<td class="nump">305,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">12,076<span></span>
</td>
<td class="nump">15,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">2,851<span></span>
</td>
<td class="nump">2,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_WarrantsAndRightsOutstandingCurrent', window );">Warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiabilityCurrent', window );">Contingent value right liability</a></td>
<td class="nump">7,761<span></span>
</td>
<td class="nump">15,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Forward contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,307<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,976<span></span>
</td>
<td class="nump">68,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">11,133<span></span>
</td>
<td class="nump">8,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_WarrantsAndRightsOutstandingNoncurrent', window );">Warrant liabilities, net of current portion</a></td>
<td class="nump">3,836<span></span>
</td>
<td class="nump">5,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiabilityNoncurrent', window );">Contingent value right liability, net of current portion</a></td>
<td class="nump">387,739<span></span>
</td>
<td class="nump">342,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">16,141<span></span>
</td>
<td class="nump">15,853<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">441,825<span></span>
</td>
<td class="nump">444,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 19)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A Preferred Stock, $0.0001 par value; no and 548,375 shares authorized as of December 31, 2024 and December 31, 2023, respectively; no and 435,120.513 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">296,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent', window );">Options for Series A Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 350,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 25,767,369 and 5,397,597 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">689,887<span></span>
</td>
<td class="nump">179,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(692,071)<span></span>
</td>
<td class="num">(614,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,621)<span></span>
</td>
<td class="num">(4,600)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(6,802)<span></span>
</td>
<td class="num">(440,184)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and stockholders&#8217; deficit</a></td>
<td class="nump">435,023<span></span>
</td>
<td class="nump">305,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value, issued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContingentValueRightLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Right Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContingentValueRightLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContingentValueRightLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Right Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContingentValueRightLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Options, Carrying Amount, Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_WarrantsAndRightsOutstandingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_WarrantsAndRightsOutstandingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_WarrantsAndRightsOutstandingNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_WarrantsAndRightsOutstandingNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330630896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">548,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">435,120.513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">435,120.513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">9,427,168.437<span></span>
</td>
<td class="nump">9,451,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">25,767,369<span></span>
</td>
<td class="nump">5,397,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">25,767,369<span></span>
</td>
<td class="nump">5,397,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">134,904.563<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">120,790.402<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">120,790.402<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">437,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">437,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">437,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330500960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 38,275<span></span>
</td>
<td class="nump">$ 26,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">38,913<span></span>
</td>
<td class="nump">26,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">45,105<span></span>
</td>
<td class="nump">71,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">30,126<span></span>
</td>
<td class="nump">40,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">7,579<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">82,810<span></span>
</td>
<td class="nump">112,420<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(43,897)<span></span>
</td>
<td class="num">(86,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7,386<span></span>
</td>
<td class="nump">4,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">2,558<span></span>
</td>
<td class="nump">12,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_FairValueAdjustmentOfContingentValueRightLiability', window );">Change in fair value of contingent value right liability</a></td>
<td class="num">(36,900)<span></span>
</td>
<td class="num">(18,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of forward contract liabilities</a></td>
<td class="num">(6,890)<span></span>
</td>
<td class="num">(149,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(77,137)<span></span>
</td>
<td class="num">(238,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(287)<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(77,424)<span></span>
</td>
<td class="num">(219,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (77,445)<span></span>
</td>
<td class="num">$ (219,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share allocable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (4.48)<span></span>
</td>
<td class="num">$ (49.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (4.49)<span></span>
</td>
<td class="num">$ (49.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">17,276,822<span></span>
</td>
<td class="nump">5,170,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">17,357,943<span></span>
</td>
<td class="nump">5,170,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_FairValueAdjustmentOfContingentValueRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment Of Contingent Value Right Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_FairValueAdjustmentOfContingentValueRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150324907200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Preferred Stock</div></th>
<th class="th"><div>Series B Preferred Stock</div></th>
<th class="th"><div>Private Placement One</div></th>
<th class="th"><div>Private Placement Two</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series B Preferred Stock</div>
</th>
<th class="th"><div>Common&#160;stock</div></th>
<th class="th">
<div>Common&#160;stock </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th">
<div>Common&#160;stock </div>
<div>Series B Preferred Stock</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Series B Preferred Stock</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityStockIssuedDuringPeriodShares', window );">Issuance of Series A preferred stock forward in connection with private placement and settlement of related forward contract (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619.627<span></span>
</td>
<td class="nump">49,570.162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Preferred Stock in connection with the Merger and settlement of related forward contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 34,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares', window );">Issuance of Series A preferred stock in connection with the merger and settlement of related forward contract (in shares)</a></td>
<td class="nump">384,930.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue', window );">Issuance of Series A Preferred Stock in connection with the Merger and settlement of related forward contract</a></td>
<td class="nump">$ 261,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">435,120.513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 296,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward', window );"><strong>Increase (Decrease) In Temporary Equity, Option, Roll Forward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger', window );">Issuance of replacement options in Merger</a></td>
<td class="nump">3,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">3,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">93,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 493,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (394,937)<span></span>
</td>
<td class="num">$ (4,558)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,101,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger', window );">Issuance of common stock forward in connection with the Merger</a></td>
<td class="nump">$ 2,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in connection with the merger and settlement of related forward contract (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger', window );">Issuance of replacement options in Merger</a></td>
<td class="nump">6,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement', window );">Issuance of common stock, license agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement', window );">Issuance of common stock, license agreement</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards', window );">Settlement of outstanding equity awards at Merger</a></td>
<td class="num">(6,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights', window );">Distribution of contingent value rights</a></td>
<td class="num">(340,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(340,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">20,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (219,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(219,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="num">$ (440,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614,647)<span></span>
</td>
<td class="num">(4,600)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">5,397,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,397,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityStockIssuedDuringPeriodShares', window );">Issuance of Series A preferred stock forward in connection with private placement and settlement of related forward contract (in shares)</a></td>
<td class="nump">99,140.326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Preferred Stock in connection with the Merger and settlement of related forward contract</a></td>
<td class="nump">$ 75,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares', window );">Transfer of Series A preferred stock and options for Series A preferred stock to permanent equity (in shares)</a></td>
<td class="num">(534,260.839)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity', window );">Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity</a></td>
<td class="num">$ (372,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward', window );"><strong>Increase (Decrease) In Temporary Equity, Option, Roll Forward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity', window );">Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity</a></td>
<td class="num">(3,703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TransferOfTemporaryEquityToPermanentEquityShares', window );">Transfer of Series A preferred stock and options for Series A preferred stock to permanent equity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,260.839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TransferOfTemporaryEquityToPermanentEquity', window );">Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity</a></td>
<td class="nump">375,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(413,470.437)<span></span>
</td>
<td class="num">(2,499,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,782,324<span></span>
</td>
<td class="nump">2,499,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A Preferred Stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B preferred stock and common stock in connection with private placement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,937,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,563,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B Preferred Stock and common stock in connection with private placement, net of issuance costs of $5,585</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised', window );">Issuance of common stock upon exercise of common warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">2,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (77,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">120,790.402<span></span>
</td>
<td class="nump">437,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,790.402<span></span>
</td>
<td class="nump">437,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="num">$ (6,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 689,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (692,071)<span></span>
</td>
<td class="num">$ (4,621)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">25,767,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,767,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Distribution Of Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Issuance Of Common Stock Forward In Connection With The Merger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Issuance Of Replacement Options In Merger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Settlement Of Outstanding Equity Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Temporary Equity, Option, Roll Forward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Common Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Common Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During The Period, Shares, Common Stock License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During The Period, Values, Common Stock License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Options, Carrying Amount, Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Options, Issuance Of Replacement Options In Merger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Options, Share-Based Payment Arrangement, Increase For Cost Recognition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Options, Transfer Of Preferred Stock To Permanent Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Acquisitions, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Acquisitions, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityStockIssuedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityStockIssuedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Transfer Of Preferred Stock To Permanent Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Transfer Of Preferred Stock To Permanent Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TransferOfTemporaryEquityToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer Of Temporary Equity To Permanent Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TransferOfTemporaryEquityToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TransferOfTemporaryEquityToPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer Of Temporary Equity To Permanent Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TransferOfTemporaryEquityToPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150324944928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 5,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150328849328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (77,424)<span></span>
</td>
<td class="num">$ (219,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Non-cash lease expense</a></td>
<td class="nump">2,437<span></span>
</td>
<td class="nump">1,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">7,579<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,582<span></span>
</td>
<td class="nump">22,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant liabilities revaluation</a></td>
<td class="num">(2,558)<span></span>
</td>
<td class="num">(12,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_FairValueAdjustmentOfContingentValueRightLiability', window );">Contingent value right liability revaluation</a></td>
<td class="nump">36,900<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Forward contract liabilities revaluation</a></td>
<td class="nump">6,890<span></span>
</td>
<td class="nump">149,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Provision (benefit) for deferred taxes</a></td>
<td class="nump">287<span></span>
</td>
<td class="num">(19,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">4,998<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent', window );">Unbilled receivable</a></td>
<td class="nump">2,981<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, deposits and other assets</a></td>
<td class="nump">1,747<span></span>
</td>
<td class="num">(1,265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,927)<span></span>
</td>
<td class="nump">2,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(5,849)<span></span>
</td>
<td class="nump">5,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(6,741)<span></span>
</td>
<td class="num">(2,761)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,674)<span></span>
</td>
<td class="num">(51,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash assumed in acquisition of Old Cartesian</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(9,093)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(8,742)<span></span>
</td>
<td class="nump">34,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series A Preferred Stock, gross in private placement</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of principal, final payment fee, and prepayment penalty on debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,457)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from issuance of common stock and Series B Preferred Stock in private placement</a></td>
<td class="nump">124,438<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity offering costs</a></td>
<td class="num">(66)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common warrants</a></td>
<td class="nump">2,877<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination', window );">Settlement of outstanding equity awards at Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">168,428<span></span>
</td>
<td class="num">(13,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">135,991<span></span>
</td>
<td class="num">(29,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">78,288<span></span>
</td>
<td class="nump">108,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">214,279<span></span>
</td>
<td class="nump">78,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplement cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock, license agreement in stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment not yet paid</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_EquityOfferingCostsInAccruedLiabilities', window );">Equity offering costs in accrued liabilities</a></td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_EquityOfferingCostsInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Offering Costs In Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_EquityOfferingCostsInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_FairValueAdjustmentOfContingentValueRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment Of Contingent Value Right Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_FairValueAdjustmentOfContingentValueRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Contract With Customer, Asset, Allowance For Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Settlement Of Equity Awards In Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333381664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the Business</a></td>
<td class="text">Description of the Business<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cartesian Therapeutics, Inc., or the Company, (formerly known as Selecta Biosciences, Inc., or Selecta) </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> incorporated in Delaware on December 10, 2007, and is headquartered in Frederick, Maryland. The Company is a clinical-stage biotechnology company </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pioneering mRNA cell therapy for the treatment of autoimmune diseases leveraging its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company believes its mRNA cell therapies have the potential to deliver deep, durable clinical benefit to a broad group of patients with autoimmune diseases because they can be administered over a short period of time, in an outpatient setting, and without pre-treatment chemotherapy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023, the Company acquired, in accordance with the terms of the Agreement and Plan of Merger, or the Merger Agreement, the assets of the Delaware corporation which, immediately prior to the Merger (as defined below), was known as Cartesian Therapeutics, Inc., or Old Cartesian, as disclosed in Note 4. The transaction was structured as a stock-for-stock transaction pursuant to which all of Old Cartesian&#8217;s outstanding shares of capital stock were exchanged based on a fixed exchange ratio for consideration of 224,099 shares of the common stock, par value $0.0001 per share, of the Company, or the common stock, and 384,930.724 shares of the newly designated Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share, or the Series A Preferred Stock. The Series A Preferred Stock is intended to have economic rights similar to the common stock, but with only limited voting rights. Additionally, the Company assumed all outstanding stock options of Old Cartesian. The common stock and Series A Preferred Stock related to the Merger were issued on December 5, 2023. For additional information, see Note 4.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company entered into a definitive agreement, or the 2023 Securities Purchase Agreement, for a private investment in public equity transaction, or the 2023 Private Placement, with the Investors (as defined below). The 2023 Securities Purchase Agreement provides for the issuance to the Investors of an aggregate of 149,330.115 shares of Series A Preferred Stock for an aggregate purchase price of approximately $60.25&#160;million. For additional information, see Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, a contractual contingent value right, or CVR, was distributed to the holders of record of the Company&#8217;s common stock and 2022 Warrants (as defined below) as of the close of business on December 4, 2023, but was not distributed to holders of shares of common stock or Series A Preferred Stock issued to stockholders of Old Cartesian or the Investors in the transactions. Holders of the CVRs will be entitled to receive certain payments from proceeds received by the Company, if any, related to the disposition or monetization of the Company&#8217;s legacy assets following the issuance of the CVRs. For additional information, see Note 6.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2024, the Company&#8217;s stockholders approved the Conversion Proposal (as defined below). For additional information, see Note 11.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on March 27, 2024, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s restated certificate of incorporation, as amended, or the Charter, to effect a reverse stock split of the Company&#8217;s issued and outstanding common stock, at a ratio in the range of 1-for-20 and 1-for-30, with such ratio to be determined at the discretion of the Company&#8217;s board of directors, or the Board of Directors. The Board of Directors subsequently approved a final reverse stock split ratio of 1-for-30, and the Company effected the Reverse Stock Split on April 4, 2024. As a result of the Reverse Stock Split, all figures in this Annual Report on Form 10-K relating to shares of the Company&#8217;s common stock (such as share amounts, per share amounts, and conversion rates and prices), have been adjusted to reflect the Reverse Stock Split for all periods presented, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Shares of common stock underlying outstanding stock options, restricted stock units and warrants were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with their terms. Additionally, the conversion ratio of the Company&#8217;s Series A Preferred Stock was proportionally adjusted. Stockholders entitled to fractional shares as a result of the Reverse Stock Split received a cash payment in lieu of receiving fractional shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2024, the Company entered into a securities purchase agreement, or the 2024 Securities Purchase Agreement, for a private investment in public equity financing, or the 2024 Private Placement, which provided for the issuance of 3,563,247 shares of common stock and 2,937,903 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share, or the Series B Preferred Stock, each at a purchase price of $20.00 per share. The 2024 Private Placement resulted in gross proceeds of approximately $130.0 million before deducting placement agent fees and other offering expenses. On September 20, 2024, the Company&#8217;s stockholders approved the Series B Conversion Proposal (as defined below). For additional information, see Note 11.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates are in preclinical and clinical development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had an accumulated deficit of $692.1 million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research and development of its product candidates and its administrative organization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company&#8217;s cash, cash equivalents, and restricted cash were $214.3 million, of which $1.7 million was restricted cash related to lease commitments. The Company believes the cash, cash equivalents and restricted cash as of December 31, 2024 will enable it to fund its current planned operations for at least the next 12 months from the date of issuance of these financial statements, though it may pursue additional cash resources through public or private equity or debt financings or by establishing collaborations with other companies. However, there is no guarantee that any of these strategic or financing opportunities will be executed on favorable terms, and some could be dilutive to existing stockholders. Further, the liability associated with the CVR Agreement (as defined below) will be settled solely through cash flow received under the Company&#8217;s License and Development Agreement, or as so amended, the Sobi License, with Swedish Orphan Biovitrum AB (publ.), or Sobi, and any other Gross Proceeds (as defined in the CVR Agreement) net of certain agreed deductions. Under the CVR Agreement, 100% of all milestone payments, royalties and other amounts paid to the Company or controlled entities under the Sobi License, and any other Gross Proceeds will be distributed, net of specified deductions, to holders of the CVRs. There is no obligation to the Company to fund any amount related to the CVR liability. See Note 6.</span></div> If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations or otherwise capitalize on its commercialization of its product candidates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330251296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Selecta (RUS), LLC, or Selecta (RUS), a Russian limited liability corporation, Selecta Biosciences Security Corporation, a Massachusetts securities corporation which the Company dissolved in December 2024, and Cartesian Bio, LLC, a Delaware limited liability company, which is a variable interest entity for which the Company is the primary beneficiary. All significant intercompany accounts and transactions have been eliminated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company&#8217;s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: estimated fair value of the intangible assets acquired in connection with the Merger, estimated fair value of the CVRs, deferred income taxes, revenue recognition, estimated accrued research and development expenses, stock-based compensation expense, estimated fair value of the liability-classified warrants, and impairment of long-lived assets. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision maker, or the CODM, for the purposes of assessing performance and allocating resources. The Company views its operations and manages its business in one operating segment, which prior to the Merger related to the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases and subsequent to the Merger relates to the research and development of cell therapy product candidates. The Company&#8217;s CODM function is fulfilled by its Chief Executive Officer. The CODM function assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations and comprehensive loss. The CODM function uses net loss to monitor budget versus actual results to assess performance of the segment. Segment assets are the same as total assets on the Company&#8217;s consolidated balance sheets. All long-lived assets are located in the United States. Long-lived assets consist of property and equipment, net, and operating lease right-of-use assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329982112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents, Marketable Securities and Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Marketable securities consist of securities with remaining maturities greater than 90 days when purchased. The Company classifies these marketable securities as available-for-sale and records them at fair value in the accompanying consolidated balance sheets. Marketable securities with less than one year until maturity are classified as short term, while marketable securities with maturities greater than one year are classified as long term. Unrealized gains or losses are included in accumulated other comprehensive loss. Premiums or discounts from par value are amortized to interest income over the life of the underlying investment. Although available to be sold to meet operating needs or otherwise, securities are generally held through maturity. The cost of securities sold is determined based on the specific identification method for purposes of recording realized gains and losses. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also in the past invested in equity securities of a company whose securities are not publicly traded and where fair value is not readily available. This investment is recorded using cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. The Company monitors this investment to evaluate whether any increase or decline in its value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. This investment is included in investments in the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term deposits, investments, accounts receivable, and unbilled receivables. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company&#8217;s deposits are financially creditworthy and, accordingly, minimal risk exists with respect to those balances. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s financial instruments consist mainly of cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and other current liabilities, investments, warrants to purchase common stock, forward contract liabilities, and contingent value rights. The carrying amounts of cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities approximate their estimated fair value due to their short-term maturities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy is used to prioritize the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements), and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Level 2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of warrant liabilities and contingent value rights are determined using Level 3 inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the consolidated balance sheet for investments approximate fair value and are assessed for impairment quarterly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, generally seven years for furniture and fixtures, five years for laboratory equipment, software and office equipment and three years for computer equipment. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Major additions and betterments are capitalized. Maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to operations as incurred. Costs incurred for construction in progress are recorded as assets and are not amortized until the construction is substantially complete and the assets are ready for their intended use.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are tested at the lowest level for which identifiable independent cash flows are available. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. The Company recognized an impairment charge on its right of use assets and related furniture and fixtures during the year ended December 31, 2024 and on a right-of-use asset during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs and fees paid to lenders are recorded as a direct deduction from the face amount of the related debt. Debt issuance costs are amortized over the term of the related debt using the effective interest method and recorded as interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in the equity of a business entity during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss consists of: (i)&#160;all components of net loss and (ii)&#160;all components of comprehensive loss other than net loss, referred to as other comprehensive loss. Other comprehensive loss is comprised of unrealized gains and losses on debt securities and foreign currency translation adjustments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and License Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. Pursuant to ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers (ASC 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. If a promised good or service is not distinct, it is combined with other promised goods or services into a performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Revenue: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently generates its revenue through collaboration and license agreements with strategic collaborators for the development and commercialization of product candidates. Collaboration and license agreements with customers are generally accounted for in accordance with ASC 606. The Company analyzes collaboration arrangements by first assessing whether they are within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (ASC 808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and evaluates whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. Collaboration agreements with customers that are not within the scope of ASC 808 are accounted for in accordance with ASC 606. To the extent the collaboration agreement is within the scope of ASC 808, the Company also assesses whether any aspects of the agreement are within the scope of other accounting literature (specifically ASC 606). If the Company concludes that some or all aspects of the agreement are distinct and represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606. The Company recognizes the shared costs incurred that are not within the scope of other accounting literature as a component of the related expense in the period incurred by analogy to ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development (ASC 730)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and records reimbursements from counterparties as an offset to the related research and development costs. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under the agreements in accordance with ASC 606, the Company performs the five steps above. As part of the accounting for the arrangement, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;The Company uses key assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Company&#8217;s arrangements typically include one or more of the following: (i) upfront fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; (iii) royalties on net sales of licensed products; (iv) reimbursements or cost-sharing of research and development expenses; and (v) profit/loss sharing arising from co-promotion arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promised goods and services identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. If not distinct, the license is combined with other promised goods and services in the contract. For licenses that are combined with other promised goods and services, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Optional licenses are evaluated to determine if they are issued at a discount, and therefore, represent material rights and accounted for as separate performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes developmental and regulatory milestone payments, the Company evaluates whether the achievement of each milestone specifically relates to the Company&#8217;s efforts to satisfy a performance obligation or transfer a distinct good or service within a performance obligation. If the achievement of a milestone is considered a direct result of the Company&#8217;s efforts to satisfy a performance obligation or transfer a distinct good or service and the receipt of the payment is based upon the achievement of the milestone, the associated milestone value is allocated to that distinct good or service. If the milestone payment is not specifically related to the Company&#8217;s effort to satisfy a performance obligation or transfer a distinct good or service, the amount is allocated to all performance obligations using the relative standalone selling price method. The Company also evaluates the milestone to determine whether they are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price to be allocated, otherwise, such amounts are constrained and excluded from the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the transaction price.&#160;Any such adjustments to the transaction price are allocated to the performance obligations on the same basis as at contract inception. Amounts allocated to a satisfied performance obligation shall be recognized as revenue, or as a reduction of revenue, in the period in which the transaction price changes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Supply Services: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are evaluated to determine if they are distinct and optional. For optional services that are distinct, the Company assesses if they are priced at a discount, and therefore, provide a material right to the licensee to be accounted for as separate performance obligations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied) in accordance with the royalty recognition constraint.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with government-sponsored organizations for research and development related activities that provide for payments for reimbursable costs. The Company recognizes grant revenue from these contracts as it performs services under these arrangements when the funding is committed. Expenses associated with these contracts are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations and comprehensive loss as the Company has determined it is the primary obligor under the arrangements relative to the research and development services it performs as lead technical expert. Amounts incurred that are subject to reimbursement from the sponsor are recorded as accounts receivable on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred in the research and development of the Company&#8217;s products are expensed as incurred. Research and development expenses include costs incurred in performing research and development activities, including salaries and benefits, stock-based compensation expenses, facilities cost, overhead costs, contract services, supplies and other outside costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third-parties. Third-party clinical trial expenses include patient costs, clinical research organization costs and costs for data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued clinical trial cost. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Non-refundable&#160;advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. The Company also records accruals for estimated ongoing clinical research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical clinical accrual estimates made by the Company have not been materially different from the actual costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more-likely-than-not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more-likely-than-not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and then in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or may require settlement by issuing variable number of shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to&#160;its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the statements of operations as a gain or loss.&#160;Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all stock-based compensation granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of estimated forfeitures. To the extent that actual forfeitures differ from the Company&#8217;s estimates, the differences are recorded as a cumulative adjustment in the period the estimates were adjusted. Stock-based compensation expense recognized in the consolidated financial statements is based on awards that ultimately vest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company applies the two-class method to compute basic and diluted net income (loss) per share attributable to common stockholders when it has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company&#8217;s Series A Preferred Stock, Series B Preferred Stock and 2022 Warrants participate in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) per share attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase common stock and Series A Preferred Stock, forward contracts to issue Series A Preferred Stock, restricted stock units, warrants to purchase common stock, employee stock purchase plan stock, contingently issuable shares, Series A Preferred Stock, and Series B Preferred Stock are considered potential dilutive common shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its contingent liabilities in accordance with ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies (ASC 450)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases in accordance with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (ASC 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company elected not to recognize leases with an original term less than one year on its balance sheet. Operating lease right-of-use assets and their corresponding lease liabilities are recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 842, the fixed and in-substance fixed contract consideration must be allocated to lease and non-lease components based on their relative fair values. Non-components of a contract (e.g., administrative tasks that do not transfer a good or service to the Company, reimbursement or payment of a lessor&#8217;s cost, etc.) do not receive an allocation of the consideration in the contract. Although allocation of consideration of lease and non-lease components is required, the Company elected the practical expedient to not separate lease components (e.g. land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The lease component results in an operating right-of-use asset being recorded on the balance sheet and amortized on a straight-line basis as lease expense. Right-of-use assets and operating lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and the estimated incremental borrowing rate upon lease modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease agreements with terms generally ranging from <span style="-sec-ix-hidden:f-467">two</span> to eight years. Some of the Company&#8217;s lease agreements include Company options to either extend and/or early terminate the lease, the costs of which are included in </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its operating lease liabilities to the extent that such options are reasonably certain of being exercised. Leases with renewal options allow the Company to extend the lease term typically between <span style="-sec-ix-hidden:f-469">one</span> and five years. When determining the lease term, renewal options reasonably certain of being exercised are included in the lease term. When determining if a renewal option is reasonably certain of being exercised, the Company considers several economic factors, including but not limited to, the significance of leasehold improvements incurred on the property, whether the asset is difficult to replace, underlying contractual obligations, or specific characteristics unique to that particular lease that would make it reasonably certain that the Company would exercise such option. Renewal and termination options were generally not included in the lease term for the Company&#8217;s existing operating leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations based on the fair value estimates as of the date of acquisition. In accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (ASC 805)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the amount of consideration paid in excess of the fair value of the identified net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates goodwill for impairment at least annually on October 1 and whenever facts and circumstances indicate that their carrying amounts may not be recoverable. For the years ended December 31, 2024 and 2023, the Company determined that there was no impairment to goodwill.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets consist of in-process research and development, or IPR&amp;D. The fair values of IPR&amp;D assets acquired in business combinations are capitalized. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry and recent and forecasted financial performance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates indefinite-lived intangible assets for impairment at least annually on October 1 and whenever facts and circumstances indicate that their carrying amounts may not be recoverable. For the years ended December 31, 2024 and 2023, the Company determined that there was no impairment to the IPR&amp;D assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Preferred Stock</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records its convertible preferred stock upon issuance at its fair value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value includes the original issuance price, the settlement of any related forward contract, and is less issuance costs. The Company classifies its convertible preferred stock outside of stockholders&#8217; deficit if the redemption of such shares is outside the Company&#8217;s control. For shares classified outside of stockholders&#8217; deficit, the Company does not adjust the carrying value of its convertible preferred stock to redemption value until it is probable of becoming redeemable. As of December 31, 2024, there were no conditions that could have required cash redemption of the convertible preferred stock and therefore, all convertible preferred stock were classified within stockholders&#8217; deficit.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Series A Preferred Stock Options </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies a portion of the fair value of the vested stock options for Series A Preferred Stock equal to the estimated redemption value on the measurement date outside of stockholders&#8217; deficit, if the redemption of the shares underlying the options are outside the Company&#8217;s control. Any fair value in excess of the estimated redemption value is recognized as additional paid-in capital. The estimated redemption value is based on the intrinsic value of the option. The Company does not adjust the carrying value of the stock options for Series A Preferred Stock until the underlying Series A Preferred Stock is probable of becoming redeemable. The Company records the stock options for Series A Preferred Stock based on the intrinsic value of the vested options.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its variable interests in variable interest entities, or VIEs, and consolidates VIEs when the Company is the primary beneficiary. The Company determines whether it is the primary beneficiary of a VIE based on its assessment of whether the Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#8217;s economic performance and (ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary conclusion. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Value Right Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CVRs distributed by the Company pursuant to the terms of the CVR Agreement (as defined below) represent financial instruments that are accounted for under the fair value option election in ASC Topic 825, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments (ASC 825).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the fair value option election, the CVRs are initially measured at the aggregate estimated fair value of the CVRs and will be subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the CVR liability was determined using a discounted cash flow methodology as of December 31, 2023 and a Monte Carlo simulation method as of December 31, 2024 to estimate future cash flows associated with the legacy assets, including the expected milestone and royalty payments under the Sobi License, net of deductions. Changes in fair value of the liability are presented in the consolidated statements of operations and comprehensive loss. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, expected volatilities of revenues (Monte Carlo simulation) and risk-adjustment discount rate (discounted cash flow methodology), which represent a Level 3 measurement within the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Contract Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for contracts related to the future issuance of its convertible preferred stock as a liability if the underlying shares include a redemption feature that may require the Company to settle the instrument by transferring an asset. The forward contract liability is carried at fair value through the date the underlying shares are issued. The fair value of the Series A Preferred Stock forward contract liability was initially measured based on the fair value of the Series A Preferred Stock issued in the 2023 Private Placement (see Note 11), less the purchase price, if any. Subsequent measurement of the fair value of the Series A Preferred Stock forward contract liability was based on the market price of the Company&#8217;s common stock, which represented the redemption and conversion value of the Series A Preferred Stock, less the purchase price, if any, on an as-converted basis. The remeasurement of the forward contract liability is based on Level 2 inputs within the fair value hierarchy as it&#8217;s based on observable market data. Changes in fair value of the liability are presented within change in fair value of forward contract liabilities in the consolidated statements of operations and comprehensive loss.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for the annual period beginning the year ended December 31, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company adopted the new standard during the year ended December 31, 2024 and the amendments have be applied retrospectively to all prior periods presented in the consolidated financial statements. See Note 21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not Yet Adopted</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual period beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently in the process of evaluating the impact of the standard&#8217;s adoption on its consolidated financial statements and related disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement Reporting- Comprehensive Income- Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2024-03), which requires public companies to disclose, in interim and annual reporting periods, additional information about certain expenses in notes to financial statements, including purchases of inventory, employee compensation, depreciation, amortization of intangible assets, and selling expenses. This guidance will be effective for the annual period beginning the year ended December 31, 2027 and for interim periods beginning January 1, 2028, with early adoption permitted. The Company is currently in the process of evaluating the impact of the standard&#8217;s adoption on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150331405824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Merger</a></td>
<td class="text">Merger<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023, the Company merged with Old Cartesian in accordance with the terms of the Merger Agreement, by and among Selecta, Sakura Merger Sub I, Inc., a wholly owned subsidiary of Selecta, or First Merger Sub, Sakura Merger Sub II, LLC, a wholly owned subsidiary of Selecta, or Second Merger Sub, and Old Cartesian. Pursuant to the Merger Agreement, First Merger Sub merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corporation and became a wholly owned subsidiary of Selecta, or the First Merger. Immediately following the First Merger, Old Cartesian merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity, or the Second Merger and, together with the First Merger, the Merger. In connection with the Second Merger, Old Cartesian changed its name to Cartesian Bio, LLC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. As a result of the Merger, Selecta changed its corporate name to Cartesian Therapeutics, Inc. and its common stock began trading on the Nasdaq Global Market under the new trading symbol &#8220;RNAC&#8221; beginning on November 14, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement was unanimously approved by the board of directors, or the Board of Directors, of Selecta and the board of directors of Old Cartesian. The Merger was consummated substantially concurrently with the entry into the Merger Agreement and was not subject to approval of the Company&#8217;s stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merger Agreement, following the consummation of the Merger on November 13, 2023, or the Closing Date, in exchange for 100% of the outstanding shares of capital stock of Old Cartesian immediately prior to the effective time of the First Merger, the Company agreed to issue to the stockholders of Old Cartesian (i) 224,099 shares of the Company&#8217;s common stock and (ii) 384,930.724 shares of Series A Preferred Stock. The issuance of the shares of common stock and Series A Preferred Stock occurred on December 5, 2023 which was after the December 4, 2023 record date for the distribution of the CVRs (see Note 6); as such, the Old Cartesian stockholders did not have rights as holders of common stock or holders of Series A Preferred Stock until such issuance on December 5, 2023. In addition, all outstanding stock options to purchase Old Cartesian common stock were assumed by the Company and converted into stock options to purchase (i) shares of the Company&#8217;s common stock or (ii) shares of the Company&#8217;s Series A Preferred Stock on terms substantially identical to those in effect prior to Merger Agreement, except for adjustments to the underlying number of shares and the exercise price based on the Merger Agreement exchange ratio. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, the Company agreed to hold a stockholders&#8217; meeting, or the Special Meeting, to submit the following proposals to a vote of its stockholders: (i) the approval of the conversion of shares of Series A Preferred Stock into shares of common stock, or the Conversion Proposal, and (ii) either or both of (A) the approval of an amendment to the Charter to increase the number of shares of common stock authorized under the Charter and (B) the approval of an amendment to the Charter to effect a reverse stock split of all outstanding shares of common stock, in either case (A) or (B) by a number of authorized shares or at a stock split ratio, as the case may be, sufficient to allow the conversion of all shares of Series A Preferred Stock issued in the Merger. The Special Meeting was held on March 27, 2024, during which the Company&#8217;s stockholders approved the Conversion Proposal, among other matters (see Note 11).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded the acquisition resulted in the Company obtaining a controlling financial interest in a VIE in accordance with ASC Topic 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation (ASC 810)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined that Old Cartesian was considered to be a VIE as it did not have sufficient equity to finance its activities without additional subordinated financial support. Prior to the Closing Date, the primary source of funding for Old Cartesian had been preferred stock financings. The Company acquired all of the outstanding shares of Old Cartesian and, therefore, is the sole equity holder and primary beneficiary. The Company has the obligation to absorb the losses and right to receive the benefits of Old Cartesian, and the power to direct the activities that most significantly affect the economic performance of Old Cartesian which the Company considers to be its development </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities. Therefore, the Company is the primary beneficiary. Further, the Company concluded the VIE qualified as a business and accounted for the transaction as the acquisition of a business in accordance with ASC 805. As the primary beneficiary, the Company was the acquirer in the transaction. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company exchanged the right to receive shares of common stock and Series A Preferred Stock for all of the outstanding equity of Old Cartesian. The Company determined the rights to receive shares exchanged in the Merger represent a forward contract. The fair value of the forward contracts was determined based on the fair value of shares of common stock and Series A Preferred Stock underlying the forward contracts as of the acquisition date. The total purchase price consists of the fair value of the forward contracts in addition to a portion of the fair value of options exchanged in the transaction related to prior service. Under the acquisition method, the total purchase price of the acquisition was allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the date of the acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The total fair value of the consideration of $168.5&#160;million as of the Closing Date is summarized as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract to issue common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract to issue Series A Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options allocated to consideration paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168,465&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the assets acquired and liabilities assumed as of the Closing Date based on the information available at that date. The following table presents the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed as of the Closing Date (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of November 13, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the IPR&amp;D assets were capitalized as of the Closing Date and are accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the carrying value of each respective IPR&amp;D asset will be amortized over its estimated useful life. Until that time, the IPR&amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the Merger is the excess of the fair value of the consideration transferred by the acquirer over the fair value of tangible assets, identifiable intangible assets and assumed liabilities as of the Closing Date and is not deductible for tax purposes. The goodwill balance is primarily attributable to the value of the assembled workforce and deferred tax liabilities associated with the transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company&#8217;s intangible assets acquired in the Merger (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Date<br/>Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for MG</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for SLE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total in-process research and development assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the intangible assets was estimated using the income approach in which the after-tax cash flows were discounted to present value. The cash flows are based on estimates used to price the transaction, and the discount rates applied </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were benchmarked with reference to the implied rate of return from the transaction model as well as the weighted average cost of capital. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period from November 13, 2023 to December 31, 2023, Old Cartesian&#8217;s revenue and net loss within the consolidated statements of operations and comprehensive loss were $0.0&#160;million and $1.6&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information reflects the consolidated results of operations of the Company as if the Merger had taken place on January 1, 2022. The unaudited pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s transaction costs of $4.9&#160;million were expensed as incurred and included in general and administrative expense in the consolidated statements of operations and comprehensive loss during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward contract related to the common stock was recorded as additional paid-in capital as the instrument is indexed to the Company&#8217;s common stock. The forward contract related to the Series A Preferred Stock was recorded as a liability as the underlying Series A Preferred Stock had a redemption feature that may have required the Company to settle the instrument by transferring an asset.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward contract was measured at fair value through the date of settlement through the issuance of the shares of Series A Preferred Stock on December 5, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150331406640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Allocable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Allocable to Common Stockholders</a></td>
<td class="text">Net Loss Per Share Allocable to Common Stockholders<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported a net loss for the years ended December 31, 2024 and 2023. The Company used the treasury stock method to determine the number of dilutive shares for the year ended December 31, 2024. The following table sets forth the computation of basic and diluted net loss per share allocable to common stockholders (in thousands, except share and per-share data):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: CVR distribution to participating securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss allocable to shares of common stock - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,424)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(257,260)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Change in fair value of forward contract liability settled in February 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss allocable to shares of common stock - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,870)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(257,260)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,276,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,170,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plus: Dilutive effect of forward contract liability settled in February 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding  - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,357,943&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,170,319&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.48)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.76)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.76)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the potential dilutive shares of common stock excluded from the computation of the diluted net loss per share allocable to common stockholders for all periods presented, as the effect would have been anti-dilutive: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options and RSUs </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,150,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">776,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,026,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,503,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract to issue Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,304,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">470,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,307,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,096,751&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333305040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds (included in cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contingent value right liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds (included in cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contingent value right liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forward contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">364,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers within the fair value hierarchy during the years ended December 31, 2024 or 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had restricted cash balances relating to secured letters of credit in connection with its real estate leases (see Note 9). The Company&#8217;s consolidated statement of cash flows includes the following as of December 31, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"></td><td style="width:70.926%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants to Purchase Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company issued warrants to purchase common stock in connection with a private placement, or the 2019 Warrants. The outstanding 2019 Warrants expired on December 23, 2024 in accordance with their terms. Pursuant to the terms of the 2019 Warrants, the Company could have been required to settle the 2019 Warrants in cash in the event of certain acquisitions of the Company and, as a result, the 2019 Warrants were required to be measured at fair value and reported as a liability on the balance sheet.&#160;On December 20, 2022, the Company amended the terms of the outstanding 2019 Warrants held by certain members of the Board of Directors, or the Amended 2019 Warrants, to remove the cash settlement provision.  As a result, the Amended 2019 Warrants were remeasured at fair value on December 20, 2022 and reclassified from a liability to equity on the balance sheet. See Note 12 for further discussion on the equity-classified Amended 2019 Warrants. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company issued warrants in connection with an underwritten offering, or the 2022 Warrants. Pursuant to the terms of the 2022 Warrants, the Company could be required to settle the 2022 Warrants in cash in the event of an acquisition of the Company under certain circumstances and, as a result, the 2022 Warrants are required to be measured at fair value and reported as a liability on the balance sheet. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the fair value of the 2019 Warrants and the 2022 Warrants upon issuance using the Black-Scholes valuation model and is required to revalue the 2019 Warrants and the 2022 Warrants at each reporting date, with any changes in fair value recorded in the consolidated statements of operations and comprehensive loss. The valuations of the 2019 Warrants and the 2022 Warrants are classified as Level 3 of the fair value hierarchy due to the need to use assumptions in the valuations that are both significant to the fair value measurement and unobservable, including the stock price volatility and the expected life of the 2019 Warrants and the 2022 Warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The changes in the fair values of the&#160;warrants are reflected in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2024 and 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of the 2019 Warrants and the 2022 Warrants were determined using the following inputs to the Black-Scholes simulation valuation:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of the underlying stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of the common stock based on the closing stock price at the end of each reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is based on the U.S. Treasury at the valuation date commensurate with the expected remaining life assumption.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The expected life of the 2019 Warrants was assumed to be equivalent to their remaining contractual term which expired on December 23, 2024. The expected life of the 2022 Warrants is assumed to be equivalent to their remaining contractual term which expire on April 11, 2027. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company estimates stock price volatility based on the Company&#8217;s historical volatility for a period of time commensurate with the expected remaining life of the warrants.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 2019 Warrants expired on December 23, 2024 and therefore, there were no 2019 Warrants outstanding as of December 31, 2024. A summary of the Black-Scholes pricing model assumptions used to record the fair value of the 2019 Warrants liability as of December 31, 2023 is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.877%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the 2022 Warrants liability is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.28</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company&#8217;s Level 3 warrant liabilities (see Note 12), for the year ended December 31, 2024 (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Value Right</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2023, as contemplated by the Merger Agreement, the Company entered into a contingent value rights agreement, or the CVR Agreement, pursuant to which each holder of common stock or a 2022 Warrant as of December 4, 2023 was distributed a CVR, issued by the Company for each share of common stock held directly or underlying a 2022 Warrant held by such holder as of December 4, 2023. Holders of warrants other than the 2022 Warrants will be entitled to receive, upon </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise of such warrants and in accordance with the terms of the warrants, 30 CVRs per each share of common stock underlying such warrants.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each CVR entitles its holder to distributions of the following, pro-rated on a per-CVR basis, during the period ending on the date on which the Royalty Term (as defined in the Sobi License) ends, or the Termination Date: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">100% of all milestone payments, royalties and other amounts paid to the Company or its controlled affiliates, or the Company Entities, under the Sobi License or, following certain terminations of the Sobi License, any agreement a Company Entity enters into that provides for the development and commercialization of SEL-212; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">100% of all cash consideration and the actual liquidation value of any and all non-cash consideration of any kind that is paid to or is actually received by any Company Entity prior to the Termination Date pursuant to an agreement relating to a sale, license, transfer or other disposition of any transferable asset of the Company existing as of immediately prior to the Merger, other than those exclusively licensed under the Sobi License or which the Company Entities are required to continue to own in order to comply with the Sobi License.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The distributions in respect of the CVRs will be made on a semi-annual basis, and will be subject to a number of deductions, subject to certain exceptions or limitations, including for (i) certain taxes payable on the proceeds subject to the CVR distribution, (ii) certain out of pocket costs incurred by the Company Entities, including audit and accounting fees incurred in connection with reporting obligations relating to the CVRs and other expenses incurred in the performance of their obligations and other actions under the CVR Agreement, (iii) a fixed semi-annual amount of $0.75&#160;million for general and administrative overhead, (iv) payments made and remaining obligations on lease liabilities of Selecta immediately prior to the Merger and (v) amounts paid and remaining obligations with regard to the Xork product candidate. Each of the deductions described in (iv) and (v) will be made only if certain milestone payments under the Sobi License are made and are also subject to certain adjustments as contemplated in the CVR Agreement. Upon the achievement of a development milestone in June 2024, Sobi became obligated to make a $30.0&#160;million payment to the Company and made such payment in July 2024. The proceeds from this payment, net of deductions specified in the CVR Agreement, is expected to be included in the next scheduled distribution to the holders of the CVR in March 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CVRs represent financial instruments that are accounted for under the fair value option election in ASC 825.  Under the fair value option election, the CVRs are initially measured at the aggregate estimated fair value of the CVRs and will be subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The liability was recorded at the date of approval, November 13, 2023, as a dividend. The estimated fair value of the CVR liability was determined using a discounted cash flow methodology as of December 31, 2023 and a Monte Carlo simulation model as of December 31, 2024 to estimate future cash flows associated with the legacy assets, including the expected milestone and royalty payments under the Sobi License, net of deductions. Changes in fair value of the CVR liability are presented in the consolidated statements of operations and comprehensive loss.  The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, expected volatility of future revenues (Monte Carlo simulation model) and risk-adjustment discount rate (discounted cash flow methodology), which represent a Level 3 measurement within the fair value hierarchy. The significant inputs used to estimate the fair value of the CVR liability, which represented a financial instrument being accounted for under the fair value option, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.877%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated cash flow dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2038</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated probability of success</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.0% - 100.0%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility of future revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.877%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated cash flow dates</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 - 2038</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated probability of success</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-adjusted discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company&#8217;s Level 3 CVR liability for the year ended December 31, 2024 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CVR liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward Contract Liabilities </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Merger Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company entered into a contract for the issuance of 384,930.724 shares of Series A Preferred Stock as part of the consideration transferred. The fair value of the forward contract at the Closing Date was $155.3&#160;million. The non-cash settlement of this liability occurred on December 5, 2023 with the issuance of the Series A Preferred Stock for $261.8&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Private Placement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company entered into a contract for the issuance of 149,330.115 shares of Series A Preferred Stock as part of the 2023 Private Placement which was settled in multiple tranches. The Company determined the obligation to issue 148,710.488 shares of Series A Preferred Stock to Dr. Timothy A. Springer, a member of the Company&#8217;s Board of Directors, and TAS Partners LLC, an affiliate of Dr. Springer, represented a forward contract. See Note 11. The initial fair value of the forward contract liability on November 13, 2023 was insignificant as the fair value of the underlying Series A Preferred Stock was equal to the purchase price of the Series A Preferred Stock as agreed upon in the 2023 Private Placement. Subsequent measurement of the fair value of the forward contract liability was based on the market price of the Company&#8217;s common stock, which represented the redemption and conversion value of the Series A Preferred Stock, less the purchase price, on an as-converted basis. The non-cash settlement of a portion of the liability occurred on December 13, 2023 with the issuance of the first tranche of the Series A Preferred Stock for $14.8&#160;million. The non-cash settlement of the remaining second and third tranches occurred on January 12, 2024 and February 11, 2024, respectively, for a total of $35.2&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the forward contract liabilities for the periods presented (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward contract liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:f-651">Change in fair value</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333469456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9 for details regarding the impairment loss the Company recognized for certain furniture and fixtures during the year ended December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $1.2 million and $0.7 million for the years ended December 31, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150441095648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll and employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued patent fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued external research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333305040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">7495 New Horizon Way Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, the Company entered into a lease agreement with 7495 RP, LLC, or the Landlord, pursuant to which it agreed to lease from the Landlord the manufacturing space located at 7495 New Horizon Way, Frederick, Maryland, or the Frederick Lease Agreement. The space consists of 19,199 leasable square feet of integrated manufacturing and office space. The lease commenced on May 1, 2024 which was the date the Landlord delivered full possession of the premises to the Company. The Frederick Lease Agreement will terminate approximately 7.2 years following the commencement date. The Company will have one option to extend the term of the Frederick Lease Agreement for a period of five years at a cost of 100% of the then-fair market value, not to exceed 103% of the then-current base rent. Base rent, which was due beginning on July 1, 2024, is $0.9&#160;million annually and is subject to an annual upward adjustment of 3% of the then-current rental rate. In addition, the Company is obligated to pay its share of operating costs and taxes related to the property. The Company paid the first month&#8217;s rent of $0.1&#160;million upon execution of the Frederick Lease Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the classification of the lease at the commencement date and concluded it should be accounted for as an operating lease. The Company recorded a lease liability and right-of-use asset of $3.6&#160;million and $3.7&#160;million, respectively, on the commencement date. The Frederick Lease Agreement includes a tenant improvement allowance of up to $0.7&#160;million which was recognized as a reduction in the right-of-use asset and lease liability at the commencement date as the Company was reasonably certain to incur reimbursable costs related to alterations equal to or exceeding the amount. Additionally, the prepaid rent was included as an adjustment to the right-of-use asset. The discount rate of 14% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term, including any reasonably certain renewal periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 7, 2024, the Company and the Landlord entered into the first amendment to the Frederick Lease Agreement, or the First Frederick Lease Agreement Amendment, providing for the expansion of the premises leased pursuant to the Frederick Lease Agreement by approximately 7,842 square feet. In connection with the expansion of the leased premises, the Company is obligated to pay $0.3&#160;million in additional annual base rent for the first year of the term, which is subject to an annual upward adjustment of 3% of the then-current rental rate, as well as its share of operating costs and taxes. The lease commenced on May 7, 2024 which was the date the Landlord delivered full possession of the premises to the Company and will be coterminous with the Frederick Lease Agreement. The rent commencement date was September 1, 2024. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the classification of the lease at the commencement date and concluded it should be accounted for as an operating lease. The Company recorded a lease liability and right-of-use asset each of $1.2&#160;million on the commencement date. The First Frederick Lease Agreement Amendment includes a tenant improvement allowance of up to $0.1&#160;million which was recognized as a reduction in the right-of-use asset and lease liability at the commencement date as the Company was reasonably certain to incur reimbursable costs related to alterations equal to or exceeding the amount. The discount rate of 14% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective August 30, 2024, the Company and the Landlord entered into the second amendment to the Frederick Lease Agreement, or the Second Frederick Lease Agreement Amendment, providing for the expansion of the premises leased pursuant to the Frederick Lease Agreement and First Frederick Lease Agreement Amendment by approximately 2,009 square feet. In connection with the expansion of the leased premises, the Company is obligated to pay $0.1&#160;million in additional annual base rent for the first year of the term, which is subject to an annual upward adjustment of 3% of the then-current rental rate, as well as its share of operating costs and taxes. The lease commenced on September 1, 2024, which was the date the Landlord delivered full possession of the premises to the Company and will be coterminous with the Frederick Lease Agreement. The rent commencement date was September 1, 2024. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the classification of the lease at the commencement date and concluded it should be accounted for as an operating lease. The Company recorded a lease liability and right-of-use asset each of $0.3&#160;million on the commencement date. The discount rate of 14% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company secured a letter of credit from Silicon Valley Bank, a division of First-Citizens Bank &amp; Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), or SVB, for $0.3 million for the Frederick Lease Agreement, the First Frederick Lease Agreement Amendment and the Second Frederick Lease Agreement Amendment, which is recognized as long-term restricted cash as of December 31, 2024 and renews automatically each year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">65 Grove Street Lease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into a lease with BRE-BMR Grove LLC for 25,078 square feet of laboratory and office space located at 65 Grove Street, Watertown, Massachusetts, or the Watertown Lease Agreement. As part of the Watertown Lease Agreement, the Company incurred $0.8 million in non-reimbursable construction costs. The lease began in March 2020, when the Company took control of the office space, and the lease term is 8 years. The discount rate of 8.9% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term, including any reasonably certain renewal periods. In connection with the Watertown Lease Agreement, the Company secured a letter of credit from SVB for $1.6 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2022, the Company entered into an amendment, or the Watertown Lease Agreement Amendment, to its lease agreement with BRE-BMR Grove LLC, originally entered into on July 23, 2019 to expand the Company&#8217;s laboratory and office space located at 65 Grove Street, Watertown, Massachusetts by 7,216 square feet. The lease term began on September 1, 2022, consistent with when the Company took control of the office space and the expected lease term is 5.7 years. The discount rate of 11.3% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods. Rent payments began in November 2022, and the base rent for the first year is $0.1&#160;million per month. The Company recorded the right-of-use asset and operating lease liabilities of $3.2&#160;million during the year ended December 31, 2022 as control of the premises was transferred to the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2022, the Company entered into a sublease agreement to sublease 7,216 square feet of space currently rented by the Company at 65 Grove Street, Watertown, Massachusetts.  The sublease commenced on October 24, 2022, when the Company, the sublessee and BRE-BMR Grove LLC, executed a Consent to Sublease.  The term of the sublease expired on March 31, 2024 with no option to extend the sublease term. Sublease income is included within other income, net in the consolidated statements of operations and comprehensive loss.   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the sublease agreement and Consent to Sublease, rent payments to BRE-BMR Grove LLC for the lease of the office space increased.  The change of consideration in the contract was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of October 24, 2022.  The discount rate of 11.9% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods as of October 24, 2022, resulting in a decrease of less than $0.1&#160;million to both the right-of-use asset and lease liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company received notice from BRE-BMR Grove LLC that the requirements to reduce the amount of the letter of credit for the Watertown Lease Agreement had been met. In connection therewith, in June 2023, the Company secured a letter of credit from JPMorgan Chase Bank, N.A. for $1.4&#160;million, which is recognized as long-term restricted cash as of December 31, 2024 and 2023, and renews automatically each year. The $1.6&#160;million letter of credit with SVB was released from restriction and returned to the Company on July 17, 2023, and therefore was reclassified into cash and cash equivalents in the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2023, in connection with entering into Amendment No. 1 to the License and Development Agreement with Sobi as described in Note 14, the Company entered into a sublease agreement with Sobi to sublease approximately 5,600 square feet of space currently rented by the Company at 65 Grove Street, Watertown, Massachusetts for which Sobi paid $1.0&#160;million upfront rental payment.  The sublease commenced on November 6, 2023, when the Company, Sobi, and BRE-BMR Grove LLC, executed a Consent to Sublease.  The term of the sublease expired on November 5, 2024 with no option to extend the sublease term. As of December 31, 2023, deferred rent of $0.8&#160;million is included within accrued expenses and other current liabilities in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company determined that the right-of-use asset related to the operating lease for approximately 7,216 square feet at 65 Grove Street was partially impaired as of November 30, 2023.  As a result, the Company recognized a $0.7&#160;million right-of-use asset impairment charge in impairment of long-lived assets on its consolidated statements of operations and comprehensive loss during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the expiration of the sublease to Sobi in November 2024 and the Company&#8217;s decision to cease use of its office and laboratory space at 65 Grove Street, Watertown, Massachusetts, the Company assessed the right-of-use assets and related furniture and fixtures associated with the Watertown Lease Agreement and Watertown Lease Agreement Amendment </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for impairment. The carrying value of each asset group was compared against the future net undiscounted cash flows projected to be generated over the remaining lease terms. These projections included management's estimates of cash inflows from potential sublease income. The carrying amount of the asset groups was found to be unrecoverable, thus the Company assessed the fair value of each asset group. The fair value was determined using the income approach, whereby the Company discounted the estimated net cash flows using a rate commensurate with the Company&#8217;s estimated incremental borrowing rate. As a result of this assessment, which included unrecoverable operating and maintenance costs, the Company determined that each asset group was fully impaired. As such, an <span style="-sec-ix-hidden:f-743">impairment charge</span> of $7.6&#160;million was recognized during the year ended December 31, 2024, $7.4&#160;million of which related to the right-of-use assets and $0.2&#160;million related to property and equipment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">704 Quince Orchard Road Leases</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company acquired two operating leases for office and laboratory space in Gaithersburg, Maryland. The leases expire in January 2027 and do not contain any renewal rights. The discount rate of 11.5% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the years ended December 31, 2024 and 2023 was $5.5 million, $3.8 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024 and 2023, the components of lease costs were as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,099)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,394&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2024 were as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the initial recording of the right-of-use assets and lease liabilities for the Frederick Lease Agreement, First Frederick Lease Agreement Amendment, and Second Frederick Lease Agreement Amendment during the year ended December 31, 2024, the impairments on the right-of-use assets for the Watertown Lease Agreement and Watertown Lease Agreement Amendment during the years ended December 31, 2024 and 2023, as applicable, and the assumption of the right-of-use assets and lease liabilities in connection with the Merger during the year ended December 31, 2023, which were non-cash, the changes in the Company&#8217;s right-of-use assets and lease liabilities for the years ended December 31, 2024 and 2023 are reflected in the non-cash lease expense and accrued expenses and other liabilities, respectively, in the consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to the Company&#8217;s operating leases:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333408352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020, the Company entered into a Loan and Security Agreement with Oxford Finance LLC, or Oxford, and Silicon Valley Bank, or the Loan and Security Agreement, and such facility, the 2020 Term Loan. On March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation, or the FDIC, was appointed as receiver. On March 13, 2023, the FDIC announced that all of Silicon Valley Bank&#8217;s deposits and substantially all of its assets had been transferred to a newly created, full-service, FDIC-operated bridge bank, Silicon Valley Bridge Bank, N.A., or SVBB. SVBB assumed all loans that were previously held by Silicon Valley Bank. On March 27, 2023, First-Citizens Bank &amp; Trust Company assumed all of SVBB&#8217;s customer deposits and certain other liabilities and acquired substantially all of SVBB&#8217;s loans and certain other assets from the FDIC, including the 2020 Term Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2023, the Company entered into a payoff letter with Oxford and SVB, pursuant to which the Company paid all outstanding amounts under the 2020 Term Loan, together with accrued interest and a prepayment penalty, resulting in the full extinguishment of the 2020 Term Loan. The total payoff amount was $22.3&#160;million, consisting of the remaining principal amount due of $19.8&#160;million, the final payment fee of $2.3&#160;million, the prepayment penalty of $0.2&#160;million, and less than $0.1&#160;million of accrued interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recorded a loss of $0.7&#160;million on the extinguishment of the 2020 Term Loan, consisting of the prepayment penalty of $0.2&#160;million and the write-off of $0.5&#160;million of unamortized debt issuance costs and venture debt termination fee, which was included within interest expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, the Company had no outstanding borrowings.</span></div>During the year ended December 31, 2024, the Company recognized no interest expense. During the year ended December 31, 2023, the Company recognized $2.1 million of interest expense related to the 2020 Term Loan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150434209024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityDisclosureTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">Convertible Preferred Stock<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Certificate of Designation of Preferences, Rights, and Limitations of the Series B Non-Voting Convertible Preferred Stock, or the Series B Certificate of Designation, was filed with the Secretary of State of the State of Delaware on July&#160;2, 2024, and provided for the designation of shares of Series B Preferred Stock and authorized the issuance of 2,937,903 shares of Series B Preferred Stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on July 2, 2024, the Company entered into the 2024 Securities Purchase Agreement with certain institutional and accredited investors, or the Purchasers. The Purchasers included (i) Dr. Timothy A. Springer, a member of the Company&#8217;s Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Dr. Chafen Lu, Dr. Springer&#8217;s wife. Pursuant to the 2024 Securities Purchase Agreement, the Company agreed to issue and sell an aggregate of 3,563,247 shares of common stock and 2,937,903 shares of Series B Preferred Stock for an aggregate purchase price of $130.0 million in the 2024 Private Placement. Each share of Series B Preferred Stock is convertible into one share of the Company&#8217;s common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to stockholder approval of a proposal to issue such shares of common stock upon conversion of such shares of Series B Preferred Stock in accordance with the Listing Rules of the Nasdaq Stock Market LLC, or the Series B Conversion Proposal. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2024 Securities Purchase Agreement, the Company issued 3,563,247 shares of common stock and 578,403 shares of Series B Preferred Stock for an aggregate purchase price of $82.8 million to the Purchasers other than Dr. Springer, TAS Partners LLC, and Dr. Lu. The Company also issued (i) 1,636,832 shares of Series B Preferred Stock to Dr. Springer, (ii) 721,361 shares of Series B Preferred Stock to TAS Partners LLC, and (iii) 1,307 shares of Series B Preferred Stock to Dr. Lu for an aggregate purchase price of $47.2 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2024 Securities Purchase Agreement, the Company agreed to submit to its stockholders the approval of the Series B Conversion Proposal, at a special meeting of stockholders, which was held on September 20, 2024. On September 20, 2024, at such special meeting, the Company&#8217;s stockholders approved the Series B Conversion Proposal, among other matters. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2024, pursuant to the terms of the Series B Certificate of Designation, 2,499,976 shares of Series B Preferred Stock automatically converted into 2,499,976 shares of common stock; 437,927 shares of Series B Preferred Stock did not automatically convert at such time due to beneficial ownership limitations. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock were classified in permanent equity as there were no conditions that could have required cash redemption of the shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock has the following rights and preferences:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the stockholder approval of the Series B Conversion Proposal the Series B Preferred Stock were not convertible into shares of common stock. Following the stockholder approval of the Series B Conversion Proposal, each share of Series B Preferred Stock automatically converted into one share of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 0.0% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion; provided, however, that such beneficial ownership limitation does not apply to Dr. Springer, TAS Partners LLC, or any of their respective affiliates. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock outstanding that was not automatically converted into common stock as a result of the stockholder approval of the Series B Conversion Proposal shall be convertible at any time at the option of the holder following stockholder approval of the Series B Conversion Proposal, only to the extent the beneficial ownership limitation does not apply to the shares of Series B Preferred Stock to be converted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock is not redeemable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock on an as-converted basis (without regard to the beneficial ownership limitation) equal to the dividends paid on shares of the common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then-outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the Series B Certificate of Designation, or (c) amend the Charter or other organizational documents in any manner that alters or changes the preferences, rights, privileges, or powers of, or restrictions provided for the benefit of the holders of Series B Preferred Stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Series B Preferred Stock shall rank on parity with the holders of common stock and the holders of Series A Preferred Stock as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, each holder of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B Preferred Stock were fully converted, which shall be paid pari passu with holders of common stock and holders of Series A Preferred Stock, plus an amount equal to any dividends declared but unpaid. If the assets available for distribution are not sufficient to pay the holders of the Series B Preferred Stock pursuant to the preceding sentence, all remaining assets will be distributed ratably to the holders of the Series A Preferred Stock, Series B Preferred Stock and common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Certificate of Designation of Preferences, Rights, and Limitations of the Series A Non-Voting Convertible Preferred Stock, or the Series A Certificate of Designation, was filed on November 13, 2023, which provided for the designation of shares of the Series A Preferred Stock and authorized the issuance of 548,375 shares of Series A Preferred Stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally on November 13, 2023, the Company entered into the 2023 Securities Purchase Agreement with (i) Dr. Timothy A. Springer, a member of the Company&#8217;s Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Seven One Eight Three Four Irrevocable Trust, a trust associated with Dr. Murat Kalayoglu, a co-founder and the former chief executive officer of Old Cartesian, who joined the Company&#8217;s Board of Directors effective immediately after the effective </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time of the Merger, or the Investors. Pursuant to the 2023 Securities Purchase Agreement, the Company agreed to issue and sell an aggregate of 149,330.115 shares of Series A Preferred Stock for an aggregate purchase price of $60.25&#160;million in the 2023 Private Placement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the 2023 Private Placement, Dr. Timothy A. Springer agreed to settle his purchases in three tranches of shares of Series A Preferred Stock, the first for a purchase price of $10.0&#160;million and each thereafter for a purchase price of approximately $20.0&#160;million, with the three tranches settling 30, 60, and 90 days, respectively, following the Closing Date. TAS Partners LLC agreed to settle its purchase for approximately $10.0&#160;million within 30 days following the Closing Date. The first, second and third tranches were settled on December 13, 2023, January 12, 2024 and February 11, 2024, respectively, under which (i) 24,785.081 shares of Series A Preferred Stock were issued to each of TAS Partners LLC and Dr. Timothy A. Springer in the first tranche, (ii) 49,570.163 shares of Series A Preferred Stock were issued to Dr. Timothy A. Springer in the second tranche, and (iii) 49,570.163 shares of Series A Preferred Stock were issued to Dr. Timothy A. Springer in the third tranche. On November 15, 2023, the Company issued 619.627 shares of Series A Preferred Stock to Seven One Eight Three Four Irrevocable Trust for $0.25&#160;million.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company determined the obligation to issue 148,710.488 shares of Series A Preferred Stock to Dr. Springer and TAS Partners LLC represented a forward contract and was accounted for as a liability with changes in fair value recorded in earnings. A portion of the liability was settled with the initial issuance of 49,570.162 shares of Series A Preferred Stock on December 13, 2023. The remaining portion of the forward contract liability was settled upon the issuance of 49,570.163 shares of Series A Preferred Stock each on January 12, 2024 and February 11, 2024, respectively (see Note 6).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2023, the Company issued 384,930.724 shares of Series A Preferred Stock as part of its consideration transferred in connection with the Merger which settled the related forward contract liability (see Note 6).</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 26, 2024, the Company, with the consent of the requisite holders of Series A Preferred Stock, amended the Series A Certificate of Designation such that the automatic conversion of the Series A Preferred Stock into common stock, or the Automatic Conversion, would occur eight business days following stockholder approval of the Conversion Proposal. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2024, the Company&#8217;s stockholders approved the Conversion Proposal, among other matters, at the Special Meeting.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2024, pursuant to the terms of the Series A Certificate of Designation, as amended, 367,919.247 shares of Series A Preferred Stock automatically converted into 12,263,951 shares of common stock, including the non-cash reclassification of an amount equal to the increase in par value of common stock from additional paid-in capital; 166,341.592 shares of Series A Preferred Stock did not automatically convert at such time due to beneficial ownership limitations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 11, 2024, pursuant to a Notice of Optional Conversion delivered to the Company by a holder of Series A Preferred Stock pursuant to the Series A Certificate of Designation, 45,551.190 shares of Series A Preferred Stock held by such holder were converted into 1,518,373 newly issued shares of common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with the guidance in ASC Topic 480,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Distinguishing Liabilities from Equity (ASC 480)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> the Series A Preferred Stock was classified outside of stockholders&#8217; deficit upon issuance and as of December 31, 2023 because the shares of Series A Preferred Stock contained redemption features that were not solely within the control of the Company. The Series A Preferred Stock was not currently redeemable, nor was it probable that the instrument would become redeemable, as it was only redeemable upon the occurrence of a contingent event. Accordingly, no accretion was recognized for the Series A Preferred Stock. As a result of the approval of the Conversion Proposal, all conditions that could have required cash redemption of the Series A Preferred Stock were removed. Since the Series A Preferred Stock was no longer redeemable, the associated balances of the Series A Preferred Stock were reclassified to permanent equity during the first quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock has the following rights and preferences:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the stockholder approval of the Conversion Proposal, the Series A Preferred Shares were not convertible. Following the stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock automatically converted into 33.333 shares of common stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 0% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion; provided, however, that such beneficial ownership limitation does not apply to Dr. Springer, TAS Partners LLC, or any of their respective affiliates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series A Preferred Stock outstanding that was not otherwise automatically converted into common stock as a result of the beneficial ownership limitation shall be convertible at any time at the option of the holder following stockholder approval of the Conversion Proposal, only to the extent the beneficial ownership limitation does not apply to the shares of Series A Preferred Stock to be converted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock was redeemable at the option of the holder at any time following the date that was 18 months after the initial issuance date of the Series A Preferred Stock, other than any shares of Series A Preferred Stock that would not have been convertible into shares of common stock as a result of the beneficial ownership limitation referred to above. The amount payable upon redemption would have been equal to the average closing sale price of the common stock listed over the ten consecutive trading days ending on, and including, the day immediately prior to the redemption date multiplied by the number of shares of common stock the Series A Preferred Stock would have been convertible into. Following the Conversion Proposal, the Series A Preferred Stock is not redeemable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock on an as-converted basis equal to the dividends paid on shares of the common stock; provided, however, that holders of Series A Preferred Stock (or any shares of common stock into which the Series A Preferred Stock are convertible) are not entitled to any CVRs or any amounts paid under the CVR Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then-outstanding shares of the Series A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (b) alter or amend the Series A Certificate of Designation, (c) amend the Charter or other organizational documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (d) issue further shares of Series A Preferred Stock (other than in connection with the exercise of the stock options to purchase Series A Preferred Stock) or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (e) prior to the stockholder approval of the Conversion Proposal or at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate either (A) a Fundamental Transaction (as defined in the Series A Certificate of Designation) or (B) any merger or consolidation of the Company or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority of the capital stock of the Company immediately after such transaction, (f) amend or fail to comply with, in any manner that would be reasonably likely to prevent, impede or materially delay the conversion (or the stockholder approval thereof), or terminate, any of the stockholder support agreements entered into in connection with the Merger, or the Support Agreements, or agree to any transfer, sale or disposition of such shares subject to the Support Agreements (except for such transfers, sales or dispositions with respect to which the approval of the Company is not required pursuant to the applicable Support Agreement) or (g) enter into any agreement with respect to any of the foregoing. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The holders of Series A Preferred Stock shall rank on parity with the common stockholders and the holders of Series B Preferred Stock as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary each holder of Series A Preferred Stock shall be entitled to receive out the assets of the Company equal to of the same amount that a holder of common stock would receive if the Series A Preferred Stock were fully converted, which shall be paid pari passu with holders of common stock and holders of Series B Preferred Stock, plus an amount equal to any dividends declared but unpaid. If the assets available for distribution are not sufficient to pay the holders of the Series A Preferred Stock pursuant to the preceding sentence, the assets will be distributed ratably to the holders of the Series A Preferred Stock, Series B Preferred Stock and common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had 120,790.402 shares of Series A Preferred Stock and 437,927 shares of Series B Preferred Stock issued and outstanding, respectively, which are convertible into a total of 4,464,273 shares of common stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333391760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Private Placement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 2, 2024, the Company and the Purchasers entered into the 2024 Securities Purchase Agreement for the 2024 Private Placement. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the 2024 Securities Purchase Agreement, the Purchasers agreed to purchase an aggregate of 3,563,247 shares of common stock and 2,937,903 shares of Series B Preferred Stock, inclusive of 2,359,500 shares of Series B Preferred Stock purchased by directors and executive officers of the Company, and related parties thereto, each at a price per share of $20.00. The 2024 Private Placement resulted in gross proceeds of approximately $130.0&#160;million before deducting placement agent fees and other offering expenses. See Note 11.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merger</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2023, the Company issued 224,099 shares of common stock as part of its consideration transferred in connection with the Merger which settled the related equity-classified forward contract (see Note 4).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Underwritten Offering</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2022, the Company entered into an underwriting agreement with SVB Securities LLC (now known as Leerink Partners LLC), as representative of the several underwriters named therein, relating to an underwritten offering of 914,285 shares of the Company&#8217;s common stock and 2022 Warrants to purchase up to 685,712 shares of common stock, or the 2022 Offering. Each share and accompanying 2022 Warrant to purchase 0.75 shares of common stock was sold at a combined offering price of $42.30. The exercise price for the 2022 Warrants is $46.50 per share. The Company received net proceeds from the 2022 Offering of approximately $36.9&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company&#8217;s common stock and also upon any distributions for no consideration of assets to the Company&#8217;s stockholders. Each 2022 Warrant is exercisable at any time and from time to time after issuance. In the event of certain corporate transactions, the holders of the 2022 Warrants will be entitled to receive the kind and amount of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such transaction. Therefore, the Company is required to account for the 2022 Warrants as liabilities and record the 2022 Warrants at fair value. The 2022 Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which holders of common stock are entitled.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;At-the-Market&#8221; Offerings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Sales Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2024, the Company entered into a Sales Agreement, or the 2024 Sales Agreement, with Leerink Partners to sell shares of the Company&#8217;s common stock, from time to time, through an &#8220;at the market&#8221; equity offering program under which Leerink Partners will act as sales agent. The shares of common stock sold pursuant to the 2024 Sales Agreement will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-283803), filed on December 13, 2024 with the SEC and related prospectus supplement, filed on January 8, 2025 with the SEC, for aggregate gross sales proceeds of up to $100.0&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Sales Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 25, 2021, the Company entered into a Sales Agreement, or the 2021 Sales Agreement, with Leerink Partners LLC (then known as SVB Leerink LLC), or Leerink Partners, pursuant to which the Company may sell shares of the Company&#8217;s common stock, from time to time, through an &#8220;at the market&#8221; equity offering program under which Leerink Partners will act as sales agent. The shares of common stock sold pursuant to the 2021 Sales Agreement, if any, would be issued and sold pursuant to a registration statement to be filed by the Company with the SEC, for aggregate remaining gross sales proceeds of up to $51.0 million. During the years ended December 31, 2024 and 2023, the Company sold no shares of its common stock pursuant to the 2021 Sales Agreement. The 2024 Sales Agreement supersedes the 2021 Sales Agreement, which is no longer in effect. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2020 Sobi Stock Purchase</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, the Company entered into a stock purchase agreement with Sobi, pursuant to which the Company sold an aggregate of 180,546 shares of its common stock at a purchase price equal to $138.4680 per share, which represented 120% of the 10-day volume-weighted average price of the Company&#8217;s common stock prior to signing, for aggregate gross proceeds of $25.0&#160;million, or the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 815, this forward sale treatment qualified as equity classification as the shares are not within the scope of ASC 480. The gross proceeds of $25.0&#160;million were determined to include a premium to the fair value of the Company&#8217;s shares as of July 28, 2020 of approximately $14.5&#160;million. As a result, such amount was included in the transaction price for revenue recognition of the Sobi License. See Note 14 for details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on June 11, 2020, the Company entered into a registration rights agreement, as amended by that certain letter agreement, dated as of November 4, 2020, or the Sobi Registration Rights Agreement, with Sobi, pursuant to which the Company agreed to prepare and file a registration statement with respect to the resale of the shares of common stock acquired in the Sobi Private Placement. The Company will be required to file this resale registration statement within 30 days following receipt by the Company of a written request from Sobi to file such resale registration statement, and to have the registration statement declared effective within ten business days after the SEC informs the Company that no review of such resale registration statement will be made or that the SEC has no further comments on such resale registration statement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Financing</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 18, 2019, the Company entered into a securities purchase agreement, or the 2019 Securities Purchase Agreement, with a group of institutional investors and certain members of the Board of Directors. Pursuant to the 2019 Securities Purchase Agreement, the Company sold an aggregate of 1,254,496 shares of its common stock at a purchase price of $43.80 per share, warrants to purchase an aggregate of 766,275 shares of common stock at a purchase price of $3.75 per share underlying each common warrant, and pre-funded warrants to purchase an aggregate of 278,070 shares of common stock at a purchase price of $43.80 per share, all with five year terms, or the 2019 Private Placement. The closing of the 2019 Private Placement occurred on December 23, 2019. The exercise price of the pre-funded warrants is $0.003 per share and the exercise price for the common warrants is $43.80 per share. In the event of a certain sale of the Company, the terms of the common warrants require us to make a payment to such common warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). This provision does not apply to the pre-funded warrants. Therefore, the Company is required to account for the common warrants as liabilities and record them at fair value, while the pre-funded warrants met the criteria to be classified as permanent equity. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the fair value of the 2019 Warrants of $40.7&#160;million upon issuance using the Black-Scholes valuation model. Issuance costs were allocated between the equity component with an offset to additional paid-in capital and the liability component recorded as expense on a relative fair value basis. Total net proceeds from the equity offering was $65.6 million, after deducting transaction costs and commissions of $4.4 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 6, the Company remeasured the Amended 2019 Warrants at the fair value of $0.8&#160;million on December 20, 2022 and reclassified this amount to additional paid-in capital. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding 2019 Warrants expired on December 23, 2024 in accordance with their terms. The remaining 2022 Warrants liability was revalued as of December 31, 2024 at $3.8 million. During the years ended December 31, 2024 and 2023, the Company recorded a decrease of $2.6 million and $12.7 million, respectively, in the fair value of the warrants in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of warrant activity for the years ended December 31, 2024 and 2023: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>&#160;classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">966,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">966,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(280,681)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(282,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685,712&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692,523&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.96&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had 350,000,000 shares of common stock authorized for issuance, $0.0001 par value per share, with 25,767,369 shares issued and outstanding. The voting, dividend and liquidation rights of the common stockholders are subject to and qualified by the rights, powers and preferences of the preferred stock. The common stock has the following characteristics:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders are entitled to one vote for each share of common stock held with respect to all matters voted on by the stockholders of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders are entitled to receive dividends, if and when declared by the Board of Directors. Through December 31, 2024, no cash dividends have been declared or paid on common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon liquidation of the Company, common stockholders are entitled to receive all assets of the Company available for distribution to such stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserved Shares</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized shares of common stock for future issuance as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares available for future stock incentive awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,205,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,706,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,026,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,512,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150434209024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans</a></td>
<td class="text">Stock Incentive Plans<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintained the 2008 Stock Incentive Plan, or the 2008 Plan, for employees, consultants, advisors, and directors. The 2008 Plan provided for the granting of incentive and non-qualified stock option and restricted stock awards as determined by the Board of Directors. In connection with the Merger, all outstanding awards issued under the 2008 Plan were cancelled, and the Board of Directors formally terminated the 2008 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s stockholders approved the 2016 Incentive Award Plan, or the 2016 Plan, which authorized 40,341 shares of common stock for future issuance under the 2016 Plan and the Company ceased granting awards under the 2008 Plan. Upon the effective date of the 2016 Plan, awards issued under the 2008 Plan remained subject to the terms of the 2008 Plan. Awards granted under the 2008 Plan that expired, lapsed or terminated became available under the 2016 Plan as shares available for future grants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, pursuant to the terms of the 2016 Plan, the Board of Directors is authorized to grant awards with respect to common stock, and may delegate to a committee of one or more members of the Board of Directors or executive officers of the Company the authority to grant options and restricted stock units. On December 9, 2020, the Board of Directors established a Stock Option Committee authorized to grant awards to certain employees and consultants subject to conditions and limitations within the 2016 Plan. In January 2024 and 2023, the number of shares of common stock that may be issued under the 2016 Plan was increased by 215,903 and 204,056 shares, respectively. In June 2024, the Company&#8217;s stockholders approved an amendment and restatement of the 2016 Plan to reserve an additional 3,466,544 shares of the Company&#8217;s common stock for issuance. As of December 31, 2024, 3,520,174 shares remain available for future issuance under the 2016 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s 2018 Employment Inducement Incentive Award Plan, or the 2018 Inducement Incentive Award Plan was adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules, which authorized 39,166 shares of its common stock for issuance. In March 2019, the Board of Directors approved an amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional 66,667 shares of the Company&#8217;s common stock for issuance thereunder. In December 2023, the Board of Directors approved an amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional 60,833 shares of the Company&#8217;s common stock for issuance thereunder. In June and December 2024, the Board of Directors approved amendments and restatements of the 2018 Inducement Incentive Award Plan to reserve an additional 360,000 and 450,000 shares, respectively, of the Company&#8217;s common stock for issuance thereunder. As of December 31, 2024, there are 611,960 shares available for future grant under the 2018 Inducement Incentive Award Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Merger Agreement, the Company assumed Old Cartesian&#8217;s 2016 Stock Incentive Plan, or the Old Cartesian Plan. The Old Cartesian Plan permits the granting of options or restricted stock to employees, officers, directors, consultants and advisors to the Company. The unvested common stock options and Series A Preferred Stock options assumed by the Company in connection with the Merger generally vest over a four-year period. Additionally, the stock options granted have a contractual term of ten years and only full shares can be exercised as per the individual award agreements. As of December 31, 2024, there are 27,270 shares available for future grant under the Old Cartesian Plan. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the outstanding stock options to purchase Old Cartesian common stock were converted into stock options to purchase 776,865 shares of common stock and 14,112.299 shares of Series A Preferred Stock of the Company. These replacement awards were revalued at their acquisition-date fair value and then attributed to pre and post-combination service. This resulted in $2.6&#160;million attributed to post-combination service to be recognized as stock-based compensation expense over the remaining terms of the replacement awards, of which $1.3 million and $0.2 million was recognized as research and development expense in the consolidated statements of operations and comprehensive loss during the years ended December 31, 2024 and 2023, respectively. Following the Automatic Conversion, the options exercisable for shares of Series A Preferred Stock became exercisable for shares of common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Settlement of Equity Compensation Awards</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the First Merger, the equity compensation awards of the Company outstanding as of the date of the Merger were settled as follows: (i) each unvested option to acquire shares of common stock and each unvested restricted stock unit award with respect to shares of common stock was accelerated and vested in full at the effective time of the First Merger; (ii) each option to acquire shares of common stock was canceled and in exchange therefore, former holders became entitled to receive an amount in cash equal to the product of (A) the total number of shares of common stock subject to the unexercised portion the stock option (determined after giving effect to the accelerated vesting) multiplied by (B) the excess, if any, of $61.80, or the Cash-out Amount, over the applicable exercise price per share of common stock under such stock option; and (iii) each restricted stock unit award with respect to shares of common stock was cancelled and the former holder of such canceled restricted stock unit became entitled, in exchange therefor, to receive an amount in cash equal to the product of (A) the total number of shares of common stock deliverable under such restricted stock unit (determined after giving effect to the accelerated vesting) multiplied by (B) the Cash-out Amount. Stock options with an exercise price in excess of the Cash-out Amount received no cash payment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The modification to accelerate the vesting of all awards upon the Merger resulted in full recognition of unrecognized compensation of $13.1&#160;million, of which $5.9&#160;million and $7.2&#160;million was classified as research and development expense and general and administrative expense, respectively, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. In addition, with the exception of any options with an exercise price greater than $61.80 per share, all awards were settled in cash for an amount equal to $61.80 less any exercise price associated with the awards. The total cash payment made to the holders of stock options and restricted stock units was $9.4&#160;million. The fair value of the awards prior to the settlement was recorded to additional paid-in capital in an amount of $6.2&#160;million and the amount in excess of fair value was recognized as additional stock-based compensation expense in an amount of $3.2&#160;million, of which $1.5&#160;million and $1.7&#160;million was classified as research and development expense and general and administrative expense, respectively, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss, including $1.5&#160;million recognized as stock-based compensation expense upon the achievement of a technical milestone by Ginkgo Bioworks Holdings, Inc., or Ginkgo, during the year ended December 31, 2023 as described in Note 16, was as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options assumed in connection with the Merger was calculated using a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes option pricing model based on the following </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A Preferred Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.29</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock or Series A Preferred Stock, as applicable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated grant date fair values of stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model based on the following weighted-average assumptions:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.182%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.94</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of the Company&#8217;s stock options granted has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. Under the simplified method, the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data and the plain nature of its stock-based awards. Expected volatilities are based on the Company&#8217;s historical volatility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $15.63 and $26.90, respectively. The total intrinsic value of stock options exercised during the year ended December 31, 2024 was $7.0 million. No stock options were exercised during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, total unrecognized compensation expense related to unvested common stock options was $10.3 million, which is expected to be recognized over a weighted average period of 2.9 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the 2016 Plan, the 2018 Inducement Incentive Award Plan, and the Old Cartesian Plan for options for common stock:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual&#160;term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic&#160;value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">776,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Converted from options for Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">470,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(458,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,781)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,706,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">656,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,564,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Old Cartesian Plan for options for Series A Preferred Stock:</span></div><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual&#160;term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic&#160;value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,112.299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Converted to options for common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,112.299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the approval of the Conversion Proposal on March 27, 2024, all conditions that could have required cash redemption of the Series A Preferred Stock underlying the stock options were removed. Since the Series A Preferred Stock was no longer redeemable, the associated balances of the stock options to purchase Series A Preferred Stock were reclassified to additional paid-in capital during the first quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Automatic Conversion, all options to purchase Series A Preferred Stock were converted into options to purchase common stock with adjustments to the underlying number of shares of common stock determined by multiplying the number of shares of Series A Preferred Stock by 33.333 and rounding down to the nearest whole number of shares and the per-share exercise price by dividing the per-share exercise price of Series A Preferred Stock by 33.333 and rounding the resulting exercise price up to the nearest whole cent. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company granted 477,037 restricted stock unit awards with a weighted average fair value of $19.86 per share based on the closing price of the Company&#8217;s common stock on the date of grant under the 2016 Plan and the Old Cartesian Plan, which generally vest over a four-year term. Forfeitures are estimated at the time of grant and are adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has estimated a forfeiture rate of 10% for restricted stock unit awards based on historical experience. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No restricted stock unit awards vested during the year ended December 31, 2024. The aggregate fair value of restricted stock unit awards that vested during the year ended December 31, 2023 was $0.7 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to the restricted stock unit awards was $5.4 million as of December 31, 2024, which is expected to be recognized over a weighted-average period of 2.9 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock units under the 2016 Plan and the Old Cartesian Plan:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>grant date<br/>fair value ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.86&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333402352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Arrangements</a></td>
<td class="text">Revenue Arrangements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and license revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Astellas Gene Therapies</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2023, the Company entered into the License and Development Agreement, or the Astellas Agreement, with Audentes Therapeutics, Inc., or Astellas. Under the Astellas Agreement, the Company granted Astellas an exclusive license to the Company&#8217;s IdeXork technology arising from Xork, to develop and commercialize Xork for use in Pompe disease in combination with an Astellas gene therapy investigational or authorized product. Xork, Genovis&#8217; IgG Protease, was licensed pursuant to an Exclusive License Agreement, or the Genovis Agreement, with Genovis AB (publ.), or Genovis, as described in Note 16 to these consolidated financial statements. Astellas paid a $10.0&#160;million upfront payment to the Company upon signing of the Astellas Agreement, and the Company was entitled to receive up to $340.0&#160;million in future additional payments over the course of the partnership that were contingent on the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales where Xork is used as a pre-treatment for an Astellas investigational or authorized product. The Company was also eligible for tiered royalty payments ranging from low to high single digits. Any proceeds received from milestone payments or royalties relating to Xork would have been required to be distributed to holders of CVRs, net of certain deductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Astellas Agreement, the Company would have had the exclusive right and responsibility to complete research and development of Xork products and to conduct all preclinical studies and clinical trials for Xork for use in Pompe disease with an Astellas gene therapy investigational or authorized product, or the Xork Development Services. Astellas reimbursed the Company for 25% of all budgeted costs incurred to complete the development of Xork for use in Pompe disease with an Astellas gene therapy investigational or authorized product. The Company would have had control and responsibility over regulatory filings, including any investigational drug applications, biologics license applications, and marketing authorization applications relating to the licensed product. Astellas would have had the exclusive right and responsibility to research, develop, and commercialize Astellas products used in combination with Xork and would have had control and responsibility over all regulatory filings, including any investigational drug applications, biologics license applications, and marketing authorization applications, relating to Astellas products and Astellas products used in combination with Xork.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the Astellas Agreement represented a service arrangement under the scope of ASC 606. The Company determined that the sublicense of Xork to Astellas, the licensed know-how, and the Xork Development Services represented a single promise and performance obligation to be transferred to Astellas over time due to the nature of the promises in the contract. As such, the Company recognized the transaction price as revenue utilizing the input method to measure the progress of satisfying the single performance obligation to Astellas.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the upfront payment of $10.0&#160;million and development cost reimbursements of $5.5&#160;million would be included in the initial transaction price. All other development milestones would be fully constrained and would only have been included in the transaction price when the applicable milestone was deemed probable of achievement. Each of these variable consideration items were evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should have been constrained until </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they became probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt and timing of such development milestones was outside the control of the Company and probability of success criteria was estimated. The Company re-evaluated the transaction price in each reporting period, as uncertain events were resolved, or as other changes in circumstances occurred. In accordance with ASC 606, the Company would have only recognized revenue associated with sales-based milestones and royalties when the subsequent sales thresholds were reached and underlying sales occurred, respectively. The Company determined that a significant financing component did not exist in its arrangement with Astellas. The Company also determined the options to negotiate additional fields, enter into a clinical supply agreement, and enter into a commercial supply agreement did not represent material rights under the Astellas Agreement. Astellas had the right to terminate the Astellas Agreement in its entirety or on a field-by-field basis, upon 90 days&#8217; written notice to the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company was notified by Astellas of its intention to terminate the Astellas Agreement, which occurred effective June 6, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, there were no unsatisfied performance obligations related to the Astellas Agreement. As of December&#160;31, 2023, the Company recorded $2.3 million as a short-term contract liability and $3.5 million as a long-term contract liability, representing deferred revenue associated with the Astellas Agreement. As of December 31, 2024 and 2023, the Company recorded a receivable of $0.1 million and $0.3 million, respectively, representing billings for the Xork Development Services that were subject to reimbursement by Astellas. Revenue of $6.3&#160;million related to the Astellas Agreement was recognized during the year ended December 31, 2024, inclusive of $3.2&#160;million of revenue recognized from performance obligations related to prior periods as a result of the change in transaction price during the year ended December 31, 2024. Revenue of $5.5&#160;million related to the Astellas Agreement was recognized during the year ended December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Takeda Pharmaceuticals USA, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 1, 2021, the Company entered into a License Agreement, or the Takeda Agreement, with Takeda Pharmaceuticals USA, Inc., or Takeda. Under the Takeda Agreement, the Company granted Takeda an exclusive license to the Company&#8217;s ImmTOR technology initially for two specified disease indications within the field of lysosomal storage disorders. Takeda paid a $3.0&#160;million upfront payment to the Company upon signing of the Takeda Agreement, and the Company was entitled to receive up to $1.124&#160;billion in future additional payments over the course of the partnership that were contingent on the achievement of development or commercial milestones or Takeda&#8217;s election to continue its activities at specified development stages. The Company was also eligible for tiered royalties on future commercial sales of any licensed products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Takeda Agreement, the Company determined the Takeda Agreement represented a service arrangement under the scope of ASC 606, and given the reversion of the rights under the Takeda Agreement represented a penalty in substance for a termination by Takeda, the contract term would remain the stated term of the Takeda Agreement. The Company determined that the research license, the licensed know-how, and the manufactured supply and delivery of materials represented a single promise and performance obligation to be transferred to Takeda over time due to the nature of the promises in the contract. The delivery of the manufactured supply was the predominant promise within the arrangement, as it was essential to the utility of the licensed intellectual property. The material supplied by the Company to Takeda was unique to the Company and cannot be obtained by other vendors. As such, consideration in the initial transaction price was allocated to the single performance obligation and the recognition period would not extend beyond the initial contractual period. The Company recognized the revenue associated with the upfront payment and combined single performance obligation utilizing the output method over the term that manufactured supply was delivered to Takeda.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the payment associated with all the performance milestones was fully constrained and only included in the transaction price when the respective milestone was deemed probable of achievement. Each of these variable consideration items were evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt and timing of such study milestones is outside the control of the Company and probability of success criteria is estimated. The Company re-evaluated the transaction price in each reporting period, as uncertain events were resolved, or as other changes in circumstances occurred. Takeda had the right to exercise covenant release rights on a field-by-field basis. If Takeda exercised its covenant release rights, the Company could have received exercise payments per indication and would have been entitled to significant development and commercial milestone payments and tiered royalties on commercial sales. The Company determined that a significant financing component did not exist in its arrangement with Takeda. The Company also determined the options to negotiate additional fields, pursue other products, enter into a supply agreement explore additional fields, and pursue additional development under the initial fields did not represent material rights under the agreement. Takeda had the right to terminate the Takeda Agreement in its entirety or on a field-by-field basis, upon 90 days&#8217; written notice to the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company was notified by Takeda of the achievement of the milestone event related to the completion of a non-clinical milestone for one of the specified disease indications within the field of lysosomal storage </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disorders under the Takeda Agreement. Accordingly, the Company received a milestone payment of $0.5&#160;million during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Takeda Agreement was terminated effective July 25, 2023, following Takeda&#8217;s decision to discontinue discovery and preclinical activities in adeno-associated virus, or AAV, gene therapy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, there were no unsatisfied performance obligations related to the Takeda Agreement. No revenue and revenue of $0.6 million related to the Takeda Agreement was recognized during the years ended December 31, 2024 and 2023, respectively.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Swedish Orphan Biovitrum AB (publ.)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 11, 2020, the Company and Sobi entered into a License and Development Agreement. Pursuant to the Sobi License, the Company agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize the SEL-212 drug candidate, which is currently in development for the treatment of chronic refractory gout. The SEL-212 drug candidate is a pharmaceutical composition containing a combination of SEL-037, or the Compound, and ImmTOR. Pursuant to the Sobi License, in consideration of the license, Sobi agreed to pay the Company a one-time, upfront payment of $75.0&#160;million. Sobi has also agreed to make milestone payments totaling up to $630.0&#160;million to the Company upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier. Any proceeds received from milestone payments or royalties relating to the Sobi License would be required to be distributed to holders of CVRs, net of certain deductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sobi License, the Company agreed to supply (at cost) quantities of the Compound and ImmTOR as necessary for completion of the two Phase 3 clinical trials of SEL-212 (DISSOLVE I and DISSOLVE II) and a six-month placebo extension. The Company was required to supply quantities of the Compound until all rights to the Compound and any materials needed to manufacture the Compound were transferred to Sobi, which transfer occurred upon the execution of Amendment No. 1 to the License and Development Agreement on October 31, 2023. Sobi has agreed to reimburse the Company for all budgeted costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, except for any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212. Sobi will have control and responsibility over all regulatory filings, including any investigational drug applications (IND), biologics license applications (BLA), and marketing authorization applications (MAA) relating to the licensed product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transactions contemplated by the Sobi License were consummated on July 28, 2020. Sobi may terminate the Sobi License for any reason upon 180 days&#8217; written notice to the Company, whereby all rights granted under the Sobi License would revert back to the Company. In addition, if Sobi were to terminate the Sobi License, the Company has the option to obtain a license to all patents and know-how necessary to exploit SEL-212 in existence as of the termination date from Sobi in return for making an equitable royalty payment to Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June 11, 2020, the Company entered into the Sobi Purchase Agreement in connection with the Sobi License. The closing of the Sobi Private Placement occurred on July 31, 2020, following the closing of the transactions contemplated under the Sobi License. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 for details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sobi License represents a service arrangement under the scope of ASC 606. In addition, given the Sobi License and Sobi Purchase Agreement were executed contemporaneously and negotiated as a package with a single commercial objective, the Company will account for the two agreements as a single contract. The term of the Sobi License commenced upon the effective date of July 28, 2020 and will continue on a product-by-product basis until the royalty terms for each country have expired. The royalty term for a given product begins upon the first commercial sale of the product in a country and ends at the later of ten years from the first commercial sale, expiration of the last valid patent claim covering the product and expiration of all regulatory exclusivity periods for the product in a country. Given the reversion of the rights under the Sobi License represents a penalty in substance for a termination by Sobi, the contract term would remain the stated term of the Sobi License.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sobi License contained three distinct performance obligations due to the nature of the promises in the contract, which includes conducting the Phase 3 DISSOLVE trials, Sobi&#8217;s option to set-up a second source supplier, and a combined obligation comprised of the delivery of the license to SEL-212, transfer of the know-how and the manufacturing and delivery of SEL-212 supply for development, or the Combined License Obligation. As the set-up of a second source supplier was optional for Sobi and the Company was to be reimbursed at cost for its efforts in the subsequent set-up and technology transfer, the option for this future service was determined to be at a significant and incremental discount to its standalone selling price and treated as a material right in the arrangement, namely a distinct performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the upfront payment of $75.0&#160;million and the $5.0&#160;million development milestone associated with the dosing of the first patient in the Phase 3 DISSOLVE trials were included in the </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction price. All other development milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of the evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company and probability of success criteria is estimated. The Company re-evaluates the transaction price in each reporting period, as uncertain events are resolved. In accordance with ASC 606, the Company will only recognize revenue associated with sales-based milestones and royalties when the subsequent sales thresholds are reached and underlying sales occur, respectively. In connection with the Sobi Purchase Agreement, the Company determined that the gross proceeds of $25.0&#160;million from the Sobi Private Placement included a premium to the fair value of the Company&#8217;s shares as of July 28, 2020 equal to approximately $14.5&#160;million. The premium amount is included in the transaction price for revenue recognition. The Company estimates and includes in the transaction price the total reimbursements to be received from Sobi for both the manufacturing and delivery of the Compound and ImmTOR as well as conducting the Phase 3 DISSOLVE trials. The Company determined that a significant financing component does not exist in its arrangement with Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the transaction price based on the relative standalone selling prices of the three distinct performance obligations. The Company estimated the standalone selling price of conducting the Phase 3 DISSOLVE trials by forecasting its anticipated costs and applying a margin reflective of the industry. The Company determined the standalone selling price of the second source supplier option by determining the discount given to Sobi multiplied by the likelihood that Sobi would have exercised the option in the future. Similar to the Phase 3 program estimate, the Company estimated the discount of the option by forecasting the set-up costs and applying a margin that is reflective of the industry. As the Company was to provide the set-up and technology transfer services and the future supply at cost, the discount of the option was equal to the margin amount. The Company considered discussions with Sobi as well as probability of regulatory success of SEL-212 in determining the likelihood of exercise. The Company estimated the standalone selling price of the Combined License Obligation by utilizing a discounted cash flow model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the delivery of the supply to Sobi best represented the pattern of delivery of the Combined License Obligation as the supply was essential to the utility of the license and know-how. The Company recognized the revenue allocated to the Combined License Obligation by utilizing the output method. The Company estimated the total supply of the Compound and ImmTOR required during the clinical trial period and recognized revenue as this supply was shipped for use in the clinical trials. The Company recognized the revenue allocated to the conducting of the Phase 3 DISSOLVE trials obligation by utilizing the input method. The Company estimated the total budgeted costs to be incurred over the Phase 3 DISSOLVE trials and recognized revenue as these costs were incurred. The Company&#8217;s costs best represented the pattern of transfer as these captured all performance of the trials completed to date and were readily able to be measured. The Company was to recognize the revenue allocated to the second source supplier option when the future services and goods were transferred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2022, the Company completed enrollment of the DISSOLVE II trial. The completion of enrollment of the DISSOLVE II trial resulted in the achievement of a development milestone and a $10.0&#160;million payment obligation from Sobi to the Company. This amount was added to the overall transaction price and payment was received during the year ended December 31, 2022.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 31, 2023, the Company and Sobi entered into Amendment No. 1 to the License and Development Agreement, pursuant to which the Company granted Sobi an exclusive license to manufacture ImmTOR solely in connection with Sobi&#8217;s development of SEL-212 under the License and Development Agreement and transferred certain contracts and manufacturing equipment to Sobi. Additionally, Sobi&#8217;s option to set-up a second source supplier was removed as a result of the amendment. Further, in connection with entry into the amendment, Sobi agreed to make employment offers to certain of the Company&#8217;s employees engaged in ImmTOR manufacturing activities on or prior to a specified date, and the Company agreed not to terminate the employment of such employees prior to such specified date. The Company maintains no responsibilities to Sobi to manufacture, or supply Sobi with, ImmTOR under the Sobi License.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2024, Sobi initiated a rolling biologics license application to the FDA for SEL-212 for the potential treatment of chronic refractory gout which resulted in the achievement of a development milestone and a $30.0&#160;million payment obligation from Sobi to the Company. As a result, the development milestone was no longer constrained and $30.0&#160;million was recognized as revenue during the year ended December 31, 2024 as there were no remaining performance obligations under the Sobi License. The proceeds from the achievement of the development milestone were received from Sobi in July 2024 and are expected to be included, net of deductions as specified in the CVR Agreement, in the next scheduled distribution to holders of the CVRs in March 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, the Company recorded a total outstanding receivable of $0.1 million and $4.6 million, respectively, representing billings for the Phase 3 DISSOLVE program that are subject to reimbursement by Sobi.  Additionally, as of December&#160;31, 2023, the Company recorded a total unbilled receivable of $3.0 million representing revenue earned but not yet billed for the Phase 3 DISSOLVE program. As of December 31, 2024, there was no unbilled receivable outstanding. Revenue of $31.9 million, inclusive of the $30.0&#160;million development milestone, related to the Sobi License was </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized during the year ended December 31, 2024, and $1.9 million of revenue recognized from performance obligations related to prior periods as a result of the change in transaction price during the year ended December 31, 2024. Revenue of $19.4 million related to the Sobi License was recognized during the year ended December 31, 2023, inclusive of $1.1 million of revenue recognized from performance obligations related to prior periods as a result of the change in transaction price during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarepta Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research License and Option Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, the Company and Sarepta Therapeutics, Inc., or Sarepta, entered into a Research License and Option Agreement, or the Sarepta Agreement. Pursuant to the Sarepta Agreement, the Company agreed to grant Sarepta a license under the Company&#8217;s intellectual property rights covering the Company&#8217;s antigen-specific biodegradable nanoparticle encapsulating ImmTOR to research and evaluate ImmTOR in combination with Sarepta&#8217;s adeno-associated virus gene therapy technology, or gene editing technology, using viral or non-viral delivery, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Indications. Sarepta initially had an option term of 24 months during which it could opt-in to obtain an exclusive license to further develop and commercialize the product to treat at least one Indication, with a potential to extend the option term for an additional fee. The Company agreed to supply ImmTOR to Sarepta for clinical supply on a cost-plus basis under the Sarepta Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sarepta paid a $2.0 million upfront payment to the Company upon signing of the Sarepta Agreement, and the Company was eligible to receive additional preclinical payments during the option term. If Sarepta opted in to an exclusive license agreement, the Company could have received&#160;option exercise payments per Indication upon execution of the exclusive license, and the Company would have been entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sarepta Agreement, the Company determined the Sarepta Agreement represented a service arrangement under the scope of ASC 606, with a 24-month contract duration. Given the reversion of the rights under the Sarepta Agreement represents a penalty in substance for a termination by Sarepta, the contract term would remain the stated term of the Sarepta Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sarepta Agreement and supply obligation including the delivery of the research license, the licensed know-how, the manufactured supply and delivery of materials represented a single promise and performance obligation to be transferred to Sarepta over time due to the nature of the promises in the contract. The delivery of the manufactured supply was the predominant promise within the arrangement, as it was essential to the utility of the licensed intellectual property. As such, consideration in the initial transaction price was allocated to the single performance obligation based on the contractual price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the payment associated with all the performance milestones was fully constrained and would only be included in the transaction price when the respective milestone was deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should have been constrained until they became probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such study milestones was outside the control of the Company and probability of success criteria was estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also determined the option to enter into a future commercial license agreement and extend the term of the option did not represent a material right since it was not priced at an incremental discount. Sarepta had the right to terminate the Sarepta Agreement for any reason upon 30 days&#8217; written notice to the Company. The Sarepta Agreement contained other customary terms and conditions, including representations and warranties, covenants, termination, and indemnification obligations in favor of each party. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021, the Company was notified by Sarepta of the achievement of the milestone event related to the completion of a non-clinical study for Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies under the Sarepta Agreement. Accordingly, the Company received a milestone payment of $3.0&#160;million during the three months ended June 30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2022, the Company was notified by Sarepta that Sarepta would be extending their options under the Sarepta Agreement. In exchange for a nine-month extension to Sarepta&#8217;s options to both Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies, the Company received a milestone payment of $2.0&#160;million during the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, the Company was notified by Sarepta of the achievement of a milestone event related to certain preclinical study milestones under the Sarepta Agreement. Accordingly, the Company received a milestone payment of $4.0&#160;million during the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2023, the Company was notified by Sarepta that Sarepta would not be exercising its exclusive option under the Sarepta Agreement. The Sarepta Agreement terminated upon the expiration of the option in March 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, there were no unsatisfied performance obligations related to the Sarepta Agreement. No revenue and revenue of $0.5 million related to the Sarepta Agreement was recognized during the years ended December 31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to Future Performance Obligations</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Remaining performance obligations represent the transaction price of contracts for which work has not been performed, or has been partially performed. As of December 31, 2024, there were no unsatisfied performance obligations from contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances from Contracts with Customers</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s contract liabilities during the year ended December 31, 2024 (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:37.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.610%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">end of period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,849)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,849)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">National Institute of Neurological Disorders and Stroke of the National Institutes of Health</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Company received funding approval from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, or NINDS, for an award of $1.5&#160;million granted for the budget period, which runs from June 2024 through May 2025. Subject to the availability of funds and satisfactory progress of the project, an additional $1.5&#160;million has been recommended by NINDS to be awarded for the budget period June 2025 through May 2026. The initial $1.5&#160;million funding was provided by NINDS to further the Company&#8217;s use of RNA-based CAR-T cells to combat autoantibody-associated autoimmune disorders. Grant funding is to be used solely for manufacturing of RNA-based CAR-T cells and analysis of samples to inform mechanism of action. The award period runs through May 31, 2026. The Company will recognize grant revenue when expenses reimbursable under the grant have been incurred. </span></div>As of December 31, 2024, the Company recorded a receivable of $0.6&#160;million that is subject to reimbursement by NINDS. Accordingly, the Company recognized grant revenue of $0.6&#160;million during the year ended December 31, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150434115104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Securities Purchase Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 2, 2024, the Company entered into the 2024 Securities Purchase Agreement with the Purchasers. The Purchasers included (i) Dr. Timothy A. Springer, a member of the Company&#8217;s Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Dr. Chafen Lu, Dr. Springer&#8217;s wife (see Note 11). The below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Series B Preferred Stock purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total aggregate purchase price<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,636,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TAS Partners LLC, affiliate of Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chafen Lu, Ph.D., wife of Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Securities Purchase Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 13, 2023, the Company entered into the 2023 Securities Purchase Agreement with (i) Dr. Timothy A. Springer, (ii) TAS Partners LLC, and (iii) Seven One Eight Three Four Irrevocable Trust, a trust associated with Dr. Murat Kalayoglu, in which the Company agreed to issue and sell an aggregate of 149,330.115 shares of Series A Preferred Stock for an aggregate purchase price of $60.25&#160;million (see Note 11). The 2023 Private Placement included a delayed settlement mechanism, and as a result, the below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Series A Preferred Stock purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total aggregate purchase price<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,140.326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The below issuances and sales to related parties of the Company were made subject to the 2023 Private Placement during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Series A Preferred Stock purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total aggregate purchase price <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,785.081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TAS Partners LLC (affiliate of Timothy A. Springer, Ph.D.)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,785.081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Seven One Eight Three Four Irrevocable Trust (affiliate of Murat Kalayoglu, MD, Ph.D.)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619.627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise of Amended 2019 Warrants</span></div>On March 26, 2024, TAS Partners LLC exercised 65,681 Amended 2019 Warrants, paid the per-share exercise price of $43.80 in cash for an aggregate exercise price of $2.9&#160;million, and received 65,681 shares of common stock and 1,970,443 CVRs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150337464352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CollaborationAndLicenseAgreementsTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Collaboration and License Agreements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 8, 2023, the Company entered into a non-exclusive, sublicensable, worldwide, perpetual patent license agreement, or the Biogen Agreement, with Biogen MA, Inc., or Biogen to research, develop, make, use, offer, sell and import products or processes containing or using an engineering T-cell modified with an mRNA comprising, or encoding a protein comprising, certain sequences licensed under the Biogen Agreement for the prevention, treatment, palliation and management of autoimmune diseases and disorders, excluding cancers, neoplastic disorders, and paraneoplastic disorders. The Company is not obligated to pay Biogen any expenses, fees, or royalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may terminate the Biogen Agreement for any reason or no reason, and Biogen may terminate the agreement after a notice-and-cure period of 30 days if the Company fails to pay a fee owed to Biogen or for any other material breach of the agreement. The Biogen Agreement will otherwise expire when all claims of all issued patents within the patents and patent applications licensed to the Company under the Biogen Agreement have expired or been finally rendered revoked, invalid or unenforceable by a decision of a court or government agency.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biogen Agreement encompasses patents and patent applications in the PCT/US2010/026825 patent family, which was filed March 10, 2010. In general, all patents that issue in this family have an expected expiration date of March 10, 2030, subject to potential patent term adjustments and/or extensions. For the U.S. patents and applications in this family, U.S. Patent 9,034,324 was awarded 677 days of patent term adjustment, which would extend the expiration date of this patent to January 16, 2032, absent any challenges to the patent term. The other issued patent in this family was not awarded any patent term adjustment, so its expected expiration date is March 10, 2030.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">National Cancer Institute of the National Institutes of Health</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 16, 2019, the Company entered into a nonexclusive, worldwide license agreement, or the NCI Agreement, with the U.S. Department of Health and Human Services, represented by the National Cancer Institute of the National Institutes of Health, or NCI.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NCI Agreement, the Company was granted a license under certain NCI patents and patent applications designated in the agreement, to make, use, sell, offer and import products and processes within the scope of the patents and applications licensed under the NCI Agreement when developing and manufacturing anti-BCMA CAR-T cell products for the treatment of myasthenia gravis, pemphigus vulgaris, and immune thrombocytopenic purpura according to methods designated in the NCI Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s entry into the NCI Agreement, Old Cartesian paid to NCI a one-time $0.1&#160;million license royalty payment. Under the NCI Agreement, the Company is further required to pay NCI a low five-digit annual royalty. The Company must also pay earned royalties on net sales in a low single-digit percentage and pay up to $0.8&#160;million in benchmark royalties upon the Company&#8217;s achievement of designated benchmarks that are based on the commercial development plan agreed between the parties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NCI Agreement, the Company must use reasonable commercial efforts to bring licensed products and licensed processes to the point of Practical Application (as defined in the NCI Agreement). Upon the Company&#8217;s first commercial sale, </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company must use reasonable commercial efforts to make licensed products and licensed processes reasonably accessible to the United States public. After the Company&#8217;s first commercial sale, the Company must make reasonable quantities of licensed products or materials produced via licensed processes available to patient assistance programs and develop educational materials detailing the licensed products. Unless the Company obtains a waiver from NCI, the Company must have licensed products and licensed processes manufactured substantially in the United States. Prior to the first commercial sale, upon NCI&#8217;s request, the Company is obligated to provide NCI with commercially reasonable quantities of licensed products made through licensed processes to be used for in vitro research.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company must use reasonable commercial efforts to initiate a Phase 3 clinical trial of a licensed product by the fourth quarter of 2024, submit a BLA with respect to a licensed product by the fourth quarter of 2026, and make a first commercial sale of a licensed product by the fourth quarter of 2028.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NCI Agreement terminates upon the expiration of the last to expire of the patent rights licensed thereunder, if not sooner terminated. The NCI Agreement encompasses patents and patent applications in the PCT/US2013/032029 patent family, which was filed March 15, 2013. In general, all patents that issue in this family have an expected expiration of March 15, 2033, subject to potential patent term adjustments and/or extensions. For the U.S. patents and applications in this family, only two patents were awarded patent term adjustments. U.S. Patent 9,765,342 was awarded 297 days of patent term adjustment, which would extend the expiration date of this patent to January 6, 2034, absent any challenges to the patent term. The other patent, U.S. Patent 10,876,123, was awarded three days of patent term adjustment, but this patent is subject to terminal disclaimers filed against other family members, so this patent will not extend beyond the March 15, 2033 date. The other issued patents in this family were not awarded any patent term adjustment, so the expected expiration date for these patents also remains March 15, 2033. There is also a pending patent application which, if issued, will expire on March 15, 2033, but could also be subject to patent term adjustment and to any potential future terminal disclaimers.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NCI has the right to terminate the NCI Agreement, after giving written notice and providing a cure period in accordance with its terms, if the Company is in default of a material obligation. The Company has the unilateral right to terminate the agreement in any country or territory by giving NCI 60 days&#8217; written notice. The Company agreed to indemnify NCI against any liability arising out of the Company&#8217;s, sublicensees&#8217; or third-parties&#8217; use of the licensed patent rights and licensed products or licensed processes developed in connection with the licensed patent rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 25, 2021, the Company entered into a Collaboration and License Agreement, or the First Ginkgo Agreement, with Ginkgo. Under the First Ginkgo Agreement, Ginkgo will design next generation IgA proteases with potentially transformative therapeutic potential. In return, Ginkgo is eligible to earn both upfront research and development fees and milestone payments, including certain milestone payments for fixed fair values in the form of the Company&#8217;s common stock, clinical and commercial milestone payments of up to $85.0&#160;million in cash. The First Ginkgo Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company will expense costs related to the First Ginkgo Agreement as incurred until regulatory approval is received in accordance with ASC 730. The Company is accounting for the contingently issuable shares to be issued in exchange for the license obtained from Ginkgo as a liability classified stock-based compensation arrangement with a non-employee which will be recognized when achievement of the milestones is probable. The Company will assess the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, will amortize these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company is also obligated to pay Ginkgo tiered royalties ranging from low-single digit to high-single digit percentages of annual net sales of collaboration products which will be expensed as the commercial sales occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, the Company entered into a Collaboration and License Agreement, or the Second Ginkgo Agreement, with Ginkgo. Under this agreement, the Company will engage with Ginkgo to develop AAV capsids designed to enhance transduction efficiency and transgene expression. In return, Ginkgo is eligible to earn both upfront research and development fees and milestone payments, including certain milestone payments in the form of shares of the Company&#8217;s common stock, clinical and commercial milestone payments of up to $207&#160;million in cash. The Second Ginkgo Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company will expense costs related to the Second Ginkgo Agreement as incurred until regulatory approval is received in accordance with ASC 730. The Company is accounting for the contingently issuable shares of common stock to be issued in exchange for the license obtained from Ginkgo as a liability-classified, stock-based compensation arrangement with a non-employee which will be recognized when achievement of the milestones is probable. The Company will assess the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, will amortize these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company is also obligated to pay Ginkgo tiered royalties ranging from low-single digit to high-single digit percentages of annual net sales of collaboration products which will be expensed as the commercial sales occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 13, 2022, the Company was notified of the achievement of the midpoint of the technical development plan under the First Ginkgo Agreement by Ginkgo. This milestone resulted in the payment of $0.5&#160;million and issuance of 29,761 shares of the Company&#8217;s common stock then-valued at $1.0&#160;million to Ginkgo during the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2023, the Company and Ginkgo mutually agreed that the completion of the technical development plan&#8217;s midpoint task under the Second Ginkgo Agreement had been achieved as of June 30, 2023. This milestone resulted in the payment of $1.0&#160;million and issuance of 44,642 shares of the Company&#8217;s common stock then-valued at $1.5&#160;million to Ginkgo during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genovis AB (publ.)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 21, 2021, the Company entered into the Genovis Agreement with Genovis. Under the Genovis Agreement, the Company paid to Genovis an upfront payment in exchange for an exclusive license to the Xork enzyme technology across all therapeutic uses in humans, excluding research, preclinical, diagnostic and other potential non-therapeutic applications of the enzyme. Genovis was eligible to earn from the Company development and sales-based milestones and sublicensing fees. The Genovis Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company was to expense costs related to the Genovis Agreement as incurred until regulatory approval was received in accordance with ASC 730. The Company would have assessed the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, would have amortized these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company was also obligated to pay Genovis tiered royalties of low double digit percentages of worldwide annual net sales of collaboration products which would have been expensed as the commercial sales occurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company made a $4.0&#160;million payment to Genovis as a result of the sublicense of Xork to Astellas. See Note 14 to these consolidated financial statements for further discussion on the Astellas Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company notified Genovis of its intention to terminate the Genovis Agreement, which occurred effective September 13, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cyrus Biotechnology, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 7, 2021, the Company and Cyrus Biotechnology, Inc., or Cyrus, entered into a collaboration and license agreement, or the Cyrus Agreement. Pursuant to the Cyrus Agreement, Cyrus agreed to grant the Company an exclusive, worldwide license to certain intellectual property to form a protein engineering collaboration combining the Company&#8217;s ImmTOR platform with Cyrus&#8217; ability to redesign protein therapeutics. The lead program was a proprietary interleukin-2, or IL-2, protein agonist designed to selectively promote expansion of regulatory T cells for treatment of patients with autoimmune diseases and other deleterious immune conditions. In return for the licensed intellectual property, the Company made an upfront payment and was obligated to pay certain discovery, development, and sales-based milestones which could have potentially totaled up to approximately $1.5&#160;billion across multiple programs. The Cyrus Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company expensed costs related to the Cyrus Agreement as incurred until regulatory approval is received in accordance with ASC 730. The Company assessed the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, would have amortized these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company was also obligated to pay Cyrus tiered royalties ranging from mid-single digit to low-double digit percentages of annual net sales of collaboration products which would have been expensed as commercial sales occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 13, 2022, the Company and Cyrus mutually agreed that the preclinical key in-vitro success milestone had been achieved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Company notified Cyrus of its termination of the Cyrus Agreement, effective December 29, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Purchase Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on September 7, 2021, the Company entered into a stock purchase agreement, or the Series B Preferred Stock Purchase Agreement, in connection with the Cyrus Agreement. Pursuant to the Series B Preferred Stock Purchase Agreement, the Company purchased 2,326,934 shares of Cyrus&#8217; Series B Preferred Stock, par value $0.0001 per share, at a purchase price of $0.8595 per share for $2.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 810, the Company has a variable interest in Cyrus resulting from its equity investment. The Company will share in Cyrus&#8217; expected losses or receive a portion of its expected returns and absorb the variability associated with changes in the entity&#8217;s net assets. However, the Company is not the primary beneficiary as it does not have the power to direct the activities most significant to Cyrus, and therefore it is not required to consolidate Cyrus. The Company has recognized the $2.0 million investment of Cyrus&#8217; Series B Preferred Stock at cost on the purchase date.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2024, no impairment indicators are present and there were no observable price changes. Therefore, the carrying value of the investment in Cyrus is $2.0 million on the accompanying consolidated balance sheets. The Company&#8217;s maximum exposure to loss related to this VIE is limited to the carrying value of the investment. The Company has not provided financing to Cyrus other than the amount contractually required by the Series B Preferred Stock Purchase Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asklepios Biopharmaceutical, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Feasibility Study and License Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, the Company entered into a feasibility study and license agreement, or the AskBio Collaboration Agreement, with Asklepios Biopharmaceutical, Inc., or AskBio. Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to license intellectual property rights to each other as part of a collaboration to research, develop, and commercialize certain AAV gene therapy products utilizing the Company&#8217;s ImmTOR platform to enable re-dosing of such AAV gene therapy products to treat serious rare and orphan genetic diseases for which there is a significant unmet medical need.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to conduct proof of concept studies to potentially validate the use of ImmTOR in conjunction with AskBio&#8217;s AAV gene therapy, or SEL-302, (previously disclosed as MMA-101, in combination with ImmTOR) for the treatment of methylmalonic acidemia, or MMA, to mitigate the formation of neutralizing anti-AAV capsid antibodies. On April 29, 2021, the Company was notified by AskBio that it intended to opt-out of development of the MMA indication. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AskBio shared responsibility for the research, development and commercialization of products developed under the SEL-399 program collaboration. The parties also shared research, development, and commercialization costs equally for all collaboration products, but with a right of either party to opt out of certain products, and thereby not be required to share costs for such products. Each party would have received a percentage of net profits under the collaboration equal to the percentage of shared costs borne by such party in the development of such product. Pursuant to the AskBio Collaboration Agreement, AskBio was responsible for manufacturing the AAV capsids and AAV vectors and the Company was responsible for manufacturing ImmTOR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AskBio mutually agreed to the termination of the AskBio Collaboration Agreement, effective December 13, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024 and 2023, the Company recognized no and $0.1 million, respectively, of collaboration expense under the AskBio Collaboration Agreement in which actual costs incurred by both parties approximate a 50% cost share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shenyang Sunshine Pharmaceutical Co., Ltd</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the Company entered into a license agreement, or the 3SBio License, with Shenyang Sunshine Pharmaceutical Co., Ltd., or 3SBio. The Company has paid to 3SBio an aggregate of $7.0 million in upfront and milestone-based payments under the 3SBio License as of December 31, 2024. The Company is required to make future payments to 3SBio contingent upon the occurrence of events related to the achievement of clinical and regulatory approval milestones of up to an aggregate of $15.0 million for products containing the Company&#8217;s ImmTOR platform.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CollaborationAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CollaborationAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332357616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes under ASC 740. Under ASC 740, the Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023, the Company acquired, in accordance with the terms of the Merger Agreement, the assets of Old Cartesian. In accordance with ASC 805-740-25-3, recognition of deferred tax assets and liabilities is required for substantially all temporary differences and acquired tax carryforwards and credits. The Company has computed estimated temporary differences and acquired tax carryforwards and credits as of the transaction date. The Company will not have tax basis in IPR&amp;D booked as part of the purchase accounting. For accounting purposes, the IPR&amp;D will not be amortized and only subject to impairment review and testing. Though the tax effects may be delayed indefinitely, ASC 740-10-55-63 states that &#8220;deferred tax liabilities may not be eliminated or reduced because a reporting entity may be able to delay the settlement of those liabilities by delaying the events that would cause taxable temporary differences to reverse.&#8221; The Company can potentially only utilize indefinite-lived assets as it relates to this indefinite lived intangible deferred tax liability reversal. As such, the Company has booked a deferred tax liability for the portion of the liability that cannot be reduced based on scheduling. Additionally, a portion of this target deferred tax liability is offset with the Company&#8217;s pre-Merger deferred tax assets on a combined basis, and as such the portion of deferred tax liability reduced by the Company&#8217;s pre-Merger deferred tax assets has been charged to income rather than to goodwill.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, the Company recognized a current tax expense of $0.3&#160;million. For the year ended December 31, 2023, the Company recognized a current tax benefit of $19.0&#160;million. The following table reconciles the federal statutory income tax rate to the Company&#8217;s effective income tax rate:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Statutory U.S. federal rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">State income taxes - net of federal benefit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Permanent items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Research tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Change in fair value of contingent value right liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">127.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Change in fair value of forward contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Valuation allowance, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(160.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Effective income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to the Company&#8217;s net deferred tax assets are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">44,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">29,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">6,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">5,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">75,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">84,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Contingent value right liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">108,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">R&amp;E Capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">26,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">19,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Patent and license costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">9,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">274,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">152,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(41,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(41,144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(2,751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(43,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(44,023)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Net deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">231,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">108,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(247,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(124,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Net deferred tax assets/(liabilities)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(16,140)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(15,853)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided a full valuation allowance against its net deferred tax assets, outside of the indefinite tax liability booked as part of the Merger. The Company believes that it is more likely than not that the net deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realization of future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded that it is more likely than not that the Company will not realize the benefit of its net deferred tax assets. The valuation allowance increased by $123.6&#160;million for the year ended December 31, 2024, primarily as a result of tax loss in the current year and the recognition of a $108.8&#160;million tax benefit related to the Company&#8217;s CVR liability. The valuation allowance decreased by $3.5&#160;million for the year ended December 31, 2023, primarily as a result of a tax benefit booked as part of the Merger. As of December 31, 2024, the Company is in the process of winding down operations in Russia and does not expect any tax liability relating to such operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December 31, 2024, the Company has federal net operating loss carryforward of $152.6&#160;million, which can be carried forward indefinitely, subject to an 80% limitation and state net operating loss carryforward of $187.8&#160;million, of which $74.4&#160;million has an unlimited carryforward and the remaining $113.4&#160;million will expire at various times through 2044. The Company has $5.2&#160;million and $1.0&#160;million, respectively, of federal and state research and development tax credit carryforwards, which will expire at various times through 2044. Utilization of the NOL carryforwards and research and orphan drug credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, and similar state law due to ownership changes that could occur in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. If the Company experiences a change of control, as defined by Section 382 of the Code and similar state law, utilization of the NOL carryforwards or research and orphan drug credit carryforwards may be subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL carryforwards or research and orphan drug credit carryforwards before utilization. The Company performed an analysis of ownership changes through December 31, 2023. Based on this analysis, the Company does not believe that any of its tax attributes through December 31, 2023 will expire unutilized due to Section 382 limitations. To the extent the Company enters into future equity transactions, there could be a limitation on the Company&#8217;s tax attributes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC 740, Income Taxes to uncertain tax positions. As of the adoption date on January 1, 2010 and through December 31, 2024, the Company had no unrecognized tax benefits or related interest and penalties accrued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company has not completed a detailed study of its research and development and orphan drug credits for the tax years ending December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 and December 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, the Company will adjust its deferred tax asset balances and include the impacts in the research tax credits and state income taxes &#8211; net of federal benefit lines in the effective rate reconciliation next year, once the updated study has been completed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act requires taxpayers to capitalize and amortize, rather than deduct, research and experimental, or R&amp;E, expenditures under Section 174 for tax years beginning after December 31, 2021. These rules became effective for the Company during the year ended December 31, 2022. As a result, the Company has capitalized R&amp;E costs of $45.1&#160;million and $43.9&#160;million for the years ended December 31, 2024 and December 31, 2023, respectively. The Company will amortize these costs for tax purposes over five years if the R&amp;E was performed in the United States and over 15 years if the R&amp;E was performed outside the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as income tax expense in the accompanying statement of operations. As of December 31, 2024, the Company had no accrued interest related to uncertain tax positions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The statute of limitations for assessment by the Internal Revenue Service and state tax authorities is open for tax years 2020 to the present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, or state tax authorities to the extent utilized in a future period. The Company files income tax returns in the United States, Massachusetts, and Maryland. There are currently no federal, state or foreign audits in progress.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150337464352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Contribution Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution plan, or the 401(k) Plan, under Section&#160;401(k) of the Internal Revenue Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The 401(k) Plan provides for matching contributions on a portion of participant contributions pursuant to the 401(k) Plan&#8217;s matching formula. All matching contributions vest ratably over two years and participant contributions vest immediately. Contributions by the Company totaled $0.2 million and $0.3 million during the years ended December 31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company approved the 2016 Employee Stock Purchase Plan, or the ESPP, which initially authorized 5,769 shares of common stock for future issuance under the ESPP to participating employees. As of December 31, 2024, 45,795 shares remain available for future issuance under the ESPP. In connection with the Merger, the Board of Directors suspended offerings under the ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no stock-based compensation expense under the ESPP for the year ended December 31, 2024 and $0.1 million of stock-based compensation expense under the ESPP for the year ended December 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332357616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company was not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position, results of operations or cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December 31, 2024, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as permitted under Delaware law, the Company indemnifies its directors for certain events or occurrences while the director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is for the director&#8217;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; insurance coverage that limits its exposure and enables it to recover a portion of any future amounts paid. The Company also has indemnification arrangements under certain of its facility leases that require it to indemnify the landlord against certain costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from certain breaches, violations, or non-performance of any covenant or condition of the Company&#8217;s lease. The term of the indemnification is for the term of the related lease agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. To date, the Company had not experienced any material losses related to any of its indemnification obligations, and no material claims with respect thereto were outstanding.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party in various other contractual disputes and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect the Company&#8217;s business, financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332844512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, in light of current market conditions, the Board of Directors took steps to extend the Company&#8217;s cash runway by pausing further development of the Company&#8217;s product candidate, SEL-302, for the treatment of methylmalonic acidemia and conducting a targeted headcount reduction. On August 17, 2023, the Company announced additional steps to extend cash runway and maximize value for stockholders by continuing to prioritize development of the Company&#8217;s product candidate, SEL-212, and support of its collaboration with Astellas for Xork, and pausing further development of all of the Company&#8217;s other clinical and preclinical product candidates that it was no longer actively advancing. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these measures, the Company implemented a restructuring plan that resulted in an approximate 90% reduction of the Company&#8217;s existing headcount as of December 31, 2024. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in the Company&#8217;s accrued restructuring balance included in accrued expenses and other current liabilities on its consolidated balance sheets (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Severance liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,535)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Severance liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized restructuring expenses consisting of one-time cash severance payments and other employee-related costs. The Company recorded these <span style="-sec-ix-hidden:f-1259"><span style="-sec-ix-hidden:f-1260"><span style="-sec-ix-hidden:f-1261"><span style="-sec-ix-hidden:f-1262">restructuring charges</span></span></span></span> based on each employee&#8217;s role to the respective research and development and general and administrative operating expense categories on its consolidated statements of operations and comprehensive loss. For the years ended December 31, 2024 and 2023, the Company recognized $0.2 million and $5.6 million in research and development expenses, respectively, and $0.6 million and $0.8 million in general and administrative expenses, respectively. Payments for the restructuring plan were substantially complete by June 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333303936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors used in determining the reportable segment include the nature of the Company&#8217;s operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note 3. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents selected financial information with respect to the Company&#8217;s single operating segment for the years ended December 31, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and license revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,004&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legacy Selecta programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for MG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Early stage programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development employee expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development facilities and other expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense, net (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,424)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219,710)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Includes impairment of long-lived assets, interest income, foreign currency transaction, net, interest expense, change in fair value of warrant liabilities, change in fair value of contingent value right liability, change in fair value of forward contract liabilities, other income, net, and income tax (expense) benefit.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332842000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date on which the consolidated financial statements were issued. The Company has concluded that no subsequent events have occurred that require disclosure, except as disclosed within these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330726896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (77,424)<span></span>
</td>
<td class="num">$ (219,710)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333260096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rnac_ChristopherJewellMember', window );">Christopher Jewell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On December 23, 2024, Christopher Jewell, our Chief Scientific Officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Dr. Jewell&#8217;s plan provides for the exercise of vested stock options and the potential associated sale of up to 15,000 shares of our common stock until and including December 31, 2025. The foregoing exercises or sales, if any, will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 31, 2025.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Christopher Jewell<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Scientific Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 23, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">373 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rnac_ChristopherJewellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rnac_ChristopherJewellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150322084848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333993456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the key responsibilities of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Board of Directors administers its cybersecurity risk oversight function directly and through the Audit Committee, which conducts regular risk assessments related to all matters affecting the enterprise, including cybersecurity, and receives periodic reports on the Company&#8217;s cybersecurity risks and activities. Our Chief Financial Officer and our Senior Director, Head of IT are the Company employees responsible for developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We partner with external cybersecurity vendors to enact a layered defense approach with controls deployed that seek to meet the requirements of the NIST Cybersecurity Framework. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Financial Officer has served as a biotechnology executive for 20 years, whose responsibilities have included direct oversight of his companies&#8217; cybersecurity risks. Our Senior Director, Head of IT has served as an Information Technology professional for over ten years and has held senior IT positions across several companies including a large pharmaceutical company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. Our Senior Director, Head of IT oversees the cybersecurity program through risk management, employee security training, and oversight and escalation of threat monitoring and incident response. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. In the event of a major security incident, we have established an escalation path for stakeholder notification and remediation efforts, and major incidents are immediately escalated to the Head of IT, Chief Financial Officer, and Chief Operations Officer. In 2024, we proactively conducted a thorough and robust cybersecurity assessment, performed by an external cybersecurity partner, to evaluate our risks and identify key areas to improve our cybersecurity posture. We have implemented processes when evaluating third-party service providers, for example by reviewing available audit reports including the System and </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organization Controls (SOC 2) reports and requesting disclosure of any previous cybersecurity events. We also perform quality audits of certain regulated vendors, which includes an assessment of the vendor&#8217;s information technology system and associated controls.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we conduct periodic risk assessments to identify and monitor against potential cybersecurity threats and incidents, as well as assess for any changes in our business practices that may affect our cybersecurity position. This risk oversight includes identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks and address any identified gaps in existing safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity program is delegated to our Senior Director, Head of IT, who reports on IT operations, risk mitigation and assessment efforts, and other general cybersecurity matters to our Chief Financial Officer, to manage the risk assessment and mitigation process. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work with third-party cybersecurity vendors to assist us in best practices for implementing strengthened cybersecurity procedures. All Company employees and third-party vendors are instructed to promptly report any suspected breach of its security measures that may affect our Company to the Senior Director, Head of IT.  Our Chief Financial Officer and Senior Director, Head of IT provide periodic briefings to the Audit Committee regarding our Company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third-parties, and related matters. The Audit Committee provides regular updates to the full Board of Directors on such reports.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not encountered cybersecurity challenges that have materially impaired our operations or financial standing. For additional information regarding risks from cybersecurity threats, please refer to Item 1A, &#8220;Risk Factors,&#8221; in this Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">One of the key responsibilities of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Board of Directors administers its cybersecurity risk oversight function directly and through the Audit Committee, which conducts regular risk assessments related to all matters affecting the enterprise, including cybersecurity, and receives periodic reports on the Company&#8217;s cybersecurity risks and activities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Board of Directors administers its cybersecurity risk oversight function directly and through the Audit Committee, which conducts regular risk assessments related to all matters affecting the enterprise, including cybersecurity, and receives periodic reports on the Company&#8217;s cybersecurity risks and activities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Chief Financial Officer and our Senior Director, Head of IT are the Company employees responsible for developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We partner with external cybersecurity vendors to enact a layered defense approach with controls deployed that seek to meet the requirements of the NIST Cybersecurity Framework. <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Financial Officer has served as a biotechnology executive for 20 years, whose responsibilities have included direct oversight of his companies&#8217; cybersecurity risks. Our Senior Director, Head of IT has served as an Information Technology professional for over ten years and has held senior IT positions across several companies including a large pharmaceutical company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. Our Senior Director, Head of IT oversees the cybersecurity program through risk management, employee security training, and oversight and escalation of threat monitoring and incident response. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. In the event of a major security incident, we have established an escalation path for stakeholder notification and remediation efforts, and major incidents are immediately escalated to the Head of IT, Chief Financial Officer, and Chief Operations Officer. In 2024, we proactively conducted a thorough and robust cybersecurity assessment, performed by an external cybersecurity partner, to evaluate our risks and identify key areas to improve our cybersecurity posture. We have implemented processes when evaluating third-party service providers, for example by reviewing available audit reports including the System and </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organization Controls (SOC 2) reports and requesting disclosure of any previous cybersecurity events. We also perform quality audits of certain regulated vendors, which includes an assessment of the vendor&#8217;s information technology system and associated controls.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Chief Financial Officer and our Senior Director, Head of IT are the Company employees responsible for developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We partner with external cybersecurity vendors to enact a layered defense approach with controls deployed that seek to meet the requirements of the NIST Cybersecurity Framework. <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Financial Officer has served as a biotechnology executive for 20 years, whose responsibilities have included direct oversight of his companies&#8217; cybersecurity risks. Our Senior Director, Head of IT has served as an Information Technology professional for over ten years and has held senior IT positions across several companies including a large pharmaceutical company.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. Our Senior Director, Head of IT oversees the cybersecurity program through risk management, employee security training, and oversight and escalation of threat monitoring and incident response. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. In the event of a major security incident, we have established an escalation path for stakeholder notification and remediation efforts, and major incidents are immediately escalated to the Head of IT, Chief Financial Officer, and Chief Operations Officer. In 2024, we proactively conducted a thorough and robust cybersecurity assessment, performed by an external cybersecurity partner, to evaluate our risks and identify key areas to improve our cybersecurity posture. We have implemented processes when evaluating third-party service providers, for example by reviewing available audit reports including the System and </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organization Controls (SOC 2) reports and requesting disclosure of any previous cybersecurity events. We also perform quality audits of certain regulated vendors, which includes an assessment of the vendor&#8217;s information technology system and associated controls.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we conduct periodic risk assessments to identify and monitor against potential cybersecurity threats and incidents, as well as assess for any changes in our business practices that may affect our cybersecurity position. This risk oversight includes identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks and address any identified gaps in existing safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity program is delegated to our Senior Director, Head of IT, who reports on IT operations, risk mitigation and assessment efforts, and other general cybersecurity matters to our Chief Financial Officer, to manage the risk assessment and mitigation process. </span></div>As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our Chief Financial Officer and our Senior Director, Head of IT are the Company employees responsible for developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We partner with external cybersecurity vendors to enact a layered defense approach with controls deployed that seek to meet the requirements of the NIST Cybersecurity Framework.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Financial Officer has served as a biotechnology executive for 20 years, whose responsibilities have included direct oversight of his companies&#8217; cybersecurity risks. Our Senior Director, Head of IT has served as an Information Technology professional for over ten years and has held senior IT positions across several companies including a large pharmaceutical company.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our Chief Financial Officer and Senior Director, Head of IT provide periodic briefings to the Audit Committee regarding our Company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third-parties, and related matters. The Audit Committee provides regular updates to the full Board of Directors on such reports.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332364608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Selecta (RUS), LLC, or Selecta (RUS), a Russian limited liability corporation, Selecta Biosciences Security Corporation, a Massachusetts securities corporation which the Company dissolved in December 2024, and Cartesian Bio, LLC, a Delaware limited liability company, which is a variable interest entity for which the Company is the primary beneficiary. All significant intercompany accounts and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company&#8217;s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: estimated fair value of the intangible assets acquired in connection with the Merger, estimated fair value of the CVRs, deferred income taxes, revenue recognition, estimated accrued research and development expenses, stock-based compensation expense, estimated fair value of the liability-classified warrants, and impairment of long-lived assets. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision maker, or the CODM, for the purposes of assessing performance and allocating resources. The Company views its operations and manages its business in one operating segment, which prior to the Merger related to the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases and subsequent to the Merger relates to the research and development of cell therapy product candidates. The Company&#8217;s CODM function is fulfilled by its Chief Executive Officer. The CODM function assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations and comprehensive loss. The CODM function uses net loss to monitor budget versus actual results to assess performance of the segment. Segment assets are the same as total assets on the Company&#8217;s consolidated balance sheets. All long-lived assets are located in the United States. Long-lived assets consist of property and equipment, net, and operating lease right-of-use assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock', window );">Cash Equivalents, Marketable Securities and Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents, Marketable Securities and Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Marketable securities consist of securities with remaining maturities greater than 90 days when purchased. The Company classifies these marketable securities as available-for-sale and records them at fair value in the accompanying consolidated balance sheets. Marketable securities with less than one year until maturity are classified as short term, while marketable securities with maturities greater than one year are classified as long term. Unrealized gains or losses are included in accumulated other comprehensive loss. Premiums or discounts from par value are amortized to interest income over the life of the underlying investment. Although available to be sold to meet operating needs or otherwise, securities are generally held through maturity. The cost of securities sold is determined based on the specific identification method for purposes of recording realized gains and losses. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also in the past invested in equity securities of a company whose securities are not publicly traded and where fair value is not readily available. This investment is recorded using cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. The Company monitors this investment to evaluate whether any increase or decline in its value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. This investment is included in investments in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div>Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term deposits, investments, accounts receivable, and unbilled receivables. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company&#8217;s deposits are financially creditworthy and, accordingly, minimal risk exists with respect to those balances.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s financial instruments consist mainly of cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and other current liabilities, investments, warrants to purchase common stock, forward contract liabilities, and contingent value rights. The carrying amounts of cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities approximate their estimated fair value due to their short-term maturities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy is used to prioritize the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements), and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Level 2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of warrant liabilities and contingent value rights are determined using Level 3 inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the consolidated balance sheet for investments approximate fair value and are assessed for impairment quarterly.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, generally seven years for furniture and fixtures, five years for laboratory equipment, software and office equipment and three years for computer equipment. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Major additions and betterments are capitalized. Maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to operations as incurred. Costs incurred for construction in progress are recorded as assets and are not amortized until the construction is substantially complete and the assets are ready for their intended use.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are tested at the lowest level for which identifiable independent cash flows are available. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. The Company recognized an impairment charge on its right of use assets and related furniture and fixtures during the year ended December 31, 2024 and on a right-of-use asset during the year ended December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs and fees paid to lenders are recorded as a direct deduction from the face amount of the related debt. Debt issuance costs are amortized over the term of the related debt using the effective interest method and recorded as interest expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in the equity of a business entity during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss consists of: (i)&#160;all components of net loss and (ii)&#160;all components of comprehensive loss other than net loss, referred to as other comprehensive loss. Other comprehensive loss is comprised of unrealized gains and losses on debt securities and foreign currency translation adjustments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Collaboration and License Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and License Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. Pursuant to ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers (ASC 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. If a promised good or service is not distinct, it is combined with other promised goods or services into a performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Revenue: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently generates its revenue through collaboration and license agreements with strategic collaborators for the development and commercialization of product candidates. Collaboration and license agreements with customers are generally accounted for in accordance with ASC 606. The Company analyzes collaboration arrangements by first assessing whether they are within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (ASC 808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and evaluates whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. Collaboration agreements with customers that are not within the scope of ASC 808 are accounted for in accordance with ASC 606. To the extent the collaboration agreement is within the scope of ASC 808, the Company also assesses whether any aspects of the agreement are within the scope of other accounting literature (specifically ASC 606). If the Company concludes that some or all aspects of the agreement are distinct and represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606. The Company recognizes the shared costs incurred that are not within the scope of other accounting literature as a component of the related expense in the period incurred by analogy to ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development (ASC 730)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and records reimbursements from counterparties as an offset to the related research and development costs. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under the agreements in accordance with ASC 606, the Company performs the five steps above. As part of the accounting for the arrangement, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;The Company uses key assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Company&#8217;s arrangements typically include one or more of the following: (i) upfront fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; (iii) royalties on net sales of licensed products; (iv) reimbursements or cost-sharing of research and development expenses; and (v) profit/loss sharing arising from co-promotion arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promised goods and services identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. If not distinct, the license is combined with other promised goods and services in the contract. For licenses that are combined with other promised goods and services, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Optional licenses are evaluated to determine if they are issued at a discount, and therefore, represent material rights and accounted for as separate performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes developmental and regulatory milestone payments, the Company evaluates whether the achievement of each milestone specifically relates to the Company&#8217;s efforts to satisfy a performance obligation or transfer a distinct good or service within a performance obligation. If the achievement of a milestone is considered a direct result of the Company&#8217;s efforts to satisfy a performance obligation or transfer a distinct good or service and the receipt of the payment is based upon the achievement of the milestone, the associated milestone value is allocated to that distinct good or service. If the milestone payment is not specifically related to the Company&#8217;s effort to satisfy a performance obligation or transfer a distinct good or service, the amount is allocated to all performance obligations using the relative standalone selling price method. The Company also evaluates the milestone to determine whether they are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price to be allocated, otherwise, such amounts are constrained and excluded from the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the transaction price.&#160;Any such adjustments to the transaction price are allocated to the performance obligations on the same basis as at contract inception. Amounts allocated to a satisfied performance obligation shall be recognized as revenue, or as a reduction of revenue, in the period in which the transaction price changes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Supply Services: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are evaluated to determine if they are distinct and optional. For optional services that are distinct, the Company assesses if they are priced at a discount, and therefore, provide a material right to the licensee to be accounted for as separate performance obligations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied) in accordance with the royalty recognition constraint.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Grant Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with government-sponsored organizations for research and development related activities that provide for payments for reimbursable costs. The Company recognizes grant revenue from these contracts as it performs services under these arrangements when the funding is committed. Expenses associated with these contracts are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations and comprehensive loss as the Company has determined it is the primary obligor under the arrangements relative to the research and development services it performs as lead technical expert. Amounts incurred that are subject to reimbursement from the sponsor are recorded as accounts receivable on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred in the research and development of the Company&#8217;s products are expensed as incurred. Research and development expenses include costs incurred in performing research and development activities, including salaries and benefits, stock-based compensation expenses, facilities cost, overhead costs, contract services, supplies and other outside costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ClinicalTrialCostsPolicyTextBlock', window );">Clinical Trial Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third-parties. Third-party clinical trial expenses include patient costs, clinical research organization costs and costs for data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued clinical trial cost. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Non-refundable&#160;advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. The Company also records accruals for estimated ongoing clinical research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical clinical accrual estimates made by the Company have not been materially different from the actual costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more-likely-than-not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more-likely-than-not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and then in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or may require settlement by issuing variable number of shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to&#160;its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the statements of operations as a gain or loss.&#160;Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all stock-based compensation granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of estimated forfeitures. To the extent that actual forfeitures differ from the Company&#8217;s estimates, the differences are recorded as a cumulative adjustment in the period the estimates were adjusted. Stock-based compensation expense recognized in the consolidated financial statements is based on awards that ultimately vest.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company applies the two-class method to compute basic and diluted net income (loss) per share attributable to common stockholders when it has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company&#8217;s Series A Preferred Stock, Series B Preferred Stock and 2022 Warrants participate in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) per share attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase common stock and Series A Preferred Stock, forward contracts to issue Series A Preferred Stock, restricted stock units, warrants to purchase common stock, employee stock purchase plan stock, contingently issuable shares, Series A Preferred Stock, and Series B Preferred Stock are considered potential dilutive common shares.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Liabilities</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its contingent liabilities in accordance with ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies (ASC 450)</span>. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases in accordance with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (ASC 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company elected not to recognize leases with an original term less than one year on its balance sheet. Operating lease right-of-use assets and their corresponding lease liabilities are recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 842, the fixed and in-substance fixed contract consideration must be allocated to lease and non-lease components based on their relative fair values. Non-components of a contract (e.g., administrative tasks that do not transfer a good or service to the Company, reimbursement or payment of a lessor&#8217;s cost, etc.) do not receive an allocation of the consideration in the contract. Although allocation of consideration of lease and non-lease components is required, the Company elected the practical expedient to not separate lease components (e.g. land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The lease component results in an operating right-of-use asset being recorded on the balance sheet and amortized on a straight-line basis as lease expense. Right-of-use assets and operating lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and the estimated incremental borrowing rate upon lease modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease agreements with terms generally ranging from <span style="-sec-ix-hidden:f-467">two</span> to eight years. Some of the Company&#8217;s lease agreements include Company options to either extend and/or early terminate the lease, the costs of which are included in </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its operating lease liabilities to the extent that such options are reasonably certain of being exercised. Leases with renewal options allow the Company to extend the lease term typically between <span style="-sec-ix-hidden:f-469">one</span> and five years. When determining the lease term, renewal options reasonably certain of being exercised are included in the lease term. When determining if a renewal option is reasonably certain of being exercised, the Company considers several economic factors, including but not limited to, the significance of leasehold improvements incurred on the property, whether the asset is difficult to replace, underlying contractual obligations, or specific characteristics unique to that particular lease that would make it reasonably certain that the Company would exercise such option. Renewal and termination options were generally not included in the lease term for the Company&#8217;s existing operating leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations based on the fair value estimates as of the date of acquisition. In accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (ASC 805)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the amount of consideration paid in excess of the fair value of the identified net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.</span></div>The Company evaluates goodwill for impairment at least annually on October 1 and whenever facts and circumstances indicate that their carrying amounts may not be recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets consist of in-process research and development, or IPR&amp;D. The fair values of IPR&amp;D assets acquired in business combinations are capitalized. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry and recent and forecasted financial performance.</span></div>The Company evaluates indefinite-lived intangible assets for impairment at least annually on October 1 and whenever facts and circumstances indicate that their carrying amounts may not be recoverable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_TemporaryEquityPolicyPolicyTextBlock', window );">Convertible Preferred Stock and Series A Preferred Stock Options</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Preferred Stock</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records its convertible preferred stock upon issuance at its fair value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value includes the original issuance price, the settlement of any related forward contract, and is less issuance costs. The Company classifies its convertible preferred stock outside of stockholders&#8217; deficit if the redemption of such shares is outside the Company&#8217;s control. For shares classified outside of stockholders&#8217; deficit, the Company does not adjust the carrying value of its convertible preferred stock to redemption value until it is probable of becoming redeemable. As of December 31, 2024, there were no conditions that could have required cash redemption of the convertible preferred stock and therefore, all convertible preferred stock were classified within stockholders&#8217; deficit.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Series A Preferred Stock Options </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies a portion of the fair value of the vested stock options for Series A Preferred Stock equal to the estimated redemption value on the measurement date outside of stockholders&#8217; deficit, if the redemption of the shares underlying the options are outside the Company&#8217;s control. Any fair value in excess of the estimated redemption value is recognized as additional paid-in capital. The estimated redemption value is based on the intrinsic value of the option. The Company does not adjust the carrying value of the stock options for Series A Preferred Stock until the underlying Series A Preferred Stock is probable of becoming redeemable. The Company records the stock options for Series A Preferred Stock based on the intrinsic value of the vested options.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable Interest Entities</span></div>The Company evaluates its variable interests in variable interest entities, or VIEs, and consolidates VIEs when the Company is the primary beneficiary. The Company determines whether it is the primary beneficiary of a VIE based on its assessment of whether the Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#8217;s economic performance and (ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary conclusion.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock', window );">Contingent Value Right Liability</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Value Right Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CVRs distributed by the Company pursuant to the terms of the CVR Agreement (as defined below) represent financial instruments that are accounted for under the fair value option election in ASC Topic 825, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments (ASC 825).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the fair value option election, the CVRs are initially measured at the aggregate estimated fair value of the CVRs and will be subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the CVR liability was determined using a discounted cash flow methodology as of December 31, 2023 and a Monte Carlo simulation method as of December 31, 2024 to estimate future cash flows associated with the legacy assets, including the expected milestone and royalty payments under the Sobi License, net of deductions. Changes in fair value of the liability are presented in the consolidated statements of operations and comprehensive loss. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, expected volatilities of revenues (Monte Carlo simulation) and risk-adjustment discount rate (discounted cash flow methodology), which represent a Level 3 measurement within the fair value hierarchy.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Forward Contract Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Contract Liabilities</span></div>The Company accounts for contracts related to the future issuance of its convertible preferred stock as a liability if the underlying shares include a redemption feature that may require the Company to settle the instrument by transferring an asset. The forward contract liability is carried at fair value through the date the underlying shares are issued. The fair value of the Series A Preferred Stock forward contract liability was initially measured based on the fair value of the Series A Preferred Stock issued in the 2023 Private Placement (see Note 11), less the purchase price, if any. Subsequent measurement of the fair value of the Series A Preferred Stock forward contract liability was based on the market price of the Company&#8217;s common stock, which represented the redemption and conversion value of the Series A Preferred Stock, less the purchase price, if any, on an as-converted basis. The remeasurement of the forward contract liability is based on Level 2 inputs within the fair value hierarchy as it&#8217;s based on observable market data. Changes in fair value of the liability are presented within change in fair value of forward contract liabilities in the consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for the annual period beginning the year ended December 31, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company adopted the new standard during the year ended December 31, 2024 and the amendments have be applied retrospectively to all prior periods presented in the consolidated financial statements. See Note 21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not Yet Adopted</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual period beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently in the process of evaluating the impact of the standard&#8217;s adoption on its consolidated financial statements and related disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement Reporting- Comprehensive Income- Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2024-03), which requires public companies to disclose, in interim and annual reporting periods, additional information about certain expenses in notes to financial statements, including purchases of inventory, employee compensation, depreciation, amortization of intangible assets, and selling expenses. This guidance will be effective for the annual period beginning the year ended December 31, 2027 and for interim periods beginning January 1, 2028, with early adoption permitted. The Company is currently in the process of evaluating the impact of the standard&#8217;s adoption on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ClinicalTrialCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ClinicalTrialCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Right Liability, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_TemporaryEquityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_TemporaryEquityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Paragraph 2AA<br> -Subparagraph (a)<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AA<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332685872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Fair Value of Consideration</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The total fair value of the consideration of $168.5&#160;million as of the Closing Date is summarized as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract to issue common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract to issue Series A Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options allocated to consideration paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168,465&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of the Purchase Price to the Estimated Fair Values of the Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table presents the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed as of the Closing Date (in thousands):<div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of November 13, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Schedule of Intangible Assets Acquired</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company&#8217;s intangible assets acquired in the Merger (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Date<br/>Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for MG</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for SLE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total in-process research and development assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Financial Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information reflects the consolidated results of operations of the Company as if the Merger had taken place on January 1, 2022. The unaudited pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of acquired indefinite-lived intangible asset by major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333300656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Allocable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders</a></td>
<td class="text">The following table sets forth the computation of basic and diluted net loss per share allocable to common stockholders (in thousands, except share and per-share data):<div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: CVR distribution to participating securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss allocable to shares of common stock - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,424)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(257,260)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Change in fair value of forward contract liability settled in February 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss allocable to shares of common stock - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,870)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(257,260)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,276,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,170,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plus: Dilutive effect of forward contract liability settled in February 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding  - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,357,943&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,170,319&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.48)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.76)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.76)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Shares of Common Stock Excluded from the Computation of the Diluted Net Loss Per Share Allocable to Common Stockholders</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the potential dilutive shares of common stock excluded from the computation of the diluted net loss per share allocable to common stockholders for all periods presented, as the effect would have been anti-dilutive: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options and RSUs </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,150,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">776,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,026,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,503,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract to issue Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,304,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">470,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,307,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,096,751&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150458349904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds (included in cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contingent value right liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds (included in cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contingent value right liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forward contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">364,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">The Company&#8217;s consolidated statement of cash flows includes the following as of December 31, 2024 and 2023 (in thousands):<div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"></td><td style="width:70.926%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text">The Company&#8217;s consolidated statement of cash flows includes the following as of December 31, 2024 and 2023 (in thousands):<div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"></td><td style="width:70.926%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurement Inputs and Valuation Techniques for 2019 Warrants Liability and CVR Liability</a></td>
<td class="text">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the 2019 Warrants liability as of December 31, 2023 is as follows:<div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.877%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the 2022 Warrants liability is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.28</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>The significant inputs used to estimate the fair value of the CVR liability, which represented a financial instrument being accounted for under the fair value option, were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.877%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated cash flow dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2038</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated probability of success</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.0% - 100.0%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility of future revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.877%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated cash flow dates</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 - 2038</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated probability of success</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-adjusted discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Roll-Forward of Fair Value for the Company&#8217;s Level 3 Warrant Liabilities, CVR Liability and Forward Contract Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company&#8217;s Level 3 warrant liabilities (see Note 12), for the year ended December 31, 2024 (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company&#8217;s Level 3 CVR liability for the year ended December 31, 2024 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CVR liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the forward contract liabilities for the periods presented (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward contract liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:f-651">Change in fair value</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330471840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150331356736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll and employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued patent fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued external research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150331350656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Costs and Additional Information Related to Operating Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024 and 2023, the components of lease costs were as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,099)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,394&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to the Company&#8217;s operating leases:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2024 were as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of Supplemental Disclosure for the Statement of Cash Flows Related to Operating Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150434197808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of warrant activity for the years ended December 31, 2024 and 2023: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>&#160;classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">966,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">966,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(280,681)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(282,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685,712&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692,523&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.96&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Authorized Shares of Common Stock for Future Issuance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized shares of common stock for future issuance as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares available for future stock incentive awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,205,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,706,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,026,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,512,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150444264160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss, including $1.5&#160;million recognized as stock-based compensation expense upon the achievement of a technical milestone by Ginkgo Bioworks Holdings, Inc., or Ginkgo, during the year ended December 31, 2023 as described in Note 16, was as follows (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions Used</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options assumed in connection with the Merger was calculated using a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes option pricing model based on the following </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A Preferred Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.29</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock or Series A Preferred Stock, as applicable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated grant date fair values of stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model based on the following weighted-average assumptions:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.182%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.94</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the 2016 Plan, the 2018 Inducement Incentive Award Plan, and the Old Cartesian Plan for options for common stock:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual&#160;term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic&#160;value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">776,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Converted from options for Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">470,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(458,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,781)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,706,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">656,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,564,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Old Cartesian Plan for options for Series A Preferred Stock:</span></div><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual&#160;term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic&#160;value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,112.299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Converted to options for common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,112.299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock units under the 2016 Plan and the Old Cartesian Plan:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>grant date<br/>fair value ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.86&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333375008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Contract Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s contract liabilities during the year ended December 31, 2024 (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:37.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.610%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">end of period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,849)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,849)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150434135872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text">The below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Series B Preferred Stock purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total aggregate purchase price<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,636,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TAS Partners LLC, affiliate of Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chafen Lu, Ph.D., wife of Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>The 2023 Private Placement included a delayed settlement mechanism, and as a result, the below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Series A Preferred Stock purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total aggregate purchase price<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,140.326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The below issuances and sales to related parties of the Company were made subject to the 2023 Private Placement during the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Series A Preferred Stock purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total aggregate purchase price <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,785.081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TAS Partners LLC (affiliate of Timothy A. Springer, Ph.D.)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,785.081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Seven One Eight Three Four Irrevocable Trust (affiliate of Murat Kalayoglu, MD, Ph.D.)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619.627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150444371552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text">The following table reconciles the federal statutory income tax rate to the Company&#8217;s effective income tax rate:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Statutory U.S. federal rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">State income taxes - net of federal benefit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Permanent items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Research tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Change in fair value of contingent value right liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">127.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Change in fair value of forward contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Valuation allowance, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(160.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Effective income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to the Company&#8217;s net deferred tax assets are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">44,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">29,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">6,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">5,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">75,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">84,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Contingent value right liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">108,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">R&amp;E Capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">26,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">19,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Patent and license costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">9,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">274,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">152,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(41,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(41,144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(2,751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(43,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(44,023)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Net deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">231,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">108,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(247,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(124,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Net deferred tax assets/(liabilities)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(16,140)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(15,853)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332682704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Change in Accrued Restructuring Balance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in the Company&#8217;s accrued restructuring balance included in accrued expenses and other current liabilities on its consolidated balance sheets (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Severance liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,535)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Severance liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332834256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents selected financial information with respect to the Company&#8217;s single operating segment for the years ended December 31, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and license revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,004&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legacy Selecta programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descartes-08 for MG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Early stage programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development employee expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development facilities and other expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense, net (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,424)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219,710)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Includes impairment of long-lived assets, interest income, foreign currency transaction, net, interest expense, change in fair value of warrant liabilities, change in fair value of contingent value right liability, change in fair value of forward contract liabilities, other income, net, and income tax (expense) benefit.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150324667008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 04, 2024</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Dec. 06, 2023</div></th>
<th class="th">
<div>Dec. 05, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 13, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692,071<span></span>
</td>
<td class="nump">$ 614,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Cash, cash equivalents, restricted cash and marketable securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member', window );">2023 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,330.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member', window );">2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction', window );">Gross proceeds | $</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member', window );">2024 Securities Purchase Agreement | Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">3,563,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member', window );">2024 Securities Purchase Agreement | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">2,937,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed', window );">Contingent value right, percentage of milestone payments, royalties and other amounts to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,099<span></span>
</td>
<td class="nump">224,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,930.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | Preferred Stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,930.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Right, Percentage Of Milestone Payments, Royalties And Other Amounts To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Gross Consideration Received On Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SaleOfStockGrossConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150324694816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150324909920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment, Software and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rnac_AstellasGeneTherapiesMember', window );">Astellas Gene Therapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment', window );">Reimbursement percentage, budgeted costs incurred to complete the development</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Percentage, Budgeted Costs Incurred To Complete The Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rnac_AstellasGeneTherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rnac_AstellasGeneTherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330309632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger - Narrative (Details) - Old Cartesian - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares)</a></td>
<td class="nump">224,099<span></span>
</td>
<td class="nump">224,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares)</a></td>
<td class="nump">384,930.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Preferred Stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,930.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329764848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger - Schedule of Fair Value of Consideration (Details) - Old Cartesian<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Nov. 13, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">$ 168,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Forward contract to issue stock and options</a></td>
<td class="nump">2,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Forward contract to issue stock and options</a></td>
<td class="nump">155,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Forward contract to issue stock and options</a></td>
<td class="nump">$ 10,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329523664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger - Schedule of Allocation of the Purchase Price to the Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 48,163<span></span>
</td>
<td class="nump">$ 48,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability', window );">Lease liability, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,853<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,298<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Expenses And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150331495264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger - Schedule of Intangible Assets Acquired (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Carrying value</a></td>
<td class="nump">$ 150,600,000<span></span>
</td>
<td class="nump">$ 150,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquisition Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | Descartes-08 for MG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquisition Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | Descartes-08 for SLE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquisition Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=rnac_Descartes08ForMGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=rnac_Descartes08ForMGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=rnac_Descartes08ForSLEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=rnac_Descartes08ForSLEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332738592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger - Schedule of Pro Forma Financial Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
<td class="nump">$ 26,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (232,259)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150331646992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Allocable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (77,424)<span></span>
</td>
<td class="num">$ (219,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DistributedEarnings', window );">Less: CVR distribution to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,550)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss allocable to shares of common stock - basic</a></td>
<td class="num">(77,424)<span></span>
</td>
<td class="num">(257,260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Less: Change in fair value of forward contract liability settled in February 2024</a></td>
<td class="num">(446)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss allocable to shares of common stock - diluted</a></td>
<td class="num">$ (77,870)<span></span>
</td>
<td class="num">$ (257,260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">17,276,822<span></span>
</td>
<td class="nump">5,170,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Plus: dilutive effect of forward contract liability settled in February 2024 (in shares)</a></td>
<td class="nump">81,121<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">17,357,943<span></span>
</td>
<td class="nump">5,170,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (4.48)<span></span>
</td>
<td class="num">$ (49.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (4.49)<span></span>
</td>
<td class="num">$ (49.76)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DistributedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of dividends declared in the period for each class of stock and the contractual amount of dividends (or interest on participating income bonds) that must be paid for the period (for example, unpaid cumulative dividends). Dividends declared in the current period do not include dividends declared in respect of prior-period unpaid cumulative dividends. Preferred dividends that are cumulative only if earned are deducted only to the extent that they are earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DistributedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150331280544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Allocable to Common Stockholders - Schedule of Potential Dilutive Shares of Common Stock Excluded from the Computation of the Diluted Net Loss Per Share Allocable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">7,307,069<span></span>
</td>
<td class="nump">20,096,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">2,150,273<span></span>
</td>
<td class="nump">776,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">692,523<span></span>
</td>
<td class="nump">1,040,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">4,026,346<span></span>
</td>
<td class="nump">14,503,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">437,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rnac_ForwardContractToIssueSharesMember', window );">Forward contract to issue Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,304,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rnac_SeriesAPreferredStockOptionsMember', window );">Series A Preferred Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">470,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rnac_ForwardContractToIssueSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rnac_ForwardContractToIssueSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rnac_SeriesAPreferredStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rnac_SeriesAPreferredStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330854928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Forward contract liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 28,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">39,088<span></span>
</td>
<td class="nump">41,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">3,836<span></span>
</td>
<td class="nump">6,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiability', window );">Contingent value right liability</a></td>
<td class="nump">395,500<span></span>
</td>
<td class="nump">358,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Forward contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,307<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">399,336<span></span>
</td>
<td class="nump">393,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">39,088<span></span>
</td>
<td class="nump">41,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiability', window );">Contingent value right liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Forward contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiability', window );">Contingent value right liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Forward contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,307<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">3,836<span></span>
</td>
<td class="nump">6,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiability', window );">Contingent value right liability</a></td>
<td class="nump">395,500<span></span>
</td>
<td class="nump">358,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Forward contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">399,336<span></span>
</td>
<td class="nump">364,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds (included in cash equivalents)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (included in cash equivalents)</a></td>
<td class="nump">39,088<span></span>
</td>
<td class="nump">41,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds (included in cash equivalents) | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (included in cash equivalents)</a></td>
<td class="nump">39,088<span></span>
</td>
<td class="nump">41,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds (included in cash equivalents) | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (included in cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds (included in cash equivalents) | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (included in cash equivalents)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContingentValueRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Right Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContingentValueRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330922656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 13, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 06, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 05, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 13, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 11, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SettlementOfDerivativeLiabilityShares', window );">Derivative liability, shares (in shares) | shares</a></td>
<td class="nump">49,570.162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,710.488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rnac_SOBIPurchaseAgreementMember', window );">SOBI Purchase Agreement | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member', window );">2023 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,330.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_IssuanceOfStockForSettlementOfForwardContractLiability', window );">Issuance of stock for settlement of liability</a></td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed', window );">Contingent value right, percentage of milestone payments, royalties and other amounts to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead', window );">Fixed semi annual amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,930.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Forward contract to issue stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Settlement of forward contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | Preferred Stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,930.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | 2022 Warrants | CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Valuation Technique, Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Valuation Technique, Option Pricing Model | 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Right Liability, Deduction From Distribution, General And Administrative Overhead</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Right, Percentage Of Milestone Payments, Royalties And Other Amounts To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_IssuanceOfStockForSettlementOfForwardContractLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Stock For Settlement Of Forward Contract Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_IssuanceOfStockForSettlementOfForwardContractLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SettlementOfDerivativeLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Derivative Liability, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SettlementOfDerivativeLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rnac_SOBIPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rnac_SOBIPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rnac_A2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rnac_A2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rnac_ContingentValueRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rnac_ContingentValueRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150321780224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 212,610<span></span>
</td>
<td class="nump">$ 76,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 214,279<span></span>
</td>
<td class="nump">$ 78,288<span></span>
</td>
<td class="nump">$ 108,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333289984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for Warrants Liability (Details) - Valuation Technique, Option Pricing Model<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Risk-free interest rate | 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Risk-free interest rate | 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.0425<span></span>
</td>
<td class="nump">0.0401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Dividend yield | 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Dividend yield | 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected life (in years) | 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected life (in years) | 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">2 years 3 months 10 days<span></span>
</td>
<td class="text">3 years 3 months 10 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected volatility | 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected volatility | 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.9292<span></span>
</td>
<td class="nump">0.8409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rnac_A2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rnac_A2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rnac_A2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rnac_A2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330870336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Company&#8217;s Level 3 Warrant Liabilities and CVR Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 6,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(2,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">3,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=rnac_ContingentValueRightMember', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">358,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">36,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 395,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=rnac_ContingentValueRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=rnac_ContingentValueRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333110032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for CVR Liability (Details) - Level&#160;3<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Estimated probability of success</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiabilityMeasurementInput', window );">Contingent value right liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Estimated probability of success | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiabilityMeasurementInput', window );">Contingent value right liability, measurement input</a></td>
<td class="nump">0.950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Estimated probability of success | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiabilityMeasurementInput', window );">Contingent value right liability, measurement input</a></td>
<td class="nump">1.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Expected volatility of future revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiabilityMeasurementInput', window );">Contingent value right liability, measurement input</a></td>
<td class="nump">0.220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Risk-adjusted discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContingentValueRightLiabilityMeasurementInput', window );">Contingent value right liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContingentValueRightLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Right Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContingentValueRightLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=rnac_ProbabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=rnac_ProbabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=rnac_MeasurementInputRevenueVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=rnac_MeasurementInputRevenueVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329767120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Forward Contract Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning balance</a></td>
<td class="nump">$ 28,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements', window );">Settlements</a></td>
<td class="num">(35,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">6,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Change in fair value of forward contract liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332232688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 12,269<span></span>
</td>
<td class="nump">$ 7,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(2,357)<span></span>
</td>
<td class="num">(5,728)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,912<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rnac_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">7,295<span></span>
</td>
<td class="nump">6,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,427<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 695<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rnac_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rnac_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330798960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330324592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee related expenses</a></td>
<td class="nump">$ 3,534<span></span>
</td>
<td class="nump">$ 4,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AccruedPatentFeesCurrent', window );">Accrued patent fees</a></td>
<td class="nump">813<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued external research and development costs</a></td>
<td class="nump">2,987<span></span>
</td>
<td class="nump">4,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AccruedAuditFeesCurrent', window );">Accrued professional and consulting services</a></td>
<td class="nump">3,674<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AccruedPropertyPlantAndEquipmentCurrent', window );">Property and equipment</a></td>
<td class="nump">782<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 12,076<span></span>
</td>
<td class="nump">$ 14,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AccruedAuditFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Audit Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AccruedAuditFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AccruedPatentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of patent fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AccruedPatentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AccruedPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Property, Plant And Equipment, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AccruedPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150324643152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - 7495 New Horizon Way Leases (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 07, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 01, 2024 </div>
<div>USD ($) </div>
<div>extension_option</div>
</th>
<th class="th">
<div>Feb. 28, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,535<span></span>
</td>
<td class="nump">$ 10,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LeaseArrangementAxis=rnac_A7495NewHorizonWayLeaseMember', window );">7495 New Horizon Way Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space leased | ft&#178;</a></td>
<td class="nump">2,009<span></span>
</td>
<td class="nump">7,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend', window );">Number of options to extend lease | extension_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LesseeOperatingLeaseMonthlyBaseRent', window );">Lease agreement, monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne', window );">Lessee, operating lease, base rent, annual upward adjustment percentage after year one</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement', window );">Lessee, operating lease, first month rent paid on execution of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne', window );">Lessee, operating lease, additional annual base rent, year one</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LeaseArrangementAxis=rnac_A7495NewHorizonWayLeaseMember', window );">7495 New Horizon Way Lease | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_OperatingLeaseCostPercentage', window );">Operating lease, cost percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LeaseArrangementAxis=rnac_A7495NewHorizonWayLeaseMember', window );">7495 New Horizon Way Lease | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_OperatingLeaseCostPercentage', window );">Operating lease, cost percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Additional Annual Base Rent, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rent, Annual Upward Adjustment Percentage After Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, First Month Rent Paid on Execution of Lease Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LesseeOperatingLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LesseeOperatingLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LesseeOperatingLeaseNumberOfOptionsToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Options To Extend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LesseeOperatingLeaseNumberOfOptionsToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_OperatingLeaseCostPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Cost Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_OperatingLeaseCostPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Tenant Improvement Allowance Recognized as Reduction in Right of Use Asset and Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LeaseArrangementAxis=rnac_A7495NewHorizonWayLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LeaseArrangementAxis=rnac_A7495NewHorizonWayLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330237296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - 65 Grove Street Lease (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 01, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 24, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 06, 2022 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lessee-paid construction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,394<span></span>
</td>
<td class="nump">$ 2,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,535<span></span>
</td>
<td class="nump">$ 10,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,579<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Right-of-use asset impairment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment of long-lived assets, location</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Asset impairment charges<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LeaseArrangementAxis=rnac_A65GroveStreetWatertownMAMember', window );">65 Grove Street, Watertown,MA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space leased | ft&#178;</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">7,216<span></span>
</td>
<td class="nump">25,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lessee-paid construction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_OperatingLeaseBaseRent', window );">Base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_UpfrontRentalPayment', window );">Upfront rental payment</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LeaseArrangementAxis=rnac_A65GroveStreetWatertownMAMember', window );">65 Grove Street, Watertown,MA | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_OperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_OperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_UpfrontRentalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Rental Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_UpfrontRentalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479341/842-30-25-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LeaseArrangementAxis=rnac_A65GroveStreetWatertownMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LeaseArrangementAxis=rnac_A65GroveStreetWatertownMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332659152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - 704 Quince Orchard Road Leases (Narrative) (Details) - operating_lease<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LeaseArrangementAxis=rnac_A704QuinceOrchardRoadLeasesMember', window );">704 Quince Orchard Road Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_NumberOfAcquiredOperatingLeases', window );">Number of acquired operating leases</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_NumberOfAcquiredOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Acquired Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_NumberOfAcquiredOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LeaseArrangementAxis=rnac_A704QuinceOrchardRoadLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LeaseArrangementAxis=rnac_A704QuinceOrchardRoadLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329917104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Moscow, Russia Lease (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lessee-paid construction costs</a></td>
<td class="nump">$ 4,394<span></span>
</td>
<td class="nump">$ 2,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LeaseArrangementAxis=rnac_MoscowRussiaLeaseMember', window );">Moscow Russia Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lessee-paid construction costs</a></td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LeaseArrangementAxis=rnac_MoscowRussiaLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LeaseArrangementAxis=rnac_MoscowRussiaLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333304224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3,856<span></span>
</td>
<td class="nump">$ 2,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,609<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Less sublease income</a></td>
<td class="num">(1,099)<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 4,394<span></span>
</td>
<td class="nump">$ 2,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332441104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturity of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 3,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">4,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">4,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">2,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,188<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">18,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">4,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 13,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150321912384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Disclosure for the Statement of Cash Flows Related to Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities:</a></td>
<td class="nump">$ 3,559<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333381952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Additional Information Related to Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332739840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 11, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Total payoff amount of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,457,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">740,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense related to term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=rnac_A2020TermLoansMember', window );">2020 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Total payoff amount of term loan</a></td>
<td class="nump">$ 22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt instrument, fee amount</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_DebtInstrumentPrepaymentFee', window );">Debt instrument, prepayment fee</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_DebtInstrumentAccruedInterest', window );">Debt instrument, accrued interest</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Deferred debt issuance cost, writeoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_DebtInstrumentPrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_DebtInstrumentPrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=rnac_A2020TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=rnac_A2020TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329625072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Series B Preferred Stock (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>Sep. 25, 2024</div></th>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Apr. 08, 2024</div></th>
<th class="th"><div>Mar. 26, 2024</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,427,168.437<span></span>
</td>
<td class="nump">9,451,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert', window );">Convertible preferred stock, shares that did not automatically convert (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,341.592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B preferred stock to common stock (in shares)</a></td>
<td class="nump">1,518,373<span></span>
</td>
<td class="nump">2,499,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,263,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member', window );">2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member', window );">2024 Securities Purchase Agreement | Timothy A. Springer, Ph.D. | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member', window );">2024 Securities Purchase Agreement | TAS Partners, LLC | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member', window );">2024 Securities Purchase Agreement | Dr. Chafen Lu | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member', window );">2024 Securities Purchase Agreement | Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,563,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member', window );">2023 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,330.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member', window );">2023 Securities Purchase Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,330.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,937,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,499,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert', window );">Convertible preferred stock, shares that did not automatically convert (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | 2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,937,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | 2024 Securities Purchase Agreement | Timothy A. Springer, Ph.D. | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,636,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | 2024 Securities Purchase Agreement | TAS Partners, LLC | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | 2024 Securities Purchase Agreement | Dr. Chafen Lu | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common&#160;stock | 2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,563,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Shares That Did Not Automatically Convert</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Gross Consideration Received On Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SaleOfStockGrossConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rnac_Dr.TimothyA.SpringerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rnac_Dr.TimothyA.SpringerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rnac_TASPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rnac_TASPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rnac_Dr.ChafenLuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rnac_Dr.ChafenLuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329383568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Series A Preferred Stock (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 25, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 08, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 12, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 13, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 05, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 15, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 13, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 12, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 26, 2024 </div>
<div>business_day</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SettlementOfDerivativeLiabilityShares', window );">Derivative liability, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,570.162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,710.488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_NumberOfBusinessDays', window );">Number of business days | business_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert', window );">Convertible preferred stock, shares that did not automatically convert (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,341.592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SettlementOfDerivativeLiabilityShares', window );">Derivative liability, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,570.163<span></span>
</td>
<td class="nump">49,570.163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B preferred stock to common stock (in shares)</a></td>
<td class="nump">1,518,373<span></span>
</td>
<td class="nump">2,499,976<span></span>
</td>
<td class="nump">12,263,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B preferred stock to common stock (in shares)</a></td>
<td class="nump">45,551.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,919.247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,782,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,930.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | Preferred Stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,930.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member', window );">2023 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,330.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023Member', window );">2023 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619.627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023TrancheOneMember', window );">2023 Private Placement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,785.081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SaleOfStockSettlementTerm', window );">Sale of stock, settlement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023TrancheThreeMember', window );">2023 Private Placement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,570.163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SaleOfStockSettlementTerm', window );">Sale of stock, settlement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023TrancheTwoMember', window );">2023 Private Placement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,570.163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SaleOfStockSettlementTerm', window );">Sale of stock, settlement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Shares That Did Not Automatically Convert</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_NumberOfBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Business Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_NumberOfBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SaleOfStockSettlementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Settlement Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SaleOfStockSettlementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SettlementOfDerivativeLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Derivative Liability, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SettlementOfDerivativeLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332236928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Conversion (Narrative) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred stock, convertible, conversion ratio</a></td>
<td class="nump">33.333<span></span>
</td>
<td class="nump">33.333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred stock, convertible, conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage', window );">Beneficially holders owned percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage', window );">Beneficially holders owned percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage', window );">Beneficially holders owned percentage</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage', window );">Beneficially holders owned percentage</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_PreferredStockConvertibleBeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Convertible, Beneficial Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_PreferredStockConvertibleBeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150441961568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Redemption (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>day</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_PreferredStockRedemptionTerm', window );">Preferred stock, redemption term</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays', window );">Preferred stock, convertible, threshold consecutive trading days</a></td>
<td class="nump">10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Convertible, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_PreferredStockRedemptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Redemption Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_PreferredStockRedemptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333000768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Voting (Narrative) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding', window );">Preferred stock, convertible, transaction restrictions, percentage of originally issued stock issued and outstanding</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Convertible, Transaction Restrictions, Percentage Of Originally Issued Stock Issued And Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329150496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Liquidation (Narrative) (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">120,790.402<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">120,790.402<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible preferred stock, common stock issuable upon conversion (in shares)</a></td>
<td class="nump">4,464,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">437,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">437,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible preferred stock, common stock issuable upon conversion (in shares)</a></td>
<td class="nump">4,464,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332759136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - 2024 Private Placement (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member', window );">2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common&#160;stock | 2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">3,563,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | 2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">2,937,903<span></span>
</td>
<td class="nump">578,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | 2024 Securities Purchase Agreement | Directors and Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">2,359,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SaleOfStockGrossConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Gross Consideration Received On Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SaleOfStockGrossConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rnac_DirectorsAndExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rnac_DirectorsAndExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150331689216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Merger (Narrative) (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember', window );">Old Cartesian | Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares (in shares)</a></td>
<td class="nump">224,099<span></span>
</td>
<td class="nump">224,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rnac_OldCartesianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330256608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Underwritten Offering (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Apr. 06, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.96<span></span>
</td>
<td class="nump">$ 45.98<span></span>
</td>
<td class="nump">$ 46.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_A2022OfferingMember', window );">2022 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">914,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or rights (in shares)</a></td>
<td class="nump">685,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares)</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 42.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 46.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 36.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_A2022OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_A2022OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329976736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - &#8220;At-the-Market&#8221; Offerings (Narrative) (Details) - At-The-Market Offering - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 13, 2024</div></th>
<th class="th"><div>Oct. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds', window );">Aggregate maximum gross sales proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 51.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SaleOfStockAggregateMaximumGrossSalesProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Maximum Gross Sales Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SaleOfStockAggregateMaximumGrossSalesProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329782832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - June 2020 Sobi Stock Purchase (Narrative) (Details) - SOBI Purchase Agreement - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jul. 28, 2020</div></th>
<th class="th"><div>Jun. 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138.4680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock', window );">Sale of stock, percentage of ten-day volume weighted average price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Redemption premium</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SOBIPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SOBIPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332394464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - December 2019 Financing (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2022</div></th>
<th class="th"><div>Dec. 18, 2019</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,523<span></span>
</td>
<td class="nump">1,040,813<span></span>
</td>
<td class="nump">1,040,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.96<span></span>
</td>
<td class="nump">$ 45.98<span></span>
</td>
<td class="nump">$ 46.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rnac_A2019WarrantsMember', window );">2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_WarrantIssued', window );">Warrant issued</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_DecemberTwoThousandNineteenFinancingMember', window );">December 2019 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_WarrantIssued', window );">Warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Warrant, increase (decrease) in equity, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_DecemberTwoThousandNineteenFinancingMember', window );">December 2019 Financing | Common Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_DecemberTwoThousandNineteenFinancingMember', window );">December 2019 Financing | Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Class of warrant or right, number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_WarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_WarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rnac_A2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rnac_A2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_DecemberTwoThousandNineteenFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_DecemberTwoThousandNineteenFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rnac_CommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rnac_CommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rnac_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rnac_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150328849472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Warrant Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ClassOfWarrantOrRightRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,040,813<span></span>
</td>
<td class="nump">1,040,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled', window );">Expired (in shares)</a></td>
<td class="num">(282,609)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercises (in shares)</a></td>
<td class="num">(65,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">692,523<span></span>
</td>
<td class="nump">1,040,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 45.98<span></span>
</td>
<td class="nump">$ 46.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringWarrantedCanceledPricePerShare', window );">Expired (in dollars per share)</a></td>
<td class="nump">44.09<span></span>
</td>
<td class="nump">503.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises', window );">Exercises (in dollars per share)</a></td>
<td class="nump">43.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 46.96<span></span>
</td>
<td class="nump">$ 45.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ClassOfWarrantOrRightRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">966,393<span></span>
</td>
<td class="nump">966,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled', window );">Expired (in shares)</a></td>
<td class="num">(280,681)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercises (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">685,712<span></span>
</td>
<td class="nump">966,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ClassOfWarrantOrRightRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">74,420<span></span>
</td>
<td class="nump">74,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled', window );">Expired (in shares)</a></td>
<td class="num">(1,928)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercises (in shares)</a></td>
<td class="num">(65,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">6,811<span></span>
</td>
<td class="nump">74,420<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ClassOfWarrantOrRightRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ClassOfWarrantOrRightRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_StockIssuedDuringPeriodSharesWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_StockIssuedDuringPeriodSharesWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_StockIssuedDuringWarrantedCanceledPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During, Warranted Canceled, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_StockIssuedDuringWarrantedCanceledPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330643424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Common Stock (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 13, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">25,767,369<span></span>
</td>
<td class="nump">5,397,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">25,767,369<span></span>
</td>
<td class="nump">5,397,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CommonStockVotingRightsNumberOfVotes', window );">Number of votes per share that common stockholders are entitled to | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared or paid on common stock | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CommonStockVotingRightsNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number Of Votes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CommonStockVotingRightsNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333994832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">11,512,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares available for future stock incentive awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">4,205,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rnac_RestrictedStockUnitsUnvestedMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">444,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">1,706,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">4,026,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">437,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">692,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rnac_RestrictedStockUnitsUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rnac_RestrictedStockUnitsUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150325138672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 13, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,512,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock&#8209;based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,582<span></span>
</td>
<td class="nump">$ 25,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount', window );">Share based compensation arrangement by share based payment award, settlement of awards, amount (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 61.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based payment arrangement, accelerated cost</a></td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards', window );">Total cash payment made to the holders of stock options and restricted stock units</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards', window );">Adjustments to additional paid in capital, settlement of outstanding equity awards at merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement', window );">Excess over fair value recognized as additional stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.63<span></span>
</td>
<td class="nump">$ 26.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred stock, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock&#8209;based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,217<span></span>
</td>
<td class="nump">$ 12,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based payment arrangement, accelerated cost</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement', window );">Excess over fair value recognized as additional stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock&#8209;based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,365<span></span>
</td>
<td class="nump">12,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based payment arrangement, accelerated cost</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement', window );">Excess over fair value recognized as additional stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,706,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in period (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate', window );">Estimated forfeitures rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested in period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate fair value of RSU awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;stock | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rnac_StockIncentivePlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares authorized for grants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease', window );">Number of shares authorized, increase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,466,544<span></span>
</td>
<td class="nump">215,903<span></span>
</td>
<td class="nump">204,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,520,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rnac_EmploymentInducementIncentiveAwardPlanMember', window );">Employment Inducement Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares authorized for grants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">60,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,667<span></span>
</td>
<td class="nump">39,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rnac_OldCartesianPlanMember', window );">Old Cartesian Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares authorized for grants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,112.299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested employee stock options</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock&#8209;based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rnac_OldCartesianPlanMember', window );">Old Cartesian Plan | Common&#160;stock | Old Cartestian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares) | shares</a></td>
<td class="nump">776,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rnac_OldCartesianPlanMember', window );">Old Cartesian Plan | Preferred Stock | Old Cartestian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares) | shares</a></td>
<td class="nump">14,112.299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Settlement Of Outstanding Equity Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of forfeitures rate of the stock options based on the historical trends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards, Stock Based Compensation Expense Recognized On Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rnac_StockIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rnac_StockIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rnac_EmploymentInducementIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rnac_EmploymentInducementIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rnac_OldCartesianPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rnac_OldCartesianPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartestianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rnac_OldCartestianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150328620256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,582<span></span>
</td>
<td class="nump">$ 25,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rnac_GinkgoBioworksHoldingsIncMember', window );">Ginkgo Bioworks Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,217<span></span>
</td>
<td class="nump">12,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,365<span></span>
</td>
<td class="nump">$ 12,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rnac_GinkgoBioworksHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rnac_GinkgoBioworksHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332326688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Schedule of Weighted Average Assumptions Used (Details) - Stock Options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.02%<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">95.21%<span></span>
</td>
<td class="nump">94.64%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue', window );">Weighted-average fair value of common stock and preferred stock (in dollars per share)</a></td>
<td class="nump">$ 19.63<span></span>
</td>
<td class="nump">$ 34.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;stock | Old Cartestian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue', window );">Weighted-average fair value of common stock and preferred stock (in dollars per share)</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Old Cartestian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue', window );">Weighted-average fair value of common stock and preferred stock (in dollars per share)</a></td>
<td class="nump">$ 403.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighed-average fair value relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rnac_OldCartestianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rnac_OldCartestianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329845216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember', window );">2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">776,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,000,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod', window );">Converted from options for Series A preferred stock (in shares)</a></td>
<td class="nump">470,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(458,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(82,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,706,035<span></span>
</td>
<td class="nump">776,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="nump">656,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">1,564,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">19.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice', window );">Converted from options for Series A preferred stock (in dollars per share)</a></td>
<td class="nump">2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">17.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">11.99<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice', window );">Vested (in dollars per share)</a></td>
<td class="nump">3.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 11.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, term</a></td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm', window );">Vested, term</a></td>
<td class="text">5 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, term</a></td>
<td class="text">7 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 12,025<span></span>
</td>
<td class="nump">$ 13,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue', window );">Vested</a></td>
<td class="nump">9,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">$ 11,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rnac_OldCartesianPlanMember', window );">Old Cartesian Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">14,112.299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock', window );">Converted to options for common stock (in shares)</a></td>
<td class="num">(14,112.299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,112.299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 79.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock', window );">Converted to options for common stock (in dollars per share)</a></td>
<td class="nump">79.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 79.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, term</a></td>
<td class="text"> <span></span>
</td>
<td class="text">5 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Assumed in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Converted To Options For Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Converted To Options For Common Stock, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Assumed in Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rnac_OldCartesianPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rnac_OldCartesianPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150444714080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares) | shares</a></td>
<td class="nump">477,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited in period (in shares) | shares</a></td>
<td class="num">(32,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares) | shares</a></td>
<td class="nump">444,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value ($)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in period (in dollars per share) | $ / shares</a></td>
<td class="nump">19.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited in period (in dollars per share) | $ / shares</a></td>
<td class="nump">19.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150325521408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Arrangements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 28, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 10, 2022</div></th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 11, 2020 </div>
<div>USD ($) </div>
<div>obligation</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">872,000<span></span>
</td>
<td class="nump">5,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,849,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,275,000<span></span>
</td>
<td class="nump">26,004,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Government Assistance Current Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">receivable<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember', window );">National Institute of Neurological Disorders and Stroke of the National Institutes of Health Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAwardAmount', window );">Government assistance, award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_GovernmentAssistancePotentialAdditionalAwardAmount', window );">Government assistance, potential additional award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmountCumulativeCurrent', window );">Government assistance, asset, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SOBIPurchaseAgreementMember', window );">SOBI Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Redemption premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rnac_AstellasGeneTherapiesMember', window );">Astellas Gene Therapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CollaborationAndLicenseAgreementsUpfrontPayment', window );">Collaboration and license agreements upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties', window );">Development and commercial milestones plus royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment', window );">Reimbursement percentage, budgeted costs incurred to complete the development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements', window );">License and option agreement, development cost reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation', window );">License and option agreement, written notice period before cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance', window );">Customer, liability, revenue recognized, including opening balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue, remaining performance obligation recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rnac_SareptaTherapeuticsInc.Member', window );">Sarepta Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation', window );">License and option agreement, written notice period before cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementUpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementOptionTerm', window );">Option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementExtensionTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies', window );">Milestone receivable for certain dystrophies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementMilestoneReceivable', window );">Milestone receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rnac_TakedaAgreementMember', window );">Takeda Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation', window );">License and option agreement, written notice period before cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable', window );">Contract with customer, asset, reclassified to receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance', window );">Customer, liability, revenue recognized, including opening balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementUpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected', window );">Future additional payments, expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,124,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Swedish Orphan Biovitrum AB (SOBI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation', window );">License and option agreement, written notice period before cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue, remaining performance obligation recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementUpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_EligiblePeriodToReceiveRoyalties', window );">Period after first commercial sale when the Company is eligible to receive royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_RevenueNumberOfPerformanceObligations', window );">Number of obligations | obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementDevelopmentMilestone', window );">Development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CollaborativeArrangementPaymentObligation', window );">Collaborative arrangement, payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,900,000<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Billed Revenues | Swedish Orphan Biovitrum AB (SOBI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CollaborationAndLicenseAgreementsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreements Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CollaborationAndLicenseAgreementsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CollaborativeArrangementPaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Payment Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CollaborativeArrangementPaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Revenue Recognized, Including Opening Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer, Liability, Revenue Recognized, Including Opening Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_DevelopmentAndCommercialMilestonesPlusRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Commercial Milestones Plus Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_DevelopmentAndCommercialMilestonesPlusRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_EligiblePeriodToReceiveRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Eligible Period To Receive Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_EligiblePeriodToReceiveRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Assistance Current Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_GovernmentAssistancePotentialAdditionalAwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Assistance, Potential Additional Award Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_GovernmentAssistancePotentialAdditionalAwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Development Cost Reimbursements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Development Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Future Additional Payments, Expected</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Milestone Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Milestone Receivable For Certain Dystrophies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Option Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Sales Milestone Payments That May Be Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Upfront Cash Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Written Notice Period Before Cancellation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Percentage, Budgeted Costs Incurred To Complete The Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_RevenueNumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_RevenueNumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetReclassifiedToReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmountCumulativeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset from government assistance, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmountCumulativeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SOBIPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SOBIPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rnac_AstellasGeneTherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rnac_AstellasGeneTherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rnac_SareptaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rnac_SareptaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rnac_TakedaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rnac_TakedaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rnac_SwedishOrphanBiovitrumABSOBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rnac_SwedishOrphanBiovitrumABSOBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150325657216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContractwithCustomerLiabilityDeferredRevenue', window );">Deferred revenue, beginning of period</a></td>
<td class="nump">$ 5,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts', window );">Deferred revenue, additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized', window );">Deferred revenue, deductions</a></td>
<td class="num">(5,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContractwithCustomerLiabilityDeferredRevenue', window );">Deferred revenue, end of period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, beginning of period</a></td>
<td class="nump">5,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance', window );">Deductions</a></td>
<td class="num">(5,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Revenue Recognized, Including Opening Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContractwithCustomerLiabilityDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContractwithCustomerLiabilityDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Deferred Revenue, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Increase From Cash Receipts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333091616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions - Schedule of Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 15, 2023</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member', window );">2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023Member', window );">2023 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="nump">619.627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rnac_Dr.TimothyA.SpringerMember', window );">Timothy A. Springer, Ph.D. | Related Party | 2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rnac_Dr.TimothyA.SpringerMember', window );">Timothy A. Springer, Ph.D. | Related Party | 2023 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,140.326<span></span>
</td>
<td class="nump">24,785.081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rnac_TASPartnersLLCMember', window );">TAS Partners, LLC | Related Party | 2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rnac_TASPartnersLLCMember', window );">TAS Partners, LLC | Related Party | 2023 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,785.081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rnac_Dr.ChafenLuMember', window );">Dr. Chafen Lu | Related Party | 2024 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rnac_SevenOneEightThreeFourIrrevocableTrustMember', window );">Seven One Eight Three Four Irrevocable Trust (affiliate of Murat Kalayoglu, MD, Ph.D.) | Related Party | 2023 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619.627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_PrivatePlacement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rnac_Dr.TimothyA.SpringerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rnac_Dr.TimothyA.SpringerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rnac_TASPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rnac_TASPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rnac_Dr.ChafenLuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rnac_Dr.ChafenLuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rnac_SevenOneEightThreeFourIrrevocableTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rnac_SevenOneEightThreeFourIrrevocableTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330650208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2024</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.96<span></span>
</td>
<td class="nump">$ 45.98<span></span>
</td>
<td class="nump">$ 46.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,877<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B preferred stock to common stock (in shares)</a></td>
<td class="nump">65,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants', window );">Issuance of CVRs upon exercise of warrants (in shares)</a></td>
<td class="nump">1,970,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Warrants exercised (in shares)</a></td>
<td class="nump">65,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 43.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common warrants</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member', window );">2023 Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,330.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member', window );">2023 Securities Purchase Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,330.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant Or Right, Exercised During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_IssuanceOfContingentValueRightForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Contingent Value Right for Exercise of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_IssuanceOfContingentValueRightForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rnac_A2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rnac_A2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SecuritiesPurchaseAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330378368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Biogen M.A., Inc. (Narrative) (Details)<br></strong></div></th>
<th class="th"><div>Sep. 08, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rnac_BiogenM.A.Inc.Member', window );">Biogen M.A., Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination', window );">Written notice for agreement termination</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Written Notice Period For Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CollaborativeArrangementWrittenNoticePeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rnac_BiogenM.A.Inc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rnac_BiogenM.A.Inc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150333374368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - National Cancer Institute of the National Institutes of Health (Narrative) (Details) - NCI Agreement<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 16, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementRoyaltyPayment', window );">License and option agreement, royalty payment</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum', window );">License and option agreement, benchmark royalties, maximum</a></td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination', window );">Written notice for agreement termination</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CollaborativeArrangementWrittenNoticePeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Written Notice Period For Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CollaborativeArrangementWrittenNoticePeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Benchmark Royalties, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Royalty Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rnac_NationalCancerInstituteAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rnac_NationalCancerInstituteAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330382656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Ginkgo Bioworks Holdings, Inc. (Narrative) (Details) - Ginkgo Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2023</div></th>
<th class="th"><div>Jun. 13, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Oct. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected', window );">Clinical and commercial milestone payment, expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207.0<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementMilestonePayments', window );">Milestone payment</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement', window );">Collaborative arrangement, number of shares issued for milestone achievement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,642<span></span>
</td>
<td class="nump">29,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount', window );">Collaborative arrangement, shares issued for milestone achievement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Shares Issued For Milestone Achievement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Shares Issued For Milestone Achievement, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Clinical And Commercial Milestone Payment, Expected</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rnac_GinkgoAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rnac_GinkgoAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150524057008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Genovis AB (publ.) (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rnac_GenovisABMember', window );">Genovis AB</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementMilestonePayments', window );">Milestone payment</a></td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rnac_GenovisABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rnac_GenovisABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150324563600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Cyrus Biotechnology, Inc. (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 07, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rnac_CyrusBiotechnologyIncMember', window );">Cyrus Biotechnology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_LicenseAndOptionAgreementMilestonePayments', window );">Milestone payment</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased', window );">Equity securities, stock purchase agreement, shares purchased (in shares)</a></td>
<td class="nump">2,326,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value, amount</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rnac_CyrusBiotechnologyIncMember', window );">Cyrus Biotechnology, Inc. | Series B Preferred Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare', window );">Equity securities, stock purchase agreement, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare', window );">Equity securities, stock purchase agreement, purchase price per share (in dollars per share)</a></td>
<td class="nump">$ 0.8595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Stock Purchase Agreement, Par Value Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Stock Purchase Agreement, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Stock Purchase Agreement, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_LicenseAndOptionAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_LicenseAndOptionAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rnac_CyrusBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rnac_CyrusBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rnac_SeriesBPreferredStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rnac_SeriesBPreferredStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330414416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Asklepios Biopharmaceutical, Inc. (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Collaboration expense</a></td>
<td class="nump">$ 82,810,000<span></span>
</td>
<td class="nump">$ 112,420,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rnac_AskBioLicenseMember', window );">AskBio License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Collaboration expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CollaborativeArrangementCostSharePercentage', window );">Cost share percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CollaborativeArrangementCostSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Cost Share Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CollaborativeArrangementCostSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rnac_AskBioLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rnac_AskBioLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329508624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details) - 3SBio License<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid', window );">Aggregate amount of upfront and milestone-based payments</a></td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform', window );">Aggregate amount for future payments upon achievement of clinical and regulatory approval milestones for products containing ImmTOR platform</a></td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Amount Of Upfront And Milestone Based Payments Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150329843680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="num">$ (19.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, deferred tax asset, increase (decrease), amount</a></td>
<td class="nump">123.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Tax benefit related to the CVR liability</a></td>
<td class="nump">108.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">74.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">113.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes', window );">Capitalized research and experimental costs, tax purposes</a></td>
<td class="nump">45.1<span></span>
</td>
<td class="nump">$ 43.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">152.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">187.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized Research And Experimental Costs, Tax Purposes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150458251232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory U.S. federal rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes - net of federal benefit</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Research tax credits</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent', window );">Change in fair value of contingent value right liability</a></td>
<td class="nump">127.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent', window );">Change in fair value of forward contract liabilities</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(13.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance, net</a></td>
<td class="num">(160.10%)<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change In Fair Value Of Contingent Value Right Liability, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change In Fair Value Of Contract Liabilities, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150330193248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,062<span></span>
</td>
<td class="nump">$ 29,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">6,024<span></span>
</td>
<td class="nump">5,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">75,567<span></span>
</td>
<td class="nump">84,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_DeferredTaxAssetsLeasingArrangements', window );">Operating lease liabilities</a></td>
<td class="nump">3,848<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies', window );">Contingent value right liability</a></td>
<td class="nump">108,832<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;E Capitalization</a></td>
<td class="nump">26,863<span></span>
</td>
<td class="nump">19,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Patent and license costs</a></td>
<td class="nump">8,540<span></span>
</td>
<td class="nump">9,140<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">274,806<span></span>
</td>
<td class="nump">152,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(41,441)<span></span>
</td>
<td class="num">(41,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(1,523)<span></span>
</td>
<td class="num">(2,751)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(43,079)<span></span>
</td>
<td class="num">(44,023)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities', window );">Net deferred tax assets before valuation allowance</a></td>
<td class="nump">231,727<span></span>
</td>
<td class="nump">108,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(247,867)<span></span>
</td>
<td class="num">(124,295)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets/(liabilities)</a></td>
<td class="num">$ (16,140)<span></span>
</td>
<td class="num">$ (15,853)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Leasing Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net Of Deferred Tax Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332966928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contribution made</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares)</a></td>
<td class="nump">11,512,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock&#8209;based compensation expense</a></td>
<td class="nump">$ 6,582,000<span></span>
</td>
<td class="nump">25,778,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rnac_EmployeeStockPurchasePlan2016Member', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares)</a></td>
<td class="nump">45,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock&#8209;based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise a plan is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rnac_EmployeeStockPurchasePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rnac_EmployeeStockPurchasePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150332880304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employee workforce, termination percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 798<span></span>
</td>
<td class="nump">$ 6,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring charges, location</a></td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring charges, location</a></td>
<td class="text">General and administrative<span></span>
</td>
<td class="text">General and administrative<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150331350656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Change in Accrued Restructuring Balance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 3,896<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">6,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Payments</a></td>
<td class="num">(4,614)<span></span>
</td>
<td class="num">(2,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 3,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45150323114128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 38,275<span></span>
</td>
<td class="nump">$ 26,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">38,913<span></span>
</td>
<td class="nump">26,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">30,126<span></span>
</td>
<td class="nump">40,450<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(77,424)<span></span>
</td>
<td class="num">(219,710)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rnac_ReportingSegmentsMember', window );">Reporting Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">38,275<span></span>
</td>
<td class="nump">26,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">38,913<span></span>
</td>
<td class="nump">26,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ResearchAndDevelopmentEmployeeExpenses', window );">Research and development employee expenses</a></td>
<td class="nump">11,952<span></span>
</td>
<td class="nump">18,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ResearchAndDevelopmentStockBasedCompensationExpense', window );">Research and development stock-based compensation expense</a></td>
<td class="nump">3,217<span></span>
</td>
<td class="nump">12,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses', window );">Research and development facilities and other expenses</a></td>
<td class="nump">10,616<span></span>
</td>
<td class="nump">7,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">30,126<span></span>
</td>
<td class="nump">40,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of long-lived assets</a></td>
<td class="nump">7,579<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense, net</a></td>
<td class="nump">33,527<span></span>
</td>
<td class="nump">133,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(77,424)<span></span>
</td>
<td class="num">(219,710)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rnac_ReportingSegmentsMember', window );">Reporting Segments | Legacy Selecta programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_MedicalExpensesOperating', window );">Medical expenses, operating</a></td>
<td class="nump">6,150<span></span>
</td>
<td class="nump">31,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rnac_ReportingSegmentsMember', window );">Reporting Segments | Descartes-08 for MG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_MedicalExpensesOperating', window );">Medical expenses, operating</a></td>
<td class="nump">12,142<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rnac_ReportingSegmentsMember', window );">Reporting Segments | Early stage programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rnac_MedicalExpensesOperating', window );">Medical expenses, operating</a></td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">$ 595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_MedicalExpensesOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Expenses, Operating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_MedicalExpensesOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ResearchAndDevelopmentEmployeeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Employee Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ResearchAndDevelopmentEmployeeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Facilities And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rnac_ResearchAndDevelopmentStockBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Stock-Based Compensation Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rnac_ResearchAndDevelopmentStockBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rnac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rnac_ReportingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rnac_ReportingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=rnac_LegacySelectaProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=rnac_LegacySelectaProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=rnac_Descartes08ForMGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=rnac_Descartes08ForMGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=rnac_EarlyStageProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=rnac_EarlyStageProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>144
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY_,PR?ZBE_S<GM="?II('NV#X0HB%N>?Y'4/XBA@Z-0$X'T ?A?@=FL"O'V
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M8[)\H#<. E"',;?_@GZ#\]#OL;[/F24'W>L>N@>#_3,7[+]P'[Z0-RU'JY[
MEEJ58^D*7'->_Y[C1&W!^'WD+[&6H5EN)F@ ::'_I 5GU2S84JN"*^V":\[S
MWX,K9KZ%X,\L]O4]T*SY>:K%9M4ZV%*K8BO-@VO.^=]C6_!$0D+\%]O5/RK,
MBM@=.)Z6FU7W8$NMRJWT#^X) Y%1$Y348S(+>([6+YBC&D.ZA&-P2\O@FO/\
MW[@R5XLMCTU9\ D1KSML#_OZ+-@<VIC6)1R#6UH&UYSO/S();H&OD8N_7_V
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M#(*ISRD37A*YM:U*(EECR01L%=$UYU2]+Z"43>P-O>/"$\L+M M^$E4TAV?
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M@EKH9+R\Z%W"@BA*^WK#9Q;')VJT6YQ88D-A8ON%Z;KTB/'%6YZX5(6R&/8
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M4L\>09I'R< F ;'*B(25T<>BV&UV57-N>UBWWN,R5\S,DAQ%:5]$> TA2<B
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M)_@,5JG0869\-?>DV2=TOGRQ>I*, QS&\V"4"(L<3L/ -1AZ$L-^%G,Y [M
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M1)0)<: K7<HN-/=U7R M.8&L@98E'B45-U&KN,%$7!6%)I<@)G8'.>E!-RG
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MI,<),8R4B,QISPZ%NLU;>?HH@MH;34QD(K[;@/OI<;+0^FXDU-F)O1T1^8'
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M98<Q*\RIB.B78A:'5^DSZ13]T]R//!U%JBGH>#[,TV$67NM@U#%D;W X F\
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M%<N)_:" M@XE9HE2AP.QTX4,6FPF9R9$MRY^),U1-NGB\<X5R,TD]Q>]'$R
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MU(<:>5$&B<?!6)@M;V*M<(X\:@W2%P']K3\ ][GVONY\RP4RG^:K37=#S9_
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M7C &!D.)WJV]IM=(P9P5Z'ERUPO<%F26->PPSX?X#%M6=-<15E", 6NW;=!
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MVDGX/3XCR >/I)R9\ 6E&Q2B2:=G6\^(1A:4]PVDXLX,TD1$QLLB"WD/3I0
M0:N53G4T1Q*&1C! >C\&!]3CJ,X,F/"ON^#E/K!6.2<8&!W*YNQ9F,X3D=66
M'^&&\2WFT7&R_2#CJ="P.\$T/*WJ>L=T^C2HV"0GD:B\SJ)$V4WSD0MW!C8K
MS-)+S=Q2TFIOD8KT:Z7!'=EL8NA8[7F\%;^_^V%LSKV\OA*_FDJGXGPZ2<@6
M9W*=!6[TA.[B^E,QU#935$5UR>HB\+NC'%$L5%4;"LY2105H;O##;MC#@H+5
M_IX6!",4EP\^YH(O$'S2&$ANFQEQJ7H)>^@T!%MUMKNZPES@42/[1&I(X.@*
MRBX=W0EGT)"X8JWJD"54U(=VK24-H:K$H@:! >]QV_+&#=W$8:3'. ,?8H;#
MC<+8!^0H*$%,,PZ-)E>-CP(0N6(T)BQ5J<B3^'NHQCJFH%GF^B8$EK)NZ8Q=
M\@UXQ<6>Q-R$;H,4*6:<-"^P9+^K:=+VL<IL0C$*(T5$<1LX1DEA@$6G;TH-
M-26/"S*4+NZ$@(PI@,-*63Z:C;QP"UO;^=DBS46@D9X9"F%NJC!HM%JP5QJ?
M]D5$_XXZ\L?:4B22[3U[V4K #A.PIEC3 +MLCNKX@ @I!ZI&^(QM"9-CZ60\
MQ74[*4^UKQ.Q)VG/)Z<\+>_1?*CPIK^+1:1B,>DI,L1,0S6"A3NH^"M$G5G2
M>")$4(\/H:-%IV71NTIUJ@]: A[C0TN"!.FRH1F8"R?L#SNMI+8"/;=N!Y+M
MYQQ[LJ?)@+ -U_\5'_4HX_CVLN6\?<#0Z!),\(8&S)9=!U;)*>)\N_0Q=NIN
M9 B,CLII;Q@:RFB8_8[O^TBW*N<J3?2?JS*=($.__AS?MZI0J/:A$H[;->()
M'O7 )])FIW!8 _!"+;U$ >4C(.;[*RWI MID>X_.TEVO;N/9'$_I/)2Q=N#I
M11UN0(_5X62D\TH_5#Q9[BK;C]AN2)JZUIY2'$[/SH]/1:'1YT/=:*:?7E>C
M6A9>1S$]PT.!HH-\<$1,[6"4>_J<7@D,0MX=%PS@>BAFR;/I_('']X)Y>GJ:
MS"?GS>@5(3*(SM#(2H(8@(4L%@MP$G++\/ZA@ N2Q=GIH"Z$\;UA3H^,X![O
M#=)9EZOVM8F\E3IGN$@?NEF7<[W#)7XBEIE8<8.YO<S9 G%SQC.*H08T_YM5
MVZ&_'(JC"[1NY^ +E=B%,^^4_J J#;W8M$-QEIR>32GF'#5U5ZFR(1&!]<9#
MP4;Y^>2"Z;&R/AP1D+@JC*F4H+/IJ> WJ$=F=52[:'2X=X%[[\HC<.Z4.B+Y
ME^D[B1GT^K#5]'22G$TFXB=CL@W212S.D^G9G+ \.4N>X:_W(\Z[3%-+@\0#
MIO1]3HEQ.I^(]SS\-7?NQ>QBMGTM&$&-(,II:ND9?/RV21HZ!^_$S!?)^2FI
M/#]/9A?GXJ/R.S 8YL-N"7GWZ?/WLJA>O&U6\JE-/(5LZL,88)BUT '/@+GP
MH7\&@E%JKXYR?1M.=[:*9SB40@VI<A5@;^DT#6.1[F=!?)K$+K&=*3F W4V3
M:LZ&O;'&U LOTB%P1<6J3@D:JWJX=:R_N\N2.)1:R\VV=9N2V I[5O' =<N%
M@N%$XTQ!(207(FDLD\XN@X%>4@2$D'L;^8-+!IW>)GLB$^7VCL(URINV8>8G
MV33IT:$Y/4G34U^+4(AN&KRW);'7<GM,*/)=.KUR#Y""8?'E3AZA&@_\6C;)
M/A@1,H1&\LV^2["+V3@L;WM1JL,;!-A:(V DBSGVX)72P#5+F8?)TD76K&D,
M\>&PE_6*OAJX@A0L<#/C3S*P1:HB($>2-Q:5!L'=Z^1MLMTUCK9EN]&SAP<H
MRI#C[E3Z'C5BG[U5+F5Z?83&3*[Z\!/*R,4\N4"]W+EY_?X'<8J*B7NA'^O'
M%^'#M@R/%Z==FXB[]9.H8<'Q/2&?N5!ZZOX8R.?Z1^1^[E$KYCI<YU!TFNK%
MC#-P?]8AN+^W@(I=V_L;'1PE<D-74[4=PV[X;7:B(R_%AT,Y38*L!4:R=%W0
MZ\.(!"9)JNPZ/_*<'[>1)5KE:UN*E37%#H4N3*9RRH>-RO-F=-SPASI4S9&&
M\H82U_G>^Z9C(F^!>H"JF2R(WNWVT*=]=1 _6YEOO2QN$4E'C64=DH":&QTA
ML'T1CVE[CL2G)/@O'(WSK!!+BHMO"@K$9DU?1=VJ*(<<=S@YGG1D%P\>3H_/
MF@M)KT;G]]O95)>RQNBBZ&S$""9Q@V.QCM8A&/1JU.WJ'([=MA4>OF_@CCAX
M?4A'1%Y^H3.B7(:W,3_+LJ;9/#AT%G1]O(:QP)6*DBY4*S1A393RMLVE<64#
M/##\FQHQY,,V/KYB)8? <N%..$GN&'!3C+,Q%OE/I'_X5FH7-N)SQ =8TEDR
MF2R8OW!P#\63V7R6S$XOGO9I?(NL/MP)R&S5X>+XH@4#PR.RM"RPDO@*,'R>
M$8]FH.Z-*OE+ VXL&29V>JL7/!?7B_\'7N/9,<FY)Z>H<:<T,-T:I+9Z]/ U
MFW1=,Z?1MCOX)-I]!.V;E\JQ&.@2)M9<B'7@:W>=[(=>K3U.N[W#WHZF/2X;
M5>L=;NP50]BD%QF9*JKPU8B2_ 5;.$&4]_$5JHKMKY^-]#I(>9^K;4<076G8
M2Z!1H>7L,9E,*<#@:X:4[_<NO[:FOED/IOJP9^!IO=O[WVT_]'9RY]WMV(=U
M)[VO(_GK)/H&E**)'A0^E&ROMI^97H:O*[O'PS>J'Z2]@:=$KE98.CE^=GH0
M3M::']Y4_*WETGAO"OYSK20"20_@_LH8W_R@#=J/;U__%U!+ P04    " #5
M.&U:_.C-VLH$  "^"P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RM
M5FUOVS80_BL'=2@20(GU9LMV$P-Y:= !;6#$;8-AV =:.EM$*%$CJ3CY]SM2
MEN(T<;!V^V*3TMUSSSV\H^YD(]6=+A -/)2BTJ=>84P]'0QT5F#)]+&LL:(W
M*ZE*9FBKU@-=*V2Y<RK%( J"T:!DO/)F)^[97,U.9&,$KW"N0#=ER=3C.0JY
M.?5"KWMPP]>%L0\&LY.:K7&!YEL]5[0;]"@Y+['27%:@<'7JG873\\3:.X/O
M'#=Z9PTVDZ64=W;S>W[J!980"LR,16#T=X\7*(0%(AI_;S&]/J1UW%UWZ%<N
M=\IER31>2''+<U.<>F,/<ERQ1I@;N?F$VWR&%B^30KM?V+2VP\B#K-%&EEMG
M8E#RJOUG#UL==AS&P1Z':.L0.=YM(,?RDADV.U%R \I:$YI=N%2=-Y'CE3V4
MA5'TEI.?F5W3N7^66L,<%2P*IA#.A) 96PH$(^%"EB6)MS RNRNDR%'IDX&A
MP-9]D&V#G+=!HCU!P@B^R,H4&CY6.>;/ 0;$N*<==;3/HS<1+S$[ACCT(0JB
MY V\N)<A=GCQ'KR/3%6\6N_*\.?94AM%5?/7:PFW<,GK<+:3IKIF&9YZU"H:
MU3UZL_?OPE'PX0VR24\V>0O]_SJS-X.\GL(O1(:O!=KG-:L>J8MKJ0SFP* B
M*&&AZ&(!0S:/R,@:;8$ '2^62XK1'3&P*K>+^/@97J/)V#H;NI!THQY!V]!0
MHBED;AGE:%!1WZ SJQJ'*E>0<]'8^P"TS>(YBWTDVM@K21EOJ%C N+0U&N=N
M"@>0$;7&,'?E4!RZ,7CFV+N(!-LG7A.TBPYL5\.LU5#O:GC *P*7C28@[0,^
M9%B;SIFP">JHW>5T"1Q.X0^;QL<]6EH=X;HI43$CU12N.T:_P4&:^DF4'-IE
M%$[\- P.X3-J/86+[S>4 [4$7S8N.^):,V5XQFM*E_30F#6*&TYROG\WCL+H
M QS$J3\<$D8?XUFN6_%)I]VLX6@K6\_F(!JF?C1ZXE*P:HU JJP85W#/1(,6
MA8YAPU1.:)5K71"<+;G@YM$>DQ$D!_E<X5(U] 5JU3A(DM%A3_@G>7:'VBHW
M3H-6N8[M)5:2BJ^5^=9](3 _8O>D_!I[K"UX8[2AP[1*=@*$A).._'$4P= /
MT\"/PPG,14,27'8%C*L5?>%^-?MQZ(=1V*?_4QR[Y(EE3!E/DGB'Y?6+,I_"
MN4N*!$J.D[%3*ID<IZ3^Y9.,]&JR^^JUEJ-KQ%Y)%36>;;E:&EIS)EYT]8\'
M1HTC&ML4*R7+U]K5/OHOC6JO$3*R+ESFY-KRQ-P'UI+='M=&-B*'@F2&)2)-
M)Y3 44?_W_3OQ6Y>LK8):'<7W"R^:8C\<!A0[<20VOH9#>&6*<6<8M2VC<H*
M&F6>BS.:1/Z0D$,_2 )_',:PH"Q(Q3.8TZB$2A$;=[5#X@?1R(^3$82)/PQB
M?S+IK<]?6M,E,(G2OLBN?JQ3HL2UIA;>&[!SC?TX2/Q1FNXW[;3H7!(JR"2(
MX:LT5"%4JD'J!Z,)J>@'DY&?#D-X[9L\V)FIZ*9<N\E1$^>F,NUXU3_MA].S
M=B9[,F\GVR],K3DQ$K@BU^ X'7J@VFFQW1A9NPEM*0W->VY9T("-RAK0^Y6D
M"M]N;(!^9)_] U!+ P04    " #5.&U:<F7/P8,1   ?.@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6RU6_MOVSBV_E>(;&?1 (KC5Q*GTQ9(,YV[
MLVAWBZ8S>R\N[@^T1,?<RJ)7E))Z__K[G4-2HF0Y3A<S0-'X(9YS>![?>9!^
M_6C*KW:M5"6^;?+"OCE95]7VU?FY3==J(^W(;%6!;U:FW,@*;\O[<[LME<QX
MT28_GX['E^<;J8N3MZ_YLT_EV]>FKG)=J$^EL/5F(\O=.Y6;QS<GDY/PP6=]
MOZ[H@_.WK[?R7MVIZM?MIQ+OSALJF=ZHPFI3B%*MWIS<3%Z]F]/S_,!O6CW:
MZ+6@G2R-^4IO?LG>G(Q)()6KM"(*$G\>U*W*<R($,?[E:9XT+&EA_#I0_YGW
MCKTLI56W)O^'SJKUFY/%B<C42M9Y]=D\_D7Y_5P0O=3DEO\7C^[9V?Q$I+6M
MS,8OA@0;7;B_\IO70[1@,3ZP8.H73%ENQXBE_$E6\NWKTCR*DIX&-7K!6^75
M$$X79)2[JL2W&NNJMS]+78K?9%XK\5%)6Y<*&J_LZ_,*Q.F1\]03>N<(30\0
MFDS%1U-4:RO>%YG*N@3.(54CVC2(]F[Z),6?5#H2LTDBIN/I_ EZLV:K,Z8W
M.[[5G[1-<T.[M>)_;Y:V*N$=_S>T:4=R/DR2(N:5W<I4O3E!2%A5/JB3MW_^
MT^1R_.,3 L\;@>=/4?\>VSQ):%C, ]3%E[42*Y,C6G5Q+RJYS*$D7E94HL*7
MMV:SE<7NSW]:3"=7/UHAK558)XM,Y%HN=:XKC2756E9"EDIL'/5,X/V*F#XP
M4PI)A'5:ER4Q0FAIHB7,2L#R:K-496-])HX7,_%2%Z!L:HM/[.FK@4>_F$KF
MXH-Z4+F8^+]3_W<F;EC85^2K:H= *K\"^%8UB!'I-*_ANP(\4FG70OVKUA"6
MU'(J7HC9=3)>+.(7K(/IC]$KQ]VKY'E+/K1*>R7^(<M20M&Q)K$Z6<PN!Q>'
M[VX1>U CV<BIMR0X:LCL(,!%<C$>-PO#W_"Y$[S']OHZF1UF[+_MFV#V!YI@
M/DDFEY/XQ5$3/&?),TQPF<RNYP<TX;X[;H*+17(Y9 +_.=+,HRPSD8(0 5)'
M@NDBF8VOFC6]M\/6F^&9[H;],GQY.4^N(32B'2'Z2/\51H!M85>JM,A"U9I#
M3<4QN]:JE&6ZWHFLYJBE[W=*8H$BU!\(1U.R3XS$+<R9\/_B?6O4A$/[LP($
MZ[0"!7[@Y@@,)&*S[SR\B32'X?5*$]Q8YT*TJ.]+A#XDNTQ3AV:T&>C=FEQG
MDN18REP6J1*<6AF8\#QQK&I2F%//]5AD<F?%JC0;ID=K2?1M#2VA6!@=VDH2
M0ZE8RPQ0V.B I?4"6'R1RXJ5;80EO,03N:HJ,A-(IWBO*PX84Q2^V"'YA*YH
M,?P"E$FN'$ ,>B^M4N)O!A]<GXX8[ON(WE$$KZ74P,Q(LA5R@Q4^5*WSD29A
M?#>"_P_<Q]4, ZMXQ>U!*\*A)]/D<C+&JZO+Y'H"M#'%_1ETL]E3Z"2YO+S&
M_[.K*Q\O*;MDGZISR?YJ8C5/IE?7Q&J13 'F'B@L&>:3-SCI$KXI[BJ3?A6_
M%.V>IN/)==?JVMH:Y!\C,L%O8 (F8YG,@&TE4C($AA&W.1([V2>A6"/ZQ*D1
MSED8Y3CL6&1DH<[70GW;:O(H$XLZ\^K7!4=(F7$H,&,P !R0@D$:N[8U825$
M)\[\,=E_3XSNSE-3YQF\_D&)I5)4W4/]) 6[>%7E:I]"DQ(\+"&;>)]49259
M4A"QFG34R! 88NL)N295'!8%>S) G_$CEF1YL'9Q#K(U9>5P1D8H[Y&E@Q\C
M\?>.)[!ZIUV=R(V#T#T]'K;=6D&+RUVC@0W3;Q:^,Y1-*!JQH[0RI6U<Y,8S
MZ]O(8%L;\^#4S]IVYN#XWY;F05,WQJC65>4@P:#2PQ7@GDZ\:B,89VR-%0PA
MR4@'57T7X TM";I69(<23Y4B0]%?6^XF_4)'YBQB-KB-$<7Q#>(M'S!;/XB'
M8K402%"J?"PU4!O<5TBQL&84L-AXR^U(5$7/#D754AT.IVCIP7"2G4CJ!Q)O
MI'&X5)=IO2'OI$1U*,ABKO(/C+$HE9$+ ;9\.,4^-X!-S&I?U'H+-F1>YE';
M4.^\ ^!^/;M+UX8Z(R(K65,;DZ&^)5K:=O98*L?[N8RA!R73M=\]L:5,G 1G
M@J'7$G4FFS#:6K-E;]'A+,Z.9+:HXQQ0<EZ%TDJUIE$+0A^-L<\:S=Z&,?V0
M^'ME6*C\/9$#!:4*_EXHI[<:>1!DZLW6R>#W%4G5])A+ ]58?5^ 9QJ%3L1J
MTS:Y+'A=F"6UPM3@)KZ:"29V:1<1#\,_&"J_V.W"?I$S%5<&N5Y]CTN-Q'^I
M AO.\QUS+'U!EBG_\E3LU]R>/ =>SG6JDXXXH$;1&[8O5SR/#  N^#AW _-*
MAT3$$PK:Z!S5ED:,I$=TY#P@\K3NHXU'/'8C>Y4[S?P./LC@?;S!"(6E$[C5
MR("LS_%>3EF9(GWJ F3:N&]K7%UL:U>O[>,!=%SG#A :1WTEW@^(=="R720+
M.[(''*-3*=* ,@OP2".NEJKS9NEF.% FK>_!#"RB3382G[7]>K8JD4=U 45
M E%2J>D$*P]\"]3KL/]U=(<%);O4+C!NX9);)1(>)J^90*@OV_B"*R+-D&@<
M:2T8C%#3/.B,MA%)EG4^Z\NSUE $E(#"OW1XNM;INE<F5CK56];VH\YS+P )
M_V]5FI%XWXE\[W+'T>!16B=\D_3:?L.[$<S:[C9, &K(ZB*;17VJ5G]2ED[>
M_QU%(4E<831QX7@U$K^U>'G(D0_ :\=:_9XTLEZTA"!">K_E[>K-]SI5#\><
MS-_1(WD8 ?294B7N93-0Z=*)*_D#?3)*ZW! TI3Q'7PAK=%Z7VU$Z;&VH=R@
M.N!9A4];40V+,W/>XJ'/[H];9P>Q8CY"J_Q#&Z8[3<U*F$1UXXA& @SRIV(\
MNEZTWT:67LQ&EU<@^$>K)PZ55CU'U# _IHOI!42?C\:3PRHYJIKI:+H0,_IO
M2#_7T]'U%-07X$**'QCCA_3,%3J^.EOY@2,V'ZDBI-U^!(8J[G%@/MK.E";3
MTZ23N0\F[OX@:&CN^G/4#QSPT&;\RJ5*KR9^.4TN+A:GQ^G,AR;I[G2$#RH[
M#?QEXJ>0DF=E*&JVN1L:[GC;'U5YC\=N[N$*;C(3)QG%OD$E$KQ1,H']L3%L
MU*X.!OGM<TQS&[6)'I0IG2,.J$6CP4A<&3!0QN[=5\3<ZY-R%5KEJM3+FELO
MXIN$/M?O,.R%#,U<[9KJOSY3'E"X&A3E)YZ-:IV>-&&68>MV#\,2CL1?^&O^
MLBD_#??X: B*H:*.<CFE.J@:W7#  852,W%]GOJFRE1;W@*+\!B7B<-SL&YC
M_MCTY+,QJ<Q26GI*.7'=%W-$E4&+R-I>7LNC7*\4B-Z8)V[-FF!/:%!S5K)#
M\B$;Y#@C:GS$EL2C>Y\XE4M)/O.Z&781E4>?S4[FP)@OE/]?DG^H%1?'OLJ_
M,TLM/B";%U:=$K5VT/2%ZVA7\?T$PJ\8YZ:7/XK)>/P#SQM@&K0E $M30"*Y
MV[@A;,E,M9LK>//*C:G))ENILU!^!U<$0](2URM0!7GN:@4<H8JC#2'_\'M2
MK*8OW$"COPL\GT3P&>8=5;N;1N_QLH3;\R9R*79BAC[VK0M];EYYID93] "9
M&:&LV39M*A<S<$V9ZW_+,)&Y>__AC),%/3&D4)[L4/,%VJ[+:MH=7\OE&F5?
MUC8JRLU^7)-+) I3G V0\4]]U4P..]"M.<@$UC/(=R'".*QI34\72-6F#%;L
M^TD'W6@DU>@T/@Z1PDKJWO.@_G" 1:*8,/7;FG:61?S#0YP3^9RP/^52WQ!A
M;96F88*,'"GO2>V /NF"C[%4;*9Y39TL5GCALL.N-M")! ?=&YBY=.&&)>:Q
MH!"DJ4_IOD,BVK7X%+,)'5*,')HF[Y9JB48!A%L!+3<R\\?T5FWTF2P*<AR/
M(N0FX4%;+_^IW$!!BJ)FL 9!I/V:AP]X/'HD!!-TI'QM!A7D>J,KZ9]NIS$4
M%B_U:1N!\AM5>7+'QO.(A2!*E<ILS"4DS'C'"4A%M%".\UD=P!@ND!K+4U&Z
MD+"?Z%K :&63-1V\<;P@.=2<QL5*J8C*P#2X;;?-,M?W'DQBKVX,T0(?-2^%
M[5'V",XWLR@O.1NBT(D)1^"9^D*X<<->00'E0#M2K/0WFM9$-G>X2PQ>C$=7
M%X37.6V(K'/O1EI.#QF"F!0NZ:Z5, ^J7"N9$>F'TP;;G6.Y^6YHQ6*109B/
M*CN5(*$>W^62Q\*1*;\$OTZV.,S.6^6>*F%/Z+]-2?VI(?\%EB(]4E+TB=F'
M2NO=>&E3^)BS"F\UB- +)0BLVP.K_:QW""+X&DU0&KV1N35#,26S?]:V<K3Z
MQ:GWF([11^+7;7,4OM;(/>&D5W8R42LJJ/RU+I0_Q&8IERJ5:+N]3AU,;>17
MD!0O9N/1N'$7O\U^YJ9-\>ZX# H/,2,HK!UN-&'NC]LY\^R<[Q8.Q".C$*ZY
M"?30QJF@;4<";A 27SYQ<^AOE:!KD%E-Y42,)&$+Z[82#2RP^".-M$GP"S\!
MH6!&W/M+5*B=$*_(Z'@6)&MGKF:6[<&$9H6A8M[K5ADW17.W$3QO[F[%@AC^
M^HP%280Q)6T<,<8I.SZ+8:>XOZ?(J(8'JYVLT4L(%CD+^^(R(*8Z3&?P+MC>
M,8@O5UTLDF+;!IVZEN8 Q L?+F/(+559,D_0H3ZX5F(RBUHXV0P.#\^08PMW
MN>[-BB6?-'H3-A<FH%J4!IG)S?WA:0N'-]^C!"=9YB8>)X>1QG#[2J>B7FZQ
MJOF22G19 U6.237OJ:D.<A@VW?F+4OT3D"8TVLAG!/6=P!' &HC'D6_0^Z=6
M@WHEI_31\GN>9[4,'.]X0AP?'OGY?F&PA^:,*(CA[QPQ5L$8K;.TZDZB3^%Z
MRTX6P\)467IF8(I#DQAGO)(.9.GLXN53[N R#4_D6^AO_,]-GUX><\?3, IO
M(4HVTY[XV.S(I3"GY %%AM%;XZ##P[>.#^S)Q*.((>@$X'#8/1<V$S>=?7J>
M]W[?K(PGEF%=G.'/;!$]U9IY%QE97%^,T)2=46]&+X8&=P,FGTZ1-'\8P(<G
MI9I_EU2@_[EU&Y?>(J>9S$97?^@4L1OP_]' L$OB6:/"<-5R<%@XNTRNZ1KF
MLV:%_MILN+-Y&^YL1E=)0SUZVVF@?]EO">)6\LBDD'D$;367$R#D;#%/KE%M
M74$\GC?YDKDD06[$)UA-<>/@;J9)JIW*IN_K]OBA0<;C+J;W8W75OZOJ<^ZM
M/W/D'I[2XXO)Q<5H%DI 1ZX9+427BYBNCF?N)O6M3GSL<A&FE$%OL0XX#1W:
M,2GMQ?1R,EJTPC"I3_XBW:=PD:Y[:O4=-IC,Z4;T>#297/P'-C@@C(-!4J73
M%N=#9(%*;^E>#TR%"M5VC]JBFH0HM]T.H3!/<B'K(KF:C$?SQ>(YLF+=3R68
MZ V:R9VX&8F[+=5JY++27SSK35&:D!^ZAT9IZ\O-G?@$!11407_X<)OPH"<,
M[7A!&?/II8*>!\87OR9.';ZN?8[[=NX6[96)K'YDG"BUR4/G\=%8]Z VB1SJ
M8SI2=7U$<^_3'8H>\V7ICP<R?TFI>,*!H)>F&N]D\_W;.,>50X)WCFE]-=01
M>_\Z<3OU'DKKM 9[4^ZDSE=PQ0.\HC.<?$HC":I9:P=4F7!O@7_VS-%T=[O1
M7SP)15)PS]'>?SL"2ZVC',*EE2YM%<+U>6 UF<=8]21PJFBV8=$&%9F?]VH:
M:GB,Z(C^5UG4=(HZF4;GV#^K9>D^;:ZI^P$ACS(3?]Y>\>UIF@;-+D;3KHC]
M:L&;V>Y=)7KJQPX!7%W#9Z->H%\#//F;B6>5!/XG$7>-1E%RSRZ2R?75Z7"9
M<)DLKI]9)80SW:$?@YU'/]K;4/*GGR92L* &<[_?:SYM?OUXXW[TUS[N?CKY
M49;W0"?$P I+:4)WXDX1PYO*;/DG@$M356;#+VDNITIZ -^O#&#3OR$&S6]"
MW_X_4$L#!!0    ( -4X;5K:W%U"7 ,  &<'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;)U5;6_;-A#^*P<M&!) L"1:?LML TG:H@/:U6BV]L.P
M#[1TLHE2I$I2<;Q?OR-EJP[JI.B^2.3IGH?/W>F.\YTV7^P6T<%C+95=1%OG
MFNLDL<46:VX'ND%%7RIM:NYH:S:);0SR,H!JF; T'2<U%RI:SH-M999SW3HI
M%*X,V+:NN=G?HM2[191%1\-'L=DZ;TB6\X9O\![=7\W*T"[I64I1H[)"*S!8
M+:*;[/HV]_[!X9/ G3U9@X]DK?47O_F]7$2I%X02"^<9.+T>\ ZE]$0DX^N!
M,^J/],#3]9']38B=8EESBW=:?A:EVRZB:00E5KR5[J/>O<5#/"//5VAIPQ-V
MG6].)Q:M=;H^@&E?"]6]^>,A#R> :?H,@!T +.CN#@HJ7W''EW.C=V"\-['Y
M10@UH$F<4+XH]\[05T$XMUP9JJ]Q>^"JA-=?6]%0QMT\<<3M/9+BP'/;\;!G
M>#(&[[5R6PNO58GE4X*$1/7*V%'9+7N1\146 QAF,;"4Y2_P#?M(AX%O^(-(
M8UA)KMS3@.'OF[5UAOZ1?\[%WC'GYYE]WUS;AA>XB*@Q+)H'C):__I*-T]]>
MT)WWNO.7V'^B0O^'!YZ8L3<7FOK..@NZ K=%J+2D_A5J Y="D46WE@#VZAJH
M3EBOT?2U\H\AO.-K;;C39G_">@&3F,U&]![';)K"G:Z;UA'VFXN7877E=MP@
MY-D()BF#=TB-M]6R!%$W1C^@=[4PC',V@7$&;UJCA&L)X>&5>/1K"VP\A7S$
MX$-5B0)/#LG&,\AF8SI?4=7;;D!07,1=H+4P)HW9*(4_M>/26\^E*&,Q(YY)
M/,TS4D@P7A1MW4KNL*3)0/]"(7B@OF3Q<#2Y@LM1/&'3JV>2'H-"GZ-9/*-V
MN@ 69]D0[A'A#^T09E0$0[R."VEI(&ZX*7U!?'DH+5R8($MJ4N)M/KE<[<FS
MT!LE_B51GJ"@@VE80W4^9V5KCJ1[Y%09W\[?%WE II, \9%N"8NPXQ8NL@&C
M425EF+K$?9$.)KW!2SB2V^?8 \S_1C&IMPV&T2WW@W/ME)P,OQK-)HQX2S]P
MJUPW!WMK?XO<=,/SFWMW!;WG9B.4!8D504GU* +3C?5NXW031NE:.QK,8;FE
MFQ"-=Z#OE:9"'3;^@/YN7?X'4$L#!!0    ( -4X;5IX@PJ@Q@(  !T&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;(U536_;, S]*X17#!L0U)])
MW"P)D+0;MD.QH,6VP["#8M.Q45ER);EI_OTH.7&S+0UVL26*?'R/,NGI5JH'
M72(:>*ZYT#.O-*:9^+[.2JR9OI0-"CHII*J9H:W:^+I1R'(75',_"H*17[-*
M>/.ILZW4?"I;PRN!*P6ZK6NF=DOD<COS0N]@N*LVI;$&?SYMV ;OT7QK5HIV
M?H^25S4*74D!"HN9MP@GR\3Z.X?O%6[UT1JLDK64#W;S)9]Y@26$'#-C$1B]
MGO :.;= 1.-QC^GU*6W@\?J _LEI)RUKIO%:\A]5;LJ9EWJ08\%:;N[D]C/N
M]0PM7B:Y=D_8=KYQ[$'6:B/K?3 QJ"O1O=GSO@Y' 6GP2D"T#X@<[RZ18WG#
M#)M/E=R"LMZ$9A=.JHLF<I6PEW)O%)U6%&?FBRQ3+>;P\9FN6:.>^H90[9F?
M[1&6'4+T"D(8P:T4IM3P4>28_PG@$YV>4W3@M(S.(MY@=@EQ.( HB)(S>'&O
M,79X\2MX*[9C:XX:F,C!"69<P\_%6AM%7\6O4YH[Q.0THNV4B6Y8AC./6D&C
M>D)O_O9-. H^G.&;]'R3<^C_=2=G$4[S^QL6#@8\&#))S:8-R ),B5!(3CU;
MB0V\JP199*NI@OK]!.B&L%ZCZF_)/F*@0BN*<77&NN%RATB=RYDYSG(!\6 8
M)_1.!O%5T--HR$T8*)!\TC"&9!P=432H!.-@U3"5E2Y'CD\T59K:AF52&PW1
MX"H=$VYZ-7K!5;) ;:<(ZZA9F=2T5I@M3951PG@P&B>64!S"2M',4V;7Z7AL
MJR[#.(T@C%+X2K51$*4C&(:C?XMX04Z#8#RRBV0PCF,X]4GX1RU;H]JXP61O
MH!6FZ][>VL^^1=?R+^[=X+QE:E,)#1P+"@TNQT,/5#>,NHV1C1L :VEHG+AE
M2?,;E76@\T)*<]C8!/T?8?X;4$L#!!0    ( -4X;5I#GH^W; \  ",Z   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;.U;:7/;.!+]*RA/,IM4T;).
M6\HDJ;*=R4RF<JV=36IK:S] )"1A0A(,0-K6_/KM;@"\1!W.SE4[^R&Q)!*-
M;G3WZX<&^?16Z<]F)43.[I(X-<^.5GF>/3DY,>%*)-ST5"92N+)0.N$Y?-7+
M$Y-IP2,:E,0GPW[_]"3A,CUZ_I1^>Z^?/U5%'LM4O-?,%$G"]?I"Q.KVV='@
MR/]P)9>K''\X>?XTXTMQ+?)_9.\U?#LII40R$:F1*F5:+)X=G0^>7(SQ?KKA
MHQ2WIO:9H25SI3[CEU?1LZ,^*B1B$>8H@<.?&W$IXA@%@1I?G,RC<DH<6/_L
MI;\DV\&6.3?B4L6?9)2OGAU-CU@D%KR(\RMU^Z-P]DQ07JAB0_^S6WOO &X.
M"Y.KQ T&#1*9VK_\SJU#;<"TOV7 T T8DMYV(M+R!<_Y\Z=:W3*-=X,T_$"F
MTFA03J;HE.M<PU4)X_+GKP689)Z>Y" +?SD)W;@+.VZX9=Q@R-ZH-%\9]GT:
MB:@IX 24*#49>DTNACLEOA!ACXT& 1OVA^,=\D:E92.2-]II&?O7^=SD&IS_
M[RXCK8AQMPA,B"<FXZ%X=@01;X2^$4?/O_UF<-K_;H>"XU+!\2[I.Y;^D''L
M;#R;L+<0]C\J+7^! /_$U\Q=>Y>REV*N"T@S-IS:)0U8OA+L4B493]=,I+G0
M(F(RS17C+,9QC"^U$)!Q.01AOK(S7+T/V.O7EP%3F@2\YFD4*QT%+"NT*3C<
M#!)N5S)<,9E;$1'^9$4NM$H:X^A+PM-B 3XIM$R7C):8Q2KD.0SE>:=I 7L)
M^@HMP\\!>P.&Q2"PU*J\9E> G7M+>NP#7+8SA JPQ.2&J04;S(+!;$9*\GD,
M=WR!Q0)U$0?A,BR+6&K2IZDK3 K7%S)T0JU\:VNH$I@RA#&@\AOPA@MFMSJW
MW)"N$8AM+DDD8H F=,>BB&.6*0-.)-@#5?!.B+Y$HF-A76M>M)-OM1V\"-+
MSX ;."?/,JWN)$"9B-?LK#=D:\&U80L5 S:C=2C;6T$24%<[BP\<DKGB-P*,
MA'\982NH)>YRD5KOXHQ>\^W*04&!P,O@HL(E90M8 J<0A  '/0RY8M#O/_32
MX%]ZO.!2@U?T9W#5#8\+$;!4Y5:'$(-OT!\U1X2%UC@EPC?3%!47_F-0\TY4
M"#872YFFN!A@UT]%7'HQ8-*P!_W>#& XCJFBI&G!8[@#@P(NFF+^,Q0;U(3[
MJZS(;CFXF$<_ YB3X:#9%OWP/QBB:=%?@8@HDKB^S=2%F=0\EDN*3I@K@TB3
M$-5FA1$,<J%B@P@T =?0D'HYOX/PT2+VHVQ8X:WYNNGAC$OKQX74X(($8?[;
M;Z;#P=EWAE3$.6 A!N5"%!G\)^Y$6.2UH-V3DWXZ3L$N[)1A#%\EI!>O2W+H
ME'?')]D'N1W&182(EL-*J"*.P)50]$-5I&@RA1NN16UY2&Y3&RU"R$B$(3=K
M+/E<QC*W7M98Y(_5XKA A4!MNQBCWFDM*B+\X<S_$(!,DPEB'S' &*;+]C3;
MGB_2&@@F0(*EB+LR 0?>V*L<4YB#/-2GR-##X*)2B5J0HX7+5/Z"-J(PF+"P
M#$E:S3IL1)LVEF.K.TPC7.V<W*@4@';-0@@X+@DRP*)"PS69S*&4$ S;@*V%
M*8]S\A9 -Q-?,*'@1W"E376/63Q!+_?8N4L8S,K (R?%,\4MJB)]G-A@J.6E
M2XI-\ZUG(FDHEB@]"9C&#RUJ" NQ(!,!)O(>=@M0I@[,K&F9P(BYTMI"+DFS
M6K@HK2(>Y09.8UM\UEU+";:)6Q!JL=3TV/>+A8TWJD)G7?6?.ZPN:U"#$%39
MST'AJ+X\6P.TJL4T<'L@GWN1 0+0C233O.'B#M3K+'VT)%&#=>PN,/-UN^(%
MT_&P7ND)9 $Y4K=%(-;3J86?W"FS'Y A^49E\LD*RL%-KC"4Q:BTW:XXEL"R
M.E  .'+UZQ:8 !/@%G9#^/>P\K&3ZYS]QER'U"#R,<?9;<JIPE1.VU-O: $V
MT0HUO199+I*YT+[6_V]5*,'!(UBF!D#Y?$SN*4.'YO!7E:7!7ZPL_8'EHUX,
MSHLEW,9&_:\K" 8\!#=]146XMB/_^)* 1AX>VAL%9!CT^[/?KX ,_C(%9 .
M@__7D3]Q':ESF]UUY ]#O;JE %R%=H;F<!GU *F03[8]=0U6PZJRCU"MQ)I=
M\/0S!#?H?B-]0!%H'%]"!OXB /+Q%O8M3[+OV >-F.JG>F2*, 0G@T: '@!,
MX8IT<L"$@06&O! 0KC#[J]04FJKCI=*9L@4%?7<E0H'13::UU=,R6@JGY=O>
M>8\]XIC9?EZ8J\.@QX\)C:\_7@0DM.'#Q;XN6G _8E\6D_L ?PE23280JW1Y
M3!TEV$;G( 0]'G*SPHO@F1>P5)1ROG5LHQ>W1) #1:X NR')L$U#\8OHV&.G
M$_8#DA1VG6ML^5F]7KF.S[ _F!W0+B7$N+CZ_OCBS943]_KU):WF<!+TSZ;M
MKF+,Y^ADI=<;?<1Z^[.E7, ^P16=J]L4.Y_&@!F0E'ENR@);WK )6><&RHG.
M/<!LO;-5D5)"_ CC9%HO0ZE*CUO4* 6W.*I&>%]'^;E8<AKWAD,JH'_ZZ&G1
M2'8(6?49!>5:Q5[1^N($94!5*8Z1,K7]PBU0,^W-_JP;]"VLX4#G[,6SCQ<V
MQP=56ZJ'9P+M^C3<%>1IQ?3VQUD]D9%"YZ;[2&$C6U"T7,K4)FA= =]^'8X"
M2DC;X,U\)+2=]VOG%N+W63 <G#;YWH=F$-KX[F PL+3NN*&T_=YA7T8]F"T(
M]YKA/^F=[4R P: W^CTRX"L2X I7!6@NSF4JE'B+^T9<1+N"WOZ=3-=VY2NN
M#'/8GO46NK-C+]GB2R4CDL*X-F^U?X[L>1!*(S4$'H-N5*,A5JF6BTMB2N06
MZK]9",+:]N$.9.R[,%<H[G1_OB*Y;^<<_%[^NA',J(\[&+/L/E[3(F.0K)N4
M^1YYXP[<_*P-FN^M07YOS6GGA#601H-7; 9T8(8]:R (O(0L<Z9>NTFM"O53
MJ%(=R"2I?=,**U+)&BA%4]5]HE6.M^323X2!KQ*!(5BVE5$.1+*"8=I=#U@J
M<M_&0%10L8P(D$P.?VP.5/LF["E8HI] J*SP 8@;Q#!CJ)IC:\04<;YA&V]L
M<SO6); Y5*8=7.IF+U5Z=Z$2@02BB%UG8+CIDNXDP(N<#35[Z?B=HGUSD^+F
M2514[85\VA_8\;F%)& (6]S8LFAW3PV1D8/$=@1N1\[?A3O<&SD=Z=U,)!L3
M* A[!:"V]1&Q3D@EF!<0MH&3X/VY<L3CH)66PC(7[/;"I*,F&&F[98GP+!9C
MA9C(9GB!'M8]6GPII!9E)%*_3]3:9M66N,UQ]I*1%<<M,2!+LMFBP;P4F*3(
MVX!AI*+#F'T,ZZ?W;Y3&FG5)V[O:7LSQKG%U^O>K[FNLJH?L<#"NZP1PTQ)"
M/.2*MA7J.E1DGU?)9Z,6>:'3C1)5'9';[O^H+-E:P$((W]AUK0Y?JJR5J3,7
MX^"&QQ0'71@YYS%MD>D9)].HBFYI1N3*-J&FZF@3 N:L]J9O58\-O"&O(513
M8^O,"W$C8I59.MNDK==J+AFA@0FUG),A( B2>[#[N9H.<*X$UJMSL]$X"4[[
M_=^^5E.TVO@DA>BD%(*F7SO9AWBH^GZN=.RJ\26%._6^V:SQ.%GP6];V4HG)
M5U3W\\[\ T,BX8A:[2&(VN9XDP1 N=,%?$7^GB+C(Y))S, W5.L4<V_T]]B+
M@UAG"\UJ-:R"WTW$;ST<TB;#5+%;YZEM1KD9? 0!V("0!% 2-"(G69 K_>3.
M)$8-AK-18$KX;#[;T&&+G8?R#?B)7B)KJ?^(91$!.*:216,,!@YN7/\;AG;@
MMF#4R>0H@!OMX"HRE<W0UAYIS+9MAX$ V.8EXBV)*"P;D&0)T3DJ\=6VV>TY
M[]5_:B!/O;V]Z1/C*HD-L@74$PE%Q6JQD'?X&>F-4:&D._9W16CH 2T)"MW*
M^8ZV<JW7Z"IZA Q7AHJG#9^E5D5&H8LNYA2P2Z!CQB;/HB#-D=47J2>/OGPO
M8@5U&?+D9[MG1YXEV!+*M7V>4&%?US(@?&BZ2C!,4KM],L*/IU K827A*5^2
M<7\S#$HT)2(%)LTL4SLWE?!,8><!LJX*(KL;:9G?)%LU\^W^= %7O0U%BCD(
MZF/C#WU?F.T!0$_I;5U;JT3MGA;7+HS/(K?%(N0!(51.M&@5O9H/*)'<TD3D
MHII7K%AN>;DM6]B!ST45;>U$JF1MI_@=V2R-6XY&<]L[LK&2-:3%@,:@H)/T
MT)T[[P;SSJC%([$*;$D]4^#B\;0#&L_Z8_;W0N*$[_# 0D?L2@&%=@\3;VE6
MOA$P5K<@("12#ZK=JG8!L6QC%_0 N/W )99',R_TLGK,M]9V,Z[,$WGGJ7W"
MN3\\(XF1HB=!<<N)>R=;->S^B?!H1Z-L\OL<2U'?R]&!\@;[T&MWI:AH/^GW
M8-*;5%N+!Z.*?S0?,^RQE_<2'OA#O$REOMAY<H='N+3'YOY18<,>$5=1A0$!
MYO$3]D^L=?0F@)5+"K]K,0AZHO<!&P73R2G\'0;3X91]Y%I2%M3N&0#]G;$9
MU*'KE=*YW2;5KL.P*42G,6UL8X\&07\V>XQ_!V?#Q^R#0@\UIA\'H]F8IC\=
MSB@>(+VA:N=K#X)M9^]J"V[;K.U;L,T1\-^$5N=T/,$OIZ#I9#2UT0U*VU_A
M>S :T-TS6*=QGTR O?X"-W?#8#"=.J-=D8)@EDGAEZ_L_0RFP7@THT5\PEXE
M66$1#C<OL$KC8#R9.#F[K'_ !J-@-AV[_4"6Q3XI,,> $*$&/LQ+*E46+ O*
M-=ZY 1E?M8PC=HG2:3=#K)5*7*V..J+M.D8E(6R;]X3<,9G,;+3,3MD[XN[4
M2[&U25*%M;UE>F9\L9/];*[@ 4>O]WB>$N<X_,SU0++J=KA5W3 >%;O,W-^=
M.92UM;0[!,2PHPA!*$/+4#PY!M6*)*L3Z\,=U-%9J*K?H72_?)P%PQF/4#'\
M'>92^[3<_+6QY_Z1=& UX=0T7<26I+K9O6JLW%&7W9$=>]F:%NV'W?<WO2L@
M<)RP?!G%OB<(&SY3?_@)2"Z]C6=?"FSL6/?@MMD*%Y_HW3T1'7.D9,MN:L[&
M4'KMXHY[(_=I8V236P"Q.&,/V:PW8P^[WA@[J;VXEV!$X>N)N.D "?8=OO+7
M\@W(<_OB7W6[?7T2N-(2-BB@\ *&PO9X<F2#QW_)54:O <Y5GJN$/JX$!XS
M&^#Z0N'#4/8+3E"^%_K\/U!+ P04    " #5.&U:GG(]XS<%  !/#   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R-5UMOVS84_BN$6_3)\45.FZQ-
M#-CQ@A5HUZ#ILH=A#[1T;!&E2)6DXKB_?M\A)<=NG70OL4B>R_>=&YF+C75?
M?4D4Q$.EC;_LE2'4;X=#GY=423^P-1F<K*RK9,#2K8>^=B2+J%3I838:O1E6
M4IG>]"+NW;CIA6V"5H9NG/!-54FWG9.VF\O>N-=M?%;K,O#&<'I1RS7=4OBK
MOG%8#7=6"E61\<H:X6AUV9N-W\Y/63X*W"G:^+UOP4R6UG[EQ?OBLC=B0*0I
M#VQ!XN>>KDAK-@08WUJ;O9U+5MS_[JQ?1^[@LI2>KJS^6Q6AO.R=]T1!*]GH
M\-EN_J"6SVNVEUOMXU^Q2;+964_DC0^V:I6!H%(F_<J'-@Y["N>C)Q2R5B&+
MN).CB'(A@YQ>.+L1CJ5AC3\BU:@-<,IP4FZ#PZF"7I@N:!DNA@&6>#W,6ZUY
MTLJ>T!IGXJ,UH?3B=U-0<6A@" @['%F'8YX]:W%!^4!,QGV1C;+39^Q-=KPF
MT=[D&5YBH7RNK6\<B7]F2Q\<:N#?8VR3K=/CMK@OWOI:YG390^%[<O?4F[YZ
M,7XS>O<,TM,=TM/GK#^9@5]K<:Q&X@NY2GRPTHA/1LR:-6JF"^2H+T))XLI6
MM31;02:0HT(H$ZR024>:0MQ2WC@5MF*V=D3HN( B#*7X]("F+\2U,M+D)#Y\
MN.H+Z]KM?E)56N5HKCNI-6W%7)JO48;=/F,_*?LF+\5*YK 1M@GJ(:,!4_HH
M'<3&H\AHTC_F4FRD%YQID%MN$V>I%6 :)<6":NE"I&57+1LEM;AQ-G2S 6C>
M&V/O)2\3.K9R304YB,*$]2I !L44@W%E76U=*]X2OEZ\1X08BZQKBR@##A:.
M<L+D<?ML)AV;3@\NC6U@F1W+($".T1XA^^K%>38^>^<Q>R(HW\82]2U- #&]
M[;3CH?>$GU(B-$1&H F,7Y'C0HAE8&@#C1P3'7C[8M5H?<(UKG+J1V@GN $<
M'XJE4\6:, 4YRS]"2V>I OX<S 8Q++=W\_D@_F4@3<41 3:-Y/I$=(.2%&BK
M>V4;#R EZ9C$(\SW IB==0&\5LZ'DRL5U'=<%:D<7LFJ?B>^.&Z%KOCWW7-@
M 6D7R31GR1V&-"<7<*L)BQPYH95<<J$J2J<R_]8H#N+1R!^83VQ_-MFF9N5L
MM5<_RN2Z*919/]40MU0'JI8P,![OE]$3;5[+K5VMA*: [8/&CKUY-^^+NG&^
M 04NB$VI$-]]>[54;=B:P$PC-EFA6@&^P?QW1Y "DEU3I!E=RCQW30(%<,A+
MC"$G'OAB;^*9(37/ 1SC2F4GB!1;YI(4],!;C?)EU\G'PO,%>\$&M&Q+.^&,
M3?DRRP83W*%:QZ9%<7GEHY_6F"-^Q?!&[9 %5<-,JU\TQ%(OQ[\-SA]-1'"8
M)]%;A+6B)'?@B<5^)AKE1H/L48Y#HLG'QC!\-N[.6/;'" [$ E.U+9,M28?$
MXR[&K,I3=4R.5@>F$7+/C8"ZA*^$XNS14XKY_PGWL1C^FN=NN&YP)] ))RE)
MO-YGVQA$WG%3%^A*W'7*<XEB\N;6MPUZ#R]\M\=S! 7/HSB0.0O]MI Y\:FC
M8(@K$36UJT%Z $9/79TQ&ZM5$6<=*CW$NRJ&*(U V&[[&,%T5/+;])YB' =B
M%@5_C/YIE/\Y#3R/C3UHJ:5U>#K@RP^./2N&>X\\S*IU?,IB=G%]IO?>;G?W
M6IZE1^*C>'IJ8X:N%:AH6D$5V7_=$RX]7],BV#H^&9<V8##&SQ(O?G(L@/.5
MQ=79+MC![G^(Z7]02P,$%     @ U3AM6N%XKRUQ$@  8$H  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL[5SK;]LX$O]7B.SN(0%4QZ_8R?8!I$D7
MV[MT&S3=O0^'^T!+M,VM+&I)*6[NK[^9(45)MB0K:7NW.!RPV/HADC/#>?SF
M$;_8*OW)K(7(V.=-G)B71^LL2W\\/37A6FRX&:A4)/#-4ND-S^"M7IV:5 L>
MT:)-?#H>#F>G&RZ3HU<OZ+-;_>J%RK-8)N)6,Y-O-EP_O!:QVKX\&AT5'WR0
MJW6&'YR^>I'RE;@3V:_IK89WIWZ72&Y$8J1*F!;+ET>7HQ]?3_%Y>N W*;:F
M\IHA)PNE/N&;M]'+HR$2)&(19K@#AW_NQ96(8]P(R/C#[7GDC\2%U=?%[C\1
M[\#+@AMQI>*_RRA;OSPZ/V*16/(\SCZH[<_"\7.&^X4J-O1_MK7/3BZ.6)B;
M3&W<8J!@(Q/[+__LY%!9<#YL63!V"\9$MSV(J+SF&7_U0JLMT_@T[(8OB%5:
M#<3)!"_E+M/PK81UV:LKE=P+G<E%+-@M"$1H+2)VEZGPTXO3# [ QTY#M]EK
MN]FX9;/1F+U32;8V[$T2B:B^P2E0YLD;%^2]'G?N>"W" 9N, C8>CJ<=^TT\
MNQ/:;]*RWT>Q294&[6-O_LAE]L"NI0EC97(MV#\N%R;3H";_;.+<[CMMWA=-
MYT>3\E"\/ +;,$+?BZ-7?_EN-!L^[Z!ZZJF>=NW^V$MZ\F;L3F@I#'N]]\7'
MM6!7N&HI0YX)II;L6ABY2CC9%KRU*T02"A,PLFWXER<1NY$;F=%C!I_+8"=_
MS"\J>?:;RF2R8AUD!4SI^KIV4@*VY88M90R+MS);NW6A%AG>.CQ\E[E5]$WF
MMXCYEH,6 #=_S>,'-K8Z9WE(M;J7H-%LZ2B)ZLR;-2PE]EHEB-OP/%LK+?\%
M'^(FTIB<@\!PW3BXF,R#B^&DQUX#=AE%$L_F<?P0[).,FU^I3<J3!R:23.!*
MF62*OL!'4"*YABU@^]M<AVOP:^QRI84 ?YM9P84@8W#JL-!D,LOM<9:-$,0)
M!-"N]P)\E#;^CHKMM!F0UI3OX>$PSE&*Q_*$76OX7FY4MGY@EP-VEVK0 J%!
MWFPC-@NABRMRC/SEN_/Q:/X<Q*&XCNC*I ;7#F<_APUAQX^7=^R6ZRS!LVYN
MKO#J&%^"+LCBDG7MH 0ID8Z6JS5?BH3=Y$'M,7_L5B[% +G!.\M8;V'6;X/C
MQQ&NQLL71 .$J)A(7<&7*T?J)#B;38+Q=%[1AU!M-G#7QNO38Y2&5+=V2EK0
M"JQ:)?Q^-!D.AA!FXA@5&R[?\WBKY3TNNHW!R2%? _:&AVM[<.>YT@#AI6V3
M'JI$E"N;+KG&JLD7O\--H]3H@[6*(] /GJ)9@D["'AQ--%4&WGG9FKR@;U]Z
M>0HO+5FFL.'ZX^W\()0(E8[(=+V/N9&&_-B'/!;>T?W"3<3_< O?<?T)4!9I
MYIY#*TFY=8P,V*\)LOD4-2,!1/V4Z&Q^'DR_G@J=CP?G7H.<E51\ -@[\03;
MU*VQR7HC>N8FMY[$VU!L5,$A>I)1,)O,@O/)N \+0%']7'(=\_$HF,Q&/3=H
M)M6Z$MAG.'\$(3=Y+ZE.YX-Q(=6OZ87 M" ZD\UDIFI=AA943>R0OH(4,K!#
MDXI0PHH-(%*T![2LRK80G]<2# VC]%K$$0:O.Y%FUN6/AS:$#=C[IH_I"&NG
M]5."1B=28\>RXB+O 3[ 0%9.4P'W9Q3+Z@2=%02E.U<!#V_V<4X77AD'TXN+
MX&(^ZX4B<D@(8&&(D;_PJT5T;]JI:N[/V13#Q;B7?D8R8HG*FD_T]Y!!@L8B
M<+9P_$(D GC$:U%;M(VU3%E<HC]KQ:T';@&FL##FQH"DB"66@C!Y@HA$6+3.
M22WA.7HX44B/14+X!1 5JAQT:LWO!62,L :W#[E9P[L(H'^!U_!RK P.$+6V
M)X*-QI"^HCYK@K8.%7K(^V-=DR3Z=ZL0;1'KD!K6'V@4%E[/7FAMOOH!^\ES
M\"54!4STB_J=BEH+_U4R@VJL+P!H184"AR$M&^1O'!,'$ APN)8+@JQ+K39>
M;+!/KY#?*E@FEP&J)0<-,WF<>211@HO ?F )!4^E5H)<"T$'=+L>HZ)W) 4N
M30F$!\;$-@J$15'3>5@R$;"/$*R#KP0[)@-D ,;Y(I9F#=\N'N@ZG8 6(ML*
M +@ \'X@[1U=#"Y^."DN/5,9:$"2%\B[C5L;=G&]RC,X+*&[D)L-) 3  9#+
ME^ #V4K>XQ=BN2R06UTHSWU.%0"%6W%/HED7?N6 +V&1 N+(/:4IG+D7U?=#
M- 79!\>NU'A=J:"24$7^O4%ME7FB&N-9J[LL]+Z.O>I*\T6^ @B&' +NO^H.
MT#R 8W+1\!HW434/Z$XJ?=O3O8)*["W@D^)SABX;7S[^&DO/? @]E=R*:, ^
ME/Z]TZ%+>QZ& [$!4X&<[EJB'B:183\[K-#IV$ S@#V9Q19!00XJ4(DBOPO>
M\&$.L"()_YEGI8XLN 'RCM$O@'XQ1(,Z*H1R0)0G&")M]D/U"4]-RF54)PF_
MK\<&5X)Y\SD$A(.*2=AG*TTEBH(WB?DVZ Y+_CXI M_;;6W$'(!TG9G# 3$B
M++0 4- ^L ?-L32Y.IK= BS&0P-62(Z@*Q@U5FVE)434E=[8I''#?U<:@47A
M!=<B>5:U[;K4VNB#+(*?0%Z"C@_\#&!O\$*,1V@GZ!)Q;0K<(_RM@ 9\UL$)
M<)?"ITL=QRPJQW  ]KMPM@-GPHKC\*2RZ@IX<UM9K*OTBB?R7]R5>B(5YI@[
M&$IY0=" Q1*;O&66"E-R:V%26BT":E<$!*=\+V.Q$K9(9 4!Y-$[D&X&68Z%
M<'ME-JOT6</=M=?&;B1H;,2]*^BQR/E/S1.RRY233OC4OK+#7O;<3-;EO@8;
MO-U((K>+W%=# >T*$#"5(^*2\ "?-"K.K;M&K&#U,4]W*B:83UDX<0^/ Q;0
M$B&#QLI<^<& _9HJ>XD]3GG6XY2=,QX<,.R!QGRL:O*B:+WN:">:-D)"GDJ$
M+ H[3#J-<V.]@N$8[C8JIQ"T Q%KUV>A5G&R[#9QB[B7>2VJ%\FL9XF<+:H/
M_ ^0DE6A+O7IH3I@0, <!0O+E7?T>)VEHX\$)$_DJ4&&>8*D#-C;FBSY/9<Q
M!CTRL*HRDH=%QVWR)48983/:E#_L:GBGD':SX12E:QTIUJ'!+X#W1TL3V"^4
M% .(,O+A"U'2!%MJCEC6HX)F&AK$U5F"KP>^5G/])OV.RR?V.RY[]CN L%_4
MO:U0C"94H9@4*MJ_@]$EW$-=C+/I>3"9G^V']+V=ZCV,%M(/]3$F??H8?[9F
MPYW 4/\>4N WJ#6@:D NI.>Y9F]!/O<J) O]J'.3(8$9OD [42%N[=I:N/N[
M'$R$_8W'_$&MXAP?#M6S)3@) O N.F'C'OWE6HHE8',0&&$BA79N&7\/;O *
ML8"1'!5JK=CO2B;N?@^+Q&5YY$7W$D'*"/SWE(PX6;\3FD3C%/)MT4IJK&\>
MN.HG=EE&TXM@,AD.1J,^.MNK4CL;#L9G#2V425,+Y6W7UT&;VE;KMR*#$,K6
M6.)PM!A[*"I5!H@F7%NF#K-G90BH&=2-.&WL$%4;1"A7"OM4E+/WW;:2\LG/
M<F-UX_MQ99^@A%H[=!-[Z"TGPX#-AM:,+H8LX@\(,'T*CUW09:W =14K@Z^O
MX;S!GK7N2Q#K,)YHXJ%.;XUO)!>$/+&$=)]<B#2 D[!:Z>Q28F97L$G8PA)"
M7OP:HN:.*_PK3W)$72/7Y*5M?A(+;3\=%?7HNDRL)[ 1 /T@/#$_/QL,SQM:
M'?OJ3F2YB@](BFX:GM\7IFO4-*FJ,P"K58YAUW0!VSN;@^W-&GI/!XDY<)Z3
MM3^P=+_?\M3:M5++H QJ9TU!S>T\&UT,9DUE^7V"@(C'!!!2Y>^K+JG>2XL$
M-BR\KU>+6*XL)O#.<P0Q?0[J/ST_[TE@-?*1Y/<T1@N:DDDPG'&D<8LQ!:Z,
MYF]H#<(:[+/F]!!9)!;,(+PN(,86Z5F1?,(%++F$](3'.18ML#]K>PB":P2:
M$%4N(?74U?I792]NO/UY7P0 -<-R2Q7@>.UI:#;NRZ+)E*W\2P"\0].>+)J)
MI(1Q%WT]3K6M.2=/\BSLV(#*_8)EE=D)*;KGLTO/)^?3X +"[1Q.Z4$AQ^J5
MIH00W3.(Q "$U4X_P<J,>UQ2+S]Q@W[^ BW *'(T)[F,I!]SIU5MPMYC\!V'
MX,#&LX89FTK\0AH1>;K;I.J9D5FO&D%@:S/U%F47]G<MN+4K[OK2\\Y@0R>@
MWZM+>SQVZ;>[JK0R;-*L0L!BC"8>(=V$<">,V8V%7<7DQG&'4LCS!B'WZ.KV
M;>8&13G\SG61W]DN,I%P"8XK9N>/Z>]VYV?HMNR]!FPRFP<7X.SK(QGM!M#5
M3 !['<\FP<79J*594V^687J?/'.]T*+-&OK\KZ&\8'U@",#.".K&\L*_[E8R
MJ*7&?3Y'99!G:)2V1O.<C6:S8#(=#<XN>OG-;]%[AJM]#]D*N>)1T^UR-'<'
M5M^GCI.*2D4B!M^GA:_(%\YM\=#4AMSG:E>5>FG/]"PX.QL-1@!Z>PB.)BJ
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M#=[HGJ8>Y"85$2DZ7J:VV6,D8C>+5FEN'+M"4J-ZTDR"6I[8A@9U.6&[H))
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M/@#?+Q7D->X-'N!_5.K5OP%02P,$%     @ U3AM6I3!V\7H#@  CRP  !D
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M/KW*?UB _ZBR3-TY&E=-K7+8,0'((&9Q[FH]P<+5.G3K;X\ H>UKYU?V0;X
M.G6=M:7'6P @M'"O^^:T[39U_!26\]S<L&;\4580_/I^+ R5 2@L\D>=XV!\
MT][M3Q)LJ"6/T<0KF7M'BM3/V)D\9X*#W=LD8"=0V/FB/^&Z>0<?+IWL4FW4
M'#?>,T2I<$\2Z+\K@AAN8JD# BEF&W_O34YJF8LI;3X'Z9QXCY8*&3 C+KL[
MMKO?(.(5M[:L 3@(&A7FH%C7ZSG80 (G'5/1E0AIBZY<-8 03(=<[]' F)M,
M*H9J#VH8@L_9U;F9>*@:[C_8\([F/5!FMOFK5)61=Y0LV5EO=,AW-69AR&X
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MRO$!N+]3JG9?<(/V9YFO_AM02P,$%     @ U3AM6L>,#B2I'0  Q7L  !D
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MX!];+U$,[;!LN!C.,;JOPIZH-SU(3=+&B?$*E"HC<WMIILFY&]S^T&3"'DI
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MP/<+8VKW!W;@?[G[\?\!4$L#!!0    ( -4X;5IT@6?@C 0  *0,   9
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MSPB41H#.IX(*?+TQ!K8_3'I_ U!+ P04    " #5.&U:I:[,3F\6  #L3@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6SM7/MO'#>2_E<(K6^1 "-I
M'I(M9VT#LO/R(DZ,R,DN<+@?.-V<&4;=S4D_)$_^^ONJBNQF3_=(LO.X["%
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M;S<(6&J!>@H/R<=KKM6X&MDG/P"<%54I&^*U),_ 6&IZ,63/*<BKE]]<BIA
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MH3V)=ACG\=+ CXMV2;B(@2.$"H=*:K5$P 3, 4@G37A4&9<&LL=@_-8)XB?
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M4*4KOY=T&%8-F7L8H**Y/QA1R5:%;.P$\?T!>"%:U:.&],\$&]B:QG&#5\X
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MDG?4V4]+ T FY_A6A%\V=ZQ!,J02#@6@U&(EA0,NT\HMV2Z]YN^D2PE'64V
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M.M@_.LC(M:^?=A-LG5X<<QOP?DG+V [LH@"^+ZP-FTTTL'V"3O\!4$L#!!0
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MCXYV%?&PN&]6'AX;,,ANMO3ULQ1)-FRFHI=8=!+Y*Q+CG-U:@]*S&U-"^;=
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MT/#%@BO[2S:U[>#,(W&EM,@;,'J0LZ+^I]LF$'N :'@ $#6 Z#^ <7  ,&@
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M2GN,N%&)26/49VZ0]2BBL'-AFD//H\,U+">"JPN")-<"0R>ALS"88EI)"NQ
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M1FH72N\0-T#A (5]4#CMG$28?EWBMFTM@GQ5SJ/F^G(C YZ0U?VZ#"\ AQ>
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ME:4!N+\P@,[J@@0T/[]R]%]02P,$%     @ U3AM6DF$5IT*,0  \K(  !D
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M2V8+FP-JCT$MDA@'B/<&"">JK$,0T63D!JJRAD02$H;+D-'C5E#18?#AX=5
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M2TY0>G7N@#\%I UF-O.*&.H4^AO'*S7)D-H0P&K03^!M.N4Y8J\S]P:PD.O
MOS5OO$AK(>-.53\A+96+GB@/,E"^?Q2H_R%5(C:2\NJ?/YIRDMG1;2 ^L,W%
MI)+0=^]BN6W>WZD01>),DTDC7_#]J"5 %F=+[- TJQ")SMHC)O6C,E WN[22
M.!(;8;,^$3U'$\,@9%9Z(@M.L91'8O^+Q-/;82,NXT38-5;HJT!MG=D#^S^]
MI]+S">_X;%U,:1ZUT!M!W2/(M#\4';9-3'[P9;9!B=##CR=N(M' $7)U0I.@
M6'8BK9._1[NSIF2H]27N128>>@.:NIVNK?_"[D*:.F?1POB*6 ]CIL!M*HGT
MJ&[-NY,M3+W>>E=[*!O5]V>&/4A<FDMYK6_YUP79/0XK@##[C?(,ZH$/U6M=
M@LSCU,YQZ?5DPZ;[MRNX"(W:+I:;K,V&'^837__,@,,2@J):/IT9*U/]IRS/
M&37SN%;AXUT>4R_;LM&2! ^D^]KT,(&Y6#$(HH-ZTUK'WCWZ"F*52YJIQQP7
MM"+_U!Z14/SM7I,,?C?2>W0V]M/5?8?FDW*Q?]15<'*"VGM#"!0QOPD_(9?,
M%ZQL4ETY $54N'L )#X5S]U\V:N7>2%$37G^\AXO*!0-^))]6UT8Q'&PMP]I
MOIQA'+IG7=S1U4IUSI])ZYJGA2\?)O$/.WH8,=;8M(SBC??H7JDZE4^H ER0
MIG'QP&3+L7F@,J152ZAH\C.)(U)]G_QY"GKX8-U*1D? :!]'7(77_<*M!#?9
M[_POQ$3@<JGI4\HRF)I-I%P*TA92^A/-%9Q\4K;()E[4OG7K/W%54Y<E!PK\
M,*>L=($%F,7SC(BX-@E*7.(@C\]"%@W1VP=+62+J8[J(M.(H (:U.*"?X&:M
M*+-QN[AM)\$<AI"FQ9:+K7RA52B3O%NDL/E(S66+/)2\:K^/ 0;@C'1&E#P6
M$,6$=>,DG0RG*LO02"08^:U17U0LWHGQ,</_1Q30\;S.+WJ"Z8WR9B.>1XIA
M)570P8:]+P.,BS=BH&H\/QCQFD(@:I!"1I@SY=-@S1=KPK&UHCLPN7O#9G32
M#)(3"(2B&!"A?E-;R8X)=R93X)_(@K4KJJ8*Y.[W/LU.)@)/J#-J33U*P?+!
M$.T#V8%$C84K8?Q>6E1)*:!Z_V^85# OBH#AA8;O[\R9U+)V>W>!QO3;@5L1
M"6[C2*H,FQ'8K0D)^78=XD%CNV'8VOK55%_>(57;)<#<<5\$;>;BFU'[\U).
MN?@YRU6NXJ.:^T%+X$AAE;Z=#+,EP1K:8UTL=ZUZQ^WS?L;&S9,"]?Z?1P@N
MIET;6D1WZ>>Y-N>:"\*% %2Z1I2-GR!W))^G="4#&P;;^3<G4W_71@5X\PVI
MO DT+EY748U3LKMPMI6[^*I=Q0B,7W!6AE^^.KVE,$N5:BYUCAQ]=@^JI.D0
M[,"FSD2AG0@Z*FZ)C[(;'($L;X,"SFZ:*9!K-H4IT2#>BND:9^QM/T,][LS7
MDVJ5LSU5DZ.L<0(V!"GK0YSV7/%3^UXHN(ICW1:2C<8,O>W;CAWB%"5RGU-M
M96+<_#C(Y )EY/E15YA.X#W/&M 'X4QE41KP)_ZE8T0%,9(.@\@@WXZRJLBG
MAUG+=GO<QX)$-\<R)A9OW4)8 ]_NI0DD\(Q,RMU$ZI18[]EVT;$IM G,S\[_
MEX+=QF2X'(H@BWV*R]YHEZ%;278:""6;#.@K!4F] V2WKKV<NT)E8(%CT8L%
M 2D!FO.%80!"TE:+46RC>*Y?&7D*T1JAPOE@ /[!I2RRR-!<[V*Y$=X_I4/<
M)'N\WZ=S1"1B2W/BM!E'YI.S0W<Z]6IPT']%*@K[XT,#E+J1.L+5'5G285QJ
M=6IN+XE7,),%^/3Y^=G%^<IV?\.SO9(SF.X5R'57^Y3D?H.>^8R8+"4^_SCH
MJ/,#ET-Z$VIV*<\OGIT]'2_E#<QPP_ZFZ=6\ SWR,R$/S_&AQOQB%KS7KJ/Z
MDX(NEAF*DY]NJ^0:W0<)-L-%7Y> Q/02',1-Q_!UN40?XF\.&-)%/8)BT^A_
M9]U<W-K2=@XQH.%^>;C0>!@1I:;U+67?MIQTSIV)L7[>WX:A+2<P=P]3+JFO
MS,DG6/(<)#2QRSK,S87L4NQ4]53QC7$$FH:XMU^,M,!81K+> I'P:C):PRHV
M+8J/,'RG2"#^_D["GB;:-\@:'>QQ%JK>Q4.U=P@VOO0G(*OMVQ(J_T'O;4S5
MB;^. AAUL:\YDVD8Y^-.KJS,HN;:%+L=Y]4[2EJDZ<UI;!WE<OF,AR'0=7/W
M@+O"KS!](S0G72N3XX]GSFB2Q7#[.R4WD@FVOV8BK8&G/XS[4,M:ABLWR(S^
MMXPPT]__ PK4%J-+*06@PM4OL.1@%*-F'F\J).7?<W$3?'CM&5M$^M$@<D[Y
M=- P:C-.K%*[3TADW3<1D'X-)D? WJXCY>0<SJ JGY54!L1UZ+9[Q;:33?LY
M<K[Y0%!>\_5G PMH9V--MO8(7RM?GX/%TN:ULW&T%MI"5<_LP%KTTYM9TA N
M0]^HR^5V3R0.SEZ3(^G*>).G-(8_.-2\HH8'..O.IN@8XQ;8365]<B)@,=LV
M/&&+)HU;X7'.S?7<T*B'<L:C;Q7#L;A\HHE77&WN>UL0[I-+3W/+!%'56T$U
M3"M87^][26+3 YOW0CU*XIY89,#1'0_DB@C-;>MFZZ@E2CO=MY'-:_/:R!4P
M2A%3VUXO^(KMN=CG).TLJ-&33W@9Y('$_H9;;%RI[5\7#D.]5;9=S81W<?KN
M-),9D)JB,>PU@:L N"/,%TDEM&RZ7&ZP] \X$^K;\0&@>HTJPR21?.D@,7F8
MDN7NMN;+GS2'F$0;-1HC-,FD80:82(XO;1$+Y2$RK$=X*JS9C(Q'*\/0@D-9
MK370:,)(=JYH7]XP5 N]$ N0/.%2[B<7 66^O?+/4SLP]L/2>GV5"W_,/3H.
M4LXY-Z7HV*2%@&V&[F^0&2WUGT_%UVFO=1B,A?8F)Q<7%?=L8IAAO#IMT%,W
MMRG?L33>3G1#PQ3$_2U.0CUQ6I[W"]UGZW'2:M'8NF'9%6J'>]9GF%!E4^3X
MWA(KCM<_6-X^S=G-9R S?=G1M:.HY2N\'D.\.=?<C5Q^>3W\A39W>7YYF7BK
M,VS5<8N.T]21#OR1&J?H-._)6C(,WV6$G<<MWSPT:#R#)9*:++U;HDCS(!=K
MHO&F7+8DG7XK?U43(:7.&)(3AABX3EX3._BS+$#:TQ#.;P3>ZJ$>CWV?$>5\
M;NE^8J0Y[/.V&YM>AL19L<9P(R8)VW([]7N_F>5X?V"3+*#XJI0_!SUR9/IF
M&=,<)([8'=5PIT9I&1>)X>8H1]J@YOR._[H#GI<C_Y\.VD9KCL;%X2&DXXCQ
M_G902T-WE:A?DMMFF+GJ4/,X>74"T>P\)QO>JT #D=A<^,C<D\!S]%5QSWL<
M5-^5#_U;QS+U[X16SB5[._@*)0+/:F%99J<3G'F01N]1=N88EC2MT#;O<KGA
MW55H2FV\:Y/:UA\9:,%SW+4&C)&W9,:)Q]773Y^=KQ(_&=]83EZA9^>/EB 2
MVM1=+O>3HV:RTQ"XSX?+.R[YG<4=/G]ZN4ID,&XR\?12J\DG0BN#'#KD/-P"
MBGMSI7)C7<0.>[I\@BXKFNI,)XF"Z^0]55GP4J1# #4:G+\1S-IO/%?<TCEM
MI^[.6\DB!RW3N06_=]:LN(DJK6#T_J!X3Y(G* Q4FXSB:#/H<BAV!::%RZ"C
M2]6DBV:TB;6YSW3V.D#51 H\"W+SU<P.)W9J3<!8;$E1GN\(RA_[G(C0SUDC
M@N$6/'Z5KV/[>6^:/E)N.5W]E!5D5_*;@;\6MG#;]G'WEPEPHU8N6L"0>.P3
M V954M9MP:DM[(H%(&\ $-P"K!'?$KEB]8Y(:7;C4S1K^4"L=^KH@:T=.&XE
M\=<;*J5JBP-8 (W>0.&[S&%:0^D3[V/@49V=?@C@K^H#4)^K;HJFKCB3Z=UT
MZO:N+_@)#"$$RA#8%I_%W"FJLU FP8^]FSAN9Z778T1E);Q4=<'H ?E6BA9)
MBB9DS09_"B<1GL7M%].PAH=NO5MC)0ZF1E"'(,JZ3;$Q#-?.L7_8E*L-"_SB
M<KAA"X*0K,TS(VW5C;GC$Y,E79>M'P57-'?U2RNKE(=PI&T!-JR(#I?U15_&
M7WGZF84K.:#8"!B4D@H_8:)$7[QF%^>%])6@LD$MW1B-3/!.2F)JF[XHD17H
M_F>7(X>D9BF0(=V,)=W$20UI>PK^M#(6D_I@()^W(G<A>>8UT;-7@\/"C:9Y
M>)7;%K0SGC7)QFY=R%/_.,,FA[>KCIFC]R&2X:UAW$.=^UA#Z\G&UD&.&.B0
M/WINH*D=P0\XS[EX%3R 7<- !B'#E=9F@G>#MDB<1Q@R[5"(^WX/8'K:>Z(G
M@=.-O9.415F;FS3\W?0G#S>?!.!O<5FKPB%7J5;N%G;MA\%TDH@>T%-LVM1[
M46,$ASI5  67]++0(/5RN8'IJXR]P+BB2>WL_I_/U/FG]I4XL8?C1E[*V$Z_
MX5IDU<B ]7'Z21RZ:_=ZF]FHY,MT&.:F";Y<6!(/P\I,S!ZKY]@CCX5R;M")
MH=@.NO";RJ;XPAIVRG,U!^\X$T<(UY++A87L+4:16>VPF[MM[>Z33JE1.1FA
M JOQ:ZT/1LJR*48@.H0%6-%.0*H:@V1B/(XGPYC;OJ$SB>]!,GR>+Z6>.CN;
M:1(@(O=,<;^<3(/.U/OU1CH0AAO!,M*3I:&KUW>XU-B[>:-P==1NFC8V:KTR
MC2R+';MBN)K:&X-7H7N&B0CR@KW;U7_3F)O0""DF\3?2O,=XQYW+(HQ;Q;P?
M.R;YK.CJ1%)2F@V7?%^OO]_7K,TY30D%I"M 9K6CS5+T2=*GIF]VXO8C$Y=A
M3527#<EFF HH^\!53L%IX*LRZPDAGG#1D(9T8P)8-"C/GZV2USKQE9U8FA@^
M>S2[M<I?+]62!DA)=&$U0Z"N%*K8DSRD!8\93JR:49*UMV;&;YO6097KA@!?
M=(6$8LG+.XH=97>3PN5^GR;^'[ZA2M3G8*22TKZY?>TBM);WK_7C2QT^/.)%
M4B[FKT%ONHLQK,-.A=L&A5 BN::PSEQ.T4E<EC(S0Z(UNN>TV)B[A%<56FYB
MY#7:>ESR78C[W)!M@?DP&CBC%FG^9I2Y&S5V9N5ZLPE=.Z+\C)IP<ADGKMYF
MR.%=4D#4:FW)7<_#^U/P+1R+7QOLG@"FO1#6R37J:U.CAF9O65-[\]3V?(.]
M@NW8<# F](0+Z$7E9WC;'@_)Q6G(=4.$=]B#B!4=GP##"?KKY*V(43T^/)2J
M/ 4I6MAFY<9--;AQVFXT)->L^/SN2A*>)HT!$D5WO9"3,4[B7N05H?[R<KE<
M$A,#*3CKY.:?=V F@/*.2L[\M4)_>M#$O,)W"17A%6$*>H<R9OU49Z*DS%:%
M4$;?NP\?_Y8>CM^^&5YGR!WE]->Q>C@GST:78/W,-57F]B#2C*3X\\X]\453
MMG8$E,$-;(4=-;ZW$-\$A.5>G:;/8^\PXFAA[HGK4X)9.+@;[+9!/D!=.4FT
MF7YC:WL^,CQ)WK AOE;-AE<\,%?V$J7!55! 3/8O9FDU=4\N6FF%1@P4G3>'
MGCQ>%>6^K)/_K&^Q(F!EVO?_]S*T_Q&L@JXQO .M0NE'=+?F,O?@&T>X@T]5
M>_-B0L(9&T,=L'<L: 18<^L*G $8TMQ6GXJOVL(GK\)7JIQ/: [#21A%I[8F
M5M3@.5=%C<=!E<7E[.2U.:WI7?=W1=> & =MVHD:%+M15**U?)%E$(^VB,T&
M0_SVV?U\+Q*=N23-4"ZZ[3IZI03+MI.D<.]W![OW%CTG(<F+)"\FEG$R(_/=
M3:=\T5^IF$S*]BD5#LS(LJX_67$?=3695OPB+0%]K-+F'1,DLK2-$[[,>(N"
M,I1D7]Y12UU7 ,N.#F J%64N5BK]#J?%Z!^?TB*6%E9*)-)_<_3?2.CX2!X#
M3:#M!A@_N@*X"&VZ70@P^0&DJR_Y*T*>MB\]+#4',0IZKU2K)NX47PDV(!=-
MFKU[8]IT +TU)L- ,(?2SRA"I'I6[@Z^;R.Y&271H&C]4%,(* 8[IPW()R:U
M]WZKB&WOO'9B=5!.R8RR?]?^N1Y.-\6?L:8QZ!]'_M*LELX26G!!$3#X:70I
MWDH2C"@MLZH-72O'1O\/^8N\4*2\_1C$8B7/+G_0=HIOVYI_G58SOLAW >;K
M.ZES#O/20:^"";ETPYJ/8.(Q] >:G3.*Y04W_>@(17\87LA\;T2;Q'<B5\9=
M4S1#%&Y\[?<B@U<DQ0R[&%C_"UN+!2FJHW(/+17*%_D9WA3*\H6YPO)8D;X%
MDA+L:DQNB\ZI/HXC&_<C/P+9_8\W7"9K #S[]GW(<XK9?^&B[@,AP609;U%L
MAH+KR^6*Z5^U<NJ=>CA_0'5Y+C7GKQDL7FNH?+Q<+E\TF3^_$EPHS!=J6B97
M_.>&Y*/]]6-K4V2'*:I'<^D;N<"CMO6_?DQ>^6LR'J;A,L@-F,:WCX(#SVA'
MYA+U)%S8%KO0O&_=LCRF.PHB2_C:>&<OGZUFR@_9.WOY[)'6$"Z/N]*=:355
M(9&?805&NH.=4Z6@J7H8<6@>",NN?-VT%@V1.6='G1Z'[H5U6K F4>%NIF\V
M%=H,F-;DHDP)U6W<;DP+5*9N 18W9DWW>:23@OL)QQF2]WC_6W*5-B5>FW.0
MI$9_6>JTT*>0J/8RE<X$]I+C<1,XT.5VV'-#4Z#BCAG>L@@M&DF!EZZ!/FX=
M$.ZZWA1Z%8 O:_'7SN(=/9/E3[[L4($:MXK["YK$25*"GV L?VR7(XFP42?>
M#>::R-W1+-39[!FV"K*W/:_,T]&5%G*/A3'<;FH\7GOIA5PW\' :#3A= V]0
M.C/5.8IQG![P\"X$?+3RD;5P'<^/Y/Y^$BDNYL(;<V3[ B#>9/O3DK!Y$@K3
MGBQ7D[T58T-OO[PK$_0O&RY>;Z@.>K)<V/.1C5A3S/VA 1,:R_L)*2?7_.>&
M3/@%O)XI!ZY+OMGD'_4-\P#D'<Q\W[ZZ?JTU/:^N?Z%?SLZ_QIQ@OH#FHV=[
M#YG]7SX_?_0B>7? !@C:PK66UPCS]<LW@%- 312(>VC&-K@D45KR_.W10*1+
M?N4K#LH'.FME7-^6*0J\< X;EN ?F'%35['6I+ZUYD)I?TT/?RP<?>/ ]/6-
M=Y:N$5^I1\+/J24;88S_2F'LYI3P)\^D,!4&Q=2&7$2A]W,.>E;(H>$Z*G<K
M7=$!1[_DFG..X\$;?$K2Z4[JR%#!!O5>2X'*D^_5#OMH_':6^>I4X1T:80Y0
M#=C*Y05G002=OZC(6\,:.KR3_&]@C@9#_4;NPM!O5DG4I$>0\^NG4\@9WIQ#
MRF\\4A;\;1N2$-!967&KJ=#FP^ I53@P+E,; O:!<CN>SNUJWZ=1DY#A4U5H
MQ%@S8/$U6!Y7M1,/F005=F\,]Q?:OB,<FS6#LX;Y&V!,FQ>9Q-T[;M+E?3X^
MQ8K<D09=. R*L(C74XGE-PV+(=6I*O:7D=ZS=?)#3$(V6@!Z)SJ_]#?&(+\8
M8".6 (X1^E,;MH@B8I+$U")_U:46MTJPBCJ#10W*0M4.&W!,ON'2*5V\I&O?
M7<YJ^]A9W!NP]:>S1//T[/R))YIKWS+*\_>SP37J_.:9M@5&RK%8.T5(.,68
MNQ_[34G.8H2C) '*#KA=O+)03IJIN'%9K&QCA&R2B^"-;'WGL=ATBT2%C">;
M@F=40205,X+6&$&FN[=\88VM2<8+R0!*62%_26S.D/+ ?[^2GJ>< *0+_+?3
MR==?+*&>?Y&$^I])#I/ZY6/* GZ3=NG+[PZNV;DKAQ<&DN;T_0/4XOQ3;&.)
MK9->O+I\\!B^#*^__.Z8[MS[M-EAD4KIMO#I^?KK9P\X*5G_Z.HC#HD]+;KZ
M0/_$YKJNP1?@]VT-6"E_X 2W=?.)EO?R_P%02P,$%     @ U3AM6II:P+=>
M!0  G T  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULC5?;;MLX$/V5
M@1L4+:#$NEB^I(D!)VFZ*9(B:+I=+!;[0$N4340B59**D_WZG2$MQ4D=PR^V
M1 Z'9V;.7'2R4OK>+#FW\%B5TISVEM;6Q_V^R9:\8N9(U5SB3J%TQ2R^ZD7?
MU)JSW!VJRGX<AL-^Q83L34_<VJV>GJC&ED+R6PVFJ2JFG\YXJ5:GO:C7+GP7
MBZ6EA?[TI&8+?L?MG_6MQK=^IR47%9=&* F:%Z>]671\-B)Y)_!3\)79> :R
M9*[4/;U<Y:>]D #QDF>6-##\>^#GO"Q)$<+XM=;9ZZZD@YO/K?9+9SO:,F>&
MGZOR+Y';Y6EOW(.<%ZPI[7>U^H.O[4E)7Z9*XWYAM98->Y UQJIJ?1@15$+Z
M?_:X]L,^!^+U@=CA]A<YE!?,LNF)5BO0)(W:Z,&9ZDXC."$I*'=6XZ[ <W9Z
MP_6":_CP@\U+;CZ>]"TJI:U^ME9PYA7$;RB(8KA1TBX-?)8YSU\JZ".:#E+<
M0CJ+=VJ\X-D1)%$ <1@/=NA+.A,3IR]Y0]]98W#%&#A7U5Q(1FP(8&8,4GZ6
M_6J$$7Z)R1R^*B$M_.32-IJ##SRQYY_9W%B-'/IWFXL\@,%V )17QZ9F&3_M
M8>(8KA]X;_K^730,/^TP;]"9-]BE?7J'>9HW)0=5P"43&GZRLG%OYPIS)^?:
M6; -]D[%VV'_6'*PRK(2"KKKH;W+XGJV>1\M'D3#\5&*M"U+EX&FE3PO%<9D
M 4A9#L*L2X+XC^<D5*@2:X6!#T*BM&H,!L9\/*9HK)C.Z1X7"@2"ATU#-U<5
M7H#9DMW# <3!*$IVB-]Q+;B!&=QB">!:X[5W[FB4ID$2CM=OJB9###"$DR'2
MG#2\-+)F(H<H# :# ?QP;GFY?P#H@F P3&%'I-,NTNG>D9YY3&M'DT]O&YTM
ML3ZA42*C(+G5S\:*RF%_YD87!I<#QB<!.8$2X%JPN2@Q(\A!Z*WJ=4Y[ZNQ$
M^C9U?&@I])8*#KA=B1@(#OO-IKJUJ=ZTB7<V/7.PLXEYF]BF3>6&3<S;]!89
M7W-N]E(=+="Y;^J!5W,LG%'BZE0"Y\PLW649/7 41US.M ,8!NDP(K(YNO!'
M[*B&H*"T0@0:"SV2$.O.&GP23E :&Z^V3TZ*U-78"FT $JM6'*7@VN>A*@X;
MLS;:[TUP[TH>UEIE5//(OPR=Z-3D_ &[L%/47A6E83 ,0_BB5+["/(7!.(B&
M"251. Q&^'2]Q7FS+-,-WVG*IL\I(],DA&M.L6QWGB">Q*_7O!'HX59/K;1C
MQ!!]?-%FJV6/&VJ203!."7(R#N+)&+YQ^QL-]DK$89>(P[T3\4I:)A>"R/PJ
MG;:ES4Z]^Z1-5RE]RF!+JYE\>O]N'$>C3P;$,YK7'G#$YM V_-<\?VZ$/A$N
MN,F8MMP<8CW$X0]NOJ 3)TDP0;;\MGEW_1E2Y ON^3(H]J?@04?"':$9=:$9
M[1T:3"'?P>$2V[[,!.*ZDD7;T[?%9[?REZ%H)&MR064(+06G%HKN(O%\$0VO
M-(6:KDNJ4N2N@*%O<'QT)872G?F&TQ8F'UPJ5:+8#-Z240K<<^P_);(%\(JO
M3#8X5(,?F^(C(*S[(\0>+)7%W*.((;_*)]S.!57CAZZ_;P?+G%E/.'TW98[0
M4'[.$9H#2=."9M*PS N['5X4Z U$I61;LEU5R;<5X+^1.WZT1-9EONBNA\,$
MOB.;)#9T+###( P'+O6QG!.I/L1)',3IY.,V5O4W)N:*G$K?!09CTTCKA^=N
MM?OTF/F)^UG<?[?<,+T0:%K)"SP:'HVP-6K_+>!?K*K=_#U7%J=Y][C$SR>N
M20#W"Z5L^T(7=!]DT_\!4$L#!!0    ( -4X;5K+7A&:L@0  /X+   9
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M(AB'K=%H^JA,#H:6T^=$5SW1K"5:$E%AB59$5#NB;)=HVA#5SU*2EP0N:TU
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M1+<6=/V@Z01#-BZW-K:6S3X;-QV%YFN-"^0W21[QCYP&@J*<P3/;TNX>UE7
MOMNJ]5PV:^K8%<<JEBKPEBVO?6<RB8[VXXR;(\G/(X[B8)M^_A5'3R$.8J<N
MTSOY"7"_IQ+^('KJ(U<'0=5!&ZL>.PL5-E5)TW,VJ!E8@Q(R:4[K2,2NV;U'
MC(-8J$X0-V!,6M\I!1/'FTV/NID)G6AV(#%UEN]*0Z/675@&ZL[>^%%QB"FL
MO!9K_C:7BN?E7=IV>'DC^9&K.X&;7@I+%'6'4SR(J/*6K_PP<FUOUA;2&)G9
MY@IX HH&8/]2X@*M/FB"YJIU_@]02P,$%     @ U3AM6FV!#I7U @  ;@8
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MAQZH;B!U!R,;-P16TM!(<=N29C@J:T#O"RG-_F #]'^%^1]02P,$%     @
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MD4D%:(H*5!(LERCW9;%L:!"X]FSZA'5A6:>6]08E E.0BX+N/PF-5V0A&D4
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M+W-H965T-#,N>&ULS5AM;]NV%OXK!UXV)( JZ_TE30(X:=?M0]>@:5=<#/O
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MJ>J1C8W4VAL01;> H]!/L0J:QDE")1>=^!LAF4;4;UC:KZ0SAE5+P=<NV6@
M \.K98?F-P3-$:BS?KT1W=U"PJ605B+A%]F0$6@0EHOO@53#% _J7I%YA'[/
MF0).W =D+F]ON7I@;TQVUEQ72MSB,,;F-VDXA)D'&QS!O[EL4"6Q_FS<9*\Q
M)/KD%/Y#H*]W@B8.^3UFC*EJ:8-8HWN-7%D/CR#VHC#'-HR\LDCA#>\PXHV=
MR&J4%$%TM\4?>W&6TKR\C.&#-#CKFV$]@LQ+BPC;*/7RO( #1$]'HJ?/)OHG
MJZNX^VR-9B\XS#0>("O'F(_Z:XEQ3#\(OYOI'S!W<R84K%G3VYTIF]9]Y.A
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MWM4/3<.AF@?5*%3SH5H U1A4XRA-;9(N#;?.E89;T#0<JKE0S8-J%*KY4"V
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MWZJ&:BY4\Z :A6H^5 N@&H-J'*6I'=+%X,ZY3FWN0/-NJ.9"-0^J4:CF0[4
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M PF1YSR#5-^)N$B(TJ<B=F0F@(1E4,(</!Q.G830=.#-RVN/PIOS7#&:PJ-
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M5F2$&1=,6(@)BY!@K;BXSK%P<(Q/R+T0.YK'0-B*B U50Y K5124A]==8:F
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M4C=I*,P!O3_G7&TFIF^HV[[H#U!+ P04    " #5.&U:6>_YB(D$  "_&
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M*M0I/W=J^#0CGLR.L(T:;*/__5"-?)+S:48\F1V12QIRB7/"W5*UJE;SU!Z
MX;>A' K=N4X[K<Y%Z-.,),^>[&24X.;!/D)SU:"Y<J)92%A3EB%X-+E,F9><
MQ23,VU":=[F4!A*BU;SK0N6T/A>53S.R,TM:J.)PTDUJW) :_X24B:Y2/U6$
M[!Q:FS"I7Z,"=!<;I]FY;'R:D?$S-A$>=;.9-&PF3C95^+X0RXO2!*YJOO1R
M<1J=R\6G&9D\XS+IXX+#0U@-G63>%1=K*5)0"MDA4!-*JPF4P<9\P513R/&
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MKH!F(&T'<WTIA-XW[)9T\S^+^7]02P,$%     @ U3AM6@8G]3N! P  Y!(
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M7+ZSZBH,=-@86?LA6DIC1](O2WL'HG()]OM*2K/;.('N5LU^ U!+ P04
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M0#ZH6+/UV)P(6M:[=\]4")K7APG!,6$J0-[?4BF&]D3]0+<!O/@?4$L#!!0
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MBG(F6NHW.8!F#0^E>8?0!H?2?#/MU_S^F",-S+2_;[,3XEHEK?],:\&$9DS
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M"SKHX_WI?@<]V9_NO:7;*NXV<Z_-W#-Z_O\S3XA(*=.Q"_3[?*J25!_"GZZ
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MOJX<L=UWW3847Q1;EP]<*9X5AW.@"0C305^?<:Y>&F8WM-K]GOP'4$L#!!0
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MA#:S1+7,S/2&TBJ8[VLA]%ZP!.T\./L)4$L#!!0    ( -4X;5I^*I7/L ,
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MME?0+@#WETK9W<0=T#7L_#=02P,$%     @ U3AM6N33K3D# P  \@@  !D
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MO4']@C=-H[S\GZSKMD:'3%<Y3^,Z6(P@#I/J+WVH=\16@#4X$&#5 =9N0/]
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M3,#OA1#ZM6-NANYBS_X 4$L#!!0    ( -4X;5J^/X!&HP(  !\&   9
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M8X-Q ;2_TAJ?)JXI#/^ _ ]02P,$%     @ U3AM6GQ!DRH"!    A0  !D
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M0K68TK3N\-O@WO\!1Z";Q^S:0Z@6H%J(:@+5)*I%J*;\YQ^_L ?N8.0Z&V^
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M!>7S]VE:;.ZL.GA.LZ_KQ;OY#U!+ P04    " #5.&U:9:II8&<#   B$P
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M1AZ:PX*LF;KFVR]0 AT;O80SF?]%V^+90>2A9"T53\MB/8.49L4ON2\7HE&
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MO+CHQXV\6P)3!G)]1:EX'*C;2WE;#?X#4$L#!!0    ( -4X;5K2AS0#(P0
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M5EDW ,*R=B,:M2]P^:52]BGP4Z ?^L5?4$L#!!0    ( -4X;5KE5W,1V ,
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M$-?1"DT/C#<F6ZDA5&_C6G+UEJ@\&:TEB^_1#8V!:C_1*L-4H'.T5O62[#)
M;(-,S/E"F96@)<M5!0EL]N#C@QX#>G<-$I-,O%>)W]?7Z-V;]^@-(A1]2]E.
M8)J(F2T56;VD'5?$%B4Q[QEBKH>^,BI3@3[2!)(V@*U4UE*]H]2%UXMX#?$%
M\MTSY#G>J(/0\K^G^SUT_-IYW^#YSSF?8@[G=\;5%?ZA/@V)KCC'= MZ?'9T
M-T'*0+3$!9$X(S\A.4-7.=NIZ+]^5Y#H1D(N_NXRN%Q_U+V^/A\N18%CF%OJ
M !# ]V!%;W]S0^=#ESD#@;6L&M56C?K0HV],24?"E&%I6-PL0RB-ZK*@Q T,
MKC[1]E$83+R9O6]*>QKD!>/QI(YJ<0YJSD$OY\^$WF\96A!FCF3TA64)H5MQ
MIC^V+JJ]<"_=K8' 6LK#6GGXRH4=#FG50& MJ\:U5>-?5-B]N"^UH 0+&Q^
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MO+8;TRAQAOWTWD0,^WRM6)3 1""YCF,J=K? ^';@8&=_XR%:+)6YX0[[*[J
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M\2R!_'V9)&)WDQ50?14Y_Q]02P,$%     @ U3AM6C<$>/(8 P  "PH  !D
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MJV*1*\9J)F8=Z[OR]8>GUO=.;%^3 %?E$[5_MK379^NS)A7=S>J=HMU<*MI
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M<TC,)3%OAXVW6'6RX/EN\.'J^6TZ'"ZA#55U,/AEN8#<K1#"6@-_O!_X8^G
M]]/5O,^XEVI]QSV)Z21FD)A)8A:)V23FD)A+8MX.FTC&_>$2P_'PYG#<D[L5
M0EAKW$_VXWXB'?>?IM-T4YT3R<14Q,_18R*ZAKL4Z3O<24PG,8/$3!*S2,PF
M,8?$7!+S)@>#^>9:.QC+_N%BXYOKP>&8)_<MA+#6F+_>C_EKZ9A_/4E0#OET
MOHK_M_/<XV>IT7?(DYA.8@:)F21FD9A-8@Z)N23F77>,Y='MX9@G-QJ06 AA
MK6"XV0?#C308[M,DB1[3;'<Z,5K-RO< 4['*JZC81D973DC)OCE!8CJ)&21F
MDIA%8C:).23FDIAW<WB<?Z-=CP^#XG!!;3(8C Z/#LC="R&L%0*W^Q"X/7%T
M4%4HXM5<68ML6[98387\@ZK/4K%O!I"83F(&B9DD9I&836(.B;DDYMV>/ M(
M;BX@L1#"6@&A#II.Q4 :$5;Z++)5U:50/N5YG!?;B+C?9%GUHX<B*K9%"^7+
MDV+&J_*7<90H7],\WAY7&#^*JDOUF C%6&V6HC[<"--"T>-\FJ2YF"EF$LV[
MDD:^9WVC!M5T5#-0S40U"]5L5'-0S44U[\2XDIZ#\]%="5 MI+1V(+TI>:GR
M0,JB,FXD;U+DZ_>.#5+34<U -1/5+%2S4<U!-1?5O%I[>Z@RZ?A4PJ^7DWS
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MTE6AK*.?QS[3D6^F=]R0FHYJ!JJ9J&:AFEUKK7=F@ZZ3+@ZZ71?5/%3S42U
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M(GZLQ;3HGEA0SO9.#K1WBFI&K;7N\:QJG1_&F^B6+52S4<U!-1?5/%3S42U
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M3&35 N7OG]*T>/VFVL!+FGW?/IR[_P-02P,$%     @ U3AM6N15D3/$ @
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M)+F(:R%UE(W#VMQF8[,B)37.+;A570O[,D-E-I.H'^T6[F59D5^(LW$C2GQ
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MM/X [R^-H5W@NZQ[([,_4$L#!!0    ( -4X;5IV?,_TFP(  !@&   :
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MSB]#VLE0F@?H_EI0/B\+YN"A.IF:?0502P,$%     @ U3AM6KI#I+7J @
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MR@;@\YF49CVP+ZC/5_%O4$L#!!0    ( -4X;5IJ(M9>V0(  $0&   :
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M!376=6;5$ZM*GQ,+92EU_#"GF$?M-M#[I5)V.W$-VC^.^!=02P,$%     @
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MNEO%/[M]FJO_'T2L625UP:VT87"3: _B>)L^3A3?UA?2)5?Z>EL/-Y3D5!B
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M@=V((Y@#\( A462>@SO/HV#SG J:?\2/_@)02P,$%     @ U3AM6I>*NQS
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MS^?OCI_/?U]^W.Q?K7>NAZ\QIIN_4$L#!!0    ( -4X;5I%#P3^B0(  -E
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M2P$"% ,4    " #5.&U:!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -4X;5H>LP,![@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M -4X;5J97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ U3AM6H78I?O6!P  HC   !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M -4X;5IO1+#=.P(  +T%   8              " @1D0  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " #5.&U:6HOY+/L'  !=*   &
M            @(&*$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ U3AM6O&)[LT1!   5Q0  !@              ("!NQH  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( -4X;5H"43SO* 8  .\9
M   8              " @0(?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " #5.&U:JX3E"E(5  "P/0$ &               @(%@)0
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ U3AM6IPBCB]=
M @  # 4  !@              ("!Z#H  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( -4X;5KE0?+$.PD  /DI   8              "
M@7L]  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #5.&U:
MJ,9&?XL.  !@)P  &               @('L1@  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ U3AM6N"#1.$7!P  ,Q$  !D
M     ("!K54  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -4X;5K:W%U"7 ,  &<'   9              "
M@5BJ  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ U3AM
M6GB#"J#& @  '08  !D              ("!ZZT  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " #5.&U:0YZ/MVP/   C.@  &0
M        @('HL   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( -4X;5J><CWC-P4  $\,   9              " @8O   !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ U3AM6N%XKRUQ$@  8$H
M !D              ("!^<4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " #5.&U:E,';Q>@.  "/+   &0              @(&AV
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( -4X;5H!$:$Z
MJ!   *(Y   9              " @<#G  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ U3AM6L>,#B2I'0  Q7L  !D
M ("!G_@  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #5
M.&U:=(%GX(P$  "D#   &0              @(%_%@$ >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -4X;5JEKLQ.;Q8  .Q.   9
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M970R."YX;6Q02P$"% ,4    " #5.&U:ENS]VKP$  !E"@  &0
M    @('73@$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M -4X;5KBP("_< (  +8%   9              " @<I3 0!X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ U3AM6O\Z"V!! @  G 4  !D
M             ("!<58! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " #5.&U:%%SW[;8$   1$P  &0              @('I6 $ >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( -4X;5H\I3,X$0(
M -T$   9              " @=9= 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ U3AM6JFR]^Z:"P  BD4  !D              ("!
M'F ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #5.&U:
M2816G0HQ  #RL@  &0              @('O:P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( -4X;5J:6L"W7@4  )P-   9
M      " @3"= 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ U3AM6LM>$9JR!   _@L  !D              ("!Q:(! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #5.&U:;KD8GB4&  !V%0
M&0              @(&NIP$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( -4X;5IM@0Z5]0(  &X&   9              " @0JN 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ U3AM6L7ZT]/3
M @  (08  !D              ("!-K$! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " #5.&U:\4$C9AT$  "C"@  &0
M@(% M $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -4X
M;5KT!RZ$Q ,  +@(   9              " @92X 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ U3AM6GY=C)6^!@  MA(  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( -4X;5I&"V1N.00  "4)   9
M  " @532 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
MU3AM6C85]-G3"@  KXL  !D              ("!Q-8! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " #5.&U:M+V$N#T"  #1!   &0
M            @('.X0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( -4X;5H'U\<T\ 0  #DA   9              " @4+D 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ U3AM6DFZ8*4A!
M\AD  !D              ("!:>D! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " #5.&U:?P6^0=T"   ""@  &0              @('!
M[0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( -4X;5I9
M[_F(B00  +\8   9              " @=7P 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ U3AM6@8G]3N! P  Y!(  !D
M     ("!E?4! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -4X;5H>;JSK7@D  *5E   9              "
M@>H* @!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ U3AM
M6NEF8!VZ @  +0@  !D              ("!?Q0" 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    " #5.&U:>@>RKH $   )'P  &0
M        @(%P%P( >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( -4X;5HHS=W?/@,  !L*   9              " @2<< @!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ U3AM6GXJE<^P P  G1,
M !D              ("!G!\" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    " #5.&U:,A+ROR\#   4"   &0              @(&#(P(
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( -4X;5I#/U6D
M&00  ),6   9              " @>DF @!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ U3AM6EV;<C!B @  O 4  !D
M ("!.2L" 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #5
M.&U:Y-.M.0,#  #R"   &0              @('2+0( >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( -4X;5I[N23GR0<  *!)   9
M          " @0PQ @!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#
M%     @ U3AM6B^W#9G\!P  CE   !D              ("!##D" 'AL+W=O
M<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " #5.&U:K>B>SLL"  !?
M"0  &0              @($_00( >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM
M;%!+ 0(4 Q0    ( -4X;5IB650=MP(  &8(   9              " @4%$
M @!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ U3AM6O.-
M8Q[> @  +@@  !D              ("!+T<" 'AL+W=O<FMS:&5E=',O<VAE
M970W,RYX;6Q02P$"% ,4    " #5.&U:2'A V,P"  #D!P  &0
M    @(%$2@( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M -4X;5J^/X!&HP(  !\&   9              " @4=- @!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ U3AM6@'!2D9D @  #P8  !D
M             ("!(5 " 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    " #5.&U:?$&3*@($   "%   &0              @(&\4@( >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( -4X;5I4KU0+IPP
M )6\   9              " @?56 @!X;"]W;W)K<VAE971S+W-H965T-S@N
M>&UL4$L! A0#%     @ U3AM6K^A09\K#@  (.P  !D              ("!
MTV," 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " #5.&U:
M9:II8&<#   B$P  &0              @($U<@( >&PO=V]R:W-H965T<R]S
M:&5E=#@P+GAM;%!+ 0(4 Q0    ( -4X;5I]I@^1;0(  (8%   9
M      " @=-U @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%
M  @ U3AM6E(>6,(_ @  B00  !D              ("!=W@" 'AL+W=O<FMS
M:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    " #5.&U:3,42T#<#  "Y#@
M&0              @('M>@( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+
M 0(4 Q0    ( -4X;5K2AS0#(P0  ,H3   9              " @5M^ @!X
M;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ U3AM6C3,#?%*
M @    8  !D              ("!M8(" 'AL+W=O<FMS:&5E=',O<VAE970X
M-2YX;6Q02P$"% ,4    " #5.&U:Y5=S$=@#  "9$P  &0
M@($VA0( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( -4X
M;5I*'0]A 0,  &4)   9              " @46) @!X;"]W;W)K<VAE971S
M+W-H965T.#<N>&UL4$L! A0#%     @ U3AM6BW@J^D@ P  &@D  !D
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M=#DR+GAM;%!+ 0(4 Q0    ( -4X;5JJINAXOQ   +[F   9
M  " @5ZB @!X;"]W;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @
MU3AM6K0Y@C^- P  TPX  !D              ("!5+," 'AL+W=O<FMS:&5E
M=',O<VAE970Y-"YX;6Q02P$"% ,4    " #5.&U:#&#_;Y@$  !%%@  &0
M            @($8MP( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4
M Q0    ( -4X;5JP/F7:Q 8  "$I   9              " @>>[ @!X;"]W
M;W)K<VAE971S+W-H965T.38N>&UL4$L! A0#%     @ U3AM6C<$>/(8 P
M"PH  !D              ("!XL(" 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX
M;6Q02P$"% ,4    " #5.&U:IMZ,+RT3  !Y)0$ &0              @($Q
MQ@( >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    ( -4X;5KD
M59$SQ (  &D(   9              " @979 @!X;"]W;W)K<VAE971S+W-H
M965T.3DN>&UL4$L! A0#%     @ U3AM6O23P7[F!0  43$  !H
M     ("!D-P" 'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&UL4$L! A0#%
M  @ U3AM6I-$*GZ?!0  2"H  !H              ("!KN(" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#$N>&UL4$L! A0#%     @ U3AM6H8QKU$W @  +P4
M !H              ("!A>@" 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL
M4$L! A0#%     @ U3AM6G9\S_2; @  & 8  !H              ("!].H"
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N>&UL4$L! A0#%     @ U3AM6M#,
MSY+* P  6Q   !H              ("!Q^T" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#0N>&UL4$L! A0#%     @ U3AM6O/'$O-G @  G04  !H
M     ("!R?$" 'AL+W=O<FMS:&5E=',O<VAE970Q,#4N>&UL4$L! A0#%
M  @ U3AM6F>_\##E P  I1(  !H              ("!:/0" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#8N>&UL4$L! A0#%     @ U3AM6KI#I+7J @  :PD
M !H              ("!A?@" 'AL+W=O<FMS:&5E=',O<VAE970Q,#<N>&UL
M4$L! A0#%     @ U3AM6FHBUE[9 @  1 8  !H              ("!I_L"
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#@N>&UL4$L! A0#%     @ U3AM6JNU
MC?1O!   0!8  !H              ("!N/X" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#DN>&UL4$L! A0#%     @ U3AM6B-AZ *H P  U@L  !H
M     ("!7P,# 'AL+W=O<FMS:&5E=',O<VAE970Q,3 N>&UL4$L! A0#%
M  @ U3AM6F.8M>6(!   WQ   !H              ("!/P<# 'AL+W=O<FMS
M:&5E=',O<VAE970Q,3$N>&UL4$L! A0#%     @ U3AM6@G@86:W P  *1
M !H              ("!_PL# 'AL+W=O<FMS:&5E=',O<VAE970Q,3(N>&UL
M4$L! A0#%     @ U3AM6I?>S!.V P  -A,  !H              ("![@\#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,3,N>&UL4$L! A0#%     @ U3AM6JN2
M'E?% @  G <  !H              ("!W!,# 'AL+W=O<FMS:&5E=',O<VAE
M970Q,30N>&UL4$L! A0#%     @ U3AM6F[->#Q"!0  KQH  !H
M     ("!V18# 'AL+W=O<FMS:&5E=',O<VAE970Q,34N>&UL4$L! A0#%
M  @ U3AM6M@*'S]J P  E1<   T              ( !4QP# 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #5.&U:EXJ[',     3 @  "P
M@ 'H'P, 7W)E;',O+G)E;'-02P$"% ,4    " #5.&U:\<=:R4\(   22P
M#P              @ '1( , >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MU3AM6C"4&E<S P  @D,  !H              ( !32D# 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ U3AM6D4/!/Z) @  V4   !,
M             ( !N"P# %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     'L
,>P#D(0  <B\#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>354</ContextCount>
  <ElementCount>566</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>111</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders??? Equity (Deficit) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals</Role>
      <ShortName>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders??? Equity (Deficit) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/Merger</Role>
      <ShortName>Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Net Loss Per Share Allocable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholders</Role>
      <ShortName>Net Loss Per Share Allocable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Stock Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/StockIncentivePlans</Role>
      <ShortName>Stock Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Revenue Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RevenueArrangements</Role>
      <ShortName>Revenue Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Merger (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/MergerTables</Role>
      <ShortName>Merger (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/Merger</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Net Loss Per Share Allocable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Allocable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholders</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/PropertyandEquipment</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/AccruedExpenses</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/Equity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Stock Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/StockIncentivePlansTables</Role>
      <ShortName>Stock Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/StockIncentivePlans</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Revenue Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RevenueArrangementsTables</Role>
      <ShortName>Revenue Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/RevenueArrangements</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/Restructuring</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/SegmentReporting</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Description of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails</Role>
      <ShortName>Description of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/DescriptionoftheBusiness</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/BasisofPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/BasisofPresentation</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Merger - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails</Role>
      <ShortName>Merger - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Merger - Schedule of Fair Value of Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails</Role>
      <ShortName>Merger - Schedule of Fair Value of Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Merger - Schedule of Allocation of the Purchase Price to the Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Merger - Schedule of Allocation of the Purchase Price to the Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Merger - Schedule of Intangible Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails</Role>
      <ShortName>Merger - Schedule of Intangible Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Merger - Schedule of Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/MergerScheduleofProFormaFinancialInformationDetails</Role>
      <ShortName>Merger - Schedule of Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Net Loss Per Share Allocable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Allocable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Net Loss Per Share Allocable to Common Stockholders - Schedule of Potential Dilutive Shares of Common Stock Excluded from the Computation of the Diluted Net Loss Per Share Allocable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Allocable to Common Stockholders - Schedule of Potential Dilutive Shares of Common Stock Excluded from the Computation of the Diluted Net Loss Per Share Allocable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Fair Value Measurements - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for Warrants Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for Warrants Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Company???s Level 3 Warrant Liabilities and CVR Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Company???s Level 3 Warrant Liabilities and CVR Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for CVR Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for CVR Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Forward Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Forward Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/AccruedExpensesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Leases - 7495 New Horizon Way Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails</Role>
      <ShortName>Leases - 7495 New Horizon Way Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Leases - 65 Grove Street Lease (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails</Role>
      <ShortName>Leases - 65 Grove Street Lease (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Leases - 704 Quince Orchard Road Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails</Role>
      <ShortName>Leases - 704 Quince Orchard Road Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Leases - Moscow, Russia Lease (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails</Role>
      <ShortName>Leases - Moscow, Russia Lease (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Leases - Schedule of Components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturity of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Leases - Schedule of Supplemental Disclosure for the Statement of Cash Flows Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/LeasesScheduleofSupplementalDisclosurefortheStatementofCashFlowsRelatedtoOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Disclosure for the Statement of Cash Flows Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Leases - Schedule of Additional Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Additional Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/Debt</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Convertible Preferred Stock - Series B Preferred Stock (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock - Series B Preferred Stock (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Convertible Preferred Stock - Series A Preferred Stock (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock - Series A Preferred Stock (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Convertible Preferred Stock - Conversion (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock - Conversion (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Convertible Preferred Stock - Redemption (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockRedemptionNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock - Redemption (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Convertible Preferred Stock - Voting (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockVotingNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock - Voting (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Convertible Preferred Stock - Liquidation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock - Liquidation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Equity - 2024 Private Placement (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails</Role>
      <ShortName>Equity - 2024 Private Placement (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Equity - Merger (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails</Role>
      <ShortName>Equity - Merger (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Equity - Underwritten Offering (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails</Role>
      <ShortName>Equity - Underwritten Offering (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Equity - ???At-the-Market??? Offerings (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails</Role>
      <ShortName>Equity - ???At-the-Market??? Offerings (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Equity - June 2020 Sobi Stock Purchase (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails</Role>
      <ShortName>Equity - June 2020 Sobi Stock Purchase (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Equity - December 2019 Financing (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails</Role>
      <ShortName>Equity - December 2019 Financing (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Equity - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails</Role>
      <ShortName>Equity - Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Equity - Common Stock (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails</Role>
      <ShortName>Equity - Common Stock (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails</Role>
      <ShortName>Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Stock Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails</Role>
      <ShortName>Stock Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Stock Incentive Plans - Schedule of Weighted Average Assumptions Used (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails</Role>
      <ShortName>Stock Incentive Plans - Schedule of Weighted Average Assumptions Used (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Stock Incentive Plans - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stock Incentive Plans - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Stock Incentive Plans - Schedule of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock Incentive Plans - Schedule of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Revenue Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails</Role>
      <ShortName>Revenue Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails</Role>
      <ShortName>Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Related-party Transactions - Schedule of Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails</Role>
      <ShortName>Related-party Transactions - Schedule of Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Related-Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related-Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Collaboration and License Agreements - Biogen M.A., Inc. (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails</Role>
      <ShortName>Collaboration and License Agreements - Biogen M.A., Inc. (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955579 - Disclosure - Collaboration and License Agreements - National Cancer Institute of the National Institutes of Health (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails</Role>
      <ShortName>Collaboration and License Agreements - National Cancer Institute of the National Institutes of Health (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Collaboration and License Agreements - Ginkgo Bioworks Holdings, Inc. (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails</Role>
      <ShortName>Collaboration and License Agreements - Ginkgo Bioworks Holdings, Inc. (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Collaboration and License Agreements - Genovis AB (publ.) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails</Role>
      <ShortName>Collaboration and License Agreements - Genovis AB (publ.) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Collaboration and License Agreements - Cyrus Biotechnology, Inc. (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails</Role>
      <ShortName>Collaboration and License Agreements - Cyrus Biotechnology, Inc. (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Collaboration and License Agreements - Asklepios Biopharmaceutical, Inc. (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails</Role>
      <ShortName>Collaboration and License Agreements - Asklepios Biopharmaceutical, Inc. (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9955584 - Disclosure - Collaboration and License Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails</Role>
      <ShortName>Collaboration and License Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9955585 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9955586 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9955587 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9955588 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9955589 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9955590 - Disclosure - Restructuring - Schedule of Change in Accrued Restructuring Balance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails</Role>
      <ShortName>Restructuring - Schedule of Change in Accrued Restructuring Balance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="rnac-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9955591 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cartesiantherapeutics.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cartesiantherapeutics.com/role/SegmentReportingTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="rnac-20241231.htm">rnac-20241231.htm</File>
    <File>rnac-20241231.xsd</File>
    <File>rnac-20241231_cal.xml</File>
    <File>rnac-20241231_def.xml</File>
    <File>rnac-20241231_lab.xml</File>
    <File>rnac-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rnac-20241231_g1.jpg</File>
    <File>rnac-20241231_g2.jpg</File>
    <File>rnac-20241231_g3.jpg</File>
    <File>rnac-20241231_g4.jpg</File>
    <File>rnac-20241231_g5.jpg</File>
    <File>rnac-20241231_g6.jpg</File>
    <File>rnac-20241231_g7.jpg</File>
    <File>rnac-20241231_g8.jpg</File>
    <File>rnac-20241231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="971">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>151
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rnac-20241231.htm": {
   "nsprefix": "rnac",
   "nsuri": "http://www.cartesiantherapeutics.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "rnac-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "rnac-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "rnac-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rnac-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rnac-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rnac-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 423,
   "keyCustom": 143,
   "axisStandard": 32,
   "axisCustom": 1,
   "memberStandard": 39,
   "memberCustom": 60,
   "hidden": {
    "total": 17,
    "http://fasb.org/us-gaap/2024": 12,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "contextCount": 354,
   "entityCount": 1,
   "segmentCount": 111,
   "elementCount": 941,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 971,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 12
   },
   "report": {
    "R1": {
     "role": "http://www.cartesiantherapeutics.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cartesiantherapeutics.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
     "longName": "9952154 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals",
     "longName": "9952155 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (Parentheticals)",
     "shortName": "Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-39",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-39",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusiness",
     "longName": "9952157 - Disclosure - Description of the Business",
     "shortName": "Description of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cartesiantherapeutics.com/role/BasisofPresentation",
     "longName": "9952158 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952159 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cartesiantherapeutics.com/role/Merger",
     "longName": "9952160 - Disclosure - Merger",
     "shortName": "Merger",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholders",
     "longName": "9952161 - Disclosure - Net Loss Per Share Allocable to Common Stockholders",
     "shortName": "Net Loss Per Share Allocable to Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cartesiantherapeutics.com/role/FairValueMeasurements",
     "longName": "9952162 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cartesiantherapeutics.com/role/PropertyandEquipment",
     "longName": "9952163 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cartesiantherapeutics.com/role/AccruedExpenses",
     "longName": "9952164 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cartesiantherapeutics.com/role/Leases",
     "longName": "9952165 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cartesiantherapeutics.com/role/Debt",
     "longName": "9952166 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStock",
     "longName": "9952167 - Disclosure - Convertible Preferred Stock",
     "shortName": "Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rnac:TemporaryEquityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rnac:TemporaryEquityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cartesiantherapeutics.com/role/Equity",
     "longName": "9952168 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cartesiantherapeutics.com/role/StockIncentivePlans",
     "longName": "9952169 - Disclosure - Stock Incentive Plans",
     "shortName": "Stock Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cartesiantherapeutics.com/role/RevenueArrangements",
     "longName": "9952170 - Disclosure - Revenue Arrangements",
     "shortName": "Revenue Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactions",
     "longName": "9952171 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreements",
     "longName": "9952172 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rnac:CollaborationAndLicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rnac:CollaborationAndLicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cartesiantherapeutics.com/role/IncomeTaxes",
     "longName": "9952173 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlans",
     "longName": "9952174 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cartesiantherapeutics.com/role/CommitmentsandContingencies",
     "longName": "9952175 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cartesiantherapeutics.com/role/Restructuring",
     "longName": "9952176 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cartesiantherapeutics.com/role/SegmentReporting",
     "longName": "9952177 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.cartesiantherapeutics.com/role/SubsequentEvents",
     "longName": "9952178 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.cartesiantherapeutics.com/role/MergerTables",
     "longName": "9955512 - Disclosure - Merger (Tables)",
     "shortName": "Merger (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersTables",
     "longName": "9955513 - Disclosure - Net Loss Per Share Allocable to Common Stockholders (Tables)",
     "shortName": "Net Loss Per Share Allocable to Common Stockholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsTables",
     "longName": "9955514 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentTables",
     "longName": "9955515 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cartesiantherapeutics.com/role/AccruedExpensesTables",
     "longName": "9955516 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cartesiantherapeutics.com/role/LeasesTables",
     "longName": "9955517 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cartesiantherapeutics.com/role/EquityTables",
     "longName": "9955518 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cartesiantherapeutics.com/role/StockIncentivePlansTables",
     "longName": "9955519 - Disclosure - Stock Incentive Plans (Tables)",
     "shortName": "Stock Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.cartesiantherapeutics.com/role/RevenueArrangementsTables",
     "longName": "9955520 - Disclosure - Revenue Arrangements (Tables)",
     "shortName": "Revenue Arrangements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsTables",
     "longName": "9955521 - Disclosure - Related-Party Transactions (Tables)",
     "shortName": "Related-Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.cartesiantherapeutics.com/role/IncomeTaxesTables",
     "longName": "9955522 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.cartesiantherapeutics.com/role/RestructuringTables",
     "longName": "9955523 - Disclosure - Restructuring (Tables)",
     "shortName": "Restructuring (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.cartesiantherapeutics.com/role/SegmentReportingTables",
     "longName": "9955524 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
     "longName": "9955525 - Disclosure - Description of the Business (Details)",
     "shortName": "Description of the Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-54",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.cartesiantherapeutics.com/role/BasisofPresentationDetails",
     "longName": "9955526 - Disclosure - Basis of Presentation (Details)",
     "shortName": "Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9955527 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
     "longName": "9955528 - Disclosure - Merger - Narrative (Details)",
     "shortName": "Merger - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails",
     "longName": "9955529 - Disclosure - Merger - Schedule of Fair Value of Consideration (Details)",
     "shortName": "Merger - Schedule of Fair Value of Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails",
     "longName": "9955530 - Disclosure - Merger - Schedule of Allocation of the Purchase Price to the Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "Merger - Schedule of Allocation of the Purchase Price to the Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails",
     "longName": "9955531 - Disclosure - Merger - Schedule of Intangible Assets Acquired (Details)",
     "shortName": "Merger - Schedule of Intangible Assets Acquired (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.cartesiantherapeutics.com/role/MergerScheduleofProFormaFinancialInformationDetails",
     "longName": "9955532 - Disclosure - Merger - Schedule of Pro Forma Financial Information (Details)",
     "shortName": "Merger - Schedule of Pro Forma Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails",
     "longName": "9955533 - Disclosure - Net Loss Per Share Allocable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share Allocable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DistributedEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails",
     "longName": "9955534 - Disclosure - Net Loss Per Share Allocable to Common Stockholders - Schedule of Potential Dilutive Shares of Common Stock Excluded from the Computation of the Diluted Net Loss Per Share Allocable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share Allocable to Common Stockholders - Schedule of Potential Dilutive Shares of Common Stock Excluded from the Computation of the Diluted Net Loss Per Share Allocable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9955535 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-94",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9955536 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9955537 - Disclosure - Fair Value Measurements - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "shortName": "Fair Value Measurements - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails",
     "longName": "9955538 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for Warrants Liability (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for Warrants Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-107",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-107",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails",
     "longName": "9955539 - Disclosure - Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Company\u2019s Level 3 Warrant Liabilities and CVR Liability (Details)",
     "shortName": "Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Company\u2019s Level 3 Warrant Liabilities and CVR Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails",
     "longName": "9955540 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for CVR Liability (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques for CVR Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-128",
      "name": "rnac:ContingentValueRightLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-128",
      "name": "rnac:ContingentValueRightLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails",
     "longName": "9955541 - Disclosure - Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Forward Contract Liabilities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Roll-Forward of Fair Value for the Forward Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "longName": "9955542 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentNarrativeDetails",
     "longName": "9955543 - Disclosure - Property and Equipment - Narrative (Details)",
     "shortName": "Property and Equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails",
     "longName": "9955544 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
     "longName": "9955545 - Disclosure - Leases - 7495 New Horizon Way Leases (Narrative) (Details)",
     "shortName": "Leases - 7495 New Horizon Way Leases (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OperatingLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-154",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
     "longName": "9955546 - Disclosure - Leases - 65 Grove Street Lease (Narrative) (Details)",
     "shortName": "Leases - 65 Grove Street Lease (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails",
     "longName": "9955547 - Disclosure - Leases - 704 Quince Orchard Road Leases (Narrative) (Details)",
     "shortName": "Leases - 704 Quince Orchard Road Leases (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "rnac:NumberOfAcquiredOperatingLeases",
      "unitRef": "operating_lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails",
     "longName": "9955548 - Disclosure - Leases - Moscow, Russia Lease (Narrative) (Details)",
     "shortName": "Leases - Moscow, Russia Lease (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-173",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails",
     "longName": "9955549 - Disclosure - Leases - Schedule of Components of Lease Costs (Details)",
     "shortName": "Leases - Schedule of Components of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails",
     "longName": "9955550 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturity of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.cartesiantherapeutics.com/role/LeasesScheduleofSupplementalDisclosurefortheStatementofCashFlowsRelatedtoOperatingLeasesDetails",
     "longName": "9955551 - Disclosure - Leases - Schedule of Supplemental Disclosure for the Statement of Cash Flows Related to Operating Leases (Details)",
     "shortName": "Leases - Schedule of Supplemental Disclosure for the Statement of Cash Flows Related to Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.cartesiantherapeutics.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails",
     "longName": "9955552 - Disclosure - Leases - Schedule of Additional Information Related to Operating Leases (Details)",
     "shortName": "Leases - Schedule of Additional Information Related to Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.cartesiantherapeutics.com/role/DebtDetails",
     "longName": "9955553 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
     "longName": "9955554 - Disclosure - Convertible Preferred Stock - Series B Preferred Stock (Narrative) (Details)",
     "shortName": "Convertible Preferred Stock - Series B Preferred Stock (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-180",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
     "longName": "9955555 - Disclosure - Convertible Preferred Stock - Series A Preferred Stock (Narrative) (Details)",
     "shortName": "Convertible Preferred Stock - Series A Preferred Stock (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-54",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
     "longName": "9955556 - Disclosure - Convertible Preferred Stock - Conversion (Narrative) (Details)",
     "shortName": "Convertible Preferred Stock - Conversion (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:PreferredStockConvertibleConversionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:PreferredStockConvertibleConversionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockRedemptionNarrativeDetails",
     "longName": "9955557 - Disclosure - Convertible Preferred Stock - Redemption (Narrative) (Details)",
     "shortName": "Convertible Preferred Stock - Redemption (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rnac:PreferredStockRedemptionTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rnac:PreferredStockRedemptionTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockVotingNarrativeDetails",
     "longName": "9955558 - Disclosure - Convertible Preferred Stock - Voting (Narrative) (Details)",
     "shortName": "Convertible Preferred Stock - Voting (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "rnac:PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "rnac:PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails",
     "longName": "9955559 - Disclosure - Convertible Preferred Stock - Liquidation (Narrative) (Details)",
     "shortName": "Convertible Preferred Stock - Liquidation (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:PreferredStockConvertibleSharesIssuable",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockConvertibleSharesIssuable",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
     "longName": "9955560 - Disclosure - Equity - 2024 Private Placement (Narrative) (Details)",
     "shortName": "Equity - 2024 Private Placement (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-207",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails",
     "longName": "9955561 - Disclosure - Equity - Merger (Narrative) (Details)",
     "shortName": "Equity - Merger (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-208",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R86": {
     "role": "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails",
     "longName": "9955562 - Disclosure - Equity - Underwritten Offering (Narrative) (Details)",
     "shortName": "Equity - Underwritten Offering (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-209",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails",
     "longName": "9955563 - Disclosure - Equity - \u201cAt-the-Market\u201d Offerings (Narrative) (Details)",
     "shortName": "Equity - \u201cAt-the-Market\u201d Offerings (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-211",
      "name": "rnac:SaleOfStockAggregateMaximumGrossSalesProceeds",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-211",
      "name": "rnac:SaleOfStockAggregateMaximumGrossSalesProceeds",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails",
     "longName": "9955564 - Disclosure - Equity - June 2020 Sobi Stock Purchase (Narrative) (Details)",
     "shortName": "Equity - June 2020 Sobi Stock Purchase (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
     "longName": "9955565 - Disclosure - Equity - December 2019 Financing (Narrative) (Details)",
     "shortName": "Equity - December 2019 Financing (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-223",
      "name": "rnac:WarrantIssued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails",
     "longName": "9955566 - Disclosure - Equity - Schedule of Warrant Activity (Details)",
     "shortName": "Equity - Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rnac:StockIssuedDuringPeriodSharesWarrantsCanceled",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails",
     "longName": "9955567 - Disclosure - Equity - Common Stock (Narrative) (Details)",
     "shortName": "Equity - Common Stock (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "rnac:CommonStockVotingRightsNumberOfVotes",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
     "longName": "9955568 - Disclosure - Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)",
     "shortName": "Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-234",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
     "longName": "9955569 - Disclosure - Stock Incentive Plans - Narrative (Details)",
     "shortName": "Stock Incentive Plans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9955570 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-260",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails",
     "longName": "9955571 - Disclosure - Stock Incentive Plans - Schedule of Weighted Average Assumptions Used (Details)",
     "shortName": "Stock Incentive Plans - Schedule of Weighted Average Assumptions Used (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-265",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-265",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails",
     "longName": "9955572 - Disclosure - Stock Incentive Plans - Schedule of Stock Option Activity (Details)",
     "shortName": "Stock Incentive Plans - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-271",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails",
     "longName": "9955573 - Disclosure - Stock Incentive Plans - Schedule of Restricted Stock Units Activity (Details)",
     "shortName": "Stock Incentive Plans - Schedule of Restricted Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-278",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-278",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails",
     "longName": "9955574 - Disclosure - Revenue Arrangements - Narrative (Details)",
     "shortName": "Revenue Arrangements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails",
     "longName": "9955575 - Disclosure - Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)",
     "shortName": "Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "rnac:ContractwithCustomerLiabilityDeferredRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "rnac:ContractwithCustomerLiabilityDeferredRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails",
     "longName": "9955576 - Disclosure - Related-party Transactions - Schedule of Related Party Transactions (Details)",
     "shortName": "Related-party Transactions - Schedule of Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-182",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-315",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails",
     "longName": "9955577 - Disclosure - Related-Party Transactions - Narrative (Details)",
     "shortName": "Related-Party Transactions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-321",
      "name": "rnac:IssuanceOfContingentValueRightForExerciseOfWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails",
     "longName": "9955578 - Disclosure - Collaboration and License Agreements - Biogen M.A., Inc. (Narrative) (Details)",
     "shortName": "Collaboration and License Agreements - Biogen M.A., Inc. (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-322",
      "name": "rnac:CollaborativeArrangementWrittenNoticePeriodForTermination",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-322",
      "name": "rnac:CollaborativeArrangementWrittenNoticePeriodForTermination",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails",
     "longName": "9955579 - Disclosure - Collaboration and License Agreements - National Cancer Institute of the National Institutes of Health (Narrative) (Details)",
     "shortName": "Collaboration and License Agreements - National Cancer Institute of the National Institutes of Health (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-323",
      "name": "rnac:LicenseAndOptionAgreementRoyaltyPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-323",
      "name": "rnac:LicenseAndOptionAgreementRoyaltyPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails",
     "longName": "9955580 - Disclosure - Collaboration and License Agreements - Ginkgo Bioworks Holdings, Inc. (Narrative) (Details)",
     "shortName": "Collaboration and License Agreements - Ginkgo Bioworks Holdings, Inc. (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-325",
      "name": "rnac:LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-325",
      "name": "rnac:LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails",
     "longName": "9955581 - Disclosure - Collaboration and License Agreements - Genovis AB (publ.) (Narrative) (Details)",
     "shortName": "Collaboration and License Agreements - Genovis AB (publ.) (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-330",
      "name": "rnac:LicenseAndOptionAgreementMilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-330",
      "name": "rnac:LicenseAndOptionAgreementMilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails",
     "longName": "9955582 - Disclosure - Collaboration and License Agreements - Cyrus Biotechnology, Inc. (Narrative) (Details)",
     "shortName": "Collaboration and License Agreements - Cyrus Biotechnology, Inc. (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-331",
      "name": "rnac:LicenseAndOptionAgreementMilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails",
     "longName": "9955583 - Disclosure - Collaboration and License Agreements - Asklepios Biopharmaceutical, Inc. (Narrative) (Details)",
     "shortName": "Collaboration and License Agreements - Asklepios Biopharmaceutical, Inc. (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-335",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails",
     "longName": "9955584 - Disclosure - Collaboration and License Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)",
     "shortName": "Collaboration and License Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-337",
      "name": "rnac:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-337",
      "name": "rnac:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955585 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9955586 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955587 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails",
     "longName": "9955588 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rnac:DefinedContributionPlanEmployersMatchingContributionVestingPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rnac:DefinedContributionPlanEmployersMatchingContributionVestingPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails",
     "longName": "9955589 - Disclosure - Restructuring - Narrative (Details)",
     "shortName": "Restructuring - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-346",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-346",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.cartesiantherapeutics.com/role/RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails",
     "longName": "9955590 - Disclosure - Restructuring - Schedule of Change in Accrued Restructuring Balance (Details)",
     "shortName": "Restructuring - Schedule of Change in Accrued Restructuring Balance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails",
     "longName": "9955591 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-347",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rnac-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "rnac_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan",
        "label": "2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan [Member]",
        "documentation": "2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_A2019WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "A2019WarrantsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Warrants",
        "label": "2019 Warrants [Member]",
        "documentation": "2019 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_A2020TermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "A2020TermLoansMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Term Loans",
        "label": "2020 Term Loans [Member]",
        "documentation": "2020 Term Loans"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_A2022OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "A2022OfferingMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Offering",
        "label": "2022 Offering [Member]",
        "documentation": "2022 Offering"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_A2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "A2022WarrantsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Warrants",
        "label": "2022 Warrants [Member]",
        "documentation": "2022 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_A65GroveStreetWatertownMAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "A65GroveStreetWatertownMAMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "65 Grove Street, Watertown,MA",
        "label": "65 Grove Street, Watertown, MA [Member]",
        "documentation": "65 Grove Street, Watertown, MA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_A704QuinceOrchardRoadLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "A704QuinceOrchardRoadLeasesMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "704 Quince Orchard Road Leases",
        "label": "704 Quince Orchard Road Leases [Member]",
        "documentation": "704 Quince Orchard Road Leases"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_A7495NewHorizonWayLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "A7495NewHorizonWayLeaseMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "7495 New Horizon Way Lease",
        "label": "7495 New Horizon Way Lease [Member]",
        "documentation": "7495 New Horizon Way Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Billing Status, Type [Axis]",
        "label": "Billing Status, Type [Axis]",
        "documentation": "Information by billing status of receivables."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r109"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r930"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "rnac_AccruedAuditFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AccruedAuditFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional and consulting services",
        "label": "Accrued Audit Fees, Current",
        "documentation": "Accrued Audit Fees, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "rnac_AccruedPatentFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AccruedPatentFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued patent fees",
        "label": "Accrued Patent Fees Current",
        "documentation": "Carrying value as of the balance sheet date of patent fees."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_AccruedPropertyPlantAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AccruedPropertyPlantAndEquipmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Accrued Property, Plant And Equipment, Current",
        "documentation": "Accrued Property, Plant And Equipment, Current"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued external research and development costs",
        "label": "Accrued Research And Development Costs Current",
        "documentation": "Carrying value as of the balance sheet date of research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r190",
      "r735"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r110",
      "r197",
      "r730",
      "r764",
      "r765"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r17",
      "r27",
      "r596",
      "r599",
      "r668",
      "r760",
      "r761",
      "r1077",
      "r1078",
      "r1079",
      "r1092",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r930",
      "r1228"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1165",
      "r1229"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "rnac_AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Distribution of contingent value rights",
        "label": "Adjustments To Additional Paid In Capital, Distribution Of Contingent Value Rights",
        "documentation": "Adjustments To Additional Paid In Capital, Distribution Of Contingent Value Rights"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock forward in connection with the Merger",
        "label": "Adjustments To Additional Paid In Capital, Issuance Of Common Stock Forward In Connection With The Merger",
        "documentation": "Adjustments To Additional Paid In Capital, Issuance Of Common Stock Forward In Connection With The Merger"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of replacement options in Merger",
        "label": "Adjustments To Additional Paid In Capital, Issuance Of Replacement Options In Merger",
        "documentation": "Adjustments To Additional Paid In Capital, Issuance Of Replacement Options In Merger"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement of outstanding equity awards at Merger",
        "terseLabel": "Adjustments to additional paid in capital, settlement of outstanding equity awards at merger",
        "label": "Adjustments To Additional Paid In Capital, Settlement Of Outstanding Equity Awards",
        "documentation": "Adjustments To Additional Paid In Capital, Settlement Of Outstanding Equity Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r492"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r138"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount for future payments upon achievement of clinical and regulatory approval milestones for products containing ImmTOR platform",
        "label": "Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform",
        "documentation": "Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount of upfront and milestone-based payments",
        "label": "Aggregate Amount Of Upfront And Milestone Based Payments Paid",
        "documentation": "Aggregate Amount Of Upfront And Milestone Based Payments Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r977",
      "r987",
      "r1020"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r980",
      "r990",
      "r1023"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r981",
      "r991",
      "r1015",
      "r1024",
      "r1028",
      "r1036"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock\u2011based compensation expense",
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r534"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Potential common shares",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of office space leased",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "rnac_AskBioLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AskBioLicenseMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AskBio License",
        "label": "AskBio License [Member]",
        "documentation": "AskBio License [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      },
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of long-lived assets",
        "totalLabel": "Asset impairment charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r44"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r166",
      "r193",
      "r225",
      "r266",
      "r275",
      "r300",
      "r304",
      "r345",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r591",
      "r593",
      "r629",
      "r722",
      "r814",
      "r884",
      "r885",
      "r930",
      "r944",
      "r1125",
      "r1126",
      "r1185"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r198",
      "r225",
      "r345",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r591",
      "r593",
      "r629",
      "r930",
      "r1125",
      "r1126",
      "r1185"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r917"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_AstellasGeneTherapiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AstellasGeneTherapiesMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Astellas Gene Therapies",
        "label": "Astellas Gene Therapies [Member]",
        "documentation": "Astellas Gene Therapies"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering",
        "label": "At-The-Market Offering [Member]",
        "documentation": "At-The-Market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r973"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r973"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r973"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_BilledRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BilledRevenuesMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Billed Revenues",
        "label": "Billed Revenues [Member]",
        "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_BiogenM.A.Inc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "BiogenM.A.Inc.Member",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biogen M.A., Inc.",
        "label": "Biogen M.A., Inc. [Member]",
        "documentation": "Biogen M.A., Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r585",
      "r911",
      "r912"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r585",
      "r911",
      "r912"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares (in shares)",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage acquired",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Pro Forma Financial Information",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r584"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r584"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r16"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Settlement of forward contract liability",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward contract to issue stock and options",
        "verboseLabel": "Forward contract to issue stock",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r74",
      "r587"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Merger"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r586"
     ]
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net loss",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets acquired:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Expenses And Other Current Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Expenses And Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Lease Liability",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development assets",
        "verboseLabel": "Acquisition Date Fair Value",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability, net of current portion",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Lease Liability",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "rnac_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right Of Use Asset",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/BasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r123",
      "r124"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of property and equipment not yet paid",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "rnac_CapitalizedResearchAndExperimentalCostsTaxPurposes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CapitalizedResearchAndExperimentalCostsTaxPurposes",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and experimental costs, tax purposes",
        "label": "Capitalized Research And Experimental Costs, Tax Purposes",
        "documentation": "Capitalized Research And Experimental Costs, Tax Purposes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash assumed in acquisition of Old Cartesian",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r188",
      "r871"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds (included in cash equivalents)",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Line Items]",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r120",
      "r221"
     ]
    },
    "rnac_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, restricted cash and marketable securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale",
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r120"
     ]
    },
    "rnac_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CashEquivalentsAndShortTermInvestmentsPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents, Marketable Securities and Investments",
        "label": "Cash Equivalents And Short Term Investments [Policy Text Block]",
        "documentation": "Cash Equivalents And Short Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ChangeInContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities:",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "rnac_ChristopherJewellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ChristopherJewellMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Christopher Jewell [Member]",
        "documentation": "Christopher Jewell"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r194",
      "r195",
      "r196",
      "r225",
      "r250",
      "r251",
      "r258",
      "r260",
      "r269",
      "r270",
      "r345",
      "r409",
      "r411",
      "r412",
      "r413",
      "r416",
      "r417",
      "r436",
      "r437",
      "r441",
      "r444",
      "r452",
      "r629",
      "r771",
      "r772",
      "r773",
      "r774",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r802",
      "r823",
      "r846",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r1058",
      "r1087",
      "r1096"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r269",
      "r436",
      "r437",
      "r439",
      "r441",
      "r444",
      "r450",
      "r452",
      "r771",
      "r772",
      "r773",
      "r774",
      "r898",
      "r1058",
      "r1087"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails",
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "rnac_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercises (in dollars per share)",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercises",
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercises"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised (in shares)",
        "label": "Class of Warrant Or Right, Exercised During Period",
        "documentation": "Class of Warrant Or Right, Exercised During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, number of securities called by each warrant or right (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "rnac_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, number of warrants exercised (in shares)",
        "label": "Class Of Warrant Or Right, Number Of Warrants Exercised",
        "documentation": "Class of Warrant or Right, Number Of Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ClassOfWarrantOrRightRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants",
        "label": "Class Of Warrant Or Right [Roll Forward]",
        "documentation": "Class Of Warrant Or Right [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "rnac_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Class Of Warrant Or Right Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Class Of Warrant Or Right Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ClinicalTrialCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ClinicalTrialCostsPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Trial Costs",
        "label": "Clinical Trial Costs [Policy Text Block]",
        "documentation": "Clinical Trial Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "rnac_CollaborationAndLicenseAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CollaborationAndLicenseAgreementsTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements",
        "label": "Collaboration And License Agreements [Text Block]",
        "documentation": "Collaboration And License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_CollaborationAndLicenseAgreementsUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CollaborationAndLicenseAgreementsUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and license agreements upfront payment",
        "label": "Collaboration And License Agreements Upfront Payment",
        "documentation": "Collaboration And License Agreements Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_CollaborativeArrangementCostSharePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CollaborativeArrangementCostSharePercentage",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost share percentage",
        "label": "Collaborative Arrangement, Cost Share Percentage",
        "documentation": "Collaborative Arrangement, Cost Share Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "rnac_CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, number of shares issued for milestone achievement (in shares)",
        "label": "Collaborative Arrangement, Number Of Shares Issued For Milestone Achievement",
        "documentation": "Collaborative Arrangement, Number Of Shares Issued For Milestone Achievement"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_CollaborativeArrangementPaymentObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CollaborativeArrangementPaymentObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, payment obligation",
        "label": "Collaborative Arrangement, Payment Obligation",
        "documentation": "Collaborative Arrangement, Payment Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, shares issued for milestone achievement, amount",
        "label": "Collaborative Arrangement, Shares Issued For Milestone Achievement, Amount",
        "documentation": "Collaborative Arrangement, Shares Issued For Milestone Achievement, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_CollaborativeArrangementWrittenNoticePeriodForTermination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CollaborativeArrangementWrittenNoticePeriodForTermination",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written notice for agreement termination",
        "label": "Collaborative Arrangement, Written Notice Period For Termination",
        "documentation": "Collaborative Arrangement, Written Notice Period For Termination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 19)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r159",
      "r725",
      "r801"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r401",
      "r402",
      "r865",
      "r1119",
      "r1122"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Liabilities",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r866"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total (in shares)",
        "verboseLabel": "Common stock authorized and reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common\u00a0stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r935",
      "r936",
      "r938",
      "r939",
      "r940",
      "r941",
      "r1092",
      "r1093",
      "r1095",
      "r1165",
      "r1227",
      "r1229"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized (in shares)",
        "terseLabel": "Common Stock, Shares Authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r802"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r102",
      "r802",
      "r820",
      "r1229",
      "r1230"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 350,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 25,767,369 and 5,397,597 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r728",
      "r930"
     ]
    },
    "rnac_CommonStockVotingRightsNumberOfVotes": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CommonStockVotingRightsNumberOfVotes",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes per share that common stockholders are entitled to",
        "label": "Common Stock, Voting Rights, Number Of Votes",
        "documentation": "Common Stock, Voting Rights, Number Of Votes"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_CommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CommonWarrantMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Warrant",
        "label": "Common Warrant [Member]",
        "documentation": "Common Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r203",
      "r205",
      "r211",
      "r717",
      "r741",
      "r742"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r172"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r875"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r77",
      "r78"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in process",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContingentValueRightLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContingentValueRightLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent value right liability",
        "label": "Contingent Value Right Liability",
        "documentation": "Contingent Value Right Liability"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContingentValueRightLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContingentValueRightLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent value right liability",
        "label": "Contingent Value Right Liability, Current",
        "documentation": "Contingent Value Right Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed semi annual amount",
        "label": "Contingent Value Right Liability, Deduction From Distribution, General And Administrative Overhead",
        "documentation": "Contingent Value Right Liability, Deduction From Distribution, General And Administrative Overhead"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContingentValueRightLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContingentValueRightLiabilityMeasurementInput",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent value right liability, measurement input",
        "label": "Contingent Value Right Liability, Measurement Input",
        "documentation": "Contingent Value Right Liability, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContingentValueRightLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContingentValueRightLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent value right liability, net of current portion",
        "label": "Contingent Value Right Liability, Noncurrent",
        "documentation": "Contingent Value Right Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContingentValueRightLiabilityPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContingentValueRightLiabilityPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Value Right Liability",
        "label": "Contingent Value Right Liability, Policy [Policy Text Block]",
        "documentation": "Contingent Value Right Liability, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContingentValueRightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContingentValueRightMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR liability",
        "label": "Contingent Value Right [Member]",
        "documentation": "Contingent Value Right"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent value right, percentage of milestone payments, royalties and other amounts to be distributed",
        "label": "Contingent Value Right, Percentage Of Milestone Payments, Royalties And Other Amounts To Be Distributed",
        "documentation": "Contingent Value Right, Percentage Of Milestone Payments, Royalties And Other Amounts To Be Distributed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Contract Liabilities",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unbilled receivables",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r458",
      "r477"
     ]
    },
    "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetReclassifiedToReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, asset, reclassified to receivable",
        "label": "Contract with Customer, Asset, Reclassified to Receivable",
        "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Contract liabilities, beginning of period",
        "periodEndLabel": "Contract liabilities, end of period",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r477"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation recognized",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Short-term contract liability",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r477"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, net of current portion",
        "verboseLabel": "Long-term contract liability",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r477"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "negatedTotalLabel": "Deductions",
        "label": "Contract with Customer, Liability, Revenue Recognized, Including Opening Balance",
        "documentation": "Contract with Customer, Liability, Revenue Recognized, Including Opening Balance"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContractwithCustomerLiabilityDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContractwithCustomerLiabilityDeferredRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Deferred revenue, beginning of period",
        "periodEndLabel": "Deferred revenue, end of period",
        "label": "Contract with Customer, Liability, Deferred Revenue",
        "documentation": "Contract with Customer, Liability, Deferred Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "parentTag": "rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, additions",
        "label": "Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts",
        "documentation": "Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "parentTag": "rnac_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred revenue, deductions",
        "label": "Contract with Customer, Liability, Deferred Revenue, Revenue Recognized",
        "documentation": "Contract with Customer, Liability, Deferred Revenue, Revenue Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ContractwithCustomerLiabilityIncreaseFromCashReceipts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ContractwithCustomerLiabilityIncreaseFromCashReceipts",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Additions",
        "label": "Contract with Customer, Liability, Increase From Cash Receipts",
        "documentation": "Contract with Customer, Liability, Increase From Cash Receipts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued upon conversion (in shares)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r54",
      "r101",
      "r136",
      "r447"
     ]
    },
    "rnac_ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares that did not automatically convert (in shares)",
        "label": "Convertible Preferred Stock, Shares That Did Not Automatically Convert",
        "documentation": "Convertible Preferred Stock, Shares That Did Not Automatically Convert"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenueAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Cost of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r419",
      "r439",
      "r675",
      "r696",
      "r721",
      "r872",
      "r874"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails",
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r1123"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails",
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r1123",
      "r1124"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense (benefit)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r1090"
     ]
    },
    "rnac_CustomerLiabilityRevenueRecognizedIncludingOpeningBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CustomerLiabilityRevenueRecognizedIncludingOpeningBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer, liability, revenue recognized, including opening balance",
        "label": "Customer, Liability, Revenue Recognized, Including Opening Balance",
        "documentation": "Customer, Liability, Revenue Recognized, Including Opening Balance"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1047"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1047"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1049"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1049"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1051"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1049"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1042"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1041"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1041"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1041"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r1044"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r1046"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r1046"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1047"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r1050"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r1048"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1045"
     ]
    },
    "rnac_CyrusBiotechnologyIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "CyrusBiotechnologyIncMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cyrus Biotechnology, Inc.",
        "label": "Cyrus Biotechnology, Inc. [Member]",
        "documentation": "Cyrus Biotechnology, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r223",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r407",
      "r408",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r430",
      "r431",
      "r433",
      "r645"
     ]
    },
    "rnac_DebtInstrumentAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "DebtInstrumentAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, accrued interest",
        "label": "Debt Instrument, Accrued Interest",
        "documentation": "Debt Instrument, Accrued Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, fee amount",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "rnac_DebtInstrumentPrepaymentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "DebtInstrumentPrepaymentFee",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, prepayment fee",
        "label": "Debt Instrument, Prepayment Fee",
        "documentation": "Debt Instrument, Prepayment Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Issuance Costs",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "rnac_DecemberTwoThousandNineteenFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "DecemberTwoThousandNineteenFinancingMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2019 Financing",
        "label": "December Two Thousand Nineteen Financing [Member]",
        "documentation": "December Two Thousand Nineteen Financing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision (benefit) for deferred taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r179",
      "r1090"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r157",
      "r561"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities, net",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544",
      "r723"
     ]
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRentCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred rent",
        "label": "Deferred Rent Credit, Current",
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r1073",
      "r1182"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent and license costs",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;E Capitalization",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "rnac_DeferredTaxAssetsLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets, Leasing Arrangements",
        "documentation": "Deferred Tax Assets, Leasing Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_DeferredTaxAssetsNetOfDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsNetOfDeferredTaxLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets before valuation allowance",
        "label": "Deferred Tax Assets, Net Of Deferred Tax Liabilities",
        "documentation": "Deferred Tax Assets, Net Of Deferred Tax Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent value right liability",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax assets/(liabilities)",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Liabilities",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contribution made",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "rnac_DefinedContributionPlanEmployersMatchingContributionVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "DefinedContributionPlanEmployersMatchingContributionVestingPeriod",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Defined Contribution Plan Employers Matching Contribution Vesting Period",
        "documentation": "Period which an employee's right to exercise a plan is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r45"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward contract liabilities",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Contract Liabilities",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r79",
      "r80",
      "r81",
      "r83",
      "r231",
      "r245"
     ]
    },
    "rnac_Descartes08ForMGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "Descartes08ForMGMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails",
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Descartes-08 for MG",
        "label": "Descartes-08 For MG [Member]",
        "documentation": "Descartes-08 For MG"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_Descartes08ForSLEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "Descartes08ForSLEMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Descartes-08 for SLE",
        "label": "Descartes-08 For SLE [Member]",
        "documentation": "Descartes-08 For SLE"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_DevelopmentAndCommercialMilestonesPlusRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "DevelopmentAndCommercialMilestonesPlusRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and commercial milestones plus royalties",
        "label": "Development And Commercial Milestones Plus Royalties",
        "documentation": "Development And Commercial Milestones Plus Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Change in fair value of forward contract liability settled in February 2024",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "rnac_DirectorsAndExecutiveOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "DirectorsAndExecutiveOfficersMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors and Executive Officers",
        "label": "Directors And Executive Officers [Member]",
        "documentation": "Directors And Executive Officers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Incentive Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r494",
      "r525",
      "r526",
      "r528",
      "r914"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units Activity",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r63"
     ]
    },
    "us-gaap_DistributedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DistributedEarnings",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: CVR distribution to participating securities",
        "label": "Distributed Earnings",
        "documentation": "The total amount of dividends declared in the period for each class of stock and the contractual amount of dividends (or interest on participating income bonds) that must be paid for the period (for example, unpaid cumulative dividends). Dividends declared in the current period do not include dividends declared in respect of prior-period unpaid cumulative dividends. Preferred dividends that are cumulative only if earned are deducted only to the extent that they are earned."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityCommonStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends declared or paid on common stock",
        "label": "Dividends, Common Stock",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r138"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r973"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r973",
      "r1016"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "rnac_Dr.ChafenLuMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "Dr.ChafenLuMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dr. Chafen Lu",
        "label": "Dr. Chafen Lu [Member]",
        "documentation": "Dr. Chafen Lu"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_Dr.TimothyA.SpringerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "Dr.TimothyA.SpringerMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timothy A. Springer, Ph.D.",
        "label": "Dr. Timothy A. Springer [Member]",
        "documentation": "Dr. Timothy A. Springer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "rnac_EarlyStageProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "EarlyStageProgramsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early stage programs",
        "label": "Early Stage Programs [Member]",
        "documentation": "Early Stage Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share allocable to common stockholders:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r247",
      "r250",
      "r258",
      "r259",
      "r260",
      "r265",
      "r581",
      "r589",
      "r604",
      "r605",
      "r718",
      "r743",
      "r876"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r250",
      "r258",
      "r259",
      "r260",
      "r265",
      "r581",
      "r589",
      "r604",
      "r605",
      "r718",
      "r743",
      "r876"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r262"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share Allocable to Common Stockholders",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r261",
      "r263",
      "r264"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r916"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory U.S. federal rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r546",
      "r572",
      "r916"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance, net",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r916",
      "r1091",
      "r1159"
     ]
    },
    "rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent value right liability",
        "label": "Effective Income Tax Rate Reconciliation, Change In Fair Value Of Contingent Value Right Liability, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Change In Fair Value Of Contingent Value Right Liability, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of forward contract liabilities",
        "label": "Effective Income Tax Rate Reconciliation, Change In Fair Value Of Contract Liabilities, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Change In Fair Value Of Contract Liabilities, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r553",
      "r1091",
      "r1159"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r1091",
      "r1159",
      "r1160"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes - net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r916",
      "r1091",
      "r1159"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r553",
      "r1091",
      "r1159"
     ]
    },
    "rnac_EligiblePeriodToReceiveRoyalties": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "EligiblePeriodToReceiveRoyalties",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period after first commercial sale when the Company is eligible to receive royalties",
        "label": "Eligible Period To Receive Royalties",
        "documentation": "Eligible Period To Receive Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll and employee related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to unvested employee stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Stock Options",
        "verboseLabel": "Outstanding common stock options",
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_EmployeeStockPurchasePlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "EmployeeStockPurchasePlan2016Member",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock Purchase Plan 2016 [Member]",
        "documentation": "Represent information pertaining to the 2016 Employee Stock Purchase Plan."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_EmploymentInducementIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "EmploymentInducementIncentiveAwardPlanMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employment Inducement Incentive Award Plan",
        "label": "Employment Inducement Incentive Award Plan [Member]",
        "documentation": "Employment Inducement Incentive Award Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Smaller Reporting Company",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment, Software and Office Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r183",
      "r207",
      "r208",
      "r209",
      "r232",
      "r233",
      "r234",
      "r236",
      "r241",
      "r243",
      "r245",
      "r268",
      "r346",
      "r347",
      "r379",
      "r455",
      "r570",
      "r571",
      "r578",
      "r579",
      "r580",
      "r582",
      "r588",
      "r589",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r603",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r646",
      "r648",
      "r668",
      "r739",
      "r760",
      "r761",
      "r762",
      "r780",
      "r846"
     ]
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Interest Type [Axis]",
        "label": "Equity Interest Type [Axis]",
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "rnac_EquityOfferingCostsInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "EquityOfferingCostsInAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity offering costs in accrued liabilities",
        "label": "Equity Offering Costs In Accrued Liabilities",
        "documentation": "Equity Offering Costs In Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "EquitySecuritiesStockPurchaseAgreementParValuePerShare",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities, stock purchase agreement, par value per share (in dollars per share)",
        "label": "Equity Securities, Stock Purchase Agreement, Par Value Per Share",
        "documentation": "Equity Securities, Stock Purchase Agreement, Par Value Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities, stock purchase agreement, purchase price per share (in dollars per share)",
        "label": "Equity Securities, Stock Purchase Agreement, Purchase Price Per Share",
        "documentation": "Equity Securities, Stock Purchase Agreement, Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "EquitySecuritiesStockPurchaseAgreementSharesPurchased",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities, stock purchase agreement, shares purchased (in shares)",
        "label": "Equity Securities, Stock Purchase Agreement, Shares Purchased",
        "documentation": "Equity Securities, Stock Purchase Agreement, Shares Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "verboseLabel": "Equity securities without readily determinable fair value, amount",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r977",
      "r987",
      "r1020"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r974",
      "r984",
      "r1017"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of debt, amount",
        "label": "Extinguishment of Debt, Amount",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_FairValueAdjustmentOfContingentValueRightLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "FairValueAdjustmentOfContingentValueRightLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of contingent value right liability",
        "terseLabel": "Contingent value right liability revaluation",
        "label": "Fair Value Adjustment Of Contingent Value Right Liability",
        "documentation": "Fair Value Adjustment Of Contingent Value Right Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Warrant liabilities revaluation",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r621",
      "r917"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r621",
      "r917"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r610",
      "r611",
      "r922"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r610",
      "r611",
      "r922"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques for 2019 Warrants Liability and CVR Liability",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r610",
      "r922"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r620",
      "r621",
      "r623",
      "r683",
      "r684",
      "r685",
      "r894",
      "r895",
      "r908",
      "r909",
      "r910",
      "r917",
      "r922"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r622"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r609",
      "r611",
      "r917",
      "r1170",
      "r1175"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r618",
      "r619",
      "r620",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r715",
      "r917",
      "r923"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a01",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r481",
      "r486",
      "r608",
      "r621",
      "r683",
      "r908",
      "r909",
      "r910",
      "r917"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r481",
      "r486",
      "r608",
      "r609",
      "r621",
      "r684",
      "r894",
      "r895",
      "r908",
      "r909",
      "r910",
      "r917"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r608",
      "r609",
      "r610",
      "r611",
      "r621",
      "r685",
      "r894",
      "r895",
      "r908",
      "r909",
      "r910",
      "r917",
      "r922"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r622"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r622"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Roll-Forward of Fair Value for the Company\u2019s Level 3 Warrant Liabilities, CVR Liability and Forward Contract Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r617",
      "r622"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r609",
      "r611",
      "r917",
      "r1170",
      "r1175"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1174"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r622"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1174"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r622"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r620",
      "r621",
      "r623",
      "r683",
      "r684",
      "r685",
      "r894",
      "r895",
      "r908",
      "r909",
      "r910",
      "r917",
      "r922"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r917",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1175"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r622"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settlements",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r622"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r622"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheForwardContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r622"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r651",
      "r656",
      "r929"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r432",
      "r450",
      "r601",
      "r628",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r740",
      "r891",
      "r917",
      "r920",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r931",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1166",
      "r1169",
      "r1170",
      "r1171",
      "r1173",
      "r1175"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transaction, net",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r631",
      "r632",
      "r633",
      "r843"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r981",
      "r991",
      "r1024"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r981",
      "r991",
      "r1024"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r981",
      "r991",
      "r1024"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r981",
      "r991",
      "r1024"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r981",
      "r991",
      "r1024"
     ]
    },
    "rnac_ForwardContractToIssueSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ForwardContractToIssueSharesMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward contract to issue Series A Preferred Stock",
        "label": "Forward Contract To Issue Shares [Member]",
        "documentation": "Forward Contract To Issue Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of forward contract liabilities",
        "negatedTerseLabel": "Forward contract liabilities revaluation",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r49",
      "r50"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r825"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "rnac_GenovisABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "GenovisABMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genovis AB",
        "label": "Genovis AB [Member]",
        "documentation": "Genovis AB"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_GinkgoAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "GinkgoAgreementMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ginkgo Agreement",
        "label": "Ginkgo Agreement [Member]",
        "documentation": "Ginkgo Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_GinkgoBioworksHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "GinkgoBioworksHoldingsIncMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ginkgo Bioworks Holdings, Inc",
        "label": "Ginkgo Bioworks Holdings, Inc [Member]",
        "documentation": "Ginkgo Bioworks Holdings, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r358",
      "r716",
      "r885",
      "r892",
      "r919",
      "r930",
      "r1113",
      "r1114"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r369",
      "r892"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment to goodwill",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r359",
      "r365",
      "r369",
      "r892",
      "r919"
     ]
    },
    "us-gaap_GovernmentAssistanceAmountCumulativeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceAmountCumulativeCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government assistance, asset, current",
        "label": "Government Assistance, Asset, Current",
        "documentation": "Amount of asset from government assistance, classified as current."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_GovernmentAssistanceAwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceAwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government assistance, award amount",
        "label": "Government Assistance, Award Amount",
        "documentation": "Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan."
       }
      }
     },
     "auth_ref": [
      "r1177"
     ]
    },
    "rnac_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance Current Statement Of Financial Position Extensible Enumeration Not Disclosed Flag",
        "label": "Government Assistance Current Statement Of Financial Position Extensible Enumeration Not Disclosed Flag",
        "documentation": "Government Assistance Current Statement Of Financial Position Extensible Enumeration Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Revenue",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r644"
     ]
    },
    "rnac_GovernmentAssistancePotentialAdditionalAwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "GovernmentAssistancePotentialAdditionalAwardAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government assistance, potential additional award amount",
        "label": "Government Assistance, Potential Additional Award Amount",
        "documentation": "Government Assistance, Potential Additional Award Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistanceTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTypeAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Type [Axis]",
        "label": "Government Assistance, Type [Axis]",
        "documentation": "Information by type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTypeDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Type [Domain]",
        "label": "Government Assistance, Type [Domain]",
        "documentation": "Type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r973"
     ]
    },
    "us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets, location",
        "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r1085",
      "r1118"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of intangible assets",
        "terseLabel": "Impairment",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r1085",
      "r1117",
      "r1118"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails": {
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r44",
      "r128",
      "r918"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r129"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r161",
      "r165",
      "r719",
      "r737",
      "r878",
      "r884",
      "r1099",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r388",
      "r393",
      "r613",
      "r617",
      "r622",
      "r757",
      "r759",
      "r830",
      "r869",
      "r921",
      "r1198"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r393",
      "r613",
      "r617",
      "r622",
      "r757",
      "r759",
      "r830",
      "r869",
      "r921",
      "r1198"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r546",
      "r547",
      "r557",
      "r566",
      "r916",
      "r1163"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r546",
      "r547",
      "r557",
      "r566",
      "r916",
      "r1163"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r540",
      "r546",
      "r554",
      "r555",
      "r556",
      "r558",
      "r565",
      "r573",
      "r575",
      "r576",
      "r577",
      "r776",
      "r916"
     ]
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Examination [Line Items]",
        "label": "Income Tax Examination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax, Examination [Table]",
        "label": "Income Tax, Examination [Table]",
        "documentation": "Disclosure of information about income tax examination currently in progress or completed during current period by tax authority. Includes, but is not limited to, description of examination, jurisdiction conducting examination, tax year under examination, likelihood of unfavorable settlement, range of possible loss, liability recorded, increase (decrease) of liability from prior period, and penalty and interest incurred or accrued."
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax (expense) benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r180",
      "r244",
      "r245",
      "r266",
      "r283",
      "r304",
      "r545",
      "r546",
      "r574",
      "r744",
      "r916"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r541",
      "r542",
      "r558",
      "r559",
      "r564",
      "r568",
      "r770"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax benefit related to the CVR liability",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r916",
      "r1159"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "rnac_IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unbilled receivable",
        "label": "Increase (Decrease) In Contract With Customer, Asset, Allowance For Credit Loss, Current",
        "documentation": "Increase (Decrease) In Contract With Customer, Asset, Allowance For Credit Loss, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r1084"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses, deposits and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "IncreaseDecreaseInTemporaryEquityOptionRollForwardRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) In Temporary Equity, Option, Roll Forward [Roll Forward]",
        "label": "Increase (Decrease) In Temporary Equity, Option, Roll Forward [Roll Forward]",
        "documentation": "Increase (Decrease) In Temporary Equity, Option, Roll Forward"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails",
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r375",
      "r377",
      "r893"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development assets",
        "verboseLabel": "Carrying value",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r377",
      "r893"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails",
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r375",
      "r377",
      "r893"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r981",
      "r991",
      "r1015",
      "r1024",
      "r1028",
      "r1036"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r1040"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r1040"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r1040"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense related to term loans",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r429",
      "r434",
      "r896",
      "r897"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r1081"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r219"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r278",
      "r304",
      "r884",
      "r1080"
     ]
    },
    "rnac_IssuanceOfContingentValueRightForExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "IssuanceOfContingentValueRightForExerciseOfWarrants",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of CVRs upon exercise of warrants (in shares)",
        "label": "Issuance of Contingent Value Right for Exercise of Warrants",
        "documentation": "Issuance of Contingent Value Right for Exercise of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_IssuanceOfStockForSettlementOfForwardContractLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "IssuanceOfStockForSettlementOfForwardContractLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock for settlement of liability",
        "label": "Issuance Of Stock For Settlement Of Forward Contract Liability",
        "documentation": "Issuance Of Stock For Settlement Of Forward Contract Liability"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Represents information pertaining to laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LeaseArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LeaseArrangementAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Arrangement [Axis]",
        "label": "Lease Arrangement [Axis]",
        "documentation": "Lease Arrangement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LeaseArrangementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LeaseArrangementDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Arrangement [Domain]",
        "label": "Lease Arrangement [Domain]",
        "documentation": "[Domain] for Lease Arrangement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee-paid construction costs",
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r929"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Costs and Additional Information Related to Operating Leases",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1180"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r665"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LegacySelectaProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LegacySelectaProgramsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legacy Selecta programs",
        "label": "Legacy Selecta Programs [Member]",
        "documentation": "Legacy Selecta Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r666"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r666"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "rnac_LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, additional annual base rent, year one",
        "label": "Lessee, Operating Lease, Additional Annual Base Rent, Year One",
        "documentation": "Lessee, Operating Lease, Additional Annual Base Rent, Year One"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, base rent, annual upward adjustment percentage after year one",
        "label": "Lessee, Operating Lease, Base Rent, Annual Upward Adjustment Percentage After Year One",
        "documentation": "Lessee, Operating Lease, Base Rent, Annual Upward Adjustment Percentage After Year One"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, first month rent paid on execution of lease agreement",
        "label": "Lessee, Operating Lease, First Month Rent Paid on Execution of Lease Agreement",
        "documentation": "Lessee, Operating Lease, First Month Rent Paid on Execution of Lease Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1181"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "rnac_LesseeOperatingLeaseMonthlyBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LesseeOperatingLeaseMonthlyBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease agreement, monthly base rent",
        "label": "Lessee, Operating Lease, Monthly Base Rent",
        "documentation": "Lessee, Operating Lease, Monthly Base Rent"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LesseeOperatingLeaseNumberOfOptionsToExtend": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LesseeOperatingLeaseNumberOfOptionsToExtend",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options to extend lease",
        "label": "Lessee, Operating Lease, Number Of Options To Extend",
        "documentation": "Lessee, Operating Lease, Number Of Options To Extend"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1179"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1179"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letters of credit outstanding, amount",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r90",
      "r91",
      "r92",
      "r94",
      "r95",
      "r96",
      "r99",
      "r225",
      "r345",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r592",
      "r593",
      "r594",
      "r629",
      "r800",
      "r877",
      "r944",
      "r1125",
      "r1185",
      "r1186"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock, and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r160",
      "r732",
      "r930",
      "r1089",
      "r1112",
      "r1176"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, convertible preferred stock, and stockholders\u2019 deficit",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r187",
      "r225",
      "r345",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r592",
      "r593",
      "r594",
      "r629",
      "r930",
      "r1125",
      "r1185",
      "r1186"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r1167"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3SBio License",
        "label": "License Agreement With Shenyang Sunshine Pharmaceutical Company Limited [Member]",
        "documentation": "Represents information pertaining to License agreement with Shenyang Sunshine Pharmaceutical co., ltd."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and option agreement, benchmark royalties, maximum",
        "label": "License And Option Agreement, Benchmark Royalties, Maximum",
        "documentation": "License And Option Agreement, Benchmark Royalties, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical and commercial milestone payment, expected",
        "label": "License And Option Agreement, Clinical And Commercial Milestone Payment, Expected",
        "documentation": "License And Option Agreement, Clinical And Commercial Milestone Payment, Expected"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementDevelopmentCostReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementDevelopmentCostReimbursements",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and option agreement, development cost reimbursements",
        "label": "License And Option Agreement, Development Cost Reimbursements",
        "documentation": "License And Option Agreement, Development Cost Reimbursements"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementDevelopmentMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone",
        "label": "License And Option Agreement, Development Milestone",
        "documentation": "License And Option Agreement, Development Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementExtensionTerm",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension term",
        "label": "License And Option Agreement, Extension Term",
        "documentation": "License And Option Agreement, Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementFutureAdditionalPaymentsExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementFutureAdditionalPaymentsExpected",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future additional payments, expected",
        "label": "License And Option Agreement, Future Additional Payments, Expected",
        "documentation": "License And Option Agreement, Future Additional Payments, Expected"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "License And Option Agreement, Milestone Payments",
        "documentation": "License And Option Agreement, Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementMilestoneReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementMilestoneReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone receivable",
        "label": "License And Option Agreement, Milestone Receivable",
        "documentation": "License And Option Agreement, Milestone Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone receivable for certain dystrophies",
        "label": "License And Option Agreement, Milestone Receivable For Certain Dystrophies",
        "documentation": "License And Option Agreement, Milestone Receivable For Certain Dystrophies"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementOptionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementOptionTerm",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option term",
        "label": "License And Option Agreement, Option Term",
        "documentation": "License And Option Agreement, Option Term"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementRoyaltyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementRoyaltyPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and option agreement, royalty payment",
        "label": "License And Option Agreement, Royalty Payment",
        "documentation": "License And Option Agreement, Royalty Payment"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales milestone payments",
        "label": "License And Option Agreement, Sales Milestone Payments That May Be Received",
        "documentation": "License And Option Agreement, Sales Milestone Payments That May Be Received"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementUpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementUpfrontCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront cash payment",
        "label": "License And Option Agreement, Upfront Cash Payment",
        "documentation": "License And Option Agreement, Upfront Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and option agreement, written notice period before cancellation",
        "label": "License And Option Agreement, Written Notice Period Before Cancellation",
        "documentation": "License And Option Agreement, Written Notice Period Before Cancellation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan facility",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r158",
      "r1195"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r1088",
      "r1123"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r93",
      "r408",
      "r1088",
      "r1123"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r489",
      "r535",
      "r611",
      "r712",
      "r756",
      "r758",
      "r766",
      "r792",
      "r793",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r867",
      "r868",
      "r890",
      "r898",
      "r913",
      "r922",
      "r923",
      "r927",
      "r928",
      "r932",
      "r1127",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-adjusted discount rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (in years)",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "rnac_MeasurementInputRevenueVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "MeasurementInputRevenueVolatilityMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility of future revenues",
        "label": "Measurement Input, Revenue Volatility [Member]",
        "documentation": "Measurement Input, Revenue Volatility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r610",
      "r611",
      "r922"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r610",
      "r611",
      "r922"
     ]
    },
    "rnac_MedicalExpensesOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "MedicalExpensesOperating",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical expenses, operating",
        "label": "Medical Expenses, Operating",
        "documentation": "Medical Expenses, Operating"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r489",
      "r535",
      "r611",
      "r712",
      "r756",
      "r758",
      "r766",
      "r792",
      "r793",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r867",
      "r868",
      "r890",
      "r898",
      "r913",
      "r922",
      "r923",
      "r927",
      "r932",
      "r1127",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds (included in cash equivalents)",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "rnac_MoscowRussiaLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "MoscowRussiaLeaseMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moscow Russia Lease",
        "label": "Moscow Russia Lease [Member]",
        "documentation": "Moscow Russia Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "rnac_NationalCancerInstituteAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "NationalCancerInstituteAgreementMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NCI Agreement",
        "label": "National Cancer Institute Agreement [Member]",
        "documentation": "National Cancer Institute Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "National Institute of Neurological Disorders and Stroke of the National Institutes of Health Funding",
        "label": "National Institute Of Neurological Disorders And Stroke Of The National Institutes Of Health Funding [Member]",
        "documentation": "National Institute Of Neurological Disorders And Stroke Of The National Institutes Of Health Funding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      },
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails",
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net income (loss)",
        "terseLabel": "Net loss",
        "netLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r122",
      "r162",
      "r185",
      "r202",
      "r204",
      "r209",
      "r225",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r256",
      "r345",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r581",
      "r589",
      "r605",
      "r629",
      "r738",
      "r822",
      "r844",
      "r845",
      "r942",
      "r1125"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss allocable to shares of common stock - basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r237",
      "r238",
      "r239",
      "r240",
      "r247",
      "r248",
      "r257",
      "r260",
      "r589"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss allocable to shares of common stock - diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r260"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r981",
      "r991",
      "r1015",
      "r1024"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_NumberOfAcquiredOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "NumberOfAcquiredOperatingLeases",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of acquired operating leases",
        "label": "Number Of Acquired Operating Leases",
        "documentation": "Number Of Acquired Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_NumberOfBusinessDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "NumberOfBusinessDays",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of business days",
        "label": "Number Of Business Days",
        "documentation": "Number Of Business Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/BasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r1100"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_OldCartesianMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "OldCartesianMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Old Cartesian",
        "label": "Old Cartesian [Member]",
        "documentation": "Old Cartesian"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_OldCartesianPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "OldCartesianPlanMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Old Cartesian Plan",
        "label": "Old Cartesian Plan [Member]",
        "documentation": "Old Cartesian Plan"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_OldCartestianMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "OldCartestianMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Old Cartestian",
        "label": "Old Cartestian [Member]",
        "documentation": "Old Cartestian"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "verboseLabel": "Collaboration expense",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r878",
      "r1099",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "rnac_OperatingLeaseBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "OperatingLeaseBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base rent",
        "label": "Operating Lease, Base Rent",
        "documentation": "Operating Lease, Base Rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r929"
     ]
    },
    "rnac_OperatingLeaseCostPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "OperatingLeaseCostPercentage",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, cost percentage",
        "label": "Operating Lease, Cost Percentage",
        "documentation": "Operating Lease, Cost Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails": {
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset impairment expense",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Disclosure for the Statement of Cash Flows Related to Operating Leases",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "documentation": "Tabular disclosure of components of income from operating lease."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r667"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofSupplementalDisclosurefortheStatementofCashFlowsRelatedtoOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r661"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "rnac_OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvement allowance",
        "label": "Operating Lease, Tenant Improvement Allowance Recognized as Reduction in Right of Use Asset and Lease Liability",
        "documentation": "Operating Lease, Tenant Improvement Allowance Recognized as Reduction in Right of Use Asset and Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r929"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r929"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "rnac_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, not subject to expiration",
        "label": "Operating Loss Carryforwards, Not Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Not Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_OperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, subject to expiration",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of the Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r154",
      "r767",
      "r768"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation adjustment",
        "terseLabel": "Currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r739"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r343"
     ]
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Other Depreciation and Amortization",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r45",
      "r113"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities:",
        "label": "Other Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r979",
      "r989",
      "r1022"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r982",
      "r992",
      "r1025"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r982",
      "r992",
      "r1025"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_PaymentForSettlementOfEquityAwardsInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PaymentForSettlementOfEquityAwardsInBusinessCombination",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settlement of outstanding equity awards at Merger",
        "label": "Payment For Settlement Of Equity Awards In Business Combination",
        "documentation": "Payment For Settlement Of Equity Awards In Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash Payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r1083"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Equity offering costs",
        "terseLabel": "Issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "rnac_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrant",
        "label": "Pre-Funded Warrant [Member]",
        "documentation": "Pre-Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_PreferredStockConvertibleBeneficialOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PreferredStockConvertibleBeneficialOwnershipPercentage",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beneficially holders owned percentage",
        "label": "Preferred Stock, Convertible, Beneficial Ownership Percentage",
        "documentation": "Preferred Stock, Convertible, Beneficial Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, convertible, conversion ratio",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, common stock issuable upon conversion (in shares)",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "rnac_PreferredStockConvertibleThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PreferredStockConvertibleThresholdConsecutiveTradingDays",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockRedemptionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, convertible, threshold consecutive trading days",
        "label": "Preferred Stock, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Preferred Stock, Convertible, Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockVotingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, convertible, transaction restrictions, percentage of originally issued stock issued and outstanding",
        "label": "Preferred Stock, Convertible, Transaction Restrictions, Percentage Of Originally Issued Stock Issued And Outstanding",
        "documentation": "Preferred Stock, Convertible, Transaction Restrictions, Percentage Of Originally Issued Stock Issued And Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred Stock",
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r935",
      "r938",
      "r939",
      "r940",
      "r941",
      "r1227",
      "r1229"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r436"
     ]
    },
    "rnac_PreferredStockRedemptionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PreferredStockRedemptionTerm",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockRedemptionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, redemption term",
        "label": "Preferred Stock, Redemption Term",
        "documentation": "Preferred Stock, Redemption Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r802"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r436"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "periodStartLabel": "Preferred stock, beginning balance (in shares)",
        "periodEndLabel": "Preferred stock, ending balance (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r802",
      "r820",
      "r1229",
      "r1230"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, value, issued",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r727",
      "r930"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "rnac_PrivatePlacement2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PrivatePlacement2023Member",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Private Placement",
        "label": "Private Placement 2023 [Member]",
        "documentation": "Private Placement 2023"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_PrivatePlacement2023TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PrivatePlacement2023TrancheOneMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Private Placement, Tranche One",
        "label": "Private Placement 2023, Tranche One [Member]",
        "documentation": "Private Placement 2023, Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_PrivatePlacement2023TrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PrivatePlacement2023TrancheThreeMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Private Placement, Tranche Three",
        "label": "Private Placement 2023, Tranche Three [Member]",
        "documentation": "Private Placement 2023, Tranche Three"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_PrivatePlacement2023TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PrivatePlacement2023TrancheTwoMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Private Placement, Tranche Two",
        "label": "Private Placement 2023, Tranche Two [Member]",
        "documentation": "Private Placement 2023, Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_PrivatePlacementOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PrivatePlacementOneMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement One",
        "label": "Private Placement One [Member]",
        "documentation": "Private Placement One"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_PrivatePlacementTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "PrivatePlacementTwoMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Two",
        "label": "Private Placement Two [Member]",
        "documentation": "Private Placement Two"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ProbabilityOfSuccessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ProbabilityOfSuccessMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated probability of success",
        "label": "Probability Of Success [Member]",
        "documentation": "Probability Of Success"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock and Series B Preferred Stock in private placement",
        "label": "Proceeds From Issuance Of Common Stock And Warrants",
        "documentation": "Proceeds From Issuance Of Common Stock And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of Series A Preferred Stock, gross in private placement",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r1107"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r22"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under Employee Stock Purchase Plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of common warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r665"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r173",
      "r177",
      "r178"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r189",
      "r736"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r665",
      "r720",
      "r736",
      "r930"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r173",
      "r177",
      "r734"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r665"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r480",
      "r489",
      "r520",
      "r521",
      "r522",
      "r535",
      "r611",
      "r686",
      "r695",
      "r712",
      "r756",
      "r758",
      "r766",
      "r792",
      "r793",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r867",
      "r868",
      "r890",
      "r898",
      "r913",
      "r922",
      "r923",
      "r927",
      "r928",
      "r932",
      "r936",
      "r1120",
      "r1127",
      "r1170",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforCVRLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r480",
      "r489",
      "r520",
      "r521",
      "r522",
      "r535",
      "r611",
      "r686",
      "r695",
      "r712",
      "r756",
      "r758",
      "r766",
      "r792",
      "r793",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r867",
      "r868",
      "r890",
      "r898",
      "r913",
      "r922",
      "r923",
      "r927",
      "r928",
      "r932",
      "r936",
      "r1120",
      "r1127",
      "r1170",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "us-gaap_ReceivablesBillingStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesBillingStatusDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables Billing Status [Domain]",
        "label": "Receivables Billing Status [Domain]",
        "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r974",
      "r984",
      "r1017"
     ]
    },
    "us-gaap_RedemptionPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedemptionPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption premium",
        "label": "Redemption Premium",
        "documentation": "The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement percentage, budgeted costs incurred to complete the development",
        "label": "Reimbursement Percentage, Budgeted Costs Incurred To Complete The Development",
        "documentation": "Reimbursement Percentage, Budgeted Costs Incurred To Complete The Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r487",
      "r672",
      "r673",
      "r724",
      "r733",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r819",
      "r821",
      "r853"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r672",
      "r673",
      "r674",
      "r675",
      "r724",
      "r733",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r819",
      "r821",
      "r853"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r826",
      "r827",
      "r830"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r487",
      "r672",
      "r673",
      "r724",
      "r733",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r819",
      "r821",
      "r853",
      "r1184"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r670",
      "r671",
      "r673",
      "r676",
      "r777",
      "r778",
      "r779",
      "r828",
      "r829",
      "r830",
      "r850",
      "r852"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of principal, final payment fee, and prepayment penalty on debt",
        "terseLabel": "Total payoff amount of term loan",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r774"
     ]
    },
    "rnac_ReportingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ReportingSegmentsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Segments",
        "label": "Reporting Segments [Member]",
        "documentation": "Reporting Segments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r419",
      "r439",
      "r675",
      "r696",
      "r721",
      "r873",
      "r874"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r1158"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r1158"
     ]
    },
    "rnac_ResearchAndDevelopmentEmployeeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentEmployeeExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development employee expenses",
        "label": "Research And Development Employee Expenses",
        "documentation": "Research And Development Employee Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r869",
      "r884",
      "r1193"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "rnac_ResearchAndDevelopmentFacilitiesAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentFacilitiesAndOtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development facilities and other expenses",
        "label": "Research And Development, Facilities And Other Expenses",
        "documentation": "Research And Development, Facilities And Other Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ResearchAndDevelopmentStockBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentStockBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development stock-based compensation expense",
        "label": "Research And Development, Stock-Based Compensation Expense",
        "documentation": "Research And Development, Stock-Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1018"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r976",
      "r986",
      "r1019"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1026"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1086",
      "r1194",
      "r1196"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash and cash equivalents",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r155",
      "r188",
      "r221",
      "r726"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term restricted cash",
        "terseLabel": "Long-term restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r169",
      "r221"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash, noncurrent",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r1072",
      "r1086"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_RestrictedStockUnitsUnvestedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "RestrictedStockUnitsUnvestedMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock units",
        "label": "Restricted Stock Units, Unvested [Member]",
        "documentation": "Restricted Stock Units, Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Restructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r392",
      "r395",
      "r400"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee workforce, termination percentage",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring charges",
        "terseLabel": "Charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r396",
      "r397",
      "r1121"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r398",
      "r399"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges, location",
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r398"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RestructuringScheduleofChangeinAccruedRestructuringBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r138",
      "r731",
      "r763",
      "r765",
      "r775",
      "r803",
      "r930"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r232",
      "r233",
      "r234",
      "r236",
      "r241",
      "r243",
      "r245",
      "r346",
      "r347",
      "r379",
      "r570",
      "r571",
      "r578",
      "r579",
      "r580",
      "r582",
      "r588",
      "r589",
      "r595",
      "r597",
      "r598",
      "r600",
      "r603",
      "r646",
      "r648",
      "r760",
      "r762",
      "r780",
      "r1229"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and license revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r266",
      "r276",
      "r277",
      "r298",
      "r304",
      "r308",
      "r310",
      "r311",
      "r475",
      "r476",
      "r714"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r870"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Arrangements",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r479"
     ]
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueNotFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant revenue",
        "label": "Revenue Not from Contract with Customer",
        "documentation": "Amount of revenue that is not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "rnac_RevenueNumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "RevenueNumberOfPerformanceObligations",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of obligations",
        "label": "Revenue, Number Of Performance Obligations",
        "documentation": "Revenue, Number Of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining performance obligation",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r210",
      "r225",
      "r266",
      "r276",
      "r277",
      "r298",
      "r304",
      "r308",
      "r310",
      "r311",
      "r345",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r629",
      "r719",
      "r884",
      "r1125"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "rnac_SOBIPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SOBIPurchaseAgreementMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOBI Purchase Agreement",
        "label": "SOBI Purchase Agreement [Member]",
        "documentation": "SOBI Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SaleOfStockAggregateMaximumGrossSalesProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SaleOfStockAggregateMaximumGrossSalesProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate maximum gross sales proceeds",
        "label": "Sale Of Stock, Aggregate Maximum Gross Sales Proceeds",
        "documentation": "Sale Of Stock, Aggregate Maximum Gross Sales Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sale common stock",
        "netLabel": "Sale of stock, consideration received on transaction",
        "terseLabel": "Total aggregate purchase price",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SaleOfStockGrossConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SaleOfStockGrossConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "label": "Sale Of Stock, Gross Consideration Received On Transaction",
        "documentation": "Sale Of Stock, Gross Consideration Received On Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "verboseLabel": "Shares issued (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SaleOfStockSettlementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SaleOfStockSettlementTerm",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, settlement term",
        "label": "Sale Of Stock, Settlement Term",
        "documentation": "Sale Of Stock, Settlement Term"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, percentage of ten-day volume weighted average price of common stock",
        "label": "Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock",
        "documentation": "Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SareptaTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SareptaTherapeuticsInc.Member",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarepta Therapeutics, Inc.",
        "label": "Sarepta Therapeutics, Inc. [Member]",
        "documentation": "Sarepta Therapeutics, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets Acquired",
        "label": "Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block]",
        "documentation": "Tabular disclosure of acquired indefinite-lived intangible asset by major class."
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potential Dilutive Shares of Common Stock Excluded from the Computation of the Diluted Net Loss Per Share Allocable to Common Stockholders",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofAllocationofthePurchasePricetotheEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofFairValueofConsiderationDetails",
      "http://www.cartesiantherapeutics.com/role/MergerScheduleofIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r585"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Consideration",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalent [Table]",
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan [Table]",
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r58",
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r916",
      "r1159"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168"
     ]
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases704QuinceOrchardRoadLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Leases7495NewHorizonWayLeasesNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/LeasesMoscowRussiaLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Disclosure of information about long-lived, depreciable assets that are subject to operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r665"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/MergerTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Allocation of the Purchase Price to the Estimated Fair Values of the Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r826",
      "r827",
      "r830"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r155",
      "r1196"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r398",
      "r399"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Change in Accrued Restructuring Balance",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r130"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r144"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Assumptions Used",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityMergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r133",
      "r135",
      "r137",
      "r138",
      "r194",
      "r195",
      "r196",
      "r269",
      "r436",
      "r437",
      "r439",
      "r441",
      "r444",
      "r450",
      "r452",
      "r771",
      "r772",
      "r773",
      "r774",
      "r898",
      "r1058",
      "r1087"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Authorized Shares of Common Stock for Future Issuance",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r101",
      "r102",
      "r135",
      "r137",
      "r138"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrant Activity",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "rnac_SecuritiesPurchaseAgreement2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SecuritiesPurchaseAgreement2023Member",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Securities Purchase Agreement",
        "label": "Securities Purchase Agreement 2023 [Member]",
        "documentation": "Securities Purchase Agreement 2023"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SecuritiesPurchaseAgreement2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SecuritiesPurchaseAgreement2024Member",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Securities Purchase Agreement",
        "label": "Securities Purchase Agreement 2024 [Member]",
        "documentation": "Securities Purchase Agreement 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r266",
      "r272",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r311",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r378",
      "r394",
      "r399",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r881",
      "r884",
      "r885",
      "r892",
      "r933",
      "r1197",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r266",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r287",
      "r289",
      "r290",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r311",
      "r879",
      "r882",
      "r883",
      "r884",
      "r886",
      "r888",
      "r889"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r307",
      "r310",
      "r880",
      "r881",
      "r887"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1075",
      "r1128"
     ]
    },
    "rnac_SeriesAPreferredStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SeriesAPreferredStockOptionsMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock options",
        "label": "Series A Preferred Stock Options [Member]",
        "documentation": "Series A Preferred Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1075",
      "r1128"
     ]
    },
    "rnac_SeriesBPreferredStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SeriesBPreferredStockPurchaseAgreementMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock Purchase Agreement",
        "label": "Series B Preferred Stock Purchase Agreement [Member]",
        "documentation": "Series B Preferred Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SettlementOfDerivativeLiabilityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SettlementOfDerivativeLiabilityShares",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, shares (in shares)",
        "label": "Settlement Of Derivative Liability, Shares",
        "documentation": "Settlement Of Derivative Liability, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SevenOneEightThreeFourIrrevocableTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SevenOneEightThreeFourIrrevocableTrustMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seven One Eight Three Four Irrevocable Trust (affiliate of Murat Kalayoglu, MD, Ph.D.)",
        "label": "Seven One Eight Three Four Irrevocable Trust [Member]",
        "documentation": "Seven One Eight Three Four Irrevocable Trust"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, accelerated cost",
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited in period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited in period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants in period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants in period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning of period (in shares)",
        "periodEndLabel": "Unvested at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning of period (in dollars per share)",
        "periodEndLabel": "Unvested at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value ($)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested in period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate fair value of RSU awards vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average fair value of common stock and preferred stock (in dollars per share)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value",
        "documentation": "Weighed-average fair value relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated forfeitures rate",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Forfeitures Rate",
        "documentation": "Represents the percentage of forfeitures rate of the stock options based on the historical trends."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized for grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized, increase (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted from options for Series A preferred stock (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Assumed in Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Assumed in Period"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Converted to options for common stock (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Converted To Options For Common Stock",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Converted To Options For Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of stock options (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]",
        "documentation": "n/a"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500"
     ]
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted to options for common stock (in dollars per share)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Converted To Options For Common Stock",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Converted To Options For Common Stock, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "n/a"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash payment made to the holders of stock options and restricted stock units",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation arrangement by share based payment award, settlement of awards, amount (in dollars per share)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards, Amount",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess over fair value recognized as additional stock-based compensation expense",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards, Stock Based Compensation Expense Recognized On Settlement",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Settlement Of Awards, Stock Based Compensation Expense Recognized On Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofRestrictedStockUnitsActivityDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ]
    },
    "rnac_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted from options for Series A preferred stock (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Assumed in Period, Weighted Average Exercise Price",
        "documentation": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Assumed in Period, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r498",
      "r517",
      "r518",
      "r519",
      "r520",
      "r523",
      "r529",
      "r530",
      "r531",
      "r532"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award expiration term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value",
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, term",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested (in dollars per share)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r929"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r222"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r184",
      "r266",
      "r272",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r311",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r378",
      "r382",
      "r394",
      "r399",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r881",
      "r884",
      "r885",
      "r892",
      "r933",
      "r1197",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockConversionNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockLiquidationNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/MergerNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r194",
      "r195",
      "r196",
      "r225",
      "r250",
      "r251",
      "r258",
      "r260",
      "r269",
      "r270",
      "r345",
      "r409",
      "r411",
      "r412",
      "r413",
      "r416",
      "r417",
      "r436",
      "r437",
      "r441",
      "r444",
      "r452",
      "r629",
      "r771",
      "r772",
      "r773",
      "r774",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r802",
      "r823",
      "r846",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r1058",
      "r1087",
      "r1096"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r102",
      "r106",
      "r107",
      "r183",
      "r207",
      "r208",
      "r209",
      "r232",
      "r233",
      "r234",
      "r236",
      "r241",
      "r243",
      "r245",
      "r268",
      "r346",
      "r347",
      "r379",
      "r455",
      "r570",
      "r571",
      "r578",
      "r579",
      "r580",
      "r582",
      "r588",
      "r589",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r603",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r646",
      "r648",
      "r668",
      "r739",
      "r760",
      "r761",
      "r762",
      "r780",
      "r846"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r268",
      "r648",
      "r714",
      "r769",
      "r791",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r802",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r821",
      "r824",
      "r825",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r846",
      "r937"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r268",
      "r312",
      "r648",
      "r714",
      "r769",
      "r791",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r802",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r821",
      "r824",
      "r825",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r846",
      "r937"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r978",
      "r988",
      "r1021"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock options and RSUs",
        "terseLabel": "Shares available for future stock incentive awards",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "rnac_StockIncentivePlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "StockIncentivePlan2016Member",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Plan",
        "label": "Stock Incentive Plan 2016 [Member]",
        "documentation": "Represents the information pertaining to the 2016 stock incentive plan, which provides for the granting of stock based awards to employees, directors, and consultants under terms and provisions established by the board of directors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, license agreement in stock-based compensation expense",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in connection with the merger and settlement of related forward contract (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r138"
     ]
    },
    "rnac_StockIssuedDuringPeriodSharesCommonWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesCommonWarrantsExercised",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of common warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Common Warrants Exercised",
        "documentation": "Stock Issued During Period, Shares, Common Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series A and Series B preferred stock to common stock (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r54",
      "r102",
      "r106",
      "r138",
      "r428"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock under employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r101",
      "r102",
      "r138"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Series B preferred stock and common stock in connection with private placement, net (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r101",
      "r102",
      "r138",
      "r771",
      "r846",
      "r860"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of vested restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r138"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r101",
      "r102",
      "r138",
      "r504"
     ]
    },
    "rnac_StockIssuedDuringPeriodSharesWarrantsCanceled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsCanceled",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Stock Issued During Period Shares Warrants Canceled",
        "documentation": "Stock Issued During Period Shares Warrants Canceled"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercises (in shares)",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "documentation": "Number of warrants exercised during the current period."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_StockIssuedDuringPeriodValueCommonWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodValueCommonWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of warrants",
        "label": "Stock Issued During Period, Value, Common Warrants Exercised",
        "documentation": "Stock Issued During Period, Value, Common Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series A Preferred Stock to common stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r102",
      "r106",
      "r107",
      "r138"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r101",
      "r102",
      "r138"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series B Preferred Stock and common stock in connection with private placement, net of issuance costs of $5,585",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r101",
      "r102",
      "r138",
      "r780",
      "r846",
      "r860",
      "r943"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r102",
      "r106",
      "r107",
      "r138"
     ]
    },
    "rnac_StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, license agreement (in shares)",
        "label": "Stock Issued During The Period, Shares, Common Stock License Agreement",
        "documentation": "Stock Issued During The Period, Shares, Common Stock License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, license agreement",
        "label": "Stock Issued During The Period, Values, Common Stock License Agreement",
        "documentation": "Stock Issued During The Period, Values, Common Stock License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_StockIssuedDuringWarrantedCanceledPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "StockIssuedDuringWarrantedCanceledPricePerShare",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Stock Issued During, Warranted Canceled, Price Per Share",
        "documentation": "Stock Issued During, Warranted Canceled, Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r106",
      "r107",
      "r125",
      "r804",
      "r820",
      "r847",
      "r848",
      "r930",
      "r944",
      "r1089",
      "r1112",
      "r1176",
      "r1229"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 deficit:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r224",
      "r435",
      "r437",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r448",
      "r449",
      "r451",
      "r455",
      "r602",
      "r849",
      "r851",
      "r864"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitParentheticals",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r929"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r678"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r678"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r678"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r679"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails",
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityAttheMarketOfferingsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityJune2020SobiStockPurchaseNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/EquityUnderwrittenOfferingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplement cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_SwedishOrphanBiovitrumABSOBIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "SwedishOrphanBiovitrumABSOBIMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swedish Orphan Biovitrum AB (SOBI)",
        "label": "Swedish Orphan Biovitrum AB (SOBI) [Member]",
        "documentation": "Swedish Orphan Biovitrum AB (SOBI)"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TASPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TASPartnersLLCMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesBPreferredStockNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RelatedpartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAS Partners, LLC",
        "label": "TAS Partners, LLC [Member]",
        "documentation": "TAS Partners, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "rnac_TakedaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TakedaAgreementMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda Agreement",
        "label": "Takeda Agreement [Member]",
        "documentation": "Takeda Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, amount",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock, $0.0001 par value; no and 548,375 shares authorized as of December 31, 2024 and December 31, 2023, respectively; no and 435,120.513 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r411",
      "r412",
      "r413",
      "r416",
      "r417",
      "r533",
      "r729"
     ]
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity Disclosure [Abstract]",
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TemporaryEquityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityDisclosureTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Temporary Equity Disclosure [Text Block]",
        "documentation": "The entire disclosure for temporary equity."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TemporaryEquityOptionsCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityOptionsCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options for Series A Preferred Stock",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Temporary Equity, Options, Carrying Amount, Attributable To Parent",
        "documentation": "Temporary Equity, Options, Carrying Amount, Attributable To Parent"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of replacement options in Merger",
        "label": "Temporary Equity, Options, Issuance Of Replacement Options In Merger",
        "documentation": "Temporary Equity, Options, Issuance Of Replacement Options In Merger"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Temporary Equity, Options, Share-Based Payment Arrangement, Increase For Cost Recognition",
        "documentation": "Temporary Equity, Options, Share-Based Payment Arrangement, Increase For Cost Recognition"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity",
        "label": "Temporary Equity, Options, Transfer Of Preferred Stock To Permanent Equity",
        "documentation": "Temporary Equity, Options, Transfer Of Preferred Stock To Permanent Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Temporary equity, par value (in dollars per share)",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r51"
     ]
    },
    "rnac_TemporaryEquityPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock and Series A Preferred Stock Options",
        "label": "Temporary Equity, Policy [Policy Text Block]",
        "documentation": "Temporary Equity, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConvertiblePreferredStockSeriesAPreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, shares authorized (in shares)",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, shares issued (in shares)",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A preferred stock in connection with the merger and settlement of related forward contract (in shares)",
        "label": "Temporary Equity, Stock Issued During Period, Acquisitions, Shares",
        "documentation": "Temporary Equity, Stock Issued During Period, Acquisitions, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A Preferred Stock in connection with the Merger and settlement of related forward contract",
        "label": "Temporary Equity, Stock Issued During Period, Acquisitions, Value",
        "documentation": "Temporary Equity, Stock Issued During Period, Acquisitions, Value"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TemporaryEquityStockIssuedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodShares",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A preferred stock forward in connection with private placement and settlement of related forward contract (in shares)",
        "label": "Temporary Equity, Stock Issued During Period, Shares",
        "documentation": "Temporary Equity, Stock Issued During Period, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A Preferred Stock in connection with the Merger and settlement of related forward contract",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityTransferOfPreferredStockToPermanentEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity",
        "label": "Temporary Equity, Transfer Of Preferred Stock To Permanent Equity",
        "documentation": "Temporary Equity, Transfer Of Preferred Stock To Permanent Equity"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TemporaryEquityTransferOfPreferredStockToPermanentEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TemporaryEquityTransferOfPreferredStockToPermanentEquityShares",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transfer of Series A preferred stock and options for Series A preferred stock to permanent equity (in shares)",
        "label": "Temporary Equity, Transfer Of Preferred Stock To Permanent Equity, Shares",
        "documentation": "Temporary Equity, Transfer Of Preferred Stock To Permanent Equity, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1105",
      "r1183"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Equity2024PrivatePlacementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TransferOfTemporaryEquityToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TransferOfTemporaryEquityToPermanentEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity",
        "label": "Transfer Of Temporary Equity To Permanent Equity",
        "documentation": "Transfer Of Temporary Equity To Permanent Equity"
       }
      }
     },
     "auth_ref": []
    },
    "rnac_TransferOfTemporaryEquityToPermanentEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "TransferOfTemporaryEquityToPermanentEquityShares",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer of Series A preferred stock and options for Series A preferred stock to permanent equity (in shares)",
        "label": "Transfer Of Temporary Equity To Permanent Equity, Shares",
        "documentation": "Transfer Of Temporary Equity To Permanent Equity, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r432",
      "r450",
      "r601",
      "r628",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r740",
      "r917",
      "r920",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r931",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1166",
      "r1169",
      "r1170",
      "r1171",
      "r1173",
      "r1175"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsAsklepiosBiopharmaceuticalIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsBiogenMAIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsCyrusBiotechnologyIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGenovisABpublNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsGinkgoBioworksHoldingsIncNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsNationalCancerInstituteoftheNationalInstitutesofHealthNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/CollaborationandLicenseAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "rnac_UpfrontRentalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "UpfrontRentalPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/Leases65GroveStreetLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront rental payment",
        "label": "Upfront Rental Payment",
        "documentation": "Upfront Rental Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r170",
      "r171",
      "r174",
      "r175"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance, deferred tax asset, increase (decrease), amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r610",
      "r922",
      "r1171"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r610",
      "r922",
      "r1171"
     ]
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Technique, Option Pricing Model",
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "documentation": "Valuation technique calculating price of option."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/LeasesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r929"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Warrant, increase (decrease) in equity, amount",
        "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r454"
     ]
    },
    "rnac_WarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "WarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant issued",
        "label": "Warrant Issued",
        "documentation": "Warrant Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.cartesiantherapeutics.com/role/EquityScheduleofWarrantActivityDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofRollForwardofFairValuefortheCompanysLevel3WarrantLiabilitiesandCVRLiabilityDetails",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofPotentialDilutiveSharesofCommonStockExcludedfromtheComputationoftheDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase common stock",
        "netLabel": "Warrant liabilities",
        "verboseLabel": "Warrant",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r935",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant liabilities",
        "terseLabel": "Warrant liabilities, net of current portion",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "rnac_WarrantsAndRightsOutstandingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "WarrantsAndRightsOutstandingCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liabilities",
        "label": "Warrants And Rights Outstanding, Current",
        "documentation": "Warrants And Rights Outstanding, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights outstanding, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "rnac_WarrantsAndRightsOutstandingNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "WarrantsAndRightsOutstandingNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liabilities, net of current portion",
        "label": "Warrants And Rights Outstanding, Noncurrent",
        "documentation": "Warrants And Rights Outstanding, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/EquityDecember2019FinancingNarrativeDetails",
      "http://www.cartesiantherapeutics.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesforWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights outstanding, term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "rnac_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cartesiantherapeutics.com/20241231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants [Policy Text Block]",
        "documentation": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plus: dilutive effect of forward contract liability settled in February 2024 (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r260"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding:",
        "verboseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.cartesiantherapeutics.com/role/NetLossPerShareAllocabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareAllocabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r260"
     ]
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://www.cartesiantherapeutics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred debt issuance cost, writeoff",
        "label": "Deferred Debt Issuance Cost, Writeoff",
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Paragraph": "2AA",
   "Subparagraph": "(a)",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479341/842-30-25-11"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>152
<FILENAME>0001453687-25-000060-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001453687-25-000060-xbrl.zip
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MH(N^7T3E#6S6M*CK8O'V!2SW5I5U&D>9/(4>R%_;;3QXQEM9E_#_B7ZR?'U
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M-;3S6,D,^SV&LG(CX+><QBJA_R\;_ 9;= <4IXU,&DUD9X\[>24WD"^!>5#
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MKKAMW8?>7H*R"XP=8Y*/D[1V/CF6DB&'YR@UF-!%]R8TW 11:B4!Z"0UM(?
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M?-,PRF(E T\6S@\CGT53QC0&PW7X>Z ^!..\=Q"%+9RRIZZ\;"=-"M=IJMY
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M?C';Q_G,X/GFP)69TN!_VF(6@!9;=.SVZMKIYK24VL E]"YIAQAART"X3N
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M:="U3L8=D-0>1#Z8C5QY+MZST1XMSMMK,8DS@X(9:"/#0%?X=E4%ZYV0HMB
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ME=_H89=VH]+% APYGL-%8,8-L$Q42WYDBJ,WP9K-,GD%$TD(]3Y%E;,'#^'
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MRL(2",5!%^#QHU4"/M,L+1?T@)VQ,K:LIIT 2M9M9/ BR+HU1JGT6" ; YT
M$Z887^=*.NW!4@@.2]E+[JZ-@FE4I<S[/LAAP+=AW]9$K[P(^ZX0X):5J9^
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M*XO1_0VJ2#:.2[8L$D(G1TW]&\$:XT=1JC1MR80S_I#JENHY394OLLR[3>B
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M&&&1MYO5U,@%:'&*6<ULF[9VPZ=4#8:+5*+S_\[4"!GAD/KU-Z(OS;R<EA5
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MQ=ZKO/3[FW,,.\L=PVOW5OG7]#;[_P)02P,$%     @ U3AM6@;BS,.\,0
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M3WNABRO07I&FN]I OR; =G%.= Z[*O\:B?LH 1+"2)0!BYD\.4 60&U @]J
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M_S@^3WLM)L%0;N:Z%) )6D"8:/Q>89+4B \.SR!5=<LI)_#56H4Y943=(5-
MY8<'5W@%Q(M>5FPAY9)I &2%?UC#\XSXDG22EYRS5O<%X&@S:@H MH4DMTDB
M5UFC:29F5S.K7+K9,4KC0C>2ITW[1SI(R:IX,"-.JNY/(Q??NQTMRKJ4KZ7
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MK_9'G/+P?LD%LQ:^K6\!UE!IZUV"'XLVAP*O0<*"VY.[[L>$4I(P^<#09.&
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M^MFMTWM\WIHQ*C!E1FTG0IS2T.CCF%&%@DV26GM.) 9V&#P?HAETZ6.O2H&
MZG%>N@L3G@"+)I8*3+]!X3;;+/BW<#5,HJ#27ED8"JU=S)F&BV0"HC$(N'&@
M?.A\( ;B46]X:KWD'Z73<FHEE79?@23[XMI^#S0.IMS]N!1>LA<85'!]R1=*
M=1LW[%,F2-$K65NW:1,4_ I04IGA+=E;/A"LBNM/D&AZG,+H\>?HAIM3#RUO
M.R _@*,CT!P[DL>&9JVN$?T<A&FY<Q_;']$SS%@&*FR06GT2(OLS/D*CWWI#
M'X!FR@E9#5QDHA9((' ^#G+H'@)E)%&('_48075R@_A)BJ.OH9GBX^%;NG@
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M*;BKC.[#V,#^AFX-W(<^/ 1F8'!6KG2KJ=\]NH]9D<^PG+\Q:8#*1!7F05,
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M:$0S]\G!7R07^ARX/7])I]CSCW.*_7U29DOX_V;-//_Q_P-02P,$%     @
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M,3(S,3(P,C0N:'1M[5I=;]LV%'W?K^!LS&T!RR'U[8\:R-(4&-8505H@V--
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M\AF[D6J:03R&P.M->X7%"AF1"A,*[L.%9%S.6"FM+@'EP!3CL@UJDK,<G[1
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MB.19FLU3-GV4M?%KN^KJ/_P[=!\<_@%02P,$%     @ U3AM6N(ICJ4\!0
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M5[061?N6V!KAZY[LZVONHV^IKV_M-*^[BAN?YNLK3M,1P-]I4#FSXVFA-8G
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MD!6\MZYZ/8ST^/8@O(+4\;K(55PD\51;84L';\JR1DM GA)0&//$#9ZU@C-
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M%V6MLLK$\UBO>S_)IB CS]*$*@A095]\08<TZ""HQWCD/?7B0%!I!60<,V\
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MX+4%R!WM^]U<[T._7F<%!@:\56Z'>,-)'L.?R)C_]OWABU<@=QH_2<Q/D5%
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M/?03ODCVH30-8$7 A]%[96K'A$%!=V[Z DLYUSG0R4KT1X##FFPC[.G-J@(
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M=S5;"7:J=B%>5&FEZQF(^+6TLS)C$_%G  DMX#HH@7<66I@+N3A#'QY8X<B
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MN\@O,"8'J^<)EN.]%&L :Z H?$7:VLU%"WTZF'/1@@&TBLSA:*@%,E4GYV(
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M'#F1$XIGEQ72V9<<9%76*(X;4D#!/*YQCT%F4[' 3&I!NMWDH;C63C<:7B.
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MN40O+GCT&4:_@S_N> ^6&YV[K ]/H^D7YOKG01C>1""X(IV\')R!I#OF)P_
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M, 8\%_A?+%3^:8KM,+:7WM)LUIOM9;"C\.J+L,.$:ASY,*;LUEY$ (S5QLN
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M6O7&X;H,*'OET]"W0_J*I_Z8!%9X]46D;Z]\.OJ6+L4:"5'YM/1MG7EC7<5
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ML+]]$'Z7I/K95U^&J\:Z^\O0COWU2-EV>K&W&D9;"AZ[S9B]UP(2QC%T?</
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MB=7Q[<(N/LSY_6"WW3J8^ZBQVYS_R<\Z5*NYVSQX?*@/=/9"/U0HU);HX%@
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MY^]'G.*P\HA_9+UKOK=&0-@1W1V+>5Z"\]G+T.?J!1@TC_\YO,^P *TDX5W
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ML(QA2F(?,6YM4J*@E4X LSDG7_#X^J)GV5A020:OD29+J!:!BA7I7#M0I0-
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M4#W@$"J[R0Y5KC?:<P3/30>08>IF?/U2[WT^M][UDF(:>*$^,[C6UCDQP/<
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M=:6# 66L49Y>J]&H-5!.Y@'>3W5@WWRJ('*#U<Y"S,#6D@[L)M'.E]@.E55
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MV"./3?L(,L5?$VL"F^KV:5HN_3,-Y$)U".BJ;'I,_EVY%DN:D<F_.9)T5CU
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M>R5M:MFD96\HZ8W:%G*J1!S1[;=MT%;"815+,K$!SJVY!-@^?+S\&#G\3G!
M_L0$D0Z@LGKR+LRC'%)P$L<#$$&"C 5WLNC.XJ^*[OS[ 0"^N@< W(*QW%H
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M*-9"B&O9YZ#5_Y!5UE_L/RK>(&5(P'4$Z.8H_.H(/0N581M;_^@!")S[2;W
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MLW.)E-+&,"4_6K?]YBCJQC %:.3D[["#NXS2^S3HR=-M?"V!T-6(&+>[),W
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M<9IV;4EEE(X3X"GZ)=M9HV@24*QBD3I44L=OLD1:X6)#1P\1=8A:=A'8 %K
M(Z>$NH65(,\K0:8G0#P<355V/9CX@T7QY^_I;=G 1_L*$.*4Q@*:;'!G;"?B
MNH?E8>(W2N*$V:,S/M.NA;J3TN^Z>A=FJ:P'U/%N^X,T/J^ _%Q?J!@/&P7,
MJO?6U-.L26ZC2-J1L4N?1%'\$;8IN\LFATO*C"^FX7XO@I?*E-S!*(&K4"79
M1&S P):X/&3V&\N1?P*&I-%PC\:F!5!'K'RJI$(#$(O1#C#%HG)%1%?O2N"
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MD7TS?366SQ,ZA^^2T1EP(0X\:K L-ES !\,D\RD&56S2U]P3SZJJIG60*J7
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M7W1BJMU<29E[%2V(ICIO-[5O+C_V"9^2MIW&;Z['H]$K]B#,WE>N):8\<JN
M?.,6WS,\^/X2@< *I;.(F']6=M-Z0R?/RAF"ACRB&E37-"RQ_7?6D>9SXI%M
M\N8 =P(T>2U'\!I70NHOU:80M)F1/7;;<Y)T6D8Z\0[QH\F>06Q&$*AKJ=/;
MV3;:$5;4&I9GL5W"G"^(=2EB?3^I0FVW(_DK:X\U2&OI6W?GU)8I^T@@N(X]
M.\GH28&C$=%QPLY]CY;GGDD@W)Y4PMLNP#DJ)D:T'>50:8^!<]+4E8VX9M/=
M)"/LB0@5C1T<2>\7V8,PQOV12*-[):!0X'E#XG(U/-6SWR77SU@'Q2!,YMQP
MHKZ:F896'E>(]Y/FMUALB_(RJ#,A!QK:M_&(^=H<VY-!Z(6\63'R,M*/['>R
MFMSNY)"K%7R%8/KJ#P8KQ*)4.N/;@M\XQ4%8X?!ONJJ)K#4LJ7#7%J5T/8XK
M+_VRKZZ,8H5NOW*$"*+VA]&0_VA%5@SA2B1/E'65.5^B#Z<:X95,ITM5Y";$
M(%^AJ1B-/IA$LU-]]\$WFL8M+'\?UD.JY%/6I<]W%,OLZ]]]1UI==9+C"X&2
M^GIB[1$XW;57&Y;"#W-9>Q5<K;8:\O:*JB@S%"5-I5U0B!^J8 MA@A7B!6D6
MB#O-.D!Q=Q/KX@)#JZD<AT@.!^RKC7=+Q5>-\;(DV>2W&(,(>6TSKYCK8,2?
MPU"K-5</N]0.,Z*>$491-25-IUC<WAK],H_S>(6/-$,0@G;/T2#!9"H\%=.%
M<01)8D4!1< !QG)*9S+XE3!M/$"A,3V8 =;T\Z%2(Z4YX]71P=_;T3M_D4XW
M&1Q%0U +3S.#SY\W"]W:5Q7)X[0.G\BPAP\)#'G^"DWGRGZB>\^2_F5Y=3SY
M>[4;88X+WX^))8[!RO;SEF7_]?O7> T[ICD_6E8+=?[]JA]]Q&4G4.OQMS:U
MFQ]"OC8G7QY_A;5XH]L2,<=[0.,U8Y%3N@>QTQ]DX4MD_K_C#>,_GZKM?46#
M24P\\W][=@GC$5G\85SW_2;_SDVNEH3*;8P3L#W2=(,"#.=ML]V@J4[$A^=E
M^K;/TR#X&V5)8V0<-HOCA0GJ+MSK*M+IB\,4O#V6K6L;H.WFJ%T<K=L9&+"H
M0D564^U 50P/(AC3ZGE8"@@HZ8+%+C6H$G%J/E,(%F=)92$G#_X3XDAG4C4=
MN)"JA%7S$E_L,1SZ:<=(",_WM%HJ/4L^!YL9OOD0;VD4^3?^M>BPDW(G^.OW
M%^+&+P1)XGLU-*9,ZFZ7ZKA>:=9>\H1K4 G9L8.M)Q[I+M8=*1U#%)4L9[=C
M7_^1'N0'=O>PBW6_X8<WG(DDV?$SYCL&2@V7-Y8KOE9TG#!UOGA="'S@G$ =
MS00%$;I>(^&7HG59NYEKU&5TSB06MA"84F&F4@1>O*0J_<F]X*7:K\Q:RF%C
M$,Y%>2>,?U9'?;L%4E9$%\EH%9'A*9'S+A",C&Q(]K*A=T#X[<F)-5]+\/_E
MH)S?+T)?+8W&6]NU%$YQ,()U\D"&3>DO(UQCW1=2K3]4.T'(=YND=1X7:D!*
M3//DJ]P,D2]]7<0/OF/WB_VO/"E49%__M6^4RG?7-MH SV9;S<W[B@2M<B;8
MDTWJX=JN9H>KF"">58*GYB]]AVH[./8[EF:NUAH,,]C:!YV/Q"8NN5=,)P7A
M!$>AY\2'3WTO'4U6IL/!7TGLS$&]+$T;F^DE2N;8+)1CR=KTO/G@@X[@2\1.
M\*E:? .R/%(\ST#G7)%1[<Z[:#FGA_!0E/52B8@1"H\5GQ!J"I!Q]4@6WX\E
M$3YD<;#H2_+SD54O6.Q@"MR4[^). 3"QJE5^O@83"A]!QO1($2D]OS/9R:JD
M'U^GGPAGE=4.21XI.8GQ0#@7TG2O)>I83H.>H+W$T!(RI(@02^L^0[DEDS"X
MG'-(>S(>@=ESX\I;/<UAI1WF#':01Z.S>*$@-YCH<%"*:_F?$#H/I[<;A:6_
M]Y>&F5YXEM\4\O'26:=Q]^]'EJ^0N7FB1:-33JHM"U\9[&F\C^*;BSHBNL-W
MS\]!/K#1#F<;BV9$U13+;1,H4LIL'_XG+HOE4:7=F0'=I8:U==C-TW!0EI,3
MX(Q.'E$?H45<96X/2(.0%O%LDJCYXZL+0R$13F,/M?L"'1C<.)(G.&A;'NQ3
M@A<T%"_?HNW)STU$/SVT06&QM.5$,WE3O@M3#Q-\%9S*:L'0T$@DJ+"VJF,A
MP3PQ.!]?5(M.NAIA1TS;]FOD.!13LQ)R'P&R6 EJEH&/Q>F++,>D.#"3&RY2
M2,FBZ-[P_\:W6[5R5U4"%PK;(R+GSD,^(3+?=-O5>G(Z!U@_R#DMKD2'QG"V
MMST9GW23!D3F0B;+9 C RAYF\/W3TR(C*I;J+O9LR&*^4=,%N]4C!1&4'I7#
MU'99B+EN$G8Y$B_,/0=QC.+C[_>@K C*^NH>E'4+QO)O"\H:%FZ-)=B>PF&Q
MA% M/<"E-#W<_E)!%*Y;$%-!P:#>*\5/M E2!*!MU1T:W+?Q3H)._1+QG*[!
MQ9."!O"K+$LYLU;:P'==!.L^_/H@);3UH/2)MXR<20MX2C,!H@%Z)=0%BA4?
MAS[XDI6$+AZKQ:O[A#+Z%-$0SX)CTNZL!%O\F;.2ED:P=R2B<O?YE$\W85)=
MV&T4([U)_6O[0CDG)#LN8.^93E^[PZ,;;:]^XAP=L#L[3(FD /=I.T-QW6(+
M\Q2P_Z"YR3%@D05EG4(PX&><Q*IE I*/9,V5M: HIY2+X"18AZ]7RE\L>#4F
M?8\(Z4)D)2CV+3B%R:*YS$<5#C8@B8 1A%M['JY((\ X'GG0HQ^15UA'?O=]
MI5-Z(T^#ETA@WB/Z& ^_Y!Y?E//)X\<3<%D=L45Q90>_F'SU)7YW=0&>+=8>
M SF#&);$/^<"L>N#:%(3SX$>10(G*,S)P_<_*^B]=2NEF<:I<#SYZLE_VKF*
M0S/\C,8G09O,VIL7[)$71O[RXBF##B^>AC&A NAX<AK\H_2 ,.QZ+LXV*U7&
M'$&Q6K/W8NBH)XO-Q"3N6$YX.(.@YC'^U5T=__MDU>H="@>P54T!!&S;SH5"
M! K@SI\Z7.;S5E2% IQJY:O2^#G6)@@464:>GUH*&K$ERIK1BB 0RJHD.*BZ
M22 RE#?.I*=B,SA(NS9>&F[0%#[K9:6E0%UK!L.:_[X0CHNE!J;*<T-8S82H
MN"7!.H2? $_?5CO]>L%0M[2Y N&Y"A'$1I6KQGIG*3E2>#%DHYP1OL47#+HV
MYK@S0DP"JZ87X+/R=LD:R;)J_:% +)ST#3YLMZTCT:NM=1RV[8_CPI5BHT6,
M$63W>\,B*S.4K$E-FEL%(*H]QK;H: 'H.)C81:=TIDHGO7Z[QU"VZZ7QG)2-
M4L?)$%2RA^&7P0F<E.'$NA4H!>N=%J*0/RC[@00-[4BP5QHZNLHC[_Z->Y.:
MCNAR;,C\8YHV.[*X',R\*+ZY\,#^8OPZ4F-(E:M)3"F4(!)>#@W^F5<9@_#H
M2!#W0T'.@&QOSS0 GY:=:V.RFA=S5;\3W@;7CY!\/B@;0)P[%;L9-CL\G%#D
M&H6:483'8$)7]P*O%.1>0OAQEH"\P#,5;';\O:N$YF&'GR6@PB/7C5$C1$.E
MPR(,ZPCOFU9)JS^NS/]L<<.S:::6!_N/*V'),/5X%783SY<'2!,!7F?YR_'D
M6?Y#(!#]8"R(#.=)?C@K^XL@:)MM;Q6"@P&7DR\?G'SV]G,<+.N0#FX+=W$U
M+.YWTHKS@I">77R2OL-I+.QU_&MW/@[X:R5T6,SI!KM%&37B?7K][$R:C,GI
M$4Y*)DR^A[]]\N#H[RRF".Y&%SDKL\__GR)ZTL-/G^#'X2*\VR4&5(^Q=K12
MXD9@- NF5_6\^_)_"J[M-.QF@M<^1Y"MJ396H!L>$"_[537M:S*&32XVF_5_
M??'%U=75<5_-CL_;2YH3*_)AQ7<H(8#['7XP,U=KXSRMXQFZ."P0.(9\8Q((
M*I#EX+'SG*T'PNMM2^X.& $M> QV1I/%5TMAD$R=7"7;KDDL)>Y1?N.\G<$6
M,V'P9ZUT//S.K*LSI2!D'S.T\NP9;#DP:<FU7>S6C&"]M5Z"MB19AJ478:$V
M&,Z[G""K74+".9(/YJWYFN%3E;G$7 G:Y^E)U%KA6Z=R2%\)<:H_H]JBAK$1
M'BT[15>ZR]FZ[=_J>OY__\?[HW0/O_J//UA8D46%__O_FG9?_/=]U#I&K1_?
M1ZUOP5@^?M3ZX(WYZT[DN$WPZOGKOT^^/SU[\_.KUY/7O[QX<?KJ?_\I!5:_
M10[<%5/CN="R"\Q+.XFN@"?;M#/$:H)G>2G\,H2X!$O^;;"._W>[G?07VH.T
MJX2>O2.SA)3]2$1&:FDVQ/VE].6X8D@M58)[P'2SPJ1?A5=.OA=6U4C :AVR
M1JH;9(S_]0?:H?]N@.\?V*V3/PGO^1<?F#V\YPD!G];5U8<M@BF/R)/Z(&)3
M7$EIO,"FPNYM$00&"TT$ X!:L*\JRJ?%-G;^)KL4TMZ3<G;!:!(932*;E&,F
M^1C([K_\FMZ^C;=])QJ&K0I\CW67R%MLF[G)%V-1BJWJ?9CK<'Y,A(JQ48(<
M[& -\?'D^<+:\6X;\T*Z$M@ZRZJ0JA=#UE@H@&95M^I=57/XS=8R,REE.-,
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MH9=>XZT[HGA@4[+.(67#]'8MK:I6D[=_5I'"[>9U^>O*6>ZK6>XNU".=BOQ
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MYD2)X\20%W]4P;30DK29I 5J1M0'K,_49;-P!E)6H@^Z:TYV[4406T%A(&O
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M/M]YZ?'>+&5,!+._? HZXI@<67HQQI2-6/O3$E!RT:\JN\N4ULSD251"=OZ
M[Z9<EC$@66NL^UT]@W5I;A6[$(YLZ]/!6^*N?G@!>'2SA68G VNT&5?:042#
M40@A7/O>D1'4@%<K1TXF<-IFR)WGOZ@X%Y#B'$B)*Z.2JE16XE@66Z/W!(>0
M*(9?B=%B1D0<?U\02JL6;&*<-+HOGK/M;/2.QO@U)D$\;(/\NM87$;]I(ZT<
MR8O9*MG6I00U#K!L(1,J?)Q#=MIH*N3LF,V'@ @L+3_RRKM_-1%:0V;YR))(
M>6!DRB8;$0DX[@@R+Z%=9D:B[P=^JSYRA+>*ARJ_J^89;5=L@T(_,?T^G;6D
MU&T7E[4]>;8LZU4O4<1H*9 Z4\N;1,ITJRP45SC<7$K4BR]K >HL+OT)G(5X
M:4!C4G\H5%7O1S\:BM*L8 JT"IA![:7=X9A<"O%PT\VR*S(*W:S_U'N#9CY@
MXLRN>\Z%C]!O<;_97D1,.7F^R#;_OECD5FQ4Z@6?]"RV*IKAT=GL$QZM'-CR
MQ!$3>E0F4_=^@V_%!N_;4'D7AD83?";MVX6UM<UKO*V>0.(P1HPUS(;=;_K-
M;7KD(,D;X+&1.[(9E=W$R?F6A47;S5(J/PRAD81RIJT7P[X="4AX7^-WLQOL
MXK2*,KJHR YFD5BQ==6^<OO$2ZQ0&(?- 7:64:I_;IM$>K_9H^^?!>=,V+@[
MYJR#*5Z%_[^YK_*\T1,@O-3K[2;%"D":6W7WA9P?[RIZ:6MAE5(BQ1;15>=R
M5<<PCS2O.#=DXJMG+UX7)-;GI>TT5[IJFYI\4T)()8V$$;\-+BK<H3RN/S4@
M#0,_5="_$DS67W<5/YWQ3WK969@0OB@&WZ(3=VIG/XEI7D7J<5B?@"_L@P7:
M3'>FU7J"_]AJ:6@YNZBK2[5I@<W,BR6'6?AK\4!9&KYP6?Y]!-P@6#'*X)^'
M*W[_IMP:[N;GS5Z3%:NHR LM4R<7$K'-%#/Q1=OE,8.+>K$12[4V"U@XO22[
M<L6$A@0K '5P'&%MHUMS4<<?^$BLODWZ !\<E+&@.S+!"^9?B!EG^>;;:C=9
M5F'>'8B2W!S#-O=MTP ]9&=21JPY,-(I5=UE3< 0CJJ@?%4 2>(NZQTQ%U +
M</5H^8L6'EV1(]L2^HDN@JVM]+@7IEZ\HT'F9YE G8MD.S0:018LN!Y5"R_%
M'XBCB3B4ISBWN$XBN<[0<W^UU/G+H1YO\H"HG6N*8&G&WLQC99'?["(6$2^J
M:CXE-= ^"[_D$U,N/?SFO"O!P;6JJHWF)T%,B +E>- 4T<CWCS)6IY(O>@,2
MM2M9QES)1$9:7;G+,-W.SRNK*Y5;O<0H^_?>BW@%9&$2I^ZZW!E:()BY'59%
MF"RDODN8OC/6;^NM9%#R/D]OZ R.)Z=(/I_'!=EP^UVV" ?7&.<JB7R(;!XP
M++OYVZ1Q!PY*KWAOF&=:9X4('2]$/T34)QZ)6-@?BUN,I';)T=9SQ6^%ZPWR
M28+@#T.P[LIU>EKWP/6)*MR,J(FXNB111QHC=EK2[%/E.KM U>#229FC]3/"
M,1!'"_(^9O>F._?+T0UE-M#?,%R]^4%>^ %/<Z+[U\Q+CB/>8U]_TVU7Z\EI
MKL%0V0[@]+:'+VC\!E8_9H493%QST?!*K*\33KF UK'4D>@^C!M:*[*KKF&[
ME+-J:P0G\VT8#5C3N[#1P38R'K.(58Y(YKF'=6^T:9A<?"G<B')340AKZ;R'
MW3J>3/+L!J:BQ96.V6%7E9TB/\@B[O8-2]5?;%$I?M4DRD^]_S#4E&[!!]9T
MKU,8-"X:L]HLB0+6O%N2[V#6Z7T]:,Q484/;71!F]_C(A(]\>(^/O 5CN:WX
MR+_\_"EMZ3I=WU06(J53(ZY*W:M7/9<V"<X!T5(V85KIPB3"?\V]$( 8HA1B
M$EM: (RYB0XC,FY4JJ'O;,O(4[3M#MEZ7MPK-B?6^EA7SDI54O.)V>>Y#K%"
M-@7(K*%)8GDG"1[2UEL1Y4_6 .!YTV_J8(E*">V/U?_/WKLVN7%<V:)_!>%[
MSHV9B")'+UOVU8PC:,JR=<[(9(ATZ',!2'27"53!]>@F_.MO[K4?N;,>Z)9&
M:K);^#)C-8%"5CYV[L?::Y5[@OG%1?_;MW\MQ!O3N)) MIU<;-IN6=Z6($40
M#I%;3^_BT8^*7ED:S[=_=9HRMZ8&J>VN.?6*_)BM-]"5/@WA=ZQQB_$.'-W1
M,^.9\Y(V(V?G0<*^/_[GNOV//TX?6VW_ZS=WF[?/O_S-QVB\YC,JWZ.F\WWJ
M(/\NJ^#!"8ES_;7(M% 2JUZ]C;'8]MGKDINDGD#KV ]+I^>J%2W/O+"Y*8^\
ME;47)SJ<\5,;^2\JLY%B3PPFJ,O. 5-8F,!E@?MK0O6^1\-9%U(>-FYU'!R:
MZ*-,-!1#=1B9T.=3P(B*,:49Y^SITH0+&+J6AH'1BNG$ G(FC%6SXH?&U38+
M)8R?'"5C<Y75G "KPV60:=W.C*D0P .1Z33CQ%K9MD+YP#8W!8_4GMO2E;$\
M)4]B^1?V=J8(RAHZ\?95XB_"LDYE=]85 ;7ABQTF]LR15"#MQ;)%^WA)$D$V
MA?QC"77-K5GRN3P0@6K')$SI+K3'T2;H,DH,4&^$MA6QLA$7OERRWK62WL$9
MX&02[!VA;,F,U-PQ_B2T_XAF)'62S'$]Y1V,"VQ>M$4.Y38(E0M7NY^M3\\4
MJ[HNNPHE%'*X!.Q0M=E^W#,S@27'9!%HF\!8-8!4'TK)7L:]%[V[S1-8A!^"
M748>#9HN)K1?--"\D3M*R@"6$ %-2G]BX]>P/GFGI)'9E[5>"@C"4!L?1V&'
ML)-: :^053?&\LJ/?][S2 -LG:NXJ>/.&XY3A\18D**'1I:)$M;2.Q>CR?T^
M4#[/6H)H!8N,RHTN'9%',F8DM_U;*?"XUN2:+V+P=5)2NEW%P&1O?)3(=^5/
ML%732W!@<@AW_3;KO12_64F=<I/'&"))96+ZS%O7YIW+[5)6LX%%'Q<] M')
M 4B<*%"?KA']MG:M'N>\V#7IRE;[K>K#(\N9?3S^+_/ 4N@+'VL+[KN^Y#(I
MIC!.*'$/\268G.NI2SR>>_EBWG9",6K7I-_ES*G<L.1VB?CAG/<5(^!VJ/H"
M%23I4FW-,*%G+Z55B1RU+W=<C4QOC#S.1(S<WQ!.F3H^M^Z%%<0Y",S31X&Z
M'=)HT^*C#D(_DO_DI.\FI"J%OB8(/*BC3:0%;P(?XRJT,O.<>)[[]XP6.[.T
M"2687A4)7O*_&F9_8=](T_H'NA^H;M+(%Y"P$#=]5% >U<&DR  .FEY;!<C[
MBW=+3</4Z\=\YWQ7-NU5-$;_TFX\ZD7][E6'YXI%6Y8_/ZG18/2BU8K KR5B
M<>?27'F&0T5P)A;'L<1PF5%[57Q(D97!1W-P1BO]T1NHMTNH88N$#-#@F]2L
M.6U2]=3:R9F><]<ZKC\FKGH6PI$[SP=B'-AA'V+STV:+?GN#$CA_821'>Z_Q
M3-O2C),?WNGSU2L8AVJ/Z(C3@O:?W#H5AV)!B '.[OZU,8V($9>P55=5Z@EW
MR3ZUP*(A7V_?U*<WQW7BV)S=1M= G9C3.;".V\]<PZ>]_S/[IUL<%@>L\]JA
MZ0RPW@BCT)83")EA=MFC@EFSZ()UUR;_87S5L$'KPC3_I+X]>W+>7YL:>J60
M9'4J.2_>^7/RS&/5$1_-,=3(D5R. PIZCO[->GBYB7;^B.A;@#O O4/9B:<"
M4KIVYG+R-SZ=<R[21'_2&>^9O$7\<Q?V-T!RNG,,L8AXA?=!2R7YDN8S,DZ%
MS]3]>152?QQ5."^=;A\*_GL_XS8G3U+5%?K<A7B47=E) ^URDS>[J=N<.N6"
MPO]85S\E+MCUC)=NWT]OT/S&/7O/4OORHM;%92,\>,<5F"D9LS3!O&;[X;(V
M#]LJX^)MIJ\"7)L7A@-)+8$Z;B%)-H++18(/2-X!9P]/8GV:\[Q'E)(25EJS
MNE "C1+\R;/FF/0BW)F07Y]?D%\?P5@^//+K8OM^IDY@0)^S1E[V-,#=1;9)
M>+S69;^Y#MTHY&%0,T0&-MH%'+\,K.V(D=IR:3/T\*MHA\)%>/*!=T0"5Q>^
M1.ZB$F26,C9^CO"-XI@KH-W8]7P2[-)2"!W7,_)" Y#E,[ =E>"<*><7SN_(
MOZ<KH-F*+MK=COM0*A#T6(8D>AN44D"R1)9I&\HMO83Q&RJ)DCB>CDGI\>?0
M?O+:)&#^R^_)U[.U$7D$ZJ7E/J*\RL!$":S/2B#.I)BB#TB,;>A[<GL 7;[<
MI3N['=*RX@CM*9>V7;V^)LO\^5P2P*,=DM9+F@:KWRM/6[XWN[Z1QBJS^R)6
M):6B=)Y_'GG8CVGC*#%A MQ-TYZ,$;NSME/P<P[< X(VNDH9%T+=#8(LB=X_
M5\SGJ;6K3C>*=&-NHL.U1?>P]=!<A1K=*ADK(-4RJ#=<4-Q]$^<P'7X1 OHN
M+G5S(]IZJ$S([=\I[RX9"6$J_<O+UQK$\*[?<3:*!H>L-%WMHG* B 5Y4.4*
M2?W($T$M85H4FD66MK$'A*U]E[)8&\+<F$X6X=V!OZJWB:.QI06EH\QLH%S)
MV>]*48^!1\%-U]61]189N-<CT?M\]4I0#2))KL6&F3X>/EDB7N)**+N)XH85
MC/-R!UD9KMXD^(QFQ"D91%9\O RNE!171+J3,&F\#_IE>C[++4'_8JA)(\+0
M2S^)J=GS/PU91<"5\<?#6(<=3 QR4VK8,K(XRVR-BL.S+T7(VG5PQP33I&DN
M_O]!X?.;OWR7[>*\D#:::C[][M,S[QMW*9& 3LRV[\U+_)5S)3 I.293#0RC
M\\))WKNC:L^"++=4D;M^<M*$)W$[O2:H+I#P]<^DRS=^DG82L9#&-[B]??Y2
MOO>6-W'\1H&IH>P#$TK0$*,)WK7E 9"B-)/;>)=P'30E+X0\1@OF+&0#'4K<
MEJ",P?]2SIAHS3=/A/4V0UO-72P&YU Y).N75$ (+%,0,$DA$=@N4;#2.> 4
M(F.YT*'\[6[VUZ2Q(SH\M/M8>2SZ#02[&E3-Q%?GM@/_J#6$I',2/[934@2T
M<Z0:FGT>7JA6TY([6C#8O4(KP6W3OD/K%*5HR+(IF;P2<H^0)JSDH85X5JW:
MEQNNUKG.E25?>^Y"72A :OI>R+_M1DVQD8S"U66I-WA:A?7@FW%%UN%]URRD
M2LP@?8$^@?W)"&WA2:14Y(*=1YER2[.AU80103\(2DZC"0RL//>M*82@$APW
M+=L>])@M182L#&\/SNL8)AM?S#"#3H+$K%Q*$YJA8\P=?@ $P/^L^^>+3QYS
M]\_+)432:YGXEVF5:#?^=[B*V_ EV88*9^J[LH\[KGL" ?^?20"XND,WYSSY
M;<6JB^K5,5-0$(0---22BK.C"8KA_/'ZU,6+LB2#FOC9O-MX+$\92X?A!34V
MI>/#*ILY@X'+U\A=\/BOVF]_CF6JFSK$"0347Y?LBK4V#=KYBR\6#/'"2\@%
MI]N(@CUM2 %?"E N-K+,9FNHD"%O]2= Z:/JF)FA1SD*#/M""?+VCJU[/X&I
MR3XLZ7;S@"2B/Q-.ABEWS 7&\G!98<"?:/N7FU,68B<4:W3NXVXB#TX"2;Y*
M,K^'&$8/%S+0AZ]O.P*E#+N6I_M<;Y4@SPW+QRQB@)DSK.^R@A]L!1O(66<%
M-W3N4%M0V:>.GALRVM08=5FKA[64,?:,5RD'MZA%E(PFF1 '7LSDQ[-PIABB
M_/5-<F"J.OY0/\H,['SN]'S"U)=SR$.%,FSJ<!,V?-8KBZZF,C#*SR<RR4PM
M%B%U_MSUGBC_ULU[3[!/C+&7C?2P%H"<V/@/ &/+1F'105/&.39'22\#7MZ>
MD#=*1Y^CA)V+*H3O%\)J07-[%U/QX>_C,25EB:L8E_(F7-;E84]>O%U#?=5?
MI\!4*Y,9GHF*VDU[ <,_\.J,Z9_R"JAPJJ+&JRF->*T>UM0WPQRIB]EB0G5L
M@EV1EX5]V(5URMX<*B8Z>'),O$K(!='WL,O#.HE3Y9ZA&R?JR,6X"J@VNL)C
MDH,YDR+^]8'.O[B SC^"L7Q@T/E'5:KZ(3CE6X )ZD9<40]<G">QB 8B_L^J
MNQ8S#9((^FYQSHW*"=GR_N0I083'(20NE_P9>84YP13N7PKF:MUV=7L=8.A.
M>%-U#!Y_E>L'8^>4SB%=8K=05;UKR[A.0\KSZH9PP NI/G'=Q0FYC42\$(5F
M?-V&Z%Z]3?7,:45QS-V0%@G_(EBI(!"!V:+<F(PA;5-];P;2IK&GC<Y3\B[<
MU1/O\6MSSTRJ%9/*V&B#;H&5Z!J NA+T%HPZ<<"[9@.UK;D?&:T8$O4HJZ%&
M]BS.QZ'ISS#B,5MY75$%_TUOE7DO<Q+V7;@E=KSBCB,R0ZIWT^QO%&-G:^!)
M@GZ<K1@QTPLWCWX-O#SX#Q])KX0BL^ZJ&\$NQF/UC*@%AH-^U;/F^9VW+^,B
M7M.;50:4871-PM,PD!9QQJV"<?:$KV.^GCC=M.@2Y ,-G(3/AG9V54V9XHGT
M/NRB#<A(GAQ]F$]&LLY,U8C@>>?TPATL4(K@2M*%A*:CJ1KIT@ "R3_']##L
ML@JL5"GI,F ;U.#!9OSXS3[7W!WD/&NZ<3@=U:; )Y0",]<#ZL/FNL8_!&#-
MK^/O@.8H58[ V@06<D("QB'_B]4LJ#:X%4ZIM W2 ]$V,1IF2J/7T:H+ /<'
M-C!$8"T0\-$E(\.W1Y\\Y9S4P%I&<0]M-RCDW/_X\LW%F#@W"Q@!H)C;;8NT
MK>,Y3-JT\L$EH7CD>#-.N>Y Q'MML0IENS_%(T<9#O<B_+B/^&VP4CCWGBI0
M0).=7G'G>783T\R=#YIU%W+2IRZ$=QG'[TB_:LQC V-T*/]!!9U\_MPZ -=<
M[@FEL_"9<QN2,*S[;8S;PN,W--\Y *A[><) Q;O0G#:T99@YIKT[_@2M%7]B
MM"3LB^8J!5=0GVT)*E[6<"*-3+M('@<PN*'SWJNBCZ3GBPFTN?EFME=G1)@$
MU;2$I U"M90:7*88?T.T+G)&SV0M%P[%C-L;MBX?\[0NL D:7;>'XKJ9.,S[
M@NQNT7\EGL8.*#S:.\6LUY5ZZUC?+"GD9:[K7+LQWU=2H^,.#*G6SW3W9(8>
MH')E LZ,,?=CT% (?$E\E8"O.S1FH288.FR/?ZE?#1FPKT&MA5&H3@R5&W0H
M#MA7 DXG5WO4R9"44D<.3\B.";,=X7ZS!(;H*^W"+=^NP'0B-1VRC'21OFO0
MC5ZO8WPIQ1TXD7?Q$7)[D7\)-'C0)R36%=@ 9UB7&/*X_<%^" .$_^5<6_?,
M[+O-T(Y:"YS?/1I<=BHHM]<V2;C48AQQM,7TYXR@R1#3&>.K5'CU::[2CWG_
MOIPG\^;Y=&RNW74I7/!=>9AOIO+(C)GF,5>L58LC,:!I%3(;._7"=$R#6U&S
M)AB+VTG/K$%YR161?FO0N:)^Y9+K -Q&[YLDM2T:>FH-\9KHN YSM]RM.;&\
MJ&M;09++ZSQ)?Y)1X/G"WZTU/I[:'9..AY,NGR/]]$YEUS0U%@QGE5L^^Z>0
M^Z,@\$^O7W[[8G5++(5UN9%9I%VI3MN+ER]&J;(X"^LUB09Q%U/97]^6)^L*
MME,4O^]V*;LG\72S$A4._,QB,1K<'4I]?'+:NFA$J4$D48]Z#:QY65,W$+<3
M/!TD*5MR2U3<8.1,6@1<9J_1K5"8^^2KT<O@KY]^1<RJ 5!SXH&4;XFQ*&NG
MY"BC>+[ZNRDR82D*^9AVK[+5FSGOFD%:ATP?4N=AB!MUO_KT,Y8?7*%>)*V=
M.Y*TV*3C18MOC^ .UW+UI_]^P6NQ+V]!B-OS<>/L8GQ8='1[EJBD=C+V2+(A
M\$ES8J4%YD0I083HN$C?+MG$PM\*):?LVNQ4#K7P_U-/PU^;VX"V<Y2$*?<O
M3;#&W7^WDIB+(IR'8>K6AA"8VZF/_OA'8TO /^X>(I=G-K=N.V,^*]SQYAS-
MCM]&\<;%:K#'G4[KIY\]H[U)#G75 )T6WL?SV!'U@5]>V&K:@B)N+SWZR-_:
MYY,G&'^M[0.A'K?,TO$RNA^4M> ^<B$1\C(Y!7?/.S%7+A)XQ3)/RS:74)#&
MQ]'1ZK0I991F++),.HG#&L>!]V[IRWKGW^="&E$Q*/UO(XZ;MR(C@$MAMRGR
M<-"0VR9>Y3KH;3#SBL"HW:(W/4YA95:/D8BE=?#KF]@OJ'6KFWA8I@>,'D5K
M< K4&1_*=DHQW.3,M.PSHGMWS ,L#3_)MV=[EOS'"Q@A@1%^>P$C? 1CN8 1
MIGVSHW Q#^#/=FL6/J+0HAU:$3/_8E?>-$Q:0LTN+BNGZ/I9C"'*=SY'!]7W
M2@4AC%WA]F,4./W%_8PWKCW4>7!,10\70BC1,\QF/J%$F3!T"@"<N8'G(  S
ML7V64*@;:G"U/4$) LYFW*4*QBE!Q(Q, A1_IHT/-+(%VENE1.WT9E02@S0+
ME*7*KFLV'#TEX,H,"P'R/GFV8;3=9R8B*UFZRY+"'8Q6J?@G_L%](;/<+)"5
M (U(/W4<J$-A,C 3/=9KZ-..^YBR1I<X83<T"/FH95&LZ3DG47N^^HN3>W44
M0QSSCQ,NB:GMW._(WXB#*\X7=R3GS&TD*[\-6I0.OAX69 V.I>:OMBZ4SN<6
M_=9/X+R_LHH&GY.JMO^^%PX[<4SI<4+5,,6[*@+'%P+F5Y.6<^WK=_P8(M;Q
MUGB^<E?.MK'G9P_O)D^?Z]!/N\SM?=1P_)[;E*BE\KXKB$0G\!%VV8Q_#E10
MDM.;+I^=$!^I*)O<="QB=TUEURV7!5*2Y4<=$[FP^CX<CKW3JVGV(CV[EAXT
MQE0X(X)\$&0MY]<A&<\,%RQ:P-D8FNACUD:;-5?A3]5%E=:$B)00>85M8-::
ML&6("+0V89+B4>S--)/IHVR 3*8EAR;3Z6;S!Z>B-2:_%>*@E/*743?1^:B;
M \5#_; 5W-@_AKB^N].YBU""YX7-K6$)BNB29I8&[.>K-^3MS"ROYR.+$_7,
M9_!L) C49!\J\H)I1_CQ:9<O^5]KEW!EFRC+E+T"\*1GWI\6!X05=JU,G"]*
M%:1_K?>X.[%!J=D1!W>)>R@GLKK[NKTG\O#QVW3&\&F>W#ET3B'1%;+'!SWN
MG/UI6I$6PZ6K+8]'94K7"TD.G,"AC:%TYNGY&D'5S:9!J9-=TA$+[(/-T*-Z
M)YY:EM[R&940 _-*?+'=9,]MF\#9B@J,9IQF2!E6\86.9<6V@ZZ2^"<N#Y%;
M0)]NF:0,3?<WJ!6ALM;ERD6*1"B68 BAD.;]$622*ED4<1QFW0X[X&EMF%Q%
M>"(+)Q2H8%5CL(&ANQ$: ;X3U$66#T,K]Q@-<%GCD'^?FRUXKO3Q&ZIA,YV:
M5,)<_<NOMUXO5D3O0B_05]D=%38%060+W5F6G)^=@7(?O=<M(8)XT^Z;V\"O
MDSN[\K"X)$W<DDJ6"=TEUM8BPYI(/-D.JZSL\W@B[;;QUTBB3N=*]AJ25UO>
ML.G&PLY;"_^0W#/QHQ.W>B.$I,  >'?#T0:M&=4J"7"Z.]Y;U6-?WDJVC"$R
M_3[U_8 _KNV]6I!<I49XN@(T.*^N-01;[F5:909PO.<RRQS\5+4+?PBU? 2#
M'=O9^\0KO+,80!H7PM-5[BC5LA5(838WFO><1=#TO@9YWSH#<,VLT<)'F-@U
M)]7DMB2TT2;>IWW)('5U(F9Q"HHTQC00&L[ 3N1U(.GX)"Z>+ 6#%>!5G&,
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MW-[R '8;CKZM%0&$A16;>">#C^'[8$2LB#2H?I DC_\M7AQ5;:EK1.7;!L2
MU$T?-SQZ[9LC943ZEO_KV&RKDO]#:%:JMCFVS"?X[X4-T:=!5CH!.VWWZ+@?
MLI8.]<\^^>PSL2J$4Z&_7C<=^GYS'OCF-H:$:*UAX@W7UA:M1*!!78>]41ZX
METTFJSH B$9=>-BSJT,@QL0S<(M?'TS]RPM,_2,8RP6F_OBNIS):M^:J&3I)
MA\Y7$32?PY_)JA.<MH>'+K$R/<)K?-&%=6+/9J)-.$D7RS.XCQZ&U?%KS02O
MTE^XG><!RXM:&I@S2]=7\IJNH5^8X\&\%Z\!GRP>-:I3PJ[K6U8SB"$2%>*N
M!F(@H)SXQ;]Z0/P!MF1TPTMUE)439#/JA.5]><@H/0DW3$)#E/H Y)3] .K1
M==!5L#R@6 (:,T2K5%U)+,Y;Q)9'$CD]]AI\Q(ADWJ/KKP=1@D$?MVC9R38*
MNQVQLWQ%SR!>9C!KBS8B/>HE\7 W;5V59#F[X1!'\5K>7)W(ER]?6VQ_*_Y&
MHX0F_R=ZC032^+0@1^:3^9@>K-84,I. G)]<%PH)/?8-^M9S:2PIA7;"T\%?
M;6DI<<K<.T0O"-'*A- ?GP9>_T@U[-[[MT2HLT>_I.:2R%%*3BASW],L<!BG
M;U.:%>"G4_Y\DZ3'..P'8P]7+_D-]4=I&M9 )@MW1AOB&GDN\(1=$+',,5=H
MZ9_R?/4BFC;4PWJEZF>_MC,"+2KY'R>!)PU+7.@XTSVKEDSCO.1,,TB"-V9I
M:R:YD<9!%&W 1/<O?9$LT(&2!'-&"*"#.C^E-Y7S+3",*1)@YE)\0DD/:[)F
M3QBB]8<O/_GL8S*17_R.8?C,H79WK1/+].>_N\HP]>!VVVHSV8,<%?+_<G?H
MEC2Z]J8SH3EMWOW0TTIX\CGL!#>.T^@XOAQE0;ARJXF0/.3M5;W'MF#R7.@1
M?_GZ]??CC*<W9SP=KGQLVW:_#QMK%A(Z,]OR.-$^)>E3__MF(PQC.K7_EJ90
M3BP]X-]G,OM"(?)_XT>W1'09RAN=C?@<0?N0>8O_@JAX-[18,^,UNIDPZ3.I
M$8&O>F/9&6H0],<8]G;N=\7\8WII#K X39OMG%M'QV]B?#%L'9! V,?[A>Z6
M(. /^B$\5>-_32F,?MEH9^+K3O2"<HV)\5>)<H-O?Y!HZ/+S11@_0 V9&YA<
MT8 .JZ]I1*_3>\;+-%Z0G_X^96!XNJI:-(@-#C S (.L1B,8'5("M;BW>?RX
MEC^SE\)B5R NL.[^=)?<(;7M?6V7U;K+2@D5 !-MY?K#7<\[N^H2"92C'!,"
M$,\?B8?%>TE!'N-W0*JH@O!D.K?-/!1LE+Z9(&L</@S46/!"(4=Z2I7YPNKV
M])#_ ,8 A%GK)<%OI7H4*1 %2?K95356*LPQPDHJ',!G90SY1&HIKHB&8&<0
M1);0NV/10!OA:/1@;NE,-$.]E7IL/%=9[3%)CW;!C [^B%_,EG09M)1%H$.B
MCLVQ=UFC&M6]BKP6YEG.B04X0>0,YT:YR0YZ2/'";&KF]4P N@G9HDN?"I?A
M+*;N+)2"@";=5=->"7WU_0!XQ1+Z#I?=0/?I7MF*<1\.HH^J8-ZTB%A7IQ'K
MCL#<UDBWO*_98XOB)-PF 3FRTND85EVV54#56ONH:6Q$.-CK%^3A9&D5\4C[
M*E]@!XI,Q]X6\\>LH$BB"?$+;$M@%WY@R==QO5TW>X)")T[<7:F:B(<TZ0<N
M03(P.H:G#%[R*E_R[24*W5:\G+CRG2^68;4Z.ZMQU8%(+(EOL0KL?MG/R'YX
M D#?[\.&"5--4F^9,=(@]#2#K@F9B9&[7L":"&,7R0-AZ\9ZI@L\.3!&',<[
M8O-,^_/Q.Q??SFJ5D>/O&25'D0ESO.$HX!AX::F['>*<<TW_V()12#T\=[J[
M4]>'@V?^%,S\"K*FQ-LXO]!+5[B1\R;'&IJ&?>)S)T?D)I%K.71_SK(;S7FY
MGN%SNDMOY2D2GW]#]XS/GI$>)L3HNML0H#S+OD[/H '%3=/^ ;-5"E-3RT4A
M+,_,ON@QT5=M<]N#G-/O%<F"1&^@OL9E1;'RUJ/91FY508$@4F=9 C.+LU6'
MS_V0DSM)[2&2J:[$-R$T QY<OI=]M O!(EW[MF2W2Y:'I"\Y1EOY%%223L+^
M]P2@^F\JS%<O6JHJ"));E7]$5X"![G%J<DI 4_#H?.V[%"W*I,?JY5!(V:(2
M6V[2FALNB!7$WRJH*N6BWHU14\*]Z.\EV1B:J]OY_C#_L3I>3(]_U;SFL&A
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MJ;EH!/!R]$E3;N(NU23>Y./R*I.LP!PV1,<@PM@;]-E+ ;(S6FA2;=@/%0>
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MV:$C%>#:)P'M] 08@'UY.$@;N#S/OX[F=A#_^=\C'@[Z\_0GD3WBVS6X'\,
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ML!2&R01]B2_8M*'1K+O,B.#?TK3.KC&(/YO]5B%.3$Z)*U,)0ERZW*24T54
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MRSYY_,OE0@W6+6#7(;GP$E^$G/LB:Q?35'739IM:J8@I,1S=V4*R^_+<':0
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M'(,4/R.L$+JZ=;,5,K,1+1&*NJ.PE&ZD=E2J4?ZXY)2;[(;UW9^=!@;"G/F
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MXJ6AI,]*SQ,KQ3!OX %BN)*$MT$QE.*N4YP.'4MTS@_1TBR*TU_;D2.#(XV
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M(@R5DDE+!G<XJ/<65"BWU+DQ-\%%## (_E6N_NW[O[_Y]UPPE8*P2KL6 -A
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M<&N$NYA6EN VF%UZF&[L+4]J=L248V?NC!')R,!3LSYQB<;6\%*D^0#Q0)^
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MU.GA?=APKU)#W!!"1=@& 68S/Q^Q<1Y)R\B%7/'J0@+ZM-I<-PUC\TM@^*]
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MRJUO5"&$"1GU=YU*4=,AEJL0WZH<K!?--<FL%.)X>^BU!EJA+O LI&M.*7?
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M=6^+.ZXM&V[.H$G-L!X%=Q&>'FK21=JFU^)NB*F9:IS9=5;J?"Z-:-<8F]_
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M,!TA7DT;_!#J3>S/8.AZS?_=%8O#P1RE='H$'7R&/S,-' /0@<.BTJ5")NP
M@1(BNY'H&K>N@YTT8*",#H=[6XC.I+%H#9TQ2<8$2EO=PZ6W)A=HV]P;T .]
M(>W*1NU6-FV:LEPV/3ULO^,]MM\6S.7AL?VV1CGY+7-<GDLOZL/K&;T^3/;,
M@!C%"[\B.:?N,D07,*H$2L,Z,#*VZ>7VXAY"VQ)DU5)AB;TJHM TKN;!7#BR
MMCY .Z>G+DNCVGGU],-&D$Y"+M2>"D5$(F"1L ;^Q])7$*"6=0QJO57D(SO$
MYD$TUB#'V+G5OBW-ID$BD0KJ(RO#53H!'="@H "B#G*@-5D]=Y]]>'G>-BWS
MPK5;X#-6<DRZ3_NLJ^V)*E,GKR-&A!A>+%/.5C3!QII)R:PEKH;?DHH.A##7
MOJA_EQ%_20WD2^P^Z;RJ;5]:VBSQ4[ZC!M>WF*V4#?923]'=2X8^'%.776=_
MR%D+2GM(;M@9Z(41:+>5U^F"/=;N,[:L0-E!;194KRC4%@V^_CH:"ZXB_6;W
M/5Y_F-J=-9</-UECH7>H0Z,XIX-*9(_-(^F=T_XZ;)VCD-ACK0B/RCRBEDFS
M=*SB#C9R;;$Q#.JH^S(63^@_(ZOX"I9&2GQ]]N2S+*Y2[A$$$P,:SKADDZ27
M\PO?N55C1KJEWARPJSYU^C&Z/KZ:;.<J'BH'!RQT:IL950'+=<%SV^RKG-8%
MTS$]!N$$VG:#C##<2E_<8.G(Z9(D,UIROA@U7]+[CQWCIOMTSA:3^AJ@J4A!
M9VJ6\NN91W"R^GI;@Z^$G2=/XPV:,!C99I^V>,5#IJ;Z/H*AM\ N)WQLQLE7
M=SL;H]"T#],!([%E)5S?2C\8D&EKP85=#2<Z/2 CAVF%SBF*3F2I$NPZID->
M3K_FVFI\ZV%WYXH]Y,C97[U&%DO2&H;6$4\.RXC[JAB#G5JPM*QQ*QV7M]6A
M^9HSCY;.<QG9L#O/@9<OK:DX53QV>1!3F*#2E%7:P.4N>.RR6B7?]=?Q'5=A
MB2/[.A?&M[RY+M]1$<!.I+KG(<IONOC3#19D%#=I>6+T+>9%*(*)B]Q@ @PP
MHM1(X0U4+!@-/FXJ/2LF9K!S-9[RA#O9X?U3VKM6XIW$<%D1?!7^KYL<Q6J*
MGALQ8MS-;\5C-LNM_JYY4[?E_EW,0$_--,>,4T3 )2,/U$Y5['XOH37KJQBZ
MD7TV!/62%(B$^SG6?_<86.^%#K@!36.7Y=T_Z]J"VN,A\B7P&@S+R@&W)P6(
MN9-]48(<;"*FC^K\ZY6M.W_^VO"I7.[ZEZCJ2\AGE&99>@/4P#XJ(HA*YRXM
MC+E)%)K=NN6NYBR8(/H8B((E/=\1'QMC[3Q5-%94(8LD30YLRH[P!CSJZA?6
ME?$(SOB<TSC!J)F O/. V97DH[\AMVQA$C8BM?OR_YQ3!V5I(.]C$.!@C)$D
M=U=*'B),QI*NPA(P1@=<X>Z3S>QMVT4G9$[P_Z'.U*"T<A YF#W^&/C$,AKB
M5@B4S"@[@C^R.4#;'B:11+&5:T"_S9Y2OI52P/*"6SFV_O''Q':X3<;R!3:\
M^IR4$0<+S+9STJ&Y)W![5KYKY=?Z^[:GP:_@<?";<HXYUJHH8GEX^ZCYY[^,
MLI]^WN=$F)R(D^4Y$;?H>=SK/]MG4CRU3(H'S%]]O-FJLWF013F')9!9_HMZ
M'#4;CE1['.U[&FW\IL&P<W+T8.V#MK*GT7Y2W_HJ[/ZTND_6OLO2%G19@MW(
MTIL&EE$%&F!U_?]V;]M%$F+AM_)>P*[1WU[>9<OVS:1^0#.I553F$MHZM*0-
M7[,K6_<=FU$MH^,?2;/]7OUD-NK4L]W'4FF8B>V$0S6G)K(X54R+^A:NLD<+
M ^N%,J5?;<(U[H16NO_]MOS^WF[!"D3"7K_3/]SN&[%YE>8=D!D?&=Q7VPJW
M&K9K<.+WCV^+9+<]Z*=[4ML=4NL?^=WN<$]JVW(>CYC4>GW@:KV=)35KP3Q&
M3.?A;5L.?(^#>9"5_O?VFV*[HH2V5^,^B2X=1X-]B[;M/)G_^:^3?J__>G\Z
M6WDZ^WNSK2<#_WV D]FK +O7P$;W;KB[V)<U?P/X_-;1U.#$/^W=L47>P_<7
M^$YVSV,ZT&_QC#R: ]V]8\,6;=W3O9=A*P_G\+8JQM[+\#0#OA\:96#[V._C
M__T^]KMA-L0:Y+,GT2+R3NV^]H+^?@[G3HVG]H=S/X?S DR;WN%A(R=M?S /
M?3"#X_L]E+UJO.,!N/507D\B&C?H^KW^;=M%[P,+]Z2H=?WAK0W__>'<D\CI
M=?U!?[BYV-D?S+TI:?=[*'M=8+>] IO""CX)Y\"Q?WB\#P)LZ=GT]HZ![3R9
M(__D:']KMO-L3H_V&;K;XR#89D6 TW.:0(K?XA)X3(D=)WW_Y-8BZ%;[L ,&
MT6,ZT%ZO[P_[3_U$=^_<7O1/_:->=^][V+Z#V?L>ML+WL,UJADW108CN?1JP
M7)WAP#\YO7T8[^'%T'>RK![589X<^</>+7CA8SO,W3NR8=\_[.U]&-MY."^&
MI_O\AKW[8DT<H]I2YFDE,AS[@Y-]'L-VGLW0/SVZ;3W0_FSNJ5C+'_;[^[/9
MRK,9WE8=VWL4GJ9'X6V:P3\3:4H;+K#Y9)('(??7=!MC/8D<AKL!6>QMF7M*
M.;TMCL7^8.XKB?YD7]FP=8<"?^Q-_[WIOZ'I7V^/^B1L_SUPU3:?SHN^?S(8
M[&/5VW8N="S[.[.59W,[J;\W^Y^FV7^7WLA/P@'0]P\/]U;F=IY-K^\?#V\;
MJ=D?SOT5-?9.]FZ [3N8D[T78.\%N*,^L'&?^R?A+7@Q./)/[UN]WAL]FPB?
M$W^P/YCM/)BC_<%LW\'TN@^1NK%7#1Z/JV"29C=!-B85(0O")^PS>''DGYS>
MLY*]MWPV$3[#T]M)G_W)W)/T&?;]/23%MI[.B]-[QJG<JP6[YS'X4%RI3.H%
M[IXHN+/Z\U%W7S*PI2=S>MM^E_N3N2]/]"WDROY0[DM)[N_3!?8^@-7;]WN:
MY]Y(@<FO1.1[1?#UV^S\1U6T?GSL]^X )/YHBM8?U6'V!R=HG3[=T]R],^L=
M]?S#XSNV MR?S@]WD-YS7LA>Q]@]A\*%T2N\%U*+\!)TCD1-HB?F6WC1/[F%
M*K$WE.Y)Q)SZW0=IU[P_G$VLV%-_?VNV\F"Z>__"WK^P9OO>JZ(5T7!#BXNG
M7C>ZOL$FW;;]>?X0&[/5%PX]+L/;]-#Y?AOS0";B_B[L[\(R>P&TGV]P6#W"
MR_#XJ7IWR!.3??JW1MC;^^;NRS>W3_99I9__5 2C6,&?X^CZY[_ ?_3CLR";
M1HEFGD<P#?D$.2;\\WLOM-==M])^][_Y$,8J3!$G/$U>P>&I#)]Z]O-Y&L?!
M2+Z@]J5Q%**;S<O4M4I*"_UQVZ7RJ!$,E< T3AYH[<]^_K7,X "]XDIY"Q5D
MGH(9C;U?5:AF(Y5Y@Y[O];O]H>_=X)K#=)K R\?>\\%)1T(',*D8=X=*G]9L
MEP^/S.9!!F\H4N]Y_ZC3]?3O)VFV;!H\D,QEX,.;,:2:J2"GM.KGO7YGH-_3
M\3Y?*?OU39![\RR"S8>]\\:EPH'=WT>)GIR[/J(!FLYE.HJ\W\TR\C(F,/E)
MEL[H^^>#KK.(,@G3!)O;PD97FM[C$RHOTJ0RS'BSW:>ME)\5LM?XFTS-8"!\
MPUA-5(;;JM=B%Z#GCN_XU9G0V313"O_F>[+S9WFAX !S]ZN;J+CRSDHD4R Z
MV-HLF*L2>%3N>Q=)V*$?ZQ_Z7CF'V24I?$\G4ZAL%B5,#ANNM7/G*[5UW.,W
MP@5XZIRBVSGR'!XQ=3>EX_U!#ROJ #F!O<,A@OD\2Z^#V%ZR][2W\,D%7*ZH
M* NBKO>JS&#Q4Q28WJ]13MIW3H1^663I%Z7O2?/G.7[U-Q7$Q151\/N+][]>
M^IO2J$]C8#8G,Y@DK2YKS7NJ[&PYP<OV#Y (YFE.5_]5IF+JG/WZ)AH75R*K
MW5\)(77M3X(16"*PZ*4_<=20$"]Z]D D=GA:W0OWOU>953JFZF $W/O+03"!
MR;X*XIM@D:/ZX5XKN$'N!M;7OG2%D\F#,(N_!%LS%^\J4Y._/ONO:!P,1X.3
MPT'OZ&@P#%0_&(S[81]^?1P.^\>3H__7ZS[[^3,J>WB=SF%$H)[\+S\%/[>=
MXRZS\D\JAWL<7M'%=\5ZHVO=KK)WU)HFH+^E-\BY(F"CHJL!7R7&G:W;@HH&
MEZ_499#O>2] ]2JNTA)F/0;507T-%1A&<Y4A#X([GK]\]2VZ !DAEBF29X84
MU'FN7NF_O!Y'^3P.%J^BA+:$?O2Z^G9LJ%RSR^C,^&O+6#I=9BX2GI"1Y>L.
M?/53\_/#;F=PU&O]JMMI_WS9JWK=SN'IX:U>M?SSP<EP/ZG[GM11M[_R51+\
MJJD'O4,F]]L'Q$X;C[5X7U@A>!C'Q'&K8^)?J%&]:7"7N[@K:KN1I3=UM]5.
M[<R%-FI?P,;0WZI^JN]-0,W'=F*;4 Q]*[7L[M('/R#N_AB2Z7Y7TR!<>)<J
M5F$1>&""@DTWVSR^OJY1ZR./'-YZ^5OM_#[R>X??NU/O?<8!5R1/W7G^3YEZ
M=XAT014ZZ=^QTO;A ]A[PGVRA/NB?^@?'=^^I?/6$.WZB=PUB?51U8J=]+;E
MB+<@KGYKQ7KW,E5_57D89(7*#[HGY"-\]]O3 KOJ]?W>\+;8<?MDGGM2EX;[
M$LCM/)E>SS\^W??(WL[#&0R'#X%%MHL2>_=<86^"+%[ F,%4+?6#/>X:K)[?
M[=^VI\6^/NY^SN;P]'!_,EMY,L-]BZLM/9E;XWP\DK+2)V!>+T]-FLWC=*%4
M,T?I:5C=/?_T<&]U;^GAG/B#H[WAO9V'\^+('_9NX:3=G\L]G<O@Z=6=/0%K
M>ZD SXLT_'(P"G(UIEQ<$.)<2O,D^TX/_'[O>&]>;.79]/K^Z<G>*M_.PWEQ
MZA_?!DUP?R[WA<=RS]C>NRC.'Y$]/@E"Z?5$7Z74#>*)VN9=_ZBWA[?8SL,Y
M]GO#?3_O[3R;@3\\VI_-=I[-\"%R%791IN^>B?XY+8)X?07L'=,:I<YT &<_
M3DNL6GVZ '3?<V>V^@X-#_U>]XXF\_?8G>U.XM]?B2=X)8Y[?O_HVZJN]E=B
M?R4>TY5XT<=*Q-O[B7;X.MS&Z??#KL;V$<)M6F4])!%LBT%R9Q#*;0'D\=XN
M!T1TD,C2,ML FN<&H<J>#P\[/8W%5H-B/.Y9",554(R>@\((0SD@C/VC3K\*
MPFA&#_(\#:.@@/<0GF#<7FIOWC>&MQUVCLU\!+81IW03X1+3&X.!N.Q=B/L8
M9 4^AEN$F(R%FD8A;-8\B](L*J+_4#2U!A@9)55 HY;JI1JH)"&R\386[JKU
M+J;)-$5,I8]7^/[^R"NR"*Q)@9"#%RF8*$W%_H:?'7AG__CTX=.9_**X"@H^
M29AM27"/%K$)?_5.95.5=;P/*VFBGA;F;OM19UC?]0 6H X*(&TO#/(K+[R"
MZT+?Y$$,.R#N;&D[1!L?"%"FWGSX5Y&58<&H>+##A'M'^VY("#Y=2<KK@N&U
M0V%X3#T)_%>NBB(F5$O\1/V[C(I%]4W!39"-<YQ)F"8)D!-^2 3K;FZ=6E;.
M>J7/?^64\;6QOEQ1 K2;$94!7RGAK;*7]-+)!.$V@4>%-*&W0!C <L(OOO<N
MR!8Q$QJ0#BP6)A7"2]X%BT<'M@GTE\FU"L:S*(GHRD?7+?F/NRH2-I<(T_6[
M(3)AT%TJ$X;=SN&WR81>U_*3YGT/T[Q8?0E@)F7(G-'ERP[[RY@QU"XRK!H$
MP43E.>-^3I1:=Z\?STVX@".,,LWH8A _!S'AJX(85L7NWX*-@6CQ(D2K-X.H
M[_FQA:BM78&NHX5L> -JV-1'G5-[ VZ+H9OAUX$W*>/878F(8'R],W6/T% ]
M=1W$95#H<4A7/T@G!R5B0/.B&4Z:M99)F2412!,&B)Y$7_'O.0,YXP8"C45X
MBW [0EI5R2O#+T7T$-(W W^GV4(D$0B<HT/OMRP%GG-99$H5OO<'#)D5H+VA
M:,KS(+PJ42SGF^[,H+8SR9)=<8^MIIZA4HC*5)4P@I9]NMT*'A'_0- RT-BD
M;?7.\XO:>C:YQT/-%X85C/L:<SA<C5Z_"7?HU^6CJUE&M8GCG$0IUX^-X6_7
M\ C1\0CT<5#O'B4MUE->=Y 8>_V[HZ@GJ:4&V8J.5]^<C204D7 6,>G4?D_:
MXBS-M&FL32<P@+,%3ILU-F'^0('CJ&'B8$\ZC\PR%$%EE%]I'CM6H^(1D>;Y
M59!,Z9Y.0)!X*'7I3H,125CP<12,9&-VGFHW,SQJP/_]*O"_YKX:T]^U!/#?
M:W>QQGU[_=OK9@WKI&>Y[]MUXS/_5=S3 GN$%/#%?_1M_B4.PB\'E^%5&L.C
MHH/!S&:JN$K'<$[31=,"TJ/PL+5>)1GHJ8DW6KC3EKV:J^P@!W4'O4?2:H-N
M)!CX:2(6D?8OP>6.LLIUEE'1 O2B/"^)%< 6]4Y-*Q#\!^@Z_-S&?1&>P.T&
M"Q+YFC*'1GJC(9/%+E_U6_@8ZMV '"N'O&M:H-0<OT5-PVG>^W7[6V<")X[;
MVAGX;K8:O.VHJHY5)T>R<,T$T?\)C[9KE [WV'?]T!1WU-UW_=B"N3S1KA_/
M?K9R//#>X6J\\R"+4R^/9F4L0CP=*W&FMM[NP7+= (1WE(=IF2 3I #*)$YO
M5BD(JQGD^3\_.<RFM;U92+(KU[\'C1Y&9WT@FN&<T.$!7"R,YL2:Y\$"=?3<
MAJ30L\&N%(S[/ &Q#O("@S_$W;,@?#3:^]U%^G>3Z)>*8H1GWL=,-ZF[) 5U
MU9[7Q?SPM&I,W%+.U_3^H6,Z;'+GJ _@79:QH>(\6*[Z)XVI;:+[Y_ CQ596
M4)@E<*3#-N#Y",/@UQ_!=*' : >6-T?SW]H*2U?'O(>#JILV,APT^Z;E97BU
M:A"*U6O?[;(0[/V?V/#'G%ASPXJK+"VG5T[TFI=O6S_>?IEW.;IA9[G&NG-2
MX .%X=DAX7N)*I8N[>$Y^+=X#=/Z.B4X<K3*JWV'D%>5O5:\*E67QV8>CAR3
MU/CO.',F>%2MC.M1/Y&S=^,65/QXB/B"_6E%\/41J"AW)/# -KZ%?3!: 5/A
MH!H"I/=C.E-H=,"\0/&'O\3<&NP[&D<V4HB[,@$>6ZCJ*(:- G7?-FQIYDT)
M#*"5XPLE=8IUDU,GJ.3.&X=P'JREO>%K@J+(HA$U-Z5T'TJ>H"[$+9-O$74M
M=R,:__79!O9@[^39;6FOU[\'6FOT0"):^SWZ=QF-R54#VLAY,(^PN.N3RH&S
MA(_@+KWA1HK(NY'E;Q[U[!.97@773H(A$"W\!<D$WX7!'9@H*RN47I'@6,3I
M_^#4(M S)$\1#(0X%G^9B5IB5AN_Q*2ED0HH'])/C/ZDYPQ_JEPI<CE,2DQ0
M: RW,@L/_[U11E3+A'DF\"O?S6STS?H2A?=Y/(ZDQ7 H] 2_QG[&G"8!&B G
M>,+OKB*8(?QZ%BR [42Y,CH>==P<Z7[9-DDQG< %AB- 1[P:P<G"(TG('Q17
M438^P*2&A>Z?[(,.CRX9S'+(TD40,Z7_!)MIFY"#YJE,F \V(LD#2;2R>8JA
MV\Z=O[!IM &PJ#71YH>_#Z0\838L.EY\=K_@IH*=H"BPP9DPL*HH-/X9SHOK
M]X:.!%GBU/4I5$0G^KSGZ$VHY]1?Z^2AL':#^G]$D?O\&Y3K;>$Z%XFY!;A$
M)'OU%>X8A8T;^WZC X&85HS2#?\DSF.Z@>/1T!WA#XR=1_=_1<:M-!&?EUE>
M8FQ-)E,A9HY4@RU&+@W=[1Z.X9S%<KSPS8MHGL9%1@I8VPO-2RC!'&:7,%-*
M$X32)M'"\0T\=*0#.#:547(BO',5!3S\ =,U0B7<C7(T_4#MH9'<[@V%%]&!
M>68_H<@#)R.DF#=@[MB149V0S8Z4,5CS-%:4*<I<T_I4#>GP(9$/(!U%WN_Z
MH)'U)POA;K]EF*GP,4M#X."Y]P)-8I1$:&A@_V-2_C@TBF^J3/NE-J9"E15@
MA_,2D1!UOFK'^X>91&W%&(T@%RPLRS)D36&^\&QR@EE>S$Y<K&F(B(64.>XE
MTR&8]T"+2%*P_Z39M6^ OW('?$JQ#4+:4;5V@?9<QBA)2?&DF5VE,0R>:R\,
M+#XG"P[+%LCEH_T1)=!^.HJC*=\@%/:P*BTW<9KBN:YE\%4\X'<TZ!Y0_3QO
M,")-GX9&[JB#XJ+N41S0&U^ALA.%&ZS[(CD0CKO[*C8(NTO0>YE1&0.OPLHH
M)R1*@1O:<V56*9_",UJ(^5J"^2#QOL ]+?&RDMKG ]N+66N-9NB;Q<1VO(-T
M_^=X=TEQQDLE#D&Z1UP< E."W5.D/7J?#T)\U2P=1Y-(\VUX9O;I_9G."B/U
M,44#(4S''+Z",0I%N?/V"<T5<A#J6%&2:V'J\M[&ZK4Z#^+Q&ED5NIX*T*\+
MYHMS4BG-K8!#"J:F7B<HBS2:S<J$^ W[?DCT1SG5,7(#^;@<L[X!<\*/$I7.
MXP"4D-!]D,H# M!Y6[XEPP)=M4E::.[$K <8M%X2\B9M-/A47$";9AAWAVKW
M)F5&;':L\C"+YJY7O;XU>,K*>P\;[?6.K,:24%$FIVFSS@\LDYP6K&F >0(K
M1L8?Y^J&62Q**^"S9TE2DE6+-+/U*OH;(/60;#'W6F$^4MNU>G]^4;]3\)$K
M<2M/L*V&FS/%="9ROVC=CZE5DS/^#$.B.A;*?V>_4"A6$)QF-$WH3'1\U0X$
M$W0N,-Y<N<:M%UC*5.0&XSKDC7D(%J.F%7="E9FT7+G:SEP!C0EGT<5B]?*Q
M(CKXY?S=F7=^]NG@LT<,PLQ/WU=S1W%*[WZ#FZIF\ZMH"M+ZNHRG 7 %7Q9(
M%Q0UL]DH#1? M54"MPMT<?C_P M"3-P7AQ;'O=LVM+(*3'-MU.V0=0%:Q*)*
M%/N<&I-3T]OGU&S!7'Y<3LW#\.DJ3]6V"%X]ITK8#0 91JL=46+FK&;6*'^U
M],S0;Y!9$<R#H;DW@;M[,(ZF$3KX2-K)("3#9V4.G\<Y_PK4++3EC(1&2Q,M
MG#R(.5&&7XG:3:Q?.E<9WF%,A&%AL/#*N83(3LP"X;<C4(&N0%']XKS?U$^!
M014!"[9)\(;;F9^)OQY7S?7-:2+V]&P&<T"A[WHX0&<Q]MA(%3=*);:R:0/E
MH[;?#Z1Y[)"J_R$L4E'T>TR?0 Z_1<F7:8J:W$V*1_@W,'O9)7N1A!W2!_F1
MFHLC\#8P $T>]MLH S*6L9ROF2 C,XT B=(6ZYJ[6,XG68HTHZ\=+.?O**.-
MNY_>4ODQ27)."^\C='3/H^2%O#5O 2:9')"W9XSU<L][3O@*5BO3TYI$[3)H
MO0L,@A!V'L%$K$?$]6*T;P.O!A2:(%O8!7W#;E\"#[='NWJ[>YMO=[RP-B)O
MM[M+SG8/A_[1L'^[[3[\ =N]9!_6<I;V8S)IA4NW=\^"5K*@,Q-=0K]TU,*0
MJC2?>&_0%,[1GFH0.RO0OZDDO<:=^L5[,2]'<><E<RS^V%P(\UC;59#OX"X,
M'7)>>1?>JE&F;^O KT.%D.D#DY$IPR?_'[!6S"\9@<6B" /E8OH;>R0"M+!@
MM6=Y 49+P#&%63!6,J%*BHN>!-T1GC=GE3062*$;3N,ETE,MEFEOH%.BUMR'
MENW[L:2^^V&D#ZYG[=A?1N*W8NOGBZRL' )= ?X4Y'>APJN$\J\=V4W?"K67
M67A%>EG?'_2/_-/!T&'1].#__-=)OW?\6N?B_5+/Q4/GELY.!%D+6]A#]9)?
MXR,G#\PP-DD0]<S#TT/[)#%V4OY@+>B8:OM1WUY&NG,.LV 1E*0%.P!Y!T3,
M:)IWR+>Q;_8RF"@-: B"YK/F+C1>MI4W8;M=Z!_*XE'YT!W=;8D'77/WNOS2
MGUL[,JK$&<WOTA&J/(H5$(P<TI561CYR]18631AC"]9 @D<B4D1A'Q%>1GN>
M&4G&9FIH1[H9%'--*,TYF"^D0%^B7!CRRM"9?95FE DFSC;A238O;)*&)5FI
M9Y]/AH>M3K"* ZRZ_!LWCDZ%KE9 U^0R^Q7A'JD8K%YT0%!@@F/NSP?#;@WD
MP 0$;<I+/=7&L5L=]7(..UXUP-&-;E-5G%^Q5<[7FTX"5E?F!-I" 0G0,(Q+
M$N<D>W2VB3JQ2F?PEJL+!*SE:B^L/[31YS(%@NRNHPU5A^:+78XY_!$<\\P-
M,7-BC,XQMV%:]E-[*'XR$Y&E?15*QN#+F"9$(91,1;-1F>'AC19V53IXO^R.
MXS3A[/ZD_*[436C2[^/SD=?8L#0^C0%B$Y3FU*5<]GC$7F;:Q;VMT:Y_:86A
MMUS[6JYK?0Z^J''04+;DXX^@Q<R"4)4$')I[_[@\(YV+?L[/D//.95Z#-;R+
M:(4R'V+V$FKF)<ZZ7J?7'WHCZZZ3#"*'@9GLGO1:+. P11JS(9BL2%267T5S
MSX(P.NDNXK!K^/HL7TRS)6S1+%QTR-RCE%Z-N*23$0E9$?F((&T47CY7(>MQ
M59C$8*K$N*F?Q2K6A#Z*PPU5N>89_UC.M/.7RG&Z==OU'#=-I\/_(C9<YHYG
MW6_0/R& .3!$;+"0[YFH.$YS7>^)%@)5>\UUM5>[@RGET=DD,49%;W#2&1Z=
MN$9+1<>HZ ,(WNHH#9@_A^\TH?563>-HX&H:0 C-U"B[L-I%NPZR*"WSAB("
M4@HK>!&3S+EQE,=*&@:(#Y5COE(NEA51G8T+8/7BF]\/^KV^+^6S=&JU6 9H
M-0&F64PMM@G&$@1KF6()N>80\ 4"[LCPD3*E;5<12D,%YZ\?Q4^JSPIA7 6Y
M=O_K9"E\7D/&&M>>0.%65L&YJA8(-*HELG0K+LM^]92K>J1V,F)>2*Q<_J 2
MS$?3AX.?_'IQ>?GA]W^^\2XN&,NV,LRP-@Q20M5]H\>R--%>APH4:"Q84 5A
M%G@LHPBM^RC,;<JGC:/K WC[ZQD-(UMEDU6,ZE$)@X>@>22$)CS!7#8DL6E:
M%JCD,*V;Q$(BBA9B)@)UU>$FS458I[WPZ=*X<;!JTIV_0:[>LKR\-9R^FCVX
MY_*W<]-6>3Z>]R6<Y+P(*!TRF),:Y :,Y.M&Q,BT%'0S63_P2;5$,600QV^O
M/[(RQ743-<0*\5DM/'"LBA)VM^B"LQ\]NOUGY11#M$TV$U3$6[\J%<!RY_(M
M8MA>@J< T@O-X:]P4352I2S8Z%3IW%@'0$=7WJ]E>*62A,+$(<@(H/X%7*AT
M?L5507HQ,5@;!],H&\?.H_LT$Y-FTM^GF6S!7)XL=(N^M!I\L,HZAILSK21-
M#EJX%C&J=\1ZC8^2;#_C0T=Y+\R5+$/]CYNTC,?D 1EA@1G:?<1-41>TWD=F
M2V[DM<F[/[=][)IQ1BMN(KW)^R-W$>N%?GVP[93\#YC"_]84X.V\TN+X>\3^
M;W7X7))NVM0U\/GFEZ21_TYIYU^\C^(\\7[__9Q^U_CBA20()-Z7!#M[@'US
M^<]?S'/PNY>DP5(F_/+D"+]94N;;VLK$0V6@WWT=%&Q*!-D75=!GO=?U2DMC
M._'-9*NI,6\J@$%@#2P=HCT(IN;*VGE6<3Y "Z_4IBW?1:W],RL9&:Q&LE_K
MKT'']U1*6M/$7D.XFK%K(UUB/:]%:WVCU:ESK$LCN'S61-_ 69&*94*-4ZH6
MXG7.M7$#RQ,WF^N&:,!YYTMA5#08#1$=K0I!898GP&RR=1WO@U-'IJ/U1@EO
MG./FM#YL#O5YR3=>7LX5^KW)S[#TIA!E<5T4@M,37(<XYMP<R;81?%U%3'3!
M9/$--Z2Q+;<Z?M#3G/-_#&SQ?7I=(: E$4I"Z7%NU4<=D:]%+%]$+[U?$;LH
MFH$!LO#.P"J;XR7!&I_ F_%8<FB_I!A=P8IC,/G1NY"_AA? &SZ?7=88*KK>
M)G#)(P%ZPC&<%P-1P _AEY=8<P,70WEO*.3Y&71&!:H C':19>HZ#4DM_)R!
M4883*C)*H*VY6?#M[TI@,M[_"N)@D4[CTJ>Z]8-)RKQ2)WL!]<RPM +4+83K
M@@TB3S-W#*"%?H@1?0%;*T5!@E<A]?Y,*5;;O@6.OSJ:S=08IQ4OI.L!Z3_F
M>Z+P"NJ5CT1['7%%K[W0K2!8%\F*KWT'-==PXDI.!HS;&Y[Z ^RLTCMTKN,J
MI*:U:1U'W4[_T/IY3=WY8=?OG9QVCD].-QF)NT?59B]E%RN!NW"*S +<R_^\
M7YT5OO+TU.\-NYU!_^C.$]H4@VO)I-R8]>-(B4)/*7M$^XXP:^-%PS6\:.(*
MLP9Q\R771E&4Y$54E.+5)_LJ9-!WI?L.I)E-%M2C9;E[A5I&V>@*#?S#HX'?
M'QXOTZ1(<_!/!\?^:7?0)+5&#A8MW:!O,!P(+J1)0,$<_O4UFC%_>=YK^*-W
MSV*Y2! Y1(W!IMU]F^4/+B'%D ^<#^8H2(Y/P,7[<1HDCFHRJ 3(+&!')4J%
MH5$,I7!,Q/HF.2"RKMB7_ X@VKQ8%2B-Z!I]^ H4-_;86%0HK=D'#+(:C&?O
MGT$<JX7W2Y!0BBN< _?9@0E2'O7!.;8HQ( 0/N+]3S";OV;QC,KZ')-G7N1E
MB-6#0-BCA14:.J*!;>#@XOZJR+$(Z\A!<N-4SM-L;E(G<S##R?.:<?SCG[_\
MHL$0Y-WH3VU.^B4:91C20NZ<N>GCYA#\BKIN[AXGF("FFI8%&"H,LZ$!#O@U
M%HF!WU.D4T7^"DZ3 C;$J/72P$)\/]A)D=T_<Y5@B,Z7="!I.\CX(3!PLSE%
M=4"!G$L+3@[ DQ4L NH+T^];:!B?/"$"="(JATV<044,879C_?MQJ33.UXE]
M!4TL<E(1L*A8W-^#ZF/-14JJ:+\JAD%/I[JBI%J/A>RMMGO;7!W,S&M2 W]!
M4U&I+S4T)-\07VY.E)X(R8#6>#PN(I.$-ZS[:A*KKY% G,"5PHI=<MO%D41F
MJ:3+=M$*P4A(J)>"^. ,U)-6Y4=8BP]GL7LRXRUOML;!D0#D-^!3;)$(.3-Q
M4 N06_=+6C0T=.-:A0$Y+R$8E )BI#/?R#BF+(=Q2K]!=Q9589..%$TL:IA^
MV[H7,<28,[R'Y8,1V% ! :,L^S&P46( E Z2%%&,(W,NK)L509K.M2AWU0Q8
MC%5K%X+DI)+;F&BBD>N7<]-9QO9<8+(F*VP"AL99[I2LI5';&EAK(^4WNSAJ
MZ!>+MN "GAF/_?*NL2J[!@L*?N?TIW-?G)<$^HB T_IEU.3()X3%V$'@<;;-
MSL9)2$A:$D-0H$86]\2O(-%ALMF5"L8\X$8 >H8*!"YO.4!>?;LY^81^5,&U
MHR8P=@@":W6RUB:^^)6 V[;0#<V &RTV28)_.E+3*&DF6!.\#[W%)D%;\ TG
M]3.+\B\&RKXZ-W?<W"P8/6((7X*(^QD0O^Q-XIS:.$(O1!E;I'&#JH!0+'&P
M<&'PRH3=TI. W1!T.CA*,+Y&#Q_Y(-#S4.7WR\Z3  -A@:CY4%Z)DSFE>2TZ
MNX$P$2U"0SS!^9"&8: $=]_)=K8,5(_X+IN$85A2%P;&,8U"@4D].NV[*,-(
M-J:A@2/<+<4;$E]^9:1]@H^J&NXT'3YB<DR)2'*"=C-(5 WLGA:BK%P&K'W$
M?!S2"FV*1%Z48^V--Q]2CI3&_T*-HPI8F6;3(#'MR[68$ &]E+:TGK0$FI(]
M=VF%W[#?3KD=U!?FHM&@I.!C_GQ&801<OTVUR-$5H5K0,9?3[M-+H1CL4RBV
M8"X/GT*Q+5R9TN]1TF<@V*29L#(IMC8=4N"2R:)L2C"ROM"+8 !CJVBR?@O\
MIL#;HF<0W13? <>6LD+E=0Z@+CHVLY)5M'9FV/' Z,2D- +HK:W/EJ\L6QT[
M)#1"K@[S4:R.DR(<;-1*(:NN-#"Q/;(_2-S 2?T;/1;<.@CI3^ U)2'#E+%&
M2F/#-600^<NYK2%KI&2VDL5L($C0VI@$US C2=$NL9P@E0R3@LMN6)]I[(X!
M/W;*>] >:=][-MA!M9+2"N/.$2EJ]H@<OCI_U<).QIS]:C6U.7E\&9 .-V^$
M,);HQ$*;A!=85]G(7</[2&UE6D;<?47K#X2.CS'OR3-@V15PWDVAD9?VML,S
M40E13-EZIV @ [--JHY0"GTXC@33UWH8V*\ZB\8',, Q(_H$"Z-NN"1'V,J:
M&VG*FU/A']\##C_H%(^L":(] D8'*A/\(K]JW$FI>-.0V.AYE1OF4GF%#\$>
M;<"ZC)58ARI>PALJF,49Z5OT^X[WSD EVB(BLCRJ)7OY7&PJ4BG%RZ7/2AOY
MW,,WF1Z0,Q2QAB@BZZB)+DP15K9BG,3A'PW;C7T0$E1BA*(+]$(2 "S[9_FM
M:)8IKGZEG/F65>GA#'],I R"+%2'+"QG1J^%47U3,JK*A.-C>0KGD+&7E+-L
MZ)1OD*N-M/6FQAWO;^D-7)Z,&);!L9V6 >$)RJ4B7%WR*<&O-QI><S+1LFE#
M'<Z+;%G,;P3P#W4:$#&^Z%H4]#:&)<(+][1,-!L7[T^+K$;:HI YL$4XV<CN
M[HCLI%"VV'J>X$&@%WA?+/8RB19J="?& [F/@-K!RC)&D="2<=;0571PK3CG
MBJ[6R)TYG$/0D-"^-U/4D4"3JENCBM#(YB2%U;!3R^3$:%=$Q5G;YM?ZT=R_
M/^A-^C\T?EP:OYWFNA5.2V0X5LB'<8-F2,CBZ_!%7P$J>77W?9@CS<$QQ6HB
MAHF[,P</N#64_G?T6B_M_J=0W9O>L'.(>U%H#%"?+P5H,+[EE,FXUH>][C5P
MW0O.!?.KX)\5EVBA<A,-014207'SU_LCO]<C3TJ= ];D0T;GUAJ06#<@TW5N
MEHVO\B/.T>]/\OY.$J\DNO7) XW9)3<%QR6<7#JZO_M#N=_K)7$=Z8'+&D5!
MO9'@QCG!#4PM@9DL50GVY_8 Y^95VQ=K?::AR%F,!$=WJ0L^SOVGOTK>/B/)
M&\00R7UGC;Z="JKI9+J,W;S9A,CVU'*_U"(Q<5L^0;9D UQH?ZX[=JYM7(!R
MH?A*8P:\<'4XGYS2S3'2UD3P]TW&H/Z!PA@QV^?4T@[AB!2[)^!=8'$6"]/*
M*.%^BI*SEBS:'S_0@<(P#J+97F+<,ZTH"<=/.*&$6V@:]W@H:1U\IUTU.7^-
M7^P/ZWX/2V(*3H)H$'(DF[)G,,V<4-8EL4*1A>NTT' #'Z[0IZ@N9WYBSSWR
MG$I_G)ICU7&F$OMO<0-M;]_@)5VFT"W^R77S<'8#12QU]ZT/CLN,("7(QWUN
M^Q(^AL@'>T&I-,E63^L>C-54_T'?[Y\.O?S?)8&M*H95J66.<043&-Y!2 7-
M?\!OLR*] :7Q'9AX07A58J<Z&XIX%Q#*S4D'SD/G!?/H-D\,=91F6,4-,)!W
M;B(9UY3EC4Y/3E&N%2R<VDZ4'>^C'H-Q#I?"^J52FLTO=QK]/38DOH>G3&JE
M<>%4&')10=2$^'3KURQ?!)9W(P3,_$I(DIQWEE@-A?X61'BQ<SBM*1)IMH@#
M[&?+_)8[J!,^BX5C/>[(=A)(*<5D$&&T2F=NB^TJ8?U0\G8:U.]^:+8&BMY2
MV!4DZQE7[]3OG9[6&1>JIE/.6:ZW?6JRL;<9EHM$X9<:F0@$QJK9P<S&M=E5
MXDS5N1[[)]CCP)FJ5.3G\"(OCPI5@P=J&Q53R["7P"W'[OO=[NF:L3]K$F1\
M^AD5'_IR35P<HT&O<DDP)LHWQ5;"R!UM7IV>+=>0!A NDQ4@.IVERPUJJ'<6
M);(8UF!J'>RU":J5Z3(!KGW5H$D%E2Q@<0.FWS):7ARG-SI+QNUO<V]"Z\3)
MY]QVWBU:A707RCB*;B&C+$;7TA[!3B-('QOR<)SW\DHE"U!%O<LRP4P$50-,
M!=6LXWN_%V.&"QM<PAM,:L1(5?L58B,Z,RF=MZ_/CEE_4$4Q)2 9>9(Z-.8F
MC:NEDY'%'W43PY?!/U<;).KV2_6:!;DWM:;,J_*$J7[8"15+@@!?#W$49' F
M7U0<7:7IF N@<"%289PK%Z4LW:-[.:FIPWUJZA;,Y;$UD9,B%D)BJ)832=W3
MK4P6U4PD9>Y*W'%GS9>U:2>F6T75L7*B55OF'W^"#A5-%IOZH7ZX6^*RG%&!
M&-(G>BC>@MJQW,NP9&FU=11$\8;=8AO? Q*\\UR]TG]Y#><XCX/%JRBA6=&/
M7E>MA$,8X!H$)HI:V3\:C[^V+ O[MR#;*C+XWUB/+%]WX*N?FI\?#SO'Q\>M
M7W4[/?TYS!:WXJ_/!L_T,WK>"<BG'_#41I/O=3N'IX?K)K_AYX>#]D&6_6+E
MI$[N;4=_HM/.ECTNI/JJ/__J]:IW$*FW3E=,4M_[$IZLX[]=]@4CE(6Y=,7X
M+AMUNLG*67MYF+4W^ ^M_5\()_.F 2=3V8Q=/.GVU;X@&):TA%>,\Y??>.(_
MYBGAUR3-YH5'XM/3&[-3I(4FR09;O-&"N[C<)[)I@Q]&EVLN\B@(OTPSA"T[
MD-5.Z/]6[>"V\7)2HL2[0V"T!/A&O9*BY.6K[;SRR_;]NUR-=8=ZU]\OG=RF
M;[XG&@Y#I9HT[-&?_4[_<+OI^8/%93&)7 ]/Q+?9[*ZW VSC>7U/;[5"=V64
M%[--2WO1'_A'Q\.&MG.7"[/Q2F_!3FK#N4QC3V8[1&:'/;]WU-L2,GM0_6A7
M9,L%-^+<,MEBGNK?;N-;&<#V79,3_WC8W_R6K*"P'\&,-]$-'^6Y#(;^4?>T
MW1/T,(>S5X\W.#;3>&+W6-BF.LS6797>T8D_[)_<\JYLCU;YN$_G16_@]X:'
M>SULNQG7&Y.1;QJX$8XA_YU"N0CDL2.\;&?%_HO^+2R6O2YV7Z;D8$L.Y4%U
ML&UF7^]5(:R*LK0W1TQZ>(:V[A3$KRTI$/V&WWWC6-/C]$A]O^W9:A[4&QSZ
MIZ>]NRFYWVV/MM3ONK\B^RN"NM.I?WS8O;6EL86WXQOD_$^4.+?=!3?TQE>$
M^15ND.:\,N:XQ<M<N2C26%!#D5P M^.%6:4!PU[998M;G@QLU16C($HO^N>'
M;BV+X+13.0T,&*4T-K>=_4P [@(\'W$!P/HI4A.4X\YAI5,/]QF 7=-5K<][
MQYU3M\E)0MAPB)L5C#$)%A-R8;'4YQ?'C JET?6>']IR%VY:X,Q)&ZC5Z=D&
M(+I04FJ//16$5_@&M7$3L^IF'E5[M=QF&</J#H3UU)!;+&7#R0]VH[O:+?G!
MRCC1%B_S=OP@:EGE+?C!R1)V8"ZU2WFM8^'%'@P[1QOP#NJ/I3D'=?@;V-)3
M9BP-9G+W]4D_)^I+H=D,@HU(>ZU< -H8%X3P0\ (G-N:N\VW8(/I#&K\SO2I
MXTZNU,BXT/W^8&(,:L$9\=56OP+@FY<S95H^<FTQUH("%W![B*U<Y"Y<AEO>
M^96!E2U>YF9WWB7$2<M*;W'O>T<GG>'JFZ]O8.M(U/MLX BYE;<^L9UJZ(<G
M/:L(K+ALW[9&>]D83PIA-^4ZF!:1*UIH:F3&9=UE6[G576=<9P_5&9M6<7*=
M=2\Z@L&UK?<(#YO;_!1%; H\!3 [N FR<5[C&%CU&@4Q<4;#.QJL:=D6W)&#
M/& O-&R1"+MR%A*J(V[:QRQ-4H2U?AQ *6^I,AP1G,M<MZ',:-&(E3].YX1/
MG9FVK78CYI6-\ B"'_D!E<8-[A/98UN)Y\-D<O!+$%-Y_>45H@Z<.8A#6USL
MOK9+TS@:4[\(ZE+!<(F3@Y$L-:>E5L"5J'QR0KU:A9]DI<9?E"IRKNQD#GOY
MYKSEM*/Q7Y]M4 O;[SW;(1HY1TT-2_Q=%@,7)M3JVS]8!K[1"/A;3#94Y8NH
MXRT(_@Z'(4S<)(@7H&UK/$;+&1#>(W+Z #+X-?67,JT(X'>F$\%&3$9CWA"]
MCK I'$,(,CW6(38J3(YD)]*JM.]#MAB&:EY86OY'0IVQ+PO"D82IGLT0424@
M[(-_="X[WF]G9Q]9 ^!Q#?@\ Q&L9Y("W)Y+EPW">+ ]&'"G_BS'^K9Q6P*G
MSPGQ3^3>TFL7L1#(_O>K?@S!T.07VK9Y@I(:QFE>,JR_ QZQQ)$0;7@R'2#\
M2D,(A+3@AA!&G\C=M3)8A&T909;-W,#_&_+1@.G8/('9%%I,"J'2$0$EP*P$
MGJ/9'IE"Q_OC*HJE^9G3==,E"W-#,\6]#K"]\*):(T[0WFFA\N\O"XD)V]8N
M"/""0"ZL1S9G25TVI5U)#AJHYCGP;MI.HQ'B(TA(PK61"LS&WV"+%YJ/@=_<
M;%7?T$%@"^S&)6S;7H!_!G&IO$_XI?>[AD_;A26OE/[(J\[_^2FW. CH%W$:
MUC1PB! TX<Q ,0")8+^/I'!(HM)^2[>-$7H5!Z>%4)H$448MKY1T%H0[(1!I
MV*C]\MS[G,ZCT#OI'_K&KM@JIP*L^,)9\0N<,\SVY0^>[,JI=4!8K=]A?P^&
M8\%P#O=@.%LPEX?OT_A ]%=H1AR0,A")^V6F E3&QAK(+I@"ZYU2OS.1V./*
M!3<\FL6Z;D&%/6-!M61S'Q%C[5O;WX,MHS)T,)/\IZY1]#"&OUB1(LV#'7JH
M$[#:NV92#N[H#=F**%G(7"P)NI<]%"(GR($V 74'-J&X2L<( ;Q8TJ)NP-:&
M]P[IP#L/LAC[6<W$X 1U:*SBI=WM7%PQTTA)QL[=MAX&F ][AX<+HUQ;3&(&
M/.:V8NN:AUL9>)F.(M I".;()^<AS--"%76\<QO:6[>O >$MD4BVZFE%=W/T
MT*JY)>!N\.LKA%*^YH[B C1H!N"Q7=/,59ZC9%X6.3D-TA%V9Z<;*M,01&X-
M.F>)Q6ZW[WPZS]*1M300DJX,0^J59+;X.L43IGG9KA'&O'FQBAQ>\JE$.;!R
MBKV2/J/IC]*7X0WKZ/&E-CFM(A1XOR/DN#?0E]=@5LDV.$=X%<'N9^'58AL!
MJ&^M*]>[&0I)@S%#!P)_ANDT(<5@EQ7GWB%YC'E-$1KMM"P$"05;#CEG".24
MSC#R1DWY<C*DLS26,,,LPILS3=,QV;)X3:)0$@P(<)4HD%1GD(:HK.7F&D=C
MN:]"=PS#6> -X%N1<SM9[FN!&0LZ(9_##2F<1V/DCO?14?FMTGW4/=HBI;NR
M[^0TT&#G KAY+MLN2CC,_J&4<)JJ[U("RD\-)HH'>Q4(502A$2TP13E*V\^Q
M<5:.245A'N"W6A+PCXTO+LU )B$:FQ-SJA-$A:2H#[ 1RIJ/:OHFHB.$6=?E
M*[TQ]<3-KUF1<;@>-;PCKQD?#?DV0/C &V<UW\8$23<OU#Q_Y;V(7GH17O9H
MLM"7@#;M1?Y2=LUL\FMXNOZXC,#8MPZXH)6,]#97B,,E)J!\^,]"&I=B:#\L
MW!\!%]+;KM]!P\/X=@?)>+9-J]'-B'VOJ_H"'@$\%"7DJ<)&W"0S*R>#K[Y^
M23"^H8$_K;]8F^L;+ODU@\G :PT#,T=.?.P%GC7N,H9OBRB''27]K_W]!%2;
M)N@WG<\E5(D'>8 '*1H8PNC:*XMC1 0\SI(^EDZK#DLC_17N:ZQ]G%46R+^F
M9V..4C<97@N[P]_1[DV05\BN:2+J>&>%F24>E9JSK9SB>MT-Q+$=%9:];^LH
M'G7&/%\R+R,;Y"V<;::'X^8TEK:0E1MFL.30?=V:#@?5A,VGZ,HA9Q:T*B%X
M[N2[\E'4]/3COAP(*)$CVA*GL_)RL:<AOU>058&D8JDTR VADDW$\E)N8\NU
MP#U"_BNW9ZR/7%HF([=I'[QZ#Y;?+<+WIBL283OA75!N;NGK6JO<O?K1>L*Z
M/B#2X!HXCP#0*H=(&/TU7-YONP;=;?L[V]^DF4W9</L:5S&QW1[A+=V&F_NX
M; JA46;P>E>B4HXCM26L)=R&+@[%W_ZC5C7$H7R:+"^$2;0*P&5,35RSW9,M
MTA+KY J7VPW'BW^V>_*0Y/J2V;)"(Q )56\X6\;N;*,$3%Q8PI\IZ0=M&=3"
MDC@UBA)W7"41>,T5/ZWX2TP1XC<S\[0ODFA@FC?Z@3N=WC/%^4)F .XLK5A[
M8?%H>_&QP2ZV^Y4S6.,F+*5^,Q!*FF6$".?9$F58=3D^IY[;G>JJ<4=,B"/*
M5PW+0AT[!=2$+*9+!#E;9"*:[#N772J6E4YL+XX*/')T:[P01/Z0V( V<'0S
M>- 2**;(^T4=Y5%LQ?'J21C5EL_6^C!<,5I3LZ57#?M)K%59'\>2\2JEB-B4
M%>WTR!5%[+DC($P.&?MX/1VLVCOL]$&^K3115E707?PD!*ZOA$E3E)$)=C$@
M[V/%.CX>=+>-[WV"XT-_$AWGKXZ0(JX'$W[0J)0NH<4K605HSW4;3[R\F69B
M>&J)SD T.AN?6>:NU!7'1#;48D;KRMK0HHXDH!(BQ[4ZHU$22'UW?#D!Q<(G
M93Q!(P1#X*XQ9;VW#NM:SG":UJZQ<3U@.M>*VF#@PLW]L82LM0[G2M'[9MA!
M1]9>29 0UQ%WV=.!?EQAU32E?( #H.P$L\GC6#)A0C:=5MAZVL2.*BYFLE(Z
M7&/Z!V<1?%&+ZL0VGH+VJV*>B*1+:/^QS?WP:S#_F>GP"O/.L=E6K-M"NR12
M %''[*-(6MS,3K\3$6#L W<74HJ0W'1#N1UU)E:"\%74$9?8ZO54%MWR4J?;
M+-,B-35S TQ*VKW6M'V3I<ET-ZR3M3D+)B6!.M=4'%*+N8A(339X&D 2E+\C
ME\OXFMC!5,Z!_: P4RH7)Y(-WIB C68]PHEJ_7(< O,=$O(Y6\FH1-,4E 7M
M*6HTS#'-B^4\QZ85IGB :ER3WIW#]EU)HLYD.6/4B5[6[P/OGD3%3QCE\?0;
MX+]D P@_/D"[/6U8#3O1F.V6LE,,6MK^"[?K[T>IDWGUD+(3U3RW&XKDFK5W
M,VYS3!E-SZ3OMSIFN$Y >V8:;+XN@AJN0Y'D6,&8J0E(2?3K^94;UG3$Z$61
MN\7] !:B'769?=PXU74M1L7++JVB2NG1-0++&:C<+EO>38ISU7M5&WD#-U9U
MMVJ2T'M+K:F$JHS^>LO7UKV&"6NTQO<L+ULBJ"LBRK'KU_[0]6AY($,RDIID
M4Z!Y,"=[%%>,GU*[R6ABG_,;"A?'3*F$C:*B4EH NE,N$KO,T/04"<Q4A0\)
M79&=8 QFBB9S=%4\+?RB]OP$/;U$H3 /D"ESR+?Q'F<O6%75RF8C$M+Q/LRE
M!Z$YXB"S4ZQI!S#Z/M?*Y%H=[7.MMF N3SG7BOV:NMJI<#*/?"U58'- 8_0=
MKXC1Q@F50]CT%:6>C^J^)[ ><RX!6!J;>8Q*U#NC-NLN;P^K-9TQCS=A/"I\
M#*I>5@D0L;60NSHSMC%-*@TPFV8!=Z^M>W);# 0:UOZ^XLUC06,J",#: PE&
M_]21UV7Q,93(6D5B*F8MKQZJ$X_9\C#;Q:1MTH$S8U*)./R*EP;&RM FM?6H
M/VCJ6LNCI):Y<9#( =A4-.IOVK(&$O)Z%:*9V*0^NSZ3V5;33X-BZ=S,MC7H
M0L=&6XYY_...V7<#HO65H#-XF;^!\R^-@XV=4[#Q;;X,5N4XOH2.[ZI69C9B
MF>JYT'UI-269Z#^<U4BQS@='J,:URA1G:6S2F#(:T;R;H5^[+*J(H3ZQ"_T2
M60<[K. <VW(1@FH8Q.B!H.B"K>[=$/.G;,<P++--B&O]I'EQYNA\MA%N(DP.
MY3"*U'?I?:3L$;U=7^7UQMYI#" K/M.9%F/#G6R:<$.)%FOOH'+8UG6VL(UW
M;0=AG*OK@7 :\7)QH+T1-@F&Y6^KMDYW1F?J+@OWZ]4E"]DLD]QI4CV:6\[M
MGFM6Z;*[DCJ0!I(93<G1S:21CG>FCZIR$1W3:LEUSZ\"SMRN.J2% ,FI1#&-
M3&<).ZYLOQ'(<'(%FVL7W*#=< S>5AT)DA*]K6QO7I:4F70IEO7#IBR<-;+H
MM+_2)-R0(BE)S3G/'1V-63FEFUHPT63\B<XV(-=]1,PVA%&I -"]A%5WI+Q6
MLJZT'Z52SILI<?^M,FZ;N7+D\183F5TA^E\MJ8S6!V.='>Y;B5+7*>H"$>*Z
MS4E1KWF9#(.]M;[^&&_()^V"?MC;\+8UKU3?"'*+'["69WSF;AYEB[?>E"?0
MT5-&/LHD?).A'-?;-\8@GG:6LG!38[B&"94U%&J&7UD^:EWW+,*X6SU&"IO9
ME'*[\#$$8Z*0@W%U:@DHKG]6(V W* IAGEKNWN,IN0%_'=V6@A/,-*9:>"N#
MS$=6#F&2FT5],9^_;(MINF]WDX.M$'\,Y0R:>7XF3G*.8<1=N/^K\Z+TH@J.
M*DI(B/6?BJI;2998&U/B&W6C"'<(U+2P_CI2)JM8"+E6R*)L?" A?PRTZG\N
MK/RJS5:SA3E0J0GY^_9Q,]TTFP:)SLCC$3E;#_^&7'\<%($#8R%QWC#,,)R"
M#^11P09H92SK+)!ZIWI)$P,RR4]4DJ5QS"$3\YI%&"N;W>),GD?$1"DW@U?"
M!" :#VPV(R4Z:#^+SA+(JSE=F:IRPDHM-Q D/#C&Q;K,UXV]US :< 'P"D:@
MK"3H2*8QU5]1S8H=LU)^5H&/8=69D08BSE,F#86. ,V"*@7@B'1&E/EL"<5)
MP:@F2X8X%,;*,0;E>O2%&#(EZ2A:O5Y#Y_B07G#'>U\)<K'=$8RO:7EFYG/W
M?)94<^@R3<HJ2!&J(F'3V%$ E\ZM=MKN>NH[J]-OK$&A4Y^"O"*,) Q%Z7UQ
M=$USD204(Z_T"ISL<^5X!23-1RX3+]_6]J7)-$7!W;RS2_)Y_D!)*/JG2>@9
M@[&*A9@V98:HI@)V<F.S8$V82)[/"] >5*. <WY%@'2D)\]C9=R&UWPW,"63
M%BY%5F/A*::61V9\Z;"_96 ;>,-&F-@RINRS1L:2+$CN3.X%%9N=#>BJG=X
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MJA,G*92S$BB].TB,%DT@V=CU.$TX,1G5;1V=]\G[E06)!BZF'(71GXQ3G-O
MESL52<*AZLMQQWM;9J@CB?.7R(UKN6N_(ORXD0DEPIRGV*V 2KHYB=]6=.2-
M<BL*0C*X3JZ;!=*=T:]U2GQ-43%G)D693I+]#3Y,)!==7(YQ-"-;3B#+*7)
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M(P9P<3<4;TGMBAY"\:FG];/BB> =\UWA:RQ*A5_3QM8SW*6=X2X)S.;)H+E
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M\9$.9<9N,J.]1YFA*R@S4&:4*C/6.9K%;*QR!(8.934MN6VV9=WLGCX&H\Q
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M'6</48[6@/4L%J3%ET3_#?NSA^ 1W(@DF5#$$R^&<)[$B1?@X*G6',O.X9:
M.\1+G#]$=">B/;DLWH8EN"B Q58@LI'I+;X:LP-X3GMZ&7R<Q_#^.+X(I[=^
MX*U)N'JZ/<+5VLVHHBNZ,#ZZ#?%:P48A*M9F;Y,FBK7W42WO@S-RX0RWL?8]
MJG^=%/)1X!Y>\18JNW&TYN&& 1^=-=UF?UOUH+4#4B5A6H?=9+DT+;)$.HUF
M[87LM1=27L&60G' '$7D?)[.)N&3$!*]H1@5G>O)WG1]V%L#\B6O$]R_-6(/
MG4:K]C\.67S6O4"D_.3E!#D1V]6F4*O=B*K2,=DD3(::J>(,%S7_S7-OI1+Z
MFR]JOY]-?]-I=,#;Z0W<3FM;:,*:BZF"LOBJ'36W(99=$,NVV^QT]X\<K/:G
MRG!>X[$84D9'_ +G*+@33H3P=OYWC+76>+GMR8VU%IG0(6J)%94$[_K5^+/<
M\^^PY5<!Z@W\?XS-/\#A#Y+XNXB3R!\F8D1=TX)1^A?6)XL4!L(&MM"9?O>W
MUY;<L+<KEZO>7J\DF-@;>I-V"3L2S-KW6U#?)6\OGR\LEWTR8>2 Z40B+2;[
M=*^]C3S \K:=SU8"US#Z$,S@822\6'P2_%_X>3+'%;75#:N@M8WC 1K'7??T
MM-J]0.L<U0O?8!474V3/.G7[!>Q9=>.7:M]Q%ZO?:HC!NQ5W?A!@W!%IMDBN
M]N2R>Q,YB],7O.S650K-QM%9?^"V!AN'&^OL6/4DK=FMDJ@UP4QJ#-S&YH7R
M=99M#VXA ;^NT/WS[+#T2C&:JNW5OVTM*I^;_L%HQT&5E&,+XZ4=M[4UG./*
M&[HC![,^C_5YK+!=W-Z67;R[XUB[TR6=:&[FLYDL9QNJIC2.'["$P!;OWEA9
M9^$MR6J#[(S"^>U$E(E6-;9E#SK1O)&EK)V=!<Z.,_- 28-: .60"'1Q=J\9
M-H[%5VVAU[:,#M/X69(!NY0"> T2^4VL09[?:7;VH^QEJ\Y#?0JJ,[5MPOD7
M'H,5K'J$,;J# OQ'E4Y";;>7V.W?PN"8#':KSW$PJCK,?E_WH*I&^B$N5FV&
MEZS@94F5I^M,_*$(8N%X=Y%@7]Z7?SN^]; "!SX^@T^01^^(7_AOL7NU4%LN
M!VJY+#9<-,FB&#77,=Y[M?%>'X%].0)+C/?R,[""Y=Y'R[U;\>ZB-6-W!3]5
M+V]-B+XA\8@B#Z&NI>$,1O9$GB?"8&9D>P9AXCQAIQG/KS+695746]5V8/4;
MMFB&AW/#+LN0S_S$FWQ&7V?D)_-(Q)?!<(Y-C#[.DV]A\K^"(F=%]^O@Z&S0
MV9CDMSH@T/H('.@16&)D;G(&3K&34PU.W<M 46'3$@P)><-A!!Z',_&]6W]2
MD>!P[0(?J'9:0(;+$GHE!90:;5P&YRR=7XUP%BBF5N/HK-,]H.+"6OP/5/P7
MD4&O+/\K1T=;;YG1<_>>_WY_JE[>>GGW]U/U\M;+N[^?JI?WY9?W;XEW.Q'P
MWY'_</:?\#_JTU,ONO,#!7*WC9NA0'C=MLW,4V5FT@,_8'3&'RXV/%MH>/ZX
M%^B\AU,8S!.Z]$&8P.N\"'X=$"+[+O(FSLR+B,,NN1>Q0'N42FL\K$25P##X
M4)S +ZC?H;((7V:*"R=THJW1[);(C[6Z)RUXTBR,?;1A/T1BXB7^@_CMT1\E
M]\H>M[['AN>'AOF*=PO3GR?E7WGQ[6XV5EJ,+\?]]'+8_XOC11L?]K%SVQYT
MV\U>K]WQ1,MKCUI#L/<;_6&GU1_W_E\3>[_(;]U':A(S[TX<WT;"^WGLC6&.
M'[S)H_<4X]FP#P*< CFF=@\&G5VRTH49CU]L8?@X@@\51@1<^D!L]O@I&)-7
MF;$X]Q%Z?/]GA0UJP$E&381G] *]13J$WEG1[N>UE)1P5%2OK;=R:Y0#I;:X
M4"0"M>3#BT%A1=Y,S,$UC%WG,AB>4)+P9GX;^R/?B^S(X]Y.]QLIX23$O32:
M]HO6M#<Y3;OND6XA9?^R%>JE5PA^E.MQ]I^WT=_.5ESGTJ>\]JHV3QP99_DV
MG\(CAOFX8CK-<17=>8'_+SJ79B?@A_-@=!W!31@D]./56&^-V9E/?CR<A/$\
M$C_@%1\GX?"GB:FT.*CC!W,Q.D_D[W  (AZ"=,,-$LU!&7V"'R.?NK'(V]=1
MG;Q4+$9.);,9\#?Y?$9FZO?B.PK>W#I::P/YH/B@J0)8W,$K[&CQ_;9(+;A.
M&-&*7;!QXSKO,.8%NO7)^1F$CX'CQ<Z-F(AAXCD?_3 >^B(8"OO;\J_OG07V
M3*O='+=><HZ/WLN84RN^'FQ N)IF>#L1X;[S">RE1[0/0_SW4$QO1>0T&Z[3
M:C3ZS%/BQ\Z]\$;_G./V1/RU+_!?%-2?KO.'%SU-X',GN&MJ>_!+GC.$ 5#,
M#VS).^'<^J (A_<!S/7NR9%6ZDYW8P:G27#R:_K]V[DS%),)2AD(WQ,5,:+$
M)6 4):J1IS=/0G\ZG0?" 1<"Z>9B9R(>X!MW^!0_B0GN A=7 NOB6//%I80!
MS\?>,)G3*\$!25"(\6H VSP*1W-$;<.CX<W3$#:%!C4-06[G$X&I.?@DCI%N
M$Q'<$\P;QNA'SG@>4!0WO0VW8N+#Z&(:6':*<+DZ]]X#/<&9A6AFX'4$CQ[!
MUV!.\%\Q<YW1/")K1&TG/#408S_!3WK.;11Z(P=#PS,"^X"*0H7I//K)?>%R
MW8JA-X_IK2 %L.FWX)V,P++T8Y:O$%\-AMM]"&X*<^&0OH2==RD]&6 _5?DB
M)Q8)EK6PK.)+X6^P!^+8[-OP7DQ#N:WE'L6^J,FKP/D&2\0GM8TGM07_:^E&
M< '_.?=A)5V9S VC$4D*;0F)M(BFL;J#SG4U *[@]<2CVXF;TFJURS^:S_(+
MO1A67S](ZQ*E8O"N>KSWA_<PD.E4@$&7"-#7<#KPJ:']X'>@OD<@5 $V!!&3
M\/&]ZX"N-+I]Z>5P-1F9#[GXE1'?V:RQT AS.GPZD@B67^9F\"4QW,]X*.&3
M'NHM+HF HWG,[;'LS\_F$997D/#3W!P/#A2L0.K]E&+I_Q:G&O_&][ XM%I#
M1ESPBYQ'D'K-)P_3IU(,>)7G4"HG137OAZ27T&?W00-[RI@H33GQ2[-9IV[;
MSCI=?ON2-9:487*.HL2.,B>C5#EAS*CDJXC*34 ]@.D"$GDUOJ$7\E]7@RPW
MC"6%'85:';=QFJ?TL98/Y29=V3+S(N?!F\R%\V^+DF_7(J+AY9:CLV0Y+NAM
MW W)BZXB,@Q'?^$;S3/ST^D<G35.0!OD\]"HUWA&KIJ1MFSDD4O/$,_FNIO<
MK>8F=X_.VH..>]ING/1;G64;'8A'T!DC@02R9+7<"'0+G7,':QO_"JFF$>QY
M2C#B-06V_%@@>(G[V+V\</P04U1WT1,OWCH"TEM-0%@@],0S,V2E5O97-,4P
M\A=@KR506G3C"YAB. 6?B9*SH %]N*@\K933HG<+%RI='6$ .S&!C^(V//#*
M\P-.G//1B 0(M.%3YC8"*9FB:D4]::M#NUUM3H/RI%)="BDR4#9+"OSQ#*UK
MA52K3V*:LG"[?&V>.%]@;3T]=)O1Q@7+0JAK8^^-ALL I3H0\M)3AH"ZY>W]
MHE )79IDW]&M[&-,U=0-:I'$180]&8)!BT $TS/2,A3POO+PTG_ 3BE<AZR*
M#V?SVPE(H6 DFG7/IM]P+;\,QLE0/E5/X9(>&$9Q@0W!0K1\D*H96:R-?MTJ
M4\J3>0LZ 7 WW\%W[W!,S[A\>TL4R@VH"="Q*-=%"O<R^&$6:FWMBU5!G5.W
M#=JWV<SW)K*T;^E9HQVUUV"F5A1VF0M/O1DLZ2\8 UE\"_7NXN4Y[BQ8G0O;
M#/H.AQND='2U_O+TS/(,CLYZC9-6?F$8'0-'<T)>UBJ*XW4\_>+PV"*_^L6U
M3;-Y\!K3(ZE%X9C#]G,0[@Y5"5L:="V2$KOXZSN[,N".))$/EZFYI>[#"4@O
M';8(<P:CC"VHW8C</0@ZK>7\W8M TI,BS8>.C+*4T0?"'VZEN9>Z"3O*@:1;
M'KZ%93F9H5K#M'P8>T@47BNU/^CZA>?09ZV'I2Y\I?"-IH7[(4E[:V!G_+?Y
M.BW47]\QU##!H 3>7'XRX7=%K V<(9B%'MXTWA,%<KD3\DSU198?HRZ4*2/<
M1S4/_\W8%9@WEHE#CM($(I$QY;*]FX".'#XI7WD<3F!_T/Y)73/6=%8T2GK[
M?\2N HP>@@O=ZI,4=MS"!4R)#5TLN&'\233[8US\ZRB$C8'5*K("5EK00U!:
M:2L\W&1]\8*'$S,B^TA*?_:;Z"/2Z<!3YH_]H32(3)29EAB#*E-R0$P8_YZB
MR2X%,KFIG@>/P]T44J?$LXF?E!TJJ510%=H^1<9GIH=2T$3JDHCB*/#,)H5W
M6@UZ O_0;DBK,I[#DO'78'2@5T8" V8D4?!(J0:&D5ATZF]#C]7YR <=@_I,
MS_VC^M,G]2>V4_._AZ'<QF <PQ: %66VAF :D\+UXG'K&>*D<(HI Y_66QZA
M[_(9K*MO>,T#YQPLN8F\'#K@W<6T/?%\HG>DX(LN^7AC_PY+B'C)P?D\#P*\
M(K^+&<9SX=E?,.;=;!S_7U:NI O#C->_\ )\1SN$@;M[@K9,PSFQJFN7V?P*
MYSXT6@+S'C']DBS5^+W+_O"M$"#NHW_,XT1='V/,%I4N$9G ,%D.3V/0GQ*(
M''.5_6?P<IF VO?'3\R[)(>%[@['V4DDQ6C.-@;=4BI4D;UAT1<S&@QK9H^I
M=Q<%$D^<F^)[F>$']/I2U]NUF>C5US!?0 %U96*0)XVI#=A$' /9]31V>0QY
M+O$,#2:,,/P2T=!7+D',%^H,UFZ(<22W^'F^;.4S*@E<^Q&'KHO"#>E=YC-0
M)$FE=@H:/]: )GCBI$2<\$>4CK3MC+'T#S":RWO@K716C.7AR7[8;*#@S">^
MF$N;$#Z"&Y9[R_Y?57#Y_\\<UKA5<#5E8Q"Q<=ZUJUD8C.AL+QBA*=+2SR\*
M15 :0/<SSX40GA$AZ.\R0G!Z=-9VN[VVVRJH;B[S )X3GQ[L<);MQM%9RSUM
M]]W31I[;,!\%^?AJX>;3%\E%M)O/"#5_S,].>,-[-JSR09]GS;?76%T*KO%-
MBR:)+2%PE@OFJ&."!6=9JFV^?^ZB,(Z-I[A94*N7+G/LILJ\K!G^CB]=):R5
MBURUV]A2$2:?G[L,6H&5,T94P8@M#D8@R(E[%+L8"VD=4;;<5 9+*CBX=T%K
MWXA9PK&#5N-Y;IN6KI?UW_Z6P4T5X8<)Q?I&T,.#<O1PC0/>=QQP.4:P&)W8
MWD^,8 9C!O[Q/\A- X_-CW]J/Q%Q4O0I7^@X8AI^!E,!TSYZ,NX:AT Q_*E2
MG$GH8OK9H+@(_>0'0?C@2=<)M%HB0\22Z2@/_7)!GR&UAB!C,'!^BB>\CF*,
M+D]<&NC$-W[.'>*? GD=W<TG_"KM8P6"'8_PEN*:EEK4%NL):E/4\0BO&A'>
M&%8&"3THCD"R"&-Z .W*5$P40(T$H8:H4RO%<O!:,$]'!Y>"23@0^\MB#-H8
M?6WC^(*LP'V!;N ,?6 )&R-?7/V06&S$<IIAI&(<WL0U*"'<4O0E08=RH)5N
M<+ [Y(N+!\X! +JUS1RDN^S"[] 'Q\R5V@>\5")/(X&8JTI/P^S1<41Q# HV
M>3-=@KW__MB/@BM\EA<CC*Z@KU2VKY9DT#XA'(PQ?D%(4(!(@A9E)*T@I%@L
M9BK('\^'0Q''XSDZZ+0O@L(N]$2SK^9<*G\L%T($A3K!( \&8S1'F7H-'R\9
ML9S"/]6/_)[@22U.K$8I1OQE>3 #@<-$39 _T+:DL\DMGZG-)/UP-1YS"F#:
M#SY>"R?.YP<18&"E:'IJ[PJ.*FVB64<XN0DJTWF@DB6/]R*@B W&+=*>.8T'
MC$6T3M-'#J.1<,?H! N]'2PZ$:<QJ;C0)$H,Y13!@Q^%@0+8(BYU9'6GSR!H
M,2":> Q4);;BA',Q_%*P[Z=@T<X3+9=%F&,\KLZE49WI"?JQ5M>),Y^%?'G
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M,5B.G\&/0'!"; Y[>Y/#;C/H(!#.'S_MZ/S_R14,>H+[<.AGD9AYID)[%1V
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MFI54G7$<RFHZ,U]3L9V^2[VD=&QZ&7,2I!*<!6*0;7>?6;LM+IUKIS:S$\/
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MQ2\DFHXQ:/?5\@XCN ,>X>K4C\&BZ)11A1J059_Q+LB/--Z3P@DLNSE.C\[
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M#/4/3N@:V!A&T=4WXJ?I;3AQT YH-7[[_NW\@O[9_,TR4D);NW98NQZ42!B
M+ K''(P=?QK.8[3!9N1):\SM;8B9!T39$52>.25Y53^J/WVR_J2UDLY"Y)^
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M1M<R5$$9*K$#MW^A]1M5N]!J\&^U&Q[L'OR[05[AQ9B J[92:SO46UF9PU'
M2_(85O)V"_C&?A.5\*G;WIHS7BV^XZW&MNHC7!_A;>1<UCG""VWQ_O8 7O7I
MK4]O?7I7R0YM[_2VZ]-;G][Z]+YJ'FO+YG/G4,SG@A8?:S3PV+9<G*[$$I]9
MX9I^?>FCJDHJ7@]JU4'5].O+Z=?78BE^<W3.-?UZ3;^^N\6KZ=<W6+R:?KVF
M7Z\'5].OU_3K->YW6_&2P8Z8I?O=H[-.TVWV-FZT6H/CZT/RPH?D=%>'I%<?
MDOJ0[,<A@6^\/KUTO^9?KT_(_IR0EVGCL?B$U 3LA_*I>N'JA:L7;B\^52]<
MO7"56KA#R ;4!.PUM^9J=O:23F!;HX?NGVXK/E/SUU9*W.HSMO2,M5_IC T:
M]1FKS]C;/&/;Z22R,#XTJ#G8Z_/U5L_7=MJ(+#Y?-0G[6Z83KX=6D[ 7PSIK
M$O;#_/Z;QQK6).QO.,.])/*V31K10?OHK.>V3SL5R6O7R(_Z7#PW6K8ERNE!
M3<->'XK].11;:]FQ^%#4/.SUH=B?0[&UAATK6%"]:EE0;\#MKXG87]GSV#YQ
M[>#_L_>NS6TC2=KH7T'HW=EC1T <$N"U>T,1LFSW>EZWY6.Y>\Y^VH#(HH@Q
M"; !4++FUY_,K"J@ !1 @'=*V-AQVQ()5&5E9N7U241B[PW-_LD U^XRY-%P
M4I&MOE,8[6$#Q?ZRF6A'@R'*F:C!8G_93+2CH1#K[[11^]3NM%<?1O_H!T].
M,"&>P*,HBZ=7DIFJGN&9R\R:"/1[6,*C$[F/3,G W:R"  2IMM1T+JZLH6FW
M!R?B0.TRI=NPTKJ@;756*KW%1SM'<6[8Z*38:$V8<Z<:R6XTTDMFI37!P5UI
MI)-+([V"R.#F$V;2=8$-1/9^*/."M,@:$WFW&-FC'F)DVW G[;B!XV1A[K<O
M/V]DN)'A[7R3G4VI&/7W5+_>B&\COJ]7? \ZY6TTV)57V(AP(\*-"%?RQ7<L
MPD.PHOM=<[1]L<Z195@S:49LZ,MJ <<VKCYYIB\ES/4FS(-3'.Y^%$VG76D6
MS?<9"YCQA'_4XB*5ASY]^9AEHIAS?F<.LLT"MOE/-YK]X?GWL-)'I.(G;[F*
MPF\,GCP&AG/PI?"O51# ,;US0C>,TX+? ]CBE 7A%[8^'M1.F&]44S:Z!]D6
MM6=NMJ5^NUUS2Z>_H\Y)'M*6O-=O6Q=7GI_3>1O\P(CD"HPGV(;K&=&,&5/8
MI2BVF[DL<(+Q[-F8K'#]]/MGYL 7F(= Z=E!,UW##VC@3*OB$*JCZB]ZXB]N
M! IY7$&C(0JE:>"?A@)&:1J.-S&^L3 "31T!3? #Y[#[TKU>AX8_U1PO[A7/
MUS06>0!]4O;CN1.&[M0%2C@AA]''+V7Q] V?<YLS'OL+V. SLA<(#=VK#M+Q
MWID[WI@9X8PQ^#P\##Z/;XQ6>+%PAAVUC8GS'!K3P%_0\_"[N/3E"OC6"5G+
M>*EG8=)^;SCUC)DS,8*$"8G<@H(A_&+N1"2_OA&B,H)/S%D4H>3#H\?P;S>B
MJ0>^YS&N*9' AAOAEYVY 4]&PLY!\<'SWH2,&5]\^,'H;4M>[\)8R5\3:25Z
M-YZQR6K.;J>)S.AA7K_#4][-_?&/1/5UN<YVO16;7$?B9_@.!FIR"6^)@A6+
MM7[M%16L _6Z9C&V9C%V?C'?DU.BL-'@US#-Z$1:O$OH+/#@IG/_*33$.(J0
M:V5_#C_$,W36B";.L8"O^"O@N4GX]I><,9G[MRH?\#NQ*;JZ$LI?BMM4^UN;
M?EMCU&!^PM#!AP\.!RUK6'OVX*#=&EG]=</K-#[YG@$1*RV^8[7L=KW)>\4_
M'PW*!^_56M3:1^V,5KN9?E?V[E'N86<Q5NM_P*XS/N3,NCV,#CP\-NC+&7Z&
MJKZ9&%>?:'8%HC4XLP5AP)LB*WYO1*U[[VTW%NW%AZ@K;/_%Q*$WFM]U'=TX
M08!.* 5X:@:C^^T>*)F.9?8[N^H6J*-\3SAKU,C=JY&[C4:";2MW_8NK0=\<
M=?8.A;L_L6O& IS@IUY!L]5GWWNX!$-]D8T;'M^H:PK<*QHSZT*H7WQOO%'?
M1+\]N+CJF/W^Z$3JW9NVB<-=U7ODJB%RE3TX[6:<)@Y0VI$QICQH-A3 \Z G
M=Y7LJ>CG57DQ6Q/GQ2C."K&%C*[,Z=+T#Y1/UM:E(XPY=$UKL/4=O=OC/NV(
MA'YWC;#ODCXO1MXKQ#0.)N^=]L758&A:P^$AQ/U($K^%Z96OH%5+%70_J5H+
ME)'T?ZW"R)T^"^Z]^J_[X.]7YU!D5+/<3>(J8M'05U%-A84L"Y"9N\@?_SB'
M/9?N\).79+JM=F>4KJARPW %9NR30@995 8\260(D0RZNBG'6%+?.3. 3\=4
MW&-B:20^']]D2.*V#"P/\A/$RO2O#?9SZ6*UEJ\NU185/_!B+)\+)E0G1R^&
M%[CP&A8LX-%P:N$*@>=AZ?AF^C$6#^66D=[YV%_-)\;,>63&/6,>&/6@M7 5
M5#X61: B<D\@*J!+(*I(V:,L: (%X-!*X2&ABS2*UR!?"%LWL:[)0?]A-8],
MS?.IN%!=R3TS%KP.=V(XD5JVRAV1I1]$O C12? B9=EAJKBPQ?7G;8H=B,96
MFC"@_*D^(D?,X@.<,2#E_7-,A@4]/_[B.Q\1C;">"[8UCOP@C/GD6KPL>U ^
M[&WA/_(S()+S,Z$*LF7@/P*5?:]E&-=9@FJ?* E;0$M?0Q1!8*72D\HO53+#
M*O&HB@ANW,D"PHZ%UZ Q707PJ<  S3Y>A;@!^47^F$OE9=IMO( Z3U!'UZ V
MYAK&R^HBG<I!2P:NZZ? C2(06G\Z95BSK>@=.+F$7&N4@_)9G7*X9\5:0?EJ
MH59P4@HAJP]H(['(C-U@O%J@?&$M:Y&N4-_J[$]59-BLU*@0IVLCCRU]OM5?
M>"WN(Q-5B,(F5;XE^+2=?,6Y!]-K%15_15=,>0P._GAIM3/T4?Z<Q7.TELX#
MN[P/F//CTIG"<G]QYD_.<XBFG"JW(*(J";.[+]SC=+JW/7)= 4:Z']!Y_T*L
MBI^"-3DGLQ9C%J #\W_<B=.]MX<]N]/OVUV'68X]L<86?'LP[EJ#:?]_T:N@
M F>40410Y&4]SI7N'/7EO[V>?6GE:J'QIW994?#I*F*E8ANO.?2")MG6&)T5
M1=HDKXU62R15B-H6U,@JE(TT[\ T_'%Y-Y[Y<U@[/I93=>%/V)R>Y88I-18P
M_NZJ+P95QYSQ3"@X?"T6G)ORO@!=/G.\!T9:6ME:O&6AM/7%ZG17^$O&>8\O
M 5LY C9C7@@*SIC[H;!OX[WIK<^BY>>Z23[#_3$W;/F0@DXE)J\TCW&ZK<!B
MA\>L%DN^!K$O9571#&B%[P/>!'L*%"F\<ZS<CLJK%DGS%RU\I71_F:)H7QXQ
M=Q#@4H>#?_11\=/-(O<+UCVC6/G<G=9AJ9;Q&_-@P_/Y,[TQ$&T9H OX7]\:
M^68N\7BN)*C=AJ\.W\# HUW0^5)"^(GN>'Z_DI<!=EG C0U\)Q (I,X)#!=D
M9+R&1IP#%$Y+?U1R!#?!G](W^'3.R;,#1B0K<WW[FFRB.(O^M;5*+#G6/,$K
MB2#Y!A.&3 $OF"C**^E'<:GC43)!6JD!HZSF7*O%TO;+YJ05,:=+C+6237 R
MP9(/&DH729S<_S&XHK7GE]<DFW%,6JC7O)24L$!KI@(^]Z!B)](]0/B"1)ER
M50^7":EWCUS[S!T,FLKU)ULHF-.5@F]N^.-R&H!O[Z(7 D0U0"NSHS(\73^!
M?F%H8*4.\X_6'7PAH-OK61YC8IE1<RFR EPL*WJ #+HE5SG<>N"TXD'3I9[8
M'2_RQ-^[C^X$^?PTSGFB+B=WNC,7A#3 ; 3]'@SAF3N>92*1D3MVEZ0)GMSY
M7!PGLD)AWLA;H0V1AT/IKX$3*!M<I" ,$*) #7R 3N?B"G^5RQ*]2 ;\H)K0
MQV? "A;]$X:94"O$L:FDBD9847#[)&I$PMVO@&VY=4Y<6Y89*%U+*CRWPZ7@
M2GC\LL.MZ<$V,=G3Y;@_8S_N^.R6-U\*/,Z4'LQVHRMZ4?D*.DR.L%:(>V#Y
M-2\_P7/2JRM60,?WF3J6L AKY-^$SP1^JA\PD_^5NTR>GWF.FB J:."O"Z00
MH]$01@[>(@K EK@_)K<)^ Q\X(OO!2DLFC^E:?.=C6>>^Q>XAP5H!YU\A ]^
MED<[N#9 G8 L/\<9KI1#B(R)-! Q+B4HLPIED NC3Y7";4FH7D]2F^LWX:N&
M&B2$"L@'?).:K5OU@IL'QS?HM-NM=KL^P$&W-;+L0P(<5%J69;6&@T'ILDZO
M.?VLFJ2W;?H_@YHX?9U4PP0EG?*OH*I]3=1BKVQ28:3;=F6IYU-^6>1&#U0W
MNKN=$RV<94Q7RNO=OKCJMG9=0KUAR>2I2<;?ME,%Y]<3&8>SGETVGQQ= [R\
M9K0B(1_N4,BK(OGW.\U4G\.S1BI@1UAUE)%]>V"KK!(I!^((ST3<"@('[5$=
M>?K.@D5*AF!-XU\FJP"/*1&=WL55NS4:%KK4K^3"B+GY,1<5;&Z-?=\:G?9^
M3</^Q=70;O4/UJQ\:LRM,?_2339G6!:S[_BDFEU)XI/9..2&69&7%4.L]*A.
MN]4;]78$66H/N[M;U'!OP<@S!1!M HCG&_2K@BE:,8!^;EMOXIUKXIU-C'*M
M(=K9KR$ZP!BEU6MBE&N-U!W@2#1\7YWOK?WR_1#Y?M=3<E\DW[^"4$O%V'P3
M&4'!M \73U<J3T>G%D]O4 -WS5C=8S"6U3XUQGH%;L(6B9I7E%SI]':?7+$Z
MX)BVK/+DRBXMW==Y<OT]G)QU<66O.[E78*O528LU]RHRXWZKG"S[XFIDM496
MD\JJHSL;L[ J^^ZR?D?#OMV+JV&WU3X8&/EILV\EN,/->DG*6TBH9R0W[3@]
M[#C?.F+U\OT35D\SM?,,T\G?4U (/#DK<"L(H@I^=0E&PY- >5,RQA*/(MN,
M)3%.1--4G$1V4W-7.]9;,P5I48AHD9L&6BGWG)_8>2ZY9QSKV=YAFK=\UN=N
M>D[.*F7VSSQC'C6#5H8$MD^=_%%!D=.WGV4@M+8-4[\>#.IU>S]/VTF#+]WI
MK$&8CB]FQ4SZIQO-<I=PF+Z%P_2=+:_UYXVF;%G]BZN^:8^Z^T[$[#LL=T*C
MMH[QT)<06> <5_3G#<&,I?'L7E?@X4TM]6.U]Z-^"K3/;X[K??;#\!.?;#_Y
MY'UP H0+J V&;PTNKBRSU\MCX>?BTT=.!9S',*&3-:*Z6QE1&\PV>#U6UM;$
M.6E%6$\/=L[!#!M>7-GFT.X???['6>K,4WMH/H"G)HQJS"9YZ8-(;BAV^("8
M5"0W!L60SV&CI=M2QTWT><" @.U)-2V 7S!_=O],$;[?6?  '[M^")@8)J*"
MUE&(B&!R(]]P1*R5Z"4 G2GF;CC)MV7L\<]OZC.7RD@ @>R%T)4S?XYP_#C+
M0T7!)'@HM>$E>X-W!0@/ IZ!!$2!>[\BF'U\KREG&H@=RKU@3)/>&LX0 SC[
M4AJGP<&(Y\^X! 5<-;,:.7DC7"5[T*^P9?PW_9I^&4,0^S20(@*/0@>,B]B
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M$(6^?36-SY]O3$/T)G]VO EL8F(:RU40KASX,#SA:>:.9X8;\4=,\$?\D=/
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M(*,18H 4(1,GR"1@CLWG/+,+>PI7]_]B8SI11_[66"V?'%#)SN1?JS BR=J
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M\>RC^7C#C7P\$R^F)X;0*&%%#ZXTNCG8<W23ED%AOGM\.[]B_%68B,Z:^'3
M>Q"S5@2N](XM(X[F),%A&W_JE/PIY@!+U??[K<,X5:.:D^SJK6M+;PE1-74
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MQG50\10V[]45PH+2QYTOK(\1Q7R&?5VO]DZSAIP'JN0/\=:KJ66WSNO6).A
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M$^?%&# 5CE'8X0'B[\#-L71(2N-"1>4)N4(T/:-<YW5*B/(V<9'_[E=QXXR
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M$H*F!L$MOM?2V++"LLY;7(D[Y D#6$X5P9$T,B=%/(ZM>J*34ER)8.7.P(I
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MZZ4/E&['?SA@%P7/5,)"W\+A17Q''BDVW%*!WB&AP].[9SIQES+U!$(%MW[
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MN^V+JZF_"BZ?F1-DLWYXH/ DT%&IX&8,<!)33,:1"0G"H6VB&*_@3L/()_+
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M%LFL7__..;D@L9(@*8FD,-'3;9%@(O/DV=?-B:5W@,2"$Q^;XSU[LDZ26-Y
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MV6+\A@'\ \G-?F3.BA-]2)/*@($ T@3VM BY))%GT*L0N]8B5?E\IOS(U0Z
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M;1 )'7>!+3<S3?NXC$Z1SL[SA?0SZ/=WB;P?-*6"F4+CWLE,#U(]$D3I=;2
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M@^WTP%PXG..LC$>4ZF##^'"KY8EF>#U[NA'Z+QQ-#P#@0&_GUNT^>8!SS-7
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M5'D26M$6MF07*X:SRD_R^%S"39B049SQ<_("NY*TTQ3& "%C^SW49Q* TXQ
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ME\K7_6Z:IU,1IR(@YK"I=(5(KSYW*J(N;9-'%/:@T9#VG@#3R8+**:"XIJ=
MHWL(N>=T1OD\Z8RF$\@<2*=8EK/%E*LV_?!.*32<3!^ #EW1 UP.&A18F''
MKGD]J&>4W"O&19!7GV<4*P\;K@[&$U^HD<ABH6>$1]]G"U,P9,KBM_B7!?QF
M?2Z0RC(5"+4V^P>N.<(83H08*YW6E,[@ +Q\BJ](1_6>,X+$Z7;*![JGQ,IX
MJT5'0D+E*S'+PPM"QB_VK0E%#9\HVF.'(I9$UC5F,HCQ?:$*/B7@B\Y6!YD,
MIJ3#^@".4(1!E+>?=B2<M3H%Q!!YHCB3_5>4U@1X1J+I8AQA@@ .33D6D$><
M ,,MSP^T/*E47L*:O S!T!QOJIL&Y>E.$I/\N)FZ;/K.<9R'<$+8&FQZY8G'
MY1[D71+$Z&?I@%TBN:O,9Y66Z")_<T(P*C]$,BW,BT(M+TR)+B)-(K4B%!.H
MJ./W\3/R75/ U'6DK@PS7>E[[4I2\>#\W!^*@%;(]8F]96\HUV?"$G#C23XR
M(< [J(0 K&A(% #9>\L$L(\E$4"P_DQP5PWIG (;(K'E@Q:+=IU06@HCN4WC
M>B:7E:M8=,$%2Z7O5INI+*J0XHFA4JU?4O!;&ICI?'=*-=/-(3WBGZX%RU/B
MXQ=QM,GJU6F%^F5R#J31OZ^, RHR90);I F02D3(9!2PGTL0 +GK$6GP-;5O
M=8C'#$H*8O[;2GD*IJ:8%N!O,N*<T:OWGIJ 1O,+IB8,^F\]->%&IB:,\X+#
MZ>P$J?//\JQZ$I>*](FMIKW4HJ)*R"83UG;/589._-L9X9&R'_;A%*OS8TOS
M8X=U?NP![.7E\V.[^?FQAS88.1]OE:.[Q/4#ZC$E:*+YN,ID.'"]R,QJ+%L$
M$OO5X[^704"#S1RPK8C!8;!7)AE4]YO3N,!U<<,-!RL>OV2[SU-8R)$D=9ID
M?APH9YV^%(+QO+*4#QKA'PB?&."?<D/3O\F-Q>V:N.!;<TZ#F#(!+-ZY9DL_
MVGX4\ 8PEW\V$H7"QW\'&Z4<;9>P-WB)A#V=NH;EO>:R.US7?'+O.QSEIA3N
M)<<PRU:KP:)HSM"N*405H#,N&GTK/))NG%&W-^:__PRI80N9?,[H\H*\D%P.
M6)P5$A2EV&@DFZP1V'[R\RNEBMP],6#6<^/&7\[A[1]M#[BS'RVTOD['P'??
M8+8(Y;"W.4*V&AEGXITWL8N21@J/W332@4Y:YJL>?U,OP1\19?$Y??2DG@'2
M,)X\W[&>T//Y#CYEZ# E]]%OV+D(R.D*3%7S%SU31+6KT((2.:TK:&>?OYZ#
M$<"[14SA&6HEIHWW%6G(Y%Y/N(MD,FG<0 D; \U]#U04H.>93U[?E?'@12(J
ME_\N?(EI+!,9-=S[QFU>XHLF#S28B>81\#Y<LM4=JK0=!"LV)>7^+IX=L^XZ
M;#?EOD^&\!KB3M1%@3J?O$+T*YQCN+*Q>VW[:*L2[SUDR S;9Q?#_KH4F28'
MQEPF.<1068!0R//2ACA^&>]NJWR7K:!QAUY?U3M-9KO<S\WP=W/UD7T7-EIU
M$'7.+@;=];7_>6E#.;ZME^R )D@%J*^1]9L7M20C(O">9 -?WHY,IM_ %[ U
M^7H;365^;.I@%C*X&ODH?I)\=F\]S=+4'/<(J!N;%67=;"*,1&3AG<D[5_QB
M_(4K<(M3B[DAJ]4X+0HFEV&X#5N@SG@:EN:<)7'QY&'Z)%Q5-].K+,92X]VG
MZ[N[FZ]_?C:NN:!5?U[_0A]@W.;G^0)./S>6#DB.B<=3"@)B4^F4+!T=Q.%*
MCL1#H]1WB0<X-))69\:EXSP8%R G.6$L=!,_(HLTE?&"ER&EK?PJKK53K(/]
M9--(@O$2B,(B=O'-:QIMN;FU>@G2H\R.53X9C:&KVU<%'PGL(,:R87>S5&<S
MQ7OB"#"0(@65''MAA_+7B?4 *#RR3J1(7:XLA5#"OI"8I-"#8U+#$)H29X8K
ML33&!_)C7YI#)<84"@]2!%>9/Q+/7>WKR-4>$"<58'T"B<#CGB_4X\MX=_WM
MTR_K.GT9[SY^O?RE0K>U=[]?7OZRON?:T;/*^V30/^#Z"& <7:_(SDK*&Y&<
M&D0+RBA &N-^OQ&W*00F+%!I3 0^$\M(/ 5=.J!$Y/51S9<MN![BE+S1#F'-
M!N_".EGI;%5FOL>^]AQA3KF9H8$3!]*A4FJ6("B:M"-.=<1GTX'F8K$W%YF
M/#2/O^1I=%A#&1M5U'33#%7J@4R<U"0>)6<L'<\.E1S#9!#,&\ $'<-4DD;/
M"24CB#0?VJ*-_A80'BXA!:C5G/@-9$LTWB"MM4DQ<OSD%Z>H8US%*[7.$T:Y
MNE_0=:8D$A+Y!$ ZKDCS5IF!.CIP=6'J>(&6V<_7\^U'O)Y;U#"X-).R61)Z
M5VTO=O"'V>6*V4H^\@/?8(SZ?<MK?0W'EO$R+\]'!R ?) &+ 3$Z)Z"(K\O4
M3O ^E6P3;-$?,L$6XRSWQ N4>RN'9GCJ(NF<S)+8ZL&[&1BL(AU<92_)9MK
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M_.^X;7E'UB>*3]Y2.^#JAM(8!$Z_,<@QDO)OOF$L3=OBO;N9?T[G40??L!
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M3@F)*K5,(L6I%X2!ZFPI[(R"\YF(5* A^90#$-J@KK"'"'Z)R@=HMJ!'F9C
M&)?^Y*A0>))AMY5)ZL7G(JIL47D 4U7I@BXX+("A9I:\Y(;#2A@"-AJG.,_D
M02GL*HC+'89X(^@H%(>B<2>QVC#% C">@DW$<,Y#?7ACF(3.&5BL%8D\;9ZU
MOE@ZWHHQ:0,B<"?H4YIZ#RYP5TLD>B8CC;A!15<!GA^@-\'SY=P5QRD.$G-)
M0NEO97WS"U3W8BKG,5W"DMZ6=TV /:3$"HN$Y]G3VQ8>(,W?3%D]@N83T4]E
M+H&"-(L< "4?E4AIL;A?='"NEDBV<'?Y/]5];2+#">^":]]9_$"3)Y/U+:X3
MD-Q/!,;QJ@B5\,X=[^F<Q\0-'A.''\]!L"4_C /E/!>71^7C\#K!6J=GI>PE
M;UY0EB5I->6%@X6F<%='H06M4P>D]X+/]>KL31NX ^*!!S94!Q Y"G*PB-.Y
M#YC\H/T4[U\&)BXO_T2B"FR5"L21B[ESXEFD#^ UXZ[9;&9/;<QAYG8U?H>J
M!=ZYC[$=M/ .2S=(:0%QO>)!Z /)'MN#0] '^BT<NU?4)2-7'2A U]/1!XH.
M>% *0;H&=Y\*PGFL(#1J#:'6$%Y!0ZA3CE(I1]TZY>@ ]O+R*4?=_)2C7K64
MHT/2HC%IO9VK0XL2(FZ9RFK#/#EAJ8Q(2J!GTSE7W3*IJ=$:'QJJ"E+!OD?5
M.M;V^'30.*52\/WJ'4LZ@VW<0&D-KWKSDGX;<XC7C66E2@+1;6.;>;R=H@:E
MI8&6O*YN7SQ?'?HROO7*?3WZ'5!I,;A=VL!DG4& #[CGY%P$R156O?-AR9T7
M 64#8%PN4$FLC@K8ZF2MTP^T $$?F\UJZ9R&51^!0H95:=FN#69L!2PB[,+@
MQ $Z3!\1VLS287HJ33$[4HBF.%AH@B43,ZDBRV-N6KQ867!#TJ7@=<1+NRTQ
M.>?Y.-CHE3A8;Q.TW9F#E3<->PT.UC^[Z/4: \PS?S4.5M!GZ[4X&+;672O,
MJG*PW:9-O4JLF;G>(U#YY4?C'690:ZUJ#Y@'5XPO9UREAYZEH\>*VVMCQ?B%
MND>M;09Z;/G'>O W\V1R95F<*!]#I5?X626_3WN#*+=1U%@KMY#8U__U_!^P
MV[_AEUR0 00?,)G?]X* $BCU&'$4\,CK'*NI$PUPXL9"2Y])UVK#L&SSP?6H
MX0VR;9'0IS*UT'^DKY](@10LCV^NJ0Z,1D/&WTQN#AU,NBA64^Z$5TOS.]%7
M,F&&_"5,^@]S;NQ(')YF(#)[BUV>V<-MYNS$M2M[.WGB*$^SE>![ 5^>]E;A
MT;,.R:5'V)3OTQ.7DW'J80V$]V187C0I\MK%'12J^^]B@)'NN9D?#W9X_&;!
MM6M\81.?HGU9LX"J3,R*^E2W]4HZ]!!TR;4ZM!05NB#!D  W(23KC5,)\1,2
M%?"#RR!D@$; =>X8,[X!,S?:/<%8B-^X-(V',!J;+;D<9;"J2$OH$27DF)L;
M!;RO$J<EN?R)-2D079"I,D9'+N7_DO< D+:)"9*0Y$IN,ETV1T/@%"P)$B.Y
MV78LW 77.SH5^&KE1P%F6\;ZR5O.M#P"W3A&NF&><HS'*KQ4RI*@;QOI'(MI
M!CC%78+X^C$+,6XC'UT&:FIQZH&&^"#.QZ;N-JE]&Z6]BN!',E4!J==Q@ :I
ME:</6IX/:@ \0)D*<8M+O5MF1IN<\.Z:>7;_]6)Q?_,=G4PAK4C*%YU IG;+
MW"]J^BF21>5;-95;Z(X.,RU9VLHU$]JU;[/0Y'U3F.^PZ ?04(=@?/T5_R$7
M-!\\UP["1(I)P!S.@T!9@N<6'C4#AU/()GJ:(L=;Y8@6.7I['%& *S)9BUIR
M<K/"@A=B28('URB>0N\:A?X"+7$E'2&W\F\K3P?(VEI2T\\H<1(34,!AB\!5
M0[=)&F5&"6?FTU@=2V3PXF!85%(I(84TX)\VUF+ =Q4UE$1'[O/1LVHH8TU#
M&96Y=B;2R\<MT 6H(_;2B>NNA1*=I-YC,<V42IUKE*4/]7SY)[49MH$9QJ^C
M/+-B85N9S K,MB@ST?9JF)UR^F5QX#C6( KC-)H;ROC!4(2=\]K_(*)&%5K<
M)!-M.7[P76L.RHP]JTP.#D)A<(1QU9N*-J1UI-BN4)[USGA7S_KA:N-\%/VM
M'+V^7@4_H*-6Z!KAK=784XHX#S>ID?19[?L.M@6[_6C<^FS&2(@4P;)15"RX
M5H.O])*$"UU\7WV(2;=TB,GGOR*0,O$H%MJ-W(S:"X^9R8^KCQ[JC\\N.HUN
M9] 8=WME\<*$.5 $+&R"+VJJMAP^U.WH,.EM 9%;TZ=9+_$KLJ<>M#"Y!:@B
M)\D#Y"L_=@/#GF:,F#N.5=K#R<0'-&2I]'B4NS/JC[-J<7P\4FPKZO@%?0WE
MK*'T,?X-U.=%\'/3 J[S2>C(J,E],6U^2S*@FW4]#C 1)\?U: BOXU&(B'5B
M-4^_'F';:IW#S,F"?C1]FS("R7P&90-9'6=KW,^JU$AJCDU7@4WH&6]ND),(
MS=% KB)I6ZF]CD=UV#@0@EL$2 RH<W.1GFC!S6UAT7ED$GC^A$[ ]RRJS8/
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MD&-R*J95VOU-UI"Y()F%CE\EN<ZJ7"LT+GPP+AH(%;B;AAZY+5;DGJ0*/G5
MOMDSFT<;8_$DA]'*.P&]CE\^<A>29:2]H)T3A_XVBTP*+5-HBK$BF=AXOMY[
M]%>(5(30BT*RKS7SBD@'=8T@(,@**SOCNKUC_J,]99I.04I*%,X]GU+FT!L
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M:Y$+S,4@:,+3.2H:.N@"L4S\0FU/J2=!_0PB_%A(!.U-RK&H7H**8^28H+T
MR I>_4@*BHD9V2NNC6[&463!,<)<QWS<B6 #?O"[>*?^P)_P0OCHEL15PCP
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M[26$VC*,4KAC&<]?@1SK/\*6!1QN[(NW_I/R\54SYC"M!*'%C)A?F2S8&**
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M55F!_NL_WQ\?O?N;HP1S?HI%V_<PVX*;Z["[[8\Z%4SK@Z<OYH,;HQ[?.Z7
M'O'Y9Y\]=NQ1*56M.[QMX Z"JB/)]@BX"\S=@"R!&IL*%,XBT5!QRXBDDI@6
MIG<P4R/<]1F/ @Q_K$D!-K"/EE#K$3IGB!/A[[<9)5H!4T9'B\G[34PD%4 C
M2Z=':(RCQ0(%*S8=DQDEHM,7YAZZ+HMH2.CL5G0K+L'M6HXA:2UF'S8QBPD#
M:AG2SIJVDQ#O$9 W.)CAH!50<54=$&\/-X%0%7MDY*\XA!G@+0[&<Q$7#7V?
MN4C$5R$3T\0%H]F0JA44C1AH 3O:!$R0EU-81S!P) <G9>&$S%%,<I%AC]#]
MC$CP._(C?(,1&$Q&4:U@+*>DQ>MX$R^@XTA"3I92CS"Y57LO*S%A@;G)$O1O
M!4DI(2TB;S812<C(&51*J$> B%$VB+!W^;3$E+>,##9I:&$XV80AIN D)'H$
MP+7H"%K:/:ZJ-??IIKE5Q1X9^0)/VG4SLJ+6P&^+4\-)GSJ1RE6SMDLJ%=2T
M0!3FZ#6+9CW"1RT#M@(CKJJU?&$FKBKVR,C2J:ZH*S0@#_C61[3E/+N$CM;\
MQ4FU7!=.R3B23H_0N,,/F$9X& 2P@-X^]"^CHT/C76%F'5-QLF1Z!88/B]FW
MPM2K>V$!CERY(]L2D0IB6E@*\^>8U$#2<K+$>@3..?-]-&%JDUQ,@ZZ)"S'X
M<!;@+=J-GJH6KL+T.4=3SMABJLZ:;(^ $YT[6^![]-1R^I"MKP6C,'-6M1U9
MO4=&OUPL?;;"^ Q3039L/\R7$M+"4)@Y)V2<F$[O!GI8XR2A;/OR+)'<,<"T
M]39''3TM/(69=H9:?/PH0Z]'*-UA'@:1&T:!T+[EL)^EH$6B,"7/U>^1Y<=X
M!NYWA^&N2UOC%XAH[5^8B<<DG)1&GS"()AS_&0D%+A]:1U0%(EH,"G/R-0E'
MT>@5!B;;U\^P0VZX4WYZ>E28KYCOE#L_)?_JTQ$OM8%]#]N?[1#,$=#B4YB@
MJ.K.3XI GRS?9*-["WQ:L-&B6)C9M-A5[R/DI9OB6V!;1T\+8F%>5+'5WD>@
MRK;*M\"IAIP6IL+\J'S_O8\H;6RB;P%0.24M-H49T^:F?!]143OE6X"1(Z#%
MH#!K4M7[:'FU?[B%Y7,$M):OV+_LH^5+-B"W@*&:FA83LTW-/D)4LBNY!435
MU'00'1OM=/83H?)=RJU@JB6IQ:K!]F<?$<MLAVT!4I&*%I?",D)V:ZV/2.26
MZK=J,$4Z6C0*RP$Y*GV$8W/Q?YM@H)R4%I3"]+ZPF]!'8*KN,E[@$)&6-Z1U
M-+50%:;X-=<DX6*R)-LGU$HN.FX#6 TY+5:%*7_I]<E>HF2VE[,-<,TX:+$L
M;K@VV"SJ(<!JK^8K"N XV0/>!LD*4EK("FL.\?[1P$EI]1@:R.[L13YFTW1G
M@$TA-P+QXHP^VV-FSD,+9F&Q(@4S80(M,;,M >D<LISV4 O;JXVV-/JXC0)W
MCCB^#8B+0R:^7/*0+&#6F@+&9<DAYSCD0_?/B 38DP=.T83X!-(\BM^B!?:Z
M=)?GD%/G<F\J+G!ON-Q:U"3\2J1UI+BPI0E?4XDS3LJ3*DIL)Y$[/GR;2N[$
MHN]]6/C&E="$SN#*41[L+OU/QT/K.X7%H%+?6;,I>, >:0BZ&>3%1Y\)1=0E
MR,\D[NP2;1,^6L2K3JOD$1>L',G+29EETY'V$O8FIT[6H$&FP2B,QPB86(GP
MV[L@?B2ZV"84MW$D.R37NF8G1W#R?IS1 ?Z46LA1*]:CW2F?O?,;NM M"V&/
M#OG2W&(B(RMSZ5M)I<LGUX\\[$T#MA#NF_,Z\?</T51>5D]MPRJLFV[?L%*-
MG41E18?'K2ZM[B1Z.Z"XC"(W&B5\VC?'9LVQ])1<9EXBH[3\M"(NZ:%P/<FE
MZ Z[40!;&G+-;YN6LV.1M$Y>6'&N.ONW,2]2 >WF3"81S4%A;K9.'>2D L8+
MI7L'C$W;R3*:&66M.Q06M:O=H=_+;)IV"[E&X?]P$.H!^?&%.+D;2ES19<-O
M.^PVFK#7^D1A<=RLBP >/ZNDJQDQ?I9]QEH256#O004(RWZ^HB(" "3A!RG^
M/7;GE/P982YFF7] BQ1$DAYYM4,/ZU(\K0<6UOK-/+"\E*/$E'Z8"NJL)76$
MJ$XB:SJZK?8^6G2".^;[GUGPB (OXQ'"?G&DCNB*7^,'[+^)[9F)%>!^\.]W
MS^&J.Y!2Z[&%#0TSCP51![&L&QX,7IE, X3$<9)RX: @N?,F\=A<."8O3?]^
MMW?BCGNR9W+<CB33.>M)82MDY]WKWBFWZ+/B[Y -(4!NMK=ZH4Y4+Y#6!0L[
M*IWUE\FOB72Y#K*/GE=V!2VW6U+X=1NW:L]-ZS.%/9F*^W"%/9K22W-[3Y"&
MZ&0QPHBP%E_#?,.]7XK8N+*X#7 5I+10:7,2]Q(8=?_PW<F'TZ_X\3<6D/]C
M] ^T4I\[:6C-.&AAK,AU+/X!+!S!PXF9B.G&*KU?F3+Z:X]A?GOZ)6 />!P&
M&(?R4X<(&Q#7@EM8VDW!?7OJ2/*.HJ]^V,.JVM;AR7]'A+IX!,>^ N^.(:_[
M!FS.1 MSU2UHT88/3QS%QHGY.,!HWXRS>-\P[K+'NX@+S+INQ7K:6G0+*Z$I
MNHKXSXXBOV_#&4SSAW,8Q?*1.?G;.>/A5A%3,PY:? OKABF^F^=S%!/X2T$M
M^>Q!%A#<(+AN&*[2EW+I3!;I:*%D"W8Z^$\+*W&E\"<<,R_TTEGL!GU?W6B/
MSK^.GMD=!,.]0SR[0XRCY=*7BXEP[BRQK%K(3-\+S3Q!&M_S#UD>SDZ[D*YE
MTKI58;FUU*VR8F6+)TNKZW=7<Z^K)JD1X.39AC?N75 >ZO(\23IW%/TY_*P5
M8ZTS%=9A2YUIS3MW)'[O*\7'EK:[@CXQ7D$_+:RP0NU>FKWRV:0Q#L3(>9;_
MV,F<<$N66G +:[)U;Z!#4@C@ZIP5?NK['%*#T_#Y74/'4NL:)9GV#5QCN'<-
M4]=0/W#!9;?^4,-'ZP2%]>!Z)UBSVL->!<<=]O!")FO9+>PU?+2P-WGE3R9P
M2ECM8:^"XW<&4>MN(:_@H86[L&!<#[=BLX>Z"H9K\F=$/+3[)E['2 MZ816Y
M'O0,K]XCKS+7'A\>G]P&Y$%,36]]Y.+.3L8T(*]#^6UA;3#.NCMP@+X3,W!2
M#GMLI7TZS%U42U"+7V$1+L4O>0ICCY>PQS?JX> Q(&&(Z6@JNJZNQMH&Y+58
M%M; 4BRS])V$P1Y::9YA*)"Y0<%W'":6Z>9810/R6F@+BV0IM' 'X_CP;\-P
M(/@,%"/Y[>AO*=+[<Q7*7/^(*!;#TN&838B,.Y(\2AWB;<Y#"WKQJ<@$=& "
M ^RA VSB&"I-"K4'.Y(W3T3$,<'!\>'1AS@33J=]MAE]+<B%9; 4Y(2! QR<
ME,4>7FF@]892?.ELZ J3;'D7RI"T%M3"LE8*:G8W*KDMEY#O,9J9#"D=-M$Z
MJEH,"VM4*8:Y'"G[UIAO,L,HG,/Q;.R5)-*9LN!S% IS7G$>B>ZL XRWY:SU
M@ZIW939VEE/F5<ETX,""$L%)9.BEPY0\)]-)DS>AJP7;\,&:OM_V*;%UYB 1
M_'@F E$/CHABRJ6P\26<CA%NR%6'_[O"<E85_KDC2E!F('D[6>;)Q:.]BVR"
M]0<FLWF(O>&#P'F&9>Y9N;_#O_'MTJQVP%;K),57?0V<).'MQ,R=#'<'V.^]
MI+1)CZ2)N@CNV_+2^D-AW<VXTW 4QW[/ &IQ62=IDL6^":Y\Y\Y@PE3K%84E
M.Q.OR.2D4L4E[W[[1\GC=IT$C"9TM2@7UNA*G\_K>[Q88NK,;:4Y?.2$=IQ,
M9&NF6O +:W<5X.>N32G&#J'[;" ;3RTN-]]%S/;(Y2\G;N<?VW+5.DAA'3!Y
ML'%9?+!Q<R!01]++7G;LKX<4D.AH(# DKL6[L&98\T!GW\>$<^;[:,+4TSDR
MN; +D^7A+,"JXSPC;(;IS5!$3!T=<]J"H1;ZDC-N&79QDF+)T%ES%,444^?F
MU?#5SQ <ONK]BK(6IZ_J%_\<UE"#*\I#$D8AEKG8D]_2KYQ-?\/(#^?/XT,=
MR:9UMY+3=4;NELC@* &=5)8DG7M:8"TE_*3DW/NF#O\OHLJ,B4;]R(+O_#?F
M>W#^XMFZ,'/V.@][7U@*-?0P)8*3R. D0NQ[-T,/PI0]$#X\6T83_YF\II:E
MUE,*ZZ&FGJ+8.L,SYR?@_.JO>^_0076^"B((5$+(9<I\-EL]6]]BQEKK+875
M4D-OD>R='/]]EV+F-$/^W<=+P@"]Y1P%"^1*]"$4>2;G:2:"UHD*BZN&3I2*
MX13DV#N3F3.-YYBN$)V-(\KGA.+;G!7/V77H/8]+M1%$ZU@E%Y:-'"L1QDFD
M<?+B"#IB?B=$ZKV#B5;&%O@>/764O:Z.GA;NP@JNHN9(<KU?HLF8=KTH>CF=
M8MB.PNFO=RC$=]AEU"4^D2)WA&<[IEK0"ZNR&Z!GUV%3QIE"#O!V\LSW_I%
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M( NA+>7$PXKM'78Q>8 SQ)E,4-73U1:D;)U=0#2P$1&L4UW"#W#T,_<A'SO
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M%8V!&%( C]X'K5@B;3#@M?+ \(;4E_T'7C@M2?;8J^@\+[$YB5@MIHYD(+4
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M\6$V414KK'?;[:3U"'(;SKK_S]GF\G[D%/^ME,3U.UU;9_>W?-QQ$OO[C/W
MG'Y'O5O/_1V7;ZZBN0)BE(T57:VA,?7@)1,:G'3U"I98K+4A<]RN2^$N3SW\
M]LD;SUI=DY#)Y_#9,UH-M:.34;PV]LR058SHA%#!MHYS-B,90GJ]7RK<OGSR
M8(DTO)MTA>5B45X=9) <6;#URD 12'<BIT'R"!)-"<H)XTWKMGKWX1E$EYO'
MH<K!XFE.F!M8D/N<+<N K-14N8@0K:67Q7/MF>%!M6YWU59=[BY7IK6.-%+
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MB@RV3#6MWZ\_(CWV;W_Z?U!+ P04    " #5.&U:;4?!<V+2   ZP@D %0
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MZ*1BW&4+B5E/*W2"#DB506K/!1>:Y]AZ]$O_57U[8DZ812<>Y?]L6:*8@LE
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MK]K,:*>B-1O$WL2Y@V>^ZH\?/OWD3GSO)J]]"-Y.L8H=H1XGD-% R_<'5AQ
M0SVFF^P(VP21>*+#-ZC:4LI+^JH4#Q:M2=E++EGK=@DG0:@ML9'C\VD7Q?2(
ME$W']-/IJL_R'>S7Z%3.OMXLT8Y,9X(2DLY=- 9TCEIB1(^Z=2ORQQ$=85Y.
M3X7>#ZJUTT8'*^BQ^1KWN]M=%,99PL3!!BM !:<AI,3 ^8A1VA2T;-VJ>1=\
M1QRG<RH-F;NI\U#%^K]?58F_*)\N-Y^'\1CS#Q]_"NG=YZ^EQY*I@DK43HJL
M#OLE207A@?,Z$(1%RUAK/NX-^AM)#ZSX0U2FO"0'BWX0WI+A\=MHC//%=((O
MP\?E ?-J^C&,ZX+HH7Q11R4\NZQ>]OS-](<ZG&(Q&\6K!>:+H*U'SCTD[R2H
M.@G6&UG]8>$+"]'[()Y<U]("X5=,W=/1?,,&G]LG+OV(^6II"/U,JKE%3-__
M'2<X"V-:U[-\232HLUNJ??/B \[>8<@7-EDF#19 %Q0]H<9"B$R1S:VRJ]-K
M2U!/)O/^^+Y1^>A:[] 9KJZJSA#ZYVCQ[OD5/8J7.+M=U2O\@!-:*HGR[63T
M/_38Y9)"]BZ T-J0Z8T!G*&CQ.3HHR$FHFSM/^^&\"MFZ0%4VJ%WT)IF6Y\7
M)\SO5R?<FCWO OU^]=L+CXD5EQ(DE0N=!P8A!(U0R%DT*=JD>>L>NFV0?R/L
M,2C0H9W%S2J>3R_C:+(4#SV)\Q&]^RJV?UVN3%*^(_A?)E7<A#Y9CED5"[((
M0J\P@=?U,22A&L%+DKIU:LY^B+\1]Y J[U"NNP/ZM8\CV30WS^.%UCD+F1,8
M61"44P8BKY/.HXLV1A-1A>.Q=QO\;U0^&ADZEV>M.2=^F=R)5E\4C#D1M\!H
MG>@9] DBR0J"3%R[[$7VK7L?[(+O&S/[J;-AVOUU<<EBL9J3]Z(\'+O[<07Z
M0MKL?*"M/L=8LX&,@!A\!BF<S5J(PNRPD-6@C_N*^=-))PU3,9<(E[OF)-U0
M_.?I["YF^O:/,,LW+MVGN=Z9IQ"\+343R->2?>*X,!QD"K3!,IV"'$:CIWW^
MU\ZK VAM<Q[.@<<IOT[O,%^-<5K6_7HIWWF8Y(>S-.9E.KNY7;L3*6L[D[D/
MNH,,=CZ 8%M/AWXVG^/RJO3QIW"5(##[[*%<LXQ/#V*.&;U2M -C;3.1I(3(
M2H#L@Q,*8U2B=5E2[S4UFQK=%M\JQ1"#LRDSVGY8K:)VCH/37 &+,85L([>Y
M=:N<GNLY^#3I4W@.-DZ6/C9AUET?'V/*](:Y8B%'X5) L+'VYM-(,C910A+>
MA:(Y>M]_W-I))"P?G2C#ACGNHK!#SNT;@NMK'N:XD]Z&#O![BM /20JI?62,
M#'MON267@G,()NH: <N<JU**:-U2[$L8YMB%"[O(^KC#'-&+Q+0)4(RV=<B/
M ^]S 9EUC)IEYIJW6/TBASGNI-&G#W/<11T=TC@WSF WHFC!:=$\T@FJ$GG
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M'W LKP5Q1S4DA.?_^>H &=P=0!XXD;NWF%OG<[<LIO!")L;HP9,RI=H;BZR
M1'NP=,D*Q6SAS<.X/=;1+&^[53M8C\DR91R=:#7N(IV"H&HY)2\::4=B*%OG
MJ[9>P\'SLX_%ZXTYV<<@PZGD8=\*X8>/M[O;TD%97;8'DJT@\5I9J^#);0!?
M4(*-,2D?I=78C=[K !T]=GL4JFSB[=XJZ^#T-934_>7=9.\,6&"GR&_WQ1TG
M?MR04/VVV(9L^")I3XLJ+" "C[6##M<.G)$>>%#>"1W(R>Y6%?9ET7U+5/Q+
M9OLN).@7T;MI,R^4YX%DHTQ&4+G0&;;TZ+/,B7,IC.\4-SE6Y/;$%+P^2O($
M[;2.X:]KQW@S)84[J;Q!B,6D.A@X@\\FUHYV FW0"=73N\)^X\6#>X%&JCCM
M(_-Y&*>K\?++.T&>"VF+DB'1#NY# (560/0H@)MLG"^%AU,.>JQ?U!=-[I/S
MVQL0I\.-Q;HX9FT8^F Q\\]7,_]\[;<;R?*]+K1D7%ME  M7H&RMW%)"0(I"
M!?H?.M\Z1Z_+0K[H)Z %X38]#D=C2\_#8<=%;5C3WTG-OT[GM;WC^"K7QF0_
MA=F$7D8[D2?9)R%!HT]UD ZG4] JL-J+H%@H7 Z:O7J QV+GQ7U[5+X$5G7(
MVNZS)R!YPIX;!BS50I<@(@2L+5)I.4QHR75J72C=\03YDCIU'>:*MQ&PT^_/
M]45?Y3KOT<3L@06;045&6Z%-$1!C\E[4_\73]6I.]RI7>E7GRD>(9/FLRC-\
M$!D,[=DL2UU,;%US^^TJ]XF\[GZ5NPL93O J]_;+_QC1CCI+[SXN$UN6$6ZR
MD9Q7F"$'70THAN!T8#7LXZ2,]7>MP[;#D)W-Y>Y.Y-E\N=M*B0=RS^8/\5X'
M+X> [7UC.P3HT6]?FVE\@-_35EW'YYC-Q0B=P$KR#97Q$1SGM8*AE)BCYJET
MRU0Y'K>&7W6>"+5VT%)/2JW\@U6RY_5MB"XB2%4TV.QE[3-.T'PMJ*S(G$HV
M^M;U8H_ .6+DIKTB-U%F3RT<LOD76JY-T@Q$JA.3A5/@+#,0"2S7!"JEUCV0
M3[;YURF824T4==B&7T.0?>T-OW;2WO#F3D\1_6$;?NE@5(BA#N/)]"R($B'\
M/_;>K,F-(UD3_2MC\^[GQ+Y<N_-0(J4^&E.+O!35;?-4%HL'A3E%0 V@)+%_
M_?4 "L5:@$(F$(FMV ^MVHCT</_2PW=G64 RR3%,,J?8.@MQ+@._!L)$'XZW
M;E5^/YW$N_#CN_++;4HX6_5L!F%C3C9!RB&!<O1_P="W2F(V)F3&XI.+9D-]
MS.9GG-10E%YBF+3G8>O2IV=SPY8[/9^-:HD^.Y:< 5O(\%;<T>7'O(,B39'2
MT>^"[R3GC@^\#*$/P=T#*/JWHUFJF[(?3OX*CD5?"*-8*D;KJ)Y<!,CDK"DL
ME6=U<,T5_G.JSAXD PF@H:$XF\ZO/X3QI[N[32C4PAHP*"WI)Z\A&D<T,8Z.
M!<E3[!2UH$]]@ #Z[JOT'SWP5?L.N[.^X6RC>R)6TZX[D-''*^B"A/8O^W;3
M?P_F/Q7?'IQKJ.N?DL,%,A."(U.CSNDK5H*/A4%.):BLT4;5[%4>4H ;S/3V
M\NO#L,9R^SMQZO/M:L*BSTJI$@+PXNDP*2LB)'/02I@LO&;,==H*L45RCQYZ
MN)MV+[9/6O"LH8F]("3\]8 0,N8(;%9!TG0F%8J"&$N!%%"PNB0PN$Y9^VW"
M>_C0,Q3>SCQK[?JNZT>XK\5Y-CI&B.1YK(N*12([/L<,+N1<"4?/A=!>=_.&
M>SWVK,LF?]JKH&)@&6U4!<,5X[V?3LA0G7\)X\5R[-\KX5^+Q];]=H\"N]T?
MUKIHKM&Q&Q7"K9[W_H;HO7KPT*]HS8);S,D"TYS\,1,L.,X46?1>2G+YO,#6
MNYFV4[7WNO,[CK\K&Y^U]&<T"YP9-&1 JSJYEV4(EB%H9[1'4:Q!U?CT76D[
M5%%98XP\6U4^A"A.I?1KXY&^^W(?1U<.C5(Q@76:@ZH3V&+MP&)1!AT%4UZV
M'O[?@:QC122&@<-D6+$,$*K<?/JOD;@N) Z4N>Q WG%2F,U%VQ4Z>\KE2!!*
MS!;D3D- 5J.MS-1>8P.RN&PU.BNQ=?W$T:"S)=%Y"LCI(X[6'N!/(4ZF]0^^
MW%-V']'CJ'WTD)RQH)B24(-)X+W.,7*MRU,C:(.WM_$1A_?LFDMCTIR5 ]11
MU7&*MW.</B6KKG#T/ EPLDZF<&3*>6$4A,ACLDG;Y%O;(!M(N1PDM.3Y +?#
M3QAF^-OD)O_X^??IY(]E7>$*I:$4XU2L6TH*J+K@QEL6@3#*>-9)V>8SC5X@
MY_(@T8KW0W2HWDZ)N[=3I&/_,/JK?G5/6:8#HLB0LW6DNUA-WFM9"TP%IN31
MQM9*8C,UEP>*1IP?8-_+NU)&"9_J+^WIR<D+L-PJ4#D4"!XU,.UUM'3JQ%OW
M.ZXEY/*0L#^_GX- [6\ZC&?SZ6VJK/UQ3"SX-/U:V>62%,GP#*)D7N\R"<$@
M@B\1N1$FEA":VP^;Z;D\2#3C_G-DZ,'\S+]-)[/9M33.*"ULS6\@J*@<N$(D
MJNQ$" 6#3@>+;RTH.B%TM FA-A3  #['54JWG^O $,QO\?<IIF4^C+Z^P07;
MQ_GJ\V0Z'_T[+#?/;SC,-5-([G<R=0LG64:%(S@7,GVK&"]T0.Q6E-4#2*UH
MOSC('46HAXR1_8SS:R6$#R8R$"I44YPT;"2["S P3SK;:UY:UX*^1,_%@:@9
M\S?Z0<.EKQ<NW,PJKW_&/_]K,AW]>S+^9_BR_/'/=>+G?/0'[I&R[O> UFGJ
M/8[7*#7]CJ 1:KG#XIEYN?[F >ZBM8HS!M5TJH5.#+RQAN AHV):"]9\P</+
M%+5+2:]]SC+I)2KN47"(INZECBR KY'H9$F)DLEG51HN';V9KD.EHAMB8G,:
MNA'[CYV"7@:BZQ&NZOCA3XM/720QF"-/47L.TGH#2G(ZA40/R9@0$N=&F8[A
M_#6??OR\<2OY35KRL7FRY@E!=RYF%Y+69X0[BO@8J=U&$GA)GGNP[T"2E=IJ
M)>IDZ6PCV<DI0PBAMMY8(VPJN>NJS4-*=$/&]7 "[<.UUH*\6F\]K;(_W&:6
MA8" V=3!X74;O-7@5%98,"F14B=YOOB8P[D,S:0P&82%C6O=OW9<9"<\8W6@
MJ/*LQMX,!/)9(<D<LI"")Y-;M9=<Y/VZ.SN'Z/Z[W]"[G8S+Z_[JQ?P-W4.[
M<&[ [J\BA0Q"*N *%9$3$\14-'#+PF*EEQ*=AJL?6X"=NK]:R*\/PP;M_@K6
M95W[1Q4K]=*0#GP2%A9[N)--3MI.XQ#/H_NK%]LW=G_UX=F@W5]*6":$S6!=
M1:(.FHY#]T(1MM"!@J'?MA#>:71_[2R\G7DV0"3\:HKA7?F X>;[V3S,<16<
MO2XY&YTD [K8:]JR+D<,:,!&&95)6AK7>KKX)EH.'P$?,.+4A.$#Y.M^0CHD
M/CYX7>;]KM3^LVE(\VL;G(M$#I'$2;L$K\$'^JKHP%4=.I=3Z]*/[51=%#@:
M"Z%]D.(Y>3_?5FY5_V QZ/_CY/M%(N!:1"M4T Y88@)4==@<)ZO$!Y:1U*81
M\8F'M#%RT?FA%X&%03D]0.G@.E(_X!C_##<5NM<!97%)TS5I _GK3-1=:62M
M.ND+<SH(7EIW$FXAZ2)@,@3[&Q81+E#\F*HWD]G\/4X3CN?A$UXSJPPKA8-,
MM2[*< 6!\T)T$HQEE%S*;JL'7WK*18BZ+2\;%@EN5%5_I]OJMYLOWRVQ.+\V
M/J"2V8,-D2XMI7,M8F2@,[?>(=DW3N]\&3QYV.6(O#5G&Q8!;J1O1=C5>'P;
M;G[]O2Z)NLK_]W8VKY'AKY"]*G.<_A\,TW=CO!8B\Q"< "$$.;"6OG(Q%J@:
M*O*4I8YN9WCL0M%E8VAP&3T'FFD.M!]&T]E\\3;4H[P/H_QN_/U?F&ZKG-Z5
M94[BTQ07&8EK6[1AO*XI"[+NX*WEN$YRT(Y':SAR'\S.".M%RF5#:SBI/,>4
MW;O!X1'I]R-5KE4I6DD6@2"?R63RELA2!4P6.80ZUL<-6V1T3\I%@*4ENY^C
MP+5%P6*ZSKOR*\&T'OW:$"6\FL],UVRC9F$YG,E*G1P7PK/FDZ!?).B"$;$/
MZY_CPC?T7#[B.(SG#[KVKFYN)G^&<<(Z[.G3>/3ORI</F%>=&D^.<C7.3S ?
MN$9DI6Y2J%V@09)79EWM+0_,1#J@]=WJ.@8F]"+@=G(271.7VSM^^_A\_\1*
M+YWA#_KI)WPX</?.OKLNI4B>N0-2OT2F3+4OB0@6PG(33=T:TKIYJR^-%X&^
M@PAH#:+:AWJO<EZP/]PL/8>5'_'51>"<QQ1!^VK.E3K@ .D]D"%%&Y <AZ>3
M.WL8V5L>?A%0.0CGUT"E00QX3J[B[%UY,T6B]-WM?#8/XTSD7WVNL+Z.IO@B
MK0;CBJDZT4*T,4&Q":-0)1O5>IOG-IHN C&#"& -0N1A&FN,_EN]D'^9DX<X
M7R8]FO74=/CL8=II^A[J,)TT&@5W@7'P;E&=Z15$93DX7EATHDC=;<SR>772
MV"R%D5F!<[KZFD)#")(N5F8Y%L$M7:VOMY.F#R9VZJ3IP_[3[:3A+),?*CP(
M0\Q1D4PTIPP")LP%E:$S7F@G32_Y;>VDZ</' _5;="'I@CII>DF@0^/%+NP[
MD&1#E(P5=&"%KJ619&>Y0 HN$Z4^)*,4[YIC.N%.FM8"[<.UYITTCPRG?Y)G
M/)U/_AS__6I5?\F#M1D5&&,$*&\1@B)[V27C4"9I$B^=)+KE0:?13=-+$I.!
MV#C$;,*%P_)#2(LPVG(!<N0I)I/!^E) &68A,/)K?;$HT'!N7>L!#,^IN+A[
MN!'#!Z@@>TS1:J5Q!YH&FG*\CI[CC#7>5U8OBGX/1@]0B+Z6-A1)RB(1H@^$
M\Q(MQ.PC:)6<2U[&+%H7H1].^%L&$Q]"]GWX.\@PTAJU6@6M5KN,A"NES@)B
M06&M9>,0N)' 4LH,64F6M=[\OHZ.PX<']Y?0VJ#@'NP=X+K_<9PFG\D6(3-D
M,5&H_H/*U0IO'<E(35)#YDG5V?X"(IT2># Z<^091>NZBQ?(N5@#H)4(!A@Y
MNH&TU0K2#L0-9!*\2-AQ;(-F8NP&CSUD,,#-\3*1 C$+)0R@"KJZ-)G>$_)P
M>&VCBCD[:SJU_YXV0+;8#\?!1Q_6#X"+#SA#^L#?KL;Y+?Z!-Y/%8+GO__J=
MF+;JVQ0YL*2<@.SJJF$I4IT=$4&FR#%@D"FTOF8ZD'5X>Z.A("?#2F$ .^1O
M.*;+]:8.K,R?B=6S^3(C]YA(:U,6CH[.$JOA-,7(6$H"$L]%TP7L);:.1'0B
M[)+ TEX2AVR3EME[S\@@=V2.@1),0@QU>7D42D:?>+*MTZAGTR:]3SJQ"<,'
M:9.^Z[ZZYC8F7TS= L3)&=>6$!G)Q/>A1.]YMD:V+VFY>_A%B7HWE@X2CMC:
M?>UYL<$9HLM9"PH)@CZ) +*P(I*IW7:MBR;/L 5^/S0T%<( X>K>A9S>:Z*)
MUXD\-2F7#2&:;C!(-GHC-5,ZMMZK<_:5MOM :% !#1#U('-Y/ATEHO%-F/UV
MG<F>0>WK1'1NZL((!2XRA!Q%G:U-?EJW$4C]_),'%%P4&/9@;NM.Z?5=F->"
MC&1D*0(IKSI'B!4BB0P<+RW3,D>+MELYT?K/OPAIMN+? 'M07FYB2D[725 .
M(HMDTDC'R' ESRC1N77*R<N!>PE/O7^LG:+?A_4-.Y:WM3N2HN$LF 0EQ3JR
MC9/U(E@$SI4O@A>>7>L2U'/I+FV'A=W8/4"/\>/KY^?).-U.IU5KZ<BL8=F
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MQ9(Z),K/'R4;S(,C@J0/WUM'EMY._^/CZ/-D_MN7J__XY??I:/P)I_<#?X)
M[C21%6IM> D0ZWI>1N:19W5-9WHR<F-3+\;&9QS.#!A0(I/V[&P=._IX]<M[
M.N(8I[.??GIS1Q 3/IFZ1,84@[6?V()#5T#&Q<Y=D43IUFNS[M,O3K)[LW"
M-_?-;Z'@^*?;%34F6"E]!B$-V3>9[-C@ZRFEXTIH*[CNV!_W]*,O3IK[,6^
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M\*>6[: $>!]3B,J85S_@N8E=L#?W!QCQLGZ&:1>B7ON YUZ"ZS36=Q>N'VS
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M%Q&,,ZS;5=* FG.&RG%$,FRU;(<BJI P)L$($;6^4_F@((J:=>"%6>:3RG[
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M%1;MB-61T[FM0AU"L.9\M/WCL[T:Z)\T:-:\'<=K2>]YT(4O__6*2CXQ67@
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M>6$8D!E"5J:QJLXA<!"*T[X((U'&QOC90,KKMNY:R&> +93KR*I?3O'^0N]
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M;_4R[+!9LL&ZV"-)NLB]>L#DSQ2'T_.3R>4YC-\/FQ_#\E#GW?OB^J^.-6/
MY)PRR4SA.1FY)M9K1KSW*N*/0A(M&P0].];N;(0>-=3T)]X> BE_;WZDR7AQ
M4S6=#DN[DI!N+&7#.+"2WPH\!\2F"BPJ"46#AL6$9V:JW2'B*3Q'8U54%_YC
M8FS=U7P3MM62:(.NI^#&T\CV$]RHI\F6%-E"#3TXGL^@%$X'B%J5O!CTC&A8
M7C80+J15VE$%KG8JTCY(\DS@8E\<Z2+]VO;%E\66":/R G@XF\_22?Z2YBBX
MYFP88(0[ZV*8$L+Y-ILT_RX7&.?IT;\U/<G_2#":G7^:+]II79?B-MDD'R)A
M0N/>JU4YER,0GXQ$NRP%E5DKTZ17F+N/?-0D1'.0VJR=LG0GWQX5,XZ_#0.N
MZEO#</K')8IY/%N];1^8K(1*T9-D!(K0HS A*DJ HA5 J7"<MTMBZCCP[KG4
MRUO>WF5>FQ]W,[K&I0C"!9J/0QC]/AREZ:P9I^GI:#[]VEPAK8=I.E!HM9O$
M \DJ,"(S<MD!C<0[KI3BR')'6_&CX\#'Q(\^95[[G/N:AA=^/IDNB'N*./$?
M<);>S^-9FI6J&=-2J2C,)Y/2'+(4T1CA]W%SO#/)@7$Q<C! 6.#H9HKR^$LG
M2;C'F:$'"O+A@Y@-I*F!YIB8M'/M5'S?LIC ]=8X7G4<O=DC[P LL[@W4128
M\%I$PTJ9'T%D $F\\(:$H(( ZPQ7OA6A7C;^,5%H!QJHF&?Y-.1_3H:S61I_
M:6;X&\OJ:>]3;B;I0S$4\5 NOSUP+./IRM$%22$1*9,B%A ZLH,*X#X:&[8C
M3RL</P6)ZFNDAW27Z_SU?PYGYQ_F> +C>?S;$/QP-)Q=?2B;)^Z23KD0&5KM
MP@1)I!&(,:6,1KQ402F7/*M=7JX-KB-A46^JJ'A%^11&=$<3;I%A!.B7YF$Y
M;6]OZ0>1JY*!RHDO6&7RZ/OQLEFB 9=%E"REVFT_.H/\"8A43TD]A*6?9/Z7
M9FG$(?FECEZR$HR/TA+)A"=@LR<FX(K(&JRIWIVY);2?@$';*N0Q;TRMA.%;
M)G])LYN=DG,A\/@D0BOT'$7&G9*76L\9H@W:ANQJEZ5["L^1,:2:Z!_3PFX7
M]'M(U]6T$6AS-A[^=VEO$D;S$J(\N4QC_,=[&!6#;,""M5EJ=/X<E+QZ38ES
M5!*7E4@YN!P?5DG:%/Y[*80CX<@.]?"8/:YGB_AB/EK4;_D LW#^Q^6[^"_\
MG46QF&8UPP_GY7'HY_''Z6QX ;/[SS=.)^@,#*P/.H=BQ4$I"Q04)S;G3+(W
ME%+PTGB]6X.ZQK2.A+Z'2H0UX<UM[T>>F&#KY2J\Y")F09*WFLC,$H&<-7JQ
MF@'+QC-HN6W6@',D'-R3?M90;+L0^L;@R.H:Z -,SZ^O@H2+V7 KB1 2UT+,
M@5@O J'1.+0<!/HA[8C48=!CHDM?LEY#BIX"WY_FI6+\NQB'R\OE%=KIQ[\N
M4^G</1#@HQ7.DF30.Y7!H$V9DB#&.QDM-UIHV(XBST'X*0A350]KZ--3"+P\
MFYW>7"1>@_Y^#K/?X>I]6KHJB-X%4)D)001*#@4&Z)YD7 LN,J.UEB$:M1V+
M6B+Y*<C4AU;6<.K%D? %^H^CX=D0G=AEF/XZ-I9N[Z&]2 C/E9"K!B(U=^C2
M.DV\T29$KR/5[6[=GAOIF#A15:IK=/[B</;J GDQSV67S).\JM]3;*83C\ 7
MTI@.D'W1Y%)8P>,?4E!%G)= (,@H0^D-VC(JT&JX8])^??FNH<"+8\^M+X!O
MMJZ!"B(Q6G+YC2LM++DG/GM/F)7HLS%F/+0K-M%IV&.B1'_R7D.-K</+=\IP
MH"LV'>+'+B1R?62=C._X\X-(4S2:1Z*BU.7I*1"O$Q 35 A9Z>!M]1Y<70 >
M"8_Z5\X:*KTX)'W[;#FFB\MEW"==#.<7 QN"CZ HT2*@N>.9*P%.],5P'[0F
M<F5=[6<XCT <&26V$_(:M;\XEOPP%?9>N>^5"7Q[" X@:\TEY412(XC,&C<Z
MGATQS.$NEZ-/7+0Z6%H/>22:[U'.:[+]*I3C[Q+0&]#R%#%X1I(KFQ9(C\Y0
M,D0[KG5FRE#I*F\1W1 >"8MVH)XU;*I06&:!Z!,*:1WRCW^MXL$E]0/_%[_#
M7P,MF"N6$Z':E#(I,J"33?%+#]$R,-YP6?W4Z0SSR'C5MZ+6D*NG .WRR^]I
M<C%@(>)FBCLH2@79'W4DSOIRRT ]BTXEVK+R7HO!CH0/O<AVC?)["J]^+/TD
MI]<848V*9\6)8@H)2BTGGFI&M$]*,9<"*+N=_N^-]U-0X.427L."[0*B&S'>
MN.>WF3^?FLF'-)FA4'^]FLXFS>5YB>U1$0""%428Q(AT4.J4LTB0P4K'\L+^
M8=76K@1I"^6GX$XO>EE#J^UBKEW@#RQ3TAMO42J^Q'\L;H.ER#EE%LTKT.#4
MEO<T:T;]6<G22=IK>+%U$O"-@5V$AM;0VGCQ0$7@(7%+K"G9##I8=.&2(MP:
MY;1CD55OOML*V)'0IC]EK*',U@':=4_B%QW*WUV4Y-0!V,2T"HIDKTQIY1@(
M,EP2M)T-LU9RJVI727P&TI'1I*8"UA!DNTS@=>!.&[2P9D,8W28WW,7K41A4
M2D=81&M+.F8)&)D(E9I;EI+1T*X"0/>QCX09NY#\&J9L%ZE=AW>5RUZJBR[=
ML[PJ1PNCTV:ZF,'*7,?#\^-X?K&Z?_C2S%"PRU;CGT9PAIX\S1YG0*@MZ<P\
M4^*CEL1!YEXX'>W#EET=.%4+Y;&S;R_:7//VMY?2;LLE="<C>?4,P]I,8T(C
MGRVRM#1XM.B\)UZ!]$%:K5/M&\D.\(Z$<GTK9@V):D6.D=R;8I(#! C:,TZX
MH,AS9RF*0D12ZEFEZ%5ZU >ZEIW]!*HCHTQE-:QARBH,_+__]D!@B/_?BQ\L
MOE\$\C7E_RC__./KYQOA_?GGG[\$F,S2= CCV9T>9+^$YN)O"S%^3<CL%!>U
M->]V2_X6SE.<CU*35[]Q^O W?DTS&(ZF]\%/AZ5*QW.GX?:#_NUV\O>%LAKY
M'H=V+X94CJ*(>\"VRWSMF+?DY9I)1CD0#0S9%7(QNAR>:-GHK!S-PM5^F_T<
MIJUS=E82/]DH\?=7]WZRK/>9DTF+0GVL-+[Q$07!'"LE(J-16G !U7-W7@*T
MX@8(H]'F;:\J<QYE[O2NHG6%H/ZC2"+._M?2EOL__W,VF:?;;^+>BXONXVAA
M'.(^E,X>OPYI3\:-=:=IH%1;!43%6-[92T%<\)2(;'DP:!* :16]>D75^W>@
M[>?*^G>1^MX*M;<!^1.7]>^DPQ=5;'^) O97UC\DG2CBM$R4RK*+-])1$.:-
MQM5!LQ4UVH"\LK+^_9.DB]QKER/\=?++]^%%,SN_>O?+M\O)<'R6)JLJJ]8Z
M8) TR;0T&+:+/,?,24DA42DXD7*[1PJ;QSC8,OY=--+4%V?MHJ3?WWTKY^ X
M3::__?9A!8@!+XT#$H%( =U ZHB5RA+J0PZ*>I9YN]='ZS[]Z#2[M0A[6+D?
MSB&G\6_SZ];=@2:'4R#HW>-.9=#(\2I(DJSDG#-EDFQWT?#HHX].F]L)KW;1
MSF\E9G,R3A^'9^>S[ZB:]*F93SY/)ND'_HMHNGZ?S*?7_51M-A(W#$NXT!HY
M%RB!H#W),@7AK%9!Q%9:[C+JT1&@-Y%7K,WYC./\P,=9&"M>1Z4#9)(UC40J
M9XOW;)#*/K(@-?>\?H2U+;KC]Q9[UEC%?6<=TM6::H.HMVZT#]'LITE+7_I[
M@B9;"+^7_K*/D&DA6!;<D>1%N4SWB&Q1B4U'2EV,(*MW!]T5'9YIQ[(_-G21
M><\LN#:38DY,.4\BIV@F28L&DT5$P?@0&77,]-!9^"&*?72(W4XW3ZCZ!8+M
MH;O;M[F?#N,0)E=WWL N*"U\3$K(<E%8W@WXDH_G@1(J+# &+ 97NZS<1C _
MCP511Q\]&*-WX!0[_%[YN>NN02T0]F1 /(]N/P9%)75N?JY>4Q<]G"0MD)H4
M."!:HGQIVN.T)3;@XG$Z>%">&Z72D;#E&7MC;V3IHH+J_653F$^&I8#/Z4/?
MO^CMNG.ZB0Z2CD33S,L5L296N(P(E0C19W"T98O9-L/MWLZHK:2F5PG7#E.?
M3H8_\ P]'4&XAB56L)3/S%+!%CW>B$P4T#SBBKB2VIM34MZW"U9O'N.XM%U)
MECV?!:LR3M_.89*FGZ?3>2DY>K?&BA8Q@6>EE9N5I;I"(N!*6#;'#!F8]K9V
M19,N^/;KB=3/HNE+-7UX+)UJ]5#G<=Z\-&?GZ*-Q/#0=%4"2M2(8QQ4N@_YX
M=(B%E'9%I,K*V;@A]9Z/^LCG^P*397V8[=-.G__LGK)+.TYJ5TFD4DFAC0G$
MEM-):D[1=<:SSSL>A*8I9EL[Z'"82:0BYZRTBL3:B.883ZZTJBRU+;W@FOOL
MJV?3ONXDTB[,J9-$VD5%^TXB?=[%=)%JIJ4BU'.++J:!4A^1$B6<Q7->!JC>
MX>9(PGV=>- ZW-=%'_L)W+1!^!;N>XDZNT=P7J*+_;"&4NMPN1C"LL358A0:
MEMX)H@.54EI+-53?9UY;N*]GLG11P6[#?=>1"FNX+8YDJ061RT9JB-<YE:9P
MU%"10:5V*:BMACO( % G);4/][U$PCTX\1VNUJ/PD@'5Q#A7RCYH1D!X2VQ.
MP1IT$;.M7V7P.%.;MK%4>M+8;E*;VB!Z2VUZD?Z>3V9YB?!WD]HD=39,VDB$
M-8C,)TN@=*IUN,<*#IK+'@J8OK;4ILILZ"+SW:0V&<9BL,H2[2(>@-G@H<@3
MD"BXX-S[''/]XND'F=K423?/IS9U$6P/-L:'TI[Z)/^S!#;'LY/)UY+RO:!T
MT-;Q')##/ LBI8G$!Z6)XBI(E12:V-5K86\"\_-8$'7TT4-JTUI@JR71!EI/
MEL,3L/9C0E128!M:;"']'@Z-IR"JF#T'3DETM'3$Y)+XA&"]<BE3RD-,YK43
MXQEC8O>\Z"+TVA&,=YPRMT(U79UT-#(OM<*-%V+$>6:TD4J[.99,D-0&;GQH
M%:]8\^&[MPRJ2;ZI*+9^,PF>SWK \XZ[8L)X;4UI)([&#&66&).LRQFR-WVF
M*;["A)2M;N3Z4LW>$U*\0E/)@B):E)I_.>$"<B(2K7,.-%CO9/6+W5>>D%*)
M2)654_M<6;OK?OP++?KA-,5?YY-EY>1A$P=><P9*,:)<>6U$@R0V&CQE!7.2
MY<A MGL*W'[,(Z%%GY+N(93Y)-+3R3"DFQ].5S^=LH%W"1)UFC!>WI^ %"B8
M7-K5(=P</:>^]E'U(J!'PJG=*:L'W_=TTH24XK04C5R!NX8\'3B+YVHRF7@C
M')%.E(*14A(*4D:5$G-0.QOK*3Q'QI=JHG],BQ>W:[DY-LN!N;2U[NZ'2QL,
M#](?:5)<PY.\_/NL5#J^O7@<&.8#HU0AJ85"4N/?H-1HD$%[9@SW6>?:1LY6
MB(^,6CM4WV/R;=?4I:!>=(8HV&:ED-)X]O]@-$^+#?-3,[E>([>;Z<![HS,8
M1DJ8&O$Z4[K\ DD9MU,AK;&L76^7%PQ^),S9B>P?<T7WG<-]IY]G,X9QO.YB
M<YT2,7T_;'":O[_[/ XU\KJW&J]VKG>]R5?*_][4777Z;AR_-..PX<=W;R5N
M:1ZL<IE909CSN#>QX(B75I(@=8C4<>.A]B%3$W^]O/(*J):W.UEQ:[(V*$R%
M^SZ5CD *F1B;$Q5&<ZNJ']O59[&KC/2]<7ES]OI>B' HJ>W?\?=.\IUI+6X@
M9+;*<*5)9JP49@F:6!6 ,&H-,),23JLRI=<"V?\U[W[(T=164@_7>X^% >OG
MO[JV: .WISOACE#W<T]<0<G-[C5T ,2**7'%/"<T,T]P_[<$I"XO+P-(7'9&
MZMKY: =!J&?NE_?/IRZ*J7TOL++1?WGW"UKIOURG5@&%R,&0J%5IZNPD<2PG
MPD66BRZ*/M-6'N^Z3]^]2]NK/IJ:PJQ=^F+3J?S/R7"&+M>7!CVZM(S>H/]=
M6CD/Q\M^F8PI+J+)A$4AB$S%9*2>$>#HCS/KP3V,L6VZ!'HIA#UD)NS;YMZA
MSC8R;8_!DB_+GXP^E"C1Y/-X.AO.YK/49/R\ZY_=?'?:Y'\D&,W.=Q)7J01M
MYR&8/D1ZB-$:ZAUH0#<!I OH-2@@S@E+F([2VZ "A^HYM\<=K?&1&6G0^Y+>
MX+$E<BDX:(!D*0-/7G(0_94(^*FC-5VXO(-H31<B'':TQH&(2J 1AA89'LE<
MXDQH*I:8CR[SR*.I[0 =>[2F$SE:16NZ*.D G.HV<-^B-5LI>4OO^B4:.@!B
MJ014ZY1)B*4HIS620/*!!"LH38K+'&J_&SL(0KTH6K-+/G513.UHS09S_L;>
M7T'D-$)PD(E-@:$% 9*X\I@J.A-]U$&C8='*>6\WWN%'=#KIK.E7X+5C/-<^
MWSB>7"ZD?HWM:W.%SMS5*5R5KP:.&>--<,3D\J2.LE@BF@4CTQ:7CT_"MB)%
MRP%?>?SF)59X;_K8&6?>IW$XOX#)OY=@AVGZ._PUO)A?#)1U4I4WN\JS7!H6
M FZQ61!-K;#)9$ZEWHX^&\=^8U(O6JK^Q.#%@4M/A2X%:0A74"IUVK@,7/I$
M!6/<E0H!;\'F/BBV&YUM?+NPQV#SWW& L^;]L/FSF?Q[^H]F%(?CL^FN\O3:
MC[[SD/$+!7.(46&+G@ %I"?GK-03B)$X&7%S!%LVQ"RLM)5]J&./"H=@C!&,
MQ*P\GB^"$UMV&P6)*4X3YZ)V)\"WJ'!G+N\B*MR!" <>%;;6:0N66 NQ%!VA
MQ7<3A"7OG,/_F^J!EJ./"G<A1[NH< <E'4#PK@W<MZCP5DK>-BK\ @T= +&2
M$ZD\%"?1E7[2.E TN%,D)@9O1="6Z]H6S4$0ZF51X1WRJ8MB:CO>2XO]84R2
M@O:6.DL2*_UX9"S1<:J)RLP+SI0/HEV5V[4??_@QWTX:::J*<V?AN@_XZ\,
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M][*J\]C'P(A=B/TQ2TS?F0 ?+RY'S56Z#@"<CF \W2(3X*F/JYT)T!IZI4R
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M:.4F;!IA]RJNI(&FMOCJ7WJMS;->O;"_QCH(N &AHQ-(HJ[<\#E)K,B&.*H
MLL@Z*]5*P^W&.PI]]R#:BL?U$Q 7C^$W/F*V41AAF"R=>I"MT69BLXK$B"C0
M3Q8R>+D%%9X<_(AY44_HM8OUKL?["4H-ZMDPE6Z&)R6S\H;1GEKFRPMWP1&Q
MY!)//H_BD2"R55H9:MJ56.PZ\A'3HY*X*Q;J;?GX8H"N2+ 6-S0$53H"4TK
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M3QN:JV^7/SQ,T__]'_\?4$L#!!0    ( -4X;5J 29 'I>   !]" 0 4
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M\"43'.<#]S[&TR+RT^?POUG[@[-_C+&7_R[._H6Q_YNO,> $S1&J\FC8 2A
M,DT/G5'7Q;=.MP;N)D4(VX(OIEU.F9>-+UHZJ0Z55N-=;W54*CUME&QO%'ZK
MM6D@NL<<.1FZ#0<=4:\@.V8(=@H0Q)E* ?@SR+RP:7H2)XP6-:UM3P%:)2O.
M_;30S>RS=:$ S+*X0'(H^B44EUY, 6;?H1KUB6<H0'K>5!11/)\"@//\,6M<
M?P/_#?S_!NS&M7X.%^EKHDR6 "7U^(-NP]C&3C;M +X?$P-&UOEPB>TSUV4T
MQ7WD&&;5;"406@[Y.;V!HMI_7)YN_!^%B[^!_P;^GP'[NQ"N(21J]!*Q,_#
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M3B>DU'#M:1^/&=%B;WRPWD#7KVB;T?1E[Y.Y] ZF3!6&W!XU12F@4*UPI,+
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M<7!DH?6EIS\DE'R!%$[F\^G3')EB4!<0S9>O^!GF3YC3>Y8?F+'.GM/N?U&
M>W'0DPD;#&6F '!9QI_+6#JB-J[19M!J_]K 9LEP>5&?EX^P^82:M1#SU/-,
M-MUS#&V<@]-.M3U5,;"]56>8>=GZEZXN0BVR79HX1 'H1FJ#)Q.YWLAC.)9O
M.?DI9MGG+1<OME=_3;9_??-DCO.7,U,OE36T\G:WO-?< L2":I60?:G,]\0(
MK%?P(JJUR6R$LE443_SUA+ZKA9<I@,/AR+!"XO#%&((>M$8,?&+=[Q[\>&2"
M['PK/52<IAWCN'D@=(@E>993@+YEV(F17]B2?6)T )Q<:4VM-7;0KYWQW;(4
M(/H5J@ZC L'@N(BABV1JO9;9))X>"GKLO/T_/3/ZE_>WW2$E0.>^+4-W6V8I
M@+:"KX)?SQHU,IY+H%92A4J00XF\X7;4W/VK1#=BW[0]9DNR&?42%JLY0RUR
M#CG(M__RLK9_:Y6;24[H2Y[5YC Y_Z\F4C/_:EJUE(;G?Y_ZPN_#.V/M9RD.
MOY\(_R?7$84_#Z3J1__UQ*JT7-<5\E@Q5+S0(U^J'A% X :Y9G3?($57>9LW
MREPUSS@^&S/,X;C4(/Q2S?VUA'3]F[BGQH:6WW\LV^YJZX?Z'Y!5+WY17I\'
MU=#-$*@/;.\J#M;@8E&7(M&;!*O!@+[3A +A&P--.'9__A>CG1GM-@.7U.[E
M"<WMH(5(;VN/.HTEK"O@[6930]3I?:?X7'Q("3I]7H^O>JK79:]XFXF<?:;U
MFVXY%2C<V P5T+6R-D*FW92MCD\0$]I()=.43]C-@M32^P.2QN9B"1PTK$:D
M<)</Z11G+5UT*F(RD%OLG+22=[!4\CIHO'=QP]M"'R^[QXK;;X)R^*2:E./W
M(]6ELWWRO^!9 C.<',JL0FAHW_G\S)Y._JFLHGRT-BD]+BYFG5K_(_:L][0]
MU"J\4 O8!>QDSU&\Q1I\VL:^!<:,T$M;K:0 @;+5] \2S5,JS[5+=CVD%MFZ
M"7X7)2]+7C_SMBNER0+V,[@N#P=MP3*V%,Q 0-UJF[RV?.Q=4C9K:>NE#OZL
M!W"Q>P9]XHW"_*=ZW':D.:!^R[N8F0&4O]YAB*9YXC*\7KYV;@TQCI?:X\:U
M1A)U%-;%6C1E<:(%;IG::4[E@GR8Z]#2)[.70XM?A[\<O\SW6GG=YB;T&^QE
M@;H>+L.RY/O0N@CH3-=<&^6:(([O% T73GJYU+V.E>QHT_"S*.F[G61(@J-2
M, OD/2DIZZR"K3ZD7L"/@Y%FU-?6Y\3[&43S ;@"G%V;OBG"<,1L:(SI/8W6
M>=::T]@+;+E&MZ9[TCB-6E._!K^JAN.9S/$WD3+XJ.!C-=F-6<YCKL%?I&MJ
M"TX8O^G5WSI-^'24X[ENMB$R/CTC[AQ\U176<>4@R1NS,T$!- QEIWH:DF6G
M4(W2]'5CTNODM"R'K^^E<P8GE;Z+V[P_]O"::<1/;N,Z ;^1,*I%[QW'84*J
M?0O JH8493RF8<(4YG+8:<L\5-L&1[:J>!ODL+@;:K7H*;>)D-2T;]<<>'2@
MMG^])T3/1[9VL5. >DTRUQB1*W8ZZ^,A*27.+?]JX:23'N(;;-*FQ<=7\/KH
MTZ='&,- _L1ELC*Y756V!</O8]^B-X,^Y2/6;'7BY)W&7/ !7GHA9NSF9DB8
ML%_9\=9)#9_6[\971RPF*4 0YAS<X(CC 5*)N+L[B.L)1A5A7]3R$87QY8W.
M:@7.MW&8,%>90EF[H<(8WW3'V=LH&:/S@HJOZ?;+IF,,;O=C'D0!2YAB@?VZ
M*K4")U9&F*MSTFX*9)W!)ON._@?U@J1ON9@5\A+-9,UAJ(&$:.KMA+8GM5<-
MLA.7QFW1SQ"SL]B?"=?PYJ6/\ATT-?'E+Q24=WP\I=J(T"\B#\C]\L?3;SNT
M;XY]<KV%N;&+"<0PJ&O@9*=;(J:BF+3.JXK&\8G '&([XW4>RVRLOXA__%@,
M8/$!W&R2.2W\#C9!3!>F.DE:O8Q0<"#E!^$'E?:TR*,X5 OJ)5(FV&R #'%*
M.0=C6_)KB3M_??-$=ZP\H\U=*>WSUM<?SBGJ%OB=SB*P$-6'-$7!D5;WN\X7
M5Y'G<3LI_#66BZ^N<L@>O;+5E"UD_B#Z1468K-C\0NVK]#1M\<\'UO\7>^\!
MUG2WY0M'01$14*1(#4I5!!1!1" 1%1 0(R"@M*@@58A(%4*B(+TI""@M+TU
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MO0S7J";G1ZYL<17+CA-%G>)O1DJ_+8\3>%(R?SX1IS9_<:.XJ\Y,]NK7K+:
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M#!ZARU/EJ,@\(1U'R^RBH$0ZMC?^,[)JS\3[_Q "AR>;*73<XIG+5>*5W4R
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MJP\5<A#YM08ZA7QS-4H>_1I$^L\B+X6MD,E27"-NOQ/C^47PWJVD73"T"'@
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M23 [<:R< )AIA# !09ECX.4'=(ZJNE"-=' L3XEILTRH 5?4DZ17TT$GCEJ
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MR?A.X*9#:7+X@"ODP)V0J@:+)N_^*1]S)L 86F!P&VJEXUWCAJGO.ES<JOZ
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M//ARBDJD^T"9J@?(_NVE-:^MWK.>HGCOKWC/T'A?2G'G%XS-18)E%5A#+\W
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M3(#Q$#H-UJD!9K^X#O9U_8 7KZ[^DCSE_CZC*^&&NY9X%!/ H]!)225%+]3
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M#[@@"?M9%/87=T<">J6Z-[4[?'EZ4Z([HQGFDQ.KD^^%'I.TQ<-F8^F22+5
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M$]? 8X-*C6%.K\^H+TA1N.<VXUF\OW8/^Z4_:JZ]J]88#HTZDRJ@UT=(R(E
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M2>9GWD!NNG00*<VX0HMAJTRCQ=^63^IO50===)<]*_$^22E5G)8%IKR0BM.
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M#D@EQ8^ WZ!DSM_/KI;)CG<U&Q1YO_15W"P^2%YH6IMR_I%FQT=>'R*WFXT
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MYJ'\58GYE+MOTK^GI)'_IJ9D"A@O2)G8WMKS^H%B _3 '<:EY"CN3=-L"AO
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M>P8\EA^VTQ$X"9TX[4YG \8(5@<3(/CAQ*PZ:S#WS1KWW7I:@*I&(R-IJOC
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M5G!+*-U"*O+^?T.;_U]J]L3_ 5!+ P04    " #5.&U:7;(%_9[+ 0 L!P(
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MG<-#>J5)RZS/)EP"!L."V>3LVVL\H9'\(/M@T</[LJ4H20.<]MR(4^A_+V=
M"TYM[M\D>;+O.N M$<^-B \6Z"IQ2A>Y'1X>4Y3$<)BS+@R2>,NX V[_9Q:$
MQF<>;F7>:WG\W"W=8?D^\'#DLI7RI IF/7GL\2&7VUI"XWG3Y*95<I=H'R$
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M9ZW^9MS;%\=6G*AUXWH"#$^Y002$<)\*D' IQ)Y[+$O;HD,((S;2Z )(NI^
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MEG5<?K=<7B4,Y=6-0QD28X@ ZJBYO:R>-1T04B[O+8((,,^=6<K)NY/Q>_A
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MY*^(2!2?B:S@8>EV2M_F,R''PKNVOPPM8_;V_*<ZM'SB7HQG^TA%"&\Q8J=
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M@]KNS*C?)G]P/X7RBU_Z4\4GAG^FIGW 68'FEA?[VB*'(GDD_WP!:I%T7O.
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MC]G@*!O<:4RU+&U+#'<80Y&\"I*8W4Y=.-C!,M4R,+*V;:R>"A(W2!O1N^4
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M:FQD=G6V":([K9P1Z2\F65H[T@>'TA^Y+3[4<S>7O<E<_<27'>/FMPJ-:Y%
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M^NU;I>5AUOJ<#>$KH6&.OI%$UH&P+>#3G@HP\"H2TAO537OH5-]$^D;LIZ!
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MH[E ,\8VW FIIL<BZ^VL3E7M-@)1S:CO)&8C]Y5Y2Z2A]&D61@VF+L1*+?=
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MC1U26!$^RDNH^5?.U) 74?LXSWJ^7;2&2"IS$KH[L\? >V+[^"U1#]R< 5Z
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M[O&DAS6]3LB(?YUD>/TE ?<I":]<N:[__+[%FD5MW(E'1XL\3GS'[Q(/G.+
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MNG*HS&^=^/?ZWC+0B;&IB6>@:2!B;7[WQ9?:L73;/["+$RG$Y$ZTO"VE5QI
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MF5YR8P&GM\)#&8/5OY%BF;P*LS;5,U4?\^/Z_YS.4M"_;O'MG13*R!Z>';%
MU[7870,4O5NO 2&2,&SI!>EIU(T.>W3+G=Z8[IP>BV>SJY?RWRKNV^2)U^WC
M:L_::#K'2U*6/*=\ME,.N\_&/F=)8%AJQ&#0G8N"LY0U*ISF;H+S6&J&3:P4
M1;]!TC6@<Q*3?46&.,/?W[@&H,J:KK)N,(#<-<#E&H#3:?%NN53F;.I (M)Q
M9A8>,YV6SP]8(]]D?&R4$ER77B:^?(T)&(NLL[?%F$/Y=,P[XQBW1:C?F]Z^
MQ]]?6;9J$->BE0\JA#.R/MR&OX6D-<8N71A.5R>\SB!D0DM6":'M+F,9:*^"
M.JX!>33-%'$6AR^,K@&S7X(V![B+(JI.&.(REU.]+ V(PXV2N'$OYI/-'HX%
M_1MY9V0"5H,>SH'YT>OK;;!2>1^)N:\I#\W[:X#OK7S^#_;>.ZRI=ML7C17%
M@O0B$!40!0&17F-#! 0$I)>H"$@7:0$"41"0(@@(" A! >E$>B=(E1JIH0<(
M14H@H81 0G+C]ZVUSEGZW;/7N7OO^YQ][_YC/@\D<[[O&+\QQF^,,6?F^UYU
M^I#FLV[%8-5*$*!J, 0C<6@:0&,LDO]B:89E-3*T=HT[A/5T,=>3W'93+\LH
M3BI'8B0-\,,%C<3;R=$ [%:YT\"SI*B=&;O7Z^(R^_JS:\"R]]D)Q#LQD@=C
MRB.>/(R%;",.(1Z37&D P:!6$'&;!LA<N6,>AA#I44 &;_L'R34]PH9&O)%'
M^*IPN@?3 ,%96-#>V?)U"G</#=!J;(BOG)4(WV;B6TK8L1(>=GD(D_,P<&"I
MJ;CP_-J)AQL'$&)%[3-,E'?:PM1QV(_$HGL7+]:V&.ADD!*-)W#M#_%=QPWS
M]$@V?5YVMPA:])&V: "^92]B@_"P<[JNJ-/]999/18]O/COT\+E&D?&OVAD%
M2, Z;@\A<='4,$UL3NNL8X':[3Q0V+9_\Z&@9F6ABTOJ,]%JHWSJ%#$);AK@
M^R0"-MWK2A6))IE92=&=K]:*!OCZ 4,Q?+YE+#%<#-PD[*^N[25P4OW5U\!S
MGL!??1<T8P]!44-P?C3 47<8P;"K3_UO5ZEFT:&!ZY$3=_^5R?2V"]0I%)@?
M4^XCV.)@P#Q578\&.*'5!MN2<\20I.BM>WC&K[I:U+/Y.S+3 "#@5/.R"7AW
M&U@-BQG\Q9ER?K./A!K0K 6&:M_Y\M]Z_;=>_UEZ8<PHCPB\5GPUY7$MOF0'
MUW-/B^YDR3(_K_.G 6PI*Z)4#L0;V(]G=.["V]&9F=VP +'-1>&&.;*_]Y=9
M."6&4KC3Z88>A2DNKOA6Y1&CU_FG')&897>]KX]<09/J,.$^'_LEJAT20@.T
M!PB5DDQGNFIAS Y?++6(KM<@ZS;&T,:6^: G<YM6AG0%C-N06_*.- !)"D[7
MH&AQ5IT2RW0"-HZ@QI5#<-ZV)N%]!;$I)&/CD<WGD1?Y37P4#")VLOJ\5<C3
MX"B*5CX-X+Q?VV)6N)XXYT166RWY,]M(O=PUCH<U#1$0^Z=Y: #JR<6?[%W]
M2[:)O'.AY&_)YMD_Y1H5@QG7EFB.97ZE ;&U.H-"BT:JRX_/@Q<]G6[//>'X
M.G=(O54BC%]L@.*=.SY&RC:K>*E<6'PKYUYX==CQQE,O.RY6HUZ!-O2DX61G
M&N"3570$9D-/QI5L3?]'/[K B-J[L.B]N$8#O%/-#:4.SQ/=*DM7D>\1O\&!
M,"0M89$L2\ 1^","1[[-@@^9BO*[XE<\CY5_].$)U7-:9A5<)DQI!.&P-(!]
M7VB+$43YEKOO<SJI<KYJ+@A@%W$K7?R!?#>#G'$@H:FAIV _O9 &(!@N-P (
MF#!750Y(U!JVQ:Q@1\\_NRM-:]1TX,QEKL>C7,KH%^AB*-V)8F_,PLF^-$"_
M9X98BU&\[0=,TU[#UY29JX3FUK8/QO7\$=7-OR']7941>I.@DS^;G^,*U2JP
MNEVA,ZL4L6MY \/5>\)SCNHY.[0$.@";>U9' R 8:("^F&&%@(NUK08ZK@&K
M&&EZ&@O,&Y+/=OF6.XL*FY*L(!B5GE2]@KX0KC0:(Z"M^3#OT%O @2KV^-\0
M*Z !Z''T;::(GMDI-,">9#Y/M>/C_+S8?>SDMIWG27[N_B"BWJB'953VKWY.
MCT$P78/O,W0[3/?"J"+5#J+ 0F-ZB$:OV]( ^DTT "IGOXOR+UUY:6\(MDNB
M$H'_U2\S!^'?4@RI;50T=8 0331"2>$P3VLW9!?/UG7CVOP6JMZ(KB+'$F N
MJ)&ZN4W"AUV_D+4/6RC-O6MZA<"Q,9!$+_DHI\O$/IRLU,$'"NU<H?:N^VY_
MT<L/,XXW=;S4?H<ZM!V@.>ZY%LUT-?4D;R'CU7Z6M%S'+F?.E(9]):4T@=],
MG/&KB%:MZ100/N!SP]$'^';B&V28#)_.E/EV=>H]/771UYI'GJ4' S:NWI0[
MO,&// 9ES;)7M,SJX(E!%M=5*::66*$\^( .91H'RY187XSO[I;&8 IM1G;%
M;2S-=<N&E\5<D'5U=;W<MJ-/;+[AUW9\GZNMSJ7T;3WS6QEU=:4#&IR/!>_Q
MRM  %&X4/2D8U@*!T%M#+/.K%/59O[+RURBE&_[/9B^U&T/E.C,&"5;YC_#M
M3=[#/#KP_9 ('[_IBN%D&@!GL!OA 6@^@BEE^!"8Z=%VU;T->HH&> MJ09#9
MUY#)PV##UIL%EP<+<**K&+6 B@VYO37&+,;XI]^-@\S;5&P<EP*ZYWZ+<0?,
M+$.+:.W9VA%EC5G[ IRL_Z=9)7)(%-_B\?J@1]YGKJ/,^DA:,\Y*)J4$<43^
MTA+L\Y)L#JI^08AOY)7H234S(R&W($&':QI.C-O^KLT\NLV34EBAX) HB:T<
MZ[[/VHH^0F.U$9(3G3/$?!8,A/<DZV!?2--L?K_AO&E.N7C1WAUM^S&\HU:(
MU-G 9B/(T_LZ]NVK;6.=S [[_<E>7IO][2'TCN"?J2,/3;G"]!H\"A\#XV,A
M*62E7C)HC(IQF_>I]7;"U)XM[I7ZX&[5EP_EP5N]=)\]07 ^O'2J]956%D;7
M:\5N4:3T//FJO5:%U^>9R)@/: G"V3L#=2"\G]G 5G09/;\U8^^?,_]F==E0
M.\JKI";_)(OZ.=;(G4*'AY+O(9V&^4YIX3I[EOZ]J.W2JQE)\Z3<)K:K- !K
M>&VXUH.T_2'TDF=NA[U9>VN/5X>$]#B&9YDCZJYYA*G+_)O7\O(V@KS\HCR+
MLW91JT4VE54$\.OT-&')#K::R.5OC=.Y1TJ.*3^NW=?'J,.)WOBK0^N( FO.
MG09S4U.A#NNZN3/][='=_1#UQC1^:@O)9_&'Q.QQJ*&_2OW03-K3L1X.\!6?
MQ]?8KA4]46IF>D><N]7\6.A24ZJQ-U='I3"QVJ.DUJQ#HJ5?ONZ*@&+\T_S+
MO9<O291VKW>/Z=ZM_#S.&Y\8KGII66],PSZ?U+"L1"]?;)^ZN'S0+5U?/4<9
M]\-F^W;^YLK&_0V @8=]X)DIN+/<F'.A..7688,G0$GVS/L3;M\ Z#02; 8>
M4N0I<93DB[U-;TYPAY<35<^1;^<1^]GLE*ZK&@V*L(7H![C%K0P9B+<^;QX=
M]O8RJZR];R\*+BCT+YO 9J4\_+ L4N7Y=#)?S:K3D-6%N'1XM;RVC]_TMZC/
MT@VWDHL)1$24$Q\_ PPN"L+)R_6()OC1.KY9%*/)\I)#0D_ADH9U]J6JQ./Y
M(A,^W3><L)*7 ;%U:4KH5.AMO"P\'=+FYW]FY,:CCX*R.R6Z>3=++71>%TI'
ML,6Z6L?>&;2PN7M(V9C/B4,UF L=;]XZ-NQ<[TDIWRK&A'9?Z];V>92A=OG.
M3MWCA&37E>P\6U>*$)@-5+;FL8Z#<<*>FM^Q21O R5DYW04()4G%<YV;BYHM
M^2TBUQ.OB(&>(L/D#&R57$GJMBD]CX(OS]V4LQM0MBTN0X3PLP\R!9?E*LL_
MI@[C\QWB5AXO.S4_8Q5JE"@%8)^)1J>Z1;D/*2-9YK":I37O,O+]!3]5-%!]
M>:4W+7BMN='-^?)M9I>V(^*FQLVS,#%8.+X<2D?P5@CR9S%*AY)>C?XB49<>
M6&H[CP;X69"2@?^H+0W^;=JU*&?S=T#^<TGZ7_2R+'#XE*S184BSU3>%1?WW
M-,#J4&>?[HI)],_L*/&/"^FCEJ#:M.W:=GA"0\O'@V#NC@QCZ;5Q_-87IPL*
M5P*[@M#)>_P-4OOT(GPNQP%.9$BD =2_@FV-5R?D7N>'=6%%2FJU\TMWUR.^
ME#U+*IBY*7(Y<[6BUBR830]\'_H?N4W5@6D0F[)0)@E#C,)7Q!6:^5?J)MZ)
M20-*8CN,WD7=#QKT'7#"%5 9H'9!=_NL%I@8E\UN[^SP6-_;R+S6$MEV=X=W
M3?08;]S@YIN/?F!^BO!0G2ZV4*[53"(<.<,[>,6IYQ-P=:[FVY46>&KCG*HB
ML!!$+R$8M--J<QP;1-"VA(!*;X?A@SZ%_5.7"E]SWWZC,:;;DW#8']LH&+=Q
MK7%XKSN;T2@NMSM[C2)K]G2WO-2HO+QZ)Z;[R\IQ1D_1*<:XB.QUJ+>7;Y&V
M>.JZ_Q4?VR"RZ=04*>B>X[<RU]64%>3Y K&$1=SPZVY#RSD;9E5Y00EAE>HV
M1 3HJ2[+DBIHV$-+RY7)I/5S;W%66KETQ0YGV%?Q.$F3^^R[(1OR F>CV8<@
M!M,N^3../8IC(/YEQ(R_XDQV1=],Y/46C@D6C?B2E;2\ZPP?#B2[1JD>69ZZ
M6CUT#LP[I9:^+'5\OG^]H'^GTRD6FL17>F;Q1;KUA)M%9Y3[-LQ7-WE?P5C;
M<Z&<7F.MFM\JG)6'K5BM7OCHC%$"LU1\2$2*K6-VUW,E7C<(D^ /"*WP5Q3N
M["5U/6JOI<[:HFG\V#&L$R!_'OA^/G'A<%#M=U8=@FX+G(/D.$--]/?/M.?A
M?)T-_U:C6/'Q3,FK2T)9EB6N<<^XF3\O\N[C,CQJ4%^Y'P]YO#%N"A"JQC?D
M/\K^_ Y]RBGQ\>PD@)&/ZX7Y2]07[#F>W +*D;HA:?"I=$+:ISUJA!>Z>'GO
MU<U-Z)M*^;!QQ@.W1:[=G-X6EIF4MP75]^OH.LIOC&LC"OL;B+H-PYOVJ,O[
MG2XBHGYM4'09PJMLWF7<76;\#OQR)K5O;^$COKDM>;JB7UQ&Y:C?DQ"_IPL<
MB<>OY"6-S#_A.ALMZ,E[DA<+=4 W"$Q1%/LDRKV^%TCC-/<F$\:U_5[*=0=C
MHQ[K#%N=GE;*BTF;; [H1;.0_-IJG-O#I]; K!W.;C(3PZ(-"M9QW5Y-58<E
M>]D.E#UTC_)%O(8Q&K<W'!JH4]G/&8,.L]RX(O?IP#D,3WS'S>; XUAE-_3'
MV32F:RV/LAE[,+$=EJ)=R>;+5)2$N;>WRC'KC4AQ\=1[RM9=**_=)SC^N\X>
M#1C9SOWX A]DB\08T IO5=7 [X7?3BBVMHU=EN.,F>QPE>[^^,IKA>O*T?[3
MB^=8W-JN.9$2B;$-H3,TP*MRG'A36\]V4E;@\J(^JY;SDSZ\X:M;/F(=7"A&
MB$H-G]9T0JUL@4R/7+LW#_AU44% <Q[X<^I9L>FS7C7M5<?>'SDDHC%M[:HP
M-D3E7!YXFLS7$(U]XZHU)/U%?7SQW>2)PG:QQ=O=[+T!:[ZG%1K;&MIE7?(7
M[$&A,ZZ>KN5(L0&2(='UCC5N0[XM<"["GHS":,UXU\R1+ JP!.G*\"%FB@(I
M3P9Y3#L/\FGSY@#/U-QXRKBVYL6R]\SOSB5>O':#'!V"E>=NG*WSEHTGV&'5
M7U$45+9\T:_,=9+WTTMJ+W(O''W0 1EY4O0U"C+GK; : (2>ZH>>SW*HJ"FN
M(%RI2?U64TW6?J4WOF8Y[G7]6NZ;]FP$%Z]!G3'>:HRLWU<./HYIGRX$:YI>
M"'$4Y9I[U3)3>?G5C'N"() 8=4->X'/624\G(7FC\/@/%AF>WO8.:7V^'O4U
MX-QV+=:$&<*0PZ,%K*<0MVE.:]6/X4TC?_T:L\P*9=D=HT%Q&L#.=&NW7&%J
M7(L@WY\P\6W*$Y?W,L)#8)T9>8X?$'THG1T3T+-PPI4+,HO2"E^_^1T;>[02
MOY9C8FE>?*/F9J3&?8P^'=:#OF?AH^/:L- :UU#<MF.^LT[;.EE#YNW'U"+4
M5$Q&K^3 B0]O\C=98[T#^*%B*4T\:\6SIZPM4UK2+@PVJ8NMC!?67-$$'"O.
M/>?!K;!ZE4%AIFE^I,:D1D9$_6YF2DU_7ZS#3@-.5' 6YX72/9ORT/&A&YN]
MKFFGMJB,U_S1U,*N$A=<KNBHJ!02$=L@03$84F6'>A#XUF*.E%4:>W$0YXO>
M?;E1K'/]L/M;10(.;(;N!)7+-3&=69Z2!+/\&'-N*[1S<XGI37C])/;R&>NU
MTYKQA][*?^V51[DR%]S\FO?><?..QE)-7SY5.+5)EY&PD159*3@[7"OG@2.Q
M*0N3;1PKC(6@M[+,EHT**5X^(0\H'4;\(T SNS:)-[[ EKE^@7[/4X]9B?G/
MQRQ[ZK1<&(LOWFQ,P&P>^-IV!*)&#,I=2@XTL;)'>R6B*IW+\-<T1Y>"!815
M\I$D1SRHM4&(X)+*N\=.37G$NR34.H2K;7H=WEAQXD!U\??3/EL+2,6L)-OW
M575GZP:\Q@TWP;E[K4YPH<8>6^9R.;:I-Z:45'KZEEH/O_0)Z0+Z\/='M(Q&
MD>VXLVF<+=T,<2.^<F2KLB5[L3.(,2DVMP5;@2X0Q!?N:^I@5WU_E-WFAT-!
MN8-52%Z718G20P@GCI,&N+#X&H;#T"NE\ 9#1![R*7*74_G6'_>)]G@--PH#
M9%K ZTB)(?AW96'ZR>MPZCCK"-(.N1M- XPCJ8,(/L3CWYYDZ)(3@-0I"LJ8
M@080. G>KZ8!,E-43]( ,<TW:0 $";3U&/V(L$)5/P':P^ON<PNY4?\77[(A
M)T1@84=<=WGT:8"3T;*(QZ28GX\!FC#$%?K ."NE7Q\[<.+I]4WH]LGV?>PI
MJL1WPAA1@MYN;=Q5IM<_KN ]G7)L^2J8WF3.O85D4Z>06ZE/NT#TPH6>Q\_U
MPB:QU$M4NRBT-3Z4JGDQC@9P1FYIH?DLHYN NY>2=?<K:( ^"0L(:"<9-@M.
MPM!Q<"^D<@?<4_V?;_+G%Y/J:0 A5B,:H *T)R0:E<%-W32@Z&Z>9""G O'M
M&S?4V(S/3_U[7A_PX#!*SB!=H\Z*Y@QH:KQ(GMA?@'X^AIWT(Q8%5(@57)G#
M#TT.+/-;SFJR7]EAFCJ)Z(ENH0$P,M'F0V/\J>N8M2V%IZX@J^$?#30 >$,E
MXI]O/_IQMD3O"O)ST "5X'UA!\+8EA0(*X%'?-O8<-WQ@86#DU;!I1A*.[V!
MISN/@W$4NC@ !=L$TL^'[>=:*=T1WN]BHJ,=\"B(;MD0">H$#="O\S\_8\F8
MW:'_;4X=H0%^O,OXO_V":H,DTCOD,>"FW,]7)<AN[<;% =_AFS\WXXK>S_YI
M?/)-6/<AZA2(F,KENG-%?;]V-T2*>H=+ETPO]364O>HC9I!TU=CH#HNFQA7^
MU*T91M?M,GT$Q+ZPV344%H1'?I."[T#H!3$H"5O^RPTZ=(IQ)N4(78VF36H=
M7<,[ZB;SF'6/?9W(\?TVQ,=V$HJJ?LJ;BJ0W\7UO3(9*L:!=7AG,'@U +[#O
MR%@;"[G.:@VECL"FF_L"Z'8W$O[[_I4'IAR!1\MQG+-'X3/'GY2DZ#4\@&2'
M&VT<9!E]W'KC@)<JA,H:B1:>/<4!.^TXEA#WO*^^)[@[H:3L]KLKD0_B!0]%
M!D6^!*N3(MKY>:N&9'KLR 8Z*0_ZU^8'MM;%/;LK=N[P]><_66,.\AQXN> >
MM9L,"R](;%'\4'.Q/ML^F\HJFE+_V!0A$.;J073_$MAR'#N^$"WFS5LE/\>S
M5[-KRYG4]FYO":U=Z%AHH+.W6@15/2O?MG%Y.-M/W1)=7[]N]V3 :&#62]6]
MZ#-ZIJ%<F5-*BU<VC"-ZOZ;!(SW)V?O5$:_%!<$M)P^%=FZBZVG2YMV*>KS0
MF[1R5^N9#KMA-5R$18'>,7Z-DZ+/7F'/FC@SK;2;Y2'/F-C?!V>'W;^7=MCO
M[@F'$XOJ4''KJ8-K$R7LQVXT7CES1F=*,CMAYIU%MM&>1^73ACV*T5*>HL@"
MJ5KC3BJ_I2]F-XM_#.2U[L^].>3+$"D&O3'M+$E1\L2Z/8O)$ZPYE34T<W=H
M4".PD*=%O?OX@6CA%?765/T!*S14"5J9@$Z4XQ$+&Q2_G=)EX=02HE^MU'9T
M?7:V!L&_+ F)OH&V1<_C,_?VY_>1Q-M[;%\.JE\PBAE<,ZG M:?=8!C@?3[0
MW,989BUFA'I0:#NYNN,K5-.09N=L\2!/67F1R7.MS%FI5=32J6C<5\EQSAH"
M;DVF =YX((Z1#EVO2[R1-F+5+C3=$'NI*,%@(>;"I[DCC,VDTK0AIA!E/NP;
MS966*9;BX84O9?T"57XKQO7)2J:R+-PW#X2(!5X7_<8@8S!S69>18C$P8)S,
MI[2J/]'\;(<E+]/E0LQ=L0_^:XJ;5O#/$$QS9PU_!G^N,T?V[ G3^6'3HH/'
M,BL'/K]D'DQ3[A"TY2:WNTBU>L^<Y[TGH*QV)QE::#6UK!=NM.VP/S0^LBDY
M)/PJ5Q&BJ=&FMZB#WIG(OCB^I5]I]Z12F0?$Z?BE3)N_/$= S9EXJ7/R+N,-
M&D YE)Y5551RE14*'<U4TY$COF\64GS<7\N-6I2=W!5@-+V+E5]I]6.;$AK0
M#;*-=*A0;^J9D2Z/N$N^9X-^<-BF 94ZJROEGN0%4%>J81PE&+=4"0W6T=MW
M=E[W43.-#%26^JEI&R/CR.[A:6!](#E\$RT3WMAJ]AQ1N:NQM.ZTZP0W7_50
M;M-W^?"L$Z5. [Q4,RVR'(@?6[++5\::I\P*AZZ*>T[>:MG+Y#1*#OKQ'$',
M['D6>X3EVMK)&SH,=Y85O0O@QU>F9 AR83/%_12-O(M9_A6RJ>7<UKL")QMK
MUWH'+1<;CCY30-BB R[P*1DEFX/9KQ>Z8=\OVHMY2OOO^81)5L>CUIX!1 +T
M*@\_>>B#I%?)PLT8GO+L.P,#=ZL3]4HK8W5)VVHQ3^Y&&;_D%CH@\"(S+;[<
M]VJVU0=#NZ[NN%KT\ YN_B,JI.5!?DC^Y4?8[D]C)0/]PS^(:+! VI",MG>3
M[^O!K76>L[O;TA+B'S.76:\4W3IC]'!&B.$<,/79C<.L!A#CIBDA4O!'2,1J
M<HJ6W>=#>1.C$Q-WH;N:%99G#O+HLX?H'.^5,FM0ZG\XM#5Y4-2P+XN@S"%G
MK$CW\H0.AH0H*V4?P=O]QYI9!+H>GEQDMYY&TP.+^Q,D><,QY]-[[6S%\=HB
M\NOA.6[#!QN8BZO8XB)Y_>CA>,5^A]2421I ;&K?M09M*=Z[%Y_Y1:>"__*0
MMECBYD;VI]%"@Y*!!PGMJ@UL!(X,?'G=C8L9\-/V.W#;\#;'L&N"3AP0;-OW
M:Q,?HFYL%?!)M"9/A=JHI*44+//X9^Y*W7#T(*A?O'-Z7O\ -LIQTA-^!G)+
MK620HN"<,VY%<M2LZ3]X+M6&\ZG+Q;3YMT\2&]^*6LN/';&W5Q4K#FJM\:C9
M>;W5A>87KJX9R)8CZ%2,^52^8ZZ3/-/6_:A%NW(-_NYQK17X-.22T;R71BW&
MO*K>I6Q AZJ>5FJ6UIN1&[H0X:)G5.H8KV%OYUTX/]Z-1S!:04H-:\L'ROC4
M[[.:JBD/XYM]^XZQVMN'V[RPR!'$(NIUBRK#ZK@S[&L>)./ZE\S*7_D&FHQ-
M:9Z3[-0]_4%\_=W<PVAWJ])I1)B$.S"P:!O(@B"V?''T0LO)<2Y'<SVY4VEJ
M^MY)'SLW^>(8UU*+=YI\B!]SIJ4C<7,)@W]9]WRL?%99+$#NS+&)6_<8BQ0K
M[SUH9] :F33R]O,:EO0JIZQN^SE_-&A'[[6F\2OG&T\M&Q@C)3P]/V'\=<7Q
M;SXC\Y<XI9IG9?NDM1GOKFFW]@RNG"K;D#3IMF>I]8GT?I[?:"08WDKPBLE]
M:B4TZ%3N<W(L5M/,/K+![H/YPL_\S#']M<1'8:%&(B316]>N:,FM*UW+!O)6
MI@T^>^)S>91_++0H-C3Z9$J80/?A?%GVXM;HR$IF2$9;\OIKC\J0Q3M1?GX'
MW%ASC@Q/7#HO5>OH(W[+FM<3(>N1<877X>($HI)Z!!:KJ9KHW=^.T"F;>:_Y
M+E:O=+B+G*"]X]S5,6IN>+YRSS42,R-65"Z+]/2<L7<Y\GI =5SJ=45<69GZ
MW#%&@,(T#AMCR=E:#V[9LPNBG' 5ZUKR=9X*8J\N+47&!#>=.RS=AS,\' J4
MZ(DV&\ ?+9[!J7]-X\175.>9F]N/Q3K<G^*L>D 6#3N7S V$QUV\D)Y6&ZV7
M/)(XRQ$_>_;-17H%K-,_3G=H<VU%C>S;LJQU[:NU(_!)X)5'IL51I_W0Y8S2
MDYQ=1KUZ@5-[4^)@40U32T?/[[O+[\.+6]0Z QU84\8ZAV,C<'Y?)T?+"O;@
M"D:8T#J^7%*:PL62L%-EQK+$4EW!ET;"J>'M,3NOA72ONX43(^"\-S)_U*P6
MKQ Q^$2)D$+GM?(3CF7VXN+!C?*FAM$I%YH><.KK=J%%V]HIPK*5# ;,D-@A
MLT4J\TIMY/+="-&<UE&%9]SXXM!#<65/W"P\-CIYN](*MWQ-Q6-+)E<@RW4[
M*HS5O<(Q-1[.><;.#5]J1^WM+96V:BV9/I1/\KLR.29'Q=-KD]8W+0G]TO^H
M3:*N'7&&N,^T5<_Z'S(>QCF_,M-).H22F=A]\#SCHK2\$IQW^IE23$S:SBP\
M,JZ5GXUPQ9NGQ>P=GE3?"^=.M8S]WGZU^Q9H.8QY RG^S#=Y095S1<_4%-)V
M8GPK\+*RDC=[F4$WNYDQ)&KP\$9/9?H<CE@D%]+<S+XZ@>!(K?$NW\%M;B@E
M2+$;,. >/+!-UO7V1SC74NJZ<:"9GM["S Y/NWQ[8^.^4=GTL7M2M1.O'U!:
MWJ:9/*Q^G+(S[3]!L(CW34O\1.\*1*=]Q#TB<#P[YL,%EN+9<<9ENE_,JG;3
M[Z;=QTGE-+,@+RD97]$ 7RFR,+S4'ZDR+EN.F]]<=Y8UGUC[BHZW?["#8%NM
MW5T:+]_VK3>D=VU%AP;^OG&4R@I1B@:(_9@'&^$'[P./^">!>0+:-&$S=@ZA
M#(?4W]E1QV^ ;= X7E%Z[S6TC%I,DZ67H77(YC.?PD57F0+_K9VK_B,/>5T.
MJ'!_G3$6R02)6A@;Q>A@%@M>:^FVKU7WJM[I<K><9#-B^V&0=5F'L5=GO6>L
M7=M"S>S[*Q'-9<:N#DLD>N^+GAI[=3>;G@G/3K0'\,3*'D=$WK+>R+(BMH,C
ME;?SJYT'H^DA[%/7I&?'CX0U=F0\&\'\?$LI_D, > S41T75V+HB:V%DJ]&M
M;*U[)?>1]BW/VY-&X'*DZ!QB=I>!2F<V_E-!_:GKYWPP#B?A\T::W+R7EAUO
M7DI@8\R@E_(F.>Y2'U$Q3R&HUNA7>^@H)T_'LPSEP450N+AC$F-VY_T/.'W8
MJZBT>"R]/U.EFR4]C=ZZO&2%$9+W]A^<NKGZ>D[?RV9\K1+8O._@0"B&@EZV
M/2"6&R 1J&T5"A.[K:F_A/6-+*#6;D!H+XS>S]IA6""''>[L+6I7<]J>@]LD
M]4YFA2K%P.H4[>J?87Z=@WS4_15P78+Z2J5]=WM)WTAJIJ#!8T8[^^G4V(Y<
M=AMWEF)I(>?97O1 Q>M=X1O[L76/,E>2/;=JHL($C2HENU=X-UW.F[ <?7Q(
MV?M"!54@H"?M$J&W\LA^_$*\*YO7[,%*@[M<7[P%WQ1_:>]9 6L//N/]2 /X
M(+<$UF"H;$W.4S:$S"7!U<F=XVXA]B)]11,^L8XNB^V_B;D&-22KDN):^(_W
M2W.)>XP4K=X^JF&;U.)<(7NK[)5P+.0;KW%?/ ]\*Q2XBMA4I0$&-E<-Z*I\
ML.'*MA=5N8G@LHW//M[31O V P)AS;STWBG0EXEZ6)L&:'.LQE>NDF=U3Y.
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M.4)+OW*LPQA;K,*57K14;,NVX*XTZC>)_)/HI%Q$)V4LG>%*/8G_.K[Z_W%
MI;B.T #M%0&N,84_OO@4O\_<6%OC].7/<^,\M_< ]%>8P98K+,NS=B+V/7L2
M*G^RLMVOI$9G950;<HOM.PA_ 49G95L]K7W#/[/J?X)#O ]HIZIPA*#)KFKD
MRVZ7@W#>9T^\?#$.+; ['$E&CPP:6(@EBKUK^&FBM+6_LG'T7UE&X@_')]
M1:/(/Q.)U*^&Z/N-S$LO9?RI*.C_K_&2^'?3P_XTO0T](>?_F9#_AJ-RQC2X
ML2J >6QRPF)*_&/!U"4-FS#-=IY#;R/2=)5CW<:C1(=^?&I(.1&<%929<]\H
M7!7$'8F(1ERY<\$X[C]A!8U/-:9IPS85L?)%C,QLL1\]C-J/O&._<F#Y /<V
MGR-*66D:_-J,Z?5Y.1 =@YD+>*Q\\L*X\7>QMHRJ0^0J<>=N2?7CYZ^5F&M=
ME'MYZ4K!"SYEX!FH@B>V%G[T5OYXSVR$.?M@D?2W#OOSE78C120NB[07;W7O
M2_8\A#AB42\IEK-#^(7X_!ZWG&\N'&.FTN3W!>MF1\<5QR;K'I](B%Q\WBP0
M/[9[R-$:I2PU;<GP%5A>D>T\4WBQZR9/=-#"H$MR[^3]"<NNG 6M,#=JR9US
M-BF"P8?D#]9%S,A69Y.B&VF 4E!SX<6-BZ3@Z4DU<(N9_E7''C8S>W1"I?[D
MG0!(_$*"C/[T<>B<B*FY](%MAI &91*P=4H,?-K>K [-$QDRXYP5IUL=WKN=
M[EQ:6#C>=J[Z::_WE6L*EHBWLA7BT)NDKS/P$,X:E83JBSD[8\A4XED5X.WZ
M(>'WM]DZH;5W;1ZR*<Z]99#9J&PZY:=-8 @"V8)"DVU:#"#DK[[)&K/:?$"Y
MY&MC]CL)E<\MA3'!5O9Z[.\/"'\(UA*UK??&UF>_7@\ 47@BFL:*$C,<,#;H
MNS7#TATRQP[Z&(V'QO.UG(H;V?W@RP.@EPI0'?Q.2Y4,P_<BE\@Q:-,4L4M_
M8$V:W&7\Y/0G<\?WV'@Y ='+3PZ\_"9H; @6H=CA RF2>(EPJ#F6V$<]Y] @
M.B3M=^KZE/(4$#^?6G>-O9)L-%QM4VX<,P96R#(U<XX\_$2$LCN3>N+FT$,"
M*D2L""J92Z(S\:QP8*8C^,A2].>GQI*]^&8E<_.D+ .V3ZQGOT4:Z4?Z7P?L
M'ZTBQ:2;+U//]0>W]O1FIX^/6SIP>'EQ<K*T\WU]>]-0X$UD<%VNO':+\]QI
MT6S$2U49R-E&*P#!&,>4O:0*Q"^&;/LHLZ=W?38;-34?FY!)KTI3"GEI>(LK
M2-TIZH%SYVTF-<3ULH@9/5(]UD=5I#P9JJ?+WC+%*W?T5F$$X!R9B?BXG;SI
M6M51=_VD3</ 0J#R&&"O5F-H>C@]V1RREF'B(E3QR-M>K)3S3:>D8<R#$I;,
M_!>&Z)-9[P)=T(O5P-.H" J/ZF6-S\*OF**H%WR:+46DVQ+))N^#IVB 21^_
M%Z(+E(:'$:2*P4I?5,AC$FS:E6FE1O>5<2.Z9KC>>X;/;S:^!8F/6AK3M_PT
MYESVML#[N4I=_]G;,;,7CEQ4.,A[E>$'G[6#U=5^Z6C6IPW\M;4;Y?XVXH+%
M%1NI=?,O+K]; ^3A3B,AD8N1F^##5%3 \>\!@G*-A8=:%9VS7WOXJ\+X;^W'
MY)AHL'\>*;_$PO6DN.J*=93,)?TIY[8+,30 V\,(&N"4=#2CAMSJ?BXI%J7[
MPF0*TGYCP),;%[,F1NW)Z>%(=77J+F@SZ;]V_LVUQMR1>C5 P MC%2SBM2HO
MR?YC4?&LOQ7FSD#RK.CMY&GXE+;HJRCI^R>D))4!QY=]#SK.N8XLN)XDV<V^
M"7DYDZO,CH6509[N9[2EG31_ [K? K9M(@4VED401RTS'TD779RH/#'?GG3$
M%XU+FHYF6H8SKM5I^V286I*"M*H&IK\,9@=;^=V.TZM@.?9^(Z7]I/'AJ--J
M /\#%NLA ><A[FV^R-<>/4S&E4,24)#7%9F[N+!'CL_N@][UO,EZ\>CM\;'G
MIX]=2-0OQC?DSBI<61NXE]ABS&/QY9W0D4T3J9?G#@?@U>J*W#;6QC'L<\C2
MRN RUR-08Q+V$P2F6=(G[:ABK:7E#-)]^3"0G?JM3%#D$N!)+(1/0_K .JN
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ME\;(_H:UA(:3>&$*:Z5>*:'.F&<G7'H%Q60R$?*D.$K/S:ULT?KH_=RT:[=
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M;*L N!^J9+?_SODD:+1BAWEM4QDW7MF[2^?CJC;%M/)I()[H&H'<$H?0NQN
M*VA7)'_9T$G"GG4[(:-R_C2H ;/'C.A:#X7C'[B&-XC16[H0#R44$TE125O7
MH*(D:;JDED5$0R2#_>+<BV?MW P_')'[V?1F*AW.K'J,M-=\\WN9Z\G),0O[
M,.AZSMA$QSFO9)MS[%5ZE<Q1DBL]0/W\AXMA>Z=^KMP#*FJEVB*%D3.K&$[8
M#PN\+A4P!=LP]*,!6M?'H]MA3-2#$(EV,Z^XF=%R_V<F$>_%"]=X)I573"\Z
MAY>&<-D ;*+YW(># _/X^X4GAGB1*^?_9"B9714:@,F65$L#W%P,A.&/;M(
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M.M?HOV7_;]G_/RJ[" WPU3Q XNC9.KGIV.JY$V<;85MY?Q._*'P73KRV7UJ
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M>7F#_15*98N@.SP56#Q W#]HQ.J@#31KM\91^PY+NZQ+! :#HR LA0-E,Q;
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M90E"XX51\']I?,E/I2Z'( H\@(3@Y70"(O;  R[KRV)=]I>F0U=ZXH+9H.U
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M>JUW(N0P0U,[SEKQ2U<D$PYJ=<_BB,:3<O4P9XIKSGB I+ZA2T(5O+0+Y_:
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M]QI^>>SBO(53ROO+;HQPVQ=RY3%9[ D4\WOD]!-\JP@/6%++S7G#AWFZ=$2
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M<AY'07WF"S$7OB-G#O[M0S=V'R!]JY@B;;/4@4\=OU\!DRY=:=@1SB]&<*:
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M"EY1I3=VR-:SG"N9J/HA=XOO45B9)6UT:K2.S<,"1Q^O2JQ">?H0@O'PE"W
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M^6CPJ[UW4H$BHZW\U&+5<Q(9/[\+WTS&U/?J+BXD+O3/'[VED](+-])K!0
M'"*'KX\Z\0 *K I&#_>+ D6Q!NWD"O,>6)66\0 +G.XL2'P0 0'#9 Y##%.(
M^8+68J=VE0BV*<<\0">W9MV_3,2Q="R7<>SB ?1-2FXH%=URF#G*>TAI;Y0A
M73U:+?WVP/?B[Z0#<5\I,UF7E?FQ0BCJO2W,2P@KVI<(V,)HC;Z8Z\QB!-[K
M'LE+IV^H,E;I8 MP!.6*!&VSPLV^?:'^>1#&52W;C@?,3)U^O,PK:;D%AN%H
MST]T;ZKR$PSHN&!Y_CV*V_NCK<<=L]=K90SK<.8JA&X75\420A+E925\I(;<
MZJ2^^?M,GE(^5DUH7W0EDZ1A]C5?SG.3WQX:;2HE/L])!Y4I+\.:1%Q6)2C0
M:9TX)70<ZM:Q)B]\K&J8!1VY9&9A^>;ZT_+(\7W]:T3W3ZXU-;;;,!Q#IY-/
MH]##+BA;CL>/D+7QTC"T1A47$W_LE+&)19N$T]/;@Q5J-D2>(Z:95\)Q!SEO
M5.3Y&IK1*P$80XCOF$_08PUT4 !RE@#?&C@V\X@?S$X.F/@WQLL0-?VP:R_?
M8:=N*BWL% SU28@,YKP,P4J6S>1GYSK/.C0""118/6ZYEI2TG.,A>P@1>_3E
M,X)T4:AC&3EX>,4$2Z_>"J=LLO*8C2L(/79[-M QF_GFH''46FZCUC8P97[[
M;?N'V_=H6"]X3X<)(_WK91(>L&?7@@?\<G/9<_Z'5![$N?]!KH\K[QKSQ&N_
MSL^P4 H8M?=?T[HC9]P#H:%Z90/FI%C@TO@A^8&1CK<JXYX#\4'A5MREKOGV
MMQ)>?;T122']L#DO:S7#!A(3UO79L"Y[3=?PY =]F:6K/9G'<MUW9W/&I,BK
M+EG7G@:.>;H;Y=8ZZF;=[N46DCLOSZ)FOSZ;DZ98\N+4HQEQ>2\_V>XR+<]L
MYN H>/CZ8SCS0O6#GPH^13YZ^@L+,SF:(MPYT4+_=NM:9TP';<]JH6^94L9@
MQ(M:D78XH$YN_WLN\U[ YG<SM("(&*]5>?P6[I'#\PIF/& \5\CH@62O)>SI
M9H.SB U0&0\8O7LJ=58+[?&^#J+<:QQSWRN]FC?QU78A8V ^^1'IO#V)CV)H
M%G6)20TR[!>AD\Y)7[2DO93]?+6AK>9I[!XEYL>#87N6UF&XMBKGJ%7'=/M9
M[<DEH8DBO"_^:MCB2Z@F;GY47#2L>V9]5M_>\N."Z;T:A>4W+H^B@76-.?8,
M?*NGCK)!RQF!<QQTXT_M=*37^/:&,V-B"3;N,DP>UJH7?+=<-REQX"ZCR['P
MW5Q*]#,]HV#FV?S]TY)HX<NOF$\85O]F>$F\ S7YHKE8Z./O(KH%GWAKDE;G
MX?LV7'QO[HNJ371<@?N_#RBQHE#'=5>"9^T\%2N:CIZ:N)\S;T1:=_R"RH_D
M1!E^2/FXID7CKT$P[>#X7VW\$W7MO>^0@(MJYFQ_E[5"N%6WK#%E,2D'&4,&
M=+E70NSXOK$='3 ^T[4WA0EX.V"-G^9LVXJ#X:NSEG#?)ZT/ G-)=Y<Z9*98
M\PO\O>A6%7;!B%DFW8:B1A69P'U.F(^!6Q7Y*G+C9[(TJLXD7N/6Y[7ST7MD
MS^>QG<13L<N>BS7?\H;%"7ZBMJ="+*'DFDW:I\S#\S\YI?T2R\LI^P12*D\4
M9WEPW92<Z8V:WZ'DU'V&1H<T(?><?=-\6&;37>;Q"TC>1URU$KU<O<C=[DS;
M^?=ZJ@S7WO[U4C&QM'>I YVULS_J')C(&-Q.5^QLZ16(8:N'8XI0*D<+-)58
MDV2ATZZ?1I,79#-F7YQ>>$TQW(CX6VEI]-3LD"\"[?KBMT&0 D[AXQ$:(E[I
M4FC:7^.5$R#Y)<%+E\F>EY?$SWT^EK9+4^!=LHOWDL;*6OJ@N=35UW&#G5M*
M9W;,)5K" 1OS<$?.14<%^Y6 E;JQX+'@6L;7[L$#=&WE1[6VG[@\J<+Y/(J2
MO%QR<J+UDU/7PGBO.A%PI;[I_P8 Y#\ (?0F'X+'56@@ 4CX\L_R5:YWBS?Q
M@+"Q+K_#!S^ 64]JN7BUOA^L=SY)6M$\?QXB68?,;U@*M^:>PIH@ISI8AZ-]
M;-#J$/6@@H>>WX!F*K\K*ZYLA_:VJ?@<RG,^_$(& :(26E6H#KY4H$#QBK(K
M+GUK1]FUD]4N@7)\"7P@H\3QE%Y>WMA0<]Q-5$$$-C WOV0ESO\IBO/#_DC)
M:7( QSCE0,=M<)]E_)JBR5OP6.=%6CC<S4E<:IAL5_E.JFY$(^N4:FJ_' _7
M[),#.U_/*X@U+I&;2?>[-=85H1*=NA$U<)H6?F#J$')7'P6+4KR;-P/TSYD\
M!>NY\U:GKZ[8 E\NW1MD(MM[])AEOJ3]35",*@3U4C9>T0;ET@F](1K,O_M:
M-2*TRD6DL23 Y_*>CH%A8TOJ2NZ1K#F;[SMF1#\BGL1/E!SZ87]5D0WEOZK>
MG<""O?]+#&O=0JW=+-&I@GQOZ90>5#7DK9SQK<.A8C;CXP8MR-;B1ND5C36V
M&ODW04&JD+0<K"/J+%I1-Q<B2+!]#$;!FO/VQ+$+'L R9_K /:]B#($H?=Q%
M&?E+K+/(G\2]6R;.\ZXAR1?S%GET!XJI7:<4?&.N*V3+:DS1;66!=:[KWO0<
MVZ=B:6.]FE6&V,=;:D]#?9RB^WD4'BZ\IRZJEJ#9-K]GI9Q=:#:=EU>Y."\]
MN,W\;L&[P7%>;9Q9SJZUQ[S:,0#T;:;-'ZCH;US97=&E*,[!I\9B;,Q.\Y"$
M=K+E#DHI(@K'BO5#CY7.8A].G;B9/$$;,>9>[<YSR<<=JKH]Z>2PK8K3ZM[>
MO/V<W.'60"F]OS4I"IH0K !.>S[B"O$-7 X$W0"[J&4%-@L^J\C:TA\'E<0B
M1.' =T],[8P>\,;1?LIZ9 GX @B2585$(?& -:Y.B?A%!>2U!.IHZ,KUJO$F
M_N_.YGV_1$OR'9LJQM<J))RG] 9I66)H.&S6;>_";[0,8>ZA#\S0H<@LBF%:
M:X&\DNV+K+Q<*YN>*QVG-55-Z3,.=\OZ8W?I&J^>/[[;2@P O"YY">-  R&6
M+?3*MT8CHEFIJZEH%KM.QZBQQX>RH)F>Q6Z132(4=)421BRAK )M-Q_9_K5S
MTTKPK4[<M['XU#0WE_6J19-9G9&XIRTO/@JF/SH/MGZX W4<IK;9Q@.JMA ,
MWIZK028&X;Y6,I*.O@PYG7L7]E\CUWNN*/^>.M-^!R@0Y\"]!EQH19\WK!ZL
M.B:TB&/MQZ1@D4=H$PUDP72R6F75:'$!E:<XC'X+(28E/@SP_OQ-[^?9%54B
MS[X.S!-PVFKJYV67$@6CJ:J8.)OV&M8!=.#*9B)C]O>^ %^!X:6A(#?^SWDY
M85YQHHF5*S^7:4@!%Z<5(*Q5-M!5=;^ZP"PQ\$;ZDS.]?/$-,MO:=3R@Q)//
MWN! YJ15CN%0O0,69T,7+&D>/&SLMEK?Q"\1?5Q&"X\4KRJBD*U+MU(&WXK6
M"$,-L3^S\'S!D$RG >A5>ZH;,3L<W<+@A!.J'VMR_.Y,YVS#7N+#5H:@L*#C
M"[&8YJV'+LSE<[Z"W&6FJ'[JPM+'S>5C1"5H/29]TN@FJ5<UGCJZJ:T0"I3O
MOY4E&<43]!7AJ\B@&#IN$H:5',=Q8]W&3B38@(LJ:1W&O]#QISVZR./71B7=
MG_E3/J]9_*B78*X'VA_:NZ&&6?./VSGBX&^JT&4HR>X6F1%%Z0+TX&_/'2XZ
M1>TOPP&<&2ZBY=LU'GU\>D\X>7)4R</]J/JN=KYAX.:RU;,1=K%A4;19;H2R
MHP4-4)F@0J<6WC&I.15&2Z"89^&\F<TCP1F&E+S*'L\@YIL\)&%J1GH+RB;4
MK;M<56F=,"JP[%I*%1/N5OQ11P-G2BD8^AQ5\ZE@;L=)W!X\8Q\RPZ@B>OXP
MY564@,X^AW?5;=(%Z:OAEZ5%=FZ!]MX,&Y\'7:28&/<YY>Q>7&_XL?(AA(PW
MA I2BY+00\'>-3U>HXZXJ.VD4K?Y,=7"L9,^;V( /+VC4[!@WL?NQ0]/ QA0
M%GK'59)S0+*CR&U=DI!3D8H!R[!P^+42?I1$O,\28'@YT&RN$\>(1*26>[I!
M?I$SBM09CYI8F*X::<S>][\+7>S76'C Y:IG"2<P@YN/UR0B@CDF$2>[$O2J
M@?;TN69CV7<>@K6.A#O-8@/D!.YU9O<G)UK]^X\N/C[_#RXA>HF>LAR'R*YD
M#*EKC@B@.+-O#(L\#?$)WQSXGJGP/A>0NE4Z[RM=;QV$.FR?,D#KE,Y93V^S
MIE2>LR%\=X_L'=!9]Q3[WEZ]\X!W(B3^Y+?4!<6?!8%W?UN-6=;M=&THE?-H
M)X*]$"C)F]TA1*;!?2KUWWA[[VBXP^]_<(00T7L+(H2(WD6-Z!$12?26Z(PQ
M1!N,$KT+@B!,]-X[P^B"(#JCSNC19D09##:?WY[]?7^_/;M[]NR>W3_N?^_S
M/N=Y[G/O<U_/O?=U)]MK6#V--N:Z84B;P4NF_74LF_JLPL>J/0XQ+$-J^%RX
MB(@4?V&[OH?WF83OVW9&W7@.5,/I$+/4">?^*K89S1>B;'L+.#B?!"L).,^:
MWN0"2YSE;@$Q'Z;R&YNB:[=&O"#;A+($SQ_:;E01!YBV>KW4_M/<#-P-1+@/
MD;^R \F97\7$7-P/PCU1+\%1Y>$N5[NV+-[I8^ES6.3,D0=P:>JE'\(FC8Q6
M3S1L"$)3 =E+!VQ[G&<AUS_P[RIO1@)9L4MI?Z$R+>G]LZ)#O+%H8ZE[#O6T
MTN<Z[3)(K"AY13')DZX0 -^]M7*/)T.FAXN5US)"<^%5[>97AC$7\4&@/2(<
M%]HJUHB#/G.Q.VF50K[G6+ODT=+>I&\EJ;?&FZ;::'K\V/[B6XVGTF6=_^']
M6ON!)"Y<HXKR.XJ&*C/&EN&D5\A:&PXX+1IG#P[1V6FR"N7M0<N'XG7Y_%=9
M7S>.&0.++4=+]@^F@G;Q;:D'I>=*]7F=0IC(@=5HCF?7-8$LNRL"F*):S.38
M4>_<N2[J;Y700?8Q/2__XC"RT_I+5_X/VQX8&AUY,(2N=.Y=7^UEO[]HC,L&
MYUGM^APO[R+(A"V\!")?W!<?H)R['XA]B/*QKI)])I=4A&PW.FJ\\J/=$S;B
M:9N_BHBYH.I19L[#$6#,7L(;IP(%_X48-T)SMX#Z!BL*_*LVX]-HX7MD#>UW
MN)I[7)=4/UWL:#^8&X0AR_LLN:^SE<0=S_T8:S'IZ/1PKJGBG+%% SHY%<4E
MKL<AAQ3MG]\:-*VSU::,W5LK>^FD"?R'/N4M%Y'7*K,Q1OXPMPDK)B=$ SWB
M?J<TWGD.;E;I?'Y#A]D.EQ3X>3+> "^IUZ4'7I4L-PD,<9?PQ:4-2<U#P&<]
M6""0L/=&'"?OOX:@=T8^'JM'^;-(M50_FE6(LC3YX,2=Z 7/>H%Z*;9Q2!;,
M:A=:UIA0-M(,O&&:JYEQ5!PO<:S^BE>\"H+X6V 1/0%W&\2<G-8#.!0UCMX'
M//<U53OD(W6Y!;03#"6OJ"V94(HN^AL%8/S/JC#I?6!B1[E91*ECSMU.+%%=
M-K?&C%2+^O)F2_9:C)TF3?,1JW1/N *&M"2'L5'*5_-R#I^A7T[JF'$P;32H
M3 #W05O8G''CBJM6<9$&G;/[MP 4]Y5TH8>_8+JHK_Y/ZP4NZY%Z0E>JD00Q
M RCIE0%NL>>&%">Q=L#=)9?8+\*,2^F> "H[MLP9SFJS0#PDZ_/)&<A7;*1U
M&,QI%RHY*'V28SNRVST[3KD7-88ZBY'T1M\"QSD?5-XHX6BWS5BE!B.]+&3T
M89HS#?X9:I5VOI2KXLJB@ > /SX?O';$+&'F'F&E0STZ[T&,!54A,4]*_J<!
M61MX'32[WV(_JW!\OF.E@HP@;_N,Z_OKM'L&@QD<[P_IQ+?M-99.J^I:="V[
MM+&)S]MO?FK_\@/U!#G= H#,2/*:"Z6A[R_9KFX!O1;+[W9>_J<P3_M_+/0G
M?EUY"^ 4N%F[L2\U6#:[43*Z[L:/OOW_K6;V?R^D0HCU+9'SP;^5EUU-MX#$
M;XA5SK'FG3L"_SUOW%P5M(ZT.J<ZKF#]KVWZIU0S)QBF$8'ZX'L>M*@\CYBW
MU#B]4D[:OKAJ.EA&^+ LQWF/2T)U<4Y%4$/,:55BN9X/& @N-7&..GM=MF5F
M%I8CJB- 49C_II?EX7=JWPHJ.F@09CN,#Q=+60PJ51?Y?+(88'C*2&\/#_%,
MRI/N4C)/C]&J653R&GS!? RC1CA3D>TBJ"+*P2)1!P=@/ M?W/IT@XZ9B;#@
MOF8R-7JM(=#C8MU:O TF_ H##_:ZD<+Q.:%AS$$]1@6X+"N,9K1=S<U(^S14
MX6P!WDAIP9TF_XTW[JO]IV0B6N%S@IH^HW3@:CW%:'K_43@"$V$!Y*#$%(<K
M*):;"M<66"QV],E(C+IVV^H4?M7;^NSVRU*&K=.E/-QY2TG@9G)%85+O@ Y8
MZ#2'5% BQ_2GGL66PPW%>23@'L_2U,7;GZ5OSBO4Y7Z43R6]N&Y&'0W&6C'C
MB@9[61,CH*HHD.F5MMS8]\M]1NQ@*;+\D3:/Y?M)>COQ/E/^M&> I$^A% UW
M\@-_=;+&]K0)9]N4 3/MV_/_B ,9.X6;6^,;P<VO])"N/+[<C@42 G(*8)I$
M(*"DG<Z9;W\(52KY$]TQ(U6I9QA$-X_[IVZ+]DPZ_Y(5I ((\*U"A[6OG-P]
M"JTU_0C?;ES/07:6BMM&(\*LV#K9!XNMU#HIY )F<]%"2L;<2J 6>%V34UB8
MJ^K]9?B2*)&&RCA#)79O73D*+X*-146&*TCY,!2&SW;8D$39B@HF\AB]V%"Y
M4W^'7F;!P5X@DLVZFR#J ^7J( +0D,B)RS>=$Y:J='B58H99ZF28/A#D6!UJ
MJ_^HU /]:3&S#BPU,6%1D5UZ0&Y H7KF.F5X.'G5&RB,50Z14IOX\%M$Y(2E
M$CJJ,0M0X_ ;!PL&NO@7+ HZ)A#%R8"0Q#+AIS!&/'0.:A10B)MZ@^$,:V!W
M/GI>FZA27Y=VI)^VG"8?O9U\2/K[8:JMUJ2D:O"O7XNI[W[?T ^NF^E163C=
MR*5-W@+>U\#]S4#6$XPB!SH&!F++VK3)M2\7/NRT6/PT>5%^%\"20XN[BQ(A
MP-7W(K<^WQW[)LE)I8/*8I=[YK,H5)'2*R\!)M9(@9+]37^VU/^93ZH1,X(J
MRL 4]\Z9*J4H+O=7#A3ZE\FOM-5'NU9Q^ *>EDE')(7$V0+$M;?@[6?YV-5$
M(5<%F;6@<+\X/Y^$1H@4A;&Y8H./ $-A=BNH(J$"D+FEH^5C\U!KT]=2HI,;
MZC0#=<!$KFU'*S!56T ^*KBCV7F'T8=C9+Y5#T-0/'_S[J#Y;2@KVK6?N+WY
M3?)FM6X\DF*ZR<8""\"\:FN=X\$\:0F]XJKZU>FK_"?P]Z,KS2/\9]G8P$#=
ML-Q#N!!F[A4F,5X!B/9_=KB)P-K--"Z?>+1]RX<(V32I4-^_=_?16Q_&B^@!
M$L(Q+R&S?@31#1>$8]$0FU:XCKB/:W][TY-^Y3HV)M\A_7?_[SA1K6(V_/Z$
M<O)$V\\XE>,%8XKA1>5ZF00O1)0R5:.NGE7'5<"^$L]L V[S.%E!A3A70;2(
MYOF%/KT#B^P0S\9ODONP^K1V-#A!F;EQ\8@&E][#P8'EGZK,9Z4X*"NJ=$D3
MZW_: ME,IDW@T>>Q9Q'=5^7\6NT>="6]4[,W>UD<#E6MQBM[353"E16;(S::
MC*M<0.<!.;QTW?RJK.UE0S3Q739_W5I6<7/K67J1@206UI?GAE-K<CDPAVW'
M)+,1]S;_EER#1;>*+):"^]ML(8Q/5 ' SUB^@WA4(CE?K(BK@A!Z))$*HF-J
M064U=U!QL#*G]Q7^Y$%U#F^&<F <-&K#R])$P^@AFQ4EPFZ5%"\*ZXK/7P52
M,86@9RI/2H0/N9/43,.&!(>XCGN5>IGOZ;AVR\?F.'9<9WBR';Q[TY)B.1<>
MOQU3 ;>5;$Q>W,<X,QYK\NK#$V5LXVG!AMYKT"R)]U[5R%X53$X&^@I&BS/J
M5V)MP:PD<B"$$G)!+@[P6E]6,<E_EQM<?&V0F[M*X[U]HV004EZ[?;IHZC21
M')+2(Y.8/UKME 1LPFAX 66?2TARF(\WJ5'1.#H<%]XQ>"P;\(/R%A#A4],P
MXR4S ?^(1E#LR!45(#MN 9&2P/D/C3F;RY9&)O 4KWM)TQ(%= ,%Z6O@@!6O
M]5O @O.A7I05E3VF*;=R?K=TG1W8;SK0"/1Q:99SF3/T<!$3C#)8E_@V]3'A
M53GUQ5M=;U:C Z/\O7_.^#P*A.=$UW4^R;P'%2OZYC*ZU68;72A"9+T1E9_
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MHXA7)( U!5>)N >VMM0Z\<XG-L,-VF<+1Z#V\OD'_*/+IPIZEM=QGF!FX"V
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M/)1_?W>HBUW7#^315MTG0KF3(_$;S^=;IDX5U5BRE=:K=__7<<%+4PU9HH>
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M2&<^B1=]]2[J\85Y.;3C&<NEB#HNM  2.G#S&%.9,L);BIH_X'PCQ#'_>TD
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MS]!;_'U)EHO]"BY\MG82M,4C3XNW!I$<-%BAZC@\?QXN9/B9=?U,12[BLS"
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MF3*E$X<0%BY28K9DJO,#5[9J.EU1712M5BY5E!_02K.N\M NQE";(<+HDP"
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MD?W$?RK7;&[$"K>6SN_Z55659W6\F%Q_"7=H;OFZ61C%G+O EEQ2JU%"_X0
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MA-;9)\6D>3]&T'=R[K &A2D[\PM)F@D]/5Y'DT2"3/^^_@PZ)!(?SW\Y7#=
M*&R;M+%V?29T'BUU;@8AZ:7*'<UKCI1,FRAJO7)I<Z^-W3\V]^T)DLI?;$!D
M$F5%C6';GVV5.UN109DJ_IQ?5MX"POY;KY66#;RC=8HK&9@:/:EEJ/G4I$?!
MO2[D]:PZ-]%] !86>4/Q6XG^9DXN,D*!+6\>9].+C/R<.^WJ.?KT;G-S\I;
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MIU[VQN&-4%:ZSY3;Y9R-I<^5*EYU^H8>2H_UB6UPK.2;\<SB=@>SXUTP$H<
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M#=I;%=$%FE4;.;%8J[FGOQX,A\-(:XP\MCOK.R*QCR'=BN!H&3IZ6-IN3V#
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M4W2(FO."&](BV") CX,Q;9KQ3^7V'R,G;&0,[TJK'#)X EX":,&\@@^"DB/
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MV)G)=='QG[E%MRF%23;H "%#V<E1>QU]-P"Z$$98X-&D;MMD5@_Z=K9V0>D
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M4"3V&:B!=]4O:!40]-2>9=SS;YEL3'T0^=^ VSQ&^F9LU ^3G/I6?Y!4O<H
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M[8]7+!,<VIJG?"1Y?KL%-M9]4_M&"/?%71C<N59-=6BMTVX=KM])UVU)+4G
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MPK E'\<D4YJE&3-I!M8H(+?@W$Q/!+F#V#)$PGW"J&&IRZ5JL!J2H=FXR+@
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ML'$SZPZ@>*[\TMOC95F08G5L$PHBF;5Y,-G(+5>O-!RM,OD5L6$ -GC<W_M
MUKA*G/E^BW?/JUZV*$3*'S[RQV,D#[TC_2^([6V(-5@LG'?>[_J2><X0U_P!
MZ'J%>C[H-KT/(!B JEH-=2I&!(DVKXQ4VY0,LD3B$ZB<?@HW[%DX!#20BYR;
M%LH# M;=:J@Q!XRP$QZZN4:>#O6ZYNG >F!FP=8K%6"Q@%MSXFM#I 0Z7[2<
MQP(;AR?&A4=%MVW>"D=]X:K3[0Y#4UNZ]TL$U3W\@[D%!**[>6DW@D1(^YM8
M7(*QO02FQYWA-^=#0>3AU\<TVVN!5?J9N4P!^3E_<LU%&;>^_3A-F4(>7B&-
M[&%[E&E;]*J5_M">=S Z'G-Y(I*G?JTT^HTLU'<WYIH:;3 K. )<'J8>O:M\
M",HT,LRS2U$8.;#SYE 'N/L!Q/5R 0&;SP ,EFC.9FJF@D4ORMA$@ES%M^&3
MTYNV[12Q4?LH.:QXS5UPF7!7",#T:Z"<_GTTJ, 8U#D[K]96M<HW7*E*%4^E
MYSU%D:&''6X)#%O(FY3]_2H&\,M? U%6Z+$EKE+K,M29GDD'_Y1!83)$6N]\
MYW/*4+U72.,1;L!'*8(SU<\467M_IY%"&TDA< E2*8EF;+HZ;.],7V310N+M
M7C#O0FIX:EIZ%73C^<0(ETK=64+349F(:D5?61;$C*K=T_"(#*=BN/1=*V<(
M&W:910L9WHGUA]+BU'77.W:B1="J+3"I(*J5&+..N83H8TM?S;])]'B'/E$W
M)Y>L*SA#,2WA8;7G>(>8P8&6KQ@SW59S-D\A<P!7'T2M= S,)I\!AJ^G=Q.D
M-,W>_14)MO[:DW13ZGEP<$N&_+Q:?L64@X=0K51./HCB4U_:99&'ZPF4%V-:
MCNJ%:J!H8?=")U?>74T]!(;(7-9,(A>*'V('*(INA2BZLMW\%Z4F[C%XODZ0
MVF= VI+1;&6TPLSHG)S9WE)9 [>:CC;1[]9Q>"G JO@>I#GG),@^TV3BV!28
M-X7EO.&4XY:&PKU!"TEH1MJB\,S*CWN4VUGW47:0VMSAQMJ<*>=>3WK'K&1N
M9LN.)ZU_:L*#$,KTJ'B4FG^4_),:>,M>80'&,YCX4U@*B*>Z5-+3W =/SS4J
MQN6DN++#"$>RV._3?P[N_%*H=7#B9OF8')+ D?BE@](_@3_/3Q>;9<<G4K#[
M+6QZ[E:;Z0#AP 'S&'P)V^CY4/>1:3<_.4&1@3Z$1XIN3;;X41X>T5 KX09Q
M7V&OF)K<Q5M9[TUG2%&08-81JZ;YM!N_N"\V?)&*>'VS7:Y$^G:Q2[ZH&$C%
MSM%8QIPTFB?\HCAXW?U3:)]M3S0"-Z9Y!E,6)2MM\)TS([XL%J_$_(=GP+K2
M+M:%V_@*#H 1H09_!D0)S!"NC/N731VRC<$N(Z.+TEGD)MT90HX&15?Z:&1_
MRM"@;5-K:R+TAYX!*(Z=14H9%."A3DP,CXZZUU_;09GH$H_3)]);R*<?4H&Q
M"O>J94< A]3[QI4]RG^D:!=RGPCV]3]DC]909!/YR9(9B57BCNIQS70+M2H[
M$0.'3SZ9;)0R#(-H1J2LZ 7B^%!1B0VN$O):@D+H6GM:N_P_M;7'^+2ECF=:
MN8ZPK%""K H'6?L/L7#]?NWJ(FRCM^L_B3T#(B3>E@9H>PG>YZV=$W8O^Z13
MIE.&$?7%?UJKBNKC$/IHV@_:S<?XJ[9>]((J.-+Q-GWU[S084\)<2=Z$:"!Q
MCG[NI:/+#UAH,R/P%&<'L98_S4=M3-[>WIX7;V!&FVC[(^&F]2+)BJXFX$I0
M "YI">]7G@%R9D3+)O<1]BV4:;,E\UKBK9-5([SB_6'?> V%^>"^,T9ICVX2
MFR1.!$M:G=$ST4SS%^!#6$ER'#MAV;PU ]XPN7DI58.WQ.-0BF3YH!3K7)?Z
MR]%;X[J@49;E@[:L%15?<W!!N/V>KLU6*)\H-:O@)MG1$\6"9S;V^ZNS):.:
M3;LF.<JV;!8J&UG,N\@-AEI P&'IVHEPSXLF8*V9_H):RU:WVLDY5POY'J[
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M$X_D3?M:NYD ":T,-%6G4+D#^@,:LAM<J<O3!L[6E\Y;-WY>(RL8S63C^GZ
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M@H\=K1M$Y!^7'W#V#JKJOU,5VIFC9C%(O@:"277G;E@\V]H-TAKHE?<[3H;
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MIZRKJ"PD?%W<51X"!@[HW0,H6!"@12!<*HHU1RN?6->7) 1G9_0H;&,$[NF
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M.*(,)EX5L[KN%V5"@";]"*3*;:V4-.Q@Y O(8.]*HKR:.A-T-+6*6F=E&CW
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M'<[P$"3N 80'%)GPO591?Y?T-?G)XIIF)FD$$VNH]/'#D$(5/$]/!5MV:'"
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MX8#$V%(C4(!JT^QG+<;&E@3+!(IZ5#*4JO_]-&)A7Z;IS[ _:SBW$65RDP-
M^%XNP^R0K 642+'DI/,CF2$SX\W:"\^XD8?%Q31\JH_:)Q(UMO#'DX0+%DPF
M$(HQ,"'(%^H6T:$?U\.X=\?3T9'B>KAQ(]%72&8SZ5>K.G@/^%(0*25L [T)
M4,T.A7-UKK2C\A^[_#0?"9625/YQ,85Z$/P8/I)2MHS(GU3U1'6842F"X-+_
MT/4#EGFM?_%IJ 9%;)H/F;ZXZ_?ZL)V'L_1B.1685D&^+\-X^]'EN.8\"G8/
MB#WI$J_<^Z;%Q_,H,T6I'U/*J[858C<0) BQS?.DZY[=ITY8QNR88P,H"Q+L
MD*&L58V1-0U[H])$[ZC^I\;(ZJV0Y='!>D3OH!GE-)OF04#E9Q7"*HR>\C_I
M5<L U1CH%H1:7PNU7FG+>G46>1/%H[:'[GK*,CP=W>1H+HC01#*?82\8*3-F
M"YYQX\AH#,8=A=CT1AOQQ?;:N:@.&KU3X\W%3B=+^$;2U[ O/>Q_E'0X#PD"
M0C-V$HLS[@%-QR[:/P=D?Q8]IXENG_ RQY<AV0O!$\)=95/O3(6N[?WR<7B+
MQ:TL-KH0*F5^*0.;3'+9**"U5R,9+6+9R1R;"B5UF%2S08PM!=HO"DU%W0,(
MO99!7>(E)MPY49\*V66[!#B H+,YZDL7B@V9;,@)%B)7MF'>]4FTF:W#,8!F
M\UO*Z9WW3C[&;7P!9'\0(QK.9MK2J!RXQS//-%1Q6WN.<F[[OKP\J=300&'[
M94OD$WUI)4V,$)5.W4.7A+*/SX02N!3"7B7,UTOD-/S+6GF0<7&TMZ7IL<^=
M%(RW[/-NJ]%DA.OI;1F/E0\3H]5Q_.+/E]:O>? \0IECK4>OTJD!B*<C/*(C
M#&1>>:H0S$@W+S\>EU+110H'9DN=$8J="UI]X&:WCA[<-1(Z+NVJ>A/D92+6
M.KTQJQQ?N]9C3WMF7L(_2(OJK,5L=9L!T)'YBIT^M@#/QAJY+1%"@3'$G$MS
MS@X&DQ28SO*=X^NM#9"_-VQN#8A:H3BF[.L;M@9%#.3+P"M"SPF)#AK4KT4R
MO#E(%=U:].);4"E#I]2=SE7L26R6F#F>^NAIRGO.@KY10K/&Z_/MK225E+Y(
MBQ42OA?2P'$(YE_PSM,?A#E2?VRYC"]P;6\)L$K-$\GO2=]%TM4&10_>-+4/
MUD7_2KB3&W25\JIK^MRE2K%T9;RG(T\:0I@6EX[(8@P9:@FYN9!EX!G?N!GK
MM<G^/)+T?M/_9"LFQ.]*45K0S(DO? ?AO7DUAS1TKS1P $?EHKTU,5IJ_LI-
MFL$8M-96UWD/@+"@8]U-%-#GZY,M"2-J=4@=TI0PY>T]T &@JT,_B*0;(4A'
MIZOI2_[DVJ7IOAU>#2OVCL.>^0O&OH.<;9>N-ZDG!H>_@CZZ) BV'NA4Q'V(
MN >0W*3< YPG %Y"T7']#X-+Z3U@*G+J]D:H )9>\!O6?@_HM0T5NP> )29W
M-!&*U8-VN";J*I9"5&S;=6G>4]B@NGZ'#>,$S%<?1J%8/>-53SGHS:[ JL'D
M5]AP<>\=]3:F'R,.)4.?EB9S911?#<LR<".X!CON 0,,,?DL!7+3^;\/FWRP
MWI$;?A"5#7)"'0EF^X)8A!;@FB!4!WT[[)(VVAA<.S*IB)_T[6Q;1$PZ'6)U
MO4EX:T7M,I9.H)'JGE0C+?6<C& RQ^0KD[=--%4A_H2,^-.&%N7$O0460\+J
M-W87U<)3?''&W9$C(0?9%2$#VB$[ SMWMSF ]>('< @5#23"Y!ZPWJB(9&&[
M"^0-.5DJ) B/VWDP-@?P#.)Y#PB>8/B+*41;\7_6Q2+]8,NZ<-$A\YC6:0/E
M'2.'->_X3HT)UKO0:VC/ [IWA1>/*<3O ;6V.8'*T?> 9*_?3&E;W@_S\X&9
MAX5\#R?"Q0YZY*3RP:E5IZ8B^76F?,) %%+>S6@OAZ\?2(]8OB,%XJWL*YJ'
MX4>N/),:?,KMTH?IQMHSW ;W6![!W6ME\9RVG) Q)Y:7X,LMFV 51RF:9$<=
MOP=8\^'NW]$@W(1R/GH8/P]ROWPO::C,BA4#\=ONGJV$MD.@/F@H%NZ-L^-2
M.KW_0 APFUD$W@.PE>\!!;@%-Y?V?V4"R@^M!PO]W3PE=R1I]P 9"N#5X0^,
M&UJ<W\N7PS].NN0@W00+WZ:/D>-C"_+R;#BF'AH0L[E S0=S;SZ8.Z%+HQ.P
MU]BZ\-0>==.OAPY1B#1=" 1PVSS\)_[D?649@@EXY<"=U(Q#/E6T&D*YUAB1
M-"A*0>U_\(4\GQ%J;+U\UZ#K)U;W)2DVE&4R#XB:MN6I"4;TT.S:8)>;..,W
MSQ<=R#(PW4T5X#MWR<$'9H=EZ!.OU4A?10H&59:,G-(2O>8Z&ZT)ZNKZN".3
M,3D,%=M0:W#P'&6XTJ-]W0M+KQ>[0?\;6 /,X;]!+?T/F@'SN?R#&?_!DJ1_
MT$J6#IU\ZH'N_TH[X%^,[@YLVB[PK4(RS=4<%CIE@PW&$C"4J;9[].<"<:'K
MF ?TCV:]Z"2L2A&92TSSW\+1Y)?Q"P9Z5MW(K-_L7:'Y4TX((;(R4-4*#K;H
MV5'[[@&V]P"T51#?)MM[Y[N!A6LO$4NL,LX78R\CKO62(KUR;S3 N<,YZ2VI
M/-$_BSE$9IO'=)*YP#;P%\LCIR&V*Q8*RL2T.4I2>HV<8T('>15WV;0_,(=D
M!!"'!:3!G*;#FZM<!DTPVQ0Q8Q>1M6_ZQN6'W[])$IN[(U -ZA>[F,K-'7RF
M["I4B9[)[FH67Q/Y:\M]?NXI432S\ACH5P1MW8Q7$*G$Z0ZEQ0$$_?6'WK\(
M=HJJYO=Q,C?N:)PXPZ3ZN@SOWO@"TD#WSZ!.?=BK2Q\S2EAIJ1K^$,JO;EW3
M'2N?#6+E7<P?=ZP9&%7V610U=F[]S"*H#"HE-A@)MT4<:OX.U!KI"C-7EW6H
MB,X;58<<\_XD?,1=D(SA<9T6.?=TWY(XU4Y#W4<DQ8WO?DY2W)/H82-GN9=M
M:0X!+PU*0WU8(OV%W@H[S5XF&U%.-C'.V.V)(ID:0J96IVZO%)%,#W%S:OY!
M-3D9-"=J*;.[5+8]F[<R?)-[LS_(&/RH\[.[";Y8I^#KDT_\#\&$-NDNN#;D
MI*,/3A UO=^AHEC=W>4FPARG+)YL57RSZ&XR%6OA)QS$6);23N\K$(Z9,6HD
MQ_O &TFJ>T!6=<'-<1)"D>G!._]06RC*> !6(0/B#,C;/TCF]0_5NU'^KSG>
M9@<#'![3]3T=:M%20*-=^T*\$(2B%?#TXH&!03/_[G/_?HW_J9Q%V-RK4IK.
ME).>EMU" D\-6-S2R+?%*X],R[ZL7<[%?]C2F*P))>$>@/4KY.S/%D[_15^8
M(/L_DC<)?)>J.M]V$_13$XO_9&.^"-(VBNS^$T9#G!%@Y"$&> !_7S\X=L_N
M7_0#V[C_J_)VGL!21WV9:X*\=-MPS..:'U#.!=X#RE;^UA_Z7QJ-V5NX.I/T
MQ87%ROZ=\TQ%GS.3U+.3DW]N)#;[-S8O+I=-KD4T RR6$/;[$BZE(]=[M,B)
MZ(,)QP=FBE/\K;/YHLL-A505&-@Y?A3XSV(R/<WH&_M+X_8(H_].7&!<Y@?:
MBY-H;1KQ7\;OVZDTZU\&&R>&5X("E*@3/S2^<CM<N8BS'<39O=![/7.".V;Y
M'#>-<;^$SHFI;Z8?& UU<FKICB^XJ/M8,!G*DX0_ K@'J/R_C/'&JZP40_0?
MI/J+KQH+Z:!2(EQ%T((^_;*[[:BQ@Y W*^CU="0W3*J>U\;]_]NC^YBP5.F!
M\<N;9E2$U"2^%YDF!C]LQ6\*_$?< /X]@BP5A_+W_OW;?]=]ZSL*Y2+0\-;,
M8\H5AA3C=$T,/!F*1+%YM:U9EV.SLO^+B3\B0_N>=O5/)AJ=#'!Y8B7PU18S
M1B3?.A4_( R!T,03(F[:SV\N+$<55"E6&B>>G*=\X5*) SR?R?S++F!QW$:/
M8*"R1F0^3L="8*_,;@$KF.%D3/$;4 5P0A.JYI%/N^AUXQ00F7/,GCOA7%+@
M#UO'#G1$1$!ZR1&NA/3#SF"-V&_O!=&>X.$-^BQ(P[A&[H!W"_5('GCD703D
MEN?X@FBY-%^;"B"5B.\%@9T-3:5B>.:\<YWJ/A3F4I-7-3)1E$CL)'#7"\/H
M>7*;"W08Z^$R[>YJD,F"XGJFYC;05L]!%)N#BDK7:BLLW'QZ3Z<]Y"GCI6"G
M6Q\@PL)>YN76D$XXN."51?]1?ZWVI._ ]"?S?1OG8Y?WSUAV4)UN:KP<E6D7
M^2'*3$&J.DO^KF,6[00AOK\7-3E"__776U%4YK )]G\2'(CBX?W7TZK_Y A@
M7Q$*F#\?5#$MBR6X]O^TY]\%I=1.>K0,-6Q$)GU?!2 Q,_WO'RG4G7,!GVAT
MAH$<+*T9M+'JXJ50-EWX(&R1P3P@X!"^=&W]B9!/PV_N=0<>7)2FL"EFG)LW
M\8O2-8% V$Z,MVJ0G/8,S_')&_%$._-L-3S"F)XG2"(X12+0AA!G;R'Y,_4G
M 7-<<0,.BU;*G:*Z+"F4&W'0Z$B^> OL=B3O-L?"VZF*]2V:(Z%6?C?7Q>"P
M/WY^<XW#Y14QAA)L.FQD,+^X:VK8C+!I)EA@M]%L\DKOZN8-?T<D&DJR6)TG
MYH<I0N7I))W$<GK!U)1%),N/R%)53E>1A1^EQ$J#--\2:D;G],LHS]9*6INC
ML#:5B!1)XCGKGNNDQ,'M1,5%)BM+,R,"ZSQ-ZMZ3H-3L!CM_*<T/.1[@8/SH
M.^Q=4N:9S^RWJ#>#IL\O6^Z6+_H&-]Z+OIE+.P%.?)!CSK4RF_PK8+;*! M9
MYZF8<>RHPA'&D'%L?]H]H2P/4-P*R)&J\]364OI[-GL;\6^S[22NE;ETK;=,
M#\7H]=LKSE1?_:/ (R#7RO3#@ZEQ@*1O5T)^9MNEQ:%_*UG%7O@_5-"Q=GI1
M:/^OIQ+_)LGG9:72[*B3/7Q(\R\(U=)E-6[\2D??6JO&!KFHC&BM_/D)$.KF
MG#EQ;TN3M*JZ&P$BZMNS$P<F5QJ5XS$Q*FC;"9C4)6ET/?)J<?+IK-Y>?Z9.
MS-SAL09Y+/19S]/;2N_7,^6JR1W.L<S)SVRT+7X_?_HI1SLC6V"&C6K3;1G8
M?X<W/YE^)>AXUJ=BHD;_"\OS)T'S<0&&C,A/T*)R8^_,R3V@J>E]%G'@>'/-
MREG3E=A%W3<@ TA?'U;PWAM734.M/4J.B]R-.QEYR583E'&##Q(T^8'D\?0.
MPLML<!1%,Y9C?_*;5H;0\=H?04TTR)GBWSA1IN?J$\!0&!H%?C[I1\ZBTZ#,
MU!K)O#4CK',L6_VR10+GMY/!!<YUK(6%]]:7S^&LX.]BF'0'? -J;Z^9;?>5
MMK.DFAC1@1GVCGT]&2"I(A$+BRW20?C,0QS%,)&W*GI.L]Q?UBGR>,F\;E8J
MQX=\LMGO46;7 71J>*R'?.^2U,0H>ZLK>9CD+#XLWT&*#1X^I?NCMZDYJF7&
M"N@9^ '_]WR N'  ^I1"<3N/!M0N^KR&^,+!VUC'::LIMD53-6Q/#68^)*E!
MC7!VRKQY4[]O9M6*NI#VWA1PL%LG!7=["/%X"/.!G*@V84H^RZ8Q_D%&6S:Q
M74[Q8!$'"?-0YT#=:E0'&Q]9>3H_1H)>H\#40PK%DFF3O-:A>P#^*OO29Z-8
MD1-K!X775E)S@]#'$;<?W4:JG)WG(*4DB83=M _%)1RYIMQZQ!!Z@^:-,\9:
ML=N=FGN<S]A1]M*,&& M@9PS'T8Z;;IHB7?J$+.7G@_5V\A[IH+.Y,*/>!AT
MFRD(!*JV$^6?BPY-X3\7@N59_IAZE E"SD_1-1RHIIJ&[^Y7UBH^+,)(A'IC
M,EOUJ;FC7K>D#]P@?D<;'9 UH#+E).1]&-523MM[N/[8Q$S;4] H TC$N6J4
M4<FD _8YVF72K:\U42O+?UUK_?<641%<"WW\%^]!J\.[K6M2K=&'Y'5/-+EP
M[BU6^0H4?OU9N!-W)1&U/4DSQAP%&JH?*S.EM":696  S8Y<ZP]K$".?SG;)
MG*ZM&HR3+;(S,;Z0ZO((\#07"UX$/@K4DV$V1R0.3!U=6W^K[F!%JZ+S0 _.
M0OA"*B*13_S<_4IV6Q8H='Y]Y7ZSU2MH\@E$C^^D-&^B<AF_=>6LN5RO4>-/
M2?NZWML/:J5'"V^ 71TZP22-9X1]X)DU*$T)87%K1!Y3;6\^>A^8EP33? F@
MHP=3$3"#L>DS^I"$L*UW9C1Q=E;>WK@"L;1OZMB:_0M-4-;B73F@GSSKRPB4
M?JI%W\P-TF.N31GE?%!_G51'OD-#>Q(M/VMN_CXJ-OG9TM8FTT'<[@M:PIRN
MR\V1#L+!J2.:57/7+-RQ3\R>24+Y&(*O>YB0;[[,=*&[5]M3+"QFO0Q,^5Q8
MOW%)_NE=[C3*/@V!9XY(P.(4D#!8<+\>%*P6,"1@.F[_=,T*U#!5?+VH['"C
M#@H.$G'XU=H1M:?OY3-!3+#9@FG4JN  'F@_-);>73HQ4X4Y08].AFCJB,9#
M')U=/OM\*0FGY,7^15T1<J-N[W.V7NK3JN9&\BSN<"BP-9F PE==3;$QX\@B
M?Z+^>KIQK4L58C><%S(4C +GBQ.6-,$59WY\.0@4"$O1[0+>:"^9+BWQEI29
M](=X<C$FLL?J NR8YP,XS,8(?99.%*;\X2>$=[-K-'"",E\[-,_J%]CZU@/M
MJ,GXGN#6(R=+KY$TI5F6CJZX8TD'RQ0L /\^9R9]]<W3#IGP/Y^&W4R!Z^3J
M,RRR-+H=@C>=WR4SWQT[&I^ 6P<NJ4V[QX<]7%G21R\MJ-;XU\F"S.I.(Z>/
M OY$+?HY>(Z>;I:M]65+1UO"'!6S4BSQ3GD0Y\Z@1B(AG'2DHS:-X*-EP\."
M1M_C^>\>D[EO"4K57PWX/!=$ AY0Q_Q,25/'% ZWHFE<2\@_O^8(G<@_=[YZ
MF)#@_=FP(#+ _Y$;/]JD'>;^^3[&GR)*.UM92.!DH.!&^C/Y)P#OYLP$.%HY
M,[DS ,X7R74:X=ZL7S9=JRY *#MW/P/F>3P,&!AYE^M1X'?[@BPMS#I[8S4<
M@?;9SCY@\I-E9TOQWRT8P)@:%8@4;C7WM6N>F+BRA2Y0LU#?@\#?J[C)SYJ]
MLVA^'%$LDF4TW?*39>;SNM#W]E/0/J'C/E<J_#U6,QU_ABMS&PDIV=N>>=M^
M2+2[9L:XA,N=(>,.:F^-I6G@2]A$9J&SJW GNQMY^ =Z35K2'Y9=^I"II![N
M_5:C8L<<2G!:Q^@I2K,HK>]YG<",T!+I)F%LK7>V97.FZEC>T_:8=F>4*PW'
M-2&=U=2ERR]M&>3I43IC3&V?%HW*:MXECWJZTY*\6GZJ[TPA$]YC--=\PL!R
M<5=EX_Y$R3NRN:49<&3O_A%:?W2A081(@HI&,FCG;%V(>6<*&G,\88K&1$M,
M#\#G<_=DL,%@*QR[^'Q00.J0:11O%#1\^&S]%7;B:NZ.LS\.["2QAPN.D;1I
M*C/-FCG^POO;U&.%G>59IK7VWL@<S)BNY_!<)3AFK%6Z>N998,T5)@,?0X9*
MQ?%JP\IUI!N3WRO5ITV#:912<1FF,<Q%E'6I=ZP34'-"I.$BK]!R=6GFL:BQ
M]\K(,\)7.$6;:@%0NZBNYY!;WIDCL/BA99N@&#>UYSS^:W;/W0]FHS_-+)8Z
M'<J-5T=]<B$IK*\V/6CC$/<  T3T9N<4O<-"LM_E_C19A[I/6OVIM/CG>P#.
M*FA@467VW$7@;HMFO#WG:-N6NQ:;7?#$2(I+!3FP+3-K]R88\C32APW]K?_B
MJ)'O>QDV!^J@FF]2K;X4$H%)S,[8/Y?Z*A"*P[TD%W7XLE]6G]W(+T4I@N44
MW _V="[LD/W?@X+<@\A+%%B]D_P&CJ75U EDA>&N16SQKA<,A+5U =Z7DC0[
M/$+.@TP5,L4]$XV2GS<8=_CK@)$68J>/U>09H9F-L@^S]&?_+>].R3TL)]S7
M260H[-?)FDC+#K12/ZG*NS.0O QZ?2D\B6#;" Z#%<C/J>><K9JO ECF7'\*
M'6*B;E^2[\L)%]36WG*^#4B<ZUC1VPV\!\ U()S[9GBMO0$N0,U4#KWGGJ"R
M,E2V^,6J0&&82TUB9+DCR;,<3]=.LI#J^)!&O>8#]%Q(Y.%SY64')G9I#Y0R
MA'S0Y3K @?%CEQ:WR\6C5F_6O=.5_->)PV2)H IJ]8_:EY^);=2T,H3&OWS_
M5LSZ5:-+[,@<B.C=6.N$DVK_\ XB'+J.3,BHKLR@=P;2*0T'H5;1=7A/KU2^
M5#M[-D;K^[D.4U*Y6,'(OGSGI*]3_[2&B8WNW?P4,2(7QC4$SLPH8VFI$^EF
M*1M4&=3TV$'SJ1 =P'<:UNO@Z2FS<,(O2QUC#DL/_94H=KTXC5/J)41NZ5DP
MT'1YUAQIM<5U#UC:&;JV_-T",W34NU/MITOHXZ$-Z'A&/[]'3XO0^FR()"D8
M.)VBZZE@MG-+5Y)U3^A5N=2LE=Q.&W=MWTZO5MN79& ;O!%'1)O,NJ:>:,P>
M/I)M.7##24X3R#>-]@ARFKMC1W*UP44'<GEPODW.G_ \EDY1ZNT<&P$AN1;C
M6OQGN)VQQ0]T.<_2],F3LD8/(=6.]'1PTJ_X9>4- <S:LM/A(I]X<>Z$8RD.
MKS9IW% U;%R3J8Z9O[><[MAOHH69F[DX7TR@&TN#/AED%WDP/%V^F\AG^3);
MTSOM7,N;C2;_2_N5'+C)]C:S+MY3PM@@UE3?H7_R^-?B/(O!.6MX/"9F3L7[
MRM%O@3&]C8IQ1UT*:28K9=\]XF/G4J??O!4$=XB'V$X\/U\<\JG0"BA+J8V1
MS)8,=]H+JCO(,:TM <Q<SPU_\W/K2WIDC@3.7*C2'*@&A CL;2DS:HM&')A]
M$B>GX:+US$G&P]E.\_"U,1J8EB=G^J][0'D6X$P69Q7?TXPBW<3AJBH)ZHX\
M*!;@U9"NQAQXHM8]1ODUI3&IAK?0PQQ]Z[1TT9D0V3GY3*9=>.]BBQX+N'0/
M($>JVLKHIF2$7O/XM_C5,'\>BJQLR<"$5W%D,],FC33N"XY+J<)&7R":70+*
M#P0FO&D%2BHM";[3PK7W@8WW@"A7I"!KAHTK]VH6@WT\8&G49-$04K^C-:>J
MBA?QMB]6).7BHC8%8SIN$:SFW <WI;D,;&N94<\*J5DQ_?GIZ*7=).=(XXVH
M@T33D>?E$J3+0(_=1B[\PXG9:!S6!-!%^R9N-"]0&/$<,]3EXG7F79"*J?*+
M"99!ZPV\$":3II#&QQ^%.5(N5$>G#;)4238M@988DOJMQ#G\PQI-.;YMDX*#
MYO@\4N(0U5L<\5\!3BV6IDG?!23UN2"]2\>C\G/#\\/(*PO#N,\)'U'!W5ZV
MR1$OJL0.^V!Y;)=Z,U[M=<AN!8AE=C:4<]#+.E4=*)&D>ILA="NJWA[KK9K9
MEF/S8:)S>T7"T^RB)1U/KYK<V"EN#+YLOC2KK@I:<-HK2S=YGVGIV=ZP]J5Y
M:DE589Z.EZD[7W+XP]=>Z>='9D>MM'%F#D&.7V[D&GXEW4CNX3MXNC:.4T]6
MTC@<-U=L\$7XW*' T<"1>>='9)_D9"=.T^)MNYD*',6K,OPSR$O[9-LH:7&T
M1LD\92F%8W#ER73^V;[)?T50LQ<>RT$#Z*)Q &-(1PV&O4%]F&N-K4+@3Z71
MS8(]U:I[P-BXW=WNG7<S*-S84"M*-SWBMZZB0FSF:#R2=4[M),Q%I""'JO1%
M<$+<I;$X6DL#_S%7?P]!>W.2V8QQA)WX6^":I=.*E^*9$.(,W%%]F$TDQ)4%
M?QF?,QG_^-PHLP!#D/Y$-#'[R%3>4X;5T%AO!N_M<T[N)9^,RR_QWEHKBW2'
MCF[O1E=E"R]&J2H97C6E:HBHLM.;=8*%V<Z&35[@Q'M5:'>'5EV*-=X5<].[
MUWM?E >%@\5?OK?#RKWSQQHYF:R=+K"2<W,*TW9B=[5Z%  J[Q\[(Q(!2B2_
M>!]ED&*"9\V.]OKWI9"G0J&N$Z5UT*GQT,GMMJS&SLO,M]_'K%OC%.1.,V55
M;CD7A5 .--YP*%LX6Y/<II+< ]9.1T(D=&>/2EA*FB*Q]U\0.&[SRW/U;.@]
M3KELC7%/:I/PUY&/)^;]>50LS^9##J"ZJ#84:K\L\UW1DU?X$JX5U1P9^BL\
MO*827.@U3%GV:<[BWY[&_Z^*X?6FRRR;V"2ZO2Z^<]+A4N.>+%6][56_:]E;
MLZ5%MPVG9 2^E_GSN9H/R(6KVE!_ +IOAY"EVN,E0H7X"#,;F(=Y Z)SV"A$
MWO@K)>%(K<1PZI29:].^Z_,#U9P),MVY?A>)O1<GW]4>: N?^1)(F9A#PIT)
M_1EQ5V/N>V#44;M^V#FQW/*;+Z^$C5(:W1)!-GH/P$(&RV;9OI7: J]GZ,M*
MR%.2[=N+H0JU5\GRD&63V7[ E6>U_^,%N-RP$_F'C^P2(4"3MFU\',"(0Y30
M2%#V(1_TQ[T_=@*UK;52_K@A3U6(7IPF7O:P;'TUG0,P8B_]HX9TVX?E[)_?
M.005[%'L2\?^5M>/1]/*.8+_\N"CAS+J34U_?Y<S=+M=(Y9>J@GA G'J=CP5
MS;/$M-:J8EFF)> *0X3!G49E'L.9%R04(S;G/^L<KPC6LYU6^[L-]0=LX"L.
M,1![!03A3 Z_CRFUE'MCE["ZBYH)JSA2]0N JK&IP8%1#+(M"TK408.JO=]7
M! 3X1\D/\_&;C.UY*>WXGHBSM3AMKZ.J%S1E#4E+#OLG7"1$1S;Y>9;N[0G\
M3JW?$%GKBC!70$@>V;AV#: ]&8NWJQ>2#H4N]?3#)_C[VF-CKP86:]*BZF@1
M2;VO$-60Y;8QG:<2:8@PLQY<NM*-''#QM("6,'_2-Z6=.K+ T9GL,X#B0OV^
MUA3"DH%/:TYC*7@JD\KEIC68KKK4K&N1"^(<XK ?;-*HI(H_\!J,.;O0 ;HZ
M^ZC[C'F2?:P<.6?1[0 XC!/@:',S>K;6]$]4&4=T]R4R:YU@J[5XT1I4NA0%
M>5'\ P6:A=#_F+I=LGU1J/^/NV&)8R5/<Z,N2O /9 G^4,_\IZ,N"A^Z)T5M
M\+^F:L\^M+M7M!D@D29>#FE<^"B8^,"7O[U1]7<I;T6MY2(=DA&<EF)EI)ZL
MPOBXB$?R1- J@!Y AM*>8S0^*[P*-$Y8UNB.VU7P:8C?P6@:??[ ,L54P;1X
M_410]64Y+#I*ZGE &:'$[6<&FT-8T+A5?-YZM!#*KD1_,BA_U%5DPPYHM%MV
M#]!;5]D\7R<R +5L*BP(54=VSM86&5IF2Q#YZUL]Z2M\!7-!#_D2+ "*&@IL
M,/GLW(.@$CX,I@U<[@CQ6DQ"? WYTB.XJV^UE0A3J@U^/^P_&K7N/%,D[5=[
M#>X7I*P#[3JEP8U&O%>)N@3'] *K7PI4C^I=UM:V)Y&I5-78?W-=6,UWQIH,
M\1M5@2CLJ$0\*E#J0@%G)O^[J]C_9L'B$C5%/\]-+L7@ZI=IKC"\W@8VLLK,
M8=/>1=O4) BJ#0\9ZV.\2DL5!'<-RD?KS<KP'?@D*Y.HO:V12 6!C7\OMNRR
MF"LV68PMWSI][=+M5$:L6XE!7'ET/>\!CVH<JCO)=JRF<Z:,!--VAK=^OV'_
M>K.Z+W8H#*=KN8EIY7 3Q7NKZ*POCQ=ND-&@8UF_U6BU;4?WR0 4<<.FL^R'
MYD%DQ(%+1"R[(URP<1#DX<+@/L=S'/;>/E.4V>WB6M^EBN-NHN-GN.+I!S1I
MFL2,+ AZJC0!O_ 7(^5[@%2))N:>^IAX-IZ(_T\G'98A>=W>@"AQ)KI/(K-(
M69=?N.Z$'\PY5>DQ0@8ZO &;<3[H*C&>@KD!/&\U)+GA?LZ]G>B)SX>Q;6HC
M7+*A?5H[@:-I1Z9/ --Q/@2V'D<V=1]P:H9D['*46!)%?,B9#)TB:T5,Y)LS
M7AI:)0=L=Z@5Q^/IXAR>:5""RF_Z.ERZ+VZ'Y)]I;2K\+O4(-BWI]O1W&Z')
M/:*K/6;*TLC@?4'61J-LHC<URH>ZCFA]U5#PREQF>T W^7G\[U#:\UI%O1]2
MQILA!&V=TZ2OO-OP4OS>B&M*I')%5>>XI5_LODB'4(CN^_CK)]K.'QX?)Y:X
MV#S&&;(+*A&V!WWYY:3G\SX([<=8NT/*:?MH#6BXH-^<;')AVJ1TW<8X];@0
MWDHV"+,:Z==C+\TA-Z2M)O%LK?^\J5UL5-(!,A%(V\II.((CHOR<XTN,ZT,X
M>OWW^+YA.#&8(]Y=XRB[LR!%B=0%7>$RLN<3?O%K6/"/:]@=LX?GXC6\V."U
M-S2E5^0II4A*> &2B<C(1)Y+)1[+T \LS<EB5NRS1<=-3U=KIT5_ 5DG&X?B
M&O!">EL-R% $.D\)/?7<ZH2E!34,C[VYE)@$2%A37Y#5@K9[O!:1#+6[.<<1
MQ88FX^3SAY^R-(N8'.DOCA@>=Z%4(DH&KGDSWEA;./*+Z7S=(-PQ)=M74=[U
MF!^<J=##5C/,_8%(J*UE35PWJ<]1! Q2CZ?-?IS[<> K,/;BX+':KY&7^\Q;
M1EU4/:B@_.^QW#W3Y'UH3)E[ND@>6/2HD:2CITH6B4F]#<VDGJ:BB9X9N-BG
M)=I\[NV$J9YB#UN,K4BLV,(A#G=O5]K$;Y_K(,>\D_>UQ39*S30!D1V23S+9
MOE71?ER,1#AM5"08O.N)@W+IMPMTO83'S34CQ#=QN882GP@LE=;V\>_B"YNY
MJ6O3$T0>'1$?75+_;N_@>MQL\RR!\,-[7@-:/9EN.(XTJ9S3GG<U1^;*W;DB
MK_(E^:\Z6,B0D7#XZHA=RUMFIVBVRB,3BG>!DI6@L]>Y&BV->="89\G 5<\#
MP[FAUXEQK'-?D%++Z9^XF/9.<!$M!\-&I/MZ.0E-[BOX/[ 9T%!GA>X!^*#:
MJZ'KYOGNLN_61HR&'BN/:4FDJT=J>R@04PH!QG2LDYZV<'2/:%SB.F6$\D:W
M\<#73_@J0%8'R,]$1;V+FB)M%\=$ZO/* 5ZM5/]=>R<&8F"]-QU0+5>O.?/4
M]\U7VFQ&G.4DHXXVXUXN@R^6\5A#O>[NDTX[[^\!$?1\O0N7M^$6G,I,N%>_
MWNQ0GFB#[#8*$FIXO%$D5UGZV-#:AP;IT!47.#F,TP^N\QE2@/:U06@]3VP5
M\[S'45U);>%\-'L_#AJS72RHA]]_&_4LS-JV&76$OS>/DF%9.#_B73#EW5$/
MQYZ;_"PK@#('-TR"Z8^(F$G=O+2%'"YN1^E:-2N^<5SU6U;Z,(HMWRD1<^5V
MU)G=A;!<<'XUYIDDFD%UHIW@;X@V.UR]))Q31?\FZ[A%;"+PR@96,"J(2#S>
MWU^#4EJC:V2Z=T;$E=C!C*'8L*.+N.R-B F\E ;)E2 G%K.:.U*W2HNKR\IK
M)S47<YW6IAS<&^,/H#,S-F:&,B-CNI"O&?)#QM_?%:V S ;:@6$R1'-("HA/
MM*[#RQD1"%E-:@0=U]R3)V&.)]%=M5,%-?9J([R[.^ I8X&)+Z 6,LULMJ@3
M-6-\3^]VP<'0BHG?26PM7&5@:?&ROO,:;JOOD]8&3OE:](%F%NE$OK3.QQQ3
M-K6-)B[YC#B64FE7U:5]9)89$=D?P08'%D?O'V*;YW;":+[8\,L':A!A/7.U
M//,-)]A,:-\YKZVP/R]YE/=0=M;@H,>[WSBFJP7S&TT21@:W=S\W\\I+74UL
MC,UQ?>6X9_^+M[< JFO9UD87GJ AN =W"+)P#<&#NT-P=_<0W(*[NRPDN!/<
M9>'NK@M=:%[VOF^?>]ZI5_7J_^]?KZIGU9P]6F=WCS&^.4;W%*2K<>9(>9V$
M("7A/WWA[_M>N^IW8>62K'W'PJ7PAKEI!"&6M&'&$)DK@@G/G*>1;RI>8%5\
M+VS(/G6WR:JN\%>Y1,G93XD#=R)T#U ^##8 20;!$=M0>0<Q.>+KOZ#\KA_U
M,W#ZE='#20Y#5R*^?\69XKZJ-0&.$V9;'^,ET8=\TU=_Y$DN&X*6C:IX3H3(
MYU8M<^G3:<(M9@VH$J'M DXU^1<YDQ)V-38VM+Z?*&L4R[S;3PZLX,F)@1!Y
M9R$IP9%^^87BJZE1;GD5&8EOHM+&P%L-A%XS=PP&Y9NFR0X*V,= )YSU-+XU
MC.I4HVLV-ZMT?A2]!>TF%*?A6IZZPM%\ R =6D5:-393Z59A;W64;2PGMS >
ME-FV4"ZWG%=9FB\.7XZV&5CIG.<WPX3@T@PK@%P<7Y9WG[E+5T!GU^S]-E1&
MM0%P8[>@VSEF$?N;8"(=RSN@?$\=)SV'JG\#\T_1+*<N-M*@^<!R'39=71J=
M\Z?9-8RDE#H)J]"[CEQEN1Y#8JQ#RXUEMU\1:;/LT?V^"'BB9KK[480%+R";
M)ZY5^HU[WR,BU0;D,3M%ADRV&\[S'Y7K0UW-,4L%5'?EDBH!O :"HG!47LBB
MY3JFPF"L P)]KPB6MMADO<ANPH^^5K%W166COD5<04W"9U[*)/(K^V062O6F
M':$@/+U^\\6NH!-)H#B0R$GDZ=,?>.=,<B3<8"MC]R1C.\&1?:.'1N_&>BU)
MV:#,EU6S*C35EG"!>H.-)K_XL[196><'QWQRH/EB6\*1A'2YI%H# [YN\=MN
MW@O1.>9O78\R=@H=DS+NHG\2!)U(H"GIR:/2/7W"-6KVCM46+5LQ)*LO?KN,
MT57$8H+K&_E Y5(XP1 W9ROR=8$!UG?G2 :(SXUPO>!( #>K-!:4K+/8RFZQ
MJX99KO.NY(Q.C)BU):]!UJ@]XSMRCL>CD@MNRM<[.;ZZWX#ZLR;;IT_G Z?>
M7N!H[=D \1ZCUXL./-&1T<4"H-B3]@JZ^(B1A[WQD120WV9SE>;4CG)E/C*W
MCI/CK_$HRAM\_/2\RBIHH:>^8,W6_(45_M%+R86?_=5B7(DOZ6<MHBL\:D[1
MA]DS'2,\^M ]W\-6G#1_3K/2+.59>OMZFBD'!4.+UYE&=4,[+,9ATD0]A#3O
M/]1HY;F[[2WTK:1!1^D7D'54Y/>5K);[F_Q#IM$7RS\#!"HS4W$(R%WMG5($
MRGY5]<U[:]\J:-&*PGY+\X?:D:?W&V IE]8M= ,JU\ZS6?VP=-]1^C>5#5R&
MIKSXLSJ[L&85J0D$=/56;@L>84\(D 3QY]:Q!O7#EDGZPU]Q6K/71]XGNE58
MB!*KX!8<%O;_/\\8 <:P':5#^>^R6WZ"_6BMN/7YGHR:M-K'L5=2&$KY3%B[
M0+Z[?>@-5TC]6?;]G8C0&7_O4@NN;)I+VV6VSYT_),CM/N+%6,!.GC:5+D,C
MMX,'0%M)[:3$M@3&[=996]K7;IH!Z^M)-[1]&^%<?V09)W"VBIFF79WZL\,W
MA4,TQRZ8S@_KT';=%?\>>NNM%W;L->SD*BW=@V)'_9XIR0^]^<V_ 19F 0(&
MOS;JJW)V[-_I'$(.FY(GG0H]XQD!/(\:>) @@\N%H(':36&$HX]6K^P0$8OS
M!/(HAI/:0C/*Z-P#G)O>)?&]9BDP-X.(JVB< 6O.8I-*#:2Q:SN:;/"^U:VH
M4L8DJ0]YCV< T?*C(-Q63I!]YSNH<(\^_N!=\'B[$F@TI%N9+^Y,;P<:JR'%
M8O!$ER))CN7Q$.(U;Q]R0]2%4AQ;;&#%6J'7^[Y@?227,_469\E*(\ZR445/
M]IY"-YM>JP-9SDT ;F>]J%3+JE6HX(Z,A=$,:7P=B3F&<:I=<-M68G\;K'ES
MN6$A8H+R04C/9_Q)Q\>V]G(]O=&K<IRKS&,+=*IH(E'N/$S"SI!S>O\DNP@]
M48\8Z5^1GCN;<:BS.4U#6G^(];HG1:^L>=Y';\?:J[UC] C5T"RQ/RUFBC\5
M7Q=R?;TU@J9HS^OHSR234)M$?*"^)AAPQQR)>M0PSK=& 5FZW4?D$8HC)#R5
M@'\**%*\+D\M2Q&J8SU'Y6ZA\V5J1&//S7"WGDJ3A0$EK#^X#"AQ77!>D+4-
M*DP4V+^W)C.Q1(Q?MTA2E&QW*KS:"'9EX/@FDELE)YZJY\;;XOJB9MJB-B.M
M.95HNW,@E+CX+%K!OQPR@UR9>HT.N=*0JW&44N$E0< U<EW<4P@'^M=Q1-.W
M=S^Y79!PS!>G]!'FC[M$%L?7!AC[]AYLM^IUII(%?Y#WNLD?8VDC7O4CGR,X
M4ZL?4$L6!'-!KKB\-+BK?+XV7*Y>:A_+,)_O90Y03)S2FO,<Z4<X$6/- *_N
M:I@$N"$8?=';:Q0':LEG.J<2/$LIEO9)3GSJ0.*"<K[+J>\K*H(Q!A'A1!L2
M%&A4F(5Q ;T'J/XR*PI85J0V_)62B1#.J%?#!P=V1,;]V/>6CWV$ZRWNQ8N3
MR++F]KOY91^\_;!W287"9,MEW=VN?I3=V;/N(4M@ ">.QUT$-5)4$N[-4LIN
MU$*C+F[YZ<YM*\6"Z*(#?Z#EWE>H>"2H?&YG+/DV#6M,:OBR59TA#]KVYCW]
M,*M_UROYE<BWG7JI<!(0,X<4U6Z\@Q*+=UA6'+FX%3TK]87J+>5]WD)2(PVO
MO< #[_0-24X_G3WKV5D<3KK!#[2=%T,R]E><,KSP!BVFS90GCON8/C[/H#V"
M$P-FBVS<!;.VZ9%!P<)!Q>;4B>Y ,OC=@_D.UCL/B$*8CW/E<5-Z="^*H&"4
M*-O5D"?!Y)::?'WAZ70,)0*RDAW[XNV1CW1I;OMO@"A9JT.MF8C KYC.6=:P
M!N[,#S/=42L/G48_C/WO&0\PR$1W(C<PK9IPW1=^?&J-<H-(Q)F\R2C#"=HA
ML=\62BMA+JILLK=&VY^L?_/JQ'9T]+EBF*O24I99S1B/ *10E@>1*+_\-%G\
M/6Z7;L2$C(X$H^.+CVQ98JOP4BY^;8UGP<'M<\7>!@FT8/#'DJ5Z^8*U3VF\
M9ZWXCQ%) A#!N8"K)_-\/FO5CK5+&)60!D;<M>J3YQWP=>1>-4N\[$8N)^J\
MNDJ+O!Z#V.)+E"X::%$U?-M7;1[W=0+ 'VPS(J1T8L!+!OWB2K#?]&W[>( 7
M\< UDO>#.FW8L_5V++KEN'WYL3N76\U@F!GF,UC8)B+MJTERJ2R#*U7!VXH<
M62MA+/DTK[OW*]5W062KO_91A[7Q7CES9*G/SSXKVB"-L0A!2(3Y'A2^3#7\
M!F"N<T?@>J==?&B0"+$-3= AW @3D-PQXB15VTV&X(M*AE5)40)1L(0&DMA'
M'*;E+%MN,O7IYZCJ&Q*/%J]%S4>CZ,8U9IY]'<M VRO:3&"=R;UW5"2"UI'0
M?F?0T3H G")GF:>,:4>*O7K,#[FISB'TQ[?0-KV_(^C0X8]LSP@)"[6):09V
MR("+YU-:QD.Z>['0[4QB:U?Z^%+39C4QF"1(=(=X[66DGB7+N9=$9[JO49"$
M#!_8P)V.D=H0&SQ"$_T/'9TA,R,2X:#<:Y1&/BX^U>7V;-Z6AH5;?L83T*4X
MV=+9LH")"^U5T=G!8M?I;M'H1&P>1KBK"OP8YR:!GIJPQ\?N6R ]!+V85.T)
M0&[,5+V/RG93G<S\;+!3X0_0\RV[H/(,N]+[2OWC1:A!?Z>?5"BVMQ7U0O!$
M0-QGJ+T@Y:"#3.N*4TNV:2"V0J5O.5+6+&=ID\!QWTSTRC^:TB-!_8FQ]<C&
M%%V5!C(TJ?V0]:P 05*&O":TZ^J(# 4KTHY(MIP9Z%AN2]0'%@UFU+J_.([;
MRE>D[6]?1J+8VCL3W+ZHF;4H%;^O#:QMBLV)L/G#A=) 09;?D:+J&B%7F3=5
MJ=5>R >_ 7,Z2_<"3U6#+#[2Y:GNOP&F-?:<Q6L[YX_@QJZ*T$RTCS_*D4EV
M]H$S9[\!/ 5F')/",DP]KY+LG11S7VKH9]YHJ+.L#(Y(REA 2"MMIR>2UXU^
MT,OM!*XN?/DZX7ER)A([>W#Y7WQPG6+NJTY^JY$_L[1"IL\!..7)7PU+I&NI
MQ#C7W+9WC^=(CS;EYKF,P)^!Z2GFI'9T<%O0Z'0K\>BSS(289+M/@0"A-S14
M;7Q:CS..")#S\6& L?AM4.9KHLTS71W.@G&ZGK\Z2\!1(1SNMGL,$3A.0+P"
M/\^XZ,<XN3K1(-Q\JV\';Z')9-/67RR?LCYM/XHSLK:#P<NJ:ME5B?Q?7^AQ
MT/IGU2LZ+8V#^>SBOL7.!]#DY\7L\X88QU&1G7)9B5-E6\#,JE G&87OVK<6
MT+0GJ+^4/<,5&*PNZ>FM,\V?*HLT%@9(=@#<7UD@C=&;<O0-S$ZW-I6#1"N9
MKS@3%CEX HP0W/GSE4^S:+MA7>P/-EUC&O&O,X2XU9#>7J$_*NYWKG7F3^/G
MVM+&+2DC3!\_LD'5#+Z_LOFC>-S==^M37(X71X(\D:?TM&5,L !IO()\BDA@
M?1+Q6/'ZST]M_B!/C0%5:U9BJ!G4@= D4C@<>$R*W\)A<?<053S7[[EPAAPB
MR"W:!I?*FA1^UV\KN2/AM'@S3FC/-T4\'WZDNQ%T 7^G^(/'(JF+[S 2,C4[
MJY[ P(_CJMBUQ.T=:'IE0"[_%E^0D:@[GPPJ67!%&<\S*)X4R;UO;:[LU&HZ
MO6[<]\4],+[=M=(><<)D*BYZ5-_YM2'%4CB@M#&8A!" :'E+V )PE$SU;[52
MAI5A$/[X&^ RO4]VGLX$GZCJ9_1Z5# FO,;9+9!$*["?,DI0>(UQ+T?Z)SH7
M"1X%G#X5:B@MX/UW>H'>EQD19)7,W6OI70!;0L1?SW\5:P%;9W%G[\:2OL[5
M @>KG%OS;#7T'7'HV.N_<YWW7_WB'2[!09M/^U=<Z!GV?-3'7S0)?U7O&?I4
M'!T@;0OV2.<FB@MY(WB<G;'U(BS%9,ML')@1KR1"4_7P)TGLWXUOGK'40E^D
M!R%WK>_'_JL[\#P2@$'.D(^^_GP*_XH$&+!F[H)/\8O_E7L*8*2R^NK2J2A4
MG_U/YP$@?+MV<#X\L8K/O_KT[V\*$!\1^T\KDP+^[2'UO9+2?Y?\[^\3AIJ&
M[<LU1A$/FV IS.P?C9J<)Y?P>B/J-P#_9B-HG>1UJBU$=K1DFTA3M8[W$=U1
MWWO38'EYLB_^*+SL<.9(UI]]I2+1MH+\L# [)$ H.#^U"A\6?8_R0X0O %O9
M?#FC.:$?P!LB6L4O>KD64F#K?D#)G4:^%D*95Z+SK'XY=Q&U?YG5F9M@'2>Y
M+]AJ>$;"6]&)%EWP[<#9[N7$CQA<,V.Q[\?B(3_\C.--Y5@;!_BUZN5>GO.6
M4T]8\3(D(=%_;>#-PZ3N@OU.AD&CAX)*+,%+;\[40I8/YNQW4IP&^(-1(1T,
MF=-O^X73++:"DU)"[V9D9#IUMC]I=3K/)WIHR$L3*L:V%_>X9Z>"+%:E @.'
M!*9S$B-V&B(.[,NZH0H]7NQ6&MMT)6A8ER9Q80<SP!G_'LKB&L>]KHEMB8=)
M[8JM1K>NV<\I0EX5:!4!7 L2N3'URV+[9K)0%7DW-[9./2ZRS)M<#P5YQ/>4
M_JN9)1,>H AZ+>33?B',&6V:J+XGK2"RS%L<2JC^KWW/+[8=LWG\DV+:LTHF
M>&8,'K+R86*-W*0:JP^3.!,>5_.]/=E8LZ[P(9*8T7ONV=+ =;-2:R_!SI;B
M26.7;U(T>I5HGY.VK>5+F!*\R82A+M"LW(0^[J;I44MG(K*Z;S"*2"0G'+T;
M.&=G!XTIRAJ)DEBG86SPU_IIA3X(/V?L1CM+@/T_0S!7:GJ*O>Z+)9\$#ATF
ML3N-[:+>">D/M#_,@'PQG/ K&5M+8\B%6"Q:&])0[)F#*E^=&7EM>^>;;NS#
MTX7:G'GD^,2LOKZYUW>#,V[D5W]Z1I@RR1DSIZ5$<+LMO_L-J'L)3IBH,1@F
MR2P@,T?I%FHI&=8P\M9%K9_==!6.]K(] YUJZU6L'/-YV\J![>"Q@AY5A9"A
MU5^QE.2\N'%KI4#$@4. '9[GDZ8983-?+/DG,<YQ1GFG,7%CZ/4F^_C6@TO6
M>S9*?=U!)G#3B"K] 5GPIV _8Y#ZZ*IO^D;+_.!V]/N37_>O5+A@YE9Z!/><
M3&,!#11KR(FHY1:M1!:J!3Y;ZB:ML7Z%Y>7C!"O,BH>3RE/2]\^G2/J,:'[P
M%D4D*#Z@-Z'\_M_5K]7B[Y7VI[/1S]3LG>,;H!M;*!UZG,VV11ZA%ZB=1ENQ
M/,]'H3LY(8@@?W/!J#C9Z*7W\61P-U4A,W?64Y6N-&U-207JNO@]NZ1\LUPY
M=>C!MFYVA.[)8C]06+_,"Y]AY"U-)NN439!%>7&56<.)63)'+:X0<7X_CZG4
M>3:Y/&QK_&DKI(+<*3>9[MC5A;.D<(GQ.5,'T4EH(@,/93D[!Y93ZJR],AXN
MY6@]A]E8V#K@FD=0;$?]N_B(:(G,D6.BM,#,]<\GM\J_SGK"EMNKT_.(H)$-
MQQ6SR[C$071^5+,5WL1MH8TN8$<(E0R1,!5Q_G6AGU#F-]FJ]Q(,JG=GM=^%
MA6.X$CW1E#QY[TV29)HR\RW".U4(%Q)<$O%L7J*U_/FD6/IMEH:?E*%'Y47$
M!M9I.[>[>]%1LK(<[U?SC+%N WW&Z6?:R\@OEWX%EJXV>X5-WWM:2$2!*=M=
M <L:$< E(%*KA\#%;2W#+G<U<(Y.=6_&>2+8AK51]S< 69*LX-GELF,@S]J6
MN3Y$#+8R!68"!JZ8X26V'X2X/2*;5S32ZELK]/G5D7_23ZBAVOB)QP*7L*8M
M>C*IGC[4'BE6N[;$;W+9++.NF[4P?D!BM;$?\=V+-7ZE>(/$'(,I:)V;YZDZ
M9IVP(6)C#+ROT6%$'SO.V\VSIM$@'.V'"[ZUILL&2\@>]GTUHM\D7:Q*T'K)
MX933WN]QI!1ESC]%T+A /4 L7?,;>\29KT [T>6YRO :; JPZEKF1U-@=NL8
ML^78,0]F+6E5L:;"/"IL=OMQY>4"R@E9%[J\[WNP9V8^HVYR-91BQVI# I&_
MI-43  G.B],*V:.P!Q!<NM#]WAW]!J#KNS>DCICP$NA^;2@Y:^EXB7)D[_;F
M/K4?WW>%Z_7RJ9PP]ITHPICP(L3KT78* T1#T+E\#B+F%)$HLK*M.RA[V@Z-
M<]X<%>.%#3P11,:UWW)>0,5=KJEB]SJ/L!E]#G*/=+#_8D-\?YA75.\?-J2<
MI)!YB4;[3.'EGJPRZENLP'V1TZ'#^5<:MLOD3&VSJPWVJ@'^28HD <:202IY
M2M]I6+P# 9.OC73Y0RQCHIMG'S]17.48&F[:"XJ."RD@6UYQGDZW</C^!F1>
M_U==/)?%V531??8M[R2Z> _IR[;0N'CB@=$]!7APGL=>\W/86@A+:;9;)XRR
MX;31^-(TW.\',]4C2D4#Y0N1.#4_38MC=_^[!=@DB.=Q8:A3.'ECD(SLE@1C
MT(\\I;>3K"ZZJV[34IW'#@G_JTZ7]N/QETV8$X./'OF3\M"+IT_Z'@J:,Z 4
MF6E#%T]D&$?&J'=JOP%MXP#6TUN'5HP!.?=>/V((VF38,W&RQ*8"96@$P;UA
M?MP@;&<N">/^1L#\R>7H]F2X$+&HK3EU7'0#HW6%!81B0,="FJBENC"@&S8
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M:%WX/0$9:P&G3_RUA;$IZ$7&%X&A5IH1G2I12=PY_3\G')I17(1%+%+NH-<
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M]G^/I?S'1<OI?/8'$'/N%UA_CY[3ZG1>#L12DEY/#@S^(W:,WV/ !@@PWN5
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M0[',F:/P"5_ZVVO:W'^4UJ_0MCX'#\E>K^PFYP2$* Q^NF.WJ.U.68A_)*N
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M0BLZ_Y,:&:(<DQ>3,EYX(5K\E&^O"IT^=8GQ+ Z>Q4Z$V_21&N?)7$? 1X'
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ME%[ Q@Z@KU;*H:!#^N]+\D-M:_O)<K$=>)@%RO35M3XMY*, .2E22^,DIR\
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M&]F"JJ4C"BG&X=)'M=\!Q2HJ#3\6%#F"EG-DO55^'3D@;0,*&JXAL>P@LJZ
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M3$3J_3S>*28I*94\[E1V[9_?N(B$[;'ETCD2IH1(1))1&W_)X$#]L18;X@E
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MAO6^@UEK1!:E'IF >=VT,3T$G!8!W-@(OVF7?DAM45X[-)Q5.<5^S\(,<_.
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M\LVMAYBJYNN2.M<P*(_K2K;9 P[UQB7)&0GP491?H+$"XU6=%R> Z$Q6^7G
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M-]']IJ;H<[VIXD"IY)>FV-'%--]%I%Q;][L#+*]Q3C+^_%XPX"T+LWRC(,#
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M_^OW@ TUC\QTQMR7_ZND$/]_,B:A"2G _P@;_;]M5$_S_Q=02P,$%     @
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MZ?II&@T598&\\-/+),N><-K&3O=P(HX:L^IX;ZS+*W"OU:/P+DTV*ZI!JRI
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M6$V* SP&7W^K31\8C*1F][) X"VF),,LZ<L\S&]*^H%K7.OLN0C<"=2$F>Y
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M]DW+\]M3A<S.2LY#;^C<!84MF$\XR?(V+4S_G;DU[LSN>T?*ANY7G%,<J%J
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MX30+"E2<4;\5TQ$AG/\(?$]'8O1DB]^N(4.1BGQH>+?8[[)?CG%S!7 )5<Z
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MF0NA&9B,,76P'><,=4A0*:)E,6#0A>'+)-#O:5"W-30UY[?7F;?2]?H5KJF
M8F-25_VSNX=!J! 2?@-+-=WI<#T2GP!^=*GP-9!F/K8Q*F-[:>*&DU,&-X=S
MSY!S_=G?Y\ZL;<!E\3[:0!E%<S_094(SWXEN4T2%W4J^1#N(VW<=LV1BUF$H
MALZTL!X:2Y$E_4"HD O7>XN^+XAK,)71%K1?RX1A&6?7/L_\Z]:%Y@73?NG6
MZ8KQQ%/M5I\N9*M;<Z5=/"B8"]L% 08F533<AG!DX)N5^ITLB-BO9!F;AV5*
M+AIE7=&*J=&?+*!-)XU*YE@@OPI> $)1Z92SZ\2+&EJA-<BO;B(B_33%F&IZ
M=\^7* <I?13(\C[W@Y09VVU.E60KX)B<#<5A@;Y%GV(<=5=KH1D/5]^%>.Z:
M<7[U&4">OFW, O7C-I.^8W30<M2MWHKX/_B8%GOQBOQ5 7QK0U3FN<.5OM]2
MFT]5<MT2N2=R3J$MIJW!^,I>(=ZK@@LS!.'YE9:$%\3,D=+D /L;K0F.:5<;
M7VRTVTJWZ*FIIQQQXDH1G>(L,(]Z1=KPAXNA+,TFEF/7:U8/GG2SYF5L^Z0Z
M5US]_!(CL?T27S6<Q+C39)Q,N[JH^YX&;K]WG79=)7XHE3MA)D?IV20]-!P1
MQ[7OG."'E-R[%6&3C-.4Y&$("N8PVN*NC158J9H]6D+.'Z4\\\]?5./?-9.C
MWK6-[^1L/F1X^7ZNC.8ZE@I>U"-L/30^-NZ-A*SI-?0%EKK(!>8N7&I,TH(\
M_393'9!^#70^[GE0SSS"@&[5.(Z18T0 (U1'.?=M&-7GP:,746]TWQC8&>/D
MQN4]B5*'-E7?I48O<]@93ME3*J:=W,?8N7)"+U3 ^*@;6FN<<5&T;D9W5'$B
MH.*HB>E0U87^;_TQP>V/[RYFYBZ05-J%-4F.F:6'?MDL'$#AX,WZ\<T4V\NQ
M847#'Z^8D$4Y%$7NO,[]FA$F^/VN$T,\AC9#CQJK/7I"'6U)256Q:OTQ@S@D
MC]6*-EY2@$K3P2EM7+2=E-JH4V/D!<)3P",L\!@B^>EGC5_V00=GU3V.*AP%
MGX5<8..- ,T'?])ZX-.[A";Y!RYH&__#$Z'!#WCTLD;Y\R[;F>X*^.PU#65?
MHV5OZ% 1'>[' 3>:)E/BP0Y-\,4TMC+PU\W!AEM9 YF5HK7!"5<LSUY1794#
M/X?>TGR E:Y[@4\>]85#L&2Y6#O@>:FK_V<6J%/&*VRO[*Y4PG!S_X<?AI^O
MW;5^:ML25E%C;.A[SY^A J25"AN/^P^38;N.^!].PR?+6@:JGFLUW_ )ECS#
MG;B)Z&9H[&J@PZAQ<^,Y/AM*'A[<>[O^KBFZ$*':$F3][%GY@.HG'DV6 AR/
MOSWBL>Z..K(X+,CN-I"$%$5%;$!O,J?&RK59H-K?&)^G2X21K9GT9IF:E)3%
MHC<!NK\,<?2#+%"F&>#$ MUP9H%^'JT(F-!NUD#8?:@<#U3 5WTPDYULL%=/
MOU!87%VID.9YW:X#'A>,E@&TR'B.KE*LG^W;%4J?CEWUPY8>*4*NO7>ORN:F
MD?XDODL3#&1WSO..A>(/H6J8!])$SRU%E;@S!Y/M=AU7W#)W1,42ZP14>%\]
M-\RT%1M^J4EZ-,442'S=)800TF*HJJ;WO'&XYG\E&B0'DOB,[;!4=[6;ENR1
M?G<@*O/*B$KE1,")["TS0Z?'&UX['3>@\^5_MDB:1+P_3#,%-].,&21?):>M
MPZM]PF^[8Z%#VV=V=\,#-E[-E0RS0(&I1DPU9P!">O7(JY%67B/TI[C NGYD
M_:OUID] Z&\"7V./"_6LA)&4F_W/\#34GT>97N&KQ=OM&=45)B[G%#!AMU_(
M(H3\'Q8_S/,O3@'QFG#KET:_35+]:X(8]"\G2MBHM(Z-2GW_FDBN?E]59O37
M&2O"]__(!<+_U>GPO\#R[_\\Y%A?6!5G^]G>7.+]0WMS<9"].7IF]RIF9%X7
MT**9D27C#*7(KZ#=>O*Z45>FUS>G*8]MA2[OO<JZW.&98CCS3KTT7'$F=E#C
MOAK.VAY^^CM6WO@86@=H)6MR,;Q'#-4#T+=^S/CF'J:&9N^;5ZLU88&\/SPB
M97$G"*S>/?,;0R<N4-O:-!B^M.&46GQ,CLH##88>6>Z"K?0VP5T[8V41WY:"
MH<N@-BI-WQP7K%*(X>,]DQ_T V>%2B;D6#X(A95YNDVHU[H=G3"[#E_5XT=R
M*3SFN"L;9Y_!J_)>(GQR56;-MUSCVR/*_"TQ2^V+4G)6'V]8<HD.F:,1B\/$
MIMWK>\^9;'_LM".Y\:.Q5*:S>MVPP%H0"^2[HB=_J^_K@.3Q6_'FLZLR7.);
M*:]PTI@QB*@V)!DOC)%!R73*0R:\:7:Q8PYQ)U+J*YV'P.J;I3.!&=K(QXK!
M,^(G!R4A:L9UQ?2FN+*?V?8SU[N"CI2VG5\3OY]R*M#Q"PGRM+ZI'GSF1F32
M[R[R5J]=DBY$I@(CPK@PVG(,DK@5RJ\SQ^M*G;DNR-_9F-*M?:4JW>KV)9FW
M.'MWI5T5A@D[(>O4%&2.8G1HYS$RXVBUU\ 8(8+8G9O&_6G!KJ1'P8^[V4 <
M=K5=IB-LR+K]+?D3)F8$KNB+A^!]KY)P^QD7L#R 2D\;W\3\I(NV)K=-9$B9
M*^S2)\YX@[SG>?L%XQQZP K[NM:(-^MBTN<\';UO%.<=>4;B6(-#4244WMXT
M2;0933Z.NM I+TNEWW^C?0?;>6[Q^Y:N?W7U)K+:G&?4TSW>E'#@<[B\#67K
MT8((4Q/3#ZV%)OS24.K*X4U#2R**_.XQ_)3'OLRZR)R5M@ZL-"M-.Y1Y(]A$
MX>#J-;6T)[NN/7]FKE8WM-1\2-H<I>CDR#R4-0Q6$BI1V\_'M@12K+/Q"2";
M#$[8D0Z05Z4Y)I(;?QV]597L-.Y1ARBX\B9+46G?5\F+<4-Z%445ZGL/IWH0
MNSHH7J;82N@Q!?W].:'(=><E"QBXJNN;($[KX>G%+?'./P*_EYD"?M3NME-H
M)X"?]"41UGIE@;#B:R::_*2F(6.?U<;289\9;;A-C.N777KC'IBB$F=H5^&?
M(Y]&"80X3OXL.%;D5Z]'LPWQ[DA*U_;OSC.X#SDIF^+TB*&UEU^&Q'K*:";?
M&_->OOA9.?M:TA4'XI]IUV.>"C^DEE*BP5#]/<0W%N@+TCJ3A.T%)Q,+4S;?
M)5].ZPAG"R@Q_GL^<ZCL;K!S^+'6)_?WAGN2$TXLKTA(_+",;]/#C$+%#<5P
M8BUR)#NN&>#4ZM&6,4.]TKDY[&U_W;P@2['>W8>YY@(.5A[#*F]T#"-WP_VO
MH/6 8XN:">Z'8N%PR.KPN[ZW\"J;)Q\X\GX<-.GP/!Q4^_%3E\]@??+K;SY?
M'-R-3"<1*^MYC7%;"N<S$&&/I90LU46?ASP^E$?*;8;)":,_XN6-3S+4@&82
M9#_:><102B^!$13^)S"5!7I0T"3VQ9U[-OVB"K25=W/S<NL0#\@0O+X,Z;8#
M;B\0P1L1\F!=FZ#7;*L^KQCSW8H:%0.O$CP%%R#K_F[S/A>P\9<%1V63<9*^
M[CICE_+(&PB[J5J:4N?MG_U%FS>WQ<F9]\3T.#ND/I;Y,Y;V$GYM/9J"<X8A
MH/'ZO+$W1FLW(J]X%J':$%F!%MY/&I/X2#-5UR3D/:NX$P^1<G;!= _@*]0W
M+?:>90KNHKX&8]36+ZKP=^Z-F"4IH6#NVZL7-N6HG0\VA9U_^2^UG(TB;>BY
M3S!T7E_W#<\9/R5G<V54>RKNA/VR02KA<^& T(/E2/"+LWWEGO1H8 #'8RB6
MG17.ZT;S+KN3 T^H/32D/([\2M%>/9F\,]=T_+U1$"X;ZPD'^;- PFQ,M)7B
M"G]8]QYM3G%A0/,75HE/$A*1*H3J!X<.I;HD*:P7U\+M83:X"';(-OT[M@_#
M]Z]85UB7GWCNW32;U>_]YW'#N>#/:I+.*<]F+VNI2Y[I4Y%X\W\\\RCQF<@"
M]=;^=<[V^J]_K  X.NCJ%#9JB-L[O_KOS\3^[TM<3G#:AN9NPM\K(/\X9.PX
M3C_YOHG]@NNT_G[+ )Y.!![@!?#^T.G(;K&5;&)K70KSL.1!8ECS\)EX&YAO
M?KJGB4M+;?CCZ-,/=.AQ*&P/_#YQBV!'%"1A']7.M.H+*[5OKU:O7IZS/CRL
MVABCNOC#X7*)B*=!PRF2:,IX56^4G1RMD#!X@/X1F*9&6 .^2)T%80 *AXNO
MM2GO2G37Y9>8)/35[U]M?A=^4V!_=$AZLQ0+Q(TYB0JAJTVV*0.<E/&&W(-U
M333;S=;7B-$OPT8%[WU"XATL$R$[_96;9D.7>*QT=B3$845;GQD#0/X[_UQ=
MX-CN=0:B>63KIQRXY_T[HJ\C\0F/8.*&.E$5,SK2,%"B*'!-!,Q;Q=,::<E&
MIU\!.1;H5A4;G2K!_4<L54,@JJ@IYA4WZAJ3H+:UIWJ/;,S!N%A%E5O8@)+.
M_I2D::85T/ /T=8(4N0#WW>3VM..(@*G+3YVF@O'=6@\UAJ,FC _*(A[,G_R
M W ,G(!EHS0?6\L>)@?P[0ZU19Z'^F/A]JY]F)A9&/+P(8*_X*U-_G92;"TS
M_SL4R>P:P]<9XC>@-;WT"K7-NS,6C,C;@^YO'Y0*SS*6:"H$^'X$7,Y8U0]:
M:TD RZ&LOB"NG"-C!;YO+[A\@:]X'I;*@UW3,"S7SYC^336(Z]][R8!RY7+N
MU3%TR'BAU2;!.3_D7C9Y\.+'/P_CH_37UIDW/PX>_<VIYI&HT,8_B,D:L7F"
M[HW%$. '&*=I!^A(JD;6_?=EOY;C?QH9F$^4,1I2-S0/UR;>2HSE^*CPXQ2X
M[ Z^3I*1BUW/9H'@F,,LT*C-O3]#226^MK\:?_=3P'RKD[C:PH=0[S=>>@Q%
MS"E:6"$!?/K(6VEGRP^M#0I[W8AFWW23Q:S%H\U&R/80QN6]4JA_!1_Q0J4[
M(I>CJC+&\8Q#EDU@$6PF2(H^&#5LK@9^!I20IC8J2/@'4$ZT%@DN]67M'K0;
M+.@G\CV-A%]_\5P365"?W)>V_NUR7FF,@AD/\?3PH>%,/ZQ@V-:#7,&]=&V\
MN"M;)T#\+D4YIVXC<2U@:K^;IW&*2(&E9SH1;U/TMF, _6;7']MW?>\9?CTJ
MF04RD<!1AWM=-;OP@"JDUXV7D&W[SM_]C-U^?(+GA[C.5=,%N_2C/V9/+#Q]
M=%;IL:4]'#YB'O/'^;<9D_\%"W1T2F\O):>"F::-[3B-_4I<8H&J,AU8H)&E
MMHJWR0++PS@IJ#=4'&T%#+]E6%!WNFWP//[ZQCG$L+BBSQMAAS88/4?]+ML]
M=;KC8,,]5Q?T4M8I!@T&(FAB74P!#IK\/ M$&1QZ?[? S]5VJ Q%Y'YBZ=)P
M/#_PN41X.V@1C?*$8^W-$P;88=)>\7\4,?XO-R/^(] Z]<U+ .F[)NCKM&S"
M=X9,"=IH-!3.#Q2L=4W2FY8R([6W^?(2NUK29T&GCG#&K:/*9\C8C;,AY6A=
M6D'^(D1PWAGH;_^3^?W/YGWR]UOC\HBTQP1Z$L^*F-=3J9"46YMGKOARSG^O
M$-M[:JR+RES,CF<@WJ/RNF@ 6V.6--NE9/G'LH;U(^:RZB6GXX^/+EG,.GU;
MU[^UO="@LL&Q")U>) _'_\+M6]''U)6NNJ[?"W'Q%VU.5-PU(@P=0+S??_X,
M;VZK*N?W5;5E+/$J_4TFN6*]WX\FTW&0WC144='ASX34-W&_?3&8MB$T)/%D
MPR8TQRS&^-LM]/6]TI9SU"VZ#Y4%2M7&\;JC\GKT>Q],$;C5-Y[Y97$$>N;X
M;7II/$BU851MS@/$UB^@**BY)TK3&4>0W_\YS.9Q<DB4!_? VY.F\:B)1QR&
M0IGPL^C3>\5H:PIX1J47R_]K#VI73YW(L^%-^"6(FO/.6>+3*,R5L@XN13>_
M6@3=22@#1=F:HQO#=AT1VTQB&;7$=C3P-D/.YYV;SL37H--S@^_/<46 N6Q;
M3APT2+YS[OIF\*GC\7FTF45DUQZX@VE(FTPFNT&[Y!4G2VL;&1 N/?[2E?<1
M)Y,.+-?&'7T>H69X\\BAN=@>7\ZUXVI]+)#_<-*]X0Z[Z9T>=UWJ3]T(Z<G,
M0-FL*GB>H="@=A"#[&)]*.1STC<&9/>2T<YZ6@@-#JM*FG$?_;G[[)?141$3
M-\<Y(F^]@W)Z$]FT2/FE_@]?SN\":E_9P DJWZ:#O@%PDZ+@%ZB3L9#4NE;/
MRV-A41=07Z7=$R5*MWM&6P[#3SD:7WE;W":H:[VO%4(/ 3HHD(<YV02P,*K8
MZ.@:C.I=)O]<MX9,72M<Y2!9/TUW>_;N(20@?3.P5'_;1'[,'%U#\Z07TU2Z
MH#,J'9#]D$MC7ZG[*PJ)]7E%VDAZ":SD_:9"O6+#AFAMU?D$M8D_/TMPM1$;
MYRH8&L O:AJ9!8JOW97Y8FA6[-I-$7SQ<2[U55EW>PR'_"3(X,D')046J-CP
M,N_8-:=!%JB.=\,^BHKMEA>C5CSX^5&G-9@%<AR[ZIISQU58Q:ZQV<8K@MBU
M4]TLD1HRHGR3SQWS^%_^,F* 9I%_(IE<!KL<K6;KYZ?]7=;+YOA!*?K'BER\
M!PM$3';9>],FNGIO^)%&Z)XD@7C^_9%UW0LC'?2S9:-+Q#MRS^)\9V.'G8G1
MQL_>MBD"\-V[J,)NG!#S**KP,G4PI6$2<[ARI 7RSJR-I]7-Q"+ ^//Z8,P5
MW[EG'#\VVRM\ "6:(.52ZV+DH!HA>YZ75I& Z?$R/DPUW#UPJ=6)H[0P;CG]
MQ7$;]5A(4*SJQ]?@B/\Z%?$/:G/9*\/[X\28PU")MH-^39A7A?,H&V=$<IK8
M]>L]&T9E+T.(A+'S9M&Z485!'PTU_>MVD9AQUYWUE;? !4V^%;I^07.IO\"4
M&B:%!EOY2.O6_N)X%7>*,B>^+!72\1I<J%KQH@Z9##^(441?!.+>,K0:J/GQ
M:21KC^K&3$+5==L3%6BJ^H:0]S&1<])Y;W^GR&Z>%3"I< )D:*[]BVF=4$'4
MEEU]I%K4[<';PJ4I4J\?BU5;P(#ZINKEMM,F<A/_==O(WW3E\KX1N#J&P%8J
M_"$[:5;;DETQUAK[N:?G,'J;N'B1.9RZ:%-V9M8N0%GQ576_3FDQ0>2LNRK
MOPM#L,779'B/_9+3GX3L ZYP-8^<" C\EK%)G_-JC'>Q$IJ_X5/W^+4Y5XS^
M4K1QX=NVJ+U7[!Z&11F^P%.:V84)AE(865BMJVHE8R5<^@E,Y]C-QD<1V[=%
MM/@&E*Y443_ME\GL/4"!IRW(M$$ ^7X*+MD02GX%Z=A>K:=GHHXZGY!TJZ_+
M70E<Q-;>C=?[\'MBP/2DUF.9P]'&'_X[I?VMN#M %>TTI75AXY@'M8L\N//@
MYS-89R#%)GE8S&]*TNN9>Q2NW^ZX+ZWKV+*1L!_Z&-"_6**9HH<5P*CY$64Q
M2IG6^DNIY2C$$$SNPH2RZ$#\,6M40>IS:[<!@7H+K8^\;2/PLPR5O<*PA21<
M;7P):0$XK]ERFLQG>'JOIM -D36(Q!8U$ GRJ(<ON_E_=Y84A?=L<NQK-5C<
M2M-D2J)%:,LIVD6D%U<^A]H,7B :Y&L<L!977Y7=QW_]_DO17Z_W_TGZO46/
MVBOTHDVM#[]'GZ<-MM:GE:'\-#,)X5G1I9>M X02;GBK@/D3>ZQ9(&>UG+V7
M+! "+(&:HD=,,>XNXOFOVU&,# B2TL=1$9U98K9!RDDWG2E\;FU1HQZODHI
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M4E4."PGGZ9AH.XTF-L]\7""H#6!B=^X6I7Z77DK7"V^Q:Y=@.O)4"I!M%;0
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MV>N!CA&<TXHU+*C*0\!"/G)+'G;R$%!3D4>W@OA5WA+\:EH3@,RPFY0\_T/
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M\>_:1^AK<_('2',$5?=QK:G^_-M%W=NRX.F0"T=%>+89<P\!-OO7'$;Q0[
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M?^Z2$ E48=EIENW29MRWIWCB)4 7ZZJ)V 0Y;7N<+:0! E6_/7)=J#OE>;#
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MN !X KY?]H+8 &7=64+5YL^!C XLDADH!.>?FQ)*68:65Y:UGOQVP[!:.8[
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MR:_V-,H>>8CN4K!995C;/J2)>6 * S@R+KB9\U\_GXMAL&EF1Z<6=IJ :/9
MA49.E\:B>Z[ORO"IAW5,-*%;57;^4]AGS1-8TI'515H]JE#(!V_\8-%-\\(+
MC7)C^96GER,9\[R3$)'5/<&':+?7HZ>S7V@]4^TITBL5T991][DP 27>+%F^
MH!M_AQA;Z<-3;,LKJ[&#?POB[1]!M 4R-D<NN&\6=>3"YQL)Z7TU&E11F'WG
MMW&+EWV<,,VIBC?% JKG@G"-P^6S6P!1__/M:<^]^STD^I\I:V*V+$/G:1B\
MKW/B1\@S9Q.5R:CB/.F 96N^T)_8(^ ,K,D\.UKUG-A6?O.#U*FO>L(=LXS>
M_O6[[^1W/S>[BKD<:MUMB ^N7]*A.4)C*=W#EBG]I/RI]MD:G8IFT^XBN:O*
M;U^UBSL9"%^'1^7"*Z2I^P2=:S1.:JZZ 'A[VSG1:=KU^C^%G\<\B:_JQPQU
M1C[DGQF+89 J=M<98&P_CX=OJ+H7FWI^RHFQ_;0>)Y\>3=,GX'.2EM$DK:N0
M S<MJ>\AT<'5P(5*T[,^-?+8.HS6DM'OYUJ/>7_]SZ]*7_?+SWJ::R6LIV=^
MN&:4J+F"'9[=^%Q/Y(\="%!ZQ+&T@PV6M-*#==P^S<0T>M.?&'+EQ,D&_I&[
MKB//]&HIK>H #5PB?NM]W!<*67 ;3H'YJ7B"/:OJ$ T_VY[KLK0;2]!CGRNN
MM0(*IW IRUGS<;^[?;S#DKUC\+.W7:3.B7;[;A/]_DS@<6K9HVD3\KKJTP^K
MR*+/:NQWC ]V5<]HW'+9FY#1K^?:B'EW'G^H%ZA264V)D R/ "]Q83VE]4/Y
M7IRDYY2(VB2J/^Y\)DTYL_\.!#H#+NX=W(G&C5&\KK8%91@L(YD4/SMGQ[*Y
MN:NN9D*3:X3[P<*8//AE]TLU7>HOW2\YRAHU+*&K-)74_!Y[>Q%TF:0FRE^'
MI!O+E'LW5KV-(U2_K ;X)_>P4I_L6K!J]$\>9H_[@JS.#SZV],,SJOCX=@O-
M2_)$X2;[J:87]?X&>W[$"JDJ%;5JTZH1?$C^RCN9=]>U[O4LR41[%VCDF2R(
M=:@QKCE;VLIYTH73P_R?JS@U[?4VBJ#L[C WDCTQEJ.PVH?,7F_!KKY.A+JS
M@EL#0=9T"_!H>Z8BR6:9+@T,LR<.JP+O\\,$C\0(BA_RE8 $/><#V0N_?;W/
MQ/X*CS]J(W6OFV30.2X2>.(M5]0,/S/Q.GG!^6VMJ-\%"Q0;Z[(O36=L:JP\
M+1@OL;*ER6'/31<PW7*RTL[2,I\W_)?.E?^./#0-=)?SO 48*3RHOR+K>8V
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MOA&I16ITU=T!Z85$FY;MT06Q&9O-UC<_/*!H/6@E_J=F07L?_?.B%5^-Q[>
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M'AX=JAPKQ(.B?G);/(\KRGVSB7:9J3RLCT;7;4UN-$C!%KXVR<E'"ZC V@<
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MH2[9-(LZ._@7^]C682=29%J=J+,PP$)4D4U,QN8AYLL67,3AJ9.BG$49<6<
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M!96OX3^W:B5[$-L7P.^:&<!D RPI(N9I;"3EW;PC3WMH6+3LCU[N@ 0 91)
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M"D5TITMVN*W6O5^?I?*X,?&\^@G7VP_FLV"&NKO/:8O][.X+4'F&8EG@76>
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M]X$.3[I6)5D\?U?RS4&<XVW+-54VSM#SAC>R!>?"?\V=1_\*S7@T?!*V((;
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MXN;OWJC ^YE;8J+4!8:QKJ;RZ("ET"S,ZV,1C'7P0D^C9Z U')OBT<K4,,Y
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M$HY=T6&] R9D,/DBF]3>#[OLL950CYVI+5IG[KIP2ZW.N-C/0<TDXF4+'ZX
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MR_Q6+N7%04B7*-*O*AE<_<5.:U;%7V7Y4:[ )XDWR^]860%XII>FBIBF1?H
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M'A5^$I6EW6:;;QUV00@(^_'A2VPZ'T&K6-I4_MZ^EQ*W"56-K:,/ ^4/FRL
MA;18*53Y)88M-;\U.7\+$ [63N$=6E2QD$JC"]2CP3\4*2Z!-CT;X75P=&>
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M#][?'KJ#+UC3^$F%JZM5[K?)ZZ[)WW:CRKE0T6U%3"DTT#&@GC74D/5^BL(
M<.;N!X%FJ?&.IJ!5#V<3T=@2A;P+'4S+^-[(U'>W-(:!!]_$-.B?2,G/=%<%
MJ?3];&!Y+PEF@)Z\Q'H53"]L=3K;.GLD95K<9OK!0[/_]I/'^[QTBS,\#8Q^
MS.'"[2U:AL2-5+5RLUT'WMQ O#=)NGS=GV[>W+BS?4"$9P"D$>;T57!84M.M
M3L+-G/M/5^3&B+ZKVOTD)2K)1W)'VM74AS#45[EHS@;N79'B=B+)#BNT^:7R
MR,6B'AZ7"AK*<E$?(9\#>B+?RS3XZN;4?T,^F=@AJ<GE+;SW^5R.SM.B+V/!
M+7@L>U 7CCD)Y=O+1)*2;0H9LPB7$WF.")4\>?SE_30 H"I3;:H)R=X"3WF+
MA5SK?O[D[B3_)[31O7D.3#NKM[I^(LP6HV,;V:?A'A?UH[F$).@K0(C3X16
MX$+T3NXL:'X&FPF*K#[6,V2)QDT^7%GFRJ/IU:3AWI5C2$K!(#J-$C-C/8\/
MZVK'6\<BTXJS57:1Y(%)5@L?S-<>:0TID*10SDTM@.P\WLU-SRIZ0@3#(J#T
MDI*9(0;OE+]5DF,]ORZP9Z,G'-W2-L#*)F;<2=]JXT6"E"VF/ 4#0_7$WZ@
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M"BH;J-HV_G;$)&S%>C_&Z%VRW+>#2MJ0Z R1B<[QG63$(M Q< ;.ME7O^H,
M'IR=W77WR(%PC>7P?HWMMJ3W L&%^EIBSK2RX6%=[4LSU\$D5^A3<M[;MX0-
MMC<15[$\W/*O1E9JG-Q!-;EW0K7*-A0+77S/EJV9F_V7I $!7"'76E1X((7.
M::?PD@1*N&L:*PQFID'65%-A13K)3V4VEV5?2<3+;&^&OP5[*05HC5:I3W?Z
M^''I[#FXT7W;"T\PN['K1C\Y.*]@J6"QO5E<WEEVK*/SI3X2CS+^82*8I>/
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M"B40T%UR?%G%H_*$A:7/14^/8=8@L!]7\@;W\Z&NA<9^*RF5&RW2(M_MD6G
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M_/+0*;J#_U)1E7WH'49R+<NT^V:BEHMV_[W=:%ZK\)PYGBV&:,1:;,69HT!
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M+Y";O[)-Q,G&6<=LKND,K6](*<FLRBKN8JCW++"2F+Z]7\4?65^62Q24':<
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M,^LW0$I<CCPVXO_?<_\?O+@:RW]=U/HWQ3\5>%G!OR/MX.\?_P902P,$%
M  @ U3AM6N",=J*-2 $ >7@! !0   !R;F%C+3(P,C0Q,C,Q7V<U+FIP9^R\
M>31;W_<W'D.KE*K6K*0M:J84-56J+:J*:HN6DI8JFJ(#%412U#Q3M,;6/.==
M4XP)8E8418V1Q%!S8KPDXO'^?+^?S[/6;SV_M3[/\_O]]:S/R=UW[95]S\[9
M^YSSNGN?>VX.?Q_.@$[?,3 R #$Q,8%BCSZ@PPG031 +,_/?QU%A/3J.G3AV
MC)7U& <;V_$3G!R<G"<Y3I[D.G7F--<IGE,G3Y[F/\USEI>/CX^36T"0GU?P
M#"\?[]]*F%B.ZK >8S]VC)V7ZR07[_]V.6P"\9Q@YF4=9F&Z"&+F86+A83IL
M!8%!(*9C3/\HH/\N3,Q';3S.=H*=X^31!56G0<Q,+"S,K"Q_M_I(ZG<D!['R
M'#MS05GO^%GS9VP7W_"J^,=].R%^XWLSW_T!BL05^[<![!S\ H)"PI*7I*1E
M9%75U*]J:&K=O*5O8'C;Z,Z#AQ:65H\>6SL\=WSAY.SR\IV'YWLON+=/X,>@
MX)#0L/#XA$^)2<F?OZ1D9>?DYN47%!:55U1656-J:NM:\*UM[1V=7=V#0[^&
M1T9_CXT32>39N?F%/XM+U(W-K>V=76!O_V^[F$ L3/\L_TN[>([L8F9E96%E
M^]LN)F:OOR_@83UV0?GX&3USMF=OSEY4\3_!>R/NV_=F=O$K]RE\]F\'./@E
M5(F2U+]-^X=E_YYA ?]'EOW+L/]IUSB(DX7IJ/-8>$ 0T,&#K'!I4%9638W-
M<\ZF6%.-HD/0^,]#D.<AZ )#E>E]>.Y!*?<N= -,-MRIA$RA.E%1(-NL0A3L
MYL$H/008^*?TNH!S$?1_5ORG_.>Q<=GD?U8$_T?Q?Q3_1_%_%/^?*[9R!OT#
MK\)+WZ%$BS^^;HW+.*9:=FFU]D5X]@&:>_?Y/W[GOYFAN>>;AK4^_PO)0#<^
MY5K/+POP*AQ5+S4+:8_Y)Q-M>6Y@S2ZKX! $PQ^,0?[1O/]FWOXU'_-VF\^0
M9@=>Z]KCIF;_BTD,4?5-+BB"C%,.0>_-_M'Z?W+G2C2S)QOUS1FC(;1RY$VZ
M\[^8N6>]8G-+LC$[#9"IA'_X[)^,W"GG727SAZ@J(F,E,_80) SY%Z?YZ-U_
M+/IOBPH-B]K$BXXAOH.><U.+*U-@;Q/,GF:%RW!*9X6#<HM1'>6'("PDKB1E
M9!A''D,1P)TC)B!><_W_JXAO8%335O2_V)@25$?W(:@&\J4TO&,$0IY#38)_
M#./?:66R&X1+EP5^_MLQ_W]0TBA#]]DA"('2^@/+J#H$Q7P^\FY?G7![WOS6
M#H=T5KGZT>F#S$L"=06W'C,+NU15Y0[L0'<[-M02KA_C-?^W24R(=A?Y.X/M
MX!,!OTP6,7FY6(737LF^71W]RMOFJAOAHL.!/5EHW<Z3,L'@"*,8DLPB50]!
MIPS?E0(^.PR+@&E7MS9[_QR'H/N+XJM=YQW_TER2:S\$S11KS6(%@5*:]O+I
MQ<VE"I?]DEVC9R_9D^;B808\7T%SJ8+GQ$S>@"MU*ZC:#(YC)"@SW-T X":!
MF=KREL3\^L,:]%PED'<-F4)2!LYS'+=QEG\4U$1.##E8D/.9-M%-,EI'+3\;
MOG-U<8V K5MTCZ?U#VMM9 HS!NWX*>#V_A,(Q5^NGH]U]$FAD2,/;&RRK;,"
MR+O13_@@]6[AOE;MA$HQ##6D XKQ![1GH&$I^8$>I<;7/_:HWJ^-'N 7EXAO
M#^^^%?479P#W#V]1F%>KUB&H%1J(J^I8&:.T[Y(N8=!CO3E\([D92S=2<B;*
MV.,M[(T][ET]\SH[I0A)7]SY5+KL!MM_B9LYJ]U^UL]!9!^:2-^%7"] ]Z*Y
MKK;AQL$[U< Z9:V?+!!*%R":\,_EW\SKMH;_1;,//C[):90D61UKVB37A^1<
M I]C7&/T0\]LI]\DQX1Y..N*2/[\KN51*CJ2K?JFLG<G-?&9> $'+[/9](+&
M@J3J(LTJ:VY^[]4A2%3>F4SK,''+[=FL&M@?U4=Z_Z9[4=&MW(!4?T"#>1'"
M;@@KM#1J5?YH*4,&9R2\-B^8%\<\47+GR8_N(B/SFE6=R 0[1YHRX^=X=2KM
M.:#48G<6J">[ATTSC1*31&IU7I33-T+G7']ZESR2E@YYS8&DG!^]$>B9+H;!
M$%&)]!]/5HW'#T'6VA!HW'Z%/M(6[D8@XU:OT$P0KA2E$,85F-U)RGJ(6J$;
M_^W\Q(S+%9VQ$ZWFO[)X:F)/Z5ITON+86@_(%$484[AW H!5RB;)*7P;PN/B
MH_B9(?FSK"HB03YX4%5%<""U4.8BIT_[\,<7:7R&N:39QC/U>^N[PMT*)BU:
MXW>4ANN5>OT6IK=)N$K<JLL,;NR!V4^TC@.LQ%:_I$=>'7\;$_V"2_#^!*;S
M,PTOV.O=03\;\IBZ'G/D>B2$NAZJIO""W#I>,BKLV;BR0AVW%N=EEM215IKW
M6"FVNW8(.N:=L?&+SI-JBK%IO''MO5<UYD53DODL[_VWE]F;EJ>+<AS9;W"_
M)V7:V(W:'07^\,*:7J/2^_<W&M& ME^'"S>=CSQ3,I@#RP)&W_UEGJYXZA"T
M0[7KH-UBC&5P'J1N*W$M:F&3T4 $E,HL],HCAGNL9)?S@W]-L.>YM ],$K'P
M=3LS(B$&7"VY'JK:XV<U<SS$,;?'D]?+RJBHM9=3LLF+955*0M'LYF"#^$XC
M8$BRA3(X+E#(IM5 7(G+J)UD5)EJ#_! Q5E:IVUC9J]=3[JCZ&#3PDEF*(!F
M2@@>.7@_:77G2BI-]A 4O;NQ.A]3B!4_!#7?H)^DD'9;K)\SSE++2DE*/"YQ
M+ZE_A-V2XJ'6-C7V6<X_LKF#["V,G[*D67U#*!P4(F2H3J3DT :FW,7QJ6#<
MU[$V7Q\UN8?ADE8\L5_#!)/$[ -.")[?A&9FB ,GR9<.00&QB[JG#T%!S22F
MLDGG4C^!\ ;<5LW%C3GWBH)-W7E>]/2?CO ='#/RIYT\!;/J2#.]]!W]4FLT
MN$&(N%<EQR5,(D;RJ!J=140,O.LDT]KCTP0:%5(*E3[9,!K&5Y]^<J1T>,Q@
MWV(64,F%N\-\>[D48V+RZC':0P38/=('U='[#C\M_PN=YR>G%TVZK>I,#K</
MDHA244Y\A5RM8=$N-_'!K8:08@3@-L0%?"I$&/%N$'LZV0PH6&O0P"@5O'Q;
M5.#P7%SO_-W9#%YFLA2(V43+1<9Y+;$1U8/^;##DGFQ1ALT<"1G_935OMJ)
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M D6:T8F( :7?<TF01J:$][<^GKX^$1A[)2%\ZP[@R^!P/+=.4P!N=E3O5E?
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MFCFI]! DUL, & ;E,!O+0U",X]^/@\0?JX+,]7G_76+:(*QZ'=W^T>3U-NY
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MD?)KK3,@EN?QOI91R6$>Z8;6OSPB; U&R!9#'UV]'<\5O<"<87903']XF37
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M% /AVMT*H5PA@..E=M6-W:+)PKAU<]OLJ86[')]TQSSR/8.I *$%SU#G%;@
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M:& (82/)[JT1'Z"Q6]&J_8>"2>N.Y:M3!J$;E828$[!06SFK8T;.]_EV+_Q
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MS!<M]_XU%B>Y&,-*U,!-]B3$\BHE$FV.VC*4P]U*I5]*N7@%WLR[Y,Q=\&Q
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MVT7X&7C;G6;6$X0Z%; U/U ;5]P1*#!SZ*7:^4$MRO43<XN2O4>Y8;#KPGF
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M\UM8TO5-33T_3X<LY*+?'(;$D8/1M\FZ G:=J@GT_SE%!?@4>?M8I$(5B50
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MW B[JED,A2#F%Z8HB$)KA\/7M3YN](4N_#<%+Z>NWBO29E@PDD_2N<$Q11E
ML$!%B, NM( 1^(UJ3Y?HI+30]]U9)[Q^;=UHN=6=-="0*+>N-6MM$E?\^0>W
MD:7-3PE'[9@+I;E51(.(WPEL4W>G\7434I>:XOC&I*)O*09V4/A&U"[G:^2O
M!%BGQA7<[C2Q"&J\S03?S $PS$L(TWWJE7Z<<0 F"=0%K%88?_!8BH]?/9XX
M-@K8J#@X.@)CG"'<*%&R)$D3Q[V81KE8FE9G(^1(\U-]H+I@6G]A]X#EO?HK
M)_"9'TXPP>-"T$U'U;J>JQ2F=:ZI'^-EN(:J+]>=4J40#2E7&HVSPB1K'C 4
M6AS3C*H)?W+(F"@J=9RZDO6T9"V?[R&ZICI>9>LLDW"&)DW>U!E:]QL"$I&Q
M*!Z_FSB):60T6>P3*<ME^RGOX ?F'PGJ/@?1/\@2QUL^!N;F._ZUHVXG5G)O
M-FU6.:$YJ;*Q+LFTD@S!;(.5R9K8 0'*&5)/=S:0^ !-%.OPH0+8JEL@7;SY
M2RD<+36_3/I-EIR](Q=3P=ER_1=9DM6CD(['7T"*9"4BI9# HD_8BO*"LSDK
M"ZJ/R&YHI7L*=+2YBG8TN8@]N?S]Z1?=C>W,($3A_\7>>T4U&6T+H[%0% %!
M>E4!0:ITD"8B)2 @2&]1D"Z$3JB1WD&Z4H(*B-1(#3W2FX#T3N@]D% #"7!Q
M[WW.^?=YN/<O=XS[<A]6OI'QE;76['.NN>;:,'%.S%/.-]H\KC$QTSG5F3+]
M5=X:=?[G ]&-&88R0VT</69&[2/0Z@I5-;ID/_9"3#=JAG*J5(#Q[T/9&W6!
MY*.V(5KRV]$;^8S0!5[>>=@6PLF@(9_[=]Y9-=<E(,A= 3GOO?>]R];U$L"V
M?PFHAZ;ZTV*>=I)"%])@TN^B: :_XZ*-M>3Q/A-DR7MA.KC;^)4/BC??L77^
M?.]_;3% M+428CG8YJM<$+X&Y$A7">[DK$Q\Q]E=2FH>*FS#3[K.+>?(E#*[
MJ,N'5NE,6>_A45A-2I_-.->.#90S:7.\DAFK.)./[>6<CHM>ST*N 9/N))[F
M#-2S&EYH+1_'7@(J7*^>^;8*+ZZFO(:S-<"LPB/V&F7RYC<DFE\AALOX+9/&
MV?G8#+JCT>:?F%WDS>Y8YD&)(+Z:()TQ4\419KW1TK#L(VQE[* GH)M*'>_]
M]$Y.:A0+C,]D>[JN^C@+=4%$ 6ISXT%:,W /*4,71->N^,W?9U&&# )=2!9Y
M\?%;YSQQ?<H/"[+4Q)@ ;Y9S!X6(4 1: "]*[:;=6BA]":AQF9@<@K"W?81H
M7U#9'9(+*MPYS[HRX2Q+4RS[>F09"-D-$BPYZ0S?9R#T;0:^L,\_6A;1O.1*
M&E5XHK!9+QW^FK3)&SU1K:L<O]@??I1B,:A(W1Z JURI]YB_9TVZ9ACD,IDC
M!R@O 4Y0'VS7SI#U3=#/B4Y#HX_B'2?1%J\3FI\EN@5 7BG<;L5E.I(C"-0:
M;<4T0*8X9N6/1 RG<;,W<PHY<SJ;5T?\R1>;Z)\W#HE= B@W#9Z*+Z:6>6P[
M\BPCLOIRQ!H=OAHU:^TD9')+_]AM9H>8X%MU< ;K;29R7>$<+Z+$@.\?.G*]
MN/\M4GWGFGHPL=1]JWS+7+O\J=<@'-'>R2PJYR3KPAV*NZ>-*=\GS#_Y<\$"
M;5%T%O+7+YZ"^'89XSS!1'%K!4]GVF3+Y](\#-WH70!9MN+KTY3Q8N#(9NGS
MFFH4Y7Q7H=T!Q&:8SV^#8J-@_Q#_:6K9.;8A\</;EDY%.()@CEEOA=X5$$#[
MZRS&,;>GC?<W,W@&R//E19X5=>?=^+6I#&_+N37U*"_M@G[HBZ;6&#\\34">
MB]YK(XR:T07YE+>2QZ ;\)&8W/:IL\>L[/?T\\99)-FDWLJ7D4L T=^U0-!@
M"BYFF2[;B9) #6UUX23]F<VAZ!8$F9V@6TU8,LIIGRB^&'^E2M+./A5EI1QG
MA>VHOZ\35WSLO>#GPK>1B8JXH!]M?$P9MDN0S#.'.-#$2QW:EUCZB:EU"Q>U
M&KZYK:_^0>I7EWIU,>[U"RQ1YV?7(KMCII0SLZ6M5M,&O=321S>NJ\5<U_G%
MZ6S&YEBDN_9CK;Y?>]=U!",<O%K ()^8$GADI1O-\X/GOT?*_A?"C[S?X8'3
M%JD^OFDC\]6-0CPU->;#O?K R9 &EC>4KT'2]DC60#Z<J3$.[(TE:[-@&?'0
M9G5PW7RUR>0QDFT(S#":5VM<N@1PUI*^R'R^(R?"<V-"GEK5+4V>T[X@W@C4
M_C0Q7"S&/C;@^\MPIRXO+2T7.;GMQC*A?W,UO%*N_2)P7%G 3LC(1GG(4Q6X
MK*M0G@B5&#2<DP-3=E;+#,4E$AP;$G;;X/:/1<X82[.* V4>:>/7&K866_!5
M<PJK3O[)(YCR31NV(VO3T^'T?KC?)>!1K0$X8M%.[$\<T5C= :>\^6I7#K>@
MEK>S,^4KT5^_EAE*>;LP1:T93R,Y?D8K2(#2-=-_1\C,R"[X3^';6%@FH$J_
MM][K_'\2RRQQ.J)D(LAJ?.*H?3'&G6J@?(=V?,#&@'%#$1!B'CF,OOE-$<S^
MZ9'DM9I]3KXJQ(3]PUI4I*2N"61D<4;97GPQ0!?2V_J*QJ RBU[FDW^1M%3/
MKX5['=ZI@H^WAM1UU7L^U4^$5LW9OF@8>5<=]18V[:<3AB_F.<4>22F$N:/(
MF-BI(!3=6W38GA^*MX;A(8) .]:/A<?= I> ZV6[M92W+@$=<EB9#I,'IV]&
M#02<)[WZ*'G?*"SH%$-_;0>76&DU2<^H0I#UV_N(WT<\6OHN8_8HHVF-O4K"
M%6LAM,8.&U3M&4N7!3B+99*0OLH /G;7:N@#XQ-?/>&M,XTV1Q<ZZ>^?JI%I
M#U4\I.TE_;LXLYQV?99JBD5U/O04;^J2IK8[/1!TSA#Y_%PJ]@X0]DGN:;SC
M'YVX/:L^]]12-^4_54>AS_D7J4B9)A_-W]0<DX^X$>V?H9Q2LG,\5.[*8&GX
M0ZE.@:.[.$5O7[7<8CA@ZM6F0?CK!X@$GT]F=#.#G^B=]\KFY5,2-^ET?/P$
M<D%"OZ?"\ T#(/;7/<4IKU<2WKKWU;W8\/4)^BJ1Z*/I+*#NM- N&GKF!BGH
MR3?N'1:=4>D$4AMR!1Y\EQ ^85:13W6.-DO<4;"7W^FY^%T%#(T!,WA\+C @
MZ_:Z*1J@QADHSK1QS!,=XWA7.6KQ%?TW8:+T#1?1P^+2OQ'<'$X_,IAY;T*>
ML1J+7-5+-K&HBB:=6[S(9T".;:VGUKDRTHC8AI?<5HCD^]>4 IX! FEMHJ6M
M)J579TO9/MN3O>@!,WWZ/$<*JA\ NLGG95UIK!U32HX>/*>%X=1%7R68S?!$
M'C;F]7> + >[^LD:5:G9L&D)P:%*ZB9UEJ\$TINZ<2)CUM1DD/;@UU+OW3AY
M]?Z26\F0=II<R-7 HO*F.N\*5+UY6"](_ZVN+Z']@R:'W;@0\X/JR-SG-:OJ
M&"LS-.A+S_)\F8Y&DES(M'8#GT2FP\[..#8M23\[RJ+L"Y'5K@1\A4=38EPR
M+FU>W&[%YU48ONQTMFUV5_HLHU)9WFCOS7K:Q&-RNI:W5&1JH9;$-62(!)XC
M[:^_EF!G^EGY?3,J'>UO*YJ\6 I6?&@=_DZ%[0JIIGB)T=YW>-G M^F#<X@<
M4><YE'FC[7"B6+'4;S^GOUB=^0^LEE!&GF7/9R_BJ <62U8:FVLJ'/,Z-ZB-
M]1D[(20D@&-.0\EE.:&+NTV\N^8R[2:A(IK4UZR\H9S[,K>6B(VF505K[R@1
MG6HM_BKCK5[6[/U3'X_W0IY"6\;GT]C)>;=N#0QH]7E7(]#(=3^./UHQEF^?
MG"<)\?P2B+XBG*?<(\D=\IHBPP:)L'D)$;6D.KZ3;.&?.:Y55AM\ U67 &9'
M;Z;8>N=T)[L]I,[G?"3, *#DQ@'PE-W=_&4Q>^?UE4Z; UG\.C9P/"XU06GA
M9;TE*=Y&?0?F6?YRW2^QW?U@M, VV2FU(YMB J*M]]8:'[% B7JG+55[SPP.
M3&]_GSAE^UAO_4TM2:#Q[;!!MI'0@\F[_4</(@GV,;F3>0[_(,LO *%K#,%]
MAU+LJ2X6#W!Q)1M4#-8A&A=_@AEMTJ0L')/O*X5-)Q:^NWDG+9 &.V@RAB%&
MRC>Y+_'5L2E19<RKO4WL(]5'/PC(_6,=M5PGGB?LP:U@2PLW5RA#!:5@C#(\
MLNT5O"<"=,^U\@]C'M\(KXD+^:8R95$4FL+^#T)W$AG*LR=OM)[6SZJ9?QGT
M//SL X# UU\U&-G\>!3M,75/:]C*2?5E^NL8CV%+\80WUF_C-7QB8JU8UJ56
MTW(8A8Z,QQW)*1QCU/HK^FF\$"+=G6K+B37=B9\F[#ZZM-\+.7$3S>A:-$^;
MV#^2N.CKG)LQ!=LTS!P8G'J-'G8?]JG%6@LLOV:6^4IV8MPCJ#J:I#V>>]'Q
M<U\VIT)Y-2!GIT$"NPIUWT2;T4YT:#2 [Y86M=B[VG+-CEMUWY-6>>%U9QB]
M7_$2PD.AXK<P1C88Q=1G1S?B(&'P,T[CI:8Z:D>2FJ]3=E(_,3.D^Q-+R&2\
M[] 1@3]Y=7S>PI!0>GK3[;>5:_.5.W1RI=,N 8N#VE=<FM)M,2TA(O9^!3[/
MH_@\,/3Z8Y7/=A4EP?/"#WMMR1&)#W3SFQN ['$N-9< *G&]ANBEW=Y^CRAQ
MTVQ^ACQW*>'3VN2;5B2]+2#_]>JWD/0E^J@53%UM/!D9Z9$FT[9.50:C^7>$
M7IS1C3_.TPN[+#=FXFU\PMG$YO0R*YKG@?#FK=:"-,L"<:U-D.8Y^(1S;W/#
MM\A>PC64S(DIU%"Y]=#P?BU![>:P1)PEMLK)D4HEZ@VO80C32M$YL3;;4<LF
M3* 1<Q)>S6 AM9ZNWE!92<DYW&U]$,KUJ;)2F&- JF>'=R!AJ:^48[$Q(Z^A
MFFP0H0V^"WM](&HAIA/NK*:3>G;--, F[M1D2N(0_<Z6G^Z!H%WO25+TA->$
M2*"Y_$'-%<',394N\^^7_%8_\KQ2,"ZTT <O?*U+-)FY&AV&NO>O4&E^4!=1
M-SMUEK'?E\/N.,^,?02W#:#Q-CRAIZLY'IKA/VBY^Z2'0RJ.-N>;VQ<W'TX*
ME?'LY7-OTZ0NK:IAR\JQ?-//[YR4'X5SL+R,9J1*!:V+"(H0/_%=_A2N0"FQ
M#/:1*'7R@&(&+QC391&TI(6@.7L9E(8;"F.HZB!F2A3Z0N A523Y3_-&']6B
M  H2FI/ADA54_;0$:C6\]VC2[?,9F[+/&*J#U6: W&!+4^)WBZUX=4;'S22M
M/=D>*@:> M[O2KW!1A3$#HI8&7W31\ =R\H&_*M@F9ABTQ])[X33YUC(&5(G
MJ:I^,+"ZQ_.<'=/KG_F'X"69)B2W-RX!>H?GE,\O^JL/_ <KN]9\F@/1C:>9
M7LYGZ.5-M0S]+.O;,RH-LOVU%ID#H /9C /C9H&M L61:J[A)42X?BT]O6B'
MRY^\1'6K2:^O=B%. O7/KA_*CGVZX$-9;">I6N7U^!0H^;!F5M%-B%2N.V\:
MZ,>VTWJO$U4\X^:XK\,22*?)>>2UB?HA"V=)'G$\VMD90EWY2),,L2K#_Y2+
MR[VL]S9[EFI4%?^15FKXXUM:-S8K"V$YI$S3\S]9?1MT/?#/!>,HO[P<I,$$
MAUA@C[20Q_FXTM9BYO,7 IXO='Q[V!$5F_9'@Y%RS3HV[B-D8=PMG4_C[!(0
M<51Q("B\IGD) $T<6>W5\RUHTVX]0>RD+VA'!Q)C=TNQ=-KAOOM;0H4./)CY
M_G=<4YZV;K'>=&IS;J9)=]DBQ#?F'V!O$R#GA3N=R;X'.-7%O3!VX]1%-XZ<
M5Z,/%6S)XRDF23[)W2J0=GLL/X%/\8$?C FFFT8+KR%RUOO[P*DC <F39^/1
MA 9,3LL/9^0"#(1![!(TE^SE[]N;^$^<R>>S(=R9[ N)^GB5:7B7Y/(>\QMK
M4+>O-=$O@=O2<-H+"<&7 /JJ/6I<_/:21.D2*YV<K4'#V'J2G I?R^>OCF[S
MNJH#M%0T ,!:5:6^7.;&4LYYXPZ29F\FOP=*\A3-?>7W%B/[39&F[- )!2Q)
M%Y-WF_8-QWF^L?;^_(UQ7919C ?E@WAQ_A9%#NX;\<K^"588A[;E='0Q%JF-
M-2@NUE[4%)Q0^8@+'-2%#3-_GA]%)RF1%=\- MTF9?3/6JK5IMN @5KAT\6+
MQ-4_'.0?8?;:\$:>4(K9+<F*'E>[1U4^2<0I3^SI'K&0<+Y9"#&K_#%&+YZ[
MZF81/7&Z[5%?.FV#"?;48RO":E_,5R/%<IQ_X]=;Y!\CL(,A'D)4TTI<365P
M*R*"CF;<1E)GV=?RQ(\,MK35H)R:>9IX5!NJ4K4%?&?K:4ZHK/!R_U--OW9O
M)FM"GSO$LB)<)>R1C0!3-\KG55#\!W?8NC[F!7N%(9H=$]_UZVD:G"14UMW3
M,\^AF1$YNMZ,H.:4?^>MX[.[$T\Y?W\A7JIL*J]HO_1><O114_,NV%,A$\A2
M[C2BN]WW^UP2CRYM-GR/?Q1-0..4,/<T<?T+[/&P!UB#AB6^SX<)M(Y_-EQ,
M'.GI_FPF,(KX="?61WRLI "YM/X &"H4XF[OO3X/?M\LMQ4HA+TBS(X8/E)Q
M9CF?ZN(PNJUT,NK6G\6DT2GLPKS&GRKII,7[&?&P81,^9220#VY0LG>*4OHZ
M<G*>95':RS<NB/)"8I[F?-<S (?#5\?\I?,M^A.>K@T_SKEQP_T^]Y'XZ?82
MB&80V[>\WB&.S?D0R.6OC-D+%[?ZNG&F&@+7+ U+2$/*#N_4A4W;@C_=^TA,
M(GLM;^\V;+ (N3!,F!8I<$@Y+U %=X%Z1 _=HG$1B]Y_JV<3+'!D6/9?,+F(
M#AC5B$?I,PN(D 76K,53@^$Y?60?K_3\ VM>H+,.-K%3&&JES;*M4,/>7DNP
M7LYV&'Z-61L7D&][/K(&%MS'CD:)&],#1)I1<[%W2;F#I5U/"GI6<GJ*SS<W
M)KRJJW?$^]C $LW>B-EQQ/[T,1)%8]@"K;3=F?GF[U6!*RC&S9ABB;]\A,P8
M5PP+\!]EQJ@=-E6^ZV=JW[J3_\D-_^%V+D/9O0X+":QW.WC*>W$WJA"7H_/T
M.!WK+$1Z"6@%WNP0+'L8#[0"]L7#JR/Z9\NTQ;,XU[Y^K]"!/I8J)=0END7'
MI-4K]_@OY5T"V P"TX= -R]&GMYAOU[-'@XE;22R6I;$K,=Z,L]IF%5B=@L%
M.N%0UD;A-5*;VDR>,JWUV\L?)K=#)%NR93HLB'#X12Z<-Z9KR38XD'T+* >/
M$D/1SP64=5"F?Q+\)N0JFA?4R?R1]+Z^BMF>9LTI?/@,M#;\HM]-9:_ZPI"
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MT&9N@F^K+P@3M!T5NF%OTAUIKA2C\4'21_>I&[$* T95J<,WVS\.+^]PY<S
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M*:E-786VIFL[I6CEK,022HZ\GW.:+#,YYV]%BB.<4!UITK\&7,TI_L4&$O\
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M:,XT\>LL, ZN76("?)=14W@WSLINT9]NWPIXMZ_*UC<HRW!J["!BIQ3KWJY
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M9[7)T;TU?P1"3"\)[:>ZBG5W._0RIQA4PZ5C-182.E%$./8E9V0>9*]M7N(
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MZ]\#C^7*T18J"N)MUF5D=R\$2N '<CMPSDZ;+?#MY)7YW9F=],]';7_+B?]
M[^KNS_-%'JSV!BL/FE$EZAJ69!^IAHYE7_5,T_Y_4I2'9]N01/W[T[&6X0]T
M?]<F_LLZ*_^OM8Q:9]O7BSQ7UN(?]_^^M?9_M_T_5V$"R5^,(BEEP4N:MBWR
M/!B)L )(CAYFWT&XK<#!,.9]S8GAW6^F* Z1BK2@Q-KM*&;[_@ B98 _$B]Q
M,< $;]F+?.IJ3J\]=*A B5.AI&PN<.3]3%""#"1KNC_\0$JZ^$M0XQZ'!^T1
MD<\0[JN'@MT#S-[.D_-8G"/>&]TP^!F)EM=.1WP7'O =7V\'7Q-J-[\F]AU+
MW+3XL[+D$O >LXHW-LNZ+L$(4'@\ER3S48[G1B$\HY$/K[$M+W=>O-/(FFLR
MDQ!!GN<0+J"3+N(@.9YLJLK7[O<\W(KA[<EG4$7LT7A.I:E]!GODCI,\-T$1
M%F#U,E/3--O0S'&P_#2$S8.W]WIW4V:-I@]WZ"7 &L3J+W?^Y8+>?!*RKC?:
MR+C8=/VX_;?'-@/UO(+$:&G:Z#.OWO)R0>+%58R*UC/Y>)R1ZK%6K>C@\47!
M)2#?S= VXV PM)EUN#0BRE.J:MOHB+G46]=X=YB6NI=H]-.=R9ZN)E^2J:5+
M ,SQ]-6- V,8U\3AWAT[PPQ8Z=.9S6-LVN=)V_A/76[NL=[]=@$PH=,U9*IK
M#OT%.[)=&^!@PI67.&/>5Z%FWDE3_^0-,VN\,&RJS/]%T?/85: %4$9P[^M8
M:!COIV@7N*"11!F>;VO@QK$/;G 1;:I9@7'KEY4\;G[O!;73+);EW;$"K!!:
MA#\&2/7[D82_-0W@TGF+0+"]C["N[LF6=G-O_.#FFQA/H>IPRK&(:HF#+JZW
M"U$XLO%7,3FGLIZU<L?K??0I(8V5H.PMF624_^(-+R$(T59NWK;TXPL]L#[=
M<6K\=-!4(;&R__0>3$N;L0/RF=Q?TXPOG%>V(@3(9SP];0XUE$^.PDP^91A[
M321OUR\Q-V(V,=X?<+P)5;(5L_E\#$&N9USH_0L( 8S[' <J]CFV,1<^\%75
M_P*ACMFAB?>__NI)/E$-.Y^^T+O&2C/X4.%T+>>D.[<[X<*GX'R?Y]KA:]G(
M2\!Z!A3U,.%?-_]Q^ /'U;OVEP#_Z/^\_8%=6?0_7ONOVW^/COC_/_IO'[V^
MH[ 5!M0Q_6&D!P <T@K\0]2Y7@(8JBX!%%O(6_[VMDO;">4X@P"F?3F#%8D1
M\L*P]C)*R\+:$#3HP9;3<ISI+P5**USJ,EIE?9&M&FI/4P$/T?R_N'OOJ*:Z
MKE\TBHJ(@H7>E2JA*+T$\H#21$1$BK0HO0B(M  A48IT4!"0&NDU1.DU2 >1
MWJ2&A-X3:H 0#C[O^]W[WG/&=[_WC'/O'7></]88:^^]]EYC[S7'W/.WYIR_
MF9Y)S.[:MQY>D/Q6%6UT(_!.Q\ZE)=NWRDTD=,:RA0 )@M\0;&.^T]WB7:LS
M@LGQ@-C%O1ZXEZ"#;:G0DM\()Q7I$S?Z0L7(C(0SY8=@1WGV43D25XX^;"@V
ME4U:F(]7-*,RL5-);(HVR9K-F[]SOL$WW?_B1KP# #QRL@$ P(KV/^D,6FF-
MZHCHE@KM M05Q[A.$\Z:-R)+_'0+8*"'7%.'JL*8MYE@S-;&V=NRD4%^1:&H
M6)UG4+V<-QEIQ4M7LI2T! '>)9O_L')[&P.TI,TEU#[8:4ZH;O,/1-T2^FN:
M12Y."2#?M%CNQ&YX++N_'[(8!9IR3>F2U3CAX199ZCSXF_%,JC])-K1>/H^$
MUJP>DM:VJ2G_\BJ^6MA/(CWC_?R-SCO53O1,T^1[M3K<[;(?G#E+I4X!-WJ:
MOU$IZS116 $<LAK[TBOQ>$@%(FBOCP%ZLW.9H --\+;P["D&E-4Z\]S3ZYK0
MU87MH[GOO\U0-ZX5W@E?&?&"F_N5I+EN+0BS%!)^X/D=W?T:2X_S!G;7CW:=
M!CWZPI291CV*TI[TM;+!1IFF=.725-LH^[YPZ7=P00@I]=#B2O_"R!P(X02)
M<[;$K+:ZQE'.5Q^@D8TVIX!@D^!30&3VR![J:M2=02;:DRS78)\P=B\@W:-M
M]TDB^MN/*P J@,?Y&HGU)T")EL(*YC(+;:-%=.DA6+].IFGV+<PL_QE\I$C)
M(J)K>Q7;(R[@LPT3K2:RT]0[H?K0UDO'$E/L3A?W[P<F*9?H#E8GG0*LL)=[
M4-U>XA4LQ68)3/=K@U7]J-O?*(%-#L*!E;E&@2A7)QVMDI(-\LS6-FA5?N95
MB.MO S==;2#_MM8+7Y2N#*$JS+4>7-2& ]_J1,%4V%SRF5_[!CG]WG_QW-/B
M1*/*^X6%,*$A)&(WJ7Q#76) DEKK^D8LZ[F?G5$C+W1YPA?K1?$1)\Q&,<V8
MNQ^5,U44X 51WU?U8DXN&7#[^.UQ<$D'Y7R(S=&;$;<[ @_LC:]AI&]S6)L[
M/AHR^0D\!3R*2?0<\MPD*XTPZ%F\7_A?,0BN_+%!"O[PXGZ]^/^ORN=&+=Q,
MBV5(/#IL-X8&FK7_CEA9X>!A,_(:=JNX@RLENQXI5X45+BP 1*K37K^??)R.
M42;9$:DZ$!>D=4-K'V(OP)SPTL/U-D5.UQV3GY9OB]U.?MWZH_XGULTH?R4<
M,'3R:5>7VA%Q'::!5D&3M6I)@;D.Q!63]#"BV+S21G!Y+*N5<-TEO226$$/A
M-WYC(R,[],W^=FW@ZPC'(BS+*I*NX@^Q?V#3G'9O_4MZ=^$9FDL###$?&?LL
MDI0K=O?^UGUO$)>W8A<[6K\5N_.:DD*>&3K<L3;L^14R;WFO)3U+#F3D8_;?
MP[Y_6/&RK>G<943#8+_LU1N'"8EN+-E4^7UO_*[[4']G[(1Q$$7WL[+,EY.G
M#FY! ]624)L6F[<9XMJUMFUIWV^71BL-;_N.?1U+@!;IU!$RC:$3@Z,;8AYE
M(B;QQ4,GF:81ESXF*):^U3^QC&X!MKW!@SU&!91D=V+(UT[$:M,3;A2NX/CW
M*V(^-QX[(]/2._<4A-D5.Z5I-5U0.2]0BRI\;V__+/WT4>7H^<A$LN/R3K+#
M>#"#WF.5/\D;R1DUR^7G+/X7R_#\:;3_LB']^>^-TE\P70)_51M]")<0P7^C
M-2$A>3_)/5?;[?I%_(LL:[%SLY_JY)3C=X;!I<R1%3J2$-T;I)W'P](0QE5?
M-^+%O=SH?JH<X\)#F81.&U?1\<\)GR+.+<HPO[>()UKA!2->D;[/0D(P5RB]
MY9B16&>(P8BT9O+SJJ&-^3#K:*'AJ,%.FRLT<GIQ?8Q&^Q'$K2@,/29D+DUX
MZ0F&(!W_BPE^NW]3-+36/B_MSK%!/:[:_B!P(;X%X$/-<&[CY4N PA63Z!<)
M+%S/6 H++,^0)Q6(;@^?T%BQ%.BRE5FA0]VAS5=Z.1 <6,'_EU:[-LL;ZL9'
M@'U.._.A>D5;L3WM8V>%X6Z..TX%AE(2BD$/N^2Z)87?3WT$RK:#KX/N$[;;
MV;$,I!!MPD;JH(]>7Z%YA\L9")R^V'GAV*@'6V77HNT,T21418E+^QLZ2#7>
M)/G.=&@P*XK<_K1G;*@=R$(%*XXI$]%\*@>(=<K"#+P&V1Q[0,:A >U8_;)!
M9:[)GMQ)B];2]A@WQ)M$">%OO&[&F:K^<EM_<17@(^K\-=H:Z5Q0MM&+$TZ3
M87>2!>BB<]O?LFK.!BB&;Q;-8<=K5X\U":X?RJ<%6AV9?,5C0!JY#EY1<F$W
M!\$506J6=(P2S^G5SF,:C#[G"_#0R;/7/KU0_MQO_LS0L*(<9<&0.[\0V.?G
M^.T@4_4FN4DW>XG9*![[T?'LFZ]H -5XD&?7VF#)5AS%)^9XM6QKPKW0H<ZR
M_FZM3CNURN5#.M#4MD;NS DT-ZCGD;#2-J+O_BG 7P^C>[@(WBI\P)>9A14D
M[W ?C+#_<[ZO-$+Y!UVG %#'R9[Z(7CIRRD DW^^[ P.%B,82"8M[6P/D^$9
M["Q=]!S?TTH?\"Q8JZ\6YWUT,D@ZX/[H2=D36*+,GMU2*'AY."(R?DCL5OS=
MNTWCJ*2%9^17@;@@5 9I>R%J5YAK3*\JJ!H3%$M5BIYR"V#AHI-0P#?<:E$6
M&B1;9;44VA\X^-F(J78FL?#F\VQ?WI7>R=NX2T"T<?$3(WTI,:\$BIRE:U4)
M/U1BF<SV-_/D.[>25Y1IR;>)R,!Z@7FGC:\6TT_LG)4VLFK"U/LO$31O1\M/
M3-^?P9C21W6TL(-$\FOTH_M0M8X3NCM[WLI8YD2;>(D)Z&\C/1300DE\;%JK
M"VX>J\-UH/8F8 LO$T>ITNV'/6#9<G;C_XPZ4WNO[IP"YH:YPYE-W-K+9D_\
M=*BV=*Y5UX4B?F2*N)&,&O=JG>:>*!=,;DT2E4U7&6W( CDK_(@Z+3BUMYK;
M$:2MD69UYS+/V&NKFI5]OR18F,KN[UGNP=KJ)4EU-(N1^KQ$-0]%>N!)A4+A
M[CPRJZ;;,-B$;N0EGCP$21)EZ.D[:?JSB#5_N-JW"H=_^/_WIP#_>YSY^,>1
M8_<!%O,1@37XJG %8/+'<OPO.2.,FL'TC;;(">J')_72D%"%JO!TUY#8Z:E?
MU@I)'M5EGJ^N?:WL^ZE_=_@BNP2-7-_T<.9A0;NK^I$7QYC(%%.!YR8C#EO!
MO/$"US?>V)SX>G8-+IG0:YHFV9(0;IUNHV9I^UG\_H\ZX_(0JBN_N]!N:*Z3
M(BES)81=7_A1_O=*MBS2$\HX.@BX5*[*RJ(.8:\,T)I,M8XS(X7)/?N<^! [
MZZPJ;,#+/(+^Y95WK#).DMPW'Z*(D9+'51M#BO=\UHM++\3U,;S^UE$=*ZO%
MHQ?KENYN8=M8[MIV"OA094$_IBP*%6]1,'I?K^=W";ED+[O3[9>I SYZ[\7W
M-)JF^7O,._=U>MICS;;;IX  )S(8>6'"9&6&.7VK7U6YIQKIHN9+3V:P--YL
MM$FI@UZ.73P%& V^^OY\C0_ES?H4DP=(!Y:8&":Z>++[6,@>'Q;7F0ZW 9N!
M]::-R0V8-?.#FD&8#FEI+F4KTI50A1,+R7"$\P[MSH]XHHQ:QVYIO'IUJ_).
MQ&N>NDZ28#2@:2G5CF2Z7U&K&PQFE(:P0%V4V-M/ =<,#4;+M;4#16[="^VZ
M\+%3'5:@H:JN(=]C"[O*;752W6B_+!8]691B?FEQ2M;PG:E$K%*@VUZQ:TCZ
MC2%E/O@HLD(F*K]IOX]N5<$V*GOU,NK=YF@TYUN%>_IC^?B:1%!!#G-QEN#R
M5MXTH5')6QKV*>6MB5K'8K(1>;/^TV\8+VF2>)7\A+ 5I,PW27JK0=0-X6XU
ML>D+L4R_X6AE3YYT""I5)HL4/HRHD@.+>G-3P06=N)GSB':A#PV_0SD]F;X1
MYL/8:="\(7>5ANZ_9O!Y< % 'R_A7FW4UW@#3C,-4QH!*>&<)3O8#B(PMZ&E
MG20--<S(A2LSW/U/BV9Z,UF&W$.;T<F'MK:1OB,ZO'/>47!NZ+.M-F7N.+7O
M)'T<-U/;K#V(^R15YU>"6P]GEME)T:_.1+]-FC(7:GE!Z?Y4.T6-'O'40:/=
M9T&^N5.-"8MB$I$N9.0TI_/JG.!@%_]^K#*N6,>H0YF]WU/;7U*?>"DQS]&(
M9?OUYI95N(/[CXG('\@?A@D%;J*Y2=Z@&X=E:K2U@@=?[O+ /8G@=<2Q,DR6
MM'4L#XZ"\Y#\GA!#(NK-W?S=BM=,LBV=JOEN=;%HYH"EV!F-SEW!E[[UCD]L
M+J'XP74MD!+KQ2FK&R3(D3E<HQP^ABVW/@64';PK/RR7]Y"'F1>O&DZX()U+
MS'W>/.3W1[D)%U'?%Y#G>2<AX31 N>[(Q3>"X7;PQHB,P!11:_HAWHV$W%/
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MO.,R)"3!=?_C$-D;[60";CUQ;[6X7E\7BQ]ZV"_P;6C+@Y04=D.HIBI6OCD
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M.V6!A^Y?;:;R>&8/+E 9/TK1Z4V/V=E3>&4@E6%D3 $.Y16> D+$!LS:1FO
M01_0^6M'4?7)++$RE5!G[*\JP]O&6E7R3]]XOWQY*_VBA][T RFG.X]*(JF
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M:'C-:.\5(36=GL>KXWIB@3TS@F.(]Y$]PZN_B_C8$#K7( MN W,Y4[TD&BB
MW_?D0L_E3GE.*3:AYTH<3NY\GP0A3L(;:XQ^U[4P! F2[I+D07XEX H0C%@C
MY"[O"HK87,>;<=1)7-^LUI#++/9WA(76C??AIRXW.D1+"G-SK.Q%<-_C9QEU
M3@O.B4_7URZ4FQ$&\WYE:+..R*G7?!%7 $(I83T,WVLOI<6.I(7IF#D^*.=[
MI8(3DLO(F_6D3[5$S1A(&5KRZZ6Q\>")D<NV@GV<\$NPS= KLF]U3=*W!*\
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M;W; %E]'F.G'AX=BN7$=<L])DDV<5]X:$: EYW(*,'ZOFANJ1FV.@A]KNED
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M7V<V+FIP9^R\!U14V;8NO$$0)0J2@Z6 @)(4"9)%)(L(2A9*)5,$29(*2D1
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MZT0/.C@)N*Q/ AB<<2HDX/9J- G G.XG 0E%._<BE'+O*!;'CO;_N3J]X+!
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M1]*%W@MT3 ?:P_64KEG2N6Z>%2;MST<CI!_))3"[6L0F=BR^-R10XL7MCN]
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MU],HG(*>?YIXYDVNYY%*./.78CP.,P]4^ZR[U1^T!7, O4XQ&PW[6-7(6S?
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M1^^CL"LO6UE5=XS(K3\8ZMZ[IK6CUC !%K3Q/X00/(_%6^ \>.&%?BX?5,O
M(ZW\]4".X4M#8O<^6(6+"29?NEI,Y2N^ [_E,5$'B7:]5SGLO'NXC7Z"^DR9
MB4RP,;4Y56@H*(AA.1S"QNY[#BL8VAP;^H2"P\R2LQ?>2?&(Z=%,ITN8;IF(
M/#N,MC[6@IY3E?3MFSK?[J',3CSGLV&*ZU_T&JGD<82=@Z1,W"%R8"EC@U=&
MQ)RSHJU(@#YL__/3\IVW,F]+99<2NXH+J\4TD47ZJ*^B]7LN,^H)$8^^*HJ+
M-^_M_,0S#*=>E;>)%UTP-8=F K8=$F[=[5I&7X9J/^NK,=,*944 _]X0CL&%
M87D:09?38JEQL6U%S[C+OHD,+G;1Q%A/;53++B)4+:)]P6A1Y](-95I0:R/H
MY>$67J/ S+Z:39I1OB$]Y^?5J3[MX$\B2G9]S\CX4L,][+/K'* SD4L/G6'^
M5MDX':S&75SWG+\RB_V^673,.Y\=$>'"IDOQ+=<-YDX_?ACWK"E.@[>F1&,_
M\ALZX5*^?>WVZU*7/?F2&WJ5@Z+9"3J+SNU?!I+C'ZIQ;=W>ZDT&O^$N5 IW
MR&K.Q+F+"FJ\E.>"Z.@[V]%"7H4;2F<%?0>HEL$WH#)8SPM<A!0BUUIJ:?R"
MZZ8.6LY9QFRT_IJ8Y8%V0_CK. ESOGLR/157XI4V:$$-J1Z..\L_(."2;:(9
M"0CWI3Y;68-";.S:%8 #AY0X8EL#SX]4?A4'8\_C4G5>%WM.7VT-6*@GJ\?R
MN_1^ZGA8Y-&\E]V&JDR.G!>2+)12IL=%C&P5IQG4OS2W-["X.F"G23MV=3 X
M>@LEXC_)(?],>'6;!B>L-:# B-D+Y,<)=[BO<3X;==Z-1$MS#=<BD0GS9N.N
M:*>'.JNZ3$5L3P[&5LDFI<8=8+1>=.#]P &D*ZL/S&*LWL%1L&+0R=7%A7*X
MJGQFJSS8X/ML_1W#*E_H%)JQS,7;9M9\4@<]5I)2@LZ';%3P),^*=\)TO+:=
M930&E$#8!GCX7C^CP^@Y/=ZUQ-R<@U="H5H]5/9QJ_Q9Y2YS@#D'_S6:.3VN
M[U 5S*8?\J4N^>'@1#_$/=.V*N,*I^S3./);-EZ/GVDJJEP,!BM#I0848)CC
M!71L*%. ^_:=L/LPI)9 QNEW7M;[IQU<S19[.R?@]^UZ?-.JJJ2=@3'?8X7L
MW@7Q*)E/J\<"&QW>("N^K0H-B#/S<D ];IEJ2NKF.IHPB1\Z*2$G&PQ+&KJ3
M(X@.T-3$X]WC]*/L<?M?T5L.!=,C/>:=+<7I]2 01#>$UT0/FOLAQCV'[R9W
M$MW+6[N%B<NZ$XO::+[T;X$2.$C;+#->%4,"=#,@)=ZW*D*W" -4\6RI;2+^
M/[\$ _$QI^@]XL1Q:0OJ\?-ZC ZU4HN:+J5H%]<EZU,VN;FUP:)M.?%(,FN5
MJ(1';B\T#U?W8;@G6*[YSL[#2Z.5Z>SV1?.:3^I&G2S7P57W7+9L["2Z.8NF
M%&(L;VFV?.;[5'JTCL=Y[&=C+7,+S!_-J,]05*?IO1QE335-H"D*]N#6E/46
MT(&]<?>^3#=Q;<SX*^S8&YY/J*U'K\C[#Y4/N$^N]J#V5Y<<?,#[<$SU:Y>2
MY(.[8]#K-@'Y>D4_:F,:K#^9K[/&%?A>?AWV]%H4R"F(RZ&+_:M&#G&8R-PX
MY*4SK7IW#"]/EQ$I^/H#9_N+<"2=XO5:_V<\U5;NT&ADQVY/U%A8BY?KA/)=
M;,#L:T]QEK49R6&\5.$/2ZYOKO7B!=]_3/ _N*UZ5FPEB#=AQ:*@^/CE"^F+
M?)?K0'03K=C5!:J7B[68O J;>0)5"V=H$J*UU,&;5<BNEG4@34KBZF'('0FF
M@>3[TG%3$2R3RQ8HK8;]P0&]W$F+^_X?OZ(#8#O@OIWJW/V[>XJ@16)LT;@Z
ME_K(IE35Z,(W+I5:3=TI;W$FW<3E'NP;$U"?K?'-6[#7SJ6UKMPF9KC]R19O
MQJ^N!1;?E3(=A(.6'Q6[L#Y4?;^MBTTXPZUYIH\+) %!T4G!:"#&EI<PZ/P(
MR0;6_D>ZTCJ?+\'OC_)76Y,?W%=+LDF^O<U24OO)B)?=-&49.G;/14&O!#);
MH85E=M=85!%=WB] L,>H55O(/7S35?0BI[ZJ^443?9-5E*%:(3]^\'@!N;LQ
MFW_;S*TV(.TX;6A,QWQU!*0]\,=G,\B^XE5Q03GXZQAD1T-Q6FA5C.:'&!K-
MNT-3NL+%;JI,]*;3XP\9'G2?$B@_J>?-AAIY9S;D''^858<AIWFRCI_'EC3%
M/[J34&B?P\4S$/^RBKILV82;,<*U _5:9I8VD&==;C]E/EJG_2A'C:]RT+-.
MMM0ZP>@QR[NG&FZ<A)7'.2_HR6Y2O2:\"VDXP//73A]B6;:CO1PNP<V&D?UT
ML_;?JEB2N?PUMY[J3;7) &2VO:P>*;D\C^I1<S"+JG59!^:3,AX\!H]?@V,J
M=OG'%/2>*#95(C'#C+H?'5/$XB?,*R,>J?>9AYKLUUD_%@GOOUD*ODO(A8)*
MH6(DX-7!7<[DW&R=@L8D&SKD.TC11M"SQX:A"DO;;CO)PIVBE78<RH#DFHL@
MKB;7<1\[==+=MT#\18=EA+@5W#5HD[^HK#=J18*VCHT$6].-S7$/,/X6]768
MY&HHJ$.N[M'$N'E7==RX7N&]P#%F%9T><HDN<MKRG9KM*]-JC661AXT6XC^1
M1V9;RY*)SW\(-&KI@!O ??L:1O#*C##IL,MM9O2-$YM^/?8,\^$70T557,W$
M9:WDE\\M]A!62(",@^6K#&'_9A+ L2M^P0+G3L<JW)M=XJ!;''K]8Z3\LV:V
M_EYH<9^IH;J[56"/KD]^,SADPJ4F#ZIN7J?'_'7.JJ2UQ%XNK[3Z>>WFF+ +
M95LO'T7M,W:*J"X9B2W]I*92?84K6(;Y-C.U[9#=KQYW4DP^G1]W\',.JM44
MB/'A*Q]"6,1_T==PM+&SLSYM*OCTN&JDTU2HMP3%CB8!09:3,Z/3":/1I2DD
M8+#ZN"2PWT)_+R6TWLUJP1G29G9'_RNDT-Y8Q]G;^1GPM/2E9NZC\V^G]:A&
M3,Y1QUO0^8R%#NH@)L8ZJEG?'?.@0B3KS%? M2[1[</QA23 _L[XD=S16/F@
M6;ORAOK8(@3?MIMH"8_0PS0TJJ@Q/P 05RL(V7A9WT6N@//'-QZ%]FP8)JHB
ML;2C*IZ3D;@#ER#0<_R*S/UV<E:#4^<MB\!"^#O#2/'7*%:%\VY6\_UL/S+D
M,=OA"6Q#8NA2@6_J[\OE>J$V]L0OINCI"#F9]\6WGTLF(_DN1".^"N,11YNI
MSB2 WF 3OC3=^)P@XP!7QRUVLEX@'W3>=K5*7=&IZQ(1%4'?NO%H2GN>\1P3
ME;L6/_"Q#2/,$BB-TX9%NN&ED<-JVQ&!K=*9"JS?/2MC;K +"Y_:J?GY\-5&
MS#TRCN5&F>Q6K,9<-+H#5GX)R]/VX/R!T8*NTK)H]XFCF;*G.TNT%ABH^]G0
M,G,61IT:\9)MW[PR??U=G>X(*R1\3V*ZR4X_S\4A*\_PB%-_5$L1<?E ?0.+
MYSPK+"HO2 (2I0[%OZ2UPBL[0^IU%KCDSXA(U04(WT>EZ0Q!-;RLS^L.BV7-
M-@I93YDKU\4)2URMN<V26K2&0@J&>$6#S(?3]$8V17<)BE(Z^EZTYD@=T\L^
M3Q*^\T=I)9CL7U7JO)QX588:8T'5-+%5N#!["L>GE=;^_ @46F_K%?IM#\R0
MYB/9:V^3>K<JN[JW-KJ7C+K#^RGX;7H8#[@-]=)8CC47T8W9N#U<DG9KZ'0V
M1:)DM;";;Z,ZLJI"*U(PQ75%[V;TZ5FI.?;#9P*BGZ_HE!"W'FY/^I=.F'M[
MN4<\<+,$'STPVD;6@LW1F;O@< 5_NWEVO*)8"<3#@;[,GQ6^$A<B*O@&=,7V
MTF=:7!1+U\RZ'/>8[@D>5.JQ F7'(KB62:-$X]K:FK$/Y9BVH^E,Y+ +(T*T
MO:B;47/\D4X=5[RYXQ6^A@ +LUW4;FEBQ4_CL24;$D!W((U8.Z)DUM?\EZ;6
MN!*&.W0]8/C)HHZP)P'8G=DMT,I5FS)]7'S921M\?9197PWX[QYJ[B\U.4RL
MN6%RF?LW835'J=_2" \,S7+&WQQ<.N96GB+H@JS"CN&%""Y<]+$MG@.GMW@6
M*KX0RVWN<#1%2?F%<6+JD6@>":A;[69VBEOEV_ZTSJ"]7>D:063",D3;89+?
ME:@&(%KS5(N1E6<V\_H>5,DFWW6RL1JBU8,^+92Y[(78@W4_"JWQA(WM>1VD
MRWR?)ZZNV__V9C?B-=S07#^PX<VIWE <K7R_>F!+ZO"I]-!-<W;ET:\U]Q&]
ML77IG9\D9ZF@SACC6+P*:]@'2'B!8X+]_M&1>4E]@6X47E7:%&B%><N'/1/2
M;4"5D(!N0G_%Z1+47O4AHL%;P^8WJY4Z&0Z4'SS05_M>_#KPU[G&KYHX.@K5
MT?""REH)_<,#ORU-C1!KZ0K;?$8"//8D V) 6X%Y>5F1G\K_P5V%!5F;(O\?
M2JH!OP8Q0Z]C:COZ-MIJX\O,QQO[(;32.U/];@*#[5:AEQVX0RC2/SX[?8]2
M4-BE(VE?0^NW)WN_U;-E^]CL"0R)A'P8=IDA+K-J" U])INZPB^&_A#W@;RM
MC./IW8SS6)?8103]]XV)TYGT13F6^>]<O5W<2R54#BC.J5"=#" BEZ%-C[X_
MUR?X(6>._@\_BB&5@EEM:M53+9EYAUUD+^UHC2^RV/0]?"'3-3U=C-P=) '"
MDQB*FN+D:E@,*N:D!ZK[?2@>7:C DH F,X974,4%2(,/S-HGE.7S8,;,H.]*
M?53GBJLFG_J;@ML<,;-O C8-'$E )<,+21UG\I7%-OU>A]+)R%[A(GG?TB?2
MRP,4.UI,$JVLAU9@B=M%R:<4'9$H<?/)U<EA,S."S*&W_&AY2!#E385G;4;@
M4"A7MH^\*G)@U_^27?XD.=]KS3YWDXH;-YB^?&DKL^5/T.)/U!N"FN=N<*Y4
MY)A.<46BN=NJ"^*KOJ?>F0FOX])Q;F6AB./0ZIA/PB B*E&<:]*U?=&>8KO'
M<9/\W[N:BEAL;!YSF)J::G_ZU6?&5F69?QV HY:Y<PU<1B>%O^5ZEU:A@^Z5
MBAI3'D[EZ]*:J"M<2:$2)?%)#Z(*>&G$7ROQ#$/="GWDQ@Q#84P_JN+!E@[8
MI?IS76WJ7]R"/A<V];D%1YUS["A;I..[-2I9(G:$?8(:QB\ZTX\^[65R3?H>
M]$J-O5?ZM*FZ>Q/+URQO(JHH9F+RB%CL0/@5IK&_ZC-&-M<_ 9I?;>,QLI"_
MC161,;[B=!"^JB)5[\VZ]NRG"G]!D:2C9F^'J;J&PG @%R&[D=NGJM>T;DA!
MGZ)J0BU^N'0IX^P'\F]V,E=6> \_X?.9-&KTK+JRT%X_#V%:8>(ZOM!^U=]R
MP2;VM'UK&WI!O.STJ.Z',C9=OC(3F93O'^^-]#Y. $21[O=&.A5S\*Z8Y]69
M&D5FZP\(Z7M"E3#>A98%FMSZN-(NLQG-4<.G/."D4T]F#WQ+W_@@=$YJPF*<
MT]3F:&"'^.CX0 J4:Y]-G0_B['0:2*A+N>C"X3?M?;+KPKIG!_99DP-0<R0
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M'LQJ/D4^9^_J!)=8$QKUU/ ?%]+4;SRW6]U^V2CA([-O4XG;FXN-Y*1<R5U
MP]HY8_)MLK7R=)3QEZ53+@9DW,QA++^F4$@;^"CC1KSI!45<0!YN=1'6)FL[
M).5*UIZ-YZH<WJRD$R#JG,KOR[!2/4](?R/S1ET:E,@7]TQXUPZ]XR>^K#&Y
MM ONR1Z7H>1:3TK<#7X9^/%@S\QL^6JA;L^$C/?/-]9$,_.!#7]0:B,_]N U
M7G\>3EU55 J>B=;9]QL1=S4P#[OBX;:\V!?O$0K;?]TO4. 3"*GSPCY,EB,<
MA)2&-3F?LBW+F]11&$7)+;>TT;[M4+%95A&=0-T+G!7,(CX,:-3;0BR;]8FY
MZ'JA%M$P<0<2D'#X(UUV1ZAT%*\(7]TD 3NNHH'<)."E*VYJ%M?;:<E9G79L
MUC?1T8=%6C"T&:=6A0Y>%ZZZ[I-G+_@DV49,I7/:(JMQI[C.@:E'(GD?T_0J
M69C)F2(C_U2#SOZA(MM.4=*RZ\;1IFUQ&A%5NGQT->Q7'\16=Z^ADC2$KZZA
MU.X?0S,B#_5_79V=%#(0&)'YV_PWGPG39!%85'_GOQ@C-K5_E,-=+!:Y:\CP
MZQSDFC@ NRIK8L&V]O&WN=*OMKM_JA4?>*CT;WY0PQ<L/_$$9Q7\-O]-A9Z6
M-118DC@RUFN'%9X7GL*5@D*3X[X6WE5P>U;&C$SI>LCJ"[]V)=VBSX:*<(]M
M11:12?Q%H"%/6Z\WC9K"==WS 4OQ,E>.@@WFIE&(C:/&5.:\I'XN0IS .YA=
ME\&X$=IY>T^R8L30U-@4C-3N#60);WJ?*$ V^1.*$J/TR4C,Q0VUD8 *Y98B
M'O$6"9^*%@.'!XY$@1A1[9E1\X9;\EK+VI>?U%Z733 %NFW5'C0_#AQFZ_L
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M2)RKK;IZRIM>3,2E;:F"P%B#5$U][=$*'DV%'P$#8G;U7YC56/E(4<+2?$N
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MZ5G*[')?9CMZUV@B20&X4  C8))_\B8%<.Q& 22-]4JL.%;_!P\<G$S)@Q3
MYWSBEN 4!?#GKSGN\K?&/]J[BT_S*0!#$&'ZG_JPD"C,BDX!GX#(V?"E6OB_
MM%9IK*M(?RW_7T;A^L_&; N2G#FT0?_L:NB?C35J\_V0B8/_LZO"?[16]SQ.
M[9T5VYEW_*,K2P%EHATN^36/B1M*ZN<?+(NE2(09<G2+U5>7C_KAMX6%E)1!
ML:8F297YA?1ZA3\P.C<R_W"%;[_4\,R#$0]'%INIJ6]5=^D8XTH:Z&@^L/\(
MY,0Q9$:T*)01GQ;'F^&7^^=&ZZ?]^DLD83 -SA!GJI1K-$$*;ZXG<-)X@N'W
MN12$F+V\O()Y^'(\4.B)?0J BE7/B@\2K\5 5.W*5LY(601=_GT\G^F87#V%
MM=25,2?:%?:9<X$SDQ2Z^*4M WEU> PS,D^S'$^SG(:4*S*GKO2\Z+A[SU@A
M6N*1_@+#I\N.[.C;CR]1O0!?F,]7Q*[N,9KYN."V(X#Z\\)VPH8"UZZ?YI]
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M-Y(%WEM,:RG@PQ,)%]J/\V.!=XLQ9;^;WC+ _%QN]G;'EBR]"8E0HSJOQDY
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MT(6YU_179(HL/Z3X"[Y9B%S-E"*C>"F -6]2N%.FC"<%4+%% 7SJV][3FBI
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MZO,XD)XI.> ?^*Z2<I=K:;ZJF[UW;W1U[O='O<XS_2R3#;8?\*"2C[$D[/P
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M_8_*!+EQ?I6L]90""*4 U %)_VD=^G^'_@LT__^P]YY1379=NV@4$%&*H("
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M."DHEZ1T-ZIW:+_W0=4]PM>D)Y=N)#G&_.C_TZMZQD"\R52?FNHR01&9Y^
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M:[I*0J'W\!IQS>=2A:E"DEDS\HM,T%6]\%.:QX<=\,G5!8YH^%P.DATFL=;
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M3U"<%S(@%P?FJ=?VC?EDJKY53%ZL>FZP*FZK]GOA\L=/?W*9S^_Y;.\_[G1
MI4'H ':,]6&"=5(EK>:?$A]"O NFD\0]Q^:F"9&)%'F>FF;V2O#W:8].]ZL)
MEV<E9>TXI5+CG5,<%G3$#?A(_=B.$6UV)W>:/.GN/%@?Y>TG?,K.M'#:<X)G
MF6MA>3[$W=GB,%!8=4'74N+)8^8=5JJ@#F>J7*P7S<,6AN@K>3"ALH/%B1^
M8IVL!WMV7>B +*\CLZ5N.D!S:K?$[L9>U(U/__&4^Y^3;/;?'*7NA'DBV9;P
MW#MQWMI_)G#X#QL5&_:P@64J,O1FQW+88J.02:#/87F"8AA/S*7BHP8L3KK@
M^-J4B5,&#;XRD)4Q_ZV9HYTCID'ETTK15SMH_^R4S0A%[UN[07E3@FC-I_/.
M[B]T&"*>J17I,\_<FB7!\:GMV,!V <P5Z$0[CQT=\-[>R)%G3#E>=M/K20U7
M4*EATW"E_O:EY#K )<#MY,U]\[AZ+^\87#HEL_E4T8P?' ^TA%NLHCAAOR<:
M.GXX34$_>5%LCN.I!^.H5_EI"YG>);.3N;N:8U(BKSL3,U>%;$155\YT1N#[
MMSGBLBXDG-?X0U''TP%M'-_L9AT?M&VEJIT6;2T' %/9RJ;U!+XQ?+\:LG5)
MUZ%TX[C"!^3KW2+6ASD(R"!O'?+]]S"B[?,_A!;7($7X@"JE"$& M 5IFBVB
M&*"(K7@O.N!L1]_8P"1Z +.E[5_\P6NF[L74BG>_P*TNOKY@V4NO'#SLG3LQ
M[J9GU]-Q$<I>SOKER$>C%-F2R0V"[5T^#SESWNON']B-/CLY?O7WRFWVH5VE
MIOG'!\.YU@*$)&)-26$+,W9:@5;#XL-\J'?UT?D)?+]_B!@\-+31?-B;TL(G
M /N4\]&U9[L1MXOIG4G(NC,VACQHQJBATE9@:J3':"#A3*;_CYD>K'%$_NC+
MM?(VQ'[:APYBTA&Y^Z+^#U6\BW-RIV8#)!Q]E62-1W:FC//ZDFK;CU>2W>9[
M3[E]4ZGRT;LB/CZ3=V<W;$C:0"8OXN<M2\"YXX"85#=>GJJ0HQV:%RAGQ.N<
M<>$-V7%<U)$\Z54BWOK=1 N,?3 4"$'K*V><E1'Q;:KHX/\*3!H?^$]0+W&U
M[#<Q#7"]+)G/_3]8WU)!/<N*3?\R_^/_,+Q5C'K;Q_]G2\E5=HO_/F+D?E%_
MB/HWL G]>R;'<A)>_I_MT')&7-4H4B9?MVTT)*;\7V<-\I;];I48*9OIN/C]
MO]]1[72-_ S:V#%[EJ3@4T@2Z3AF#E<90Y]\FHQDS.QD7#)_V3WVGX9V\:$@
MJ'C@7#$=L.MNC2/RE=,!@^EE)7(V!2L892^#5X:SIKMN&'<@[SX'"XEY?I&T
MU]G AFY>8+L]J.,'N9X@:+Z6@_@-AC0(VDYS5CFSUS%<3\N#C0JSG'#%*W1
MJV!!Z'T\=37ZX3>FD7GTO8&K<YTEF<5'B^ZB9.M5X-9\ 1MH#K$9^&18\]Z&
M?LWK;KXVN0TPTR^M]WT>\!9#C!L= *"<+B-I_*  \<NHB)V1QV"WNO*>IE8%
M@=Q?D[VWGICL#6B!R_/60Z;4Z];6/YV8@@0&#Z!D<S'R:JM'?ZBJA(%V85:*
MXJ#8.,46]<^-Q\[7[';,ZFPL?/Y^3>Z]\O*,06G(?-06 WYQ\4&M E2D,]CT
M_;9L:NCX>""@CW]5(,Z-K5;3NU-K8]YT2FI8/@Z(?W1"J=@H-DYP)H%;<G8M
M>3>XVY.4?Q^U"(=TQ[.K__RY 3*TA772 4P4)L()IF3=QF\-X25B9*]->GW]
M>UAFAYTMG(ZSF\YVFQ;P^'/GEN!1\5K(D$5*7S=\3DM/S:U7<-B4#CC]-UBW
MF?PH5!3?'MSK">?4U/#T R>Z?=>%#.75?*F4C!_D:JE ="KMUF:7"'-38"2?
M.3BS1Y;41"@X9RU+:(S3I0R3OA7@6 AX>X%/\>7=H[L=,'=8/Z[2[2W<G0Z8
MBEH\0"84/Q_S,Y:P&)4PNKR=7VN=MN/(/9GK"OD(^3E@T1]L"8D='[?&X1_A
M2 \.3*/2:]L1+% )_=J1??@9CSKXM)X'WSW+7ZQO\N1FZ_A^%:_5WC*'!)5"
M'B1C^LE!6@%R'KK^7%CVV=)UG*P_T (F2'F,AW<T<U?#ST"3C0ER7U#+35C_
MUN[EVD,']D>';0 P@C"PY88/G$>]SQ\,-2)<O#=\\-YDLCAK-?0#TN#TVS*R
M*ENH+5D&JM;A!*!65R,Y2?!YM_<T7HK4N-^DA<5(M?)YIN1B[2?.U>_-5L2M
M!_7O_%QH^C9!NX!Z'P#G LVA-A=#".*="^#(9L)$?+68:TU87#]^^WS9/TYG
MW[3DXG?)Q,K0Z,A[PK*D=E*N]NG9F2IR'C*DZ!B7GWC<Z[RXP[H.NP#BQD+?
M/JS#M[R>I@->= 7R5>U&62NNNC,P2V@^F<@B61 Q)-E%.-?]K^Y(KB8@O&A
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MD X!$@B])J&$8-K-M[_?[F?OL>\=YYYQQF#]Q9N5M>9\UISS>3/GF@*49-4
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MQ(EWY%X8>QII1 ;M"D3OU)0^]BZ9B^:X!DC.*<S@<L"J*7;,10F!6/VY"%2
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M>W ^?[3(]C,^_>*CA*C-A4V: 3QM&S[+"Q2Q[T%ZF#[%*WV&/EMFV!D\2P4
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M?X<*H)EM7. 2- FX)$?IH.U+:M>KK8.<C<^K1P>MSJT%E]+L3UEO0(,#OB>
M=C!+=C!+&(3O4MAZ%$1'HO[MF/Q0[A<ONHRQI9<\N@R1UVRXM7384SI$2G6?
MH7. KF.[)&0#<4@]*Z]VV[G-@"!H0-N5.Z&OQZXA>D=;#N(^H>F_"+HP 'O\
MA<DJX6=9Q+>],=71""[R<L-%[FTG3V(P1+.!D$(%G#E+T%KBA/I_Z?GJ-C6%
M X%_<7CH<2[PK23@908*PS2LM[A]0QJZ3,]M(V7'26:E02"]"4VCDLM&6D^V
M.J]<W7W/<2O)RGR#[IDF^W%RA>5<CKJ1V^#'XQ#EHSW=U-=C"V4*\M['HE(D
M(&U]D*"8]66K>!S3,FN/!RJ.D^"?7ANJ7G%!ICRQ237M:A?=]SF+E^T<?5\V
MX6ZP&>,V:9)%/:$4>]RG!K] $>L1Z%,AEVL_5[MUM=U6YXK5['Y:*A_@_#&L
M_/*7K?QF)Y06A5)@ITK<(/,,KD *B.KA7:Q8.#H:U:/P-E>MA? 1)Q+TZ\&6
MVH,/^;7FS8RZ<MWUJ/<BITHO*H1L4%C#?X*PI50 &/H6SO,7$BF3-)VUNH!V
MH#LHZ9WL-4/@=' %7%#QF+?28Z/I2@GXRM78HHUCR;+B/*N\(<]C4=GP:2J@
M*J",>#=HN2/\!K8D,3D28K^4G,J46:=4>LI44>CQ*RNKD2<LH4^^0CS)K[TI
MU]QR 5-ONCT61-&8U^7H>I" />*=]T=MSS$](6Z->+:.'_.S]$*LE9>_&F5H
MEA4T[8=-(^T#,Y5VO2W7(,E$8'B70,FK-D6UGN0X4;;*<$G"WF7FUH0Q^Y-K
MB"OFV3$V&1I& , #-<4.:7$F-"N)$P5ZLQQ0A>-=8NBQ1T4?:U]\YNDT)JAS
MO4;#*Z6@Z^NE[+69KAB)&"$Z? 6WJ34O8C.$)M%\>Q4D*@85J+-"!<SFX1D;
MR-GAJAY(8#UN$A-K;36>-6!DK#=(OCB X>S7F \N"79-S!9D0&WW 6W,=#7J
MWX?(LY6GO=PZIH6'[SK_YXU!_MLVGR?+Z/7=S"\0"=K'EUACK$.4CP?+@YF@
M%?K:,W[%.0B-QV([ZLB!D.K%1P>.ZTEPL&F,*+-_?*MX=YOJF'+%DTG+HO&2
M1K,;S/PIX28MW])R<]37\I2#U3%%B).*GZON#AE3_:3<OJ)1D-PLM...YNG2
M#2B+"M$_#M6%E)U0*%=0J&,B+-Z\TI#\Z]?BV3,?[PE_B5%+,@Z9A]?".[]J
M"I8$58-$W<P(O@]2#3S]I5O,N*KUBG+H*/L1A@]'ZAZ.'6_^E=$]JAH23 MY
MJ "I$$?NU4!0G6FGH+"'WIB7MI@;F_O-[FLC+MZ2Z)@,]0A%M7P,/?="PDK(
ME&LTU%V!>4L6IXWIKO!8W!5L;SK8"!3(^ (IUHCDMC&X7E:;NDA_$JO%F$\\
M 6'!P!Y8B]Q"Q10JSC.<,7=$-R@OE@KP8#W3MQ@*8R,HV/YN\<8;E0F&OKTT
MM51GD+%UZ^N0[.KM7@.=0>ZYCLH\.W)^&W^0;Q\V2/PA;CCV*;H_1\Q8QJ/.
MMJ%-]=).^2R?^6UU/J$X#VNOAH81_3^?9T$#-(V.NOT/FNU=AEW#)O?E*/6B
M^/Q'3H&;' G&TB;$YUFMOQ0N</[XU(GKY+^=8OD^ZN+)RW/\'2JC035]?Y7N
M\ 8][+*JCZ0"+*>+TUMJI#J\/<Y[Y2XEL=S)2 3LC7W]R7])WL*Y/C1L-SQY
MM;)],CM^P?L8M$\%R _7Q^'^RJ6O9:G"2=LW>0#/SG4MN5U5$+_9@-^Y[O#A
M<ZI!-\J9L46V%N([^FJMBJ1(M#*&$<+WUJ#GB^JK?%V*06XAGFU%?W&+JY_'
M*LJ]*.8GYJ>9/@)8V&\_^D57F)5.DW,22LWU,\+]>"/LC.Y+$05:_$RZ9$<S
M)14J3"J4X>G*X0_>4T[RE;-,G=$^ _U5TP%Z@H\Z%OI EFNF).#1\;\V4#U@
M38*+^(V\0L@7#0UG0BNV>-/TA52MKC5:ZF7<0-BZ(*PD'HKM+Q@"3AD'(B5Q
MS&]>0[1*M[,*T=/&XYZ%S8T?FR3<BCY0  *9$OEK>-#G"7MWV0"W42=N&&6T
M"9FN%E6[;4K?X0_;_G,_Z]>46M..E>'C<ZG*B2*&G,SB_+<0#&=L3OED-:!-
M$;QFV(;XPP6>XTZ?_'*[VU,2E/&S1E?\!3/KHR_=9N>E<]9I;9#B?<>W8NEO
MU-PPO!ONWKFQ.BI+JJ4"E$,MN7L)LGV93EJ_CRKLC<<+>!0=1SP+C>4[F+Z6
M@Z0_O8"+*7^9-%A(?T C&F?L">#E05!L..,X1,>#"1%6Y"A=^WYUUTL\(,G-
MYOB*V,TTE)>;'44T^0CF]?F0U(;97O,[_!]<EO+OA\-Z-ZL(F I@T53TK=BZ
MAESHXV?D+LYQ/U;CY<AK%/+Y+%&EZ1MQ,Q4@56QNYO +K*XA7I#?"'Q-T3:-
M@S)K*J$).R!C8Z].V:.:U-OB=X1U/.4 _?S;<8MUW@@]#4\IHP6EVY3)T-WP
ML--W$F$9]/ @[J&A[M3K:+ZGUT8R3OK95U@_G"\-3?7)V":-D68R6QHS4%A!
M4II6<1PVT1[_;NH0<P',R]">+\H&<D#IX@6';"2S=3R\ICE,F1%WT19^9M]W
M'%(#/1$>#00HSDLTUFXZO1 \0D[C20=#?<.4/[A57C5S29I^)-34W3&_OHKB
MZYA_(6]O5 3G0I#:R&H,^32N; 4&CNQ-/_U]N5*_700(XI\/2NI$_P8C>E^5
M]I<X(8)S'YUV[[_P;8;?5BQHWJ=#KF5WR'_"*PT#0WWU=_L_W3SS?_<X-?RO
M5:=/_J46]5^[93H:430+2< /Y4KMFWGN&Y5<RG+GZ$,$BE;ZJ #-Z?T*<5EQ
MQK*: VB/:)5^KVBBJBBOIED%H5CTK#M%?L*X6X0[TZ2N+3#FU[H)J+Z\Y*<F
MZX^@89.7NB' ]N17;>I3X3)!-/_(26('%V_?[(NNK=!&A#;N7AU ]GB-SK]7
M;'Y_)E(UZ*=X6A3H^8DB%3"B0OJZ_Y0*R/4X,;\G(Y0C[TU*[Z54:(6QJ=\S
M7]N&DAOO(>.F#AM/5K&!^"#"&Y$HHNIFR''7^ECF$K[Y:WV-Y-#JI[>X6N>N
MEZ^<)3L"S@/.O+J_>$% &3ZKU'M B.H:=6]C;<B^74> EP;EHAF]*IPN%?7S
M[3^[LB84V1Z..?/&G_N/X#_V7M"?3 F&K=H=$"FCF% 2AN&D(PPS\'NZ>7!L
MZL3.@PKPAKX\@*\U["H2-4C/"&^6344WFQ1>7RW^+=T\7JE\Z0MH,\OKHTJM
MB)/5)I_<N$FSP:T=;OW[@,]]N((E8*PFW1)&(*BD6S7+*^\TR:$&IY=)D]%[
M=OOM%W+V=^6EU@P^)NT$S^D/CICEC:&D@"=K\'37H#>=30KQ?K&'%;[ZWZ=J
MFR/HI^RBOYE>B!"*^+E8NCYA90:)?;E70;@!A,^#5NPA&.0<J$>%"FA0VO_3
MU8&4(W]1248(MZ@L>6HSFQ]WM_&T>"H93<J71%YB/) :^ND2NW)>[89Y^)-;
M"ZAOA'4LPW)@MT)LF^PU@CEEVQC$/;,M\'33+B/[:=&\K:Z8\+A>P)#6#%T;
M& 0XG;S$<*C1Z70*.Q+A!]\9N1 4:(A=RV[IQVM)]<K:!(I45*N<UF3QL7>Z
M#ST8@LK\^-'1T;<S2QJC4=N+< Z78%]099X\]$3*Q<RN[>]'-#]0 >M9%(N3
M_M7K7RM ?TM Y.___56\D5\'^<<3P?^ SCK+0YFXR7\ R.R?U?A)_?XW6>N_
ME:F?)DHZ  W\50_ROW]*S7!1!O=-HN%"T%?$T]M0QIYB>536IWFFAG?%O_:(
MKX66A6NR>G&>+5GZNX:+84XKT,];N<(3M49@^[TB5/:9=M.R/JX2U( *1OOO
M%95!\\&(SPV\]3P-D4B7'V]&HD$#Z>';E?H7--A_%A9FRE#LJ8"5>5HP/I;3
MIN.1G47V)-BA_MR#_SIAZ$"=JP-#O+%86\BE[P2/TB!7JQ^M4Q##8JUO"-!<
MK>^EF+.& L$9 4$+KP>:57U3SWA!],AY"C!O36.?Q1%F1- S)KZGGE=1AJFR
MZOX:'QV-5SI&WV30F#7*4U#1O!B</'#._4_-OY- ?)G]GZG!\>(YD+V#UYX#
M:BH1/KG=6JNM@^.-T=3QQ/9UB'!,+#773ZF8BLXY;MJ%[<XT-XX?$A2,%PTE
M6982 K#?)33H&BT4T6TE9:D;37Y_$MN^2$:79^(W<#I^V-(,B;"B27M^NOJK
MM[9K73^7_4-*11IZR$"2&!P_]Z?>*'&!"JB8(P?\)^TZ+ W\9V3YOKFR3(N2
MH%%U4!&2Z)2R\?GQ7411-]Y;2,1=_X=^X(6D0/7SU[[VI<TE@>&UTS%UK'SA
M(Q3M,>6O6<L/?HP]VW]D4L/MB+2A H*N@'I;X_^M.'Y:]"/EKQ9U+:1F/EV%
MO<T*RTSR9Q;L,2,)C%/D@J VV(';CZ& 6H_FP'>9[ 97BW1M^!V$<:OO8W[V
MRKB%T[F_('%BST:%%<VX(X%5U?5CTCB-MRMY!A%1ZX-<U9"=T>*5A(2<G8H(
M-?;#^H\TG,B_#P@)BZZ(+G1^WU ?_33QI9&03,190PEBFM4_,&UI8C8I61!(
MLF^@W!_??B*69>28#J>'$:1G3J!+^ITH7@(G>F>_WSNXA& U0KRCY"OU5:*J
ML5J*KN0V<\.'^WKT^E92RIB8L)7IAT19Q+UP8?>FCH?"F6\U]<L\K,[K 4==
MFU.^/-[9CF6HF6YTW)S*Q-?8.R"Z?#RO\ZW&V'1)Q.F=_Z[)=KOC;,:<:5UU
M?1P2B>"37[HMY*/+9Z%[FNZ6$("!CTLO )7?@,Z&YXR1;O=NT10K )('+;K^
MKU27KNO^'WS&7T65EMQE_]Y^_U4L:V$%^QNCR7^#0NB_0,/_?5-:AMV3_C%>
MF9_@%1@[J>>3>KO'ZS],9V$R'A^_I?S)SFW?>W:],P3VBD)/$.QJ6H#-^">J
MZ3?4-3<<<)C*6-[B#[PD\R(T4A>R7 "YW(13Z,!$;RM$3_=:@YA)QM"SC4N!
M;E%(YFGV&IE?@X(-F$LYEC,,#Z=3\AI)_\"/U?3=\7(OV%7/<GG//6]AY\:L
MRY9. >>Y;7_R/^&^$QD*T+!*RZO-SMZ&#6G :+9BC=VA:M4I3RH+^O$ V(6*
M<M+OI ($$GV7ZM[C,YLFIQJ7,'2HL/2IGON78WET^)Z A9T#+)Y\DWJ<]K/\
M'&T35$ G11E[F.6!1/)XJNZOVU1/1-<554S/B3A:#'FO74E_%IW*UVZH^DTL
MY]5MV/?_8+I+KUP>N.XH3P6DEH7?!+6^RWJ9D/\'A0ND C1":CHH[+?^9/:.
M)" O1D"[OX4.:=R+NWWLDCLU<[*C]6)<SOE/K[X[_F9C\4930+('WH.)R5[0
M$R.=YGF^-SLG7N,1X/JOGM@]0^D*VW]HX4&1<^;1FFHEZFCC?P&#^/]?O%49
M DB"-!#?G,3E_?W\0[O>TDLR7TPTSIM8Z^JZV^?'R7(6ROZ;QJBH<J8\PDDF
M^8"T<>KFO_R:5:F/SNS)8R3Q8-^W2>&**[-$WG"5GEYHN7[O=&-G8E69FC0B
M#>REG#VS_;6<]530<1<5P F1+ G*Z_Q3>+,WZJO^VIQ3^SE;+@Y6^E/G+D:>
MHV>[S?T*6[(\$D&YP>Q&$.]FWX;/C,?3(J:K2+>66):=*P?LOL?VQ?K<QLKS
M3AOOQZWMA8^XS P>ZW+_))D3:I: D4B.S&ZD\N2XSF]T^L70AAC#6X$WS.I5
MGJT0S3WE>]-"A?VY5Y%JY))P/I(Z-CD&8H8&<O44NSE)6H1)X2I<??SX3U=R
MB\LU6C&LG:YP($P3[P2=Q@?]]J09>D*D/,?4G@YS=;"YL?+>60.#9:NG$7HF
MUZY?U]-5#X7S9,VMSTV(-59X-9&:<^-U@R11N^-8DZXES^1NV63^<FU^>%/J
MP)CU]T;.$<U'_.R7%#$:+Z]W!"0D>8R&LY)<:$P_^:PN&G;&W;O,+?4^'KVT
M6]2@_>3IR]T4"US*L"+&9 1$ R4LB]C?-'JLX?X?7A;]/1:E"4>+&M[Q4RBF
M(AP]C2E^8/YE!YQ=FQ]]B[B#?#:BL"<NVCHWU?Q'S9JA..$_<91*>S2HFPJX
M !'!AJ'B((^_%<=_1ER7F$[F2GU]M</",]$VR>95.\9.FQ47D+*,8=H,%__M
MS?M@U%_#OZFVR<*9H[=+9L[F+/_A10&>!H_/6O+AQ3W_)BWUOQO_HY35A^UE
M#Z'?W,LL$HH:]]<*B% W.^\DX!);VI)T3PE.\,ZQ(AA'<+D_?BOY^W#L^I[;
M <FF)TR8-ZXV5H5/>7K"\]%D<<*]IN?C^?.[XII].:@2]Q,J (3-;50C<8EW
MMHDGZTV(=OTFL&P-.]IZ.B#TU9OGQ< ^W]6%HJ5OK'/O,W0GGPX:[(;7)B!V
MX5U:U@:3?O#8@,#4P:*@.^@UP\/5CUP@[?+AG9^#5(#<I?-Q=!( 9J[68Q/6
M8"=,7<G@"0W(IRV^706!+^\*V@:V!,,7H1VCE/P<J)&C UC:O%;@B^DUFX_3
M([+DW8\+R1!K=FS!\OIKRC5;E'&A@Z&+?&59< $YS5RQ1W/<7GO63IFE)TV+
MU<'_5)L:X?%B&+ +SNOOP2I,XL$!X[5EC7$L87:#O3Q3:5WT5A=F(]>)N@8@
M,>7%=GMZK$6N;/HX\!G9V@3KE(/^H"WL_IUPHJU*KB'>!7,R'8ZU377_%'R&
M<[?8DS]F\<7H*H1U$@T5TKRR2.HY9)'FPBW),QK>/!3P%7A?NOVT9S991F O
MRY-CQUTU9A(U8-N]795W R%X0UKS2:HPU*AQ\MG8TD2%Y,22X_ZLQ-:SQ#!;
MNI]"20:P$7G.I?!J*J!>&7[Z231T";01+I:)3K@KE"^70G>FT6F@P6N=X2M_
M*?19'H,M 6B&W<N$09AP)J6X0:-)%8^*A[W,]/@'BKZR<IAP?O,U=?84GNLV
MSJD,OHKIZ,(_911#\MB:Z:A6;I)9#=@O@+@WC6P$D5L]I^"?ZW.E1S&8RIT*
M?P_![,%KQD,M:I?';B<U3PC!ELV2>=WTF$IIRZK%2$WR&,5J3XO,6+9MJX\,
ML#X)F5Y-;L][(W(-&D]AP=$#F>N2+\ANBERJGI+;T>3U*9F;-96L+;XAV9Q2
MF(&M><IQ;Z;?TBFH,JL/#P*=H@R Z.M"DV.R6C<$=C,*<)QWXDVSC/7P"*4;
MIC=G2'M5_ Q[^$/Q!!;9?&_3:.BBN<>>H1,Y:_-KEC78 Q?."&QM\ @D)M=1
M 4MEFO(^Y83,^^.'4#8/7H&SS4\_+]3G@(5^NC3=POUZ;?A+II#'-U+CM%,Y
M16),?.JA09AYO[^KX_:CZ7/2+MLI(H%/4=PGB8^Q\4X9X[W[!/NEP%B2^M(<
M)@XI-.E7<=63)8A?CDTQ..,B7,+H4\K8M3OU8]=D2 98M806(Z+!4.4<26G2
M+]':B)#I&BS79/WZZE7G/!/;%-V#K5][OQ+@^YUL7S]SW ),/G089@M1\SAQ
M4L80AL@+E1,3#M]>.BIX:[EZ=\IB,,Y4@"7-\MSY+[,ET.$2$.LJ@H]VLC-"
MKPHM[VJ=>K=ZS$_#/P-M)K"7TA]XU^*!GM&UU0A^:>XYZTR2'^ZUD\CX\]I6
M:T.<$L'5UK8"5H<YSY39/#9_QHUB9 %N3UL#*6IO D1;LV)5,Z)U';?\4:R0
MT$*("38F#VW,8@@R:6'A]A)3-.(LJ#84_++J*&QK</30(:F9J$^0[J2<PK$F
M',7CQUO4"Y'S-I+S';Y?C1EEMMU?Q1M >E*O76-4K!*]RH<.'V@3G=94QYX?
M,6RM;AJGYT1)I? 4><EC=&-S==R/#0#=OZ)M]T]SO$0INB^'"VPP55(Z,IH@
M-Q_#ISTALE 7O ]#]HNFN"YEI6\)/ <7VIY\>FDHWBJSVZDB*1*K<M!,G"R?
M#K#D*S51S+3VH(@F;>+UOP;!E_<2E[1D.Z;!^=N(H^DXM!*XZ5GBLYJ%Z^?N
M_OI5- 'XIF=B*G%^"*>VJY@?I,<L9?RP*U>B+K19:@+S*&.**].PUG;LM,I
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MT-%092QZVRC,M:N!0VTOP^-MQMUSIMB!$B\-@P];QOZBV/LPH4WH!1(#48\
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M66?R%F&)D$L%A)#>;7LC^^!#3!5P9O'M7'-ZC.+%RW0/SMK@'."[S+BR7BI
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MN/4P<;$W"UTIS=XX-8H[0#"AWOC61=S&0#_/F38I/CMMFHM8J4MFN:P2D:S
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MUEHY?(5M7[_F)/-"-NLMZF";%79_S6A^F!KJM$5P*_2NKJYC:]G.>.CM$"$
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MLO6@M<G&5OQ2_>48@V7UP<J:\7ANB%W8'H]0U:<<W6Q?3KDH.:ZO-5FUZF;
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M(O5? MO@]>2YH7:9AM*[@89>%2H2RXYP!IN*P0(')S>O:H6H-?[G#S34!]=
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M)<TJ0261%:UM@B5)W(R&1R^:F/+4YNKKW=VE"4><G2_!P*)<\/8%OM(_:V+
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M,GX7;/CX,/]&)"-A],9)3H0E#?JV;Z(7&]<N^""16W1+FWO4)>4=8R0_:"!
M\?#<QK7SQWD4KWNT#!WDMTS6>6.V6SF.><P&1+C1:/#(:I&"X;5S\ 53)4_V
MUBE:2UYN_LG@ UN/QTT-[T:^K[MQ3;3^?20#RR;/\5J'FH%A 4U7 +.Z<_A_
M'#2]_^0P_N\WL?\5/=)_T!"RQ!#]S#9NO)PRG3ATOG1$LUW0)$X3H@ML9Z:,
M65 BVPQF^UV![%$;$QR=')T9<) O^?+6V*/*ZN-LDM.@)\>'"W7<O8NT4!BF
M=7IQQL+=&=@Q]GI.VRF@.(IU0+*?22UJ.=4DQ83C"R?[PD4*[:Q!SN.)*T#;
M2WR=64CR\_Z+$6AOYF3H04T[.^O!@\)%,D'%#7MD3C8(-S.]TM#L%\Z39!;^
MN6]O;K;5[>-G0-$6BK29&H*)T9P2.E9 AJ=^5G5>U1%XM?LQYB=W&*OZPZ@H
MZR,Z.,WSA2D=545#SPOH&*CI>^6N2P9>[O+RI<YB<:CM0675LB#8*.G1"8IF
M*WS/ZKV6.D6SQ@]D>^$'WO<:3/4<\@GQHA:HO\^#5HJ)T"30.W3-&?[?3V+8
MOWQ:3:H:3 KYOH?6R4\J_'OL.;TO>JJJ37\%]:^@_/Y__1EB58*#<>O.]MF%
M;=;WUN)3QG<9=F8%L5G8'W2OW8/U9PUC="(M.1IJQBHY].MJI=!1]\+75%@S
M,]^$^,JU J%T3[8UT>PY2X- O5%(;=-7X840D:FTI&<CX@'G?ZI$WAY= 7P]
M*XUT0J7@#MST1T]+5'SLV%IZZQ&-,$-7\R8_U\SGD.:L6&..^;6PRV N\-2"
M_[/@1R.K$]9C=_5ASD_D]^ T<<L$W%;CE!J[)C[SO <YD;5.*PT3[X6.5Y!U
M')L$(-Y5PM!?W&_\C]<:^J'A2-A0E>_]AKJQXYEDI:^_S?OP;Y(>* =&$.D>
M_DQ39^IYJ:WMLZA$9[DY607NS![54B%\+ECPYNB^G=M1[+.NS%@BHQXE*9G"
M1BP"^ADN^W893#%C,OVKL27)3*=!\%1#!$M"7D;L]IEDU]!S/RJ;K77D/4S&
MZZ' FR:!^V8-=(R[TO)V=4P*M]0E8A:N !'([(@*I.7\H//]+L'C H'#%U<
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M>0:B])_1H]O\ I\SV(62-*GF8#;5T<,5^?.&2--^J8WAH<7W,69%&Z^>)!,
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MZ(5L=61HF]QC...@SD@*]5W/(1_#5W')S\+SAC>X!.I^]UT'240G86OAIYB
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MCC#QHR7J+_XTR!W=\2XK!_RTDH_Q^-&ZE;NN24MWM'L)ON*P?107?R(G4Z
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MPPH&N_"];U'DH B>#@O5BI0/E#>LA5U#CN/.BXS-O]&ALV,42KB@,E""5
MJ4Z&!LMJ&O?Z^GMOE#8_Q8 >&6Y1PR$XSQV29RK.'\J,3-'%_]280/OTX['-
MFKTBG=49E@JG&J"]FKVCAW)X[[#$:'/G0W[BT<+<.I)4#DHC; ZWB$KB(4_1
M8\^U'PV[+-G9!)H),)L05DT+O4@%F71I5N0T &0Z[#<+<"0[V, M%Z#*E<?2
M+8CG";74UV7PRE*T38I[$2!5#N&N*"%^P$Z%TC\F>MX9R(-QFGTG+N=Y-@^H
M#@(9!^U++Y8@X&87LSV&&SZPV*6#<A]R3S(J,3D6!K2X?LT/G.2WHO,F_*XF
MUKUGKSJY%0/446L3;R3,Q'))U%4)06I&98=X<R/NX^L;OAX">?]4Q%^!3<65
ML8_^ 7<9?M>^7?.Y_YMG&%W!Z!OM&+0FMC'EP?_"6F(RX7$UVQ"T?N8PJD:5
MOYAW9Q4@K%FI]O!69L'*3?&E(MXSCLNOP/KPB(SE[PQO\SD!'-FR"HAV[D$E
M?D-2+N'_E_0C1Q*9JP!K9O>L8XG'H_S!LS3^I(R52VGP^@;7U&9"@E6\B$2[
MWS5U*>^R>8+!-[^;?XL =OZ(E2%FO8"(_:5G&\1GX+ER3#',.$.,8CO H/8[
M$S;8;@F=4D^&0 SA67<RM=N__'*D^6.34SH'^9U)W)=QOCS-7P$V^2%<D+W7
MG);^$3AA^P]@+85(3$6=V+,R8[Z++_4K<+%^]1?Y+_)W9&DP_G)X%4)$PL9$
MW\7^D3#:37O 6OKF@_\D&?Y@6[<Z\C=02P,$%     @ U3AM6B5HQ:5CC0$
M1[T! !0   !R;F%C+3(P,C0Q,C,Q7V<W+FIP9]R[!UA3V[8V'*1W07J7(BC2
M>PTH'1$!%2$4I4@G%.DEB-*;@(" ]"Y2I/?0D2Y=0N\=$DH($,*/>Y][[MEG
MG^_>??_G_[_OWF\F(WF2E377&.\8XYUCSC5S]?-J$7!30T5=!8"%A07X</T
M7,T '@*P;]SX];QN.-=/7 )<7!P<7")\?#P"$B(2$F(B8F)2,LJ;I&049,3$
M-VEN4MRBHJ:F)B&GI:.AHJ.DHJ;ZU0D6]O4Y.+B$N+B$5*3$I%3_Y7;5"J @
MN"&&,X.-Q0ZX08&%38%UU0E@!0"P<+%^:X"_-:P;USKBX1,0$A%?_Z#Z)N &
M%C;V#1SL7UI?'_6[/@[ H<"EO"VDB'=+YQ4^NS.5\-O8+ *.!]_:J'5'X)PB
M9BZ!A$0TM'3T#%QWN'GNWA,5$Y>0E))^J*2LHJJFKJ'W]-ES_1<&AN86EJ^M
MK&UL7=^XN7MX>GF_>Q\4'!(:%AX7_S$A,>E3<DIV3FY>?D%AT9>*RJKJFMJZ
M^H;VCLZN[I[OO7VC8^,3DU,_IV%+RRNK:^L;FUO;B,.CXQ/D*>KL_)==6 !L
MK']K_](NBFN[;N#@8./@_[(+ZX;'KQ]0X.#>%L*C5-3!?^5\BUWX+0'5@]BL
M;VV$'"*Z<&HSEQ$B&D[1)2[$+]-^L^RO&1;X_\JROQOV[W;! "386-?.PZ8
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MZ?&E):8YO"SY6!,G[LZ+&5MU/>[RPX=7+O,5=!X0]7QI(Y\NT!><G8G/X%?
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M%A#["$W^KI!,&J.[P ]D,)NSO2.H%8<_3<B[?@6X)<[)#'S_\MU\0_W4<;3
MZXNR9MJFKM,K0(L6B]G%%6#A3E'U((J;)M0KGK5Y&W_V^@!40ZE^G*AT1U37
M]VN,1#YD$K(@UVR]83I*_MO9OG\XN[!Y,ILB?%KEQ?U.<HFBYYT/"Q!DVGFR
M1J9>N_DC."9F/!"1N""7P9C7*\SG(T/07);!4U-OOK.(@RN ;XKL[UT]L2M1
M4S"P-Q<^$R[7EGG'!F3?8*:SV*A6FZ)M7WMJF/5^N+QWW87]\ C*TH@Q\G95
ME3ZZ>#?=LG.@#!7RNP(<Q*M^:KD"G/9^N;&C>R$)+N]9/R-:D]V7'3A,[E&0
M&<_W60""I_7ZCL(/CJ0.T4W!/=?3KR26S[_488IIN!BQ&S"%7*R._(:M[7M]
M[WA0CKHY@X994#).:\ NQ+N^1YGIW7PN+6TC OETID4Q0P2E<$:^<OXD/P-2
M_RY_ZMEI]L+O&N3\UM,$5<.X.N-7<YU0;ZVYF ,?"$$;2U6):R&NO4$6F];;
M]9-[$(\95 CW:+3;QJG0A<2<WV;C/SI6:Q_<&<"7+0R.=!1>60/Z8EC2MLK<
M"D,-$OM$N!-X<87A1JQSI<XCP>IRA1LF$%?:2K^I^8CYWQT2\SLDSYHNAF7+
MIN/[C@)_68VTJ)'S\*U#V^(VC@_6K)=':JWN'Z*O(;J<7<F7&F3:&=XG?[WP
M[#3GX3]B49OAA8R"OM;F'N*%#FST'QXU_NZ )USS^3J:+U1*5CL[O>8X^<)H
M"WXA],L<_$KPEXN1K'\T1W^/MN4EJZ56NGD16 0%. ,A9,VKE9$EFOUZ2+K3
MA/<)1PTT]AK2$()5[[]'B, ?(T170CH G\9:^^#;Q7P=L/'ZJVOT/CL*U)KO
MAD6-1)ZEQ2P X:R3T6Z7;*N_L/#_ Q;7[&$WCDX$OHH9H!AX<#9+<QVFDIC;
MO7)?P/)'0[S(IX?HM2?S5O(F XD]A8Y"J-^U*"T^4"[[0WQ]13:.=]HKO[=$
M)[UL\3# ?J57\$!JV#9CN.GB\4(E=_R&_9'LD"]40 :Q UWK*1!U+=O"_BTZ
MAG\_OVPH)GPT=X&RZ>D6_O34A<:B%T2=@!NQ@YJ:2^='^&<MS3'0:!*L3I31
M2-[?\YT]2WK\6"]FZ0DQS3%>$Z@'6)&+82,L!-F^YC/NKT:?XGL;M1#3*S 5
MW7>NLL"*Z5F1C" %"14P>%K/]>@?S?@W^\FK;OIR17:LB16 Z/E?#!K((2>:
MI=] (<DKII6Y1;1=E^2^\NX'8JH7^'W@5'A9+;KMX(P!#@U@)62#EV: EYVC
M-)\T58=EO;Y- ]A5^H(O6]@SN/ !4&8%2CT$B5L+6F*?-BL &^6 $= \??)7
M7U["?:N?5WB<R0C\B.;MUAT0(;,E5^,W@>7/C)S/C#?^(M;)ZJJ(5=6I@JQ2
MGSW:>M;-L$F!,YMM_^N0\W?+HY[,K=FIZ!:_G.U\;6^9$!#Z!B,4IVVO/_'
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M_T/.>T<UU6U[PT%4!$0$03I1 9&N4J4D*@(B0@0$I$9%0$! I 4("45$NH*
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M!@WV=5!&Y$.FU@GM%:XH!_4=H2T]I"/[6QRZ$1P"/%4K7@!KVFS[8 $W&C)
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MXTY7FOO'CGY>]/OR?G;'>J&CY!*J&M<)(',K";Z\3WRX,+0&G(@H^B'/:6[
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MV7. YZ^E*LD^Q/XF+#-<GBFL%OC5'.:O\S;1TO+:7G#[MQLK/:]O]NBJK#Y
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M%K@,?E. #&T]K$S:PW+ GO9YIO:7/T#9;\>_P%[YKM,5!9\KG> RWA=T&S2
MBG-AKZ-JLY.>O*%NBN\[P2<H?$Y*U<AV-"Y,K^IGQ,PC"$] ^43''+3CQ2O=
M$"KHZ)9PQ8+P"9)L*OY(9&]WI#SR)WIG?/ 96\]9_EMWQZTOVXD$W\P[Z84N
M!EU#= "9ZN5A.7 = COCN!-NUD2[SGP)XYN@#4CJ\N1\^A1^,,LP6*D &:^9
MP[PK1_,NIT!"BW>FU%I'.QV*<!;]"NY6=S]\YN;6Q%\2>8ZMGAC3\"VR8Y*4
M%0I B=/BT5,77O9J%Z(,$&Y'4I"6@Z:M+E8H6;0QXMI'$= )<^^@ML7;+4=Z
MG(ARK+#,9<RQ;C_.OG$OG),,OB\9<9VAM[1_J3= 1ZX1S:1/1-&XL_X<$"%[
ML$'L#]J(,M6?(0B8BNWY ]I;HPR@J?Q$GP@0]U\[CL,[R'*RW-KK93I@'.64
M#':_.".C/N(N+L"3/JXRG^'\"K*9[@"L'*DWL#SV,.^WLU/0MKU[<DB4[ R9
M58YZ0Y2J2$Q61ZU%0HXX$X9,7.3T*P?*N_5!?>"K@X-<P;S[%W]'?'W\(LX
M(!B?4F8QFE)@9&RI-)YP[:=Q%/!><,2UHNB[_U:HC,WE/PN9%5I J/[*E*4#
MEII_5;__WWZF#N&U^CDP^>;]P\6J_#LYCA<Y^#;0KFFBC]I4RR[\>G0Z_360
MK1=+O0KDK+R?NT3Q!M]@G ^EG,H=-%/W6:JS)'N04 TS/*8'M7SX:.66;\\?
M6:6#GHG'UZCY^#DX(TR8FI/U8'EX=81QOK7OF0\$9_NFH:!C^+!Z6VCJ/^O7
MH"7)K?A>8/,>CA<[[+)><GG$1?:>-!T _B3&,/%RB4%/D&)6N )>25J%IF6
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MS!$?$:<3A82H'8$G7JLKTDMDUN3W2VKE;1RE$FM#U(>\>:*:^-D_7PC97C%
M!S"_OZ *FA60-;???.7U("8.MO_+R+WW@<$KA>T>NAP'&1BIJN0V8^6^JO_#
M8?[&SU.JDCS7+$D=VL>! [DP$=<(5.+,3%A#0(1"&D046*<&,4TY<+GWMM'>
MO/!3+0(KKBF'#'R"6:BPNJ@]#F2"*[6277 K. ).Y:Q=W[W.T^Q&]T7Y!E1C
M?"]OMRVF[D"00XCK^Q*[6KU(77)B]Y?\Y '<2E.KS=F&6WS?++D<VKF?U?BU
MJHX,5577A:8O)?M4[I8> MSL$A]7#8BF'DPD<)E=#(ZVU-U#F]%0=#_DJ29?
M7F[5#L_7T,F^\0"?*J]]Y][O6P>H>>V>%6SB[1O/6"Z_;;N:A G:-T3^K:65
MS.]%%@[*5L/9@3?>].-D)<L4;9EH9!WTI?'1_.;V_&:K\JVW+<J!C$1"G?6(
ML9G5796"X^,'21,ZKJVE@:LCH)=G08^1!).AR;*R,0V;JQ,8=>,?I4/J<U&'
M@%]Z 76Q#5)"A+L&!!F>Y;^<=0UMX_F\O:-+I'XUN;'GV'[OM*^YT'MZ&WB&
MHJM-<DF5E+-2%U >%&B^8NFB7NR?L [=JL6&7>]OT>82IT9,NOZF0JI2#KJA
MS8-0VZU?+<@-WGE7?9.I24A2IEW>GT;^F_4=2&P;;VH@_\403_XY&OX1Q1_^
MR+]%HAX)L/_GO\3^4A*ZE2WTSO/YFYR7%Y:M3QQUTEN-!Y7?KTTA"RV7%?HK
M%RH>-$7^7#F?\$$M!KK$*Q'&%=QH$Q]S];3IZ#9)*5-6*B&)/3MZ;VM?[9S]
M+Q#;-C;TX"]'957PE;,8G9<+.I8[=NJU@1+9^W2SS;P^JR?+#1\YE)W:7\7P
MHIW,\E>&$N=VG'?^]>UZV_[U]8[]#RTR?HF?KY+HW2UP_+>EB)^A'A<7=RS4
M$29YAI9AS_#((:C%."(.*#'07[;Z[ZS<PWPI3T9]_D52-NG3M=!+&+;A:7+B
MMT. YA.PE9TP\T)E3Z>ZRJ<(X4/ MZXEB1_1O[\796=G SHZVRYO7\V0NSG1
M*&R4U7XITJ0O]!Y3_7&S"]-/<TBE)1[3G55VD9-GN^-DTU.<9=\*!E3<#SD$
M>'[9*05.FS#6_E"ZU]-H8\N(VEX&C0L/W(IE),Q?K/HCD>S%'4@'4M-'T*'G
MCU\<M8)6L/V8Z<\Q_]\E=N?,/Z][LA-HW:,QX")_]NZ,U"MB;VU\V^M+B,S)
M986LTJD0+6D]K>M$I#IC[ #^!10*4_/AMAL@KK\$1W^>L4J$E2%$>?;V4/&_
M).\ XGT!9OA=N""2X-SAA+E6?M-!(B%OR8QUKYY[:YVKYCS\B:J8*FU2M)=Q
M@L+56%VV8JHN6!5#Y/.7B^H_KEY8_("9A.KQD RMA$;Z%AH91I74;62A^[?6
MUN!%']VT@,+UDF<=E/05*<[0RLDTS&J1SN[2<Y@\Y:WM#))I2=D@(G/UWJ!4
MB5 (_DEEO-@X$Q-[W#=RS,[RKAEIQ715+?<WUV/%R22N<WE+&LT&PCJW+L5Q
MWA<Z8?Z2=VX#?HGB0I@I=9;$:]6ZP =R?@_'(HV_!>'#Y7<]ET<:&VZ\-](!
M@_/R\(A?M%VTI?3UG$*=VTH*VQ5)&.M5W87N\C^"C/TCZUG0C" Y)J([A?!
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M7+6]&#'?\68+Q2C8G>J3Z%S?&E/E=T;[D0I=W->/OSHE&CQZ+/B#N[H@C'T
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MRY]/.'-GOV&Q$KJ4>OWYNH1T%RQG$$G <LTI4:G[(-J)IW#FHTA9=@AHB.6
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M[ %577XFR0;VYCJVA%D$U&@O!%QR)N7]RK>01WK2K-V7C-B#M^2ED*_/=:K
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M&D.DMB!YN68W=8@2<'U-.5MLB8]U$S-TV#ATZ']*3T066.B0W,X!#-U$3:P
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M_:J%NGB32[%&,<%)R75E@;989]EO<4ITK/;O^(:%9(<2]_Y@6^8^.$D(11;
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M33VU(*N3/ E'/5DM'(A8LH)Z[_#1H9X/1Y%8HO4_84!;?*R9\7=3RS<6AN>
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M O%KJ."B:5S:%D6?DO_[K^WO-)7(A8URQ0L0Z 3$[,NTL>\WPOVV$-B;0RI
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MKB5!NW),1P61J=J%KBG@V['.C*G7DICW/Z:6I+2)7"O8YK,@981)BTMWGQ[
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M$8/"*^)EZ*\RXET(Z^B>@L:]+5,<^-U]HEMPJ<",G$2JGN6 &CL?^"GD QW
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MG9IT,R,;%7 VWXZ<3!(O<9<.=H6%%<P^)"X,\9?&YWVZR&UR-!AR'*E^HX#
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MCG?.I#_RKH[H!E"WSFF&+ RCD!V1%,ELRK*F=LN*S_I=][ZL]..[(+[-G!2
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MU0=1TD=6,:/?YL)CW!S'5]JL]9"6(?D[S-OIQTGQ5PK\#)!<',SXI+!A9;Y
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MR0?Y )<=*W*5\M&,*M?U[\%6KU5G?*'X*#3R/FMXPIVT"))WVRO2A3U6\]W
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MNP_:DYD6KYA\)#2DFI<G=O_33[Q#7\_B-[^/2<N!]@R$*@^4-=)IY.GM>2E
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ML^^QM(L8"%6QQZ>4![WA\ %[61O@ZK +,6 %P$3=9&/<K"6%WJB K$NQR?[
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M)^W'G#IMKX453X#O/\[XXG3W 46V<@C>E)6@#R1LRBQ&FR4-$,$]\S-#"/(
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M*KWVTN!]I-C(_EIWQ&2SO2:=6VYX>KF.5/,%>$W-V,VZQ%<H1D] "U375Y<
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MMSK)Q)ERWXJ?8\*Y)DR;0(Z#]B_13JT/^[E[Z4V<O#/34_OR94*B\=XX]_5
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M'L_BU5V[X?A]>7F'0!7'Q7LC,F/P<GTR61D5==?HP="/\(]74?=U(+02;@)
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M3ODT.;J/?A,*MQ:^!)%M11DCOG[&+'TJY42>1X3Q/.P0) I&0^0A,)EA1RI
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M,:N5&H;KS_.9]BAS?IY'J)@*,+?E9Z:<2U1/63]<A=X2-?6B6AF9.[T&&!!
M6;,@95<KD<%+4HSC<5XB,<IR2FC&<\\A1<ZU3MM&MH.%FF-#^0;9]EA SLDQ
MVC9Y (?K-_/WGVB<6C+"",0S.N6^PW\&"&9^O8F2(;!<,"AAKLH(Z]JS.*!J
MF0Y^R>V0REHGT[S[W';@4.YM%C56(ZE4+5V'=//AY35@?;5WL9OE:FQ%',_R
MIL@ZN.)(>^IH,>!=N#\O.9T_N)]1V.)DXV^M9 GPX?9GGR#TB35TYVJ_?S?I
M,]K(P+.[D@XA?ED%8D! "0_G8CO9UL5L72R;DTN@Q@WC)"KW^UB_EQ>JJ7R(
M;MTJ4WCVGT^8X)YN=H0VY*8KZD%#-T'51@_*]=GZ1YV!J,OK8AQK_-7VX!Q?
M=^P#IO55D@L8EBIHKL>.O?'RO1^7  2/C'&JR^Q?D?J2,DAQ?W)UE,ZR+:EQ
M6SZ*JJGHU"(S/1/R  '&2_6/!0\A;_IQ07N0=)["^*T$_BB+1F0?W@W%-652
M0S%XK.@_4</"\;U%2&/+R_J7U7[*G42?CJ;L@H.0<XG&@Z#W^W0F]Q;LKHQ'
MSW9"VK"UBT5KL$B_#P:ZLYW!M[/+RB"CI;9H+A!N(P$K$'M+7&23-'E]0Y!3
MIJ>F$EN+D\,/K15\*(; 1P>.@VQ151U_*.\++2X)R_WB5ZL9!#IL#:ZH_="M
M??N):( %$TU7FY^V1#5!<,9T\,B_1_TJCBC_,C)_5ZL;+7+W7%Z6R,KVIS3B
MY+0)J3W@N+!;5_=VPJ@O3-<E^*5B%+G9.J8NP*4<U09ZW19]J%UGT>'T-O+3
M5Y816S=R9J1QY]7;D[NV#%.&JGX\+94SH32&GI<>(298&#H $Q!UQ>[&0ZL
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M9 E4%JS?UL:-PHC@F#RPP@&SD*HE[!I <C'^LQK\M'$&1[\WN,.Q:"XH?GQ
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M\(M6D8@6ZTZ/C'Z!= -/%SNH<?F<\:J9N?Z9G\ N(_K$=KSV=TTP9BLA#/,
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M?4+ZNX1IJ[MA-54!G,!#<D&#77:^YS#]]X,PQ<)8HR?G4Y8GB'[MTRP;^Z_
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MZ2">YE!Y3.RYLCVGXV\/#XG6@J?VP5*K?3XM=R=XN<Q)O9Q)R><L8,<;M<&
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M@C6.]PC#4/YL2KZSLJH#:11G'VNL5EUL1(*SOWE'.Y,4Y ]Y(7U_DM*M&Z=
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ME/EZYC;&'^N+<\=L:3&:*:##TE$WBG0%4U%S7@#X9-BS*^("(+(PBU !$!_
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M<0 @.-?*A'"NP/R:ZGE3.*>Y%L<Z&VVVS=1+2XEDUQHW&'G665])^D<+0.3
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MJ/H6*W=\OQMQ?B;D**=7O Z-\F$5C79M]C+WXE 0J?:1$.N_R7A_0U.%570
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MBX?Q>7(SV <%I5G!%9LE;JXN.\HEYWCXWW]U2I/<H&(SF_>B*/EIX=U>!2!
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M[V1]Z5\L;B>WJ$:6*&'+E7D4>! T:UAC<F4ZE!$&7;WH*?^^X(K!>0$QKL*
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M:-=%?V. %]1:$*%F@()AF9?0OJB MP@"@(PQ*!C::[]Q&*8'/0_SDO0VX?O
M410,ZX+,D*U0[1SY_6RG0!ID990I/_#0<Q5N:>F7NCHLJR*@VLU&-=Z6D@"
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M!J_"P0W<JPBE+WM"U?OQP+.Q.Z*EX,U#V@3 0:JH59?U1G5O MMM2M+(3B"
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MM;$'7^'GV\P:&DO."0\W^XY[$%J"3$6+9G>U*U8C6C6KK-RD7&LK^RHK7SX
M#[*N<PW[ 1$!29MD+_V/:Q) >B9V6CY=/-"='J9GDW>E95HL V@O%C2 EPN(
MBVD1(?(/PR#*+*$.3OZ-(V>Z'IJE[%'V(\MY<"\"X$G7!4@&+[QGC"4 =0.1
M[9?<![3'O23$CP3IKE$<JMU^29+Q[FN4QB85%==:M,70&R$1]B-G:_ %P<I+
MIB64:[P+=3JE!G(!GP?EJJJUN+,#?2/^LN0./'<.O8(DQ>2=R&F6OF"4'5)N
M3&\WNN<UUQ(^&NH\VS;1Q\V->=&CW)"R7T?SUM+ 91QNPGS^:L^\4X?J.?0U
MS#/P;5R*W%VI7R]@==C#$XF/.-S,B/3(O">Z"GQ7;W(^++WI4(F/4:)/NWS
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MX_3#^1I<=+*Z'_K\]D']9VF1AR91-*HI09T;Y@F>)35&=[YDW4F,9;!_"0O
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M@4Q4WB0L-2WARTFBDR%SQ;CMBC;^? !;K*[=(1A5-2Y<NQ])LT)3V\=4SIY
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M$QY+U?M43$R67T!70$87^@C<D M9I*#![W&A\^[]/:AEPA-=5G!YOOBCETS
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M--&.^YU^HL+GGQ%O*MJ&0UM52.%J@4M#9>PFDI:N7#%],YE)SP$\ZV.?< $
M0%-![BB4YB N:R^UJL_!0(LK^WF$I(YN;>7\_L2:1P=O0(UH1Q3^K_B\NHJ1
M9K94.Z\[4EVF5%(,>0H:"]CI@$E:A )*;PA#L*VYK:"9;#S>9T\FJ$(<PJ1[
M/J-.>DC2H;09[1=K,B?G5B.T*FLSD1V(WTJN1HCXG3,N.GHV=NU^I@[_6=G=
M7Z&;#>+_9<JK2<NV_;DY*7IR0@(S,)(?Z9<J+-< =+.<O?/+7-D)T]:+]51
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M22G8;(\O.,?GM1K)5\AY&^\^22_Q#_RT)CPT+>;N'-*\34823;JD1K#MH;4
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M#8__\3P>@'HAA(\B4H^JH\DLOT.S %BS%^,]: ]X<%,4A=T#6T/IRU\9.;_
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MIIYJ2VNE64 N]#-X(ZDGS>V '9KR4^NDQ3+VD83V%?VVP$E:W+DMUZ1S@5#
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M<1)6M[\C[:$R\5IV&]3L07<N."JIU.ZYL%M\IURV.0C3\Z#\I^G+LY@60M
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MD!+S0OJ34U%7&]_' 2PF_[L#JO*<&[ZD<L6(M6CKK,V*;ELSVP>M."1'<M@
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MN<=3TJ!8 A)_H:QO?1P:T*S;C@3;(L-DIPZ47N<6P]<C1*#XBRPA/EB3SKI
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M:+AUTC(% )AZX[*M2YU&03#;*3(*P;P7RHQ3?&GN0MAH0)(NAL^4D^*;A.8
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MPA>XU/ECC!$AQ&L'(-0Q'!<5$"/6,IV_#MS^+NY! ?@!2?9_RDE?0$)SKRB
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MQ0W8'"8ITMV9Q[9D:YJ%:!P5V2@0NI]35Y:N%_(#,-%AZ8J?Y/#;PF[@X;]
M!?11V1'FV^4[;X=46=9X%O_5U<<(?UN<>):_/6;4V#I;)-%+9MAG/*GDO3$K
M_X4;I%7^W.7O*Q8U\X'PLN)XC(UIDDF2?KSY6)\C@Z1T39"<7A/V4FV8A=R
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MAA.WJ9"L@A5N#XR#7-5Z?6F3-XW39'EC2Y8"6!Y;P_^LS-U. MJ.(G<K+U$
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M EC:N@.W(JFXK&Y7#2CN!B;ADXF$K:FE\7VJ"B6=IJ96:ON1.;DZ@0=S(Q0
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M3T/MTL0<H9NT$49XAOMZ?SYG4Z1V1>3%A]/3A%WR>:P[KQQFK+CHK#63I+"
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M_;264.^[+HU??TZ*GD=#[?;Y"6HRIS/GB;XVQ7>Q<M!"J3T']C=3,[]9GA!
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M4<5^Y-S]EC=7U3!2<#IGJ91T&3(+<UVLN^*6.K%-*^1Q]Y=$2<O9-YR+4O!
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MDY^U=@7B%LQFD;_FF&9=Q:QNGW2[W"8EE9T8M"*WYQ;K$(?1&V/-I$3-]G.
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MP4D+'&N.CAY514D3'K TGT+\!*TKOZVM>UJB5+/U^1OU;JO^NEP*U0C=^*/
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M"8&U2"@9P2N?H.I!K6SP94K5O8#9L]"U49&SS"KGY]980P"<;U/HF]&K];9
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M0C"$F[SU]8^0"^7A /Z^)GI\6#"Z.+K8PR(O1+ 5E%:;^VQ(FK'>M+2MCSX
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M/K,S 30.::HI]JONBAH=T-(T^)W$\F6$">;VKL8GQP%THJ*XT.#QJN#@E)@
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MX54S+=)Y; .TO[>^7/HU60TF4- NR:I&O)3[+N3'8^#K[J!.I<LF 99ZRH#
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MB"Q5S,/Z'TIM1\9M6U.,*4)NG0X8Q-'X9(@RI$*1Q7R>6S%'$ /1+X_#1;[
M)7>-CA2PU2MJ;=^E +TY^%GC>%H/_GUHKO& R>4)!9";,5M*R%.5@O"V[?^+
M4\ %[=L7-W+4NRI%I7M]\9$J_T1&&]%;X-K3SYD\PS9KF]D1U#<5HA>VA>6\
MJ>VO-==#/GW8C1UZ^EIUR^)'+QI1!82F5%"1YN'2/XCEU#4)I#+(>)RVZ4&9
M82K>_M!;;\Z&[= C'QDU/'<\9E[90,I1UL#M>/37)V$;ER6SU]SN@T?C,.+E
M!*\%X]'BBNCW*/6XY=M'P8(-O$N60*7(Z.TK741 (TCN(WTCN*^%);7.1U6O
M;[NWRKK:I,)=I-Y7=$"5H+MG)]B"NF]BK<M#\\:,_YYZL6GV=VR%/S$'9&T%
M'1TR,*DY5#]L?\9*+5378C\KB=^Q!CNF E/9?M?R$70 ;/MF-9S?K35X<$"C
M+63KMGC>)H\!DN4MHN7 -_NYD:+Z8*<H2:KTUM;]J_PN?9;F\V_SMS_@^!4D
M I,E0 /7$B^NFA$JVYXZ36"/I*<UCPJ\LCF]:=EXL(:VU\0F_MV<[[AXI_M\
MY37T,%F$]=SPCT5FCA4NC'5$=6_D(8G*;N+G(71G_C>]M)2%J!&<3#W5MJ&<
M;QBYQ_)&?ODNJYA6/9F];C$86P#3]['K#5QH$7Q>[(D VQC_HWZ5TCC=E8F$
MX;E;MI"EDI-6?OH9L\!=%999$B<ZQSMQKM%G)^;>^=]_5+.2%P?L#S2(.?0M
MSZ!*)N7&"GI*O;>MG*M56OW1/3J@ ]'8<?6M4=J,LO/U);05U2_I@@^4/WG*
M_[U4V2IH\X6+Z/HW[Y#<Y 8JUL/>FC?6PD9U_!FG$/,[IEB(O0F\66ZAGZF.
MF,_4+[E*-<NQPQ:"(R@R7)I"./:.[WB]UJ^U;-05'&8D]&-,"S6UH4[W7G&J
M7QIYOO?]F_7+&>M?%3[A7R:>6W-VZ;6<1+-2 *1@W&/4 WS2NV@9M4OCG$W(
MNU87]_\\VHZ' $\N7O<WOMT^KJ@GT7L4^06 ):W[J5#.+^\09^B)T0'+3\$[
MX]13,=LO<;L!=ON=$=P9W+[Q\LK"[7A1R91*<#J)W_U1^(FI#S_>T+"YMQ&'
M:35P]DXB")T]YUL1T6UY <I. =AL/^+L;A'X7F^@ED&0[SDZ0.0!5][[6+!I
MJYL)\+?7&[6\J"%>VE-)=G9/K&13C^.,!([5"?2O85EGY4X!^[>LT^,K*PZ&
MKNXNRJ[Z]8^1#@CF(P!IX=MV@DH0H@-X<P1.5AE=;)Q3G K'0TG:(SNLDCD0
M.F#D*(+0#/[EYR\^WD@0_D?4OF/S2:G@H1WWJD5L"9^@ S9J491'R%_J!S"T
M,;0QM#&T,;0QM#&T,;0QM#&T,;0QM#&T_>/:LHQZ(LQQHI?&[W0MGL;DEYG&
M#+8^B0[]3@> NG&(7\:/+Q#5420D':!D00?02+%T0)2.9H;[N5@]V^>4G]A;
M97;86X4O9:0_JR@W;/EQ#3R+\CDQN,Q&_"2UJJNC:?LP1GEY#T'<VN.LX4G^
M_8K7]V%6?W55>2?J(/EFQ;@+><4'8!"H5U93G(267<LTF.QT,@E1&0 O)G+!
MO<<=#"KU$=N?OC+E^EH=45&S/$@)!_Z/Z5Q+(RL.Y,$4>L]V%%-!&CP_T;EF
M_TSGNN61#><@I>/0^XRHL:J]ZSPL1P<CBRM;1'P454U&@=.F!@L)2:?]G 34
M,(G #&CC=+5-; HU3LBZ-VN=E@=/U8:<IXAWPM0(CFIDFU!"%*7M)-#NXVL^
MV\=T0!'&5H":_-S?L?A7MP$=EGG'/6U,R@:9$S1^[^)=K]O_X%/-:?G'PO'S
M3,-VZ'V_^GCJ+WY=CQG:&-H8VAC:&-H8VAC:&-H8VAC:&-H8VAC:&-H8VGY3
M&V'D $6 T!.*TP31 ?=(T3[9!E7G?7+25%@DQI?>?J+=7]#],Z]D"TQWIY8;
M1P>0F881,Z'H5B,J]Z]KLXIV$?47''?^JKM3XHW=.G-PIQ'S%Z59/S5B[L*?
MJ-4B7<"&@6V1$</"^-(Z5%!"<49H;K'A6+O4(I\A?-"&+TC"^550]&N 1=,I
MKL8!<<<8TDLZ8*]=/BEW3%&E&K(7Q.-=8TR(RW<A2J] C)1!7ZWN82P:H(*Y
M H<FF(IL8QZ*PX>I[Q4$\F#7J$FT,]Z6-9[1(X[E/:$>&4;&W\[4YZW46TZ^
M>GS5XI&6PQ0=8($*W$)_0?0CJ_@/]N:>+NS-.?5Z&?>DY]JY.)RAZO"G0]<>
M2AR8O<:__0WW=%)?>F#[0T<3YT@%DB4$Z--+/31B$Y?Q@FN64PBGM> 5@&'4
MX5VQO./G1AK82!>@U6+]=  .GC\*/G8=)^OQ3;B)K&&_Y:O&MFRN]D)8,DNK
MY<QTU"=T]CQHN6;++%DV85ZS\-/K,@G-W5=XW2?" 11-:B3"B0X P/91TS&7
M2*NU'^<E[. 78V87..N[!5\=$#O4,G4A^@8E(U^A=YZY&AMA=H!:B&&>VXH*
MYD^F _9CBOFFGKIQ)N^ND>8Z]"@R^=6#;/PCW][WB&JA[7]_Y]&B [X8T '5
M1:(BBVND/=(?59P/K@@$[_[09K87 +]&^SK"+X4@G=VH17+#1$B?QZA&B(,.
M,BCGSG5-B1\2C7-[$/9A\N=C+@BP+]6XW#RYQ_:4.[BX81$%7AQZ/XM@PC"1
MW(RZ0_*]#@WD4H>P,=Q7?TA<VB5_1O^ 0"/Y6M\^X?6;M?Q<[11#"Z?BRG,-
MA@4*;_QO] L](R#+1Z."D/4I^)' (K9] Y7HT#5%F1LECUANOA]0<0GEDSBR
MZP?-?=<7RF4JRAT:2@<4NKS&!RB3S6+Y0\\A_2X^\YFR,G\XZCF\HMI'!SA@
M)1$V4"0WEG*4C%.)!''"3/&T7'"P%$];R>S6^]<N7%8>N\%%M7POU(Y'AVV8
MEYY^MOO*<["Y\)6_>W6/P<)T@"-R$(08_*S906.&,>.GBK-9+9:XBHW)GQ&"
MDJYE5B:[/6_E'56))C[Y>$A_5NB+6% )8C?\$$GEBYX$-47T<)7HQ-M#!][+
M^J0U.'=<*9%WR4/5P ]_5^!Q(&* W]>&#O8WBAY^8\]7SNO>>(W9;;.G[B_M
MSV*+\=MO'?8OC159O]G^S,#O@%VMWLL[!+T"M_S%(!^CB#\FZJF"P=B*R&ZM
MU9E'5]$A<&G:U_*-ZM?GNIPJOCG6&#961()]7.0/O'"G [QA&8-7T=\3G*)S
MPG8H>A]D[] M^);Q-I?L)9<WE*[G3UO@)?,=ASM,VYK%_EZG8!&&F=8K9_L,
MTY;J75:3.N\<%+4J[YRGY31--0;>K%+<W\CQDE!#5"CNV2'VX!#XB)7UD7QT
MH^H"'?!>)<V9UK2)&$)'K9N>V[C9Y2(BQ6.8@W;^D5:RFJRBS!<F171^L)JE
M#SE*[J6P?=ET)QC>UU!$_: #1O_ #+T,_/^T)?&W%OP5U1KZ5[,8_H]&2#'P
MOX;/=!WV"8:'5)6QT#5*OI3)O5C:+=IU('6-F3Q/:UJ_6C55>3B\)]&P/2%1
MQN;9G$ZD09FFZ975*SAL%>0H['07)=%LL/5C=#XTTSC@P9M!<'4?[5@;KY6;
M(>(P[1PI= Q>5![W!-:S]/!<*2*!JPO!DN&ZW&4;(+PV_^<YD(EI,CW_>0XD
M1HHT1@:.>$,7N7L#]$RU-+A\W OCRQXC.D$K8J7#P,5'CDOBAI4B)OXAHH(C
MV[M<XZ:"GK'.86H>UY!8)?_&;_:KK#=38L/M<Y:.J@Z-)IT[E)>6+<!4Q?SA
M5&\WY.\G#1_:</%F#N>=N#^(;L%.>3XHM);7J;4CTP&OB1P<9M6T0=W"D*56
MG/!GPQ<*.M5C[5UKIZ+V9W.L&-NUI1T\G_+\=W_:#/R7X"W]Y2 :=#LZ'+5R
M6V$[ZGO@UT8]LK[9<@UH_<M)--L;6R1BXI4#BGARV^N[=?T?W-CX?S6)IN+7
MG;N_.YL0 [\@/$+6+_?[W22E%,XE0.)3O%],1E:CEURTTOZ#Z>(+.E3!>533
M;6SJTZ67Z-D5@Z$,X3+KLY!E@<-<_@V=N? /O7]BNHC<8;JHEA_\>5@$;47F
M/K@MN1&'B1!KO6CN? ==R5;GBXC&64HT6HC)^6K@;:>7JY:1& $2V#?35HP8
M$KY8[G]QK"UN.">4Q//CH5\@Q(LB1JH:PT88:0VL:6#7PKIX(@Y\+/R"&# ;
MWZDI<*N#&1)*B=:]F.--TJG64XYFW*U*$_;D%M>^VZD9Y)I)4'^=CU8H12F3
MI*-7VBT9,5M$)O&XNWT9-/#S"_S!S^:[)7*'F37AYN!WSWC$*J130?UD\R:,
M^O)^!G0%K#^#?@O?=F^-H,_@V^YM97+[>FI0U,;2H D*]M/T"?@]7_8OZ-3L
M,=>31F6&9+FLMJV^K;F3X=YAJYU>VQOCISN/_P"M;PS\LUL!?W/%_QUO+P._
M%_8U<3<^BTIN#SGXL5'@>V\+'< +MFPQ==SVX)[<DV=9C8]5$10YBMJR\E4>
M64#%4P>VPL,7JG'SYD)M:H,K\ QI 3:M8_SJ8937W>YOAMBTRSYV.=L45)8^
MBAEL#>8[Z7FJMY3"1LTJ1H70E&/1/N4CH2<.OBMQ$=6GO<XG-X/+$+OEJ?8$
MZ"CT)Z9.J:N@EBSE_V#JW$7;H@,*_.^(^Z #:<(4#H)0-9]64_=BQ?P!'LZM
MEV7G#E064D218PJ$>A6IC:LPFQ/2&0N.PAJE<Z]7I#Z6/2N!]\1V8C=1J2!V
M0ESD>"XGG_$-;,3=_/BTZ"3=#3V=YH]K"CW=<!.8 NDU#AB\U3%GM'?56/9+
MPA#&SE:;<BFQP<QWIX^Z>]LO?8[?J"L3*/@KMY23=GIQ(U3!,F$SYZ<VZEGR
M=XH^>C.)R":1\;1(* T+OMEKEQ*^N=K_SV+(9.!_!EGH+WU$2"KD%Q2,CT'-
MO_01S5A_2<'X#ZWV#[.[A#/P!\3%N,*4/N^(VV6=Q?)7H0LN)ZQ*5M]9F2^Q
M;7)XAML7+05U.'PE98R'+B#\QT:*',WVJWDHBEM/=+2:X7;1 ;?)C3^1^_9@
M[,,-G98X?XI<?^3L1*Y=_+7<5"<T.VF(+#:#.![GKW5[94WKZ'/CQ?/83Y]
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MQ_5?>07_ 8[;_MW!.&YDX'\$CFD4)XW9&SJ^+[%0)W"A/,VQ9$2W].ZYB._
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M71JD(BI==2OP=DY&3==9O"9Z^RY'I[EEM8P'($(W4;F;;0+1&I 7OEKAQ96
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M+=LE2R#"5@$]=L+W9EO7\K,&9PQUUMI9!;\D-@'W;;A%$HWUYH 6B;_FWN+
M%7W)H=A>ZO<MW_[DW"+YO65I:*:M30]&UJ DI/Z2F\M]<A;?8.O%M3+W(WO;
MD"N3=I)4%?#&ER#]F%W$BGH\#+O9SHXJV@[4\#XZ(7R-,HX=C;AL50BK.8-I
M.I<4TVL0:C=XCF]%+/TN.*E+<B-6OU/*_65%)E72IW_[:6F(%2B2IQX.VH42
M64P([PM83Y5N@MOM^0K>PCAXUKQ,QT<D6$0P@2GG-O%XRAEL!A,(AEQRP_+
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MAL$-^A/+L:8+#>L+X::]Z#PT*[%ZY2W$OA.CN\\H, 'D^0XZ+O8>16SS!J3
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MJ#__UM9^_^V=O5IABJVR-6#NWJ)PYQ0]/FA^_,)6ZIW&$S>DSUP=#T\BP1)
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M<LKD@@P3<->%#5^G6 90VCD6[E](K= YKIU7&\JCOW?W\V^ !\\6E"3?"0F
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M"SZZ9H=!-!INL># ,PA<\>ME(+_SXR0NMX8/&7'%5&R"%7-R^+65?0LVL=,
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M[Q7/X^9O *AW4P$'ZU+(EU0E>.<-T!DH$^FE9!S9H<9E=N-'M5P(T5<@3R1
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M+@VSW@C$7JYX/ZT[N98LXFA^V3/L>XP,>TCAD?H2. G&2M8DN"_R:T7XXC*
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M2^V'(3X)-$%<3(#ZO88:X8L+E@+8UP-]KW-4"""\8Q\:&UM+1*QPW6#@HD$
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M[! F?']T/E;=L<$D-ROP0>*1,=M9LA'NZ?$[9!(8FXOFV ](@WR 9[:)+HG
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MXP_^0^'PG99+MY]&B/&^=NWFL[(_:[A9=:Q(8L-F=<:*&XWL.SD-9-CVR&1
MK#KB+[6,NS^C5R_L/O?&[%3L#^U^R3V33G@]\I&6)<W0M CP+S$O*IOQIRLV
M6QN\\K(%<056$BV9,Q\B,QSOMP7S<C%_]Z+?F 639",^^R+XU'(OH5.W&D\
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M;1,$CD0MF?<BG]C:4B\1M###,]4K[8^-^1H'$QS*]1_&Z?9S*P OOJ.O <1
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MB;-YHA$,R/WM.X]GOA@0N,R_TF.UK9.I!!\CA)Z#KA%EPIW#?QB+V5G_N[0
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M5&P9WCBC\>6?:AV-?'I9C1\NI@O7W(3:HJ_19>L/H9+_79=YJ7U*CP7X>Z/
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M.C] J7J_>9-I?I#/I]233];OS\3_YZ?7-<'",!D<LK>A&<+E_6G;'$KY>/=
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M+A-Y:YB@-KF+@AF6;<T*\+Q[7!#KZC+ W,RA<BMM,:D[-SAA,R@*,YN+Z'H
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M7)JS65SJDMC&!95%1W'E/OO>=G8P''.6!70A68! $&F.;/7R\JG?8S3KR:9
M,>-H,P.<$ LP"#2<:I(^SW8^G5<QMH]@\3@H0V74@M[3DO-BS/76R0?R"89O
M[:*/KE[Q.@-UWV?D"B!!Q=6X5:8BNHF\NLQ'%L>1_<A1]F[\!P-O*M@<.F0Q
M#QKHM0A<-WD"0W[<7"-,!!&74%R([74&+>/MV#*LNTX//GEQY>N[7,%"XMO5
MN]?.5YV!(*C\S.,P8=RXSCP+L-3#1K!Y]K" KSD8=H3T?)# O*.W:5YUY8._
M9,"7^+<YC2WQQ&Q'8K:OFE7D]5.W#)8^TU5!!9K#A[ "A4Z(O7^ ZX_ %2F'
M9N'V;QY5(O%G -F)C6)H"A[QS: 11A- ;/I$;*E^)GP5C60![B@68*[W-60[
MLLJBY:3,Y6V?:-D5)-,TD8T=@?<W+7V?#<]M,EKKAT5*S(LN91VO>TU].9U>
MYAP1VUD,?;?Z]Q9PS_QIA:./MG()Q&I/0;":O)>&V^T_2FD;:[4[(%\7 /<R
MF]=.R]QC+/HS__P,J@ZYE$<,FK"V';NQRDYYKMS7R[O7W'RTX$/!;4NUJL=J
M1 !9.5]S R9#\)OEQGZ2Y0\20/^T]CC=XR/L-B@EOJ+I ^L3B<TV)-(48GC)
MT6H,FZURN#A#';QED!9&D+BB67*G;2"\MC6=;#><6N56I?U+HM4[_6LT'ZQP
MEF+# H2ADLQAE(S)\<87SD]JA:^J!Z@.'*_S-+EMNV)V<2ABTYB$9^SS(\*Z
M"?NZGPYYUZ#;;11_7:RC*BV%NI;Z[+U/3M:6@WW)NF[T59*V&C_[8CX&NX?A
M1.U[#8.6;?K/'([:C'%WW]6$S&_>*W>V7LRTG]8#8".PHV)'81TP4,T@@2G/
ML/A8\ULKT5,U1N*0)&TP4-.,#AOWN61E+_[ZI\@[0#/!WN@ X5@]+@&W W.L
M^$ES&6A'6BE]U**14N'Z(T?'+=L4>G]_('2T)2BE:)?)?NI8UQ&T?Q\<UD#=
ME24_73NMNL\"['L@DGS,"E3^;B_$)\.'_RN1L3>+:/-9\B?=K;=W1T_\75H!
M(1.R84[79^ ZZE;-8$X8^1&FR$S[JP!*)T.EZ^V-1$=9T?3I W;UV2X""CS1
M0^YS&:BB(K$&N[N@JM]RGC=EP*KE0;L >H=3\ZA6C7M<6_;I?@_GZW:-%U-3
M29B)_7+;E5!-2T64>>)J-W0/>G^G9,!8PHW!"+X#A%=U;1GXQWZIO3["1E[/
M1 I>DI!RN_-H05NY)GQT==">!5A03,L^65:X;U6M_3IS_U2H\>V&8X9G]"O>
MBP"[G'\K_@6-0?C )*_./D<N!Y-A$W.]8\]F=E.5)@=)6R>(RZEVRF+#0ATG
MBX\3KRM9RG +;Y9[2M%/8-EIMA#AZI,/Y=1\R3C)]&1WE\6CEF^:7IX+X;/R
M>BH14IR:+A2<FD\_G>>E.ZC_Z=TIO3=-20>$W=O_^$P6!]Y<Z9-0;B[FU_W[
M4>;_10J9_5N)-<&J70W7?YB*V[J]BE@_-C:O"41E_[W$NDV*IL<",B]6X<:]
M4%M[>2('_UO@_L?57^)VQR>I]^Q(-=1+&_DHV@1%\]O*,A&DJUS>_%Y 3/@L
M*^A%-L[+^7S(Z>9T\CD+TG[NG;0A4__)_Z!J_' 8"@"]/:@'<\DR=MT/3Y?@
M?UR,3Z@.\Q9I<KK83DEVLO\XKVQL4[.H4KPC^5]/4!%0BGX %*9%4H?2,"XD
MI\]2CE2?7O_?A!87;PO?6\'BO+Q2CTW9ZW%A,ZWE_SWO/U70/+@!KM.DG1<3
M254:NM-F3DK290%[/+0C"^PL6R)=#HFG!F98G<UK)[<F+9X*GMG>_(-D#L&A
M(\6OBKHWRY-\XC>>1HP^7CMN8R25>3BY>^(VY*4>34F$BR<MK3'7.\C7-TBT
MK*#-7T"?(F=#M@34U-)W1 / =0 O A;1I1FF8#>UKALF8F+?4L9L)8W<UM!H
MGVCL.7E$]\V@V'36JQ=62]* .3[DOZ__PK]&%PF../K_69Q9RA%'_W3])V<I
M2I^=YNM2-A+A,E?U)QM?/;D2KEG5?Z [\I;T(<=N7@'NPX9O%."]KZJ98N4Q
MA(6@#SB*'X0%B)K)G!(=P'6-4,YO"6Y"F0)$%D"N8 'QE43\IM0ZC"'1R0)Z
MSD <+$-F*0TFHBS@&#:6!<0:(L J!.DJ6IV9L,6^S*[K.*HCU\A']R:&)I('
M]V&VF 40WT.9:G=!U\+=+*"$L'U(<3Z,<0X(TSVOR0+X'3I1ZP8+"/ (^VK)
MI1PH#A0'B@/%@>) <: X4!PH#A0'B@/%@>) <: X4!PH#A0'B@/%@>) <: X
M4!PH#A0'B@/%@>) _5.@8'_[2-^^ 693U;L,9H7:' ("R 5BY.\!:HN&)2EG
MXPO&NSK4HB<4LZ)Y,'O-)+'*27+40S4B-K6]N:%JCU)YN-X 0EUU_X#-"!QQ
M]"\K6@#$?/C@A_4?BL,ULE:-:0\>\BAFEBKFG[4$<*R)?P-02P,$%     @
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M!3_P]^4#+E:+E# O"W  TSSR(>(!A5E..,P92L(XBN(DC(PRVG:&GU@]2&)
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MY8<?CT5;AV 11TF6\X3#F/J9#&H3FS-#%/HQ2FG&<1IRK<0Q<]*SA;LN!3.
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MDF"RY[F,N.7LJBV-,OP#I=6:LP\_9" OEXT7VM[J+QY<^%F89Q'W(<M](C:
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M6$ML=1NBJ(&>G,N[CX-RG''9L3O>S+<;!X5Y>9UQ^#%S ^*J_,:7G IEW,6
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M^=OJL7A?U/2V>.#L8UE),_;O>"D[V^N>7XX,,;%9]]N7KY^ )+TLZW7%@>)
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M7JMTT,-NRL,$XDJU]91?W';-59[Q8)+N8*C@G:+0'/[5A^J!SI<SR>* E:G
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M^5&?$MWTNP]2J:>'^=*LK2-/M@F0I]:8(,^_'\JX1=O$FNUS($_"<%K9^40
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M3#<Z".U0,'I*)F\UH@>)3%P6>DK0_4K0DY^^>(I9=^*4B>0R#',<D)ABPO,
MLSQ+<98E&9$B*>+2=4K9))9.2^\__R-,@_]J[#NZ'@?$;B->)"9L#PZ;F(XP
M1>:H)/XG3[W&=)BCXIV8'.7E+#0K?:\6ZHFFO8#\4JVD^>G/CXOYJNTAVNA<
M#FUJA;.TC$0>EA$N"AJH4S))<4ZY.B]IEA4E+4(I0!D44 9&OQ/0W]]&4T9\
M31J9XD1@& V*K&7@:T2\H+<%&T[^[S[K03-SU6D!PT_?]]C ^.TDC/!HDB,6
MON(_4/+31FP<P=F+L;BNXS"&2LE:+:5.)U-+OGQXDG=55\KYM;Q9EI7Z(IH0
MCGTF/V#)L1-_6TY0SPH23V9";\>-F4VTX><*G/X/ >^TJAD1-YB&\0P9;-H2
M' "WD4H .M/-38(+OS4<R>%Q1_.%?Y?B::&6/9!0U;Q[&?S+S%F>!7&AG'E*
M,4]$CDD1%Y@)TUR99%1Y$3&/0>E,4 ;&-E\Z=O36.)2=V%SIRZ/!#[IYX,#H
M !AV2]MF1#"!MHUW'.'&C2,8OHP;*/EIC1M'</:,&]=U7KW<:M/=B01E*;,D
MPCPGID=Q@AG1ET5%&$5AD&9Y7KY2A=54+;:&VU77'."NZ$#_>S#53 ]/6GV7
MYF*=+E_^\S_R*,S^JT&?Y;-Z63'ZC>J;P]6P:$>Y+[]^V_0%-Y?I_>*Z-;6.
M=@T__VK%5K;=OM[*6P9:@J.45'5*VZIK_FM64MFT'WOEXJF)&YA- ?*()5*^
M&J5]F#>K>LZ>5E+<T'JIJ#>SD-"XB*7$/,U33-(TT$W3,IPR$A&3,<!3EYZI
M^Z2LMOO%/5(_JT/Y[T8+BYX%O765&_A(Z]6<SQ_;]@^-?@$..O@0AI;77(Z0
MN-UQ;8BAGIK'VZWCHOBZVCI 8=I[K>,B[EUJG?CHQ#FVUYS+A6Z+L?VD[L@S
M*Y),!EG,,8M2O=,CM=/+,,<YC7E)2A;(/ 'YLB,P.;;A9](@F4F#?.S2(.FP
MJ13=L(:XXF>B5-A3K\W2%W[EEP'TEP^EHP[?PX KT^CK#:246@#UVHFBIUC\
M:Z1_6H#L+:G3AI:C^I;WFLHW^5C5VM@ YL,<>WS,;$%#$:U)CI(3<TXN7]OG
M&)EIM\ 98?>^QN<^[_95O!;_\]2L],K-774MA(E-T<4MG8M/RZYQEKF<:RN$
M^]I_O0F4;Y 401CGD;(3].4]"7+,"MVL5%"6!WD@10D*%5W"S,B6P;KI@3[U
M@2[!11C;J82ID(.IC0%7VL':\(4T8[K=7L=:?\7?<G>%UFB_/XDV6,/X@,F3
M%KJ(E4DUE0_0=K69ES7A _ENEJOYZN6]U('6Q:>ED'_^O_)E%G!1I(%(<)SF
M(28R93CG48R3,J5YF4<1RXCM5+Z#%$;632U-U!%%ABI29.T']!W&Y;3J\2(M
M3)^ !04-[#LIC-/4OL,K3C:Z[Z1 P_E]IS_H9EC\*)?*=EY<+\6U>)@O=0C$
M] 'N+NZ[O%-.2Y%+D>.LT*5(2:B\[S(FF&=<_4 DK Q!H_BLJ(Z\'3L>S-T.
MW>("9C;8(6AG'WC'!;9QAY!L,[!.OO&?XPN2V=.I;D=STN,;!,/N.0U[V-$%
MX5SG637*]S;3XSBOG[8GQ"W%U]5W60]^M*D1>/]4U[I7R?J^LHRS+$VYQ$F4
M<$QR1I1*R5,<)E%.U,_5B0Y2*7[9&UGW=-R='PHRQ9NP=%U>#5^@,]/QB3I&
M31#2@+UUOZ]5G&%WZV)YP_ 5ZECV/')J7#A].3U^F9O6#1H%V#W':!PJ\.3I
M+]7R5E9?9'7]?&^:0_/5$UTL7K2+!DB8/K/,R.I04<>Z6?@7];^^%\5V&XR.
MG38@ <V1/H?1:07H&1Z8-O.+#"@5VE)FI_3G<VM/EO)L*>0PS=GV$9^561O5
ML3FVXS+A)641#@-28)(5(<Y)%N* I@5/DD+F(>P>V);RV&$20]M'U=4AU"RO
M;L;  AA$:2NKQK$^P/*-6CMUB.X;*)HZ 8==M=2I!1SFX^K+SKN'^_^N_OAI
M^3A_OVQ$[3 9]^0J8[L])H'V;OY@VD\I%M!/7VX_Z8S:9JY  $W /8W&^2/=
M'Q! _^0<!F/,N+62U6VZ[>FEIYMK:R7BUD1;NR<<4_[G2[KD<QVF;5:UZ5G3
MME&-DU@F"<$)34-,PB3#-%%G."GC+$ZRJ,@BV%R4PW1&WL=KJFA#UJECZC&8
M[$YI#\+#]JZ+W/ ,\M-2^4H"/T)EVCSNTZ+NI6*?^;B?+)]#5F,9\RQ* XH3
MQ@DF>1ICEA.&:92S,DO3@L'N/RQHCIU"N9LJ!#2X+4"S-+7]0@';T/L)4\-^
M0N.8WO;RCI1(]?KFMCT$Y]*K_)G8IAU95PJFHW??= ?(9M 3L@O:S:@4:9J4
MRN\N=5.BQ(Q&2#F6D2!$!)2'(;-NRVA!<&1%T%>_+:#5;-: G=8#8\  4P(]
M<:2HHY;\=I_<C@//L #:*7J&QZV+XL4PP5HH F0^V3G19IWI&B8"I-KJDPAY
MSD'O?9YS?0^I+RU,B]Q-Y\7Y0C:KMJN#G)O"MAGE<5A&48%3EA:Z=7N.\T 9
M0[%0)E%&RB2E5J.9P91'UH1KBJA>DP3L>1"&%CIQ+&1@RK'CPFSZEH]-L]0K
MM('LV^B0 ?3E6-"Y*4Z/$,)4J L,)W4I:,'IE*J+G%O:U6F!"WM!=#7$FLIO
M\]7WO=+A9KMV>+O0>-V9X$<Z7WZNFN;3DB^>A!2?EIN*8)I$1283+,O<Y.R%
MF%%9XBB*RC"BB4ACEXK@R02PVI@7UQF__Z[KBW2.>ZF;#3QKR1R[.8S^1BVC
M8F_J!5W<]V$@!?I#B7&@OT.S-S-WKRG$6IPKI 5"/VB1_H9ZH?3[]U]>/?F;
M\-T@8G2^7Z=KQ%2OXV@KB<D8&+'83-=BLMURS6^R;9PD?U;BJ$/U5M;S2FAI
M[I=F%2/^C!>L9"(3. Y*IH?R<IQ'G."(I#E-N!2Q /5<'YOAL6.Q^O:X*V?G
MP^0>V::'CE#&=LG;LSN&WM([ =[0WGYZ?W5XU-*PMEUMNUKJX1&ZOY2N>$(#
M%B>NA?. XY3U<I>P^_9JZCR [U1WYX.NVP$Q.+_:-D?SYI\?E<O43S'^IHSQ
MKNXE)C2@24XQC7F!25RDF$H2J']*025/J("E^=N3'EEI:\*X5)25[=B-_-8]
M"&"Z&@"DG=8=!QZ8_AQ:[(8)98\K-I#F8S,?77,R0C41' !/B@] >%(5!@=D
M5QDYK #/;KNKA3I=/RW%W7RUD+;9;-M/C;SC#0W[#+4=B4[OW\N$@>W/NYKJ
M:X-=:T;,G^?BB2[0:3E!B6>'17)*--M9:K+$LL,B#!/)CGS"L1ZWJL0?\X4N
MY5/[JYO(;@:R-_O_%K*<JU-=FOGMM]5BSE]F>4ZEI(7$:11EF)11C&G!.2:1
M[@Q&1)936*GNA0R-O"DW-+LI]ANFVCGVP-JZB_&W.Z>G1!6F'7K.3(7<'IA7
MAW^T_0ZN4,LD^KW[<Y1$&E\0^BHIOI2=::N-/8&W5XCL:UW7$6++1JTC:.OI
MU/,VI-;:*6W[A&Z;%JS0S4-BG.:Y\DN2G&":1BD6&<FR,LM+F8+4I#7ED?5A
M3WIC:!OBX/ZH]DC:*;Q1\(%IMBT6KM 1I%ZFT5Y@/+Q-/+.E._$D-" <^Q/2
MH O VQ*]5XM<UY*^KX2<T;PD69)&F(=,ST$+"TQ%$>(LE1&14<$29N7&["X\
MLG[0I)"FA30Q^]9#6[*?WO*72 3<T7;"@-H+'>+<J:O0UD*3-1,ZQ/ZPA]#!
MW[L=MH/2]BX%;=T@D\DR+P2)L%"[07<<Y)@IQP.GE)%,IC16.P1RNAXG-?9V
MZ9I #+)C_PX[2$^@9'=R^I$=MK&V1V'TC3!&Z"5Z7CA/Y]X)0I,>=.<%WCW9
M+)Z 'V773V*NWLQG_8)T.AV+=%MQ6>!"[U42) RSD.>8YZP($U:0/+<^S7;6
M'GF'=M103\[^2-O%X/RI=H%DP"M(6Z% 1]L1]IU.M]VU)CO@C@@Q/...?00>
ME?[4%N7>U:U[JK;@;5WQ+]7J6E2/)N$,6'YMO>#H83/#!^ICP3TW)NJC69+B
M23VN![NBCC7[R+<]:N>#XJ, !MN,#EB-4,,-!L(IRFY/9;( /%CP86P>_K";
M+7RKP);J<!;#:>U!&14AI0G.F4YS(G&.:50*3"3E)%*_I&J%9UFSRM8./D0&
M\L4?$K/^_J^)MMV?8>;O06!D'H4T24J<E$S!D0<Y+K*LP(GD,B>A9'F90]R#
M2V%Q4*#^0;'S!BX5%:;Z=J0<X;[^E#R>3/^#)"8U^D\)N6ONG_SLI>-R=\MG
M/^FIO _&2GKWTOVR'=TJ0R;RB)28AWK*4" RG!=ICJ.414JOQ8S%@=O$7&L>
M1M[!P^F1^W7@ Z[,T-?^$Q<.SK5_ 7;J8&188=IB'$0O&*$+QL3[%%U[#EYI
MD"X8HN.S=.%+75A"U=XC7B^'?3</C&94'_A2+>NM)'K]?#>3D7]?SO_U)!O#
MVL8U*8HXRX-,&6\ARS&)28)IGH4XR9(X*C-2Q+"6'Y-P/:'*' S8W4OX:UVC
M-;=HPZY)EHZ"L$#K<O+M*;M;<W<="[%&_5[8Z>4W][9AFMSQY4XR6'<*1'T7
M4HW*\^L444WQ&HX64$U"?.*9GVW?R$UKJ\;TC[[[3I=M47*C1'F6S4J*WZ1N
M 2%%UQ#X1ZU'/]"57,/SK5HLNG'E,QHR'O!08!9%ZAQC)<<LR3,L9)"F/&,R
M*$"^]AN3;^03KV<%T:[Y\KUIEB-T\OJF8!C]\'_];:(1HR-]2RR]C;?%]8B>
MS*#X:[O=]D96X\,<*A+3K%VAKG_O0.9NWL!*2=WU@6BNT%KP*[3^KO6-OHWP
M2$L_M+9&&>GX-E_L:P]B'4FZO\8,UW%?K;?QKR.SZ68$?).:';YZTF:'^H>L
MG[?4;5Y$,DZ)P&42$G,?@"F5ZC^R3 1+*"4ER+D\0V_D0W*+.NK(H]\U ZCC
M !@P.X>?W7'E$178\7$1(&#E;2FF)V5ZCMJDRLU2]%UE8_N8HP?PQ!JI_(KE
MZN99A[S4*FWO9R)(IB^\LK#(,,EICED<41SF11Z%/"R+ I04=X3.V#&@-55D
MR")-UZGY\S&<+&W1RZ4'VH0N@L,ML=-B^;*(CE"9UC(Y+>J>A7#FXWY*V?5$
M-MZVDGKH+F837B:I+ BF(4DPT2-7J!#JL&:!8&F:!DD87E+"OD]RY"W<$T2+
M>:E\U_D2O4A:-T 7U@(YNYWL%P_8ICY0J[Y&1].?H$+]N+@C5:8?(/BJ%>G'
M 3A7B7[B23=MT#=0NI6U\3;6J=I9DH<1+4+,:4$QB>,24TY2'(5Q60@1"U8D
ML%2>8Z1&3^?Y(E=H434->I0U:C1I1!?Z:ZM#]ZM*=R!ZJ):H&8RT ::\'T71
M3A_X0 :F!7J*2)%L8SJC1%G.">9IOQ\E,^DN/R?L[MX^^WG''6W" ^MO8)GF
M12+#7)W@I=K'/ YQP=6.ED52"A:RM&0@QWM[^;'/[6XDV/FOI@T4EIO164#@
M%K26#;[M#HK@:[-M+S[M%CLHV-[&.OPIAR[A7>.I^;^ET$ZS>OC[]5+H0[B>
MF[;("]T&K;FC?]X^U8_J8&IFG,BXI+'$)$SUX)0\PU32!&<EY;$0(B&)?:]P
M./V1-^2 (51W')G;<3G@21VHC>Z2L*)_HL>.+T"/; ?03^_L":"$;?TABCTS
MIEGVD!W384^AJ#A"MY.@".@W/BZ:;EW'_:,*:S[NCLG)%N0.RT[7B-Q=YJUV
MY!<LXWI=L:+SI12]#7;-U3?N::%;:G^0Y9S/5[.<QD%09OJ5Y!$F-(EQ(>(<
M"Y(E19KFB92@?.#S)$?6W0."2+04H7<49T$+2"P22@3.8RF4M1EQG/,XP EC
M(BVC-&;%N@7[I+!MMTU_>\#9WN_X_ Y!KWA:VNNVX>B'(3 =_>,A-8=;'EMA
MO5WTG"4X\5V/+0#[USW63SJV'5K0IOE:FHJ-#]6#(C:C>233LDAPF AE^!:"
M*GVI3C0A24IC2I,DLBJH/DYB;-M6$S29_&WE3TL4Z'(> ,9N:U\F+M#^!$H*
M[_5S5!A?37WV"4S;O>>H@'MM>HY_TCG3HC>0/LAGN:@>36;()F_D?;4TCN]=
M=2MK79#PL:I-BDCS[F5]Y1B0*,H23G&9!NJ@)C3#+%"^*I-A'I$BR:)2 /,Q
M+N=J_*R-C<,ZX'*[+VC/J(X,=ZR:'/Z6V2OWVU\_+\[64)CX=4!MB:G>A$MN
MB3_D_&6@>.!IZCP5?S >R&;QN+BK&C;FU"VM5R]WBG"CR,VKY6=E=GU:R8=F
MEN91H91KK+R@7-E#C!28Q6F*BSPG>910SO(,IF%/$QQ=>;9VOJ&/!@R@WS4+
MR/  UHAG,+15=OZ0@>JQBT!Q4$YVDGK3.V?(3:Q2[(3?UQ:6SSGVKY9+65/=
M__5:/,R7<WWKL)H_RYMVE,TLD &C)(YP0DU[:I%@&A%M>+%(!@DM(UA9Y1EZ
M(ZN!CKHYN.D6?6#7Z3.HV>U\CUC -OX0AFW2Z.;,""-XVV<[(7UU=3Y#;=JF
MS7:B[_5DMGS,X4;P6@$6]96\7=)7$9-,)&F!I6#JI \BG=:>2AP4K$S*."XR
MDEA?^1T@,/*6U@37Q<F &Z9#4%A<Q%TH(&R?;LEV/K7-3DC /=F%PKI=A-F]
M4-CEU@E!3MY>'7INNNNI$UQOW3^=^ISK9)>?=1&NJ=.]OK^_?J;SQ?7#"C;F
MY> 28]\2W=_7YI($&8+V\ZW/27Y:-7@4&J8A#LZ&V?" #N"!KA^JI^7Q.R"'
M@3$GA;Y@>LSA=2<>)7-2N/VY,J<_#M^.-_]:O5S_48OF6OQ/K\(MM^&!1T?>
M?EU6F"GT4U^^S50\^TUX2-[SF^]"46&;[JB4'K//SPCEM*D.K3?99CHAS' 3
MG?J8FX?[]5%J^WEY_UE/_USWJIF)*)5QE.F>R311GFT28Y;J6A$F8IH%4B2A
M5:K;&3HC[SA#;-CN'.;('@-'YH)$09S@/-7=E*C4UZ$RP24M69RP7*I?PO+G
M/<#CE#Y_5^F\J:JGCA;C &;G\7L  ::JU@21H7AET:L)[.&?$<J39W^,RJ0>
M_1E1=SWY<Q]W\.!O'AX7U4M;42.>>%=;P]5_Y\_2G$BWZ@O0G9N9%+0D68EC
MH?NVICG!.0ERG.:1S&58)C)FUJX]A/+89L::%;3A!:V9:4]FI-D!^,H@9"TB
M!6/A!;15K*%RB2^ , ,$'L;"SBTBX1-#6-S"!8>3 0W0@M-%.ESDW J!."W@
M9D]^D&RU:5_R4<K6GY[)-*5!2!F.(AEC$LD,4YX7.(XE9XRF5"2@QEU'Z(RL
M6C55-%^3O4*EE(B>CAB 8+(SE#P(#].31NY/ [D536^1$DNI/%E*QZA,:BF=
M$7774CKW<7C<Q&SZ7Y:B7KS<#V(R]D',HPN,O ,52:EH:IM]0]8^?G)<[O-1
M%"\BP_9=>W8>E-EKH/*L:$X1E>.K3A97.2O8,+IR_L,.HZG4CA5FUR[H_2Q,
MHC(JDPBKT[# ),\RY7*P'"<Q3;B0*<^I5?.-O97'OCCH:2%-##"4:DOZTUOL
M(IF V\I.'-@XJD.LNPVCVEIINE%4AP38&D1U\ ..B35TOOQ<-<W7Y<]4=UN_
MK74,:O6B[="5CB";K+^92,M0;8P$%R&A.I-98IIRB2,12\IID,J(P4J.[ A;
M??4N*3O2+*!JB<2\>:P:'8(KT6/'2EMSV[,"3+VQP]7.S/2(E5LBCJ*/?M <
M_$UC]<%@-3<I> JNGAOC6J[0S5G X,DY(/E]Y>C8$9TV50<$Q%[&#NQIQS9U
MN@;C^O&QEGQNXA??='O,YN?K;S_;7PM:+S;R<=N6[@P90"T'Z ?% [2UU7EH
M[-2!5U1@FN <(",TMK*6UE<3N[/TIFUG9RO^7F,[ZP?=-OJG):_U?<$'V?[Y
M:7DG'QZKFM8O[<WSMT%GU92*@A9<#VT6,28RI[A(4X$Y8ZPL64C*Q"I[SX7X
MR#JB9P7]T#/S-S37\RLZ?OJ6W9<TK@5A;:=$QD(0ID\\@P=6+BXH>-(S(-*3
MJAP74':UC],:E\ZA,PUXY[IUWWO:Z,(E_8<F]ZSLG>6JV8S;8;HRDT0E3CGG
MF @I,-4=*'@2L#P6C!4,U'S3@8>Q39?!4*4-3TASXSIESAY>2SMF7-!@FJAG
M0?=VUTZ.YJ =':7_,N!EU'%$%T#B?<B</0>O-&0.#-'Q(7/PI;PT\6[6;?-X
M%L4TB *<A!G!)"I"G$>4XK),BI2')1&950[$.4)C:YV=;M:-<UO!HTA9ZA8/
M\@-=(Q?1+VWDO2?7.)V\F]?I1'A.V#.]O/<_[[9I/\Z75/%KLJ.,$_6U_*5I
MAX5=/^BAE/]N<T6"+.>49!G.1**<G)(FF-&XQ,K8X"$/N/)Z0*F:EG1'WM)?
MJB7F^@QL4Q+EF<J[BQ"TV]LCX +;ZAT#?;*BX0%7)59<(,/&%1HRXG%:(4QR
M7_,&+:E..S$0!L7>S#_@XX['O8FSFDC,ER<=<U'_T%V(FT]-\R2%<HHVI=*S
M) Z$D$F$)<]"K'4&SE.981Y$!8M$(5.[.TD7XF.;!;1U1$SW[RNT-.R8'QB&
MT-QPI#W_U:"\7X\0:#\ #;1"8"^R),F+/-!1J53!S@)<%"7'91#0C">$<$IA
M.>1C >^46/[S%L+30&IIHHT$$]!LZ[Z:/[=?S2_KKV8'W*?U5W/ CD=[S@$$
M7S8>A/2T=I\#*'NVH,L:[JF6'^8-7U1ZC,0F"L+SC"9)2;!RZ0H]X27&N0@"
M3 .19W'& N7F05,M#] 967=KJO"<RD-XV*D%#U+"-(#)J=Q01+^/$MDY(Y;'
MI,I#5"9/JCPAZJ&DRE,?=W3:^O&+@^DNS?J'_SV7M6YN]=*UCY2$L2@("8Z3
MB"E+()*8YEF"DRRAD0Q"$20<Y+I!J(^\@0=#7M>$363SR_6OC@TX8>!:>G5C
M00;T[2Y"RWW^/$1JWW/DK6B_SCQX""Q'Y[J#%H'G<'^3O%*V^<O7\J:N]9S9
MC3;[;-EES7:9,>\_6NK:]%7TJZ6LGII%5SZ^.Z]Z>%I^]MF##8J#4SJT%8')
M,J,AX@Z3I$'/.91P=I>SFRZ/QG!N;>@N74E&)<\R':<H,^4_Z_O47)0Y#LLX
M2$46!IFT+]P\3V_L<[)E /%!1U3C-J.?96T2_=&M^KK)NE;;P3@6@!)$"S1/
M:X@1, (>C!T\ZX:Q=U7K'/>>LD-AI@4J@'),O^BX%6&>0\E3Q:6]J"?K+"V6
MF:ZZTEZFK9I*P&/PJI&;Y4I/N1)"+=;<5LV*+OZ_^>/[2LA90,N"E5F!,YG'
M;=4Z57H/1X*(E-&2L-1*^9TF,[+.:PFCCO(5:FDC11QIZO8%)B> .JW7_(D/
M4V>NDH-J4<X+YE28<F+9R:I4SHLV+%FQ^+2;FZ\;37\M!WW%3/_VB)99$H<,
M)VE$,$DRAO,\8%C&:298&NCI&1!W_B"5D;?F^VJA6*BZAJ<#VFT_U,&_3=-M
MM/I.EVC[(9<&^H<!M7/A+X8)MH7'1PCLSI]$P)/;?IC&I.[Y23%WW?#3'W;P
M3,S9_HXV4@R=T@&!=R^;C]Q2TV_!N+%?'TUZW]>GE5) 2]V1\#>I[WZEN%:>
M%+V7-W_*FL\;>5O/N506A?JIG@-==0\J4^.]&6-LK/]93J.4F=F3H4PPB1G#
MK!1,&022L[P@>5A8-9]_2T*-KM0Z\MJYJEH&S+B)X7AH<TLI]#ZM!^.D+2\L
MWQ*8-B[=&V%UQ M6S3TV[&\'D88*^MT+&GZND[,-/EVACF/UEXVP5Z@7%W7R
MHEY@9"0VHTVZ+YMRPKHU= T!:N4&^_!OY%5!7.(WPO+X?K?/;YG5]^;L]\^3
MI__&WN#)<,);X76ZF,5;D?A08.2M\7;A/>X7N?H@Z_FS,=Q-HMZZ4V%WOR.^
M+K_I;B&UXE@)-6]^FZ^^_[*L6"/K9UVS\6GYJ&2:%4D>TX!G."G20-EM<8$I
M"P5.4Y)$,DW#6+*9GHI;B9]7M%X!KWR],0K1FKOL6BO.=_)^OM3S*Q&C"YT2
MZ7@3[._UZ,08GF8IYKS0:=19CFDI.":ILJHC*1E+DN[UW"PMNTV\A9?3,PL(
M48FW]%Z U_BO@K3K7?\54NRB#;]M&C?Z8<WRWU#/M"X.6[.-#-_H#\4X&G*.
M6M9'R!/P#JOO9 )_#+Y.QH%W@(^F)?BGY#)K9],7_JZZ%L*T=:&+6SH7GY;=
MR'A]HZ)5T-=R<*YW]R[J0]5R*4T>I>;N[KO\2=;WLIZ1+&!%Q!(<$I$H[5VD
M.,]#ACF-XSB5)4GM@K#CLCERP*/G2:=5;,4XRNZB<+[4%\X=9ZTB67V7J&4.
M,D-GM/=H$<1X$V\'ION'\Q"4F[=A&FFNE?Y&'=]7:/T.OY9;+F#?C\!\>/,.
MM0#H[FV]0\@TI;?P+MV" *__3H'SGL:&^O34J-&H3SA[:FP$MR=8C4[-S4<^
M7+-^O7I/ZUIW*S76QBPBF2RC.%/>E'*I2)#KZXHDQW$NRH2',LQ9"BMTLJ(+
MV?9.%4[K3@VF2E5N&(%Y3)8@!@$IBS#%$8E33$@089;FA:[4XV49BR#(0"/=
MO4/H<BDS)8!V7J1W6( WR\>:?UPAND(]$ZWKZ,_' PGMR6VSHSFI)P:"8=>Y
M@CWLV/GLX5&Y</H8^%I^4C;*\GZN7#'CP#6?ED*6\^5\)1?*J1,W?_+%DX[B
M_%A5XH_Y8C$+>)S(6&F,,-7EI@%77A%)2URF&8U)E,5YG,"T\"7LC*Z<-\QI
M#VB^9@]1PQ^P#=HEP)>A3!,J"*8\%I@D),:,!00G!96"4IGE*:C$9RK879S.
M-6L3XFNGV*="#:;OM[^E&[[:,*#2^AO6\&?-&_IAS1WJV3N>H !O2^<!)5]M
MZBYA9=JV=1Y VVMCYV--AZA<G\VLXT'OE<]1/<AZ'1S\T!4A?)//<ODDUW_P
MZGXY_[<4,\*+@I* X8*Q4)TQDB@CM>28QF$6I%G,19C:=>N^G!FK37M)!^^>
M 52WI*^0D.*I;>0&B+U<AKA%C&Q\%!V3*+M"!1-Z[!D;3."[0FN$O_4(=W]!
M&P8G0QH0R9H,<;=HU=C(PV)17L Z&6^ZC,)T,24O2&S%C?RL""],??]]>?]I
M^5'?-GTM=3J'6-XKY^B7Y7.S$NL1MC_6RY7XM+RMZW_4P-'-S@1&-H#_(6F-
M=74DUG]#[[_KE!=]U3*H[M9UKEL3DG_4@^G;5B^W];RJD7ZV07??E<M/:SE,
M/C2Q 26E;%:VJN^R]W'Z?)GL5<".EDG?@N>AUA?#Z529[$YULG+EBX$9UC!?
MOIC#("AEI*OW_H4^R%DH2TK5*85%) 4F-..897&.BS*-"LX$2^PZ-NZL.[)V
MZR@A30HP FH@]VEU<H$TP#M8&T%@PY_VV78;_3189[K!3_O,;XU].O!KQ[:$
MKIFAK:K>3$!L3&&5TLW+3>IG*>>K)_72=W)&C5[_H-R[=?K+C*11F&8BPCQG
M$A,1"9RS0CFL)(ZS+(Z#$-CP\$V(-?+F[UAI3\@VL?"B>IFW!9YMZ\ WP>PK
MU\RPD]4,G54U$'58!;FN=1C(>Z"BP<B,M- #F\UC\\,W]1I]M55\&T)-V[#Q
M;<A\)(C[QKAS']38Z.EMLOFZO/ESI?R?IWGSO0U-ZQ9ZLS#,RBPK8TR#@& 2
M)QSG<9)A&69A'O P4;_MH[YW]J?J6<(.$=X[^+G7#VJ46QQH_U& &U2>Q]+N
M&/(#C8^1C#=[J)QLV^DT@=%*4H_#%T_3FWSNHI7XAT8NVCT(C^[]H[Y9BLYW
MWO65WS_7XA_UKD<-"^ZYKC]%;$\NA6T4Z;V.0*F_FAC4RE\PSQG^\[&\*9!W
M".6-!KKGV-VE\#F%[IR)3A:YNQ268>#NXK4<[L1W!LAU)IAIXUWJ]M[KYGPF
MY?:NNI7U UW*=K3MZF7&(A9$M"@P"7F*B8RU?212G)4)S4K=YS\H /:1#YZF
M,9UZ=DQ7^R.M#,U^'#;D./K!5:5C#*T4)EET]0*X_+WT)5I<M$_Q3IR4Z.Y4
MRT'+@?4K^EKN 7Y7H36+W9,3 @ZX;Y\0>+<;]PE> .S2W1-B)Z_=+Z4QW<6[
M)S2VKMY]K7G!,/1AT$&/6N_,P#3-99RF$I=,2$Q2FN \S6-<9I$L:1'E>18"
MY\X<IS9ZGN_[86UC?X[H,^7;S[\ LWQ/@18G"2O34!>MI 23(B\PBPC#<2("
MFHLPDQD%#YB_'#*7D4AMTUSZ3.<+4S&N#]WR2<>2.A3G:L<L33$Z-?:U/Q0M
M@^Q^L'&/?*\CVH.@]TCSY4^+Z7.R_!%*T\^4/RWRP6GR9QYQTY&W=:7LR=6+
M7G"EW 6M>!_UN_ZED>73XO.\E#,>,EYF08Q3(C-,HCC A9 ACB,JDB1/B,AC
MR+:WH#GR]K]I5O,';<^C)T,2+11-V ZW <YNIWN& [;C>^)7R) WA\::@2O4
MLH ^GX('O.<! GO:^S84)]4!  AV=0'DT8D3%/9;5WW;S)F?\2 0B50V0U"$
M.LT@)[H$2.*X2&46A"*FH57#SG'9'%GS;";<=5Q,E"=P^M6,?._O#?#)[_$/
M];Y$OVON^U8%/FVA4?%][0OVTTS^-2[,K8#V=@%N1\U-QW^37,Y-$Z/FW7RA
M/GC_\XJNGIIN:)@RZW(JJ'+M CT--PZ4>RQ)JF>S!B63LJ EJ-#^-+F1=>Z
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M_M3)$G+&2\$Y3W*<4*'\JY!DF,I"6RTIS=-89C%/(/K!E9&1E<:FF<E\)1^
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M67V<%A&EE.DV*Q%$,A*0D@S!-&>H*#$I>1E;FQ4GB(R\_CJJ#OOB*30LC(0
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M#4F@!GB:J++8L7FPU(3OA*ZC>KR\EE@S-RW#/T\%L0$8W[MTV#'6_AXUPP9
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M3>!:O1"0,)<[8SE6SQ![_ZN9LVY5R[<\HG0^5?_\^$BD6'[=M!9I&@F2RXA
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M--8M70IN=ZQPH#GRH6)+"ZB771JO6B)FL96&Q\%M.VSIFU2 A@.P94'7R^@
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MZQG**%%"YA!C'$-$\TA]2M4?11Y3GHA$NI57.D-O] ONU<N\UIEIO]"&X#^
M7%6 =S$M:_+#M2W9.03M%GE 7-P6^C:<IZ%LHGJZ:]U?6NJG0[V] WC.R!DX
M9N<4M7<)TSDC^JG(G'.O^:W_D[ETNP)NO28I/!>$9APR@7/=W+" 1!84LKS,
M19$E*4V<2H&X$!]?,QA6+/-1+\?23BV,A9";CCA(VMW':*^ XR@M2GQ "*1
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M;>79B1[0;6\AI5<_KE-C3M:%ZXQ0_=Y;YQZ]\*+M=['^I(Z +T1;-&:%=^7
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M!ZC=^=SS!0:,W8 =UL" MQLPX [T[/D[8?W Y.F\O)"924\_/\#MGV6>5KW
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M\7I/YOSO=3-TM\D@:P>3?EDOMU]QPX8N=JL&U@2[F9L=5T"S!5[J7T [9'C
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M4$:8S!*<PYQE J(XSF$9YRD4&49%@G)",B/KS)AB8$VL28*.#[!AI VP*3:
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MD)*H0*20(B^-Y@,;T@ON<+;4P9K\&*IAAXR.<\"9Z5*/<-@ZGQT2@]$#GX:
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M[K.:./QO31WTY$%+W[87[RG QM605Q@LU8PS @Y==\](=T&_W5,K3]QI]XR
MASUVSSW@TK9$N]K-,OS=LVZ"WYJD;<66,FX?5\M_D*HQ5]__$!6;-_6'45D2
MQ$J8):B$2"844I$74!)$"5<&(J&Q>1<3!PY"FX.*FV9DV4H"UG#074D\/ZF_
MBHZ+P6__Z!ATK*IU>@GC2F(2:&TC\1K"EAW0\K-Q\5N6;D#+%.BY ANV0J-I
MTS8E,*J.752"H&O98.4"9,;[K;@L/&'[E0ODWNW&<LE"KB5U.K?Q&_EQ;!);
MDI0TEC&#15+&$.E!);C(2\ABW<B*9F4:639Q/4TLN(O?)!(KVK:1QE&$S#Q&
M7W+;*=RMR.%FU-E(Z*W0;H34Q%5WYX4^+,$S>,9M*W\2=2W$IH;RDS(2Q:<Y
MH?.%LAV[6\CZW;/XIR#5!_6EF65%E'(9%S!*$ST,F2%EQ]$<"AF7$9-QQ@IN
ML[UM&0B\Y=4WI[3;ZM8(FFW_D+C8J826DV&A;</,#=BP<Z/;6U/1%>QJCH!F
MR9^F< 7#D_:P)C^I1G$%9U_+.*_CX$)^FC/=MOIVV44WMFT_R$+4O\[5?];*
M6>VI?GL@ZU_)ZQOQ13 Q?U&V-TU)7#"&(:$20Y1'.:2)^F=*2BQHQF6:&35^
M\\)-Z+QLS05X[-D 3QT?%O[-Q7@;>(Y3HFBIP5K.@&*MBQGOM IJX-WPUP>9
M:Z Y!(I%\$: GLDI,;?P+Z?$WLW7G.(=V'F>OC ;]4(O)C*=1^H+CQWOU-NB
MEX2Q^Q86K9=\5S5W=70AOJE%NY;A),]*7! *4T%T0FVFSI.<<YAE11EE>59D
MPJH!E"GAT.&'-L:W::G2W?6L*M"S<@,T,X[-V(WAM0F2^@7-*2;J 2_'&*BY
M\%Y#G@9DKQ#A- ?C>$#3XGDW]?)%</'XU.:LBL?Y\^,,4Z5'2LH@4QH%HJB,
M(8XB"2-!$.6E$&EIU9#X@$)@A;&E!YY:@G8:X1 1LZU_D9QV>WP@XOT9$:TW
M\4DQ/.W6P_4GW98GQ=O??Z<_Z-AQIOI.EO/_;4S.MZMEO5K,.>E*Z!6%NC='
M[V17P$,6FWK!;8E93(40I$QAQBF'"!<<4J$\1T80PB6.(U18I:9YX2KPAA[R
MJ*,Y RZ;NK4AGSHZN>$4;%EUK@#V\]K,-,CD+\-.ZTSU'NP[DOC$S5<#$B\\
M3=MOQ">,!^U%O"[NIH+UB+G]2;^BH#(M4@QI+*0>@II DM,$2H:R1&*<9,*J
M'/H(C<#J45,$F]R-MZO:-IOW&"QF"NM"8>W4CR8VS6SC$;$\:8=C%";=ZR,B
M[N_<L8\ZFD([%_1[=0 Z0*CS,K^HS7\OU%=AN9YQDHLX$2E$<=;TUBL@)64)
M44(PPA0A5EI-*K9E(/ .[AF ?8D8[U@ BLO3%3Y^L#4T30(B9FF%[,?P#NJD
M>G; EZ9LM^/(H[GAB(4OR\*6_+1&A",X!_:"ZSJ._5/$6K=DN:]6+W,N^)O7
MWVK!/RXWO12VC9EG)4Z3A"82<DIT^D":0X)D"J.,T)RD&&/!;+J0F9.V4D/V
M+<ITL\"F+<A3QXJN7?S+LZY:G"__ZJ.3BCG(9EHI#'1V^DBCUC18NA^B]EN/
MVK:I2HC>WO8 ^.JG8DYXVH8JUH <=%2Q7\$A>^#CDE5:L;T3[9\?M5/4^#BZ
M<.7M<[U>/8JJ:0%WNUBL_M"V_8=5];82?+[6+1G[/H",YE)@3F#!BQRB3.:P
M)%D$BZ+(BZ00&6-XMA3?]0CW<7WDE2^C_8;;_3;DSGC;_;:D\\5";;*J";/I
M.W&+P+8W^,?UU/20NF9,-IR!O_0\_A5\7(*>3:#Y!#VC-Z!A5?W1,ZO[JH"6
M7:#Y/=\',N +L<@XN,:+<<L\F/P%V:4A^ 9R-!W!&['ITA)\X[.3GN!]<9=R
M*IVI3\\W!J G&@/\7=3J +A[7NO).7I0RIZ]_T7H2*?Z>2_:,UE\$]7C+$E3
MK$XZ C&)=;]]JH>G9ARF+$(H2I*LD$:IO%>5(O#M0LO6#= 5L#;U1-=ZIP9'
MZI_A3=D=P6V+&#K>2N9-WTJ&CK:2Z5_X0+XCMR0;&<% 2/#M3_(EL2E<^Q-\
M61R+W_X,7QK+6KHKOZSQ>KQK,3=A3=^5\=^M"[PV,VYWB:UI]8&PINS@]L>\
MGF5EG#)19#!A2'GI."&P+#,)F2"YR(HLMAPQ<T@BL!'1>0\]1?"[IFF92G$$
M%[-KOLNDM3N(+06UOK$[+8NGF[DC!":]@3LMX/Y-V\@G77NQ?!'?YSI58+G^
M3![%C!"*>)25L"B1@$@(M>W2+(=1RFD6YY*DF5&/X5,$0J<^MWU'MC2!)FK;
M;F4/D_$MYT-2NPUG*:1#1Y7CDES02&5OP8G[IQP7Y[!MRHG/>8V/;:)TVUMQ
M?9;.E\_J9]TOU4&\35_,91[1(H)QG$J(DHQ"&N4E+#E'9<S+C,96-0I^V I]
M=NKHD&S&;^CW"5:;"+;G0)KMV[@HR!808Z\!N&/#=9OLQ8Y5L.4US,0#K_"%
M#=_9,O4SA/8<@30,^[FN;J=E!>.S6_Y?WU:?5\M[L?HL5MKA^;#<YN,9Z,2S
MBP16<]OA;[J67H]CN7]_!SZK_^_<37Q8K=;+E6E:TWEDQI685U#L])(E'IX[
ME!@+/F('J34Z9<+X5H><7WD2M6 L8+_3S1_PV0W@MR?%\K+5+>T-Q0QGG.6,
M),HA*1E$*5%&4)()*,I<)")#!1?H\L+_0\*!]W]'L$LA:DGZJ#4_@J!!B" 0
M+G8J8+QBO >L-5Z" N:C#O\RX$*4W%L!Z*FR_C0*;D7T1];[">KE3TMI5AH_
M\KR#<GW[6CW7;^;JD&0/R]5B]?WUXY*U8^!G,B(L+5$$$1-*F18D@B6*2QB7
M68Y(%">8F2O3$4*A?41-&>R0OM%3H'^Q4 AC,!EH3$_"6UZWGI(;_-Z2-KQC
M/@N A0;T!(2;QK/_(M@I-@/A1A79V//3*2X#*784E<GG'5PV'6LZ,@;'U%G[
M_[O[VM_&<>WN[_TK!+3HTP+F@I(H4>P%"F1F,A<#[$X&V=P6Q7XP^*;$K6/G
M2L[,I'_]0U*27V);)BE*R;:XW4D<B>>%YN$YY#F_<_KUD2W-#@0_HK4NT]RU
ME7$(R<Y(;A&,#1?:,0S3!,?JG6,AD5]\=6;,Z2*K?J$.8JH+CWIL^'?R\6E=
MT>JE1?7OPX>=$\$*)5T!D@SK;BTI Q23#,A8<*'^1V!A#\OM0GGDA;H/Q_V[
M(BOKZ$HC6I2RJJ1HH;G+=66^WXM5I&9U);GQD747#/7HXKO^OC\M*6]20721
M=BTWF^6V,W0EESKU>CL,[S)*_1"]G>;-PB49:S;<+,B6BZAA8Q9=1IT>2VD.
M;LQ8RO/S:X(JT<WE\5%$KP_D-.!T3I&/G =>DM< ;].CLDGM48'G]<\G9?2D
MN%OKC_9R?:[N53"J"TN^*).V6-4+WK@H5,)4ED4&\BS!  F9 L9U53&52 A"
M("\RMPY4;R:+RZKUZF#5<&;V#=GRIL^R==>P:1M1^D^WW1WGGV(*W7:MD,TI
M][X'UWO? _WQJXS1K9C15L[WUJ=R\%R]DXZ5_G+\J7I7#IZNT%TLAS/DMV5N
M(ZLOJR=%ZU?Y72Z3]G0K19QF$,5 P!0!!&,,"BI*(,HT3V$A$BJ< #)Z:(T<
M]1A2__R/<0[_DKCM,7WZL=L% DGM9J?WFQ(V=&>1H1PEE\] G8VGA8B!S%L?
MI4D-D(7(KTV$S2N>?N]IG]H0^RI_F+_4<U3@0M*"@*Q(-01GB0"A4H4B,8M3
MF$($$Z<&-%94IS_.^* AX]KCC"8:U![&0>LQFW.-6;22YC1CT9'@&@1+?_)/
MV2PK,D=?U6J*+/W*T(IW] %[0NS6Y"@NF@<"HE(X21W*F[*B.:WGXZ*&(R_%
MZ64_8]0VU?JT_K&Z73^OQ&=)-\^5/*XH;LX#FGZI\5RW+L4DC@'/<0)0@B0@
M(I> )C"CA9 0$M%!3MS9&RD_;JP6SR'0Q)T'0E?#VTS9HZX27VPK\96-DNV9
MED_?9L]9L#- (RK5RR)M%:DYB@Q+4<N3N>8\@CE0RNT.#$.W;!ZFFT!VRY.)
M20W9,$6]MFP#1_.LR=N''#W" $6P*')8@(QS%3V5I0!%GN2 %ZPD>9HG!#FY
M6WW$1O:ROJFM@B^>="L2Y?X<,.)8K->G,#O;$TH-;A;F@.HT>*$V@H:J[NLC
M-6V=GX701Q5_-N]X!E;\08KGI;PI;V6]J9[YQGA-5RMQV]QQ&F#<.XT3-4_B
M3!"<)"##L<;\)04H"&< 8B*$% F-"ZNR0 _:(R__ _H&"SCZP]!U+-5UT:9E
M)#2.CMQL@X=ZW(,?=T%#A4 .E*<-A-Q5<A0.>0SAGM"EQVXQQW4NBRE1MTSF
M.O'J!&N]I1A]DAK=9[%J;G@T _]FG\QU2NK^11U 8/>%>U[68$7Z%^3R2N4Z
M-=YD:5P]PNRG</4]YK<=[UVGU&J1?EVOZ.Z3._533<V17MT>T),8<TA0!AAE
M'* L42XXE"G 7%]AE#&*1>JR)3O2'WFI?EPO%7-K72SX71Y<P.H#S_W?;S8/
MLHHV#U2C^^V_Y-?=S'4:[/;R$97KZNN/KU=G!\!3.X&< %?JDSH"GJIY[0SX
M#N..*O*[Y,K/V+S$";M;;)2SFR8E2G5K18()! @F!: YQ0"669)RRAC*B"VB
MR.O!1S9"AH8^%8B3?V'_&G74[>%$CI31;RV&BNAF"ERE<\(1.2>&%X;(T6"3
MX8><$V,?.^3L,[[G;OHRSUQF-/E8,$^9A#@'G$"UT<N8 480 7%*"YBF4!2Y
M5;W6.0*C[^2[R\E9]$_P%PAA'#W1*OJNJ?\E2C,X4Y_I_V\3J"/ZO'E85XO_
MU1E4YECND^3&,$5I/(OT=\-L5Z\_3?\2)=D,YWB6YL0\D<U2@F<9P=W(B^9F
M3_]MO4L_<:,RB]1(.I%%[89+2VMP=G9M#P;]Y\S503#3]7LS75V6A=%:R.._
MT^($._)[-?S$QWRGA3L^VCOSG&>+(.VO_;J@3&.#+62M]GC>X!1OT6M2E"*2
MR1Q 46*U%7,&:,8H*$J,J=J*,6=.(<-EDB/;%@T1T5*,ECL^+"-Y!\W9K=*P
M^G!;MXV[OD=\%NW(C]-#T%K:4&U\+A.<MG&/M0*.6O78O^G;HWCOR.]+,[@Y
M\-MV"+PIU<?K1WE3Z9S.2C[(5:WVL^;#ZY\;_2M;RNO5\V,+V3-/65R(F'$
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MC)>LODM]V'O%>?5,E[5Q.N<Y9@F5.08R$43CJ4G \AB!M*19+DN:4^B4R3&
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M&^4_ZBL%9915=+&H_[9:,QU"ZWH,@Z%QR.&'EVZ,EX]+6M=-#NZ\0#AC*&=
MQCE43E^N0MT\18 AG(N8"<+LL+PGXWAD [L'U<M>MMD0+Y'AP#,C?/Q9M#/
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MC\L"OXX5+-[PO+]9TKJ^*5O\Q9OJ=G'_L&DQLA@B,2V3'"0I1,IMSP0@)4H
M03A#4G<P%IG3_<UY6F/?WVC*^LRS@^M<5Y&A[MG;M$]KEC<U873AZ-?YJ\']
M0N:R@*$N9'HH37LA<UGDHPL9BU?\PO;OLMH81,&NN,1D1ID#A?KN@6X^+<37
M]>;J6;D/RIQPNER^M&_-,[V%DQB##'$&4,P24*2%6OP2)DDI5% )K?#KA[,R
M_K5NQUOTM"W"J9LBG+8 9J,8C,1"&+PSNL]CQ)O7W<^( \R179 YC>:=@\NM
MTH\JGQK6(LU;I)@S^:@'[$7MZY,IVBV4G$;AWB'DF(IW#AR'Z^I2P#B PJ2!
MXG!-O X0 XP8T)^\_JDAJ6O%S8++[1_K]J]U/$<2Y3 M"4A+F@*D?@0%(3&0
M:0IS3#,5.EIUAAK$Q<B;34=>[30:+2Y$FVX_96<PP:GRX94S3]7VGC,"J-KD
M@<A4L Z+E.&4N1=(CJ[R<$62;ZC[DA8)*FD.),F4[C'D@"&&0)86/(>%Q%(R
MU_K)B30_L(;R#94^("(+J<9 L9INY]-:$L/5WC/U]J& 4"J#]#)FB'>1A[</
M_FS59!466@_FMW.W)\?U7.T"&2X$!HG@$""98,!8H5RL)(XA+FB&1.H"B-(-
M[+2_^L*@5 TQ-[.R%=W.4O@(Y+;X.PKA5O%KG@,MS.VPDZZUU\*\7CY'?_<X
M0MEB_C;ECS?EWYX4(P:J;=M)=3\SHS:(Y2Q/8\8P!((F$J RU> 3*04T3EG)
M4Y'DJ15FB3\+8U^*;*&0J6%*[S[/#5LF#_ZQ8PR8#F)=Y9?++;R?YBT.1$;7
MI]LBWZFRX4?7ZK0<F;;-NR;-!\EL=3^(?"A].IQ[C*Y7O_..<?3K=LPQ2#6]
MQQM^(T]WK#%(\H/CC&$C><)F+FJ^7-?/E4[LWLO.NVT0$'3E<7V4G%?O4&6)
M"N1RH@*[-,MSY4.E)2 4$@"3&$.$"<U$['*@,9"?D3<%<[BD<TT44=TB2F.:
MN@)E#E2XG><VH1K=]H(+L W1'Z-<O =21RB,S('<3(N0&49U1_B8@8;UNC-\
M?%RO#GMQ$E)F.1$<9!@J=S8M"L"DR$"!TUQD/(]3:F7&SA$8_7Y/4_1HQ7I*
M%U8W;H,D=+U'VQ?.I^'!*2F=KKL&2>M[B>4FM>NMU%F1+MPU';\WY0W26:Y?
MW0N=?\['8-#Z09<B?*=+;824._;[P[K:Z!K#+P:XI7'&7N'MYR(N$2\9B&E&
M582,8D")R$$*8Z:B9$A0;)54Y,_"V$9' Y[L,36+?J/5_\@&".]WR9\K@ZIJ
MHN4])EW6K9?B;>S7V.ITM'"O-&FB-L-19 I9]WAR2E ,I5$76SFV9CVMJ;V&
M0UG8(8KHM\%>(T]HI8=(?FC'!XWD9NF%7,RO552W>;D2HM(9J.K'F^IN_6,U
M3WG&2:F\0UQB#:(($T#T);XL25Q"#+-<6MW:]] 8^T[>4(U:LK-($]9W:)JT
MG?GHTT^_Q0TDM9M)]1+8>H5;B-33L4Z]W82)ZH===-@WYB2+UT*H;G7:/.KA
M:-TLQ4=:;=3"7M!5YZ>769H30@$L8PB04/^A0L: H1CSO& 9*:W6WCD"(R\\
M13':D738J4_IPL*S&2BAVR([%,XG,CLYX_;>QD!I_7P)RREU<Q=Z).EU!DZ]
M-]U6W\/UP4;>]YPG#(\R.E+^*FDMC]Q5GJ2<0IR!+*,2H)APP C4?4]P+%!2
MD*)P*N?HH36R]6AH.@+S]&C&[O XD+QNMJ0A.HL:LN/685D(& K/IX?2M/ ^
MET4^0ONQ>,43_(<_2/&\E#?E:6B(?6S;*]U-0WD7=P9Z?7>Z@G-8EA("F$ !
M$,X%(#01NITMR5A>9"5QZIDRG*6QKYY:!G4>0G,-U7 3==PXHO8,GP([8S*M
M8H->1NT@PSO&HC\,:^-8I7":"H6&,YRA:7%N@BGP",$FW,@^8=&3U$"&JWMC
MBS7Q6ZG;1BG[AU44! @LA 8^(3K1O0 09E#&,!$YL3]@/DUC9)NFR42]W5*L
ME6$3&@T6T3$ZZN@U/LW,9-]$MT'$=8F1!HOM&2:YB^\8,O4*UA\UG7YUPL"I
ME_?#V*G_T8GA%ULCUZ5H;[&W3%+RE]6F6JSJ!?\/W<MMSO,RD2:K.N<E0#0C
MH$C* B1$2IQR'J=9,0GTH@/3(UN\+;&FW=UQ3P#9\FB9]SCI?%HZ?.]LEOQ=
M0D_PQ2V\XE:2'<*BZ07<?@.,).\ <M%#[V\-M^C"\I\#:M%C$H+!+/K0]G!C
M?UUPW5SK:M42O+JOI.'KD_PNEVO3$WZ;YSI'C# 9(^7.QJG:/)!$@''.@*1E
MS(JT0 7"UMZM$^F1MX ]DKLB @>/T$V-%G[Q:,IQ/ !LV# W\]W11L?)+-K7
MVF^C:\W!O1Y->WY>=T@MNKGC7HKH]=+=1IS.>?>2],"G]QO!I[@K@3'I"BB[
M7-<LACF.&2A+@@$J6 Y8(3' C$B,M'.>VEO6$P1&MI^:X+8.V*4ZZ(0J+*SC
M0 '=;."!;#[WJ:>$="EP&B:LG\FRFU#'<J3S@O07&YUX;\)2HO-<'Q8*]3SG
M=QYPM30*E>*T$WG=]$6=0YP1AN,88$$(0) (0 O$ 6$\D3AC.2F<^IW8D1W[
M9D4'X/_\CT4"R5^:6LY3/6'=XG%+?6(-AR&*&,1"HV3P H*BR"%(***<E!(R
MBN;?9<76;Z?1??+6.FUJU,W1!IA8IW:G%.'U%/CJZ?J"BIS/!]PD#A3A6Q*=
M-$9W4\3K*-OQ;<_C6;UPOM3ULQ2?GE7X?=\$Y"8$;^"K:D5+5TYM ;!V"?=S
M%%,B*"6 BB155D7M=$1D O LRY,"PYQ!Y'3N.H2;D8WWCKZY&%>,R3JZ>@W[
MIENQ\J:@QM@DQ\/50;-A>6HZE8X=S513\&KXBAK&MB>9AK=9=#@#^]A[.P8#
MGG*&T%.HX\M!O$Q[+AE";4<'CD$&'>D"J[YPVGG8.N8_I886DN)*,4KOY0$"
MT5R21!E22$&"9:;L:4( D3D">1JG!*6Y8*55P/P&O(]L?0TC4@2!/)MR1@/=
M9+W-/(6_T*IM;[1>-PR;19U042O5*\RV":^WPD_&5+=< 3E_7Y==X:?$^<YK
M!!;>6\/+S^NJE(N-[H#2=DKD$N,4I1P(4<8 ,<15*  YX"++!2),9$QN6V*]
MA]:71R)8V<-7O;/<MZ\MV??=!_-X@D?.Q!AIOMYY-\R#;\.?IR'FV;EXZR0-
M#\[?U_85?DJFZXQYGH5A?;#V>D5=_5S4<\YARGE1:L O"%"L=ID"9S&@L<SS
MA$H&$Z<ZC#-TQDY$[EI"[9&-_M"$'?OEG%.3G<$.(+R;<?61V[OKU1FI K>\
M>DWE3?I=G1'U7+.K<X][WN55DMZ4MY(NK^N-\HR^56OEVVQ>YAP7(BMS#"3%
M&"#(":"D8*9FJLBIQ&F:.]W>G2$T\F+59/51X[HL-2IX_435?Y<Z.=HQ:?:L
MHBROD *([[9<.\DUS:@A&G54 UX479 KU-70.3+37@9=$/;H^N?2\VYK5G(Q
M__1=B/JF4CMX=5VM[NMOXF9U_??-R]6/2M1?-_KS'_5MN>0;M9G?;9;:55#;
M^\?OE?BOJLWQL%BU@4B-G1VY^+X0<B4,PG_CI5_32C>U:.!J([5!M?Z\<81J
MTZ[*//AC8>I+RJ7DK1/?W$(?1 VE&O;C6H7WZHG_DK2RLQBAIJG?L+S!#+G9
MGZDG)R#J76#=]J"[*$JM^>-B9_5"T9_$. 965F=#0P_K ^5WJM_$UV<][*[1
M1'?L)^8)2@@LE)]4$"$ (@D!+",,Q+C I2XR3[ #+*@3[;'OS;NN*S]V75>J
MINO*RK"T][>]JB3?%H!N:N\WDR,KT\TD-GJ\V76ON=EVKVFXV?M;O;T<<4&U
M=]2="U;?:#KT!.D[WPG(2Y>.@'U>VNA'ZG,;<D*(/B]9#['Y_(;P1*EOLWGN
MZ,^N ?Q"UKH@5OD>^[<]\S2FC*6H!+ L)$!%G(,B@1G(,,$,(XCSC'E<?5@S
M,,W%Q:ZVVL2]C>4&ZQ(\JU_4O$C;S'AW!=O%QF'UY>>L=AE@BH=HCXD&8DCK
M;I^/@%CSKJ*'0I6WICLM?KRK.HZ0XIT'\*F3X;QZEN)6UBKLX ]7*[%7B6/
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M;-R]67-;29(F^MZ_(F_>UQN5L2]MW3W&E)0ULE:E9)*J:^:^P&+QD# - FP
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MO[ZZ7*T7Y[#L)+;%DD+3G6A.1!E5NIP)2;QUD6AC%3/4Y>1KA^@]R!KGWFI
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MW,JL;6TT:14O+]:)UQHC;$BR].U,)&511L8 HYK5=OKW$3+. -%AG?V3!=X
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M;L;-7.%^-2FC/+1DBF1I')%@H(SYX"3S#%HI[46JW9SR'A'C%F#61\MI4F[
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MNON%K9^<Y*03" S3\$C 76I#B=H2RL&FS$!Q%$3M1F #L#%N9#[8-<[8"F_
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M!$K_T?+.X6X;TAWN%),ZQQR(IZ7#=N2>^"11V#19"SEYF6O?I#R-PG%/\&?
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MV7)1U)L\ 0DYN1M.&'#.*=!9J""CS=RVMHM[DC;R^<Z <!M"-T=#[@?.XVR
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M8".+^?!M=VWMI1-9\@R2US;-SM'.[HJ 8)@N'B,ZTWJVV&YJ3K5M'W"Q0/R
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M^E]U=7[0#D*_#-/\">M)9AW%47_7>A[J<6]_IJ&I#43S')-5>?)>:9D 4]W
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MTD%!1J1P Y4@;G$;T>4&^)$]>$#3X6<?;O=@W6X"U.LDV=T^I;6N1B9R0:>
MUQ$^RI&:=@83A.1%\(5IM,WW-#QWH&F+U$;/ 1TL@PX M47#YM*A8AB3L%!8
M%*!88N#J&&Z=36)6"253:R ]>I!.LD&'"WJ[4O9@KG< G6_C3?3,,&06;/2L
M.HP,?,!"P6P6V9+2I0_I(J0?#3(-!/MB5#^$RQ/"9+6\I,/7$7-+XMWE7]7
M7T<4)F)*L7855),;BH/:[0(HDE&2&^7#3I5K] 7W$$*_ND/'4]\];65L:X/4
MA,,3(^0]?MGVSK9)NMEAG)S1)3DP6'<EJ1J(:OJ/R2H72]>(*&P FYT/-(VB
M:2/SQ=@"F#K4>K/\GP^SSXO+3W^=_<^O7Y:S^4=<WJZN#@*YTT1&J*6:)4"4
M=.<8V7+/F#4L;0U.>*K$^LGOF X:(TEST9ZU4R/DP]FO[X@E<_JTGW_^?D,
M$SX9QS.88NI^3VO!H2L@H_)%<)'$]D*6)[#QV*=/$VH?"14'LW-J/!"LO_\4
M"LY_OKHYO0E62I]!2$,F.9/#%GSEBG1<"6T%USNVZFQ_]#1Q\?'TPP&,[""N
MV0SLJW#^ZUX^:O7=7_?_Y#H&5)F7E#)(33X] =R!L^2/8W):\>AB;%X=O_OI
MINWR&2O[,I)T.L/=YA(Z'X6564*A"P3*IOK(;S@IT!)="CRB:#U[Y=M33!M1
MCR7O9V"U!_,[@\]&\5:"I7,<,DI-.KRNKT#2X47FF)";J&WKAHMO3]$/?/:1
MZS,PV8/)'<#D?M')S[<=!=8HJX6@N\)XJ!VTEGB2"G#!I;/>E<#'K/W[>="<
MEM$Z",>R68?SO /@;'41?"*.KLZN+C\MEK/_C?G<,!%+KD/VC,B@G%00'+$K
M",N=2Q3_N=:NT/,GZJ<2<$^1+T;C?P=HNO_R>U7U*/UB35+M=JQ]V_=L_;E2
MJ)3U :35I&)MUN"E+V"%%0*++$6W?E<8<KY^J@C;(&TTV4P=X]\C[!_+Q6KU
M/?F1L[P>(%SGM"><?<7\]@%Y)A9/ 6\"QG+MIPP!(K<*B*M$. N,N:UFQ*>J
M,09_][2OY^U@=0S6=Z#1GFZXNW=W?ONRF%__Q54E,6LG;4*$'!*YHE$;B%@8
M>/3<65UT3*V-YA['G/;5K+U^&UM2'8#QWG7;Y:;Q4I!+"Q0E>Z (1H*C( BT
M5,YH&P1YNN/9UT::<+1,UJ@&MK%T#I@M<MFH0(V(NKY!;Z[JX] [7,X6^?IF
MW=VGM^7>);RKU#M/W.ELF01F):L$4S"MB6HIDA'(BBFJ=<;BL!-/&[". ,WC
MR6]J;_ %,_#A4[A\,\N_+"XIREK473XI7%S\M?E7YS)'GJQ&J-P$%1('GY!#
M#/2;]7VDI-W*O \ZQK23<!K[B,<3R&L88G%V]"$6+WWCT8=8#&+!T898J%!4
MSBQ!J4E"E2DV]J@5V6NF,'CA#6MMPR8=8E%,T(BJ8JGZ)U(*B+5@/[N"VI2D
MC6P]K^>$AU@,0<>0(19#I-!#@/)DPYD3"94D!JEH#"@4 KPP&F00=<@'4Z[Y
M8,/#>CTG&6(Q2-P[]WH.X7T/('JY?<B%;()1#L@+%77N9X9@2P"AA+11^SHK
M;<34\6GU>@X2__!>SR&RF#HXV*U[K'(E>:<@"E:+I#+YG!3Y0,&2K? ZI.UY
MX*/WZDW9ZSE(P,-[]89P>VK\O%O.OM:M@Q<A;9.19<A9R@21XF$B(VJ(V7#(
M/O&2'3IG=FOP?/H[NN_JW!LIC?C:(SPJE\CBOYWCAJ# 4V8B6=!!1B)(>' $
M>"*H2.TY"RSNEF+8Y=NF42Y-9?H23@YB<,>(^4#"OR')672:C#A$IQF9\,@@
M:EYJ9WR2.12F=3@4,_>^;QI%,P5J]F5RS[CY8[$A2(MB4M*DCBW:NH%70L"@
M(4===!&\D+X^&#4WWS;-N_8DF-F+P1T$5M]=K69S7*W.TG^N9JOU3OMU@" #
M>N_)Y4)ER&RK:K9+E%#SNB4Z^A^VGL/TQ%'ZG<)T2&3>@N^=PJ?^2!ITX_]Y
MI@77@4'QJH:;=.\"<0F<"3F9XK*RQP#2@T--&UXU$?T.<-I?#E-;LK<7^?N;
MYX*;AL,HD=F@0 1&=\VP"!&- 1$3S[6R.Z2XD]WZ]K/[0\,!DENT8V,'ZN4Z
MMWXSR/[ZL?KM<KTF@Q3P=W]]H,]9WYW"M=>.O#-49&L5YPJ"\!:,*E9QS(EL
M;V,ML^O9^AV-<XC]&D4RW2.N4K6YE:4H3O>2[F+Q@6YEL!"LB:!%70Q4ZF*@
MUL-P=SU;#X-16B-C$/SV%%,'\'MT + K224G$=#HVESM;-UWEP%)67OO7,K-
M5RSW-W!Y'(D_VWFQ!_OWAM!77,;%Z&L#F+.%H?*0/'>U;Y)#M(FX1'%O8G6^
M=/&-D738VH!))O0<].+:A/<=:*+'1E:7D*0W&G22B@*4X,$KAR!(=0>I>1;-
MRS].9VW (/'NL#9@ *\[0,NC55HW;;-DXXLE$\^9)E)<,. C8_5.,<^B94XW
M?YA_^CC]- ON(^E'UP8<SO8>$/3L"$8C/+>V/B#&F&N'D+KN/:/+Y6,*41G3
MW[S3229N-#%>!\N@ T ]/J QYVQS\@[HN*$..<\0@V&@#3F)] /7O'7-V<G-
M.QTDZ)WFG0[A>@?0^782IW!TJW@(H%V==Q;H5H5B* 9(VC.OE8S-UU*<Q+S3
M08)]<=[I$"YW )-:7H?_N:K7Z"O]YS:Q$9CF3%+ F%-.9-&3)Q5</)CB, 2A
M@C-CU+4^<I1^AVP<6M5Z*-_[A,]-QI\+BYETKXN&F%-4@""< 59<JK,_10C-
M%VT]=9CI*U@/%O7+\-F#[_T!Z'9*D0^,Y0#.ZU*;2!UXGB+HH+G+K 1IFK?X
M/G:0[H"SCY"?A\X>'.\ -H_W\DD>K C:@#3U]5EPA"A+K8JQ"8W,)O#F'L[>
M<Z%&ZW,<RV0=SO,.@+/5\O3-8*)@8K9)<[ I*B)'(0299%T@Y9*.6CC;>L;%
M"T?J)]FSI] 7XTF@ T -&C\4$G?H1*1+5]]UN+;@C'%KY2VYPA!+\X$!)SX:
MZA"HC2:;OG"WPU0.:Y 9F\BRE[J7BJ$F+G(%A7Q0C)D+L=W%T>',E"-/CVJ$
MO,;2F6QFRO9@K%_Q\O)BG8#[@,O/Y)+RX#UYHU'75#U& S43 IH+IT4R,>K=
M%A4\^14]#G;:!R,-&3EUD>/=T=^6-[@N+2=T_SP+<79Q:]O/N=61<ZU!<$>!
MKJB[IRS+D#,:BCJ,-*+L!HU=OJ['\4O[PZ0Y@SLP78^4BSZLC%EME\8\9KW/
M,Z:<G&)@O>"D.D,$;W.=J")*T58JC:TS3&U.WN,4ID.,W03RG%KQW1!P0_J;
M\-?JW.AH7+84KW!.U]#S3-=0DB+C-G@>8VW9VTG//?;I/<Y.VENM'<R^#K38
M@;/'B":IF'; 3*P5\?23U[* 2$1J5CXIU3S%.?[L.-<_ ">0W]3:ZK!1929Q
MGC$7<$+8^I3NP3/AR;M@Q6KO3/:[#14>?W:<[Q]^1Q;(:<^.N[N&HPZ,>^9K
MCC@E;E=BCS8:KHXA-$YD"&@H$M6Z0"Q: #<RZI@#Z;G62:-)1\.%8))C@9,.
M9W4AH(J5<@W&:(.8$KFGS0OT3G<TW!!T#!D--T0*4Z^##?./FSX@*UFVG&(7
M@QX4HH.@G0"??'2:3LUVZ]U[:=WKS1?V.^IMD/@6A_*R!P#<M-@(,LF<[D-,
MF0C/3$.,6(!+KU [I8K?Z>5P%PA,OKAU/V%MBWL/SDTL\'_.YK//5Y\W!Y="
M*)&# ^?J;BY=(CC&% 1R +ETQ433XM8_^-*)A;Z/R!8M^#>UX,.?]P[NO5"$
M;0O<D6I3(M7UU<*!599H\CZ*M-,[[DN"O_^E$R[D;2'XO?G71:KGJ8XI+HJS
MEFR<=YK848,_1\>O72HV.^9=:M\7=% SXB1#9O;Q"=KRO@,0/=(V57P=*(@6
M'-T:4-Q)",XER$&C4X*9L#W^[&_4C#A(O"\W(P[A=0=HN>Z*^^[1KCC&C##2
M:<BBIIW09G"<"3#6R4!7*IGF98[/'*>?^K1])/UH,^+A;.\ 08^G++5AWD0I
M  /#.D32T?U*"91UEOE:7F#&['_^>5")["0390XQ5H?SO /@/):57*<K[Q*4
M[ZNDS@.7F#D+=+,\T65EA.@,@V"CMU$HHWQJC*5=S]:/4MH3!L\.]6@DDZF?
MI9XDZCN<8YFE6;AX^\><ONO3[,L[7*8JPH]X[@K:Z&R!8((A_5X7I\>$8+1-
MV@=I=QVCMM_W]U@DNP^TCB6"TWZ!>H\9/W^Y'/L%ZIFO.>(+U*[$'NT%RJE8
M0D+B8K)DBWF=H9^\!>FB=<9Q[1AK;&%&>X%ZY+[=\7M=^<E+1NY]HKO+/:A4
M//CZK(*2%<G1%;6=3MQ)L3W\EMZ?E8:(_!E5=@!KNS6+=:CWZM/B(M>2<DQ7
M]7Y^6(8\FW]<%U#)B#JF$FHNC8@4OK[-D1=@*7+)6:F8M^<=#S6,+YQ@6M-X
M-&R-))+3-I2_+RZ)Z%&-Y!-?<40#N0N11S..DFN,12,D4U=(\E@@ADQ.F*C-
MO"D%+TYF<]\+M^RN5^8]TA?-UC^N[AS2M^7M<O9Q-J]54M<E??>J^\[F^>W5
MY>HRS.NU/->Z7DKRE:6OB]I+MA"4LH#1(W<)C<^[[BDYPG%[-]=#0+BC2IU*
MV*>M?W^>D8AR&#U2>>Y[CJB)=R:WD3J^O@"WL&<QNXA)@D3R'Y2HVU4BUW47
M3W2J>&>P]1#2AR<8LPY.<%:,,@PP%:P=:!3G6YFA^DY"1(8*FW<I]UH'=X#<
MAQ2]#6%Y!RGBIU_MDJ"_K20"PU*'\ZL$SF$ G7EBWM0U5<W'_AST(#Y)D=P@
M<>_\(#Z$]QV Z)&G._1!>FOIR%)%,M?10#!9@3:V4&SFZG*CO^V#^"#QOOP@
M/H37':#EN3&Q.>2(5G Z>]TNPG4!Q[T!G;!H;KARNOFPNA.:SCM(T@.F\PYA
M>S<(>N)MOSB7ZL3BHF3=6U04!#+UP'@)1(>QR3;?"G]@2<51GIB:(>APMG>
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M=V#RGDZM>9-E*$P!QTAQJ'2^EO8C9)>*#(IL=VZ]G? $L]:#Q+USUGH([SL
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MJ:$TIK9F;V9+3/3GJ[-Y_N'/3=/7VU)FB3Y_HUUY#D76"?9HDB#CGP5%G[)
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M'<#VR381X1U7-G*0=3"M4L@A,J_)7NB@$QJ*I)HGP YIS3ER*7LCN[T_SSO
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M^^+Q&[D;,&2<J-]JD8MP"$DSLG"<D;HR00#+7&*($85KW5)VO!6D5KLZ/U^
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MXT1S3PV?,:8$1@]A]X$:XIH'9_-\V]^TJ+_UK>(@]:!DS5<S23I#\9 AZE!
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MP]5\Y+W]6?YPI7...0-'I&!?D!*+*#U()E6*/C%FCAXF-J;QU=1TG,3U'!.
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M=#XH>F B'+0@ S+:Y509=B08$7'+AI8M/M8.2S]2.']/1@\6.._SK,/YW98
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MSE023C"U2,(=G^&>VXD8G-T,F01@G9DC%3+<TU0G #4X_W\_&0T <X]/YGK
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M+F $)HE#ED@>@^%61G$4*.X;+SQ&CNXX(#Q4/,.#W[T1]&B7(V%,DMAZ.$?
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M48:<(0:\($*0%4&"H\TUML(;(4L_#7_\_;HW;8]B;@KQ?$!X64_V"RPF[Y-
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M34]I&$20H:"47^3P#F#Y<"#S 3BWZA8*6_CG>'%YNIPOFJLX>_^GGRQ#3BJ
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M3Z*T+&DAA<*JW7S&KE^N6^%]-&@58OT _*I7^I2,P$7T6H/BA4V$W(P"(ZM
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M_P%02P$"% ,4    " #5.&U:5W%-@HZ(  #IQ@, '@              @ $
M    97AH:6)I=#$P,U]E;7!L;WEM96YT:6YD=6,N:'1M4$L! A0#%     @
MU3AM6@$MX.[C#0  U%X  !X              ( !RH@  &5X:&EB:70Q,#5N
M;VXM96UP;&]Y965D:7)E+FAT;5!+ 0(4 Q0    ( -4X;5H&XLS#O#$  /8^
M 0 >              "  >F6  !E>&AI8FET,3DQ:6YS:61E<G1R861I;F=P
M;RYH=&U02P$"% ,4    " #5.&U:PQR<=Z("   E"P  '@
M@ 'AR   97AH:6)I=#(Q,7-U8G-I9&EA<FEE<V]F8V$N:'1M4$L! A0#%
M  @ U3AM6OGY,)LO!    "<  !<              ( !O\L  &5X:&EB:70R
M,S%?,3(S,3(P,C0N:'1M4$L! A0#%     @ U3AM6KS=JVKZ!P  L2@  !<
M             ( !(]   &5X:&EB:70S,3%?,3(S,3(P,C0N:'1M4$L! A0#
M%     @ U3AM6HU"*>/<!P  =R@  !<              ( !4M@  &5X:&EB
M:70S,3)?,3(S,3(P,C0N:'1M4$L! A0#%     @ U3AM6N(ICJ4\!0   2<
M !<              ( !8^   &5X:&EB:70S,C%?,3(S,3(P,C0N:'1M4$L!
M A0#%     @ U3AM6GIRA0=<,@  SCL! !X              ( !U.4  &5X
M:&EB:70T,3)D97-C<FEP=&EO;F]F<V5C+FAT;5!+ 0(4 Q0    ( -4X;5KO
M6_U-$@@  #T6   <              "  6P8 0!E>&AI8FET-#%R;F%C<W!E
M8VEM96YS=&\N:'1M4$L! A0#%     @ U3AM6M %SP)ZK , L=$D !$
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M2P$"% ,4    " #5.&U:L8OXM8O#  "\U@  %               @ &NGP@
M<FYA8RTR,#(T,3(S,5]G,RYJ<&=02P$"% ,4    " #5.&U:%^#4=61< 0#)
ME $ %               @ %K8PD <FYA8RTR,#(T,3(S,5]G-"YJ<&=02P$"
M% ,4    " #5.&U:X(QVHHU( 0!Y> $ %               @ $!P H <FYA
M8RTR,#(T,3(S,5]G-2YJ<&=02P$"% ,4    " #5.&U:&XWFNSG5 0#Q'0(
M%               @ ' " P <FYA8RTR,#(T,3(S,5]G-BYJ<&=02P$"% ,4
M    " #5.&U:)6C%I6.- 0!'O0$ %               @ $KW@T <FYA8RTR
M,#(T,3(S,5]G-RYJ<&=02P$"% ,4    " #5.&U::73S>FBW  !\RP  %
M            @ ' :P\ <FYA8RTR,#(T,3(S,5]G."YJ<&=02P$"% ,4
M" #5.&U:3&*\\ALH @!)>@0 %               @ %:(Q  <FYA8RTR,#(T
M,3(S,5]G.2YJ<&=02P$"% ,4    " #5.&U:Z*$##;^V 0#H(A$ %0
M        @ &G2Q( <FYA8RTR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @
MU3AM6D]62L=U, $ 94@. !4              ( !F0(4 ')N86,M,C R-#$R
@,S%?<')E+GAM;%!+!08     &0 9 +8&  !!,Q4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>rnac-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rnac="http://www.cartesiantherapeutics.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rnac-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rnac:ChristopherJewellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rnac:ChristopherJewellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rnac:ChristopherJewellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-27</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-27</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:Descartes08ForMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:Descartes08ForSLEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rnac:ForwardContractToIssueSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rnac:ForwardContractToIssueSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rnac:SeriesAPreferredStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rnac:SeriesAPreferredStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rnac:ContingentValueRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-06</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-06</startDate>
            <endDate>2023-12-06</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">rnac:ProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">rnac:ProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">rnac:MeasurementInputRevenueVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">rnac:ProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rnac:ContingentValueRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rnac:ContingentValueRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rnac:ContingentValueRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-13</startDate>
            <endDate>2023-12-13</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-12</startDate>
            <endDate>2024-02-11</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rnac:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rnac:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-28</startDate>
            <endDate>2024-02-28</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-07</startDate>
            <endDate>2024-05-07</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A7495NewHorizonWayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-01</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-01</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-06</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-24</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-17</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A704QuinceOrchardRoadLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:A704QuinceOrchardRoadLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:MoscowRussiaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rnac:LeaseArrangementAxis">rnac:MoscowRussiaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rnac:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-11</startDate>
            <endDate>2023-09-11</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rnac:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rnac:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rnac:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rnac:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.TimothyA.SpringerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:TASPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.ChafenLuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.ChafenLuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-25</startDate>
            <endDate>2024-09-25</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-25</startDate>
            <endDate>2024-09-25</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-13</startDate>
            <endDate>2023-12-13</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-12</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-11</startDate>
            <endDate>2024-02-11</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-15</startDate>
            <endDate>2023-11-15</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2023-12-13</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-12</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-08</startDate>
            <endDate>2024-04-08</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-08</startDate>
            <endDate>2024-04-08</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2024-04-08</startDate>
            <endDate>2024-04-08</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rnac:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartesianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:A2022OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:A2022OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-06</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-13</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-25</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-28</startDate>
            <endDate>2020-07-28</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-18</startDate>
            <endDate>2019-12-18</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-18</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rnac:CommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-18</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rnac:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-18</startDate>
            <endDate>2019-12-18</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rnac:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-18</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-20</startDate>
            <endDate>2022-12-20</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rnac:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartestianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartestianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoBioworksHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartestianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rnac:OldCartestianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:OldCartesianPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2024-03-27</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:AstellasGeneTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:AstellasGeneTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:AstellasGeneTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:AstellasGeneTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:AstellasGeneTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SwedishOrphanBiovitrumABSOBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-10</startDate>
            <endDate>2022-06-10</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rnac:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">rnac:NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">rnac:NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">rnac:NationalInstituteOfNeurologicalDisordersAndStrokeOfTheNationalInstitutesOfHealthFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.TimothyA.SpringerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:TASPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.ChafenLuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SecuritiesPurchaseAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.TimothyA.SpringerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:Dr.TimothyA.SpringerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:TASPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rnac:SevenOneEightThreeFourIrrevocableTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:PrivatePlacement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rnac:A2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:BiogenM.A.Inc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:NationalCancerInstituteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-16</startDate>
            <endDate>2019-09-16</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-25</startDate>
            <endDate>2021-10-25</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-13</startDate>
            <endDate>2022-06-13</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-19</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GinkgoAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:GenovisABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:CyrusBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-07</startDate>
            <endDate>2021-09-07</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rnac:SeriesBPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:CyrusBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-07</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:CyrusBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-07</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:CyrusBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:AskBioLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:AskBioLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rnac:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rnac:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:LegacySelectaProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:LegacySelectaProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:Descartes08ForMGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:Descartes08ForMGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:EarlyStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">rnac:EarlyStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rnac:ReportingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>rnac:segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="extension_option">
        <measure>rnac:extension_option</measure>
    </unit>
    <unit id="operating_lease">
        <measure>rnac:operating_lease</measure>
    </unit>
    <unit id="business_day">
        <measure>rnac:business_day</measure>
    </unit>
    <unit id="day">
        <measure>rnac:day</measure>
    </unit>
    <unit id="vote">
        <measure>rnac:vote</measure>
    </unit>
    <unit id="obligation">
        <measure>rnac:obligation</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0001453687</dei:EntityCentralIndexKey>
    <ecd:TrdArrDuration contextRef="c-5" id="f-61">P373D</ecd:TrdArrDuration>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-52"
      decimals="INF"
      id="f-337"
      unitRef="number">0.0333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-63"
      decimals="INF"
      id="f-438"
      unitRef="number">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-64"
      decimals="INF"
      id="f-439"
      unitRef="number">0.0333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-52"
      decimals="INF"
      id="f-440"
      unitRef="number">0.0333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-68" id="f-467">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-68" id="f-469">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-651">http://fasb.org/us-gaap/2024#GainLossOnDerivativeInstrumentsNetPretax</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-743">http://fasb.org/us-gaap/2024#AssetImpairmentCharges</us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-258" id="f-1259">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-261" id="f-1260">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-259" id="f-1261">http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-262" id="f-1262">http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-37798</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Cartesian Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">26-1622110</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">7495 New Horizon Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Frederick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">21703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">348-8698</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">RNAC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-29" unitRef="usd">193901954</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">25907101</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive Proxy Statement relating to its 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-36">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One of the key responsibilities of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Board of Directors administers its cybersecurity risk oversight function directly and through the Audit Committee, which conducts regular risk assessments related to all matters affecting the enterprise, including cybersecurity, and receives periodic reports on the Company&#x2019;s cybersecurity risks and activities. Our Chief Financial Officer and our Senior Director, Head of IT are the Company employees responsible for developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We partner with external cybersecurity vendors to enact a layered defense approach with controls deployed that seek to meet the requirements of the NIST Cybersecurity Framework. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Financial Officer has served as a biotechnology executive for 20 years, whose responsibilities have included direct oversight of his companies&#x2019; cybersecurity risks. Our Senior Director, Head of IT has served as an Information Technology professional for over ten years and has held senior IT positions across several companies including a large pharmaceutical company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. Our Senior Director, Head of IT oversees the cybersecurity program through risk management, employee security training, and oversight and escalation of threat monitoring and incident response. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. In the event of a major security incident, we have established an escalation path for stakeholder notification and remediation efforts, and major incidents are immediately escalated to the Head of IT, Chief Financial Officer, and Chief Operations Officer. In 2024, we proactively conducted a thorough and robust cybersecurity assessment, performed by an external cybersecurity partner, to evaluate our risks and identify key areas to improve our cybersecurity posture. We have implemented processes when evaluating third-party service providers, for example by reviewing available audit reports including the System and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Organization Controls (SOC 2) reports and requesting disclosure of any previous cybersecurity events. We also perform quality audits of certain regulated vendors, which includes an assessment of the vendor&#x2019;s information technology system and associated controls.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we conduct periodic risk assessments to identify and monitor against potential cybersecurity threats and incidents, as well as assess for any changes in our business practices that may affect our cybersecurity position. This risk oversight includes identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks and address any identified gaps in existing safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity program is delegated to our Senior Director, Head of IT, who reports on IT operations, risk mitigation and assessment efforts, and other general cybersecurity matters to our Chief Financial Officer, to manage the risk assessment and mitigation process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to work with third-party cybersecurity vendors to assist us in best practices for implementing strengthened cybersecurity procedures. All Company employees and third-party vendors are instructed to promptly report any suspected breach of its security measures that may affect our Company to the Senior Director, Head of IT.  Our Chief Financial Officer and Senior Director, Head of IT provide periodic briefings to the Audit Committee regarding our Company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third-parties, and related matters. The Audit Committee provides regular updates to the full Board of Directors on such reports.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not encountered cybersecurity challenges that have materially impaired our operations or financial standing. For additional information regarding risks from cybersecurity threats, please refer to Item 1A, &#x201c;Risk Factors,&#x201d; in this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-37">One of the key responsibilities of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Board of Directors administers its cybersecurity risk oversight function directly and through the Audit Committee, which conducts regular risk assessments related to all matters affecting the enterprise, including cybersecurity, and receives periodic reports on the Company&#x2019;s cybersecurity risks and activities.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-38">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-39">Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Board of Directors administers its cybersecurity risk oversight function directly and through the Audit Committee, which conducts regular risk assessments related to all matters affecting the enterprise, including cybersecurity, and receives periodic reports on the Company&#x2019;s cybersecurity risks and activities.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-41">Our Chief Financial Officer and our Senior Director, Head of IT are the Company employees responsible for developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We partner with external cybersecurity vendors to enact a layered defense approach with controls deployed that seek to meet the requirements of the NIST Cybersecurity Framework. &lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Financial Officer has served as a biotechnology executive for 20 years, whose responsibilities have included direct oversight of his companies&#x2019; cybersecurity risks. Our Senior Director, Head of IT has served as an Information Technology professional for over ten years and has held senior IT positions across several companies including a large pharmaceutical company.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-40">Our Chief Financial Officer and our Senior Director, Head of IT are the Company employees responsible for developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We partner with external cybersecurity vendors to enact a layered defense approach with controls deployed that seek to meet the requirements of the NIST Cybersecurity Framework. &lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Financial Officer has served as a biotechnology executive for 20 years, whose responsibilities have included direct oversight of his companies&#x2019; cybersecurity risks. Our Senior Director, Head of IT has served as an Information Technology professional for over ten years and has held senior IT positions across several companies including a large pharmaceutical company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. Our Senior Director, Head of IT oversees the cybersecurity program through risk management, employee security training, and oversight and escalation of threat monitoring and incident response. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. In the event of a major security incident, we have established an escalation path for stakeholder notification and remediation efforts, and major incidents are immediately escalated to the Head of IT, Chief Financial Officer, and Chief Operations Officer. In 2024, we proactively conducted a thorough and robust cybersecurity assessment, performed by an external cybersecurity partner, to evaluate our risks and identify key areas to improve our cybersecurity posture. We have implemented processes when evaluating third-party service providers, for example by reviewing available audit reports including the System and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Organization Controls (SOC 2) reports and requesting disclosure of any previous cybersecurity events. We also perform quality audits of certain regulated vendors, which includes an assessment of the vendor&#x2019;s information technology system and associated controls.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-42">Our Chief Financial Officer and our Senior Director, Head of IT are the Company employees responsible for developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We partner with external cybersecurity vendors to enact a layered defense approach with controls deployed that seek to meet the requirements of the NIST Cybersecurity Framework.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-43">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-44">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Financial Officer has served as a biotechnology executive for 20 years, whose responsibilities have included direct oversight of his companies&#x2019; cybersecurity risks. Our Senior Director, Head of IT has served as an Information Technology professional for over ten years and has held senior IT positions across several companies including a large pharmaceutical company.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-45">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. Our Senior Director, Head of IT oversees the cybersecurity program through risk management, employee security training, and oversight and escalation of threat monitoring and incident response. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. In the event of a major security incident, we have established an escalation path for stakeholder notification and remediation efforts, and major incidents are immediately escalated to the Head of IT, Chief Financial Officer, and Chief Operations Officer. In 2024, we proactively conducted a thorough and robust cybersecurity assessment, performed by an external cybersecurity partner, to evaluate our risks and identify key areas to improve our cybersecurity posture. We have implemented processes when evaluating third-party service providers, for example by reviewing available audit reports including the System and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Organization Controls (SOC 2) reports and requesting disclosure of any previous cybersecurity events. We also perform quality audits of certain regulated vendors, which includes an assessment of the vendor&#x2019;s information technology system and associated controls.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we conduct periodic risk assessments to identify and monitor against potential cybersecurity threats and incidents, as well as assess for any changes in our business practices that may affect our cybersecurity position. This risk oversight includes identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks and address any identified gaps in existing safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity program is delegated to our Senior Director, Head of IT, who reports on IT operations, risk mitigation and assessment efforts, and other general cybersecurity matters to our Chief Financial Officer, to manage the risk assessment and mitigation process. &lt;/span&gt;&lt;/div&gt;As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-46">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-47">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-48">Our Chief Financial Officer and Senior Director, Head of IT provide periodic briefings to the Audit Committee regarding our Company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third-parties, and related matters. The Audit Committee provides regular updates to the full Board of Directors on such reports.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-49">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-50">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-4" id="f-51">On December 23, 2024, Christopher Jewell, our Chief Scientific Officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Dr. Jewell&#x2019;s plan provides for the exercise of vested stock options and the potential associated sale of up to 15,000 shares of our common stock until and including December 31, 2025. The foregoing exercises or sales, if any, will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 31, 2025.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-5" id="f-52">December 23, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-5" id="f-53">Christopher Jewell</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-5" id="f-54">Chief Scientific Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-55">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-6" decimals="INF" id="f-56" unitRef="shares">15000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-5" id="f-57">December 31, 2025</ecd:TrdArrExpirationDate>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-7" id="f-58">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-7" id="f-59">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-7" id="f-60">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-62">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-63">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-64">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-65">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-66" unitRef="usd">212610000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-9" decimals="-3" id="f-67" unitRef="usd">76911000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-8" decimals="-3" id="f-68" unitRef="usd">872000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-9" decimals="-3" id="f-69" unitRef="usd">5870000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-8" decimals="-3" id="f-70" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-9" decimals="-3" id="f-71" unitRef="usd">2981000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-8" decimals="-3" id="f-72" unitRef="usd">3144000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-9" decimals="-3" id="f-73" unitRef="usd">4967000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-8" decimals="-3" id="f-74" unitRef="usd">216626000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-9" decimals="-3" id="f-75" unitRef="usd">90729000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-76" unitRef="usd">9912000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-9" decimals="-3" id="f-77" unitRef="usd">2113000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-8" decimals="-3" id="f-78" unitRef="usd">5535000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-9" decimals="-3" id="f-79" unitRef="usd">10068000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-8" decimals="-3" id="f-80" unitRef="usd">150600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-9" decimals="-3" id="f-81" unitRef="usd">150600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-8" decimals="-3" id="f-82" unitRef="usd">48163000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-9" decimals="-3" id="f-83" unitRef="usd">48163000</us-gaap:Goodwill>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-8" decimals="-3" id="f-84" unitRef="usd">1669000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-9" decimals="-3" id="f-85" unitRef="usd">1377000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-8" decimals="-3" id="f-86" unitRef="usd">2000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-9" decimals="-3" id="f-87" unitRef="usd">2000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-8" decimals="-3" id="f-88" unitRef="usd">518000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-9" decimals="-3" id="f-89" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-8" decimals="-3" id="f-90" unitRef="usd">435023000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-9" decimals="-3" id="f-91" unitRef="usd">305050000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-3" id="f-92" unitRef="usd">288000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-9" decimals="-3" id="f-93" unitRef="usd">3150000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-8" decimals="-3" id="f-94" unitRef="usd">12076000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-9" decimals="-3" id="f-95" unitRef="usd">15572000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-8" decimals="-3" id="f-96" unitRef="usd">2851000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-9" decimals="-3" id="f-97" unitRef="usd">2166000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-8" decimals="-3" id="f-98" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-9" decimals="-3" id="f-99" unitRef="usd">2311000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <rnac:WarrantsAndRightsOutstandingCurrent contextRef="c-8" decimals="-3" id="f-100" unitRef="usd">0</rnac:WarrantsAndRightsOutstandingCurrent>
    <rnac:WarrantsAndRightsOutstandingCurrent contextRef="c-9" decimals="-3" id="f-101" unitRef="usd">720000</rnac:WarrantsAndRightsOutstandingCurrent>
    <rnac:ContingentValueRightLiabilityCurrent contextRef="c-8" decimals="-3" id="f-102" unitRef="usd">7761000</rnac:ContingentValueRightLiabilityCurrent>
    <rnac:ContingentValueRightLiabilityCurrent contextRef="c-9" decimals="-3" id="f-103" unitRef="usd">15983000</rnac:ContingentValueRightLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-104" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-105" unitRef="usd">28307000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-106" unitRef="usd">22976000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-107" unitRef="usd">68209000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-108" unitRef="usd">11133000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-9" decimals="-3" id="f-109" unitRef="usd">8789000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-110" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-9" decimals="-3" id="f-111" unitRef="usd">3538000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <rnac:WarrantsAndRightsOutstandingNoncurrent contextRef="c-8" decimals="-3" id="f-112" unitRef="usd">3836000</rnac:WarrantsAndRightsOutstandingNoncurrent>
    <rnac:WarrantsAndRightsOutstandingNoncurrent contextRef="c-9" decimals="-3" id="f-113" unitRef="usd">5674000</rnac:WarrantsAndRightsOutstandingNoncurrent>
    <rnac:ContingentValueRightLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-114" unitRef="usd">387739000</rnac:ContingentValueRightLiabilityNoncurrent>
    <rnac:ContingentValueRightLiabilityNoncurrent contextRef="c-9" decimals="-3" id="f-115" unitRef="usd">342617000</rnac:ContingentValueRightLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-8" decimals="-3" id="f-116" unitRef="usd">16141000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-9" decimals="-3" id="f-117" unitRef="usd">15853000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="c-8" decimals="-3" id="f-118" unitRef="usd">441825000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-9" decimals="-3" id="f-119" unitRef="usd">444680000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-8" id="f-120" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-9" id="f-121" unitRef="usd" xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-122"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-123"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-8" decimals="INF" id="f-124" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-9" decimals="INF" id="f-125" unitRef="shares">548375</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-8" decimals="INF" id="f-126" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-8" decimals="INF" id="f-127" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-9" decimals="INF" id="f-128" unitRef="shares">435120.513</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-9" decimals="INF" id="f-129" unitRef="shares">435120.513</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-8" decimals="-3" id="f-130" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-9" decimals="-3" id="f-131" unitRef="usd">296851000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent contextRef="c-8" decimals="-3" id="f-132" unitRef="usd">0</rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent>
    <rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent contextRef="c-9" decimals="-3" id="f-133" unitRef="usd">3703000</rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-134"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-135"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-11"
      decimals="INF"
      id="f-136"
      unitRef="shares">134904.563</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-10"
      decimals="INF"
      id="f-137"
      unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-11"
      decimals="INF"
      id="f-138"
      unitRef="shares">120790.402</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-139"
      unitRef="shares">120790.402</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-10"
      decimals="INF"
      id="f-140"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-141"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-11" decimals="-3" id="f-142" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-10" decimals="-3" id="f-143" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-144"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-145"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-12"
      decimals="INF"
      id="f-146"
      unitRef="shares">437927</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-13"
      decimals="INF"
      id="f-147"
      unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-148"
      unitRef="shares">437927</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-12"
      decimals="INF"
      id="f-149"
      unitRef="shares">437927</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-13"
      decimals="INF"
      id="f-150"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-151"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-12" decimals="-3" id="f-152" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-13" decimals="-3" id="f-153" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-154"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-155"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-156" unitRef="shares">9427168.437</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-9" decimals="INF" id="f-157" unitRef="shares">9451625</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-158" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-8" decimals="INF" id="f-159" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-160" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-9" decimals="INF" id="f-161" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-8" decimals="-3" id="f-162" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-9" decimals="-3" id="f-163" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-164"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-165"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-9" decimals="INF" id="f-166" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-167" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="INF" id="f-168" unitRef="shares">25767369</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-169" unitRef="shares">25767369</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-9" decimals="INF" id="f-170" unitRef="shares">5397597</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-171" unitRef="shares">5397597</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-8" decimals="-3" id="f-172" unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-9" decimals="-3" id="f-173" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-8" decimals="-3" id="f-174" unitRef="usd">689887000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-9" decimals="-3" id="f-175" unitRef="usd">179062000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-3" id="f-176" unitRef="usd">-692071000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-9" decimals="-3" id="f-177" unitRef="usd">-614647000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-8" decimals="-3" id="f-178" unitRef="usd">-4621000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-9" decimals="-3" id="f-179" unitRef="usd">-4600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-180" unitRef="usd">-6802000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-181" unitRef="usd">-440184000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-8" decimals="-3" id="f-182" unitRef="usd">435023000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-9" decimals="-3" id="f-183" unitRef="usd">305050000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">38275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-185" unitRef="usd">26004000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">638000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-14" decimals="-3" id="f-187" unitRef="usd">0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">38913000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-3" id="f-189" unitRef="usd">26004000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">45105000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-191" unitRef="usd">71260000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">30126000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-193" unitRef="usd">40450000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">7579000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-14" decimals="-3" id="f-195" unitRef="usd">710000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">82810000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-14" decimals="-3" id="f-197" unitRef="usd">112420000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">-43897000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-199" unitRef="usd">-86416000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">7386000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-14" decimals="-3" id="f-201" unitRef="usd">4964000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-14" decimals="-3" id="f-203" unitRef="usd">38000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-14" decimals="-3" id="f-205" unitRef="usd">2833000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">-2558000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-14" decimals="-3" id="f-207" unitRef="usd">-12746000</us-gaap:FairValueAdjustmentOfWarrants>
    <rnac:FairValueAdjustmentOfContingentValueRightLiability contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">36900000</rnac:FairValueAdjustmentOfContingentValueRightLiability>
    <rnac:FairValueAdjustmentOfContingentValueRightLiability contextRef="c-14" decimals="-3" id="f-209" unitRef="usd">18300000</rnac:FairValueAdjustmentOfContingentValueRightLiability>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">-6890000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-14" decimals="-3" id="f-211" unitRef="usd">-149600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">606000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-213" unitRef="usd">691000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">-77137000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-215" unitRef="usd">-238710000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">287000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-217" unitRef="usd">-19000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">-77424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-219" unitRef="usd">-219710000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">-21000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-221" unitRef="usd">-53000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-14" decimals="-3" id="f-223" unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">-77445000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-14" decimals="-3" id="f-225" unitRef="usd">-219752000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-226"
      unitRef="usdPerShare">-4.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-227"
      unitRef="usdPerShare">-49.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-228"
      unitRef="usdPerShare">-4.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-229"
      unitRef="usdPerShare">-49.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-230" unitRef="shares">17276822</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="0" id="f-231" unitRef="shares">5170319</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-232" unitRef="shares">17357943</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="0" id="f-233" unitRef="shares">5170319</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-234"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-15" decimals="-3" id="f-235" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent contextRef="c-15" decimals="-3" id="f-236" unitRef="usd">0</rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-16"
      decimals="INF"
      id="f-237"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-238" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-239"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-240" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-241"
      unitRef="shares">5101459</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-242" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-243" unitRef="usd">493322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-244" unitRef="usd">-394937000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-245" unitRef="usd">-4558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-246" unitRef="usd">93828000</us-gaap:StockholdersEquity>
    <rnac:TemporaryEquityStockIssuedDuringPeriodShares
      contextRef="c-22"
      decimals="INF"
      id="f-247"
      unitRef="shares">619.627</rnac:TemporaryEquityStockIssuedDuringPeriodShares>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-248" unitRef="usd">250000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <rnac:TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares
      contextRef="c-14"
      decimals="INF"
      id="f-249"
      unitRef="shares">384930.724</rnac:TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares>
    <rnac:TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue contextRef="c-14" decimals="-3" id="f-250" unitRef="usd">261753000</rnac:TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue>
    <rnac:TemporaryEquityStockIssuedDuringPeriodShares
      contextRef="c-23"
      decimals="INF"
      id="f-251"
      unitRef="shares">49570.162</rnac:TemporaryEquityStockIssuedDuringPeriodShares>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-23" decimals="-3" id="f-252" unitRef="usd">34848000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-24"
      decimals="INF"
      id="f-253"
      unitRef="shares">6171</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-25" decimals="-3" id="f-254" unitRef="usd">231000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-14" decimals="-3" id="f-255" unitRef="usd">231000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-24"
      decimals="INF"
      id="f-256"
      unitRef="shares">21226</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger contextRef="c-25" decimals="-3" id="f-257" unitRef="usd">2713000</rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger>
    <rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger contextRef="c-14" decimals="-3" id="f-258" unitRef="usd">2713000</rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-24"
      decimals="INF"
      id="f-259"
      unitRef="shares">224099</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <rnac:TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger contextRef="c-14" decimals="-3" id="f-260" unitRef="usd">3643000</rnac:TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger>
    <rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger contextRef="c-25" decimals="-3" id="f-261" unitRef="usd">6801000</rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger>
    <rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger contextRef="c-14" decimals="-3" id="f-262" unitRef="usd">6801000</rnac:AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger>
    <rnac:StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement
      contextRef="c-24"
      decimals="INF"
      id="f-263"
      unitRef="shares">44642</rnac:StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement>
    <rnac:StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement contextRef="c-25" decimals="-3" id="f-264" unitRef="usd">1500000</rnac:StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement>
    <rnac:StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement contextRef="c-14" decimals="-3" id="f-265" unitRef="usd">1500000</rnac:StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement>
    <rnac:AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards contextRef="c-25" decimals="-3" id="f-266" unitRef="usd">6169000</rnac:AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards>
    <rnac:AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards contextRef="c-14" decimals="-3" id="f-267" unitRef="usd">6169000</rnac:AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards>
    <rnac:AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights contextRef="c-25" decimals="-3" id="f-268" unitRef="usd">340300000</rnac:AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights>
    <rnac:AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights contextRef="c-14" decimals="-3" id="f-269" unitRef="usd">340300000</rnac:AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights>
    <rnac:TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition contextRef="c-14" decimals="-3" id="f-270" unitRef="usd">60000</rnac:TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-3" id="f-271" unitRef="usd">20964000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-272" unitRef="usd">20964000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-26" decimals="-3" id="f-273" unitRef="usd">-53000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-274" unitRef="usd">-53000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-26" decimals="-3" id="f-275" unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-14" decimals="-3" id="f-276" unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-277" unitRef="usd">-219710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-278" unitRef="usd">-219710000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-9" decimals="INF" id="f-279" unitRef="shares">435120.513</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-9" decimals="-3" id="f-280" unitRef="usd">296851000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent contextRef="c-9" decimals="-3" id="f-281" unitRef="usd">3703000</rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-28"
      decimals="INF"
      id="f-282"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-283" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-29"
      decimals="INF"
      id="f-284"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-285" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-286"
      unitRef="shares">5397597</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-287" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-288" unitRef="usd">179062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-289" unitRef="usd">-614647000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-290" unitRef="usd">-4600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-291" unitRef="usd">-440184000</us-gaap:StockholdersEquity>
    <rnac:TemporaryEquityStockIssuedDuringPeriodShares contextRef="c-1" decimals="INF" id="f-292" unitRef="shares">99140.326</rnac:TemporaryEquityStockIssuedDuringPeriodShares>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">75197000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <rnac:TemporaryEquityTransferOfPreferredStockToPermanentEquityShares contextRef="c-1" decimals="INF" id="f-294" unitRef="shares">534260.839</rnac:TemporaryEquityTransferOfPreferredStockToPermanentEquityShares>
    <rnac:TemporaryEquityTransferOfPreferredStockToPermanentEquity contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">372048000</rnac:TemporaryEquityTransferOfPreferredStockToPermanentEquity>
    <rnac:TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">3703000</rnac:TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity>
    <rnac:TransferOfTemporaryEquityToPermanentEquityShares
      contextRef="c-34"
      decimals="INF"
      id="f-297"
      unitRef="shares">534260.839</rnac:TransferOfTemporaryEquityToPermanentEquityShares>
    <rnac:TransferOfTemporaryEquityToPermanentEquity contextRef="c-35" decimals="-3" id="f-298" unitRef="usd">375751000</rnac:TransferOfTemporaryEquityToPermanentEquity>
    <rnac:TransferOfTemporaryEquityToPermanentEquity contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">375751000</rnac:TransferOfTemporaryEquityToPermanentEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-34"
      decimals="INF"
      id="f-300"
      unitRef="shares">-413470.437</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-36"
      decimals="INF"
      id="f-301"
      unitRef="shares">13782324</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-36" decimals="-3" id="f-302" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-37" decimals="-3" id="f-303" unitRef="usd">-2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-38" decimals="-3" id="f-304" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-39" decimals="-3" id="f-305" unitRef="usd">5585000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-39"
      decimals="INF"
      id="f-306"
      unitRef="shares">2937903</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-40"
      decimals="INF"
      id="f-307"
      unitRef="shares">3563247</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-41" decimals="-3" id="f-308" unitRef="usd">124438000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="-3" id="f-309" unitRef="usd">124438000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-39"
      decimals="INF"
      id="f-310"
      unitRef="shares">-2499976</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-40"
      decimals="INF"
      id="f-311"
      unitRef="shares">2499976</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-43"
      decimals="INF"
      id="f-312"
      unitRef="shares">458544</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-35"
      decimals="INF"
      id="f-313"
      unitRef="shares">1179000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">1179000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <rnac:StockIssuedDuringPeriodSharesCommonWarrantsExercised
      contextRef="c-43"
      decimals="INF"
      id="f-315"
      unitRef="shares">65681</rnac:StockIssuedDuringPeriodSharesCommonWarrantsExercised>
    <rnac:StockIssuedDuringPeriodValueCommonWarrantsExercised contextRef="c-35" decimals="-3" id="f-316" unitRef="usd">2877000</rnac:StockIssuedDuringPeriodValueCommonWarrantsExercised>
    <rnac:StockIssuedDuringPeriodValueCommonWarrantsExercised contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">2877000</rnac:StockIssuedDuringPeriodValueCommonWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-318" unitRef="usd">6582000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">6582000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-44" decimals="-3" id="f-320" unitRef="usd">-21000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">-21000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-45" decimals="-3" id="f-322" unitRef="usd">-77424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">-77424000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-8" decimals="INF" id="f-324" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-8" decimals="-3" id="f-325" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent contextRef="c-8" decimals="-3" id="f-326" unitRef="usd">0</rnac:TemporaryEquityOptionsCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-46"
      decimals="INF"
      id="f-327"
      unitRef="shares">120790.402</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-328" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-47"
      decimals="INF"
      id="f-329"
      unitRef="shares">437927</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-330" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-48"
      decimals="INF"
      id="f-331"
      unitRef="shares">25767369</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-332" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-333" unitRef="usd">689887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-334" unitRef="usd">-692071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-335" unitRef="usd">-4621000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-336" unitRef="usd">-6802000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">-77424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-339" unitRef="usd">-219710000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">1151000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-14" decimals="-3" id="f-341" unitRef="usd">843000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-14" decimals="-3" id="f-343" unitRef="usd">79000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">2437000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-14" decimals="-3" id="f-345" unitRef="usd">1754000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">7579000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-14" decimals="-3" id="f-347" unitRef="usd">710000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">-273000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-14" decimals="-3" id="f-349" unitRef="usd">-477000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">6582000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-14" decimals="-3" id="f-351" unitRef="usd">22524000</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-14" decimals="-3" id="f-353" unitRef="usd">455000</us-gaap:PaidInKindInterest>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">-2558000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-14" decimals="-3" id="f-355" unitRef="usd">-12746000</us-gaap:FairValueAdjustmentOfWarrants>
    <rnac:FairValueAdjustmentOfContingentValueRightLiability contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">36900000</rnac:FairValueAdjustmentOfContingentValueRightLiability>
    <rnac:FairValueAdjustmentOfContingentValueRightLiability contextRef="c-14" decimals="-3" id="f-357" unitRef="usd">18300000</rnac:FairValueAdjustmentOfContingentValueRightLiability>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">-6890000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-14" decimals="-3" id="f-359" unitRef="usd">-149600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-14" decimals="-3" id="f-361" unitRef="usd">-740000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">287000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-363" unitRef="usd">-19000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">-4998000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-14" decimals="-3" id="f-365" unitRef="usd">-726000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <rnac:IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">-2981000</rnac:IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent>
    <rnac:IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent contextRef="c-14" decimals="-3" id="f-367" unitRef="usd">-181000</rnac:IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">-1747000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-14" decimals="-3" id="f-369" unitRef="usd">1265000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">-2927000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-14" decimals="-3" id="f-371" unitRef="usd">2834000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">-5849000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-14" decimals="-3" id="f-373" unitRef="usd">5256000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">-6741000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-14" decimals="-3" id="f-375" unitRef="usd">-2761000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-376" unitRef="usd">-23674000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-14" decimals="-3" id="f-377" unitRef="usd">-51161000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredFromAcquisition contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition contextRef="c-14" decimals="-3" id="f-379" unitRef="usd">6561000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-14" decimals="-3" id="f-381" unitRef="usd">28254000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-382" unitRef="usd">9093000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-383" unitRef="usd">206000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">351000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-385" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">-8742000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-14" decimals="-3" id="f-387" unitRef="usd">34609000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c-1" decimals="-3" id="f-388" unitRef="usd">40000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c-14" decimals="-3" id="f-389" unitRef="usd">20250000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-14" decimals="-3" id="f-391" unitRef="usd">27457000</us-gaap:RepaymentsOfLongTermDebt>
    <rnac:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">124438000</rnac:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <rnac:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-14" decimals="-3" id="f-393" unitRef="usd">0</rnac:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-394" unitRef="usd">66000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-14" decimals="-3" id="f-395" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-396" unitRef="usd">2877000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-14" decimals="-3" id="f-397" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <rnac:PaymentForSettlementOfEquityAwardsInBusinessCombination contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">0</rnac:PaymentForSettlementOfEquityAwardsInBusinessCombination>
    <rnac:PaymentForSettlementOfEquityAwardsInBusinessCombination contextRef="c-14" decimals="-3" id="f-399" unitRef="usd">6169000</rnac:PaymentForSettlementOfEquityAwardsInBusinessCombination>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-400" unitRef="usd">1179000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-14" decimals="-3" id="f-401" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-402" unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-14" decimals="-3" id="f-403" unitRef="usd">231000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-404" unitRef="usd">168428000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-14" decimals="-3" id="f-405" unitRef="usd">-13145000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-406" unitRef="usd">-21000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-14" decimals="-3" id="f-407" unitRef="usd">-53000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-408" unitRef="usd">135991000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-14" decimals="-3" id="f-409" unitRef="usd">-29750000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-3" id="f-410" unitRef="usd">78288000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-15" decimals="-3" id="f-411" unitRef="usd">108038000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-412" unitRef="usd">214279000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-3" id="f-413" unitRef="usd">78288000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-14" decimals="-3" id="f-415" unitRef="usd">1853000</us-gaap:InterestPaidNet>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="-3" id="f-416" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-14" decimals="-3" id="f-417" unitRef="usd">1500000</us-gaap:StockIssued1>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-418" unitRef="usd">847000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-14" decimals="-3" id="f-419" unitRef="usd">128000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <rnac:EquityOfferingCostsInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-420" unitRef="usd">451000</rnac:EquityOfferingCostsInAccruedLiabilities>
    <rnac:EquityOfferingCostsInAccruedLiabilities contextRef="c-14" decimals="-3" id="f-421" unitRef="usd">0</rnac:EquityOfferingCostsInAccruedLiabilities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-422">Description of the Business&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cartesian Therapeutics, Inc., or the Company, (formerly known as Selecta Biosciences, Inc., or Selecta) &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; incorporated in Delaware on December 10, 2007, and is headquartered in Frederick, Maryland. The Company is a clinical-stage biotechnology company &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pioneering mRNA cell therapy for the treatment of autoimmune diseases leveraging its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company believes its mRNA cell therapies have the potential to deliver deep, durable clinical benefit to a broad group of patients with autoimmune diseases because they can be administered over a short period of time, in an outpatient setting, and without pre-treatment chemotherapy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 13, 2023, the Company acquired, in accordance with the terms of the Agreement and Plan of Merger, or the Merger Agreement, the assets of the Delaware corporation which, immediately prior to the Merger (as defined below), was known as Cartesian Therapeutics, Inc., or Old Cartesian, as disclosed in Note 4. The transaction was structured as a stock-for-stock transaction pursuant to which all of Old Cartesian&#x2019;s outstanding shares of capital stock were exchanged based on a fixed exchange ratio for consideration of 224,099 shares of the common stock, par value $0.0001 per share, of the Company, or the common stock, and 384,930.724 shares of the newly designated Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share, or the Series A Preferred Stock. The Series A Preferred Stock is intended to have economic rights similar to the common stock, but with only limited voting rights. Additionally, the Company assumed all outstanding stock options of Old Cartesian. The common stock and Series A Preferred Stock related to the Merger were issued on December 5, 2023. For additional information, see Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger, the Company entered into a definitive agreement, or the 2023 Securities Purchase Agreement, for a private investment in public equity transaction, or the 2023 Private Placement, with the Investors (as defined below). The 2023 Securities Purchase Agreement provides for the issuance to the Investors of an aggregate of 149,330.115 shares of Series A Preferred Stock for an aggregate purchase price of approximately $60.25&#160;million. For additional information, see Note&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger, a contractual contingent value right, or CVR, was distributed to the holders of record of the Company&#x2019;s common stock and 2022 Warrants (as defined below) as of the close of business on December 4, 2023, but was not distributed to holders of shares of common stock or Series A Preferred Stock issued to stockholders of Old Cartesian or the Investors in the transactions. Holders of the CVRs will be entitled to receive certain payments from proceeds received by the Company, if any, related to the disposition or monetization of the Company&#x2019;s legacy assets following the issuance of the CVRs. For additional information, see Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2024, the Company&#x2019;s stockholders approved the Conversion Proposal (as defined below). For additional information, see Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on March 27, 2024, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s restated certificate of incorporation, as amended, or the Charter, to effect a reverse stock split of the Company&#x2019;s issued and outstanding common stock, at a ratio in the range of 1-for-20 and 1-for-30, with such ratio to be determined at the discretion of the Company&#x2019;s board of directors, or the Board of Directors. The Board of Directors subsequently approved a final reverse stock split ratio of 1-for-30, and the Company effected the Reverse Stock Split on April 4, 2024. As a result of the Reverse Stock Split, all figures in this Annual Report on Form 10-K relating to shares of the Company&#x2019;s common stock (such as share amounts, per share amounts, and conversion rates and prices), have been adjusted to reflect the Reverse Stock Split for all periods presented, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Shares of common stock underlying outstanding stock options, restricted stock units and warrants were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with their terms. Additionally, the conversion ratio of the Company&#x2019;s Series A Preferred Stock was proportionally adjusted. Stockholders entitled to fractional shares as a result of the Reverse Stock Split received a cash payment in lieu of receiving fractional shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 2, 2024, the Company entered into a securities purchase agreement, or the 2024 Securities Purchase Agreement, for a private investment in public equity financing, or the 2024 Private Placement, which provided for the issuance of 3,563,247 shares of common stock and 2,937,903 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share, or the Series B Preferred Stock, each at a purchase price of $20.00 per share. The 2024 Private Placement resulted in gross proceeds of approximately $130.0 million before deducting placement agent fees and other offering expenses. On September 20, 2024, the Company&#x2019;s stockholders approved the Series B Conversion Proposal (as defined below). For additional information, see Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product candidates are in preclinical and clinical development. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liquidity and Management&#x2019;s Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, the Company had an accumulated deficit of $692.1 million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research and development of its product candidates and its administrative organization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, the Company&#x2019;s cash, cash equivalents, and restricted cash were $214.3 million, of which $1.7 million was restricted cash related to lease commitments. The Company believes the cash, cash equivalents and restricted cash as of December 31, 2024 will enable it to fund its current planned operations for at least the next 12 months from the date of issuance of these financial statements, though it may pursue additional cash resources through public or private equity or debt financings or by establishing collaborations with other companies. However, there is no guarantee that any of these strategic or financing opportunities will be executed on favorable terms, and some could be dilutive to existing stockholders. Further, the liability associated with the CVR Agreement (as defined below) will be settled solely through cash flow received under the Company&#x2019;s License and Development Agreement, or as so amended, the Sobi License, with Swedish Orphan Biovitrum AB (publ.), or Sobi, and any other Gross Proceeds (as defined in the CVR Agreement) net of certain agreed deductions. Under the CVR Agreement, 100% of all milestone payments, royalties and other amounts paid to the Company or controlled entities under the Sobi License, and any other Gross Proceeds will be distributed, net of specified deductions, to holders of the CVRs. There is no obligation to the Company to fund any amount related to the CVR liability. See Note 6.&lt;/span&gt;&lt;/div&gt; If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations or otherwise capitalize on its commercialization of its product candidates.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-53"
      decimals="INF"
      id="f-423"
      unitRef="shares">224099</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-54"
      decimals="INF"
      id="f-424"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-55"
      decimals="INF"
      id="f-425"
      unitRef="shares">384930.724</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-54"
      decimals="INF"
      id="f-426"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-56"
      decimals="INF"
      id="f-427"
      unitRef="shares">149330.115</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-56" decimals="-4" id="f-428" unitRef="usd">60250000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-57"
      decimals="INF"
      id="f-429"
      unitRef="shares">3563247</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-58"
      decimals="INF"
      id="f-430"
      unitRef="shares">2937903</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-59"
      decimals="INF"
      id="f-431"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-60"
      decimals="INF"
      id="f-432"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <rnac:SaleOfStockGrossConsiderationReceivedOnTransaction contextRef="c-61" decimals="-5" id="f-433" unitRef="usd">130000000.0</rnac:SaleOfStockGrossConsiderationReceivedOnTransaction>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-5" id="f-434" unitRef="usd">-692100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <rnac:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale contextRef="c-8" decimals="-5" id="f-435" unitRef="usd">214300000</rnac:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-8" decimals="-5" id="f-436" unitRef="usd">1700000</us-gaap:RestrictedCashAndCashEquivalents>
    <rnac:ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed
      contextRef="c-62"
      decimals="INF"
      id="f-437"
      unitRef="number">1</rnac:ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-441">Basis of Presentation&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Selecta (RUS), LLC, or Selecta (RUS), a Russian limited liability corporation, Selecta Biosciences Security Corporation, a Massachusetts securities corporation which the Company dissolved in December 2024, and Cartesian Bio, LLC, a Delaware limited liability company, which is a variable interest entity for which the Company is the primary beneficiary. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company&#x2019;s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: estimated fair value of the intangible assets acquired in connection with the Merger, estimated fair value of the CVRs, deferred income taxes, revenue recognition, estimated accrued research and development expenses, stock-based compensation expense, estimated fair value of the liability-classified warrants, and impairment of long-lived assets. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision maker, or the CODM, for the purposes of assessing performance and allocating resources. The Company views its operations and manages its business in one operating segment, which prior to the Merger related to the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases and subsequent to the Merger relates to the research and development of cell therapy product candidates. The Company&#x2019;s CODM function is fulfilled by its Chief Executive Officer. The CODM function assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations and comprehensive loss. The CODM function uses net loss to monitor budget versus actual results to assess performance of the segment. Segment assets are the same as total assets on the Company&#x2019;s consolidated balance sheets. All long-lived assets are located in the United States. Long-lived assets consist of property and equipment, net, and operating lease right-of-use assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-442">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Selecta (RUS), LLC, or Selecta (RUS), a Russian limited liability corporation, Selecta Biosciences Security Corporation, a Massachusetts securities corporation which the Company dissolved in December 2024, and Cartesian Bio, LLC, a Delaware limited liability company, which is a variable interest entity for which the Company is the primary beneficiary. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-443">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company&#x2019;s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: estimated fair value of the intangible assets acquired in connection with the Merger, estimated fair value of the CVRs, deferred income taxes, revenue recognition, estimated accrued research and development expenses, stock-based compensation expense, estimated fair value of the liability-classified warrants, and impairment of long-lived assets. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-444">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision maker, or the CODM, for the purposes of assessing performance and allocating resources. The Company views its operations and manages its business in one operating segment, which prior to the Merger related to the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases and subsequent to the Merger relates to the research and development of cell therapy product candidates. The Company&#x2019;s CODM function is fulfilled by its Chief Executive Officer. The CODM function assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations and comprehensive loss. The CODM function uses net loss to monitor budget versus actual results to assess performance of the segment. Segment assets are the same as total assets on the Company&#x2019;s consolidated balance sheets. All long-lived assets are located in the United States. Long-lived assets consist of property and equipment, net, and operating lease right-of-use assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-445"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-446">Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents, Marketable Securities and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Marketable securities consist of securities with remaining maturities greater than 90 days when purchased. The Company classifies these marketable securities as available-for-sale and records them at fair value in the accompanying consolidated balance sheets. Marketable securities with less than one year until maturity are classified as short term, while marketable securities with maturities greater than one year are classified as long term. Unrealized gains or losses are included in accumulated other comprehensive loss. Premiums or discounts from par value are amortized to interest income over the life of the underlying investment. Although available to be sold to meet operating needs or otherwise, securities are generally held through maturity. The cost of securities sold is determined based on the specific identification method for purposes of recording realized gains and losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also in the past invested in equity securities of a company whose securities are not publicly traded and where fair value is not readily available. This investment is recorded using cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. The Company monitors this investment to evaluate whether any increase or decline in its value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. This investment is included in investments in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term deposits, investments, accounts receivable, and unbilled receivables. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company&#x2019;s deposits are financially creditworthy and, accordingly, minimal risk exists with respect to those balances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s financial instruments consist mainly of cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and other current liabilities, investments, warrants to purchase common stock, forward contract liabilities, and contingent value rights. The carrying amounts of cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities approximate their estimated fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy is used to prioritize the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements), and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Level 2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of warrant liabilities and contingent value rights are determined using Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#x2019;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the consolidated balance sheet for investments approximate fair value and are assessed for impairment quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, generally seven years for furniture and fixtures, five years for laboratory equipment, software and office equipment and three years for computer equipment. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Major additions and betterments are capitalized. Maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to operations as incurred. Costs incurred for construction in progress are recorded as assets and are not amortized until the construction is substantially complete and the assets are ready for their intended use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are tested at the lowest level for which identifiable independent cash flows are available. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. The Company recognized an impairment charge on its right of use assets and related furniture and fixtures during the year ended December 31, 2024 and on a right-of-use asset during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs and fees paid to lenders are recorded as a direct deduction from the face amount of the related debt. Debt issuance costs are amortized over the term of the related debt using the effective interest method and recorded as interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in the equity of a business entity during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss consists of: (i)&#160;all components of net loss and (ii)&#160;all components of comprehensive loss other than net loss, referred to as other comprehensive loss. Other comprehensive loss is comprised of unrealized gains and losses on debt securities and foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration and License Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. Pursuant to ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers (ASC 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#x2019;s ordinary activities in exchange for consideration. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. If a promised good or service is not distinct, it is combined with other promised goods or services into a performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration and License Revenue: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently generates its revenue through collaboration and license agreements with strategic collaborators for the development and commercialization of product candidates. Collaboration and license agreements with customers are generally accounted for in accordance with ASC 606. The Company analyzes collaboration arrangements by first assessing whether they are within the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (ASC 808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), and evaluates whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. Collaboration agreements with customers that are not within the scope of ASC 808 are accounted for in accordance with ASC 606. To the extent the collaboration agreement is within the scope of ASC 808, the Company also assesses whether any aspects of the agreement are within the scope of other accounting literature (specifically ASC 606). If the Company concludes that some or all aspects of the agreement are distinct and represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606. The Company recognizes the shared costs incurred that are not within the scope of other accounting literature as a component of the related expense in the period incurred by analogy to ASC Topic 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development (ASC 730)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and records reimbursements from counterparties as an offset to the related research and development costs. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under the agreements in accordance with ASC 606, the Company performs the five steps above. As part of the accounting for the arrangement, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;The Company uses key assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the Company&#x2019;s arrangements typically include one or more of the following: (i) upfront fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; (iii) royalties on net sales of licensed products; (iv) reimbursements or cost-sharing of research and development expenses; and (v) profit/loss sharing arising from co-promotion arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promised goods and services identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. If not distinct, the license is combined with other promised goods and services in the contract. For licenses that are combined with other promised goods and services, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Optional licenses are evaluated to determine if they are issued at a discount, and therefore, represent material rights and accounted for as separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes developmental and regulatory milestone payments, the Company evaluates whether the achievement of each milestone specifically relates to the Company&#x2019;s efforts to satisfy a performance obligation or transfer a distinct good or service within a performance obligation. If the achievement of a milestone is considered a direct result of the Company&#x2019;s efforts to satisfy a performance obligation or transfer a distinct good or service and the receipt of the payment is based upon the achievement of the milestone, the associated milestone value is allocated to that distinct good or service. If the milestone payment is not specifically related to the Company&#x2019;s effort to satisfy a performance obligation or transfer a distinct good or service, the amount is allocated to all performance obligations using the relative standalone selling price method. The Company also evaluates the milestone to determine whether they are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price to be allocated, otherwise, such amounts are constrained and excluded from the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the transaction price.&#160;Any such adjustments to the transaction price are allocated to the performance obligations on the same basis as at contract inception. Amounts allocated to a satisfied performance obligation shall be recognized as revenue, or as a reduction of revenue, in the period in which the transaction price changes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Manufacturing Supply Services: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#x2019;s discretion are evaluated to determine if they are distinct and optional. For optional services that are distinct, the Company assesses if they are priced at a discount, and therefore, provide a material right to the licensee to be accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied) in accordance with the royalty recognition constraint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grant Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracts with government-sponsored organizations for research and development related activities that provide for payments for reimbursable costs. The Company recognizes grant revenue from these contracts as it performs services under these arrangements when the funding is committed. Expenses associated with these contracts are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations and comprehensive loss as the Company has determined it is the primary obligor under the arrangements relative to the research and development services it performs as lead technical expert. Amounts incurred that are subject to reimbursement from the sponsor are recorded as accounts receivable on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred in the research and development of the Company&#x2019;s products are expensed as incurred. Research and development expenses include costs incurred in performing research and development activities, including salaries and benefits, stock-based compensation expenses, facilities cost, overhead costs, contract services, supplies and other outside costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical Trial Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third-parties. Third-party clinical trial expenses include patient costs, clinical research organization costs and costs for data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued clinical trial cost. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Non-refundable&#160;advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. The Company also records accruals for estimated ongoing clinical research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical clinical accrual estimates made by the Company have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#x2019;s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more-likely-than-not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more-likely-than-not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and then in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or may require settlement by issuing variable number of shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to&#160;its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the statements of operations as a gain or loss.&#160;Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all stock-based compensation granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of estimated forfeitures. To the extent that actual forfeitures differ from the Company&#x2019;s estimates, the differences are recorded as a cumulative adjustment in the period the estimates were adjusted. Stock-based compensation expense recognized in the consolidated financial statements is based on awards that ultimately vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company applies the two-class method to compute basic and diluted net income (loss) per share attributable to common stockholders when it has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company&#x2019;s Series A Preferred Stock, Series B Preferred Stock and 2022 Warrants participate in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) per share attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase common stock and Series A Preferred Stock, forward contracts to issue Series A Preferred Stock, restricted stock units, warrants to purchase common stock, employee stock purchase plan stock, contingently issuable shares, Series A Preferred Stock, and Series B Preferred Stock are considered potential dilutive common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its contingent liabilities in accordance with ASC Topic 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies (ASC 450)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its leases in accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (ASC 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company elected not to recognize leases with an original term less than one year on its balance sheet. Operating lease right-of-use assets and their corresponding lease liabilities are recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance in ASC 842, the fixed and in-substance fixed contract consideration must be allocated to lease and non-lease components based on their relative fair values. Non-components of a contract (e.g., administrative tasks that do not transfer a good or service to the Company, reimbursement or payment of a lessor&#x2019;s cost, etc.) do not receive an allocation of the consideration in the contract. Although allocation of consideration of lease and non-lease components is required, the Company elected the practical expedient to not separate lease components (e.g. land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The lease component results in an operating right-of-use asset being recorded on the balance sheet and amortized on a straight-line basis as lease expense. Right-of-use assets and operating lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and the estimated incremental borrowing rate upon lease modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into lease agreements with terms generally ranging from &lt;span style="-sec-ix-hidden:f-467"&gt;two&lt;/span&gt; to eight years. Some of the Company&#x2019;s lease agreements include Company options to either extend and/or early terminate the lease, the costs of which are included in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;its operating lease liabilities to the extent that such options are reasonably certain of being exercised. Leases with renewal options allow the Company to extend the lease term typically between &lt;span style="-sec-ix-hidden:f-469"&gt;one&lt;/span&gt; and five years. When determining the lease term, renewal options reasonably certain of being exercised are included in the lease term. When determining if a renewal option is reasonably certain of being exercised, the Company considers several economic factors, including but not limited to, the significance of leasehold improvements incurred on the property, whether the asset is difficult to replace, underlying contractual obligations, or specific characteristics unique to that particular lease that would make it reasonably certain that the Company would exercise such option. Renewal and termination options were generally not included in the lease term for the Company&#x2019;s existing operating leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations based on the fair value estimates as of the date of acquisition. In accordance with ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (ASC 805)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the amount of consideration paid in excess of the fair value of the identified net assets acquired as a result of the Company&#x2019;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates goodwill for impairment at least annually on October 1 and whenever facts and circumstances indicate that their carrying amounts may not be recoverable. For the years ended December 31, 2024 and 2023, the Company determined that there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets consist of in-process research and development, or IPR&amp;amp;D. The fair values of IPR&amp;amp;D assets acquired in business combinations are capitalized. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with indefinite lives, including IPR&amp;amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#x2019;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#x2019;s outlook and market performance of the Company&#x2019;s industry and recent and forecasted financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates indefinite-lived intangible assets for impairment at least annually on October 1 and whenever facts and circumstances indicate that their carrying amounts may not be recoverable. For the years ended December 31, 2024 and 2023, the Company determined that there was no impairment to the IPR&amp;amp;D assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company records its convertible preferred stock upon issuance at its fair value.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value includes the original issuance price, the settlement of any related forward contract, and is less issuance costs. The Company classifies its convertible preferred stock outside of stockholders&#x2019; deficit if the redemption of such shares is outside the Company&#x2019;s control. For shares classified outside of stockholders&#x2019; deficit, the Company does not adjust the carrying value of its convertible preferred stock to redemption value until it is probable of becoming redeemable. As of December 31, 2024, there were no conditions that could have required cash redemption of the convertible preferred stock and therefore, all convertible preferred stock were classified within stockholders&#x2019; deficit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Series A Preferred Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies a portion of the fair value of the vested stock options for Series A Preferred Stock equal to the estimated redemption value on the measurement date outside of stockholders&#x2019; deficit, if the redemption of the shares underlying the options are outside the Company&#x2019;s control. Any fair value in excess of the estimated redemption value is recognized as additional paid-in capital. The estimated redemption value is based on the intrinsic value of the option. The Company does not adjust the carrying value of the stock options for Series A Preferred Stock until the underlying Series A Preferred Stock is probable of becoming redeemable. The Company records the stock options for Series A Preferred Stock based on the intrinsic value of the vested options.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its variable interests in variable interest entities, or VIEs, and consolidates VIEs when the Company is the primary beneficiary. The Company determines whether it is the primary beneficiary of a VIE based on its assessment of whether the Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance and (ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary conclusion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Value Right Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CVRs distributed by the Company pursuant to the terms of the CVR Agreement (as defined below) represent financial instruments that are accounted for under the fair value option election in ASC Topic 825, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments (ASC 825).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the fair value option election, the CVRs are initially measured at the aggregate estimated fair value of the CVRs and will be subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the CVR liability was determined using a discounted cash flow methodology as of December 31, 2023 and a Monte Carlo simulation method as of December 31, 2024 to estimate future cash flows associated with the legacy assets, including the expected milestone and royalty payments under the Sobi License, net of deductions. Changes in fair value of the liability are presented in the consolidated statements of operations and comprehensive loss. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, expected volatilities of revenues (Monte Carlo simulation) and risk-adjustment discount rate (discounted cash flow methodology), which represent a Level 3 measurement within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Forward Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for contracts related to the future issuance of its convertible preferred stock as a liability if the underlying shares include a redemption feature that may require the Company to settle the instrument by transferring an asset. The forward contract liability is carried at fair value through the date the underlying shares are issued. The fair value of the Series A Preferred Stock forward contract liability was initially measured based on the fair value of the Series A Preferred Stock issued in the 2023 Private Placement (see Note 11), less the purchase price, if any. Subsequent measurement of the fair value of the Series A Preferred Stock forward contract liability was based on the market price of the Company&#x2019;s common stock, which represented the redemption and conversion value of the Series A Preferred Stock, less the purchase price, if any, on an as-converted basis. The remeasurement of the forward contract liability is based on Level 2 inputs within the fair value hierarchy as it&#x2019;s based on observable market data. Changes in fair value of the liability are presented within change in fair value of forward contract liabilities in the consolidated statements of operations and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for the annual period beginning the year ended December 31, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company adopted the new standard during the year ended December 31, 2024 and the amendments have be applied retrospectively to all prior periods presented in the consolidated financial statements. See Note 21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual period beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently in the process of evaluating the impact of the standard&#x2019;s adoption on its consolidated financial statements and related disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement Reporting- Comprehensive Income- Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2024-03), which requires public companies to disclose, in interim and annual reporting periods, additional information about certain expenses in notes to financial statements, including purchases of inventory, employee compensation, depreciation, amortization of intangible assets, and selling expenses. This guidance will be effective for the annual period beginning the year ended December 31, 2027 and for interim periods beginning January 1, 2028, with early adoption permitted. The Company is currently in the process of evaluating the impact of the standard&#x2019;s adoption on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <rnac:CashEquivalentsAndShortTermInvestmentsPolicyTextBlock contextRef="c-1" id="f-447">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents, Marketable Securities and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Marketable securities consist of securities with remaining maturities greater than 90 days when purchased. The Company classifies these marketable securities as available-for-sale and records them at fair value in the accompanying consolidated balance sheets. Marketable securities with less than one year until maturity are classified as short term, while marketable securities with maturities greater than one year are classified as long term. Unrealized gains or losses are included in accumulated other comprehensive loss. Premiums or discounts from par value are amortized to interest income over the life of the underlying investment. Although available to be sold to meet operating needs or otherwise, securities are generally held through maturity. The cost of securities sold is determined based on the specific identification method for purposes of recording realized gains and losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also in the past invested in equity securities of a company whose securities are not publicly traded and where fair value is not readily available. This investment is recorded using cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. The Company monitors this investment to evaluate whether any increase or decline in its value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. This investment is included in investments in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</rnac:CashEquivalentsAndShortTermInvestmentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-448">&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term deposits, investments, accounts receivable, and unbilled receivables. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company&#x2019;s deposits are financially creditworthy and, accordingly, minimal risk exists with respect to those balances.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-449">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s financial instruments consist mainly of cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and other current liabilities, investments, warrants to purchase common stock, forward contract liabilities, and contingent value rights. The carrying amounts of cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities approximate their estimated fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy is used to prioritize the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements), and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Level 2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of warrant liabilities and contingent value rights are determined using Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#x2019;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the consolidated balance sheet for investments approximate fair value and are assessed for impairment quarterly.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, generally seven years for furniture and fixtures, five years for laboratory equipment, software and office equipment and three years for computer equipment. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Major additions and betterments are capitalized. Maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to operations as incurred. Costs incurred for construction in progress are recorded as assets and are not amortized until the construction is substantially complete and the assets are ready for their intended use.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-65" id="f-451">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-66" id="f-452">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-67" id="f-453">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-454">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are tested at the lowest level for which identifiable independent cash flows are available. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. The Company recognized an impairment charge on its right of use assets and related furniture and fixtures during the year ended December 31, 2024 and on a right-of-use asset during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-455">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs and fees paid to lenders are recorded as a direct deduction from the face amount of the related debt. Debt issuance costs are amortized over the term of the related debt using the effective interest method and recorded as interest expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-456">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in the equity of a business entity during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss consists of: (i)&#160;all components of net loss and (ii)&#160;all components of comprehensive loss other than net loss, referred to as other comprehensive loss. Other comprehensive loss is comprised of unrealized gains and losses on debt securities and foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-457">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration and License Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. Pursuant to ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers (ASC 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#x2019;s ordinary activities in exchange for consideration. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. If a promised good or service is not distinct, it is combined with other promised goods or services into a performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration and License Revenue: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently generates its revenue through collaboration and license agreements with strategic collaborators for the development and commercialization of product candidates. Collaboration and license agreements with customers are generally accounted for in accordance with ASC 606. The Company analyzes collaboration arrangements by first assessing whether they are within the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (ASC 808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), and evaluates whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. Collaboration agreements with customers that are not within the scope of ASC 808 are accounted for in accordance with ASC 606. To the extent the collaboration agreement is within the scope of ASC 808, the Company also assesses whether any aspects of the agreement are within the scope of other accounting literature (specifically ASC 606). If the Company concludes that some or all aspects of the agreement are distinct and represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606. The Company recognizes the shared costs incurred that are not within the scope of other accounting literature as a component of the related expense in the period incurred by analogy to ASC Topic 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development (ASC 730)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and records reimbursements from counterparties as an offset to the related research and development costs. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under the agreements in accordance with ASC 606, the Company performs the five steps above. As part of the accounting for the arrangement, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;The Company uses key assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the Company&#x2019;s arrangements typically include one or more of the following: (i) upfront fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; (iii) royalties on net sales of licensed products; (iv) reimbursements or cost-sharing of research and development expenses; and (v) profit/loss sharing arising from co-promotion arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promised goods and services identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. If not distinct, the license is combined with other promised goods and services in the contract. For licenses that are combined with other promised goods and services, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Optional licenses are evaluated to determine if they are issued at a discount, and therefore, represent material rights and accounted for as separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes developmental and regulatory milestone payments, the Company evaluates whether the achievement of each milestone specifically relates to the Company&#x2019;s efforts to satisfy a performance obligation or transfer a distinct good or service within a performance obligation. If the achievement of a milestone is considered a direct result of the Company&#x2019;s efforts to satisfy a performance obligation or transfer a distinct good or service and the receipt of the payment is based upon the achievement of the milestone, the associated milestone value is allocated to that distinct good or service. If the milestone payment is not specifically related to the Company&#x2019;s effort to satisfy a performance obligation or transfer a distinct good or service, the amount is allocated to all performance obligations using the relative standalone selling price method. The Company also evaluates the milestone to determine whether they are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price to be allocated, otherwise, such amounts are constrained and excluded from the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the transaction price.&#160;Any such adjustments to the transaction price are allocated to the performance obligations on the same basis as at contract inception. Amounts allocated to a satisfied performance obligation shall be recognized as revenue, or as a reduction of revenue, in the period in which the transaction price changes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Manufacturing Supply Services: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#x2019;s discretion are evaluated to determine if they are distinct and optional. For optional services that are distinct, the Company assesses if they are priced at a discount, and therefore, provide a material right to the licensee to be accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied) in accordance with the royalty recognition constraint.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c-1" id="f-458">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grant Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracts with government-sponsored organizations for research and development related activities that provide for payments for reimbursable costs. The Company recognizes grant revenue from these contracts as it performs services under these arrangements when the funding is committed. Expenses associated with these contracts are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations and comprehensive loss as the Company has determined it is the primary obligor under the arrangements relative to the research and development services it performs as lead technical expert. Amounts incurred that are subject to reimbursement from the sponsor are recorded as accounts receivable on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-459">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred in the research and development of the Company&#x2019;s products are expensed as incurred. Research and development expenses include costs incurred in performing research and development activities, including salaries and benefits, stock-based compensation expenses, facilities cost, overhead costs, contract services, supplies and other outside costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <rnac:ClinicalTrialCostsPolicyTextBlock contextRef="c-1" id="f-460">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical Trial Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third-parties. Third-party clinical trial expenses include patient costs, clinical research organization costs and costs for data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued clinical trial cost. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Non-refundable&#160;advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. The Company also records accruals for estimated ongoing clinical research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical clinical accrual estimates made by the Company have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;</rnac:ClinicalTrialCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-461">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#x2019;s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more-likely-than-not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more-likely-than-not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <rnac:WarrantsPolicyTextBlock contextRef="c-1" id="f-462">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and then in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or may require settlement by issuing variable number of shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to&#160;its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the statements of operations as a gain or loss.&#160;Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.&lt;/span&gt;&lt;/div&gt;</rnac:WarrantsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-463">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all stock-based compensation granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of estimated forfeitures. To the extent that actual forfeitures differ from the Company&#x2019;s estimates, the differences are recorded as a cumulative adjustment in the period the estimates were adjusted. Stock-based compensation expense recognized in the consolidated financial statements is based on awards that ultimately vest.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-464">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company applies the two-class method to compute basic and diluted net income (loss) per share attributable to common stockholders when it has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company&#x2019;s Series A Preferred Stock, Series B Preferred Stock and 2022 Warrants participate in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) per share attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase common stock and Series A Preferred Stock, forward contracts to issue Series A Preferred Stock, restricted stock units, warrants to purchase common stock, employee stock purchase plan stock, contingently issuable shares, Series A Preferred Stock, and Series B Preferred Stock are considered potential dilutive common shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-465">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its contingent liabilities in accordance with ASC Topic 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies (ASC 450)&lt;/span&gt;. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-466">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its leases in accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (ASC 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company elected not to recognize leases with an original term less than one year on its balance sheet. Operating lease right-of-use assets and their corresponding lease liabilities are recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance in ASC 842, the fixed and in-substance fixed contract consideration must be allocated to lease and non-lease components based on their relative fair values. Non-components of a contract (e.g., administrative tasks that do not transfer a good or service to the Company, reimbursement or payment of a lessor&#x2019;s cost, etc.) do not receive an allocation of the consideration in the contract. Although allocation of consideration of lease and non-lease components is required, the Company elected the practical expedient to not separate lease components (e.g. land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The lease component results in an operating right-of-use asset being recorded on the balance sheet and amortized on a straight-line basis as lease expense. Right-of-use assets and operating lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and the estimated incremental borrowing rate upon lease modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into lease agreements with terms generally ranging from &lt;span style="-sec-ix-hidden:f-467"&gt;two&lt;/span&gt; to eight years. Some of the Company&#x2019;s lease agreements include Company options to either extend and/or early terminate the lease, the costs of which are included in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;its operating lease liabilities to the extent that such options are reasonably certain of being exercised. Leases with renewal options allow the Company to extend the lease term typically between &lt;span style="-sec-ix-hidden:f-469"&gt;one&lt;/span&gt; and five years. When determining the lease term, renewal options reasonably certain of being exercised are included in the lease term. When determining if a renewal option is reasonably certain of being exercised, the Company considers several economic factors, including but not limited to, the significance of leasehold improvements incurred on the property, whether the asset is difficult to replace, underlying contractual obligations, or specific characteristics unique to that particular lease that would make it reasonably certain that the Company would exercise such option. Renewal and termination options were generally not included in the lease term for the Company&#x2019;s existing operating leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-69" id="f-468">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-69" id="f-470">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-471">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations based on the fair value estimates as of the date of acquisition. In accordance with ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (ASC 805)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-472">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the amount of consideration paid in excess of the fair value of the identified net assets acquired as a result of the Company&#x2019;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.&lt;/span&gt;&lt;/div&gt;The Company evaluates goodwill for impairment at least annually on October 1 and whenever facts and circumstances indicate that their carrying amounts may not be recoverable.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-473" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-14" decimals="INF" id="f-474" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy contextRef="c-1" id="f-475">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets consist of in-process research and development, or IPR&amp;amp;D. The fair values of IPR&amp;amp;D assets acquired in business combinations are capitalized. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with indefinite lives, including IPR&amp;amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#x2019;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#x2019;s outlook and market performance of the Company&#x2019;s industry and recent and forecasted financial performance.&lt;/span&gt;&lt;/div&gt;The Company evaluates indefinite-lived intangible assets for impairment at least annually on October 1 and whenever facts and circumstances indicate that their carrying amounts may not be recoverable.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-1" decimals="INF" id="f-476" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <rnac:TemporaryEquityPolicyPolicyTextBlock contextRef="c-1" id="f-477">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company records its convertible preferred stock upon issuance at its fair value.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value includes the original issuance price, the settlement of any related forward contract, and is less issuance costs. The Company classifies its convertible preferred stock outside of stockholders&#x2019; deficit if the redemption of such shares is outside the Company&#x2019;s control. For shares classified outside of stockholders&#x2019; deficit, the Company does not adjust the carrying value of its convertible preferred stock to redemption value until it is probable of becoming redeemable. As of December 31, 2024, there were no conditions that could have required cash redemption of the convertible preferred stock and therefore, all convertible preferred stock were classified within stockholders&#x2019; deficit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Series A Preferred Stock Options &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies a portion of the fair value of the vested stock options for Series A Preferred Stock equal to the estimated redemption value on the measurement date outside of stockholders&#x2019; deficit, if the redemption of the shares underlying the options are outside the Company&#x2019;s control. Any fair value in excess of the estimated redemption value is recognized as additional paid-in capital. The estimated redemption value is based on the intrinsic value of the option. The Company does not adjust the carrying value of the stock options for Series A Preferred Stock until the underlying Series A Preferred Stock is probable of becoming redeemable. The Company records the stock options for Series A Preferred Stock based on the intrinsic value of the vested options.&lt;/span&gt;</rnac:TemporaryEquityPolicyPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="c-1" id="f-478">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;The Company evaluates its variable interests in variable interest entities, or VIEs, and consolidates VIEs when the Company is the primary beneficiary. The Company determines whether it is the primary beneficiary of a VIE based on its assessment of whether the Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance and (ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary conclusion.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <rnac:ContingentValueRightLiabilityPolicyPolicyTextBlock contextRef="c-1" id="f-479">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Value Right Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CVRs distributed by the Company pursuant to the terms of the CVR Agreement (as defined below) represent financial instruments that are accounted for under the fair value option election in ASC Topic 825, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments (ASC 825).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the fair value option election, the CVRs are initially measured at the aggregate estimated fair value of the CVRs and will be subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the CVR liability was determined using a discounted cash flow methodology as of December 31, 2023 and a Monte Carlo simulation method as of December 31, 2024 to estimate future cash flows associated with the legacy assets, including the expected milestone and royalty payments under the Sobi License, net of deductions. Changes in fair value of the liability are presented in the consolidated statements of operations and comprehensive loss. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, expected volatilities of revenues (Monte Carlo simulation) and risk-adjustment discount rate (discounted cash flow methodology), which represent a Level 3 measurement within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;</rnac:ContingentValueRightLiabilityPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-480">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Forward Contract Liabilities&lt;/span&gt;&lt;/div&gt;The Company accounts for contracts related to the future issuance of its convertible preferred stock as a liability if the underlying shares include a redemption feature that may require the Company to settle the instrument by transferring an asset. The forward contract liability is carried at fair value through the date the underlying shares are issued. The fair value of the Series A Preferred Stock forward contract liability was initially measured based on the fair value of the Series A Preferred Stock issued in the 2023 Private Placement (see Note 11), less the purchase price, if any. Subsequent measurement of the fair value of the Series A Preferred Stock forward contract liability was based on the market price of the Company&#x2019;s common stock, which represented the redemption and conversion value of the Series A Preferred Stock, less the purchase price, if any, on an as-converted basis. The remeasurement of the forward contract liability is based on Level 2 inputs within the fair value hierarchy as it&#x2019;s based on observable market data. Changes in fair value of the liability are presented within change in fair value of forward contract liabilities in the consolidated statements of operations and comprehensive loss.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-481">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for the annual period beginning the year ended December 31, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company adopted the new standard during the year ended December 31, 2024 and the amendments have be applied retrospectively to all prior periods presented in the consolidated financial statements. See Note 21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual period beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently in the process of evaluating the impact of the standard&#x2019;s adoption on its consolidated financial statements and related disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement Reporting- Comprehensive Income- Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2024-03), which requires public companies to disclose, in interim and annual reporting periods, additional information about certain expenses in notes to financial statements, including purchases of inventory, employee compensation, depreciation, amortization of intangible assets, and selling expenses. This guidance will be effective for the annual period beginning the year ended December 31, 2027 and for interim periods beginning January 1, 2028, with early adoption permitted. The Company is currently in the process of evaluating the impact of the standard&#x2019;s adoption on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-482">Merger&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 13, 2023, the Company merged with Old Cartesian in accordance with the terms of the Merger Agreement, by and among Selecta, Sakura Merger Sub I, Inc., a wholly owned subsidiary of Selecta, or First Merger Sub, Sakura Merger Sub II, LLC, a wholly owned subsidiary of Selecta, or Second Merger Sub, and Old Cartesian. Pursuant to the Merger Agreement, First Merger Sub merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corporation and became a wholly owned subsidiary of Selecta, or the First Merger. Immediately following the First Merger, Old Cartesian merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity, or the Second Merger and, together with the First Merger, the Merger. In connection with the Second Merger, Old Cartesian changed its name to Cartesian Bio, LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger was intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. As a result of the Merger, Selecta changed its corporate name to Cartesian Therapeutics, Inc. and its common stock began trading on the Nasdaq Global Market under the new trading symbol &#x201c;RNAC&#x201d; beginning on November 14, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger Agreement was unanimously approved by the board of directors, or the Board of Directors, of Selecta and the board of directors of Old Cartesian. The Merger was consummated substantially concurrently with the entry into the Merger Agreement and was not subject to approval of the Company&#x2019;s stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Merger Agreement, following the consummation of the Merger on November 13, 2023, or the Closing Date, in exchange for 100% of the outstanding shares of capital stock of Old Cartesian immediately prior to the effective time of the First Merger, the Company agreed to issue to the stockholders of Old Cartesian (i) 224,099 shares of the Company&#x2019;s common stock and (ii) 384,930.724 shares of Series A Preferred Stock. The issuance of the shares of common stock and Series A Preferred Stock occurred on December 5, 2023 which was after the December 4, 2023 record date for the distribution of the CVRs (see Note 6); as such, the Old Cartesian stockholders did not have rights as holders of common stock or holders of Series A Preferred Stock until such issuance on December 5, 2023. In addition, all outstanding stock options to purchase Old Cartesian common stock were assumed by the Company and converted into stock options to purchase (i) shares of the Company&#x2019;s common stock or (ii) shares of the Company&#x2019;s Series A Preferred Stock on terms substantially identical to those in effect prior to Merger Agreement, except for adjustments to the underlying number of shares and the exercise price based on the Merger Agreement exchange ratio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Merger Agreement, the Company agreed to hold a stockholders&#x2019; meeting, or the Special Meeting, to submit the following proposals to a vote of its stockholders: (i) the approval of the conversion of shares of Series A Preferred Stock into shares of common stock, or the Conversion Proposal, and (ii) either or both of (A) the approval of an amendment to the Charter to increase the number of shares of common stock authorized under the Charter and (B) the approval of an amendment to the Charter to effect a reverse stock split of all outstanding shares of common stock, in either case (A) or (B) by a number of authorized shares or at a stock split ratio, as the case may be, sufficient to allow the conversion of all shares of Series A Preferred Stock issued in the Merger. The Special Meeting was held on March 27, 2024, during which the Company&#x2019;s stockholders approved the Conversion Proposal, among other matters (see Note 11).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded the acquisition resulted in the Company obtaining a controlling financial interest in a VIE in accordance with ASC Topic 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation (ASC 810)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company determined that Old Cartesian was considered to be a VIE as it did not have sufficient equity to finance its activities without additional subordinated financial support. Prior to the Closing Date, the primary source of funding for Old Cartesian had been preferred stock financings. The Company acquired all of the outstanding shares of Old Cartesian and, therefore, is the sole equity holder and primary beneficiary. The Company has the obligation to absorb the losses and right to receive the benefits of Old Cartesian, and the power to direct the activities that most significantly affect the economic performance of Old Cartesian which the Company considers to be its development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;activities. Therefore, the Company is the primary beneficiary. Further, the Company concluded the VIE qualified as a business and accounted for the transaction as the acquisition of a business in accordance with ASC 805. As the primary beneficiary, the Company was the acquirer in the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company exchanged the right to receive shares of common stock and Series A Preferred Stock for all of the outstanding equity of Old Cartesian. The Company determined the rights to receive shares exchanged in the Merger represent a forward contract. The fair value of the forward contracts was determined based on the fair value of shares of common stock and Series A Preferred Stock underlying the forward contracts as of the acquisition date. The total purchase price consists of the fair value of the forward contracts in addition to a portion of the fair value of options exchanged in the transaction related to prior service. Under the acquisition method, the total purchase price of the acquisition was allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the date of the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The total fair value of the consideration of $168.5&#160;million as of the Closing Date is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.070%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract to issue common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract to issue Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options allocated to consideration paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the assets acquired and liabilities assumed as of the Closing Date based on the information available at that date. The following table presents the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed as of the Closing Date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.070%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of November 13, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the IPR&amp;amp;D assets were capitalized as of the Closing Date and are accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the carrying value of each respective IPR&amp;amp;D asset will be amortized over its estimated useful life. Until that time, the IPR&amp;amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the Merger is the excess of the fair value of the consideration transferred by the acquirer over the fair value of tangible assets, identifiable intangible assets and assumed liabilities as of the Closing Date and is not deductible for tax purposes. The goodwill balance is primarily attributable to the value of the assembled workforce and deferred tax liabilities associated with the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the Company&#x2019;s intangible assets acquired in the Merger (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Descartes-08 for MG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Descartes-08 for SLE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total in-process research and development assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the intangible assets was estimated using the income approach in which the after-tax cash flows were discounted to present value. The cash flows are based on estimates used to price the transaction, and the discount rates applied &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were benchmarked with reference to the implied rate of return from the transaction model as well as the weighted average cost of capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the period from November 13, 2023 to December 31, 2023, Old Cartesian&#x2019;s revenue and net loss within the consolidated statements of operations and comprehensive loss were $0.0&#160;million and $1.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information reflects the consolidated results of operations of the Company as if the Merger had taken place on January 1, 2022. The unaudited pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(232,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s transaction costs of $4.9&#160;million were expensed as incurred and included in general and administrative expense in the consolidated statements of operations and comprehensive loss during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The forward contract related to the common stock was recorded as additional paid-in capital as the instrument is indexed to the Company&#x2019;s common stock. The forward contract related to the Series A Preferred Stock was recorded as a liability as the underlying Series A Preferred Stock had a redemption feature that may have required the Company to settle the instrument by transferring an asset.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The forward contract was measured at fair value through the date of settlement through the issuance of the shares of Series A Preferred Stock on December 5, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c-70"
      decimals="INF"
      id="f-483"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-53"
      decimals="INF"
      id="f-484"
      unitRef="shares">224099</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-55"
      decimals="INF"
      id="f-485"
      unitRef="shares">384930.724</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-486">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The total fair value of the consideration of $168.5&#160;million as of the Closing Date is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.070%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract to issue common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract to issue Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options allocated to consideration paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-71" decimals="-5" id="f-487" unitRef="usd">168500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-53" decimals="-3" id="f-488" unitRef="usd">2713000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-72" decimals="-3" id="f-489" unitRef="usd">155308000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-73" decimals="-3" id="f-490" unitRef="usd">10444000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-71" decimals="-3" id="f-491" unitRef="usd">168465000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-492">The following table presents the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed as of the Closing Date (in thousands):&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.070%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of November 13, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-70" decimals="-3" id="f-493" unitRef="usd">6561000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-70" decimals="-3" id="f-494" unitRef="usd">309000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-70" decimals="-3" id="f-495" unitRef="usd">215000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset contextRef="c-70" decimals="-3" id="f-496" unitRef="usd">915000</rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-70" decimals="-3" id="f-497" unitRef="usd">150600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill contextRef="c-70" decimals="-3" id="f-498" unitRef="usd">48163000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-70" decimals="-3" id="f-499" unitRef="usd">206763000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities contextRef="c-70" decimals="-3" id="f-500" unitRef="usd">2530000</rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities>
    <rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability contextRef="c-70" decimals="-3" id="f-501" unitRef="usd">292000</rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiability>
    <rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability contextRef="c-70" decimals="-3" id="f-502" unitRef="usd">623000</rnac:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-70" decimals="-3" id="f-503" unitRef="usd">34853000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-70" decimals="-3" id="f-504" unitRef="usd">38298000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-70" decimals="-3" id="f-505" unitRef="usd">168465000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock contextRef="c-1" id="f-506">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the Company&#x2019;s intangible assets acquired in the Merger (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Descartes-08 for MG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Descartes-08 for SLE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total in-process research and development assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-74" decimals="-3" id="f-507" unitRef="usd">93900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-75" decimals="-3" id="f-508" unitRef="usd">56700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-70" decimals="-3" id="f-509" unitRef="usd">150600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual contextRef="c-76" decimals="-5" id="f-510" unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual contextRef="c-76" decimals="-5" id="f-511" unitRef="usd">-1600000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c-1" id="f-512">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information reflects the consolidated results of operations of the Company as if the Merger had taken place on January 1, 2022. The unaudited pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(232,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-14" decimals="-3" id="f-513" unitRef="usd">26004000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-14" decimals="-3" id="f-514" unitRef="usd">-232259000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-77" decimals="-5" id="f-515" unitRef="usd">4900000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-516">Net Loss Per Share Allocable to Common Stockholders&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported a net loss for the years ended December 31, 2024 and 2023. The Company used the treasury stock method to determine the number of dilutive shares for the year ended December 31, 2024. The following table sets forth the computation of basic and diluted net loss per share allocable to common stockholders (in thousands, except share and per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(219,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: CVR distribution to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss allocable to shares of common stock - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(257,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Change in fair value of forward contract liability settled in February 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss allocable to shares of common stock - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(257,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,276,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,170,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plus: Dilutive effect of forward contract liability settled in February 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding  - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,357,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,170,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the potential dilutive shares of common stock excluded from the computation of the diluted net loss per share allocable to common stockholders for all periods presented, as the effect would have been anti-dilutive: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options and RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,150,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;776,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,026,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,503,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract to issue Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,304,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;470,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,307,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,096,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-517">The following table sets forth the computation of basic and diluted net loss per share allocable to common stockholders (in thousands, except share and per-share data):&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(219,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: CVR distribution to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss allocable to shares of common stock - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(257,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Change in fair value of forward contract liability settled in February 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss allocable to shares of common stock - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(257,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,276,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,170,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plus: Dilutive effect of forward contract liability settled in February 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding  - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,357,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,170,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-518" unitRef="usd">-77424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-519" unitRef="usd">-219710000</us-gaap:NetIncomeLoss>
    <us-gaap:DistributedEarnings contextRef="c-1" decimals="-3" id="f-520" unitRef="usd">0</us-gaap:DistributedEarnings>
    <us-gaap:DistributedEarnings contextRef="c-14" decimals="-3" id="f-521" unitRef="usd">37550000</us-gaap:DistributedEarnings>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-522" unitRef="usd">-77424000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-523" unitRef="usd">-257260000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DilutiveSecurities contextRef="c-1" decimals="-3" id="f-524" unitRef="usd">-446000</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities contextRef="c-14" decimals="-3" id="f-525" unitRef="usd">0</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-526" unitRef="usd">-77870000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-14" decimals="-3" id="f-527" unitRef="usd">-257260000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-528" unitRef="shares">17276822</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="0" id="f-529" unitRef="shares">5170319</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="0" id="f-530" unitRef="shares">81121</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-14" decimals="0" id="f-531" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-532" unitRef="shares">17357943</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="0" id="f-533" unitRef="shares">5170319</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-534"
      unitRef="usdPerShare">-4.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-535"
      unitRef="usdPerShare">-49.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-536"
      unitRef="usdPerShare">-4.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-537"
      unitRef="usdPerShare">-49.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-538">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the potential dilutive shares of common stock excluded from the computation of the diluted net loss per share allocable to common stockholders for all periods presented, as the effect would have been anti-dilutive: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options and RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,150,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;776,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,026,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,503,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract to issue Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,304,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;470,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,307,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,096,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-78" decimals="0" id="f-539" unitRef="shares">2150273</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-79" decimals="0" id="f-540" unitRef="shares">776865</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-80" decimals="0" id="f-541" unitRef="shares">692523</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-81" decimals="0" id="f-542" unitRef="shares">1040813</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-82" decimals="0" id="f-543" unitRef="shares">4026346</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-83" decimals="0" id="f-544" unitRef="shares">14503993</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-84" decimals="0" id="f-545" unitRef="shares">437927</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-85" decimals="0" id="f-546" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-86" decimals="0" id="f-547" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-87" decimals="0" id="f-548" unitRef="shares">3304677</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-88" decimals="0" id="f-549" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-89" decimals="0" id="f-550" unitRef="shares">470403</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-551" unitRef="shares">7307069</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-14" decimals="0" id="f-552" unitRef="shares">20096751</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-553">Fair Value Measurements&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds (included in cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contingent value right liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds (included in cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contingent value right liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forward contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;393,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;364,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers within the fair value hierarchy during the years ended December 31, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024 and 2023, money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, the Company had restricted cash balances relating to secured letters of credit in connection with its real estate leases (see Note 9). The Company&#x2019;s consolidated statement of cash flows includes the following as of December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.926%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants to Purchase Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company issued warrants to purchase common stock in connection with a private placement, or the 2019 Warrants. The outstanding 2019 Warrants expired on December 23, 2024 in accordance with their terms. Pursuant to the terms of the 2019 Warrants, the Company could have been required to settle the 2019 Warrants in cash in the event of certain acquisitions of the Company and, as a result, the 2019 Warrants were required to be measured at fair value and reported as a liability on the balance sheet.&#160;On December 20, 2022, the Company amended the terms of the outstanding 2019 Warrants held by certain members of the Board of Directors, or the Amended 2019 Warrants, to remove the cash settlement provision.  As a result, the Amended 2019 Warrants were remeasured at fair value on December 20, 2022 and reclassified from a liability to equity on the balance sheet. See Note 12 for further discussion on the equity-classified Amended 2019 Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, the Company issued warrants in connection with an underwritten offering, or the 2022 Warrants. Pursuant to the terms of the 2022 Warrants, the Company could be required to settle the 2022 Warrants in cash in the event of an acquisition of the Company under certain circumstances and, as a result, the 2022 Warrants are required to be measured at fair value and reported as a liability on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the fair value of the 2019 Warrants and the 2022 Warrants upon issuance using the Black-Scholes valuation model and is required to revalue the 2019 Warrants and the 2022 Warrants at each reporting date, with any changes in fair value recorded in the consolidated statements of operations and comprehensive loss. The valuations of the 2019 Warrants and the 2022 Warrants are classified as Level 3 of the fair value hierarchy due to the need to use assumptions in the valuations that are both significant to the fair value measurement and unobservable, including the stock price volatility and the expected life of the 2019 Warrants and the 2022 Warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The changes in the fair values of the&#160;warrants are reflected in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of the 2019 Warrants and the 2022 Warrants were determined using the following inputs to the Black-Scholes simulation valuation:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated fair value of the underlying stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of the common stock based on the closing stock price at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The risk-free interest rate is based on the U.S. Treasury at the valuation date commensurate with the expected remaining life assumption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The expected life of the 2019 Warrants was assumed to be equivalent to their remaining contractual term which expired on December 23, 2024. The expected life of the 2022 Warrants is assumed to be equivalent to their remaining contractual term which expire on April 11, 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company estimates stock price volatility based on the Company&#x2019;s historical volatility for a period of time commensurate with the expected remaining life of the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The 2019 Warrants expired on December 23, 2024 and therefore, there were no 2019 Warrants outstanding as of December 31, 2024. A summary of the Black-Scholes pricing model assumptions used to record the fair value of the 2019 Warrants liability as of December 31, 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Black-Scholes pricing model assumptions used to record the fair value of the 2022 Warrants liability is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects a roll-forward of fair value for the Company&#x2019;s Level 3 warrant liabilities (see Note 12), for the year ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Value Right&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 6, 2023, as contemplated by the Merger Agreement, the Company entered into a contingent value rights agreement, or the CVR Agreement, pursuant to which each holder of common stock or a 2022 Warrant as of December 4, 2023 was distributed a CVR, issued by the Company for each share of common stock held directly or underlying a 2022 Warrant held by such holder as of December 4, 2023. Holders of warrants other than the 2022 Warrants will be entitled to receive, upon &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercise of such warrants and in accordance with the terms of the warrants, 30 CVRs per each share of common stock underlying such warrants.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each CVR entitles its holder to distributions of the following, pro-rated on a per-CVR basis, during the period ending on the date on which the Royalty Term (as defined in the Sobi License) ends, or the Termination Date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;100% of all milestone payments, royalties and other amounts paid to the Company or its controlled affiliates, or the Company Entities, under the Sobi License or, following certain terminations of the Sobi License, any agreement a Company Entity enters into that provides for the development and commercialization of SEL-212; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;100% of all cash consideration and the actual liquidation value of any and all non-cash consideration of any kind that is paid to or is actually received by any Company Entity prior to the Termination Date pursuant to an agreement relating to a sale, license, transfer or other disposition of any transferable asset of the Company existing as of immediately prior to the Merger, other than those exclusively licensed under the Sobi License or which the Company Entities are required to continue to own in order to comply with the Sobi License.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The distributions in respect of the CVRs will be made on a semi-annual basis, and will be subject to a number of deductions, subject to certain exceptions or limitations, including for (i) certain taxes payable on the proceeds subject to the CVR distribution, (ii) certain out of pocket costs incurred by the Company Entities, including audit and accounting fees incurred in connection with reporting obligations relating to the CVRs and other expenses incurred in the performance of their obligations and other actions under the CVR Agreement, (iii) a fixed semi-annual amount of $0.75&#160;million for general and administrative overhead, (iv) payments made and remaining obligations on lease liabilities of Selecta immediately prior to the Merger and (v) amounts paid and remaining obligations with regard to the Xork product candidate. Each of the deductions described in (iv) and (v) will be made only if certain milestone payments under the Sobi License are made and are also subject to certain adjustments as contemplated in the CVR Agreement. Upon the achievement of a development milestone in June 2024, Sobi became obligated to make a $30.0&#160;million payment to the Company and made such payment in July 2024. The proceeds from this payment, net of deductions specified in the CVR Agreement, is expected to be included in the next scheduled distribution to the holders of the CVR in March 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CVRs represent financial instruments that are accounted for under the fair value option election in ASC 825.  Under the fair value option election, the CVRs are initially measured at the aggregate estimated fair value of the CVRs and will be subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The liability was recorded at the date of approval, November 13, 2023, as a dividend. The estimated fair value of the CVR liability was determined using a discounted cash flow methodology as of December 31, 2023 and a Monte Carlo simulation model as of December 31, 2024 to estimate future cash flows associated with the legacy assets, including the expected milestone and royalty payments under the Sobi License, net of deductions. Changes in fair value of the CVR liability are presented in the consolidated statements of operations and comprehensive loss.  The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, expected volatility of future revenues (Monte Carlo simulation model) and risk-adjustment discount rate (discounted cash flow methodology), which represent a Level 3 measurement within the fair value hierarchy. The significant inputs used to estimate the fair value of the CVR liability, which represented a financial instrument being accounted for under the fair value option, were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated cash flow dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 - 2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated probability of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.0% - 100.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility of future revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated cash flow dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024 - 2038&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated probability of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-adjusted discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects a roll-forward of fair value for the Company&#x2019;s Level 3 CVR liability for the year ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CVR liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forward Contract Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Merger Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger, the Company entered into a contract for the issuance of 384,930.724 shares of Series A Preferred Stock as part of the consideration transferred. The fair value of the forward contract at the Closing Date was $155.3&#160;million. The non-cash settlement of this liability occurred on December 5, 2023 with the issuance of the Series A Preferred Stock for $261.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2023 Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company entered into a contract for the issuance of 149,330.115 shares of Series A Preferred Stock as part of the 2023 Private Placement which was settled in multiple tranches. The Company determined the obligation to issue 148,710.488 shares of Series A Preferred Stock to Dr. Timothy A. Springer, a member of the Company&#x2019;s Board of Directors, and TAS Partners LLC, an affiliate of Dr. Springer, represented a forward contract. See Note 11. The initial fair value of the forward contract liability on November 13, 2023 was insignificant as the fair value of the underlying Series A Preferred Stock was equal to the purchase price of the Series A Preferred Stock as agreed upon in the 2023 Private Placement. Subsequent measurement of the fair value of the forward contract liability was based on the market price of the Company&#x2019;s common stock, which represented the redemption and conversion value of the Series A Preferred Stock, less the purchase price, on an as-converted basis. The non-cash settlement of a portion of the liability occurred on December 13, 2023 with the issuance of the first tranche of the Series A Preferred Stock for $14.8&#160;million. The non-cash settlement of the remaining second and third tranches occurred on January 12, 2024 and February 11, 2024, respectively, for a total of $35.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the forward contract liabilities for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:f-651"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-554">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds (included in cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contingent value right liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds (included in cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contingent value right liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forward contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;393,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;364,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-90" decimals="-3" id="f-555" unitRef="usd">39088000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-91" decimals="-3" id="f-556" unitRef="usd">39088000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-92" decimals="-3" id="f-557" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-93" decimals="-3" id="f-558" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-559" unitRef="usd">39088000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-95" decimals="-3" id="f-560" unitRef="usd">39088000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-96" decimals="-3" id="f-561" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-97" decimals="-3" id="f-562" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-94" decimals="-3" id="f-563" unitRef="usd">3836000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-95" decimals="-3" id="f-564" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-96" decimals="-3" id="f-565" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-97" decimals="-3" id="f-566" unitRef="usd">3836000</us-gaap:WarrantsAndRightsOutstanding>
    <rnac:ContingentValueRightLiability contextRef="c-94" decimals="-3" id="f-567" unitRef="usd">395500000</rnac:ContingentValueRightLiability>
    <rnac:ContingentValueRightLiability contextRef="c-95" decimals="-3" id="f-568" unitRef="usd">0</rnac:ContingentValueRightLiability>
    <rnac:ContingentValueRightLiability contextRef="c-96" decimals="-3" id="f-569" unitRef="usd">0</rnac:ContingentValueRightLiability>
    <rnac:ContingentValueRightLiability contextRef="c-97" decimals="-3" id="f-570" unitRef="usd">395500000</rnac:ContingentValueRightLiability>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-94" decimals="-3" id="f-571" unitRef="usd">399336000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-95" decimals="-3" id="f-572" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-96" decimals="-3" id="f-573" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-97" decimals="-3" id="f-574" unitRef="usd">399336000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-98" decimals="-3" id="f-575" unitRef="usd">41161000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-99" decimals="-3" id="f-576" unitRef="usd">41161000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-100" decimals="-3" id="f-577" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-101" decimals="-3" id="f-578" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-102" decimals="-3" id="f-579" unitRef="usd">41161000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-580" unitRef="usd">41161000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-104" decimals="-3" id="f-581" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-582" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-102" decimals="-3" id="f-583" unitRef="usd">6394000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-103" decimals="-3" id="f-584" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-104" decimals="-3" id="f-585" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-105" decimals="-3" id="f-586" unitRef="usd">6394000</us-gaap:WarrantsAndRightsOutstanding>
    <rnac:ContingentValueRightLiability contextRef="c-102" decimals="-3" id="f-587" unitRef="usd">358600000</rnac:ContingentValueRightLiability>
    <rnac:ContingentValueRightLiability contextRef="c-103" decimals="-3" id="f-588" unitRef="usd">0</rnac:ContingentValueRightLiability>
    <rnac:ContingentValueRightLiability contextRef="c-104" decimals="-3" id="f-589" unitRef="usd">0</rnac:ContingentValueRightLiability>
    <rnac:ContingentValueRightLiability contextRef="c-105" decimals="-3" id="f-590" unitRef="usd">358600000</rnac:ContingentValueRightLiability>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-102" decimals="-3" id="f-591" unitRef="usd">28307000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-103" decimals="-3" id="f-592" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-104" decimals="-3" id="f-593" unitRef="usd">28307000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-105" decimals="-3" id="f-594" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-102" decimals="-3" id="f-595" unitRef="usd">393301000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-103" decimals="-3" id="f-596" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-104" decimals="-3" id="f-597" unitRef="usd">28307000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-105" decimals="-3" id="f-598" unitRef="usd">364994000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet contextRef="c-1" decimals="INF" id="f-599" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet contextRef="c-14" decimals="INF" id="f-600" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet contextRef="c-1" decimals="INF" id="f-601" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet contextRef="c-14" decimals="INF" id="f-602" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-604">The Company&#x2019;s consolidated statement of cash flows includes the following as of December 31, 2024 and 2023 (in thousands):&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.926%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-603">The Company&#x2019;s consolidated statement of cash flows includes the following as of December 31, 2024 and 2023 (in thousands):&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.926%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-605" unitRef="usd">212610000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-9" decimals="-3" id="f-606" unitRef="usd">76911000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-8" decimals="-3" id="f-607" unitRef="usd">1669000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-9" decimals="-3" id="f-608" unitRef="usd">1377000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-609" unitRef="usd">214279000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-3" id="f-610" unitRef="usd">78288000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-106"
      decimals="INF"
      id="f-611"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-612">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the 2019 Warrants liability as of December 31, 2023 is as follows:&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Black-Scholes pricing model assumptions used to record the fair value of the 2022 Warrants liability is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The significant inputs used to estimate the fair value of the CVR liability, which represented a financial instrument being accounted for under the fair value option, were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated cash flow dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 - 2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated probability of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.0% - 100.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility of future revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated cash flow dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024 - 2038&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated probability of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-adjusted discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-107" decimals="4" id="f-613" unitRef="number">0.0479</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-108" decimals="4" id="f-614" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-109" id="f-615">P0Y11M23D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-110" decimals="4" id="f-616" unitRef="number">0.8367</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-111" decimals="4" id="f-617" unitRef="number">0.0425</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-112" decimals="4" id="f-618" unitRef="number">0.0401</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-113" decimals="4" id="f-619" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-114" decimals="4" id="f-620" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-115" id="f-621">P2Y3M10D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-116" id="f-622">P3Y3M10D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-117" decimals="4" id="f-623" unitRef="number">0.9292</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-118" decimals="4" id="f-624" unitRef="number">0.8409</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-625">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects a roll-forward of fair value for the Company&#x2019;s Level 3 warrant liabilities (see Note 12), for the year ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects a roll-forward of fair value for the Company&#x2019;s Level 3 CVR liability for the year ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CVR liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the forward contract liabilities for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:f-651"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-119" decimals="-3" id="f-626" unitRef="usd">6394000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-120" decimals="-3" id="f-627" unitRef="usd">2558000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-121" decimals="-3" id="f-628" unitRef="usd">3836000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-122"
      decimals="INF"
      id="f-629"
      unitRef="shares">30</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <rnac:ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed
      contextRef="c-123"
      decimals="INF"
      id="f-630"
      unitRef="number">1</rnac:ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed>
    <rnac:ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed
      contextRef="c-123"
      decimals="INF"
      id="f-631"
      unitRef="number">1</rnac:ContingentValueRightPercentageOfMilestonePaymentsRoyaltiesAndOtherAmountsToBeDistributed>
    <rnac:ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead contextRef="c-123" decimals="-4" id="f-632" unitRef="usd">750000</rnac:ContingentValueRightLiabilityDeductionFromDistributionGeneralAndAdministrativeOverhead>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-124" decimals="-5" id="f-633" unitRef="usd">30000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <rnac:ContingentValueRightLiabilityMeasurementInput contextRef="c-125" decimals="3" id="f-634" unitRef="number">0.950</rnac:ContingentValueRightLiabilityMeasurementInput>
    <rnac:ContingentValueRightLiabilityMeasurementInput contextRef="c-126" decimals="3" id="f-635" unitRef="number">1.000</rnac:ContingentValueRightLiabilityMeasurementInput>
    <rnac:ContingentValueRightLiabilityMeasurementInput contextRef="c-127" decimals="3" id="f-636" unitRef="number">0.220</rnac:ContingentValueRightLiabilityMeasurementInput>
    <rnac:ContingentValueRightLiabilityMeasurementInput contextRef="c-128" decimals="3" id="f-637" unitRef="number">0.950</rnac:ContingentValueRightLiabilityMeasurementInput>
    <rnac:ContingentValueRightLiabilityMeasurementInput contextRef="c-129" decimals="3" id="f-638" unitRef="number">0.137</rnac:ContingentValueRightLiabilityMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-130" decimals="-3" id="f-639" unitRef="usd">358600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-131" decimals="-3" id="f-640" unitRef="usd">-36900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-132" decimals="-3" id="f-641" unitRef="usd">395500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-55"
      decimals="INF"
      id="f-642"
      unitRef="shares">384930.724</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-72" decimals="-5" id="f-643" unitRef="usd">155300000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-133" decimals="-5" id="f-644" unitRef="usd">261800000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-56"
      decimals="INF"
      id="f-645"
      unitRef="shares">149330.115</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <rnac:SettlementOfDerivativeLiabilityShares
      contextRef="c-54"
      decimals="INF"
      id="f-646"
      unitRef="shares">148710.488</rnac:SettlementOfDerivativeLiabilityShares>
    <rnac:IssuanceOfStockForSettlementOfForwardContractLiability contextRef="c-134" decimals="-5" id="f-647" unitRef="usd">14800000</rnac:IssuanceOfStockForSettlementOfForwardContractLiability>
    <rnac:IssuanceOfStockForSettlementOfForwardContractLiability contextRef="c-135" decimals="-5" id="f-648" unitRef="usd">35200000</rnac:IssuanceOfStockForSettlementOfForwardContractLiability>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="c-9" decimals="-3" id="f-649" unitRef="usd">28307000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements contextRef="c-1" decimals="-3" id="f-650" unitRef="usd">35197000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-652" unitRef="usd">-6890000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="c-8" decimals="-3" id="f-653" unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-654">Property and Equipment&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 9 for details regarding the impairment loss the Company recognized for certain furniture and fixtures during the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $1.2 million and $0.7 million for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-655">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-136" decimals="-3" id="f-656" unitRef="usd">7295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-137" decimals="-3" id="f-657" unitRef="usd">6280000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-67" decimals="-3" id="f-658" unitRef="usd">415000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-138" decimals="-3" id="f-659" unitRef="usd">702000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-139" decimals="-3" id="f-660" unitRef="usd">3427000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-140" decimals="-3" id="f-661" unitRef="usd">61000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-65" decimals="-3" id="f-662" unitRef="usd">268000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-141" decimals="-3" id="f-663" unitRef="usd">452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-142" decimals="-3" id="f-664" unitRef="usd">169000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-143" decimals="-3" id="f-665" unitRef="usd">196000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-144" decimals="-3" id="f-666" unitRef="usd">695000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-145" decimals="-3" id="f-667" unitRef="usd">150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-8" decimals="-3" id="f-668" unitRef="usd">12269000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-9" decimals="-3" id="f-669" unitRef="usd">7841000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-670" unitRef="usd">2357000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-9" decimals="-3" id="f-671" unitRef="usd">5728000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-672" unitRef="usd">9912000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-9" decimals="-3" id="f-673" unitRef="usd">2113000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-674" unitRef="usd">1200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-14" decimals="-5" id="f-675" unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-676">Accrued Expenses&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll and employee related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued patent fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued external research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued professional and consulting services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-677">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll and employee related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued patent fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued external research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued professional and consulting services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-678" unitRef="usd">3534000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-679" unitRef="usd">4390000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <rnac:AccruedPatentFeesCurrent contextRef="c-8" decimals="-3" id="f-680" unitRef="usd">813000</rnac:AccruedPatentFeesCurrent>
    <rnac:AccruedPatentFeesCurrent contextRef="c-9" decimals="-3" id="f-681" unitRef="usd">472000</rnac:AccruedPatentFeesCurrent>
    <rnac:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-8" decimals="-3" id="f-682" unitRef="usd">2987000</rnac:AccruedResearchAndDevelopmentCostsCurrent>
    <rnac:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-9" decimals="-3" id="f-683" unitRef="usd">4896000</rnac:AccruedResearchAndDevelopmentCostsCurrent>
    <rnac:AccruedAuditFeesCurrent contextRef="c-8" decimals="-3" id="f-684" unitRef="usd">3674000</rnac:AccruedAuditFeesCurrent>
    <rnac:AccruedAuditFeesCurrent contextRef="c-9" decimals="-3" id="f-685" unitRef="usd">4331000</rnac:AccruedAuditFeesCurrent>
    <rnac:AccruedPropertyPlantAndEquipmentCurrent contextRef="c-8" decimals="-3" id="f-686" unitRef="usd">782000</rnac:AccruedPropertyPlantAndEquipmentCurrent>
    <rnac:AccruedPropertyPlantAndEquipmentCurrent contextRef="c-9" decimals="-3" id="f-687" unitRef="usd">128000</rnac:AccruedPropertyPlantAndEquipmentCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-688" unitRef="usd">286000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-689" unitRef="usd">516000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-690" unitRef="usd">12076000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-691" unitRef="usd">14733000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-692">Leases &lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;7495 New Horizon Way Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2024, the Company entered into a lease agreement with 7495 RP, LLC, or the Landlord, pursuant to which it agreed to lease from the Landlord the manufacturing space located at 7495 New Horizon Way, Frederick, Maryland, or the Frederick Lease Agreement. The space consists of 19,199 leasable square feet of integrated manufacturing and office space. The lease commenced on May 1, 2024 which was the date the Landlord delivered full possession of the premises to the Company. The Frederick Lease Agreement will terminate approximately 7.2 years following the commencement date. The Company will have one option to extend the term of the Frederick Lease Agreement for a period of five years at a cost of 100% of the then-fair market value, not to exceed 103% of the then-current base rent. Base rent, which was due beginning on July 1, 2024, is $0.9&#160;million annually and is subject to an annual upward adjustment of 3% of the then-current rental rate. In addition, the Company is obligated to pay its share of operating costs and taxes related to the property. The Company paid the first month&#x2019;s rent of $0.1&#160;million upon execution of the Frederick Lease Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the classification of the lease at the commencement date and concluded it should be accounted for as an operating lease. The Company recorded a lease liability and right-of-use asset of $3.6&#160;million and $3.7&#160;million, respectively, on the commencement date. The Frederick Lease Agreement includes a tenant improvement allowance of up to $0.7&#160;million which was recognized as a reduction in the right-of-use asset and lease liability at the commencement date as the Company was reasonably certain to incur reimbursable costs related to alterations equal to or exceeding the amount. Additionally, the prepaid rent was included as an adjustment to the right-of-use asset. The discount rate of 14% was determined based on the Company&#x2019;s incremental borrowing rate adjusted for the lease term, including any reasonably certain renewal periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective May 7, 2024, the Company and the Landlord entered into the first amendment to the Frederick Lease Agreement, or the First Frederick Lease Agreement Amendment, providing for the expansion of the premises leased pursuant to the Frederick Lease Agreement by approximately 7,842 square feet. In connection with the expansion of the leased premises, the Company is obligated to pay $0.3&#160;million in additional annual base rent for the first year of the term, which is subject to an annual upward adjustment of 3% of the then-current rental rate, as well as its share of operating costs and taxes. The lease commenced on May 7, 2024 which was the date the Landlord delivered full possession of the premises to the Company and will be coterminous with the Frederick Lease Agreement. The rent commencement date was September 1, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the classification of the lease at the commencement date and concluded it should be accounted for as an operating lease. The Company recorded a lease liability and right-of-use asset each of $1.2&#160;million on the commencement date. The First Frederick Lease Agreement Amendment includes a tenant improvement allowance of up to $0.1&#160;million which was recognized as a reduction in the right-of-use asset and lease liability at the commencement date as the Company was reasonably certain to incur reimbursable costs related to alterations equal to or exceeding the amount. The discount rate of 14% was determined based on the Company&#x2019;s incremental borrowing rate adjusted for the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective August 30, 2024, the Company and the Landlord entered into the second amendment to the Frederick Lease Agreement, or the Second Frederick Lease Agreement Amendment, providing for the expansion of the premises leased pursuant to the Frederick Lease Agreement and First Frederick Lease Agreement Amendment by approximately 2,009 square feet. In connection with the expansion of the leased premises, the Company is obligated to pay $0.1&#160;million in additional annual base rent for the first year of the term, which is subject to an annual upward adjustment of 3% of the then-current rental rate, as well as its share of operating costs and taxes. The lease commenced on September 1, 2024, which was the date the Landlord delivered full possession of the premises to the Company and will be coterminous with the Frederick Lease Agreement. The rent commencement date was September 1, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the classification of the lease at the commencement date and concluded it should be accounted for as an operating lease. The Company recorded a lease liability and right-of-use asset each of $0.3&#160;million on the commencement date. The discount rate of 14% was determined based on the Company&#x2019;s incremental borrowing rate adjusted for the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company secured a letter of credit from Silicon Valley Bank, a division of First-Citizens Bank &amp;amp; Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), or SVB, for $0.3 million for the Frederick Lease Agreement, the First Frederick Lease Agreement Amendment and the Second Frederick Lease Agreement Amendment, which is recognized as long-term restricted cash as of December 31, 2024 and renews automatically each year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;65 Grove Street Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company entered into a lease with BRE-BMR Grove LLC for 25,078 square feet of laboratory and office space located at 65 Grove Street, Watertown, Massachusetts, or the Watertown Lease Agreement. As part of the Watertown Lease Agreement, the Company incurred $0.8 million in non-reimbursable construction costs. The lease began in March 2020, when the Company took control of the office space, and the lease term is 8 years. The discount rate of 8.9% was determined based on the Company&#x2019;s incremental borrowing rate adjusted for the lease term, including any reasonably certain renewal periods. In connection with the Watertown Lease Agreement, the Company secured a letter of credit from SVB for $1.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2022, the Company entered into an amendment, or the Watertown Lease Agreement Amendment, to its lease agreement with BRE-BMR Grove LLC, originally entered into on July 23, 2019 to expand the Company&#x2019;s laboratory and office space located at 65 Grove Street, Watertown, Massachusetts by 7,216 square feet. The lease term began on September 1, 2022, consistent with when the Company took control of the office space and the expected lease term is 5.7 years. The discount rate of 11.3% was determined based on the Company&#x2019;s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods. Rent payments began in November 2022, and the base rent for the first year is $0.1&#160;million per month. The Company recorded the right-of-use asset and operating lease liabilities of $3.2&#160;million during the year ended December 31, 2022 as control of the premises was transferred to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 6, 2022, the Company entered into a sublease agreement to sublease 7,216 square feet of space currently rented by the Company at 65 Grove Street, Watertown, Massachusetts.  The sublease commenced on October 24, 2022, when the Company, the sublessee and BRE-BMR Grove LLC, executed a Consent to Sublease.  The term of the sublease expired on March 31, 2024 with no option to extend the sublease term. Sublease income is included within other income, net in the consolidated statements of operations and comprehensive loss.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the sublease agreement and Consent to Sublease, rent payments to BRE-BMR Grove LLC for the lease of the office space increased.  The change of consideration in the contract was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of October 24, 2022.  The discount rate of 11.9% was determined based on the Company&#x2019;s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods as of October 24, 2022, resulting in a decrease of less than $0.1&#160;million to both the right-of-use asset and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company received notice from BRE-BMR Grove LLC that the requirements to reduce the amount of the letter of credit for the Watertown Lease Agreement had been met. In connection therewith, in June 2023, the Company secured a letter of credit from JPMorgan Chase Bank, N.A. for $1.4&#160;million, which is recognized as long-term restricted cash as of December 31, 2024 and 2023, and renews automatically each year. The $1.6&#160;million letter of credit with SVB was released from restriction and returned to the Company on July 17, 2023, and therefore was reclassified into cash and cash equivalents in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2023, in connection with entering into Amendment No. 1 to the License and Development Agreement with Sobi as described in Note 14, the Company entered into a sublease agreement with Sobi to sublease approximately 5,600 square feet of space currently rented by the Company at 65 Grove Street, Watertown, Massachusetts for which Sobi paid $1.0&#160;million upfront rental payment.  The sublease commenced on November 6, 2023, when the Company, Sobi, and BRE-BMR Grove LLC, executed a Consent to Sublease.  The term of the sublease expired on November 5, 2024 with no option to extend the sublease term. As of December 31, 2023, deferred rent of $0.8&#160;million is included within accrued expenses and other current liabilities in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company determined that the right-of-use asset related to the operating lease for approximately 7,216 square feet at 65 Grove Street was partially impaired as of November 30, 2023.  As a result, the Company recognized a $0.7&#160;million right-of-use asset impairment charge in impairment of long-lived assets on its consolidated statements of operations and comprehensive loss during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the expiration of the sublease to Sobi in November 2024 and the Company&#x2019;s decision to cease use of its office and laboratory space at 65 Grove Street, Watertown, Massachusetts, the Company assessed the right-of-use assets and related furniture and fixtures associated with the Watertown Lease Agreement and Watertown Lease Agreement Amendment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for impairment. The carrying value of each asset group was compared against the future net undiscounted cash flows projected to be generated over the remaining lease terms. These projections included management's estimates of cash inflows from potential sublease income. The carrying amount of the asset groups was found to be unrecoverable, thus the Company assessed the fair value of each asset group. The fair value was determined using the income approach, whereby the Company discounted the estimated net cash flows using a rate commensurate with the Company&#x2019;s estimated incremental borrowing rate. As a result of this assessment, which included unrecoverable operating and maintenance costs, the Company determined that each asset group was fully impaired. As such, an &lt;span style="-sec-ix-hidden:f-743"&gt;impairment charge&lt;/span&gt; of $7.6&#160;million was recognized during the year ended December 31, 2024, $7.4&#160;million of which related to the right-of-use assets and $0.2&#160;million related to property and equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;704 Quince Orchard Road Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger, the Company acquired two operating leases for office and laboratory space in Gaithersburg, Maryland. The leases expire in January 2027 and do not contain any renewal rights. The discount rate of 11.5% was determined based on the Company&#x2019;s incremental borrowing rate adjusted for the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for the years ended December 31, 2024 and 2023 was $5.5 million, $3.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2024 and 2023, the components of lease costs were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,099)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the initial recording of the right-of-use assets and lease liabilities for the Frederick Lease Agreement, First Frederick Lease Agreement Amendment, and Second Frederick Lease Agreement Amendment during the year ended December 31, 2024, the impairments on the right-of-use assets for the Watertown Lease Agreement and Watertown Lease Agreement Amendment during the years ended December 31, 2024 and 2023, as applicable, and the assumption of the right-of-use assets and lease liabilities in connection with the Merger during the year ended December 31, 2023, which were non-cash, the changes in the Company&#x2019;s right-of-use assets and lease liabilities for the years ended December 31, 2024 and 2023 are reflected in the non-cash lease expense and accrued expenses and other liabilities, respectively, in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes additional information related to the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-146" decimals="0" id="f-693" unitRef="sqft">19199</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-147" id="f-694">P7Y2M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <rnac:LesseeOperatingLeaseNumberOfOptionsToExtend
      contextRef="c-147"
      decimals="INF"
      id="f-695"
      unitRef="extension_option">1</rnac:LesseeOperatingLeaseNumberOfOptionsToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-147" id="f-696">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <rnac:OperatingLeaseCostPercentage contextRef="c-148" decimals="2" id="f-697" unitRef="number">1</rnac:OperatingLeaseCostPercentage>
    <rnac:OperatingLeaseCostPercentage contextRef="c-149" decimals="2" id="f-698" unitRef="number">1.03</rnac:OperatingLeaseCostPercentage>
    <rnac:LesseeOperatingLeaseMonthlyBaseRent contextRef="c-150" decimals="-5" id="f-699" unitRef="usd">900000</rnac:LesseeOperatingLeaseMonthlyBaseRent>
    <rnac:LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne
      contextRef="c-150"
      decimals="INF"
      id="f-700"
      unitRef="number">0.03</rnac:LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne>
    <rnac:LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement contextRef="c-151" decimals="-5" id="f-701" unitRef="usd">100000</rnac:LesseeOperatingLeaseFirstMonthRentPaidOnExecutionOfLeaseAgreement>
    <us-gaap:OperatingLeaseLiability contextRef="c-147" decimals="-5" id="f-702" unitRef="usd">3600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-147" decimals="-5" id="f-703" unitRef="usd">3700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <rnac:OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability contextRef="c-147" decimals="-5" id="f-704" unitRef="usd">700000</rnac:OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-147" decimals="2" id="f-705" unitRef="number">0.14</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-152" decimals="0" id="f-706" unitRef="sqft">7842</us-gaap:AreaOfRealEstateProperty>
    <rnac:LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne contextRef="c-153" decimals="-5" id="f-707" unitRef="usd">300000</rnac:LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne>
    <rnac:LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne
      contextRef="c-153"
      decimals="INF"
      id="f-708"
      unitRef="number">0.03</rnac:LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne>
    <us-gaap:OperatingLeaseLiability contextRef="c-152" decimals="-5" id="f-709" unitRef="usd">1200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-152" decimals="-5" id="f-710" unitRef="usd">1200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <rnac:OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability contextRef="c-152" decimals="-5" id="f-711" unitRef="usd">100000</rnac:OperatingLeaseTenantImprovementAllowanceRecognizedAsReductionInRightOfUseAssetAndLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-152" decimals="2" id="f-712" unitRef="number">0.14</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-154" decimals="0" id="f-713" unitRef="sqft">2009</us-gaap:AreaOfRealEstateProperty>
    <rnac:LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne contextRef="c-155" decimals="-5" id="f-714" unitRef="usd">100000</rnac:LesseeOperatingLeaseAdditionalAnnualBaseRentYearOne>
    <rnac:LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne
      contextRef="c-155"
      decimals="INF"
      id="f-715"
      unitRef="number">0.03</rnac:LesseeOperatingLeaseBaseRentAnnualUpwardAdjustmentPercentageAfterYearOne>
    <us-gaap:OperatingLeaseLiability contextRef="c-154" decimals="-5" id="f-716" unitRef="usd">300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-154" decimals="-5" id="f-717" unitRef="usd">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-152" decimals="2" id="f-718" unitRef="number">0.14</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-156" decimals="-5" id="f-719" unitRef="usd">300000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-157" decimals="0" id="f-720" unitRef="sqft">25078</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseCost contextRef="c-158" decimals="-5" id="f-721" unitRef="usd">800000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-157" id="f-722">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-157" decimals="3" id="f-723" unitRef="number">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:RestrictedCash contextRef="c-159" decimals="-5" id="f-724" unitRef="usd">1600000</us-gaap:RestrictedCash>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-160" decimals="0" id="f-725" unitRef="sqft">7216</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-160" id="f-726">P5Y8M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-160" decimals="3" id="f-727" unitRef="number">0.113</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <rnac:OperatingLeaseBaseRent contextRef="c-161" decimals="-5" id="f-728" unitRef="usd">100000</rnac:OperatingLeaseBaseRent>
    <us-gaap:OperatingLeaseLiability contextRef="c-162" decimals="-5" id="f-729" unitRef="usd">3200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-162" decimals="-5" id="f-730" unitRef="usd">3200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-163" decimals="0" id="f-731" unitRef="sqft">7216</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-164" decimals="3" id="f-732" unitRef="number">0.119</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseLiability contextRef="c-164" decimals="-5" id="f-733" unitRef="usd">100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-164" decimals="-5" id="f-734" unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-159" decimals="-5" id="f-735" unitRef="usd">1400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-165" decimals="-5" id="f-736" unitRef="usd">1400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-166" decimals="-5" id="f-737" unitRef="usd">1600000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-167" decimals="0" id="f-738" unitRef="sqft">5600</us-gaap:AreaOfRealEstateProperty>
    <rnac:UpfrontRentalPayment contextRef="c-168" decimals="-5" id="f-739" unitRef="usd">1000000</rnac:UpfrontRentalPayment>
    <us-gaap:DeferredRentCreditCurrent contextRef="c-169" decimals="-5" id="f-740" unitRef="usd">800000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-163" decimals="0" id="f-741" unitRef="sqft">7216</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-170" decimals="-5" id="f-742" unitRef="usd">700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-5" id="f-744" unitRef="usd">7600000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-1" decimals="-5" id="f-745" unitRef="usd">7400000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-5" id="f-746" unitRef="usd">200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <rnac:NumberOfAcquiredOperatingLeases
      contextRef="c-171"
      decimals="INF"
      id="f-747"
      unitRef="operating_lease">2</rnac:NumberOfAcquiredOperatingLeases>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-172" decimals="3" id="f-748" unitRef="number">0.115</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost contextRef="c-173" decimals="-5" id="f-749" unitRef="usd">5500000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-174" decimals="-5" id="f-750" unitRef="usd">3800000</us-gaap:LeaseCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-751">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2024 and 2023, the components of lease costs were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,099)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes additional information related to the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-752" unitRef="usd">3856000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-14" decimals="-3" id="f-753" unitRef="usd">2828000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-754" unitRef="usd">1609000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-14" decimals="-3" id="f-755" unitRef="usd">965000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-756" unitRef="usd">28000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-14" decimals="-3" id="f-757" unitRef="usd">8000</us-gaap:ShortTermLeaseCost>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-3" id="f-758" unitRef="usd">1099000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-14" decimals="-3" id="f-759" unitRef="usd">1172000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-760" unitRef="usd">4394000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-14" decimals="-3" id="f-761" unitRef="usd">2629000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-762">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-8" decimals="-3" id="f-763" unitRef="usd">3645000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-8" decimals="-3" id="f-764" unitRef="usd">4538000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-8" decimals="-3" id="f-765" unitRef="usd">4345000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-8" decimals="-3" id="f-766" unitRef="usd">2314000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-8" decimals="-3" id="f-767" unitRef="usd">1409000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-8" decimals="-3" id="f-768" unitRef="usd">2188000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-8" decimals="-3" id="f-769" unitRef="usd">18439000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-8" decimals="-3" id="f-770" unitRef="usd">4455000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-8" decimals="-3" id="f-771" unitRef="usd">13984000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="c-1" id="f-772">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-773" unitRef="usd">3559000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-14" decimals="-3" id="f-774" unitRef="usd">2696000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-8" id="f-775">P4Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-9" id="f-776">P4Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-8" decimals="3" id="f-777" unitRef="number">0.117</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-9" decimals="3" id="f-778" unitRef="number">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-779">Debt&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 31, 2020, the Company entered into a Loan and Security Agreement with Oxford Finance LLC, or Oxford, and Silicon Valley Bank, or the Loan and Security Agreement, and such facility, the 2020 Term Loan. On March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation, or the FDIC, was appointed as receiver. On March 13, 2023, the FDIC announced that all of Silicon Valley Bank&#x2019;s deposits and substantially all of its assets had been transferred to a newly created, full-service, FDIC-operated bridge bank, Silicon Valley Bridge Bank, N.A., or SVBB. SVBB assumed all loans that were previously held by Silicon Valley Bank. On March 27, 2023, First-Citizens Bank &amp;amp; Trust Company assumed all of SVBB&#x2019;s customer deposits and certain other liabilities and acquired substantially all of SVBB&#x2019;s loans and certain other assets from the FDIC, including the 2020 Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 11, 2023, the Company entered into a payoff letter with Oxford and SVB, pursuant to which the Company paid all outstanding amounts under the 2020 Term Loan, together with accrued interest and a prepayment penalty, resulting in the full extinguishment of the 2020 Term Loan. The total payoff amount was $22.3&#160;million, consisting of the remaining principal amount due of $19.8&#160;million, the final payment fee of $2.3&#160;million, the prepayment penalty of $0.2&#160;million, and less than $0.1&#160;million of accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company recorded a loss of $0.7&#160;million on the extinguishment of the 2020 Term Loan, consisting of the prepayment penalty of $0.2&#160;million and the write-off of $0.5&#160;million of unamortized debt issuance costs and venture debt termination fee, which was included within interest expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024 and 2023, the Company had no outstanding borrowings.&lt;/span&gt;&lt;/div&gt;During the year ended December 31, 2024, the Company recognized no interest expense. During the year ended December 31, 2023, the Company recognized $2.1 million of interest expense related to the 2020 Term Loan.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-175" decimals="-5" id="f-780" unitRef="usd">22300000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="c-175" decimals="-5" id="f-781" unitRef="usd">19800000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-176" decimals="-5" id="f-782" unitRef="usd">2300000</us-gaap:DebtInstrumentFeeAmount>
    <rnac:DebtInstrumentPrepaymentFee contextRef="c-176" decimals="-5" id="f-783" unitRef="usd">200000</rnac:DebtInstrumentPrepaymentFee>
    <rnac:DebtInstrumentAccruedInterest contextRef="c-176" decimals="-5" id="f-784" unitRef="usd">100000</rnac:DebtInstrumentAccruedInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-177" decimals="-5" id="f-785" unitRef="usd">-700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <rnac:DebtInstrumentPrepaymentFee contextRef="c-178" decimals="-5" id="f-786" unitRef="usd">200000</rnac:DebtInstrumentPrepaymentFee>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost contextRef="c-177" decimals="-5" id="f-787" unitRef="usd">500000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:LineOfCredit contextRef="c-179" decimals="INF" id="f-788" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c-178" decimals="INF" id="f-789" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="INF" id="f-790" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-14" decimals="-5" id="f-791" unitRef="usd">2100000</us-gaap:InterestExpenseDebt>
    <rnac:TemporaryEquityDisclosureTextBlock contextRef="c-1" id="f-792">Convertible Preferred Stock&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Certificate of Designation of Preferences, Rights, and Limitations of the Series B Non-Voting Convertible Preferred Stock, or the Series B Certificate of Designation, was filed with the Secretary of State of the State of Delaware on July&#160;2, 2024, and provided for the designation of shares of Series B Preferred Stock and authorized the issuance of 2,937,903 shares of Series B Preferred Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on July 2, 2024, the Company entered into the 2024 Securities Purchase Agreement with certain institutional and accredited investors, or the Purchasers. The Purchasers included (i) Dr. Timothy A. Springer, a member of the Company&#x2019;s Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Dr. Chafen Lu, Dr. Springer&#x2019;s wife. Pursuant to the 2024 Securities Purchase Agreement, the Company agreed to issue and sell an aggregate of 3,563,247 shares of common stock and 2,937,903 shares of Series B Preferred Stock for an aggregate purchase price of $130.0 million in the 2024 Private Placement. Each share of Series B Preferred Stock is convertible into one share of the Company&#x2019;s common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subject to stockholder approval of a proposal to issue such shares of common stock upon conversion of such shares of Series B Preferred Stock in accordance with the Listing Rules of the Nasdaq Stock Market LLC, or the Series B Conversion Proposal. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2024 Securities Purchase Agreement, the Company issued 3,563,247 shares of common stock and 578,403 shares of Series B Preferred Stock for an aggregate purchase price of $82.8 million to the Purchasers other than Dr. Springer, TAS Partners LLC, and Dr. Lu. The Company also issued (i) 1,636,832 shares of Series B Preferred Stock to Dr. Springer, (ii) 721,361 shares of Series B Preferred Stock to TAS Partners LLC, and (iii) 1,307 shares of Series B Preferred Stock to Dr. Lu for an aggregate purchase price of $47.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the 2024 Securities Purchase Agreement, the Company agreed to submit to its stockholders the approval of the Series B Conversion Proposal, at a special meeting of stockholders, which was held on September 20, 2024. On September 20, 2024, at such special meeting, the Company&#x2019;s stockholders approved the Series B Conversion Proposal, among other matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 25, 2024, pursuant to the terms of the Series B Certificate of Designation, 2,499,976 shares of Series B Preferred Stock automatically converted into 2,499,976 shares of common stock; 437,927 shares of Series B Preferred Stock did not automatically convert at such time due to beneficial ownership limitations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series B Preferred Stock were classified in permanent equity as there were no conditions that could have required cash redemption of the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series B Preferred Stock has the following rights and preferences:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Conversion&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the stockholder approval of the Series B Conversion Proposal the Series B Preferred Stock were not convertible into shares of common stock. Following the stockholder approval of the Series B Conversion Proposal, each share of Series B Preferred Stock automatically converted into one share of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 0.0% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion; provided, however, that such beneficial ownership limitation does not apply to Dr. Springer, TAS Partners LLC, or any of their respective affiliates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Series B Preferred Stock outstanding that was not automatically converted into common stock as a result of the stockholder approval of the Series B Conversion Proposal shall be convertible at any time at the option of the holder following stockholder approval of the Series B Conversion Proposal, only to the extent the beneficial ownership limitation does not apply to the shares of Series B Preferred Stock to be converted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series B Preferred Stock is not redeemable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock on an as-converted basis (without regard to the beneficial ownership limitation) equal to the dividends paid on shares of the common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Voting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then-outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the Series B Certificate of Designation, or (c) amend the Charter or other organizational documents in any manner that alters or changes the preferences, rights, privileges, or powers of, or restrictions provided for the benefit of the holders of Series B Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of Series B Preferred Stock shall rank on parity with the holders of common stock and the holders of Series A Preferred Stock as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, each holder of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B Preferred Stock were fully converted, which shall be paid pari passu with holders of common stock and holders of Series A Preferred Stock, plus an amount equal to any dividends declared but unpaid. If the assets available for distribution are not sufficient to pay the holders of the Series B Preferred Stock pursuant to the preceding sentence, all remaining assets will be distributed ratably to the holders of the Series A Preferred Stock, Series B Preferred Stock and common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Certificate of Designation of Preferences, Rights, and Limitations of the Series A Non-Voting Convertible Preferred Stock, or the Series A Certificate of Designation, was filed on November 13, 2023, which provided for the designation of shares of the Series A Preferred Stock and authorized the issuance of 548,375 shares of Series A Preferred Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally on November 13, 2023, the Company entered into the 2023 Securities Purchase Agreement with (i) Dr. Timothy A. Springer, a member of the Company&#x2019;s Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Seven One Eight Three Four Irrevocable Trust, a trust associated with Dr. Murat Kalayoglu, a co-founder and the former chief executive officer of Old Cartesian, who joined the Company&#x2019;s Board of Directors effective immediately after the effective &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;time of the Merger, or the Investors. Pursuant to the 2023 Securities Purchase Agreement, the Company agreed to issue and sell an aggregate of 149,330.115 shares of Series A Preferred Stock for an aggregate purchase price of $60.25&#160;million in the 2023 Private Placement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the 2023 Private Placement, Dr. Timothy A. Springer agreed to settle his purchases in three tranches of shares of Series A Preferred Stock, the first for a purchase price of $10.0&#160;million and each thereafter for a purchase price of approximately $20.0&#160;million, with the three tranches settling 30, 60, and 90 days, respectively, following the Closing Date. TAS Partners LLC agreed to settle its purchase for approximately $10.0&#160;million within 30 days following the Closing Date. The first, second and third tranches were settled on December 13, 2023, January 12, 2024 and February 11, 2024, respectively, under which (i) 24,785.081 shares of Series A Preferred Stock were issued to each of TAS Partners LLC and Dr. Timothy A. Springer in the first tranche, (ii) 49,570.163 shares of Series A Preferred Stock were issued to Dr. Timothy A. Springer in the second tranche, and (iii) 49,570.163 shares of Series A Preferred Stock were issued to Dr. Timothy A. Springer in the third tranche. On November 15, 2023, the Company issued 619.627 shares of Series A Preferred Stock to Seven One Eight Three Four Irrevocable Trust for $0.25&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company determined the obligation to issue 148,710.488 shares of Series A Preferred Stock to Dr. Springer and TAS Partners LLC represented a forward contract and was accounted for as a liability with changes in fair value recorded in earnings. A portion of the liability was settled with the initial issuance of 49,570.162 shares of Series A Preferred Stock on December 13, 2023. The remaining portion of the forward contract liability was settled upon the issuance of 49,570.163 shares of Series A Preferred Stock each on January 12, 2024 and February 11, 2024, respectively (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 5, 2023, the Company issued 384,930.724 shares of Series A Preferred Stock as part of its consideration transferred in connection with the Merger which settled the related forward contract liability (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 26, 2024, the Company, with the consent of the requisite holders of Series A Preferred Stock, amended the Series A Certificate of Designation such that the automatic conversion of the Series A Preferred Stock into common stock, or the Automatic Conversion, would occur eight business days following stockholder approval of the Conversion Proposal. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2024, the Company&#x2019;s stockholders approved the Conversion Proposal, among other matters, at the Special Meeting.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 8, 2024, pursuant to the terms of the Series A Certificate of Designation, as amended, 367,919.247 shares of Series A Preferred Stock automatically converted into 12,263,951 shares of common stock, including the non-cash reclassification of an amount equal to the increase in par value of common stock from additional paid-in capital; 166,341.592 shares of Series A Preferred Stock did not automatically convert at such time due to beneficial ownership limitations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 11, 2024, pursuant to a Notice of Optional Conversion delivered to the Company by a holder of Series A Preferred Stock pursuant to the Series A Certificate of Designation, 45,551.190 shares of Series A Preferred Stock held by such holder were converted into 1,518,373 newly issued shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In accordance with the guidance in ASC Topic 480,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; Distinguishing Liabilities from Equity (ASC 480)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; the Series A Preferred Stock was classified outside of stockholders&#x2019; deficit upon issuance and as of December 31, 2023 because the shares of Series A Preferred Stock contained redemption features that were not solely within the control of the Company. The Series A Preferred Stock was not currently redeemable, nor was it probable that the instrument would become redeemable, as it was only redeemable upon the occurrence of a contingent event. Accordingly, no accretion was recognized for the Series A Preferred Stock. As a result of the approval of the Conversion Proposal, all conditions that could have required cash redemption of the Series A Preferred Stock were removed. Since the Series A Preferred Stock was no longer redeemable, the associated balances of the Series A Preferred Stock were reclassified to permanent equity during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series A Preferred Stock has the following rights and preferences:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Conversion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the stockholder approval of the Conversion Proposal, the Series A Preferred Shares were not convertible. Following the stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock automatically converted into 33.333 shares of common stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 0% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion; provided, however, that such beneficial ownership limitation does not apply to Dr. Springer, TAS Partners LLC, or any of their respective affiliates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Series A Preferred Stock outstanding that was not otherwise automatically converted into common stock as a result of the beneficial ownership limitation shall be convertible at any time at the option of the holder following stockholder approval of the Conversion Proposal, only to the extent the beneficial ownership limitation does not apply to the shares of Series A Preferred Stock to be converted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prior to the stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock was redeemable at the option of the holder at any time following the date that was 18 months after the initial issuance date of the Series A Preferred Stock, other than any shares of Series A Preferred Stock that would not have been convertible into shares of common stock as a result of the beneficial ownership limitation referred to above. The amount payable upon redemption would have been equal to the average closing sale price of the common stock listed over the ten consecutive trading days ending on, and including, the day immediately prior to the redemption date multiplied by the number of shares of common stock the Series A Preferred Stock would have been convertible into. Following the Conversion Proposal, the Series A Preferred Stock is not redeemable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock on an as-converted basis equal to the dividends paid on shares of the common stock; provided, however, that holders of Series A Preferred Stock (or any shares of common stock into which the Series A Preferred Stock are convertible) are not entitled to any CVRs or any amounts paid under the CVR Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Voting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then-outstanding shares of the Series A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (b) alter or amend the Series A Certificate of Designation, (c) amend the Charter or other organizational documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (d) issue further shares of Series A Preferred Stock (other than in connection with the exercise of the stock options to purchase Series A Preferred Stock) or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (e) prior to the stockholder approval of the Conversion Proposal or at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate either (A) a Fundamental Transaction (as defined in the Series A Certificate of Designation) or (B) any merger or consolidation of the Company or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority of the capital stock of the Company immediately after such transaction, (f) amend or fail to comply with, in any manner that would be reasonably likely to prevent, impede or materially delay the conversion (or the stockholder approval thereof), or terminate, any of the stockholder support agreements entered into in connection with the Merger, or the Support Agreements, or agree to any transfer, sale or disposition of such shares subject to the Support Agreements (except for such transfers, sales or dispositions with respect to which the approval of the Company is not required pursuant to the applicable Support Agreement) or (g) enter into any agreement with respect to any of the foregoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The holders of Series A Preferred Stock shall rank on parity with the common stockholders and the holders of Series B Preferred Stock as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary each holder of Series A Preferred Stock shall be entitled to receive out the assets of the Company equal to of the same amount that a holder of common stock would receive if the Series A Preferred Stock were fully converted, which shall be paid pari passu with holders of common stock and holders of Series B Preferred Stock, plus an amount equal to any dividends declared but unpaid. If the assets available for distribution are not sufficient to pay the holders of the Series A Preferred Stock pursuant to the preceding sentence, the assets will be distributed ratably to the holders of the Series A Preferred Stock, Series B Preferred Stock and common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, the Company had 120,790.402 shares of Series A Preferred Stock and 437,927 shares of Series B Preferred Stock issued and outstanding, respectively, which are convertible into a total of 4,464,273 shares of common stock.&lt;/span&gt;&lt;/div&gt;</rnac:TemporaryEquityDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-59"
      decimals="INF"
      id="f-793"
      unitRef="shares">2937903</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-57"
      decimals="INF"
      id="f-794"
      unitRef="shares">3563247</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-58"
      decimals="INF"
      id="f-795"
      unitRef="shares">2937903</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <rnac:SaleOfStockGrossConsiderationReceivedOnTransaction contextRef="c-61" decimals="-5" id="f-796" unitRef="usd">130000000.0</rnac:SaleOfStockGrossConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-59"
      decimals="INF"
      id="f-797"
      unitRef="shares">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-180"
      decimals="INF"
      id="f-798"
      unitRef="shares">3563247</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-181"
      decimals="INF"
      id="f-799"
      unitRef="shares">578403</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-182" decimals="-5" id="f-800" unitRef="usd">82800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-183"
      decimals="INF"
      id="f-801"
      unitRef="shares">1636832</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-184"
      decimals="INF"
      id="f-802"
      unitRef="shares">721361</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-185"
      decimals="INF"
      id="f-803"
      unitRef="shares">1307</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-186" decimals="-5" id="f-804" unitRef="usd">47200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-187"
      decimals="INF"
      id="f-805"
      unitRef="shares">-2499976</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-188"
      decimals="INF"
      id="f-806"
      unitRef="shares">2499976</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <rnac:ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert
      contextRef="c-187"
      decimals="INF"
      id="f-807"
      unitRef="shares">437927</rnac:ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="c-12"
      decimals="INF"
      id="f-808"
      unitRef="number">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <rnac:PreferredStockConvertibleBeneficialOwnershipPercentage contextRef="c-189" decimals="3" id="f-809" unitRef="number">0.000</rnac:PreferredStockConvertibleBeneficialOwnershipPercentage>
    <rnac:PreferredStockConvertibleBeneficialOwnershipPercentage contextRef="c-190" decimals="3" id="f-810" unitRef="number">0.199</rnac:PreferredStockConvertibleBeneficialOwnershipPercentage>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-54"
      decimals="INF"
      id="f-811"
      unitRef="shares">548375</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-56"
      decimals="INF"
      id="f-812"
      unitRef="shares">149330.115</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-56" decimals="-4" id="f-813" unitRef="usd">60250000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-191" decimals="-5" id="f-814" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-192" decimals="-5" id="f-815" unitRef="usd">20000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-193" decimals="-5" id="f-816" unitRef="usd">20000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <rnac:SaleOfStockSettlementTerm contextRef="c-191" id="f-817">P30D</rnac:SaleOfStockSettlementTerm>
    <rnac:SaleOfStockSettlementTerm contextRef="c-193" id="f-818">P60D</rnac:SaleOfStockSettlementTerm>
    <rnac:SaleOfStockSettlementTerm contextRef="c-192" id="f-819">P90D</rnac:SaleOfStockSettlementTerm>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-191" decimals="-5" id="f-820" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <rnac:SaleOfStockSettlementTerm contextRef="c-191" id="f-821">P30D</rnac:SaleOfStockSettlementTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-194"
      decimals="INF"
      id="f-822"
      unitRef="shares">24785.081</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-195"
      decimals="INF"
      id="f-823"
      unitRef="shares">49570.163</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-196"
      decimals="INF"
      id="f-824"
      unitRef="shares">49570.163</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-197"
      decimals="INF"
      id="f-825"
      unitRef="shares">619.627</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-197" decimals="-4" id="f-826" unitRef="usd">250000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <rnac:SettlementOfDerivativeLiabilityShares
      contextRef="c-54"
      decimals="INF"
      id="f-827"
      unitRef="shares">148710.488</rnac:SettlementOfDerivativeLiabilityShares>
    <rnac:SettlementOfDerivativeLiabilityShares
      contextRef="c-198"
      decimals="INF"
      id="f-828"
      unitRef="shares">49570.162</rnac:SettlementOfDerivativeLiabilityShares>
    <rnac:SettlementOfDerivativeLiabilityShares
      contextRef="c-199"
      decimals="INF"
      id="f-829"
      unitRef="shares">49570.163</rnac:SettlementOfDerivativeLiabilityShares>
    <rnac:SettlementOfDerivativeLiabilityShares
      contextRef="c-200"
      decimals="INF"
      id="f-830"
      unitRef="shares">49570.163</rnac:SettlementOfDerivativeLiabilityShares>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-133"
      decimals="INF"
      id="f-831"
      unitRef="shares">384930.724</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <rnac:NumberOfBusinessDays
      contextRef="c-201"
      decimals="INF"
      id="f-832"
      unitRef="business_day">8</rnac:NumberOfBusinessDays>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-202"
      decimals="INF"
      id="f-833"
      unitRef="shares">367919.247</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-203"
      decimals="INF"
      id="f-834"
      unitRef="shares">12263951</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <rnac:ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert
      contextRef="c-204"
      decimals="INF"
      id="f-835"
      unitRef="shares">166341.592</rnac:ConvertiblePreferredStockSharesThatDidNotAutomaticallyConvert>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-205"
      decimals="INF"
      id="f-836"
      unitRef="shares">45551.19</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-206"
      decimals="INF"
      id="f-837"
      unitRef="shares">1518373</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockConvertibleConversionRatio contextRef="c-8" decimals="INF" id="f-838" unitRef="number">33.333</us-gaap:PreferredStockConvertibleConversionRatio>
    <rnac:PreferredStockConvertibleBeneficialOwnershipPercentage contextRef="c-68" decimals="2" id="f-839" unitRef="number">0</rnac:PreferredStockConvertibleBeneficialOwnershipPercentage>
    <rnac:PreferredStockConvertibleBeneficialOwnershipPercentage contextRef="c-69" decimals="3" id="f-840" unitRef="number">0.199</rnac:PreferredStockConvertibleBeneficialOwnershipPercentage>
    <rnac:PreferredStockRedemptionTerm contextRef="c-1" id="f-841">P18M</rnac:PreferredStockRedemptionTerm>
    <rnac:PreferredStockConvertibleThresholdConsecutiveTradingDays contextRef="c-1" decimals="INF" id="f-842" unitRef="day">10</rnac:PreferredStockConvertibleThresholdConsecutiveTradingDays>
    <rnac:PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding contextRef="c-8" decimals="INF" id="f-843" unitRef="number">0.30</rnac:PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-844"
      unitRef="shares">120790.402</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-11"
      decimals="INF"
      id="f-845"
      unitRef="shares">120790.402</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-846"
      unitRef="shares">437927</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-12"
      decimals="INF"
      id="f-847"
      unitRef="shares">437927</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c-12"
      decimals="INF"
      id="f-848"
      unitRef="shares">4464273</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c-11"
      decimals="INF"
      id="f-849"
      unitRef="shares">4464273</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-850">Equity&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Financings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 2, 2024, the Company and the Purchasers entered into the 2024 Securities Purchase Agreement for the 2024 Private Placement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the 2024 Securities Purchase Agreement, the Purchasers agreed to purchase an aggregate of 3,563,247 shares of common stock and 2,937,903 shares of Series B Preferred Stock, inclusive of 2,359,500 shares of Series B Preferred Stock purchased by directors and executive officers of the Company, and related parties thereto, each at a price per share of $20.00. The 2024 Private Placement resulted in gross proceeds of approximately $130.0&#160;million before deducting placement agent fees and other offering expenses. See Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 5, 2023, the Company issued 224,099 shares of common stock as part of its consideration transferred in connection with the Merger which settled the related equity-classified forward contract (see Note 4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Underwritten Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 6, 2022, the Company entered into an underwriting agreement with SVB Securities LLC (now known as Leerink Partners LLC), as representative of the several underwriters named therein, relating to an underwritten offering of 914,285 shares of the Company&#x2019;s common stock and 2022 Warrants to purchase up to 685,712 shares of common stock, or the 2022 Offering. Each share and accompanying 2022 Warrant to purchase 0.75 shares of common stock was sold at a combined offering price of $42.30. The exercise price for the 2022 Warrants is $46.50 per share. The Company received net proceeds from the 2022 Offering of approximately $36.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company&#x2019;s common stock and also upon any distributions for no consideration of assets to the Company&#x2019;s stockholders. Each 2022 Warrant is exercisable at any time and from time to time after issuance. In the event of certain corporate transactions, the holders of the 2022 Warrants will be entitled to receive the kind and amount of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such transaction. Therefore, the Company is required to account for the 2022 Warrants as liabilities and record the 2022 Warrants at fair value. The 2022 Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which holders of common stock are entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;At-the-Market&#x201d; Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 13, 2024, the Company entered into a Sales Agreement, or the 2024 Sales Agreement, with Leerink Partners to sell shares of the Company&#x2019;s common stock, from time to time, through an &#x201c;at the market&#x201d; equity offering program under which Leerink Partners will act as sales agent. The shares of common stock sold pursuant to the 2024 Sales Agreement will be issued pursuant to the Company&#x2019;s shelf registration statement on Form S-3 (File No. 333-283803), filed on December 13, 2024 with the SEC and related prospectus supplement, filed on January 8, 2025 with the SEC, for aggregate gross sales proceeds of up to $100.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 25, 2021, the Company entered into a Sales Agreement, or the 2021 Sales Agreement, with Leerink Partners LLC (then known as SVB Leerink LLC), or Leerink Partners, pursuant to which the Company may sell shares of the Company&#x2019;s common stock, from time to time, through an &#x201c;at the market&#x201d; equity offering program under which Leerink Partners will act as sales agent. The shares of common stock sold pursuant to the 2021 Sales Agreement, if any, would be issued and sold pursuant to a registration statement to be filed by the Company with the SEC, for aggregate remaining gross sales proceeds of up to $51.0 million. During the years ended December 31, 2024 and 2023, the Company sold no shares of its common stock pursuant to the 2021 Sales Agreement. The 2024 Sales Agreement supersedes the 2021 Sales Agreement, which is no longer in effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 2020 Sobi Stock Purchase&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 11, 2020, the Company entered into a stock purchase agreement with Sobi, pursuant to which the Company sold an aggregate of 180,546 shares of its common stock at a purchase price equal to $138.4680 per share, which represented 120% of the 10-day volume-weighted average price of the Company&#x2019;s common stock prior to signing, for aggregate gross proceeds of $25.0&#160;million, or the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 815, this forward sale treatment qualified as equity classification as the shares are not within the scope of ASC 480. The gross proceeds of $25.0&#160;million were determined to include a premium to the fair value of the Company&#x2019;s shares as of July 28, 2020 of approximately $14.5&#160;million. As a result, such amount was included in the transaction price for revenue recognition of the Sobi License. See Note 14 for details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also on June 11, 2020, the Company entered into a registration rights agreement, as amended by that certain letter agreement, dated as of November 4, 2020, or the Sobi Registration Rights Agreement, with Sobi, pursuant to which the Company agreed to prepare and file a registration statement with respect to the resale of the shares of common stock acquired in the Sobi Private Placement. The Company will be required to file this resale registration statement within 30 days following receipt by the Company of a written request from Sobi to file such resale registration statement, and to have the registration statement declared effective within ten business days after the SEC informs the Company that no review of such resale registration statement will be made or that the SEC has no further comments on such resale registration statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2019 Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 18, 2019, the Company entered into a securities purchase agreement, or the 2019 Securities Purchase Agreement, with a group of institutional investors and certain members of the Board of Directors. Pursuant to the 2019 Securities Purchase Agreement, the Company sold an aggregate of 1,254,496 shares of its common stock at a purchase price of $43.80 per share, warrants to purchase an aggregate of 766,275 shares of common stock at a purchase price of $3.75 per share underlying each common warrant, and pre-funded warrants to purchase an aggregate of 278,070 shares of common stock at a purchase price of $43.80 per share, all with five year terms, or the 2019 Private Placement. The closing of the 2019 Private Placement occurred on December 23, 2019. The exercise price of the pre-funded warrants is $0.003 per share and the exercise price for the common warrants is $43.80 per share. In the event of a certain sale of the Company, the terms of the common warrants require us to make a payment to such common warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). This provision does not apply to the pre-funded warrants. Therefore, the Company is required to account for the common warrants as liabilities and record them at fair value, while the pre-funded warrants met the criteria to be classified as permanent equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the fair value of the 2019 Warrants of $40.7&#160;million upon issuance using the Black-Scholes valuation model. Issuance costs were allocated between the equity component with an offset to additional paid-in capital and the liability component recorded as expense on a relative fair value basis. Total net proceeds from the equity offering was $65.6 million, after deducting transaction costs and commissions of $4.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 6, the Company remeasured the Amended 2019 Warrants at the fair value of $0.8&#160;million on December 20, 2022 and reclassified this amount to additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding 2019 Warrants expired on December 23, 2024 in accordance with their terms. The remaining 2022 Warrants liability was revalued as of December 31, 2024 at $3.8 million. During the years ended December 31, 2024 and 2023, the Company recorded a decrease of $2.6 million and $12.7 million, respectively, in the fair value of the warrants in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of warrant activity for the years ended December 31, 2024 and 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;&#160;classified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability classified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;966,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;503.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;966,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(280,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(282,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;685,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, the Company had 350,000,000 shares of common stock authorized for issuance, $0.0001 par value per share, with 25,767,369 shares issued and outstanding. The voting, dividend and liquidation rights of the common stockholders are subject to and qualified by the rights, powers and preferences of the preferred stock. The common stock has the following characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Voting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stockholders are entitled to one vote for each share of common stock held with respect to all matters voted on by the stockholders of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stockholders are entitled to receive dividends, if and when declared by the Board of Directors. Through December 31, 2024, no cash dividends have been declared or paid on common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon liquidation of the Company, common stockholders are entitled to receive all assets of the Company available for distribution to such stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reserved Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has authorized shares of common stock for future issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares available for future stock incentive awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,205,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,706,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,026,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,512,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-57"
      decimals="INF"
      id="f-851"
      unitRef="shares">3563247</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-58"
      decimals="INF"
      id="f-852"
      unitRef="shares">2937903</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-207"
      decimals="INF"
      id="f-853"
      unitRef="shares">2359500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-60"
      decimals="INF"
      id="f-854"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <rnac:SaleOfStockGrossConsiderationReceivedOnTransaction contextRef="c-61" decimals="-5" id="f-855" unitRef="usd">130000000</rnac:SaleOfStockGrossConsiderationReceivedOnTransaction>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-208"
      decimals="INF"
      id="f-856"
      unitRef="shares">224099</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-209"
      decimals="INF"
      id="f-857"
      unitRef="shares">914285</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-210"
      decimals="INF"
      id="f-858"
      unitRef="shares">685712</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c-210" decimals="2" id="f-859" unitRef="shares">0.75</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-210"
      decimals="2"
      id="f-860"
      unitRef="usdPerShare">42.30</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-210"
      decimals="2"
      id="f-861"
      unitRef="usdPerShare">46.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-209" decimals="-5" id="f-862" unitRef="usd">36900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <rnac:SaleOfStockAggregateMaximumGrossSalesProceeds contextRef="c-211" decimals="-5" id="f-863" unitRef="usd">100000000</rnac:SaleOfStockAggregateMaximumGrossSalesProceeds>
    <rnac:SaleOfStockAggregateMaximumGrossSalesProceeds contextRef="c-212" decimals="-5" id="f-864" unitRef="usd">51000000.0</rnac:SaleOfStockAggregateMaximumGrossSalesProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-213"
      decimals="INF"
      id="f-865"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-214"
      decimals="INF"
      id="f-866"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-215"
      decimals="INF"
      id="f-867"
      unitRef="shares">180546</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-216"
      decimals="4"
      id="f-868"
      unitRef="usdPerShare">138.4680</us-gaap:SaleOfStockPricePerShare>
    <rnac:SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock
      contextRef="c-215"
      decimals="INF"
      id="f-869"
      unitRef="number">1.20</rnac:SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-215" decimals="-5" id="f-870" unitRef="usd">25000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-215" decimals="-5" id="f-871" unitRef="usd">25000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RedemptionPremium contextRef="c-217" decimals="-5" id="f-872" unitRef="usd">14500000</us-gaap:RedemptionPremium>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-218"
      decimals="INF"
      id="f-873"
      unitRef="shares">1254496</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-219"
      decimals="2"
      id="f-874"
      unitRef="usdPerShare">43.80</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-219"
      decimals="INF"
      id="f-875"
      unitRef="shares">766275</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-220"
      decimals="2"
      id="f-876"
      unitRef="usdPerShare">3.75</us-gaap:SaleOfStockPricePerShare>
    <rnac:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="c-221"
      decimals="INF"
      id="f-877"
      unitRef="shares">278070</rnac:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-220"
      decimals="2"
      id="f-878"
      unitRef="usdPerShare">43.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-220" id="f-879">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-222"
      decimals="3"
      id="f-880"
      unitRef="usdPerShare">0.003</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-220"
      decimals="2"
      id="f-881"
      unitRef="usdPerShare">43.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rnac:WarrantIssued contextRef="c-218" decimals="-5" id="f-882" unitRef="usd">40700000</rnac:WarrantIssued>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-218" decimals="-5" id="f-883" unitRef="usd">65600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-218" decimals="-5" id="f-884" unitRef="usd">4400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <rnac:WarrantIssued contextRef="c-223" decimals="-5" id="f-885" unitRef="usd">800000</rnac:WarrantIssued>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-224" decimals="-5" id="f-886" unitRef="usd">3800000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 contextRef="c-225" decimals="-5" id="f-887" unitRef="usd">-2600000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 contextRef="c-226" decimals="-5" id="f-888" unitRef="usd">-12700000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-889">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of warrant activity for the years ended December 31, 2024 and 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;&#160;classified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability classified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;966,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;503.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;966,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(280,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(282,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;685,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-227" decimals="0" id="f-890" unitRef="shares">74539</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-228" decimals="0" id="f-891" unitRef="shares">966393</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-15" decimals="0" id="f-892" unitRef="shares">1040932</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-15"
      decimals="2"
      id="f-893"
      unitRef="usdPerShare">46.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rnac:StockIssuedDuringPeriodSharesWarrantsCanceled contextRef="c-229" decimals="0" id="f-894" unitRef="shares">119</rnac:StockIssuedDuringPeriodSharesWarrantsCanceled>
    <rnac:StockIssuedDuringPeriodSharesWarrantsCanceled contextRef="c-230" decimals="0" id="f-895" unitRef="shares">0</rnac:StockIssuedDuringPeriodSharesWarrantsCanceled>
    <rnac:StockIssuedDuringPeriodSharesWarrantsCanceled contextRef="c-14" decimals="0" id="f-896" unitRef="shares">119</rnac:StockIssuedDuringPeriodSharesWarrantsCanceled>
    <rnac:StockIssuedDuringWarrantedCanceledPricePerShare
      contextRef="c-14"
      decimals="2"
      id="f-897"
      unitRef="usdPerShare">503.10</rnac:StockIssuedDuringWarrantedCanceledPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-231" decimals="0" id="f-898" unitRef="shares">74420</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-119" decimals="0" id="f-899" unitRef="shares">966393</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-9" decimals="0" id="f-900" unitRef="shares">1040813</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-9"
      decimals="2"
      id="f-901"
      unitRef="usdPerShare">45.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rnac:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="c-232" decimals="0" id="f-902" unitRef="shares">65681</rnac:StockIssuedDuringPeriodSharesWarrantsExercised>
    <rnac:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="c-120" decimals="0" id="f-903" unitRef="shares">0</rnac:StockIssuedDuringPeriodSharesWarrantsExercised>
    <rnac:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="c-1" decimals="0" id="f-904" unitRef="shares">65681</rnac:StockIssuedDuringPeriodSharesWarrantsExercised>
    <rnac:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises
      contextRef="c-1"
      decimals="2"
      id="f-905"
      unitRef="usdPerShare">43.80</rnac:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises>
    <rnac:StockIssuedDuringPeriodSharesWarrantsCanceled contextRef="c-232" decimals="0" id="f-906" unitRef="shares">1928</rnac:StockIssuedDuringPeriodSharesWarrantsCanceled>
    <rnac:StockIssuedDuringPeriodSharesWarrantsCanceled contextRef="c-120" decimals="0" id="f-907" unitRef="shares">280681</rnac:StockIssuedDuringPeriodSharesWarrantsCanceled>
    <rnac:StockIssuedDuringPeriodSharesWarrantsCanceled contextRef="c-1" decimals="0" id="f-908" unitRef="shares">282609</rnac:StockIssuedDuringPeriodSharesWarrantsCanceled>
    <rnac:StockIssuedDuringWarrantedCanceledPricePerShare
      contextRef="c-1"
      decimals="2"
      id="f-909"
      unitRef="usdPerShare">44.09</rnac:StockIssuedDuringWarrantedCanceledPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-233" decimals="0" id="f-910" unitRef="shares">6811</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-121" decimals="0" id="f-911" unitRef="shares">685712</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-8" decimals="0" id="f-912" unitRef="shares">692523</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-8"
      decimals="2"
      id="f-913"
      unitRef="usdPerShare">46.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-914" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-915"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="INF" id="f-916" unitRef="shares">25767369</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-917" unitRef="shares">25767369</us-gaap:CommonStockSharesOutstanding>
    <rnac:CommonStockVotingRightsNumberOfVotes contextRef="c-8" decimals="INF" id="f-918" unitRef="vote">1</rnac:CommonStockVotingRightsNumberOfVotes>
    <us-gaap:DividendsCommonStock contextRef="c-1" decimals="INF" id="f-919" unitRef="usd">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-920">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has authorized shares of common stock for future issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares available for future stock incentive awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,205,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,706,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,026,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,512,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-233"
      decimals="INF"
      id="f-921"
      unitRef="shares">692523</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-234"
      decimals="INF"
      id="f-922"
      unitRef="shares">4205199</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-235"
      decimals="INF"
      id="f-923"
      unitRef="shares">444238</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-236"
      decimals="INF"
      id="f-924"
      unitRef="shares">1706035</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-237"
      decimals="INF"
      id="f-925"
      unitRef="shares">4026346</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-238"
      decimals="INF"
      id="f-926"
      unitRef="shares">437927</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-8" decimals="INF" id="f-927" unitRef="shares">11512268</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-928">Stock Incentive Plans&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintained the 2008 Stock Incentive Plan, or the 2008 Plan, for employees, consultants, advisors, and directors. The 2008 Plan provided for the granting of incentive and non-qualified stock option and restricted stock awards as determined by the Board of Directors. In connection with the Merger, all outstanding awards issued under the 2008 Plan were cancelled, and the Board of Directors formally terminated the 2008 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company&#x2019;s stockholders approved the 2016 Incentive Award Plan, or the 2016 Plan, which authorized 40,341 shares of common stock for future issuance under the 2016 Plan and the Company ceased granting awards under the 2008 Plan. Upon the effective date of the 2016 Plan, awards issued under the 2008 Plan remained subject to the terms of the 2008 Plan. Awards granted under the 2008 Plan that expired, lapsed or terminated became available under the 2016 Plan as shares available for future grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, pursuant to the terms of the 2016 Plan, the Board of Directors is authorized to grant awards with respect to common stock, and may delegate to a committee of one or more members of the Board of Directors or executive officers of the Company the authority to grant options and restricted stock units. On December 9, 2020, the Board of Directors established a Stock Option Committee authorized to grant awards to certain employees and consultants subject to conditions and limitations within the 2016 Plan. In January 2024 and 2023, the number of shares of common stock that may be issued under the 2016 Plan was increased by 215,903 and 204,056 shares, respectively. In June 2024, the Company&#x2019;s stockholders approved an amendment and restatement of the 2016 Plan to reserve an additional 3,466,544 shares of the Company&#x2019;s common stock for issuance. As of December 31, 2024, 3,520,174 shares remain available for future issuance under the 2016 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company&#x2019;s 2018 Employment Inducement Incentive Award Plan, or the 2018 Inducement Incentive Award Plan was adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules, which authorized 39,166 shares of its common stock for issuance. In March 2019, the Board of Directors approved an amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional 66,667 shares of the Company&#x2019;s common stock for issuance thereunder. In December 2023, the Board of Directors approved an amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional 60,833 shares of the Company&#x2019;s common stock for issuance thereunder. In June and December 2024, the Board of Directors approved amendments and restatements of the 2018 Inducement Incentive Award Plan to reserve an additional 360,000 and 450,000 shares, respectively, of the Company&#x2019;s common stock for issuance thereunder. As of December 31, 2024, there are 611,960 shares available for future grant under the 2018 Inducement Incentive Award Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Merger Agreement, the Company assumed Old Cartesian&#x2019;s 2016 Stock Incentive Plan, or the Old Cartesian Plan. The Old Cartesian Plan permits the granting of options or restricted stock to employees, officers, directors, consultants and advisors to the Company. The unvested common stock options and Series A Preferred Stock options assumed by the Company in connection with the Merger generally vest over a four-year period. Additionally, the stock options granted have a contractual term of ten years and only full shares can be exercised as per the individual award agreements. As of December 31, 2024, there are 27,270 shares available for future grant under the Old Cartesian Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger, the outstanding stock options to purchase Old Cartesian common stock were converted into stock options to purchase 776,865 shares of common stock and 14,112.299 shares of Series A Preferred Stock of the Company. These replacement awards were revalued at their acquisition-date fair value and then attributed to pre and post-combination service. This resulted in $2.6&#160;million attributed to post-combination service to be recognized as stock-based compensation expense over the remaining terms of the replacement awards, of which $1.3 million and $0.2 million was recognized as research and development expense in the consolidated statements of operations and comprehensive loss during the years ended December 31, 2024 and 2023, respectively. Following the Automatic Conversion, the options exercisable for shares of Series A Preferred Stock became exercisable for shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Settlement of Equity Compensation Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon consummation of the First Merger, the equity compensation awards of the Company outstanding as of the date of the Merger were settled as follows: (i) each unvested option to acquire shares of common stock and each unvested restricted stock unit award with respect to shares of common stock was accelerated and vested in full at the effective time of the First Merger; (ii) each option to acquire shares of common stock was canceled and in exchange therefore, former holders became entitled to receive an amount in cash equal to the product of (A) the total number of shares of common stock subject to the unexercised portion the stock option (determined after giving effect to the accelerated vesting) multiplied by (B) the excess, if any, of $61.80, or the Cash-out Amount, over the applicable exercise price per share of common stock under such stock option; and (iii) each restricted stock unit award with respect to shares of common stock was cancelled and the former holder of such canceled restricted stock unit became entitled, in exchange therefor, to receive an amount in cash equal to the product of (A) the total number of shares of common stock deliverable under such restricted stock unit (determined after giving effect to the accelerated vesting) multiplied by (B) the Cash-out Amount. Stock options with an exercise price in excess of the Cash-out Amount received no cash payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The modification to accelerate the vesting of all awards upon the Merger resulted in full recognition of unrecognized compensation of $13.1&#160;million, of which $5.9&#160;million and $7.2&#160;million was classified as research and development expense and general and administrative expense, respectively, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. In addition, with the exception of any options with an exercise price greater than $61.80 per share, all awards were settled in cash for an amount equal to $61.80 less any exercise price associated with the awards. The total cash payment made to the holders of stock options and restricted stock units was $9.4&#160;million. The fair value of the awards prior to the settlement was recorded to additional paid-in capital in an amount of $6.2&#160;million and the amount in excess of fair value was recognized as additional stock-based compensation expense in an amount of $3.2&#160;million, of which $1.5&#160;million and $1.7&#160;million was classified as research and development expense and general and administrative expense, respectively, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss, including $1.5&#160;million recognized as stock-based compensation expense upon the achievement of a technical milestone by Ginkgo Bioworks Holdings, Inc., or Ginkgo, during the year ended December 31, 2023 as described in Note 16, was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.914%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options assumed in connection with the Merger was calculated using a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Black-Scholes option pricing model based on the following &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of common stock or Series A Preferred Stock, as applicable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated grant date fair values of stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model based on the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.315%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term of the Company&#x2019;s stock options granted has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. Under the simplified method, the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data and the plain nature of its stock-based awards. Expected volatilities are based on the Company&#x2019;s historical volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $15.63 and $26.90, respectively. The total intrinsic value of stock options exercised during the year ended December 31, 2024 was $7.0 million. No stock options were exercised during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, total unrecognized compensation expense related to unvested common stock options was $10.3 million, which is expected to be recognized over a weighted average period of 2.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity under the 2016 Plan, the 2018 Inducement Incentive Award Plan, and the Old Cartesian Plan for options for common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;contractual&#160;term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;intrinsic&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;776,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Converted from options for Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;470,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(458,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,706,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;656,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,564,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity under the Old Cartesian Plan for options for Series A Preferred Stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Series A &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;contractual&#160;term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;intrinsic&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,112.299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Converted to options for common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,112.299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the approval of the Conversion Proposal on March 27, 2024, all conditions that could have required cash redemption of the Series A Preferred Stock underlying the stock options were removed. Since the Series A Preferred Stock was no longer redeemable, the associated balances of the stock options to purchase Series A Preferred Stock were reclassified to additional paid-in capital during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the Automatic Conversion, all options to purchase Series A Preferred Stock were converted into options to purchase common stock with adjustments to the underlying number of shares of common stock determined by multiplying the number of shares of Series A Preferred Stock by 33.333 and rounding down to the nearest whole number of shares and the per-share exercise price by dividing the per-share exercise price of Series A Preferred Stock by 33.333 and rounding the resulting exercise price up to the nearest whole cent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2024, the Company granted 477,037 restricted stock unit awards with a weighted average fair value of $19.86 per share based on the closing price of the Company&#x2019;s common stock on the date of grant under the 2016 Plan and the Old Cartesian Plan, which generally vest over a four-year term. Forfeitures are estimated at the time of grant and are adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has estimated a forfeiture rate of 10% for restricted stock unit awards based on historical experience. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No restricted stock unit awards vested during the year ended December 31, 2024. The aggregate fair value of restricted stock unit awards that vested during the year ended December 31, 2023 was $0.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to the restricted stock unit awards was $5.4 million as of December 31, 2024, which is expected to be recognized over a weighted-average period of 2.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted stock units under the 2016 Plan and the Old Cartesian Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;br/&gt;grant date&lt;br/&gt;fair value ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-239"
      decimals="INF"
      id="f-929"
      unitRef="shares">40341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease
      contextRef="c-240"
      decimals="INF"
      id="f-930"
      unitRef="shares">215903</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease
      contextRef="c-241"
      decimals="INF"
      id="f-931"
      unitRef="shares">204056</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease
      contextRef="c-242"
      decimals="INF"
      id="f-932"
      unitRef="shares">3466544</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-243"
      decimals="INF"
      id="f-933"
      unitRef="shares">3520174</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-244"
      decimals="INF"
      id="f-934"
      unitRef="shares">39166</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-245"
      decimals="INF"
      id="f-935"
      unitRef="shares">66667</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-246"
      decimals="INF"
      id="f-936"
      unitRef="shares">60833</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-247"
      decimals="INF"
      id="f-937"
      unitRef="shares">360000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-248"
      decimals="INF"
      id="f-938"
      unitRef="shares">450000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-248"
      decimals="INF"
      id="f-939"
      unitRef="shares">611960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-249" id="f-940">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-249" id="f-941">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-250"
      decimals="INF"
      id="f-942"
      unitRef="shares">27270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-251"
      decimals="INF"
      id="f-943"
      unitRef="shares">776865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-252"
      decimals="INF"
      id="f-944"
      unitRef="shares">14112.299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-253" decimals="-5" id="f-945" unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-249" decimals="-5" id="f-946" unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-254" decimals="-5" id="f-947" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount
      contextRef="c-54"
      decimals="2"
      id="f-948"
      unitRef="usdPerShare">61.80</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="c-255" decimals="-5" id="f-949" unitRef="usd">13100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="c-256" decimals="-5" id="f-950" unitRef="usd">5900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="c-257" decimals="-5" id="f-951" unitRef="usd">7200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount
      contextRef="c-54"
      decimals="2"
      id="f-952"
      unitRef="usdPerShare">61.80</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount
      contextRef="c-54"
      decimals="2"
      id="f-953"
      unitRef="usdPerShare">61.80</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards contextRef="c-255" decimals="-5" id="f-954" unitRef="usd">9400000</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards>
    <rnac:AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards contextRef="c-14" decimals="-5" id="f-955" unitRef="usd">6200000</rnac:AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement contextRef="c-14" decimals="-5" id="f-956" unitRef="usd">3200000</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement contextRef="c-258" decimals="-5" id="f-957" unitRef="usd">1500000</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement contextRef="c-259" decimals="-5" id="f-958" unitRef="usd">1700000</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-959">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss, including $1.5&#160;million recognized as stock-based compensation expense upon the achievement of a technical milestone by Ginkgo Bioworks Holdings, Inc., or Ginkgo, during the year ended December 31, 2023 as described in Note 16, was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.914%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-260" decimals="-5" id="f-960" unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-261" decimals="-3" id="f-961" unitRef="usd">3217000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-258" decimals="-3" id="f-962" unitRef="usd">12985000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-262" decimals="-3" id="f-963" unitRef="usd">3365000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-259" decimals="-3" id="f-964" unitRef="usd">12793000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-965" unitRef="usd">6582000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-14" decimals="-3" id="f-966" unitRef="usd">25778000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-967">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options assumed in connection with the Merger was calculated using a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Black-Scholes option pricing model based on the following &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of common stock or Series A Preferred Stock, as applicable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated grant date fair values of stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model based on the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.315%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-263" decimals="4" id="f-968" unitRef="number">0.0483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-264" decimals="4" id="f-969" unitRef="number">0.0492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-263"
      decimals="INF"
      id="f-970"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-264"
      decimals="INF"
      id="f-971"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-263" id="f-972">P3Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-264" id="f-973">P3Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-263" decimals="4" id="f-974" unitRef="number">0.8377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-264" decimals="4" id="f-975" unitRef="number">0.8387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue
      contextRef="c-263"
      decimals="2"
      id="f-976"
      unitRef="usdPerShare">12.00</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue
      contextRef="c-264"
      decimals="2"
      id="f-977"
      unitRef="usdPerShare">403.47</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-265" decimals="4" id="f-978" unitRef="number">0.0402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-266" decimals="4" id="f-979" unitRef="number">0.0395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-265"
      decimals="INF"
      id="f-980"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-266"
      decimals="INF"
      id="f-981"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-265" id="f-982">P6Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-266" id="f-983">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-265" decimals="4" id="f-984" unitRef="number">0.9521</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-266" decimals="4" id="f-985" unitRef="number">0.9464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue
      contextRef="c-265"
      decimals="2"
      id="f-986"
      unitRef="usdPerShare">19.63</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue
      contextRef="c-266"
      decimals="2"
      id="f-987"
      unitRef="usdPerShare">34.54</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-988"
      unitRef="usdPerShare">15.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-14"
      decimals="2"
      id="f-989"
      unitRef="usdPerShare">26.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-990" unitRef="usd">7000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-14"
      decimals="INF"
      id="f-991"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-267" decimals="-5" id="f-992" unitRef="usd">10300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-268" id="f-993">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-994">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity under the 2016 Plan, the 2018 Inducement Incentive Award Plan, and the Old Cartesian Plan for options for common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;contractual&#160;term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;intrinsic&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;776,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Converted from options for Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;470,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(458,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,706,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;656,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,564,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity under the Old Cartesian Plan for options for Series A Preferred Stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Series A &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;contractual&#160;term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;intrinsic&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,112.299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Converted to options for common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,112.299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-269"
      decimals="INF"
      id="f-995"
      unitRef="shares">776865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-269"
      decimals="2"
      id="f-996"
      unitRef="usdPerShare">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-270" id="f-997">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-269" decimals="-3" id="f-998" unitRef="usd">13760000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-271"
      decimals="INF"
      id="f-999"
      unitRef="shares">1000092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-271"
      decimals="2"
      id="f-1000"
      unitRef="usdPerShare">19.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod
      contextRef="c-271"
      decimals="INF"
      id="f-1001"
      unitRef="shares">470403</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod>
    <rnac:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice
      contextRef="c-271"
      decimals="2"
      id="f-1002"
      unitRef="usdPerShare">2.40</rnac:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-271"
      decimals="INF"
      id="f-1003"
      unitRef="shares">458544</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-271"
      decimals="2"
      id="f-1004"
      unitRef="usdPerShare">2.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-271"
      decimals="INF"
      id="f-1005"
      unitRef="shares">82781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-271"
      decimals="2"
      id="f-1006"
      unitRef="usdPerShare">17.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-272"
      decimals="INF"
      id="f-1007"
      unitRef="shares">1706035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-272"
      decimals="2"
      id="f-1008"
      unitRef="usdPerShare">11.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-271" id="f-1009">P7Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-272" decimals="-3" id="f-1010" unitRef="usd">12025000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c-271"
      decimals="INF"
      id="f-1011"
      unitRef="shares">656258</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <rnac:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
      contextRef="c-271"
      decimals="2"
      id="f-1012"
      unitRef="usdPerShare">3.22</rnac:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice>
    <rnac:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm contextRef="c-271" id="f-1013">P5Y4M9D</rnac:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm>
    <rnac:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue contextRef="c-272" decimals="-3" id="f-1014" unitRef="usd">9674000</rnac:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-272"
      decimals="INF"
      id="f-1015"
      unitRef="shares">1564044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-272"
      decimals="2"
      id="f-1016"
      unitRef="usdPerShare">11.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-271" id="f-1017">P7Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-272" decimals="-3" id="f-1018" unitRef="usd">11961000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-273"
      decimals="INF"
      id="f-1019"
      unitRef="shares">14112.299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-273"
      decimals="2"
      id="f-1020"
      unitRef="usdPerShare">79.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-254" id="f-1021">P5Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-273" decimals="-3" id="f-1022" unitRef="usd">8601000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock
      contextRef="c-249"
      decimals="INF"
      id="f-1023"
      unitRef="shares">14112.299</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedToOptionsForCommonStock>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock
      contextRef="c-249"
      decimals="2"
      id="f-1024"
      unitRef="usdPerShare">79.94</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceConvertedToOptionsForCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-250"
      decimals="INF"
      id="f-1025"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-250"
      decimals="2"
      id="f-1026"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-249" id="f-1027" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-250" id="f-1028" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="c-274"
      decimals="3"
      id="f-1029"
      unitRef="number">33.333</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="c-274"
      decimals="3"
      id="f-1030"
      unitRef="number">33.333</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-275"
      decimals="INF"
      id="f-1031"
      unitRef="shares">477037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-275"
      decimals="2"
      id="f-1032"
      unitRef="usdPerShare">19.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-275" id="f-1033">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate
      contextRef="c-275"
      decimals="2"
      id="f-1034"
      unitRef="number">0.10</rnac:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-275"
      decimals="INF"
      id="f-1035"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-276" decimals="-5" id="f-1036" unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-277" decimals="-5" id="f-1037" unitRef="usd">5400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-275" id="f-1038">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-1039">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted stock units under the 2016 Plan and the Old Cartesian Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;br/&gt;grant date&lt;br/&gt;fair value ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-278"
      decimals="INF"
      id="f-1040"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-278"
      decimals="2"
      id="f-1041"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-275"
      decimals="INF"
      id="f-1042"
      unitRef="shares">477037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-275"
      decimals="2"
      id="f-1043"
      unitRef="usdPerShare">19.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-275"
      decimals="INF"
      id="f-1044"
      unitRef="shares">32799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-275"
      decimals="2"
      id="f-1045"
      unitRef="usdPerShare">19.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-277"
      decimals="INF"
      id="f-1046"
      unitRef="shares">444238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-277"
      decimals="2"
      id="f-1047"
      unitRef="usdPerShare">19.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-1048">Revenue Arrangements&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration and license revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Astellas Gene Therapies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2023, the Company entered into the License and Development Agreement, or the Astellas Agreement, with Audentes Therapeutics, Inc., or Astellas. Under the Astellas Agreement, the Company granted Astellas an exclusive license to the Company&#x2019;s IdeXork technology arising from Xork, to develop and commercialize Xork for use in Pompe disease in combination with an Astellas gene therapy investigational or authorized product. Xork, Genovis&#x2019; IgG Protease, was licensed pursuant to an Exclusive License Agreement, or the Genovis Agreement, with Genovis AB (publ.), or Genovis, as described in Note 16 to these consolidated financial statements. Astellas paid a $10.0&#160;million upfront payment to the Company upon signing of the Astellas Agreement, and the Company was entitled to receive up to $340.0&#160;million in future additional payments over the course of the partnership that were contingent on the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales where Xork is used as a pre-treatment for an Astellas investigational or authorized product. The Company was also eligible for tiered royalty payments ranging from low to high single digits. Any proceeds received from milestone payments or royalties relating to Xork would have been required to be distributed to holders of CVRs, net of certain deductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Astellas Agreement, the Company would have had the exclusive right and responsibility to complete research and development of Xork products and to conduct all preclinical studies and clinical trials for Xork for use in Pompe disease with an Astellas gene therapy investigational or authorized product, or the Xork Development Services. Astellas reimbursed the Company for 25% of all budgeted costs incurred to complete the development of Xork for use in Pompe disease with an Astellas gene therapy investigational or authorized product. The Company would have had control and responsibility over regulatory filings, including any investigational drug applications, biologics license applications, and marketing authorization applications relating to the licensed product. Astellas would have had the exclusive right and responsibility to research, develop, and commercialize Astellas products used in combination with Xork and would have had control and responsibility over all regulatory filings, including any investigational drug applications, biologics license applications, and marketing authorization applications, relating to Astellas products and Astellas products used in combination with Xork.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the Astellas Agreement represented a service arrangement under the scope of ASC 606. The Company determined that the sublicense of Xork to Astellas, the licensed know-how, and the Xork Development Services represented a single promise and performance obligation to be transferred to Astellas over time due to the nature of the promises in the contract. As such, the Company recognized the transaction price as revenue utilizing the input method to measure the progress of satisfying the single performance obligation to Astellas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company concluded the upfront payment of $10.0&#160;million and development cost reimbursements of $5.5&#160;million would be included in the initial transaction price. All other development milestones would be fully constrained and would only have been included in the transaction price when the applicable milestone was deemed probable of achievement. Each of these variable consideration items were evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should have been constrained until &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;they became probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt and timing of such development milestones was outside the control of the Company and probability of success criteria was estimated. The Company re-evaluated the transaction price in each reporting period, as uncertain events were resolved, or as other changes in circumstances occurred. In accordance with ASC 606, the Company would have only recognized revenue associated with sales-based milestones and royalties when the subsequent sales thresholds were reached and underlying sales occurred, respectively. The Company determined that a significant financing component did not exist in its arrangement with Astellas. The Company also determined the options to negotiate additional fields, enter into a clinical supply agreement, and enter into a commercial supply agreement did not represent material rights under the Astellas Agreement. Astellas had the right to terminate the Astellas Agreement in its entirety or on a field-by-field basis, upon 90 days&#x2019; written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the Company was notified by Astellas of its intention to terminate the Astellas Agreement, which occurred effective June 6, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, there were no unsatisfied performance obligations related to the Astellas Agreement. As of December&#160;31, 2023, the Company recorded $2.3 million as a short-term contract liability and $3.5 million as a long-term contract liability, representing deferred revenue associated with the Astellas Agreement. As of December 31, 2024 and 2023, the Company recorded a receivable of $0.1 million and $0.3 million, respectively, representing billings for the Xork Development Services that were subject to reimbursement by Astellas. Revenue of $6.3&#160;million related to the Astellas Agreement was recognized during the year ended December 31, 2024, inclusive of $3.2&#160;million of revenue recognized from performance obligations related to prior periods as a result of the change in transaction price during the year ended December 31, 2024. Revenue of $5.5&#160;million related to the Astellas Agreement was recognized during the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Takeda Pharmaceuticals USA, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License and Development Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 1, 2021, the Company entered into a License Agreement, or the Takeda Agreement, with Takeda Pharmaceuticals USA, Inc., or Takeda. Under the Takeda Agreement, the Company granted Takeda an exclusive license to the Company&#x2019;s ImmTOR technology initially for two specified disease indications within the field of lysosomal storage disorders. Takeda paid a $3.0&#160;million upfront payment to the Company upon signing of the Takeda Agreement, and the Company was entitled to receive up to $1.124&#160;billion in future additional payments over the course of the partnership that were contingent on the achievement of development or commercial milestones or Takeda&#x2019;s election to continue its activities at specified development stages. The Company was also eligible for tiered royalties on future commercial sales of any licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Takeda Agreement, the Company determined the Takeda Agreement represented a service arrangement under the scope of ASC 606, and given the reversion of the rights under the Takeda Agreement represented a penalty in substance for a termination by Takeda, the contract term would remain the stated term of the Takeda Agreement. The Company determined that the research license, the licensed know-how, and the manufactured supply and delivery of materials represented a single promise and performance obligation to be transferred to Takeda over time due to the nature of the promises in the contract. The delivery of the manufactured supply was the predominant promise within the arrangement, as it was essential to the utility of the licensed intellectual property. The material supplied by the Company to Takeda was unique to the Company and cannot be obtained by other vendors. As such, consideration in the initial transaction price was allocated to the single performance obligation and the recognition period would not extend beyond the initial contractual period. The Company recognized the revenue associated with the upfront payment and combined single performance obligation utilizing the output method over the term that manufactured supply was delivered to Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company concluded the payment associated with all the performance milestones was fully constrained and only included in the transaction price when the respective milestone was deemed probable of achievement. Each of these variable consideration items were evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt and timing of such study milestones is outside the control of the Company and probability of success criteria is estimated. The Company re-evaluated the transaction price in each reporting period, as uncertain events were resolved, or as other changes in circumstances occurred. Takeda had the right to exercise covenant release rights on a field-by-field basis. If Takeda exercised its covenant release rights, the Company could have received exercise payments per indication and would have been entitled to significant development and commercial milestone payments and tiered royalties on commercial sales. The Company determined that a significant financing component did not exist in its arrangement with Takeda. The Company also determined the options to negotiate additional fields, pursue other products, enter into a supply agreement explore additional fields, and pursue additional development under the initial fields did not represent material rights under the agreement. Takeda had the right to terminate the Takeda Agreement in its entirety or on a field-by-field basis, upon 90 days&#x2019; written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2023, the Company was notified by Takeda of the achievement of the milestone event related to the completion of a non-clinical milestone for one of the specified disease indications within the field of lysosomal storage &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;disorders under the Takeda Agreement. Accordingly, the Company received a milestone payment of $0.5&#160;million during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Takeda Agreement was terminated effective July 25, 2023, following Takeda&#x2019;s decision to discontinue discovery and preclinical activities in adeno-associated virus, or AAV, gene therapy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024 and 2023, there were no unsatisfied performance obligations related to the Takeda Agreement. No revenue and revenue of $0.6 million related to the Takeda Agreement was recognized during the years ended December 31, 2024 and 2023, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Swedish Orphan Biovitrum AB (publ.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License and Development Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 11, 2020, the Company and Sobi entered into a License and Development Agreement. Pursuant to the Sobi License, the Company agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize the SEL-212 drug candidate, which is currently in development for the treatment of chronic refractory gout. The SEL-212 drug candidate is a pharmaceutical composition containing a combination of SEL-037, or the Compound, and ImmTOR. Pursuant to the Sobi License, in consideration of the license, Sobi agreed to pay the Company a one-time, upfront payment of $75.0&#160;million. Sobi has also agreed to make milestone payments totaling up to $630.0&#160;million to the Company upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier. Any proceeds received from milestone payments or royalties relating to the Sobi License would be required to be distributed to holders of CVRs, net of certain deductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Sobi License, the Company agreed to supply (at cost) quantities of the Compound and ImmTOR as necessary for completion of the two Phase 3 clinical trials of SEL-212 (DISSOLVE I and DISSOLVE II) and a six-month placebo extension. The Company was required to supply quantities of the Compound until all rights to the Compound and any materials needed to manufacture the Compound were transferred to Sobi, which transfer occurred upon the execution of Amendment No. 1 to the License and Development Agreement on October 31, 2023. Sobi has agreed to reimburse the Company for all budgeted costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, except for any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212. Sobi will have control and responsibility over all regulatory filings, including any investigational drug applications (IND), biologics license applications (BLA), and marketing authorization applications (MAA) relating to the licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transactions contemplated by the Sobi License were consummated on July 28, 2020. Sobi may terminate the Sobi License for any reason upon 180 days&#x2019; written notice to the Company, whereby all rights granted under the Sobi License would revert back to the Company. In addition, if Sobi were to terminate the Sobi License, the Company has the option to obtain a license to all patents and know-how necessary to exploit SEL-212 in existence as of the termination date from Sobi in return for making an equitable royalty payment to Sobi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on June 11, 2020, the Company entered into the Sobi Purchase Agreement in connection with the Sobi License. The closing of the Sobi Private Placement occurred on July 31, 2020, following the closing of the transactions contemplated under the Sobi License. See Note&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12 for details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Sobi License represents a service arrangement under the scope of ASC 606. In addition, given the Sobi License and Sobi Purchase Agreement were executed contemporaneously and negotiated as a package with a single commercial objective, the Company will account for the two agreements as a single contract. The term of the Sobi License commenced upon the effective date of July 28, 2020 and will continue on a product-by-product basis until the royalty terms for each country have expired. The royalty term for a given product begins upon the first commercial sale of the product in a country and ends at the later of ten years from the first commercial sale, expiration of the last valid patent claim covering the product and expiration of all regulatory exclusivity periods for the product in a country. Given the reversion of the rights under the Sobi License represents a penalty in substance for a termination by Sobi, the contract term would remain the stated term of the Sobi License.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Sobi License contained three distinct performance obligations due to the nature of the promises in the contract, which includes conducting the Phase 3 DISSOLVE trials, Sobi&#x2019;s option to set-up a second source supplier, and a combined obligation comprised of the delivery of the license to SEL-212, transfer of the know-how and the manufacturing and delivery of SEL-212 supply for development, or the Combined License Obligation. As the set-up of a second source supplier was optional for Sobi and the Company was to be reimbursed at cost for its efforts in the subsequent set-up and technology transfer, the option for this future service was determined to be at a significant and incremental discount to its standalone selling price and treated as a material right in the arrangement, namely a distinct performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company concluded the upfront payment of $75.0&#160;million and the $5.0&#160;million development milestone associated with the dosing of the first patient in the Phase 3 DISSOLVE trials were included in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;transaction price. All other development milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of the evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company and probability of success criteria is estimated. The Company re-evaluates the transaction price in each reporting period, as uncertain events are resolved. In accordance with ASC 606, the Company will only recognize revenue associated with sales-based milestones and royalties when the subsequent sales thresholds are reached and underlying sales occur, respectively. In connection with the Sobi Purchase Agreement, the Company determined that the gross proceeds of $25.0&#160;million from the Sobi Private Placement included a premium to the fair value of the Company&#x2019;s shares as of July 28, 2020 equal to approximately $14.5&#160;million. The premium amount is included in the transaction price for revenue recognition. The Company estimates and includes in the transaction price the total reimbursements to be received from Sobi for both the manufacturing and delivery of the Compound and ImmTOR as well as conducting the Phase 3 DISSOLVE trials. The Company determined that a significant financing component does not exist in its arrangement with Sobi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the transaction price based on the relative standalone selling prices of the three distinct performance obligations. The Company estimated the standalone selling price of conducting the Phase 3 DISSOLVE trials by forecasting its anticipated costs and applying a margin reflective of the industry. The Company determined the standalone selling price of the second source supplier option by determining the discount given to Sobi multiplied by the likelihood that Sobi would have exercised the option in the future. Similar to the Phase 3 program estimate, the Company estimated the discount of the option by forecasting the set-up costs and applying a margin that is reflective of the industry. As the Company was to provide the set-up and technology transfer services and the future supply at cost, the discount of the option was equal to the margin amount. The Company considered discussions with Sobi as well as probability of regulatory success of SEL-212 in determining the likelihood of exercise. The Company estimated the standalone selling price of the Combined License Obligation by utilizing a discounted cash flow model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the delivery of the supply to Sobi best represented the pattern of delivery of the Combined License Obligation as the supply was essential to the utility of the license and know-how. The Company recognized the revenue allocated to the Combined License Obligation by utilizing the output method. The Company estimated the total supply of the Compound and ImmTOR required during the clinical trial period and recognized revenue as this supply was shipped for use in the clinical trials. The Company recognized the revenue allocated to the conducting of the Phase 3 DISSOLVE trials obligation by utilizing the input method. The Company estimated the total budgeted costs to be incurred over the Phase 3 DISSOLVE trials and recognized revenue as these costs were incurred. The Company&#x2019;s costs best represented the pattern of transfer as these captured all performance of the trials completed to date and were readily able to be measured. The Company was to recognize the revenue allocated to the second source supplier option when the future services and goods were transferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 29, 2022, the Company completed enrollment of the DISSOLVE II trial. The completion of enrollment of the DISSOLVE II trial resulted in the achievement of a development milestone and a $10.0&#160;million payment obligation from Sobi to the Company. This amount was added to the overall transaction price and payment was received during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 31, 2023, the Company and Sobi entered into Amendment No. 1 to the License and Development Agreement, pursuant to which the Company granted Sobi an exclusive license to manufacture ImmTOR solely in connection with Sobi&#x2019;s development of SEL-212 under the License and Development Agreement and transferred certain contracts and manufacturing equipment to Sobi. Additionally, Sobi&#x2019;s option to set-up a second source supplier was removed as a result of the amendment. Further, in connection with entry into the amendment, Sobi agreed to make employment offers to certain of the Company&#x2019;s employees engaged in ImmTOR manufacturing activities on or prior to a specified date, and the Company agreed not to terminate the employment of such employees prior to such specified date. The Company maintains no responsibilities to Sobi to manufacture, or supply Sobi with, ImmTOR under the Sobi License.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 28, 2024, Sobi initiated a rolling biologics license application to the FDA for SEL-212 for the potential treatment of chronic refractory gout which resulted in the achievement of a development milestone and a $30.0&#160;million payment obligation from Sobi to the Company. As a result, the development milestone was no longer constrained and $30.0&#160;million was recognized as revenue during the year ended December 31, 2024 as there were no remaining performance obligations under the Sobi License. The proceeds from the achievement of the development milestone were received from Sobi in July 2024 and are expected to be included, net of deductions as specified in the CVR Agreement, in the next scheduled distribution to holders of the CVRs in March 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024 and 2023, the Company recorded a total outstanding receivable of $0.1 million and $4.6 million, respectively, representing billings for the Phase 3 DISSOLVE program that are subject to reimbursement by Sobi.  Additionally, as of December&#160;31, 2023, the Company recorded a total unbilled receivable of $3.0 million representing revenue earned but not yet billed for the Phase 3 DISSOLVE program. As of December 31, 2024, there was no unbilled receivable outstanding. Revenue of $31.9 million, inclusive of the $30.0&#160;million development milestone, related to the Sobi License was &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized during the year ended December 31, 2024, and $1.9 million of revenue recognized from performance obligations related to prior periods as a result of the change in transaction price during the year ended December 31, 2024. Revenue of $19.4 million related to the Sobi License was recognized during the year ended December 31, 2023, inclusive of $1.1 million of revenue recognized from performance obligations related to prior periods as a result of the change in transaction price during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sarepta Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research License and Option Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2020, the Company and Sarepta Therapeutics, Inc., or Sarepta, entered into a Research License and Option Agreement, or the Sarepta Agreement. Pursuant to the Sarepta Agreement, the Company agreed to grant Sarepta a license under the Company&#x2019;s intellectual property rights covering the Company&#x2019;s antigen-specific biodegradable nanoparticle encapsulating ImmTOR to research and evaluate ImmTOR in combination with Sarepta&#x2019;s adeno-associated virus gene therapy technology, or gene editing technology, using viral or non-viral delivery, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Indications. Sarepta initially had an option term of 24 months during which it could opt-in to obtain an exclusive license to further develop and commercialize the product to treat at least one Indication, with a potential to extend the option term for an additional fee. The Company agreed to supply ImmTOR to Sarepta for clinical supply on a cost-plus basis under the Sarepta Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sarepta paid a $2.0 million upfront payment to the Company upon signing of the Sarepta Agreement, and the Company was eligible to receive additional preclinical payments during the option term. If Sarepta opted in to an exclusive license agreement, the Company could have received&#160;option exercise payments per Indication upon execution of the exclusive license, and the Company would have been entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Sarepta Agreement, the Company determined the Sarepta Agreement represented a service arrangement under the scope of ASC 606, with a 24-month contract duration. Given the reversion of the rights under the Sarepta Agreement represents a penalty in substance for a termination by Sarepta, the contract term would remain the stated term of the Sarepta Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Sarepta Agreement and supply obligation including the delivery of the research license, the licensed know-how, the manufactured supply and delivery of materials represented a single promise and performance obligation to be transferred to Sarepta over time due to the nature of the promises in the contract. The delivery of the manufactured supply was the predominant promise within the arrangement, as it was essential to the utility of the licensed intellectual property. As such, consideration in the initial transaction price was allocated to the single performance obligation based on the contractual price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company concluded the payment associated with all the performance milestones was fully constrained and would only be included in the transaction price when the respective milestone was deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should have been constrained until they became probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such study milestones was outside the control of the Company and probability of success criteria was estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also determined the option to enter into a future commercial license agreement and extend the term of the option did not represent a material right since it was not priced at an incremental discount. Sarepta had the right to terminate the Sarepta Agreement for any reason upon 30 days&#x2019; written notice to the Company. The Sarepta Agreement contained other customary terms and conditions, including representations and warranties, covenants, termination, and indemnification obligations in favor of each party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 13, 2021, the Company was notified by Sarepta of the achievement of the milestone event related to the completion of a non-clinical study for Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies under the Sarepta Agreement. Accordingly, the Company received a milestone payment of $3.0&#160;million during the three months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 10, 2022, the Company was notified by Sarepta that Sarepta would be extending their options under the Sarepta Agreement. In exchange for a nine-month extension to Sarepta&#x2019;s options to both Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies, the Company received a milestone payment of $2.0&#160;million during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2022, the Company was notified by Sarepta of the achievement of a milestone event related to certain preclinical study milestones under the Sarepta Agreement. Accordingly, the Company received a milestone payment of $4.0&#160;million during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 13, 2023, the Company was notified by Sarepta that Sarepta would not be exercising its exclusive option under the Sarepta Agreement. The Sarepta Agreement terminated upon the expiration of the option in March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024 and 2023, there were no unsatisfied performance obligations related to the Sarepta Agreement. No revenue and revenue of $0.5 million related to the Sarepta Agreement was recognized during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction Price Allocated to Future Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Remaining performance obligations represent the transaction price of contracts for which work has not been performed, or has been partially performed. As of December 31, 2024, there were no unsatisfied performance obligations from contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances from Contracts with Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the Company&#x2019;s contract liabilities during the year ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;end of period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grant revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;National Institute of Neurological Disorders and Stroke of the National Institutes of Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024, the Company received funding approval from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, or NINDS, for an award of $1.5&#160;million granted for the budget period, which runs from June 2024 through May 2025. Subject to the availability of funds and satisfactory progress of the project, an additional $1.5&#160;million has been recommended by NINDS to be awarded for the budget period June 2025 through May 2026. The initial $1.5&#160;million funding was provided by NINDS to further the Company&#x2019;s use of RNA-based CAR-T cells to combat autoantibody-associated autoimmune disorders. Grant funding is to be used solely for manufacturing of RNA-based CAR-T cells and analysis of samples to inform mechanism of action. The award period runs through May 31, 2026. The Company will recognize grant revenue when expenses reimbursable under the grant have been incurred. &lt;/span&gt;&lt;/div&gt;As of December 31, 2024, the Company recorded a receivable of $0.6&#160;million that is subject to reimbursement by NINDS. Accordingly, the Company recognized grant revenue of $0.6&#160;million during the year ended December 31, 2024.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <rnac:CollaborationAndLicenseAgreementsUpfrontPayment contextRef="c-279" decimals="-5" id="f-1049" unitRef="usd">10000000</rnac:CollaborationAndLicenseAgreementsUpfrontPayment>
    <rnac:DevelopmentAndCommercialMilestonesPlusRoyalties contextRef="c-279" decimals="-5" id="f-1050" unitRef="usd">340000000</rnac:DevelopmentAndCommercialMilestonesPlusRoyalties>
    <rnac:ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment
      contextRef="c-279"
      decimals="INF"
      id="f-1051"
      unitRef="number">0.25</rnac:ReimbursementPercentageBudgetedCostsIncurredToCompleteTheDevelopment>
    <rnac:CollaborationAndLicenseAgreementsUpfrontPayment contextRef="c-279" decimals="-5" id="f-1052" unitRef="usd">10000000</rnac:CollaborationAndLicenseAgreementsUpfrontPayment>
    <rnac:LicenseAndOptionAgreementDevelopmentCostReimbursements contextRef="c-279" decimals="-5" id="f-1053" unitRef="usd">5500000</rnac:LicenseAndOptionAgreementDevelopmentCostReimbursements>
    <rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation contextRef="c-279" id="f-1054">P90D</rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-280" decimals="INF" id="f-1055" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-281" decimals="-5" id="f-1056" unitRef="usd">2300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-281" decimals="-5" id="f-1057" unitRef="usd">3500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-280" decimals="-5" id="f-1058" unitRef="usd">100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-281" decimals="-5" id="f-1059" unitRef="usd">300000</us-gaap:AccountsReceivableNetCurrent>
    <rnac:CustomerLiabilityRevenueRecognizedIncludingOpeningBalance contextRef="c-282" decimals="-5" id="f-1060" unitRef="usd">6300000</rnac:CustomerLiabilityRevenueRecognizedIncludingOpeningBalance>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice contextRef="c-282" decimals="-5" id="f-1061" unitRef="usd">3200000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <rnac:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance contextRef="c-283" decimals="-5" id="f-1062" unitRef="usd">5500000</rnac:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance>
    <rnac:LicenseAndOptionAgreementUpfrontCashPayment contextRef="c-284" decimals="-5" id="f-1063" unitRef="usd">3000000</rnac:LicenseAndOptionAgreementUpfrontCashPayment>
    <rnac:LicenseAndOptionAgreementFutureAdditionalPaymentsExpected contextRef="c-284" decimals="-6" id="f-1064" unitRef="usd">1124000000</rnac:LicenseAndOptionAgreementFutureAdditionalPaymentsExpected>
    <rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation contextRef="c-284" id="f-1065">P90D</rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation>
    <us-gaap:ContractWithCustomerAssetReclassifiedToReceivable contextRef="c-285" decimals="-5" id="f-1066" unitRef="usd">500000</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-286" decimals="INF" id="f-1067" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-287" decimals="INF" id="f-1068" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <rnac:CustomerLiabilityRevenueRecognizedIncludingOpeningBalance contextRef="c-288" decimals="INF" id="f-1069" unitRef="usd">0</rnac:CustomerLiabilityRevenueRecognizedIncludingOpeningBalance>
    <rnac:CustomerLiabilityRevenueRecognizedIncludingOpeningBalance contextRef="c-285" decimals="-5" id="f-1070" unitRef="usd">600000</rnac:CustomerLiabilityRevenueRecognizedIncludingOpeningBalance>
    <rnac:LicenseAndOptionAgreementUpfrontCashPayment contextRef="c-289" decimals="-5" id="f-1071" unitRef="usd">75000000</rnac:LicenseAndOptionAgreementUpfrontCashPayment>
    <rnac:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived contextRef="c-289" decimals="-5" id="f-1072" unitRef="usd">630000000</rnac:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived>
    <rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation contextRef="c-289" id="f-1073">P180D</rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation>
    <rnac:EligiblePeriodToReceiveRoyalties contextRef="c-289" id="f-1074">P10Y</rnac:EligiblePeriodToReceiveRoyalties>
    <rnac:RevenueNumberOfPerformanceObligations
      contextRef="c-290"
      decimals="INF"
      id="f-1075"
      unitRef="obligation">3</rnac:RevenueNumberOfPerformanceObligations>
    <rnac:LicenseAndOptionAgreementUpfrontCashPayment contextRef="c-289" decimals="-5" id="f-1076" unitRef="usd">75000000</rnac:LicenseAndOptionAgreementUpfrontCashPayment>
    <rnac:LicenseAndOptionAgreementDevelopmentMilestone contextRef="c-289" decimals="-5" id="f-1077" unitRef="usd">5000000</rnac:LicenseAndOptionAgreementDevelopmentMilestone>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-215" decimals="-5" id="f-1078" unitRef="usd">25000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RedemptionPremium contextRef="c-217" decimals="-5" id="f-1079" unitRef="usd">14500000</us-gaap:RedemptionPremium>
    <rnac:RevenueNumberOfPerformanceObligations
      contextRef="c-290"
      decimals="INF"
      id="f-1080"
      unitRef="obligation">3</rnac:RevenueNumberOfPerformanceObligations>
    <rnac:CollaborativeArrangementPaymentObligation contextRef="c-291" decimals="-5" id="f-1081" unitRef="usd">10000000</rnac:CollaborativeArrangementPaymentObligation>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-292" decimals="-5" id="f-1082" unitRef="usd">30000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-293" decimals="-5" id="f-1083" unitRef="usd">30000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-294" decimals="-5" id="f-1084" unitRef="usd">100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-295" decimals="-5" id="f-1085" unitRef="usd">4600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-296" decimals="-5" id="f-1086" unitRef="usd">3000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-297" decimals="-5" id="f-1087" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-293" decimals="-5" id="f-1088" unitRef="usd">31900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-293" decimals="-5" id="f-1089" unitRef="usd">30000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice contextRef="c-293" decimals="-5" id="f-1090" unitRef="usd">1900000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-298" decimals="-5" id="f-1091" unitRef="usd">19400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice contextRef="c-298" decimals="-5" id="f-1092" unitRef="usd">1100000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <rnac:LicenseAndOptionAgreementOptionTerm contextRef="c-299" id="f-1093">P24M</rnac:LicenseAndOptionAgreementOptionTerm>
    <rnac:LicenseAndOptionAgreementUpfrontCashPayment contextRef="c-299" decimals="-5" id="f-1094" unitRef="usd">2000000.0</rnac:LicenseAndOptionAgreementUpfrontCashPayment>
    <rnac:LicenseAndOptionAgreementOptionTerm contextRef="c-299" id="f-1095">P24M</rnac:LicenseAndOptionAgreementOptionTerm>
    <rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation contextRef="c-299" id="f-1096">P30D</rnac:LicenseAndOptionAgreementWrittenNoticePeriodBeforeCancellation>
    <rnac:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived contextRef="c-300" decimals="-5" id="f-1097" unitRef="usd">3000000</rnac:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived>
    <rnac:LicenseAndOptionAgreementExtensionTerm contextRef="c-301" id="f-1098">P9M</rnac:LicenseAndOptionAgreementExtensionTerm>
    <rnac:LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies contextRef="c-302" decimals="-5" id="f-1099" unitRef="usd">2000000</rnac:LicenseAndOptionAgreementMilestoneReceivableForCertainDystrophies>
    <rnac:LicenseAndOptionAgreementMilestoneReceivable contextRef="c-303" decimals="-5" id="f-1100" unitRef="usd">4000000</rnac:LicenseAndOptionAgreementMilestoneReceivable>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-304" decimals="INF" id="f-1101" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-305" decimals="INF" id="f-1102" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-306" decimals="INF" id="f-1103" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-307" decimals="-5" id="f-1104" unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-8" decimals="INF" id="f-1105" unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-1106">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the Company&#x2019;s contract liabilities during the year ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;end of period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <rnac:ContractwithCustomerLiabilityDeferredRevenue contextRef="c-9" decimals="-3" id="f-1107" unitRef="usd">5849000</rnac:ContractwithCustomerLiabilityDeferredRevenue>
    <rnac:ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts contextRef="c-1" decimals="-3" id="f-1108" unitRef="usd">0</rnac:ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts>
    <rnac:ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized contextRef="c-1" decimals="-3" id="f-1109" unitRef="usd">5849000</rnac:ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized>
    <rnac:ContractwithCustomerLiabilityDeferredRevenue contextRef="c-8" decimals="-3" id="f-1110" unitRef="usd">0</rnac:ContractwithCustomerLiabilityDeferredRevenue>
    <us-gaap:ContractWithCustomerLiability contextRef="c-9" decimals="-3" id="f-1111" unitRef="usd">5849000</us-gaap:ContractWithCustomerLiability>
    <rnac:ContractwithCustomerLiabilityIncreaseFromCashReceipts contextRef="c-1" decimals="-3" id="f-1112" unitRef="usd">0</rnac:ContractwithCustomerLiabilityIncreaseFromCashReceipts>
    <rnac:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance contextRef="c-1" decimals="-3" id="f-1113" unitRef="usd">5849000</rnac:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance>
    <us-gaap:ContractWithCustomerLiability contextRef="c-8" decimals="-3" id="f-1114" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:GovernmentAssistanceAwardAmount contextRef="c-308" decimals="-5" id="f-1115" unitRef="usd">1500000</us-gaap:GovernmentAssistanceAwardAmount>
    <rnac:GovernmentAssistancePotentialAdditionalAwardAmount contextRef="c-308" decimals="-5" id="f-1116" unitRef="usd">1500000</rnac:GovernmentAssistancePotentialAdditionalAwardAmount>
    <us-gaap:GovernmentAssistanceAwardAmount contextRef="c-308" decimals="-5" id="f-1117" unitRef="usd">1500000</us-gaap:GovernmentAssistanceAwardAmount>
    <rnac:GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-1" id="f-1118">receivable</rnac:GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:GovernmentAssistanceAmountCumulativeCurrent contextRef="c-309" decimals="-5" id="f-1119" unitRef="usd">600000</us-gaap:GovernmentAssistanceAmountCumulativeCurrent>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-310" decimals="-5" id="f-1120" unitRef="usd">600000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-1121">Related-Party Transactions&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 2, 2024, the Company entered into the 2024 Securities Purchase Agreement with the Purchasers. The Purchasers included (i) Dr. Timothy A. Springer, a member of the Company&#x2019;s Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Dr. Chafen Lu, Dr. Springer&#x2019;s wife (see Note 11). The below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Series B Preferred Stock purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total aggregate purchase price&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Timothy A. Springer, Ph.D.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,636,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TAS Partners LLC, affiliate of Timothy A. Springer, Ph.D.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Chafen Lu, Ph.D., wife of Timothy A. Springer, Ph.D.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2023 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On November 13, 2023, the Company entered into the 2023 Securities Purchase Agreement with (i) Dr. Timothy A. Springer, (ii) TAS Partners LLC, and (iii) Seven One Eight Three Four Irrevocable Trust, a trust associated with Dr. Murat Kalayoglu, in which the Company agreed to issue and sell an aggregate of 149,330.115 shares of Series A Preferred Stock for an aggregate purchase price of $60.25&#160;million (see Note 11). The 2023 Private Placement included a delayed settlement mechanism, and as a result, the below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Series A Preferred Stock purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total aggregate purchase price&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Timothy A. Springer, Ph.D.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,140.326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The below issuances and sales to related parties of the Company were made subject to the 2023 Private Placement during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Series A Preferred Stock purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total aggregate purchase price &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Timothy A. Springer, Ph.D.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,785.081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TAS Partners LLC (affiliate of Timothy A. Springer, Ph.D.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,785.081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Seven One Eight Three Four Irrevocable Trust (affiliate of Murat Kalayoglu, MD, Ph.D.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;619.627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise of Amended 2019 Warrants&lt;/span&gt;&lt;/div&gt;On March 26, 2024, TAS Partners LLC exercised 65,681 Amended 2019 Warrants, paid the per-share exercise price of $43.80 in cash for an aggregate exercise price of $2.9&#160;million, and received 65,681 shares of common stock and 1,970,443 CVRs.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c-1" id="f-1122">The below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Series B Preferred Stock purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total aggregate purchase price&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Timothy A. Springer, Ph.D.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,636,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TAS Partners LLC, affiliate of Timothy A. Springer, Ph.D.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Chafen Lu, Ph.D., wife of Timothy A. Springer, Ph.D.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;The 2023 Private Placement included a delayed settlement mechanism, and as a result, the below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Series A Preferred Stock purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total aggregate purchase price&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Timothy A. Springer, Ph.D.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,140.326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The below issuances and sales to related parties of the Company were made subject to the 2023 Private Placement during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Series A Preferred Stock purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total aggregate purchase price &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Timothy A. Springer, Ph.D.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,785.081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TAS Partners LLC (affiliate of Timothy A. Springer, Ph.D.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,785.081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Seven One Eight Three Four Irrevocable Trust (affiliate of Murat Kalayoglu, MD, Ph.D.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;619.627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-183"
      decimals="INF"
      id="f-1123"
      unitRef="shares">1636832</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-311" decimals="-3" id="f-1124" unitRef="usd">32737000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-184"
      decimals="INF"
      id="f-1125"
      unitRef="shares">721361</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-312" decimals="-3" id="f-1126" unitRef="usd">14427000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-185"
      decimals="INF"
      id="f-1127"
      unitRef="shares">1307</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-313" decimals="-3" id="f-1128" unitRef="usd">26000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-314"
      decimals="INF"
      id="f-1129"
      unitRef="shares">149330.115</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-314" decimals="-4" id="f-1130" unitRef="usd">60250000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-315"
      decimals="INF"
      id="f-1131"
      unitRef="shares">99140.326</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-315" decimals="-3" id="f-1132" unitRef="usd">40000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-316"
      decimals="INF"
      id="f-1133"
      unitRef="shares">24785.081</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-316" decimals="-3" id="f-1134" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-317"
      decimals="INF"
      id="f-1135"
      unitRef="shares">24785.081</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-317" decimals="-3" id="f-1136" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-318"
      decimals="INF"
      id="f-1137"
      unitRef="shares">619.627</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-318" decimals="-3" id="f-1138" unitRef="usd">250000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <rnac:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="c-319"
      decimals="INF"
      id="f-1139"
      unitRef="shares">65681</rnac:ClassOfWarrantOrRightExercisedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-320"
      decimals="2"
      id="f-1140"
      unitRef="usdPerShare">43.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-319" decimals="-5" id="f-1141" unitRef="usd">2900000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-321"
      decimals="INF"
      id="f-1142"
      unitRef="shares">65681</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <rnac:IssuanceOfContingentValueRightForExerciseOfWarrants
      contextRef="c-321"
      decimals="INF"
      id="f-1143"
      unitRef="shares">1970443</rnac:IssuanceOfContingentValueRightForExerciseOfWarrants>
    <rnac:CollaborationAndLicenseAgreementsTextBlock contextRef="c-1" id="f-1144">Collaboration and License Agreements&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 8, 2023, the Company entered into a non-exclusive, sublicensable, worldwide, perpetual patent license agreement, or the Biogen Agreement, with Biogen MA, Inc., or Biogen to research, develop, make, use, offer, sell and import products or processes containing or using an engineering T-cell modified with an mRNA comprising, or encoding a protein comprising, certain sequences licensed under the Biogen Agreement for the prevention, treatment, palliation and management of autoimmune diseases and disorders, excluding cancers, neoplastic disorders, and paraneoplastic disorders. The Company is not obligated to pay Biogen any expenses, fees, or royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may terminate the Biogen Agreement for any reason or no reason, and Biogen may terminate the agreement after a notice-and-cure period of 30 days if the Company fails to pay a fee owed to Biogen or for any other material breach of the agreement. The Biogen Agreement will otherwise expire when all claims of all issued patents within the patents and patent applications licensed to the Company under the Biogen Agreement have expired or been finally rendered revoked, invalid or unenforceable by a decision of a court or government agency.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Biogen Agreement encompasses patents and patent applications in the PCT/US2010/026825 patent family, which was filed March 10, 2010. In general, all patents that issue in this family have an expected expiration date of March 10, 2030, subject to potential patent term adjustments and/or extensions. For the U.S. patents and applications in this family, U.S. Patent 9,034,324 was awarded 677 days of patent term adjustment, which would extend the expiration date of this patent to January 16, 2032, absent any challenges to the patent term. The other issued patent in this family was not awarded any patent term adjustment, so its expected expiration date is March 10, 2030.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;National Cancer Institute of the National Institutes of Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective September 16, 2019, the Company entered into a nonexclusive, worldwide license agreement, or the NCI Agreement, with the U.S. Department of Health and Human Services, represented by the National Cancer Institute of the National Institutes of Health, or NCI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NCI Agreement, the Company was granted a license under certain NCI patents and patent applications designated in the agreement, to make, use, sell, offer and import products and processes within the scope of the patents and applications licensed under the NCI Agreement when developing and manufacturing anti-BCMA CAR-T cell products for the treatment of myasthenia gravis, pemphigus vulgaris, and immune thrombocytopenic purpura according to methods designated in the NCI Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s entry into the NCI Agreement, Old Cartesian paid to NCI a one-time $0.1&#160;million license royalty payment. Under the NCI Agreement, the Company is further required to pay NCI a low five-digit annual royalty. The Company must also pay earned royalties on net sales in a low single-digit percentage and pay up to $0.8&#160;million in benchmark royalties upon the Company&#x2019;s achievement of designated benchmarks that are based on the commercial development plan agreed between the parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NCI Agreement, the Company must use reasonable commercial efforts to bring licensed products and licensed processes to the point of Practical Application (as defined in the NCI Agreement). Upon the Company&#x2019;s first commercial sale, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company must use reasonable commercial efforts to make licensed products and licensed processes reasonably accessible to the United States public. After the Company&#x2019;s first commercial sale, the Company must make reasonable quantities of licensed products or materials produced via licensed processes available to patient assistance programs and develop educational materials detailing the licensed products. Unless the Company obtains a waiver from NCI, the Company must have licensed products and licensed processes manufactured substantially in the United States. Prior to the first commercial sale, upon NCI&#x2019;s request, the Company is obligated to provide NCI with commercially reasonable quantities of licensed products made through licensed processes to be used for in vitro research.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company must use reasonable commercial efforts to initiate a Phase 3 clinical trial of a licensed product by the fourth quarter of 2024, submit a BLA with respect to a licensed product by the fourth quarter of 2026, and make a first commercial sale of a licensed product by the fourth quarter of 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The NCI Agreement terminates upon the expiration of the last to expire of the patent rights licensed thereunder, if not sooner terminated. The NCI Agreement encompasses patents and patent applications in the PCT/US2013/032029 patent family, which was filed March 15, 2013. In general, all patents that issue in this family have an expected expiration of March 15, 2033, subject to potential patent term adjustments and/or extensions. For the U.S. patents and applications in this family, only two patents were awarded patent term adjustments. U.S. Patent 9,765,342 was awarded 297 days of patent term adjustment, which would extend the expiration date of this patent to January 6, 2034, absent any challenges to the patent term. The other patent, U.S. Patent 10,876,123, was awarded three days of patent term adjustment, but this patent is subject to terminal disclaimers filed against other family members, so this patent will not extend beyond the March 15, 2033 date. The other issued patents in this family were not awarded any patent term adjustment, so the expected expiration date for these patents also remains March 15, 2033. There is also a pending patent application which, if issued, will expire on March 15, 2033, but could also be subject to patent term adjustment and to any potential future terminal disclaimers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;NCI has the right to terminate the NCI Agreement, after giving written notice and providing a cure period in accordance with its terms, if the Company is in default of a material obligation. The Company has the unilateral right to terminate the agreement in any country or territory by giving NCI 60 days&#x2019; written notice. The Company agreed to indemnify NCI against any liability arising out of the Company&#x2019;s, sublicensees&#x2019; or third-parties&#x2019; use of the licensed patent rights and licensed products or licensed processes developed in connection with the licensed patent rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ginkgo Bioworks Holdings, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 25, 2021, the Company entered into a Collaboration and License Agreement, or the First Ginkgo Agreement, with Ginkgo. Under the First Ginkgo Agreement, Ginkgo will design next generation IgA proteases with potentially transformative therapeutic potential. In return, Ginkgo is eligible to earn both upfront research and development fees and milestone payments, including certain milestone payments for fixed fair values in the form of the Company&#x2019;s common stock, clinical and commercial milestone payments of up to $85.0&#160;million in cash. The First Ginkgo Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company will expense costs related to the First Ginkgo Agreement as incurred until regulatory approval is received in accordance with ASC 730. The Company is accounting for the contingently issuable shares to be issued in exchange for the license obtained from Ginkgo as a liability classified stock-based compensation arrangement with a non-employee which will be recognized when achievement of the milestones is probable. The Company will assess the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, will amortize these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company is also obligated to pay Ginkgo tiered royalties ranging from low-single digit to high-single digit percentages of annual net sales of collaboration products which will be expensed as the commercial sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2022, the Company entered into a Collaboration and License Agreement, or the Second Ginkgo Agreement, with Ginkgo. Under this agreement, the Company will engage with Ginkgo to develop AAV capsids designed to enhance transduction efficiency and transgene expression. In return, Ginkgo is eligible to earn both upfront research and development fees and milestone payments, including certain milestone payments in the form of shares of the Company&#x2019;s common stock, clinical and commercial milestone payments of up to $207&#160;million in cash. The Second Ginkgo Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company will expense costs related to the Second Ginkgo Agreement as incurred until regulatory approval is received in accordance with ASC 730. The Company is accounting for the contingently issuable shares of common stock to be issued in exchange for the license obtained from Ginkgo as a liability-classified, stock-based compensation arrangement with a non-employee which will be recognized when achievement of the milestones is probable. The Company will assess the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, will amortize these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company is also obligated to pay Ginkgo tiered royalties ranging from low-single digit to high-single digit percentages of annual net sales of collaboration products which will be expensed as the commercial sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 13, 2022, the Company was notified of the achievement of the midpoint of the technical development plan under the First Ginkgo Agreement by Ginkgo. This milestone resulted in the payment of $0.5&#160;million and issuance of 29,761 shares of the Company&#x2019;s common stock then-valued at $1.0&#160;million to Ginkgo during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2023, the Company and Ginkgo mutually agreed that the completion of the technical development plan&#x2019;s midpoint task under the Second Ginkgo Agreement had been achieved as of June 30, 2023. This milestone resulted in the payment of $1.0&#160;million and issuance of 44,642 shares of the Company&#x2019;s common stock then-valued at $1.5&#160;million to Ginkgo during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Genovis AB (publ.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 21, 2021, the Company entered into the Genovis Agreement with Genovis. Under the Genovis Agreement, the Company paid to Genovis an upfront payment in exchange for an exclusive license to the Xork enzyme technology across all therapeutic uses in humans, excluding research, preclinical, diagnostic and other potential non-therapeutic applications of the enzyme. Genovis was eligible to earn from the Company development and sales-based milestones and sublicensing fees. The Genovis Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company was to expense costs related to the Genovis Agreement as incurred until regulatory approval was received in accordance with ASC 730. The Company would have assessed the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, would have amortized these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company was also obligated to pay Genovis tiered royalties of low double digit percentages of worldwide annual net sales of collaboration products which would have been expensed as the commercial sales occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, the Company made a $4.0&#160;million payment to Genovis as a result of the sublicense of Xork to Astellas. See Note 14 to these consolidated financial statements for further discussion on the Astellas Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the Company notified Genovis of its intention to terminate the Genovis Agreement, which occurred effective September 13, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cyrus Biotechnology, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On September 7, 2021, the Company and Cyrus Biotechnology, Inc., or Cyrus, entered into a collaboration and license agreement, or the Cyrus Agreement. Pursuant to the Cyrus Agreement, Cyrus agreed to grant the Company an exclusive, worldwide license to certain intellectual property to form a protein engineering collaboration combining the Company&#x2019;s ImmTOR platform with Cyrus&#x2019; ability to redesign protein therapeutics. The lead program was a proprietary interleukin-2, or IL-2, protein agonist designed to selectively promote expansion of regulatory T cells for treatment of patients with autoimmune diseases and other deleterious immune conditions. In return for the licensed intellectual property, the Company made an upfront payment and was obligated to pay certain discovery, development, and sales-based milestones which could have potentially totaled up to approximately $1.5&#160;billion across multiple programs. The Cyrus Agreement was assessed for collaboration components and was determined not to be within the scope of ASC 808 as the risk and rewards are not shared by both parties. The Company expensed costs related to the Cyrus Agreement as incurred until regulatory approval is received in accordance with ASC 730. The Company assessed the capitalization of costs incurred after the receipt of regulatory approval and, if applicable, would have amortized these payments based on the expected useful life of each asset, typically based on the expected commercial exclusivity period. The Company was also obligated to pay Cyrus tiered royalties ranging from mid-single digit to low-double digit percentages of annual net sales of collaboration products which would have been expensed as commercial sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 13, 2022, the Company and Cyrus mutually agreed that the preclinical key in-vitro success milestone had been achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, the Company notified Cyrus of its termination of the Cyrus Agreement, effective December 29, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on September 7, 2021, the Company entered into a stock purchase agreement, or the Series B Preferred Stock Purchase Agreement, in connection with the Cyrus Agreement. Pursuant to the Series B Preferred Stock Purchase Agreement, the Company purchased 2,326,934 shares of Cyrus&#x2019; Series B Preferred Stock, par value $0.0001 per share, at a purchase price of $0.8595 per share for $2.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 810, the Company has a variable interest in Cyrus resulting from its equity investment. The Company will share in Cyrus&#x2019; expected losses or receive a portion of its expected returns and absorb the variability associated with changes in the entity&#x2019;s net assets. However, the Company is not the primary beneficiary as it does not have the power to direct the activities most significant to Cyrus, and therefore it is not required to consolidate Cyrus. The Company has recognized the $2.0 million investment of Cyrus&#x2019; Series B Preferred Stock at cost on the purchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December 31, 2024, no impairment indicators are present and there were no observable price changes. Therefore, the carrying value of the investment in Cyrus is $2.0 million on the accompanying consolidated balance sheets. The Company&#x2019;s maximum exposure to loss related to this VIE is limited to the carrying value of the investment. The Company has not provided financing to Cyrus other than the amount contractually required by the Series B Preferred Stock Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asklepios Biopharmaceutical, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Feasibility Study and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2019, the Company entered into a feasibility study and license agreement, or the AskBio Collaboration Agreement, with Asklepios Biopharmaceutical, Inc., or AskBio. Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to license intellectual property rights to each other as part of a collaboration to research, develop, and commercialize certain AAV gene therapy products utilizing the Company&#x2019;s ImmTOR platform to enable re-dosing of such AAV gene therapy products to treat serious rare and orphan genetic diseases for which there is a significant unmet medical need.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to conduct proof of concept studies to potentially validate the use of ImmTOR in conjunction with AskBio&#x2019;s AAV gene therapy, or SEL-302, (previously disclosed as MMA-101, in combination with ImmTOR) for the treatment of methylmalonic acidemia, or MMA, to mitigate the formation of neutralizing anti-AAV capsid antibodies. On April 29, 2021, the Company was notified by AskBio that it intended to opt-out of development of the MMA indication. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and AskBio shared responsibility for the research, development and commercialization of products developed under the SEL-399 program collaboration. The parties also shared research, development, and commercialization costs equally for all collaboration products, but with a right of either party to opt out of certain products, and thereby not be required to share costs for such products. Each party would have received a percentage of net profits under the collaboration equal to the percentage of shared costs borne by such party in the development of such product. Pursuant to the AskBio Collaboration Agreement, AskBio was responsible for manufacturing the AAV capsids and AAV vectors and the Company was responsible for manufacturing ImmTOR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and AskBio mutually agreed to the termination of the AskBio Collaboration Agreement, effective December 13, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2024 and 2023, the Company recognized no and $0.1 million, respectively, of collaboration expense under the AskBio Collaboration Agreement in which actual costs incurred by both parties approximate a 50% cost share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shenyang Sunshine Pharmaceutical Co., Ltd&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014, the Company entered into a license agreement, or the 3SBio License, with Shenyang Sunshine Pharmaceutical Co., Ltd., or 3SBio. The Company has paid to 3SBio an aggregate of $7.0 million in upfront and milestone-based payments under the 3SBio License as of December 31, 2024. The Company is required to make future payments to 3SBio contingent upon the occurrence of events related to the achievement of clinical and regulatory approval milestones of up to an aggregate of $15.0 million for products containing the Company&#x2019;s ImmTOR platform.&lt;/span&gt;&lt;/div&gt;</rnac:CollaborationAndLicenseAgreementsTextBlock>
    <rnac:CollaborativeArrangementWrittenNoticePeriodForTermination contextRef="c-322" id="f-1145">P30D</rnac:CollaborativeArrangementWrittenNoticePeriodForTermination>
    <rnac:LicenseAndOptionAgreementRoyaltyPayment contextRef="c-323" decimals="-5" id="f-1146" unitRef="usd">100000</rnac:LicenseAndOptionAgreementRoyaltyPayment>
    <rnac:LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum contextRef="c-323" decimals="-5" id="f-1147" unitRef="usd">800000</rnac:LicenseAndOptionAgreementBenchmarkRoyaltiesMaximum>
    <rnac:CollaborativeArrangementWrittenNoticePeriodForTermination contextRef="c-323" id="f-1148">P60D</rnac:CollaborativeArrangementWrittenNoticePeriodForTermination>
    <rnac:LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected contextRef="c-324" decimals="-5" id="f-1149" unitRef="usd">85000000</rnac:LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected>
    <rnac:LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected contextRef="c-325" decimals="-6" id="f-1150" unitRef="usd">207000000</rnac:LicenseAndOptionAgreementClinicalAndCommercialMilestonePaymentExpected>
    <rnac:LicenseAndOptionAgreementMilestonePayments contextRef="c-326" decimals="-5" id="f-1151" unitRef="usd">500000</rnac:LicenseAndOptionAgreementMilestonePayments>
    <rnac:CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement
      contextRef="c-327"
      decimals="INF"
      id="f-1152"
      unitRef="shares">29761</rnac:CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement>
    <rnac:CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount contextRef="c-327" decimals="-5" id="f-1153" unitRef="usd">1000000</rnac:CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount>
    <rnac:LicenseAndOptionAgreementMilestonePayments contextRef="c-328" decimals="-5" id="f-1154" unitRef="usd">1000000</rnac:LicenseAndOptionAgreementMilestonePayments>
    <rnac:CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement
      contextRef="c-329"
      decimals="INF"
      id="f-1155"
      unitRef="shares">44642</rnac:CollaborativeArrangementNumberOfSharesIssuedForMilestoneAchievement>
    <rnac:CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount contextRef="c-329" decimals="-5" id="f-1156" unitRef="usd">1500000</rnac:CollaborativeArrangementSharesIssuedForMilestoneAchievementAmount>
    <rnac:LicenseAndOptionAgreementMilestonePayments contextRef="c-330" decimals="-5" id="f-1157" unitRef="usd">4000000</rnac:LicenseAndOptionAgreementMilestonePayments>
    <rnac:LicenseAndOptionAgreementMilestonePayments contextRef="c-331" decimals="-8" id="f-1158" unitRef="usd">1500000000</rnac:LicenseAndOptionAgreementMilestonePayments>
    <rnac:EquitySecuritiesStockPurchaseAgreementSharesPurchased
      contextRef="c-331"
      decimals="INF"
      id="f-1159"
      unitRef="shares">2326934</rnac:EquitySecuritiesStockPurchaseAgreementSharesPurchased>
    <rnac:EquitySecuritiesStockPurchaseAgreementParValuePerShare
      contextRef="c-332"
      decimals="4"
      id="f-1160"
      unitRef="usdPerShare">0.0001</rnac:EquitySecuritiesStockPurchaseAgreementParValuePerShare>
    <rnac:EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare
      contextRef="c-332"
      decimals="4"
      id="f-1161"
      unitRef="usdPerShare">0.8595</rnac:EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-333" decimals="-5" id="f-1162" unitRef="usd">2000000.0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-334" decimals="-5" id="f-1163" unitRef="usd">2000000.0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-334" decimals="-5" id="f-1164" unitRef="usd">2000000.0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OperatingExpenses contextRef="c-335" decimals="INF" id="f-1165" unitRef="usd">0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-336" decimals="-5" id="f-1166" unitRef="usd">100000</us-gaap:OperatingExpenses>
    <rnac:CollaborativeArrangementCostSharePercentage
      contextRef="c-336"
      decimals="2"
      id="f-1167"
      unitRef="number">0.50</rnac:CollaborativeArrangementCostSharePercentage>
    <rnac:CollaborativeArrangementCostSharePercentage
      contextRef="c-335"
      decimals="2"
      id="f-1168"
      unitRef="number">0.50</rnac:CollaborativeArrangementCostSharePercentage>
    <rnac:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid contextRef="c-337" decimals="-5" id="f-1169" unitRef="usd">7000000.0</rnac:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid>
    <rnac:AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform contextRef="c-338" decimals="-5" id="f-1170" unitRef="usd">15000000.0</rnac:AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1171">Income Taxes&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for income taxes under ASC 740. Under ASC 740, the Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#x2019;s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 13, 2023, the Company acquired, in accordance with the terms of the Merger Agreement, the assets of Old Cartesian. In accordance with ASC 805-740-25-3, recognition of deferred tax assets and liabilities is required for substantially all temporary differences and acquired tax carryforwards and credits. The Company has computed estimated temporary differences and acquired tax carryforwards and credits as of the transaction date. The Company will not have tax basis in IPR&amp;amp;D booked as part of the purchase accounting. For accounting purposes, the IPR&amp;amp;D will not be amortized and only subject to impairment review and testing. Though the tax effects may be delayed indefinitely, ASC 740-10-55-63 states that &#x201c;deferred tax liabilities may not be eliminated or reduced because a reporting entity may be able to delay the settlement of those liabilities by delaying the events that would cause taxable temporary differences to reverse.&#x201d; The Company can potentially only utilize indefinite-lived assets as it relates to this indefinite lived intangible deferred tax liability reversal. As such, the Company has booked a deferred tax liability for the portion of the liability that cannot be reduced based on scheduling. Additionally, a portion of this target deferred tax liability is offset with the Company&#x2019;s pre-Merger deferred tax assets on a combined basis, and as such the portion of deferred tax liability reduced by the Company&#x2019;s pre-Merger deferred tax assets has been charged to income rather than to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2024, the Company recognized a current tax expense of $0.3&#160;million. For the year ended December 31, 2023, the Company recognized a current tax benefit of $19.0&#160;million. The following table reconciles the federal statutory income tax rate to the Company&#x2019;s effective income tax rate:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Statutory U.S. federal rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;State income taxes - net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Research tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Change in fair value of contingent value right liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Change in fair value of forward contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Valuation allowance, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(160.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Effective income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences that give rise to the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;44,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;29,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;5,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;75,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;84,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;3,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Contingent value right liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;108,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;R&amp;amp;E Capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;26,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;19,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Patent and license costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;8,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;9,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;274,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;152,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(41,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(41,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(1,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(2,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(43,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(44,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Net deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;231,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;108,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(247,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(124,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Net deferred tax assets/(liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(16,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(15,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has provided a full valuation allowance against its net deferred tax assets, outside of the indefinite tax liability booked as part of the Merger. The Company believes that it is more likely than not that the net deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realization of future tax benefits is dependent on many factors, including the Company&#x2019;s ability to generate taxable income. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded that it is more likely than not that the Company will not realize the benefit of its net deferred tax assets. The valuation allowance increased by $123.6&#160;million for the year ended December 31, 2024, primarily as a result of tax loss in the current year and the recognition of a $108.8&#160;million tax benefit related to the Company&#x2019;s CVR liability. The valuation allowance decreased by $3.5&#160;million for the year ended December 31, 2023, primarily as a result of a tax benefit booked as part of the Merger. As of December 31, 2024, the Company is in the process of winding down operations in Russia and does not expect any tax liability relating to such operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At December 31, 2024, the Company has federal net operating loss carryforward of $152.6&#160;million, which can be carried forward indefinitely, subject to an 80% limitation and state net operating loss carryforward of $187.8&#160;million, of which $74.4&#160;million has an unlimited carryforward and the remaining $113.4&#160;million will expire at various times through 2044. The Company has $5.2&#160;million and $1.0&#160;million, respectively, of federal and state research and development tax credit carryforwards, which will expire at various times through 2044. Utilization of the NOL carryforwards and research and orphan drug credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, and similar state law due to ownership changes that could occur in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. If the Company experiences a change of control, as defined by Section 382 of the Code and similar state law, utilization of the NOL carryforwards or research and orphan drug credit carryforwards may be subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL carryforwards or research and orphan drug credit carryforwards before utilization. The Company performed an analysis of ownership changes through December 31, 2023. Based on this analysis, the Company does not believe that any of its tax attributes through December 31, 2023 will expire unutilized due to Section 382 limitations. To the extent the Company enters into future equity transactions, there could be a limitation on the Company&#x2019;s tax attributes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC 740, Income Taxes to uncertain tax positions. As of the adoption date on January 1, 2010 and through December 31, 2024, the Company had no unrecognized tax benefits or related interest and penalties accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, the Company has not completed a detailed study of its research and development and orphan drug credits for the tax years ending December 31, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023 and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As a result, the Company will adjust its deferred tax asset balances and include the impacts in the research tax credits and state income taxes &#x2013; net of federal benefit lines in the effective rate reconciliation next year, once the updated study has been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act requires taxpayers to capitalize and amortize, rather than deduct, research and experimental, or R&amp;amp;E, expenditures under Section 174 for tax years beginning after December 31, 2021. These rules became effective for the Company during the year ended December 31, 2022. As a result, the Company has capitalized R&amp;amp;E costs of $45.1&#160;million and $43.9&#160;million for the years ended December 31, 2024 and December 31, 2023, respectively. The Company will amortize these costs for tax purposes over five years if the R&amp;amp;E was performed in the United States and over 15 years if the R&amp;amp;E was performed outside the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as income tax expense in the accompanying statement of operations. As of December 31, 2024, the Company had no accrued interest related to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The statute of limitations for assessment by the Internal Revenue Service and state tax authorities is open for tax years 2020 to the present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, or state tax authorities to the extent utilized in a future period. The Company files income tax returns in the United States, Massachusetts, and Maryland. There are currently no federal, state or foreign audits in progress.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1172" unitRef="usd">300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-14" decimals="-5" id="f-1173" unitRef="usd">-19000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1174">The following table reconciles the federal statutory income tax rate to the Company&#x2019;s effective income tax rate:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Statutory U.S. federal rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;State income taxes - net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Research tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Change in fair value of contingent value right liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Change in fair value of forward contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Valuation allowance, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(160.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Effective income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1175" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-14" decimals="3" id="f-1176" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1177" unitRef="number">0.105</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-14" decimals="3" id="f-1178" unitRef="number">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="3" id="f-1179" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-14" decimals="3" id="f-1180" unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-1181" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-14" decimals="3" id="f-1182" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent contextRef="c-1" decimals="3" id="f-1183" unitRef="number">1.279</rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent>
    <rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent contextRef="c-14" decimals="3" id="f-1184" unitRef="number">0</rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentValueRightLiabilityPercent>
    <rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent contextRef="c-1" decimals="3" id="f-1185" unitRef="number">-0.019</rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent>
    <rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent contextRef="c-14" decimals="3" id="f-1186" unitRef="number">-0.132</rnac:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-1187" unitRef="number">-1.601</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-14" decimals="3" id="f-1188" unitRef="number">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1189" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-14" decimals="3" id="f-1190" unitRef="number">-0.039</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1191" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-14" decimals="3" id="f-1192" unitRef="number">0.080</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1193">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences that give rise to the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;44,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;29,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;5,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;75,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;84,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;3,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Contingent value right liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;108,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;R&amp;amp;E Capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;26,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;19,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Patent and license costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;8,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;9,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;274,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;152,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(41,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(41,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(1,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(2,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(43,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(44,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Net deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;231,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;108,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(247,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(124,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Net deferred tax assets/(liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(16,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(15,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-8" decimals="-3" id="f-1194" unitRef="usd">44062000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-9" decimals="-3" id="f-1195" unitRef="usd">29841000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-8" decimals="-3" id="f-1196" unitRef="usd">6024000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-9" decimals="-3" id="f-1197" unitRef="usd">5649000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-8" decimals="-3" id="f-1198" unitRef="usd">1070000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-9" decimals="-3" id="f-1199" unitRef="usd">8000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c-8" decimals="-3" id="f-1200" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c-9" decimals="-3" id="f-1201" unitRef="usd">705000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-8" decimals="-3" id="f-1202" unitRef="usd">75567000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-9" decimals="-3" id="f-1203" unitRef="usd">84626000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <rnac:DeferredTaxAssetsLeasingArrangements contextRef="c-8" decimals="-3" id="f-1204" unitRef="usd">3848000</rnac:DeferredTaxAssetsLeasingArrangements>
    <rnac:DeferredTaxAssetsLeasingArrangements contextRef="c-9" decimals="-3" id="f-1205" unitRef="usd">2718000</rnac:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies contextRef="c-8" decimals="-3" id="f-1206" unitRef="usd">108832000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies contextRef="c-9" decimals="-3" id="f-1207" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-8" decimals="-3" id="f-1208" unitRef="usd">26863000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-9" decimals="-3" id="f-1209" unitRef="usd">19778000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-8" decimals="-3" id="f-1210" unitRef="usd">8540000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-9" decimals="-3" id="f-1211" unitRef="usd">9140000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-8" decimals="-3" id="f-1212" unitRef="usd">274806000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-9" decimals="-3" id="f-1213" unitRef="usd">152465000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-8" decimals="-3" id="f-1214" unitRef="usd">41441000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-9" decimals="-3" id="f-1215" unitRef="usd">41144000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-1216" unitRef="usd">115000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-9" decimals="-3" id="f-1217" unitRef="usd">128000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-8" decimals="-3" id="f-1218" unitRef="usd">1523000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-9" decimals="-3" id="f-1219" unitRef="usd">2751000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-8" decimals="-3" id="f-1220" unitRef="usd">43079000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-9" decimals="-3" id="f-1221" unitRef="usd">44023000</us-gaap:DeferredIncomeTaxLiabilities>
    <rnac:DeferredTaxAssetsNetOfDeferredTaxLiabilities contextRef="c-8" decimals="-3" id="f-1222" unitRef="usd">231727000</rnac:DeferredTaxAssetsNetOfDeferredTaxLiabilities>
    <rnac:DeferredTaxAssetsNetOfDeferredTaxLiabilities contextRef="c-9" decimals="-3" id="f-1223" unitRef="usd">108442000</rnac:DeferredTaxAssetsNetOfDeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-3" id="f-1224" unitRef="usd">247867000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-9" decimals="-3" id="f-1225" unitRef="usd">124295000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities contextRef="c-8" decimals="-3" id="f-1226" unitRef="usd">16140000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-9" decimals="-3" id="f-1227" unitRef="usd">15853000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-1228" unitRef="usd">123600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-5" id="f-1229" unitRef="usd">-108800000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-339" decimals="-5" id="f-1230" unitRef="usd">-3500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-340" decimals="-5" id="f-1231" unitRef="usd">152600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-341" decimals="-5" id="f-1232" unitRef="usd">187800000</us-gaap:OperatingLossCarryforwards>
    <rnac:OperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-8" decimals="-5" id="f-1233" unitRef="usd">74400000</rnac:OperatingLossCarryforwardsNotSubjectToExpiration>
    <rnac:OperatingLossCarryforwardsSubjectToExpiration contextRef="c-8" decimals="-5" id="f-1234" unitRef="usd">113400000</rnac:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-340" decimals="-5" id="f-1235" unitRef="usd">5200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-341" decimals="-5" id="f-1236" unitRef="usd">1000000</us-gaap:TaxCreditCarryforwardAmount>
    <rnac:CapitalizedResearchAndExperimentalCostsTaxPurposes contextRef="c-1" decimals="-5" id="f-1237" unitRef="usd">45100000</rnac:CapitalizedResearchAndExperimentalCostsTaxPurposes>
    <rnac:CapitalizedResearchAndExperimentalCostsTaxPurposes contextRef="c-14" decimals="-5" id="f-1238" unitRef="usd">43900000</rnac:CapitalizedResearchAndExperimentalCostsTaxPurposes>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-1239">Employee Benefit Plans&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a defined contribution plan, or the 401(k) Plan, under Section&#160;401(k) of the Internal Revenue Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The 401(k) Plan provides for matching contributions on a portion of participant contributions pursuant to the 401(k) Plan&#x2019;s matching formula. All matching contributions vest ratably over two years and participant contributions vest immediately. Contributions by the Company totaled $0.2 million and $0.3 million during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company approved the 2016 Employee Stock Purchase Plan, or the ESPP, which initially authorized 5,769 shares of common stock for future issuance under the ESPP to participating employees. As of December 31, 2024, 45,795 shares remain available for future issuance under the ESPP. In connection with the Merger, the Board of Directors suspended offerings under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized no stock-based compensation expense under the ESPP for the year ended December 31, 2024 and $0.1 million of stock-based compensation expense under the ESPP for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <rnac:DefinedContributionPlanEmployersMatchingContributionVestingPeriod contextRef="c-1" id="f-1240">P2Y</rnac:DefinedContributionPlanEmployersMatchingContributionVestingPeriod>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-1241" unitRef="usd">200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-14" decimals="-5" id="f-1242" unitRef="usd">300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-342"
      decimals="INF"
      id="f-1243"
      unitRef="shares">5769</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-343"
      decimals="INF"
      id="f-1244"
      unitRef="shares">45795</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-344" decimals="INF" id="f-1245" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-345" decimals="-5" id="f-1246" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1247">Commitments and Contingencies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, the Company was not a party to any litigation that could have a material adverse effect on the Company&#x2019;s business, financial position, results of operations or cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December 31, 2024, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, as permitted under Delaware law, the Company indemnifies its directors for certain events or occurrences while the director is, or was, serving at the Company&#x2019;s request in such capacity. The term of the indemnification is for the director&#x2019;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#x2019; insurance coverage that limits its exposure and enables it to recover a portion of any future amounts paid. The Company also has indemnification arrangements under certain of its facility leases that require it to indemnify the landlord against certain costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from certain breaches, violations, or non-performance of any covenant or condition of the Company&#x2019;s lease. The term of the indemnification is for the term of the related lease agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. To date, the Company had not experienced any material losses related to any of its indemnification obligations, and no material claims with respect thereto were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party in various other contractual disputes and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect the Company&#x2019;s business, financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-1248">Restructuring&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, in light of current market conditions, the Board of Directors took steps to extend the Company&#x2019;s cash runway by pausing further development of the Company&#x2019;s product candidate, SEL-302, for the treatment of methylmalonic acidemia and conducting a targeted headcount reduction. On August 17, 2023, the Company announced additional steps to extend cash runway and maximize value for stockholders by continuing to prioritize development of the Company&#x2019;s product candidate, SEL-212, and support of its collaboration with Astellas for Xork, and pausing further development of all of the Company&#x2019;s other clinical and preclinical product candidates that it was no longer actively advancing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of these measures, the Company implemented a restructuring plan that resulted in an approximate 90% reduction of the Company&#x2019;s existing headcount as of December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the change in the Company&#x2019;s accrued restructuring balance included in accrued expenses and other current liabilities on its consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Severance liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Severance liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized restructuring expenses consisting of one-time cash severance payments and other employee-related costs. The Company recorded these &lt;span style="-sec-ix-hidden:f-1259"&gt;&lt;span style="-sec-ix-hidden:f-1260"&gt;&lt;span style="-sec-ix-hidden:f-1261"&gt;&lt;span style="-sec-ix-hidden:f-1262"&gt;restructuring charges&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; based on each employee&#x2019;s role to the respective research and development and general and administrative operating expense categories on its consolidated statements of operations and comprehensive loss. For the years ended December 31, 2024 and 2023, the Company recognized $0.2 million and $5.6 million in research and development expenses, respectively, and $0.6 million and $0.8 million in general and administrative expenses, respectively. Payments for the restructuring plan were substantially complete by June 30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="c-346"
      decimals="2"
      id="f-1249"
      unitRef="number">0.90</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-1250">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the change in the Company&#x2019;s accrued restructuring balance included in accrued expenses and other current liabilities on its consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Severance liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Severance liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-15" decimals="-3" id="f-1251" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-14" decimals="-3" id="f-1252" unitRef="usd">6431000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-14" decimals="-3" id="f-1253" unitRef="usd">2535000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-9" decimals="-3" id="f-1254" unitRef="usd">3896000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-9" decimals="-3" id="f-1255" unitRef="usd">3896000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-1256" unitRef="usd">798000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-1" decimals="-3" id="f-1257" unitRef="usd">4614000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-8" decimals="-3" id="f-1258" unitRef="usd">80000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-261" decimals="-5" id="f-1263" unitRef="usd">200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-258" decimals="-5" id="f-1264" unitRef="usd">5600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-262" decimals="-5" id="f-1265" unitRef="usd">600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-259" decimals="-5" id="f-1266" unitRef="usd">800000</us-gaap:RestructuringCharges>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1267">Segment Reporting&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Factors used in determining the reportable segment include the nature of the Company&#x2019;s operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note 3. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents selected financial information with respect to the Company&#x2019;s single operating segment for the years ended December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.200%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration and license revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legacy Selecta programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Descartes-08 for MG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Early stage programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development facilities and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other expense, net (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Includes impairment of long-lived assets, interest income, foreign currency transaction, net, interest expense, change in fair value of warrant liabilities, change in fair value of contingent value right liability, change in fair value of forward contract liabilities, other income, net, and income tax (expense) benefit.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1268">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents selected financial information with respect to the Company&#x2019;s single operating segment for the years ended December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.200%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration and license revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legacy Selecta programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Descartes-08 for MG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Early stage programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development facilities and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other expense, net (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Includes impairment of long-lived assets, interest income, foreign currency transaction, net, interest expense, change in fair value of warrant liabilities, change in fair value of contingent value right liability, change in fair value of forward contract liabilities, other income, net, and income tax (expense) benefit.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-347" decimals="-3" id="f-1269" unitRef="usd">38275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-348" decimals="-3" id="f-1270" unitRef="usd">26004000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-347" decimals="-3" id="f-1271" unitRef="usd">638000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-348" decimals="-3" id="f-1272" unitRef="usd">0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-347" decimals="-3" id="f-1273" unitRef="usd">38913000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-348" decimals="-3" id="f-1274" unitRef="usd">26004000</us-gaap:Revenues>
    <rnac:MedicalExpensesOperating contextRef="c-349" decimals="-3" id="f-1275" unitRef="usd">6150000</rnac:MedicalExpensesOperating>
    <rnac:MedicalExpensesOperating contextRef="c-350" decimals="-3" id="f-1276" unitRef="usd">31826000</rnac:MedicalExpensesOperating>
    <rnac:MedicalExpensesOperating contextRef="c-351" decimals="-3" id="f-1277" unitRef="usd">12142000</rnac:MedicalExpensesOperating>
    <rnac:MedicalExpensesOperating contextRef="c-352" decimals="-3" id="f-1278" unitRef="usd">343000</rnac:MedicalExpensesOperating>
    <rnac:MedicalExpensesOperating contextRef="c-353" decimals="-3" id="f-1279" unitRef="usd">1028000</rnac:MedicalExpensesOperating>
    <rnac:MedicalExpensesOperating contextRef="c-354" decimals="-3" id="f-1280" unitRef="usd">595000</rnac:MedicalExpensesOperating>
    <rnac:ResearchAndDevelopmentEmployeeExpenses contextRef="c-347" decimals="-3" id="f-1281" unitRef="usd">11952000</rnac:ResearchAndDevelopmentEmployeeExpenses>
    <rnac:ResearchAndDevelopmentEmployeeExpenses contextRef="c-348" decimals="-3" id="f-1282" unitRef="usd">18363000</rnac:ResearchAndDevelopmentEmployeeExpenses>
    <rnac:ResearchAndDevelopmentStockBasedCompensationExpense contextRef="c-347" decimals="-3" id="f-1283" unitRef="usd">3217000</rnac:ResearchAndDevelopmentStockBasedCompensationExpense>
    <rnac:ResearchAndDevelopmentStockBasedCompensationExpense contextRef="c-348" decimals="-3" id="f-1284" unitRef="usd">12985000</rnac:ResearchAndDevelopmentStockBasedCompensationExpense>
    <rnac:ResearchAndDevelopmentFacilitiesAndOtherExpenses contextRef="c-347" decimals="-3" id="f-1285" unitRef="usd">10616000</rnac:ResearchAndDevelopmentFacilitiesAndOtherExpenses>
    <rnac:ResearchAndDevelopmentFacilitiesAndOtherExpenses contextRef="c-348" decimals="-3" id="f-1286" unitRef="usd">7148000</rnac:ResearchAndDevelopmentFacilitiesAndOtherExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-347" decimals="-3" id="f-1287" unitRef="usd">30126000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-348" decimals="-3" id="f-1288" unitRef="usd">40450000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-347" decimals="-3" id="f-1289" unitRef="usd">7579000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-348" decimals="-3" id="f-1290" unitRef="usd">710000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:OtherNonoperatingExpense contextRef="c-347" decimals="-3" id="f-1291" unitRef="usd">33527000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c-348" decimals="-3" id="f-1292" unitRef="usd">133294000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss contextRef="c-347" decimals="-3" id="f-1293" unitRef="usd">-77424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-348" decimals="-3" id="f-1294" unitRef="usd">-219710000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1295">Subsequent Events&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events through the date on which the consolidated financial statements were issued. The Company has concluded that no subsequent events have occurred that require disclosure, except as disclosed within these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
